1.1;5;13;13;1pter-p36.13;CTRCT8, CCV;;Cataract, congenital, Volkmann type;115665;Fd;linked to Rh in Scottish family;Cataract 8, multiple types (2);
1.2;9;25;01;1p36.23;ENO1, PPH, MPB1;;Enolase-1, alpha;172430;S, F, R, REa;;Enolase deficiency (1);4(Eno1)
1.3;12;22;87;1pter-p36;ERPL1, HLM2;;Endogenous retroviral pol gene-like sequence 1 (oncogene HLM2);131190;REa, F;;;
1.4;4;14;11;1p36.11;HMGCL;;3-hydroxy-3-methylglutaryl-Coenzyme A lyase;613898;REa, A;;HMG-CoA lyase deficiency, 246450 (3);4(Hmgcl)
1.5;4;30;15;1p36.33;AGRN, CMS8;;Agrin;103320;REa;;Myasthenic syndrome, congenital, 8, with pre- and postsynaptic defects, 615120 (3);4(Agrn)
1.6;6;24;16;1p36.33;GNB1, MRD42;;Guanine nucleotide-binding protein, beta polypeptide-1;139380;REa, A;;Mental retardation, autosomal dominant 42, 616973 (3); Leukemia, acute lymphoblastic, somatic, 613065 (3);4(Gnb1)
1.7;10;2;07;1p35.2;SDC3, SYND3, SDCN;;Syndecan 3;186357;REc, R, H;;{Obesity, association with}, 601665 (3);4(Synd3)
1.8;8;28;98;1pter-p22.1;SAI1, MTS1, TFS1;;Suppression of anchorage independence-1 (malignant transformation suppression-1);154280;S, H;;;4(Tfs1)
1.9;12;6;16;1p36.33;ATAD3A, HAYOS;;ATPase family, AAA domain-containing, member 3A;612316;REc;one family with AR inheritance reported;Harel-Yoon syndrome, 617183 (3);4(Atad3)
1.10;10;6;08;1p36.33;ATAD3B, TOB3, KIAA1273;;ATPase family, AAA domain-containing, member 3B;612317;R, REc;;;
1.11;11;29;16;1p36.33;ATAD3C;;ATPase family, AAA domain-containing, member 3C;617227;REc;;;
1.12;5;6;13;1p36.33;C1orf86, FAAP20;;Chromosome 1 open reading frame 86;615183;REc;;;
1.13;7;3;06;1p36.33;CALML6, CAGLP;;Calmodulin-like 6;610171;REc;;;
1.14;9;30;10;1p36.33;CCNL2;;Cyclin L2;613482;REc;;;4(Ccnl2)
1.15;3;23;14;1p36.33;CPSF3L, INTS11, RC68;;Cleavage and polyadenylation-specific factor 3-like;611354;REc;;;
1.16;10;13;15;1p36.33;FAM132A, C1QDC2, C1QTNF12;;Family with sequence similarity 132, member A;616593;REc;;;
1.17;11;1;13;1p36.33;GLTPD1, CPTP;;Glycolipid transfer protein domain-containing protein 1;615467;REc;;;
1.18;12;19;14;1p36.33;ISG15, G1P2, IFI15, IMD38;;ISG15 ubiquitin-like modifier;147571;REa, REc;;Immunodeficiency 38, 616126 (3);
1.19;3;23;09;1p36.33;MIR200A, MIRN200A;;Micro RNA 200A;612090;REc;;;
1.20;3;23;09;1p36.33;MIR200B, MIRN200B;;Micro RNA 200B;612091;REc;;;
1.21;3;23;09;1p36.33;MIR429, MIRN429;;Micro RNA 429;612094;REc;;;
1.22;1;9;17;1p36.33;MXRA8, ASP3;;Matrix remodeling-associated protein 8;617293;REc;;;4(Mxra8)
1.23;2;20;07;1p36.33;NOC2L, NIR;;Nucleolar complex-associated protein 2, S. cerevisiae, homolog of;610770;REc;;;
1.24;8;18;14;1p36.33;PERM1, C1orf170;;PPARGC1-and ESRR-induced regulator, muscle, 1;615921;REc;;;
1.25;1;21;16;1p36.33;SAMD11, MRS;;Sterile alpha motif domain-containing protein 11;616765;REc;;;
1.26;10;10;11;1p36.33;SDF4, CAB45;;Stromal cell-derived factor 4;614282;REc;;;
1.27;9;21;17;1p36.33;SSU72;;Ssu72, S. cerevisiae, homolof of;617680;REc, H;;;4(Ssu72)
1.28;4;24;01;1p36.33;TAS1R3, T1R3;;Taste receptor type 1, member 3;605865;REn, REc;;;4(Tas1r3)
1.29;12;2;14;1p36.33;TMEM240, C1orf70, SCA21;;Transmembrane protein 240;616101;REc, Fd;;Spinocerebellar ataxia 21, 607454 (3);
1.30;10;27;89;1p36.23;CA6;;Carbonic anhydrase VI;114780;REa, A, REc, R;;;
1.31;2;18;08;1p36.33;NADK;;NAD kinase;611616;REc;;;
1.32;4;4;16;1p36.23;PER3, FASPS3;;Period, Drosophila, homolog of, 3;603427;REc;mutation identified in 1 FASPS3 family;?Advanced sleep phase syndrome, familial, 3, 616882 (3);
1.33;7;18;06;1p36.32;ACTRT2, ARPT2, ARPM2;;Actin-related protein T2;608535;REc;;;
1.34;5;21;07;1p36.32;AJAP1, SHREW1;;Adherens junction-associated protein 1;610972;R, REc;;;
1.35;2;2;16;1p36.32;CEP104, GLYBP, KIAA0562, JBTS25;;Centrosomal protein, 104kD;616690;R, REc;;Joubert syndrome 25, 616781 (3);
1.36;8;29;13;1p36.33;MIB2;;Mindbomb, Drosophila, homolog of, 2;611141;A, REc;;;
1.37;4;8;13;1p36.32;MIR551A;;Micro RNA 551A;615148;REc;;;
1.38;09;06;18;1p36.32;MMEL1, NEPII, NEP2, NL1, SEP;;Membrane metalloendopeptidase-like 1;618104;REc;;;
1.39;10;25;12;1p36.32;PEX10, NALD, PBD6A, PBD6B;;Peroxisome biogenesis factor 10;602859;REc;;Peroxisome biogenesis disorder 6A (Zellweger), 614870 (3); Peroxisome biogenesis disorder 6B, 614871 (3);
1.40;7;9;09;1p36.32;PLCH2, PLCL4;;Phospholipase C, eta-2;612836;REc;;;
1.41;8;27;15;1p36.32;TPRG1L, FAM79A;;Tumor protein p63 regulated 1-like;611460;R, REc;;;
1.42;4;8;03;1p36.32-p36.13;DYT13;;Dystonia 13, torsion;607671;Fd;;Dystonia 13, torsion (2);
1.43;4;16;11;1p36.32-p35.3;KONDS;;Kondoh syndrome (mental retardation, microcephaly, growth retardation, joint contractures, and facial dysmorphism);606242;Fd;linked to rs966321 and rs1441834;Kondoh syndrome (2);
1.44;10;5;11;1p36.31;GPR153;;G protein-coupled receptor 153;614269;REc;;;4(Gpr153)
1.45;3;24;06;1p36.31;HES2;;Hairy/enhancer of split, Drosophila, homolog of, 2;609970;REc;;;
1.46;3;24;06;1p36.31;HES3;;Hairy/enhancer of split, Drosophila, homolog of, 3;609971;REc;;;
1.47;3;24;06;1p36.33;HES4;;Hairy/enhancer of split, Drosophila, homolog of, 4;608060;REc;;;
1.48;3;24;06;1p36.32;HES5;;Hairy/enhancer of split, Drosophila, homolog of, 5;607348;REc;;;
1.49;3;12;15;1p36.31;KLHL21, KIAA0469;;Kelch-like 21;616262;R, REc;;;
1.50;4;27;16;1p36.31;RNF207, C1orf188;;RING finger protein 207;616923;REc;;;
1.51;1;20;09;1p36.31;THAP3;;THAP domain-containing protein 3;612532;REc;;;
1.52;11;4;93;1p36.31;RPL22, EAP;;Ribosomal protein L22;180474;Ch, REc;fused with AML1 in t(3;21);;
1.53;9;18;12;1p36.31;DNAJC11;;DNAJ/HSP40 homolog, subfamily C, member 11;614827;REc;;;
1.54;1;5;12;1p36.31-p36.13;DFNB96;;Deafness, autosomal recessive 96;614414;Fd;between rs3817914 and rs477558;Deafness, autosomal recessive 96 (2);
1.55;8;18;12;1p36.33;AURKAIP1, AKIP, AIP;;Aurora kinase A-interacting protein 1;609183;R, REc;;;
1.56;12;22;17;1p36.33;B3GALT6, SEMDJL1, EDSSPD2;;UDP-Gal:beta-Gal beta-1,3-galactosyltransferase polypeptide 6;615291;REc;;Spondyloepimetaphyseal dysplasia with joint laxity, type 1, with or without fractures, 271640 (3); Ehlers-Danlos syndrome, spondylodysplastic type, 2, 615349 (3);4(B3galt6)
1.57;1;27;11;1p36.33;CDK11B, CDC2L1, P58, CDK11;;Cyclin-dependent kinase 11B;176873;REa, A, Pcm, A;;;
1.58;1;27;11;1p36.33;CDK11A, CDC2L2;;Cyclin-dependent kinase 11A;116951;A;;;
1.59;8;4;99;1p36.32;DFFB, CAD, DFF2;;DNA fragmentation factor, 40kD, beta subunit;601883;A;;;
1.60;9;11;12;1p36.33;GABRD, GEFSP5, EIG10, EJM7;;Gamma-aminobutyric acid (GABA) A receptor, delta;137163;REa, R, REc;;{Epilepsy, generalized, with febrile seizures plus, type 5, susceptibility to}, 613060 (3); {Epilepsy, idiopathic generalized, 10}, 613060 (3); {Epilepsy, juvenile myoclonic, susceptibility to}, 613060 (3);
1.61;12;24;08;1p36.32;MEGF6, EGFL3;;Multiple epidermal growth factor-like domains 6;604266;R;;;
1.62;6;15;99;1p36.33;TNFRSF18, AITR, GITR;;Tumor necrosis factor receptor superfamily, member 18;603905;R;;;
1.63;3;30;99;1p36.31;KCNAB2, KCNA2B;;Potassium voltage-gated channel, shaker-related subfamily, beta member 2;601142;A;;;
1.64;11;1;99;1p36.33;MMP23A, MMP21, MIFR;;Matrix metalloproteinase 23A;603320;REc;;;
1.65;11;1;99;1p36.33;MMP23B, MMP22;;Matrix metalloproteinase 23B;603321;REc;;;
1.66;1;12;11;1p36.22;MTHFR;;Methylenetetrahydrofolate reductase;607093;A;;Homocystinuria due to MTHFR deficiency, 236250 (3); {Schizophrenia, susceptibility to}, 181500 (3); {Vascular disease, susceptibility to} (3); {Neural tube defects, susceptibility to}, 601634 (3); {Thromboembolism, susceptibility to}, 188050 (3);4(Mthfr)
1.67;9;9;13;1p36.32;PRDM16, MEL1, LVNC8, CMD1LL;;PR domain-containing protein 16;605557;REc, Ch;;Left ventricular noncompaction 8, 615373 (3); Cardiomyopathy, dilated, 1LL, 615373 (3);
1.68;8;9;99;1p36.3;PTPRZ2;;Protein-tyrosine phosphatase, receptor-type, zeta-2;604008;A;;;
1.69;1;20;98;1p36.13;RNU1A, RNU1;;RNA, U1A small nuclear;180680;REa, A;?same as A12M2;;3(Rnu1b1)
1.70;10;5;12;1p36.33-p36.32;SKI, SGS;;Avian sarcoma viral (v-ski) oncogene homolog;164780;REa, A, Ch;formerly mapped to 1q22-q24;Shprintzen-Goldberg syndrome, 182212 (3);
1.71;12;23;02;1p36.31;TNFRSF25, TNFRSF12, DR3, LARD;;Tumor necrosis factor receptor superfamily, member 25;603366;A, Ch;;;
1.72;9;28;10;1p36.22;UBE4B, UFD2A, KIAA0684;;Ubiquitination factor E4B;613565;REc;;;
1.73;4;6;13;1p36.22;UBIAD1, TERE1, SCCD;;UbiA prenyltransferase domain-containing protein 1;611632;A, Fd;;Corneal dystrophy, Schnyder type, 121800 (3);
1.74;3;20;08;1p36.33;VWA1, WARP;;von Willebrand factor A domain-containing protein 1;611901;REc;;;
1.75;6;20;01;1p36.32;WDR8;;WD repeat-containing protein 8;606040;A;;;
1.76;11;22;13;1p36.31;ZBTB48, HKR3;;Zinc finger- and BTB domain-containing protein 48;165270;REa, A;;;
1.77;2;6;94;1p36.12;HTR1D;;5-hydroxytryptamine (serotonin) receptor-1D;182133;REa, A;;;4(Htr1d)
1.78;6;10;98;1p36.22;DFFA, DFF1;;DNA fragmentation factor, 45kD, alpha subunit;601882;A;;;
1.79;3;10;11;1p36.22;MASP2;;Mannan-binding lectin serine protease 2;605102;A, R;;MASP2 deficiency, 613791 (3);
1.80;12;22;17;1p36.22;PLOD1, LH1, LLH, EDSKCL1;;Procollagen-lysine, 2-oxoglutarate 5-dioxygenase (lysine hydroxylase);153454;REa, A;;Ehlers-Danlos syndrome, kyphoscoliotic type, 1, 225400 (3);4(Plod)
1.81;9;15;96;1p36.33;SCNN1D;;Sodium channel, voltage-gated, type I, delta polypeptide;601328;A;;;
1.82;12;18;98;1p36.22;TNFRSF1B, TNFR2, TNFBR;;Tumor necrosis factor receptor superfamily, member 1B;191191;REa, A, Fd;;;4(Tnfr1)
1.83;12;14;98;1p36.32;TNFRSF14, HVEM, TR2;;Tumor necrosis factor receptor superfamily, member 14 (herpesvirus entry mediator);602746;A;;;
1.84;1;11;07;1p36.21;CASP9, APAF3;;Caspase 9, apoptosis-related cysteine protease;602234;A;;;
1.85;3;16;06;1p36.31;ESPN;;Espin, mouse, homolog of;606351;R, H;;Deafness, autosomal recessive 36, 609006 (3); Deafness, neurosensory, without vestibular involvement, autosomal dominant (3);4(espn)
1.86;2;28;08;1p36.33;MRPL20;;Mitochondrial ribosomal protein L20;611833;R;;;
1.87;2;17;11;1p36.12;C1QA;;Complement component 1, q subcomponent, A chain;120550;REa, REb;;C1q deficiency, 613652 (3);
1.88;2;17;11;1p36.12;C1QB;;Complement component 1, q subcomponent, B chain;120570;REa, REb;;C1q deficiency, 613652 (3);(C1qb)
1.89;2;17;11;1p36.12;C1QC, C1QG;;Complement component 1, q subcomponent, C chain;120575;REn, REb;;C1q deficiency, 613652 (3);
1.90;9;9;08;1p36.13;FBXO42, FBX42, KIAA1332;;F-box only protein 42;609109;REc;;;4(Fbox42)
1.91;9;9;08;1p36.22;FBXO6, FBX6, FBG2;;F-box only protein 6;605647;REc;;;4(Fbxo6)
1.92;1;8;07;1p36.13;HSPB7, CVHSP;;Heat-shock 27kD protein 7;610692;REc;;;
1.93;7;18;14;1p36.23;UTS2;;Urotensin II;604097;REc;;;
1.94;12;30;04;1p36.22;APITD1;;Apoptosis-inducing, TAF9-like domain 1;609130;REa, REc;;;
1.95;7;17;09;1p36.22;CTNNBIP1, ICAT;;Catenin, beta-interacting protein 1;607758;R, REc;;;
1.96;3;20;09;1p36.22;DRAXIN, C1orf187;;Dorsal repulsive axon guidance protein;612682;REc;;;
1.97;7;27;09;1p36.22;EXOSC10, PMSCL2;;Exosome component 10;605960;R, REc;;;
1.98;5;24;13;1p36.22;LZIC;;Leucine zipper and CTNNBIP1 domains-containing protein;610458;REc;;;
1.99;11;05;18;1p36.22;MIIP, IIP45;;Migration and invasion inhibitory protein;608772;REc;;;
1.100;9;25;12;1p36.22;NMNAT1, NMNAT, PNAT1, LCA9;;Nicotinamide nucleotide adenylyltransferase 1;608700;REc;;Leber congenital amaurosis 9, 608553 (3);
1.101;9;9;08;1p36.22;PTCHD2, DISP3, KIAA1337;;Patched domain-containing protein 2;611251;REc;;;
1.102;2;28;07;1p36.22;SLC25A33;;Solute carrier family 25 (mitochondrial carrier), member 33;610816;REc;;;4(Slc25A33)
1.103;12;18;07;1p36.22;SPSB, SSB1;;SPRY domain- and SOCS box-containing 1;611657;R, REc;;;
1.104;9;22;08;1p36.22;CASZ1, SRG;;Castor zinc finger protein 1;609895;A, REc;;;4(Srg)
1.105;10;10;18;1p36.22-p36.21;VPS13D, SCAR4;;Vacuolar protein sorting 13, yeast, homolog of, D;608877;REc;;Spinocerebellar ataxia, autosomal recessive 4, 607317 (3);4(Vps13d)
1.106;3;5;18;1p36.21;AGMAT, AUH;;Agmatinase;617887;REc;;;
1.107;2;11;08;1p36.21;CTRC, CLCR;;Chymotrypsin;601405;REc;;{Pancreatitis, chronic, susceptibility to}, 167800 (3);
1.108;7;20;15;1p36.21;EFHD2, SWS1;;EF-hand domain family, member D2;616450;REc;;;
1.109;9;9;08;1p36.22;FBXO44, FBX44, FBX6A, FBG3;;F-box only protein 44;609111;REc;;;4(Fbxo44)
1.110;2;28;06;1p36.21;GBD2;;Gallbladder disease 2;609918;Fd;between D1S1597 and D1S47;Gallbladder disease 2 (2);
1.111;5;6;13;1p36.21;LRRC38;;Leucine-rich repeat-containing protein 38;615212;REc;;;
1.112;12;10;13;1p36.21;PDPN, TI1A, T1A2, GP36, OTS8, AGGRUS;;Podoplanin;608863;REc, R;;;
1.113;7;8;16;1p36.21;PLEKHM2, SKIP, KIAA0842;;Pleckstrin homology domain-containing protein, family M, member 2;609613;REc;;;
1.114;3;12;07;1p36.21;SLC25A34;;Solute carrier family 25, member 34;610817;REc;;;4(Slc25A34)
1.115;9;2;12;1p36.21;CELA2A, ELA2A;;Chymotrypsin-like elastase family, member 2A;609443;REc, R;;;
1.116;9;2;12;1p36.21;CELA2B, ELA2B;;Chymotrypsin-like elastase family, member 2B;609444;REc;;;
1.117;3;31;15;1p36.22;KIF1B, CMT2A, CMT2A1, NBLST1;;Kinesin family member 1B;605995;Fd, REc, D;mutation identified in 1 CMT2A1 family;?Charcot-Marie-Tooth disease, type 2A1, 118210 (3); Pheochromocytoma, 171300 (3); {Neuroblastoma, susceptibility to, 1}, 256700 (3);4(Kif1b)
1.118;8;30;16;1p36.22;MFN2, KIAA0214, CMT2A2A, HMSN6A, CMT2A2B;;Mitofusin 2;608507;R, REa, REc;;Charcot-Marie-Tooth disease, axonal, type 2A2A, 609260 (3); Hereditary motor and sensory neuropathy VIA, 601152 (3); Charcot-Marie-Tooth disease, axonal, type 2A2B, 617087 (3);
1.119;4;20;17;1p36.22;MTOR, FRAP1, SKS;;Mechanistic target of rapamycin;601231;R, A;;Smith-Kingsmore syndrome, 616638 (3); Focal cortical dysplasia, type II, somatic, 607341 (3);
1.120;7;8;09;1p36.13;NBPF1, KIAA1693;;Neuroblastoma breakpoint family, member 1;610501;R, REc;pseudogenes on 3 and 5;;
1.121;9;15;11;1p36.12;NBPF3;;Neuroblastoma breakpoint family, member 3;612992;REc, A;;;
1.122;4;29;14;1p36.22;NPPA, PND, ANP, ATFB6, ATRST2;;Natriuretic peptide precursor A;108780;REa, A, H;;Atrial fibrillation, familial, 6, 612201 (3); Atrial standstill 2, 615745 (3);4(Pnd)
1.123;5;9;95;1p36.22;NPPB, BNP;;Natriuretic peptide precursor B;600295;H, REa, A, REn;;;4(Nppb)
1.124;10;25;12;1p36.22;PEX14, PBD13A;;Peroxisome biogenesis factor 14;601791;R, REc;;Peroxisome biogenesis disorder 13A (Zellweger), 614887 (3);
1.125;5;23;14;1p36.22;PIK3CD, APDS, IMD14;;Phosphatidylinositol 3-kinase, catalytic, 110kD, delta;602839;A, R;;Immunodeficiency 14, 615513 (3);
1.126;3;12;08;1p36.2;SCZD12;;Schizophrenia 12;608543;Fd;max lod at D1S1612;{Schizophrenia 12}, 181500 (2);
1.127;8;4;99;1p36.23;SLC2A5, GLUT5;;Solute carrier family 2 (facilitated glucose transporter), member 5;138230;REa, A, REc, R;;;
1.128;10;11;06;1p36.23;SLC2A7, GLUT7;;Solute carrier family 2 (facilitated glucose transporter), member 7;610371;REc;;;
1.129;10;5;10;1p36.22;TARDBP, TDP43, ALS10;;TAR DNA-binding protein;605078;R, REc;pseudogenes on 2, 6, 8, 13, 20;Amyotrophic lateral sclerosis 10, with or without FTD, 612069 (3); Frontotemporal lobar degeneration, TARDBP-related, 612069 (3);4(Tardbp)
1.130;4;10;90;1p36.22;PGD;;6-phosphogluconate dehydrogenase;172200;F, S;;;4(Pgd)
1.131;3;16;10;1p36.13;PAX7, RMS2;;Paired box homeotic gene-7;167410;Psh, H, REa, A;fused with FKHR in rhabdomyosarcoma;Rhabdomyosarcoma 2, alveolar, 268220 (3);4(Pax7)
1.132;3;24;88;1p35.3;FGR, SRC2;;Oncogene FGR;164940;A, REb, REa, Fd;same as SRC2;;4(Fgr)
1.133;9;22;97;1p36.2-p36.1;GLC3B;;Glaucoma 3, primary infantile, B;600975;Fd;;Glaucoma 3, primary infantile, B (2);
1.134;6;17;16;1p36.23;RERE, NEDBEH;;RE repeats-encoding gene;605226;REc, Ch;;Neurodevelopmental disorder with or without anomalies of the brain, eye, or heart, 616975 (3);
1.135;6;28;17;1p36.23;SLC45A1, DNB5, IDDNPF;;Solute carrier family 45, member 1;605763;REc;;Intellectual developmental disorder with neuropsychiatric features, 617532 (3);
1.136;10;3;11;1p36.13;ZBTB17, ZNF151, MIZ1;;Zinc finger- and BTB domain-containing protein 17;604084;A;;;
1.137;1;1;95;1p36.12;CDA;;Cytidine deaminase;123920;A, Psh;;;
1.138;2;19;08;1p35.3;EPB41, EL1;;Erythrocyte surface protein band 4.1;130500;F, REb;;Elliptocytosis-1, 611804 (3);4(Elp1)
1.139;5;14;18;1p36.11;RHCE, RHNA;;Rhesus system C and E polypeptides;111700;F, D, Fd;?order: C-E-D;[Blood group, Rhesus] (3); Rh-null disease, amorph type, 617970 (3);
1.140;5;25;05;1p36.11;RHD;;Rhesus system D polypeptide;111680;F, D, Fd;;[Rh-negative blood type] (3);
1.141;5;23;12;1p36.13;AKR7A2, AKR7, AFAR;;Aldo-keto reductase family 7, member A2;603418;REn;pseudogenes on Xq25 and 1p12;;
1.142;8;8;13;1p36.13;AKR7A3, AFAR2;;Aldo-keto reductase family 7, member A3;608477;REc, A;;;
1.143;8;8;13;1p36.13;AKR7A4, AFAR3;;Aldo-keto reductase family 7, member A4;608478;REc, A;;;
1.144;12;22;08;1p36.13;ARHGEF10L, GRINCHGEF, KIAA1626;;RHO guanine nucleotide exchange factor 10-like protein;612494;REc;;;
1.145;12;22;08;1p36.13;ARHGEF19, WGEF;;RHO guanine nucleotide exchange factor 19;612496;REc;;;4(Arhgef19)
1.146;10;13;15;1p36.12;ASAP3, UPLC1, CENTB6, DDEFL1, ACAP4;;ARF GTPase-activating protein with SH3 domain, ankyrin repeat, and PH domain 3;616594;REc;;;
1.147;3;30;16;1p36.13;EMC1, KIAA0090, CAVIPMR;;Endoplasmic reticulum membrane protein complex, subunit 1;616846;Psh;;Cerebellar atrophy, visual impairment, and psychomotor retardation, 616875 (3);
1.148;7;17;09;1p36.21;FBLP1, MIGFILIN;;Filamin-binding LIM protein 1;607747;REc;;;
1.149;9;28;15;1p36.13;MINOS1, MIO10, MIC10;;Mitochondrial inner membrane organizing system protein 1;616574;REc;;;
1.150;2;18;08;1p36.13;NECAP2;;NECAP endocytosis-associated protein 2;611624;R, REc;;;
1.151;1;28;08;1p36.13;OTUD3, KIAA0459;;OTU domain-containing protein 3;611758;R, REc;;;
1.152;1;16;07;1p36.13;PADI1;;Peptidylarginine deiminase, type I;607934;REc, REn;;;
1.153;1;16;07;1p36.13;PADI2;;Peptidylarginine deiminase, type II;607935;REc, REn;;;
1.154;12;22;16;1p36.13;PADI3, UHS1;;Peptidylarginine deiminase, type III;606755;REc, REn;;Uncombable hair syndrome, 191480 (3);
1.155;1;16;07;1p36.13;PADI4, PADI5, PAD;;Peptidylarginine deiminase, type IV;605347;REc, REn;;{Rheumatoid arthritis, susceptibility to}, 180300 (3);
1.156;12;6;16;1p36.13;PADI6, PREMBL2;;Peptidylarginine deiminase, type VI;610363;REn;;Preimplantation embryonic lethality 2, 617234 (3);
1.157;8;21;12;1p36.13;PQLC2;;PQ loop repeat-containing protein 2;614760;REc;;;
1.158;10;25;16;1p36.13;RNF186;;Ring finger protein 186;617163;REc;;;
1.159;1;25;18;1p13.3;SLC25A24, SCAMC1;;Solute carrier family 25 (mitochondrial carrier, phosphate carrier), member 24;608744;REc, H;;Fontaine progeroid syndrome, 612289 (3);2(Slc25a24)
1.160;9;30;10;1p36.21-p36.13;SPEN, MINT, SHARP, HIAA0929;;SPEN, Drosophila, homolog of;613484;REc;;;
1.161;7;22;14;1p36.13;UBR4, ZUBR1, RBAF600, KIAA1307;;Ubiquitin protein ligase E3 component n-recognin 4;609890;R, REc;;;
1.162;9;22;08;1q21.2;APH1A;;Anterior pharynx defective 1, C. elegans, homolog of, A;607629;R, REc;;;
1.163;1;11;95;1p36.12;ID3;;Inhibitor of DNA binding 3, dominant negative, helix-loop-helix protein;600277;RE, A;;;
1.164;10;24;97;1p36.13;D1S1733E, DAN;;Differential-screening-selected gene aberrant in neuroblastoma;600613;A;aberrant in some neuroblastomas;;4(D4H1S1733E)
1.165;1;29;16;1p36.11;MAN1C1;;Mannosidase, alpha, class 1C, member 1;616772;REc;;;
1.166;1;3;05;1p36.13-p34.3;ANIB3;;Aneurysm, intracranial berry, 3;609122;Fd;;Aneurysm, intracranial berry, 3 (2);
1.167;10;24;14;1p36.13-p34.3;EA8;;Episodic ataxia, type 8;616055;Fd;between rs2743201 and rs215791;Episodic ataxia, type 8 (2);
1.168;8;23;09;1p36.12;B6QTL1;;Vitamin B6 plasma level QTL 1;612957;Fd;associated with rs4654748;{Vitamin B6 plasma level QTL 1} (2);
1.169;1;9;13;1p36.12;CAMK2N1;;Calcium/calmodulin-dependent protein kinase II inhibitor 1;614986;REc;;;
1.170;8;18;14;1p36.12;EIF4G3, EIF4GII;;Eukaryotic translation initiation factor 4-gamma, 3;603929;REc;;;
1.171;7;17;09;1p36.12;EPHA8, EEK, HEK3;;Ephrin receptor EphA8 (eph- and elk-related kinase);176945;REa, REc;;;
1.172;11;3;14;1p36.12;HP1BP3, HP1BP74;;Heterochromatin protein 1-binding protein 3;616072;REc;;;
1.173;3;3;16;1p36.12;KDM1A, LSD1, AOF2, BHC110, KIAA0601, CPRF;;Lysine-specific demethylase 1A;609132;R, REc;;Cleft palate, psychomotor retardation, and distinctive facial features, 616728 (3);
1.174;7;20;12;1p36.12;KIF17, KIAA1405;;Kinesin family member 17;605037;REc;;;
1.175;4;27;09;1p36.12;MUL1, MULAN, C1orf166;;Mitochondrial ubiquitin ligase activator of NFKB1;612037;REc;;;
1.176;3;1;01;1p36.12;PLA2G2D, SPLASH;;Phospholipase A2, group IID;605630;R;;;4(Pla2g2d)
1.177;5;25;13;1p36.12;TCEA3;;Transcription elongation factor A, 3;604128;REc;;;
1.178;2;2;16;1p36.12;UBXN10;;UBX domain protein 10;616783;REc;;;
1.179;4;5;11;1p36.12-p35.1;BFIS4, BFIC4;;Seizures, benign familial infantile, 4;612627;Fd;between D1S2864 and D1S2830;Seizures, benign familial infantile, 4 (2);
1.180;7;7;14;1p36.1-p35.3;AHDC1, MRD25;;AT-hook DNA-binding motif-containing protein 1;615790;REc;;Xia-Gibbs syndrome, 615829 (3);
1.181;7;20;12;1p36.11;CD52, CDW52;;CD52 molecule;114280;REc;;;
1.182;7;2;18;1p36.11;CLIC4, MTCLIC;;Chloride intracellular channel 4;606536;REc;;;
1.183;2;25;15;1p36.11;CNKSR1, CNK1;;Connector enhancer of KSR 1;603272;R, REc;;;
1.184;6;22;14;1p36.13;CROCC, ROOTLETIN, KIAA0445;;Ciliary rootlet coiled-coil protein;615776;REc;;;
1.185;1;23;18;1p36.11;DHDDS, HDS, RP59, DEDSM;;Dehydrodolichyl diphosphate synthase;608172;REc;mutation identified in 1 CDG1BB patient;Retinitis pigmentosa 59, 613861 (3); Developmental delay and seizures with or without movement abnormalities, 617836 (3); ?Congenital disorder of glycosylation, type 1bb, 613861 (3);
1.186;4;6;11;1p36.11;FCN3, HAKA1;;Ficolin 3;604973;R, REc;;Immunodeficiency due to ficolin 3 deficiency, 613860 (3);
1.187;5;19;17;1p36.11;GPATCH3;;G-patch domain-containing protein 3;617486;REc;;;
1.188;3;11;14;1p36.11;GRHL3, SOM, TFCP2L4, VWS2;;Grainyhead-like 3;608317;REc, Fd;;Van der Woude syndrome 2, 606713 (3);
1.189;10;7;02;1p36.12;HNRPR, HNRNPR;;Heterogeneous nuclear ribonucleoprotein R;607201;R;;;
1.190;2;11;13;1p36.11;IFNLR1, IL28RA;;Interferon, lambda receptor 1;607404;REc;;;
1.191;4;27;09;1p36.11;LIN28, LIN28A;;Lin28, C. elegans, homolog of;611043;REc, H;;;4(Lin28)
1.192;12;30;14;1p36.11;LYPLA2, APT2;;Lysophospholipase II;616143;REc;;;
1.193;2;8;12;1p36.11;MAP3K6, MAPKKK6, ASK2;;Mitogen-activated protein kinase kinase kinase 6;604468;REc;;;
1.194;2;23;16;1p36.11;MYOM3;;Myomesin 3;616832;REc;;;4(Myom3)
1.195;8;19;13;1p36.11;NUDC;;Nuclear distribution gene C, A. nigulans, homolog of;610325;REc, A;;;
1.196;4;29;14;1p36.11;PAFAH2;;Platelet-activating factor acetylhydrolase 2;602344;REc;;;
1.197;7;17;09;1p36.11;PAQR7, MPRA, PGLP;;Progestin and ADIPOQ receptor family, member 7;607779;REc;;;
1.198;8;20;12;1p36.11;PIGV, HPMRS1;;Phosphatidylinositol glycan, class V;610274;REc;;Hyperphosphatasia with mental retardation syndrome 1, 239300 (3);
1.199;3;11;08;1p36.11;PNRC2;;Proline-rich nuclear receptor coactivator 2;611882;REc;;;
1.200;7;19;12;1p36.11;SFN;;Stratifin;601290;REc;;;
1.201;3;7;14;1p36.11;SH3BGRL3;;SH3 domain-binding glutamic acid-rich protein-like protein 3;615679;REc, A;;;
1.202;1;17;13;1p36.11;SLC30A2, ZNT2, TNZD;;Solute carrier family 30 (zinc transporter), member 2;609617;REc;;Zinc deficiency, transient neonatal, 608118 (3);4(Slc30a2)
1.203;7;27;09;1p36.11;SRRM1, SRM160;;Serine/arginine repetitive matrix 1 (ser/arg-related nuclear matrix protein, 160kD);605975;R, REc;;;
1.204;7;18;14;1p36.11;STPG1, MAPO2, C1orf201;;Sperm-tail PG-rich repeat-containing protein 1;615826;REc;;;4(Stpg1)
1.205;7;17;09;1p36.11;SYF2, P29;;SYF2 RNA splicing factor, S. cerevisiae, homolog of;607090;R, REc;;;
1.206;2;14;08;1p36.11;SYTL1, SLP1, JFC1;;Synaptotagmin-like protein 1;608042;R, REc;;;
1.207;6;22;14;1p36.11;TMEM50A, SMP1;;Transmembrane protein 50A;605348;REc;between RHD and RHCE;;
1.208;5;24;13;1p36.11;TMEM57, FLJ10747;;Transmembrane protein 57;610301;REc, H;;;4(Tmem57)
1.209;2;10;14;1p36.11;TRIM63, RNF28, SMRZ, MURF1;;Tripartite motif containing 63;606131;A;;;
1.210;2;19;16;1p36.11;TRNP1;;TMF1-regulated nuclear protein 1;616824;REc;;;
1.211;5;29;15;1p36.11;UBXN11, SOC;;UBX domain protein 11;609151;REc;;;
1.212;12;22;15;1p36.11;ZNF593, ZT86;;Zinc finger protein 593;616698;REc;;;
1.213;1;29;16;1p36.11;ZNF683, HOBIT;;Zinc finger protein 683;616775;REc;;;
1.214;11;13;17;1p36.11;WASF2, WAVE2, SCAR2;;WAS protein family member 2;605875;REc;?pseudogene on Xp11.21;;
1.215;8;28;97;1p36.13;CAPZB, CAPPB;;Capping protein (actin filament) muscle Z-line, beta;601572;A;;;
1.216;1;8;16;1p36.12;CDC42, TKS;;Cell division cycle 42 (GTP-binding protein, 25kD);116952;H, R, REc;;Takenouchi-Kosaki syndrome, 616737 (3);4(cdc42)
1.217;1;1;95;1p35.3;CHC1, RCC1;;Regulator of chromosome condensation;179710;REb, A;;;4(Chc1)
1.218;5;25;14;1p36.12;DDOST, OST, OST48, CDG1R;;Dolichyl-diphosphooligosaccharide-protein glycosyltransferase;602202;A;mutation (cmpd het) identified in 1 CDG1R patient;?Congenital disorder of glycosylation, type Ir, 614507 (3);
1.219;7;16;09;1p36.21;DHRS3, RETSDR1;;Short-chain dehydrogenase/reductase family, member 3;612830;A, R;;;
1.220;11;17;16;1p36.12;ECE1;;Endothelin converting enzyme 1;600423;A, R, Psh;mutation identified in 1 HCAD patient;?Hirschsprung disease, cardiac defects, and autonomic dysfunction, 613870 (3); {Hypertension, essential, susceptibility to}, 145500 (3);
1.221;5;6;13;1p36.13;EPHA2, ECK, CTPP1, CTPA, ARCC2, CTRCT6;;Ephrin receptor EphA2;176946;A, REa, Fd;;Cataract 6, multiple types, 116600 (3);
1.222;4;11;97;1p36.11;EXTL1;;Exostosin-like 1;601738;R, A;;;
1.223;8;28;02;1p36.11;HMGN2, HMG17;;High-mobility group nucleosomal binding protein 2;163910;REa, A;;;
1.224;4;1;01;1p36.12;HSPG2, PLC, SJS, SJA, SJS1;;Heparan sulfate proteoglycan of basement membrane (perlecan);142461;A, REa, LD;;Schwartz-Jampel syndrome, type 1, 255800 (3); Dyssegmental dysplasia, Silverman-Handmaker type, 224410 (3);4(Plc)
1.225;2;28;03;1p36.11;MDS2;;Myelodysplasia syndrome gene 2;607305;A;fused with ETV6 in myelodysplastic syndrome;;
1.226;3;6;01;1p36.11;NR0B2, SHP;;Nuclear receptor subfamily 0, group B, member 2;604630;REa, A;;Obesity, mild, early-onset, 601665 (3);
1.227;11;3;98;1p35.3;RNU17A, RNE1;;RNA, U17a small nucleolar;180645;REn;in IVS1 of CHC1;;
1.228;11;3;98;1p35.3;RNU17B;;RNA, U17b small nucleolar;603239;REn;;;
1.229;12;15;99;1p35.3;RNU17D, U17HG;;RNA, U17d small nucleolar;603238;REn;;;
1.230;8;30;09;1p36.11;RPS6KA1, RSK1;;Ribosomal protein S6 kinase, 90kD, 1;601684;REa, REc;;;
1.231;2;20;98;1p36.21;RSC1A1, RS1;;Regulatory solute carrier protein, family 1, member 1;601966;A;;;
1.232;12;19;11;1p36.11;SRSF10, FUSIP1, TASR, TASR1, TASR2;;Splicine factor, serine/arginine-rich, 10;605221;REc;pseudogenes on chr. 9, 12, 20;;
1.233;2;15;96;1p36.11;TCEB3;;Transcription elongation factor B (SIII), polypeptide 3 (110kD, elongin A);600786;A;;;
1.234;9;2;09;1q21.1;TRNAN1, TRN1, TRN;;tRNA asparagine;189880;REa, RE;;;
1.235;8;1;14;1p36.12;EPHB2, EPHT3, DRT, ERK, PCBC, CAPB;;eph tyrosine kinase 3 (ephrin receptor EphB2);600997;Psh, A, Fd;;{Prostate cancer/brain cancer susceptibility, somatic}, 603688 (3);4(Ephb2)
1.236;4;23;96;1p36.1-p35;MEMO1;;Methylation modifier for class I HLA;601201;D;;;
1.237;10;22;95;1p36.13;MFAP2, MAGP, MAGP1;;Microfibrillar-associated protein-2;156790;REa, A;;;4(Mfap2)
1.238;2;26;95;1p36.12;RAP1GA1;;RAP1, GTPase activating protein 1;600278;A, REa;;;
1.239;2;4;09;1p36.11;RPL11, DBA7;;Ribosomal protein L11;604175;REa, R, A;;Diamond-Blackfan anemia 7, 612562 (3);
1.240;07;16;18;1p36.13;SDHB, SDH2, SDHIP, PGL4;;Succinate dehydrogenase complex, subunit B, iron sulfur (Ip);185470;S, REa, A;1 of 2 polypeptides;Paragangliolas 4, 115310 (3); Pheochromocytoma, 171300 (3); Paraganglioma and gastric stromal sarcoma, 606864 (3); Gastrointestinal stromal tumor, 606444 (3);
1.241;4;2;15;1p36.11;SLC9A1, NHE1, APNH, LIKNS;;Solute carrier family 9 (sodium/hydrogen exchanger), member 1 (antiporter, Na+/H+, amiloride sensitive);107310;A, F, Fd;mutation identified in 1 LIKNS family;?Lichtenstein-Knorr syndrome, 616291 (3);4(Apnh, Nhe1)
1.242;7;17;01;1p36.11;STMN1, LAP18, SMN;;Stathmin;151442;REa, A;;;4(Lap18)
1.243;1;1;95;1p36.11;GPR3;;G protein-coupled receptor-3;600241;A;;;
1.244;3;17;94;1p35.3;OPRD1;;Opioid receptor, delta-1;165195;H, A;;;4(Nbor, Oprd1)
1.245;8;12;09;1p36.12;ALPL, HOPS, TNSALP;;Alkaline phosphatase, liver/bone/kidney;171760;S, H, Fd, F, A;;Hypophosphatasia, infantile, 241500 (3); Hypophosphatasia, childhood, 241510 (3); Odontohypophosphatasia, 146300 (3); Hypophosphatasia, adult, 146300 (3);4(Akp2)
1.246;3;17;06;1p36.31;ACOT7, BACH, LACH;;Acyl-CoA thioesterase 7;602587;REc;;;
1.247;2;15;06;1p36;AD7CNTP;;Alzheimer disease neuronal thread protein;607413;R, REc;;;
1.248;1;25;99;1p36.13;ALDH4A1, ALDH4, P5CDH;;Aldehyde dehydrogenase 4 family, member A1 (delta-1-pyrroline 5-carboxylate dehydrogenase);606811;A;;Hyperprolinemia, type II, 239510 (3);
1.249;11;7;08;1p36;ALPQTL2;;Alkaline phosphatase, plasma level of, QTL 2;612367;Fd;linkage with rs1780324;{Alkaline phosphatase, plasma level of, QTL 2} (2);
1.250;1;11;17;1p36.13;ATP13A2, PARK9, KRPPD, SPG78;;ATPase, type 13A2;610513;REc, Fd;mutation identified in 1 family with CLN12;Kufor-Rakeb syndrome, 606693 (3); Spastic paraplegia 78, autosomal recessive, 617225 (3);4(Atp13a2)
1.251;10;6;09;1p36;BCC1;;Basal cell carcinoma, susceptibility to, 1;605462;Fd;associated with rs7538876;{Basal cell carcinoma, susceptibility to, 1} (2);
1.252;5;14;02;1p36;BMND3;;Bone mineral density QTL 3;606928;Fd;?another locus at 3p21;[Bone mineral density QTL 3] (2);
1.253;8;31;12;1p36.31-p36.23;CAMTA1, KIAA0833, CANPMR;;Calmodulin-binding transcription activator 1;611501;REc;;Cerebellar ataxia, nonprogressive, with mental retardation, 614756 (3);
1.254;2;20;07;1p36.31;CHD5;;Chromodomain helicase DNA-binding protein 5;610771;REc, H;;;4(Chd5)
1.255;6;19;98;1p36.22;CLCN6;;Chloride channel 6;602726;REa, A;;;
1.256;11;3;09;1p36.13;CLCNKA;;Chloride channel, kidney, A;602024;Fd, REc;11kb from CLCNKB; simultaneous mutation in CLCNKA and CLCNKB;Bartter syndrome, type 4b, digenic, 613090 (3);
1.257;8;24;04;1p36.13;CLCNKB;;Chloride channel, kidney, B;602023;Fd, REc;unequal crossingover with CLCNKA;Bartter syndrome, type 3, 607364 (3); Bartter syndrome, type 4b, digenic, 613090 (3);
1.258;3;3;15;1p36.22;CLSTN1, KIAA0911;;Calsyntenin 1;611321;REc;;;4(Clstn1)
1.259;1;4;93;1p36;CMM, MLM, DNS;;Cutaneous malignant melanoma/dysplastic nevus;155600;F, Fd, D;some linkage studies negative; see 9p;{Melanoma, cutaneous malignant, 1} (2);
1.260;12;30;09;1p36.11;CNR2, CB2, CX5;;Cannabinoid receptor 2;605051;R, REc;;;
1.261;4;22;15;1p36.33;DVL1, DRS2;;Dishevelled 1 (homologous to Drosophila dsh);601365;Psh, A;;Robinow syndrome, autosomal dominant 2, 616331 (3);
1.262;2;01;01;1p36.22;CORT;;Cortistatin;602784;H, R, REc;;;4(Cort)
1.263;1;20;09;1p36;DEL1p36, C1DELp36;;Chromosome 1p36 deletion syndrome;607872;Ch;contiguous gene deletion syndrome;Chromosome 1p36 deletion syndrome (4);
1.264;3;13;06;1p36.23;DJ1, PARK7;;Oncogene DJ-1;602533;Fd, R;;Parkinson disease 7, autosomal recessive early-onset, 606324 (3);
1.265;2;23;95;1p36.12;E2F2;;E2F transcription factor 2;600426;A;;;
1.266;4;18;97;1p35.3;EYA3;;Eyes absent, Drosophila, homolog of, 3;601655;A, H;;;4(Eya3)
1.267;9;9;08;1p36.22;FBXO2, FBX2, FBG1, NFB42;;F-box only protein 2;607112;REc;;;4(Fbxo2)
1.268;5;29;12;1p36.22;H6PD, GDH, G6PDH, CORTRD1;;Hexose-6-phosphate dehydrogenase;138090;S, F;digenic triallelic mutations with HSD11B1;Cortisone reductase deficiency 1, 604931 (3);
1.269;6;9;09;1p36;IBD7;;Inflammatory bowel disease 7;605225;Fd;associated with rs6426833;{Inflammatory bowel disease 7} (2);
1.270;4;17;01;1p36.31;ICMT;;Isoprenylcysteine carboxylmethyltransferase;605851;R;;;
1.271;2;7;17;1p36.11;KDF1, C1orf172, ECTD12;;Keratinocyte differentiation factor 1;616758;REc, H;mutation identified in 1 ECTD12 family;?Ectodermal dysplasia 12, hypohidrotic/hair/tooth/nail type, 617337 (3);4(Kdf1)
1.272;4;2;01;1p36.12;LUZP1;;Leucine zipper protein 1;601422;H, R;;;4(Luzp)
1.273;12;16;16;1p36.22;MAD2L2, MAD2B, FANCV;;Mitotic arrest-deficient 2, S. cerevisiae, homolog-like 2;604094;R;mutation identified in 1 FANCV patient; pseudogene on 14q21-q23;?Fanconi anemia, complementation group V, 617243 (3);
1.274;9;16;03;1p36.23;MIG6, RALT;;Mitogen-inducible gene 6;608069;R, REc;;;
1.275;3;23;09;1p36.22;MIR34A, MIRN34A;;Micro RNA 34A;611172;REc;;;
1.276;2;23;09;1p36;MS4;;Multiple sclerosis, susceptibility to, 4;612596;Fd;associated with rs10492972;{Multiple sclerosis, susceptibility to, 4} (2);
1.277;7;22;11;1p36;MYP14;;Myopia 14;610320;Fd;between D1S552 and D1S1622;Myopia 14 (2);
1.278;12;30;02;1p36.31;NPHP4, SLSN4;;Nephrocystin 4;607215;Fd, REc;;Nephronophthisis 4, 606966 (3); Senior-Loken syndrome 4, 606996 (3);
1.279;7;9;06;1p36.32;PANK4;;Pantothenate kinase 4;606162;REn;;;
1.280;6;1;04;1p36.12;PINK1, PARK6;;PTEN-induced putative kinase 1;608309;R, REc, Fd;;Parkinson disease 6, early onset, 605909 (3);
1.281;4;24;18;1p36.31;PLEKHG5, KIAA0720, DSMA4, CMTRIC;;Pleckstrin homology domain- and RhoGEF domain-containing protein G5;611101;REc, Fd, R, Fd;;Spinal muscular atrophy, distal, autosomal recessive, 4, 611067 (3); Charcot-Marie-Tooth disease, recessive intermediate C, 615376 (3);
1.282;9;28;96;1p36.21;PRDM2, RIZ;;PR domain-containing protein 2 (retinoblastoma protein-binding zinc-finger protein RIZ);601196;REc, A;;;4(Riz)
1.283;7;09;06;1p36.33;PRKCZ, PKC2;;Protein kinase C, zeta form;176982;REc;;;
1.284;11;29;99;1p36.11;RUNX3, CBFA3, PEBP2A3, AML2;;Runt-related transcription factor 3;600210;A, REa;;;4(Aml2, Cbfa3)
1.285;6;4;13;1p36.32;SMIM1, VEL;;Small integral membrane protein 1;615242;REc;;[Blood group, Vel system], 615264 (3);
1.286;2;12;03;1p36.31;TAS1R1, T1R1;;Taste receptor type 1, member 1;606225;R, REc;;;4(T1r1)
1.287;2;12;03;1p36.13;TAS1R2, T1R2;;Taste receptor type 1, member 2;606226;R, REc;;;4(T1r2)
1.288;1;15;14;1p36.33;TNFRSF4, TXGP1L, OX40, ACT35, IMD16;;Tumor necrosis factor receptor superfamily, member 4;600315;A;mutation identified in 1 IMD16 family;?Immunodeficiency 16, 615593 (3);4(Ox40)
1.289;12;18;98;1p36.22;TNFRSF8, CD30, D1S166E;;Tumor necrosis factor receptor superfamily, member 8 (CD30 antigen; Ki-1 antigen);153243;A;;;4(Cd30)
1.290;12;18;98;1p36.23;TNFRSF9, ILA, CD137;;Tumor necrosis factor receptor superfamily, member 9 (interleukin-activated receptor; Ly63, mouse, homolog of);602250;REa;;;(Cd157)
1.291;11;13;18;1p36.32;TP73;;p53-related protein;601990;D;imprinted;;
1.292;9;2;09;1p36.13;TRNAE1, TRNE, TRE;;tRNA glutamic acid;180640;A;;;
1.293;4;21;17;1p36.12;USP48, USP31;;Ubiquitin-specific peptidase 48;617445;REc;;;
1.294;7;9;06;1p36.23;VAMP3;;Vesicle-associated membrane protein 3;603657;REc;;;
1.295;6;27;08;1p36.12;ZBTB40, KIAA0478;;Zinc finger- and BTB domain-containing protein 40;612106;REc;;;
1.296;1;2;08;1p36.12;ZNF436, KIAA1710;;Zinc finger protein 436;611703;REc;;;
1.297;5;29;02;1p36.11;GALE;;UDP galactose-4-epimerase;606953;S, LD;;Galactose epimerase deficiency, 230350 (3);
1.298;3;12;96;1p36.13;HTR6;;5-hydroxytryptamine (serotonin) receptor-6;601109;REa;;;
1.299;11;1;06;1p36.11;LDLRAP1, ARH, FHCB2, FHCB1;;Low density lipoprotein receptor adaptor protein 1;605747;Fd;;Hypercholesterolemia, familial, autosomal recessive, 603813 (3);
1.300;11;18;16;1p36.11;SELENON, SEPN1, SELN, RSMD1, CFTD;;Selenoprotein N;606210;REc, Fd;;Muscular dystrophy, rigid spine, 1, 602771 (3); Myopathy, congenital, with fiber-type disproportion, 255310 (3);
1.301;11;1;04;1p36-p34;DYX8;;Dyslexia, susceptibility to, 8;608995;Fd;between D1S552 and D1S1622;{Dyslexia, susceptibility to, 8} (2);
1.302;12;23;14;1p36.13;PLA2G5, FRFB;;Phospholipase A2, group V;601192;A;;[Fleck retina, familial benign], 228980 (3);4(Pla2g5)
1.303;5;4;00;1p34.3;PABPC4, PABP4, IPABP, APP1;;Polyadenylate-binding protein, cytoplasmic, 4;603407;Psh, R;;;
1.304;12;3;91;1p36.22;SRM, SPS1;;Spermidine synthase-1;182891;REa, A, Psh;?pseudogene on 3p14-q21;;
1.305;4;29;16;1p36.11;ARID1A, C1orf4, B120, SMARCF1, MRD14, CSS2;;AT rich interactive domain 1A, SWI-like;603024;A;;Coffin-Siris syndrome 2, 614607 (3);
1.306;1;15;13;1p35.3;ATP1F1, IF1;;ATPase inhibitory factor 1;614981;REc;;;
1.307;3;28;11;1p36.11;CATSPER4;;Cation channel, sperm-associated, 4;609121;REc;;;4(Catsper4)
1.308;1;27;04;1p35.1;CSMD2, KIAA1884;;Cub and Sushi multiple domains 2;608398;REc;;;
1.309;7;17;09;1p35.3;GMEB1;;Glucocorticoid modulatory element-binding protein 1;604409;R, REc;;;
1.310;1;9;17;1p35.3;MECR, NRBF1, DYTOABG;;Mitochondrial trans-2-enoyl-CoA reductase;608205;REc;;Dystonia, childhood-onset, with optic atrophy and basal ganglia abnormalities, 617282 (3);
1.311;11;7;08;1p35.3;MED18;;Mediator complex subunit 18;612384;REc;;;
1.312;2;21;07;1p36.11;PDIK1L;;PDLIM1-interacting kinase 1-like;610785;REc;;;
1.313;7;16;12;1p35.3;PHACTR4;;Phosphatase and actin regulator 4;608726;R, REc;;;
1.314;2;1;11;1p35.3;PTPRU, GLEPP1, PTPU2;;Protein tyrosine phosphatase, receptor type, U;602454;REc;;;
1.315;5;13;03;1p35.3;SEST2, HI95;;Sestrin 2;607767;A;;;9(Sest2)
1.316;10;25;17;1p35.3;SMPDL3B, ASML3B;;Sphingolyelin phosphodiesterase, acid-like, 3B;617737;REc;;;
1.317;12;19;11;1p35.3;SRSF4, SFRS4, SRp75;;Splicing factor, serine/arginine-rich, 4;601940;R, REc;;;
1.318;7;2;18;1p35.3;STX12, STX13;;Syntaxin 12;606892;REc;;;
1.319;9;22;08;1p35.3;TAF12;;TAF12 RNA polymerase II, TATA box-binding protein-associated factor, 20kD;600773;R, REc;;;
1.320;1;30;18;1p35.3;THEMIS2, C1orf38, ICB1;;Thymocyte selection-associated protein family, member 2;617856;REc;;;
1.321;12;18;14;1p34.3;MEAF6, C1orf149, EAF6;;MYST/ESA1-associated factor 6;611001;R, REc;;;
1.322;11;09;18;1p34.3;ADPRHL2, ARH3, CONDSIAS;;ADP-ribosylhydrolase-like 2;610624;REc;;Neurodegeneration, childhood-onset, stress-induced, with variable ataxia and seizures, 618170 (3);
1.323;1;9;13;1p34.3;ZC3H12A, MCPIP, MCPIP1;;Zinc finger CCCH domain-containing protein 12A;610562;REc;;;
1.324;8;8;13;1p35.2;HCRTR1, OX1R;;Hypocretin receptor 1;602392;REc, R;;;
1.325;7;16;09;1p35.2;NKAIN1;;Na+/K+ transporting ATPase-interacting 1;612871;REc;;;4(Nkain1)
1.326;5;3;18;1p35.2;PUM1, KIAA0099, SCA47;;Pumilio, Drosophila, homolog of, 1;607204;REa, REc;;Spinocerebellar ataxia 47, 617931 (3);
1.327;4;2;12;1p35.2;SERINC2;;Serine incorporator 2;614549;REc;;;
1.328;7;27;09;1p35.2;SNRNP40, SPF38, PRPF8BP;;Small nuclear ribonucleoprotein 40kDa (U5);607797;R, REc;;;
1.329;11;3;14;1p35.2;TINAGL1, TINAGRP;;Tubulointerstitial nephritis antigen-like protein 1;616064;REc;;;
1.330;9;24;08;1p36.11;RCAN3, DSCR1L2, MCIP3;;Regulator of calcineurin 3;605860;REc;;;4(Dscr1l2)
1.331;6;12;17;1p35.1;BSDC1;;BSD domain-containing protein 1;617518;REc;;;
1.332;11;23;11;1p35.2;CCDC28B, MGC1203;;Coiled-coil domain-containing protein 28B;610162;REc;;{Bardet-Biedl syndrome 1, modifier of}, 209900 (3);
1.333;8;29;02;1p34.3;DNALI1, P28;;Dynein, axonemal, light intermediate polypeptide 1;602135;REa, R;;;
1.334;3;20;08;1p35.1;FNDC5, FRCP2;;Fibronectin type III domain-containing protein 5;611906;R, REc, H;;;4(Fndc5)
1.335;2;18;96;1p34.3;GJA4, CX37;;Gap junction protein, alpha-4, 37kD (connexin 37);121012;REa, A, REc;;;(Gja4)
1.336;6;13;17;1p34.3;GJB3, CX31, DFNA2B, EKVP1;;Gap junction protein, beta-3;603324;REn, REc, Psh, A;same YAC as GJA4;Erythrokeratodermia variabilis et progressiva 1, 133200 (3); Deafness, autosomal dominant 2B, 612644 (3); Deafness, autosomal recessive (3); Deafness, autosomal dominant, with peripheral neuropathy (3); Deafness, digenic, GJB2/GJB3, 220290 (3);
1.337;6;13;17;1p34.3;GJB4, CX30.3, EKVP2;;Gap junction protein, beta-4;605425;REn, Fd;;Erythrokeratodermia variabilis et progressiva 2, 617524 (3);
1.338;11;29;00;1p34.3;GJB5, CX31.1;;Gap junction protein, beta-5;604493;R, REc;;;
1.339;1;3;17;1p35.1;HMGB4;;High mobility group box 4;617285;REc, H;;;4(Hmgb4)
1.340;3;26;07;1p35.1;IBRDC3, NKLAM;;IBR domain-containing protein 3;610872;R, REc;;;
1.341;5;26;13;1p35.2;KPNA6;;Karyopherin alpha-6;610563;R, REc;;;
1.342;1;14;16;1p35.1;TRIM62, DEAR1;;Tripartite motif-containing protein 62;616755;A;;;
1.343;7;17;14;1p35.1;ZBTB8OS, ARCH;;Zinc finger- and BTB domain-containing protein 8, opposite strand;615891;REc;;;
1.344;4;2;16;1p35.1;ZSCAN20, ZNF31, KOX29;;Zinc finger- and SCAN domain-containing protein 20;611315;REc;;;
1.345;9;1;16;1p35.2;ADGRB2, BAI2;;Adhesion G protein-coupled receptor B2;602683;A;;;
1.346;5;3;18;1p35;C1DELp35, DEL1p35;;Chromosome 1p35 deletion syndrome;617930;Ch;SRO 1.03 Mb containing 23 genes;Chromosome 1p35 deletion syndrome (4);
1.347;8;21;91;1p35;EBVS1;;Epstein-Barr virus integration site;132850;A;;;
1.348;3;21;93;1p35.3;G1P3, IFI616;;Interferon, alpha-inducible protein (clone IFI-6-16);147572;A, T;;;
1.349;5;26;98;1p35.2;MATN1, CRTM, CMP;;Matrilin 1, cartilage matrix protein;115437;REa, A, Fd;;;
1.350;3;19;10;1p36.13;PLA2G2A, PLA2B, PLA2L, MOM1;;Phospholipase A2, group IIA, platelets, synovial fluid;172411;REa, Fd;;{Colorectal cancer}, 114500 (3);4(Pla2g2a)
1.351;7;27;09;1p35.3;PPP1R8, NIPP1, ARD1;;Protein phosphatase-1, regulatory subunit-8;602636;REa, REc;;;
1.352;3;1;01;1p35.2;PTP4A2, PTP4A, PRL2, HH13;;Protein tyrosine phosphatase, type 4A, 2;601584;REc;;;
1.353;4;7;94;1p35.3;RPA2;;Replication protein A2, 32kD;179836;Psh, A;;;
1.354;11;22;16;1p36.12;WNT4, SERKAL;;Wingless-type MMTV integration site family, member 4;603490;A, R;mutation identified in 1 SERKAL family;?SERKAL syndrome, 611812 (3); Mullerian aplasia and hyperandrogenism, 158330 (3);4(Wnt4)
1.355;2;10;06;1p35.1;YARS, CMTDIC, TYRRS, YTS, YRS;;Tyrosyl-tRNA synthetase;603623;Fd, REc;;Charcot-Marie-Tooth disease, dominant intermediate C, 608323 (3);
1.356;8;26;15;1p35.3;YTHDF2;;YTH N6-methyladenosine RNA-binding protein 2;610640;Ch, REc;fused with AML1 in t(1;21);;
1.357;7;11;16;1p34.3;CSF3R, GCSFR, SCN7;;Colony-stimulating factor-3 receptor (granulocyte);138971;A, REb, Psh, REa;;Neutropenia, severe congenital, 7, autosomal recessive, 617014 (3);
1.358;5;22;14;1p35.2;LCK, IMD22;;Lymphocyte-specific protein tyrosine kinase;153390;A, H, Ch;LCK/TCRB fusion in leukemia; mutation identified in 1 IMD22 patient;?Immunodeficiency 22, 615758 (3);4(Lck)
1.359;9;29;96;1p35.3;PTAFR;;Platelet-activating factor receptor;173393;REa, A;;;
1.360;6;8;15;1p35.1;HPCA, DYT2;;Hippocalcin, 23kD, Ca2+-binding protein;142622;REa, REc;;Dystonia 2, torsion, autosomal recessive, 224500 (3);
1.361;4;23;08;1p34.3;MRPS15;;Mitochondrial ribosomal protein S15;611979;R, REc;;;
1.362;5;11;16;1p34.3;AGO1, EIF2C1, GERP95, EIF2C;;Argonaute 1, RISC catalytic component;606228;A;;;
1.363;7;1;02;1p34.2;CITED4;;CBP/P300-interacting transactivator, with glu/asp-rich carboxy terminal domain, 4;606815;A;;;
1.364;6;27;08;1p34.3;EIF2C3, AGO3;;Eukaryotic translation initiation factor 2C, subunit 3 (argonaute 3);607355;R, REc, H;;;4(Ago3)
1.365;7;23;03;1p34.3;EIF2C4, AGO4, KIAA1567;;Eukaryotic translation initiation factor 2C, 4 (argonaute 4);607356;R, REc, H;;;4(Eif2c4)
1.366;8;18;98;1p34.2;GUCA2A, GUCA2;;Guanylate cyclase activator 2A (guanylin 2, intestinal, heat-stable);139392;A;;;4(Guca2)
1.367;1;22;07;1p35.1;TSSK3, STK22C, STK22D;;Testis-specific serine/threonine kinase 3;607660;A;;;4(Stk22d)
1.368;1;30;12;1p34.2;EBNA1BP2, EBP2;;EBNA1-binding protein 2;614443;REc;;;
1.369;4;17;13;1p34.3;AKIRIN1;;Akirin 1;615164;REc;;;
1.370;9;10;12;1p34.3;C1orf109;;Chromosome 1 open reading frame 109;614799;REc;;;
1.371;3;24;06;1p34.3;CDCA8;;Cell division cycle-associated protein 8;609977;REc;possible pseudogene on chr.7;;
1.372;9;10;07;1p34.3;EPHA10;;Ephrin receptor EphA10;611123;REc;;;
1.373;2;28;06;1p34.3;GBD3;;Gallbladder disease 3;609919;Fd;new D2S255;Gallbladder disease 3 (2);
1.374;4;1;08;1p34.3;GJA9, CX59;;Gap junction protein, alpha-9;611923;REc;;;
1.375;5;16;05;1p34.3;GNL2, NGP1;;Guanine nucleotide-binding protein-like 2;609365;R, REc;;;
1.376;6;13;12;1p34.2;HEYL;;Hariy/enhancer of split-related with YRPW motif-like protein;609034;R, A;;;
1.377;7;7;13;1p34.3;KIAA0319L, KIAA1837;;KIAA0319-like;613535;R, REc;;;
1.378;4;6;18;1p34.3;LSM10;;Lsm10, U7 small nuclear RNA-associated protein;617909;REc;;;
1.379;2;2;14;1p34.2;MYCL, LMYC;;Oncogene MYC, lung carcinoma-derived;164850;REa, A, F, REn;;;4(Lmyc1)
1.380;2;16;04;1p34.3;NCDN, KIAA0607;;Neurochondrin;608458;R, REc;;;
1.381;1;15;09;1p34.3;RSPO1, FLJ40906;;Roof plate-specific spondin, mouse, homolog of, 1;609595;REc;;Palmoplantar hyperkeratosis with squamous cell carcinoma of skin and sex reversal, 610644 (3); Palmoplantar hyperkeratosis and true hermaphroditism, 610644 (3);
1.382;3;11;08;1p35.1;S100PBP, S100PBPR;;S100P-binding protein;611889;REc;;;
1.383;4;10;14;1p34.3;SF3A3, SF3A60, SAP61, PRP9;;Splicing factor 3A, subunit 3;605596;REc;;;
1.384;6;12;17;1p34.3;SNIP1, PMRED;;SMAD nuclear interacting protein 1;608241;REc;;Psychomotor retardation, epilepsy, and craniofacial dysmorphism, 614501 (3);
1.385;6;30;05;1p34.3;STK40, SHIK;;Serine/threonine protein kinase 40;609437;R, REc;;;
1.386;7;2;18;1p34.3;TEKT2, TEKTB1;;Tektin 2;608953;R, REc;;;
1.387;1;18;12;1p34.3;TFAP2E;;Transcription factor AP2-epsilon;614428;REc;;;
1.388;7;13;15;1p34.3;THRAP3, TRAP150;;Thyroid hormone receptor-associated protein 3;603809;REc;;;
1.389;5;21;07;1p34.3;TRAPPC3, BET3;;Trafficking protein particle complex, subunit 3;610955;R, REc;;;
1.390;6;30;05;1p34.3;UTP11L, CGI94;;UTP11-like protein;609440;R, REc;;;
1.391;8;27;15;1p34.3;ZMYM4, ZNF262, KIAA0425;;Zinc finger, MYM-type 4;613568;REc;;;
1.392;1;29;01;1p34.3;CLASPIN;;Claspin, Xenopus, homolog of;605434;REc;;;
1.393;1;23;08;1p35.1;SYNC1;;Syncoilin 1;611750;REc;;;
1.394;5;25;13;1p35.1;AZIN2, ODC1L, KIAA1945;;Antizyme inhibitor 2;608353;REc;;;
1.395;5;26;13;1p34.2;NT5C1A, CN1A, CNI, CN1;;5'-nucleotidase, cytosolic, IA;610525;REc;;;
1.396;2;25;10;1p34.3;COL8A2, FECD1, PPCD2;;Collagen VIII, alpha-2 polypeptide;120252;A;;Corneal dystrophy, Fuchs endothelial, 1, 136800 (3); Corneal dystrophy, posterior polymorphous 2, 609140 (3);
1.397;7;6;05;1p34.1;MUTYH, MYH;;MutY, E. coli, homolog of;604933;A;;Adenomas, multiple colorectal, 608456 (3); Gastric cancer, somatic, 613659 (3); Colorectal adenomatous polyposis, autosomal recessive, with pilomatricomas, 132600 (3);
1.398;11;12;12;1p34.2;BMP8B, OP2;;Bone morphogenetic protein-8b (osteogenic protein 2);602284;H, REc;;;4(Bmp8)
1.399;12;22;17;1p34.2;CAP1;;Cyclase-associated actin cytoskeleton regulatory protein 1;617801;REc;;;
1.400;11;30;06;1p34.2;CLDN19, HOMG5;;Claudin 19;610036;REc, Fd;;Hypomagnesemia 5, renal, with ocular involvement, 248190 (3);4(Cldn19)
1.401;7;13;17;1p34.2;COL9A2, EDM2, STL5;;Collagen IX, alpha-2 polypeptide;120260;REa, A, REn, Fd;mutation identified in1 STL5 family;Epiphyseal dysplasia, multiple, 2, 600204 (3); ?Stickler syndrome, type V, 614284 (3);4(Col9a2)
1.402;2;20;08;1p34.2;ELOVL1, SSC1;;Elongation of very long chain fatty acids-like 1;611813;REc;;;
1.403;10;12;14;1p34.2;FOXJ3, KIAA1041;;Forkhead box J3;616035;REc;;;
1.404;2;25;15;1p34.2;MED8;;Mediator complex subunit 8;607956;R, REc;;;
1.405;7;30;15;1p34.2;MFSD2A, MCPH15;;Major facilitator superfamily domain-containing protein 2A;614397;REc;;Microcephaly 15, primary, autosomal recessive, 616486 (3);
1.406;4;8;13;1p34.2;MIR30C1;;Micro RNA 30C-1;615151;REc;;;
1.407;8;19;04;1p34.3;NOR1;;Oxidored-nitro domain-containing protein 1;608854;REc;;;
1.408;5;24;13;1p34.2;OXCT2, FLJ0030;;3-oxoacid CoA transferase 2;610289;REc;;;
1.409;7;27;09;1p34.1;PIK3R3;;Phosphatidylinositol 3-kinase, regulatory, 3;606076;R, REc;;;
1.410;8;8;13;1p34.2;PPIE, CYP33;;Peptidyl-prolyl isomerase E;602435;REc, Psh, REa;;;
1.411;2;20;98;1p34.3;PSMB2;;Proteasome subunit, beta type, 2;602175;A;;;
1.412;12;17;15;1p34.2;SLC2A1, GLUT1, HTLVR, DYT18, PED, GLUT1DS, EIG12, DYT9, SDCHCN;;Solute carrier family 2 (facilitated glucose transporter), member 1;138140;REa, A, Fd;probably in 1p33;GLUT1 deficiency syndrome 1, infantile onset, severe, 606777 (3); GLUT1 deficiency syndrome 2, childhood onset, 612126 (3); {Epilepsy, idiopathic generalized, susceptibility to, 12}, 614847 (3); Dystonia 9, 601042 (3); Stomatin-deficient cryohydrocytosis with neurologic defects, 608885 (3);
1.413;4;22;16;1p34.2;SMAP2, SMAP1L;;Small ADP-ribosylation factor GTPase-activating protein 2;616916;REc;;;
1.414;1;25;18;1p34.2;SVBP, CCDC23;;Small vasohibin-binding protein;617853;REc;;;
1.415;11;1;13;1p34.2;SZT2, KIAA0467, EIEE18;;Seizure threshold 2, mouse, homolog of;615463;REc;;Epileptic encephalopathy, early infantile, 18, 615476 (3);
1.416;2;16;18;1p34.2;TRIT1, IPT, COXPD35;;tRNA isopentenyltransferase 1;617840;REc;;Combined oxidative phosphorylation deficiency 35, 617873 (3);
1.417;12;11;12;1p34.2;WDR65;;WD repeat-containing protein 65;614259;REc, H, Fd;;;1(Wdr65)
1.418;9;24;08;1p34.3;YRDC, IRIP;;YRDC domain-containing protein;612276;REc;;;4(Yrdc)
1.419;4;24;18;1p34.2;ZFP69, ZNF642;;Zinc finger protein 69;617939;REc;;;4(Zfp69)
1.420;5;21;02;1p34.2;CDC20;;Cell division cycle 20, S. cerevisiae, homolog of;603618;R;pseudogene on 9q13-q21;;
1.421;6;15;99;1p34.3;NDUFS5;;NADH dehydrogenase (ubiquinone) Fe-S protein 5, 15kD;603847;REa, R;;;
1.422;5;7;03;1p32.3;OSBPL9, ORP9;;Oxysterol-binding protein-like protein 9;606737;REc;;;
1.423;11;27;18;1p34.1;ARTN;;Artemin;603886;REc;;;
1.424;7;17;14;1p34.2;CTPS1, CTPS, IMD24;;Cytidine 5'-triphosphate synthetase 1;123860;REa, A;;Immunodeficiency 24, 615897 (3);
1.425;2;25;15;1p34.1;DNMAP1, DMAP1;;DNMT1-associated protein 1;605077;REc;;;
1.426;5;31;05;1p34.1;EIF2B3;;Eukaryotic translation initiation factor 2B, subunit 3;606273;R, REc;;Leukoencephalopathy with vanishing white matter, 603896 (3);
1.427;10;3;07;1p35.2;EIF3I, EIF3S2, TRIP1;;Eukaryotic translation initiation factor 3, subunit I;603911;A;pseudogene on 7q32;;
1.428;9;9;08;1p34.2;FOXO6;;Forkhead box O6;611457;REc;;;4(Foxo6)
1.429;2;24;97;1p35.2-p35.1;HDAC1, RPD3L1;;Histone deacetylase-1;601241;A;;;
1.430;9;7;12;1p34.1;IPO13, IMP13, KIAA0724, RANBP13;;Importin 13;610411;R, REc;;;
1.431;5;29;12;1p34.2-p34.1;KDM4A, JMJD2A, JHDM3A, KIAA0677;;Lysine-specific demethylase 4A;609764;R, REc;;;
1.432;8;24;04;1p34.1;KIF2C, KNSL6, MCAK;;Kinesin family, member 2C;604538;R, REc;;;
1.433;12;30;14;1p34.1;LURAP1, LRAP35A;;Leucine-rich adaptor protein 1;616129;REc;;;
1.434;9;24;08;1p34.1;MAST2, MAST205, KIAA0807;;Microtubule-associated serine/threonine kinase 2;612257;R, REc;;;
1.435;1;20;06;1p34.1;MMACHC;;MMACHC gene;609831;REn, Fd;;Methylmalonic aciduria and homocystinuria, cblC type, 277400 (3);
1.436;9;16;12;1p34.1;NASP;;Nuclear autoantigenic sperm protein;603185;REc;;;
1.437;3;6;18;1p34.1;PRDX1, PRXI, PAGA, NKEFA;;Peroxiredoxin 1;176763;A;pseudogene PAGB on 9p22;Methylmalonic aciduria and homocystinuria, cblC type, digenic, 277400 (3);
1.438;2;1;11;1p34.1;PLK3, CNK, PRK;;Polo-like kinase 3;602913;REc;previously assigned to 8p21 by FISH;;
1.439;4;13;98;1p34.3;POU3F1;;POU domain, class 3, transcription factor-1;602479;A;;;4(Pou3f1)
1.440;5;17;04;1p34.2;PPIH;;Peptidyl-prolyl isomerase H;606095;R;;;
1.441;2;23;08;1p34.2;RIMS3, NIM3, KIAA0137;;Protein regulating synaptic membrane exocytosis 3;611600;R, REc;;;
1.442;12;30;14;1p34.1;RNF220;;RING finger protein 220;616136;REc;;;
1.443;5;30;17;1p34.1;ST3GAL3, SIAT6, ST3GALII, MRT12, EIEE15;;ST3 beta-galactoside alpha-2,3-sialyltransferase 3;606494;R, REc;mutation identified in 1 EIEE15 family;Mental retardation, autosomal recessive 12, 611090 (3); ?Epileptic encephalopathy, early infantile, 15, 615006 (3);
1.444;1;4;08;1p34.1;TCTEX1D4;;TCTEX1 domain-containing 4;611713;REc;;;
1.445;4;20;17;1p34.1;TOE1, PCH7;;Target of EGR1;613931;REc;;Pontocerebellar hypoplasia, type 7, 614969 (3);
1.446;12;21;09;1p34.1;TSPAN1, NET1;;Tetraspanin 1;613170;REn;;;
1.447;3;31;11;1p33;UQCRH;;Ubiquinol-cytochrome c reductase hinge protein;613844;REc;pseudogene on 1p36;;
1.448;10;4;05;1p34.1;ZNF393;;Zinc finger protein-393;609602;REc, H;;;4(Znf393)
1.449;8;4;97;1p34.1-p32;PTOS1;;Ptosis, congenital 1, autosomal dominant;178300;A;;Ptosis, hereditary congenital, 1 (2);
1.450;2;1;95;1p34.1;RPS8;;Ribosomal protein S8;600357;REa, Psh, A;;;
1.451;8;24;09;1p35.1;AK2;;Adenylate kinase-2, mitochondrial;103020;S, F, R;;Reticular dysgenesis, 267500 (3);4(Ak2)
1.452;3;21;93;1p35.2;COL16A1;;Collagen XVI, alpha-1 polypeptide;120326;A, REa;;;
1.453;8;21;07;1p34.1;DPH2, DPH2L2;;DPH2, S. cerevisiae, homolog of;603456;A;;;
1.454;6;6;91;1p34.2;EDN2;;Endothelin-2;131241;REa, A;vasoactive intestinal contractor (VIC) = mouse and rat equivalent;;
1.455;11;13;18;1p33-p32;ELAVL4, HUD, PNEM;;Embryonic lethal, abnormal vision, Drosophila, homolog of, like-4 (Hu antigen D);168360;A, H;;;4(Hud)
1.456;12;28;05;1p34.2;ERMAP, SC, RD;;Erythroblast membrane-associated protein;609017;REc, H, F;;[Blood group, Scianna system], 111750 (3); [Blood group, Radin], 111620 (3);4(Ermap)
1.457;6;22;99;1p34.3;FHL3, SLIM2;;Four-and-a-half LIM domains-3;602790;R;;;
1.458;9;18;08;1p36.11;FUCA1;;Fucosidase, alpha-L- 1, tissue;612280;S, F, R, A, REa;8cM distal to RH; pseudogene on 2q31-q32;Fucosidosis, 230000 (3);4(Fuca)
1.459;2;4;02;1p34.2;HIVEP3, KRC;;Human immunodeficiency virus type 1 enhancer-binding protein 3;606649;REc;;;
1.460;10;9;94;1p34.3;INPP5B;;Inositol polyphosphate-5-phosphatase, 75kD;147264;REa, A;;;4(Inpp5b)
1.461;3;6;09;1p34.2;KCNQ4, DFNA2A;;Potassium voltage-gated channel, KQT-like subfamily, member 4;603537;A;;Deafness, autosomal dominant 2A, 600101 (3);
1.462;11;13;96;1p35.2;LAPTM5;;Lysosomal-associated multispanning membrane protein-5;601476;A;;;
1.463;10;09;07;1p32.3;LRP8, APOER2, MCI1;;Low density lipoprotein receptor-related protein 8 (Apolipoprotein E receptor 2);602600;REa, A, Fd;;{Myocardial infarction, susceptibility to}, 608446 (3);
1.464;6;7;10;1p35.1;MARCKSL1, MLP, MRP;;MARCKS-like protein 1;602940;H, Psh, A;;;4(Mlp)
1.465;3;9;12;1p34.2;MPL, TPOR, MPLV, THCYT2;;Myeloproliferative leukemia virus, homolog of;159530;A;;Thrombocytopenia, congenital amegakaryocytic, 604498 (3); Thrombocythemia 2, 601977 (3); Myelofibrosis with myeloid metaplasia, somatic, 254450 (3);
1.466;2;3;15;1p34.2;P3H1, LEPRE1, GROS1, OI8;;Prolyl 3-hydroxylase 1;610339;Psh, R, REc;;Osteogenesis imperfecta, type VIII, 610915 (3);
1.467;5;19;06;1p35.2;PEF1;;Peflin;610033;REc;;;
1.468;3;6;08;1p34.3;RRAGC, RAGC;;RAS-related GTP-binding protein C;608267;R, REc;;;
1.469;6;23;15;1p34.2;SCMH1;;Sex comb on midleg, Drosophila, homolog of, 1;616396;A;;;4(Scmh1)
1.470;8;31;01;1p34.3;SFPQ, PSF;;Splicing factor, proline- and glutamine-rich;605199;Ch;fusion gene with TFE3 in RCC;;
1.471;11;19;10;1p34.1;UROD;;Uroporphyrinogen decarboxylase;613521;S, A, REa;;Porphyria cutanea tarda, 176100 (3); Porphyria, hepatoerythropoietic, 176100 (3);4(Urod)
1.472;2;23;12;1p34.2;YBX1, NSEP1, YB1, DBPB;;Y box binding protein 1 (major histocompatibility complex, class II, Y box-binding protein I);154030;A;;;
1.473;6;23;05;1p34.2;ZMPSTE24, FACE1, STE24, MADB;;Zinc metalloproteinase STE24;606480;A, R;;Mandibuloacral dysplasia with type B lipodystrophy, 608612 (3); Restrictive dermopathy, lethal, 275210 (3);
1.474;10;9;94;1p34.3;GRIK3, GLUR7;;Glutamate receptor, ionotropic, kainate 3;138243;REa, A;;;
1.475;5;29;98;1p34.2;GUCA2B, UGN;;Guanylate cyclase activator 2B (uroguanylin);601271;A;;;4(Guca1b)
1.476;7;2;98;1p32.3;MAGOH;;Mago nashi, Drosophila, homolog of, proliferation-associated;602603;R;;;4(Magoh)
1.477;09;27;18;1p34.1;POMGNT1, MEB, MDDGA3, MDDGB3, MDDGC3, RP76, LGMDR15;;Protein 0-mannose beta-1,2-N-acetylglucosaminyltransferase;606822;Fd, LD;;Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 3, 253280 (3); Muscular dystrophy-dystroglycanopathy (congenital with mental retardation), type B, 3, 613151 (3); Muscular dystrophy-dystroglycanopathy (limb-girdle), type C, 3, 613157 (3); Retinitis pigmentosa 76, 617123 (3);
1.478;1;1;95;1p34.2;TIE, JTK14, TIE1;;Tyrosine kinase with immunoglobulin and epidermal growth factor homology domains;600222;A;;;
1.479;5;28;98;1p33;FOXD2, FKHL17, FREAC9;;Forkhead box D2;602211;A;;;
1.480;8;31;10;1p34-p32;MACST;;Macrostomia;613545;Ch;max lod at D1S2797;Macrostomia (2);
1.481;9;11;91;1p33;CYP4B1;;Cytochrome P450, subfamily IVB, polypeptide 1;124075;REa;;;4(Cyp4a)
1.482;11;4;91;1p31.3;DDIT1, GADD45;;DNA damage-inducible transcript-1;126335;REa;;;
1.483;7;28;15;1p33;AGBL4, CCP6;;ATP/GTP-binding protein-like 4;616476;REc;;;
1.484;1;11;07;1p33;CYP4A11;;Cytochrome P450, subfamily IVA, polypeptide 11;601310;Psh, REc;;;
1.485;8;2;13;1p33;CYP4A22;;Cytochrome P450, family 4, subfamily A, polypeptide 22;615341;REc;;;
1.486;1;9;13;1p33;CYP4X1, CYPIVX1;;Cytochrome P450, family 4, subfamily X, polypeptide 1;614999;REc;;;
1.487;5;28;15;1p33;DMBX1, OTX3;;Diencephalon/mesencephalon homeobox 1;607410;REc;;;
1.488;11;19;13;1p33;FAAH;;Fatty acid amide hydrolase;602935;R, REc;;{Drug addiction, susceptibility to}, 606581 (3);4(Faah)
1.489;3;18;11;1p32.3;FAF1, HFAF1;;Fas-associated factor 1;604460;REc;;;
1.490;10;13;09;1p33;KNCN, KINO, L5;;Kinocilin;611455;REc;;;4(Kncn)
1.491;7;17;09;1p33;MKNK1, MNK1;;Mitogen-activated protein kinase-interacting serine/threonine kinase 1;606724;R, REc;;;
1.492;11;3;94;1p34.3;MTF1;;Metal-regulatory transcription factor 1;600172;A;;;
1.493;5;30;17;1p33;NSUN4;;NOP2/SUN RNA methyltransferase family, member 4;615394;REc;;;
1.494;4;6;11;1p33;OFC13;;Orofacial cleft 13;613857;Fd;associated with rs3827730;Orofacial cleft 13 (2);
1.495;12;14;16;1p33;PDZK1IP1, MAP17;;PDZK1-interacting protein 1;607178;REc, H;near SLC in human, mouse, chicken, zebrafish;;
1.496;6;23;15;1p33;SKINTL, SKINTP;;SKINT1-like pseudogene;616392;REc;;;
1.497;1;20;17;1p34.1;SLC6A9, GLYT1, GCENSG;;Solute carrier family 6 (neurotransmitter transporter, glycine), member 9;601019;A;;Glycine encephalopathy with normal serum glycine, 617301 (3);4(Slc6a9)
1.498;5;3;11;1p33;SPATA6, SRF1, HASH;;Spermatogenesis-associated protein 6;613947;REc;;;
1.499;12;27;13;1p33;STIL, SIL, MCPH7;;SCL/TAL1-interrupting locus;181590;REn, REc;within about 250kb of SCL;Microcephaly 7, primary, autosomal recessive, 612703 (3);
1.500;12;10;12;1p33;TRABD2B, TIKI2;;TRAB domain-containing protein 2B;614913;REc;;;
1.501;9;8;06;1p34.1;BEST4, VMD2L2;;Bestrophin 4;607336;A;;;
1.502;9;10;12;1p32.3;DMRTA2;;Doublesex- and MAB3-related transcription factor A2;614804;REc;;;
1.503;5;4;09;1p33-p32;BMND14;;Bone mineral density quantitative trait locus 14;612728;Fd;associated with rs17131547;[Bone mineral density QTL 14] (2);
1.504;12;6;01;1p34.3;MYCBP;;MYC-binding protein;606535;A;;;
1.505;5;2;01;1p34.1;AKR1A1, ALR;;Aldo-keto reductase family 1, member A1 (aldehyde reductase);103830;A;;;
1.506;8;9;99;1p34.1;B4GALT2;;Beta-1,4-galactosyltransferase 2;604013;A, REc;;;
1.507;6;15;99;1p32.3;DIO1, TXDI1;;Deiodinase, iodothyronine, type I;147892;A;;;4(Dio1)
1.508;9;22;95;1p22.1;TGFBR3;;Transforming growth factor, beta receptor III (betaglycan, 300kD);600742;Psh, A;;;
1.509;10;31;01;1p32.3;DHCR24, KIAA0018;;24-dehydrocholesterol reductase;606418;REa, REc;;Desmosterolosis, 602398 (3);
1.510;1;27;11;1p33-p31.1;FWS;;Forsythe-Wakeling syndrome;613606;Fd;between rs2354462 and rs718883;Forsythe-Wakeling syndrome (2);
1.511;3;17;94;1p35.2;FABP3;;Fatty acid-binding protein 3, muscle;134651;REa, A;;;4(Fabph1)
1.512;3;24;06;1p32.3;ACOT11, THEA, BFIT, BFIT1, BFIT2, KIAA0707;;Acyl-CoA thioesterase 11;606803;REa, R, H;;;4(Thea)
1.513;11;19;13;1p34.1;ATP6V0B, ATP6F;;ATPase, H+ transporting, V0 subunit b;603717;A, R;;;4(Atp6v0b)
1.514;12;24;08;1q32.3;BATF3;;Basic leucine zipper transcription factor, ATF-like, 3;612470;REc;;;
1.515;4;6;18;1p32.3;LEXM, C1orf177, LEM;;Lymphocyte expansion molecule;616446;REc;;;
1.516;9;14;17;1p32.3;COA7, RESA1, SELRC1, C1orf163;;Cytochrome C oxidase assembly factor;615623;REc;mutation identified in 1 COX4D patient;?Mitochondrial complex IV deficiency, 220110 (3);
1.517;8;19;13;1p32.3;GLIS1;;Glis family zinc finger protein 1;610378;REc, R;;;4(Glis1)
1.518;11;3;14;1p32.3;PCSK9, NARC1, HCHOLA3, FH3, LDLCQ1;;Proprotein convertase, subtilisin/kexin-type, 9;607786;REc, Fd;;Hypercholesterolemia, familial, 3, 603776 (3); {Low density lipoprotein cholesterol level QTL 1}, 603776 (3);
1.519;5;17;04;1p32.3;PODN;;Podocan;608661;REc;;;
1.520;7;14;16;1p32.3;PRPF38A, PRP38A;;Precursor mRNA-processing factor 38, S. cerevisiae, homolog of, A;617031;REc;;;
1.521;7;3;06;1p32.3;TMEM48, NDC1;;Transmembrane protein 48;610115;R, REc;;;
1.522;8;18;16;1p32.3;TMEM59, DCF1;;Transmembrane protein 59;617084;REc;;;
1.523;6;30;05;1p32.3;TXNDC12, TLP19, ERP18;;Thioredoxin domain-containing protein 12;609448;REc;;;
1.524;5;13;09;1p32.3;USP24, KIAA1057;;Ubiquitin-specific protease 24;610569;R, REc;;;
1.525;6;12;17;1p32.3;YIPF1;;YIP1 domain family, member 1;617521;REc;;;
1.526;11;11;14;1p32.3;ZFYVE9, MADHIP, SARA;;Zinc finger, FYVE domain containing 9;603755;REc;;;
1.527;9;10;12;1p32.3;DMRTB1;;Doublesex- and MAB3-related transcription factor B1;614805;REc;;;
1.528;7;2;98;1p32.3;NRD1;;Nardilysin (N-arginine dibasic convertase);602651;A;;;
1.529;6;9;08;1p32.3;PARS2;;Prolyl-tRNA synthetase 2;612036;REc;;;
1.530;10;26;17;1p32.2;PLPP3, PPAP2B;;Phospholipid phosphatase 3;607125;REc;;;
1.531;8;18;16;1p32.2-p32.1;OMA1, MPRP1;;OMA1 zinc metallopeptidase;617081;R, REc;;;
1.532;7;7;15;1p32.1;FGGY, FLJ10986;;FGGY carbohydrate kinase domain-containing protein;611370;REc;;;
1.533;4;17;08;1p32.1;HOOK1, HK1;;Hook, Drosophila, homolog of, 1;607820;REc, A;;;4(Hook1)
1.534;3;5;08;1p32.3;MRPL37;;Mitochondrial ribosomal protein L37;611843;REc;;;
1.535;09;26;18;1p32.1;MYSM1, 2ADUB, KIAA1915, BMFS4;;MYB-like, SWIRM, and MPN domains-containing protein 1;612176;REc;;Bone marrow failure syndrome 4, 618116 (3);
1.536;8;10;16;1p31.3;DNAJC6, DJC6, KIAA0473, PARK19;;DNAJ, E. coli, homolog of, subfamily C, member 6;608375;R, REc;;Parkinson disease 19a, juvenile-onset, 615528 (3); Parkinson disease 19b, early-onset, 615528 (3);
1.537;6;18;99;1p31.3;USP1;;Ubiquitin-specific protease 1;603478;A, R;;;
1.538;4;14;11;1p32.2;C8A;;Complement component-8, alpha polypeptide;120950;F, A, Ch, Fd;;C8 deficiency, type I, 613790 (3);
1.539;3;10;11;1p32.2;C8B;;Complement component-8, beta polypeptide;120960;F, A, Ch, H, Fd;;C8 deficiency, type II, 613789 (3);4(C8b)
1.540;10;6;08;1p32.3;CDCP2;;Cub domain-containing protein 2;612320;REc;?associated with PARK10;;
1.541;6;18;99;1p32.3;CDKN2C, INK4C;;Cyclin-dependent kinase inhibitor 2C;603369;A;;;
1.542;12;31;16;1p32.3;CPT2, IIAE4;;Carnitine palmitoyltransferase II;600650;REa, A;formerly at 1p13;CPT II deficiency, myopathic, stress-induced, 255110 (3); CPT II deficiency, infantile, 600649 (3); CPT II deficiency, lethal neonatal, 608836 (3); {Encephalopathy, acute, infection-induced, 4, susceptibility to}, 614212 (3);
1.543;11;13;94;1p32.3;EPS15;;Epidermal growth factor receptor pathway substrate-15;600051;REc;;;
1.544;2;15;17;1p33;FOXE3, FKHL12, ASMD, CTRCT34, ASGD2, AAT11;;Forkhead box E3;601094;A;;Anterior segment dysgenesis 2, multiple subtypes, 610256 (3); Cataract 34, multiple types, 612968 (3); {Aortic aneurysm, familial thoracic 11, susceptibility to}, 617349 (3);
1.545;6;22;14;1p32.3;GPX7, NPGPX;;Glutathione peroxidase 7;615784;REc;;;
1.546;5;24;13;1p35.2;KHDRBS1, SAM68;;KH domain-containing, RNA-binding, signal transduction-associated protein 1;602489;REc;;;
1.547;1;30;01;1p34.2;NFYC, CBFC;;Nuclear transcription factor Y, gamma;605344;REc, H;;;4(Nfyc)
1.548;5;15;11;1p32.3;ORC1, ORC1L;;Origin recognition complex, subunit 1, S. cerevisiae, homolog;601902;Psh, A;;Meier-Gorlin syndrome 1, 224690 (3);
1.549;4;10;15;1p32;PARK10, AAOPD;;Parkinson disease 10;606852;Fd;max lod at D1S2652; ?associated with CDCP2;{Parkinson disease 10} (2);
1.550;1;5;12;1p34.2;PPT1, CLN1;;Palmitoyl-protein thioesterase 1;600722;Fd, LD, REn, A, REc;;Ceroid lipofuscinosis, neuronal, 1, 256730 (3);
1.551;3;1;06;1p34.1;PRNPIP, PINT1;;Prion protein-interacting protein;609917;REc, R;;;
1.552;1;20;17;1p34.1;PTCH2;;Patched, Drosophila, homolog of, 2;603673;R, Psh;;Medulloblastoma, somatic, 155255 (3); Basal cell carcinoma, somatic, 605462 (3); Basal cell nevus syndrome, 109400 (3);4(Ptch2)
1.553;9;10;14;1p34.2;PTPRF, LAR, BNAH2;;Protein tyrosine phosphatase, receptor type, f polypeptide;179590;A;mutation identified in 1 BNAH2 family;?Breasts and/or nipples, aplasia or hypoplasia of, 2, 616001 (3);4(Ptprf)
1.554;1;25;12;1p34.1;RAD54L, HR54, HRAD54;;RAD54, S. cerevisiae, homolog-like;603615;A;;{Breast cancer, invasive ductal}, 114480 (3); Lymphoma, non-Hodgkin, somatic, 605027 (3); Adenocarcinoma, colonic, somatic (3);
1.555;1;26;93;1p34.2;RLF;;Rearranged L-myc fusion sequence;180610;REa, REn;<800kb from MYCL1;;
1.556;5;1;17;1p32.3;SCP2;;Sterol carrier protein-2;184755;Psh, REa;mutation identified in 1 LKDMN patient;?Leukoencephalopathy with dystonia and motor neuropathy, 613724 (3);4(Scp2)
1.557;9;3;10;1p32;STQTL23;;Stature quantitative trait locus 23;613548;Fd;linked to rs628667;{Stature QTL 23} (2);
1.558;6;10;02;1p32.1;TACSTD2, TROP2, M1S1;;Tumor-associated calcium signal transducer 2;137290;REa, A;;Corneal dystrophy, gelatinous drop-like, 204870 (3);
1.559;8;27;15;1p33;TAL1, TCL5, SCL;;T-cell acute lymphocytic leukemia-1;187040;Ch, RE;proximal to MYCL1;Leukemia, T-cell acute lymphocytic, somatic, 613065 (3);4(Scl)
1.560;5;25;13;1p34.1;TESK2;;Testis-specific protein kinase 2;604746;A;;;
1.561;2;12;08;1p33;CMPK1, CMPK, UMPK, UMK, CMK;;Cytidine monophosphate (UMP-CMP) kinase 1, cytosolic;191710;S, R, F;;;
1.562;7;28;17;1p32.2;DAB1, SCA37;;Disabled, Drosophila, homolog 1;603448;R, H, Fd;;Spinocerebellar ataxia 37, 615945 (3);4(Dab1)
1.563;8;21;91;1p32.1;JUN;;Avian sarcoma virus 17 (v-jun) oncogene homolog;165160;REa, A, H;;;4(Jun)
1.564;2;16;04;1p34.3;MACF1, ACF7, KIAA1251;;Microtubule-actin cross-linking factor 1;608271;R, REc, A;;;4(Macf1)
1.565;4;11;11;1p31.1;NEXN, NELIN, CMD1CC, CMH20;;Nexilin, rat, homolog of;613121;REc;;Cardiomyopathy, dilated, 1CC, 613122 (3); Cardiomyopathy, hypertrophic, 20, 613876 (3);
1.566;9;13;89;1p32.3;RAB3B;;Brain antigen RAB3B;179510;REb, A;;;
1.567;2;17;09;1p32.3;RNF11;;Ring finger protein 11;612598;Psh, R;;;
1.568;1;22;09;1p31.3;SLC35D1, UGTREL7, KIAA0260, SHNKND;;Solute carrier family 35 (UDP-glucuronic acid/UDP-N-acetylgalactosamine dual transporter), member D1;610804;R, A;;Schneckenbecken dysplasia, 269250 (3);
1.569;8;8;91;1p21.2;VCAM1;;Vascular cell adhesion molecule-1;192225;REa, A;;;3(Vcam1)
1.570;3;21;93;1p34.1;IPP;;Intracisternal A particle-promoted polypeptide;147485;REa;;;4(Ipp)
1.571;3;1;05;1p31.3;AK3;;Adenylate kinase-3, mitochondrial;103030;REc, H;;;4(Ak3)
1.572;4;2;16;1p31.3;ATG4C, APG4C;;Autophagy 4, S. cerevisiae, homolog of, C;611339;REc;;;
1.573;8;3;12;1p31.3;DIRAS3, ARHI;;DIRAS family, GTP-binding RAS-like protein 3;605193;Psh, A;;;
1.574;6;26;14;1p31.3;DOCK7, KIAA1771, EIEE23;;Dedicator of cytokinesis 7;615730;REc;;Epileptic encephalopathy, early infantile, 23, 615859 (3);4(Dock7)
1.575;8;28;17;1p31.3;EFCAB7, KIAA1799;;EF-hand calcium-binding domain-containing protein 7;617632;REc;;;
1.576;9;23;13;1p31.3;GNG12;;Guanine nucleotide-binding protein, gamma 12;615405;REc, R;;;6(Gng12)
1.577;9;23;13;1p31.3;GNG12AS1;;GNG12 antisense RNA 1;615406;REc;;;
1.578;1;12;11;1p31.3;IL23R, IBD17;;Interleukin 23 receptor;607562;REc;;{Inflammatory bowel disease 17, protection against}, 612261 (3); {Psoriasis, protection against}, 605606 (3);
1.579;07;28;18;1p31.3;PATJ, INADL;;PALS1-associated tight junction protein;603199;REc, R;;;
1.580;7;17;09;1p31.3;ITGB3BP, NRIF3;;Integrin, beta-3, binding protein of;605494;R, REc;;;
1.581;7;10;93;1p31.3;JAK1;;Janus kinase 1 (a protein-tyrosine kinase);147795;REa, A, Fd;related gene on 9p24;;4(Jak1)
1.582;5;4;12;1p31.3;KANK4;;KN motif- and ankyrin repeat domain-containing protein 4;614612;REc;;;
1.583;3;8;16;1p31.3;MEIR1, KIAA1610;;Mesoderm induction-early response protein 1;616848;REc;;;
1.584;3;23;09;1p31.3;MIR101-1, MIRN101-1;;Micro RNA 101-1;612511;REc;another locus, MIRN101-2, on 9p24;;
1.585;3;14;13;1p31.3;OPHLC, C1DUPp31.3, DUP1p31.3;;Omphalocele due to duplication of 1p31.3;164750;Ch;duplication of 710kb at 1p31.3;Omphalocele due to duplication of 1p31.3 (4);
1.586;3;14;06;1p31.3;RAVER2, KIAA1579;;Raver2, mouse, homolog of;609953;R, REc;;;
1.587;8;31;17;1p31.3;ROR1, NTRKR1;;Receptor tyrosine kinase-like orphan receptor 1;602336;A;mutation identified in 1 DFNB108 family;?Deafness, autosomal recessive 108, 617654 (3);
1.588;7;14;14;1p31.3;SERBP1, PAIRBP1;;Serpine1 mRNA-binding protein 1;607378;REc;;;
1.589;8;20;08;1p31.3;SGIP1;;SH3-domain GRB2-like (endophilin)-interacting protein 1;611540;REc;;;
1.590;12;5;02;1p32.3;SSBP3;;Single-stranded DNA-binding protein 3;607390;REc;;;
1.591;8;19;13;1p31.3;TM2D1, BBP;;TM2 domain-containing protein 1;610080;R, REc;;;
1.592;5;6;03;1p32.3;TTC4;;Tetratricopeptide repeat domain 4;606753;A;pseudogene on 7p14-p13;;
1.593;5;26;13;1p31.1;TYW3;;tRNA-wybutosine-synthesizing protein 3, S. cerevisiae, homolog of;611245;REc;;;
1.594;9;23;13;1p31.3;WLS, GPR177, EVI;;WNTless, Drosophila, homolog of;611514;REc, R;;;
1.595;7;2;98;1p32.1;CYP2J2;;Cytochrome P450, subfamily IIJ (arachidonic acid epoxygenase), polypeptide 2;601258;REa, A;;;4(Cyp2j2)
1.596;10;30;17;1p31.3;NFIA, BRMUTD;;Nuclear factor I/A;600727;A;;Brain malformations with or without urinary tract defects, 613735 (3);4(Nfia)
1.597;11;13;12;1p31.3-p31.1;POROK5, DSAP3;;Porokeratosis 5, disseminated superficial actinic;612293;Fd;between D1S438 and D1S464;Porokeratosis 5, disseminated superficial actinic (2);
1.598;4;24;08;1p31.3;DEPDC1;;DEP domain-containing 1;612002;REc;;;
1.599;6;9;98;1p31.3;IL12RB2;;Interleukin 12 receptor, beta-2;601642;A, Psh, R;;;
1.600;9;10;09;1p31.2;PBC3;;Biliary cirrhosis, primary, 3;613008;Fd;associated with rs3790567;{Biliary cirrhosis, primary, 3} (2);
1.601;6;15;95;1p31.1;PTGER3, EP3;;Prostaglandin E receptor 3, EP3 subtype;176806;A;;;3(Ptger3)
1.602;6;30;15;1p31.1;ADGRL2, LPHN2, LPHH1, CIRL2, CL2, KIAA0786;;Adhesion G protein-coupled receptor L2;607018;Ch, REc;;;
1.603;6;30;15;1p31.1;ADGRL4, ETL, ELTD1;;Adhesion G protein-coupled receptor L4;616419;R, H, REc;;;3(Adgrl4)
1.604;4;5;13;1p31.1;ANKRD13C;;Ankyrin repeat domain-containing protein 13C;615125;RE;;;
1.605;5;31;05;1p31.1;CTH;;Cystathionine gamma-lyase;607657;R, REc;previously assigned to chr.16;Cystathioninuria, 219500 (3); Homocysteine, total plasma, elevated (3);
1.606;4;2;16;1p31.1;DNAJB4, HLJ1;;DNAJ/HSP40 homolog, subfamily B, member 4;611327;REc;;;
1.607;1;29;16;1p31.1;FAM73A, MIGA1;;Miga, Drosophila, homolog of, 1;616773;REc;;;
1.608;5;25;13;1p31.1;FPGT, GFPP;;Fucose-1-phosphate guanylyltransferase;603609;REc;;;
1.609;6;1;09;1p31.1;FUBP1, FUBP, FBP;;Far upstream element-binding protein 1;603444;REc;;;
1.610;5;25;13;1p31.1;HHLA3;;Human endogenous retrovirus-H long terminal repeat-associating 3;604372;REc;;;
1.611;6;11;11;1p31.1;IFI44L;;Interferon-induced protein 44-like;613975;REc;;;
1.612;3;14;07;1p31.1;IFI44, P44;;Interferon-induced protein 44;610468;R, REc;;;
1.613;12;3;07;1p31.1;LHX8;;LIM homeobox 8;604425;REc;;;
1.614;1;30;12;1p31.1;LRRC7, DENSIN, KIAA1365;;Leucine-rich repeat-containing protein 7;614453;Psh, REc;;;
1.615;5;9;18;1p31.1;LRRIQ3, LRRC44;;Leucine rich repeats- and IQ motif-containing protein 3;617957;REc;;;
1.616;12;21;09;1p31.1;NEGR1, KILON;;Neuronal growth regulator 1;613173;REc;;;
1.617;7;27;09;1p31.1;PIGK, GPI8;;Phosphatidylinositol glycan, class K;605087;REa, REc;;;
1.618;4;18;11;1p31.1;PRKACB;;Protein kinase, cAMP-dependent, catalytic, beta;176892;REa, A, REc;;;
1.619;6;16;95;1p31.1;PTGFR;;Prostaglandin F receptor (FP);600563;A;;;3(Ptgfr)
1.620;12;19;11;1p31.1;SRSF11, SFRS11;;Splicing factor, serine/arginine-rich, 11;602010;REc;;;
1.621;8;19;13;1p31.1;ST6GALNAC3, SIAT7C;;ST6 alpha-N-acetyl-neuraminyl-2,3-beta-galactosyl-1, 3-N-acetylgalactosaminide alpha-2,6-sialyltransferase 3;610133;R, REc;;;
1.622;7;8;09;1p31.1;ST6GALNAC5, SIAT7E;;ST6 alpha-N-acetyl-neuraminyl-2,3-beta-galactosyl-1, 3-N-acetylgalactosaminide alpha-2,6 sialyltransferase 5;610134;REc;;;
1.623;11;09;18;1p31.1;TNNI3K, CCDD;;TNNI3-interacting kinase;613932;REc;;Cardiac conduction disease with or without dilated cardiomyopathy, 616117 (3);
1.624;4;8;13;1p31.1;USP33, VDU1;;Ubiquitin-specific protease 33;615146;R, REc;;;
1.625;11;1;01;1p31.3;INSL5;;Insulin-like 5;606413;R;;;
1.626;6;27;08;1p22.3;LPAR3, EDG7, LPA3;;Lysophosphatidic acid receptor 3;605106;R, H;;;3(Edg7)
1.627;4;27;12;1p31.1-p21.1;SPG29;;Spastic paraplegia 29, autosomal dominant;609727;Fd;max lod at D1S2865;Spastic paraplegia 29, autosomal dominant (2);
1.628;6;26;02;1p31.1;ACADM, MCAD;;Acyl-Coenzyme A dehydrogenase, C-4 to C-12 straight chain;607008;REa,A;;Acyl-CoA dehydrogenase, medium chain, deficiency of, 201450 (3);3(Acadm)
1.629;1;12;07;1p31.1;AK5;;Adenylate kinase 5;608009;R;;;
1.630;5;8;97;1p31;AIR;;Acute insulin response;601676;Fd;;Acute insulin response (2);
1.631;11;19;11;1p31.3;FOXD3, AIS1, VAMAS2;;Forkhead box D3;611539;Fd, Psh, H;;{Autoimmune disease, susceptibility to, 1}, 607836 (3);4(Foxd3)
1.632;1;7;11;1p31.3;ANGPTL3, ANGPT5, FHBL2;;Angiopoietin-like 3;604774;R, H;;Hypobetalipoproteinemia, familial, 2, 605019 (3);4(Angptl3, hypl)
1.633;4;17;07;1p31;ASRT4;;Asthma-related traits, susceptibility to, 4;610906;Fd;max lod at D1S2890;{Asthma-related traits, susceptibility to, 4} (2);
1.634;11;3;09;1p32.3;BSND;;Barttin;606412;Fd, REc;;Bartter syndrome, type 4a, 602522 (3); Sensorineural deafness with mild renal dysfunction, 602522 (3);
1.635;11;6;98;1q22;CLK2;;CDC-like kinase 2;602989;Psh, REn;near GDLD and PRKAA2; conflicting assignment 1q21;;
1.636;6;20;91;1p21.2;DBT, BCATE2;;Dihydrolipoamide branched chain transacylase (E2 component of branched chain keto acid dehydrogenase complex);248610;REa, A;pseudogene on 3q24;Maple syrup urine disease, type II, 248600 (3);
1.637;12;11;12;1p31.3;LEPR, OBR, LEPRD;;Leptin receptor;601007;H, REc, R, Fd;;Obesity, morbid, due to leptin receptor deficiency, 614963 (3);4(Lepr)
1.638;9;7;10;1p31.3;LEPROT, OBRGRP;;Leptin receptor overlapping transcript;613461;REc;transcribed in same direction as LEPR;;
1.639;6;2;98;1p31.1;MSH4;;mutS, E. coli, homolog of, 4;602105;A;;;
1.640;7;17;14;1p31;OFC14;;Orofacial cleft 14;615892;Fd;;Orofacial cleft 14 (2);
1.641;3;26;02;1p31;PAOD1;;Peripheral arterial occlusive disease 1;606787;Fd;;Peripheral arterial occlusive disease 1 (2);
1.642;10;9;94;1p31.3;PDE4B, DPDE4;;Phosphodiesterase-4B, cAMP-specific (dunce-like phosphodiesterase E4);600127;RE, A;;;4(Pde4b)
1.643;6;3;14;1p31.3;PGM1, GSD14, CDG1T;;Phosphoglucomutase-1;171900;F, S, R;distal to ACADM; formerly 1p22.1;Congenital disorder of glycosylation, type It, 614921 (3);4(Pgm2)
1.644;3;9;98;1p31.1;PIN1L;;Peptidyl-prolyl cis/trans isomerase, NIMA-interacting-like;602051;A;?transcribed pseudogene;;
1.645;8;17;98;1p32.2;PRKAA2, AMPK;;Protein kinase, AMP-activated, alpha-2 catalytic subunit;600497;Psh, A;;;
1.646;2;12;01;1p31.1;RABGGTB;;Rab geranylgeranyltransferase, beta subunit;179080;REa, A;;;3(Rabggtb)
1.647;5;21;18;1p31.3;RPE65, RP20, LCA2;;RPE65 retinoid isomerohydrolase;180069;REa, A, Fd;;Leber congenital amaurosis 2, 204100 (3); Retinitis pigmentosa 20, 613794 (3);3(Rpe65)
1.648;11;18;16;1p22.3;SELENOF, SEP15;;Selenoprotein F;606254;REc;;;
1.649;1;11;95;1p31.1;CRYZ;;Crystallin, zeta (quinone reductase);123691;REa, A;;;
1.650;8;12;01;1p31-p21;AVSD1, AVCD;;Atrioventricular septal defect, susceptibility to, 1;606215;Fd;;{Atrioventricular septal defect, susceptibility to, 1} (2);
1.651;1;30;01;1p31.3;ALG6, CDG1C;;Alg6, S. cerevisiae, homolog of;604566;REc;;Congenital disorder of glycosylation, type Ic, 603147 (3);
1.652;3;11;16;1p22.3;CLCA1, CACC1;;Chloride channel accessory 1;603906;A;;;
1.653;3;11;16;1p22.3;CLCA2;;Chloride channel accessory 2;604003;R;;;
1.654;3;11;16;1p22.3;CLCA3;;Chloride channel accessory 3;604337;R, REc;;;
1.655;3;11;16;1p22.3;CLCA4, CACC2;;Chloride channel accessory 4;616857;REc;;;3(Clca4)
1.656;5;19;06;1p22.3;COL24A1;;Collagen, type XXIV, alpha-1;610025;REc, R;;;
1.657;01;26;00;1p22.3;CYR61, IGFBP10;;Cysteine-rich angiogenic inducer, 61 (insulin-like growth factor-binding protein-10);602369;A;;;3(Igfbp10)
1.658;3;11;09;1p31.1-p22.3;DNASE2B, DLAD;;Deoxyribonuclease II beta;608057;A;;;
1.659;1;30;01;1p22.3;LMO4;;LIM domain only 4;603129;A;;;3(Lmo4)
1.660;11;11;14;1p22.2;BARHL2;;BARH-like 2;605212;R;;;
1.661;8;28;09;1p22.3;MCOLN3;;Mucolipin 3;607400;R, H, REc;;;3(Mcoln3)
1.662;5;9;18;1p22.3;WDR63;;WD repeat-containing protein 63;617968;REc;;;
1.663;1;28;08;1p22.2;CCBL2, KAT3;;Cysteine conjugate beta-lyase 2;610656;REc;;;3(Kat3)
1.664;4;3;14;1p22.2;HFM1, MER3, POF9;;Hfm1, ATP-dependent DNA helicase, S. cerevisiae, homolog of;615684;REc;;Premature ovarian failure 9, 615724 (3);
1.665;12;23;08;1p22.2;GBP1;;Guanylate binding protein 1, interferon-inducible, 67kD;600411;REa, REc;;;3(Gbp1)
1.666;12;24;08;1p22.2;GBP2;;Guanylate-binding protein 2, interferon-inducible;600412;REc;;;
1.667;12;24;08;1p22.2;GBP3;;Guanylate-binding protein 3;600413;REc;;;
1.668;12;24;08;1p22.2;GBP4;;Guanylate-binding protein 4;612466;REc;;;
1.669;12;24;08;1p22.2;GBP5;;Guanylate-binding protein 5;611467;REc;;;
1.670;12;24;08;1p22.2;GBP6;;Guanylate-binding protein 6;612467;REc;;;
1.671;12;24;08;1p22.2;GBP7;;Guanylate-binding protein 7;612468;REc;;;
1.672;7;22;09;1p22.2;LRRC8B, TALRRP, KIAA0231;;Leucine-rich repeat-containing protein 8B;612888;REc;;;5(Lrrc8b)
1.673;7;22;09;1p22.2;LRRC8C, FAD158, AD158;;Leucine-rich repeat-containing protein 8C;612889;REc;;;5(Lrrc8c)
1.674;7;22;09;1p22.2;LRRC8D, LRRC5;;Leucine-rich repeat-containing protein 8D;612890;REc;;;5(Lrrc8d)
1.675;11;30;06;1p22.2;PKN2, PRKCL2, PRK2, PAK2;;Protein kinase N2;602549;REc, R;;;
1.676;7;18;14;1p22.2;GTF2B, TFIIB, TF2B;;General transcription factor IIb;189963;REc;;;
1.677;4;27;12;1p22.2;ZNF326, ZIRD;;Zinc finger protein 326;614601;REc;;;
1.678;8;25;11;1p22.2;ZNF644, MYP21;;Zinc finger protein 644;614159;REc;;Myopia 21, autosomal dominant, 614167 (3);
1.679;7;21;14;1p22.1;ABCA4, ABCR, STGD1, FFM, RP19, CORD3, ARMD2;;ATP-binding transporter, retina-specific;601691;R, REc, Fd;;Stargardt disease 1, 248200 (3); Retinitis pigmentosa 19, 601718 (3); Cone-rod dystrophy 3, 604116 (3); {Macular degeneration, age-related, 2}, 153800 (3); Fundus flavimaculatus, 248200 (3); Retinal dystrophy, early-onset severe, 248200 (3);
1.680;1;14;07;1p22.1;ARHGAP29, PARG1;;RHO GTPase-activating protein 29;610496;R, REc;;;
1.681;7;18;14;1p22.1;BCAR3, SH2D3B, NSP2;;Breast cancer antiestrogen resistance 3;604704;REc;;;
1.682;8;30;17;1p22.1;BRDT, SPGF21;;Bromodomain, testis-specific;602144;R, REc;mutation identified in 1 SPGF21 patient;?Spermatogenic failure 21, 617644 (3);
1.683;5;23;13;1p22.1;DNTTIP2, ERBP, FCF2;;DNTT-interacting protein 2;611199;REc;;;
1.684;11;13;96;1p22.1;DR1;;Down-regulator of transcription 1, TBP-binding (negative cofactor 2);601482;A;;;
1.685;3;27;17;1p22.1;EPHX4, ABHD7;;Epoxide hydrolase 4;617401;REc;;;
1.686;4;2;12;1p22.1;FAM69A;;Family with sequence similarity 69, member A;614542;REc;;;
1.687;9;16;12;1p22.1;FNBP1L, TOCA1, C1orf39;;Formin binding protein 1-like;608848;REc;;;
1.688;11;2;11;1p22.1;GCLM, GLCLR;;Glutamate-cysteine ligase, modifier subunit;601176;REa, A, REc;;{Myocardial infarction, susceptibility to}, 608446 (3);3(Glclr)
1.689;4;24;18;1p22.1;KIAA1107, APACHE;;KIAA1107 gene;617945;R, REc;;;5(Kiaa1107)
1.690;3;22;06;1p22.1;MTF2, PCL2, M96;;Metal-regulatory transcription factor 2;609882;R, REc;;;
1.691;10;13;09;1p22.1;RPAP2, C1orf82;;RNA polymerase II-associated protein 2;611476;R, REc;;;
1.692;2;3;09;1p22.1;RPL5, DBA6;;Ribosomal protein L5;603634;R, RE, REc;;Diamond-Blackfan anemia 6, 612561 (3);
1.693;11;27;18;1p22.1;SNORD21, RNU21;;Small nucleolar RNA, C/D box 21;603635;REc;;;
1.694;3;25;16;1p22.1;TMED5;;Transmembrane p24 trafficking protein 5;616876;REc;;;
1.695;6;7;16;1p31.1;ZRANB2, ZNF265, ZIS;;Zinc finger RANBP2-type domain-containing protein 2;604347;A, R;;;
1.696;10;20;15;1p22.3;BCL10, IMD37;;B-cell leukemia/lymphoma 10;603517;Ch;mutation identified in 1 IMD37 patient;Lymphoma, MALT, somatic, 137245 (3); {Lymphoma, follicular, somatic}, 605027 (3); {Male germ cell tumor, somatic}, 273300, (3); {Sezary syndrome, somatic}, (3); {Mesothelioma, somatic}, 156240 (3); ?Immunodeficiency 37, 616098 (3);
1.697;11;24;98;1p22.2-p22.1;CDC7L1, CDC7;;Cell division cycle 7, S. Cerevisiae, homolog-like 1;603311;R;;;5(Cdc7l1)
1.698;11;2;04;1p22;CMM4;;Melanoma, cutaneous malignant, 4;608035;Fd;between D1S430 and D1S2664;{Melanoma, cutaneous malignant, 4} (2);
1.699;12;5;95;1p22.3;CTBS, CTB;;Chitobiase, di-N-acetyl-;600873;Psh, A;;;
1.700;9;9;08;1p13.2;CSDE1, D1S155E, UNR;;Cold-shock domain-containing E1, RNA-binding;191510;REn;130bp 5' to NRAS;;
1.701;11;6;00;1p22.3;DDAH1;;Dimethylarginine dimethylaminohydrolase-1;604743;R, A;;;
1.702;5;19;09;1p21.3;DPYD, DPD;;Dihydropyrimidine dehydrogenase;612779;REa, A;;Dihydropyrimidine dehydrogenase deficiency, 274270 (3); 5-fluorouracil toxicity, 274270 (3);
1.703;12;24;08;1p22.1;EVI5, NB4S;;Ecotropic viral integration site 5;602942;Ch;;;
1.704;11;22;16;1p22.1;GFI1, ZNF163, SCN2;;Growth factor independent 1;600871;REa, A;mutation identified in 1 SCN2 patient and 1 NICINA patient;?Neutropenia, severe congenital 2, autosomal dominant, 613107 (3); ?Neutropenia, nonimmune chronic idiopathic, of adults, 607847 (3);5(Gfi1)
1.705;12;5;95;1p22.3;GNG5;;Guanine nucleotide-binding protein (G protein), gamma 5;600874;Psh, A;;;
1.706;7;17;09;1p22.3;HS2ST1;;Heparan sulfate 2-O-sulfotransferase 1;604844;R, REc;;;
1.707;2;14;13;1p22;KAZA2;;Kala-azar, susceptibility to, 2;611381;Fd;;{Kala-azar, susceptibility to, 2} (2);
1.708;8;28;09;1p22.3;MCOLN2;;Mucolipin 2;607399;R, H, REc;incorrectly assigned to chr.3;;3(Mcoln2)
1.709;10;25;11;1p21.3;MIR137, MIRN137;;Micro RNA 137;614304;REc;;;
1.710;7;1;05;1p13.1;TRIM45;;Tripartite motif-containing protein 45;609318;REc;;;
1.711;1;4;93;1p22;UOX;;Urate oxidase, pseudogene;191540;REa, A;nonsense mutations responsible for absence of enzyme in man and hominoid primates;[Urate oxidase deficiency] (1);
1.712;3;27;15;1p21.3;ABCD3, PXMP1, PMP70, CBAS5;;ATP-binding cassette, subfamily D, member 3 (peroxisomal membrane protein 1, 70kD);170995;REa, A;mutation identified in 1 CBAS5 family;?Bile acid synthesis defect, congenital, 5, 616278 (3);3(Pmp70)
1.713;2;20;98;1p21.3;CNN3;;Calponin 3, acidic;602374;A;;;
1.714;10;7;88;1p21.3;F3, TFA;;Coagulation factor III;134390;S, REb, Fd, A;;;
1.715;4;22;02;1p22.1;GLML, GVM, VMGLOM;;Glomulin;601749;Fd, REc;;Glomuvenous malformations, 138000 (3);
1.716;4;30;15;1p21.3;ALG14, CMS15;;Alg14, S. cerevisiae, homolog of;612866;REc;mutation identified in 1 CMSWTA family;?Myasthenic syndrome, congenital, 15, without tubular aggregates, 616227 (3);
1.717;7;17;14;1p21.3;RWDD3, RSUME;;RWD domain-containing protein 3;615875;REc;;;
1.718;1;9;17;1p21.3-p21.2;PLPPR4, LPPR4, PRG1, KIAA0455;;Phospholipid phosphatase-related protein 4;607813;REc;;;
1.719;1;9;17;1p21.3;PLPPR5, LPPR5, PAP2D, PAP2;;Phospholipid phosphatase-related protein 5;617287;REc;;;3(Plppr5)
1.720;4;21;17;1q21.3;S100A16, AAG13;;S100 calcium-binding protein A16;617437;REc;;;3(S100a16)
1.721;12;10;12;1p21.3;SNX7;;Sorting nexin 7;614904;REc;;;
1.722;5;11;07;1p13.2;CHIA, TSA1902, CHIT2;;Chitinase, acidic;606080;R;;;
1.723;3;1;06;1p21.3-p13.3;RP32;;Retinitis pigmentosa-32;609913;Fd;max lod at D1S485;Retinitis pigmentosa 32 (2);
1.724;8;21;07;1p21.2;DPH5, HSPC143;;DPH5, S. crevisiae, homolog of;611075;R, REc;;;
1.725;12;7;07;1p21.2;FRRS1, SDR2;;Ferric chelate reductase 1;611578;R, REc;;;
1.726;5;11;16;1p21.2;GPR88, STRG, COCPMR;;G protein-coupled receptor 88;607468;A, REc;mutation identified in 1 COCPMR family;?Chorea, childhood-onset, with psychomotor retardation, 616939 (3);
1.727;3;20;14;1p21.2;PALMD, PALML;;Palmdelphin;610182;REc, R, H;;;3(Palmd)
1.728;5;26;13;1p21.2;RTCD1, RPC;;RNA terminal phosphate cyclase domain-containing protein 1;611286;REc, R;;;
1.729;10;13;17;1p21.2;SASS6, SAS6, MCPH14;;SAS-6 centriolar assembly protein;609321;REc;mutation identified in 1 MCPH14 family;?Microcephaly 14, primary, autosomal recessive, 616402 (3);
1.730;2;25;08;1p21.2;SLC30A7, ZNT7;;Solute carrier family 30 (zinc transporter), member 7;611149;REc, H;;;3(Slc30a7)
1.731;11;01;18;1p21.1;RNPC3, SNRNP65, KIAA1839, IGHD5;;RNA-binding region-containing protein 3;618016;REc;mutation identified in 1 IGHD5 family;?Growth hormone deficiency, isolated, type V, 618160 (3);
1.732;6;13;07;1p21.1-p13.3;MRT4;;Mental retardation, autosomal recessive, 4;611107;Fd;between D2S429 and D1S187;Mental retardation, autosomal recessive, 4 (2);
1.733;1;11;07;1p13.2;DDX20;;DEAD/H box 20;606168;R, REc;;;
1.734;7;16;14;1p21.1-q21.3;HYPT5, MUHH2;;Hypotrichosis 5;612841;Fd;max lod at D1S2881;Hypotrichosis 5 (2);
1.735;3;26;07;1p21.2;AGL, GDE;;Amylo-1,6-glucosidase, 4-alpha-glucanotransferase (glycogen debranching enzyme);610860;REc, A;;Glycogen storage disease IIIa, 232400 (3); Glycogen storage disease IIIb, 232400 (3);
1.736;10;23;87;1p21.1;AMY1A;;Amylase, salivary, alpha-1A;104700;F, A, REa;multiple amylase genes;;3(Amy1)
1.737;10;31;91;1p21.1;AMY1B;;Amylase, salivary, alpha-1B;104701;REn;;;
1.738;11;4;91;1p21.1;AMY1C;;Amylase, salivary, alpha-1C;104702;REn;;;
1.739;9;14;88;1p21.1;AMY2A;;Amylase, pancreatic, alpha-2A;104650;F, A, REa;;;3(Amy2)
1.740;6;4;90;1p21.1;AMY2B;;Amylase, pancreatic, alpha-2B;104660;F, A, REa, Fd;distal to NGFB;;
1.741;2;25;11;1p21.1;COL11A1, STL2;;Collagen XI, alpha-1 polypeptide;120280;REb, A;;Stickler syndrome, type II, 604841 (3); Marshall syndrome, 154780 (3); {Lumbar disc herniation, susceptibility to}, 603932 (3); Fibrochondrogenesis 1, 228520 (3);3(Col11a1)
1.742;12;22;00;1p13.3;CELSR2, EGFL2, MEGF3;;Cadherin EGF LAG seven-pass G-type receptor 3 (epidermal growth factor-like 2);604265;Psh, R;;;
1.743;8;3;18;1p21.2;CDC14A, DFNB32;;Cell division cycle 14, S. cerevisiae, homolog A;603504;R;;Deafness, autosomal recessive 32, with or without immotile sperm, 608653 (3);
1.744;7;18;12;1q21.1;FAM72D;;Family with sequence similarity 72, member D;614712;REc;;;
1.745;4;6;15;1p13.2;MAGI3, KIAA1634;;Membrane-associated guanylate kinase, WW and PDZ domains-containing, 3;615943;R, H;;;3(Magi3)
1.746;11;11;14;1p21.1;OLFM3, NOE3;;Olfactomedin 3;607567;REc;;;3(Olfm3)
1.747;7;27;09;1p13.3;PROK1, PK1, PRK1, EGVEGF;;Prokineticin 1;606233;R, REc;;;
1.748;2;16;04;1p21.3;PTBP2, NPTB;;Polypyrimidine tract-binding protein 2;608449;REc;;;
1.749;9;18;08;1p21.2;S1PR1, EDG1, S1P1;;Sphingosine-1-phosphate receptor 1;601974;REc;;;
1.750;12;3;01;1p21.2;SLC35A3, AMRS;;Solute carrier family 35 (UDP-GlcNAc transporter), member 3;605632;A;mutation identified in 1 family;?Arthrogryposis, mental retardation, and seizures, 615553 (3);
1.751;5;23;06;1p21;STQTL7;;Stature quantitative trait locus 7;609822;Fd;max lod at D1S1631;{Stature QTL 7} (2);
1.752;8;9;01;1p13.2;BCAS2, DAM1;;Breast carcinoma amplified sequence 2;605783;A;;;
1.753;11;4;93;1p13.3;CD53, MOX44;;CD53 antigen;151525;REa, A;;;3(Cd53)
1.754;1;9;95;1p13.3;KCNA3;;Potassium voltage-gated channel, shaker-related subfamily, member 3;176263;REa, A;mapped probably in error to chr.13;;
1.755;3;30;00;1p21-p13.3;WS2B;;Waardenburg syndrome, type 2B;600193;Fd;;Waardenburg syndrome, type 2B (2);
1.756;5;9;95;1p13.2;ADORA3;;Adenosine A3 receptor;600445;Fd, REn, H;;;3(Adora3)
1.757;11;3;09;1p13.3;ALX3, FND1;;Aristaless-like homeobox 3;606014;R;;Frontonasal dysplasia 1, 136760 (3);
1.758;11;9;13;1p13.2;AMPD1, MMDD;;Adenosine monophosphate deaminase-1, muscle;102770;REa, A;;Myopathy due to myoadenylate deaminase deficiency, 615511 (3);3(Ampd1)
1.759;10;27;97;1p13.3;CSF1, MCSF;;Colony-stimulating factor-1 (macrophage);120420;A, REa, H;incorrectly assigned to chr.5;;3(Csfm)
1.760;8;26;15;1p13.3;AHCYL1, DCAL, IRBIT;;Adenosylhomocysteine-like 1;607826;Psh, REc;;;
1.761;3;12;14;1p13.3;AMIGO1, ALI2, KIAA1163;;Adhesion molecule with Ig-like domain 1;615689;REc;;;
1.762;6;3;14;1p13.3;AMPD2, SPG63, PCH9;;Adenosine monophosphate deaminase-2, isoform L;102771;H, REa, A;mutation identified in 1 SPG63 family;?Spastic paraplegia 63, 615686 (3); Pontocerebellar hypoplasia, type 9, 615809 (3);3(Ampd2)
1.763;1;13;16;1p13.3;CEPT1;;Choline/ethanolamine phosphotransferase 1;616751;REn, REc;;;
1.764;5;25;13;1p13.2;CHI3L2, YKL39;;Chitinase 3-like 2;601526;REc;;;
1.765;6;20;17;1p13.3;CLCC1, MCLC;;Chloride channel CLIC-like 1;617539;REc;;;
1.766;7;17;09;1p13.3;CYMP;;Chymosin pseudogene;118943;Psh, REc;;;
1.767;3;14;13;1p13.3-p13.2;DENND2D;;DENN/MADD domain-containing protein 2D;615111;REc;;;
1.768;1;9;13;1p13.3;EPS8L3, EPS8R3;;EPS8-like protein 3;614989;REc;;;3(Eps8l3)
1.769;7;17;09;1p13.3;GPR61;;G protein-coupled receptor 61;606916;Psh, REc;;;
1.770;9;12;93;1p13.3;GSTM1;;Glutathione S-transferase M1;138350;A, REa, Fd, Psh, REn;;;
1.771;9;12;93;1p13.3;GSTM2, GST4;;Glutathione S-transferase M2, muscle;138380;Psh, A, REn;;;
1.772;9;12;93;1p13.3;GSTM3, GST5;;Glutathione S-transferase M3, brain;138390;Psh, A, REn;;;
1.773;11;4;93;1p13.3;GSTM4;;Glutathione S-transferase M4;138333;A, REn, Psh;;;
1.774;7;14;14;1p13.3;HENMT1, C1orf59, HEN1;;Hen1 methyltransferase, arabidopsis, homolog of;612178;REc;;;
1.775;5;19;15;1p13.3;KCNA2, EIEE32;;Potassium channel, voltage-gated, Shaker-related subfamily, member 2;176262;REc;;Epileptic encephalopathy, early infantile, 32, 616366 (3);12(Kcna2)
1.776;2;7;17;1p13.3;KCNC4;;Potassium voltage-gated channel, Shaw-related subfamily, member 4;176265;REa, A;;;
1.777;5;24;13;1p13.3;KIAA1324, EIG121;;KIAA1324 gene;611298;R, REc;;;
1.778;8;28;09;1p13.3;GSTM5;;Glutathione S-transferase M5;138385;Psh, A, REn;pseudogene on chr.3;;
1.779;7;31;15;1p13.3;DRAM2, TMEM77, CORD21;;Damage-regulated autophagy modulator 2;613360;REc;;Cone-rod dystrophy 21, 616502 (3);
1.780;8;19;13;1p13.3;MIR197;;Micro rNA 197;611189;REc;;;
1.781;9;12;08;1p13.3;NTNG1, LMNT1, KIAA0976;;Netrin G1;608818;R, REc;;;
1.782;3;6;08;1p13.3;PRMT6;;Protein arginine N-methyltransferase 6;608274;REc;;;
1.783;7;10;93;1p13.2;RAP1A, KREV1;;RAS-related protein RAP1A;179520;A;pseudogene on 14q24.3;;
1.784;3;23;15;1p13.3;SLC6A17, NTT4, MRT48;;Solute carrier family 6 (neurotransmitter transporter), member 17;610299;REc;;Mental retardation, autosomal recessive 48, 616269 (3);
1.785;11;27;18;1p13.3;SLC16A4, MCT5;;Solute carrier family 16 (monocarboxylic acid transporter) member 4;603878;REc;;;
1.786;1;31;11;1p13.3;SORT1, NT3, LDLCQ6;;Sortilin;602458;A, REc;;[Low density lipoprotein cholesterol level QTL6], 613589 (3);
1.787;3;23;18;1p13.3;STRIP1, FAR11A, FAM40A;;Striatin-interacting protein 1;617918;REc;;;
1.788;4;20;17;1p13.3;TAF13, TAF2K, MRT60;;TAF13 RNA polymerase II, TATA box-binding protein-associated factor, 18kD;600774;REc;;Mental retardation, autosomal recessive 60, 617432 (3);
1.789;9;10;07;1p13.3;UBL4B;;Ubiquitin-like 4B;611127;REc, H;;;3(Ubl4b)
1.790;12;4;09;1p13.3;VAV3;;Vav3 oncogene;605541;REc;;;
1.791;4;10;14;1p13.3;WDR47, NEMITIN, KIAA0893;;WD repeat-containing protein 47;615734;REc;;;
1.792;6;3;15;1p13.2;KCND3, KCND3S, KCND3L, SCA19, SCA22, BRGDA9;;Potassium voltage-gated channel, Shal-related subfamily, member 3;605411;A, R, Fd;;Spinocerebellar ataxia 19, 607346 (3); Brugada syndrome 9, 616399 (3);
1.793;12;28;08;1p13.2;DCLRE1B, SNM1B, APOLLO;;DNA cross-link repair protein 1B;609683;REc;;;
1.794;10;11;17;1p12;WARS2, NEMMLAS;;Tryptophanyl-tRNA synthetase 2;604733;R;;Neurodevelopmental disorder, mitochondrial, with abnormal movements and lactic acidosis, with or without seizures, 617710 (3);
1.795;4;15;08;1p13.1;CASQ2;;Calsequestrin, fast-twitch, skeletal muscle-2;114251;A;;Ventricular tachycardia, catecholaminergic polymorphic, 2, 611938 (3);
1.796;4;27;12;1p13.2;AP4B1, SPG47, CPSQ5;;Adaptor-related protein complex 4, beta-1 subunit;607245;R, REc;;Spastic paraplegia 47, autosomal recessive, 614066 (3);
1.797;2;25;15;1p13.2;ATP5F1;;ATP synthase, H+ transporting, mitochondrial FO complex, subunit B, isoform 1;603270;REc;;;
1.798;9;21;11;1p13.2;C1orf88, PIFO;;Chromosome 1 open reading frame 88 (pitchfork, mouse, homolog of);614234;REc;;;
1.799;7;17;09;1p13.2;CAPZA1, CAPPA1;;Capping protein, muscle Z-line, alpha-1;601580;REc;;;3(Capza1)
1.800;3;14;13;1p13.2;CTTNBP2NL;;CTTNBP2 N terminus-like protein;615100;REc;;;
1.801;5;30;17;1p13.2;FAM19A3, TAFA3;;Family with sequence similarity 19, member A3, CC motif chemokine-like;617497;REc;;;
1.802;10;23;15;1p13.3;LAMTOR5, HBXIP, XIP;;Late endosomal/lysosomal adaptor, mitogen-activated protein kinase and mammalian target of rapamycin activator 5;608521;R, REc;;;
1.803;1;31;07;1p13.2;MOV10, KIAA1631;;Moloney leukemia virus 10, mouse, homolog of;610742;R, REc;;;
1.804;3;9;17;1p13.2;NR1H5P, FXRB;;Nuclear receptor subfamily 1, group H, member 5, pseudogene;617386;REc;;;
1.805;1;4;16;1p13.2;NRAS, ALPS4, NS6, CMNS, NCMS;;Neuroblastoma RAS viral (v-ras) oncogene homolog;164790;REa, A;cen-CD2-NGFB-NRAS;?RAS-associated autoimmune lymphoproliferative syndrome type IV, somatic, 614470 (3); Noonan syndrome 6, 613224 (3); Epidermal nevus, somatic, 162900 (3); Thyroid carcinoma, follicular, somatic, 188470 (3); Colorectal cancer, somatic, 114500 (3); Melanocytic nevus syndrome, congenital, somatic, 137550 (3); Neurocutaneous melanosis, somatic, 249400 (3); Schimmelpenning-Feuerstein-Mims syndrome, somatic mosaic, 163200 (3);3(Nras)
1.806;5;25;13;1p13.2;OVGP1;;Oviductal glycoprotein 1;603578;REc;;;
1.807;3;22;06;1p13.2;PPM1J, PP2CZ, PPP2CZ;;Protein phosphatase, magnesium-dependent, 1J;609957;REc;;;
1.808;8;3;12;1p13.2;RHOC, ARHC, ARH9, RHOH9;;RAS homolog gene family, member C (oncogene RHO H9);165380;REa, A;incorrectly assigned to chr.5;;
1.809;7;18;14;1p13.2;RSBN1, ROSBIN;;Round spermatid basic protein 1;615858;REc;;;
1.810;12;18;07;1p13.2;SIKE;;Suppressor of IKK-epsilon;611656;REc;;;
1.811;7;27;09;1p13.2;SYT6;;Synaptotagmin 6;607718;R, REc;;;
1.812;12;2;09;1p13.2;TSPAN2, NET3;;Tetraspanin 2;613133;REc;;;
1.813;1;17;08;1p13.2;WDR77, MEP50;;WD repeat-containing protein 77;611734;R, REc;;;
1.814;11;24;14;1p13.2;SLC16A1, MCT1, HHF7, MCT1D;;Solute carrier family 16 (monocarboxylic acid transporters), member 1;600682;Psh, A;;Erythrocyte lactate transporter defect, 245340 (3); Hyperinsulinemic hypoglycemia, familial, 7, 610021 (3); Monocarboxylate transporter 1 deficiency, 616095 (3);
1.815;11;20;95;1p13.1;CD2;;CD2 antigen (p50), sheep red blood cell receptor;186990;REa, A, RE;;;3(Ly37)
1.816;7;13;12;1p13.3;GPSM2, LGN, PINS, DFNB82, CMCS;;G protein signaling modulator 2;609245;REc;;Chudley-McCullough syndrome, 604213 (3);
1.817;4;30;93;1p12;HSD3B1;;Hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase, type 1 (placental, peripheral);109715;Fd, A;;;3(Hsd3b1)
1.818;4;6;16;1p12;HSD3B2;;Hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase, type 2 (adrenal, gonadal);613890;A;;Adrenal hyperplasia, congenital, due to 3-beta-hydroxysteroid dehydrogenase 2 deficiency, 201810 (3);3(Hsd3b2)
1.819;4;15;98;1p13.3;KCNA10;;Potassium voltage-gated channel, shaker-related subfamily, member 10;602420;A;;;
1.820;8;19;13;1p13.2;OLFML3, OLF44;;Olfactomedin-like 3;610088;REc;;;
1.821;11;24;14;1p13.2;NGF, NGFB, HSAN5;;Nerve growth factor, beta;162030;REa, H, A, Fd, RE;same 310kb fragment as TSHB; order: cen-CD2-CD58-ATP1A1-NGF-TSHB-NRAS-tel;Neuropathy, hereditary sensory and autonomic, type V, 608654 (3);3(Ngfb)
1.822;12;2;09;1p13.3;PSRC1, DDA3;;Proline/serine-rich coiled-coil protein 1;613126;REc, H;;;3(Psrc1)
1.823;3;6;08;1p13.1;SLC22A15, FLIPT1;;Solute carrier family 22 (organic cation transporter), member 15;608275;REc;;;
1.824;10;2;12;1p13.1;TTF2;;Transcription termination factor, RNA polymerase II;604718;REc;;;
1.825;3;29;06;1p13-p12;VCTN1, B7H4, B7X, B7S1;;V-set domain containing T cell activation inhibitor 1;608162;REc, H;;;3(B7h4)
1.826;11;15;18;1p34.2;PPCS, CMD2C;;Phosphopantothenoylcysteine synthetase;609853;REc;;Cardiomyopathy, dilated, 2C, 618189 (3);
1.827;3;20;06;1p12;REG4;;Regenerating islet-derived family, member 4;609846;REc;;;
1.828;6;30;98;1p13.1;PTGFRN, FPRP;;Prostaglandin F2 receptor negative regulator;601204;Psh, REc;;;
1.829;10;12;90;1p13.1;CD58, LFA3;;CD58 antigen (lymphocyte function-associated antigen 3);153420;S, REa, A, RE;?same as MSK1; gene cloned;;
1.830;6;4;12;1p13.3;GNAI3, ARCND1;;Guanine nucleotide-binding protein (G-protein), alpha-inhibiting activity polypeptide-3;139370;REa, A, Fd;;Auriculocondylar syndrome 1, 602483 (3);3(Gnai3)
1.831;4;6;11;1p13.3;GNAT2, ACHM4;;Guanine nucleotide-binding protein (G-protein), alpha-transducing (transducin) activity polypeptide-2;139340;REa, A;;Achromatopsia 4, 613856 (3);3(Gnat2)
1.832;7;17;09;1p12;HAO2, HAOX2;;Hydroxyacid oxidase 2;605176;REc;;;
1.833;2;5;15;1p13.1;IGSF3, LCDD;;Immunoglobulin superfamily, member 3;603491;A, RE;mutation identified in 1 LCDD family;?Lacrimal duct defect, 149700 (3);
1.834;3;15;13;1p13.2;LRIG2, LIG2, KIAA0806, UFS2;;Leucine-rich repeats- and immunoglobulin-like domains-containing protein 2;608869;A, H;;Urofacial syndrome 2, 615112 (3);3(Lrig2)
1.835;2;2;01;1p12;MAN1A2;;Mannosidase, alpha, class 1A, member 2;604345;A;;;3(Man1a2)
1.836;9;10;98;1p13.3;PSMA5, PSC5;;Proteasome component 5;176844;REc;;;
1.837;5;25;00;1p13.2;PHTF1;;Putative homeodomain transcription factor 1;604950;A;;;
1.838;3;27;09;1p13.2;PTPN22, PEP, PTPN8, LYP;;Protein tyrosine phosphatase, nonreceptor-type 22;600716;A;;{Diabetes, type 1, susceptibility to}, 222100 (3); {Rheumatoid arthritis, susceptibility to}, 180300 (3); {Systemic lupus erythematosus susceptibility to}, 152700 (3);
1.839;6;28;01;1p13.3;RBM15, SPEN, OTT;;One-twenty two protein (RNA binding motif protein 15; Spen, Drosophila, homolog of);606077;Ch;;Megakaryoblastic leukemia, acute (2);
1.840;10;11;17;1p13.3;SARS, SERS, NEDMAS;;Seryl-tRNA synthetase;607529;R, REc;mutation identified in 1 NEDMAS family;?Neurodevelopmental disorder with microcephaly, ataxia, and seizures, 617709 (3);
1.841;8;28;17;1p13.2;ST7L, ST7R;;Suppressor of tumorigenicity 7-like protein;617640;REc;;;
1.842;6;9;98;1p13.2;SYCP1, SCP1;;Synaptonemal complex protein-1;602162;A;;;
1.843;12;24;08;1p12;TBX15;;T-box 15;604127;A;;Cousin syndrome, 260660 (3);3(Tbx15)
1.844;8;14;15;1p13.2;TRIM33, TIF1G, RFG7, PTC7;;Tripartite motif-containing protein 33;605769;A;fused with RET to form PTC7;;
1.845;9;4;08;1p13.2;TSHB, CHNG4;;Thyroid-stimulating hormone, beta polypeptide;188540;REa, RE, Fd;centromeric to NGFB;Hypothyroidism, congenital, nongoitrous 4, 275100 (3);3(Tshb)
1.846;7;24;15;1p13.1;VANGL1, STBM2;;Vang-like 1;610132;REc;;Caudal regression syndrome, 600145 (3); {Neural tube defects, susceptibility to}, 182940 (3);
1.847;5;23;00;1p13;VUR;;Vesicoureteral reflux;193000;Fd;;Vesicoureteral reflux (2);
1.848;11;01;18;1p13.2;WNT2B, WNT13, XWNT2;;Wingless-type MMTV integration site family, member 2B;601968;A;;Diarrhea 9, 618168 (3);
1.849;5;9;01;1p12;HMGCS2;;3-hydroxy-3-methylglutaryl-Coenzyme A synthase 2, mitochondrial;600234;A;;HMG-CoA synthase-2 deficiency, 605911 (3);
1.850;5;4;00;1p12;WDR3;;WD repeat-containing protein 3;604737;A;;;
1.851;1;29;01;1p12;ADAM30;;A disintegrin and metalloproteinase domain 30;604779;R;;;
1.852;6;29;18;1p13.1;ATP1A1, CMT2DD;;ATPase, Na+K+ transporting, alpha-1 polypeptide;182310;REa, REb, A, Fd;;Charcot-Marie-Tooth disease, axonal, type 2DD, 618036 (3);3(Atp1a1)
1.853;1;6;97;1p11.2;FCGR1B;;Fc fragment of IgG, high affinity Ib, receptor for (CD64);601502;REa, A;;;
1.854;10;10;18;1p12;GDAP2;;Ganglioside-induced differentiation-associated protein 2;618128;REc;;;
1.855;8;2;13;1p13.3;LRIF1, RIF1;;Ligand-dependent nuclear receptor-interacting factor 1;615354;REc;;;
1.856;9;21;11;1p13.3;NBPF4;;Neuroblastoma breakpoint family, member 4;613994;REc, A;;;
1.857;9;21;11;1p13.3;NBPF5;;Neuroblastoma breakpoint family, member 5;613995;REc, A;;;
1.858;9;21;11;1p13.3;NBPF6;;Neuroblastoma breakpoint family, member 6;613996;REc, A;;;
1.859;9;21;11;1p12;NBPF7;;Neuroblastoma breakpoint family, member 7;613997;REc, A;;;
1.860;07;19;18;1p12;NOTCH2, AGS2, HJCYS;;Notch, Drosophila, homolog of, 2;600275;REa, A;;Alagille syndrome 2, 610205 (3); Hajdu-Cheney syndrome, 102500 (3);3(Notch2)
1.861;07;19;18;1p12;NOTCH2NLR;;NOTCH2 N-terminal-like-related, pseudogene;618026;REc;;;
1.862;10;12;14;1p12;PHGDH, NLS1, PHGDHD;;Phosphoglycerate dehydrogenase;606879;A, R;;Phosphoglycerate dehydrogenase deficiency, 601815 (3); Neu-Laxova syndrome 1, 256520 (3);
1.863;9;24;15;1p12;SPAG17, PF6;;Sperm-associated antigen 17;616554;REc;;;
1.864;7;18;12;1p11.2;SRGAP2C;;SLIT-ROBO Rho GTPase-activating protein 2C;614704;REc;;;
1.865;5;9;18;1p12;TENT5C, FAM46C;;Terminal nucleotidyltransferase 5C;613952;REc;;;
1.866;3;6;98;1p21.2;EXTL2;;Exostosin-like 2;602411;A;;;3(Extl2)
1.867;1;9;95;1p13.1;NHLH2, HEN2;;Nescient helix loop helix 2;162361;REa, A;;;3(Nscl2)
1.868;7;18;12;1p11.2;FAM72B;;Family with sequence similarity 72, member B;614711;REc;;;
1.869;10;15;02;1p11;MNRI;;Meningioma, radiation-induced;606190;Ch;;Meningioma, radiation-induced (2);
1.870;5;4;12;1p;ANON1;;Anorexia nervosa, susceptibility to, 1;606788;Fd;;{Anorexia nervosa, susceptibility to, 1} (2);
1.871;2;5;01;1p;PSORS7;;Psoriasis susceptibility 7;605606;Fd;;{Psoriasis susceptibility 7} (2);
1.872;1;2;91;1q44;ADSS;;Adenylosuccinate synthetase (Ade(-)H-complementing);103060;S;;;13(Nid)
1.873;11;14;91;1q23.3;HSPA6;;Heat-shock 70kD protein-6 (HSP70B');140555;REa;;;
1.874;11;14;91;1q23.3;HSPA7;;Heat-shock 70kD protein-7 (HSP70B);140556;REa;;;
1.875;8;28;97;1q;LRE2;;LINE retrotransposable element-2;151628;REa;inserted in DMD gene;;
1.876;2;2;16;1q22;PMF1;;Polyamine-modulated factor 1;609176;R, A, REc;;;
1.877;4;19;12;1q21.1;RBM8A, RBM8B, TAR, C1DELq21.1, DEL1q21.1;;RNA-binding motif protein 8A;605313;Psh, R;pseudogene on chr.14;Thrombocytopenia-absent radius syndrome, 274000 (3);
1.878;4;17;01;1q21.3;TMOD4;;Tropomodulin 4, muscle;605834;R;;;3(Tmod4)
1.879;10;09;18;1q22;DPM3, CDG1O;;Dolichyl-phosphate mannosyltransferase 3;605951;REc;;Muscular dystrophy-dystroglycanopathy (limb-girdle), type C, 15, 612937 (3);
1.880;7;20;09;1q12-q21.3;GNRHR2;;Gonadotropin-releasing hormone receptor 2;612875;REc;?processed pseudogene;;
1.881;6;3;94;1q21.3;S100A9, CAGB, CFAG;;S100 calcium-binding protein A9 (calgranulin B);123886;REa;;;3(Cagb)
1.882;9;13;89;1q12-q22;TRNL;;tRNA asparagine-like;189890;REa, RE;;;
1.883;9;12;93;1q24.2;DPT;;Dermatopontin;125597;REa;;;
1.884;11;9;95;1q22;MEF2D;;MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D);600663;REc;;;3(Mef2d)
1.885;1;16;01;1q12-q24;CORD8;;Cone-rod dystrophy 8;605549;Fd;;Cone-rod dystrophy 8 (2);
1.886;7;16;09;1q23.3;DDR2, NTRKR3, TKT;;Discoidin domain receptor family, member 2;191311;Psh;;Spondylometaepiphyseal dysplasia, short limb-hand type, 271665 (3);
1.887;4;6;15;1q21.2;ACP6, LPAP, ACPL1;;Acid phosphatase 6, lysophosphatide;611471;A;;;
1.888;8;30;07;1q21;AD13;;Alzheimer disease-13;611152;Fd;max lod D1S498;{Alzheimer disease-13} (2);
1.889;9;12;13;1q21.2;ADAMTSL4, TSRC1, ECTOL2;;ADAMTS-like 4;610113;REc, H;;Ectopia lentis, isolated, autosomal recessive, 225100 (3); Ectopia lentis et pupillae, 225200 (3);3(Adamtsl4)
1.890;6;18;99;1q21.3;ANXA9, ANX31;;Annexin A9 (annexin XXXI);603319;A;;;
1.891;8;27;15;1q21.3;ARNT;;Aryl hydrocarbon receptor nuclear translocator;126110;REa, Fd, A;;;3(Arnt)
1.892;5;26;98;1q21.2;BCL9;;B-cell CLL/lymphoma-9;602597;A, Ch;;;
1.893;5;11;00;1q21.2;CA14;;Carbonic anhydrase XIV;604832;A;;;
1.894;2;24;15;1q23.2;CASQ1, VMCQA;;Calsequestrin, fast-twitch, skeletal muscle-1;114250;REa, A;;Myopathy, vacuolar, with CASQ1 aggregates, 616231 (3);
1.895;8;2;13;1q21.3;CELF3, TNRC4, BRUNOL1;;CUGbp- and ELAV-like family, member 3;612678;REc;;;
1.896;9;28;09;1q21.1;CHD1L, ALC1;;Chromodomain helicase DNA-binding protein 1-like;613039;A;;;
1.897;9;9;02;1q21.3;CHRNB2, EFNL3;;Cholinergic receptor, nicotinic, beta polypeptide-2;118507;REa, H, A;linked to AMY in mouse;Epilepsy, nocturnal frontal lobe, 3, 605375 (3);3(Acrb2)
1.898;11;28;01;1q21.3;CTMP;;C-terminal modulator protein;606388;REc;;;
1.899;9;2;96;1q21.3;CTSK;;Cathepsin K;601105;REn, Fd;;Pycnodysostosis, 265800 (3);
1.900;6;3;94;1q21.3;CTSS;;Cathepsin S;116845;A;;;3(Ctss)
1.901;6;9;98;1q22;DAP3;;Death associated protein 3;602074;A;;;
1.902;3;25;13;1q21.2;ECM1, URBWD;;Extracellular matrix protein-1;602201;REc, A;;Urbach-Wiethe disease, 247100 (3);
1.903;1;6;97;1q21.1;FCGR1C;;Fc fragment of IgG, high affinity Ic, receptor for (CD64);601503;REa, A;;;
1.904;4;18;08;1q21.3;FLG, ATOD2;;Filaggrin;135940;REa, A, REn, Fd;;Ichthyosis vulgaris, 146700 (3); {Dermatitis, atopic, susceptibility to, 2}, 605803 (3);3(flg)
1.905;2;17;12;1q22;GBA;;Glucosidase, acid beta;606463;S, A, D, Fd;pseudogene GBAP ~16kb 3' to GBA;Gaucher disease, type I, 230800 (3); Gaucher disease, type II, 230900 (3); Gaucher disease, type III, 231000 (3); Gaucher disease, type IIIC, 231005 (3); Gaucher disease, perinatal lethal, 608013 (3); {Parkinson disease, late-onset, susceptibility to}, 168600 (3); {Lewy body dementia, susceptibility to}, 127750 (3);3(Gba)
1.906;8;28;97;1q22;GENEY;;Gene Y;600986;REn;;;3(GeneY)
1.907;12;11;07;1q23.1;HDGF;;Hepatoma-derived growth factor;600339;Psh, A, REc;previously assigned to Chr.X;;
1.908;3;11;03;1q21.2;HIST2H2AA, H2AFO, H2A;;Histone 2, H2aa;142720;A;;;
1.909;1;14;13;1q21.2;HIST2H2AB, H2AB;;Histone gene cluster 2, H2A histone family, member B;615014;REc;;;
1.910;3;12;03;1q21.2;HIST2H3C, H3F2;;Histone 2, H3c;142780;REa, A;;;
1.911;9;13;89;1q21.2;H4FN, H4F2;;H4 histone, family 2;142750;REa, A;100-200 histone genes; some on chromosome 6 and 12, as well as perhaps 7;;
1.912;1;15;04;1q21.1;HJV, HFE2A;;Hemojuvelin;608374;Fd, REc;between D1S442 and D1S2347;Hemochromatosis, type 2A, 602390 (3);
1.913;4;30;01;1q23.1;IRTA1;;Immunoglobulin superfamily receptor translocation-associated gene 1;605876;REc;fused with IGHA1 in multiple myeloma;;
1.914;4;30;01;1q23.1;IRTA2;;Immunoglobulin superfamily receptor translocation-associated gene 2;605877;REc;;;
1.915;11;4;93;1q21.3;IVL;;Involucrin;147360;REa, A, REn;;;
1.916;3;10;00;1q21.3;JTB, PAR;;Jumping translocation breakpoint;604671;Ch;;;
1.917;3;4;10;1q21.3;KPRP;;Keratinocyte proline-rich protein;613260;REc;;;
1.918;2;17;09;1q21.3;LCE1A, LEP1;;Late cornified envelope protein 1A;612603;REc, H;;;3(Lce1a)
1.919;2;17;09;1q21.3;LCE1B, LEP2;;Late cornified envelope protein 1B;612604;REc, H;;;3(Lce1b)
1.920;2;17;09;1q21.3;LCE1C, LEP3;;Late cornified envelope 1C;612605;REc, H;;;3(Lce1c)
1.921;2;17;09;1q21.3;LCE1D, LEP4;;Late cornified envelope protein 1D;612606;REc, H;;;3(Lce1d)
1.922;2;17;09;1q21.3;LCE1E;;Late cornified envelope protein 1E;612607;REc, H;;;3(Lce1e)
1.923;2;17;09;1q21.3;LCE1F, LEP6;;Late cornified envelope protein 1F;612608;REc, H;;;3(Lce1f)
1.924;2;18;09;1q21.3;LCE2A, LEP9;;Late cornified envelope protein 2A;612609;REc, H;;;3(Lce2a)
1.925;2;18;09;1q21.3;LCE2B, LEP10, XP5;;Late cornified envelope protein 2B;612610;REc, H;;;3(Lce2b)
1.926;2;18;09;1q21.3;LCE2C, LEP11;;Late cornified envelope protein 2C;612611;REc, H;;;3(Lce2c)
1.927;2;18;09;1q21.3;LCE2D, LEP12;;Late cornified envelope protein 2D;612612;REc, H;;;3(Lce2d)
1.928;2;23;09;1q21.3;LCE3A, LEP13;;Late cornified envelope protein 3A;612613;REc, H;;;3(Lce3a)
1.929;2;23;09;1q21.3;LCE3B, LEP14;;Late cornified envelope protein 3B;612614;REc, H;;;3(Lce3b)
1.930;2;23;09;1q21.3;LCE3C, LEP15;;Late cornified envelope protein 3C;612615;REc, H;;;3(Lce3c)
1.931;2;23;09;1q21.3;LCE3D, LEP16;;Late cornified envelope protein 3D;612616;REc, H;within intron 2 of LCE3C;;3(Lce3d)
1.932;2;23;09;1q21.3;LCE3E, LEP17;;Late cornified envelope protein 3E;612617;REc, H;;;3(Lce3e)
1.933;2;23;09;1q21.3;LCE4A, LEP8;;Late cornified envelope protein 4A;612618;REc, H;;;3(Lce4a)
1.934;2;23;09;1q21.3;LCE5A, LEP18;;Late cornified envelope protein 5A;612619;REc, H;;;3(Lce5a)
1.935;8;20;07;1q21.3;LELP1;;Late cornified envelope-like proline-rich 1;611042;REc;;;
1.936;10;7;10;1q21.3;LOR;;Loricrin;152445;REa, A, REn;;Vohwinkel syndrome with ichthyosis, 604117 (3);3(lor)
1.937;7;4;95;1q21.2;MCL1;;Myeloid cell leukemia sequence 1 (BCL2-related);159552;REa, A;;;3(Mcl1)
1.938;5;23;16;1q21.3;MLLT11, AF1Q;;Myeloid/lymphoid or mixed-lineage leukemia, translocated to, 11;604684;Ch;;;
1.939;2;26;08;1q21.3;MRPL9;;Mitochondrial ribosomal protein L9;611824;R;;;
1.940;4;24;08;1q21.2;MRPS21;;Mitochondrial ribosomal protein S21;611984;R, REc;9 pseudogenes;;
1.941;8;3;99;1q22;MTX1, MTXN;;Metaxin 1;600605;H, REn;between GBA and TSP3;;3(Mtxn)
1.942;7;12;13;1q22;MUC1, PUM, MCKD1;;Mucin 1, transmembrane;158340;REa, A, Fd;5cM proximal to SPTA1;Medullary cystic kidney disease 1, 174000 (3);3(Muc1)
1.943;11;24;16;1q22;NAXE, APOA1BP, AIBP, PEBEL;;NAD(P)HX epimerase;608862;REc;;Encephalopathy, progressive, early-onset, with brain edema and/or leukoencephalopathy, 617186 (3);
1.944;12;13;00;1q21.1;PDZK1;;PDZ domain-containing 1;603831;Psh, R;;;
1.945;10;29;03;1q21.3;PGRPIA;;Peptidoglycan recognition protein, intermediate, alpha;608197;REc;;;
1.946;10;29;03;1q21.3;PGRPIB;;Peptidoglycan recognition protein, intermediate, beta;608198;REc;;;
1.947;7;2;01;1q21.1;PIAS3;;Protein inhibitor of activated STAT3;605987;Psh, R;;;
1.948;1;14;09;1q22;PKLR, PK1;;Pyruvate kinase, liver and RBC type;609712;REa, A, REn;;Pyruvate kinase deficiency, 266200 (3); Adenosine triphosphate, elevated, of erythrocytes, 102900 (3);3(Pk1)
1.949;10;21;96;1q23.1;PRCC, RCCP1;;Papillary renal cell carcinoma, translocation-associated;179755;Ch;t(X;1)(p11;q21); fuses with TFE3 in RCCP;Renal cell carcinoma, papillary, 605074 (3);
1.950;7;19;18;1q21.3;PSMB4, PRAAS3;;Proteasome subunit, beta type, 4;602177;A;mutation identified in 1 PRAAS3 patient and 1 digenic family;?Proteasome-associated autoinflammatory syndrome 3 and digenic forms, 617591 (3);
1.951;4;16;03;1q21;PSORS4;;Psoriasis susceptibility 4;603935;Fd;;{Psoriasis susceptibility 4} (2);
1.952;2;14;01;1q21;PTCPRN, PRN1;;Papillary thyroid carcinoma with papillary renal neoplasia;605642;Fd;;Thyroid carcinoma, papillary, with papillary renal neoplasia (2);
1.953;10;17;00;1q21;RFH1, AORF;;Renal failure, progressive, with hypertension;161900;Fd;;Nephropathy-hypertension (2);
1.954;10;28;15;1q21.3;RORC, RORG, RZRG, IMD42;;RAR-related orphan receptor C;602943;Psh, A;;Immunodeficiency 42, 616622 (3);3(Rorc)
1.955;3;28;17;1q21.3;RPS27, MPS1, DBA17;;Ribosomal protein S27;603702;R, RE, REc;mutation identified in 1 DBA17 patient;?Diamond-Blackfan anemia 17, 617409 (3);
1.956;11;17;94;1q21.3;S100A1;;S100 protein, alpha polypeptide;176940;REb, A, REn;;;
1.957;3;4;10;1q21.3;RPTN;;Repetin;613259;REc, A, H;;;3(Rptn)
1.958;11;17;94;1q21.3;S100A2, S100L;;S100 calcium-binding protein A2;176993;REn;;;
1.959;11;17;94;1q21.3;S100A3, S100E;;S100 calcium-binding protein A3;176992;REn;;;
1.960;11;17;94;1q21.3;S100A4, CAPL;;S100 calcium-binding protein A4 (calcium protein, calvasculin, metastasin, murine placental homolog);114210;REa, H, REn;;;3(Capl)
1.961;11;17;94;1q21.3;S100A5, S100D;;S100 calcium-binding protein A5;176991;REn, A;;;
1.962;11;17;94;1q21.3;S100A6, CACY;;S100 calcium-binding protein A6 (calcyclin);114110;A, REn;;;3(Cacy)
1.963;2;9;95;1q21.3;S100A7;;S100 calcium-binding protein A7;600353;REc, A, Fd;;;
1.964;11;26;02;1q21.3;S100A8, CAGA, CFAG;;S100 calcium-binding protein A8 (calgranulin A);123885;S, REa;over-expressed in 1q21-linked psoriasis;;3(Caga)
1.965;7;11;94;1q21.3;S100A10, CAL1L;;S100 calcium-binding protein A10 (annexin II ligand, calpactin I, light polypeptide (p11));114085;H, REn;on chr.3 in mouse;;
1.966;10;14;98;1q21.3;S100A11;;S100 calcium-binding protein A11;603114;A;;;
1.967;10;14;98;1q21.3;S100A12, CAAF1, CGRP;;S100 calcium-binding protein A12;603112;REc;between S100A8 and S100A9;;
1.968;3;9;98;1q21.3;S100A13;;S100 calcium-binding protein A13;601989;REc;;;
1.969;1;11;07;1q21.3;S100A14, BCMP84;;S100 Calcium-binding protein A14;607986;A, REn;;;
1.970;5;13;02;1q22;SCAMP3, PROPIN1;;Secretory carrier membrane protein 3;606913;REc;;;
1.971;9;9;11;1q23.3;SDHC, PGL3;;Succinate dehydrogenase complex, subunit C, integral membrane protein, 15kD;602413;A, S, M;;Paragangliomas 3, 605373 (3); Paraganglioma and gastric stromal sarcoma, 606864 (3); Gastrointestinal stromal tumor, 606764 (3);
1.972;1;4;00;1q21.3;SETDB1;;SET domain protein, bifurcated, 1;604396;REa, A, R;;;
1.973;3;10;00;1q23.1;SH2D2A, TSAD;;SH2 domain protein 2A;604514;Psh, A;;;
1.974;6;16;95;1q21.3;SHC1;;SHC (Src homology 2 domain-containing) transforming protein-1;600560;REa, A;;;
1.975;10;4;02;1q23.2;SLAMF8, BLAME;;SLAM family, member 8;606620;R;;;
1.976;2;15;02;1q21.3;SLC39A1, ZIRTL;;Solute carrier family 39 (zinc transporter), member 3 (zinc/iron-regulated transporter-like);604740;;REc;;3(Zirtl)
1.977;3;23;06;1q21.3;SMCP, MCSP, MCS;;Sperm mitochondria-associated cysteine-rich protein;601148;A;;;
1.978;5;19;15;1q21.3;SPRR4;;Small proline-rich protein 4;616363;REc;;;
1.979;3;11;09;1q23.1;SPTA1, EL2, SPH3, HS3, HPP;;Spectrin, alpha, erythrocytic-1;182860;REa, A, Fd;17cM proximal to FY;Elliptocytosis-2, 130600 (3); Pyropoikilocytosis, 266140 (3); Spherocytosis, type 3, 270970 (3);1(Spna1)
1.980;7;4;95;1q22;THBS3, TSP3;;Thrombospondin 3;188062;H;;;3(Thbs3)
1.981;6;16;99;1q21.3;TUFT1;;Tuftelin 1;600087;A;?mutant in amelogenesis imperfecta;;
1.982;1;7;02;1q21.1;TXNIP, VDUP1;;Thioredoxin-interacting protein;606599;R, H;;;3(Txnip)
1.983;6;5;08;1q22;UBQLN4, A1U, C1orf6;;Ubiquitin 4;605440;REc;;;
1.984;2;25;08;1q21.3;VPS72, CFL1, YL1;;Vacuolar protein sorting 72, yeast, homolog of;600607;RE;;;
1.985;6;17;17;1q22;ARHGEF2, GEFH1, KIAA0651, NEDMHM;;RHO guanine nucleotide exchange factor 2;607560;R, REc;mutation identified in 1 NEDMHM family;?Neurodevelopmental disorder with midbrain and hindbrain malformations, 617523 (3);
1.986;8;25;04;1q21-q22;ASPG3;;Asperger syndrome, susceptibility to, 3;608781;Fd;max lod at D1S484;{Asperger syndrome susceptibility 3} (2);
1.987;5;11;00;1q23.3;DUSP1, YVH1;;Dual-specificity phosphatase 12;604835;R;;;
1.988;11;5;97;1q22;EFNA1, EPLG1, TNFAIP4;;eph-related receptor tyrosine kinase ligand 1 (tumor necrosis factor, alpha-induced protein 4);191164;A;;;3(Epl1)
1.989;11;5;97;1q21.3;EFNA3, EPLG3;;eph-related receptor tyrosine kinase ligand 3 (ephrin A3);601381;A;;;3(Epl3)
1.990;11;5;97;1q21.3;EFNA4, EPLG4;;eph-related receptor tyrosine kinase ligand 4 (ephrin-A4);601380;A;;;3(Epl4)
1.991;2;28;08;1q23.1;MRPL24;;Mitochondrial ribosomal protein L24;611836;R;;;
1.992;1;11;07;1q23.3;NIT1;;Nitrilase 1;604618;REc, R;;;1(Nit1)
1.993;4;18;94;1q21.3;NPR1, ANPRA;;Natriuretic peptide receptor A/guanylate cyclase A;108960;REa, A;;;
1.994;6;6;00;1q23.1;NTRK1, TRKA, MTC;;Neurotrophic tyrosine kinase, receptor, type 1;191315;REa, A;TRK = chimera of TPM3 and NTRK1;Insensitivity to pain, congenital, with anhidrosis, 256800 (3); Medullary thyroid carcinoma, familial, 155240 (3);
1.995;10;14;18;1q21.3;SELENBP1, SP56, EHMTO;;Selenium-binding protein 1;604188;A;;Extraoral halitosis due to MTO deficiency, 618148 (3);
1.996;7;10;93;1q21.3;SPRR1A;;Small proline-rich protein 1A;182265;REa, A, REn;;;
1.997;7;10;93;1q21.3;SPRR1B;;Small proline-rich protein 1B;182266;REa, A;;;
1.998;7;10;93;1q21.3;SPRR2A;;Small proline-rich protein 2A;182267;REa, A, REn;about 7 SPRR2 genes;;
1.999;7;10;93;1q21.3;SPRR2B;;Small proline-rich protein 2B;182268;REa, A;;;
1.1000;7;10;93;1q21-q22;SPRR2C;;Small proline-rich protein 2C;182269;REa, A;prob. pseudogene;;
1.1001;7;10;93;1q21.3;SPRR3;;Small proline-rich protein 3;182271;REa, A, REn;;;
1.1002;7;18;13;1q21.2;VPS45A, VPS45, SCN5;;Vacuolar protein sorting 45, yeast, homolog of, A;610035;A;;Neutropenia, severe congenital, 5, autosomal recessive, 615285 (3);
1.1003;1;11;07;1q23.3;ADAMTS4;;A disintegrin-like and metalloproteinase with thrombospondin type 1 motif, 4 (aggrecanase 1);603876;R, REc;;;
1.1004;4;30;91;1q23.2;APCS, SAP;;Amyloid P component, serum;104770;REa, A, Fd;probably close to CRP;{?Amyloidosis, secondary, susceptibility to} (1);1(Sap)
1.1005;2;20;03;1q23.3;APOA2;;Apolipoprotein A-II;107670;REa, A, Fd, RE;;Apolipoprotein A-II deficiency (3); {Hypercholesterolemia, familial, modifier of}, 143890 (3);1(Apoa2)
1.1006;1;23;18;1q23.2;ATP1A2, FHM2, MHP2;;ATPase, Na+K+ transporting, alpha-2 polypeptide;182340;REa, A, Fd, RE;;Migraine, familial hemiplegic, 2, 602481 (3); Alternating hemiplegia of childhood 1, 104290 (3); Migraine, familial basilar, 602481 (3);1(Atpa3)
1.1007;1;17;03;1q21-q23;BMND2;;Bone mineral density QTL 2;605833;Fd;;[Bone mineral density QTL 2] (2);
1.1008;3;21;93;1q23.1;CD1A;;Thymocyte antigen CD1A;188370;A, REa, REn;genes A, B, C, D in cluster;;3(Ly38)
1.1009;3;21;93;1q23.1;CD1B;;Thymocyte antigen CD1B;188360;A, REa, REn;;;
1.1010;3;21;93;1q23.1;CD1C;;Thymocyte antigen CD1C;188340;A, REa, REn;;;
1.1011;3;21;93;1q23.1;CD1D;;Thymocyte antigen CD1D;188410;A, REa, H, REn;;;3(Cd1d)
1.1012;10;9;94;1q23.1;CD1E;;Thymocyte antigen CD1E;188411;A, REa, REn;;;
1.1013;7;2;98;1q23.1;CD5L;;CD5 antigen-like (scavenger receptor cysteine rich family);602592;R, A;;;
1.1014;5;1;91;1q23.2;CRP;;C-reactive protein;123260;REa, A;;;1(Crp)
1.1015;9;22;96;1q21-q23;DFNA7;;Deafness, autosomal dominant 7;601412;Fd;;Deafness, autosomal dominant 7 (2);
1.1016;1;27;04;1q21-q23;DFNA49;;Deafness, autosomal dominant 49;608372;Fd;max lod at D1S3784 and D1S3786;Deafness, autosomal dominant 49 (2);
1.1017;9;8;11;1q21-q23;ERVK-7, HERV-KIII, HERV-K102;;Endogenous retrovirus group K, member 7;614013;R, REc;;;
1.1018;12;5;95;1q23.1;ETV3, PE1;;ets variant gene 3;164873;REa, A;;;
1.1019;8;6;15;1q23.3;FCGR2A, IGFR2, CD32;;Fc fragment of IgG, low affinity IIa, receptor for (CD32);146790;REb, REn, Fd, RE;FCG2 and FCG3 within 250kb;{Lupus nephritis, susceptibility to}, 152700 (3); {Malaria, severe, susceptibility to}, 611162 (3); {Pseudomonas aeruginosa, susceptibility to chronic infection by, in cystic fibrosis}, 219700 (3);1(Ly17, Cd32)
1.1020;3;11;03;1q21.2;HIST2H2BE, H2B;;Histone 2, H2be;601831;REa, A;;;
1.1021;3;11;03;1q21.2;HIST2H2AC, H2AFQ;;Histone 2, H2ac;602797;REc;;;
1.1022;10;24;00;1q23.1;INSRR, IRR;;Insulin receptor-related receptor;147671;REa, R;;;
1.1023;3;23;09;1q23.1;PYHIN1, IFIX;;Pyrin and Hin domain family, member 1;612677;REc;;;
1.1024;12;21;09;1q21-q23;SLEB14;;Systemic lupus erythematosus, susceptibility to, 14;613145;Fd;associated with rs3093061;{Systemic lupus erythematosus, susceptibility to, 14} (2);
1.1025;12;5;95;1q22;SSR2;;Signal sequence receptor, beta;600867;A;;;
1.1026;2;21;14;1q23.2;VANGL2, LTAP;;Vang-like 2 (loop-tail, mouse, homolog of);600533;REc, H;;Neural tube defects, 182940 (3);1(Lp)
1.1027;5;4;00;1q23.2;TAGLN2;;Transgelin 2;604634;REc, H;;;1(Tagln2)
1.1028;2;28;03;1q23.2;ATP1A4, ATP1AL2;;ATPase, Na+/K+ transporting, alpha-4 polypeptide;607321;REc;;;1(Atp1a4)
1.1029;3;15;11;1p11.2;C1orf152, COAS3;;Chromosome 1 open reading frame 152;608609;REc;;;
1.1030;11;11;14;1q21.1;CD160, BY55;;CD160 antigen;604463;REc;;;
1.1031;12;17;08;1q21.1;DEL1q21, C1DELq21;;Chromosome 1q21.1 deletion syndrome;612474;Ch;contiguous gene deletion syndrome;Chromosome 1q21.1 deletion syndrome (4);
1.1032;12;17;08;1q21.1;DUP1q21, C1DUPq21;;Chromosome 1q21.1 duplication syndrome;612475;Ch;contiguous gene duplication syndrome;Chromosome 1q21.1 duplication syndrome (4);
1.1033;3;9;00;1q21.1;FMO5;;Flavin-containing monooxygenase 5;603957;Psh, REc, A;;;
1.1034;5;3;13;1q21.2;GJA8, CX50, CTRCT1, CZP1, CAE1;;Gap junction membrane channel protein alpha-8 (connexin 50);600897;A, F;;Cataract 1, multiple types, 116200 (3);3(Gja8)
1.1035;7;16;09;1q21.1;GPR89A;;G protein-coupled receptor 89A;612821;REc;;;
1.1036;7;16;09;1q21.2;GPR89B, GPHR;;G protein-coupled receptor 89B;612806;REc;;;
1.1037;3;12;07;1q21.1;HYDIN2, KIAA1864;;Hydin, mouse, homolog of, 2;610813;R, REc;duplicated copy 16q22.2;;
1.1038;5;25;13;1q21.1;ITGA10;;Integrin, alpha-10;604042;REc;;;
1.1039;9;22;09;1q21.1;NBLST6;;Neuroblastoma, susceptibility to, 6;613017;Ch;?contiguous gene deletion or duplication disease;{Neuroblastoma, susceptibility to, 6} (2);
1.1040;9;21;11;1q21.1;NBPF10;;Neuroblastoma breakpoint family, member 10;614000;REc;;;
1.1041;9;21;11;1q21.2;NBPF11;;Neuroblastoma breakpoint family, member 11;614001;REc, A;;;
1.1042;9;21;11;1q21.1;NBPF12, COAS1, KIAA1245;;Neuroblastoma breakpoint family, member 12;608607;REc, A;;;
1.1043;9;21;11;1p11.2;NBPF8;;Neuroblastoma breakpoint family, member 8;613998;REc, A;;;
1.1044;9;21;11;1q21.2;NBPF9;;Neuroblastoma breakpoint family, member 9;613999;REc, A;;;
1.1045;9;21;11;1q21.2;NBPF14;;Neuroblastoma breakpoint, member 14;614003;REc, A;;;
1.1046;2;5;07;1q21.1;NBPF15, MGC8902;;Neuroblastoma breakpoint family, member 15;610414;REc, A;contains 6 copies of DUF1220 domain;;
1.1047;9;21;11;1q21.1;NBPF16;;Neuroblastoma breakpoint family, member 16;614005;REc, A;;;
1.1048;9;21;11;1q21.2;NBPF19;;Neuroblastoma breakpoint family, member 19;614006;REc;;;
1.1049;9;21;11;1q21.1;NBPF20;;Neuroblastoma breakpoint family, member 20;614007;REc;;;
1.1050;6;24;15;1q21.1;NBPF17P, NBPF23;;Neuroblastoma breakpoint family, member 17, pseudogene;612970;REc;;;
1.1051;6;22;18;1q21.1;NOTCH2NLA;;NOTCH2 N-terminal-like protein A;618023;REc;;;
1.1052;7;18;18;1q21.2;NOTCH2NLB;;NOTCH2 N-terminal-like protein B;618024;REc;;;
1.1053;6;22;18;1q21.2;NOTCH2NLC;;NOTCH2 N-terminal-like protein C;618025;REc;;;
1.1054;1;20;99;1q23.2;PEA15, HMAT1, PED;;Phosphoprotein enriched in astrocytes, 15kD;603434;R, A;;;
1.1055;1;20;17;1q21.1;PEX11B, PEX14B;;Peroxisome biogenesis 11B;603867;REc;mutation identified in 1 PEX14B patient;?Peroxisome biogenesis disorder 14B, 614920 (3);
1.1056;3;15;11;1q21.2;PDE4DIP, MMGL, KIAA0454, KIAA0477;;Phosphodiesterase 4D-interacting protein;608117;R, REc, A;;;
1.1057;4;26;17;1q21.1;POLR3C, RPC62, RPC3;;Polymerase III, RNA, subunit C;617454;REc;;;
1.1058;4;27;17;1q21.1;POLR3GL;;Polymerase III, RNA, subunit G-like;617457;REc;;;
1.1059;3;15;11;1q21.1;PPIAL4A, COAS2;;Peptidylprolyl isomerase A (cyclophilin A)-like 4A;608608;REc;;;
1.1060;11;11;14;1q21.1;PRKAB2;;Protein kinase, AMP-activated, noncatalytic, beta-2;602741;REc;;;
1.1061;7;18;12;1q21.1;SRGAP2B;;SLIT-ROBO Rho GTPase-activating protein 2B;614703;REc;;;
1.1062;7;18;12;1q21.1;SRGAP2D;;SLIT-ROBO Rho GTPase-activating protein 2D;614705;A;;;
1.1063;8;1;12;1q21.1;UAQTL6;;Uric acid concentration, serum, quantitative trait locus 6;614747;Fd;associated with C/T variant at chr1_142697422;[Uric acid concentration, serum, QTL6] (2);
1.1064;7;13;98;1q21.3;PIK4CB;;Phosphatidylinositol 4-kinase, catalytic, beta polypeptide;602758;REa, A, R;;;
1.1065;10;23;02;1q21.3;RFX5;;Regulatory factor X, 5 (influences HLA class II expression);601863;A;;Bare lymphocyte syndrome, type II, complementation group C, 209920 (3); Bare lymphocyte syndrome, type II, complementation group E, 209920 (3);
1.1066;12;21;09;1q21.2;BOLA1;;BolA, E. coli, homolog of, 1;613181;REc;;;
1.1067;6;22;14;1q21.2;CIART, CHRONO, GM129;;Circadian-associated repressor of transcription;615782;REc;;;
1.1068;7;17;09;1q21.3;ENSA;;Endosulfine, alpha;603061;REc;;;
1.1069;11;24;14;1q21.2;FALEC, FAL1;;Focally amplified long noncoding RNA in epithelial cancer;616092;REc;;;
1.1070;3;9;16;1q21.1;FAM72C;;Family with sequence similarity 72, member C;616853;REc;;;
1.1071;4;16;14;1q21.2;GJA5, CX40, ATFB11;;Gap junction protein, alpha-5, 40kD (connexin 40);121013;REa, A, REc;;Atrial fibrillation, familial, 11, 614049 (3); Atrial standstill, digenic (GJA5/SCN5A), 108770 (3);3(Gja5)
1.1072;9;2;08;1q21.3;GOLPH3L, GPP34R;;Golgi phosphoprotein 3-like;612208;R, REc;;;
1.1073;5;15;15;1q21.2;PRPF3, HPRP3, RP18;;Precursor mRNA-processing factor 3, S. cerevisiae, homolog of;607301;Fd, A;;Retinitis pigmentosa 18, 601414 (3);
1.1074;9;25;18;1q22;LMNA, LMN1, EMD2, FPLD2, CMD1A, HGPS;;Lamin A/C;150330;A, Fd, R;;Emery-Dreifuss muscular dystrophy 2, autosomal dominant, 181350 (3); Cardiomyopathy, dilated, 1A, 115200 (3); Lipodystrophy, familial partial, type 2, 151660 (3); Emery-Dreifuss muscular dystrophy 3, autosomal recessive, 616516 (3); Charcot-Marie-Tooth disease, type 2B1, 605588 (3); Muscular dystrophy, congenital, 613205 (3); Mandibuloacral dysplasia, 248370 (3); Hutchinson-Gilford progeria, 176670 (3); Restrictive dermopathy, lethal, 275210 (3); Heart-hand syndrome, Slovenian type, 610140 (3); Malouf syndrome, 212112 (3);3(Lmna)
1.1075;1;23;08;1q21.2;OTUD7B, CEZANNE;;OTU domain-containing protein 7B;611748;R, REc;;;
1.1076;6;2;15;1q21.2;PLEKHO1, CKIP1;;Pleckstrin homology domain-containing protein, family O, member 1;608335;R, REc;;;
1.1077;6;5;12;1q21.2;SF3B4, SF3B49, SAP49, AFD1;;Splicing factor 3B, subunit 4;605593;R, REc;;Acrofacial dysostosis 1, Nager type, 154400 (3);
1.1078;5;21;07;1q22;SMG5, EST1B, KIAA1089;;SMG5, C. elegans, homolog of;610962;R, REc;;;
1.1079;6;22;12;1q21.2;SV2A, SV2;;Synaptic vesicle glycoprotein 2A;185860;REc, R;;;
1.1080;8;5;14;1q21.2;TARS2, COXPD21;;Threonyl-tRNA synthetase 2;612805;REc;mutation identified in one COXPD21 family;?Combined oxidative phosphorylation deficiency 21, 615918 (3);
1.1081;2;26;16;1q21.3;ZNF687, KIAA1441, PDB6;;Zinc finger protein 687;610568;REc, Ch;fused with AML1 in t(1;21);Paget disease of bone 6, 616833 (3);
1.1082;11;4;04;1q23.3;F11R, JAM1;;F11 receptor (junctional adhesion molecule 1);605721;REc;;;
1.1083;5;27;05;1q21.2;FCGR1A, IGFR1, CD64;;Fc fragment of IgG, high affinity Ia, receptor for (CD64);146760;REa, H, A;;[IgG receptor I, phagocytic, familial deficiency of] (3);3(Fcgr1)
1.1084;8;9;99;1p12;SEC22L1, SEC22B;;Secretion deficient 22, S. Cerevisiae, homolog-like 1;604029;R;;;
1.1085;6;30;08;1q21.3;TNFAIP8L2, TIPE2;;Tumor necrosis factor-alpha-induced protein 8-like 2;612112;REc, H;;;3(Tnfaip8l2)
1.1086;6;28;17;1q23.2;CADM3, IGSF4B, TSLL1, NECL1, SYNCAM3;;Cell adhesion molecule 3;609743;A, H;;;1(Igsf4b)
1.1087;12;21;09;1q23.1;FCRL1, FCRH1;;Fc receptor-like protein 1;606508;REc;;;
1.1088;11;27;01;1q23.1;FCRH3;;Fc receptor-like protein 3;606510;REc;;;
1.1089;11;27;01;1q23.1;SPAP1, SPAP1A, SPAP1B, SPAP1C;;SH2 domain-containing phosphatase anchor protein 1;606509;REc;;;
1.1090;1;30;01;1q21.3;ADAM15, MDC15;;A disintegrin and metalloproteinase domain 15;605548;A;;;
1.1091;1;14;13;1q21.3;ADAR, DRADA, DSH, DSRAD, IFI4, G1P1, AGS6;;Adenosine deaminase, RNA-specific;146920;A, REc, REa;;Dyschromatosis symmetrica hereditaria, 127400 (3); Aicardi-Goutieres syndrome 6, 615010 (3);3(Adar)
1.1092;9;27;17;1q21.3;AQP10;;Aquaporin 10;606578;REc;;;
1.1093;9;22;08;1q21.3;ATP8B2, ATPID;;ATPase, class I, type 8B, member 2;605867;REc;;;
1.1094;7;20;12;1q21.3;BNIPL, BNIPS, BNIPL1, BNIPL2;;BCL2/adenovirus E1B 19kD protein-interacting protein 2-like;611275;R, REc;;;
1.1095;4;20;17;1q21.3;C1orf43, NS5ATP4, NICE3;;Chromosome 1 open reading frame 43;617428;REc;;;
1.1096;4;19;12;1q21.3;CERS2, LASS2;;Ceramide synthase 2;606920;R;;;
1.1097;9;2;11;1q21.3;CHTOP, C10orf77, SRAG, FOP;;Chromatin target of PRMT1;614206;REc;;;
1.1098;1;13;11;1q21.3;CKS1B, CKS1;;CDC28 protein kinase 1B;116900;REc;previously to 8q21 by FISH;;
1.1099;8;4;97;1q23.1;CRABP2, RBP6;;Cellular retinoic acid-binding protein-2;180231;A, REc;;;
1.1100;6;20;07;1q21.3;CREB3L4, CREB4, AIBZIP;;cAMP responsive element binding protein 3-like 4;607138;REc, A;;;
1.1101;4;20;17;1q21.3;CRCT1, NICE1, C1orf42;;Cysteine-rich c-terminal 1;617426;REc;;;
1.1102;10;27;08;1q21.3;CRTC2, TORC2;;CREB-regulated transcription coactivator 2;608972;R, REc;;;
1.1103;7;1;16;1q21.3;FLAD1, FADS, LSMFLAD;;Flavin adenine dinucleotide synthetase, S. cerevisiae, homolog of;610595;REc;;Lipid storage myopathy due to flavin adenine dinucleotide synthetase deficiency, 255100 (3);
1.1104;08;10;18;1q21.3;FLG2, IFPS, PSS6;;Filaggrin family, member 2;616284;REc;;Peeling skin syndrome 6, 618084 (3);
1.1105;6;7;11;1q21.3;HAX1, SCN3;;HCLS1-associated protein X1;605998;R, REc;;Neutropenia, severe congenital 3, autosomal recessive, 610738 (3);
1.1106;1;18;06;1q21.3;HORMAD1, NOHMA;;HORMA domain-containing 1;609824;REc, H;;;3(Nohma)
1.1107;2;16;10;1q21.3;HRM2;;Hair morphology 2 (curly hair);139450;Fd;associated with rs11803731;Hair, curly (2);
1.1108;4;10;15;1q21.3;HRNR;;Hornerin;616293;REc, H;;;3(Hrnr)
1.1109;8;1;12;1q21.3;IL6R, IL6RQ, IL6Q;;Interleukin-6 receptor;147880;REa, A;IL6R-like gene on chr.9;[Interleukin-6 receptor, soluble, serum level of, QTL], 614689 (3); [Interleukin 6, serum level of, QTL], 614752 (3);
1.1110;3;23;14;1q21.3;INTS3, INT3, SOSSA;;Integrator complex subunit 3;611347;REc;;;
1.1111;9;10;03;1q21.3;KCNN3, SK3, SKCA3;;Potassium channel, calcium-activated, intermediate/small conductance, subfamily N, member 3;602983;A, Psh, R;;;
1.1112;9;16;12;1q21.3;LINGO4, LRRN6D;;Leucine-rich repeat- and Ig domain-containing NOGO receptor-interacting protein 4;609794;REc;;;
1.1113;5;25;13;1q21.3;OAZ3, AZ3;;Ornithine decarboxylase antizyme 3;605138;REc;;;
1.1114;11;13;15;1q21.3;PMVK, PMK, POROK1;;Phosphomevalonate kinase;607622;Psh, REc;;Porokeratosis 1, multiple types, 175800 (3);
1.1115;1;13;16;1q21.3;POGZ, KIAA0461, MRD37, WHSUS;;POGO transposable element with ZNF domain;614787;REc;;White-Sutton syndrome, 616364 (3);
1.1116;5;25;17;1q21.3;PRUNE1, DRES17, NMIHBA;;Prune exopolyphosphatase 1;617413;A;;Neurodevelopmental disorder with microcephaly, hypotonia, and variable brain anomalies, 617481 (3);
1.1117;7;27;09;1q21.3;PYGO2;;Pygopus, Drosophila, homolog of, 2;606903;R, REc;;;
1.1118;2;1;11;1q21.3;RAB13;;RAB13, member RAS oncogene family;602672;REc;previously assigned to 12q13 by in situ hybridization;;
1.1119;7;2;02;1q22;RHBG;;Rhesus blood group, B glycoprotein;607079;A, H;;;3(Rhbg)
1.1120;7;18;12;1q21.2;RPRD2;;Regulation of nuclear pre-mRNA domain-containing 2;614695;REc;;;
1.1121;10;2;12;1q21.3;PSMD4, S5A, RPN10;;Proteasome 26S subunit, non-ATPase, 4;601648;REc;;;3(Psmd4)
1.1122;4;20;17;1q21.3;S100A7A, S100A15, NICE2;;S100 calcium-binding protein A7A;617427;REc;;;
1.1123;8;19;09;1q21.3;SCNM1, MGC3180;;Sodium channel modifier 1;608095;REc;;;
1.1124;4;21;15;1q21.3;SEMA6C, KIAA1869;;Semaphorin 6C;609294;REc;;;16(Sema6c)
1.1125;2;25;15;1q21.3;SHE;;SH2 domain-containing protein E;610482;R, REc;;;
1.1126;7;27;09;1q21.3;SLC27A3, FATP3;;Solute carrier family 27 (fatty acid transporter), member 3;604193;R, REc;;;
1.1127;8;21;08;1q21.3;SNX27, MRT1;;Sorting nexin 27;611541;R, REc;;;
1.1128;8;2;17;1q21.3;SPRR2D;;Small proline-rich protein 2D;617587;REc, REn;;;
1.1129;8;2;17;1q21.3;SPRR2E;;Small proline-rich protein 2E;617588;REc, REn;;;
1.1130;7;27;17;1q21.3;SPRR2F;;Small proline-rich protein 2F;617589;REc;;;
1.1131;7;27;17;1q21.3;SPRR2G;;Small proline-rich protein 2G;617590;REc;;;
1.1132;12;23;16;1q21.3;TCHH, THH, THL, TRHY, UHS3;;Trichohyalin;190370;A, RE;mutation identified in 1 UHS3 patient;?Uncombable hair syndrome 3, 617252 (3);
1.1133;3;7;14;1q21.3;THEM5, ACOT15;;Thioesterase superfamily member 5;615653;REc, H, REn;;;3(Them5)
1.1134;7;20;15;1q21.3;UBAP2L, NICE4;;Ubiquitin-associated protein 2-like;616472;REc;;;
1.1135;4;20;17;1q21.3;UBE2Q1, GTAP, NICE5;;Ubiquitin-conjugating enzyme E2Q family member 1;617429;REc;;;
1.1136;9;20;14;1q21.3;ZBTB7B, ZFP67, CKROX, THPOK;;Zinc finger- and BTB domain-containing protein 7B;607646;REc;;;
1.1137;3;21;93;1q23.3;CD48, BCM1, BLAST1;;CD48 antigen (B-cell membrane protein);109530;REa, A, REn;;;1(Bcm1)
1.1138;4;27;09;1q23.3;ITLN1, INTL, LFR, HL1;;Intelectin 1;609873;Psh, A, REc;;;
1.1139;4;27;09;1q23.3;ITLN2, HL2;;Intelectin 2;609874;Psh, A;;;
1.1140;9;11;95;1q23.3;LY9;;T-lymphocyte surface antigen Ly-9;600684;REn;within 410kb of CD48;;1(Ly9)
1.1141;10;4;05;1q21.2;ANP32E, LANPL;;Acidic leucine-rich nuclear phosphoprotein 32 family, member E;609611;REc;;;
1.1142;12;6;17;1q22;ASH1L, KIAA1420, ASH1, MRD52;;ash1 (absent, small, or homeotic), Drosophila, homolog of;607999;REc;;Mental retardation, autosomal dominant 52, 617796 (3);
1.1143;3;3;95;1q23.1;IFI16;;Interferon, gamma-inducible protein 16;147586;REa, A;;;
1.1144;3;8;00;1q23.1-q23.2;AIM2;;Absent in melanoma 2;604578;A;;;
1.1145;2;12;09;1q23.3;CD244, NAIL, NKR2B4, SLAMF4;;CD244 antigen;605554;REc;;{Rheumatoid arthritis, susceptibility to}, 180300 (3);
1.1146;7;6;07;1q23.3;FCGR2B, CD32;;Fc fragment of IgG, low affinity IIb, receptor for;604590;REc;;{Systemic lupus erythematosus, susceptibility to}, 152700 (3); {Malaria, resistance to}, 611162 (3);
1.1147;11;13;15;1q22;FDPS, FPS, POROK9;;Farnesyl diphosphate synthase;134629;R, REc;;Porokeratosis 9, multiple types, 616631 (3);
1.1148;8;19;13;1q22;GON4L, KIAA1606;;GON4-like protein;610393;REc;;;
1.1149;3;24;06;1q22;HCN3, KIAA1535;;Hyperpolarization-activated cyclic nucleotide-gated potassium channel 3;609973;R, REc;;;
1.1150;12;4;02;1q21.3;LENEP, LEP503;;Lens epithelial protein;607377;A;;;
1.1151;7;15;13;1q22;LAMTOR2, MAPBPIP, p14;;Late endosomal/lysosomal adaptor, MAPK and MTOR activator 2;610389;R, REc;;Immunodeficiency due to defect in MAPBP-interacting protein, 610798 (3);
1.1152;8;20;07;1q22;MEX3A;;Mex-3, C. elegans, homolog of, A;611007;REc;;;
1.1153;3;23;09;1q22;MIR9-1, MIRN9-1;;Micro RNA 9-1;611186;REc;;;
1.1154;3;3;95;1q23.1;MNDA;;Myeloid cell nuclear differentiation antigen;159553;REa, REn;;;
1.1155;11;28;18;1q23.3;MPZ, CMT1B, CMTDID, DSS, CHN2;;Myelin protein zero;159440;REb, A, F, Fd, D;;Charcot-Marie-Tooth disease, type 1B, 118200 (3); Dejerine-Sottas disease, 145900 (3); Hypomyelinating neuropathy, congenital, 2, 618184 (3); Charcot-Marie-Tooth disease, type 2J, 607736 (3); Roussy-Levy syndrome, 180800 (3); Charcot-Marie-Tooth disease, type 2I, 607677 (3); Charcot-Marie-Tooth disease, dominant intermediate D, 607791 (3);1(Mpp)
1.1156;9;22;17;1q22;MSTO1, MMYAT;;Misato 1, mitochondrial distribution and morphology regulator;617619;REc;;Myopathy, mitochondrial, and ataxia, 617675 (3);
1.1157;7;12;94;1q23.2;NHLH1, HEN1;;Nescient helix loop helix 1;162360;H, REa, A;closely linked to Sap in mouse;;1(Nscl)
1.1158;4;19;12;1q22;PAQR6;;Progestin and ADIPOQ receptor family, member 6;614579;REc;;;
1.1159;9;12;96;1q23.3;PPOX;;Protoporphyrinogen oxidase;600923;A;;Porphyria variegata, 176200 (3);
1.1160;10;25;12;1q23.2;PEX19, PXF, HK33, D1S2223E, PBD12A;;Peroxisome biogenesis factor 19 (peroxisomal farnesylated protein);600279;REa, A;;Peroxisome biogenesis disorder 12A (Zellweger), 614886 (3);
1.1161;7;29;09;1q22;RAB25, RAB11C;;Ras-associated protein RAB25;612942;R, REc;;;
1.1162;8;7;13;1q22;RIT1, RIT, ROC1, NS8;;Ric-like protein without CAAX motif 1;609591;REc;;Noonan syndrome 8, 615355 (3);3(Rit)
1.1163;1;26;17;1q22;RUSC1, NESCA;;RUN domain- and SH3 domain-containing protein 1;617318;R, REC;;;
1.1164;5;30;17;1q22;RXFP4, RLN3R2, GPR100, GPCR142;;Relaxin/insulin-like family peptide receptor 4;609043;REc;;;3(Gpr100)
1.1165;11;30;06;1q22;SEMA4A, SEMB, RP35, CORD10;;Semaphorin 4A;607292;REc;;Retinitis pigmentosa 35, 610282 (3); Cone-rod dystrophy 10, 610283 (3);
1.1166;9;2;08;1q23.3;SH2D1B, EAT2;;SH2 domain-containing 1B;608510;A;;;
1.1167;3;12;07;1q22;SLC25A44;;Solute carrier family 25, member 44;610824;REc;;;3(Slc25a44)
1.1168;1;21;11;1q22;SLC50A1, RAG1AP1;;Solute carrier family 50 (sugar transporter), member 1;613683;REc;;;
1.1169;4;17;13;1q21.3;SNAPIN, SNAPAP, BLOC1S7, BLOS7;;SNAP-associated protein;607007;R, REc;;;
1.1170;7;16;02;1q23.3;USP21, USP23;;Ubiquitin-specific protease 21;604729;R;;;
1.1171;2;15;17;1q22;YY1AP1, YAP, HCCA2, GRNG;;YY1 associated protein 1;607860;REc;;Grange syndrome, 602531 (3);
1.1172;6;23;98;1q24.1;ALDH9A1, ALDH9, E3;;Aldehyde dehydrogenase 9 family, member A1;602733;A, REa;;;
1.1173;8;13;15;1q23.3;ATF6, ACHM7;;Activating transcription factor-6;605537;REc;;Achromatopsia 7, 616517 (3);
1.1174;8;5;14;1q24.2;CD247, CD3Z, TCRZ, IMD25;;CD247 antigen;186780;REa, A, REn;mutation identified in one IMD25 patient;?Immunodeficiency 25, 610163 (3);1(T3z, Cd3z)
1.1175;3;17;06;1q23.2;IGSF9, KIAA1355;;Immunoglobulin superfamily, member 9;609738;REc, REn, H;;;1(Igsf9)
1.1176;8;17;98;1q23.3;LMX1A, LMX1;;LIM homeo box transcription factor-1, alpha;600298;A;;;
1.1177;2;8;11;1q23.2;NCSTN;;Nicastrin;605254;REn;;Acne inversa, familial, 1, 142690 (3);
1.1178;5;9;95;1q24.2;OTF1, OCT1;;Octamer-binding transcription factor-1;164175;REa, REn, A;;;1(Otf1)
1.1179;5;2;94;1q23.3;RXRG;;Retinoid X receptor, gamma;180247;H, A;;;1(Rxrg)
1.1180;8;24;04;1q23.3;SLAMF1, SLAM, CDW150, CD150;;SLAM family, member 1;603492;REc;;;
1.1181;8;2;13;1q21.3;TPM3, NEM1, CFTD, CAPM1;;Tropomyosin 3;191030;REa, A;TRK = chimera of TPM3 and NTRK1; NEM1 to 1q21-q23 by Fd;Nemaline myopathy 1, autosomal dominant or recessive, 609284 (3); CAP myopathy 1, 609284 (3); Myopathy, congenital, with fiber-type disproportion, 255310 (3);1(Tpm3)
1.1182;7;11;17;1q23.3;USF1, HYPLIP1;;Upstream transcription factor 1;191523;REa, A, Fd;;{Hyperlipidemia, familial combined, susceptibility to}, 602491 (3);1(Usf1)
1.1183;7;1;05;1q24.1;UCK2, TSA903;;Uridine/cytidine kinase 2;609329;REc;;;
1.1184;3;22;06;1q23.2;CCDC19, NESG1;;Coiled-coil domain-containing 19;605152;REc;;;
1.1185;4;19;01;1q21.3;PIP5K1A;;Phosphatidylinositol-4-phosphate 5-kinase, type I, alpha;603275;A;;;
1.1186;2;2;07;1q24.2;ATP1B1;;ATPase, Na+K+ transporting, beta-1 polypeptide;182330;REa, A, REn;;[Blood pressure regulation QTL], 145500 (2);1(Atp1b1)
1.1187;8;9;99;1q23.3;B4GALT3;;Beta-1,4-galactosyltransferase 3;604014;A;;;
1.1188;6;8;01;1q23;BDET;;Bleeding disorder, east Texas type;605913;Fd;;Bleeding disorder, east Texas type (2);
1.1189;1;23;90;1q23;D1S61, D1S111, MS336;;Minisatellite 33.6;157560;REa, A;;;
1.1190;7;13;99;1q22;CCT3, TRIC5;;Chaperonin-containing TCP1, subunit 3, gamma (TCP1 (t-complex-1) ring complex, polypeptide 5);600114;A;;;3(Tric5)
1.1191;5;4;12;1q24.2;F5, THPH2, RPRGL1;;Coagulation factor V (proaccelerin, labile factor);612309;REa, A, Fd, REn;Order: F5-GRMP-LYAM1-ELAM1 in 300kb segment;Factor V deficiency, 227400 (3); {Thrombophilia, susceptibility to, due to factor V Leiden}, 188055 (3); {Stroke, ischemic, susceptibility to}, 601367 (3); {Budd-Chiari syndrome}, 600880 (3); Thrombophilia due to activated protein C resistance, 188055 (3); {Pregnancy loss, recurrent, susceptibility to, 1}, 614389 (3);1(Cf5)
1.1192;11;11;14;1q24.3;FASLG, TNFSF6, APT1LG1, FASL, ALPS1B;;Fas ligand (TNF superfamily, member 6);134638;A;;Autoimmune lymphoproliferative syndrome, type IB, 601859 (3); {Lung cancer, susceptibility to}, 211980 (3);1(Fas1)
1.1193;7;10;91;1q23.2;FCER1A;;Fc IgE receptor, alpha polypeptide;147140;REa, A;;;1(Fcer1a)
1.1194;8;11;91;1q23.3;FCER1G;;Fc fragment of IgE, high affinity I, receptor for, gamma polypeptide;147139;H, A;probably on 1q close to CD32;;1(Fcer1a)
1.1195;7;31;08;1q23.3;FCGR2C, CD32C;;Fc fragment of IgG, low affinity IIc, receptor for;612169;REc;;Thrombocytopenic purpura, autoimmune, 188030 (1);
1.1196;3;25;14;1q23.3;FCGR3A, CD16, IGFR3, IMD20;;Fc fragment of IgG, low affinity III, receptor for (CD16);146740;REb, REn;FCGR2A and FCGR3A within 250kb antigen;Immunodeficiency 20, 615707 (3);
1.1197;8;3;12;1q23.3;FCGR3B;;Fc fragment of IgG, low affinity IIIb, receptor for;610665;REc;;Neutropenia, alloimmune neonatal (3);
1.1198;7;12;02;1q23.3;FREB;;Fc receptor homolog expressed in B cells;606891;REc;;;
1.1199;3;8;00;1q24.1;MGST3;;Glutatione S-transferase, microsomal, 3;604564;A;;;
1.1200;2;2;07;1q23.3;RGS5;;Regulator of G protein signaling-5;603276;Psh, R;;[Blood pressure regulation QTL], 145500 (2);
1.1201;12;13;18;1q23.3;NDUFS2, MC1DN6;;NADH dehydrogenase (ubiquinone) Fe-S protein 2, 49kD;602985;REc, A;;Mitochondrial complex I deficiency, nuclear type 6, 618228 (3);
1.1202;2;6;08;1q23.3;NUF2, NUF2R, CDCA1;;NUF2, S. cerevisiae, homolog of;611772;R;;;
1.1203;8;28;17;1q23.3;PBX1, CAKUHED;;Pre-B cell leukemia transcription factor-1;176310;Ch, A;pseudogene PBXP1 on chr.3;Congenital anomalies of kidney and urinary tract syndrome with or without hearing loss, abnormal ears, or developmental delay, 617641 (3);1(Pbx)
1.1204;6;15;99;1q25.1;TNFSF18, AITRL, GITRL;;Tumor necrosis factor ligand superfamily, member 18;603898;R;;;
1.1205;8;30;02;1q24.2;XCL1, SCYC1, SCM1, LTN, LPTN;;Chemokine, C motif, ligand 1 (lymphotactin);600250;H, REa, A;;;1(Lptn)
1.1206;8;30;02;1q24.2;XCL2, SCYC2, SCM1B;;Chemokine, C motif, ligand 2;604828;A;;;
1.1207;2;4;02;1q23.3;SLAMF7, CRACC, CS1;;SLAM family, member 7;606625;REc;;;
1.1208;4;17;01;1q24.2;TBX19;;T-box 19;604614;R;;Adrenocorticotropic hormone deficiency, 201400 (3);
1.1209;7;1;15;1q23.2;COPA, AILJK;;Coatomer protein complex, subunit alpha;601924;A;;{Autoimmune interstitial lung, joint, and kidney disease}, 616414 (3);
1.1210;4;30;93;1q24.3;FMO1;;Flavin-containing monooxygenase 1, fetal liver;136130;Psh, A;;;
1.1211;6;4;08;1q24.3;FMO2;;Flavin-containing monooxygenase 2, pulmonary;603955;Psh, REc;probably cluster of FMO genes at 1q23-q25;;
1.1212;10;26;97;1q24.3;FMO3, TMAU;;Flavin-containing monooxygenase 3;136132;Psh;;Trimethylaminuria, 602079 (3);
1.1213;6;4;08;1q24.3;FMO4;;Flavin-containing monooxygenase 2, adult liver;136131;REc;;;
1.1214;4;23;08;1q25.1;MRPS14;;Mitochondrial ribosomal protein S14;611978;R, REc;;;
1.1215;12;22;17;1q24.3;PIGC, GPI2, GPIBD16, MRT62;;Phosphatidylinositol glycan, class C;601730;REc, A;;Glycosylphosphatidylinositol biosynthesis defect 16, 617816 (3);
1.1216;3;20;18;1q24.2;SELE, ELAM1;;Selectin E (endothelial leukocyte adhesion molecule-1);131210;REn;;;1(Elam)
1.1217;7;14;11;1q24.2;SELL, LYAM1, LAM1, LNHR;;Selectin L (lymphocyte adhesion molecule 1);153240;A, REn;;;1(Lnhr)
1.1218;7;31;17;1q24.2;SELP, GRMP;;Selectin P (granulocyte membrane protein, 140kD; antigen CD62);173610;REn, A;in same 300kb segment as LYAM1, ELAM1;;1(Grmp)
1.1219;3;1;12;1q25.1;SERPINC1, AT3, AT3D, THPH7;;Antithrombin III;107300;F, D, A, REa, Fd;~17cM distal to FY;Thrombophilia due to antithrombin III deficiency, 613118 (3);1(At3)
1.1220;12;22;16;1q23.1;BCAN;;Brevican;600347;REc;;;
1.1221;2;22;13;1q21.3;GATAD2B, KIAA1150, p68, MRD18;;GATA zinc finger domain-containing protein 2B;614998;REc;;Mental retardation, autosomal dominant 18, 615074 (3);
1.1222;1;30;02;1q23.2;IGSF8, PGRL, CD81P3;;Immunoglobulin superfamily, member 8;606644;REc, R;;;
1.1223;4;15;08;1q23.1;ISG20L2;;Interferon-stimulated exonuclease gene 20-kD-like 2;611930;REc;;;
1.1224;6;13;12;1q23.1;KIRREL, NEPH1;;Kin of IRRE-like;607428;REc;;;
1.1225;8;18;04;1q23.3;KIS;;Kinase-interacting stathmin;608849;R;;;
1.1226;11;11;14;1q23.1;NES;;Nestin;600915;REc;;;
1.1227;12;10;13;1q23.3;NR1I3, CAR, MB67;;Nuclear receptor subfamily 1, group I, member 3;603881;REc;;;
1.1228;8;3;12;1q23.1;PEAR1;;Platelet endothelial aggregation receptor 1;610278;REc, R;;;
1.1229;8;24;04;1q23.2-q23.3;SLAMF6, NTBA;;SLAM family, member 6;606446;R, REc;;;
1.1230;11;19;13;1q22;TMEM79, MATT;;Transmembrane protein 79;615531;REc, H;;;3(Tmem79)
1.1231;3;27;17;1q23.2;ACKR1, DARC, FY, GPD, WBCQ1;;Atypical chemokine receptor 1 (Duffy antigen receptor for chemokines);613665;F, Fc, Fd, A;by A, 1q22-q23;[Blood group, Duffy system], 110700 (3); {Malaria, vivax, protection against}, 611162 (3); [White blood cell count QTL], 611862 (3);1(Fy, Darc)
1.1232;7;18;14;1q23.2;DCAF8, WDR42A, GAN2;;DDB1- and CUL4-associated factor 8;615820;REc;mutation identified in 1 GAN2 family;?Giant axonal neuropathy 2, autosomal dominant, 610100 (3);
1.1233;7;7;14;1q23.2;KCNJ9, GIRK3;;Potassium inwardly-rectifying channel, subfamily J, member 9;600932;A;;;
1.1234;9;1;11;1q23.2;KCNJ10, SESAME;;Potassium inwardly-rectifying channel, subfamily J, member 10;602208;H, REc;;SESAME syndrome, 612780 (3); Enlarged vestibular aqueduct, digenic, 600791 (3);1(Kcnj10)
1.1235;8;23;06;1q23.2;PIGM;;Phosphatidylinositol glycan, class M;610273;R, REc;;Glycosylphosphatidylinositol deficiency, 610293 (3);
1.1236;2;23;08;1q24.2;TIPRL, TIP41, TIP;;TIP41-like protein;611807;REc;;;
1.1237;10;3;11;1q23.3;ARHGAP30;;RHO GTPase-activating protein 30;614264;REc;;;
1.1238;9;26;17;1q23.3;CD84, SLAMF5;;CD84 antigen;604513;REc;;;
1.1239;12;3;14;1q23.3;CFAP126, FLTP;;Cilia- and flagella-associated protein 126;616119;REc;;;
1.1240;1;11;07;1q23.3;DEDD, DEFT;;Death effector domain-containing protein;606841;R, REc;;;
1.1241;12;6;16;1q23.3;FCRLB, FCRL2, FREB2, FCRY;;Fc receptor-like protein B;609251;REc;;;
1.1242;12;5;03;1q25.1;GAS5;;Growth arrest-specific 5;608280;REc;;;
1.1243;2;10;11;1q23.3;HSD17B7;;17-beta-hydroxysteroid dehydrogenase VII;606756;REc;;;
1.1244;3;18;17;1q23.3;KLHDC9, KARCA1;;Kelch domain-containing protein 9;617375;REc;;;
1.1245;6;28;17;1q23.3;NECTIN 4, PVRL4, PRR4, EDSS1;;Nectin 4;609607;REc;;Ectodermal dysplasia-syndactyly syndrome 1, 613573 (3);
1.1246;1;1;10;1q23.3;NOS1AP, CAPON, KIAA0464;;Nitric oxide synthase 1 (neuronal) adaptor protein;605551;R, REc;;;
1.1247;9;9;10;1q23.3;PFDN2;;Prefoldin 2;613466;REc;;;
1.1248;2;21;10;1q23.3;QTV;;QT interval, variation in;610141;Fd;associated with rs12143842;[QT interval, variation in] (2);
1.1249;5;5;09;1q23.3;RGS4;;Regulator of G protein signaling 4;602516;REc;;;
1.1250;2;13;12;1q24.2;SLC19A2, THTR1, TRMA, THMD1;;Solute carrier family 19 (thiamine transporter), member 2;603941;Fd, REc;;Thiamine-responsive megaloblastic anemia syndrome, 249270 (3);
1.1251;12;15;16;1q23.3;SPATA46;;Spermatogenesis-associated protein 46;617257;REc;;;
1.1252;10;12;14;1q23.3;TSTD1, KAT;;Thiosulfate sulfurtransferase (rhodanese)-like domain-containing protein 1;616041;REc;;;
1.1253;5;25;13;1q23.3;UAP1, SPAG2;;ADP-N-acetylglucosamine pyrophosphorylase 1;602862;REc;;;
1.1254;08;07;18;1q23.3;UFC1, NEDSG;;Ubiquitin-fold modifier-conjugating enzyme 1;610554;REc;;Neurodevelopmental disorder with spasticity and poor growth, 618076 (3);
1.1255;1;20;11;1p32.3;ZCCHC11, KIAA0191;;Zinc finger CCHC domain-containing protein 11;613692;R, REc;;;
1.1256;4;9;15;1q24.2;ADCY10, SAC, HCA2;;Adenylyl cyclase 10, soluble;605205;REc;;{Hypercalciuria, absorptive, susceptibility to}, 143870 (3);
1.1257;11;30;00;1q24;DFNM1;;Deafness, nonsyndromic, modifier 1;605429;Fd;;{Deafness, nonsyndromic, modifier 1} (2);
1.1258;3;9;00;1q25.1;GPR52;;G protein-coupled receptor 52;604106;REc;;;
1.1259;8;31;17;1q24.2;MPZL1, PZR;;Myelin protein zero-like 1;604376;REc;;;
1.1260;9;9;10;1q24.2;NME7, MN23H7;;Nonmetastatic cells 7, protein expressed in;613465;REc;;;
1.1261;7;28;11;1q24.2;PRRX1, PMX1, PHOX1, AGOTC;;Paired-related homeobox gene 1;167420;H, Fd, A;;Agnathia-otocephaly complex, 202650 (3);1(Pmx)
1.1262;5;26;13;1q24.2;RCSD1, CAPZIP;;RCSD domain-containing protein 1;610579;REc;;;
1.1263;3;2;98;1q25.1;TNR;;Tenascin R (restrictin, janusin);601995;A, R;;;4(Tnr)
1.1264;09;27;18;1q25.2;TOR1AIP1, LAP1, LAP1B, LGMD2Y;;Torsin A-interacting protein 1;614512;REc;mutation identified in 1 MRRSDC family;?Muscular dystrophy, autosomal recessive, with rigid spine and distal joint contractures, 617072 (3);
1.1265;3;29;12;1q25.2;TOR1AIP2, LULL1;;Torsin A-interacting protein 2;614513;REc;;;
1.1266;9;19;13;1q25.2;QSOX1;;Quiescin Q6 sulfhydryl oxidase 1;603120;A;;;
1.1267;2;4;92;1q25.2;ABL2, ABLL, ARG;;Abelson murine leukemia viral (v-abl) oncogene homolog 2 (arg, Abelson-related gene);164690;REa, A, Ch;fused with ETV6 in AML;Leukemia, acute myeloid, with eosinophilia (1);1(Abll)
1.1268;8;10;05;1q25.3-q31.1;HMCN1, FBLN6, FIBL6, ARMD1;;Hemicentin (fibulin 6);608548;REc;;{Macular degeneration, age-related, 1}, 603075 (3);
1.1269;1;23;01;1q31.1;PRG4, CACP, MSF, SZP, HAPO;;Proteoglycan 4 (megakaryocyte stimulating factor; hemangiopoietin);604283;Fd, A;;Camptodactyly-arthropathy-coxa vara-pericarditis syndrome, 208250 (3);1(Prg4)
1.1270;8;28;01;1q25.1;SIP;;SIAH1-interacting protein;606186;REc;;;
1.1271;5;12;09;1q24.1;TADA1L, STAF42;;Transcriptional adaptor 1-like;612763;REc;;;
1.1272;5;13;02;1q24.3;VAMP24;;Vesicle-associated membrane protein 4;606909;R, REc;;;
1.1273;9;27;17;1q24.1;GPA33;;Glycoprotein A33;602171;REc;;;
1.1274;8;10;18;1q24.1;ILDR2;;Immunoglobulin-like domain-containing receptor 2;618081;REc;;;1(Ldlr2)
1.1275;5;6;13;1q24.1;LRRC52;;Leucine-rich repeat-containing protein 52;615218;REc;;;
1.1276;9;10;09;1q24.1;MAEL;;Maelstrom, Drosophila, homolog of;611368;REc;;;
1.1277;1;29;08;1q25.1-q25.2;RFWD2, COP1;;Ring finger- and WD repeat domain-containing protein 2;608067;REc;pseudogenes on chr. 3, 9, 18;;
1.1278;6;3;14;1q24.1;TMCO1, CFSMR;;Transmembrane and coiled-coil domains protein 1;614123;REc;;Craniofacial dysmorphism, skeletal anomalies, and mental retardation syndrome, 213980 (3);
1.1279;7;24;12;1q24.2;BRP44, MPC2;;Brain protein 44;614737;REc;;;
1.1280;7;19;18;1q24.2;CREG1;;Cellular repressor of E1A-stimulated genes 1;618055;REc;;;
1.1281;3;27;12;1q24.2;DCAF6, IQWD1, NRIP;;DDB1 and CUL4 associated factor 6;610494;R, REc;;;
1.1282;4;15;11;1q24.2;GORAB, SCYL1BP1, NTKLBP1, GO;;Golgin, RAB6-interacting;607983;R, REc;;Geroderma osteodysplasticum, 231070 (3);
1.1283;9;24;08;1q24.2;GPR161;;G protein-coupled receptor 161;612250;R, REc;;;
1.1284;7;17;09;1q24.2;KIFAP3, SMAP;;Kinesin-associated protein 3;601836;R, REc;;;
1.1285;6;4;13;1q24.2;METTL18, C1orf156;;Methyltransferase-like 18;615255;REc;;;
1.1286;4;6;15;1q24.2;SCYL3, PACE1;;SCY1-like 3, S. cerevisiae, homolog of;608192;REc;;;
1.1287;1;17;08;1q25.2;C1orf76, NDSP;;Neuroblastoma-derived secretory protein;611727;REc;;;
1.1288;7;18;12;1q24.3;DNM3, KIAA0820;;Dynamin 3;611445;REc;;;
1.1289;10;10;18;1q24.3;EEF1AKNMT, METTL13, FEAT, KIAA0859, DFNB26M;;EEF1A lysine and N-terminal methyltransferase;617987;REc;mutation identified in 1 family;?{Deafness, autosomal recessive 26, modifier of}, 605429 (3);
1.1290;3;23;09;1q24.3;MIR199A2, MIRN199A2;;Micro RNA 199A2;610720;REc;;;
1.1291;3;23;09;1q24.3;MIR214, MIRN214;;Micro RNA 214;610721;REc;;;
1.1292;7;18;11;1q24.3;MIR3120;;Micro RNA 3120;614722;REc;in intron 13 of DNM3 in sense orientation;;
1.1293;3;18;17;1q24.3;PRRC2C, KIAA1096;;Proline-rich coiled-coil protein 3C;617373;REc;;;
1.1294;10;24;12;1q24.3;MYOC, TIGR, GLC1A, JOAG, GPOA;;Myocilin (trabecular meshwork-induced glucocorticoid response protein);601652;REc, R, Fd, A;;Glaucoma 1A, primary open angle, 137750 (3);1(Tigr)
1.1295;8;30;07;1q25;AD14;;Alzheimer disease 14;611154;Fd;max lod at D1S218;{Alzheimer disease-14} (2);
1.1296;7;13;09;1q25.2;ASTN1, ASTN;;Astrotactin 1;600904;A;;;1(Astn)
1.1297;4;6;18;1q25.3;TRMT1L, C1orf25, TRM1L;;tRNA methyltransferase 1-like;611673;REc;;;
1.1298;4;30;09;1q25.3;DHX9, DDX9, NDHII;;DEAH (Asp-Glu-Ala-His) box polypeptide 9;603115;H;;;1(Ddx9)
1.1299;8;21;07;1q25.2;FAM20B;;Family with sequence similarity 20, member B;611063;R, REc;;;
1.1300;10;2;09;1q25.2;LHX4, CPHD4;;LIM homeo box gene 4;602146;A, Ch;fused to IGH in ALL;Pituitary hormone deficiency, combined, 4, 262700 (3);
1.1301;5;31;05;1q25.3;NCF2;;Neutrophil cytosolic factor-2, 65kD;608515;REa, A;;Chronic granulomatous disease due to deficiency of NCF-2, 233710 (3);1(Ncf2)
1.1302;9;7;07;1q25.3;NPL, C1orf13, C112;;N-acetylneuraminate pyruvate lyase;611412;REc;;;
1.1303;5;3;07;1q25;PDON2;;Periodontitis, aggressive, 2;608526;Fd;between D1S196 and D1S533;Periodontitis, aggressive, 2 (2);
1.1304;12;24;08;1q31.1;PLA2G4A, PLA2G4;;Phospholipase A2, group IVA, cytosolic;600522;A;;Phospholipase A2, group IV A, deficiency of (3);
1.1305;8;20;07;1q25.3;RGSL1;;Regulator of G protein signaling-like 1;611012;REc;;;
1.1306;8;2;07;1q25;RGSL2;;Regulator of G protein signaling-like 2;611013;REc;related to AD linked to 1q25;;
1.1307;1;24;02;1q25.3;RNASEL, RNS4, PRCA1, HPC1;;Ribonuclease L (2',5'-oligoisoadenylate synthetase-dependent);180435;A, Fd;;Prostate cancer 1, 601518 (3);
1.1308;5;21;07;1q25.3;SMG7, EST1C, KIAA0250;;SMG7, C. elegans, homolog of;610964;R, REc;;;
1.1309;3;12;96;1q25.2;SOAT1, STAT, ACAT;;Sterol O-acyltransferase 1 (acyl-Coenzyme A: cholesterol acyltransferase 1);102642;A, REa;;;
1.1310;4;18;05;1q25.1;TNFSF4, GP34, OX4OL;;Tumor necrosis factor ligand superfamily, member 4;603594;A, H;;{Myocardial infarction, susceptibility to}, 608446 (3);1(Tnfsf4)
1.1311;1;1;95;1q31.1;TPR;;Tumor potentiating region (translocated promoter region);189940;REa, A;fused with MET in chemically induced tumor;;
1.1312;7;12;16;1q25.3;TSEN15, SEN15, C1orf19, PCH2F;;tRNA splicing endonuclease 15, S. cerevisiae, homolog of;608756;REc;;Pontocerebellar hypoplasia, type 2F, 617026 (3);
1.1313;3;8;91;1q22;BGLAP;;Bone gamma-carboxyglutamic acid protein;112260;REa, REb;;;3(Bglap)
1.1314;4;29;97;1q25.3;CACNA1E, CACNL1A6;;Calcium channel, voltage-dependent, alpha 1E subunit;601013;A;;;
1.1315;2;8;17;1q31.2;CDC73, HRPT2, C1orf28;;Cell division cycle protein 73, S. cerevisiae, homolog of;607393;Fd, REc;;Hyperparathyroidism-jaw tumor syndrome, 145001 (3); Hyperparathyroidism, familial primary, 145000 (3); Parathyroid adenoma with cystic changes, 145001 (3); Parathyroid carcinoma, 608266 (3);
1.1316;2;21;02;1q25.3;LAMC2, LAMNB2, LAMB2T;;Laminin, gamma-2 (nicein, 100kD; kalinin, 105kD; BM600, 100kD);150292;A, Fd;;Epidermolysis bullosa, junctional, Herlitz type, 226700 (3); Epidermolysis bullosa, junctional, non-Herlitz type, 226650 (3);
1.1317;10;25;10;1q25.2;PDCN, NPHS2, SRN1;;Podocin;604766;REc, Fd;modifies phenotype of NPHS1 mutations to FSGS;Nephrotic syndrome, type 2, 600995 (3);
1.1318;6;19;98;1q25.3;RGS16;;Regulator of G protein signaling-16;602514;A;;;
1.1319;3;31;03;1q25.2;TOR3A, ADIR;;Torsin family 3, member A (ATP-dependent interferon-responsive protein);607555;REc;;;
1.1320;12;16;93;1q31.1;PDC;;Phosducin, pineal gland;171490;H, REa, A;;;1(Pdc)
1.1321;7;10;92;1q32.1;ATP2B4, ATP2B2, PMCA4;;ATPase, Ca++ transporting, plasma membrane, 4;108732;REa, A, Fd;;;
1.1322;10;8;07;1q25.1;CENPL;;Centromeric protein L;611503;REc;;;
1.1323;6;14;07;1q25.1;DARS2, ASPRS. LBSL;;Aspartyl-tRNA synthetase 2;610956;R, REc;;Leukoencephalopathy with brain stem and spinal cord involvement and lactate elevation, 611105 (3);
1.1324;12;17;15;1q25.1;KIAA0040;;KIAA0040 gene;616696;Psh, REc;;;
1.1325;9;21;17;1q25.1;KLHL20, KLEIP, KLHLX;;Kelch-like 20;617679;REc;;;
1.1326;7;17;09;1q25.1;PRDX6;;Peroxiredoxin 6;602316;REc;;;
1.1327;10;30;06;1q25.1;RC3H1, KIAA2025;;Roquin;609424;REc;;;
1.1328;5;3;17;1q25.1;TNN;;Tenascin N;617472;REc;;;
1.1329;6;9;15;1q25.3;XPR1, SYG1, IBGC6;;Xenotropic and polytropic retrovirus receptor;605237;R;;Basal ganglia calcification, idiopathic, 6, 616413 (3);1(Xpr1)
1.1330;2;20;98;1q32.1;LAD1;;Ladinin;602314;H;;;1(Lad1)
1.1331;11;27;18;1q25.2;ANGPTL1;;Angiopoietin-like 1;603874;REc;;;
1.1332;2;15;18;1q25.2;CEP350, CAP350, KIAA0480;;Centrosomal protein 350;617870;R, REc;;;
1.1333;12;22;17;1q25.2;RALGPS2, FLJ10244;;RAL guanine nucleotide exchange factor with PH domain and SH3 domain-binding motif 2;617819;REc;;;
1.1334;8;3;12;1q25.2;RASAL2, NGAP;;Ras protein activator-like 2;606136;REc;;;
1.1335;7;13;09;1q25.2;SEC16B, LZTR2, RGPR, SEC16S;;Sec16, S. cerevisiae, homolog of, B;612855;REc;;;
1.1336;10;31;17;1q25.2;TDRD5, TUDOR3;;Tudor domain-containing protein 5;617748;REc;;;
1.1337;5;13;15;1q25.2-q25.3;ACBD6;;Acyl-CoA-binding domain-containing protein 6;616352;REc;;;
1.1338;12;27;13;1q25.2-q25.3;LINC-COX2;;Long intergenic noncoding RNA COX2;615492;REn;;;
1.1339;1;1;95;1q31.1;PTGS2;;Prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase);600262;REa, A;;;
1.1340;1;16;07;1q25.3;APOBEC4;;Apolipoprotein B mRNA-editing enzyme, catalytic polypeptide-like 4;609908;REc;;;
1.1341;11;11;14;1q25.3;ARPC5, ARC16;;Actin-related protein 2/3 complex, subunit 5;604227;REc;;;
1.1342;11;21;18;1q25.3;COLGALT2, GLT25D2, KIAA0584;;Collagen beta(1-0)galactosyltransferase 2;617533;R, REc;;;
1.1343;11;05;18;1q25.3;EDEM3, C1orf22;;Endoplasmic reticulum degradation-enhancing alpha-mannosidase-like protein 3;610214;REc;;;
1.1344;7;17;09;1q25.3;IER5;;Immediate-early response gene 5;607177;R, REc;;;
1.1345;5;26;13;1q25.3;IVNS1ABP, NS1BP, ND1;;Influenza virus NS1A protein-binding protein;609209;REc, R;;;
1.1346;8;17;98;1q25.3;MR1, HLALS;;Major histocompatibility complex, class I-related;600764;A;;;
1.1347;9;11;12;1q25.3;NMNAT2, PNAT2, KIAA0479;;Nicotinamide nucleotide adenylyltransferase 2;608701;REc;;;
1.1348;7;27;09;1q25.3;RGL1, RGL;;Ral guanine nucleotide dissociation stimulator-like 1;605667;R, REc;;;
1.1349;11;2;04;1q25.3;RNF2, RING2, RING1B, HIPI3, DING, BAP1;;RING finger protein 2;608985;R, REc;;;
1.1350;8;1;16;1q25.3;STX6;;Syntaxin 6;603944;REc;;;
1.1351;4;19;06;1q25.3;VDAC4;;Voltage-dependent anion channel 4;610030;Psh, REc;;;
1.1352;7;31;08;1q31.3;ASPM, MCPH5;;Abnormal spindle-like, microcephaly-associated;605481;Fd, REc;;Microcephaly 5, primary, autosomal recessive, 608716 (3);
1.1353;5;23;00;1q31.2;B3GALT2, GLCT2;;UDP-galactose:beta-N-acetylglucosamine beta-1,3-galactosyltransferase 2;603018;REc;;;
1.1354;12;13;00;1q31;BOS2;;Branchiootic syndrome 2;120502;Fd;;Branchiootic syndrome 2 (2);
1.1355;5;12;09;1q31;CELIAC7;;Celiac disease, susceptibility to, 7;612005;Fd;associated with rs2816316;{Celiac disease, susceptibility to, 7} (2);
1.1356;1;24;93;1q32.1;CTSE;;Cathepsin E;116890;REa, A, Fd;closely linked to REN;;
1.1357;3;29;06;1q25.3;GLUL, GLNS;;Glutamate-ammonia ligase (glutamine synthase);138290;Psh, A, REc;pseudogene on chr.9;Glutamine deficiency, congenital, 610015 (3);
1.1358;3;30;18;1q32.1;KIF14, KIAA0042, MKS12, MCPH20;;Kinesin family member 14;611279;Psh, REc, H;mutation identified in 1 MKS12 family;?Meckel syndrome 12, 616258 (3); Microcephaly 20, primary, autosomal recessive, 617914 (3);1(Kif14)
1.1359;10;29;96;1q31.2;RGS2, G0S8;;G0 to G1 switch regulatory 8, 24kD;600861;A;;;
1.1360;10;15;09;1q25.3;LAMC1, LAMB2;;Laminin, gamma-1 (formerly LAMB2);150290;REa, Fd;at least 3 genes, ?linked;;1(Lamb2)
1.1361;3;21;07;1q32.3;LQK1;;LQK1 protein;610864;REc;;;
1.1362;1;24;03;1q31;MGR6, FHM3;;Migraine, several forms;607516;Fd;;{Migraine with or without aura, susceptibility to, 6} (2); {Migraine, familial hemiplegic, 4} (2);
1.1363;2;6;08;1q32.1;NAV1, POMFIL3, KIAA1151;;Neuron navigator 1;611628;R;;;
1.1364;8;17;98;1q32.1;PFKFB2;;Fructose-2,6-bisphosphatase, cardiac isozyme;171835;REa, A;;;
1.1365;6;27;02;1q32.1;PHLDA3, TIH1;;Pleckstrin homology-like domain, family A, member 3;607054;REc;;;1(Phlda3)
1.1366;10;15;09;1q31;PVOP1;;Pelvic organ prolapse, susceptibility to, 1;176780;Fd;associated with rs10911193;{Pelvic organ prolapse, susceptibility to, 1} (2);
1.1367;6;11;97;1q31.2;RGS1, IER1, IR20;;Regulator of G-protein signaling 1;600323;A;;;
1.1368;6;23;15;1q32.1;UBE2T, HSPC150, FANCT;;Ubiquitin-conjugating enzyme E2T;610538;R, REc;;Fanconi anemia, complementation group T, 616435 (3);
1.1369;3;8;07;1q31.2;TROVE2, RO60, SSA2;;TROVE domain family, member 2;600063;A;;;
1.1370;4;17;13;1q32.1;CDK18, PCTK3;;Cyclin-dependent kinase 18;169190;A;;;
1.1371;7;27;11;1q32.1;CHIT, CHITD;;Chitotriosidase;600031;Fd, A;;[Chitotriosidase deficiency], 614122 (3);
1.1372;1;1;12;1q32.1;IL10, CSIF, GVHDS;;Interleukin-10;124092;Psh, R;;{HIV-1, susceptibility to}, 609423 (3); {Graft-versus-host disease, protection against}, 614395 (3); {Rheumatoid arthritis, progression of}, 180300 (3);
1.1373;7;17;09;1q32.1;KIF21B, KIAA0449;;Kinesin family member 21B;608322;R, REc;;;1(Kif21b)
1.1374;6;26;01;1q31.3;LHX9;;LIM homeo box gene 9;606066;REc;;;1(Lhx9)
1.1375;7;22;09;1q31.3-q32.1;PTPRC, CD45, LCA;;Protein tyrosine phosphatase, receptor type, c polypeptide;151460;A, S;;{Hepatitis C virus, susceptibility to}, 609532 (3); Severe combined immunodeficiency, T cell-negative, B-cell/natural killer-cell positive, 608971 (3);1(Ly5)
1.1376;3;8;07;1q32.1;SLC41A1;;Solute carrier family 41, member 1;610801;REc;;;1(Slc41a1)
1.1377;7;22;09;1q31.3;CFHR1, FHR1, HFL1, CFHL1;;Complement factor H-related 1;134371;R;;{Macular degeneration, age-related, reduced risk of}, 603075 (3); {Hemolytic uremic syndrome, atypical, susceptibility to}, 235400 (3);
1.1378;7;22;09;1q31.3;CFHR2, FHR2, HFL3, CFHL2;;Complement factor H-related 2;600889;REc, R;in same 165kb YAC as F13B;;
1.1379;7;22;09;1q31.3;CFHR3, FHR3, HLF4, CFHL3;;Complement factor H-related 3;605336;R;;{Macular degeneration, age-related, reduced risk of}, 603075 (3); {Hemolytic uremic syndrome, atypical, susceptibility to}, 235400 (3);
1.1380;7;22;09;1q31.3;CFHR4, FHR4, CFHL4;;Complement factor H-related 4;605337;R;;;
1.1381;11;29;18;1q31.3;CRB1, RP12, LCA8;;Crumbs, Drosophila, homolog of, 1;604210;Fd, REc;;Retinitis pigmentosa-12, 600105 (3); Leber congenital amaurosis 8, 613835 (3); Pigmented paravenous chorioretinal atrophy, 172870 (3);
1.1382;3;21;93;1q31.3;F13B;;Coagulation factor XIII, B polypeptide;134580;Fd, A, RE;;Factor XIIIB deficiency, 613235 (3);1(F13b)
1.1383;12;3;90;1q32.1;MYOG, MYF4;;Myogenic factor-4; myogenin;159980;REa, A;;;1(Myog)
1.1384;6;4;97;1q31-q42;PHA2A, PHA2;;Pseudohypoaldosteronism type IIA;145260;Fd;;Pseudohypoaldosteronism, type IIA (2);
1.1385;7;14;11;1q32.1;PIGR;;Polymeric immunoglobulin receptor;173880;REa, A, Fd;;;
1.1386;1;20;11;1q42.13;PSEN2, AD4, STM2, CMD1V;;Presenilin 2;600759;Psh, REc, REn;;Alzheimer disease-4, 606889 (3); Cardiomyopathy, dilated, 1V, 613697 (3);
1.1387;01;04;19;1q31.1;OCLM, TISR;;Oculomedin;604301;REc;;;
1.1388;01;04;19;1q31.1;ODR4, C1orf27;;Odorant response abnormal 4, C. elegans, homolog of;609335;REc;;;
1.1389;8;31;17;1q31.1;PACERR, PTGS2AS1;;PTGS2 antisense NFKB1 complex-mediated expression regulator RNA, noncoding;617650;REc;;;
1.1390;12;30;05;1q31.1;PSNP2;;Supranuclear palsy, progressive, 2;609454;Fd;between D1S238 and D1S2823;Supranuclear palsy, progressive, 2 (2);
1.1391;12;18;08;1q31.2;RGS21;;Regulator of G protein signaling 21;612407;REc;;;1(Rgs1)
1.1392;7;25;18;1q31.3;ATP6V1G3;;ATPase, H+ transporting, V1 subunit G3;618071;REc;;;
1.1393;4;4;02;1q31.2;GLRX2, GRX2;;Glutaredoxin 2;606820;REc;;;
1.1394;3;15;10;1q31.3;DENND1B, FAM31B, C1orf18;;DENN/MADD domain-containing 1B;613292;REc;;;
1.1395;12;21;10;1q32.3;FLVCR1, AXPC1, PCARP;;Feline leukemia virus subgroup C receptor 1;609144;R;;Ataxia, posterior column, with retinitis pigmentosa, 609033 (3);
1.1396;4;25;06;1q31.3;KCNT2, SLICK, EIEE57;;Potassium channel, subfamily T, member 2;610044;REc;mutation identified in 1 EIEE57 patient;?Epileptic encephalopathy, early infantile, 57, 617771 (3);
1.1397;5;11;09;1q32.1;MIR181A1, MIR213, MIRN181A1;;Micro RNA 181A1;612742;REc;;;
1.1398;5;11;09;1q32.1;MIR181B1, MIRN181B1;;Micro RNA 181B1;612744;REc;;;
1.1399;4;15;02;1q31.3;NEK7;;Never-in-mitosis gene A-related kinase 7;606848;Psh, R;;;
1.1400;7;5;90;1q32.1;TNNI1;;Troponin-I, skeletal, slow;191042;REa, Psh;;;1(Tnni1)
1.1401;4;16;14;1q31.3-q32.1;NYS7;;Nystagmus 7, congenital, autosomal dominant;614826;Fd;between D1S218 and D1S2655;Nystagmus 7, congenital, autosomal dominant (2);
1.1402;8;17;98;1q32.1;AVPR1B, AVPR3;;Arginine vasopressin receptor-1B;600264;A;;;
1.1403;5;9;97;1q32.1;BTG2, PC3;;B-cell translocation gene 2 (pheochromocytoma cell-3);601597;REa, A;;;
1.1404;7;9;90;1q32.2;C4BPA;;Complement component 4-binding protein, alpha polypeptide;120830;F, REa, A, RE;same RE fragment as C4BPB;;1(C4bp)
1.1405;7;9;90;1q32.1;C4BPB;;Complement component 4-binding protein, beta polypeptide;120831;RE, A;;;
1.1406;4;22;10;1q32.1;CACNA1S, CACNL1A3, CCHL1A3, TTPP1, HOKPP1;;Calcium channel, voltage-dependent, L type, alpha 1S subunit;114208;H, REa, A, Fd;in mouse, mutation causes muscular dysgenesis;Hypokalemic periodic paralysis, type 1, 170400 (3); {Malignant hyperthermia susceptibility 5}, 601887 (3); {Thyrotoxic periodic paralysis, susceptibility to, 1}, 188580 (3);1(Cchl1a3, mdg)
1.1407;3;11;92;1q32.2;CD34;;CD34 antigen;142230;REa, A;;;1(Cd34)
1.1408;8;11;17;1q32.2;CD55, DAF, CROM, CHAPLE;;CD55 antigen (blood group Cromer);125240;REa, A;;[Blood group Cromer], 613793 (3); Complement hyperactivation, angiopathic thrombosis, and protein-losing enteropathy, 226300 (3);
1.1409;6;6;16;1q31.3;CFH, HF1, HUS, ARMD4, AHUS1;;Complement factor H;134370;F, REa, RE, H, Fd;;{Hemolytic uremic syndrome, atypical, susceptibility to, 1}, 235400 (3); Complement factor H deficiency, 609814 (3); {Macular degeneration, age-related, 4}, 610698 (3); Basal laminar drusen, 126700 (3);1(Cfh)
1.1410;12;21;12;1q31.3;CFHR5, CFHL5, FHR5, CFHR5D;;Complement factor H-related 5;608593;A, R, REc;;Nephropathy due to CFHR5 deficiency, 614809 (3);
1.1411;7;6;07;1q32.2;CR1, C3BR;;Complement component (3b/4b) receptor-1;120620;F, REa, A, RE;;CR1 deficiency (1); {?SLE susceptibility} (1); [Blood group, Knops system], 607486 (3); {Malaria, severe, resistance to}, 611162 (3);
1.1412;4;30;01;1q32.2;CR1L;;Complement component receptor 1-like;605886;REc;;;
1.1413;7;6;12;1q32.2;CR2, C3DR, SLEB9, CVID7;;Complement component (3d/Epstein-Barr virus) receptor-2;120650;F, REa, A, RE;;{Systemic lupus erythematosus, susceptibility to, 9}, 610927 (3); Immunodeficiency, common variable, 7, 614699 (3);1(Cr2)
1.1414;5;12;99;1q32.1;CSRP1, CSRP;;Cysteine and glycine-rich protein-1;123876;REa, A;;;3(Csrp)
1.1415;3;20;09;1q32.1;CYB5BR1, NQO3A2, B5R.1;;Cytochrome b5 reductase 1;608341;REc;;;
1.1416;11;13;98;1q32.1;ELF3, ESX;;E74-like factor 3 (ETS domain transcription factor, serine box, epithelial-specific);602191;A;;;
1.1417;1;1;95;1q32.1;ELK4, SAP1;;ELK4, ETS-domain protein (SRF accessory protein 1);600246;A;;;1(Elk4)
1.1418;7;18;12;1q32.1;FAM72A, LMPIP, UGENE;;Family with sequence similarity 72, member A;614710;REc;;;
1.1419;9;8;11;1q32;GFND1;;Glomerulopathy with fibronectin deposits 1;137950;Fd;max lod at D1S2782;Glomerulopathy with fibronectin deposits 1 (2);
1.1420;3;10;05;1q32.2;HHAT, MART2, SKI1;;Hedgehog acyltransferase;605743;REc;;;
1.1421;2;28;01;1q32.1;IL19;;Interleukin 19;605687;R;;;
1.1422;2;7;01;1q32.1;IL20;;Interleukin 20;605619;R;;;1(Il20)
1.1423;6;27;01;1q32.1;IL24, ST16, MDA7;;Interleukin 24 (suppression of tumorigenicity 16);604136;R;;;
1.1424;09;11;18;1q32.1;KDM5B, JARID1B, PUT1, PLU1, RBBP2H1A, MRT65;;Lysine-specific demethylase 5B;605393;A;;Mental retardation, autosomal recessive 65, 618109 (3);
1.1425;10;23;14;1q32.1;KISS1, HH13;;KISS1 metastasis suppressor;603286;A, R;mutation identified in 1 HH13 family;?Hypogonadotropic hypogonadism 13 with or without anosmia, 614842 (3);
1.1426;2;12;15;1q32.2;LAMB3, AI1A;;Laminin, beta-3 (nicein, 125kD; kalinin, 140kD; BM600, 125kD);150310;Fd;;Epidermolysis bullosa, junctional, Herlitz type, 226700 (3); Epidermolysis bullosa, junctional, non-Herlitz type, 226650 (3); Amelogenesis imperfecta, type IA, 104530 (3);
1.1427;2;4;02;1q32.1;LGR6;;Leucine-rich repeat-containing G protein-coupled receptor-6;606653;A;;;
1.1428;11;11;14;1q32.1;LMOD1, SMLMOD, 1D;;Leiomodin 1;602715;REc;;;
1.1429;8;17;09;1q32.2;MCP, CD46, AHUS2;;Membrane cofactor protein (CD46, trophoblast-lymphocyte cross-reactive antigen);120920;REa, A, REn;;{Hemolytic uremic syndrome, atypical, susceptibility to, 2}, 612922 (3);
1.1430;6;19;98;1q32.1;MDM4;;Mouse double minute 4, homolog of;602704;A;;;1(Mdm4)
1.1431;5;29;12;1q32.1;NUAK2, SNARK;;NUAK family, SNF1-like kinase, 2;608131;A;;;
1.1432;2;2;10;1q32;PARK16;;Parkinson disease 16;613164;Fd;associated with rs823128;{Parkinson disease 16} (2);
1.1433;3;25;15;1q32;PFHB2;;Progressive familial heart block, type II;140400;Fd;between D1S70 and D1S505;Progressive familial heart block, type II (2);
1.1434;7;14;98;1q32.1;PIK3C2B;;Phosphatidylinositol 3-kinase, class 2, beta polypeptide;602838;A;;;
1.1435;3;6;01;1q32.1;PKP1;;Plakophilin-1;601975;Psh, A;;Ectodermal dysplasia/skin fragility syndrome, 604536 (3);
1.1436;10;15;97;1q32.1;PRELP;;Proline arginine-rich end leucine-rich repeat protein;601914;A;;;
1.1437;01;04;19;1q32-q41;PTPN14, PEZ, CATLPH;;Protein tyrosine phosphatase, nonreceptor-type, 14;603155;A, REn, Fd;;Choanal atresia and lymphedema, 613611 (3);
1.1438;3;9;00;1q32.1;RAB7L1;;RAB7-like 1;603949;A;;;
1.1439;12;18;95;1q32.1;RBBP5, RBQ3;;Retinoblastoma-binding protein-5;600697;Psh, A;;;
1.1440;11;3;09;1q32.1;REN, HNFJ2;;Renin;179820;REa, A, D, Fd, Ch;~24cM distal to AT3;[Hyperproreninemia] (3); Renal tubular dysgenesis, 267430 (3); Hyperuricemic nephropathy, familial juvenile 2, 613092 (3);1(Ren1)
1.1441;2;14;13;1q32.1;SNRPE, HYPT11;;Small nuclear ribonucleoprotein polypeptide E;128260;REa, A, F;;Hypotrichosis 11, 615059 (3);
1.1442;5;4;00;1q32.1;SOX13, ICA12;;SRY-box 13;604748;A;;;
1.1443;7;6;00;1q32.1;TIMM17A, TIM17A;;Translocase of inner mitochondrial membrane 17, yeast, homolog of, A;605057;A;;;
1.1444;7;26;10;1q32.1;TNNT2, CMH2, CMD1D, RCM3, LVNC6;;Troponin-T2, cardiac;191045;REa, Fd, A;;Cardiomyopathy, hypertrophic, 2, 115195 (3); Cardiomyopathy, dilated, 1D, 601494 (3); Cardiomyopathy, familial restrictive, 3, 612422 (3); Left ventricular noncompaction 6, 601494 (3);
1.1445;2;18;98;1q32.3;TRAF5;;TNF receptor-associated factor 5;602356;A;;;1(Traf5)
1.1446;12;21;06;1q31.2;UCHL5, UCH37;;Ubiquitin carboxyl-terminal hydrolase L5;610667;REc;;;
1.1447;1;9;13;1q32.2;CAMK1G, CLICK3;;Calcium/calmodulin-dependent protein kinase IG;614994;REc;;;
1.1448;3;15;16;1q41;CENPF, CILD31, STROMS;;Centromere autoantigen F, 400kD;600236;A;;Stromme syndrome, 243605 (3);1(Cenpf)
1.1449;1;30;12;1q32.2;G0S2;;G0/G1 switch gene 2;614447;REc;;;
1.1450;5;29;12;1q32.2;HSD11B1, HSD11, HSD11L, CORTRD2;;Hydroxysteroid, 11-beta, dehydrogenase 1;600713;REa, REc;digenic triallelic mutations with H6PD;Cortisone reductase deficiency 2, 614662 (3);
1.1451;12;21;12;1q32.2;IRF6, VWS, LPS, PIT, PPS1, OFC6;;Interferon regulatory factor 6;607199;REc, Fd;OFC6 in enhancer 5' of IRF6;van der Woude syndrome, 119300 (3); Popliteal pterygium syndrome 1, 119500 (3); {Orofacial cleft 6}, 608864 (3);
1.1452;7;9;15;1q32.2;KCNH1, EAG, TMBTS, ZLS1;;Potassium voltage-gated channel, subfamily H, member 1 (ether-a-go-go, drosophila, homolog of);603305;Psh;;Temple-Baraitser syndrome, 611816 (3); Zimmermann-Laband syndrome 1, 135500 (3);
1.1453;1;20;99;1q32.1;RABIF, RASGFR3, MSS4;;Rab-interacting factor (Ras-specific guanine-releasing factor-3; mammalian suppressor of SEC4);603417;A;;;
1.1454;4;25;12;1q32.1;ADIPOR1, CGI45;;Adiponectin receptor 1;607945;REc;;;1(Adipor1)
1.1455;5;18;95;1q32.1;ADORA1, RDC7;;Adenosine A1 receptor;102775;A;;;
1.1456;10;23;15;1q32.1;ARL8A, GIE2;;ADP-ribosylation factor-like 8A;616597;REc;;;
1.1457;11;1;13;1q32.1;BLACAT1, LINC00912;;Bladder cancer-associated transcript 1, noncoding;615480;REc;;;
1.1458;12;30;14;1q32.1;C1orf186, RHEX;;Chromosome 1 open reading frame 186;616088;REc;;;
1.1459;3;24;11;1q32.1;CAMSAP1L, CAMSAP2, KIAA1078;;Calmodulin-regulated spectrin-associated protein 1-like 1;613775;REc;;;
1.1460;4;23;08;1q32.1;CHI3L1, GP39, YKL40, ASRT7;;Chitinase 3-like 1 (cartilage glycoprotein-39);601525;REa, REc;;{Schizophrenia, susceptibility to}, 181500 (3); {Asthma-related traits, susceptibility to, 7}, 611960 (3);
1.1461;9;9;13;1q32.1;CNTN2, TAX, TAX1, FAME5;;Contactin 2 (transiently-expressed axonal glycoprotein);190197;A;1 family identified with mutation;?Epilepsy, myoclonic, familial adult, 5, 615400 (3);
1.1462;11;11;13;1q32.1;DDX59, OFD5;;DEAD box polypeptide 59;615464;REc;;Orofaciodigital syndrome V, 174300 (3);
1.1463;1;27;18;1q32.1;DSTYK, KIAA0472, RIP5, DUSTYPK, CAKUT1, SPG23;;Dual serine/threonine and tyrosine protein kinase;612666;R, REc, Fd;;Congenital anomalies of kidney and urinary tract 1, 610805 (3); Spastic paraplegia 23, 270750 (3);
1.1464;1;24;10;1q32.1;EIF2D, HCA56;;Eukaryotic translation initiation factor 2D;613709;REc, H;;;1(Eif2d)
1.1465;3;20;06;1q32.1;ETNK2, EKI2;;Ethanolamine kinase 2;609859;REc;;;1(Etnk2)
1.1466;1;1;95;1q32.1;FMOD;;Fibromodulin;600245;Psh, A;;;
1.1467;2;20;98;1q32.1;GPR25;;G protein-coupled receptor-25;602174;A;;;
1.1468;8;15;17;1q32.1;GPR37L1, ETBRLP2;;G protein-coupled receptor 37-like 1;617630;REc;;;
1.1469;2;12;09;1q32.1;IBD23;;Inflammatory bowel disease 23;612381;Fd;associated with rs3024505;{Inflammatory bowel disease 23} (2);
1.1470;1;26;17;1q32.1;IGFN1, EEF1A2BP1;;Immunoglobulin-like and fibronectin type III domains-containing protein 1;617309;REc;;;
1.1471;7;17;09;1q32.1;IKBKE;;I-kappa-B kinase-epsilon;605048;R, REc;;;
1.1472;08;07;18;1q32.1;INAVA, C1orf106, IBD29;;Innate immunity activator;618051;REc;;{Inflammatory bowel disease 29}, 618077 (3);
1.1473;3;29;12;1q32.1;KLHDC8A;;Kelch domain-containing protein 8A;614503;REc;;;
1.1474;3;30;12;1q32.1;KLHL12, DKIR;;Kelch-like 12;614522;REc;;;
1.1475;2;25;15;1q32.1;LEMD1;;LEM domain-containing protein 1;610480;R, REc;;;
1.1476;09;06;18;1q32.1;LRRN2, GAC1, LRANK1;;Leucine-rich repeat protein, neuronal, 2;605492;A;;;
1.1477;12;10;13;1q32.1;MAPKAPK2, MK2;;Mitogen-activated protein kinase-activated protein kinase 2;602006;REc;;;
1.1478;7;22;16;1q32.1;MIR1231;;Micro RNA 1231;617040;REc;;;
1.1479;11;4;93;1q32.1;MYBPH;;Myosin-binding protein H;160795;A;;;
1.1480;4;10;14;1q32.1;NFASC, KIAA0756;;Neurofascin;609145;REc, R;;;
1.1481;1;28;00;1q32.1;NR5A2, FTF, HB1F;;Nuclear receptor subfamily 5, group A, member 2 (fetoprotein transcription factor);604453;A;;;
1.1482;3;20;08;1q32.1;NUCKS1, NUCKS;;Nuclear casein kinase and cyclin-dependent kinase substrate 1;611912;REc, H;;;1(Nucks1)
1.1483;7;27;09;1q32.1;PEPP3, KIAA0969;;Phosphatidylinositol 3-phosphate-binding PH domain protein 3;607771;R, REc;;;
1.1484;9;22;16;1q32.1;PM20D1;;Peptidase M20 domain-containing protein 1;617124;REc;;;
1.1485;8;20;01;1q32.1;PPP1R12B, MYPT2;;Protein phosphatase 1, regulatory subunit 12B (myosin phosphatase target subunit 2);603768;A;;;
1.1486;2;16;16;1q32.1;PPP1R15B, CREP, MSSGM2;;Protein phosphatase 1, regulatory subunit 15B;613257;REc;;Microcephaly, short stature, and impaired glucose metabolism 2, 616817 (3);
1.1487;8;16;12;1q32.1;PPFIA4;;Protein-tyrosine phosphatase, receptor-type, F polypeptide-interacting protein alpha 4;603145;REc;;;
1.1488;11;27;94;1q32.1;PTPN7;;Protein tyrosine phosphatase, nonreceptor-type, 7;176889;A, Ch;;;
1.1489;1;17;06;1q32.1;SLC45A3, PRST, PCANAP6, IPCA6;;Solute carrier family 45, member 3 (prostein);605097;R;;;
1.1490;4;30;15;1q32.1;SYT2, CMS7, MYSPC;;Synaptotagmin-2;600104;H, REc;;Myasthenic syndrome, congenital, 7, presynaptic, 616040 (3);1(Syt2)
1.1491;4;2;03;1q32.1;RASSF5, NORE1;;Ras association (RalGDS/AF-6) domain family 5 (Nore1, mouse, homolog of);607020;REc;;;1(Nore1)
1.1492;2;2;17;1q32.1;SHISA4, C1orf40, TMEM58;;Shisa family, member 4;617326;REc;;;
1.1493;8;8;13;1q32.1;SLC26A9;;Solute carrier family 26 (sulfate transporter), member 9;608481;REc;;;
1.1494;3;14;07;1q32.1;SRGAP2, KIAA0456;;Slit-robo GTPase-activating protein, rho, 2;606524;R, REc;;;
1.1495;6;5;08;1q32.1;YOD1, OTUD2, DUBA8;;YOD1 OTU deubiquitinating enzyme 1, S. cerevisiae, homolog of;612023;REc;;;
1.1496;12;15;10;1q32.1;ZBED6;;Zinc finger BED domain-containing protein 6;613512;REc;in intron 1 of ZC3H11A;;
1.1497;12;15;10;1q32.1;ZC3H11A, KIAA0663;;Zinc finger CCCH domain-containing protein 11A;613513;REc;;;
1.1498;11;30;06;1q32.3;DTL, RAMP, DCAF2, CDT2;;Denticleless, Drosophila, homolog of;610617;A;;;
1.1499;6;10;98;1q32.1;RNPEP;;Arginyl aminopeptidase (aminopeptidase B);602675;A;;;
1.1500;10;23;87;1q42.13;GUK1;;Guanylate kinase-1;139270;S, D;;;
1.1501;10;23;87;1q32.1-q42;GUK2;;Guanylate kinase-2;139280;S, D;genetic independence of GUK1 and GUK2 unproved;;
1.1502;2;3;05;1q32.1;DYRK3;;Dual-specificity tyrosine phosphorylation-regulated kinase 3;603497;TM, REc;;;1(Dyrk3)
1.1503;9;7;10;1q32.1;FAIM3, TOSO, FCMR;;Fas apoptotic inhibitory molecule 3;606015;R, REn;;;
1.1504;3;23;09;1q32.2;MIR29C, MIRN29C;;Micro RNA 29C;610784;REc;;;
1.1505;12;21;09;1q32.2;MIR205, MIRN205;;Micro RNA 205;613147;REc;;;
1.1506;7;27;09;1q32.2;PLXNA2, OCT, PLXN2;;Plexin A2 (OCT transmembrane protein);601054;REa, REc;;;
1.1507;12;17;07;1q32.1;SARG, C1orf116;;Specifically androgen-regulated gene;611680;REc;;;
1.1508;7;25;18;1q32.2;SYT14, SCAR11;;Synaptotagmin 14;610949;REc;mutation identified in 1 SCAR11 family;?Spinocerebellar ataxia, autosomal recessive 11, 614229 (3);
1.1509;12;20;96;1q32.3;PROX1;;Prospero-related homeo box 1;601546;REc;;;(Prox1)
1.1510;12;27;13;1q32.3;NEK2, RP67;;Never in mitosis gene a-related kinase 2;604043;A, REc;pseudogenes on chr. 2, 14, and 22; mutation identified in 1 family;?Retinitis pigmentosa 67, 615565 (3);
1.1511;5;25;10;1q32.3;ATF3;;Activating transcription factor 3;603148;REc;;;
1.1512;1;30;01;1q32.1;FCAMR;;Fc fragment of IgA and IgM, receptor for;605484;A;;;1(Fcamr)
1.1513;3;24;14;1q32.3;INTS7, INT7;;Integrator complex subunit 7;611350;R, REc;;;
1.1514;3;4;08;1q32.3;NENF, CIR2;;Neuron-derived neurotrophic factor;611874;REc;;;
1.1515;4;3;09;1q32.3;RD3, LCA12, C1orf36;;Retinal degeneration 3, mouse, homolog of;180040;REc, H;;Leber congenital amaurosis 12, 610612 (3);1(rd3)
1.1516;6;12;17;1q32.3;RPS6KC1, RPK118;;Ribosomal protein S6 kinase C1;617517;REc;;;
1.1517;2;25;08;1q32.3;SLC30A1, ZNT1;;Solute carrier family 30 (zinc transporter), member 1;609521;REc;;;
1.1518;2;25;15;1q32.3;VASH2;;Vasohibin 2;610471;REc;;;
1.1519;7;22;11;1q32.2;TRAF3IP3, T3JAM;;TRAF3-interacting protein 3;608255;REc;;;1(T3jam)
1.1520;10;30;08;1q41;AIDA;;Axin interactor, dorsalization-associated;612375;REc;;;
1.1521;7;18;14;1q41;BPNT1;;3'(2'),5'-bisphosphate nucleotidase 1;604053;REc;;;
1.1522;9;16;12;1q41;DUSP10, MKP5;;Dual-specificity phosphatase 10;608867;REc;;;
1.1523;8;24;98;1q41;ESRRG;;Estrogen-related receptor, gamma;602969;Psh;;;
1.1524;3;26;16;1q41;GPATCH2, GPATC2;;G-patch domain-containing protein 2;616836;REc;;;
1.1525;5;30;03;1q42.12;H3F3A, H3F3;;H3 histone, family 3A;601128;REc;;;
1.1526;12;26;14;1q41;IARS2, CAGSSS;;Isoleucyl-tRNA synthetase 2;612801;REc;mutation identified in 1 CAGSSS family;?Cataracts, growth hormone deficiency, sensory neuropathy, sensorineural hearing loss, and skeletal dysplasia, 616007 (3);
1.1527;12;29;06;1q32.3;SMYD2;;SET and MYND domain-containing protein 2;610663;R, REc;;;
1.1528;11;16;98;1q41;KCNK2, TREK;;Potassium channel, subfamily K, member 2;603219;R;;;
1.1529;3;4;10;1q41;KCTD3;;Potassium channel tetramerization domain-containing protein 3;613272;REc;;;
1.1530;6;1;12;1q32.3;LINC00538, YIYA;;Long intergenic noncoding RNA 538;614635;REc;;;
1.1531;9;21;15;1q41;LYPLAL1;;Lysophospholipase-like 1;616548;REc;;;
1.1532;7;17;09;1q41;MARK1, KIAA1477;;MAP/microtubule affinity-regulating kinase 1;606511;R, REc;;;
1.1533;3;23;09;1q41;MIR194-1, MIRN194-1;;Micro RNA 194-1;610940;REc;;;
1.1534;3;23;09;1q41;MIR215, MIRN215;;Micro RNA 215;610943;REc;;;
1.1535;7;27;11;1q41;MOSC1, MARC1;;Molybdenum cofactor sulfurase C-terminal domain-containing protein 1;614126;REc;;;
1.1536;7;27;11;1q41;MOSC2, MARC2;;Molybdenum cofactor sulfurase C-terminal domain-containing protein 2;614127;REc;;;
1.1537;2;2;16;1q32.3;NSL1, DC8, C1orf48;;NSL1, MIS12 kinetochore complex component;609174;REc;;;
1.1538;6;4;97;1q32.3;PPP2R5A;;Protein phosphatase-2, regulatory subunit B (B56), alpha isoform;601643;A;;;
1.1539;9;17;11;1q41;RAB3GAP2, RAB3GAP150, p150, KIAA0839, WARBM2;;RAB3 GTPase-activating protein (noncatalytic) subunit 2;609275;R, REc, Fd;;Martsolf syndrome, 212720 (3); Warburg micro syndrome 2, 614225 (3);
1.1540;4;26;12;1q41;RMD1;;Rippling muscle disease 1;600332;Fd, REc;;Rippling muscle disease-1 (2);
1.1541;8;19;13;1q41;RRP15;;Ribosomal RNA-processing 15, S. cerevisiae, homolog of;611193;REc;;;
1.1542;7;11;16;1q41;SLC30A10, ZNT10, HMNDYT1;;Solute carrier family 30 (zinc transporter), member 10;611146;REc;;Hypermanganesemia with dystonia 1, 613280 (3);
1.1543;5;23;07;1q41;SPATA17, MSRG11;;Spermatogenesis-associated protein 17;611032;REc, H;;;1(Spata17)
1.1544;7;18;14;1q41;SUSD4;;Sushi domain-containing protein 4;615827;REc;;;
1.1545;9;14;12;1q41;TGFB2, LDS4;;Transforming growth factor, beta-2;190220;REa, A, Fd;;Loeys-Dietz syndrome 4, 614816 (3);1(Tgfb2)
1.1546;12;5;13;1q41;TLR5, TIL3, SLEB1, MELIOS;;Toll-like receptor-5;603031;A;;{Legionnaire disease, susceptibility to}, 608556 (3); {Systemic lupus erythematosus, resistance to}, 601744 (3); {Systemic lupus erythematosus, susceptibility to, 1}, 601744 (3); {Melioidosis, susceptibility to}, 615557 (3);
1.1547;3;25;16;1q32.1;TMEM9, TMEM9A, DERM4;;Transmembrane protein 9;616877;REc;;;
1.1548;12;8;00;1q42.2;TSNAX, TRAX;;Translin-associated factor X;602964;A, RE, H;;;8(Tsnax)
1.1549;1;27;04;1q41;USH2A, RP39;;Usherin;608400;Fd;;Usher syndrome, type 2A, 276901 (3); Retinitis pigmentosa 39, 613809 (3);1(Ush2a)
1.1550;12;21;09;1q41-q42;AUTS11;;Autism, susceptibility to, 11;610836;Fd;associated with rs12740310, rs3737296, and rs12310279;{Autism susceptibility 11} (2);
1.1551;9;22;08;1q41;CAPN2;;Calpain, large polypeptide L2;114230;REa, REb;;;
1.1552;5;22;07;1q42.13;CDC42BPA, PK428, MRCKA;;CDC42-binding protein kinase alpha;603412;A;;;
1.1553;1;31;11;1q41-q42;DEL1q41q42, C1DELq41q42;;Chromosome 1q41-q42 deletion syndrome;612530;Ch;contiguous gene deletion of 1.7Mb;Chromosome 1q41-q42 deletion syndrome (4);
1.1554;5;3;18;1q41;EPRS, PARS, HLD15;;Glutamyl-prolyl-tRNA synthetase;138295;REa, A;;Leukodystrophy, hypomyelinating, 15, 617951 (3);1(Eprs)
1.1555;5;12;99;1q42.13;GALNT2;;UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 2;602274;A;;;
1.1556;3;21;93;1q41;HLX1;;H.20-like homeobox 1;142995;A, Fd;;;1(Hlx1)
1.1557;4;16;98;1q42.11;NVL;;Nuclear valosin-containing protein-like;602426;A, REa;;;
1.1558;10;16;92;1q42.12;ITPKB;;Inositol 1,4,5-trisphosphate 3-kinase B;147522;A;;;
1.1559;7;30;15;1q43;CHRM3, PBS, EGBRS;;Cholinergic receptor, muscarinic, 3;118494;A, REa;mutation identified in 1 PBS family;?Prune belly syndrome, 100100 (3);
1.1560;1;7;14;1q41-q44;OTSC10;;Otosclerosis 10;615589;Fd;;Otosclerosis 10 (2);
1.1561;1;29;01;1q42.13;ABCB10, MTABC2;;ATP-binding cassette, subfamily B, member 10;605454;REc;pseudogene on 15q13-q14;;
1.1562;11;14;18;1q42.13;ARF1, PVNH8;;ADP-ribosylation factor-1;103180;A;;Periventricular nodular heterotopia 8, 618185 (3);
1.1563;10;6;09;1q42;BCC2;;Basal cell carcinoma, susceptibility to, 2;613058;Fd;associated with rs801114;{Basal cell carcinoma, susceptibility to, 2} (2);
1.1564;7;17;09;1q42.2;CAPN9;;Calpain 9;606401;R, REc;;;
1.1565;3;3;03;1q41;DISPA;;Dispatched, Drosophila, homolog of, A;607502;R;;;
1.1566;2;21;06;1q42.12;DNAH14, HL18;;Dynein, axonemal, heavy chain 14;603341;REc;;;
1.1567;12;16;05;1q42;EA3;;Episodic ataxia, type 3;606554;Fd;max lod at D1S235;Episodic ataxia, type 3 (2);
1.1568;1;11;16;1q42.2;GNPAT, DHAPAT, RCDP2;;Glyceronephosphate O-acyltransferase;602744;TM;;Rhizomelic chondrodysplasia punctata, type 2, 222765 (3);
1.1569;1;14;13;1q42.13;HIST3H2A;;Histone gene cluster 3, H2A histone;615015;REc;;;
1.1570;1;31;13;1q42.13;HIST3H2BB, H2Bb;;Histone gene cluster 3, H2B histone family, member B;615046;REc;;;
1.1571;3;11;03;1q42.13;HIST3H3, H3FT, H3T;;Histone 3, H3;602820;REa, A;;;
1.1572;8;8;91;1q42;HRES1;;HTLV-1 related endogenous sequence;143025;REa, A;;;
1.1573;4;10;00;1q42;MDC1B;;Muscular dystrophy, congenital, 1B;604801;Fd;;Muscular dystrophy, congenital, 1B (2);
1.1574;9;7;10;1q41;MIA3, TANGO1, TANGO, KIAA0268;;Melanoma inhibitory activity family, member 3;613455;REc, R;;;
1.1575;9;2;12;1q42.2;MLK4, KIAA1804;;Mixed-lineage kinase 4;614793;REc;;;
1.1576;11;19;13;1q42.12;PARP1, ADPRT, PPOL, PARP;;Poly(ADP-ribose) polymerase 1;173870;REa, A;?processed pseudogenes on chr.13 and 14;;
1.1577;6;8;89;1q42;PEPC;;Peptidase C;170000;S, R, Fd;1q25, 1q32 = conflicting localizations;;1(Pep3)
1.1578;4;4;07;1q42.13;RHOU, WRCH1;;Ras homolog gene family, member U;606366;R;;;
1.1579;7;20;01;1q42.13;RNF16;;RING finger protein-16;606123;REa, R;;;11(Rnf16)
1.1580;2;1;01;1q41;TAF1A, RAFI48, SL1;;TATA box-binding protein-associated factor 1A;604903;R, A;;;
1.1581;5;26;13;1q42.2;TRIM67;;Tripartite motif-containing protein 67;610584;REc;;;
1.1582;2;17;15;1q42.13;WNT3A;;Wingless-type MMTV integration site family, member 3A;606359;A;;;
1.1583;10;10;01;1q42.13;WNT14;;Wingless-type MMTV integration site family, member 14;602863;REc, A;;;
1.1584;4;20;15;1q43;ACTN2, CMD1AA, CMH23;;Actinin, alpha-2;102573;REa, A, Fd;;Cardiomyopathy, dilated, 1AA, with or without LVNC, 612158 (3); Cardiomyopathy, hypertrophic, 23, with or without LVNC, 612158 (3);13(Actn2)
1.1585;10;4;05;1q42.2;AGT, SERPINA8;;Angiotensinogen;106150;A, REa;;{Hypertension, essential, susceptibility to}, 145500 (3); {Preeclampsia, susceptibility to} (3); Renal tubular dysgenesis, 267430 (3);8(Agt)
1.1586;12;26;14;1q42.2;EGLN1, PHD2, HIFPH2, C1orf12, ZMYND6, SM20, ECYT3, HALAH;;Egl9, C. elegans, homolog of, 1;606425;R, REc, A;;Erythrocytosis, familial, 3, 609820 (3); [Hemoglobin, high altitude adaptation], 609070 (3);
1.1587;7;17;01;1q43;EXO1, HEX1;;Exonuclease 1, S. cerevisiae, homolog of;606063;A;;;
1.1588;7;1;97;1q42.2;KCNK1, TWIK1;;Potassium channel, subfamily K, member 1;601745;A;;;
1.1589;4;18;05;1q43;LGALS8, PCTA1;;Lectin, galactoside-binding, soluble, 8;606099;R;;;
1.1590;10;12;90;1q42.13;RAB4A, RAB4;;Ras-associated protein RAB4A;179511;A;;;1(Rab4a)
1.1591;12;5;16;1q42.3;TBCE, KCS, KCS1, HRD, PEAMO;;Tubulin-specific chaperone E;604934;Fd;;Kenny-Caffey syndrome, type 1, 244460 (3); Hypoparathyroidism-retardation-dysmorphism syndrome, 241410 (3); Encephalopathy, progressive, with amyotrophy and optic atrophy, 617207 (3);
1.1592;5;4;00;1q42.3;TM7SF1;;Transmembrane 7 superfamily, member 1;604658;REa, A;;;
1.1593;7;17;09;1q42.12;ACBD3, GOCAP1, GOLPH1, GCP60;;Acyl-Coenzyme A binding domain containing 3;606809;R, REc;;;
1.1594;3;11;16;1q42.13;ACTA1, ASMA, NEM3, CFTD1, SHPM;;Actin, alpha-1, skeletal muscle;102610;REa, H, A;mutation identified in 1 SHPM family;Nemaline myopathy 3, autosomal dominant or recessive, 161800 (3); Myopathy, actin, congenital, with excess of thin myofilaments, 161800 (3); Myopathy, actin, congenital, with cores, 161800 (3); Myopathy, congenital, with fiber-type disproportion 1, 255310 (3); ?Myopathy, scapulohumeroperoneal, 616852 (3);8(Actsk1)
1.1595;8;18;17;1q42.2;DISC1, SCZD9;;Disrupted in schizophrenia 1;605210;Ch, H, RE;;{Schizophrenia 9, susceptibility to}, 604906 (3);8(Disc1)
1.1596;9;20;01;1q42.2;DISC2;;Disrupted in schizophrenia 2;606271;Ch;noncoding antisense RAN;Schizophrenia, 181500 (2);
1.1597;5;18;18;1q42.12;LEFTY2, EBAF, TGFB4, LEFTA, LEFTYA;;Left-right determination factor 2;601877;A;;;1(lefty2)
1.1598;9;20;17;1q42.12;EPHX1;;Epoxide hydroxylase 1, microsomal xenobiotic;132810;REa, A;mutation identified in 1 FHCA patient;?Hypercholanemia, familial, 607748 (3);1(Eph1)
1.1599;8;16;11;1q43;FH, HLRCC, MCUL1, FMRD;;Fumarate hydratase;136850;S, R, D, Psh;;Fumarase deficiency, 606812 (3); Leiomyomatosis and renal cell cancer, 150800 (3);
1.1600;6;22;18;1q42.12;LBR, PHA, PHASK;;Lamin B receptor;600024;A, Fd;;Pelger-Huet anomaly, 169400 (3); Greenberg skeletal dysplasia, 215140 (3); ?Reynolds syndrome, 613471 (3); Pelger-Huet anomaly with mild skeletal anomalies, 618019 (3);
1.1601;4;21;99;1q42.12;LEFTB, LEFTY1;;Left-right determination, factor B;603037;REn;;;1(lefty1)
1.1602;3;20;06;1q42.12;MIXL1, MIXL, MIX;;MIX1 homeobox-like protein 1;609852;R, A, H;;;1(Mixl1)
1.1603;6;4;98;1q41;TP53BP2, ASPP2;;Tumor protein p53-binding protein-2;602143;A;;;
1.1604;12;28;08;1q42.3;ARID4B, SAP180, RBP1L1, RBBP1L1, BRCAA1;;AT-rich interactive domain-containing protein 4B;609696;REc, A;;;
1.1605;7;20;06;1q43;RYR2, VTSIP, ARVD2, ARVC2;;Ryanodine receptor-2 (cardiac);180902;REa, A, Fd;;Ventricular tachycardia, catecholaminergic polymorphic, 1, 604772 (3); Arrhythmogenic right ventricular dysplasia 2, 600996 (3);13(Ryr2)
1.1606;5;16;17;1q42.11;CNIH4, CNIH2;;Cornichon family AMPA receptor auxiliary protein 4;617483;REc;;;
1.1607;7;18;14;1q42.11;DEGS1, DES1, MLD;;Delta(4)-desaturase, sphingolipid, 1;615843;REc;;;
1.1608;10;15;91;1q42.11-q42.13;RN5S1@;;RNA, 5S cluster 1;180420;A;25-30% at 1q31 (RN5S3@);;
1.1609;9;9;08;1q42.11;FBXO28, FBX28, KIAA0483;;F-box only protein 28;609100;REc;;;1(Fbxo28)
1.1610;12;6;16;1q42.12;LIN9;;Lin9, C. elegans, homolog of;609375;REc;;;
1.1611;8;18;14;1q42.12;SRP9, ALURBP;;Signal recognition particle, 9-kD;600707;REc;;;
1.1612;1;20;16;1q42.13;CCSAP, CSAP, C1orf96;;Centriole-, cilia-, and spindle-associated protein;616762;REc;;;
1.1613;6;13;12;1q42.12;ENAH, ENA, MENA, NDPP1;;Enabled, Drosophila, homolog of;609061;REc;;;1(Enah)
1.1614;12;19;18;1q42.13;GJC2, GJA12, CX47, PMLDAR, HLD2, SPG44, LMPHM3;;Gap junction protein, gamma-2 (47kD);608803;REc;;Leukodystrophy, hypomyelinating, 2, 608804 (3); Spastic paraplegia 44, autosomal recessive, 613206 (3); Lymphatic malformation 3, 613480 (3);
1.1615;6;25;18;1q42.13;IBA57, C1orf69, MMDS3, SPG74;;IBA57, S. cerevisiae, homolog of;615316;REc;;Multiple mitochondrial dysfunctions syndrome 3, 615330 (3); ?Spastic paraplegia 74, autosomal recessive, 616451 (3);
1.1616;3;11;08;1q42.13;MRPL55;;Mitochondrial ribosomal protein L55;611859;REc;;;
1.1617;11;12;18;1q42.13;NUP133, NPHS18;;Nucleoporin, 133kD;607613;R, REc;;Nephrotic syndrome, type 18, 618177 (3);
1.1618;2;4;16;1q42.13;PGBD5;;Piggybac transposable element-derived 5;616791;REc;;;
1.1619;6;19;15;1q42.12;PYCR2, HLD10;;Pyrroline-5-carboxylate reductase 2;616406;REc;;Leukodystrophy, hypomyelinating, 10, 616420 (3);
1.1620;2;22;11;1q42.13;RNF186, RACO1;;Ring finger protein 187;613754;REc;;;
1.1621;1;31;15;1q42.13;TRIM11;;Tripartite motif-containing protein 11;607868;R, REc;;;
1.1622;8;15;17;1q42.11-q42.12;WDR26, SKDEAS;;WD repeat-containing protein 26;617424;REc;;Skraban-Deardorff syndrome, 617616 (3);
1.1623;12;30;14;1q42.13;ADCK3, COQ8, CABC1, SCAR9, ARCA2, COQ10D4;;AARF domain-containing kinase 3;606980;R, REc, Fd;;Coenzyme Q10 deficiency, primary, 4, 612016 (3);
1.1624;7;15;16;1q42.2;ARV1, EIEE38;;ARV1, S. cerevisiae, homolog of;611647;R, REc;;Epileptic encephalopathy, early infantile, 38, 617020 (3);
1.1625;7;31;15;1q42.2;COA6, C1orf31, CEMCOX4;;Cytochrome c oxidase assembly factor 6;614772;REc;;Cardioencephalomyopathy, fatal infantile, due to cytochrome c oxidase deficiency 4, 616501 (3);
1.1626;3;27;17;1q42.2;COG2, LDLC, CDG2Q;;Component of oligomeric golgi complex 2;606974;R, REc;mutation identified in 1 CDG2Q patient;?Congenital disorder of glycosylation, type IIq, 617395 (3);
1.1627;7;1;13;1q42.2;EXOC8, EXO84, SEC84;;Exocyst complex component 8;615283;REc;;;
1.1628;8;31;17;1q42.2;PCNX2, KIAA0435;;Pecanex, Drosophila, homolog of, 2;617656;R, REc;;;8(Pcnx2)
1.1629;2;19;08;1q42.2;SIPA1L2, KIAA1389;;SIPA1-like protein 2;611609;R, REc;;;
1.1630;2;4;15;1q42.2;SPRTN, DVC1, C1orf124, RJALS;;SprT-like N-terminal domain protein;616086;REc;;Ruijs-Aalfs syndrome, 616200 (3);
1.1631;10;10;14;1q42-q43;EDARADD, ED3, EDA3, ECTD11B, ECTD11A;;EDAR-associated death domain;606603;REc;;Ectodermal dysplasia 11B, hypohidrotic/hair/tooth type, autosomal recessive, 614941 (3); Ectodermal dysplasia 11A, hypohidrotic/hair/tooth type, autosomal dominant, 614940 (3);13(Edaradd)
1.1632;10;8;98;1q42.2-q43;PCAP;;Predisposing for prostate cancer;602759;Fd;;{Prostate cancer, susceptibility to}, 176807 (2);
1.1633;1;5;07;1q42.2-q43;SHFL1, SHFLD;;Split-hand/foot malformation with long bone deficiency 1;119100;Fd;between rs1124110 and rs535043;Split-hand/foot malformation with long bone deficiency 1 (2);
1.1634;10;7;13;1q42.3;ERO1LB;;Endoplasmic reticulum oxidoreduction 1-like beta;615437;REc;;;13(Ero1l)
1.1635;4;23;13;1q42.3;B3GALNT2, MGC39558, MDDGA11;;Beta-1,3-N-acetylgalactosaminyltransferase 2;610194;REc;;Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies, type A, 11, 615181 (3);
1.1636;5;25;13;1q42.3;GNG4;;Guanine nucleotide-binding protein, gamma 4;604388;REc;;;
1.1637;11;13;17;1q42.3;IRF2BP2, CVID14;;Interferon regulatory factor 2-binding protein 2;615332;REc;mutation identified in 1 CVID14 family;?Immunodeficiency, common variable, 14, 617765 (3);
1.1638;1;30;15;1q42.3;LYST, CHS1;;Lysosomal trafficking regulator;606897;Fd;;Chediak-Higashi syndrome, 214500 (3);13(Lyst, bg)
1.1639;9;18;08;1q42.2;TARBP1, TRP185;;TAR RNA-binding protein 1;605052;R, REc;;;
1.1640;9;27;17;1q42.3;TOMM20, MAS20, KIAA0016;;Translocase of outer mitochondrial membrane 20, S. cerevisiae, homolog of;601848;REc;;;
1.1641;3;23;14;1q43;BECN2, BECN1L1;;Beclin 2;615687;REc, H;;;1(Becn2)
1.1642;2;21;02;1q43;CHML, REP2;;Choroideremia-like;118825;REa, REc;;;
1.1643;2;4;15;1q43;FMN2, MRT47;;Formin 2;606373;H, REc;;Mental retardation, autosomal recessive 47, 616193 (3);1(Fmn2)
1.1644;5;28;02;1q42.3;GGPS1, GGPPS1;;Geranylgeranyl diphosphate synthase 1;606982;A;;;
1.1645;12;27;16;1q43;GREM2, PRDC, STHAG9;;Gremlin 2 homolog, cystine knot superfamily;608832;REc;;Tooth agenesis, selective, 9, 617275 (3);
1.1646;2;21;02;1q43;KMO;;Kynurenine 3-monooxygenase;603538;REc;;;
1.1647;7;12;13;1q43;MTR, HMAG;;5-methyltetrahydrofolate-homocysteine methyltransferase 1;156570;S, A;;Homocystinuria-megaloblastic anemia, cblG complementation type, 250940 (3); {Neural tube defects, folate-sensitive, susceptibility to}, 601634 (3);13(Mtr)
1.1648;6;8;89;1q42.3;NID;;Nidogen;131390;A;;;
1.1649;2;18;02;1q43;OPN3, ECPN;;Opsin 3;606695;Psh, A;;;
1.1650;4;20;11;1q43;RGS7;;Regulator of G protein signaling 7;602517;REc;;;1(Rgs7)
1.1651;12;15;10;1q43;ZP4, ZPB;;Zona pellucida glycoprotein 4;613514;REc;;;
1.1652;12;4;08;1q43-q44;DFNB45;;Deafness, autosomal recessive 45;612433;Fd;between D1S547 and D1S2836;Deafness, autosomal recessive 45 (2);
1.1653;10;16;14;1q43-q44;SDCCAG8, CCCAP, SLSN7, BBS16;;Serologically defined colon cancer antigen 8;613524;REc;;Senior-Loken syndrome 7, 613615 (3); Bardet-Biedl syndrome 16, 615993 (3);
1.1654;3;15;07;1q44;AHCTF1, ELYS;;AT hook containing transcription factor 1;610853;REc;;;
1.1655;8;22;14;1q43-q44;AKT3, PKBG, MPPH2;;v-Akt murine thymoma viral oncogene homolog 3;611223;A;;Megalencephaly-polymicrogyria-polydactyly-hydrocephalus syndrome 2, 615937 (3);1(Akt3)
1.1656;6;12;17;1q44;CATSPERE, C10orf101;;Cation channel, sprem-associated, auxiliary subunit epsilon;617510;REc;;;
1.1657;9;21;09;1q43;CEP170, KIAA0470;;Centrosomal protein, 170kD;613023;R, REc;;;
1.1658;9;7;10;1q44;CNST;;Consortin;613439;REc;;;
1.1659;2;21;14;1q44;COX20, FAM36A;;Cytochrome c oxidase 20, S. cerevisiae, homolog of;614698;REc;;Mitochondrial complex IV deficiency, 220110 (3);
1.1660;7;20;12;1q44;DESI2, PPPDE1;;Desumoylating isopeptidase 2;614638;REc;;;
1.1661;3;10;17;1q44;HNRNPU, HNRPU, SAFA, EIEE54;;Heterogeneous nuclear ribonucleoprotein U;602869;REc;;Epileptic encephalopathy, early infantile, 54, 617391 (3);
1.1662;9;8;11;1q44;KIF26B;;Kinesin family member 26B;614026;REc;;;
1.1663;8;10;16;1q44;LYPD8;;LY6/PLAUR domain-containing protein 8;617067;REc;;;
1.1664;6;14;18;1q44;NLRP3, CIAS1, FCU, FCAS1, NALP3, PYPAF1, DFNA34, KEFH;;NLR family, pyrin domain containing 3;606416;REn, Fd;;Familial cold inflammatory syndrome 1, 120100 (3); Muckle-Wells syndrome, 191900 (3); CINCA syndrome, 607115 (3); Deafness, autosomal dominant 34, with or without inflammation, 617772 (3); Keratoendothelitis fugax hereditaria, 148200 (3);
1.1665;1;5;16;1q44;OR2W3;;Olfactory receptor family 2 subfamily W member 3;616729;REc;;;
1.1666;12;17;07;1q44;OR13G1;;Olfactory receptor, family 13, subfamily G, member 1;611677;REc;;;
1.1667;6;27;14;1q44;SMYD3;;SET and MYND domain-containing protein 3;608783;REc;;;
1.1668;11;11;14;1q44;TFB2M;;Transcription factor B2, mitochondrial;607055;R, REc;;;
1.1669;3;23;93;1q44;ZNF124;;Zinc finger protein-124 (HZF-16);194631;A;;;
1.1670;5;12;15;1q44;ZNF695, SBZF3;;Zinc finger protein 695;616348;REc;;;
1.1671;4;20;17;1q44;ZBTB18, ZNF238, RP58, MRD22;;Zinc finger and BTB domain containing 18;608433;A, REc, Psh;;Mental retardation, autosomal dominant 22, 612337 (3);
1.1672;11;10;17;1q44;ZNF692, AREBP;;Zinc finger protein 692;617758;REc;;;
1.1673;4;19;11;1q44;ZNF496, NIZP1, ZFP496;;Zinc finger protein 496;613911;REc;;;11(Znf496)
1.1674;11;3;11;Chr.1;SPGF2, ASG;;Spermatogenic failure 2;108420;Ch;inversion of chromosome 1;Spermatogenic failure 2 (2);
2.1;7;22;13;2pter-p24;CTRCT29;;Cataract 29, coralliform;115800;Fd;between D2S297 and D2S2269;Cataract 29, coralliform (2);
2.2;6;14;10;2p25.3;ADI1, SIPL;;Acireductone dioxygenase 1;613400;REc;;;
2.3;5;4;12;2p25.3;COLEC11, CLK1, 3MC2;;Collectin 11;612502;REc;;3MC syndrome 2, 265050 (3);
2.4;4;2;16;2p25.3;FAM110C;;Family with sequence similarity 110, member C;611395;REc;;;
2.5;1;26;17;2p25.3;PXDN, D2S448E, KIAA0230, PRG2, PXN, COPOA, ASGD7;;Peroxidasin, Drosophila, homolog of;605158;REa, R, A;;Anterior segment dysgenesis 7, with sclerocornea, 269400 (3);
2.6;1;26;17;2p25.3;SH3YL1;;SH3 domain- and SYLF domain-containing protein 1;617314;REc;;;
2.7;2;19;10;2p25.3;TMEM18;;Transmembrane protein 18;613220;REc;;;
2.8;9;21;17;2p25.3;TRAPPC12, TTC15, PEBAS;;Trafficking protein particle complex, subunit 12;614139;REc;;Encephalopathy, progressive, early-onset, with brain atrophy and spasticity, 617669 (3);
2.9;2;12;08;2p25.2;CMPK2;;Cytidine monophosphate (UMP-CMP) kinase 2, mitochondrial;611787;REc;;;
2.10;7;11;17;2p25.3;EIPR1, TSSC1;;EARP complex and GARP complex interacting protein 1;608998;REc, H;;;12(Tssc1)
2.11;8;27;09;2p25.1;ITGB1BP1, ICAP1, ICAP1A, ICAP1B;;Integrin cytoplasmic domain-associated protein 1 beta;607153;R, REc;;;
2.12;12;28;08;2p25.2;RSAD2, VIPERIN;;Radical S-adenosyl methionine domain containing 2;607810;R, REc;;;
2.13;7;25;18;2p25.1;ATP6V1C2;;ATPase, H+ transporting, V1 subunit C2;618070;REc;;;
2.14;12;23;05;2p25.1;GRHL1, LBP32, MGR;;Grainyhead-like 1;609786;R, REc;;;
2.15;1;22;08;2p25.1;GREB1;;GREB1 protein;611736;R, REc;;;
2.16;7;17;09;2p25.1;HPCAL1;;Hippocalcin-like 1;600207;REa, REc;;;
2.17;1;11;17;2p25.1;KIDINS220, ARMS, SINO;;Kinase D-interacting substrate, 220kD;615759;REc;;Spastic paraplegia, intellectual disability, nystagmus, and obesity, 617296 (3);
2.18;10;13;09;2p25.1;MBOAT2, LPCAT4;;Membrane-bound O-acyltransferase domain-containing 2;611949;R, REc;;;
2.19;2;4;15;2p25.1;NOL10, PQBP5;;Nucleolar protein 10;616197;REc;;;
2.20;8;6;13;2p25.1;NTSR2;;Neurotensin receptor 2;605538;REc;;;
2.21;6;12;12;2p25.1;TYHAQ;;Tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, theta isoform;609009;REa, REc;pseudogene on chr.22;;
2.22;3;14;06;2p25.1-p24.3;DFNB47;;Deafness, neurosensory, autosomal recessive 47;609946;Fd;max lod at D2S1400 and D2S262;Deafness, neurosensory, autosomal recessive 47 (2);
2.23;8;23;16;2p21;DYNC2LI1, D2LIC, LIC3, SRTD15;;Dynein, cytoplasmic 2, light intermediate chain 1;617083;REc;;Short-rib thoracic dysplasia 15 with polydactyly, 617088 (3);
2.24;7;7;89;2p25.3;ACP1;;Acid phosphatase 1, soluble;171500;D, S, A;;;12(Acp1)
2.25;11;3;14;2p25.1;ADAM17, TACE, NISBD1;;A disintegrin and metalloproteinase domain 17;603639;R;mutation identified in 1 NISBD1 family;?Inflammatory skin and bowel disease, neonatal, 1, 614328 (3);12(Tace)
2.26;12;18;08;2p25;ALLC;;Allantoicase;612396;Psh, REc;nonfunctional in humans;;
2.27;1;15;96;2p25.1;ID2;;Inhibitor of DNA binding 2, dominant negative;600386;REa, A;;;
2.28;8;27;09;2p23.3;ITSN2, SH3D1B, SWAP, KIAA1256;;Intersectin 2;604464;REc;;;
2.29;5;21;99;2p25.1;KCNF1, KH1;;Potassium voltage-gated channel, subfamily F, member 1;603787;A;;;
2.30;2;13;14;2p25.1;KLF11, TIEG2, FKLF1, FKLF, MODY7;;Kruppel-like factor 11;603301;Psh;;Maturity-onset diabetes of the young, type VII, 610508 (3);12(Klf11)
2.31;5;27;05;2p25.1;ODC1;;Ornithine decarboxylase-1;165640;REa, A;pseudogene ODCP on 7q31-qter;{Colonic adenoma recurrence, reduced risk of}, 114500 (3);12(Odc)
2.32;10;11;05;2p25;PEE2;;Preeclampsia/eclampsia 2;609402;Fd;;Preeclampsia/eclampsia 2 (2);
2.33;7;29;15;2p25.3;RNASEH1, PEOB2;;Ribonuclease H1;604123;Psh;pseudogenes on chr. 17 and chr.1;Progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal recessive 2, 616479 (3);12(Rnaseh1)
2.34;2;4;09;2p25.3;RPS7, DBA8;;Ribosomal protein S7;603658;A;;Diamond-Blackfan anemia 8, 612563 (3);
2.35;7;17;14;2p25.2;SOX11, MRD27;;SRY (sex-determining region Y)-box 11;600898;A;;Mental retardation, autosomal dominant 27, 615866 (3);
2.36;2;1;01;2p25.1;RAF1B, RAFI63, SL1;;TATA box-binding protein-associated factor 1B;604904;R, A;;;
2.37;7;11;11;2p23.3;SAP14, SF3B14, P14;;Spliceosome-associated protein, 14kD;607835;REc;;;
2.38;11;05;18;2p25.3;SNTG2, SYN5;;Syntrophin, gamma-2;608715;R;;;
2.39;5;12;09;2p23.3;SUPT7L, SUPT7H, SPT7l, KIAA0764, STAF65G;;Suppressor of TY 7-like;612762;R, REc;;;
2.40;9;29;09;2p25.3;TPO, TPX, TDH2A;;Thyroid peroxidase;606765;REa, A, Fd;;Thyroid dyshormonogenesis 2A, 274500 (3);12(Tpo)
2.41;11;22;17;2p25-p22;ETM2, ETM;;Tremor, hereditary essential, 2;602134;Fd;max lod at D2S272;Essential tremor, hereditary, 2 (2);
2.42;6;10;03;2p25-p24;HYT3;;Hypertension, essential, susceptibility to, 3;607329;Fd;;{Hypertension, essential, susceptibility to, 3}, 145500 (2);
2.43;8;22;07;2p25.1;PDIA6, ERP5;;Protein disulfide isomerase, family A, member 6;611099;A;;;
2.44;4;10;90;2p25.1;RRM2;;Ribonucleotide reductase, M2 polypeptide;180390;REa, A;pseudogenes on 1p, 1q, Xp;;12(Rrm2)
2.45;7;27;09;2p25-p12;PPKP3;;Keratoderma, palmoplantar, punctate type III;101850;Fd;max lod at ACP1 and IGKC;?Keratoderma, palmoplantar, punctate type 3 (2);
2.46;4;6;15;2p24.3;FAM84A, NSE1;;Family with sequence similarity 84, member A;611234;R, REc;;;
2.47;12;30;14;2p24.3;GACAT3, LINC01458;;Gastric cancer-associated transcript 3, noncoding;616132;REc;;;
2.48;9;20;14;2p24.3;MYCNUT;;MYCN upstream transcript, noncoding;615968;REc;;;
2.49;12;24;08;2p24.2;GEN1;;GEN1, Drosophila, homolog of;612449;REc;;;
2.50;8;29;08;2p24.2;MSGN1;;Mesogenin 1;612209;REc;;;
2.51;5;24;13;2p24.2;NT5C1B, CN1B, AIRP;;5'-nucleotidase, cytosolic, Ib;610526;REc, R;;;
2.52;2;9;16;2p24.2;RDH14, SDR7C4, PAN2;;Retinol dehydrogenase 14;616796;REc;;;
2.53;10;4;05;2p24.2;SMC6L1, SMC6;;Structural maintenance of chromosomes 6-like 1;609387;R, REc;;;
2.54;5;19;06;2p24.1;HS1BP3, FLJ14249, ETM2;;HS1-binding protein 3;609359;REc;;;
2.55;1;17;18;2p24.1;LDAH, C2orf43;;Lipid droplet associated hydrolase;613570;REc;;;
2.56;7;21;11;2p24.3;MYCN, NMYC, ODED, MODED;;Oncogene NMYC;164840;REa, A, Fd;proximal to APOB;Feingold syndrome 1, 164280 (3);12(Nmyc1)
2.57;8;27;09;2p24.3;MYCNOS, NCYM;;Oncogene NCYM, opposite strand;605374;R, REc;;;
2.58;8;3;12;2p24.1;RHOB, ARHB, ARH6, RHOH6;;RAS homolog gene family, member B (oncogene RHO H6);165370;REa, A;;;
2.59;6;29;94;2p24.1;SDC1;;Syndecan 1;186355;REa, H;close to NMYC in mouse;;12(Synd1)
2.60;2;11;14;2p24.1;WDR35, NAOFEN, KIAA1336, CED2, SRTD7;;WD repeat-containing protein 35;613602;REc;;Cranioectodermal dysplasia 2, 613610 (3); Short-rib thoracic dysplasia 7 with or without polydactyly, 614091 (3);
2.61;10;12;16;2p23.3;ZNF513, RP58;;Zinc finger protein 513;613598;REc;mutation identified in 1 RP58 family;?Retinitis pigmentosa 58, 613617 (3);
2.62;8;2;13;2p24.1-p23.3;ATAD2B, KIAA1240;;ATPase family, AAA domain-containing, member 2B;615347;R, REc;;;
2.63;7;8;10;2p23.2;C2orf71;;Chromosome 2 open reading frame 71;613425;REc;;Retinitis pigmentosa 54, 613428 (3);
2.64;12;9;13;2p24.1;APOB, FLDB, LDLCQ4;;Apolipoprotein B (including Ag(x) antigen);107730;REa, A;1 gene for liver apo-B100 and gut apo-B48; Ag linked;Hypobetalipoproteinemia, 615558 (3); Hypercholesterolemia, due to ligand-defective apo B, 144010 (3);12(Apob)
2.65;3;8;07;2p24-p22;CLQTL2;;Cholesterol level quantitative trait locus 2;610760;Fd;max lod at D2S1360;[Cholesterol level QTL 2] (2);
2.66;5;24;01;2p25.1;DDEF2, PAP;;Development- and differentiation-enhancing factor 2;603817;R;;;
2.67;5;13;96;2p24.3;DDX1;;DEAD/H box-1;601257;;;;
2.68;1;3;06;2p24;GEFSP4;;Generalized epilepsy with febrile seizures plus, type 4;609800;Fd;max lod at D2S305;Epilepsy, generalized, with febrile seizures plus, type 4 (2);
2.69;6;15;99;2p24.2;KCNS3, KV9.3;;Potassium voltate-gated channel, delayed-rectifier, subfamily S, member 3;603888;REc;;;
2.70;2;23;05;2p24;KTCN4;;Keratoconus 4;609271;Fd;between D2S305 and D2S2373;Keratoconus 4 (2);
2.71;9;1;15;2p25.3;MYT1L, KIAA1106, MRD39;;Myelin transcription factor 1-like;613084;Psh, H;;Mental retardation, autosomal dominant 39, 616521 (3);12(Myt1l)
2.72;9;7;04;2p24.1;ODD, OSR1;;ODD-skipped, Drosophila, homolog of;608891;REc;;;
2.73;3;9;00;2p25.1;ROCK2;;RHO-associated coiled-coil-containing protein kinase 2;604002;R, A;;;
2.74;6;9;06;2p11.2;VPS24, CHMP3, NEDF;;Vacuolar protein sorting 24, yeast, homolog of;610052;R, REc;;;
2.75;7;17;01;2p24.1;GDF7;;Growth/differentiation factor 7;604651;A;;;
2.76;1;10;18;2p24.1;MATN3, EDM5, HOA, OS2;;Matrilin 3;602109;A, Fd;mutation identified in 1 SEMDM family;Epiphyseal dysplasia, multiple, 5, 607078 (3); {Osteoarthritis susceptibility 2}, 140600 (3); ?Spondyloepimetaphyseal dysplasia, 608728 (3);12(Matn3)
2.77;7;29;15;2p24.3;NBAS, NAG, SOPH, ILFS2;;Neuroblastoma-amplified sequence;608025;A;;Short stature, optic nerve atrophy, and Pelger-Huet anomaly, 614800 (3); Infantile liver failure syndrome 2, 616483 (3);
2.78;10;13;05;2p23.3;TCF23;;Transcription factor 23;609635;REc;;;5(Tcf23)
2.79;2;27;18;2p23.3;ADCY3, BMIQ19;;Adenylate cyclase-3;600291;REa, A;;{Obesity, susceptibility to, BMIQ19}, 617885 (3);
2.80;6;3;98;2p23.3;CENPA;;Centromere protein A, 17kD;117139;R, Psh;;;5(Cenpa)
2.81;8;29;08;2p23.3;ABHD1, LABH1;;Abhydrolase domain-containing 1;612195;REc;;;5(Abhd1)
2.82;7;11;16;2p23.3;AGBL5, CCP5, RP75;;AATP/GTP-binding protein-like 5;615900;REc;;Retinitis pigmentosa 75, 617023 (3);
2.83;11;22;16;2p23.3;ASXL2, KIAA1685, SHAPNS;;Additional sex combs-like 2;612991;REc;;Shashi-Pena syndrome, 617190 (3);
2.84;2;25;15;2p23.3;C2orf44, WDCP;;WD repeat- and coiled-coil-containing protein;616234;REc;;;
2.85;10;08;07;2p23.3;CENPO;;Centromeric protein O;611504;R, REc;;;
2.86;7;14;14;2p23.3;CGREF1, CGR11;;Cell growth regulator with EF-hand domain 1;606137;REc;;;
2.87;4;24;18;2p23.3;CIB4, KIP4;;Calcium- and integrin-binding protein 4;610646;REc;;;
2.88;5;23;11;2p23.3;DNAJC5G;;DNAJ/HSP40 homolog, subfamily C, member 5, gamma;613946;REc;;;
2.89;8;17;10;2p23.3;DNAJC27, RBJ;;DNAJ/HSP40 homolog, subfamily, C, member 27;613527;REc;;;
2.90;1;27;04;2p23.3;DPYSL5, CRMP5, CRAM;;Dihydropyrimidinase-like 5;608383;R, REc;;;5(Dpysl5)
2.91;7;12;13;2p23.3;DRC1, CCDC164, C2orf39, CILD21;;Dynein regulatory complex, subunit 1, Chlamydomonas, homolog of;615288;REc;;Ciliary dyskinesia, primary, 21, 615294 (3);
2.92;2;9;16;2p23.3;EFR3B, KIAA0953;;Efr3, S. cerevisiae, homolog of, B;616797;R, REc;;;
2.93;10;29;03;2p23.3;EIF2B4;;Eukaryotic translation initiation factor 2B, subunit 4;606687;R;;Leukoencephalopathy with vanishing white matter, 603896 (3); Ovarioleukodystrophy, 603896 (3);
2.94;8;27;09;2p23.3;FKBP1B, PKBP1L;;FK506-binding protein 1B;600620;R, REc;;;
2.95;3;20;08;2p23.3;FNDC4, FRCP1;;Fibronectin type III domain-containing protein 4;611905;R, REc, H;;;5(Fndc4)
2.96;5;29;15;2p23.3;IFT172, SLB, KIAA1179, SRTD10, RP71;;Intraflagellar transport 172, Chlamydomonas, homolog of;607386;R, REc;;Short-rib thoracic dysplasia 10 with or without polydactyly, 615630 (3); Retinitis pigmentosa 71, 616394 (3);
2.97;1;7;09;2p23.3;POMC, OBAIRH;;Proopiomelanocortin (adrenocorticotropin/beta-lipotropin);176830;REa, A;;Obesity, adrenal insufficiency, and red hair due to POMC deficiency, 609734 (3); {Obesity, early-onset, susceptibility to}, 601665 (3);12(Pomc1)
2.98;10;12;14;2p23.3;PPM1G, PP2CG;;Protein phosphatase, magnesium/manganese-dependent, 1G;605119;REc;;;
2.99;2;9;17;2p23.3;PRTHD1, C2orf79;;Peptidyl-tRNA hydrolase domain-containing 1;617342;REc;;;
2.100;3;31;09;2p23.3;RAB10;;Ras-associated protein;612672;REc;;;
2.101;11;18;16;2p23.3;SELENOI, SELI;;Selenoprotein I;607915;REc;;;
2.102;7;18;14;2p23.3;SLC5A6, SMVT;;Solute carrier family 5 (sodium dependent vitamin transporter), member 6;604024;REc;;;
2.103;2;25;08;2p23.3;SLC30A3, ZNT3;;Solute carrier family 30 (zinc transporter), member 3;602878;REc;;;5(Slc30a3)
2.104;4;6;15;2p23.3;TMEM214;;Transmembrane protein 214;615301;REc;;;
2.105;8;3;12;2p23.3;TP53I3, PIG3;;Tumor protein p53-inducible protein 3;605171;REc;;;
2.106;8;13;15;2p23.3;TRIM54, RNF30, MURF3;;Tripartite motif containing 54;606474;R, REc;;;
2.107;10;13;09;2p23.3;XAB1, MBDIN;;XPA-binding protein;611479;REc;;;
2.108;8;27;09;2p23.3;EMILIN1, EMILIN;;Elastin microfibril interfacer 1;130660;REc;;;
2.109;11;1;10;2p23.3;GCKR, GKRP, FGQTL5;;Glucokinase (hexokinase 4) regulatory protein;600842;A, Fd, REc;;[Fasting plasma glucose level QTL 5], 613463 (3);
2.110;6;23;11;2p23.3;KHK;;Ketohexokinase (fructokinase);614058;A, Fd, REc, Psh;;[Fructosuria], 229800 (3);
2.111;8;27;09;2p23.3;SLC4A1AP;;Solute carrier family 4 (anion exchanger), member 1, adaptor protein;602655;REc;;;
2.112;8;27;01;2p23.3;MAPRE3, EB3, RP3, EBF3;;Microtubule-associated protein, RP/EB family, member 3;605788;A, R;;;
2.113;3;14;06;2p23.3-p22.3;GINGF3, HGF3, GGF3;;Fibromatosis, gingival, 3;609955;Fd;between D2S2221 and D2S1788;Fibromatosis, gingival, 3 (2);
2.114;10;13;13;2p23.2;BRE, BRCC4, BRCC45;;Brain and reproductive organ-expressed protein;610497;REc, R;;;
2.115;8;31;11;2p23.2;FOSL2;;FOS-like antigen-2;601575;A;;;
2.116;1;27;04;2p23.1;GALNT14;;UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 14;608225;REc;;;
2.117;6;16;06;2p23.2;PLB1, PLB, FLJ30866;;Phospholipase B1;610179;R, REc;;;
2.118;9;10;07;2p23.2;RBKS;;Ribokinase;611132;REc;;;
2.119;9;8;11;2p23.2;SPDYA, SPY1, RINGOA;;Speedy, xenopus, homolog of, A;614029;REc;;;
2.120;2;4;15;2p23.2;WDR43, UTP5, KIAA0007;;WD repeat-containing protein 43;616195;REc, Psh;;;
2.121;11;05;18;2p23.1;CAPN13, FLJ23523;;Calpain 13;610228;R, REc;;;
2.122;11;05;18;2p23.1;CAPN14;;Calpain 14;610229;R, REc;;;
2.123;1;31;08;2p23.1;LBH;;Limb bud and heart development, mouse, homolog of;611763;R, REc;;;
2.124;9;28;11;2p23.1;LCLAT1, ALCAT1, AGPAT8;;Lysocardiolipin acyltransferase 1;614241;REc;;;17(Lclat1)
2.125;6;1;18;2p23.3;GAREM2;;GRB2-associated regulator of MAPK1, subtype 2;617999;REc;;;
2.126;12;28;08;2p23.1;YPEL5;;Yippee-like 5;609726;REc;;;17(Ypel5)
2.127;9;24;08;2q32.1;DNAJC10, ERDJ5, JPDI;;DNAJ/HSP40 homolog, subfamily C, member 10;607987;REc;;;
2.128;9;22;09;2p23.2-p23.1;ALK, NBLST3;;Anaplastic lymphoma kinase (Ki-1);105590;Ch, H;;{Neuroblastoma, susceptibility to, 3}, 613014 (3);17(Alk)
2.129;3;22;18;2p23.3;DNMT3A, TBRS;;DNA methyltransferase 3A;602769;A;;Tatton-Brown-Rahman syndrome, 615879 (3); Acute myeloid leukemia, somatic, 601626 (3);
2.130;3;19;08;2p23.3;HADHA, MTPA;;Hydroxyacyl-Coenzyme A dehydrogenase/3-ketoacyl-Coenzyme A thiolase/ enoyl-Coenzyme A hydratase (trifunctional protein), alpha subunit;600890;A;;LCHAD deficiency, 609016 (3); Trifunctional protein deficiency, 609015 (3); HELLP syndrome, maternal, of pregnancy, 609016 (3); Fatty liver, acute, of pregnancy, 609016 (3);
2.131;3;19;08;2p23.3;HADHB;;Hydroxyacyl-Coenzyme A dehydrogenase/3-ketoacyl-Coenzyme A thiolase /enoyl-Coenzyme A hydratase (trifunctional protein), beta subunit;143450;A;;Trifunctional protein deficiency, 609015 (3);
2.132;8;2;13;2p23.3;KCNK3, TASK, PPH4;;Potassium channel, subfamily K, member 3;603220;R;;Pulmonary hypertension, primary, 4, 615344 (3);5(Kcnk3)
2.133;11;20;98;2p23.3;KIF3C;;Kinesin family member 3C;602845;A;;;12(Kif3c)
2.134;1;30;18;2p23.3;MFSD2B;;Major facilitator superfamily domain-containing protein 2B;617845;REc;;;
2.135;12;29;99;2p23.3;NCOA1, SRC1;;Nuclear receptor coactivator 1;602691;A;;;
2.136;6;18;01;2p23.3;NRBP;;Nuclear receptor-binding protein;606010;A;;;
2.137;5;31;17;2p23.2;PPP1CB, NSLH2;;Protein phosphatase-1, catalytic subunit, beta isoform;600590;REa, A;;Noonan syndrome-like disorder with loose anagen hair 2, 617506 (3);12(Ppp1cb)
2.138;11;28;01;2p23.3;PREB;;Prolactin regulatory element-binding protein;606395;A;;;5(Preb)
2.139;10;21;02;2p23.1;SRD5A2;;Steroid-5-alpha-reductase, alpha polypeptide-2 (3-oxo-5 alpha-steroid delta 4-dehydrogenase alpha-2);607306;REa, A;;Pseudovaginal perineoscrotal hypospadias, 264600 (3);
2.140;8;17;99;2p23.3;DTNB;;Dystrobrevin, beta;602415;A;;;12(Dtnb)
2.141;8;4;09;2p23.3;OTOF, DFNB9, NSRD9, AUNB1;;Otoferlin;603681;Fd, REc;symbolized DFNB6 by authors;Deafness, autosomal recessive 9, 601071 (3); Auditory neuropathy, autosomal recessive, 1, 601071 (3);
2.142;8;17;98;2p22.1;SLC8A1, NCX1;;Solute carrier family 8, member 1 (sodium-calcium exchanger-1);182305;REa, A;;;
2.143;4;18;05;2p23.3;SNX17;;Sorting nexin 17;605963;R, REc;;;
2.144;7;27;16;2p23.1;XDH, XAN1;;Xanthine dehydrogenase (xanthine oxidase);607633;REb, A;;Xanthinuria, type I, 278300 (3);17(Xd)
2.145;12;27;10;2p23.3;MPV17, MTDPS6;;Mpv17 transgene, mouse, glomerulosclerosis, homolog of;137960;REa, A;;Mitochondrial DNA depletion syndrome 6 (hepatocerebral type), 256810 (3);5(Mpv17)
2.146;3;18;08;2p23.3;UCN, UROC;;Urocortin;600945;REa, REc;;;
2.147;5;16;05;2p22.2-p22.1;ARL3IP2, ATL2;;ADP-ribosylation-like factor 6-interacting protein 2 (atlastin 2);609368;REc;;;
2.148;6;9;08;2p22.3;DPY30;;DPY30, C. elegans, homolog of;612032;REc;;;
2.149;7;23;15;2p22.3;MIR558;;Micro RNA 558;616473;REc;BIRC6 is host gene;;
2.150;12;4;14;2p22.3;NLRC4, CARD12, CLAN, IPAF, AIFEC, FCAS4;;NLR family, caspase recruitment domain-containing 4;606831;REc;mutation identified in 1 FCAS4 family;Autoinflammation with infantile enterocolitis, 616050 (3); ?Familial cold autoinflammatory syndrome 4, 616115 (3);
2.151;10;11;16;2p22.2;SULT6B1;;Sulfotransferase family 6B, member 1;617152;REc;;;
2.152;6;17;17;2p22.3;YIPF4;;Yip1 domain family, member 4;617534;REc;;;
2.153;4;26;10;2p22.3-p21;CANDF1, CMCT;;Candidiasis, familial, 1;114580;Fd;between D2S367 and D2S2240;Candidiasis, familial, 1, autosomal dominant (2);
2.154;7;16;09;2p22.2;CEBPZ, CBF, NOC1;;CCAAT/enhancer-binding protein, zeta;612828;REc;;;
2.155;9;23;08;2p22.2;FAM82A1, FAM82A, RMD2;;Family with sequence similarity 82, member A1;611872;REc;;;
2.156;7;18;14;2p22.2;FEZ2;;Fasciculation and elongation protein zeta 2;604826;REc;;;
2.157;1;30;18;2p22.2;MACOM;;Macrophthalmia, colobomatous, with microcornea;602499;Ch;;Macrophthalmia, colobomatous, with microcornea (4);
2.158;8;1;14;2p22.2;NDUFAF7, MIDA;;NADH dehydrogenase (ubiquinone) complex I, assembly factor 7;615898;REc;;;
2.159;8;27;09;2p22.2;QPCT, QC;;Glutaminyl-peptide cyclotransferase;607065;R, REc;;;
2.160;9;18;17;2p22.2;VIT, VIT1;;Vitrin;617693;REc;;;
2.161;9;20;14;2p22.1;GEMIN6;;GEM-associated protein 6;607006;REc;;;
2.162;3;31;15;2p22.1;MAP4K3, GLK;;Mitogen-activated protein kinase kinase kinase kinase 3;604921;REc;;;
2.163;9;17;11;2p22.1-p21;HNFJ3;;Hyperuricemic nephropathy, familial juvenile, 3;614227;Fd;between rs372139 and rs896986;Hyperuricemic nephropathy, familial juvenile, 3 (2);
2.164;5;26;13;2p22.1;HNRNPLL, HNRPLL, SRRF;;Heterogeneous nuclear ribonucleoprotein L-like;611208;REc;;;
2.165;3;24;14;2p23.2;MRPL33;;Mitochondrial ribosomal protein L33;610059;R;;;
2.166;8;21;12;2p22.2;STRN;;Striatin, calmodulin-binding protein;614765;REc, A;;;
2.167;1;7;09;2p22.3;BIRC6, KIAA1289;;Baculoviral IAP repeat-containing protein-6;605638;R, REc;;;
2.168;8;28;01;2p22.2;CRIM1;;Cysteine-rich motor neuron protein 1;606189;R, A;;;
2.169;1;26;17;2p22.2;CYP1B1, GLC3A, ASGD6;;Cytochrome P450, subfamily I, dioxin-inducible, polypeptide 1;601771;REa, REn, A, Fd;;Glaucoma 3A, primary open angle, congenital, juvenile, or adult onset, 231300 (3); Anterior segment dysgenesis 6, multiple subtypes, 617315 (3);
2.170;1;2;03;2p21;EML4, ROPP120;;Echinoderm microtubule associated protein like-4;607442;R, A;;;
2.171;2;12;08;2p22.3;MEMO1, MEMO, C2orf4;;Mediator of cell motility 1;611786;REc;;;
2.172;1;16;08;2p21-p16;MSH2, COCA1, FCC1, HNPCC1;;mutS, E. coli, homolog of, 2;609309;Fd, REa, Ch;;Colorectal cancer, hereditary nonpolyposis, type 1, 120435 (3); Muir-Torre syndrome, 158320 (3); Mismatch repair cancer syndrome, 276300 (3);
2.173;8;27;09;2p24.1;PUM2, KIAA0235;;Pumilio, Drosophila, homolog of, 2;607205;REa, REc;;;
2.174;12;19;11;2p22.1;SRSF7, SFRS7;;Splicing factor, arginine/serine-rich 7, 35kD;600572;A;;;
2.175;2;25;08;2p22.3;SLC30A6, ZNT6;;Solute carrier family 30 (zinc transporter), member 6;611148;REc, H;;;17(Slc30a6)
2.176;9;28;15;2p22.1;SOS1, GINGF, GF1, HGF, NS4;;Son of sevenless, Drosophila, homolog of, 1;182530;A, Fd, REc;mutation identified in 1 GINGF1 family;?Fibromatosis, gingival, 1, 135300 (3); Noonan syndrome 4, 610733 (3);17(Sos1)
2.177;4;27;12;2p22.3;SPAST, SPG4;;Spastin;604277;Fd;;Spastic paraplegia 4, autosomal dominant, 182601 (3);
2.178;1;28;08;2p22.1;THUMPD2, C2orf8;;THUMP domain-containing 2;611751;A;;;
2.179;7;12;92;2p16.3;HTLF;;Human T-cell leukemia virus enhancer factor;143089;REa, A;;;
2.180;10;24;14;2p22.1;GALM, GLAT;;Galactose mutarotase;137030;S;;;
2.181;12;8;00;2p21;ABCG5;;ATP-binding cassette, subfamily G, member 5;605459;REc;;Sitosterolemia, 210250 (3);
2.182;6;21;16;2p21;ABCG8, GBD4;;ATP-binding cassette, subfamily G, member 8;605460;REc;;Sitosterolemia, 210250 (3); {Gallbladder disease 4}, 611465 (3);
2.183;3;2;17;2p21;ATP6V1E2, ATP6E1;;ATPase, H+ transporting, V1 subunit E1;617385;REc;;;
2.184;1;13;17;2p23.3;CAD, CDG1Z, EIEE50;;CAD trifunctional protein of pyrimidine biosynthesis;114010;REa, A, S, D;;Epileptic encephalopathy, early infantile, 50, 616457 (3);
2.185;3;13;15;2p21;CALM2, LQT15;;Calmodulin-2;114182;Psh, A;;Long QT syndrome 15, 616249 (3);
2.186;6;4;13;2p21;CAMKMT, C2orf34;;Calmodulin lysine N-methyltransferase;609559;REc;;;
2.187;8;27;09;2p22.2;CDC42EP3, CEP3, BORG2;;CDC42 effector protein 3;606133;R, REc;;;
2.188;8;27;09;2p21;COX7A2L, COX7RP, EB1;;Cytochrome c oxidase subunit VIIA, polypeptide 2-like;605771;R, REc;;;
2.189;5;22;14;2p21;CRIPT, SSMDF;;Cystine-rich PDZ binding protein;604594;REc;;Short stature with microcephaly and distinctive facies, 615789 (3);
2.190;4;21;10;2p21;DEL2p21, C2DELp21;;Homozygous 2p21 deletion syndrome;606407;Ch;contiguous gene syndrome disrupting SLC3A1 and PREPL genes;Hypotonia-cystinuria syndrome (4);
2.191;5;2;01;2p23.1;EHD3;;EH domain-containing 3;605891;R;;;
2.192;12;19;11;2p21;EPCAM, ACSTD1, TROP1, M4S1, MIC18, DIAR5, HNPCC8;;Epithelial cellular adhesion molecule;185535;A, REa;previously assigned to 4q;Diarrhea 5, with tufting enteropathy, congenital, 613217 (3); Colorectal cancer, hereditary nonpolyposis, type 8, 613244 (3);
2.193;08;17;18;2p16.3;FBXO11, FBX11, VIT1, PRMT9, IDDFBA;;F-box only protein 11;607871;REc;?2p16;Intellectual developmental disorder with dysmorphic facies and behavioral abnormalities, 618089 (3);17(Fbxo11)
2.194;9;21;17;2p21;HAAO, VCRL1;;3-hydroxyanthranilate 3,4-dioxygenase;604521;REc;;Vertebral, cardiac, renal, and limb defects syndrome 1, 617660 (3);
2.195;8;27;09;2p21;KCNG3, KV6.3;;Potassium voltage-gated channel, subfamily G, member 3;606767;REc;;;
2.196;10;7;08;2p21;LEPQTL1, LSL;;Leptin serum levels quantitative trait locus 1;601694;Fd;;[Leptin serum levels QTL1] (2);
2.197;4;9;09;2p16.3;LHCGR, LHR, LCGR;;Luteinizing hormone/choriogonadotropin receptor;152790;A;;Precocious puberty, male, 176410 (3); Leydig cell hypoplasia with pseudohermaphroditism, 238320 (3); Leydig cell hypoplasia with hypergonadotropic hypogonadism, 238320 (3); Luteinizing hormone resistance, female, 238320 (3); Leydig cell adenoma, somatic, with precocious puberty, 176410 (3);
2.198;1;22;09;2p25.1;LPIN1;;Lipin 1;605518;REc;related to LSL;Myoglobinuria, acute recurrent, autosomal recessive, 268200 (3);12(Lpin1)
2.199;9;20;14;2p21;LRPPRC, LRP130, LSFC;;Leucine-rich PPR motif-containing protein;607544;R, Fd, Ld;;Leigh syndrome, French-Canadian type, 220111 (3);
2.200;8;5;11;2p21;PKDCC, VLK, SGK493;;Protein kinase domain-containing protein, cytoplasmic, mouse, homolog of;614150;REc;;;
2.201;4;30;09;2p21;PLEKHH2;;Pleckstrin homology domain-containing protein, family H, member 2;612723;REc;;;
2.202;10;19;01;2p21;PPM1B;;Protein phosphatase, magnesium-dependent, 1, beta isoform;603770;R;formerly PP2CB;;
2.203;07;28;18;2p21;PREPL, KIAA0436, CMS22;;Prolyl endopeptidase-like;609557;R, REc, D;;Myasthenic syndrome, congenital, 22, 616224 (3);
2.204;8;4;99;2p21;PRKCE, PKCE;;Protein kinase C, epsilon;176975;REc;;;
2.205;7;1;02;2p22.2;PRKCN;;Protein kinase C, nu;607077;R;;;
2.206;7;11;93;2p22.2;PRKR;;Protein kinase, interferon-inducible double stranded RNA dependent;176871;A;;;17(Prkr)
2.207;8;3;12;2p21;RHOQ, ARHQ, TC10;;Ras-homolog gene family, member Q;605857;R;;;
2.208;4;15;11;2p21;SIX3, HPE2;;Sine oculis homeo box, Drosophila, homolog of, 3;603714;Ch, REc, A, R, Fd;;Holoprosencephaly 2, 157170 (3); Schizencephaly, 269160 (3);17(Six3)
2.209;7;12;02;2p21;SOCS5, CIS6, KIAA0671;;Suppressor of cytokine signaling 5;607094;A;also signals at 3p22;;
2.210;5;1;91;2p16.2;SPTBN1;;Spectrin, beta, nonerythrocytic-1 (beta-fodrin);182790;REa, A;;;
2.211;2;18;08;2p21;THADA, KIAA1767;;Thyroid adenoma-associated gene;611800;REc;;;
2.212;5;19;15;2p21;TTC7A, TTC7, KIAA1140, MINAT, GIDID;;Tetratricopeptide repeat domain 7A;609332;R, REc;;Gastrointestinal defects and immunodeficiency syndrome, 243150 (3);17(Ttc7a)
2.213;6;10;08;2p21;ZFP36L2, ERF2, TIS11D;;Zinc finger protein 36-like 2;612053;REc;incorrectly mapped to 6p21.3;;
2.214;1;27;11;2p21;MCFD2, F5F8D2;;Multiple coagulation factor deficiency protein 2;607788;REc;;Factor V and factor VIII, combined deficiency of, 613625 (3);
2.215;2;11;08;2p21;EPAS1, MOP2, HIF2A, ECYT4;;Endothelial PAS domain protein 1;603349;A, R;;Erythrocytosis, familial, 4, 611783 (3);
2.216;1;4;11;2p16.3;FSHR, ODG1;;Follicle stimulating hormone receptor;136435;A, Fd;;Ovarian dysgenesis 1, 233300 (3); Ovarian response to FSH stimulation, 276400 (3); Ovarian hyperstimulation syndrome, 608115 (3);
2.217;2;4;96;2p21;PIGF;;Phosphatidylinositol glycan, class F;600153;A;pseudogene on 5;;17(Pigf)
2.218;8;25;04;2p21-p13;SCA25;;Spinocerebellar ataxia 25;608703;Fd;;Spinocerebellar ataxia 25 (2);
2.219;3;7;14;2p21-p12;DFNA58;;Deafness, autosomal dominant 58;615654;Fd;between D2S2259 and D2S2114;Deafness, autosomal dominant 58 (2);
2.220;9;9;10;2p16.3;GTF2A1L, ALF;;General transcription factor IIA, 1-like;605358;Psh, REc;;;
2.221;11;19;11;2p16.3;NRXN1, PTHSL2, SCZD17;;Neurexin 1;600565;R, REc;;Pitt-Hopkins-like syndrome 2, 614325 (3); {Schizophrenia, susceptibility to, 17}, 614332 (3);
2.222;10;26;18;2p16.3;PPP1R21, CCDC128, KLRAQ1;;Protein phosphatase 1, regulatory subunit 21;618159;REc;;;
2.223;4;21;10;2p21;SLC3A1, ATR1, D2H, NBAT;;Solute carrier family 3 (cystine, dibasic and neutral amino acid transporters), member 1;104614;REa, Fd, A;;Cystinuria, 220100 (3);
2.224;10;4;12;2p16.3;STON1, STN1, SBLF, SALF;;Stonin 1;605357;REc, Psh;;;
2.225;2;16;18;2p16.2;ASB3;;Ankyrin repeat-containing SOCS box protein 3;605760;REc;;;11(Asb3)
2.226;4;21;17;2p16.2;CHAC2;;ChaC, E. coli, homolog of, 2;617446;REc;;;
2.227;1;26;12;2p16.2;ERLEC1, C2orf30;;Erlectin (endoplasmic reticulum lectin 1);611229;REc;;;
2.228;4;28;10;2p16.2;ACYP2, ACYP;;Acylphosphatase 2, muscle type;102595;REc;;;
2.229;8;27;09;2p16.2;PSME4, PA200, KIAA0077;;Proteasome activator subunit 4;607705;REa, REc;;;
2.230;8;31;16;2p16.1;BCL11A, CTIP1, EVI9, KIAA1809, DILOS;;B-cell CLL/lymphoma 11A;606557;A;;Dias-Logan syndrome, 617101 (3);
2.231;6;1;17;2p16.1;CCDC88A, KIAA1212, HKRP1, GIRDIN, APE, GIV, PEHOL;;Coiled-coil domain-containing protein 88A;609736;R, REc;mutation identified in 1 PEHOL family;?PEHO syndrome-like, 617507 (3);11(Ape)
2.232;9;8;14;2p16.1;HBFQTL5;;Fetal hemoglobin quantitative trait locus 5;142335;Fd;associated with rs11886868;[Fetal hemoglobin QTL5] (2);
2.233;3;23;09;2p16.1;MIR216, MIRN216;;Micro RNA 216;610944;REc;;;
2.234;3;14;13;2p16.1;MIR217;;Micro RNA 217;615096;REc;;;
2.235;3;17;16;2p16.1;PAPOLG;;Poly(A) polymerase, gamma;616865;REc;;;
2.236;9;30;03;2p16.1;PHF9, FANCL;;PHD finger protein 9;608111;R;;Fanconi anemia, complementation group L, 614083 (3);
2.237;11;29;12;2p16.1;PNPT1, OLD35, COXPD13, DFNB70;;Polyribonucleotide nucleotidyltransferase 1;610316;R, REc;;Combined oxidative phosphorylation deficiency 13, 614932 (3); Deafness, autosomal recessive 70, 614934 (3);
2.238;2;5;16;2p16.1;PPP4R3B, PP4R3B, SMEK2, KIAA1387;;Protein phosphatase 4, regulatory subunit 3, beta;610352;REc, R;;;
2.239;3;17;16;2p16-p15;PUS10, DOBI;;Pseudouridylate synthase 10;612787;REc;;;
2.240;3;31;16;2p16.1;RPS27A, UBA80, HUBCEP80, CEP80, UBCEP1;;Ribosomal protein S27a;191343;R, REc;;;
2.241;1;20;09;2p16.1-p15;DEL2p16.1-p15, C2DELp161-p15;;Chromosome 2p16.1-p15 deletion syndrome;612513;Ch;contiguous gene deletion syndrome;Chromosome 2p16.1-p15 deletion syndrome (4);
2.242;4;19;06;2p16;ASRT3;;Asthma-related traits, susceptibility to, 3;609958;Fd;max lod at rs2063871;{Asthma-related traits, susceptibility to, 3} (2);
2.243;9;7;00;2p16;CNC2;;Carney complex, type II;605244;Fd;;Carney complex, type II (2);
2.244;6;2;99;2p16.1;EFEMP1, FBNL, DHRD;;EGF-containing fibulin-like extracellular matrix protein 1 (fibrillin-like);601548;A, Fd, REc, R;;Doyne honeycomb degeneration of retina, 126600 (3);
2.245;2;21;02;2p16.2;GPR75;;G protein-coupled receptor 75;606704;REc;;;
2.246;12;1;11;2p16.3;MSH6, GTBP, HNPCC5;;MutS, E. coli, homolog of, 6;600678;REc, H;0.5 Mb from MSH2;Colorectal cancer, hereditary nonpolyposis, type 5, 614350 (3); Endometrial cancer, familial, 608089 (3); Mismatch repair cancer syndrome, 276300 (3);
2.247;3;15;96;2p15;MDH1;;Malate dehydrogenase, soluble;154200;S, D, A;proximal to APOB;;11(Mor2)
2.248;9;3;10;2p16;STQTL24;;Stature quantitative trait locus 24;613549;Fd;linked to rs1520446;{Stature QTL 24} (2);
2.249;5;11;98;2p15;XPO1, CRM1;;Exportin-1 (required for chromosome region maintenance);602559;A;;;
2.250;11;29;99;2p16-p15;DYX3;;Dyslexia, susceptibility to, 3;604254;Fd;;{Dyslexia, susceptibility to, 3} (2);
2.251;7;1;11;2p16-p15;GLC1H;;Glaucoma 1, open angle, H;611276;Fd;between D2S123 AND D2S2165;Glaucoma 1, open angle, H (2);
2.252;4;28;97;2p14;PPP3R1, CALNB1;;Protein phosphatase-3 (formerly 2B), regulatory subunit B (19kD), alpha isoform (calcineurin B, type I);601302;REa, A;;;
2.253;1;29;01;2p21;SIX2;;Sine oculis homeo box, Drosophila, homolog of, 2;604994;R;;;17(Six2)
2.254;5;29;98;2p16.1;VRK2;;Vaccinia-related kinase-2;602169;R;;;
2.255;6;16;99;2p16.1;MTIF2;;Mitochondrial translational initiation factor 2;603766;A, Psh;;;
2.256;11;3;05;2p15;COMMD1, MURR1;;Copper metabolism Murr1 domain-containing 1;607238;R;;;
2.257;6;26;13;2p15;B3GNT2, B3GNT1, B3GNT;;Beta-1,3-N-acetylglucosyaminyltransferase 2;605581;REc;;;
2.258;5;26;05;2p15;CCT4, CCTD, SRB;;Chaperonin containing T-complex polypeptide 1, subunit 4;605142;H, REc;;;11(mf)
2.259;4;23;08;2p15;EHBP1, KIAA0903, HPC12;;EH domain-binding protein 1;609922;R, REc;;{Prostate cancer, hereditary, 12}, 611868 (3);
2.260;10;27;10;2p15;FAM161A, RP28;;Family with sequence similarity 161, member A;613596;REc, Fd;;Retinitis pigmentosa 28, 606068 (3);
2.261;10;25;12;2p15;PEX13, ZWS, NALD, PBD11A, PBD11B;;Peroxisome biogenesis factor 13 (peroxin 13);601789;A;;Peroxisome biogenesis disorder 11A (Zellweger), 614883 (3); Peroxisome biogenesis disorder 11B, 614885 (3);
2.262;12;17;12;2p15;TMEM17;;Transmembrane protein 17;614950;REc;;;
2.263;7;1;13;2p15;USP34, KIAA0570;;Ubiquitin-specific protease 34;615295;R, REc;;;
2.264;1;29;15;2p15;WDPCP, C2orf86, BBS15, CHDTHP;;WD repeat-containing planar cell polarity effector;613580;REc;mutation identified in 1 BBS15 family and 1 CHDTHP patient;?Bardet-Biedl syndrome 15, 615992 (3); ?Congenital heart defects, hamartomas of tongue, and polysyndactyly, 217085 (3);
2.265;12;29;09;2p14;ETAA1, ETAA16;;Ewing tumor-associated antigen 1;613196;REc, A;;;
2.266;10;24;11;2p13.3;NFU1, HIRIP, MMDS1;;NFU1 iron-sulfur cluster scaffold, S. cerevisiae, homolog of;608100;R, M;;Multiple mitochondrial dysfunctions syndrome 1, 605711 (3);
2.267;11;11;14;2p14;ACTR2, ARP2;;Actin-related protein 2;604221;REc;;;
2.268;5;23;07;2p13.3;AFPL, C2orf13;;Aprataxin- and PNK-like factor;611035;REc;;;
2.269;4;8;16;2p14;CEP68, KIAA0582;;Centrosomal protein, 68kD;616889;R, REc;;;
2.270;4;6;18;2p14;LGALSL;;Galectin-like protein;617902;REc;;;
2.271;4;1;96;2p14;RAB1, RAB1A;;RAB1, member RAS oncogene family;179508;REa, R;;;11(Rab1)
2.272;1;25;18;2p14;SERTAD2, TRIPBR2, KIAA0127;;SERTA domain-containing protein 2;617851;REc;;;
2.273;11;25;15;2p14;SLC1A4, SATT, ASCT1, SPATCCM;;Solute carrier family 1 (glutamate/neutral amino acid transporter), member 4;600229;A, REc;;Spastic tetraplegia, thin corpus callosum, and progressive microcephaly, 616657 (3);
2.274;10;11;07;2p14;SPRED2;;Sprouty-related EVH1 domain-containing protein 2;609292;REc;;;11(Spred2)
2.275;6;1;12;2p15-p14;VPS54, VPS54L, WR;;Vacuolar protein sorting 54, S. Cerevisiae, homolog of;614633;H, REc;;;14(Vps54)
2.276;7;3;06;2p14-p13.3;HRPT3;;Hyperparathyroidism 3;610071;Fd;between D2S2368 and D2S358;Hyperparathyroidism 3 (2);
2.277;12;17;95;2p13.3;ADD2;;Adducin-2, beta;102681;REa, A;;;6(Add2)
2.278;11;6;94;2p13.2;EMX1;;Empty spiracles, Drosophila, homolog of, 1;600034;REa, A;close to VAX2;;6(Dmx1)
2.279;4;18;97;2p14;MEIS1;;Meis1, mouse, homolog of;601739;A;;;11(Meis1)
2.280;7;20;09;2p14-p13;RLS7;;Restless legs syndrome, susceptibility to, 7;612853;Fd;associated with rs2300478;{Restless legs syndrome 7} (2);
2.281;11;29;00;2p16.1;RTN4, NOGO;;Neurite outgrowth inhibitor (reticulon 4);604475;R;;;
2.282;10;23;87;2p15;UGP2, UGPP2;;Uridyl diphosphate glucose pyrophosphorylase-2;191760;REa, A;;;
2.283;4;15;09;2p13.2;SPR;;Sepiapterin reductase;182125;A;;Dystonia, dopa-responsive, due to sepiapterin reductase deficiency, 612716 (3);1(Spr)
2.284;11;29;01;2q21.3;CCNT2;;Cyclin T2;603862;R;;;
2.285;6;23;15;2p13.3;AAK1, KIAA1048;;Adaptor protein 2-associated kinase 1;616405;R, REc;;;
2.286;6;27;16;2p13.3;ANKRD53;;Ankyrin repeat domain-containing protein 53;617009;REc;;;
2.287;3;3;16;2p13.3;BMP10;;Bone morphogenetic protein 10;608748;REc;;;
2.288;3;20;15;2p13.3;FAM136A;;Family with sequence similarity 136, member A;616275;REc;;;
2.289;6;27;05;2p13.3;GKN1, CA11;;Gastrokine 1;606402;REc;;;
2.290;8;27;02;2p13.1;LOXL3;;Lysyl oxidase-like 3;607163;REc;;;
2.291;1;6;09;2p13.3;MCEE;;Methylmalonyl-CoA epimerase;608419;REc;;Methylmalonyl-CoA epimerase deficiency, 251120 (3);
2.292;8;27;09;2p13.3;NAGK, GNK;;N-acetylglucosamine kinase;606828;R, REc;;;
2.293;8;20;07;2p13.3;PAIP2B;;Polyadenylate-binding protein-interacting protein 2B;611018;R, REc;;;
2.294;9;2;12;2p14;PELI1;;Pellino, Drosophila, homolog of, 1;614797;REc;;;
2.295;5;22;07;2p13.3;PCYOX1, PCL1, KIAA0908;;Prenylcysteine oxidase 1;610995;R, REc;;;
2.296;9;7;12;2p13.3;PROKR1, PKR1, GPR73;;Prokineticin receptor 1;607122;REc, R;;;
2.297;5;25;13;2p13.3;SNRPG;;Small nuclear ribonucleoprotein polypeptide G;603542;REc;;;
2.298;09;27;18;2p13.2;DYSF, LGMDR2, MMD1;;Dysferlin;603009;Fd, A;;Muscular dystrophy, limb-girdle, autosomal recessive 2, 253601 (3); Myopathy, distal, with anterior tibial onset, 606768 (3); Miyoshi muscular dystrophy 1, 254130 (3);6(Dysf)
2.299;4;18;12;2p13.2;CYP26B1, CYP26A2, P450RAI2, RHFCA;;Cytochrome P450, subfamily XXVIB, polypeptide 1;605207;REc;;Craniosynostosis with radiohumeral fusions and other skeletal and craniofacial anomalies, 614416 (3);
2.300;9;9;08;2p13.2;FBXO41, FBX41, KIAA1940;;F-box only protein 41;609108;REc;;;6(Fbxo41)
2.301;8;27;09;2p13.2;EXOC6B, SEC15B, KIAA0919;;Exocyst complex component 6B;607880;R, REc;;;
2.302;11;19;11;2p13.3-p13.2;ZNF638, NP220;;Zinc finger protein 638;614349;REc;;;
2.303;6;3;14;2p13.1;ACTG2, ACTA3, VSCM;;Actin, gamma-2, smooth muscle, enteric;102545;REa, A;;Visceral myopathy, 155310 (3);
2.304;9;15;17;2p13.3;ANTXR1, TEM8, ATR, GAPO;;Anthrax toxin receptor 1;606410;REc;mutation identified in 1 HCI patient;GAPO syndrome, 230740 (3); {?Hemangioma, capillary infantile, susceptibility to}, 602089 (3);
2.305;1;18;12;2p13.3;ASPRV1, SASP, TAPS, MUNO;;Aspartic peptidase, retroviral-like 1;611765;REc;;;
2.306;3;20;16;2p13.1;BOLA3, MMDS2;;BolA, E. coli, homolog of, 3;613183;REc, M;;Multiple mitochondrial dysfunctions syndrome 2 with hyperglycinemia, 614299 (3);
2.307;8;27;09;2p13.1;DUSP11, PIR1;;Dual specificity phosphatase-11, RNA/RNP complex-interacting;603092;TM, REc;;;
2.308;4;23;13;2p13.1;MOGS, GCS1, CDG2B;;Mannosyl-oligosaccharide glucosidase;601336;A, Psh;;Congenital disorder of glycosylation, type IIb, 606056 (3);
2.309;11;05;18;2p13.1;PCGF1, NSPC1;;Polycomb group RING finger protein 1;610231;R, REc, H;;;6(Pcgf1)
2.310;9;12;13;2p13.1;STAMBP, AMSH, MICCAP;;STAM binding protein;606247;A, REc;;Microcephaly-capillary malformation syndrome, 614261 (3);
2.311;6;13;12;2p13.1;TET3, KIAA0401;;TET oncogene family, member 3;613555;R, REc;;;
2.312;10;31;17;2p13.1;TPRKB, GAMOS5;;TP53RK-binding protein;608680;A, REc;;Galloway-Mowat syndrome 5, 617731 (3);
2.313;2;26;02;2p13.1;NAT8, TSC510;;N-acetyltransferase 8;606716;R;;;
2.314;5;25;13;2p13.1;NAT8B, CML2;;N-acetyltransferase 8B;608190;REc;;;
2.315;7;17;02;2p13.1;TLX2, HOX11L1;;T-cell leukemia, homeobox 2;604240;REc;;;
2.316;4;10;02;2p13.1;ALMS1, ALSS, KIAA0328;;Alstrom syndrome gene;606844;LD, Fd, REc;;Alstrom syndrome, 203800 (3);
2.317;2;9;92;2p13.3;ANXA4, ANX4;;Annexin A4 (placental anticoagulant protein II);106491;Psh, A;;;6(Anx4)
2.318;11;30;06;2p13.3;ARHGAP25, KAIA0053;;RHO GTPase-activating protein 25;610587;Psh, REc;;;
2.319;6;16;99;2p13.1;AUP1;;Ancient ubiquitous protein 1;602434;REc;;;6(Aup1)
2.320;12;26;13;2p13.2;CCT7;;Chaperonin containing T-complex polypeptide 1, subunit 7;605140;REc;;;
2.321;3;7;14;2p13.3;CD207, LANGERIN, CLEC4K;;CD207 antigen;604862;R;mutation identified in 1 patient;[?Birbeck granule deficiency], 613393 (3);6(Langerin)
2.322;3;3;09;2p13.1;DCTN1, HMN7B;;Dynactin 1 (p150, glued, Drosophila, homolog of);601143;A, R;;Neuropathy, distal hereditary motor, type VIIB, 607641 (3); {Amyotrophic lateral sclerosis, susceptibility to}, 105400 (3); Perry syndrome, 168605 (3);
2.323;8;17;16;2p13.1;DGUOK, DGK, MTDPS3, PEOB4, NCPH;;Deoxyguanosine kinase, mitochondrial;601465;Fd, REc;;Mitochondrial DNA depletion syndrome 3 (hepatocerebral type), 251880 (3); Progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal recessive 4, 617070 (3); Portal hypertension, noncirrhotic, 617068 (3);
2.324;12;15;98;2p13.1;DOK1;;Downstream of tyrosine kinase 1;602919;R;;;6(Dok1)
2.325;8;24;92;2p13.2;EGR4, NGFIC;;Early growth response-4;128992;A;;;6(Egr4)
2.326;4;30;15;2p13.3;GFPT1, GFAT1, GFPT1L, MSLG, CMS12, CMSTA1;;Glutamine-fructose-6-phosphate transaminase;138292;A;;Myasthenia, congenital, 12, with tubular aggregates, 610542 (3);
2.327;7;9;15;2p13.1;INO80B, PAPA1, HMGA1L4;;INO80 complex, subunit B;616456;A;;;
2.328;8;27;02;2p13.1;LBX2;;Lady bird-like homeo box 2;607164;Psh, R;;;6(Lbx2)
2.329;11;27;94;2p13.3;MAD;;MAD protein (MAX-binding protein);600021;A;;;
2.330;8;20;98;2p13;OFC2;;Orofacial cleft-2;602966;Fd;?relation to TGFA;Orofacial cleft-2 (2);
2.331;11;6;94;2p15;OTX1;;Orthodenticle, Drosophila, homolog of, 1;600036;REa, A;;;
2.332;10;28;99;2p13;PEE1, PREG1;;Preeclampsia/eclampsia 1;189800;Fd;?distinct loci at 2p25 and 9p13;Preeclampsia/eclampsia 1 (2);
2.333;4;23;98;2p13.1;RTKN;;Rhotekin;602288;Psh;;;6(Rtkn)
2.334;4;10;15;2p13;PARK3;;Parkinson disease 3;602404;Fd;;{Parkinson disease 3} (2);
2.335;6;28;99;2p13.1;SEMAW;;Semaphorin W;603706;R;;;6(Semawa)
2.336;12;27;13;2p13.2;SFXN5;;Sideroflexin 5;615572;REc;;;
2.337;5;6;03;2p13.1;SLC4A5, NBC4;;Solute carrier family 4, sodium bicarbonate cotransporter, member 5;606757;REc;;;
2.338;7;10;93;2p13.3;TGFA;;Transforming growth factor, alpha;190170;REa, A;;;6(Tgfa)
2.339;4;17;13;2p13.3;TIA1, WDM;;TIA1 cytotoxic granule-associated RNA-binding protein;603518;A, Fd;;Welander distal myopathy, 604454 (3);
2.340;12;31;99;2p13.3;VAX2;;Ventral anterior homeo box 2;604295;R;;;6(Vax2)
2.341;6;3;02;2p14;C1D, SUNCOR;;Nuclear DNA-binding protein C1D;606997;REc;pseudogene on chr.10;;
2.342;3;9;98;2p13.3;PCBP1;;Poly(rC)-binding protein-1;601209;A;;;
2.343;8;27;09;2p13.2;RAB11RIP5, RIP11, KIAA0857;;Rab11 family-interacting protein 5;605536;R, REc;;;
2.344;5;1;91;2p16.1;REL;;Oncogene REL, avian reticuloendotheliosis;164910;REa;;;11(Rel)
2.345;7;22;13;2p12;CTRCT27, CCNP;;Cataract 27, nuclear progressive;607304;Fd;near D2S2333;Cataract 27, nuclear progressive (2);
2.346;5;27;05;2p11.2;CD8A;;CD8 antigen, alpha polypeptide (p32);186910;REa, A;distal to IGK;CD8 deficiency, familial, 608957 (3);6(Ly2)
2.347;9;12;93;2p11.2;CD8B1, CD8B;;CD8 antigen, beta polypeptide 1 (p37);186730;REa, H;pseudogene, CD8B2, on 2q12;;6(Ly3)
2.348;1;6;11;2p12;DFNA43;;Deafness, autosomal dominant 43;608394;Fd;max lod at D2S139;Deafness, autosomal dominant 43 (2);
2.349;8;14;00;2p11.2;EIF2AK3, PEK, PERK, WRS;;Eukaryotic translation initiation factor 2-alpha kinase 3;604032;A, R, Fd;;Wolcott-Rallison syndrome, 226980 (3);
2.350;9;23;08;2p13.3;FIGLA, POF6;;Factor in germline alpha, mouse, homolog of;608697;REc;;Premature ovarian failure 6, 612310 (3);
2.351;3;13;07;2p11.2;GGCX, VKCFD1;;Gamma-glutamyl carboxylase;137167;REa, A;;Vitamin K-dependent clotting factors, combined deficiency of, 1, 277450 (3); Pseudoxanthoma elasticum-like disorder with multiple coagulation factor deficiency, 610842 (3);
2.352;4;11;97;2p12;HK2;;Hexokinase-2, muscle;601125;Fd;no recombination with TGFA;;
2.353;7;24;15;2p11.2;IGKC, IGKCD;;Immunoglobulin kappa constant region;147200;REa, A;;Kappa light chain deficiency, 614102 (3);6(Igkc)
2.354;4;15;08;2p12;IGKJ@;;Immunoglobulin kappa light chain joining gene cluster;146970;REa, A;5 genes;;
2.355;4;15;08;2p12;IGKV@;;Immunoglobulin kappa light chain variable gene cluster;146980;REa, A;25+ genes in 4 classes; orphon gene 1.5Mb telomeric of IGKC;;6(Igkv)
2.356;6;18;91;2p11.2;IGKDEL;;Immunoglobulin kappa polypeptide deleting element;146780;RE;;;6(Igkrs)
2.357;2;5;16;1p36.12;PLA2G2F;;Phospholipase A2, group IIf;616793;REc;;;4(Pla2g2f)
2.358;3;26;07;2p12;LRRTM1;;Leucine-rich repeat transmembrane protein 1;610867;REn, H;;;6(Lrrtm1)
2.359;3;26;07;2p12;LRRTM4;;Leucine-rich repeat transmembrane protein 4;610870;REn, H;;;6(Lrrtm4)
2.360;3;5;08;2p13.1;MRPL53;;Mitochondrial ribosomal protein L53;611857;R, REc;pseudogene on 1;;
2.361;3;17;94;2p12;PAP;;Pancreatitis-associated protein;167805;REa, A, REc;;;
2.362;10;7;02;2p12;POLE4;;Polymerase, DNA, epsilon-4;607269;REc;;;
2.363;12;19;16;2p13.1;HTRA2, OMI, PARK13, PRSS25, MGCA8;;HTRA serine peptidase 2;606441;REc, A;;{Parkinson disease 13}, 610297 (3); 3-methylglutaconic aciduria, type VIII, 617248 (3);
2.364;3;14;96;2p12;REG1A, PSPS1, REG;;Regenerating islet-derived 1 alpha (pancreatic stone protein, pancreatic thread protein);167770;A, Psh, REc;;;12(Reg1)
2.365;2;28;06;2p12;REG3G, PAP1B;;Regenerating islet-derived 3-gamma;609933;REc;;;
2.366;10;4;93;2p12;REGL, PSPS2;;Regenerating islet-derived, rat, homolog-like (pancreatic stone protein-like; pancreatic thread protein-like);167771;A;;;?3(Reg2)
2.367;5;28;02;2p13.1;WBP1;;WW domain-binding protein 1;606961;A;;;
2.368;2;1;11;2p12-p11.2;DEL2p12p11.2, C2DELp12p11.2;;Chromosome 2p12-p11.2 deletion syndrome;613564;Ch;contiguous gene deletion syndrome;Chromosome 2p12-p11.2 deletion syndrome (4);
2.369;5;21;07;2p11.2;SFTPB, SFTB3, SMDP1;;Pulmonary surfactant-associated protein B, 18kD;178640;REa, A;;Surfactant metabolism dysfunction, pulmonary, 1, 265120 (3);6(Sftp3)
2.370;5;13;02;2p11.2;VAMP8;;Vesicle-associated membrane protein 8;603177;R;;;6(Vamp8)
2.371;11;09;18;2p12;CTNNA2, CAPR, CTNR, CDCBM9;;Catenin, alpha-2 (cadherin-associated protein, related);114025;A;;Cortical dysplasia, complex, with other brain malformations 9, 618174 (3);6(Capr)
2.372;1;31;00;2p11.2;GNLY, D2S69E, TLA519;;Granulysin (T-lymphocyte activation gene 519);188855;A;;;
2.373;3;5;03;2p12-q22;HSR;;Hand skill, relative;139900;Fd;;[Handedness] (2);
2.374;5;2;94;2p22.3;LTBP1;;Latent transforming growth factor beta binding protein 1;150390;REa;;;
2.375;9;29;13;2p11.2;ELMOD3, RBED1, DFNB88;;ELMO/CED12 domain-containing protein 3;615427;REc;one family identified with mutation;?Deafness, autosomal recessive 88, 615429 (3);
2.376;2;21;06;2p11.2;DNAH6, HL2;;Dynein, axonemal, heavy chain 6;603336;A, R, REc;;;
2.377;10;21;08;2p11.2;FOXI3;;Forkhead box I3;612351;REc;;;
2.378;2;20;09;2p11.2;IMMT, HMP;;Inner membrane protein, mitochondrial (mitofilin);600378;REc, R;pseudogene on chr.21;;
2.379;7;18;12;2p11.2;KCMF1, DEBT91, FIGC;;Potassium channel modulatory factor 1;614719;REc, H;;;
2.380;10;24;11;2p11.2;KDM3A, JMJD1A, JHDM2A, TSGA, KIAA0742;;Lysine-specific demethylase 3A;611512;R, REc;;;
2.381;8;4;97;2p11.2;MAT2A, MATA2, SAMS2;;Methionine adenosyltransferase II, alpha;601468;A;;;
2.382;3;5;08;2p11.2;MRPL35;;Mitochondrial ribosomal protein L35;611841;REc;pseudogenes on 6, 10, and X;;
2.383;5;19;15;2p11.2;PARTICL;;Promoter of MAT2A antisense radiation-induced circulating long noncoding RNA;616350;REc;overlaps promoter of MAT2A on opposite strand;;
2.384;7;9;15;2p11.2;POLR1A, RPA194, AFDCIN;;Polymerase I, RNA, subunit A;616404;REc;;Acrofacial dysostosis, Cincinnati type, 616462 (3);
2.385;12;10;12;2p11.2;PTCD3;;Pentatricopeptide repeat domain-containing protein 3;614918;REc;;;
2.386;1;21;15;2p11.2;REEP1, C2orf23, SPG31, HMN5B;;Receptor expression-enhancing protein 1;609139;Fc, R, REc;mutation identified in 1 HMN5B family;Spastic paraplegia 31, autosomal dominant, 610250 (3); ?Neuronopathy, distal hereditary motor, type VB, 614751 (3);
2.387;7;27;17;2p11.2;RETSAT;;Retinol saturase;617597;REc;;;
2.388;4;23;09;2p11.2;RGPD1, RGP1;;RANBP2-like and GRIP domain-containing protein 1;612704;REn;;;
2.389;4;23;09;2p11.2;RGPD2, RGP2;;RANBP2-like and GRIP domain-containing protein 2;612705;REn;;;
2.390;12;22;08;2p11.2;RNF181;;Ring finger protein 181;612490;R, REc;;;
2.391;2;17;15;2p11.2;RPIA, RPI, RPIAD;;Ribose 5-phosphate isomerase A;180430;R, REc;mutation identified in 1 RPAID patient;?Ribose 5-phosphate isomerase deficiency, 608611 (3);
2.392;9;16;16;2p11.2;SIAT9, ST3GALV, SPDRS;;Sialyltransferase 9;604402;REc, Fd;;Salt and pepper developmental regression syndrome, 609056 (3);
2.393;12;13;17;2p11.2;SMYD1, BOP, ZMYND18;;SET and MYND domain-containing protein 1;606846;REc;;;
2.394;12;27;10;2p11.2;SUCLG1, SUCLA1, MTDPS9;;Succinate-CoA ligase, alpha subunit;611224;R, REc;;Mitochondrial DNA depletion syndrome 9 (encephalomyopathic type with methylmalonic aciduria), 245400 (3);
2.395;6;13;12;2p11.2;TCF7L1;;Transcription factor 7-like 1;604652;REc;;;
2.396;3;4;10;2p11.2;TGOLN2, TGN46, TGN38;;Trans-golgi network protein 2, 46kD;603062;A;;;
2.397;8;19;13;2p11.2;THNSL2, THS2;;Threonine synthase-like 2;611261;REc;;;
2.398;1;14;16;2p11.2;TMEM150A, TMEM150;;Transmembrane protein 150A;616757;REc;;;
2.399;3;7;14;2p11.2;TMSB10;;Thymosin, beta-10;188399;REc;;;
2.400;12;10;12;2p11.2;TRABD2A, TIKI1;;TRAB domain-containing protein 2A;614912;REc;;;
2.401;2;23;08;2p11.2;USP39, SAD1;;Ubiquitin-specific protease 39;611594;REc;;;
2.402;8;27;09;2p11.2;VAMP5;;Vesicle-associated membrane protein 5 (myobrevin);607029;R, REc;;;
2.403;6;24;99;2p11.2;ZFP103, KF1;;Zinc finger protein 103, mouse, homolog of;602507;A;;;
2.404;9;19;00;2p12;C2orf3, TCF9, GCF;;GC factor;189901;A;;;
2.405;1;30;07;2q11.2;ANKRD23, DARP;;Ankyrin repeat domain-containing protein 23;610736;REc;;;
2.406;2;28;08;2p12;MRPL19, MRPL15, KIAA0104;;Mitochondrial ribosomal protein L19;611832;Psh, R;;;
2.407;4;23;08;2q11.1;MRPS5;;Mitochondrial ribosomal protein S5;611972;R, REc;;;
2.408;1;25;88;2p11.2;FABP1;;Fatty acid-binding protein, liver;134650;REa, A;;;6(Fabpl)
2.409;11;23;16;2q11.2;NEURL3, LINCR;;Neuralized E3 ubiquitin protein ligase 3;617206;REc;;;
2.410;7;15;04;2p12;TACR1, TAC1R, NK1R;;Tachykinin receptor 1 (substance P receptor; neurokinin-1 receptor);162323;REa, Psh, Fd;;;
2.411;9;2;08;2p11.2;PLGLB1, PLGL, PRGB;;Plasminogen-like B1;173340;REa, A;;;
2.412;9;20;00;2p14;PLEK;;Pleckstrin;173570;H;;;11(Plek)
2.413;12;4;95;2p24.2;VSNL1;;Visinin-like 1;600817;Fd;;;
2.414;1;5;99;2p13.3;ATP6B1, VPP3;;ATPase, H+ transporting, lysosomal, beta polypeptide, 58kD (vacuolar proton pump, subunit 3);192132;REa, R, Fd;;Renal tubular acidosis with deafness, 267300 (3);8(Atp6b1)
2.415;3;8;91;2q11.2;COX5B;;Cytochrome c oxidase, subunit Vb;123866;REa;7 pseudogenes on 4, 6, 7, 11, 12, 13, and 22;;
2.416;2;14;02;2cen-q13;GLC1B;;Glaucoma 1, open angle, B (adult-onset);606689;Fd;;Glaucoma 1B, primary open angle, adult onset, (2);
2.417;10;23;87;2q14.2;INHBB;;Inhibin, beta-2;147390;REa;;;1(Inhbb)
2.418;10;23;87;2q11.1;MAL;;T-lymphocyte maturation-associated protein;188860;REa;;;
2.419;12;19;90;2q14.2;RALB;;RAS-like protein B;179551;REa;;;
2.420;1;1;95;2p11.2;CAPG;;Capping protein (actin filament), gelsolin-like;153615;Psh, A;;;
2.421;3;24;05;2q;AUTS5;;Autism, susceptibility to, 5;606053;Fd;max lod at D2S188;{Autism susceptibility 5} (2);
2.422;2;28;06;2q;COPD;;Pulmonary disease, chronic obstructive, severe early-onset;606963;Fd;?SERPINE2;Pulmonary disease, chronic obstructive, severe early-onset (2);
2.423;10;7;98;2q11.2;CNGA3, CNG3, ACHM2;;Cyclic nucleotide-gated channel, alpha-3;600053;Fd, R;;Achromatopsia 2, 216900 (3);
2.424;10;15;98;2q11.2;DUSP2, PAC1;;Dual-specificity phosphatase-2;603068;REa, A;;;
2.425;7;26;10;2q11.2;TMEM127;;Transmembrane protein 127;613403;REc;;{Pheochromocytoma, susceptibility to}, 171300 (3);
2.426;4;25;08;2q11-q12;CELIAC8;;Celiac disease, susceptibility to, 8;612006;Fd;associated with rs917997 and rs13015714;{Celiac disease, susceptibility to, 8} (2);
2.427;12;17;12;2q13;EDAR, DL, ED3, EDA3, HRM1, ECTD10A, ECTD10B;;Ectodysplasin 1, anhidrotic receptor (downless, mouse, homolog of);604095;Fd, R;;Ectodermal dysplasia 10A, hypohidrotic/hair/nail type, autosomal dominant, 129490 (3); Ectodermal dysplasia 10B, hypohidrotic/hair/tooth type, autosomal recessive, 224900 (3); [Hair morphology 1, hair thickness], 612630 (3);
2.428;10;3;11;2q13;RANBP2, NUP358, ANE1, IIAE3;;RAN-binding protein 2;601181;A;;{Encephalopathy, acute, infection-induced, 3, susceptibility to}, 608033 (3);10(Ranbp2)
2.429;3;20;08;2q11-q14;NNO3;;Nanophthalmos 3;611897;Fd;max lod at D2S2265;Nanophthalmos 3 (2);
2.430;8;17;98;2q14.1;SLC20A1, GLVR1;;Solute carrier family 20, phosphate transporter, member 1 (Gibbon ape leukemia virus receptor-1);137570;REa, A;;;2(Slc20a1)
2.431;9;9;10;2q11.1;KCNIP3, KCHIP3, CSEN, DREAM;;Potassium channel-interacting protein 3;604662;REc;;;
2.432;10;25;16;2q11.1;PROM2, PROML2;;Prominin 2;617160;REc, H;;;2(Prom2)
2.433;1;30;01;2q11.2;ACTR1B, ARP1B, CTRN2;;Actin-related protein 1B;605144;REa, A;;;
2.434;4;23;98;2q12.3;SULT1C1;;Sulfotransferase 1C1;602385;Psh;;;
2.435;6;18;15;2q11.2;ADRA2B, ADRA2L1, FAME2;;Adrenergic, alpha-2B-, receptor;104260;REa, REc, Fd;;Epilepsy, myoclonic, familial adult, 2, 607876 (3);
2.436;12;7;07;2q11.2;ARID5A, MRF1;;AT-rich interactive domain-containing protein 5A;611583;R, REc;;;
2.437;5;17;18;2q11.2;NCAPH, CAPH, BRRN1, MCPH23;;Non-SMC condensin I complex subunit H;602332;REa, REc, R;mutation identified in 1 MCPH23 patient;?Microcephaly 23, primary, autosomal recessive, 617985 (3);
2.438;7;31;15;2q11.2;COA5, C2orf64, PET191, CEMCOX3;;Cytochrome c oxidase assembly factor 5;613920;REc;mutation identified in 1 CEMCOX3 family;?Cardioencephalomyopathy, fatal infantile, due to cytochrome c oxidase deficiency 3, 616500 (3);
2.439;8;27;09;2q11.2;CHST10, HNK1ST;;Carbohydrate sulfotransferase 10;606376;R, REc;;;
2.440;8;31;12;2q11.2;CIAO1, WDR39;;WD repeat-containing protein CIAO1;604333;A, R;;;
2.441;8;31;09;2q11.2;CNNM3, ACDP3;;Cyclin M3;607804;R, REc;previously assigned to 2p12-p11.2;;
2.442;8;31;09;2q11.2;CNNM4, ACDP4;;Cyclin M4;607805;R, Fd, REc;;Jalili syndrome, 217080 (3);1(Cnnm4)
2.443;9;30;09;2q24.1;CYTIP, PSCDBP, HE;;Cytohesin 1 interacting protein;604448;Re, R;;;
2.444;6;23;15;2q11.2;GPAT2;;Glycerol-3-phosphate acyltransferase 2, mitochondrial;616431;REc;;;
2.445;2;9;00;2q12.1;IL1RL1;;Interleukin 1 receptor-like 1;601203;REa, A, R;;;
2.446;10;24;00;2q11.2;INPP4A, INPP4;;Inositol polyphosphate-4-phosphatase, type I, 107kD;600916;A;;;
2.447;10;25;17;2q11.2;KANSL3, NSL3, KIAA1310;;Kat8 regulatory NSL complex, subunit 3;617742;REc;;;
2.448;4;4;16;2q11.2;LMAN2L, VIPL, MRT52;;LMAN2-like protein;609552;REc;mutation identified in 1 MRT52 family;?Mental retardation, autosomal recessive, 52, 616887 (3);
2.449;4;30;15;2q11.2;LIPT1, LIPT1D;;Lipoyltransferase 1;610284;A;;Lipoyltransferase 1 deficiency, 616299 (3);
2.450;9;21;15;2q11.2;LYG2, LYSG2;;Lysozyme G-like 2;616547;REc;;;
2.451;2;25;15;2q11.2;MAP4K4, HGK, NIK, KIAA0687;;Mitogen-activated protein kinase kinase kinase kinase 4;604666;REc;;;
2.452;2;28;08;2q11.2;MRPL30, MRPL28;;Mitochondrial ribosomal protein L30;611838;R;;;
2.453;12;17;07;2q11.2;PDCL3, PHLP3, VIAF;;Phosducin-like 3;611678;R, REc;;;
2.454;8;3;12;2q11.2;REV1L, REV1;;Rev1, S. cerevisiae, homolog of;606134;REc;;;
2.455;4;21;17;2q11.2;RPL31;;Ribosomal protein L31;617415;Psh;;;
2.456;1;1;96;2q12.1;SLC9A2;;Solute carrier family 9 (sodium/hydrogen exchanger), member 2;600530;REa, A;;;1(Slc9a2)
2.457;2;19;10;2q11.2;SNRNP200, ASCC3L1, KIAA0788, RP33;;Small nuclear ribonucleoprotein 200kD (U5);601664;R, REc, Fd;;Retinitis pigmentosa 33, 610359 (3);
2.458;12;22;15;2q11.2;STARD7, GTT1;;START domain-containing protein 4;616712;REc;;;
2.459;1;27;04;2q12.3;SULT1C2;;Sulfotransferase family 1C, member 2;608357;REc;;;
2.460;3;7;14;2q11.2;TMEM131, KIAA0257, CC28;;Transmembrane protein 131;615659;REc, R;;;
2.461;5;9;18;2q11.2;TSGA10, SPGF26;;Testis-specific protein 10;607166;Psh, A;mutation identified in 1 SPGF26;?Spermatogenic failure 26, 617961 (3);
2.462;2;4;09;2q11.2;TXNDC9, PHLP3;;Thioredoxin domain-containing protein 9;612564;REc;;;
2.463;12;22;17;2q11.2;UNC50, UNCL, GMH1;;Unc50, inner nuclear membrane RNA-binding protein;617826;REc;;;
2.464;5;23;16;2q11.2;VWA3B, SCAR22;;von Willebrand factor A domain-containing protein 3B;614884;REc;mutation identified in 1 SCAR22 family;?Spinocerebellar ataxia, autosomal recessive 22, 616948 (3);
2.465;3;1;01;2q11.1;ZNF2;;Zinc finger protein-2;194500;REa, A;;;
2.466;5;5;00;2q12.1;GPR45;;G protein-coupled receptor 45;604838;A;;;
2.467;10;17;96;2q11.2;LAF4;;Lymphoid nuclear protein related to AF4;601464;A, Ch;;;1(Laf4)
2.468;2;19;04;2q12.3;ST6GALII, KIAA1877;;Beta-galactoside alpha-2,6-sialyltransferase II;608472;R, REc;;;
2.469;3;1;00;2q12.1;IL18R1, IL1RRP;;Interleukin 18 receptor 1;604494;R;;;
2.470;3;10;00;2q12.1;IL18RAP, ACPL;;Interleukin 18 receptor accessory protein;604509;R;;;
2.471;8;17;98;2q11.2-q12.1;IL1R1, IL1RA;;Interleukin-1 receptor, type I;147810;REa, A;;;1(Il1r)
2.472;2;9;00;2q12.1;IL1RL2, IL1RRP2;;Interleukin 1 receptor-like 2;604512;R;;;
2.473;3;8;00;2q11.2;MGAT4A;;Alpha-1,3-mannosyl-glycoprotein beta-1,4-N-acetylglucosaminyltransferase, isozyme A;604623;A;;;
2.474;5;12;00;2q12.2;NCK2;;NCK adaptor protein 2;604930;A;;;
2.475;12;23;05;2q12.2;UXS1, UGD;;UDP-glucuronate decarboxylase 1;609749;R, REc;;;
2.476;6;30;16;2q11.2;ZAP70, SRK, ADMIO2, IMD48;;Zeta-chain associated protein kinase, 70kD (syk-related tyrosine kinase);176947;A;;Autoimmune disease, multisystem, infantile-onset, 2, 617006 (3); Immunodeficiency 48, 269840 (3);1(Zap70)
2.477;7;9;06;2q14.2;MARCO;;Macrophage receptor with collagenous structure;604870;A;;;1(Marco)
2.478;6;23;98;2q12.2;FHL2, DRAL;;Four and a half LIM domains-2 (Down-regulated in rhabdomyosarcoma LIM protein);602633;A;;;
2.479;9;28;00;2q12-q14;IGKV1OR2-108, IGO1;;Immunoglobulin orphon (transposed element) 1;147185;A;;;
2.480;8;27;01;2q14.1;PAX8;;Paired box homeotic gene-8;167415;REa, A;;Hypothyroidism, congenital, due to thyroid dysgenesis or hypoplasia, 218700 (3);2(Pax8)
2.481;1;5;93;2q14.2;DBI;;Diazepam-binding inhibitor;125950;A, REa;?on 6q21-qter;;
2.482;12;21;98;2q11.2;IL1R2, IL1RB;;Interleukin-1 receptor, type II;147811;REa, A;;;1(Il1rb)
2.483;9;10;07;2q37.1;SNORD82, RNU82;;Small nucleolar RNA, C/D box, 82;611133;REc;;;
2.484;2;26;95;2q37.1;NCL;;Nucleolin;164035;REa;;;
2.485;9;1;11;2q14.1;IL37, IL1F7, FIL1Z, IL1H4, IL1RP1;;Interleukin 37;605510;R;;;
2.486;12;11;18;2q12.1;LINC01159, LINC-BRN1B;;Long intergenic noncoding RNA 1159;618208;REc;;;1(Linc01159)
2.487;8;17;16;2q12.1;LNC13;;Long noncoding RNA 13;617071;REc;;;
2.488;4;23;08;2q12.1;MRPS9;;Mitochondrial ribosomal protein S9;611975;R, REc;;;
2.489;11;02;18;2q12.1;PANTR1, LINC01158;;POU3F3-adjacent noncoding transcript 1;618169;REc;;;
2.490;4;13;98;2q12.1;POU3F3;;POU domain, class 3, transcription factor-3;602480;A;previously mapped to 3p14.2;;1(Pou3f3)
2.491;4;30;09;2q12.1;SLC9A4, NHE4;;Solute carrier family 9 (sodium/hydrogen exchanger), member 4;600531;REa;;;1(Slc9a4)
2.492;8;27;09;2q12.1-q12.2;TGFBRAP1, TRAP1;;Transforming growth factor-beta receptor-associated protein 1;606237;REc;;;
2.493;9;2;08;2q12.2;PLGLA, PRGA;;Plasminogen-like A;612212;R, REc;;;
2.494;10;11;16;2q12.3;SULT1C3;;Sulfotransferase family 1C, member 3;617151;REn;;;
2.495;4;23;09;2q12.3;GCC2, GCC185, KIAA0336;;GRIP and coiled-coil domains-containing protein 2;612711;R, REc;;;
2.496;10;11;16;2q12.3;SLC5A7, CHT1, HMN7A, CMS20;;Solute carrier family 5 (choline transporter), member 7;608761;REc, R;;Neuronopathy, distal hereditary motor, type VIIA, 158580 (3); Myasthenic syndrome, congenital, 20, presynaptic, 617143 (3);
2.497;4;23;09;2q12.2;RGPD3, RGP3;;RANBP2-like and GRIP domain-containing protein 3;612706;REn;;;
2.498;4;23;09;2q12.3;RGPD4, RGP4;;RANBP2-like and GRIP domain-containing protein 4;612707;REn;;;
2.499;4;23;09;2q13;RGPD5, RGP5, BS63;;RANBP2-like and GRIP domain-containing protein 5;612708;REn;;;
2.500;4;23;09;2q13;RGPD6, RGP6;;RANBP2-like and GRIP domain-containing protein 6;612709;REn;;;
2.501;4;23;09;2q12.3-q13;RGPD7, RGP7;;RANBP2-like and GRIP domain-containing protein 7;612710;REn;;;
2.502;4;23;09;2q14.1;RGPD8, RGP8, RANBP2L1;;RANBP2-like and GRIP domain-containing protein 8;602752;A, REc;;;
2.503;3;6;08;2q14.1;DPP10, DPRP3, KIAA1492;;Dipeptidyl peptidase X;608209;REc;;;
2.504;8;8;13;2q13;ANAP1, APC1;;Anaphase-promoting complex, subunit 1;608473;Psh, A, R;;;
2.505;10;11;16;2q13;BCL2L11, BIM;;BCL2-like 11;603827;A, REc;;;
2.506;1;12;15;2q14.1;CKAP2L, RADMIS;;Cytoskeleton-associated protein 2-like;616174;REc;;Filippi syndrome, 272440 (3);
2.507;3;31;03;2q13;COMA;;Cogan-type congenital oculomotor apraxia;257550;D;independent gene or feature of nephronophthisis;Oculomotor apraxia, congenital, Cogan-type (2);
2.508;3;17;08;2q13-q14;FBLN7, TM14;;Fibulin 7;611551;REc;;;
2.509;10;15;97;2q13;MALL, BENE;;mal, T-cell differentiation protein-like;602022;REn, REc;;;
2.510;9;1;11;2q14.1;IL36RN, IL1F5, FIL1D, IL1HY1, IL1RP3, PSORP, PSORS14;;Interleukin 36 receptor antagonist;605507;R, REc;;Psoriasis 14, pustular, 614204 (3);
2.511;9;1;11;2q14.1;IL36A, IL1F6, FIL1E;;Interleukin 36, alpha;605509;REc, R;;;
2.512;9;1;11;2q14.1;IL36B, IL1F8, IL1H2, FIL1H;;Interleukin 36, beta;605508;R, REc;;;
2.513;9;1;11;2q14.1;IL36G, IL1F9, IL1H1, IL1RP2;;Interleukin 36, gamma;605542;REc, R;;;
2.514;7;12;17;2q13;MIR4435-2HG, MORRBID;;MIR4435-2 host gene (long noncoding RNA MORRBID);617144;REc;;;
2.515;6;16;99;2q11.2;NPAS2, MOP4;;Neuronal PAS domain protein 2;603347;R, Psh;;;1(Npas2)
2.516;6;16;04;2q13;NPHP1, NPH1, SLSN1, JBTS4;;Nephrocystin;607100;Fd;;Nephronophthisis 1, juvenile, 256100 (3); Senior-Loken syndrome-1, 266900 (3); Joubert syndrome 4, 609583 (3);
2.517;1;30;12;2q14.1;PSD4, EFA6B, TIC;;Pleckstrin and Sec7 domains-containing protein 4;614442;REc;;;
2.518;11;27;00;2q14.1;RABL2A;;RAB-like 2A;605412;A;;;
2.519;1;22;08;2q13;SEPT10;;Septin 10;611737;REc;pseudogene on 8q22.1-q12;;
2.520;11;23;16;2q13;TMEM87B;;Transmembrane protein 87B;617203;REc;;;
2.521;12;4;03;2q14.1;TTL;;Tubulin-tyrosine ligase;608291;REc;;;2(Ttl)
2.522;3;1;12;2q14.3;PROC, PC, THPH3, THPH4;;Protein C (inactivator of coagulation factors Va and VIIIa);612283;REa, A;;Thrombophilia due to protein C deficiency, autosomal dominant, 176860 (3); Thrombophilia due to protein C deficiency, autosomal recessive, 612304 (3);
2.523;8;21;07;2q14.1;CBWD2;;Cobalamin synthetase W domain-containing protein 2;611079;REc;;;
2.524;8;21;07;2q14.1;FOXD4L1;;Forkhead box D4-like 1;611084;REc;;;
2.525;3;22;93;2q14.2;EN1;;Engrailed-1;131290;REa;;;1(En1)
2.526;11;7;17;2q14.3;BIN1, AMPHL, CNM2;;Box-dependent MYC-interacting protein-1 (amphiphysin-like);601248;Psh, A;;Centronuclear myopathy 2, 255200 (3);18(Bin1)
2.527;6;22;14;2q13;BUB1;;Budding uninhibited by benzimidazoles 1, S. cerevisiae, homolog of (mitotic checkpoint gene BUB1);602452;A, R;;Colorectal cancer with chromosomal instability, somatic (3);2(Bub1)
2.528;8;27;09;2q14.2-q14.3;CLASP1, KIAA0622;;CLIP-associated protein 1;605852;R, REc;;;
2.529;5;26;13;2q14.3;CNTNAP5, CASPR5;;Contactin-associated protein-like 5;610519;REc;;;
2.530;1;17;08;2q14.2;EPB41L5, KIAA1548;;Erythrocyte membrane protein band 4.1-like 5;611730;R, REn;;;
2.531;12;10;14;2q14.2;GLI2, HPE9, CJS;;GLI-Kruppel family member GLI2 (oncogene GLI2);165230;REa, A;;Holoprosencephaly 9, 610829 (3); Culler-Jones syndrome, 615849 (3);
2.532;6;11;98;2q14.1;IL1A;;Interleukin-1, alpha;147760;H, REa, A;within 430kb of IL1B, IL1RN;;2(Il1a)
2.533;5;27;05;2q14.1;IL1B;;Interleukin-1, beta;147720;REa, A, H;within 430kb of IL1RN, IL1A;{Gastric cancer risk after H. pylori infection}, 137215 (3);2(Il1b)
2.534;7;1;13;2q14.1;IL1F10, IL1HY2;;Interleukin 1 family, member 10;615296;REc;;;
2.535;12;23;05;2q14.2;TFCP2L1, CRTR1, LBP9;;Transcription factor CP2-like 1;609785;R, REc;;;
2.536;6;9;08;2p14;WDR92, LOC116143, MONAD;;WD repeat-containing protein 92;610729;R, REc;;;
2.537;11;14;14;2q14.3;GYPC, GE, GPC;;Glycophorin C;110750;A;;{Malaria, resistance to}, 611162 (3); [Blood group, Gerbich], 616089 (3);
2.538;9;14;89;2q14-q21;LCO;;Liver cancer oncogene;165320;REa, REb, A;;?Hepatocellular carcinoma (1);
2.539;2;10;95;2q14-q21;VIS1, HIS1;;Viral integration site 1;164755;A;;;2(His1)
2.540;11;9;99;2q14-q22;CMD1H;;Cardiomyopathy, dilated, 1H;604288;Fd;;Cardiomyopathy, dilated, 1H (2);
2.541;4;22;10;2q14.1;ACTR3, ARP3;;Actin-related protein 3;604222;REc;;;
2.542;12;24;08;2q14.1;BMIQ13;;Body mass index quantitative trait locus 13;612459;Fd;associated with rs7566605;[Body mass index QTL13] (2);
2.543;6;17;16;2q14.1;CHCHD5, MIC14;;Coiled coil-helix-coiled coil-helix domain-containing protein 5;616978;REc;;;
2.544;12;4;08;2q14.1-q14.2;INSIG2;;Insulin-induced gene 2;608660;REc;;;
2.545;11;8;95;2q14.2;SCTR;;Secretin receptor;182098;A;;;
2.546;4;6;11;2q13;MERTK, RP38;;Mer tyrosine kinase protooncogene;604705;A, Fd;;Retinitis pigmentosa 38, 613862 (3);
2.547;7;9;06;2q14.1;DDX18;;DEAD/H box 18;606355;R, REc;;;
2.548;9;27;17;2q14.1;POLR1B;;Polymerase I, RNA, subunit B;602000;REc;;;
2.549;1;28;08;2q12.2;C2orf40, ECRG4;;Esophageal cancer-related gene 4;611752;REc;;;
2.550;11;19;11;2q14.2;C1QL2, CTRP10, C1QTNF10;;Complement component 1, q subcomponent-like 2;614330;REc;;;
2.551;10;1;17;2q14.2;PTPN4, PTPMEG1;;Protein-tyrosine phosphatase, nonreceptor-type, 4;176878;REc;;;
2.552;7;9;09;2q14.1;IL1RN, MVCD4, DIRA;;Interleukin-1 receptor antagonist;147679;REa, Fd, A;;{Gastric cancer risk after H. pylori infection}, 137215 (3); {Microvascular complications of diabetes 4}, 612628 (3); Interleukin 1 receptor antagonist deficiency, 612852 (3);
2.553;11;20;15;2q14.2;RNU4ATAC, U4ATAC, MOPD1, TALS, RFMN;;RNA, U4, small nuclear, AT-AC form;601428;REc, Fd;;Microcephalic osteodysplastic primordial dwarfism, type I, 210710 (3); Roifman syndrome, 616651 (3);
2.554;5;24;13;2q14.2;STEAP3, TSAP6, AHMIO2;;Six-transmembrane epithelial antigen of prostate 3;609671;A;mutation identified in 1 AHMIO2 family;?Anemia, hypochromic microcytic, with iron overload 2, 615234 (3);1(Steap3)
2.555;09;27;18;2q14.3;LIMS2, PINCH2, MDRCMTT;;LIM and senescent cell antigen-like domains 2;607908;REc;mutation identified in 1 LGMD2W family;?Muscular dystrophy, autosomal recessive, with cardiomyopathy and triangular tongue, 616827 (3);
2.556;6;27;14;2q14.3;MAP3K2, MEKK2;;Mitogen-activated protein kinase kinase kinase 2;609487;REc, R;;;
2.557;3;6;18;2q14.3;NIFK, MKI67IP, NOPP34;;Nucleolar protein interacting with the FHA domain of MKI67;611970;REc;;;
2.558;9;27;17;2q14.3;POLR2D;;Polymerase II, RNA, subunit D;606017;REc, A;;;
2.559;12;28;08;2q14.3;SAP130;;Sin3A-associated protein, 130kD;609697;R, REc;;;
2.560;8;27;09;2q14.3;UGGT1, HUGT1;;UDP-glucose glycoprotein glucosyltransferase 1;605897;REc;;;
2.561;8;10;18;2q14.3;WDR33, WDC146;;WD repeat-containing protein 33;618082;REc, A;;;
2.562;4;27;12;2q14.3-q21.3;DYT21;;Dystonia 21;614588;Fd;;Dystonia 21 (2);
2.563;4;16;03;2q22.1;CXCR4, D2S201E, NPY3R, WHIMS;;Chemokine (C-X-C motif) receptor 4 (neuropeptide Y receptor Y3);162643;Psh, A;;WHIM syndrome, 193670 (3); Myelokathexis, isolated (3);
2.564;6;2;15;2q14.3;ERCC3, XPB, TTD2;;Excision-repair cross-complementing rodent repair deficiency, complementation group 3;133510;S, A;;Xeroderma pigmentosum, group B, 610651 (3); Trichothiodystrophy 2, photosensitive, 616390 (3);
2.565;10;15;98;2q14.3;GPR17;;G protein-coupled receptor-17;603071;REa, A;;;
2.566;10;17;12;2q14.3;HS6ST1, HS6ST, HH15;;Heparan sulfate 6-O-sulfotransferase 1;604846;R, REc;;{Hypogonadotropic hypogonadism 15 with or without anosmia}, 614880 (3);
2.567;1;23;09;2q21.3;LCT, LAC, LPH;;Lactase (lactase-phlorizin hydrolase);603202;REa, Fd, A, Psh;;Lactase deficiency, congenital, 223000 (3);
2.568;2;5;09;2q21.3;MCM6;;Minichromosome maintenance deficient (mis5, S. pombe) 6;601806;A;mutations in introns 9 and 13;Lactase persistence/nonpersistence, 223100 (3);
2.569;7;1;97;2q21.2-q21.3;MGAT5;;Mannosyl (alpha-1,6-)-glycoprotein beta-1,6-N-acetyl- glucosaminyltransferase;601774;A;;;
2.570;3;23;09;2q21.3;MIR128-1, MIRN128-1, MIR128A;;Micro RNA 128-1;611774;REc;;;
2.571;9;1;15;2q21;NMTC3;;Nonmedullary thyroid carcinoma 3;606240;Fd;;{Thyroid carcinoma, nonmedullary, 3} (2);
2.572;11;20;98;2q21.2;GPR39;;G protein-coupled receptor-39;602886;A;;;
2.573;3;17;94;2q24.3;SCN7A, SCN6A;;Sodium channel, voltage-gated, type VII, alpha polypeptide;182392;Pcm;;;
2.574;9;23;08;2q21.1;ADHD5;;Attention deficit-hyperactivity disorder, susceptibility to, 5;612311;Fd;max lod at rs985162;{Attention deficit-hyperactivity disorder, susceptibility to, 5} (2);
2.575;11;16;15;2q21.1;CFC1, CRYPTIC, HTX2;;Cryptic protein;605194;R;;Heterotaxy, visceral, 2, autosomal, 605376 (3);
2.576;9;7;10;2q21.1;FAM128A, MOZART2A;;Family with sequence similarity 128, member A;613449;REc;;;
2.577;9;7;10;2q21.1;FAM128B, MOZART2B;;Family with sequence similarity 128, member B;613450;REc;;;
2.578;9;2;09;2q21.1;IMP4, BXDC4;;Imp4, S. cerevisiae, homolog of;612981;REc;;;
2.579;12;27;01;2q14.3;MYO7B;;Myosin VIIb;606541;R, A;;;18(Myo7b)
2.580;6;7;10;2q21.1;POTEE, POTE2;;POTE ankyrin domain family, member E;608914;REc, A;5 POTE2 genes within 2Mb segment;;
2.581;8;18;12;2q21.1;POTEKP, ACT, ACTBL3, POTEK, FKSG30;;POTE ankyrin domain family, member K, pseudogene;611266;REc;;;
2.582;8;27;09;2q21.1;PTPN18, BDP1;;Protein-tyrosine phosphatase, nonreceptor-type, 18;606587;R, REc;;;
2.583;3;2;01;2q14.3;TSN;;Translin;600575;REa, A;;;
2.584;7;22;09;2q21.1;RAB6C, WTH3;;Ras-associated protein RAB6C;612909;REc;;;
2.585;5;24;13;2q21.1;SMPD4, NSMASE3, KIAA1418;;Sphingomyelin phosphodiesterase 4, neutral membrane;610457;REc;;;
2.586;4;6;18;2q21.1;TUBA3D, KTCN9;;Tubulin, alpha-3D;617878;REc;;Keratoconus 9, 617928 (3);
2.587;12;4;03;2q21.1-q22;CHDS2;;Coronary heart disease, susceptibility to, 2;608316;Fd;;{Coronary heart disease, susceptibility to, 2} (2);
2.588;2;26;16;2q21.1;CCDC115, CCP1, CDG2O;;Coiled-coil domain-containing protein 115;613734;REc;;Congenital disorder of glycosylation, type IIo, 616828 (3);1(Ccdc115)
2.589;5;24;13;2q21.2;LYPD1, PHTS;;LY6/PLAUR domain-containing protein 1;610450;REc;;;
2.590;3;14;13;2q21.2;NCKAP5, NAP5;;NCK-associated protein 5;608789;REc;;;
2.591;12;22;17;2q21.3;DARS, HBSL, HBSL;;Aspartyl tRNA synthetase;603084;REc;;Hypomyelination with brainstem and spinal cord involvement and leg spasticity, 615281 (3);
2.592;3;22;06;2q21.3;RAB3GAP1, WARBM1, P130;;RAB3 GTPase-activating protein, catalytic subunit;602536;REc;;Warburg micro syndrome 1, 600118 (3);
2.593;5;19;16;2q21.3;ZRANB3;;Zinc finger RANBP2-type domain-containing protein 3;615655;REc;;;
2.594;5;29;15;2q21.3;UBXN4, UBXD2, KIAA2042, ERASIN;;UBX domain protein 4;611216;REc, R;;;
2.595;6;30;08;2q21.1;ARHGEF4, ASEF;;RHO guanine nucleotide exchange factor 4;605216;A;;;
2.596;7;3;06;2q22.3;GTDC1;;Glycosyltransferase-like domain containing 1;610165;REc;;;
2.597;1;13;16;2q22.1;HNMT, MRT51;;Histamine N-methyltransferase;605238;A, REc;;{Asthma, susceptibility to}, 600807 (3); Mental retardation, autosomal recessive 51, 616739 (3);
2.598;6;4;98;2q23.3;NEB, NEM2;;Nebulin;161650;REa, Ch, A, R, Fd;;Nemaline myopathy 2, autosomal recessive, 256030 (3);2(Neb)
2.599;4;19;07;2q22.3;ZEB2, ZFHX1B, SMADIP1, SIP1;;Zinc finger E box-binding homeobox 2;605802;Ch;;Mowat-Wilson syndrome, 235730 (3);
2.600;11;21;02;2p16.3;KCNK12, THIK2;;Potassium channel, subfamily K, member 12;607366;REc;;;
2.601;4;6;11;2q23.3;CACNB4, EJM6, EA5, EIG9;;Calcium channel, voltage-dependent, beta 4 subunit;601949;A, Psh, R;;{Epilepsy, juvenile myoclonic, susceptibility to, 6}, 607682 (3); {Epilepsy, idiopathic generalized, susceptibility to, 9}, 607682 (3); Episodic ataxia, type 5, 613855 (3);2(Cacnb4)
2.602;11;16;10;2q24.1;NR4A2, NURR1, NOT, TINUR;;Nuclear receptor subfamily 4, group A, member 2;601828;A, REa;;;2(Nurr1)
2.603;3;15;11;2q23.1;ORC4, ORC4L;;Origin recognition complex, subunit 4, S. cerevisiae, homolog of;603056;A, REa;;Meier-Gorlin syndrome 2, 613800 (3);
2.604;8;27;09;2q24.3;GRB14;;Growth factor receptor-bound protein 14;601524;REc;;;
2.605;5;2;08;2q22-q24;MAFD5;;Major affective disorder 5;611535;Fd;;{Major affective disorder 5} (2);
2.606;7;18;14;2q22.1;NXPH2, NPH2;;Neuroxophilin 2;604635;REc;;;
2.607;9;21;17;2q22.2;KYNU, KYNUU, VCRL2;;Kynureninase;605197;REc;mutation identified in 1 KYNUU family;?Hydroxykynureninuria, 236800 (3); Vertebral, cardiac, renal, and limb defects syndrome 2, 617661 (3);
2.608;1;24;09;2q22.3-q23.1;ACVR2A, ACVR2;;Activin A receptor, type IIA;102581;A;;;
2.609;5;26;13;2q22.2-q22.3;ARHGAP15, BM046;;Rho GTPase-activating protein 15;610578;R, REc;;;
2.610;3;27;12;2q31.1;DCAF17, C20orf37;;DDB1- and CUL4-associated factor 17;612515;REc;;Woodhouse-Sakati syndrome, 241080 (3);
2.611;1;1;95;2q24.2;DPP4, CD26, ADCP2;;Dipeptidylpeptidase IV (CD26; adenosine deaminase complexing protein-2);102720;S, REa, A;;;
2.612;8;18;98;2q24.2;FAP, FAPA;;Fibroblast activation protein, alpha subunit;600403;REa, A;;;
2.613;8;1;08;2q23.3;RPRM;;Reprimo;612171;A;;;
2.614;5;2;06;2q24.1;ACVR1, ACVRLK2, ALK2, FOP;;Activin A receptor, type I;102576;REa, A;;Fibrodysplasia ossificans progressiva, 135100 (3);
2.615;2;28;01;2q24.2;BAZ2B;;Bromodomain adjacent to zinc finger domain, 2B;605683;REa, R;;;
2.616;5;25;00;2q24.2;PLA2R1, PLA2R;;Phospholipase A2 receptor 1;604939;A;;;
2.617;10;31;08;2q23.3;ARL5;;ADP-ribosylation factor-like 5;608960;R;;;
2.618;2;11;11;2q24.3;SCN2A, SCN2A1, BFIC3, EIEE11, BFIS3, BFNIS;;Sodium channel, voltage-gated, type II, alpha subunit;182390;REa, Pcm, A;4 related genes on chr.2;Seizures, benign familial infantile, 3, 607745 (3); Epileptic encephalopathy, early infantile, 11, 613721 (3);2(Scn2a)
2.619;1;17;01;2q24.2;SLC4A10;;Solute carrier family 4 (sodium bicarbonate cotransporter-like), member 10;605556;A, REa, R;;;
2.620;8;9;99;2q23-q24.3;DFNA16;;Deafness, autosomal dominant 16;603964;Fd;;Deafness, autosomal dominant 16 (2);
2.621;4;6;01;2q23-q31;DFNB27;;Deafness, autosomal recessive 27;605818;Fd;;Deafness, autosomal recessive 27 (2);
2.622;11;29;99;2q24.1;PKP4;;Plakophilin-4;604276;A, REa;;;
2.623;8;20;07;2q23.1;EPC2;;Enhancer of polycomb, Drosophila, homolog of, 2;611000;R, REc;;;
2.624;8;1;14;2q23.1-q23.2;KIF5C, NKHC2, CDCBM2;;Kinesin family member 5C;604593;R, REc;;Cortical dysplasia, complex, with other brain malformations 2, 615282 (3);
2.625;10;15;07;2q23.1;MBD5, KIAA1461, MRD1;;Methyl-CpG-binding domain protein 5;611472;R, REc;;Mental retardation, autosomal dominant 1, 156200 (3);
2.626;4;20;10;2q23.2;LYPD6;;LY6/PLAUR domain-containing protein 6;613359;REc;;;
2.627;4;8;08;2q23.2;C2orf25, MMADHC;;Chromosome 2 open reading frame 25;611935;REc;;Homocystinuria, cblD type, variant 1, 277410 (3); Methylmalonic aciduria, cblD type, variant 2, 277410 (3); Methylmalonic aciduria and homocystinuria, cblD type, 277410 (3);
2.628;7;29;15;2q23.3;ARL6IP6, AIP6;;ADP-ribosylation factor-like 6-interacting protein 6;616495;REc;;;
2.629;3;31;15;2q23.3;FMNL2, KIAA1902;;Formin-like 2;616285;REc;;;
2.630;6;29;99;2q23.3;NMI;;NMYC interactor;603525;A;previously assigned to 22q13.3;;
2.631;8;17;09;2q23.3;PRPF40A, HYPA, FNBP3, FBP11;;Precursor mRNA-processing factor 40, S. cerevisiae, homolog of, A;612941;REc;;;
2.632;8;3;12;2q23.3;RND3, RHOE, ARHE;;RHO family GTPase 3;602924;REc, R;;;
2.633;7;9;06;2q23.3;STAM2;;Signal-transducing adaptor molecule 2;606244;R, REc;;;
2.634;8;27;09;2q23.3;TNFAIP6;;Tumor necrosis factor, alpha-induced protein-6;600410;Psh, REc;;;
2.635;1;20;09;2q31.1;ABCB11, BSEP, SPGP, PFIC2, BRIC2;;ATP-binding cassette, subfamily B, member 11 (bile salt export pump);603201;Fd, LD, REc;;Cholestasis, progressive familial intrahepatic 2, 601847 (3); Cholestasis, benign recurrent intrahepatic, 2, 605479 (3);
2.636;9;22;08;2q24.2;CD302, DCL1, KIAA0022;;CD302 antigen;612246;R, REc;;;
2.637;8;19;13;2q24.3;COBLL1, COBLR1, KIAA0977;;COBL-like protein 1;610318;REc;;;2(Cobll1)
2.638;4;7;15;2q24.2;IFIH1, MDA5, AGS7, SGMRT1;;Interferon induced with helicase C domain 1;606951;REc;;Aicardi-Goutieres syndrome 7, 615846 (3); Singleton-Merten syndrome 1, 182250 (3);
2.639;2;27;17;2q24.3;SCN1A, GEFSP2, SMEI, FEB3A, EIEE6, FHM3;;Sodium channel, voltage-gated, type I, alpha polypeptide;182389;REA, A, FD;;Epilepsy, generalized, with febrile seizures plus, type 2, 604403 (3); Migraine, familial hemiplegic, 3, 609634 (3); Febrile seizures, familial, 3A, 604403 (3); Epileptic encephalopathy, early infantile, 6 (Dravet syndrome), 607208 (3);2(Scn1a)
2.640;4;24;18;2q24.3;SCN3A, FFEVF4, EIEE62;;Sodium channel, voltage-gated, type III, alpha polypeptide;182391;H, Psh, A;;Epilepsy, familial focal, with variable foci 4, 617935 (3); Epileptic encephalopathy, early infantile, 62, 617938 (3);2(Scn3a)
2.641;12;30;14;2q24.3;SCN9A, NENA, PN1, FEB3B, GEFSP7, SFNP, HSAN2D;;Sodium channel, voltage-gated, type IX, alpha subunit;603415;REc, Fd;;Erythermalgia, primary, 133020 (3); Paroxysmal extreme pain disorder, 167400, (3); Insensitivity to pain, congenital, 243000 (3); Febrile seizures, familial, 3B, 613863 (3); Epilepsy, generalized, with febrile seizures plus, type 7, 613863 (3); Small fiber neuropathy, 133020 (3); {Dravet syndrome, modifier of}, 607208 (3); HSAN2D, autosomal recessive, 243000 (3);
2.642;8;2;16;2q31.1;SLC25A12, ARALAR, EIEE39;;Solute carrier family 25 (mitochondrial carrier, Aralar), member 12;603667;A, REa, R, REc;;Epileptic encephalopathy, early infantile, 39, 612949 (3);
2.643;11;17;10;2q24.3;GALNT3, HHS, HFTC1;;UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 3;601756;A;;Tumoral calcinosis, hyperphosphatemic, familial, 1, 211900 (3);
2.644;8;21;07;2q31.1;LRP2, DBS;;Low density lipoprotein-related protein 2;600073;A;;Donnai-Barrow syndrome, 222448 (3);
2.645;4;30;15;2q31.1;CHRNA1, ACHRD, CMS1B, CMS1A;;Cholinergic receptor, nicotinic, alpha polypeptide-1, muscle;100690;REa, A;;Myasthenic syndrome, congenital, 1A, slow-channel, 601462 (3); Myasthenic syndrome, congenital, 1B, fast-channel, 608930 (3); Multiple pterygium syndrome, lethal type, 253290 (3);2(Acra)
2.646;7;8;10;2q24-q32;FGQTL1;;Fasting plasma glucose level QTL 1;612108;Fd;associated with rs560887;[Fasting plasma glucose level QTL 1] (2);
2.647;7;8;10;2q31.1;G6PC2, IGRP;;Glucose-6-phosphatase, catalytic, 2;608058;REc, R, H;;;2(Igrp)
2.648;6;15;99;2q24-q32;MMDK, MDK;;Mesomelic dysplasia, Kantaputra type;156232;Fd;;Mesomelic dysplasia, Kantaputra type (2);
2.649;1;11;95;2q37.1;NPPC;;Natriuretic peptide precursor C;600296;H;;;1(Nppc)
2.650;4;22;10;2q24.1;ACVR1C, ALK7;;Activin A receptor, type IC;608981;A;;;
2.651;8;19;13;2q24.1;ERMN, JN, KIAA1189;;Ermin;610072;R, REc;;;
2.652;1;27;04;2q23.3-q24.1;GALNT13, KIAA1918;;UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 13;608369;R, REc;;;
2.653;3;27;09;2q24.1;GPD2;;Glycerol-3-phosphate dehydrogenase 2 (mitochondrial);138430;A, Psh, REc;pseudogene on 19;{Diabetes, type 2, susceptibility to}, 125853 (3);
2.654;12;2;96;2q24.1;KCNJ3, GIRK1;;Potassium inwardly-rectifying channel, subfamily J, member 3;601534;REa, A, Fd;;;
2.655;5;8;09;2q24.1;SYNSTH;;Synesthesia;612759;Fd;max lod at D2S142;Synesthesia (2);
2.656;2;9;17;2q24.1;UPP2;;Uridine phosphorylase 2;617340;REc;;;
2.657;4;22;10;2q24.1-q31.1;INTLQ2;;Intelligence quantitative trait locus 3;610295;Fd;;{Intelligence QTL3} (2);
2.658;4;6;13;2q24.1;GALNT5, GALNACT5;;UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 5;615129;REc;;;
2.659;8;27;09;2q24.2;GCA;;Grancalcin;607030;R, REc;;;
2.660;2;12;15;2q24.2;ITGB6, AI1H;;Integrin, beta-6;147558;REa, REc;;Amelogenesis imperfecta, type IH, 616221 (3);
2.661;3;6;08;2q24.2;KCNH7, ERG3, HERG3, Kv11.3;;Potassium channel, voltage-gated, subfamily H, member 7;608169;R, REc;;;
2.662;6;7;10;2q24.2;MARCH7;;Membrane-associated RING-CH finger protein 7;613334;REc;;;
2.663;8;27;09;2q24.2;PSMD14, POH1, PAD1;;Proteasome 26S subunit, non-ATPase, 14;607173;R, REc;;;
2.664;3;29;16;2q24.2;RBMS1, MSSP, SCR2;;RNA-binding motif protein, single strand-interacting, 1;602310;REc;;;
2.665;4;2;16;2q24.2;TANC1, KIAA1728;;Tetratricopeptide repeat-, ankyrin repeat-, and coiled-coil-containing protein 1;611397;REc;;;
2.666;3;18;13;2q24.2;TANK, ITRAF;;TRAF family member-associated NF-Kappa-B activator;603893;REc;;;
2.667;12;19;18;2q24.2;TBR1, IDDAS;;T-box, brain, 1;604616;H, REc;;Intellectual developmental disorder with autism and speech delay, 606053 (3);2(Tbr1)
2.668;11;11;14;2q24.3;B3GALT1;;UDP-GAL:beta-GlcNAc beta-1,3-galactosyltransferase, polypeptide 1;603093;REc;;;
2.669;8;2;13;2q24.3;CERS6, LASS6;;Ceramide synthase 6;615336;REc;;;
2.670;12;23;05;2q24.3;CMYA3, XIRP2;;Cardiomyopathy-associated protein 3;609778;R, REc;;;
2.671;2;18;09;2q24.3;IDDM19;;Diabetes mellitus, insulin-dependent, 19;610155;Fd;associated with rs1990760;{Diabetes mellitus, insulin-dependent, 19} (2);
2.672;8;26;15;2q24.3;SLC38A11;;Solute carrier family 38 (amino acid transporter), member 11;616526;REc;;;
2.673;8;27;09;2q24.3;STK39, SPAK;;Serine/threonine protein kinase 39;607648;R, REc;;;
2.674;2;11;14;2q24.3;TTC21B, THM1, NPHP12, SRTD4, ATD4;;Tetratricopeptide repeat domain 21B;612014;REc;;Nephronophthisis 12, 613820 (3); Short-rib thoracic dysplasia 4 with or without polydactyly, 613819 (3);
2.675;1;11;16;2q31.2;AGPS, ADHAPS, RCDP3;;Alkylglycerone-phosphate synthase;603051;A;;Rhizomelic chondrodysplasia punctata, type 3, 600121 (3);2(Agps)
2.676;10;16;14;2q31.1;BBS5;;BBS gene 5;603650;REc, Fd;;Bardet-Biedl syndrome 5, 615983 (3);
2.677;10;12;14;2q31.2;CCDC141, CAMDI;;Coiled-coil domain-containing protein 141;616031;REc;;;
2.678;4;21;16;2q31.1;CDCA7, JPO1, ICF3;;Cell division cycle-associated 7;609937;A;;Immunodeficiency-centromeric instability-facial anomalies syndrome 3, 616910 (3);
2.679;8;17;15;2q31.1;GAD1, SCP, CPSQ1;;Glutamate decarboxylase-1, brain, 67kD;605363;REa, H, A, Psh, Fd, LD;mutation identified in 1 CPSQ1 family;?Cerebral palsy, spastic quadriplegic, 1, 603513 (3);2(Gad1)
2.680;12;9;98;2q31;IDDM7;;Insulin-dependent diabetes mellitus-7;600321;H, Fd;;{Diabetes mellitus, insulin-dependent, 7} (2);
2.681;1;24;01;2q32.1;ITGAV, VNRA;;Integrin, alpha-V (vitronectin receptor, alpha polypeptide);193210;REa, A, REc;;;
2.682;08;17;18;2q31.1;LNPK, KIAA1715, NEDEHCC;;Lunapark;610236;REc, H;;Neurodevelopmental disorder with epilepsy and hypoplasia of the corpus callosum, 618090 (3);2(Lnp)
2.683;3;23;09;2q31.1;MIR10B, MIRN10B;;Micro RNA 10B;611576;REc;;;
2.684;1;7;02;2q33.1;MPP4, DLG6;;Membrane protein, palmitoylated 4;606575;REc;;;
2.685;10;30;17;2q31.2;NFE2L2, NRF2, IMDDHH;;Nuclear factor, erythroid-derived 2-like 2;600492;A;;Immunodeficiency, developmental delay, and hypohomocysteinemia, 617744 (3);
2.686;10;28;08;2q31;PNKD2;;Paroxysmal nonkinesigenic dyskinesia 2;611147;Fd;between D2S2188 and D2S364;Paroxysmal nonkinesigenic dyskinesia 2 (2);
2.687;12;9;09;2q31;SHFM5;;Split-hand/foot malformation 5;606708;Fd;between EVX2 and D2S294;Split-hand/foot malformation 5 (2);
2.688;7;1;97;2q31.1;SP3;;Sp3 transcription factor;601804;Psh, A;;;
2.689;09;27;18;2q31.2;TTN, CMD1G, TMD, LGMDR10, MPRM, HMERF, SALMY;;Titin;188840;REa, R;;Cardiomyopathy, familial hypertrophic, 9, 613765 (3); Cardiomyopathy, dilated, 1G, 604145 (3); Tibial muscular dystrophy, tardive, 600334 (3); Muscular dystrophy, limb-girdle, autosomal recessive 10, 608807 (3); Myopathy, proximal, with early respiratory muscle involvement, 603689 (3); Salih myopathy, 611705 (3);2(Ttn)
2.690;4;17;01;2q32.1;CALCRL, CGRPR, CRLR;;Calcitonin receptor-like;114190;R;;;
2.691;1;4;93;2q31.1;EVX2;;Even-skipped homeo box-2;142991;REn;13kb 5' to HOX4I;;2(Evx2)
2.692;2;26;93;2q31.1;HOXD3, HOX4A;;Homeo box-D3;142980;RE;;;2(Hox4.1)
2.693;4;1;14;2q31.1;HOXD4, HOX4B;;Homeo box-D4;142981;A, RE;;;2(Hox4.2)
2.694;2;26;93;2q31.1;HOXD9, HOX4C;;Homeo box-D9;142982;RE;;;2(Hox4.3)
2.695;7;19;04;2q31.1;HOXD10, HOX4D;;Homeo box-D10;142984;REa, RE;;Vertical talus, congenital, 192950 (3); Charcot-Marie-Tooth disease, foot deformity of, 192950 (3);2(Hox4.4)
2.696;2;26;93;2q31.1;HOXD8, HOX4E;;Homeo box-D8;142985;RE;;;2(Hox4.5)
2.697;2;26;93;2q31.1;HOXD11, HOX4F;;Homeo box-D11;142986;RE;;;2(Hox4.6)
2.698;2;26;93;2q31.1;HOXD1, HOX4G;;Homeo box-D1;142987;RE;;;2(Hox4.7)
2.699;2;26;93;2q31.1;HOXD12, HOX4H;;Homeo box-D12;142988;REc;upstream from HOX4A-G;;2(Hox4.8)
2.700;5;9;16;2q31.1;HOXD13, HOX4I, SPD1, BDSD;;Homeo box-D13;142989;REc, Fd;mutation identified in 1 BDSD family;Synpolydactyly 1, 186000 (3); Brachydactyly, type E, 113300 (3); Brachydactyly, type D, 113200 (3); Syndactyly, type V, 186300 (3); ?Brachydactyly-syndactyly syndrome, 610713 (3);2(Hox4.9)
2.701;7;16;92;2q31.3;ITGA4, CD49D;;Integrin, alpha-4 (antigen CD49D, alpha-4 subunit of VLA-4 receptor);192975;Psh, A;;;
2.702;9;23;08;2q31.1;CHN1, CHN, ARHGAP2, RHOGAP2, DURS2;;Chimerin 1 (GTPase-activating protein, rho, 2);118423;REa, A, Fd;;Duane retraction syndrome 2, 604356 (3);
2.703;12;30;92;2q32.1;TFPI, LACI;;Tissue factor pathway inhibitor (lipoprotein-associated coagulation inhibitor);152310;REa, A;;;
2.704;4;15;09;2q32.1;FRZB, FRZB1, SRFP3, OS1;;Frizzled-related protein;605083;REc;;{Osteoarthritis susceptibility 1}, 165720 (3);
2.705;11;19;11;2q32.2;PMS1, PMSL1, HNPCC3;;Postmeiotic segregation increased, S. cerevisiae, like 1;600258;REa, A;;;
2.706;9;22;08;2q31.1;ATP5G3;;ATP synthase, mitochondrial, C subunit-3;602736;REa, REc;;;
2.707;9;10;12;2q31.1;CIR1;;CBF1-interacting corepressor;605228;REc;;;
2.708;8;18;08;2q31.1;DHRS9, RDHTBE;;Short-chain dehydrogenase/reductase family, member 9;612131;REc;;;
2.709;1;5;11;2q31.1;DUP2q31.1, C2DUPq31.1;;Chromosome 2q31.1 duplication syndrome;613681;Ch;duplication of 9 HOXD genes and MTX2;Chromosome 2q31.1 duplication syndrome (4);
2.710;2;21;06;2q31.1;DYNC1I2, DNCI2, IC2;;Dynein, cytoplasmic-1, intermediate chain-2;603331;REc, H;;;2(Dnci2)
2.711;12;11;18;2q31.1;HAGLR, MDGT;;HOXD antisense growth-associated long noncoding RNA;618209;REc;;;2(Haglr)
2.712;1;10;09;2q31.1;ITGA6;;Integrin, alpha-6;147556;REa, REc;;Epidermolysis bullosa, junctional, with pyloric stenosis, 226730 (3);
2.713;4;10;14;2q31.1;KLHL41, KBTBD10, SARCOSIN, NEM9;;Kelch-like family member 41;607701;R, REc;;Nemaline myopathy 9, 615731 (3);
2.714;8;3;12;2q31.1;METAP1D, MAP1D;;Methionyl aminopeptidase type 1D (mitochondrial);610267;REc;;;
2.715;4;17;12;2q31.1;MTX2;;Metaxin 2;608555;REc;;;
2.716;3;3;03;2q24.3;NOSTRIN;;Nitric oxide synthase trafficker;607496;REc;;;
2.717;8;30;11;2q31.1;OLA1, GTBP9;;OBG-like ATPase 1;611175;REc;;;
2.718;9;9;13;2q31.1;PDK1;;Pyruvate dehydrogenase kinase, isoenzyme 1;602524;REc;;;
2.719;8;27;09;2q31.1;PPIG;;Peptidyl-prolyl isomerase G (cyclophilin G);606093;R, REc;;;
2.720;12;17;12;2q31.1;SCRN3, SES3;;Secernin 3;614967;REc;;;
2.721;12;6;16;2q31.1;SP5;;Transcription factor Sp5;609391;REc;;;2(Sp5)
2.722;7;14;14;2q24.3;SPC25, SPBC25;;SPC25, NDC80 kinetochore complex component;609395;REc;;;
2.723;4;28;10;2q31.1;SSB, LARP3;;Sjogren syndrome antigen B;109090;A, Psh, REc;;;
2.724;3;31;11;2q31.1;UBR3;;Ubiquitin protein ligase E3 component N-recognin 3;613831;REc;;;3(Ubr3)
2.725;2;9;15;2q31.1;WIPF1, WASPIP, WIP, WAS2;;WAS/WASL-interacting protein family, member 1;602357;REc;mutation identified in 1 WAS2 patient;?Wiskott-Aldrich syndrome 2, 614493 (3);
2.726;11;7;17;2q31.1;ZAK, MLTK, MRK, SFMMP, CNM6;;Leucine zipper- and sterile alpha motif-containing kinase;609479;R, REc;;Split-foot malformation with mesoaxial polydactyly, 616890 (3); Centronuclear myopathy 6 with fiber-type disproportion, 617760 (3);
2.727;4;24;06;2q31.1;MYO3B;;Myosin IIIB;610040;REc;;;
2.728;6;30;06;2q31.2;PJVK, DFNB59;;Pejvakin;610219;Fd;;Deafness, autosomal recessive 59, 610220 (3);
2.729;11;11;14;2q31.2;FKBP7, FKBP23;;FK506-binding protein 7;607062;REc;;;
2.730;2;1;11;2q31.2;HNRPA3, D10S102, FBRNP;;Heterogeneous nuclear ribonucleoprotein A3;605372;REc, REn;;;
2.731;3;8;07;2q31.2;PDE11A, PDE11A1, PDE11A2, PDE11A3, PPNAD2;;Phosphodiesterase 11A;604961;REc, Fd;;Pigmented nodular adrenocortical disease, primary, 2, 610475 (3);
2.732;3;18;08;2q31.2;PLEKHA3, FAPP1;;Pleckstrin homology domain-containing protein, family A, member 3;607774;REc;;;
2.733;10;4;16;2q31.2;RBM45;;RNA binding motif protein 45;608888;REc;;;
2.734;10;27;08;2q31.2-q31.3;ZNF385B, ZFN533;;Zinc finger protein 385B;612344;REc;;;
2.735;10;27;08;2q31.2;DEL2q31;;Chromosome 2q31.2 deletion syndrome;612345;Ch;contiguous gene deletion syndrome;Chromosome 2q31.2 deletion syndrome (4);
2.736;11;4;98;2q31.1;HAT1;;Histone acetyltransferase-1;603053;TM;;;
2.737;2;27;13;2q31.3;CERKL, RP26;;Ceramide kinase-like;608381;REc;;Retinitis pigmentosa 26, 608380 (3);
2.738;5;6;13;2q31.3;CWC2, KIAA1604, NCM;;CWC22 spliceosome-associated protein, X. cerevisiae, homolog of;615186;REc;;;
2.739;6;17;17;2q31.1;FASTKD1, KIAA1800;;Fast kinase domains 1;617529;REc;;;
2.740;2;21;12;2q31.3;MIR1258;;Micro RNA 1258;614488;REc;on opposite strand from ZNF385B;;
2.741;12;13;18;2q33.1;NDUFB3, MC1DN25;;NADH-ubiquinone oxidoreductase 1 beta subcomplex, 3;603839;R;pseudogenes on chr. 1, 9, and 14;Mitochondrial complex I deficiency, nuclear type 25, 618246 (3);
2.742;6;24;08;2q31.2;PRKRA, PACT, RAX, DYT16;;Protein kinase, interferon-inducible double-stranded RNA-dependent activator;603424;REc;;Dystonia 16, 612067 (3);
2.743;12;27;13;2q31.3;SCHLAP1, PCAT114, LINC00913;;SWI/SNF complex antagonist associated with prostate cancer 1, noncoding;615568;REc;;;
2.744;8;8;13;2q31.3;SSFA2, CS1;;Sperm-specific antigen 2;118990;REc;;;
2.745;1;16;14;2q31.3-q32.1;DA10;;Arthrogryposis, distal, type 10;187370;Fd;max lod at D2S364;Arthrogryposis, distal, type 10 (2);
2.746;11;7;01;2q31.1;ATF2, CREB2;;Activating transcription factor 2;123811;REa, A;;;
2.747;1;8;95;2q31.1;DLX1;;Distal-less homeo box-1;600029;REa, A, H;;;
2.748;1;8;95;2q31.1;DLX2, TES1;;Distal-less homeo box-2;126255;REa, A;;;2(Dlx2)
2.749;1;15;96;2q32.2;INPP1;;Inositol polyphosphate-1-phosphatase;147263;Psh, A;;;1(Inpp1)
2.750;5;11;00;2q33.3;KLF7, UKLF;;Kruppel-like factor 7;604865;A;;;
2.751;8;27;09;2q32.3;MYO1B;;Myosin IB;606537;R, REc;;;
2.752;11;4;99;2q31.3;NEUROD1, NIDDM;;Neurogenic differentiation 1;601724;A;;{Diabetes mellitus, noninsulin-dependent}, 125853 (3); Maturity-onset diabetes of the young 6, 606394 (3);2(Neurod)
2.753;11;30;00;2q32.3;PCGEM1;;Prostate-specific gene PCGEM1;605443;A;;;
2.754;3;17;03;2q32.2;SLC40A1, SLC11A3, FPN1, IREG1, HFE4;;Solute carrier family 40 (iron-regulated transporter), member 1;604653;A;;Hemochromatosis, type 4, 606069 (3);1(Slc11a3)
2.755;9;22;17;2q32.3;CAVIN2, SDPR, SDR;;Caveolae-associated protein 2;606728;A;;;
2.756;5;29;01;2q32.3;TMEFF2, HPP1, TR;;Transmembrane protein with EGF-like and 2 follistatin-like domains 2;605734;A;;;
2.757;1;11;89;2q34;RPE;;Ribulose 5-phosphate 3-epimerase;180480;S, D;;;
2.758;8;8;91;2q32.2;GLS, GLS1;;Glutaminase;138280;REa, A;;;1(Gls)
2.759;10;22;18;2q32.1;FSIP2, SPGF34;;Fibrous sheath-interacting protein 2;615796;;;Spermatogenic failure 34, 618153 (3);
2.760;12;5;03;2q32.1;NUP35, NP44;;Nucleoporin, 35kD;608140;R, REc;;;
2.761;5;7;03;2q31.2;OSBPL6, ORP6;;Oxysterol-binding protein-like protein 6;606734;REc;;;
2.762;8;30;09;2q32.1;PDE1A;;Phosphodiesterase-1A;171890;REc;;;
2.763;2;21;10;2q31.3-q32.1;PPP1R1C, IPP5;;Protein phosphatase 1, regulatory subunit 1C;613240;REc;;;
2.764;9;10;09;2q32.1;SCZD14;;Schizophrenia 14;612361;Fd;associated with rs1344706;{Schizophrenia, susceptibility to, 14} (2);
2.765;10;19;99;2q31.3;UBE2E3, UBCH9;;Ubiquitin-conjugating enzyme E2E 3;604151;A, REa, R;;;
2.766;9;23;08;2q32.1;ZNF804A, C2orf10;;Zinc finger protein 804A;612282;REc;;;
2.767;5;11;00;2q32.1;NCKAP1, NAP1;;NCK-associated protein 1;604891;REa, A;;;
2.768;10;27;97;2q32.1-q32.3;ARVD4;;Arrhythmogenic right ventricular dysplasia 4;602087;Fd;;Arrhythmogenic right ventricular dysplasia 4 (2);
2.769;4;10;90;2q34;MYL1;;Myosin, light polypeptide-1, alkali; skeletal, fast;160780;REa, H;;;1(Mylt)
2.770;3;15;13;2q32.2;C2orf88, SMAKAP;;Small membrane protein kinase A-anchoring protein;615117;REc;;;
2.771;12;22;17;2q32.2;COL3A1, EDSVASC;;Collagen III, alpha-1 polypeptide;120180;REa, A;in same 35kb segment as COL5A2;Ehlers-Danlos syndrome, vascular type, 130050 (3);1(Col3a1)
2.772;12;22;17;2q32.2;COL5A2, EDSCL2;;Collagen V, alpha-2 polypeptide;120190;REa, A;very close to COL3A1;Ehlers-Danlos syndrome, classic type, 2, 130010 (3);
2.773;12;23;05;2q32.2;FLJ25415;;FLJ25415 gene;609803;REc;;;
2.774;8;13;11;2q32.2;GDF8, MSTN, MSLHP;;Growth differentiation factor-8 (myostatin);601788;H, R;;Muscle hypertrophy, 614160 (3);1(Cmpt, Gdf8)
2.775;1;8;07;2q32.2;HIBCH;;3-hydroxyisobutyryl-CoA hydrolase;610690;REc;;3-hydroxyisobutryl-CoA hydrolase deficiency, 250620 (3);
2.776;9;29;10;2q32.2;MFSD6, MMR2;;Major facilitator superfamily domain-containing protein 6;613476;REc;;;
2.777;8;26;15;2q32.2;NEMP2, TMEM194B;;Nuclear envelope integral membrane protein 2;616497;REc;;;
2.778;4;7;10;2q32.2;ORMDL1;;ORM1-like protein 1;610073;REc;pseudogene on 10p14;;
2.779;1;29;07;2q33.1;SUMO1, UBL1, SMT3, OFC10;;Small ubiquitin-like modifier 1;601912;A, Ch;mutation identified in 1 OFC10 patient;?Orofacial cleft 10, 613705 (3);1(Sumo1)
2.780;12;26;14;2q32.2;STAT1, CANDF7, IMD31A, IMD31B, IMD31C;;Signal transducer and activator of transcription-1;600555;A;;Immunodeficiency 31A, mycobacteriosis, autosomal dominant, 614892 (3); Immunodeficiency 31B, mycobacterial and viral infections, autosomal recessive, 613796 (3); Immunodeficiency 31C, autosomal dominant, 614162 (3);1(Stat1)
2.781;7;18;12;2q32.2-q32.3;STAT4, SLEB11;;Signal transducer and activator of transcription-4;600558;A;;{Systemic lupus erythematosus, susceptibility to, 11}, 612253 (3);1(Stat4)
2.782;2;3;06;2q32.1-q32.2;GULP1, CED6;;PTB domain-containing engulfment adaptor protein 1;608165;REc;;;
2.783;12;22;16;2q32.3;HECW2, NEDL2, KIAA1301, NDHSAL;;HECT, C2, and WW domains-containing E3 ubiquitin-protein ligase 2;617245;REc, Psh;;Neurodevelopmental disorder with hypotonia, seizures, and absent language, 617268 (3);
2.784;6;26;08;2q32.3;OBFC2A, SSB2;;Oligonucleotide/oligosaccharide-binding fold-containing protein 2A;612103;REc;;;
2.785;5;4;12;2q32.3;STK17B, DRAK2;;Serine/threonine protein kinase 17b;604727;REc;;;
2.786;4;23;98;2q32.2;NAB1;;NGFI-A-binding protein, ERG1-binding protein;600800;A;;;1(Nab1)
2.787;7;10;08;2q33.3;CREB1;;cAMP-response element-binding protein-1;123810;REa, A;fusion gene with EWSR1;Histiocytoma, angiomatoid fibrous, somatic, 612160 (3);1(Creb1)
2.788;7;1;02;2q33.3;ADAM23, MDC3;;A disintegrin and metalloproteinase domain 23;603710;R;;;
2.789;9;21;12;2q33.1;ALS2, ALSJ, PLSJ, IAHSP;;Alsin;606352;Fd, REc;;Amyotrophic lateral sclerosis 2, juvenile, 205100 (3); Primary lateral sclerosis, juvenile, 606353 (3); Spastic paralysis, infantile onset ascending, 607225 (3);
2.790;2;27;03;2q33.2;ALS2CR8, CARF;;Amyotrophic lateral sclerosis 2 chromosome region, candidate 8 (calcium response factor);607586;REc;;;
2.791;7;14;98;2q33.1;AOX1;;Aldehyde oxidase-1;602841;Psh, A;;;
2.792;4;8;13;2q35;BCS1L, FLNMS, GRACILE, BJS, PTD, MC3DN1;;bcs1, S. cerevisiae, homolog-like;603647;REc, Fd, LD;;Mitochondrial complex III deficiency, nuclear type 1, 124000 (3); Leigh syndrome, 256000 (3); Bjornstad syndrome, 262000 (3); GRACILE syndrome, 603358 (3);
2.793;2;13;14;2q33.1-q33.2;BMPR2, PPH1, POVD1;;Bone morphogenetic receptor, type II;600799;Fd;;Pulmonary hypertension, familial primary, 1, with or without HHT, 178600 (3); Pulmonary hypertension, primary, fenfluramine or dexfenfluramine-associated, 178600 (3); Pulmonary venoocclusive disease 1, 265450 (3);
2.794;7;26;10;2q33.1;BOLL, BOULE;;BOL-like (Boule, Drosophila, homolog of);606165;R, A, H;;;1(Boule)
2.795;11;18;14;2q33.1;CASP8, MCH5, ALPS2B;;Caspase 8, apoptosis-related cysteine protease;601763;A;mutation identified in 1 ALPS2B family;?Autoimmune lymphoproliferative syndrome, type IIB, 607271 (3); Hepatocellular carcinoma, somatic, 114550 (3); {Breast cancer, protection against}, 114480 (3); {Lung cancer, protection against}, 211980 (3);1(Casp8)
2.796;12;7;07;2q33.1;CFLAR, FLIP, CASPER, FLAME1, CASH;;CASP8- and FADD-like apoptosis regulator;603599;A, R;;;
2.797;8;16;99;2q33.1;CLK1, CLK, STY;;CDC-like kinase 1;601951;A;;;
2.798;7;24;15;2q33.2;CTLA4, IDDM12, CELIAC3, ALPS5;;Cytotoxic T-lymphocyte-associated serine esterase-4;123890;A, REn;;{Hashimoto thyroiditis}, 140300 (3); {Systemic lupus erythematosus, susceptibility to}, 152700 (3); {Diabetes mellitus, insulin-dependent, 12}, 601388 (3); {Celiac disease, susceptibility to, 3}, 609755 (3); Autoimmune lymphoproliferative syndrome, type V, 616100 (3);1(Ctla4)
2.799;11;6;01;2q32.2;DIRC1;;Disrupted in renal cancer 1;606423;REc;;;
2.800;1;12;99;2q33.1;FZD7;;Frizzled, Drosophila, homolog of, 7;603410;A;;;
2.801;1;30;01;2q33.2;ICOS, AILIM, CVID1;;Inducible costimulator;604558;R;;Immunodeficiency, common variable, 1, 607594 (3);
2.802;4;19;01;2q33.1;NIF3L1;;Ngg1 interacting factor 3, S. pombe, homolog of, like 1;605778;REc;;;1(Nif3l1)
2.803;4;9;96;2q33.1;ORC2, ORC2L;;Origin recognition complex, subunit 2, S. cerevisiae, homolog of;601182;A;;;
2.804;2;18;02;2q33.1;PLDL1, PLCE, PLCL;;Phospholipase C-like 1;600597;RE;;;
2.805;7;14;14;2q33.1;PPIL3;;Peptidyl-prolyl isomerase-like 3;615811;REc;;;
2.806;10;21;96;2q34;PTHR2;;Parathyroid hormone receptor 2;601469;A;;;
2.807;12;11;18;2q33.1;RFTN2;;Lipid raft linking protein 2;618215;REc;;;
2.808;2;28;07;2q33;RLS4;;Restless legs syndrome, susceptibility to, 4;610439;Fd;between D2S311 and D2S317;{Restless legs syndrome 4} (2);
2.809;5;27;14;2q33.1;SATB2, KIAA1034, GLSS;;Special AT-rich sequence-binding protein 2;608148;REc;;Glass syndrome, 612313 (3);
2.810;7;21;15;2q33.1;CASP10, MCH4, ALPS2;;Caspase 10, apoptosis-related cysteine protease;601762;Psh, REc, A;;Autoimmune lymphoproliferative syndrome, type II, 603909 (3); Lymphoma, non-Hodgkin, somatic, 605027 (3); Gastric cancer, somatic, 613659 (3);
2.811;8;24;92;2q33.2;CD28;;CD28 antigen (Tp44);186760;A, REn;;;1(Cd28)
2.812;4;30;15;2q37.1;CHRND, ACHRD, SCCMS, CMS3A, CMS3B, CMS3C;;Cholinergic receptor, nicotinic, delta polypeptide;100720;H, REa, A, LD, RE;mutation identified in 1 CMS3A patient and 1 CMS3C family;?Myasthenic syndrome, congenital, 3A, slow-channel, 616321 (3); Myasthenic syndrome, congenital, 3B, fast-channel, 616322 (3); ?Myasthenic syndrome, congenital, 3C, associated with acetylcholine receptor deficiency, 616323 (3); Multiple pterygium syndrome, lethal type, 253290 (3);1(Acrd)
2.813;4;22;15;2q37.1;CHRNG, ACHRG;;Cholinergic receptor, nicotinic, gamma polypeptide;100730;H, REa, LD, RE, Fd;tightly linked to CHRND by RE;Escobar syndrome, 265000 (3); Multiple pterygium syndrome, lethal type, 253290 (3);1(Acrg)
2.814;5;14;04;2q33.3;EEF1B2, EEF1B1;;Eukaryotic translation elongation factor-1, beta-2;600655;Psh;pseudogene on chr.15;;
2.815;7;1;97;2q33.3;FZD5;;Polarity gene 'frizzled,' Drosophila, homolog of;601723;H;;;1(Mfz5)
2.816;12;5;91;2q35;IGFBP2;;Insulin-like growth factor-binding protein-2, 36kD;146731;REa, A;;;1(Igfbp2)
2.817;1;5;06;2q33.2;NBEAL1, ALS2CR17;;Neurobeachin-like 1;609816;REc;;;
2.818;12;13;18;2q33.3;NDUFS1, MC1DN5;;NADH dehydrogenase (ubiquinone) Fe-S protein 1, 75kD;157655;A;;Mitochondrial complex I deficiency, nuclear type 5, 618226 (3);
2.819;5;19;09;2q33.1;STRADB, ILPIP, ALS2CR2;;STE20-related kinase adaptor beta;607333;REn;pseudogenes on chromosomes 1 and 9;;
2.820;2;28;06;2q33.1;TRAK2, GRIF1, ALS2CR3, KIAA0549, OIP98;;Gamma-aminobutyric acid receptor-interacting factor 1;607334;REn;;;
2.821;4;4;00;2q33.3;CRYGA, CRYG1;;Crystallin, gamma A;123660;REa, A;;;1(Cryg1)
2.822;9;12;13;2q33.3;CRYGB, CRYG2, CTRCT39;;Crystallin, gamma B;123670;REa, A;;Cataract 39, multiple types, autosomal dominant, 615188 (3);1(Len2)
2.823;5;3;13;2q33.3;CRYGC, CRYG3, CTRCT2, CCL;;Crystallin, gamma C;123680;REa, A;;Cataract 2, multiple types, 604307 (3);
2.824;5;3;13;2q33.3;CRYGD, CRYG4, CTRCT4, CACA, CCA3, PCC;;Crystallin, gamma D;123690;REa, A;;Cataract 4, multiple types, 115700 (3);1(Crygd, Lop2)
2.825;1;29;04;2q35;IHH, BDA1;;Indian hedgehog;600726;REa, A, Fd;;Acrocapitofemoral dysplasia, 607778 (3); Brachydactyly, type A1, 112500 (3);
2.826;2;28;06;2q36.1;PI7, PN1, SERPINE2;;Protease inhibitor 7 (protease nexin I);177010;REa, M;near MYL1; ?COPD susceptibility;;
2.827;10;10;11;2q33-q36;EJM9;;Epilepsy, juvenile myoclonic, susceptibility to, 9;614280;Fd;max lod at D2S2248;{Epilepsy, juvenile myoclonic, susceptibility to, 9} (2);
2.828;10;26;99;2q35;IGFBP5, IBP5;;Insulin-like growth factor-binding protein 5;146734;H;;;1(Igfbp5)
2.829;1;4;93;2q35;INHA;;Inhibin, alpha;147380;REa, RE;proximal to PAX3;;1(Inha)
2.830;8;29;02;2q36.3;CCL20, SCYA20, MIP3A, LARC;;Chemokine, C-C motif, ligand 20;601960;R, Psh;;;
2.831;8;18;98;2q35;CYP27A1, CYP27, CTX;;Cytochrome P450, subfamily XXVIIA, polypeptide 1 (sterol 27-hydroxylase);606530;REa;;Cerebrotendinous xanthomatosis, 213700 (3);1(Cyp27)
2.832;2;18;09;2q33.1;ANIB9;;Aneurysm, intracranial berry, 9;612586;Fd;associated with rs700651;{Aneurysm, intracranial berry, 9} (2);
2.833;12;30;14;2q33.1;CDK15, PFTAIRE2, ALS2CR7;;Cyclin-dependent kinase 15;616147;REc;;;
2.834;3;24;14;2q32.3;DNAH7, KIAA0944;;Dynein, axonemal, heavy chain 7;610061;R, REc;;;
2.835;1;30;15;2q33.1;FTCDNL1, FONG;;Formiminotransferase cyclodeaminase N-terminal like;614308;REc;;;
2.836;7;18;14;2q33.1;GTF3C3, TFIIIC102;;General transcription factor 3C, polypeptide 3;604888;REc;;;
2.837;4;27;12;2q33.1;HSPD1, SPG13, HSP60, HLD4;;Heat-shock 60kD protein 1;118190;Fd, REn, A;;Spastic paraplegia 13, autosomal dominant, 605280 (3); Leukodystrophy, hypomyelinating, 4, 612233 (3);
2.838;9;4;02;2q33.1;HSPE1, HSP10;;Heat-shock 10kD protein;600141;REn;;;
2.839;12;22;16;2q33.1;MAIP1, C2orf47;;Matrix AAA peptidase-interacting protein 1;617267;REc;;;
2.840;6;23;15;2q33.1;MARS2, SPAX3, COXPD25;;Methionyl-tRNA synthetase 2;609728;R, REc, Fd;mutation identified in 1 COXPD25 family;Spastic ataxia 3, autosomal recessive, 611390 (3); ?Combined oxidative phosphorylation deficiency 25, 616430 (3);
2.841;8;30;17;2q33.1;MOB4, MOBKL3, PREI3, MOB1, MOB3;;MOB family, member 4;609361;R, REc;;;
2.842;1;8;16;2q33.1;NOP58, NOP5;;Nop58, S. cerevisiae, homolog of;616742;REc;;;
2.843;2;25;16;2q33.1;PGAP1, MRT42;;Post-GPI attachment to proteins 1;611655;REc;;Mental retardation, autosomal recessive 42, 615802 (3);
2.844;10;26;11;2q33.1;SF3B1, SF3B155, SAP155, MDS;;Splicing factor 3B, subunit 1;605590;R, REc;;Myelodysplastic syndrome, somatic, 614286 (3);1(Sf3b1)
2.845;12;4;08;2q33.1;SGOL2, SGO2, TRIPIN;;Shugoshin-like 2;612425;REc;;;
2.846;4;15;11;2q33.1;SPATS2L, SGNP;;Spermatogenesis-associated serine-rich protein 2-like;613817;REc;;;
2.847;7;2;18;2q33.2;ABI2, AIP1;;ABL interactor 2;606442;REc;;;
2.848;1;18;12;2q33.1;TMEM237, ALS2CR4, JBTS14;;Transmembrane protein 237;614423;REc;;Joubert syndrome 14, 614424 (3);
2.849;10;28;15;2q33.2;WDR12;;WD repeat-containing protein 12;616620;A, REc;;;1(Wdr12)
2.850;11;4;13;2q33.3;FASTKD2, KIAA0971;;FAST kinase domains 2;612322;R, REc;mutation identified in 1 family;?Mitochondrial complex IV deficiency, 220110 (3);
2.851;2;6;07;2q33.3;GPR1;;G protein-coupled receptor-1;600239;R;conflicting assignment to 15q21.6;;
2.852;8;28;17;2q33.3;GPR1AS;;GPR1 antisense RNA;617636;REc;;;
2.853;6;4;13;2q33.3;METTL21A, FAM119A;;Methyltransferase-like 21A;615257;REc;;;
2.854;4;15;09;2q33.3;OS4, GOA1;;Osteoarthritis susceptibility 4;610839;Fd;max lod at D2S2358;{Osteoarthritis susceptibility 4} (2);
2.855;1;14;13;2q34;IDH1;;Isocitrate dehydrogenase, soluble;147700;S, D;;{Glioma, susceptibility to, somatic}, 137800 (3);1(Idh1)
2.856;8;1;16;2q33.3;ZDBF2, KIAA1571;;Zinc finger DBF domain-containing protein 2;617059;REc, Psh;;;
2.857;1;18;13;2q35;ABCA12, ARCI4A, ARCI4B, ICR2B, LI2;;ATP-binding cassette, subfamily A, member 12;607800;R, H, Fd;;Ichthyosis, congenital, autosomal recessive 4A, 601277 (3); Ichthyosis, congenital, autosomal recessive 4B (harlequin), 242500 (3);1(Abca12)
2.858;11;22;13;2q33.3;C2orf80, GONDA1;;Chromosome 2 open reading frame 80;615536;REc;;;
2.859;8;24;04;2q35;CTDSP1, NLIIF, SCP1;;C-terminal domain of RNA polymerase II polypeptide A, small phosphatase of, 1;605323;REc;;;
2.860;11;19;13;2q34;ERBB4, HER4, ALS19;;Avian erythroblastic leukemia viral (v-erb-b2) oncogene homolog 4;600543;A;;Amyotrophic lateral sclerosis 19, 615515 (3);
2.861;12;28;17;2q35;FN1, FN, LETS, FNZ, GFND2, SMDCF;;Fibronectin-1;135600;S, REa, A;;Glomerulopathy with fibronectin deposits 2, 601894 (3); Spondylometaphyseal dysplasia, corner fracture type, 184255 (3); Plasma fibronectin deficiency, 614101 (1);1(Fn1)
2.862;8;24;12;2q34;KANSL1L, C2orf67, MSL1V2;;KAT8 regulatory NSL complex subunit 1-like;613833;REc;;;
2.863;9;5;01;2q34;LANCL1, GPR69A;;LanC-like 1 (G protein-coupled receptor 69A);604155;R, A;;;
2.864;12;9;98;2q34;IDDM13;;Insulin-dependent diabetes mellitus-13;601318;Fd;;{Diabetes mellitus, insulin-dependent, 13} (2);
2.865;2;23;12;2q34;IKZF2, ANF1A2, HELIOS;;Ikaros family zinc finger 2;606234;REc;;;
2.866;5;25;00;2q33.3;NRP2, VEGF1265R2, NPN2;;Neuropilin 2;602070;REa, R;;;
2.867;8;1;08;2q34;SPAG16, PF20;;Sperm-associated antigen 16;612173;A, H;;;1(Spag16)
2.868;1;10;89;2q34;TCL4;;T-cell leukemia/lymphoma-4;186860;Ch, RE;;Leukemia/lymphoma, T-cell (2);
2.869;4;27;11;2q34;ACADL, LCAD;;Acyl-Coenzyme A dehydrogenase, long chain;609576;A;;;1(Acadl)
2.870;9;18;08;2q36.1;ACSL3, FACL3, ACS3;;Acyl-CoA synthetase long-chain family member 3;602371;Psh, A;;;
2.871;10;4;05;2q35;BARD1;;BRCA1-associated RING domain 1;601593;Psh, REc;;{Breast cancer, susceptibility to}, 114480 (3);
2.872;10;23;87;2q34;MAP2;;Microtubule-associated protein-2;157130;REa, A;;;
2.873;12;11;02;2q34-q35;SLEN2;;Systemic lupus erythematosus with nephritis, susceptibility to, 2;607966;Fd;;{Systemic lupus erythematosus with nephritis, susceptibility to, 2} (2);
2.874;6;19;00;2q35;ZNF142;;Zinc finger protein-142;604083;R, A;;;
2.875;8;7;14;2q35;CRYBA2, CTRCT42;;Crystallin, beta A2;600836;REa;mutation identified in 1 CTRCT42 family;?Cataract 42, 115900 (3);1(cryba2)
2.876;4;19;16;2q34-q36;DUP2q35, C2DUPq35, SDTY1, SD1;;Chromosome 2q35 duplication syndrome (syndactyly, type I);185900;Fd;;Syndactyly, type 1, with or without craniosynostosis (4);
2.877;1;24;02;2q35;SMARCAL1, HARP, SIOD;;SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily A-like;606622;REc;;Schimke immunoosseous dysplasia, 242900 (3);1(Smarcal1)
2.878;1;16;07;2q37.3;AQP12A, AQPX2, AQP12;;Aquaporin 12A;609789;REc;;;
2.879;5;25;13;2q35;AAMP;;Angio-associated migratory cell protein;603488;REc;;;
2.880;6;27;17;2q35;ANKZF1, ZNF744;;Ankyrin repeat- and zinc finger domain-containing 1;617541;REc;;;
2.881;2;1;11;2q35;ARPC2, ARC34;;Actin-related protein 2/3 complex, subunit 2;604224;REc;;;
2.882;8;29;08;2q35;ATG9A, APG9L1;;Autophagy 9, S. cerevisiae, homolog of, A;612204;REc;;;
2.883;6;7;04;2q35;ATIC, PURH, AICAR;;5-aminoimidazole-4-carboxyamide ribonucleotide formyltransferase/IMP cyclohydrolase;601731;REc;;AICA-ribosiduria due to ATIC deficiency, 608688 (3);
2.884;7;25;17;2q35;CFAP65, CCDC108;;Cilia- and flagella-associated protein 65;614270;REc;;;
2.885;1;24;01;2q35;CDK5R2, NCK5AI;;Cyclin-dependent kinase 5, regulatory subunit 2;603764;A;;;
2.886;9;12;13;2q34;CPS1, PHN;;Carbamoyl-phosphate synthetase 1, mitochondrial;608307;REa, Fd, A;urea cycle enzyme;Carbamoylphosphate synthetase I deficiency, 237300 (3); {Pulmonary hypertension, neonatal, susceptibility to}, 615371 (3); {Venoocclusive disease after bone marrow transplantation} (3);1(Cps)
2.887;7;8;11;2q35;CXCR1, IL8RA;;Chemokine, CXC motif, receptor 1;146929;REa, A, Psh;;{AIDS, slow progression to}, 609423 (3);
2.888;2;8;11;2q35;CXCR2, IL8RB, IL8R2;;Chemokine, CXC motif, receptor 2;146928;A, REa, Psh;;;1(Il8r2)
2.889;09;27;18;2q35;DES, CMD1I, MFM1, SCPNK;;Desmin;125660;REa, A;1 family with LGMD2R identified with mutation;Myopathy, myofibrillar, 1, 601419 (3); Cardiomyopathy, dilated, 1I, 604765 (3); Scapuloperoneal syndrome, neurogenic, Kaeser type, 181400 (3);1(Des)
2.890;7;11;16;2q35;DNAJB2, HSJ1, HSPF3, DSMA5;;DnaJ, E. coli, homolog of, subfamily B, member 2 (heat-shock protein, DNAJ-like 1);604139;R, REc;;Spinal muscular atrophy, distal, autosomal recessive, 5, 614881 (3);
2.891;3;23;14;2q35;DNPEP, ASPEP, DAP;;Aspartyl aminopeptidase;611367;REc;;;
2.892;11;19;13;2q35;GMPPA, AAMR;;GDP-mannose pyrophosphorylase A;615495;REc;;Alacrima, achalasia, and mental retardation syndrome, 615510 (3);
2.893;6;2;06;2q35;GPBAR1, BG37;;G protein-coupled bile acid receptor 1;610147;REc;;;
2.894;6;7;10;2q35;MARCH4, RNF174, KIAA1399;;Membrane-associated RING-CH finger protein 4;608208;R, REc;;;
2.895;3;23;09;2q35;MIR26B, MIRN26B;;Micro RNA 26B;612152;REc;;;
2.896;3;23;09;2q35;MIR375, MIRN375;;Micro RNA 375;611173;REc;;;
2.897;8;31;17;2q35;MR1, TAHCCP2, KIPP1184, BRP17, PNKD1, FPD1, PDC, DYT8;;Myofibrillogenesis regulator 1;609023;Fd, REc;;Paroxysmal nonkinesigenic dyskinesia 1, 118800 (3);
2.898;1;2;08;2q35;MREG, DSU;;Melanoregulin;609207;REc, H;;;1(Dsu)
2.899;2;10;04;2q35;MTBS1;;Mycobacterium tuberculosis, susceptibility to infection by;607949;Fd;;{Tuberculosis, susceptibility to} (2);
2.900;9;22;09;2q35;NBLST5;;Neuroblastoma, susceptibility to, 5;613016;Fd;associated with rs6435862, rs3768716;{Neuroblastoma, susceptibility to, 5} (2);
2.901;1;14;09;2q35;NHEJ1, XLF;;Nonhomologous end-joining factor 1;611290;REc;;Severe combined immunodeficiency with microcephaly, growth retardation, and sensitivity to ionizing radiation, 611291 (3);
2.902;8;24;09;2q35;OBSL1, KIAA0657, 3M2;;Obscurin-like 1;610991;R, REc;;3-M syndrome 2, 612921 (3);
2.903;8;27;09;2q35;PECR, TERP;;Peroxisomal trans-2-enoyl-CoA reductase;605843;REc;;;
2.904;1;28;10;2q34;PIKFYVE, PIP5K3;;Phosphatidylinositol kinase, FYVE-finger containing;609414;Fd, REc;;Corneal fleck dystrophy, 121850 (3);
2.905;11;19;09;2q35;PRKAG3;;Protein kinase, AMP-activated, noncatalytic, gamma 3;604976;REc;;;
2.906;5;4;09;2q35;RESP18;;Regulated endocrine-specific protein 18;612721;REc;;;
2.907;9;22;14;2q35;RNF25, AO7;;Ring finger protein 25;616014;REc;;;
2.908;3;29;10;2q35;RPL37A;;Ribosomal protein L37A;613314;REc;;;
2.909;8;27;08;2q35;RQCD1, RCD1, CNOT9;;Required for cell differentiation 1, S. pombe, homolog of;612054;REc;;;
2.910;12;21;09;2q35;NRAMP1, NRAMP, SLC11A1;;Solute carrier family 11 (proton-coupled divalent metal ion transporter), member 1;600266;REn, REc, Psh, H, Fd;within 220 kb of VIL1;{Mycobacterium tuberculosis, susceptibility to infection by}, 607948 (3); {Buruli ulcer, susceptibility to}, 610446 (3);1(Nramp)
2.911;9;19;14;2q35;SPEG, APEG1, CNM5;;SPEG complex locus;615950;REc;;Centronuclear myopathy 5, 615959 (3);
2.912;3;25;03;2q35;STK36, FU, KIAA1278;;Serine/threonine protein kinase 36;607652;R, REn;;;
2.913;8;19;13;2q35;TMBIM1, RECS1;;Transmembrane BAX inhibitor motif-containing protein 1;610364;REc, R;;;
2.914;7;5;15;2q35;TUBA4A, TUBA1, ALS22;;Tubulin, alpha-4A;191110;REc;;Amyotrophic lateral sclerosis 22 with or without frontotemporal dementia, 616208 (3);1(Tuba4a)
2.915;2;12;16;2q34;UNC80, C2orf21, KIAA1843;;Unc-80 homolog, NALCN activator;612636;R, REc;;Hypotonia, infantile, with psychomotor retardation and characteristic facies 2, 616801 (3);
2.916;5;5;00;2q35;WNT6;;Wingless-type MMTV integration site family, member 6;604663;A;;;1(Wnt6)
2.917;7;22;11;2q35;WNT10A, SSPS, STHAG4, OODD;;Wingless-type MMTV integration site family, member 10A;606268;REc, Fd;;Odontoonychodermal dysplasia, 257980 (3); Schopf-Schulz-Passarge syndrome, 224750 (3); Tooth agenesis, selective, 4, 150400 (3);
2.918;6;6;94;2q35;XRCC5;;X-ray repair, complementing defective, repair in Chinese hamster cells-5;194364;REa, R, A;included in YAC contig spanning 2q33-q34;;1(Xrcc5)
2.919;9;29;10;2q35;ZFAND2B, AIRAPL;;Zinc finger AN1 domain-containing protein 2B;613474;REc;;;
2.920;1;22;08;2q35;ACCN4, ASIC4, BNAC4;;Cation channel, amiloride-sensitive, neuronal, 4;606715;R, REc;;;
2.921;5;22;03;2q36.1;KCNE4, MIRP3;;Potassium channel, voltage-gated, ISK-related subfamily, member 4;607775;REc;;;
2.922;1;11;05;2q35-q36;PSHK2;;Pseudohyperkalemia, familial, 2, due to red cell leak;609153;Fd;max lod at D2S1338;Pseudohyperkalemia, familial, 2, due to red cell leak (2);
2.923;2;3;99;2q36.1;SCG2, CHGC;;Secretogranin II (chromogranin C);118930;A;;;1(Scg2)
2.924;6;4;90;2q35;TNP1;;Transition protein-1;190231;REa, A;;;1(Tp1)
2.925;2;18;08;2q35;TNS1, TNS;;Tensin 1;600076;REa, H;;;1(Tns)
2.926;11;13;18;2q35;VIL1;;Villin-1;193040;A;;;1(Vil)
2.927;6;4;97;2q35;PTPRN, IA2;;Protein tyrosine phosphatase, receptor type N (islet cell antigen 2);601773;A, R;;;1(Ptprn)
2.928;3;5;95;2q37.3;GPC1;;Glypican 1;600395;A;;;
2.929;2;25;16;2q35;ABCB6, MTABC3, MCOPCB7, LAN, DUH3, PSHK2;;ATP-binding cassette, subfamily B, member 6;605452;A, Fd;;Microphthalmia, isolated, with coloboma 7, 614497 (3); [Blood group, Langereis system], 111600 (3); Dyschromatosis universalis hereditaria 3, 615402 (3); Pseudohyperkalemia, familial, 2, due to red cell leak, 609153 (3);
2.930;4;20;04;2q36;ACRPV;;Acropectorovertebral dysplasia (F syndrome);102510;Fd;;Acropectorovertebral dysplasia (2);
2.931;7;18;14;2q36.3;AGFG1, HRB, RIP, RAB;;ADP-ribosylation factor GTPase-activating protein with FG repeats 1;600862;A;;;
2.932;6;5;18;2q36.1;FARSLB, FRSB, NEDBLLA;;Phenylalanine-tRNA synthetase-like, beta subunit;609690;REc;mutation identified in 1 NEDBLLA patient;?Neurodevelopmental disorder with brain, liver, and lung abnormalities, 618007 (3);
2.933;8;27;09;2q35;FEV;;Fifth Ewing sarcoma variant;607150;REa, REc;fused with EWS in tumors;;
2.934;5;23;11;2q36;IGAN2;;IgA nephropathy, susceptibility to, 2;613944;Fd;between D2S1323 and D2S362;{IgA nephropathy, susceptibility to, 2} (2);
2.935;1;11;07;2q36.3;IRS1;;Insulin receptor substrate-1;147545;REa, A;;{Diabetes mellitus, noninsulin-dependent}, 125853 (3); {Coronary artery disease, susceptibility to} (3);1(Irs1)
2.936;9;9;13;2q36.1;MRPL44, COXPD16;;Mitochondrial ribosomal protein L44;611849;R, REc;Mutation identified in 1 family;?Combined oxidative phosphorylation deficiency 16, 615395 (3);
2.937;10;9;94;2q35;SLC2C, AE3;;Anion exchanger 3, neuronal;106195;A, Psh, Fd;;;1(Ae3)
2.938;12;18;07;2q36.3;SPHKAP, SKIP, KIAA1678;;SPHK1 interactor, AKAP domain containing;611646;R, REc;;;
2.939;9;12;02;2q35;STK11IP, KIAA1898, LIP1;;Serine/threonine kinase 11 interacting protein;607172;R;;;
2.940;11;22;99;2q37.3;AGXT, SPAT;;Alanine-glyoxylate aminotransferase, liver-specific peroxisomal;604285;A, REa;;Hyperoxaluria, primary, type 1, 259900 (3);
2.941;5;4;12;2q36.3;COL4A3;;Collagen IV, alpha-3 polypeptide (Goodpasture antigen);120070;REa, A, RE;noncollagenous domain = Goodpasture antigen;Alport syndrome, autosomal recessive, 203780 (3); Hematuria, benign familial, 141200 (3); Alport syndrome, autosomal dominant, 104200 (3);
2.942;5;8;97;2q36.3;COL4A4;;Collagen IV, alpha-4 polypeptide;120131;REa, A;head-to-head with COL4A4 in same YAC;Alport syndrome, autosomal recessive, 203780 (3); Hematuria, familial benign (3);
2.943;2;8;13;2q37.1;ECEL1, XCE, DA5D;;Endothelin-converting enzyme-like 1;605896;A;;Arthrogryposis, distal, type 5D, 615065 (3);
2.944;2;18;98;2q37.2;GBX2;;Gastrulation brain homeobox 2;601135;Psh, A;;;1(Gbx2)
2.945;5;12;89;2q24.2;GCG;;Glucagon;138030;REa, A;;[?Hyperproglucagonemia] (1);2(Gcg)
2.946;8;15;97;2q37.1;INPP5D, SHIP;;Inositol polyphosphate-5-phosphatase, 145kD;601582;A;;;1(Inpp5d)
2.947;4;7;14;2q37.1;PDE6D, JBTS22;;Phosphodiesterase 6D, cGMP-specific, rod, delta;602676;A, R;mutation identified in 1 JBTS22 family;?Joubert syndrome 22, 615665 (3);1(Pde6d)
2.948;8;27;09;2q37.1;PTMA, TMSA;;Prothymosin, alpha (gene sequence 28);188390;REa, REc;;;
2.949;2;14;01;2q37.3;RAMP1;;Receptor activity-modifying protein 1;605153;R;;;1(Ramp1)
2.950;12;1;14;2q36.1;AP1S3, PSORS15;;Adaptor-related protein complex 1, sigma-3 subunit;615781;REc;;{Psoriasis 15, pustular, susceptibility to}, 616106 (3);
2.951;4;14;10;2q35;CHPF, CSS2;;Chondroitin polymerizing factor;610405;REc;;;
2.952;9;27;17;2q36.1;EPHA4, HEK8, TYRO1;;Ephrin receptor EphA4;602188;REc;;;
2.953;8;3;12;2q36.1;MOGAT1, MGAT1, DGAT2L1;;Monoacylglycerol O-acyltransferase 1;610268;REc, R;;;
2.954;2;23;12;2q36.1;PAX3, WS1, HUP2, CDHS, WS3;;Paired box homeotic gene-3;606597;Ch, Fd, H, A, Psh;;Waardenburg syndrome, type 1, 193500 (3); Waardenburg syndrome, type 3, 148820 (3); Craniofacial-deafness-hand syndrome, 122880 (3); Rhabdomyosarcoma 2, alveolar, 268220 (3);1(Sp)
2.955;7;16;09;2q36.1;SGPP2, SPP2;;Sphingosine-1-phosphate phosphatase 2;612827;REc;;;
2.956;8;10;18;2q36.1;WDFY1, FENS1;;WD repeat-and FYVE domain-containing protein 1;618080;REc;;;
2.957;2;21;10;2q36.1-q36.3;SPDA3;;Spondyloarthropathy, susceptibility to, 3;613238;Fd;max lod at D2S2228;{Spondyloarthropathy, susceptibility to, 3} (2);
2.958;12;10;10;2q36.2;RJBS;;Rajab syndrome;613658;Fd;between D2S351 and D2S2390;Rajab syndrome (2);
2.959;10;13;09;2q36.2;DOCK10, KIAA0694, ZIZ3;;Dedicator of cytokinesis 10;611518;R, REc;;;
2.960;2;27;12;2q36.2;CUL3, PHA2E;;Cullin 3;603136;R, REc;;Pseudohypoaldosteronism, type IIE, 614496 (3);
2.961;8;25;16;2q36.3;MFF, C2orf33, EMPF2;;Mitochondrial fission factor;614785;REc;;Encephalopathy due to defective mitochondrial and peroxisomal fission 2, 617086 (3);
2.962;12;10;13;2q36.3;NYPA2, KIAA1486;;Neuronal tyrosine-phosphorylated phosphoinositide 3-kinase adaptor 2;615478;REc, R;;;
2.963;8;17;09;2q36.3;PID1, NYGGF4;;Phosphotyrosine interaction domain-containing 1;612930;REc;;;
2.964;6;12;17;2q36.3;RHBDD1, RRP4, RHBDL4;;Rhomboid domain-containing 1;617515;REc;;;
2.965;2;13;12;2q36.3;SLC19A3, THMD2, BBGD;;Solute carrier family 19 (folate transporter), member 3;606152;A, H, Fd;;Thiamine metabolism dysfunction syndrome 2 (biotin- or thiamine-responsive encephalopathy type 2), 607483 (3);1(Slc19a3)
2.966;10;15;13;2q36.3;TM4SF20, SLI5;;Transmembrane 4 L6 family, member 20;615404;REc;;{Specific language impairment 5}, 615432 (3);
2.967;11;7;17;2q36.3;TRIP12, MRD49;;Thyroid hormone receptor interactor 12;604506;REa, REc;;Mental retardation, autosomal dominant 49, 617752 (3);
2.968;3;14;96;2q37.1;HTR2B;;5-hydroxytryptamine (serotonin) receptor-2B;601122;A;;;
2.969;4;12;92;2q37.1;ALPP;;Alkaline phosphatase, placental (Regan isozyme);171800;REb, REa, A, RE;;;4(Akp2)
2.970;4;12;92;2q37.1;ALPPL2;;Alkaline phosphatase, placental-like 2;171810;REa, A;;;
2.971;9;22;08;2q37.3;ASB1;;Ankyrin repeat-containing SOCS box protein 1;605758;R, REc;;;1(Asb1)
2.972;10;14;15;2q37;BDMR, C2DELq37, DEL2q37;;Chromosome 2q37 deletion syndrome;600430;Ch;;Chromosome 2q37 deletion syndrome (4);
2.973;7;20;15;2q37.3;COL6A3, DYT27, BTHLM1, UCMD1;;Collagen VI, alpha-3 polypeptide;120250;REa, A;close to CRBP1;Bethlem myopathy 1, 158810 (3); Ullrich congenital muscular dystrophy 1, 254090 (3); Dystonia 27, 616411 (3);1(Col6a3)
2.974;8;11;15;2q37.3;ACKR3, CXCR7, CMKOR1, GPR159, RDC1;;Atypical chemokine receptor 3;610376;A;;;
2.975;4;29;03;2q36.3;DNER;;Delta-and notch-like egf-related receptor;607299;REc;;;
2.976;3;9;00;2q37.1;GPR55;;G protein-coupled receptor 55;604107;A;;;
2.977;12;29;99;2q37.3;HDLBP, VGL;;High-density lipoprotein-binding protein;142695;REa, A;;;
2.978;3;28;12;2q37;IBGC2;;Basal ganglia calcification, idiopathic, 2;606656;Fd;;Basal ganglia calcification, idiopathic, 2 (2);
2.979;9;1;05;2q37.1;ITM2C, BRI3;;Integral membrane protein 2C;609554;REc;;;
2.980;8;25;11;2q37.1;KCNJ13, SVD, LCA16;;Potassium inwardly-rectifying channel, subfamily J, member 13;603208;R, Fd;;Snowflake vitreoretinal degeneration, 193230 (3); Leber congenital amaurosis 16, 614186 (3);
2.981;10;3;11;2q37.3;KIF1A, ATSV, UNC104, SPG30, HSN2C, MRD9;;Kinesin family member 1A;601255;Psh, A;incorrectly assigned to chr.9;Spastic paraplegia 30, autosomal recessive, 610357 (3); Neuropathy, hereditary sensory, type IIC, 614213 (3); Mental retardation, autosomal dominant 9, 614255 (3);
2.982;5;31;05;2q37.3;MLPH;;Melanophilin;606526;R, H;;Griscelli syndrome, type 3, 609227 (3);1(Mlph)
2.983;1;8;01;2q37.1;NEU2, SIAL2;;Neuraminidase 2;605528;A, R;;;
2.984;7;17;01;2q37.1;NGEF;;Neuronal guanine nucleotide exchange factor;605991;REc, A;;;1(Ngef)
2.985;10;1;07;2q37.3;SEPT2, NEDD5, DIFF6;;Septin 2;601506;A;;;
2.986;3;26;02;2q37.1;TRPM8, TRPP8;;Transient receptor potential cation channel, subfamily M, member 8;606678;REc;;;
2.987;6;7;10;2q37.1;UGT1A1, UGT1, GNT1, BILIQTL1;;UDP glycosyltransferase 1 family, polypeptide A1;191740;REa;;Crigler-Najjar syndrome, type I, 218800 (3); [Gilbert syndrome], 143500 (3); Crigler-Najjar syndrome, type II, 606785 (3); Hyperbilirubinemia, familial transient neonatal, 237900 (3); [Bilirubin, serum level of, QTL1], 601816 (3);1(Ugt1)
2.988;11;1;01;2q37.1;UGT1A3, UGT1C;;UDP-glycosyltransferase 1 family, polypeptide A3;606428;REa, REn;;;
2.989;11;1;01;2q37.1;UGT1A4, UGT1D;;UDP-glycosyltransferase 1 family, polypeptide A4;606429;REa, REn;;;
2.990;11;1;01;2q37.1;UGT1A5;;UDP-glycosyltransferase 1 family, polypeptide A5;606430;REa, REn;;;
2.991;11;1;01;2q37.1;UGT1A8;;UDP-glycosyltransferase 1 family, polypeptide A8;606433;REa, REn;;;
2.992;11;1;01;2q37.1;UGT1A6;;UDP-glycosyltransferase 1 family, polypeptide A6;606431;REa, REn;;;
2.993;11;1;01;2q37.1;UGT1A7;;UDP-glycosyltransferase 1 family, polypeptide A7;606432;REa, REn;;;
2.994;11;1;01;2q37.1;UGT1A9;;UDP-glycosyltransferase 1 family, polypeptide A9;606434;REa, REn;;;
2.995;11;1;01;2q37.1;UGT1A10;;UDP-glycosyltransferase 1 family, polypeptide A10;606435;REa, REn;;;
2.996;6;10;98;2q37.1;SPP2;;Secreted phosphoprotein-2, 24kD;602637;R, A;;;
2.997;6;22;01;2q37.1;ALPI;;Alkaline phosphatase, intestinal;171740;A, REa, RE, REc;close to ALPP; proximal to PAX3;;1(Akp3)
2.998;7;20;12;2q37.1;ARL4C, ARL7;;ADP-ribosylation factor-like 4C;604787;REc;;;
2.999;8;15;17;2q37.1;ARMC9, KIAA1868, JBTS30;;Armadillo repeat-containing protein 9;617612;REc;;Joubert syndrome 30, 617622 (3);
2.1000;8;2;16;2q37.1;ATG16L1, APG16L, IBD10;;Autophagy 16-like 1;610767;REc;;{Inflammatory bowel disease (Crohn disease) 10}, 611081 (3);
2.1001;7;22;13;2q37.1;B3GNT7;;Beta-1,3-N-acetylglucosaminyltransferase 7;615313;REc;;;
2.1002;8;1;08;2q37.1;CAB39;;Calcium-binding protein 39;612174;R, REc;;;
2.1003;9;22;14;2q37.1;COPS7B;;COP9 signalosome, subunit 7B;616010;REc;;;
2.1004;1;9;07;2q37.1;DGKD;;Diacylglycerol kinase, delta, 130kD;601826;REc;;;
2.1005;2;18;08;2q37.1;EFHD1;;EF-hand domain family, member D1;611617;REc;;;
2.1006;2;21;06;2q37.1;EIF4E2, EIF4EL3, 4EHP;;Eukaryotic translation initiation factor 4E family, member 2;605895;R, REc;;;
2.1007;9;9;08;2q36.3;FBXO36, FBX36;;F-box only protein 36;609105;REc;;;1(Fbxo36)
2.1008;4;10;15;2q37.1;GIGYF2, KIAA0642, PARK11;;GRB10-interacting GYF protein 2;612003;R, REc, Fd;;{Parkinson disease 11}, 607688 (3);1(Gigyf2)
2.1009;3;23;09;2q37.1;HJURP;;Holliday junction recognition protein;612667;REc;;;
2.1010;3;23;06;2q37.1;MYP12;;Myopia 12;609995;Fd;max lod at D2S2344;Myopia 12 (2);
2.1011;5;19;06;2q37.1;NMUR1, GPR66, FM3;;Neuromedin U receptor 1;604153;REc;;;
2.1012;4;15;11;2q37.1;PRSS56, MCOP6;;Protease, serine, 56;613858;REc, Fd;;Microphthalmia, isolated 6, 613517 (3);
2.1013;1;22;18;2q37.1;PSMD1;;Proteasome 26S subunit, non-ATPase, 1;617842;REc, A;;;
2.1014;01;04;19;2q37.1;RNU20;;RNA, U20 small nucleolar;604012;REc;;;
2.1015;2;25;14;2q37.1;SCARNA5;;Small Cajal body-specific RNA 5;615640;REc;within intron 9 of ATG16L1;;
2.1016;2;25;14;2q37.1;SCARNA6;;Small Cajal body-specific RNA 6;615641;REc;within intron 12 of ATG16L1;;
2.1017;7;7;05;2q37.1;SP100;;Nuclear antigen SP100;604585;R, REc;;;
2.1018;10;11;06;2q37.1;SP110, IFI41, IFI75, VODI;;SP110 nuclear body protein (interferon-induced protein 41, 30kD; interferon-induced protein 75, 52kD);604457;R, Fd;;Hepatic venoocclusive disease with immunodeficiency, 235550 (3); {Mycobacterium tuberculosis, susceptibility to}, 607948 (3);
2.1019;4;23;09;2q37.1;SAG, RP47;;S-antigen; retina and pineal gland (arrestin);181031;REa, A, Fd;;Oguchi disease-1, 258100 (3); Retinitis pigmentosa 47, 613758 (3);1(Sag)
2.1020;10;26;17;2q37.1;SP140L;;Nuclear body protein SP140-like;617747;REc;;;
2.1021;9;7;10;2q37.1;STQTL21;;Stature quantitative trait locus 21;613440;Fd;associated with rs6717918;{Stature QTL 21} (2);
2.1022;9;10;09;2q37.1;TIGD1;;TIGGER transposable element-derived gene 1;612972;REc;;;
2.1023;5;24;13;2q37.1;USP40;;Ubiquitin-specific protease 40;610570;REc, R;;;
2.1024;2;5;01;2q37.2;SH3BP4, BOG25;;SH3 domain-binding protein 4;605611;A;;;
2.1025;7;20;01;2q37.1-q37.3;HPE6;;Holoprosencephaly 6;605934;Ch;;Holoprosencephaly 6 (2);
2.1026;11;05;18;2q37.2;AGAP1, CENTG2, KIAA1099;;Arf GTPase-activating protein with GTPase domain, ankyrin repeat, and pleckstrin homology domain 1;608651;R, REc;;;
2.1027;3;16;12;2q37.1;DIS3L2, PRLMNS;;Dis3 mitotic control, S. cerevisiae, homolog-like 2;614184;REc;;Perlman syndrome, 267000 (3);
2.1028;10;13;15;2q37.3;HDAC4, HDACA;;Histone deacetylase 4;605314;A, Ch;;;
2.1029;4;2;16;2q37.3;ATG4B, APG4B, KIAA0943;;Autophagy 4, S. cerevisiae, homolog of, B;611338;REc;;;
2.1030;9;27;17;2q37.3;BOK, BCL2L9;;BCL2-related ovarian killer;605404;REc;;;
2.1031;4;17;09;2q37.3;CAPN10, NIDDM1;;Calpain-10;605286;A, REc;;{Diabetes mellitus, noninsulin-dependent 1}, 601283 (3);
2.1032;9;22;14;2q37.3;COPS8, CSN8;;COP9 signalosome, subunit 8;616011;REc, H;;;1(Csn8)
2.1033;10;23;08;2q37.3;D2HGDH, D2HGD;;D-2-hydroxyglutarate dehydrogenase;609186;REc;;D-2-hydroxyglutaric aciduria, 600721 (3);
2.1034;5;25;13;2q37.3;DTYMK, TYMK, CDC8;;Deoxythymidylate kinase;188345;REc;;;
2.1035;2;15;18;2q37.3;ERFE, FAM132B, CTRP15;;Erythroferrone;615099;REc;;;1(Fam132b)
2.1036;8;2;17;2q37.3;FARP2, FRG, FIR;;FERM, ARHGEF, and pleckstrin domain-containing protein 2;617586;REc;;;
2.1037;2;7;07;2q37.3;GAL3ST2, GP3ST;;Galactose-3-O-sulfotransferase 2;608237;REc;;;
2.1038;6;19;98;2q37.3;GPR35;;G protein-coupled receptor-35;602646;A;;;
2.1039;8;31;06;2q37.3;HES6;;Hairy/enhancer of split, Drosophila, homolog of, 6;610331;R, REc;;;
2.1040;3;15;04;2q37.3;ING5;;Inhibitor of growth-5;608525;R, REc;;;
2.1041;7;1;11;2q37.3;LRRFIP1, GCF2, TRIP, FLAP1;;Leucine-rich repeat in FLII-interacting protein 1;603256;REc;;;
2.1042;5;6;13;2q37.3;MIR149;;Micro RNA 149;615209;REc;;;
2.1043;1;13;15;2q37.3;MTERF4, MTERFD2;;Mitochondrial transcription termination factor 4;615393;REc;;;
2.1044;12;13;18;2q37.3;NDUFA10, MC1DN22;;NADH-ubiquinone oxidoreductase 1 alpha subcomplex, 10;603835;REa, REc;;Mitochondrial complex I deficiency, nuclear type 22, 618243 (3);
2.1045;5;25;13;2q37.3;NEU4;;Neuraminidase 4;608527;REc;;;1(Neu4)
2.1046;6;12;03;2q37.3;OTOSP;;Otospiralin;607877;A, R;;;
2.1047;3;3;03;2q37.3;PASK, KIAA0135;;Pas domain-containing serine-threonine kinase;607505;REc;;;
2.1048;1;6;11;2q37.3;PDCD1, SLEB2;;Programmed cell death 1;600244;A, Fd;;{Systemic lupus erythematosus, susceptibility to, 2}, 605218 (3); {Multiple sclerosis, disease progression, modifier of}, 126200 (3);
2.1049;5;13;13;2q37.3;PER2, FASPS1, KIAA0347;;Period, Drosophila, homolog of, 2;603426;Fd, A, REc;;Advanced sleep phase syndrome, familial, 1, 604348 (3);
2.1050;8;20;98;2q37.3;PPP1R7, SDS22;;Protein phosphatase 1, regulatory subunit 7;602877;REa, REc;;;
2.1051;9;27;17;2q37.3;PRLH, PRRP;;Prolactin-releasing hormone;602663;REc;;;
2.1052;10;28;09;2q37.3;RAB17;;Ras-associated protein;602206;REc;;;
2.1053;9;28;00;2q37.3;RNPEPL1;;Arginyl aminopeptidase-like 1 (aminopeptidase B-like);605287;REn;;;
2.1054;8;21;07;2q37.3;SCLY, SCL;;Selenocysteine lyase;611056;R, REc;;;
2.1055;11;18;15;2q37.3;SNED1, SNEP;;SUSHI, NIDOGEN, and EGF-like domains protein 1;616634;REc;;;1(Sned1)
2.1056;9;20;14;2q37.3;STK25, SOK1, YSK1;;Serine/threonine protein kinase 25;602255;REc;;;
2.1057;1;20;09;2q37.3;THAP4;;THAP domain-containing protein 4;612533;REc;;;
2.1058;1;2;08;2q37.3;TMEM16G, PCANAP5, IPCA5, DTMPP, NGEP;;Transmembrane protein 16G;605096;REc;;;
2.1059;11;4;15;2q37.3;TRAF3IP1, MIPT3, SLSN9;;TNF receptor-associated factor 3-interacting protein 1;607380;REc;;Senior-Loken syndrome 9, 616629 (3);
2.1060;10;11;17;2q37.3;UBE2F, NCE2;;Ubiquitin-conjugating enzyme E2F;617700;REc;;;
2.1061;8;11;15;2q37.3;TWIST2, DERMO1, SETLSS, FFDD3, BBRSAY, AMS;;Twist, Drosophila, homolog of, 2 (dermis-expressed protein 1, mouse, homolog of);607556;REc;;Focal facial dermal dysplasia 3, Setleis type, 227260 (3); Barber-Say syndrome, 209885 (3); Ablepharon-macrostomia syndrome, 200110 (3);
2.1062;4;6;00;Chr.2;TSE2;;Transsuppressor of expression 2;601136;M;;;
3.1;3;10;11;3pter-p25;DEL3pterp25, C3DELpterp25;;3p- syndrome (chromosome 3pter-p25 deletion syndrome);613792;Ch;contiguous gene deletion syndrome;3p- syndrome (4);
3.2;12;22;89;3p22.1;CCK;;Cholecystokinin;118440;REb, REa;;;9(Cck)
3.3;3;10;11;3p22.2;CX3CR1, GPR13, V28;;Chemokine (C-X3-C) receptor 1 (G protein-coupled receptor-13);601470;REa;;{Rapid progression to AIDS from HIV1 infection}, 609423 (3); {Coronary artery disease, resistance to}, 607339 (3); {Macular degeneration, age-related, 12}, 613784 (3);
3.4;2;15;96;3p21.31;SEP;;SEP transmembrane protein;601053;REa;;;
3.5;3;17;05;3p26.2;CRBN, MRT2;;Cereblon;609262;Fd, REc;between D3S3525 and D3S1560;Mental retardation, autosomal recessive 2, 607417 (3);
3.6;12;17;07;3p26.1;EGO;;Eosinophil granule ontogeny;611662;REc;;;
3.7;1;8;01;3p25.3;OGG1;;8-hydroxyguanine DNA glycosylase;601982;A;;Renal cell carcinoma, clear cell, somatic, 144700 (3);6(Ogg1)
3.8;3;5;95;3p25.3;OXTR;;Oxytocin receptor;167055;A, Psh;3p25 by others; within 7-10kb of CAV3;;
3.9;10;23;15;3p26.1;ARL8B, GIE1;;ADP-ribosylation factor-like 8B;616596;REc;;;
3.10;2;28;03;3p26.3;CHL1, CALL, L1CAM2;;CHL1, mouse, homolog of (L1 cell adhesion molecule 2);607416;A, D;;;6(Chl1)
3.11;4;3;03;3p26.1;EDEM, KIAA0212;;ER degradation-enhancing alpha-mannosidase-like protein;607673;R;;;
3.12;4;19;12;3p26.1;GRM7, MGLUR7;;Glutamate receptor, metabotropic, 7;604101;R, REc;;;
3.13;6;10;16;3p26.1;ITPR1, SCA15, SCA16, SCA29;;Inositol 1,4,5-triphosphate receptor, type 1;147265;REa, A, Fd, REc;;Spinocerebellar ataxia 15, 606658 (3); Spinocerebellar ataxia 29, congenital nonprogressive, 117360 (3); Gillespie syndrome, 206700 (3);6(Itpr1)
3.14;5;12;17;3p25.3;SSUH2, C3orf32, FLS485;;Ssu2, C. elegans, homolog of;617479;REc;;;
3.15;8;24;09;3p26.1-p25.1;ARHI2;;Age-related hearing impairment 2;612976;Fd;associated with rs11928865, rs779701, and rs779706;{Age-related hearing impairment 2} (2);
3.16;9;30;10;3p26.1;BHLHE40, HLHB2, STRA13, DEC1;;Basic helix-loop-helix family, member E40;604256;A;;;
3.17;5;30;00;3p12.3;CNTN3, PANG;;Contactin 3 (plasmocytoma-associated neuronal glycoprotein);601325;REa, H;;;6(Pang)
3.18;5;1;08;3p26;HPC5;;Prostate cancer, hereditary, 5;609299;Fd;between D3S1270 and D3S4559;{Prostate cancer, hereditary, 5}, 176807 (2);
3.19;3;8;04;3p26;IBD9;;Inflammatory bowel disease 9;608448;Fd;;{Inflammatory bowel disease 9} (2);
3.20;3;20;06;3p26.1;SETMAR, METNASE;;SET and Mariner transposase domains-containing protein;609834;REc;;;
3.21;5;23;06;3p26;STQTL5;;Stature quantitative trait locus 5;608982;Fd;max lod between D3S1297 and D3S1304;{Stature QTL 5} (2);
3.22;10;29;03;3p26.1;SUMF1, FGE;;Sulfatase-modifying factor-1;607939;REc, H;;Multiple sulfatase deficiency, 272200 (3);6(Sumf1)
3.23;5;25;05;3p25.3;ATP2B2, PMCA2;;ATPase, Ca++ transporting, plasma membrane, 2;108733;REa;;{Deafness, autosomal recessive 12, modifier of}, 601386 (3);
3.24;2;9;17;3p25.3;BRPF1, BR140, IDDDFP;;Bromodomain- and PHD finger-containing protein 1, 140kD;602410;A;;Intellectual developmental disorder with dysmorphic facies and ptosis, 617333 (3);
3.25;6;9;08;3p26.3-p26.2;CNTN4;;Contactin 4;607280;REc, Fd;;;
3.26;10;17;02;3p26.3;CNTN6, NB3;;Contactin 6;607220;A;;;
3.27;2;20;03;3p25.3;GHRL;;Ghrelin;605353;REc;;{Obesity, susceptibility to}, 601665 (3);
3.28;11;5;02;3p25.3;VHL;;VHL gene;608537;Fd, D, RE;;von Hippel-Lindau syndrome, 193300 (3); Renal cell carcinoma, somatic, 144700 (3); Pheochromocytoma, 171300 (3); Hemangioblastoma, cerebellar, somatic (3); Erythrocytosis, familial, 2, 263400 (3);
3.29;9;12;08;3p26-p24.2;MYMY1, MYMY;;Moyamoya disease;252350;Fd;max lod at D3S3050;Moyamoya disease (2);
3.30;6;7;94;3p26.2;IL5RA;;Interleukin-5 receptor, alpha;147851;REa, A;;;6(Il5r)
3.31;5;11;00;3p25.3;LMCD1;;LIM and cysteine-rich domains 1;604859;R;;;6(Lmcd1)
3.32;11;11;14;3p25.3;ARPC4, ARC20;;Actin-related protein 2/3 complex, subunit 4;604226;REc;;;
3.33;5;9;12;3p25.3;ATG7, APG7L, GSA7;;Autophagy 7, S. cerevisiae, homolog of;608760;REc, R;;;
3.34;2;25;14;3p25.3;BRK1, C3orf10, HSPC300;;BRICK1, SCAR/WAVE actin-nucleating complex subunit;611183;REc;;;
3.35;8;28;09;3p25.3;CAMK1, CAMKI;;Calcium/calmodulin-dependent protein kinase I;604998;REa, REc;;;
3.36;4;24;03;3p25.3;CRELD1, AVSD2;;Cysteine-rich protein with EGF-like domains 1;607170;R, REc, H;;{Atrioventricular septal defect, susceptibility to, 2}, 606217 (3); Atrioventricular septal defect, partial, with heterotaxy syndrome, 606217 (3);6(Creld1)
3.37;3;14;01;3p25.3;FANCD2, FANCD, FACD, FAD;;Fanconi anemia, complementation group D2;613984;M;;Fanconi anemia, complementation group D2, 227646 (3);
3.38;1;9;13;3p25.3;IL17RE;;Interleukin 17 receptor E;614995;REc;;;
3.39;4;6;10;3p25.3;IRAK2;;Interleukin 1 receptor-associated kinase 2;603304;REc;;;
3.40;9;24;14;3p25.3;JAGN1, SCN6;;Jagunal, Drosophila, homolog of, 1;616012;REc;;Neutropenia, severe congenital, 6, autosomal recessive, 616022 (3);6(Jagn1)
3.41;8;22;07;3p25.3;MTMR14, C3orf29, HJUMPY;;Myotubularin-related protein 14;611089;REc;;{Centronuclear myopathy, autosomal, modifier of}, 160150 (3);
3.42;11;10;17;3p25.3;RPUSD3;;RNA pseudouridylate synthase domain-containing protein 3;617759;REc;;;
3.43;4;29;14;3p25.3;SETD5, KIAA1757;;SET domain-containing protein 5;615743;REc;;Mental retardation, autosomal dominant 23, 615761 (3);
3.44;2;2;10;3p25.3;SLC6A11, GAT3, GAT4;;Solute carrier family 6 (neurotransmitter transporter, GABA), member 11;607952;REc;;;
3.45;4;26;10;3p25.3;TADA3, TADA3L, ADA3;;Transcriptional adaptor 3;602945;R, REc;;;
3.46;7;6;15;3p25.3;IL17RC, IL17RL, CANDF9;;Interleukin 17 receptor C;610925;REc;;Candidiasis, familial, 9, 616445 (3);
3.47;11;28;18;3p22.1;TRAK1, OIP106, KIAA1042, EIEE68;;Trafficking protein, kinesin-binding 1;608112;R, REc;;Epileptic encephalopathy, early infantile, 68, 618201 (3);9(hyrt)
3.48;5;7;03;3p23;OSBPL10, ORP10;;Oxysterol-binding protein-like protein 10;606738;REc;;;
3.49;2;25;15;3p25.2;CAND2, TIP120B, KIAA0667;;Cullin-associated neddylation -dissociated 2;610403;R, REc;;;
3.50;8;19;13;3p25.2;IQSEC1, KIAA0763;;IQ motif- and Sec7 domain-containing protein 1;610166;R, REc;;;
3.51;12;17;12;3p25.2;TAMM41, RAM41, C3orf31;;Translocator assembly and maintenance, mitochondrial, S. cerevisiae, homolog of;614948;REc;;;
3.52;4;15;03;3p25.2-p25.1;UVM2;;Melanoma, uveal, susceptibility to, 2;606661;Ch, D;;{Melanoma, uveal, susceptibility to, 2} (2);
3.53;11;29;04;3p25.1;BTD;;Biotinidase;609019;A;;Biotinidase deficiency, 253260 (3);
3.54;09;25;18;3p25.3;CAV3, LQT9, MPDT, RMD2;;Caveolin-3;601253;A, REc;within 7-10kb of OXTR;Rippling muscle disease, 606072 (3); Creatine phosphokinase, elevated serum, 123320 (3); Myopathy, distal, Tateyama type, 614321 (3); Cardiomyopathy, familial hypertrophic, 192600 (3); Long QT syndrome 9, 611818 (3);
3.55;5;23;13;3p25.3;CIDEC, FSP27, CIDE3, FPLD5;;Cell death-inducing DFFA-like effector C;612120;REc;1 patient identified with mutation;?Lipodystrophy, familial partial, type 5, 615238 (3);
3.56;4;30;15;3p25.1;COLQ, EAD, CMS5;;Collagenic tail of endplate acetylcholinesterase;603033;A, R;;Myasthenic syndrome, congenital, 5, 603034 (3);
3.57;5;24;13;3p25.3;LHFPL4;;LHFP-like protein 4;610240;REc;;;
3.58;2;2;04;3p25.2;MKRN2;;Makorin 2;608426;REc;;;6(Mkrn2)
3.59;4;24;08;3p25.1;MRPS25;;Mitochondrial ribosomal protein S25;611987;R, REc;;;
3.60;10;21;99;3p25.1;NR2C2, TR4, TAK1;;Nuclear receptor subfamily 2, group C, member 2;601426;REa, A;;;
3.61;3;27;09;3p25.2;PPARG, PPARG1, PPARG2, CIMT1, GLM1;;Peroxisome proliferator activated receptor, gamma;601487;REa, Fd, A;PPARG1, PPARG2 from same gene;Obesity, severe, 601665 (3); [Obesity, resistance to] (3); Insulin resistance, severe, digenic, 604367 (3); Lipodystrophy, familial partial, type 3, 604367 (3); Carotid intimal medial thickness 1, 609338 (3); {Diabetes, type 2}, 125853 (3);
3.62;8;3;14;3p25.2;RAF1, CRAF, NS5, CMD1NN;;Oncogene RAF1;164760;REa, Fd, A;;Noonan syndrome 5, 611553 (3); LEOPARD syndrome 2, 611554 (3); Cardiomyopathy, dilated, 1NN, 615916 (3);6(Raf1)
3.63;10;28;02;3p25.3;SRGAP3, KIAA0411, MEGAP;;Slit-robo GTPase-activating protein, rho, 3;606525;R, Ch;;;
3.64;8;19;99;3p25;ST11, PETS1;;Suppression of tumorigenicity 11, pancreas;602011;D;;?Pancreatic endocrine tumors (1);
3.65;11;2;04;3p25.2;SYN2;;Synapsin II;600755;REa, H, REn;;{Schizophrenia, susceptibility to}, 181500 (3);6(Syn2)
3.66;10;3;02;3p25.2;TIMP4;;Tissue inhibitor of metalloproteinase 4;601915;A;;;6(Timp4)
3.67;3;27;13;3p25.1;TMEM43, ARVD5, ARVC5, EDMD7;;Transmembrane protein 43;612048;REc, Fd;;Arrhythmogenic right ventricular dysplasia 5, 604400 (3); Emery-Dreifuss muscular dystrophy 7, AD, 614302 (3);
3.68;7;18;06;3p25.1;WNT7A;;Wingless-type MMTV integration site family, member 7A;601570;A, Fd;;Ulna and fibula, absence of, with severe limb deficiency, 276820 (3); Fuhrmann syndrome, 228930 (3);
3.69;2;19;10;3p25.1;XPC, XPCC;;XPC gene;613208;REa, A, RE;;Xeroderma pigmentosum, group C, 278720 (3);6(Xpc)
3.70;10;5;11;3p24.3;PLCL2, KIAA1092;;Phospholipase C-like 2;614276;R, REc;;;
3.71;9;19;00;3p25.3;RAD18;;Rad18, S. cerevisiae, homolog of;605256;A, R;;;
3.72;5;7;97;3p25.3;SEC13L1, D3S1231E, SEC13R;;SEC13, S. cerevisiae, like 1;600152;Psh, A;;;6(Sec13n)
3.73;10;9;94;3p25.1;FBLN2;;Fibulin-2;135821;A;;;6(Fbln2)
3.74;6;19;15;3p25.3;SLC6A1, GABATR, MAE;;Solute carrier family 6 (neurotransmitter transporter, GABA), member 1;137165;A;;Myoclonic-atonic epilepsy, 616421 (3);
3.75;5;27;05;3p25-p22;OVCAS1;;Ovarian cancer, susceptibility to, 1;607893;Fd;between D3S1597 and D3S3611;{Ovarian cancer, susceptibility to} (2);
3.76;3;5;95;3p25.1;SLC6A6, TAUT;;Solute carrier family 6 (neurotransmitter transporter, taurine), member 6;186854;REa, A;;;6(Slc6a6)
3.77;9;10;07;3p25.1;ANKRD28, PITK, KIAA0379;;Ankyrin repeat domain-containing protein 28;611122;R, REc;;;
3.78;2;18;16;3p25.1;CCDC174, HSPC212, IHPM;;Coiled-coil domain-containing protein 174;616735;Psh, REc;;Hypotonia, infantile, with psychomotor retardation, 616816 (3);
3.79;8;21;07;3p25.1;CHDH4, MIA40;;Coiled-coil-helix-coiled-coil-helix domain-containing protein 4;611077;REc;;;
3.80;12;4;03;3p25.1;EAF1;;ELL-associated factor 1;608315;R, REc;;;
3.81;8;31;12;3p25.1;FGD5;;FYVE, RhoGEF, and PH domain-containing protein 5;614788;REc;;;
3.82;4;6;13;3p25.1;GALNT15, GALNACT15;;UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 15;615131;REc;;;
3.83;6;22;14;3p25.1;HACL1, HPCL2;;2-hydroxyacyl-CoA lyase 1;604300;REc;;;
3.84;8;28;09;3p25.1;NUP210, GP210, KIAA0906;;Nucleoporin, 210kD;607703;R, REc;;;
3.85;11;19;10;3p25.1;SH3BP5, SAB;;SH3 domain-binding protein 5;605612;REc, A;previously mapped to 1q431;;14(Sh3bp5)
3.86;6;2;16;3p26.2;TRNT1, SIFD, RPEM;;tRNA nucleotidyltransferase, CCA-adding, 1;612907;REc;pseudogenes on chromosomes 1 and 22;Sideroblastic anemia with B-cell immunodeficiency, periodic fevers, and developmental delay, 616084 (3); Retinitis pigmentosa and erythrocytic microcytosis, 616959 (3);
3.87;11;21;02;3p25.1;LSM3;;LSM3 protein;607283;REc;;;
3.88;7;8;16;3p25.1;RBSN,  ZFYVE20;;Rabenosyn 5;609511;R, REc;;;
3.89;11;15;08;3p25.2;TSEN2, SEN2, PCH2B;;tRNA splicing endonuclease 2, S. cerevisiae, homolog of;608753;REc;;Pontocerebellar hypoplasia type 2B, 612389 (3);
3.90;8;20;10;3p25.1-p23;LGMD1H;;Muscular dystrophy, limb-girdle, type 1H;613530;Fd;between D3S1263 and D3S1277;Muscular dystrophy, limb-girdle, type 1H (2);
3.91;10;23;15;3p25.1;COL6A4P1, DVWA, DIVA, LOC344875;;Collagen, type VI, alpha 4, pseudogene 1;612397;REc;;;
3.92;8;21;07;3p25.1;DPH3, KTI11, ZCSL2, DELGIP1;;DPH3, S. cerevisiae, homolog of;608959;R, REc;;;
3.93;4;15;09;3p24.3;OS6;;Osteoarthritis susceptibility 6;612401;Fd;associated with rs11718863 and rs7639618;{Osteoarthritis susceptibility 6} (2);
3.94;12;11;18;3p24.3;RFTN1, KIAA0084;;Lipid raft linking protein 1;618210;REc;;;
3.95;2;4;15;3p24.3;SGOL1, SGO, SGO1, CAID;;Shugoshin-like 1;609168;REc;;Chronic atrial and intestinal dysrhythmia, 616201 (3);
3.96;4;29;14;3p24.3;TBC1D5, KIAA0210;;TBC1 domain family, member 5;615740;REc, R;;;
3.97;9;4;08;3p24.2;THRB, ERBA2, THR1, PRTH;;Thyroid hormone receptor, beta (avian erythroblastic leukemia viral (v-erb-a) oncogene homolog-2);190160;REa, A, RE, Fd;;Thyroid hormone resistance, 188570 (3); Thyroid hormone resistance, autosomal recessive, 274300 (3); Thyroid hormone resistance, selective pituitary, 145650 (3);
3.98;8;3;12;3p24.2;UBE2E1, UBCH6;;Ubiquitin-conjugating enzyme E2E 1;602916;REc;;;
3.99;10;2;12;3p24.2;NR1D2, RVR, BD73;;Nuclear receptor subfamily 1, group D, member 2;602304;REc;;;
3.100;8;31;06;3p24.2;OXSM, KS;;3-oxoacyl-ACP synthase, mitochondrial;610324;REc;;;14(Oxsm)
3.101;12;27;13;3p24.2;RPL15, DBA12;;Ribosomal protein L15;604174;REa, R, REc;mutation identified in 1 family;?Diamond-Blackfan anemia 12, 615550 (3);
3.102;3;5;98;3p24.3;UBE2E2;;Ubiquitin-conjugating enzyme E2E 2 (homologous to yeast UBC4/5);602163;A;;;
3.103;1;2;08;3p24.2-p23;FEB9;;Febrile seizures, familial, 9;611634;Fd;between D3S3727 and D3S3567;Febrile seizures, familial, 9 (2);
3.104;3;1;06;3p24.1;AZI2, AZ2, NAP1, TILP;;5-azacytidine-induced gene 2, mouse, homolog of;609916;REc;;;
3.105;1;28;14;3p24-p23;GADL1;;Glutamate decarboxylase-like 1;615601;REc;;;
3.106;7;11;17;3p24.1;TGFBR2, HNPCC6, AAT3, MFS2, LDS2;;Transforming growth factor, beta receptor II, 70-80kD;190182;A, REa, Fd;;Colorectal cancer, hereditary nonpolyposis, type 6, 614331 (3); Esophageal cancer, somatic, 133239 (3); Loeys-Dietz syndrome 2, 610168 (3);9(Tgbfr2)
3.107;12;22;00;3p21.31;CELSR3, EGFL1, MEGF2;;Cadherin EGF LAG seven-pass G-type receptor 3 (epidermal growth factor-like 1);604264;R;;;
3.108;8;20;15;3p24;ATOD9;;Dermatitis, atopic, 9;613519;Fd;max lod at D3S1768;{Dermatitis, atopic, susceptibility to, 9} (2);
3.109;12;30;98;3p24.3;CAF;;CREBBP-associated factor;602303;A;;;17(Caf)
3.110;11;28;01;3p25.1;CAPN7, PALBH;;Calpain 7;606400;R;;;
3.111;10;17;00;3p22.3;CCR4, CKR4, CMKBR4;;Chemokine (C-C) receptor-4;604836;R, REc;;;
3.112;4;17;13;3p24.1;CMC1, C3orf68;;Cytochrome C oxidase assembly mitochondrial protein 1, S. cerevisiae, homolog of;615166;REc;;;
3.113;4;15;03;3p24.3;DAZL, DAZH, SPGYLA;;Deleted in azoospermia-like;601486;A, R;?founding member of DAZ gene family;{Spermatogenic failure, susceptibility to} (3);
3.114;6;9;15;3p24.2;NGLY1, PNG1, CDDG, CDG1V;;N-glycanase 1;610661;R, REc;;Congenital disorder of deglycosylation, 615273 (3);
3.115;11;19;13;3p24.2;RARB, HAP, MCOPS12;;Retinoic acid receptor, beta polypeptide;180220;REa, A;= HAP = HBV-activated protein;Microphthalmia, syndromic 12, 615524 (3);14(Rarb)
3.116;1;30;01;3p24.2;TOP2B;;Topoisomerase (DNA) II, beta, 180kD;126431;REa, Fd;;;
3.117;8;27;01;3p24.1;RBMS3;;RNA-binding motif protein, single strand-interacting, 3;605786;A;;;
3.118;9;22;03;3p24-p22;HSN1B;;Hereditary sensory neuropathy, type IB;608088;Fd;max lod at D3S2338;Neuropathy, hereditary sensory, type IB (2);
3.119;8;18;98;3p24.3;RAB5A, RAB5;;RAS-associated protein RAB5A;179512;A;;;
3.120;4;23;98;3p22.3-p22.2;STAC;;SRC homology three (SH3) and cysteine-rich domain;602317;R, H;;;9(Stac)
3.121;3;14;06;3p24-p21;ASPG4;;Asperger syndrome, susceptibility to, 4;609954;Fd;max lod at D3S2432;{Asperger syndrome susceptibility 4} (2);
3.122;6;9;98;3p24.3;SATB1;;Special AT-rich sequence binding protein-1;602075;A;;;
3.123;1;14;14;3p23;STT3B, SIMP, CDG1X;;STT3B, subunit of the oligosaccharyltransferase complex (catalytic);608605;REc;mutation identified in 1 family;?Congenital disorder of glycosylation, type Ix, 615597 (3);
3.124;12;23;05;3p22.3;UBP1, LBP1A, LBP1B;;Upstream binding protein 1;609784;R, REc;;;
3.125;8;4;09;3p22.2;ACAA1;;Acetyl-Coenzyme A acyltransferase 1 (peroxisomal 3-oxoacyl-Coenzyme A thiolase);604054;REa, A;;;
3.126;1;17;08;3p21.31;CDCP1, SIMA135;;CUB domain-containing protein 1;611735;A;;;
3.127;1;11;89;3p23-p21;SCLC1;;Small-cell cancer of lung;182280;Ch, D;centromeric to ERBA2;Small-cell cancer of lung (2);
3.128;6;16;99;3p21.31;SMARCC1, BAF155;;SWI/SNF related, matrix-associated, actin-dependent regulator of chromatin, subfamily C, member 1;601732;R, Psh;;;
3.129;6;28;02;3p21.31;TDGF1;;Teratocarcinoma-derived growth factor-1;187395;REa, A;;Forebrain defects (3);9(Tdgf1)
3.130;8;28;09;3p22.3;CLASP2;;CLIP-associated protein 2;605853;R, REc;;;
3.131;12;5;11;3p22.3;CMTM6, CKLFSF6;;CKLF-like marvel transmembrane domain-containing 6;607889;REc;;;9(Cklfsf6)
3.132;12;5;11;3p22.3;CMTM7, CKLFSF7;;CKLF-like marvel transmembrane domain-containing 7;607890;REc;;;9(Cklfsf7)
3.133;12;5;11;3p22.3;CMTM8, CKLFSF8;;CKLF-like marvel transmembrane domain-containing 8;607891;REc;;;9(Cklfsf8)
3.134;12;21;09;3p22.2;DCLK3, DCK3, CLR;;Doublecortin-like kinase 3;613167;REc;;;9(Dclk2)
3.135;7;17;14;3p22.3;DYNC1LI1, LIC1;;Dynein, cytoplasmic 1, light intermediate chain 1;615890;REc;;;
3.136;8;28;09;3p22.3;FBXL2, FBL2;;F-box and leucine-rich repeat protein 2;605652;R, REc;;;
3.137;2;11;08;3p22.3;GPD1L, KIAA0089;;Glycerol-3-phosphate dehydrogenase 1-like;611778;REc, Fd;;Brugada syndrome 2, 611777 (3);
3.138;9;16;03;3p22.3;PDCD6IP, AIP1, ALIX, KIAA1375;;Programmed cell death 6-interacting protein;608074;R;;;
3.139;12;23;05;3p22.2;CMYA1, XIN;;Cardiomyopathy-associated protein 1;609777;R, REc;;;
3.140;2;2;14;3p22.2;DDH2;;Developmental dysplasia of the hip 2;615612;Fd;between rs4481097 and rs4626072;Developmental dysplasia of the hip 2 (2);
3.141;9;8;11;3p22.2;LRRFIP2;;Leucine-rich repeat in FLII-interacting protein 2;614043;REc;;;
3.142;3;23;09;3p22.2;MIR26A, MIRN26A1;;Micro RNA 26A1;612151;REc;;;
3.143;12;4;13;3p22.2;SCN10A, FEPS2;;Sodium channel, voltage-gated, type X, alpha subunit;604427;Psh, REc;;Episodic pain syndrome, familial, 2, 615551 (3);
3.144;12;3;13;3p22.2;SCN11A, HSAN7, FEPS3;;Sodium channel, voltage-gated, type XI, alpha subunit;604385;R, REc;;Neuropathy, hereditary sensory and autonomic, type VII, 615548 (3); Episodic pain syndrome, familial, 3, 615552 (3);9(Scn11a)
3.145;01;04;19;3p22.2;SLC22A13, ORCTL3, OCTL1;;Solute carrier family 22 (organic anion/urate transporter), member 13;604047;REc;;;
3.146;01;04;19;3p22.2;SLC22A14, ORCTL4, OCTL2;;Solute carrier family 22, member 14;604048;REc;;;
3.147;8;25;11;3p22.1-p21.3;ANO10, TMEM16K, SCAR10;;Anoctamin 10;613726;REc;;Spinocerebellar ataxia, autosomal recessive 10, 613728 (3);
3.148;7;14;17;3p22.1;CTNNB1, MRD19, EVR7;;Catenin (cadherin-associated protein), beta 1, 88kD;116806;A, REn, Psh, REc;;Mental retardation, autosomal dominant 19, 615075 (3); Colorectal cancer, somatic, 114500 (3); Pilomatricoma, somatic, 132600 (3); Ovarian cancer, somatic, 167000 (3); Hepatocellular carcinoma, somatic, 114550 (3); Medulloblastoma, somatic, 155255 (3); Exudative vitreoretinopathy 7, 617572 (3);9(Catnb)
3.149;2;25;15;3p22.2;EPM2AIP1, KIAA0766;;EPM2A-interacting protein 1;607911;R, REc, H;;;9(Epm2aip1)
3.150;10;25;16;3p22.1;HHATL, MBOAT3, C3orf3, KIAA1173;;Hedgehog acyltransferase-like protein;608116;REc;;;
3.151;8;2;13;3p22.1;KLHL40, SYRP, KBTBD5, NEM8;;Kelch-like 40;615340;REc;;Nemaline myopathy 8, autosomal recessive, 615348 (3);
3.152;2;21;14;3p22.1;NKTR;;Natural tumor-killer recognition sequence;161565;REa, REc;mouse gene close to Cck;;9(Nktr)
3.153;10;14;18;3p22.1;POMGNT2, GTDC2, C3orf39, AGO61, MDDGA8, MDDGC8;;Protein O-mannose beta-1,2-N-acetylglucosaminyltransferase 2;614828;REc;;Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies, type A, 8, 614830 (3); Muscular dystrophy-dystroglycanopathy (limb-girdle) type C, 8, 618135 (3);
3.154;4;21;17;3p22.1;RPL14;;Ribosomal protein L14;617414;Psh, REc;;;
3.155;7;14;14;3p22.1;SEC22C;;Secretion deficient 22, S. cerevisiae, homolog of, C;604028;REc;;;
3.156;3;17;16;3p22.1;SLC25A38, SIDBA2;;Solute carrier family 25, member 38;610819;REc;;Anemia, sideroblastic, 2, pyridoxine-refractory, 205950 (3);9(Slc25a38)
3.157;6;22;12;3p22.1;SNORA62, RNU108, RNE2;;Small nucleolar RNA, H/ACA box, 62;180646;REc;;;
3.158;6;27;16;3p22.1;ULK4, FAM7C1;;Unc51-like kinase 4;617010;REc;;;9(Ulk4)
3.159;8;25;11;3p21.31;NBEAL2, KIAA0540, GPS, BDPLT4;;Neurobeachin-like 2;614169;REc;;Gray platelet syndrome, 139090 (3);
3.160;11;28;01;3p22.2;AXUD1;;Axin1 upregulated;606458;R;;;
3.161;9;9;08;3p22.1;CCR8, CMKBR8, CMKBRL2, CKRL1;;Chemokine (C-C) receptor 8;601834;Psh;;;
3.162;10;6;11;3p22.3;CRTAP, CASP, OI7;;Cartilage-associated protein;605497;A;;Osteogenesis imperfecta, type VII, 610682 (3);9(Crtap)
3.163;10;4;12;3p22;HHV8S;;Human herpesvirus 8, susceptibility to;614836;Fd;;{Human herpesvirus 8, susceptibility to} (2);
3.164;3;23;09;3p22.3;MIR128-2, MIR128B, MIRN128-2;;Micro RNA 128-2;611769;REc;;;
3.165;1;29;01;3p24.1;SLC4A7, NBC2, NBC3;;Solute carrier family 4, sodium bicarbonate cotransporter, member 7;603353;A;;;
3.166;5;9;95;3p22.1;VIPR1;;Vasoactive intestinal peptide receptor 1;192321;A;incorrectly assigned to 2q37;;9(Vipr1)
3.167;7;8;95;3p21.31;TGM4;;Transglutaminase-4, prostate;600585;A;;;
3.168;11;13;07;3p22.2;ACVR2B, ACTRIIB, HTX4;;Activin A receptor, type IIB;602730;REc, A;;Heterotaxy, visceral, 4, autosomal, 613751 (3);
3.169;2;19;02;3p22.1;CYP8B1, CYP12;;Cytochrome P450, subfamily VIIIB, polypeptide 1;602172;A, R;;;9(Cyp8b1)
3.170;4;17;00;3p22.2;DLEC1, DLC1;;Deleted in lung and esophageal cancer 1;604050;REn;;Lung cancer, 211980 (1); Esophageal cancer, 133239 (1);
3.171;8;9;99;3p22.2;GOLGA4;;Golgi autoantigen, golgin subfamily a, 4;602509;REc;;;
3.172;2;22;11;3p22.2;EXOG, ENDOGL1, ENGL;;Endo/exonuclease, ENDOG-like;604051;A;;;
3.173;9;18;12;3p22.2;MYD88, MYD88D;;Myeloid differentiation primary response gene 88;602170;Psh;;Pyogenic bacterial infections, recurrent, due to MYD88 deficiency, 612260 (3); Macroglobulinemia, Waldenstrom, somatic, 153600 (3);9(Myd88)
3.174;8;9;99;3p22.2;OSR1;;Oxidative stress-responsive 1;604046;REn;;;
3.175;8;25;11;3p22.2;PLCD1, NDNC3;;Phospholipase C, delta-1;602142;A;;Nail disorder, nonsyndromic congenital, 3, (leukonychia), 151600 (3);
3.176;8;5;97;3p21.31;TNA;;Tetranectin (plasminogen-binding protein);187520;Psh, R;;;
3.177;8;9;99;3p22.2;XYLB;;Xylulokinase, H. influenzae, homolog of;604049;REn;;;
3.178;6;9;10;3p21.31;PTHR1, PTHR, PFE;;Parathyroid hormone receptor-1;168468;REa, A, Psh;;Metaphyseal chondrodysplasia, Murk Jansen type, 156400 (3); Chondrodysplasia, Blomstrand type, 215045 (3); Eiken syndrome, 600002 (3); Failure of tooth eruption, primary, 125350 (3);
3.179;2;28;03;3p22.1;MOBP;;Myelin-associated oligodendrocyte basic protein;600948;R, H;;;9(Mobp)
3.180;1;30;01;3p21.31;PFKFB4;;6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 4;605320;A;;;
3.181;6;18;90;3p21.31;ZNF35, HF10;;Zinc finger protein-35 (HF.10);194533;REa, A;;;
3.182;2;2;11;3p22.3;GLB1, MPS4B;;Galactosidase, beta-1;611458;S, EM, A;3p14.2-p11 excluded;GM1-gangliosidosis, type I, 230500 (3); GM1-gangliosidosis, type II, 230600 (3); GM1-gangliosidosis, type III, 230650 (3); Mucopolysaccharidosis type IVB (Morquio), 253010 (3);9(Bgl)
3.183;8;28;09;3p22.2;GORASP1, GOLPH5, GRASP65, P65;;Golgi reassembly stacking protein 1, 65kD;606867;R, A;;;
3.184;5;12;09;3p22.1;LYZL4;;Lysozyme-like 4;612750;REc;;;
3.185;10;5;17;3p21.31;TOPAZ1, C3orf77;;Testis- and ovary-specific PAZ domain protein 1;614412;REc;;;9(Topaz1)
3.186;7;31;08;3p22.2;WDR48, KIAA1449;;WD repeat-containing protein 48;612167;REc;;;
3.187;2;14;08;3p22.1;MYRIP, SLAC2C;;Myosin VIIA- and RAB-interacting protein;611790;REc;;;
3.188;6;7;10;3p21.32;MIR138-1, MIRN138-1;;Micro RNA 138-1;613394;REc;;;
3.189;12;18;08;3p21.31;ALS2CL;;ALS2 C-terminal-like protein;612402;REc;;;9(Als2cl)
3.190;3;14;14;3p21.31;AMIGO3, ALI3;;Adhesion molecule with Ig-like domain 3;615691;REc;;;
3.191;3;9;00;3p21.31;BSN, ZNF231;;Bassoon, mouse, homolog of;604020;A, R, Psh;;;
3.192;1;9;13;3p21.31;CAMKV, 1G5;;CAM kinase-like vesicle-associated;614993;REc;;;9(Camkv)
3.193;7;2;18;3p21.31;CSPG5, NGC;;Chondroitin sulfate proteoglycan 5;606775;A, REc;;;
3.194;12;19;17;3p21.31;DHX30, DDX30, RETCOR, KIAA0890, NEDMIAL;;DEAH box polypeptide 30;616423;R, REc;;Neurodevelopmental disorder with severe motor impairment and absent language, 617804 (3);
3.195;3;7;13;3p21.31;ELP6, TMEM103, C3orf75;;Elongator acetyltransferase complex, subunit 6;615020;REc;;;
3.196;6;1;12;3p21.31;EXOSC7, RRP42;;Exosome component 7;606488;REc;;;
3.197;09;27;18;3p21.31;GMPPB, KIAA1851, MDDGA14, MDDGB14, MDDGC14, LGMDR19;;GDP-mannose pyrophosphorylase B;615320;REc;;Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 14, 615350 (3); Muscular dystrophy-dystroglycanopathy (limb-girdle), type C, 14, 615352 (3); Muscular dystrophy-dystroglycanopathy (congenital with mental retardation), type B, 14, 615351 (3);
3.198;8;28;09;3p21.31;IHPK1, IP6K1, KIAA0263;;Inositol hexaphosphate kinase 1;606991;R, Ch;;;
3.199;2;25;15;3p21.31;KIF9;;Kinesin family member 9;607910;R, REc;;;
3.200;7;13;17;3p21.31;KIF15, KLP2, KNSL7;;Kinesin family, member 15;617569;REc;;;
3.201;11;24;14;3p21.31;KLHDC8B, CHL;;Kelch domain-containing protein 8B;613169;A, REc;;{Hodgkin lymphoma, susceptibility to}, 236000 (3);
3.202;4;25;08;3p21.31;LTF;;Lactotransferrin;150210;REa, A;;;9(Ltf)
3.203;3;29;13;3p21.31;MIR191;;Micro RNA 191;615150;REc;;;
3.204;11;23;16;3p21.31;MIR4271;;Micro RNA 4271;617176;REc;;;
3.205;8;27;15;3p21.31;MON1A, SAND1;;Mon1, S. cerevisiae, homolog of, A;611464;R, REc;;;6(Mon1a)
3.206;12;13;18;3p21.31;NDUFAF3, MC1DN18;;NADH dehydrogenase 1 alpha subcomplex, assembly factor 3;612911;REc;;Mitochondrial complex I deficiency, nuclear type 18, 618240 (3);
3.207;4;25;12;3p21.31;P4HTM, PH4;;Prolyl 4-hydroxylase, transmembrane;614584;REc;;;
3.208;2;25;15;3p21.31;PRSS50;;Protease, serine, 50;607950;REa, R;;;
3.209;5;17;18;3p21.31;QRICH1, VERBRAS;;Glutamine-rich protein 1;617387;REc;;Ververi-Brady syndrome, 617982 (3);
3.210;2;24;12;3p21.31;RNF123, KPC1;;Ring finger protein 123;614472;REc;;;
3.211;10;30;06;3p21.31;SCAP;;SREBP cleavage-activating protein;601510;R, REc;;;
3.212;11;17;16;3p21.1;SELENOK, SELK, HSPC030;;Selenoprotein K;607916;REc;;;
3.213;1;19;11;3p21.31;SLC25A20, CACT, CAC;;Solute carrier family 25 (carnitine/acylcarnitine translocase), member 20 (carnitine-acylcarnitine translocase);613698;A;pseudogene on 6p12;Carnitine-acylcarnitine translocase deficiency, 212138 (3);
3.214;7;14;14;3p21.31;TMA7, HSPC016;;Translation machinery-associated 7, S. cerevisiae, homolog of;615808;REc;;;
3.215;2;5;16;3p21.31;TRAIP, TRIP, RNF206, SCKL9;;TRAF-interacting protein;605958;R, REc;;Seckel syndrome 9, 616777 (3);
3.216;6;16;99;3p21.31;USP4, UNP;;Ubiquitin-specific protease-4;603486;A, H, REc;;;9(Unp)
3.217;2;24;12;3p21.31;USP19, KIAA0891;;Ubiquitin-specific protease 19;614471;REc;;;
3.218;2;1;11;3p21.31;WDR6;;WD repeat-containing protein 6;606031;REc;previously assigned to 15q21 by FISH;;
3.219;1;5;06;3p21.31;ZD1;;Zygodactyly 1;609815;Fd;max lod at D3S2409;Zygodactyly 1 (2);
3.220;10;11;16;3p21.31;ZDHHC3, DHHC3, GODZ;;Zinc finger DHHC domain-containing protein 3;617150;REc;;;
3.221;8;11;15;3p22.1;ACKR2, CCBP2, CMKBR9, D6, CCR9, CCR10;;Atypical chemokine receptor 2;602648;R, A;;;
3.222;11;19;11;3p21.1;BAP1, TPDS;;BRCA1 associated protein-1 (ubiquitin carboxy-terminal hydrolase);603089;A, R;;Tumor predisposition syndrome, 614327 (3);
3.223;7;2;02;3p21.31;CACNA2D2, KIAA0558;;Calcium channel, voltage-dependent, alpha-2/delta subunit 2;607082;R, REc;;;
3.224;3;2;98;3p21.31;CAMP, FALL39;;Cathelicidin antimicrobial peptide;600474;A;;;
3.225;12;19;11;3p21.2;CISH, BACTS2;;Cytokine inducible SH2-containing protein;602441;Ch;;{Tuberculosis, susceptibility to}, 607948 (3); {Malaria, susceptibility to}, 611162 (3); {Bacteremia, susceptibility to}, 614383 (3);9(Cish)
3.226;9;9;08;3p21.31;CCR3, CKR3, CMKBR3;;Chemokine (C-C) receptor 3;601268;R, REc;;;
3.227;9;9;08;3p21.31;CCR9;;Chemokine, CC motif, receptor 9;604738;R, A;;;
3.228;12;2;14;3p21.31;COL7A1, NDNC8;;Collagen VII, alpha-1 polypeptide;120120;REa, A;;Epidermolysis bullosa dystrophica, AD, 131750 (3); Epidermolysis bullosa dystrophica, AR, 226600 (3); Epidermolysis bullosa, pretibial, 131850 (3); EBD, Bart type, 132000 (3); EBD, localisata variant (3); Transient bullous of the newborn, 131705 (3); Epidermolysis bullosa pruriginosa, 604129 (3); Toenail dystrophy, isolated, 607523 (3); EBD inversa, 226600 (3);
3.229;4;26;08;3p21.31;CYB561D2, 101F6;;Cytochrome b-561 domain containing 2;607068;REc;;;
3.230;7;24;17;3p21.1;DNAH1, HL11, DNAHC1, HDHC7, SPGF18, CILD37;;Dynein, axonemal, heavy chain-1;603332;Psh, A;mutation identified in 1 CILD37 family;Spermatogenic failure 18, 617576 (3); ?Ciliary dyskinesia, primary, 37, 617577 (3);14(Dnah1)
3.231;9;28;00;3p22.1;ENTPD3, CD39L3;;Ectonucleoside triphosphate diphosphohydrolase 3;603161;R, Psh;;;
3.232;8;6;13;3p21.31;FYCO1, CATC2, CTRCT18;;FYVE and coiled-coil domain containing 1;607182;REc, Fd;;Cataract 18, autosomal recessive, 610019 (3);
3.233;6;27;02;3p21.31;FUS2;;FUS2 gene;607073;REc;;;
3.234;8;25;11;3p21.31;GPX1, GPXD;;Glutathione peroxidase-1;138320;S, REa, Psh, A;?pseudogene on 3p11-p12;Hemolytic anemia due to glutathione peroxidase deficiency, 614164 (1);
3.235;6;16;99;3p21.31;HYAL2, LUCA2;;Hyaluronoglucosaminidase 2;603551;REc, H;;;9(Hyal2)
3.236;8;31;99;3p21.31;HYAL3, LUCA3;;Hyaluronoglucosaminidase 3;604038;REn;;;
3.237;9;9;08;3p21.3;IBD12;;Inflammatory bowel disease 12;612241;Fd;;{Inflammatory bowel disease 12} (2);
3.238;9;28;98;3p21.31;IFRD2;;Interferon-related developmental regulator-2;602725;REc;;;
3.239;3;9;00;3p22.2;ITGA9;;Integrin, alpha-9;603963;REn;;;
3.240;7;22;16;3p21.31;LARS2, PRLTS4, HLASA;;Leucyl-tRNA synthetase, mitochondrial;604544;REc;mutation identified in 1 HLASA patient;Perrault syndrome 4, 615300 (3); ?Hydrops, lactic acidosis, and sideroblastic anemia, 617021 (3);
3.241;2;22;00;3p21.31;LIMD1;;LIM domain-containing protein 1;604543;REc;;;9(Limd1)
3.242;9;11;02;3p21.31;LRRC2;;Leucine-rich repeat-containing 2;607180;REc;;;
3.243;10;16;14;3p21.31;LZTFL1, BBS17;;Leucine zipper transcription factor-like 1;606568;REc;;Bardet-Biedl syndrome 17, 615994 (3);9(Lztfl1)
3.244;9;16;16;3p21.2;MAPKAP3, 3PK, MDPT3;;Mitogen-activated protein kinase-activated protein kinase-3;602130;REc;mutation identified in 1 MDPT3 family;?Macular dystrophy, patterned, 3, 617111 (3);
3.245;12;28;08;3q21.3;MGLL, MGL, HUK5;;Monoglyceride lipase;609699;REc, H, R;;;6(Mgll)
3.246;1;16;08;3p22.2;MLH1, COCA2, HNPCC2;;mutL, E. coli, homolog of, 1;120436;Fd, A;;Colorectal cancer, hereditary nonpolyposis, type 2, 609310 (3); Mismatch repair cancer syndrome, 276300 (3); Muir-Torre syndrome, 158320 (3);
3.247;4;25;08;3p21.31;NME6;;Nonmetastatic cells 6, protein expressed in;608294;R;;;
3.248;8;22;16;3p21.31;MST1R, RON, NPCA3;;Macrophage stimulating 1 receptor (c-met-related tyrosine kinase);600168;A;;{Nasopharyngeal carcinoma, susceptibility to, 3}, 617075 (3);
3.249;9;22;16;3p21.31;NPR2L, NPRL2, FFEVF2;;Npr2, S. cerevisiae, homolog of;607072;REc;;Epilepsy, familial focal, with variable foci 2, 617116 (3);
3.250;1;3;02;3p21.31;PTPN23, KIAA1471, HDPTP;;Protein-tyrosine phosphatase, nonreceptor-type, 23;606584;R, REc;;;
3.251;2;12;07;3p21.31;RASSF1;;RAS association domain family protein 1;605082;D, REc;epigenetically inactivated;Lung cancer, 211980 (2);
3.252;8;3;12;3p21.31;RHOA, ARHA, ARH12, RHOH12;;Ras homolog gene family, member A (oncogene RHO H12);165390;A, Psh;;;
3.253;4;29;02;3p21.31;RMB5, LUCA15;;RNA-binding motif protein 5;606884;REc;;;
3.254;4;29;02;3p21.31;RBM6, DEF3;;RNA-binding motif protein 6;606886;REc;;;9(Rbm6)
3.255;10;12;14;3p22.1;RPSA, LAMR1, LAMBR, ICAS;;Ribosomal protein SA;150370;A;;Asplenia, isolated congenital, 271400 (3);9(Lamr1)
3.256;4;30;09;3p21.31;RTP3, TMEM7;;Receptor-transporting protein 3;607181;REc;;;
3.257;1;14;02;3p21.31;SACM1L, SAC1, KIAA0851;;SAC1 suppressor of actin mutations 1-like;606569;REc;;;
3.258;3;15;96;3p21.31;SEMA3F, SEMA4;;Semaphorin III/F;601124;REc;;;
3.259;7;8;96;3p21.31;SEMA5;;Semaphorin A(V);601281;REc;;;
3.260;2;2;17;3p21.31;SHISA5, SCOTIN;;Shisa family, member 5;607290;REc;pseudogene on Xq13.1-q13.3;;
3.261;4;20;10;3p21.31;SLC6A20, XT3;;X transporter protein 3;605616;REc;;Hyperglycinuria, 138500 (3); Iminoglycinuria, digenic, 242600 (3);9(Xt3)
3.262;5;2;06;3p21.31;SLC26A6;;Solute carrier family 26 (anion transporter), member 6;610068;REc;;;
3.263;6;27;02;3p21.31;SLC38A3, SN1, G17;;Solute carrier family 38, member 3;604437;REc;;;
3.264;12;27;01;3p21.2;TLR9;;Toll-like receptor 9;605474;REc;;;
3.265;11;11;14;3p21.31;TMEM115, PL6;;Transmembrane protein 115;607069;REc;;;
3.266;3;9;98;3p21.3;TRR;;Transfer RNA arginine;601994;REc, A;;;
3.267;3;18;08;3p21.31;UCN2, SRP, UR;;Urocortin II;605902;REc;;;
3.268;4;4;05;3p21.31;FUS1;;FUS1 gene;607052;REc;;;
3.269;2;28;94;3p21.31;UQCRC1;;Ubiquinol-cytochrome c reductase core protein I;191328;REn;close upstream of COL7A1;;
3.270;10;15;13;3p21.31;ZMYND10, BLU;;Zinc finger MYND domain-containing protein 10;607070;REc;;Ciliary dyskinesia, primary, 22, 615444 (3);
3.271;6;1;07;3p21.31;ATRIP;;ATR-interacting protein;606605;REc;;;
3.272;3;8;00;3p24.1;EOMES, TBR2;;Eomesodermin, Xenopus laevis, homolog of;604615;R;?translocation separating regulatory element from promoter;;9(Tbr2)
3.273;2;11;15;3p21.31;HYAL1, MPS9;;Hyaluronoglucosaminidase 1;607071;A;mutation identified in 1 MPS9 patient;?Mucopolysaccharidosis type IX, 601492 (3);9(Hyal1)
3.274;6;16;99;3p21.31;PRKAR2A;;Protein kinase, cAMP-dependent, regulatory, type II, alpha;176910;REa, Psh;;;
3.275;2;23;16;3p21.31;SETD2, SET2, HYPB, HBP231, KIAA1732, LLS;;SET domain-containing protein 2;612778;A, REc;;Luscan-Lumish syndrome, 616831 (3);
3.276;7;14;09;3p21.31;TREX1, AGS1, CRV, HERNS;;3' repair exonuclease 1;606609;REc, Fd;;Aicardi-Goutieres syndrome 1, dominant and recessive, 225750 (3); Chilblain lupus, 610448 (3); Vasculopathy, retinal, with cerebral leukodystrophy, 192315 (3); {Systemic lupus erythematosus, susceptibility to}, 152700 (3);
3.277;4;19;06;3p21.2;PARP3, ADPRTL3;;Poly(ADP-ribose) polymerase 3;607726;REc, A, H;;;9(Adprtl3)
3.278;8;28;02;3p21.31;XCR1, CCXCR1, GPR5;;Chemokine, C motif, receptor 1 (G protein-coupled receptor-5);600552;A;;;
3.279;2;22;10;3p21.1;TNNC1, CMD1Z, CMH13;;Troponin-C1, slow;191040;Psh, REa, R;;Cardiomyopathy, dilated, 1Z, 611879 (3); Cardiomyopathy, hypertrophic, 13, 613243 (3);7(Tnnc1)
3.280;12;19;16;3p21.2;DCAF1, RIP, VPRBP, KIAA0800;;DDB1- and CUL4-associated factor 1;617259;R, REc;;;
3.281;6;1;18;3p21.31;IMPDH2, IMPD2;;Inosine-5'-monophosphate dehydrogenase, type II;146691;Psh, A;;[IMPDH2 enzyme activity, variation in], 617995 (3);
3.282;9;23;13;3p21.2;PCBP4, MGC10;;Poly(rC)-binding protein 4;608503;REc, A;;;9(Pcbp4)
3.283;9;10;12;3p21.2;POC1A, PIX2, SOFT;;POC1 centriolar protein, Chlamydomonas, homolog of, A;614783;REc;;Short stature, onychodysplasia, facial dysmorphism, and hypotrichosis, 614813 (3);
3.284;3;14;06;3p21.2;PPM1M, PP2CE;;Protein phosphatase 1M (protein phosphatase 2C, eta isoform);608979;R, REc;;;
3.285;6;21;01;3p21.31;AMT, NKH, GCE;;Aminomethyltransferase (glycine cleavage system protein T);238310;REa;;Glycine encephalopathy, 605899 (3);
3.286;4;8;02;3p21.2;GRM2, MGLUR2;;Glutamate receptor, metabotropic, 2;604099;Psh, R;;;
3.287;10;2;09;3p14.3;HESX1, RPX, CPHD5;;Homeo box gene expressed in ES cells;601802;A;;Septooptic dysplasia, 182230 (3); Pituitary hormone deficiency, combined, 5, 182230 (3); Growth hormone deficiency with pituitary anomalies, 182230 (3);14(Hesx1)
3.288;10;6;92;3p21.1;ITIH1;;Inter-alpha (globulin) inhibitor, H1 polypeptide;147270;A, H;;;14(Intin1)
3.289;10;6;92;3p21.1;ITIH3;;Inter-alpha (globulin) inhibitor, H3 polypeptide;146650;A, H;;;14(Intin3)
3.290;2;7;06;3p14.3;SPATA12, SRG5;;Spermatogenesis-associated protein 12;609869;REc;;;
3.291;6;19;98;3p14.3;SLAP;;Sarcolemmal-associated protein;602701;A;;;
3.292;5;27;05;3p21.1;ITIH4, PK120, ITIHL1;;Inter-alpha (globulin) inhibitor, H4 polypeptide;600564;A;;{Hypercholesterolemia, susceptibility to}, 143890 (3);14(Itih4)
3.293;2;24;06;3p21.2;ACY1, ACY1D;;Aminoacylase-1;104620;S, REa, REn;;Aminoacylase 1 deficiency, 609924 (3);9(Acy)
3.294;7;8;95;3p21.2;ALAS1;;Aminolevulinate, delta-, synthase-1;125290;REa, A, R, Psh;;;
3.295;7;16;09;3p21.2;ARMET, ARP;;Arginine-rich protein, mutated in early stage tumors;601916;REc, D;;;
3.296;11;1;13;3p21.1;CACNA1D, CACNL1A2, CCHL1A2, SANDD, PASNA;;Calcium channel, voltage-dependent, L type, alpha 1D subunit;114206;REa, H, REc;;Sinoatrial node dysfunction and deafness, 614896 (3); Primary aldosteronism, seizures, and neurologic abnormalities, 615474 (3);14(Cch1a2)
3.297;11;28;01;3p21.1-p14.3;CACNA2D3;;Calcium channel, voltage-dependent, alpha-2/delta subunit 3;606399;REc;;;
3.298;8;28;09;3p14.2;CADPS, CAPS;;Ca(2+)-dependent activator protein for secretion;604667;Psh, REc;;;
3.299;3;20;06;3p21.1;DCP1A, SMIF;;Decapping enzyme 1, X. cerevisiae, homolog of, A;607010;R, REc;;;
3.300;2;21;06;3p14.3;DNAH12, DNAHC3, HL19;;Dynein, heavy chain-5;603340;REa, REc;;;
3.301;4;26;10;3p14.3-p14.2;FAM107A, DRR1, TU3A;;Family with sequence similarity 107, member A (downregulated in renal cell carcinoma 1);608295;REc, A;;;
3.302;4;19;05;3p21.1;GNL3, NS, E2IG3;;Guanine nucleotide-binding protein-like 3;608011;R, REc;;;
3.303;5;13;02;3p21.2;GPR62;;G protein-coupled receptor 62;606917;REc;;;
3.304;1;29;01;3p21.1;IL17RB, IL17BR, IL17RH1;;Interleukin 17, receptor B;605458;R;;;
3.305;10;13;09;3p21.2;MIRLET7G, LET7G, MIRNLET7G;;Micro RNA Let7G;612102;REc;;;
3.306;11;23;16;3p21.1;MUSTN1, MUSTANG;;Musculoskeletal embryonic nuclear protein 1;617195;REc;;;
3.307;5;24;02;3p21.1;NEK4, STK2, NRK2;;NIMA (never in mitosis gene a)-related kinase 4 (serine/threonine protein kinase-2);601959;REa;;;
3.308;11;22;13;3p21.1;NISCH, IRAS, KIAA0975;;Nischarin;615507;REc;;;
3.309;9;28;12;3p13;PROK2, PK2, BV8, HH4;;Prokineticin 2;607002;R;;Hypogonadotropic hypogonadism 4 with or without anosmia, 610628 (3);6(Prok2)
3.310;2;17;09;3p21.2;RBM15B, OTT3, HUMAGCGB;;RNA-binding motif protein 15B;612602;REc;;;
3.311;5;15;08;3p21.1;RFT1, CDG1N;;RFT1, S. cerevisiae, homolog of;611908;REc;;Congenital disorder of glycosylation, type In, 612015 (3);
3.312;9;9;13;3p21.1;SFMBT1, RU1;;SCM-like protein with 4 MBT domains 1;607319;REc;;;
3.313;8;19;13;3p21.1;SPCS1, SPC12;;Signal peptidase complex, subunit 1, S. cerevisiae, homolog of;610358;R, REc;;;
3.314;11;23;16;3p21.1;TMEM110, STIMATE;;Transmembrane protein 110;617189;REc;;;
3.315;8;28;09;3p21.2;TWF2, PTK9L, A6RP;;Twinfilin, actin-binding protein, Drosophila, homolog of, 2;607433;R, REc;;;
3.316;9;9;10;3p21.2;WDR82, TMEM113;;WD repeat-containing protein 82;611059;R, REc;;;
3.317;8;11;15;3p14.3;APPL1, APPL, MODY14;;Adaptor protein containing PH domain, PTB domain, and leucine zipper motif 1;604299;A;;{Maturity-onset diabetes of the young, type 14}, 616511 (3);
3.318;1;18;12;3p14.3;DNASE1L3, SLEB16;;Deoxyribonuclease I-like 3;602244;A, R;;Systemic lupus erythematosus 16, 614420 (3);
3.319;1;14;02;3p21.33;ABHD5, CGI58, IECN2, NCIE2;;Abhydrolase domain containing 5;604780;Fd, REc;;Chanarin-Dorfman syndrome, 275630 (3);
3.320;6;7;94;3p21.31;APEH, D3S48E;;N-acylaminoacyl-peptide hydrolase;102645;REa, A, D;;;
3.321;8;28;09;3p21.31;ARIH2, ARI2, TRIAD1;;Ariadne, Drosophila, homolog of, 2;605615;R, REc;;;
3.322;11;4;93;3p21.31;CDC25A;;Cell division cycle 25A;116947;REa, Psh, A;;;
3.323;5;28;08;3p21;CELIAC9;;Celiac disease, susceptibility to, 9;612007;Fd;associated with rs6441961;{Celiac disease, susceptibility to, 9} (2);
3.324;9;9;08;3p21.31;CCR1, CMKBR1, CKR1, HM145;;Chemokine (C-C) receptor 1;601159;A;;;9(Cmkbr1)
3.325;9;8;08;3p21.31;CCR2, CMKBR2;;Chemokine (C-C) receptor 2;601267;REn;;{HIV infection, susceptibility/resistance to} (3);
3.326;1;27;04;3p21.31;CCRL2;;Chemokine, CC motif, receptor-like protein 2;608379;REc;;;
3.327;1;13;09;3p21.31;CCR5, CMKBR5, CCCKR5, IDDM22;;Chemokine (C-C) receptor 5;601373;REc, R;;{HIV infection, susceptibility/resistance to} (3); {West nile virus, susceptibility to}, 610379 (3); {Hepatitis C virus, resistance to}, 609532 (3); {Diabetes mellitus, insulin-dependent, 22}, 612522 (3);
3.328;9;9;08;3p21.31;CXCR6, STRL33, BONZO;;Chemokine, CXC motif, receptor 6;605163;REa, Psh;;;
3.329;09;27;18;3p21.31;DAG1, DAG, MDDGC9, MDDGA9, LGMDR16;;Dystrophin-associated glycoprotein-1;128239;REa, A;;Muscular dystrophy-dystroglycanopathy (limb-girdle), type C, 9, 613818 (3); Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 9, 616538 (3);9(Dag1)
3.330;11;20;98;3p21.2;DUSP7, MKPX, PYST2;;Dual-specificity phosphatase-7;602749;Psh, A;;;9(Dusp7)
3.331;9;9;08;3p21.31;FBXW12, FBW12, FBXO35, FBXO12;;F-box and WD40 domain protein 12;609075;REc;;;
3.332;4;15;11;3p21.2;GLYCTK, GLYCTK1;;Glycerate kinase;610516;REc;;D-glyceric aciduria, 220120 (3);
3.333;8;10;98;3p21.31;GNAI2, GNAI2B, GIP;;Guanine nucleotide-binding protein (G protein), alpha-inhibiting activity polypeptide-2;139360;REa, A;on 12p13-p12, GNAI2L;Pituitary ACTH-secreting adenoma (3); Ventricular tachycardia, idiopathic, 192605 (3);9(Gnai2)
3.334;2;8;18;3p21.31;GNAT1, CSNBAD3, CSNB1G;;Guanine nucleotide-binding protein (G protein), alpha-transducing (transducin) activity polypeptide-1;139330;REa, A;;Night blindness, congenital stationary, autosomal dominant 3, 610444 (3); Night blindness, congenital stationary, type 1G, 616389 (3);9(Gnat1)
3.335;1;25;11;3p21;HSCR6;;Hirschsprung disease, susceptibility to, 6;606874;Fd;;{Hirschsprung disease, susceptibility to, 6} (2);
3.336;9;30;02;3p21.31;IHPK2, IP6K2;;Inositol hexaphosphate kinase 2;606992;REc;;;
3.337;9;6;11;3p21.31;LAMB2, LAMS, NPHS5;;Laminin, beta-2 (laminin S);150325;REa, A;;Nephrotic syndrome, type 5, with or without ocular abnormalities, 614199 (3); Pierson syndrome, 609049 (3);
3.338;5;9;97;3p21.31;MAP4;;Microtubule-associated protein 4;157132;A;;;9(Map4)
3.339;8;27;92;3p21.31;MST1, HGFL;;Macrophage-stimulating-1 (hepatocyte growth factor-like);142408;REn, H;;;9(Hgfl)
3.340;7;16;09;3p21.31;NCKIPSD, AF3P21, SPIN90;;NCK-interacting protein with SH3 domain;606671;Ch;;;
3.341;10;13;09;3p21.31;NICN1;;Nicolin 1;611516;REc;processed pseudogene on X;;9(Nicn1)
3.342;7;13;09;3p21.1;PBRM1, PB1, BAF180;;Polybromo 1, chicken, homolog of;606083;R, REc;;;
3.343;4;15;11;3p21;PSC;;Cholangitis, primary sclerosing;613806;Fd;;Cholangitis, primary sclerosing (2);
3.344;4;29;14;3p21.31;QARS, GLNRS, MSCCA;;Glutaminyl-tRNA synthetase;603727;REa, REc;;Microcephaly, progressive, seizures, and cerebral and cerebellar atrophy, 615760 (3);
3.345;9;24;09;3p22.2;SCN5A, LQT3, VF1, HB1, SSS1, CMD1E, CDCD2;;Sodium channel, voltage-gated, type V, alpha polypeptide;600163;Fd, A;;Long QT syndrome-3, 603830 (3); Brugada syndrome 1, 601144 (3); Heart block, progressive, type IA, 113900 (3); Heart block, nonprogressive, 113900 (3); Ventricular fibrillation, familial, 1, 603829 (3); Sick sinus syndrome 1, 608567 (3); Cardiomyopathy, dilated, 1E, 601154 (3); {Sudden infant death syndrome, susceptibility to}, 272120 (3); Atrial fibrillation, familial, 10, 614022 (3);
3.346;5;12;09;3p22.1;SNRK, KIAA0096;;SNF-related kinase;612760;REc;;;
3.347;1;11;07;3p22.1;SS18L2;;SS18-like gene 2;606473;A;;;
3.348;12;17;15;3p21.31;ZNF589, SZF1;;Zinc finger protein 589;616702;A;;;
3.349;12;7;95;3p21.31;TCTA;;T-cell leukemia translocation altered gene;600690;Ch;;;
3.350;12;11;02;3p21.31;TMIE, DFNB6;;Transmembrane inner ear-expressed gene;607237;Fd, H;;Deafness, autosomal recessive 6, 600971 (3);?9(sr)
3.351;1;6;14;3p21.31;UBE7, UBE1L;;Ubiquitin-activating enzyme-7;191325;RE;;;
3.352;1;30;01;3p13;GPR27, SREB1;;G protein-coupled receptor 27;605187;R;;;
3.353;11;8;94;3p25.3;HRH1;;Histamine receptor, subclass H1;600167;REa, A;;;6(Hrh1)
3.354;8;25;11;3p14.3;WNT5A;;Wingless-type MMTV integration site family, member 5A;164975;Psh, A;;Robinow syndrome, autosomal dominant 1, 180700 (3);
3.355;3;14;96;3p14.1;TMF1;;TATA element modulatory factor 1;601126;A;;;
3.356;6;30;08;3p14.3;ARHGEF3, XPLN;;RHO guanine nucleotide exchange factor 3;612115;A;;;
3.357;3;11;09;3p21-p13;MPVQTL2;;Mean platelet volume quantitative trait locus 2;612574;Fd;associated with rs12485738;[Mean platelet volume QTL2] (2);
3.358;12;22;14;3q22.3;A4GNT;;Alpha-1,4-N-acetylglucosaminyltransferase;616709;R;;;
3.359;6;2;16;3p14.3;ADHB6;;Abhydrolase domain-containing protein 6;616966;REc;;;
3.360;2;27;17;3p14.3;ACOX2, BRCACOX, CBAS6;;Acyl-Coenzyme A oxidase 2, branched chain;601641;A, Psh;;Bile acid synthesis defect, congenital, 6, 617308 (3);
3.361;12;15;16;3p14.3;ERC2, CAST, KIAA0378;;ELKS/RAB6-interacting/CAST family, member 2;617250;Psh, REc;;;
3.362;7;29;15;3p14.3;FAM208A, RAP140, C3orf63, KIAA1105;;Family with sequence similarity 208, member A;616493;REc, R;;;
3.363;1;31;12;3p14.3;FLNB, SCT, AOI, LRS1;;Filamin B;603381;REa, REc, A, R, Fd;;Spondylocarpotarsal synostosis syndrome, 272460 (3); Larsen syndrome, 150250 (3); Atelosteogenesis, type I, 108720 (3); Atelosteogenesis, type III, 108721 (3); Boomerang dysplasia, 112310 (3);
3.364;7;11;11;3p14.3;HESRG;;Embryonic stem cell-related protein;611473;REc;;;
3.365;3;17;08;3p14.3;PXK, MONAKA;;PXK domain-containing serine/threonine kinase;611450;REc;;;
3.366;9;23;13;3p14.3;RPP14;;Ribonuclease P, 14kD subunit;606112;REc;;;
3.367;2;12;16;3p14.1;SLC25A26, SAMC, COXPD28;;Solute carrier family 25 (mitochondrial carrier, phosphate carrier), member 26;611037;REc;;Combined oxidative phosphorylation deficiency 28, 616794 (3);
3.368;7;22;16;3p21.1;TKT, SDDHD;;Transketolase;606781;REa, A;;Short stature, developmental delay, and congenital heart defects, 617044 (3);
3.369;1;29;01;3p14.1;ADAMTS9;;A disintegrin-like and metalloproteinase with thrombospondin type 1 motif, 9;605421;A, Psh;;;
3.370;6;11;13;3p14.3;IL17RD, SEF, HH18;;Interleukin 17, receptor D (Sef, zebrafish, homolog of);606807;REc;;Hypogonadotropic hypogonadism 18 with or without anosmia, 615267 (3);
3.371;5;28;13;3p14.2;FAM3D;;Family with sequence similarity 3, member D;608619;REc, R;;;
3.372;8;5;02;3p14.2;FRA3B, FHIT;;Fragile histidine triad gene;601153;REf, H;deleted in RCC;;14(Fhit, Fra14A2)
3.373;3;22;93;3p14.2;PTPRG, PTPG;;Protein tyrosine phosphatase, receptor type, gamma polypeptide;176886;REa, A, Fd;;;
3.374;6;1;09;3p14.2;FEZF2, ZNF312, FEZL, TOF;;FEZ family zinc finger 2;607414;REc;;;
3.375;1;11;18;3p14.2;SNTN, S100AL, S100A1L;;Sentan, cilia apical structural protein;617832;REc;;;
3.376;1;22;04;3p14.3;ARF4, ARF2;;ADP-ribosylation factor 4;601177;REc, R;;;
3.377;2;15;12;3p14.1;ATXN7, SCA7, OPCA3;;Ataxin 7;607640;Fd, REc;;Spinocerebellar ataxia 7, 164500 (3);
3.378;2;15;12;3p14.1;ATXN7AS1, SCAANT1;;ATXN7 antisense noncoding transcript 1;614481;REc;;;
3.379;7;12;13;3p14.1;EOGT, EOGT1, C3orf64, AOS4;;EGF domain-specific O-linked N-acetylglucosamine transferase;614789;REc;;Adams-Oliver syndrome 4, 615297 (3);
3.380;5;30;17;3p14.1;FAM19A1, TAFA1;;Family with sequence similarity 19, member A1, CC motif chemokine-like;617495;REc;;;
3.381;5;30;17;3p14.1;FAM19A4, TAFA4;;Family with sequence similarity 19, member A4, CC motif chemokine-like;617498;REc;;;
3.382;4;24;15;3p13;FOXP1, QRF1;;Forkhead box P1;605515;REc;;Mental retardation with language impairment and with or without autistic features, 613670 (3);
3.383;4;26;17;3p14.1;FRMD4B, GRSP1, KIAA1013;;FERM domain-containing protein 4B;617467;REc;;;
3.384;10;23;15;3p14.1;KBTBD8, TAKRP, KIAA1842;;KELCH repeat- and BTB/POZ domain-containing protein 8;616607;REc;;;
3.385;1;5;15;3p14.1;LMOD3, NEM10;;Leiomodin 3;616112;REc;;Nemaline myopathy 10, 616165 (3);
3.386;3;3;09;3p14.1;MAGI1, BAIAP1, WWP3, TNRC19;;Membrane-associated guanylate kinase, WW and PDZ domains-containing, 1;602625;A;;;
3.387;1;30;18;3p14.1;PSMD6, KIAA0107;;Proteasome 26S subunit, non-ATPase, 6;617857;Psh, REc;;;
3.388;5;25;13;3p14.1;SUCLG2;;Succinate-CoA ligase, GDP-forming, beta subunit;603922;REc;;;
3.389;4;23;08;3p14.1;THOC7, NIF3L1BP1;;THO complex, subunit 7;611965;R, REc;;;
3.390;11;27;18;3p14.1;UBE1C, UBA3;;Ubiquitin-activating enzyme E1C;603172;REc;;;
3.391;4;23;07;3p14.1-q12.3;HYT7;;Hypertension, essential, susceptibility to, 7;610948;Fd;;{Hypertension, essential, susceptibility to, 7} (2);
3.392;1;26;17;3p13;MITF, WS2A, CMM8, COMMAD;;Microphthalmia-associated transcription factor;156845;REa, A, Fd;;Waardenburg syndrome, type 2A, 193510 (3); Waardenburg syndrome/ocular albinism, digenic, 103470 (3); Tietz albinism-deafness syndrome, 103500 (3); {Melanoma, cutaneous malignant, susceptibility to, 8}, 614456 (3); COMMAD syndrome, 617306 (3);6(mi)
3.393;1;12;11;3p14.1;ARL6IP5;;ADP-ribosylation-like factor 6-interacting protein 5;605709;REc;;;
3.394;2;16;04;3p21.2;DOCK3;;Dedicator of cytokinesis 3;603123;R, Ch;;;
3.395;2;21;06;3p13;EIF4E3;;Eukaryotic translation initiation factor 4E family, member 3;609896;R, REc;;;
3.396;2;25;09;3p14.1;LRIG1, LIG1;;Leucine-rich repeats- and immunoglobulin-like domains-containing protein 1;608868;A, H;;;6(Lrig1)
3.397;3;25;16;3p14.1;PRICKLE2;;Prickle-like 2;608501;REc;;;
3.398;3;3;10;3p13;EBLN2;;Endogenous Borna-like N element-containing protein 2;613250;REc;;;
3.399;4;20;04;3p14-q13;KTCN3;;Keratoconus 3;608586;Fd;;Keratoconus 3 (2);
3.400;6;14;18;3q13.31;ATP6V1A, HO68, ARCL2D, IECEE3;;ATPase, H+ transporting, V1 subunit A;607027;R, REc;;Cutis laxa, autosomal recessive, type IID, 617403 (3); Epileptic encephalopathy, infantile or early childhood, 3, 618012 (3);
3.401;3;29;10;3p13;GXYLT2, GLT8D4;;Glucoside xylosyltransferase 2;613322;REc;;;
3.402;12;28;08;3p13;PDZRN3, KIAA1095;;PDZ domain-containing ring finger protein 3;609729;REc;;;
3.403;4;7;11;3p13;PPP4R2, PP4R2;;Protein phosphatase 4, regulatory subunit 2;613822;REc;;;
3.404;8;30;09;3p13;RYBP, YEAF1;;Ring1- and YY1-binding protein;607535;R, REc;;;
3.405;4;6;16;3p13;SAMMSON, LINC01212;;Survival-associated mitochondrial melanoma-specific oncogenic noncoding RNA;616895;REc;;;
3.406;12;14;10;3p13;SHQ1;;Shq1, S. cerevisiae, homolog of;613663;REc;;;
3.407;7;22;11;3p14.3;PDHB, PDHBD;;Pyruvate dehydrogenase, E1 beta polypeptide;179060;REa;;Pyruvate dehydrogenase E1-beta deficiency, 614111 (3);
3.408;3;29;07;3p12.3;ROBO2, SAX3, KIAA1568;;Roundabout, Drosophila, homolog of, 2;602431;REc;;Vesicoureteral reflux 2, 610878 (3);16(Robo2)
3.409;6;28;17;3p12.1;CADM2, IGSF4D, SYNCAM2, NECL3;;Cell adhesion molecule 2;609938;REc;;;16(Igsf4d)
3.410;9;21;12;3p12.2;GBE1, GSD4, APBD;;Glycogen branching enzyme;607839;REa;;Glycogen storage disease IV, 232500 (3); Polyglucosan body disease, adult form, 263570 (3);
3.411;8;4;98;3p11.2-p11.1;HTR1F, HTR1EL, MR77;;5-hydroxytryptamine receptor 1F;182134;R, A, Psh;;;
3.412;9;11;02;3p12.3;ROBO1, DUTT1, SAX3;;Roundabout, Drosophila, homolog of, 1;602430;REc, D;;;
3.413;1;24;04;3p11.1;CGGBP1;;CGG triplet repeat binding protein 1;603363;REc, REa, A;;;
3.414;9;28;10;3q11.2;ARL6, BBS3, RP55;;ADP-ribosylation factor-like 6;608845;Fd, REc;mutation identified in 1 RPS55 family;Bardet-Biedl syndrome 3, 600151 (3); {Bardet-Biedl syndrome 1, modifier of}, 209900 (3); ?Retinitis pigmentosa 55, 613575 (3);
3.415;4;30;02;3p12-q13;DYX5;;Dyslexia, susceptibility to, 5;606896;Fd;?same locus as SSD;{Dyslexia, susceptibility to, 5} (2);
3.416;4;6;18;3q13.12-q13.13;IFT57, ESRRBL1, HIPPI, OFD18;;Intraflagellar transport 57, chlamydomonas, homolog of (HIP1 protein interactor);606621;R, REc;mutation identified in 1 OFD18 family;?Orofaciodigital syndrome XVIII, 617927 (3);
3.417;2;10;04;3p12-q13;SSD;;Speech-sound disorder;608445;Fd;?same locus as DYX5;{Speech-sound disorder} (2);
3.418;1;25;11;3p12-q13.2;PBC1;;Biliary cirrhosis, primary, 1;109720;Fd;associated with rs6441286;Biliary cirrhosis, primary, 1 (2);
3.419;5;3;93;3q25.33;IL12A;;Interleukin-12A (natural killer cell stimulatory factor-1, cytotoxic lymphocyte maturation factor-1, p35);161560;REa, Psh;;;
3.420;7;11;93;3q13.31;ZNF80;;Zinc finger protein-80 (pT17);194553;REa;;;
3.421;7;18;12;3p11.2;CHMP2B, DMT1, VPS2B, ALS17;;CHMP family, member 2B;609512;Fd, REc;;Dementia, familial, nonspecific, 600795 (3); Amyotrophic lateral sclerosis 17, 614696 (3);
3.422;8;18;98;3p11.1;EPHA3, ETK1, HEK;;Ephrin receptor EphA3 (human embryo kinase 1);179611;REa, A;;;
3.423;10;2;09;3p11.2;POU1F1, PIT1, CPHD1;;POU domain, class 1, transcription factor 1 (Pit1, growth hormone factor 1);173110;Fd, A;;Pituitary hormone deficiency, combined, 1, 613038 (3);16(Pit1,dw)
3.424;9;11;02;3p;CRCL;;Creatinine clearance QTL;607135;Fd;in African Americans;Creatinine clearance QTL (2);
3.425;8;25;04;3p21.31;MYL3, CMH8;;Myosin, light polypeptide-3, alkali; ventricular, skeletal, slow;160790;REa, H;;Cardiomyopathy, hypertrophic, 8, 608751 (3);9(Mylc)
3.426;11;24;14;3p21.1;PRKCD, CVID9, ALPS3;;Protein kinase C, delta;176977;REa, H;mutation identified in 1 family;Autoimmune lymphoproliferative syndrome, type III, 615559 (3);14(Pkcd)
3.427;9;8;11;3cen-q13;ERVK-5, HERV-KII;;Endogenous retrovirus group K, member 5;614012;R, REc;;;
3.428;9;18;00;3q13.33;COX17;;Cytochrome c oxidase assembly protein COX17;604813;R;pseudogene on chr. 13?;;
3.429;10;20;99;3q12.3;RPL24;;Ribosomal protein L24;604180;REa, R;;;
3.430;5;1;91;3q21.3;RPN1;;Ribophorin I;180470;REa, Ch;;;6(Rpn1)
3.431;10;7;14;3q12.2;TFG, HMSNP, SPG57;;TRK-fused gene;602498;A;fused with NR4A3 or NTRK1; mutation identified in 1 SPG57 family;Hereditary motor and sensory neuropathy, Okinawa type, 604484 (3); ?Spastic paraplegia 57, autosomal recessive, 615658 (3);
3.432;11;19;09;3q11.1-q11.2;ARL13B, ARL2L1, JBTS8;;ADP-ribosylation factor-like 13B;608922;REc;;Joubert syndrome 8, 612291 (3);
3.433;10;13;15;3q11.2;DHFRL1;;Dihydrofolate reductase-like 1;616588;REc;;;
3.434;5;25;13;3q11.2;EPHA6, HEK12, EHK2;;Ephrin receptor EphA6;600066;REc;;;
3.435;12;30;14;3q12.3;IMPG2, IPM200, RP56, VMD5;;Interphotoreceptor matrix proteoglycan 2;607056;R, A;;Retinitis pigmentosa 56, 613581 (3); Macular dystrophy, vitelliform, 5, 616152 (3);
3.436;5;30;17;3q11.2;NSUN3;;NOP2/SUN RNA methyltransferase family, member 3;617491;REc;;;
3.437;3;1;12;3q11.1;PROS1, THPH5, THPH6;;Protein S, alpha;176880;REa, REc;pseudogene PROSP contiguous on chr.3;Thrombophilia due to protein S deficiency, autosomal dominant, 612336 (3); Thrombophilia due to protein S deficiency, autosomal recessive, 614514 (3);
3.438;4;1;96;3q11.2;GPR15;;G protein-coupled receptor-15;601166;A;;;
3.439;3;16;10;3q11.2-q13.12;CAMPD1;;Camptodactyly 1;114200;Fd;between D3S2465 and D3S3044;Camptodactyly 1 (2);
3.440;4;30;09;3q11.2;CPOX;;Coproporphyrinogen oxidase;612732;REa, A;;Coproporphyria, 121300 (3); Harderoporphyria, 121300 (3);
3.441;9;27;01;3q12.2;TARSH;;Target of Nesh-SH3;606279;R;;;
3.442;8;20;07;3q12.1;TMEM30C, CDC50C;;Transmembrane protein 30C;611030;REc;;;
3.443;11;28;88;3q13.2;MOX2;;MRC OX-2 antigen;155970;REa, A;;;
3.444;7;11;91;3q12.1;COL8A1;;Collagen VIII, alpha-1 polypeptide;120251;A;;;
3.445;2;21;13;3q12.1;DCBLD2, ESDN;;Discoidin, CUB, and LCCL domain-containing protein 2;608698;REc, Psh;;;
3.446;9;2;09;3q12.1;FILIP1L;;Filamin A-interacting protein 1-like;612993;REc;;;
3.447;6;10;08;3q11.2;MINA, MINA53, MDIG;;MYC-induced nuclear antigen;612049;REc;;;
3.448;8;30;09;3q12.1;ST3GAL6, ST3GALVI;;ST3 beta-galactoside alpha-2,3-sialyltransferase 6;607156;R, REc;;;
3.449;10;1;17;3q12.1-q12.2;TBC1D23, PCH11;;TBC1 domain family, member 23;617687;REc;;Pontocerebellar hypoplasia, type 11, 617695 (3);
3.450;7;17;14;3q12.3;CEP97;;Centrosomal protein, 97kD;615864;REc;;;
3.451;9;1;16;3q12.2;ADGRG7, GPR128;;Adhesion G protein-coupled receptor G7;612307;REc;;;
3.452;1;29;16;3q12.2;NIT2;;Nitrilase family member 2;616769;REc;;;
3.453;4;27;16;3q12.2;TMEM45A, DERP7, DNAPTP4;;Transmembrane protein 45A;616928;REc;;;
3.454;9;27;17;3q12.2;TOMM70A;;Translocase of outer mitochondrial membrane 70, yeast, homolog of, A;606081;REc, R;;;
3.455;8;19;13;3q21.3;CHST13, C4ST3;;Carbohydrate sulfotransferase 13;610124;REc;;;
3.456;5;6;13;3q12.3;PCNP;;PEST-containing nuclear protein;615210;REc;;;
3.457;7;9;09;3q12.3;SENP7, KIAA1707;;Sentrin-specific protease family, member 7;612846;REc;;;
3.458;6;17;16;3q12.3;TRMT10C, RG9MTD1, MRPP1, COXPD30;;tRNA methyltransferase 10, S. cerevisiae, homolog of, C;615423;REc;;Combined oxidative phosphorylation deficiency 30, 616974 (3);
3.459;11;09;18;3q12.3;ZBTB11;;Zinc finger- and BTB domain-containing protein 11;618181;REc;;;
3.460;8;18;14;3q12.3;ZPLD1;;Zona pellucida-like domain-containing protein 1;615915;REc;;;
3.461;8;28;09;3q13.31;GAP43;;Neuron growth-associated protein 43;162060;REa, REc;;;16(Gap43)
3.462;5;22;03;3q13.2;GCET2, HGAL;;Germinal center-expressed transcript 2;607792;REc;;;
3.463;10;18;10;3q13.33;GOLGB1, GCP372;;Golgi autoantigen, golgin subfamily B, 1;602500;REc;;;
3.464;9;29;96;3q13.33;HCLS1;;Hematopoietic cell-specific Lyn substrate 1;601306;A;;;
3.465;9;21;11;3q21.1-q21.2;KALRN, HAPIP, DUO, CHDS5;;Kalirin;604605;Fd, REc;;{Coronary heart disease, susceptibility to, 5}, 608901 (3);
3.466;4;14;05;3q27.1;MAGEF1;;Melanoma antigen, family F, 1;609267;Psh, REc;;;
3.467;1;28;00;3q13.13;MORC1;;MORC family CW-type zinc finger 1 (microrchidia, mouse, homolog of);603205;H, A;;;16(Morc)
3.468;6;28;17;3q13.13;NECTIN3, PVRL3, PRR3;;Nectin 3;607147;R, REc;;;
3.469;5;25;00;3q13.13;TRAT1, TRIM;;T-cell receptor-associated transmembrane adaptor 1;604962;A;;;
3.470;4;16;11;3q21.2;UMPS, OPRT;;Uridine monophosphate synthetase (orotate phosphoribosyl transferase and orotidine-5'-decarboxylase);613891;S, A;;Orotic aciduria, 258900 (3);
3.471;1;3;02;3q13.33;NR1I2, PXR, SXR, PARq;;Nuclear receptor subfamily 1, group I, member 2;603065;R, A;;;
3.472;1;13;09;3q13.2;CD200R1, MOX2R, OX2R;;CD200 receptor 1;607546;REc;;;
3.473;12;13;00;3q13.13;GUCA1C, GCAP3;;Guanylate cyclase activator 1C;605128;Psh, A;;;
3.474;11;25;96;3q13.1;MHS4;;Malignant hyperthermia susceptibility 4;600467;Fd;;{Malignant hyperthermia susceptibility 4} (2);
3.475;12;10;15;3q13.11;CBLB;;CAS-BR-M murine ecotropic retroviral transforming sequence B;604491;Psh, A;;;
3.476;7;20;09;3q12.3;NFKBIZ, INAP, MAIL, IKBZ;;Nuclear factor of kappa light chain gene enhancer in B cells inhibitor, zeta;608004;REc;;;16(Inap)
3.477;2;19;97;3q13.11;ALCAM;;Activated leukocyte cell adhesion molecule;601662;A;;;
3.478;3;24;06;3p12.1;VGLL3, VGL3;;Vestigial-like 3;609980;REc;;;
3.479;1;14;00;3q13.12;CD47, MER6, IAP;;CD47 antigen (Rh-related antigen; integrin-associated protein);601028;S, A;;;
3.480;10;28;15;3q13.12;DUBR, DUM, LINC0883;;DPPA2 upstream-binding RNA, noncoding;616619;REc;;;16(Dubr)
3.481;8;25;11;3q13.1-q13.2;CD96, TACTILE;;CD96 antigen;606037;R, REc, Ch;;C syndrome, 211750 (3);
3.482;5;17;18;3q13.13;CIP2A, KIAA1524, p90;;Cell proliferation-regulating inhibitor of protein phosphatase 2A;610643;R, REc;;;
3.483;1;30;12;3q13.13;DPPA2, PESCRG1, ECAT15-2;;Developmental pluripotency-associated gene 2;614445;REc;;;16(Dppa2)
3.484;7;27;11;3q13.13;DPPA4;;Developmental pluripotency-associated gene 4;614125;REc;;;
3.485;7;13;17;3q13.13;DZIP3, KIAA0675;;DAZ-interacting zinc finger protein 3;608672;Psh, REc;;;
3.486;5;25;13;3q13.13;HHLA2;;Human endogenous retrovirus-H long terminal repeat-associating 2;604371;REc;;;
3.487;3;1;06;3q13.13;MYH15;;Myosin, heavy chain 15;609929;REc;;;
3.488;7;14;14;3q13.13;RETNLB, RELMB, FIZZ2;;Resistin-like protein, beta;605645;REc;;;
3.489;11;05;18;3q13.2;BOC;;Brother of CDON;608708;R;;;
3.490;2;25;15;3q13.2;BTLA;;B- and T-lymphocyte attenuator;607925;REc;;;
3.491;4;23;08;3q13.2;C3orf52, TTMP;;Chromosome 3 open reading frame 52;611956;REc;;;
3.492;7;24;17;3q13.2;CFAP44, WDR52, SPGF20;;Cilia- and flagella-associated protein 44;617559;REc;mutation identified in 1 SPGF20 patient;?Spermatogenic failure 20, 617593 (3);
3.493;3;6;07;3q13.31;NAT13, NAT5, SAN;;N-acetyltransferase 13;610834;REc;;;
3.494;8;30;16;3q13.2;NEPRO, C3orf17;;Nucleolus and neural progenitor protein;617089;REc;;;
3.495;5;24;13;3q13.2;PHLDB2;;Pleckstrin homology-like domain, family B, member 2;610298;REc, R;;;
3.496;7;1;16;3q13.2;PLCXD1;;Phospholipase C, phosphatidylinositol-specific, X domain-containing protein 2;617015;REc;;;
3.497;7;2;18;3q13.2;SIDT1;;SID1 transmembrane family, member 1;606816;REc;;;
3.498;4;30;09;3q13.2;SLC9A10;;Solute carrier family 9, member 10;612738;REc;;;
3.499;11;3;11;3q13.2;SPICE1, CCDC52;;Spindle- and centriole-associated protein 1;613447;REc;;;
3.500;9;9;13;3q13.2;TAGLN3, NP24, NP22;;Transgelin 3;607953;REc, R;;;
3.501;12;5;03;3q13.2;URB, SSG1;;Urb, mouse, homolog of;608298;R, H, REc;;;16(Urb)
3.502;7;11;17;3q13.2;USF3;;Upstream transcription factor family, member 3;617568;REc;;;
3.503;5;28;13;3q13.13;ZBED2;;Zinc finger BED domain-containing protein 2;615246;REc;;;
3.504;9;16;14;3q13.31;ZBTB20, ZNF288, DPZF, PRIMS;;Zinc finger and BTB-domain containing 20;606025;A, R;;Primrose syndrome, 259050 (3);
3.505;2;28;03;3q13.33;PLA1A, PSPLA1;;Phosphatidylserine-specific phospholipase A1-alpha;607460;A, H;;;16(Pla1a)
3.506;6;7;12;3q13.2-q13.33;STUT3;;Stuttering, familial persistent, 3;614655;Fd;max lod at D3S1310;Stuttering, familial persistent, 3 (2);
3.507;8;31;12;3q21.1;ADCY5, FDFM;;Adenylate cyclase-5;600293;REa, A;;Dyskinesia, familial, with facial myokymia, 606703 (3);16(Adcy5)
3.508;11;3;98;3q13.31;LSAMP, LAMP;;Limbic system-associated membrane protein;603241;A;;;16(Lsamp)
3.509;5;4;12;3q13.32-q13.33;ARHGAP31, CDGAP, KIAA1204, AOS1;;Rho GTPase-activating protein 31;610911;R, REc;;Adams-Oliver syndrome 1, 100300 (3);
3.510;7;9;07;3q13.33;ARGFX;;Arginine-fifty homeobox;611164;REc;pseudogenes on 5q23.2 and 17q11.2;;
3.511;8;9;99;3q13.32;B4GALT4;;Beta-1,4-galactosyltransferase 4;604015;REc;;;
3.512;11;22;17;3q13.31;DRD3, ETM1, FET1;;Dopamine receptor D3;126451;REb, A;;{Schizophrenia, susceptibility to}, 181500 (3); {Essential tremor, hereditary, 1}, 190300 (3);
3.513;5;3;13;3q13.33;FSTL1, FRP, MIR198;;Follistatin-like 1;605547;R, REc;FSTL1 mRNA can encode a protein or produce an micoRNA;;
3.514;5;25;00;3q13.33;GSK3B;;Glycogen synthase kinase 3-beta;605004;A, R, Psh;;;
3.515;8;27;08;3q21.2;MUC13;;Mucin 13, cell surface-associated;612181;A;;;
3.516;5;4;00;3q13.33;POLQ;;Polymerase, DNA, theta;604419;R;;;
3.517;10;15;09;3q13.33;POPDC2, POP2;;Popeye domain-containing protein 2;605823;R, REc;;;
3.518;5;26;05;3q13.33;STXBP5L, LLGL4;;Syntaxin-binding protein 5-like;609381;REc;;;
3.519;7;13;09;3q13.31;TIGIT;;T-cell immunoreceptor with immunoglobulin and ITIM domains;612859;REc;;;
3.520;4;15;11;3q22.1;TRH;;Thyrotropin-releasing hormone;613879;REa, H, A;;Thyrotropin-releasing hormone deficiency, 275120 (1);6(Trh)
3.521;4;23;98;3q13.32;UPK1B;;Uroplakin 1B;602380;A;;;
3.522;4;17;13;3q13.33;MAATS1, AAT1, C3orf15;;MYCBP-associated testis-expressed protein 1;609910;REc;;;
3.523;9;29;13;3q13.31;DEL3q13.31, C13DELq13.31;;Chromosome 3q13.31 deletion syndrome;615433;Ch;;Chromosome 3q13.31 deletion syndrome (4);
3.524;10;24;14;3q13.31;TUSC7, LSAMPAS3, LOC285194;;Tumor suppressor candidate 7, noncoding;616057;REc;;;
3.525;2;2;17;3q13.31;ZDHHC23, NIDD;;Zinc finger DHHC-type containing 23;617334;REc;;;
3.526;6;13;12;3q13.33;ADPRH;;ADP-ribosylarginine hydrolase;603081;REc;;;
3.527;11;11;14;3q13.33;EAF2;;ELL-associated factor 2;607659;REc;;;
3.528;4;19;12;3q13.33;GPR156, GABABL;;G protein-coupled receptor 156;610464;REc;;;
3.529;8;8;13;3q13.33;GTF2E1, TF2E1;;General transcription factor IIE, polypeptide 1;189962;REc;;;
3.530;4;29;14;3q13.33;HGD, AKU;;Homogentisate 1,2-dioxygenase (homogentisate oxidase);607474;Fd, H, Psh, A, REc;;Alkaptonuria, 203500 (3);16(aku)
3.531;1;18;18;3q13.33;IQCB1, NPHP5, KIAA0036;;IQ motif-containing protein B1;609237;REc;;Senior-Loken syndrome 5, 609254 (3);
3.532;5;25;13;3q13.33;NDUFB4;;NADH-ubiquinone oxidoreductase 1 beta subcomplex, 4;603840;REc;;;
3.533;09;27;18;3q13.33;POGLUT1, CLP46, KTELC1, RUMI, C3orf9, DDD4, LGMDR21;;Protein O-glucosyltransferase 1;615618;REc;mutation identified in 1 LGMDR21 family;Dowling-Degos disease 4, 615696 (3); ?Muscular dystrophy, limb-girdle, autosomal recessive 21, 617232 (3);
3.534;10;2;12;3q13.33;SLC15A2, PEPT2;;Solute carrier family 15 (H+/peptide transporter), member 2;602339;REc;;;
3.535;12;13;18;3q13.33;TIMMDC1, C3orf1, MC1DN31;;Translocase of inner mitochondrial membrane domain-containing protein 1;615534;REc;;Mitochondrial complex I deficiency, nuclear type 31, 618251 (3);
3.536;12;4;03;3q21.3;ABTB1, BPOZ;;Ankyrin repeat and BTB/POZ domain containing 1;608308;R;;;
3.537;4;1;01;3q21;ATOD1;;Dermatitis, atopic, 1;603165;Fd;max lod at D3S3606;{Dermatitis, atopic, susceptibility to, 1} (2);
3.538;12;9;95;3q13.33;CD80, CD28LG, LAB7;;CD80 antigen (CD28 antigen ligand 1, B7-1 antigen);112203;REa, Psh, A;;;3(Cd80)
3.539;3;2;98;3q13.33;CD86, CD28LG2, LAB72;;CD86 antigen (CD28 antigen ligand 2, B7-2 antigen);601020;A;;;16(Cd86)
3.540;10;23;15;3q22.1;COL6A4P2;;Collagen, type VI, alpha-4, pseudogene 2;616612;REc;;;9(Col6a4)
3.541;10;23;15;3q22.1;COL6A5, COL29A1;;Collagen, type VI, alpha-5;611916;REc;;;
3.542;10;24;15;3q22.1;COL6A6;;Collagen, type VI, alpha-6;616613;REc;;;9(Col6a6)
3.543;1;13;16;3q21.1;CSTA, STFA, STF1, AREI, PSS4;;Cystatin A (stefin A);184600;REa, D;;Peeling skin syndrome 4, 607936 (3);16(Stf1)
3.544;10;30;02;3q21.1;DIRC2, RCC4;;Disrupted in renal carcinoma 2;602773;Ch, REc;t(2;3)(q35;q21) in renal cell carcinoma;Renal cell carcinoma, 144700 (1);
3.545;12;21;09;3q21.1;DTX3L, BBAP;;DTX3-like;613143;REc;head-to-head with PARP9;;
3.546;7;8;10;3q21;FGQTL6, BWQTL3, PGQTL1;;Fasting plasma glucose level QTL 6; Birth weight QTL 3; Plasma glucose, 2-hour, QTL 1;613460;Fd;associated with rs11708067 and rs11708067;[Fasting plasma glucose level QTL 6] (2); [Birth weight QTL 3] (2); [Plasma glucose, 2-hour, QTL 1] (2);
3.547;12;19;05;3q21.3;GP9;;Glycoprotein IX, platelet;173515;REb, REc;;Bernard-Soulier syndrome, type C, 231200 (3);
3.548;4;10;14;3q21.3;GATA2, DCML, MONOMAC, IMD21;;GATA-binding protein-2;137295;REa, REc;;Immunodeficiency 21, 614172 (3); Emberger syndrome, 614038 (3); {Myelodysplastic syndrome, susceptibility to}, 614286 (3); {Leukemia, acute myeloid, susceptibility to}, 601626 (3);6(Gata2)
3.549;6;5;12;3q21.3-q22.1;IFT122, WDR10, CED1;;Intraflagellar transport 122, homolog of;606045;A;;Cranioectodermal dysplasia 1, 218330 (3);
3.550;2;14;01;3q21.1;KPNA1, RCH2, SRP1;;Karyopherin, alpha-1;600686;A;;;
3.551;9;16;16;3q22.2;KY, MFM7;;Kyphoscoliosis peptidase;605739;R;;Myopathy, myofibrillar, 7, 617114 (3);9(ky)
3.552;12;18;18;3q21.3;LINC01565;;Long intergenic noncoding RNA 1565;618259;REc;;;
3.553;6;2;16;3q21.3;MCM2, CDCL1, DFNA70;;Minichromosome maintenance deficient, S. cerevisiae, 2, homolog of (mitotin);116945;A;mutation identified in 1 DFNA70 family;?Deafness, autosomal dominant 70, 616968 (3);
3.554;3;10;11;3q21.1;MYLK, MLCK, AAT7;;Myosin-light-polypeptide kinase;600922;Psh, REc;pseudogene on 3p13;Aortic aneurysm, familial thoracic 7, 613780 (3);
3.555;10;26;98;3q22.3;NCK;;Non-catalytic region of tyrosine kinase;600508;A, REn, REa;;;
3.556;6;10;08;3q21.1;PARP9, BAL1, BAL;;Poly(ADP-ribose) polymerase 9;612065;A, REa, REc, REn;;;
3.557;6;24;08;3q21.1;PARP15, BAL3;;Poly(ADP-ribose) polymerase 15;612066;REc;;;
3.558;12;14;99;3q21;PSORS5;;Psoriasis susceptibility 5;604316;Fd;;{Psoriasis susceptibility 5} (2);
3.559;3;3;03;3q21.3;RAB7, CMT2B, PSN;;Ras-associated protein RAB7;602298;Psh, A, Fd;;Charcot-Marie-Tooth disease, type 2B, 600882 (3);9(Rab7)
3.560;6;16;99;3q21.3;RUVBL1, NMP238, TIP49;;RUVB, E. coli, homolog-like 1;603449;A;;;
3.561;1;24;12;3q22.1-q22.2;SLCO2A1, OATP2A1, PGT, SLC21A2, PHOAR2;;Solute carrier organic anion transporter family, member 2A1;601460;Psh, A;;Hypertrophic osteoarthropathy, primary, autosomal recessive 2, 614441 (3);
3.562;9;1;11;3q22.1;TF, TFQTL1;;Transferrin;190000;S, H, REa, D, A;;Atransferrinemia, 209300 (3);9(Trf)
3.563;2;22;07;3q21.3;TXNRD3, TRXR3, TR2;;Thioredoxin reductase 3;606235;REc;;;
3.564;12;22;16;3q21.2;ZNF148, ZFP148, GDACCF;;Zinc finger protein-148;601897;REc, A;;Global developmental delay, absent or hypoplastic corpus callosum, and dysmorphic facies, 617260 (3);
3.565;12;27;01;3q21.3;KLF15, KKLF;;Kruppel-like factor 15;606465;A;;;
3.566;11;2;99;3q21.3;MBD4, MED1;;Methyl-CpG-binding domain protein 4;603574;A;;;6(Mdb4)
3.567;12;13;06;3q21-q22;HCFP1, MBS2;;Facial paresis, hereditary congenital, 1;601471;Fd;;Facial paresis, hereditary congenital, 1 (2);
3.568;12;23;05;3q22.1;NEK11;;Never in mitosis gene A-related kinase 11;609779;REc;;;
3.569;6;21;01;3q22.3;PCCB;;Propionyl Coenzyme A carboxylase, beta polypeptide;232050;REa, A, D;pccB complementation group;Propionicacidemia, 606054 (3);
3.570;12;22;89;3q23;RBP1, CRBP1;;Retinol-binding protein-1, cellular;180260;REa, A;close to CRBP2;;9(Crbp)
3.571;10;4;93;3q22.1;ACPP;;Acid phosphatase, prostate;171790;REa, A;;;
3.572;11;5;97;3q22.2;EPHB1, EPHT2, NET;;eph tyrosine kinase 2 (ephrin receptor EphB1);600600;Psh, A;;;
3.573;5;29;12;3q23;GRK7, GPRK7;;G protein-coupled receptor kinase 7;606987;R;;;
3.574;12;29;99;3q22.1;ATP2C1, BCPM, HHD;;ATPase, Ca(2+)-sequestering;604384;Fd, REc;;Hailey-Hailey disease, 169600 (3);
3.575;6;4;97;3q21-q24;GLC1C;;Glaucoma 1, open angle, C;601682;Fd;;Glaucoma 1C, primary open angle (2);
3.576;6;27;02;3q23;PCOLCE2;;Procollagen C-endopeptidase enhancer-2;607064;REc;;;
3.577;1;31;13;3q22.1;RHO, RP4, OPN2, CSNBAD1;;Rhodopsin (opsin 2);180380;REa, A, Fd;;Retinitis pigmentosa 4, autosomal dominant or recessive, 613731 (3); Night blindness, congenital stationary, autosomal dominant 1, 610445 (3); Retinitis punctata albescens, 136880 (3);6(Rho)
3.578;5;19;15;3q24;AGTR1, AGTR1A, AT2R1;;Angiotensin receptor 1;106165;REa;;{Hypertension, essential}, 145500 (3); Renal tubular dysgenesis, 267430 (3);
3.579;5;24;12;3q22.1;BFSP2, CP49, CP47, CTRCT12;;Beaded filament structural protein 2 (cytoskeletal protein, 49 kD);603212;REa;;Cataract 12, multiple types, 611597 (3);
3.580;8;25;11;3q25.1;CLRN1, USH3A, USH3, RP61;;Clarin 1;606397;Fd, REc;frequent in Finland; ?digenic interaction with MYO7A;Usher syndrome, type 3A, 276902 (3); Retinitis pigmentosa 61, 614180 (3);3(Ush3)
3.581;1;27;11;3q25.1;MED12L, NOPAR, KIAA1635;;Mediator complex subunit 12-like;611318;Psh, REc;;;
3.582;2;3;99;3q25.1;TM4SF1, M3S1, TAAL6;;Transmembrane-4 superfamily, member 1;191155;REa;;;
3.583;9;8;11;3q21-q25.2;ERVK-4, HERV-KI;;Endogenous retrovirus group K, member 4;614011;R, REc;;;
3.584;8;22;16;3q25.2;MME, CD10, CALLA, NEP, CMT2T, SCA43;;Membrane metallo-endopeptidase (common acute lymphocytic leukemia antigen);120520;REa, A;mutation identified in 1 SCA43 family;Charcot-Marie-Tooth disease, axonal, type 2T, 617017 (3); ?Spinocerebellar ataxia 43, 617018 (3);9(Mme)
3.585;1;1;95;3q27.3;SIAT1;;Sialyltransferase-1 (beta-galactoside alpha-2,6-sialyltransferase);109675;REa, A;;;
3.586;4;6;18;3q26.2;TERC, TRC3, TR, DKCA1, PFBMFT2;;Telomerase RNA component;602322;H, Fd;;Dyskeratosis congenita, autosomal dominant 1, 127550 (3); {Aplastic anemia}, 614743 (3); {Pulmonary fibrosis, idiopathic, susceptibility to}, 614743 (3);3(Terc)
3.587;10;15;97;3q27.1;EPHB3, ETK2;;EPH-like tyrosine kinase-2;601839;Psh;;;
3.588;12;2;99;3q21.3;PLXNA1, NOVP, NOV, PLXN1;;Plexin A1 (NOV transmembrane protein);601055;REa;;;
3.589;12;22;87;3q23;RBP2, CRBP2;;Retinol-binding protein-2, cellular;180280;REa;close to CRBP1;;9(Crbp2)
3.590;10;22;18;3q13.3-q21.1;CASR, HHC1, PCAR1, FIH, EIG8, HYPOC1;;Calcium-sensing receptor;601199;Fd, REa;15cM from RHO;Hypocalciuric hypercalcemia, type I, 145980 (3); Hyperparathyroidism, neonatal, 239200 (3); Hypocalcemia, autosomal dominant, 601198 (3); Hypocalcemia, autosomal dominant, with Bartter syndrome, 601198 (3); {Epilepsy idiopathic generalized, susceptibility to, 8}, 612899 (3);16(Gprc2a)
3.591;10;11;16;3q21.1;CCDC14;;Coiled-coil domain-containing protein 14;617147;REc;;;
3.592;09;06;18;3q21.1;FAM162A, ,C3orf28, E2IG5;;Family with sequence similiarity 162, member A;608017;R, REc;;;
3.593;9;9;08;3q13.33;FBXO40, FBX40, KIAA1195;;F-box only protein 40;609107;R, REc;;;16(Fbxo40)
3.594;3;28;11;3q13.33;ILDR1, DFNB42;;Immunoglobulin-like domain-containing receptor 1;609739;REc;;Deafness, autosomal recessive 42, 609646 (3);
3.595;11;01;07;3q21.2;OSBPL11, ORP11;;Oxysterol-binding protein-like protein 11;606739;REc;previously assigned to chr.8;;
3.596;4;19;06;3q21.1;PARP14, KIAA1268;;Poly(ADP-ribose) polymerase 14;610028;R, REc;;;
3.597;5;11;16;3q21.1;PDIA5, PDIR;;Protein disulfide isomerase, family A, member 5;616942;REc;;;
3.598;8;18;14;3q21.1;PTPLB, HACD2;;Protein tyrosine phosphatase-like (proline instead of catalytic arginine), member B;615939;REc;;;
3.599;1;28;08;3q21.1;ROPN1, ODF6;;Rhophilin-associated tail protein 1;611757;REc;;;
3.600;11;25;08;3q21.1;SEC22A, SEC22L2;;Secretion deficient 22, S. cerevisiae, homolog of, A;612442;R, REc;;;
3.601;9;6;11;3q21.2;HEG1, KIAA1237;;Heart of glass, zebrafish, homolog of, 1;614182;REc;;;
3.602;7;14;14;3q21.2;ITGB5;;Integrin, beta-5;147561;REc;;;
3.603;8;26;15;3p14.3;PDE12;;Phosphodiesterase 12;616519;REc;;;
3.604;3;8;07;3q21.2-q21.3;SLC41A3;;Solute carrier family 41, member 3;610803;R, REc;;;
3.605;8;30;09;3q21.2;SNX4;;Sorting nexin 4;605931;R, REc;;;
3.606;1;27;11;3q21.3;ALDH1L1, FTHFD;;Aldehyde dehydrogenase 1 family, member L1;600249;REc;;;
3.607;2;13;14;3q21.3;CHCHD6, CHCM1;;Coiled-coil-helix-coiled-coil-helix domain-containing protein 6;615634;REc;;;
3.608;7;19;18;3q21.3;CNBP, ZNF9, CNBP1, DM2, PROMM;;CCHC-type zinc finger nucleic acid-binding protein;116955;REa, A, Fd;;Myotonic dystrophy 2, 602668 (3);
3.609;11;19;13;3q21.3;COPG1;;Coatomer protein complex, subunit gamma-1;615525;REc;;;
3.610;6;21;13;3q21.3;DNAJB8, DJ6;;DNAJ/HSP40 homolog, subfamily B, member 8;611337;REc, R;;;
3.611;9;9;13;3q21.3;EEFSEC, SELB, EFSEC;;Eukaryotic elongation factor, selenocysteine-tRNA-specific;607695;REc;;;
3.612;11;11;14;3q21.3;H1FX, H1X;;H1 histone family, member X;602785;REc;;;
3.613;5;12;09;3q21.3;ISY1, KIAA1160;;ISY1 splicing factor, S. cerevisiae, homolog of;612764;R, REc;;;
3.614;10;29;15;3q21.3;PODXL2, EG;;Podocalyxin-like 2;616627;REc;;;
3.615;01;04;19;3q21.3;SEC61A1, SEC61, HNFJ4;;Sec61 translocon, alpha-1 subunit;609213;REc;;Hyperuricemic nephropathy, familial juvenile, 4, 617056 (3);
3.616;5;12;15;3q21.3;UROC1, UROCD;;Urocanase domain-containing protein 1;613012;REc;mutation identified in 1 UROCD patient;?Urocanase deficiency, 276880 (3);
3.617;5;22;14;3q21.3;ZXDC;;ZCD family zinc finger protein C;615746;REc;;;
3.618;6;4;98;3q25.1;AADAC, DAC;;Arylacetamide deacetylase (esterase);600338;R;;;
3.619;8;11;15;3q22.1;ACKR4, CCRL1, PPR1;;Atypical chemokine receptor 4;606065;A;;;
3.620;6;19;01;3q22;DFNA18;;Deafness, autosomal dominant 18;606012;Fd;;Deafness, autosomal dominant 18 (2);
3.621;6;20;17;3q22.3;FAIM;;Fax apoptotic inhibitory molecule;617535;REc;;;
3.622;9;9;10;3q22.1;NPHP3, NPH3, RHPD1, MKS7;;Nephrocystin 3;608002;Fd, REc;;Nephronophthisis 3, 604387 (3); Renal-hepatic-pancreatic dysplasia 1, 208540 (3); Meckel syndrome 7, 267010 (3);
3.623;7;22;16;3q22;PARK21;;Parkinson disease 21;616361;Fd;conflicting mapping on 20pter-p12;Parkinson disease 21 (2);
3.624;8;28;09;3q22.1;PLXND1;;Plexin D1;604282;REn, REc;;;
3.625;3;31;15;3q22.2-q22.3;PP2R3A, PR72, PR130;;Protein phosphatase 2, regulatory subunit B'', alpha;604944;R, REc;;;
3.626;9;4;02;3q22;SLSN3;;Senior-Loken syndrome 3;606995;Fd;?allelic with NPHP3;Senior-Loken syndrome 3 (2);
3.627;10;11;16;3q22.1;UBA5, UBE1DC1, EIEE44, SCAR24;;Ubiquitin-like modifier activating enzyme 5;610552;REc;mutation identified in 1 SCAR24 family;Epileptic encephalopathy, early infantile, 44, 617132 (3); ?Spinocerebellar ataxia, autosomal recessive 24, 617133 (3);
3.628;4;13;98;3q23;ATP1B3;;ATPase, Na+/K+ transporting, beta 3 polypeptide;601867;A;;;9(Atp1b3)
3.629;1;21;97;3q23;RASA2, GAP1M;;RAS p21 protein activator 2;601589;A;;;
3.630;8;30;07;3q22-q24;AD15;;Alzheimer disease 15;611155;Fd;max lod at D3S1579;{Alzheimer disease-15} (2);
3.631;1;6;12;3q23;ATR, FRP1, SCKL1, FCTCS;;Ataxia-telangiectasia and Rad3-related (FRAP-related protein-1);601215;A, Fd;mutation identified in 1 FCTCS family;Seckel syndrome 1, 210600 (3); ?Cutaneous telangiectasia and cancer syndrome, familial, 614564 (3);
3.632;4;20;11;3q22-q24;DWS, C3DELq22q24, DEL3q22q24;;Dandy-Walker syndrome;220200;Ch;ZIC1 and ZIC4 good candidate genes;Dandy-Walker syndrome (4);
3.633;6;12;07;3q22-q24;OTSC5;;Otosclerosis 5;608787;Fd;max lod at D3S1569;Otosclerosis 5 (2);
3.634;8;9;99;3q23;RNF7, ROC2, SAG;;RING finger protein-7 (regulator of cullins 2; sensitive to apoptosis gene);603863;A;;;
3.635;4;23;98;3q23;TRPC1, TRP1;;Transient receptor potential channel 1;602343;A;also called Htrp-1;;
3.636;5;4;00;3q22-q25;PABPL1;;Polyadenylate-binding protein-like 1;173865;A;;;
3.637;10;18;11;3q22.1;ACAD11;;Acyl-CoA dehydrogenase family, member 11;614288;REc;;;
3.638;5;25;13;3q22.1;CPNE4, CPN4;;Copine IV;604208;REc;;;
3.639;7;13;16;3q22.1;DNAJC13, RME8, KIAA0678;;DNAJ/HSP40 homolog, subfamily C, member 13;614334;R, REc;;;
3.640;4;27;12;3q22.1;MRPL3, MRL3, COXPD9;;Mitochondrial ribosomal protein L3;607118;R, REc;;Combined oxidative phosphorylation deficiency 9, 614582 (3);
3.641;3;18;17;3q22.1;NUDT16;;Nudix hydrolase 16;617381;REc;;;
3.642;9;27;17;3q22.1;PIK3R4;;Phosphatidylinositol 3-kinase, regulatory subunit 4;602610;REc;;;
3.643;7;18;14;3q22.1;RAB6B;;Ras-associated protein RAB6B;615852;REc;;;
3.644;3;29;16;3q22.1;SRPRB, APMCF1;;Signal recognition particle receptor, beta subunit;616883;REc;;;
3.645;1;4;16;3q22.1;TMCC1, KIAA0779;;Transmembrane and coiled-coil domain family 1;616242;REc;;;
3.646;2;24;17;3q22.1;TMEM108, RTLN, KIAA1690;;Transmembrane protein 108;617361;REc;;;
3.647;8;30;09;3q22.1;TOPBP1, KIAA0259;;DNA topoisomerase II-binding protein 1;607760;R, REc;;;
3.648;5;29;12;3q22.2;AMOTL2, KIAA0989;;Angiomotin-like 2;614658;REc;;;
3.649;2;23;12;3q22.2;ANAPC13, APC13, SWM1;;Anaphase-promoting complex, subunit 13;614484;REc;;;
3.650;3;7;14;3q22.2;CEP63, SCKL6;;Centrosomal protein, 63kD;614724;REc;mutation identified in 1 family;?Seckel syndrome 6, 614728 (3);
3.651;10;2;12;3q22.2;RYK, RYK1;;RYK receptor-like tyrosine kinase;600524;REc, Ch;;;9(Ryk1)
3.652;10;25;11;3q22.3;CEP70;;Centrosomal protein, 70kD;614310;REc;;;
3.653;9;20;14;3q22.3;DBR1;;Debranching enzyme 1, S. cerevisiae, homolog of;607024;REc;;;
3.654;8;7;17;3q22.3;DZIP1L, DZIP2, PKD5;;DAZ-interacting zinc finger protein 1-like;617570;REc;;Polycystic kidney disease 5, 617610 (3);9(Dzip1l)
3.655;12;11;15;3q22.3;ESYT3, FAM62C;;Extended synaptotagmin-like protein 3;616692;REc;;;
3.656;2;2;04;3q22.3;MRAS, RRAS3;;Muscle Ras viral oncogene homolog;608435;REc;;;
3.657;2;25;14;3q22.3;MSL2, KIAA1585;;Male-specific lethal 2, Drosophila, homolog of;614802;REc;;;
3.658;9;9;08;3q22.3;PIK3CB, PI3KCB;;Phosphatidylinositol 3-kinase, catalytic, beta;602925;R, REc;;;
3.659;12;15;17;3q22.3;SLC35G2, TMEM22;;Solute carrier family 35, member G2;617812;REc;;;
3.660;8;31;17;3q22.3;STAG1, MRD47;;Stromal antigen 1;604358;REc;;Mental retardation, autosomal dominant 47, 617635 (3);
3.661;3;3;15;3q23;CLSTN2;;Calsyntenin 2;611323;REc;;;
3.662;12;8;17;3q23;COPB2, MCPH19;;Coatomer protein complex, subunit beta-2;606990;A;mutation identified in 1 MCPH19 family;?Microcephaly 19, primary, autosomal recessive, 617800 (3);
3.663;11;2;04;3q22.3;FOXL2, BPES, BPES1, PFRK, POF3;;Forkhead transcription factor FOXL2;605597;Ch, Fd;;Blepharophimosis, epicanthus inversus, and ptosis, type 1, 110100 (3); Blepharophimosis, epicanthus inversus, and ptosis, type 2, 110100 (3); Premature ovarian failure 3, 608996 (3);
3.664;09;26;18;3q23;MRPS22, C3orf5, COXPD5, ODG7;;Mitochondrial ribosomal protein S22;605810;REc;;Combined oxidative phosphorylation deficiency 5, 611719 (3); Ovarian dysgenesis 7, 618117 (3);
3.665;8;29;07;3q23;NMNAT3, PNAT3;;Nicotinamide nucleotide adenylyltransferase 3;608702;R, REc;;;
3.666;4;19;12;3q23;PAQR9;;Progestin and ADIPOQ receptor family, member 9;614580;REc;;;
3.667;8;28;09;3q23;PLS1;;Plastin-1;602734;REa, REc;;;
3.668;10;19;99;3q24;PLSCR1, MMTRA1B;;Phospholipid scramblase 1;604170;A;;;
3.669;3;10;03;3q24;PLSCR2;;Phospholipid scramblase 2;607610;R;;;
3.670;3;10;03;3q24;PLSCR4;;Phospholipid scramblase 4;607612;REc;;;
3.671;12;30;14;3q23;SLC25A36, PNC2;;Solute carrier family 25 (mitochondrial carrier, pyrimidine nucleotide transporter), member 36;616149;REc;;;
3.672;6;5;00;3q22.3;SOX14;;SRY-box 14;604747;A, R, REc;;;
3.673;12;18;07;3q23;SPSB4, SSB4;;SPRY domain- and SOCS box-containing 4;611660;REc;;;
3.674;2;17;09;3q23;STQTL10;;Stature quantitative trait locus 10;612221;Fd;associated with rs6440003;{Stature QTL 10} (2);
3.675;3;5;98;3q23;TFDP2, DP2;;Transcription factor Dp-2 (E2F dimerization partner 2);602160;A;;;
3.676;1;24;18;3q23;U2SURP, SR140, KIAA0332;;U2 small nuclear ribonucleoprotein-associated SURP domain-containing protein;617849;R, REc;;;
3.677;2;17;09;3q23;ZBTB38;;Zinc finger- and BTB domain-containing protein 38;612218;REc;;;
3.678;6;4;02;3q24-q25;CP;;Ceruloplasmin;117700;F, H, REa, A;~15cM from TF;[Hypoceruloplasminemia, hereditary], 604290 (3); Cerebellar ataxia, 604290 (3); Hemosiderosis, systemic, due to aceruloplasminemia, 604290 (3);9(Cp)
3.679;2;13;15;3q24;PLOD2, LH2, TLH, BRKS2;;Procollagen-lysine, 2-oxoglutarate 5-dioxygenase (lysine hydroxylase) 2;601865;Psh, A;;Bruck syndrome 2, 609220 (3);9(Plod2)
3.680;8;29;08;3q24;C3orf58, DIA1;;Chromosome 3 open reading frame 58;612200;REc;;;
3.681;6;2;06;3q24;CHST2;;Carbohydrate sulfotransferase-2 (GlcNAc-6-O-sulfotransferase; N-acetylglucosamine-6-O-sulfotransferase);603798;REc;mapped by FISH to 7q31;;
3.682;8;28;09;3q24;CPA3;;Carboxypeptidase A3, mast cell;114851;Psh, REc;;;
3.683;7;18;14;3q24;CPB1, PCPB, PASP;;Carboxypeptidase B1, tissue;114852;REc;;;
3.684;8;28;15;3q25.31;GMPS;;Guanine monophosphate synthetase;600358;A, Ch;fusion gene with MLL in AML;;
3.685;11;28;01;3q25.1;GPR86;;G protein-coupled receptor 86;606380;REc;;;
3.686;11;28;01;3q25.1;GPR87;;G protein-coupled receptor 87;606379;REc;;;
3.687;7;16;01;3q24;HPS3;;HPS gene 3;606118;HZ, Fd;;Hermansky-Pudlak syndrome 3, 614072 (3);3(Hps3)
3.688;12;27;13;3q24;SLC9A9, AUTS16;;Solute carrier family 9 (sodium/hydrogen exchanger), member A9;608396;Ch, REc;mutation identified in 1 family;{?Autism susceptibility 16}, 613410 (3);
3.689;11;18;16;3q25.1;SELENOT, SELT;;Selenoprotein T;607912;REc;;;
3.690;7;17;12;3q25.1;WWTR1, TAZ;;WW domain-containing transcription regulator 1;607392;R;;;
3.691;3;5;18;3q24;ZIC4;;Zic family, member 4;608948;R, D;;;9(Zic4)
3.692;10;20;15;3q24;ZIC1, CRS6;;Zic family, member 1;600470;A, D;;Craniosynostosis 6, 616602 (3);9(Zic1)
3.693;9;15;11;3q25.1;P2RY12, P2Y12, BDPLT8;;Purinergic receptor P2Y, G protein-coupled, 12;600515;R;;Bleeding disorder, platelet-type, 8, 609821 (3);
3.694;9;9;08;3q25.31-q25.32;VEPH1, MELT, KIAA1692;;Ventricular zone-expressed PH domain-containing protein, zebrafish, homolog of, 1;609594;R, REc;;;
3.695;2;5;14;3q24;GYG1, GSD15;;Glycogenin 1;603942;A;mutation identified in 1 GSD15 patient;?Glycogen storage disease XV, 613507 (3); Polyglucosan body myopathy 2, 616199 (3);
3.696;4;21;16;3q25.1;SUCNR1, GPR91;;Succinate receptor 1;606381;REc;;;
3.697;3;8;07;3q24-q26;HDLCQ5;;High density lipoprotein cholesterol level QTL 5;610761;Fd;max lod at D3S3053;[High density lipoprotein cholesterol level QTL 5] (2);
3.698;1;30;02;3q24-q26;UVM1;;Melanoma, uveal, susceptibility to, 1;606660;Ch;;{Melanoma, uveal, susceptibility to, 1} (2);
3.699;2;3;13;3q26.1;B3GALT3, GLCT3, GLOB;;UDP-galactose:beta-N-acetylglucosamine beta-1,3-galactosyltransferase 3;603094;REc;;[Blood group, globoside system], 615021 (3); [Blood group, P1PK system, P(k) phenotype], 111400 (3);
3.700;2;6;08;3q25.32;IQCJ;;IQ motif-containing protein J;611622;REc;;;
3.701;12;27;01;3q25.1-q25.2;MBNL1, KIAA0428, EXP;;Muscleblind-like protein;606516;R, REc;;;
3.702;6;23;98;3q25.2;P2RY1, P2Y1;;Purinergic receptor P2Y, G-protein coupled, 1;601167;Psh, REc;;;
3.703;5;5;98;3q25.32;PTX3;;Pentraxin-3;602492;REa, A;;;
3.704;5;28;98;3q25.1;SIAH2;;Seven in absentia, Drosophila, homolog of, 2;602213;A;;;
3.705;8;30;09;3q25.1;TM4SF4, ILTMP;;Transmembrane 4 superfamily, member 4;606567;R, REc;;;
3.706;5;28;08;3q25-q26;CELIAC10;;Celiac disease, susceptibility to, 10;612008;Fd;associated with rs17810546;{Celiac disease, susceptibility to, 10} (2);
3.707;4;10;14;3q25-q26;ETL6;;Epilepsy, familial temporal lobe, 6;615697;Fd;between D3S1584 and D3S3520;Epilepsy, familial temporal lobe, 6 (2);
3.708;8;12;98;3q25.32;SHOX2, SHOT, OG12;;Short stature homeo box 2;602504;A, R;;;3(Og12)
3.709;2;3;06;3q26.1;SI;;Sucrase-isomaltase;609845;REa, A, Fd;;Sucrase-isomaltase deficiency, congenital, 222900 (3);3(Sis)
3.710;8;18;04;3q23;XRN1, SEP1;;Exoribonuclease 1;607994;R;;;
3.711;6;7;04;3q25-q27;ASPG1;;Asperger syndrome, susceptibility to, 1;608638;Fd;max lod with D3S3037;{Asperger syndrome susceptibility 1} (2);
3.712;5;16;07;3q25-q27;AUTS8;;Autism, susceptibility to, 8;607373;Fd;;{Autism susceptibility 8} (2);
3.713;8;27;01;3q26.2;EIF5A2;;Eukaryotic translation initiation factor 5A2;605782;R;;;
3.714;5;31;05;3q27.1;MCCC1, MCCA;;3-Methylcrotonyl-CoA carboxylase 1;609010;R, A;;3-Methylcrotonyl-CoA carboxylase 1 deficiency, 210200 (3);
3.715;8;26;04;3q26.2;PRKCI;;Protein kinase C, iota;600539;H, REc;pseudogene on X;;3(Prkci)
3.716;12;22;15;3q25.1;COMMD2;;COMM domain-containing protein 2;616699;REc;;;
3.717;3;19;09;3q25.1;EIF2A;;Eukaryotic translation initiation factor 2A;609234;REc;;;
3.718;3;18;17;3q25.1;IGSF10;;Immunoglobulin superfamily, member 10;617351;REc;;;
3.719;8;29;96;3q25.32;MLF1;;Myeloid leukemia factor-1;601402;Ch;;Leukemia, acute myeloid, 601626 (1);
3.720;8;19;13;3q25.1;P2RY14, BPR105, KIAA0001;;Purinergic receptor P2Y, G protein-coupled, 14;610116;Psh, REn;;;
3.721;9;21;17;3q25.1;SERP1, RAMP4;;Stress-associated endoplasmic reticulum protein 1;617674;REc;;;
3.722;3;23;14;3q25.1;TMEM183B, C1orf37DUP;;Transmembrane protein 183B;611365;REc;;;
3.723;10;25;17;3q25.1;TSC22D2, KIAA0669;;TSC22 domain family, member 2;617724;REc, H;;;3(Tsc22d2)
3.724;2;20;97;3q25.1;PFN2, PFL, D3S1319E;;Profilin-2;176590;REc;mapped previously to chr.1;;
3.725;11;16;98;3q24;SMARCA3, SNF2L3, HIP116;;SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 3;603257;Psh, A;;;
3.726;6;27;17;3q25.2;ARHGEF26, SGEF;;Rho guanine nucleotide exchange factor 26;617552;REc;;;
3.727;4;30;09;3q25.2;DHX36, G4R1, RHAU, KIAA1488;;DEAH (Asp-Glu-Ala-His) box polypeptide 36;612767;REc;;;
3.728;4;8;16;3q25.2;DWORF, LOC100507537;;Dwarf open reading frame;616891;REc;;;
3.729;8;8;13;3q25.2;RAP2B;;Ras-related protein 2B;179541;R, REc;;;
3.730;8;16;10;3q25.3;BWQTL2;;Birth weight quantitative trait locus 2;613459;Fd;associated with rs900400;[Birth weight QTL 2] (2);
3.731;4;7;05;3q25.32;LXN, ECI, TCI;;Latexin;609305;R, REc;;;3(Lxn)
3.732;8;30;09;3q25.32;RARRES1, TIG1;;Retinoic acid receptor responder 1;605090;R, REc;;;
3.733;5;5;10;3q25.31;CCNL1, ANIA6A;;Cyclin L1;613384;REc;;;
3.734;8;27;15;3q25.31;LEKR1;;Leucine-, glutamate-, and lysine-rich protein 1;613536;REc;;;
3.735;7;9;09;3q25.31;PLCH1, PLCL3, KIAA1069;;Phospholipase C, eta-1;612835;REc;;;
3.736;4;27;12;3q25.31;SLC33A1, ACATN, AT1, SPG42, CCHLND;;Solute carrier family 33 (acetyl-CoA transporter), member 1;603690;A, R, REc;;Spastic paraplegia 42, autosomal dominant, 612539 (3); Congenital cataracts, hearing loss, and neurodegeneration, 614482 (3);3(Acatn)
3.737;6;13;12;3q25.31;SSR3, TRAPG;;Signal sequence receptor, gamma;606213;R, REc;;;
3.738;12;17;08;3q25.31;TIPARP;;TCDD-inducible poly(ADP-ribose) polymerase;612480;REc;;;
3.739;10;15;13;3q25.32;GFM1, EFG1, GFM, COXPD1;;Mitochondrial elongation factor G1;606639;R, M, Fd, REc;;Combined oxidative phosphorylation deficiency 1, 609060 (3);
3.740;6;7;10;3q25.32;RSRC1, SRRP53;;Arginine/serine-rich coiled-coil protein 1;613352;REc;;;
3.741;1;30;12;3q25.33;ARL14, ARF7;;ADP-ribosylation factor-like 14;614439;REc;;;
3.742;1;17;18;3q25.33;IFT80, KIAA1374, WDR56, SRTD2, ATD2;;Intraflagellar transport 80, Chlamydomonas, homolog of;611177;R, REn;;Short-rib thoracic dysplasia 2 with or without polydactyly, 611263 (3);
3.743;2;25;14;3q25.33;SCARNA7;;Small Cajal body-specific RNA 7;615644;REc;;;
3.744;12;13;18;3q21.3;ACAD9, MC1DN20;;Acyl-CoA dehydrogenase family, member 9;611103;REc;;Mitochondrial complex I deficiency, nuclear type 20, 611126 (3);
3.745;5;15;08;3q26;AGA1, MPB;;Alopecia, androgenetic, 1;109200;Fd;;Alopecia, androgenetic, 1 (2);
3.746;8;10;18;3q27.1;CLCN2, EGMA, ECA2, EGI11, EJM8, LKPAT, HALD2;;Chloride channel-2;600570;Psh;;{Epilepsy, juvenile myoclonic, susceptibility to, 8}, 607628 (3); {Epilepsy, juvenile absence, susceptibility to, 2}, 607628 (3); {Epilepsy, idiopathic generalized, susceptibility to, 11}, 607628 (3); Leukoencephalopathy with ataxia, 615651 (3); Hyperaldosteronism, familial, type II, 605635 (3);
3.747;3;20;08;3q26.31;FNDC3B, FAD104;;Fibronectin domain III-containing protein 3B;611909;REc;;;3(Fndc3b)
3.748;10;9;94;3q26;MDS1;;Myelodysplasia syndrome-1;600049;Ch, REc, A;cen--EVI1--MDS1--EAP--tel;Myelodysplasia syndrome-1 (3);
3.749;1;8;16;3q26.2;MECOM, EVI1, RUSAT2;;MDS1 and EVS1 complex locus;165215;A, Ch, REc;;Radioulnar synostosis with amegakaryocytic thrombocytopenia 2, 616738 (3);3(Evi1)
3.750;4;13;05;3q26;MYP8;;Myopia 8;609257;Fd;;Myopia 8 (2);
3.751;8;3;12;3q28;OSTN;;Osteocrin;610280;REc, H;;;16(Ostn)
3.752;8;23;17;3q26.31;PLD1, CVDD;;Phospholipase D1, phosphatidylcholine-specific;602382;REa, A;;Cardiac valvular defect, developmental, 212093 (3);3(Pld1)
3.753;10;7;99;3q26.1;SERPINI1, PI12;;Protease inhibitor 12;602445;A;;Encephalopathy, familial, with neuroserpin inclusion bodies, 604218 (3);
3.754;12;28;08;3q26.1;SLITRK3, KIAA0848;;SLIT- and NTRK-like family, member 3;609679;R, REc, H;;;3(Slitrk3)
3.755;6;16;99;3q26.31;TNFSF10, TRAIL, APO2L;;Tumor necrosis factor ligand superfamily, member 10;603598;A;;;
3.756;1;24;01;3q25.33;CAPC;;Chromosome-associated protein C;605575;A;;;
3.757;11;4;98;3q25.31;KCNAB1, KCNA1B;;Potassium voltage-gated channel, shaker-related subfamily, beta member 1;601141;Psh, A, REc;;;3(Kcna1b)
3.758;2;1;11;3q25.33;KPNA4, QIP1;;Karyopherin alpha-4;602970;REc;;;
3.759;8;20;07;3q26.1;NMD3;;NMD3, S. cerevisiae, homolog of;611021;R, REc;;;
3.760;1;25;05;3q26.1;PDCD10, TFAR15, CCM3;;Programmed cell death 10;609118;REc, Fd;;Cerebral cavernous malformations 3, 603285 (3);
3.761;4;8;08;3q25.3-q26.1;PPM1L, PP2CE;;Protein phosphatase 1-like;611931;REc;;;
3.762;9;7;12;3q26.1;SPTSSB, C3orf57, SSSPTB, ADMP;;Serine palmitoyltransferase, small subunit B;610412;REc, R;;;
3.763;12;30;14;3q25.33;TRIM59, RNF104, MRF1, IFT80L;;Tripartite motif-containing protein 59;616148;REc, H;;;3(Trim59)
3.764;4;25;18;3q26.1;BCHE, CHE1, BCHED;;Butyrylcholinesterase;177400;F, D, A;distal to CP, TF;{Apnea, postanesthetic, susceptibility to, due to BCHE deficiency}, 617936 (3); Butyrylcholinesterase deficiency, 617936 (3);
3.765;6;13;95;3q26.31;ECT2;;Epithelial cell transforming sequence 2 oncogene;600586;A, Psh;;;3(Ect2)
3.766;2;5;01;3q26.1;SERPIN12, PI14, MEPI;;Protease inhibitor 14;605587;REn, A;;;
3.767;8;7;01;3q26.1-q26.3;MNG3;;Multinodular goiter-3;606082;Fd;;Goiter, multinodular, 3 (2);
3.768;12;5;13;3q26.2;SLC2A2, GLUT2;;Solute carrier family 2 (facilitated glucose transporter), member 2;138160;REa, A, Fd;;{Diabetes mellitus, noninsulin-dependent}, 125853 (3); Fanconi-Bickel syndrome, 227810 (3);
3.769;7;11;11;3q26.2;ARPM1;;Actin-related protein M1;608534;REc;;;
3.770;8;28;09;3q26.2;GOLIM4, GOLPH4, GPP130;;Golgi integral membrane protein 4;606805;R, REc;;;
3.771;9;12;13;3q26.2;MYNN;;Myoneurin;606042;REc;;;
3.772;2;2;11;3q26.2;SEC62, TLOC1, HTP1;;Sec62, S. cerevisiae, homolog of;602173;REc;;;
3.773;5;29;13;3q26.2;SKIL, SNO;;SKI-like;165340;REc;;;
3.774;4;3;14;3q26.2;SLC7A14, KIAA1613, RP68;;Solute carrier family 7, member 14;615720;REc;;Retinitis pigmentosa 68, 615725 (3);
3.775;7;18;14;3q26.2;TRV-AAC1-1, TRNAV24;;Transfer RNA valine (AAC) 1-1;615310;REc;;;
3.776;1;26;01;3q26.2;CLDN11, OTM, OSP;;Claudin 11 (oligodendrocyte transmembrane protein);601326;REa, A;;;
3.777;6;16;99;3q26.33;USP13, ISOT3;;Ubiquitin-specific protease-13;603591;R, Psh, REc;;;
3.778;7;15;16;3q26.2-q26.3;TNIK, KIAA0551, MRT54;;TRAF2-and NCK-interacting kinase;610005;R, REc;;Mental retardation, autosomal recessive 54, 617028 (3);
3.779;11;26;12;3q26.2-q26.31;APMR2;;Alopecia-mental retardation syndrome 2;610422;Fd;between D3S1564 and D3S2427;Alopecia-mental retardation syndrome 2 (2);
3.780;3;19;09;3q26.2-q26.33;FEB10;;Febrile seizures, familial, 10;612637;Fd;between D3S3656 and D3S1232;Febrile seizures, familial, 10 (2);
3.781;8;21;07;3q26.33;PEX5L, PEX5R, PXR2B;;Peroxisome biogenesis factor 5-like;611058;REc;;;
3.782;11;1;13;3q27.2;TRA2B, SFRS10;;Splicing factor, arginine/serine-rich, 10 (transformer 2, drosophila, homolog of, beta);602719;R;;;
3.783;5;1;91;3q29;APOD;;Apolipoprotein D;107740;REb, A;;;16(Apod)
3.784;8;20;07;3q26.33;ACTL6A, BAF53, BAF53A;;Actin-like 6A;604958;REc;;;
3.785;3;15;11;3q26.33;CCDC39;;Coiled-coil domain-containing protein 39;613798;REc;;Ciliary dyskinesia, primary, 14, 613807 (3);
3.786;11;27;18;3q26.33;NDUFB5;;NADH-ubiquinone oxidoreductase 1 beta subcomplex, 5;603841;REc;;;
3.787;4;30;15;3q26.33;SOX2OT, NCRNA00043;;SOX2 overlapping transcript, noncoding;616338;REc;;;
3.788;4;21;10;3q26.33;DCUN1D1, RP42;;DCN1 domain-containing protein 1;605905;REc;previously mapped to 6q16;;
3.789;7;3;06;3q26.33;DNAJC19, TIM14;;DnaJ (Hsp40) homolog, subfamily C, member 19 (translocase of inner mitochondrial membrane 14, yeast, homolog of);608977;R, REc;;3-methylglutaconic aciduria, type V, 610198 (3);
3.790;5;6;13;3q26.33;GNB4, CMTD1F;;Guanine nucleotide-binding protein, beta-4;610863;R, REc;;Charcot-Marie-Tooth disease, dominant intermediate F, 615185 (3);
3.791;2;13;15;3q26.31;GHSR, GHDP;;Growth hormone secretagogue receptor;601898;REc;;Growth hormone deficiency, isolated partial, 615925 (3);
3.792;3;5;08;3q26.33;MRPL47;;Mitochondrial ribosomal protein L47;611852;R, REc;;;
3.793;8;19;04;3q26.31;NAALADL2;;N-acetylated alpha-linked acidic dipeptidase-like 2;608806;Ch, REc;?involved in Cornelia de Lange syndrome;;
3.794;2;21;10;3q26.31;NCEH1, NCEH, KIAA1363;;Neutral cholesterol ester hydrolase 1;613234;REc;;;
3.795;8;28;09;3q26.31;NLGN1;;Neuroligin 1;600568;R, REc;;;
3.796;10;09;18;3q26.32;PIK3CA, CLOVE, MCAP, MCM, MCMTC, CWS5, CLAPO;;Phosphatidylinositol 3-kinase, catalytic, alpha polypeptide;171834;REa, A;;Ovarian cancer, somatic, 167000 (3); Breast cancer, somatic, 114480 (3); Colorectal cancer, somatic, 114500 (3); Gastric cancer, somatic, 613659 (3); Hepatocellular carcinoma, somatic, 114550 (3); Nonsmall cell lung cancer, somatic, 211980 (3); Keratosis, seborrheic, somatic, 182000 (3); Nevus, epidermal, somatic, 162900 (3); CLOVE syndrome, somatic, 612918 (3); Megalencephaly-capillary malformation-polymicrogyria syndrome, somatic, 602501 (3); Cowden syndrome 5, 615108 (3); CLAPO syndrome, somatic, 613089 (3); Macrodactyly, somatic, 155500 (3);
3.797;4;30;15;3q26.31;SPATA16, SPGF6;;Spermatogenesis-associated protein 16;609856;R, REc, Fd;mutation identified in 1 SPGF6 family;?Spermatogenic failure 6, 102530 (3);
3.798;4;30;01;3q27.1;DCLAMP;;Lysosome-associated membrane glycoprotein, dendritic cell-specific;605883;A;;;
3.799;1;22;07;3q26.33;SOX2, MCOPS3;;SRY (sex determining region Y)-box 2;184429;A, D;;Microphthalmia, syndromic 3, 206900 (3); Optic nerve hypoplasia and abnormalities of the central nervous system, 206900 (3);
3.800;3;9;12;3q27.1;THPO, MGDF, MPLLG, TPO, THCYT1;;Thrombopoietin (megakaryocyte growth and development factor);600044;A;;Thrombocythemia 1, 187950 (3);16(Thpo)
3.801;11;13;01;3q26.32;WIG1;;Wildtype p53-induced gene;606452;A;;;
3.802;1;29;01;3q26.32;KCNMB3;;Potassium large conductance calcium-activated channel, subfamily M, beta member 3;605222;A, Psh, R;;;
3.803;11;26;12;3q26.3-q27.3;APMR1;;Alopecia-mental retardation syndrome 1;203650;Fd;max lod at D3S3583;Alopecia-mental retardation syndrome 1 (2);
3.804;5;24;13;3q29;ATP13A3, AFURS1;;ATPase, type 13A3;610232;REc;;;
3.805;11;11;14;3q26.32;KCNMB2;;Potassium channel, calcium-activated, large conductance, subfamily M, beta member 2;605214;R, REc;;;
3.806;5;11;16;3q26.32;TBL1XR1, TBLR1, IRA1, C21, MRD41;;Transducin-beta-like 1 receptor 1;608628;REc, R;;Mental retardation, autosomal dominant 41 , 616944 (3); Pierpont syndrome, 602342 (3);
3.807;3;27;13;3q26.32-q28;FAME4, FCMTE4;;Epilepsy, familial adult myoclonic, 4;615127;Fd;between D3S3730 and D3S1580;Epilepsy, myoclonic, familial adult, 4 (2);
3.808;9;20;00;3q27.1;ABCC5, MRP5, MOATC;;ATP-binding cassette, subfamily C, member 5;605251;R, A;;;
3.809;2;17;09;3q27.3;ADIPOQ, APM1, GBP28, ADIPQTL1;;Adipocyte-, C1q-, and collagen domain-containing;605441;A, REc;;Adiponectin deficiency, 612556 (3);16(Apm1)
3.810;1;25;18;3q27.3;AHSG, APMR1;;Alpha-2HS-glycoprotein;138680;F, S, D, REa, A, REn;mutation identified in 1 APMR1 family;?Alopecia-mental retardation syndrome 1, 203650 (3);
3.811;6;22;04;3q27.1;ALG3, NOT56L, CDGS4, CDG1D;;Alg3, S. cerevisiae, homolog of;608750;R;;Congenital disorder of glycosylation, type Id, 601110 (3);
3.812;9;9;14;3q27;AOMS1, SYNX;;Abdominal obesity-metabolic syndrome QTL1;605552;Fd;epistatic gene on 17p12;Abdominal obesity-metabolic syndrome 1 (2);
3.813;8;28;09;3q26.33;ATP11B, ATPIR;;ATPase, class VI, type 11B;605869;REc;;;
3.814;4;3;01;3q27.3;BCL6;;B-cell CLL/lymphoma-6;109565;Ch, A;;Lymphoma, B-cell (2);16(Bcl6)
3.815;6;16;99;3q27.1;CHRD;;Chordin;603475;R, REc, REn;near THPO, CLCN2, EIF4G1;;16(Chrd)
3.816;6;13;07;3q28;CLDN16, PCLN1, HOMG3;;Claudin 16 (paracellin 1);603959;Fd;;Hypomagnesemia 3, renal, 248250 (3);
3.817;8;6;13;3q27.3;CRYGS, CRYG8, CTRCT20;;Crystallin, gamma S;123730;REa, Fd;;Cataract 20, multiple types, 116100 (3);
3.818;4;8;16;3q27.1;DVL3, DRS3;;Dishevelled 3 (homologous to Drosophila dsh);601368;Psh, A;;Robinow syndrome, autosomal dominant 3, 616894 (3);
3.819;1;28;14;3q27.2;EHHADH, PBFE, LBFP, FRTS3;;Enoyl-Coenzyme A, hydratase/3-hydroxyacyl Coenzyme A dehydrogenase;607037;A, REn;mutation identified in 1 family;?Fanconi renotubular syndrome 3, 615605 (3);
3.820;10;29;03;3q27.1;EIF2B5, LVWM, CACH, CLE;;Eukaryotic translation initiation factor 2B, subunit 5;603945;Fd,R;;Leukoencephalopathy with vanishing white matter, 603896 (3); Ovarioleukodystrophy, 603896 (3);
3.821;4;10;15;3q27.1;EIF4G1, EIF4G, PARK18;;Eukaryotic translation initiation factor 4 gamma, 1;600495;Psh;amplified in squamous cell lung cancer;{Parkinson disease 18}, 614251 (3);
3.822;7;5;01;3q27.3;FETUB;;Fetuin B;605954;REc;;;
3.823;3;1;12;3q27.3;HRG, THPH11;;Histidine-rich glycoprotein;142640;REa, A, Fd, REn;;Thrombophilia due to HRG deficiency, 613116 (3); Thrombophilia due to elevated HRG, 613116 (1);
3.824;7;3;06;3q27.1;HTR3C;;5-hydroxytryptamine receptor 3C;610121;A, REn;;;
3.825;7;3;06;3q27.1;HTR3D;;5-hydroxytryptamine receptor 3, subunit D;610122;A, REn;;;
3.826;7;3;06;3q27.1;HTR3E;;5-hydroxytryptamine receptor 3, subunit E;610123;A, REn;;;
3.827;10;28;08;3q27.3;KNG1, KNG;;Kininogen 1;612358;Psh, A, REn;;[Kininogen deficiency], 228960 (3); [High molecular weight kininogen deficiency], 228960 (3);
3.828;11;30;06;3q27.1;MAPO6D1, SL21;;MAP6 domain-containing protein 1;610593;REc;;;
3.829;1;19;07;3q27.2;MAP3K13, LZK;;Mitogen-activated protein kinase kinase kinase 13 (leucine zipper-bearing kinase);604915;R, REc;;;
3.830;5;22;07;3q27.1;PARL;;Presenilin-associated rhomboid-like protein;607858;R, REc;;;
3.831;3;5;95;3q27.3;RFC4;;Replication factor C4, 37kD (activator 1, 37kD);102577;Psh, A;;;
3.832;2;28;03;3q27.3;RPL39L;;Ribosomal protein L39-like;607547;REc;;;
3.833;7;1;05;3q27.3;RTP4;;Receptor-transporting protein 4;609350;R, REc;;;
3.834;1;19;07;3q27.2;SENP2, SMT3IP2, AXAM2, KIAA1331;;Sentrin-specific protease family, member 2;608261;R, REc;;;
3.835;10;23;18;3q28;TP63, TP73L, KET, EEC3, SHFM4, LMS, RHS, OFC8;;Tumor protein p63 (tumor protein p73-like);603273;A, R;;Ectrodactyly, ectodermal dysplasia, and cleft lip/palate syndrome 3, 604292 (3); Split-hand/foot malformation 4, 605289 (3); Hay-Wells syndrome, 106260 (3); ADULT syndrome, 103285 (3); Limb-mammary syndrome, 603543 (3); Rapp-Hodgkin syndrome, 129400 (3); Orofacial cleft 8, 618149 (3);16(Trp63)
3.836;6;16;99;3q27.2-q27.3;DGKG, DAGK3;;Diacylglycerol kinase, gamma, 90-kD;601854;A;;;
3.837;7;16;14;3q27.2;LIPH, LAH2, ARWH2, HYPT7;;Lipase H;607365;REc;;Hypotrichosis 7, 604379 (3); Woolly hair, autosomal recessive 2 with or without hypotrichosis, 604379 (3);
3.838;10;10;14;3q27.3;MASP1, CRARF, 3MC1;;Mannan-binding lectin serine protease-1 (C4/C2 activating component of Ra-reactive factor);600521;A;;3MC syndrome 1, 257920 (3);16(Crarf)
3.839;9;7;00;3q27-q28;SPG14;;Spastic paraplegia 14, autosomal recessive;605229;Fd;;Spastic paraplegia 14, autosomal recessive (2);
3.840;8;19;13;3q27.1;B3GNT5;;Beta-1,3-N-acetylglucosaminyltransferase 5;615333;REc;;;
3.841;10;10;14;3q27.1;CAMK2N2, CAMKIIN;;Calcium/calmodulin-dependent protein kinase II inhibitor 2;608721;R, REc;;;
3.842;2;25;14;3q27.1;ECE2, KIAA0604;;Endothelin-converting enzyme 2;610145;REc, A, R;;;
3.843;1;13;17;3q27.1;KLHL24, KRIP6, EBSSH;;Kelch-like 24;611295;REc;;Epidermolysis bullosa simplex, generalized, with scarring and hair loss, 617294 (3);
3.844;8;28;09;3q27.1;MIR1224, MIRN1224;;Micro RNA 1224;611620;REc;;;
3.845;8;28;09;3q27.1;PSMD2, S2, TRAP2;;Proteasome 26S subunit, non-APTase, 2;606223;R, REc;;;
3.846;4;26;10;3q27.1;YEATS2, KIAA1197;;YEATS domain-containing protein 2;613373;REc;;;
3.847;7;25;18;3q27.3;DNAJB11, HEDJ, DJ9, ABBP2, PKD6;;DNAJ/HSP40 homolog, subfamily B, member 11;611341;REc;;Polycystic kidney disease 6 with or without polycystic liver disease, 618061 (3);
3.848;9;7;11;3q27.1;KLHL6, FLJ00029;;Kelch-like 6;614214;REc;;;
3.849;7;14;14;3q27.3;RTP1;;Receptor-transporting protein 1;609137;REc;;;
3.850;7;14;14;3q27.3;RTP2;;Receptor-transporting protein 2;609138;REc;;;
3.851;5;3;11;3q27.3;SNORA63, RNU107, RNE3;;Small nucleolar RNA, H/ACA box, 63;180647;REc;;;
3.852;4;2;16;3q27.3;SNORA81;;Small nucleolar RNA, H/ACA box, 81;611334;REc;in intron 3 of EIF2A;;
3.853;9;28;00;3q27.1;AP2M1, CLAPM1;;Adaptor-related protein complex 2, mu 1 subunit;601024;REa, A;;;
3.854;8;20;15;3q28;CCDC50, C3orf6, DFNA44;;Coiled-coil domain-containing protein 50;611051;Fd, REc;mutation identified in 1 DFNA44 family;?Deafness, autosomal dominant 44, 607453 (3);
3.855;5;28;08;3q28;CELIAC11;;Celiac disease, susceptibility to, 11;612009;Fd;associated with rs1464510;{Celiac disease, susceptibility to, 11} (2);
3.856;8;28;09;3q27.3;EIF4A2;;Eukaryotic translation initiation factor-4A, isoform 2;601102;R, REc;previously 18p11.2 by FISH;;16(Eif4a2)
3.857;1;26;97;3q27.2;ETV5, ERM;;ets variant gene 5 (ets-related molecule);601600;A;;;
3.858;4;26;17;3q28-q29;FGF12, FHF1, EIEE47;;Fibroblast growth factor-12;601513;REa, H, A;;Epileptic encephalopathy, early infantile, 47, 617166 (3);16(Fhf1)
3.859;5;4;99;3q26.33;FXR1;;Fragile X mental retardation, autosomal homolog;600819;REa, A;pseudogene on 12q12;;
3.860;1;30;12;3q28;GMNC, GEMC1;;Geminin coiled-coil domain-containing protein;614448;REc;;;
3.861;8;6;07;3q27.2;IGF2BP2, IMP2;;Insulin-like growth factor 2 mRNA-binding protein 2;608289;R, Fd;;{Diabetes mellitus, noninsulin-dependent, susceptibility to}, 125853 (3);
3.862;11;4;98;3q28;IL1RAP;;Interleukin 1 receptor accessory protein;602626;A, R;;;
3.863;9;2;11;3q28;LNCR5;;Lung cancer susceptibility 5;614210;Fd;associated with rs4488809;{Lung cancer susceptibility 5} (2);
3.864;10;1;95;3q27-q28;LPP;;Lipoma-preferred-partner gene;600700;Ch, RE;fused with HMGIC in lipoma; fused with MLL in leukemia;Lipoma (3); Leukemia, acute myeloid, 601626 (3);
3.865;3;23;09;3q28;MIR28, MIRN28;;Micro RNA 28;612154;REc;;;
3.866;6;19;01;3q27.1;POLR2H, RPB8;;Polymerase II, RNA, subunit H;606023;R;;;
3.867;3;25;14;3q28;PYDC2, POP2;;Pyrin domain-containing protein 2;615701;REc;;;
3.868;10;23;87;3q27.3;SST;;Somatostatin;182450;REa;;;16(Smst)
3.869;8;27;12;3q28;TMEM207;;Transmembrane protein 207;614786;REc;;;
3.870;10;10;18;3q28;UTS2B, URP;;Urotensin 2B;618134;REc;;;
3.871;7;19;06;3q28;CLDN1, SEMP1, ILVASC;;Claudin 1;603718;REa, R, Fd;;Ichthyosis, leukocyte vacuoles, alopecia, and sclerosing cholangitis, 607626 (3);
3.872;1;10;02;3q29;HRASLS;;HRAS-like suppressor;606487;A;;;
3.873;1;7;03;3q29;HES1, HRY;;Hairy and enhancer of split, Drosophila, homolog of;139605;A;;;
3.874;4;7;16;3q29;OPA1, NTG, NPG, BERHS, MTDPS14;;Optic atrophy 1 gene;605290;Fd, REc;mutation identified in 1 MTDPS14 family;Optic atrophy 1, 165500 (3); {Glaucoma, normal tension, susceptibility to}, 606657 (3); Optic atrophy plus syndrome, 125250 (3); Behr syndrome, 210000 (3); ?Mitochondrial DNA depletion syndrome 14 (encephalocardiomyopathic type), 616896 (3);?16(Bst)
3.875;2;25;15;3q29;ATP13A4;;ATPase, type 13A4;609556;A;;;
3.876;1;24;13;3q29;BDH1, BDH;;3-hydroxybutyrate dehydrogenase 1;603063;REc;;;
3.877;8;28;09;3q29;CENTB2, KIAA0041, ACAP2;;Centaurin, beta-2;607766;Psh, REc;;;
3.878;3;23;14;3q29;CEP19, C3orf34, MOSPGF;;Centrosomal protein, 19kD;615586;REc, Fd;mutation identified in 1 family;Morbid obesity and spermatogenic failure, 615703 (3);
3.879;8;22;05;3q29;CPN2;;Carboxypeptidase N, polypeptide 2, 83-KD;603104;A, H, Ch;conflicting assignment to chr.8;;16(Cpn2)
3.880;6;22;05;3q29;DLG1;;Discs, large, Drosophila, homolog of, 1;601014;REc;deleted in 3q29 microdeletion syndrome;;16(Dlgh1)
3.881;9;9;08;3q29;FBXO45, FBX45;;F-box only protein 45;609112;REc;;;16(Fbxo45)
3.882;5;2;16;3q29;FYTTD1, UIF;;Forty-two-three domain-containing protein 1;616933;REc;;;
3.883;8;8;13;3q29;GP5;;Glycoprotein V, platelet;173511;A;;;
3.884;12;17;08;3q29;IQCG;;IQ motif-containing protein G;612477;REc;;;
3.885;7;14;14;3q29;LMLN;;Leishmanolysin-like;609380;REc;;;
3.886;2;22;07;3q29;LSG1;;Large subunit GTPase 1, S. cerevisiae, homolog of;610780;R, REc;;;
3.887;10;23;87;3q29;MFI2, MAP97;;Melanoma-associated antigen p97;155750;S, A;;;
3.888;4;15;08;3q29;DEL3q29, MICRODEL3q29;;Chromosome 3q29 microdeletion syndrome;609425;Ch;contiguous gene deletion syndrome;Chromosome 3q29 microdeletion syndrome (4);
3.889;5;24;13;3q29;MUC20;;Mucin 20, cell surface-associated;610360;REc;;;
3.890;4;15;08;3q29;DUP3q29, MICRODUP3q29;;Chromosome 3q29 microduplication syndrome;611936;Ch;contiguous gene duplication syndrome;Chromosome 3q29 microduplication syndrome (4);
3.891;3;30;12;3q29;MIR570;;Micro RNA 570;614538;REc;;;
3.892;8;8;91;3q29;MUC4;;Mucin 4, tracheobronchial;158372;REa, A;;;
3.893;10;28;15;3q29;NCBP2, CBP20, NIP1;;Nuclear CAP-binding protein 2;605133;REc;;;
3.894;7;22;13;3q29;NRROS, LRRC33;;Negative regulator of oxygen species;615322;REc;;;
3.895;6;25;08;3q29;OSTA;;Organic solute transporter, alpha;612084;REc;;;16(Osta)
3.896;2;3;15;3q28;P3H2, LEPREL1, MCVD;;Prolyl 3-hydroxylase 2;610341;REc, H;;Myopia, high, with cataract and vitreoretinal degeneration, 614292 (3);16(Leprel1)
3.897;6;22;05;3q29;PAK2, PAK65;;p21-activated kinase 2;605022;REc;deleted in 3q29 microdeletion syndrome;;
3.898;3;6;14;3q29;PCYT1A, CTPCT, PCYT1, SMDCRD;;Phosphate cytidylyltransferase 1, choline, alpha isoform;123695;H, R;;Spondylometaphyseal dysplasia with cone-rod dystrophy, 608940 (3);16(Ctpct)
3.899;9;9;10;3q29;PIGX;;Phosphatidylinositol glycan, class X;610276;REc;;;
3.900;12;17;07;3q29;PIGZ, SMP3;;Phosphatidylinositol glycan, class Z;611671;REc;;;
3.901;5;8;97;3q29;PPP1R2, IPP2;;Protein phosphatase-1, regulatory (inhibitor) subunit 2;601792;A;pseudogenes on chr. 5 and 6;;
3.902;4;1;09;3q29;RNF168;;RING finger protein 168;612688;REc;;RIDDLE syndrome, 611943 (3);
3.903;12;4;15;3q29;RUBCN, RUBICON, KIAA0226, SCAR15;;RUN domain and cysteine-rich domain containing, Beclin 1-interacting protein;613516;REc, R;mutation identified in 1 family;?Spinocerebellar ataxia, autosomal recessive 15, 615705 (3);
3.904;7;9;09;3q29;SENP5;;Sentrin-specific protease family, member 5;612845;REc;;;
3.905;3;27;17;3q29;TCTEX1D2, SRTD17;;TCTEX1 domain-containing protein 2;617353;REc;;Short-rib thoracic dysplasia 17 with or without polydactyly, 617405 (3);
3.906;1;8;16;3q29;TFRC, TFR, CD71, IMD46;;Transferrin receptor;190010;S, H, REa, A, R, F;;Immunodeficiency 46, 616740 (3);16(Trfr)
3.907;8;28;09;3q29;TNK2, ACK, ACK1;;Tyrosine kinase, non-receptor, 2;606994;R, REc;;;
3.908;6;19;15;3q29;UBXN7, KIAA0794;;UBX domain protein 7;616379;REc;;;
3.909;3;14;13;3q29;WDR53;;WD repeat-containing protein 53;615110;REc;;;
3.910;4;2;12;3q29;XXYLT1, C3orf21;;Xyloside xylosyltransferase 1;614552;REc;;;
3.911;5;28;98;3p21.2;RPL29, HIP;;Ribosomal protein L29;601832;Psh, R, A;;;9(Rpl29)
3.912;1;13;09;3q29;RPL35A, DBA5;;Ribosomal protein L35A;180468;REa, A;previous assignment to chr.18 in error;Diamond-Blackfan anemia 5, 612528 (3);
4.1;1;7;02;4p16.3;ADD1;;Adducin-1, alpha;102680;REa, REb;;{Hypertension, essential, salt-sensitive}, 145500 (3);5(Add1)
4.2;9;8;11;4p16.3;ATP5I, ATP5K;;ATP synthase, H+ transporting, mitochondrial FO complex, subunit E;601519;REc;;;5(Atp5k)
4.3;7;20;12;4p16.3;C4orf48;;chromosome 4 open reading frame 48;614690;REc;;;
4.4;5;17;18;4p16.3;CPLX1, CPX1, EIEE63;;Complexin 1;605032;REc;;Epileptic encephalopathy, early infantile, 63, 617976 (3);
4.5;12;10;13;4p16.3;CRIPAK, FLJ3443;;Cysteine-rich inhibitor of PAK1;610203;REc;;;
4.6;3;25;03;4p16.3;D4S234E, D4S234;;D4S234E gene;607645;REc;;;
4.7;10;15;98;4p16.3;DGKQ, DAGK4;;Diacylglycerol kinase, theta, 110kD;601207;REc, H;;;5(Dagk4)
4.8;12;5;16;4p16.3;FAM53A, DNTNP;;Family with sequence similarity 53, member A;617229;REc;;;
4.9;10;11;06;4p16.3;FGFR3, ACH;;Fibroblast growth factor receptor-3;134934;REn, Fd;;Achondroplasia, 100800 (3); Hypochondroplasia, 146000 (3); Thanatophoric dysplasia, type I, 187600 (3); Crouzon syndrome with acanthosis nigricans, 612247 (3); Muenke syndrome, 602849 (3); Bladder cancer, somatic, 109800 (3); Colorectal cancer, somatic, 114500 (3); Cervical cancer, somatic, 603956 (3); LADD syndrome, 149730 (3); CATSHL syndrome, 610474 (3); Nevus, epidermal, somatic, 162900 (3); Thanatophoric dysplasia, type II, 187601 (3); Spermatocytic seminoma, somatic, 273300 (3); SADDAN, 616482 (3);5(Fgfr3)
4.10;5;29;12;4p16.3;GRK4, GPRK2L, GPRK4;;G protein-coupled receptor kinase 4;137026;RE, H;;;5(Gprk2l)
4.11;11;1;10;4p16.3;HAUS3, DGT3, C4orf15;;HAUS augmin-like complex, subunit 3;613430;REc;;;
4.12;4;20;17;4p16.3;HTT, HD, IT15, LOMARS;;Huntingtin;613004;Fd;distal to D4S10;Huntington disease, 143100 (3); Lopes-Maciel-Rodan syndrome, 617435 (3);5(Hdh)
4.13;10;29;03;4p16.3;IDUA, IDA;;Iduronidase, alpha-L-;252800;REa, A, S;;Mucopolysaccharidosis Ih, 607014 (3); Mucopolysaccharidosis Is, 607016 (3); Mucopolysaccharidosis Ih/s, 607015 (3);5(Idua)
4.14;2;1;00;4p16.3;LETM1;;Leucine zipper/EF-hand-containing transmembrane protein 1;604407;A;;;
4.15;9;30;13;4p16.3;LRPAP1, A2MRAP, MYP23;;Low density lipoprotein-related protein-associated protein 1 (alpha-2-macroglobulin receptor-associated protein 1);104225;A, REn;;Myopia 23, autosomal recessive, 615431 (3);
4.16;9;22;17;4p16.3;LYAR;;Ly1 antibody-reactive protein, mouse, homolog of;617684;REc;;;1(Lyar)
4.17;8;30;09;4p16.3;MAEA, EMP;;Macrophage erythroblast attacher;606801;R, REc;;;
4.18;11;30;11;4p16.3;MDCMP;;Muscular dystrophy, congenital, merosin-positive;609456;Fd;max lod at D4S432;Muscular dystrophy, congenital, merosin-positive (2);
4.19;3;22;93;4p16.3;MYL5;;Myosin, light polypeptide-5, regulatory;160782;RE;;;
4.20;1;29;14;4p16.3;NAT8L, CML3, NACED;;N-acetyltransferase 8-like;610647;REc;mutation identified in 1 patient;?N-acetylaspartate deficiency, 614063 (3);
4.21;2;16;18;4p16.3;NKX1-1, SAX2;;NK1 homeobox 1;617869;REc;;;
4.22;4;20;17;4p16.3;NSD2, WHSC1, MMSET;;Nuclear receptor-binding SET domain protein 2;602952;REc, Ch;;;
4.23;7;13;09;4p16.3;NOP14, NOL14, RES425;;Nop14, S. cerevisiae, homolog of;611526;REc;;;
4.24;6;27;17;4p16.3;PCGF3, RNF3, RNF3A;;Polycomb group RING finger protein 3;617543;REc;;;
4.25;12;22;09;4p16.3;PDE6B, PDEB, RP40, CSNBAD2;;Phosphodiesterase-6B, cGMP-specific, rod, beta;180072;REa, A, Fd;;Night blindness, congenital stationary, autosomal dominant 2, 163500 (3); Retinitis pigmentosa-40, 613801 (3);5(Pdeb, rd)
4.26;5;2;16;4p16.3;PIGG, GPI7, MRT53;;Phosphatidylinositol glycan anchor biosynthesis class G protein;616918;REc;;Mental retardation, autosomal recessive 53, 616917 (3);
4.27;11;20;98;4p16.3;RNF4;;RING finger protein-4;602850;REn;;;
4.28;6;9;08;4p16.3;RNF212, ZHP3;;Ring finger protein 212;612041;REn;;Recombination rate QTL 1, 612042 (3);
4.29;5;30;01;4p16.3;SH3BP2, CRPM;;SH3-domain binding protein 2;602104;REn, Fd;;Cherubism, 118400 (3);
4.30;3;27;01;4p16.3;SLBP, HBP;;Histone stem-loop binding protein;602422;REc;;;
4.31;7;1;16;4p16.3;SLC26A1, SAT1, CAON;;Solute carrier family 26 (sulfate transporter), member 1;610130;R;mutation identified in 1 CAON patient;?Nephrolithiasis, calcium oxalate, 167030 (3);
4.32;5;11;01;4p16.3;SPON2;;Spondin 2;605918;R;;;
4.33;5;5;15;4p16.3;TACC3;;Transforming, acidic, coiled-coil-containing protein 3;605303;Psh, R;;;5(Tacc3)
4.34;5;22;07;4p16.3;TETRAN, TPO1;;Tetracycline transporter-like protein;610977;REc;;;
4.35;9;22;14;4p16.3;TMEM129;;Transmembrane protein 129;615975;REc;;;
4.36;11;24;15;4p16.3;TMEM175;;Transmembrane protein 175;616660;REc;;;
4.37;12;29;06;4p16.3;TNIP2, ABIN2, FLIP1;;TNFAIP3-interacting protein 2;610669;R, REc;;;
4.38;5;26;12;4p16.3;UVSSA, KIAA1530, UVSS3;;UV-stimulated scaffold protein A;614632;R, REc;;UV-sensitive syndrome 3, 614640 (3);
4.39;6;10;10;4p16.3;WHS;;Wolf-Hirschhorn syndrome;194190;Ch;contiguous gene syndrome; critical region 200kb region 1.9Mb from telomere;Wolf-Hirschhorn syndrome (4);
4.40;6;10;10;4p16.3;WHSC2;;WHS candidate 2 gene;606026;REc;;;
4.41;2;25;15;4p16.3;ZBTB49, ZNF509;;Zinc finger- and BTB domain-containing protein 49;616238;REc;;;
4.42;5;13;13;4p16.3;ZNF141, D4S90, PAPA6;;Zinc finger protein-141 (clone pHZ-44);194648;Psh, A, Ch;1 family identified with mutation;?Polydactyly, postaxial, type A6, 615226 (3);
4.43;1;18;12;4p16.2;CYTL1, C17;;Cytokine-like protein 1;607930;R, REc;;;
4.44;4;30;15;4p16.3;DOK7, C4orf25, CMS10;;Downstream of tyrosine kinase 7;610285;REc;mutation identified in 1 FADS family;Myasthenic syndrome, congenital, 10, 254300 (3); ?Fetal akinesia deformation sequence, 208150 (3);
4.45;5;23;13;4p16.1;JAKMIP1, JAMIP1, MARLIN1;;Janus kinase and microtubule-interacting protein 1;611195;REc;;;
4.46;6;12;14;4p16.3;OTOP1;;Otopetrin 1;607806;REc, H;;;5(Otop1)
4.47;4;17;07;4p16.3;POLN;;Polymerase, DNA, nu;610887;REc, H;;;5(Poln)
4.48;7;16;13;4p16.3;RGS12;;Regulator of G protein signaling 12;602512;REc, H;;;5(Rgs12)
4.49;2;23;09;4p16.3;ADRA2C, ADRA2L2;;Adrenergic, alpha-2C-, receptor;104250;REa, Fd;linked to D4S10;{Congestive heart failure and beta-blocker response, modifier of} (3);
4.50;1;5;12;4p16.1;AFAP1, AFAP, AFAP110;;Actin filament-associated protein 1;608252;REc;;;
4.51;4;17;13;4p16.1;BLOC1S4, BLOS4, CNO;;Biogenesis of lysosome-related organelles complex 1, subunit 4;605695;R, REc, H;;;5(cno)
4.52;1;11;16;4p15.33;BOD1L1, FAM44A;;BOD1-like protein 1;616746;REc;;;
4.53;7;17;14;4p16.1;CLNK, MIST;;Cytokine-dependent hematopoietic cell linker;611434;REc;;;
4.54;6;19;12;4p16.1;CPZ;;Carboxypeptidase Z;603105;REc;;;
4.55;8;30;09;4p16.1;GPR78;;G protein-coupled receptor 78;606921;REc;;;
4.56;6;27;08;4p16.1;HMX1, H6;;Homeo box (H6 family) 1;142992;Psh, Fd;;Oculoauricular syndrome, 612109 (3);5(Hmx1)
4.57;1;16;07;4p16.1;HTRA3, PRSP;;HTRA serine peptidase 3;608785;REc;;;
4.58;4;21;16;4p16.1;MRFAP1, PAM14, PGR1`;;MORF4 family- associated protein 1;616905;REc;;;
4.59;12;17;12;4p16.2;MSX1, HOX7, HYD1, OFC5, STHAG1, ECTD3;;Muscle segment homeo box, Drosophila, homolog of, 1 (homeo box 7);142983;REa, A, D, Fd;;Tooth agenesis, selective, 1, with or without orofacial cleft, 106600 (3); Orofacial cleft 5, 608874 (3); Ectodermal dysplasia 3, Witkop type, 189500 (3);5(Hox7)
4.60;4;13;10;4p15.33;NKX3-2, BAPX1, SMMD;;Bagpipe homeo box, Drosophila, homolog of;602183;Fd;;Spondylo-megaepiphyseal-metaphyseal dysplasia, 613330 (3);5(Bapx1)
4.61;8;30;09;4p16.1;SORCS2, KIAA1329;;SORCS receptor 2;606284;R, REc;;;
4.62;4;26;10;4p16.1;TADA2B, ADA2B;;Transcriptional adaptor 2B;608790;REc;;;
4.63;10;11;12;4p16.1;TBC1D14, KIAA1322;;TBC1 domain family, member 14;614855;R, REc;;;
4.64;10;10;18;4p16.1;TRMT44, METTL19;;tRNA methyltransferase 44, S. cerevisiae, homolog of;614309;REc;;;
4.65;7;21;15;4p16.1;USP17L9P, USP17;;Ubiquitin-specific protease 17-like family member 9, pseudogene;607011;A;;;
4.66;1;14;14;4p16.1;WFS1, WFRS, WFS, DFNA6, DFNA14, DFNA38, WFSL, CTRCT41;;Wolframin;606201;Fd;mutation identified in 1 CTRCT41 family;Wolfram syndrome 1, 222300 (3); Deafness, autosomal dominant 6/14/38, 600965 (3); Wolfram-like syndrome, autosomal dominant, 614296 (3); {Diabetes mellitus, noninsulin-dependent, association with}, 125853 (3); ?Cataract 41, 116400 (3);
4.67;10;25;17;4p16.1;ZNF518B, KIAA1729;;Zinc finger protein 518B;617734;REc;;;
4.68;4;8;98;4p16.2;CRMP1, DPYSL1, DRP1;;Collapsin response mediator protein-1;602462;REc;;;
4.69;5;18;18;4p16.1;DRD5, DRD1B, DRD1L2;;Dopamine receptor D5;126453;REa, A, REc, R, Psh, Fd;pseudogenes on 2p11 and 1q21;{Blepharospasm, primary benign}, 606798 (3); {Attention deficit-hyperactivity disorder, susceptibility to}, 143465 (3);5(Drd5)
4.70;1;24;09;4p16.1;ABLIM2, KIAA1808;;Actin-binding LIM protein family, member 2;612544;REc, H;;;5(Ablim2)
4.71;7;8;95;4p16;CRSA, CRS3;;Craniosynostosis, Adelaide type;600593;Fd;;Craniosynostosis, Adelaide type (2);
4.72;3;27;18;4p16.3;CTBP1, HADDTS;;C-terminal binding protein 1;602618;R;;Hypotonia, ataxia, developmental delay, and tooth enamel defect syndrome, 617915 (3);
4.73;4;10;17;4p16.2;EVC;;EVC gene;604831;Fd;mutation identified in 1 WAD patient;Ellis-van Creveld syndrome, 225500 (3); ?Weyers acrofacial dysostosis, 193530 (3);
4.74;4;26;01;4p16.3;FGFRL1;;Fibroblast growth factor receptor-like 1;605830;A;;;
4.75;3;9;98;4p16.3;GAK;;Cyclin G associated kinase;602052;A;;;
4.76;3;11;09;4p16.1;GRPEL1, HMGE;;GrpE, E. coli, homolog of;606173;REc;;;
4.77;5;4;00;4p16.3;HGFAC, HGFA;;Hepatocyte growth factor activator;604552;A, REa;;;
4.78;5;7;03;4p15.32;KSP37;;Killer-specific secretory protein, 37kD;607713;REc;;;
4.79;5;8;15;4p16.2;EVC2, LBN, WAD;;EVC2 (limbin) gene;607261;H, REc, Fd;;Ellis-van Creveld syndrome, 225500 (3); Weyers acrofacial dysostosis, 193530 (3);5(Lbn)
4.80;1;13;09;4p16;PLSA1, PLSA;;Primary lateral sclerosis, adult, 1;611637;Fd;max lod at D4S2936;Primary lateral sclerosis, adult, 1 (2);
4.81;7;2;01;4p16.1;PPP2R2C, PR52;;Protein phosphatase 2A, regulatory subunit B, gamma isoform;605997;R;;;
4.82;7;8;95;4p16.1;S100P;;S100 calcium-binding protein P;600614;A;;;
4.83;9;6;11;4p16.3;ZFYVE28, LST2, KIAA1643;;Zinc finger FYVE domain-containing protein 28;614176;R, REc;;;
4.84;1;24;09;4p16.1;SLC2A9, GLUT9, UAQTL2;;Solute carrier family 2 (facilitated glucose transporter), member 9;606142;Psh, R;;{Uric acid concentration, serum, QTL 2}, 612076 (3); Hypouricemia, renal, 2, 612076 (3);
4.85;12;21;00;4p16-p15.2;SLEB3;;Systemic lupus erythematosus, susceptibility to, 3;605480;Fd;;{Systemic lupus erythematosus, susceptibility to, 3} (2);
4.86;11;13;18;4p16-p15;MNDEC;;Microtia with nasolacrimal duct imperforation and eye coloboma;611863;REn;copy number variant (CNV) association;Microtia with nasolacrimal duct imperforation and eye coloboma (4);
4.87;4;27;12;4p16-p15;SPG38;;Spastic paraplegia 38, autosomal dominant;612335;Fd;between D4S432 and D4S1599;Spastic paraplegia 38, autosomal dominant (2);
4.88;4;22;10;4p16-q34;INTLQ1;;Intelligence quantitative trait locus 1;603783;Fd;associated with D4S2943, MSX1, and D4S1607;{Intelligence QTL1} (2);
4.89;8;30;09;4p15.32;FBXL5, FBL5;;F-box and leucine-rich repeat protein 5;605655;R, REc;;;
4.90;7;18;14;4p15.33;HS3ST1, 3OST, 3OST1;;Heparan sulfate (glucosamine)3-O-sulfotransferase 1;603244;REc;;;
4.91;9;9;13;4p15.33;RAB28, CORD18;;Ras-associated protein 28;612994;REc;;Cone-rod dystrophy 18, 615374 (3);
4.92;1;13;11;4p15.32;BST1;;Bone marrow stromal cell antigen 1;600387;REc;previously assigned to 14q32.3;;
4.93;5;24;13;4p15.32;MED28, EG1, MAGICIN;;Mediator complex subunit 28;610311;REc;;;
4.94;4;8;16;4p15.32;TAPT1, CMVFR, OCLSBG;;Transmembrane anterior posterior transformation 1;612758;REc;;Osteochondrodysplasia, complex lethal, Symoens-Barnes-Gistelinck type, 616897 (3);5(Tapt1)
4.95;1;13;09;4p15.2;GBA3, CBGL1;;Glucosidase, beta, acid 3;606619;R, REc;;;
4.96;1;29;16;4p15.31;MIR218-1;;Micro RNA 218-1;616770;REn, REc;within intron of SLIT2;;5(Mir218-1)
4.97;4;15;09;4p15.32;QDPR, DHPR;;Quinoid dihydropteridine reductase;612676;S, A, REa, D;;Hyperphenylalaninemia, BH4-deficient, C, 261630 (3);5(Qdpr)
4.98;5;25;16;4p15.2;SLC34A2;;Solute carrier family 34 (sodium/phosphate cotransporter), member 2;604217;REc, Fd;;Pulmonary alveolar microlithiasis, 265100 (3);
4.99;1;12;99;4p16.1;ACOX3;;Acyl-coenzyme A oxidase 3, pristanoyl;603402;A;;;
4.100;7;8;10;4p15.32;CC2D2A, KIAA1345, MKS6;;Coiled-coil and C2 domains-containing protein 2A;612013;REc;;Joubert syndrome 9, 612285 (3); Meckel syndrome 6, 612284 (3); COACH syndrome, 216360 (3);
4.101;4;30;09;4p15.2;DHX15, DDX15, DBP1, HRH2;;DEAH (Asp-Glu-Ala-His) box polypeptide 15;603403;A;;;
4.102;8;30;09;4p15.32;FGFBP1, FGFBP, HBP17;;Fibroblast growth factor-binding protein 1;607737;R, REc;;;
4.103;11;13;01;4p15.3;HDL3, HLN2;;Huntington disease-like 3;604802;Fd;;Huntington disease-like 3 (2);
4.104;10;29;03;4p15.3-p15.2;KCNIP4, KCHIP4;;Kv channel-interacting protein 4;608182;REc;;;
4.105;8;30;09;4p15.31;NCAPG, CAPG;;Non-SMC condensin I complex subunit G;606280;R, REc;;;
4.106;2;17;09;4p15.31;LCORL, MLR1;;Ligand-dependent nuclear receptor corepressor-like protein;611799;R, REc;;;
4.107;3;23;09;4p15.32;PROM1, PROML1, AC133, RP41, CORD12, CD133, MCDR2, STGD4;;Prominin 1;604365;Fd, REc;;Retinitis pigmentosa 41, 612095 (3); Cone-rod dystrophy 12, 612657 (3); Stargardt disease 4, 603786 (3); Macular dystrophy, retinal, 2, 608051 (3);
4.108;2;17;09;4p15.3;STQTL13;;Stature quantitative trait locus 13;612226;Fd;associated with rs16896068;{Stature QTL 13} (2);
4.109;12;1;03;4p15.2;SOD3;;Superoxide dismutase-3, extracellular;185490;REa, R, Fd, A;;[Superoxide dismutase, elevated extracellular] (3);
4.110;8;30;09;4p15.2;ANAPC4, APC4;;Anaphase-promoting complex, subunit 4;606947;R, REc;;;
4.111;9;1;16;4p15.2;ADGRA3, GPR125;;Adhesion G protein-coupled receptor A3;612303;REc;;;
4.112;12;4;03;4p15.2;LGI2, KIAA1916;;Leucine-rich gene, glioma-inactivated, 2;608301;REc;;;
4.113;6;27;08;4p15.2;PI4K2B;;Phosphatidylinositol 4-kinase, type 2, beta;612101;R, REc;;;
4.114;9;10;12;4p15.2;RBPJ, RBPSUH, IGKJRB1, AOS3;;Recombination signal-binding protein 1 for kappa J region;147183;REc;pseudogenes at 9q13, 9p13, and 3q25;Adams-Oliver syndrome 3, 614814 (3);5(Rbpsuh)
4.115;3;28;11;4p15.2;SEPSECS, SLA, LP, PCH2D;;O-phosphoserine tRNA-selenocysteine tRNA synthase;613009;R, REc;;Pontocerebellar hypoplasia type 2D, 613811 (3);
4.116;4;26;17;4p15.2;SMIM20, MITRAC7, C4orf52;;Small integral membrane protein 20;617465;REc;;;
4.117;2;2;01;4p15.31;SLIT2;;Slit, Drosophila, homolog of, 2;603746;A;;;
4.118;2;14;08;4p15.2;ZCCHC4;;Zinc finger CCHC domain-containing protein 4;611792;R, REc;;;
4.119;6;15;99;4p15.2;CCKAR;;Cholecystokinin A receptor;118444;Psh, H, A;;;5(Cckar)
4.120;3;27;09;4p15.2;PPARGC1A, PPARGC1;;Peroxisome proliferator-activated receptor-gamma, coactivator 1, alpha;604517;R;;;
4.121;3;12;07;4p15.2;STIM2, KIAA1482;;Stromal interaction molecule 2;610841;REc, R, H;;;5(Stim2)
4.122;3;1;01;4p14;UGDH, UDPGDH;;UDP-glucose dehydrogenase;603370;H, R;;;5(Udgh)
4.123;9;9;03;4p14;KLHL5;;Kelch-like 5;608064;REc;;;
4.124;4;23;08;4p15.1-q12;NPC1, NPCA1;;Nasopharyngeal carcinoma 1;607107;Fd;?associated with acyl-CoA thioesterase 7-like;{Nasopharyngeal carcinoma 1} (2);
4.125;5;22;03;4p14;CHRNA9;;Cholinergic receptor, neuronal nicotinic, alpha polypeptide 9;605116;A, R;;;
4.126;3;20;06;4p14;TBC1D1, KIAA1108;;TBC1 domain family, member 1;609850;REa, H;;;5(Tbc1d1)
4.127;5;9;95;4p15.32;CD38;;CD38 antigen (p45); ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase;107270;S, A;;;
4.128;10;7;02;4p15;EPPS;;Epilepsy, partial, with pericentral spikes;607221;Fd;;Epilepsy, partial, with pericentral spikes (2);
4.129;2;4;99;4p15.32;LDB2, CLIM1;;LIM domain-binding factor-2;603450;R;;;
4.130;11;20;98;4p15.1;PCDH7, BHPCDH;;Protocadherin-7;602988;Psh;;;
4.131;10;08;08;4p15-p14;BMIQ7;;Body mass index quantitative trait locus 7;608410;near D4S2912;;{Obesity, susceptibility to, BMIQ7} (2);
4.132;4;14;05;4p14-p13;APBB2, FE65L1;;Amyloid beta A4 precursor protein-binding, family B, member 2 (Fe65-like 1);602710;R, REc;;;
4.133;8;30;09;4p14;ARAP2, CENTD1, KIAA0580;;ArfGAP with RhoGAP domain, ankyrin repeat and PH domain 2;606645;R, REc;;;
4.134;6;16;16;4p14;DTHD1;;Death domain-containing protein 1;616979;REc;;;
4.135;11;20;98;4p14;HIP2;;Huntingtin-interacting protein-2;602846;A;;;
4.136;9;10;07;4p14;KLB, BKL;;Klotho, beta;611135;REc;;;
4.137;12;6;16;4p14;KLF3, BKLF;;Kruppel-like factor 3;609392;REc;;;
4.138;3;20;16;4p14;LIAS, PDHLD, HGCLAS;;Lipoic acid synthase;607031;REc;;Hyperglycinemia, lactic acidosis, and seizures, 614462 (3);
4.139;12;10;13;4p14;MIR574, MIR574-3p;;Micro RNA 574;615469;REc;;;
4.140;5;30;17;4p14;NSUN7;;NOP2/SUN RNA methyltransferase family, member 7;617185;REc;;;
4.141;10;3;11;4p14;PDS5A, KIAA0648, SCC112;;PDS5, regulator of cohesion maintenance, S. Cerevisiae, homolog of, A;613200;R, REc;;;
4.142;5;26;13;4p14;RELL1;;Relt-like 1;611212;R, REc;;;
4.143;2;21;10;4p14;TLR1, TIL. LPRS5;;Toll-like receptor-1;601194;A;;{Leprosy, protection against}, 613223 (3); {Leprosy, susceptibility to, 5}, 613223 (3);
4.144;8;30;09;4p14;TLR6;;Toll-like receptor 6;605403;REc;;;5(Tlr6)
4.145;7;2;18;4p14;TLR10;;Toll-like receptor 10;606270;REc;;;
4.146;2;15;17;4p13;UCHL1, PARK5, SPG79, NDGOA;;Ubiquitin C-terminal esterase L1;191342;A, Psh;mutation identified in 1 PARK5 family;{?Parkinson disease 5, susceptibility to}, 613643 (3); Spastic paraplegia 79, autosomal recessive, 615491 (3);
4.147;1;9;13;4p14;UCH1LAS;;Ubiquitin carboxyl-terminal esterase L1, antisense;614991;REn;;;
4.148;3;5;95;4p14;RFC1, RECC1;;Replication factor C1, 145kD (activator 1, 145kD);102579;A;;;5(Rfc1)
4.149;4;23;08;4p14;LOC344967;;Acyl-CoA thioesterase 7-like;611963;REc;?associated with nasopharyngeal carcinoma;;
4.150;4;10;15;4p14;WDR19, SRTD5, ATD5, NPHP13, CED4;;WD repeat-containing protein 19;608151;R;mutation identified in 1 CED4 family and 1 SRTD5 family;Nephronophthisis 13, 614377 (3); ?Cranioectodermal dysplasia 4, 614378 (3); ?Short-rib thoracic dysplasia 5 with or without polydactyly, 614376 (3); Senior-Loken syndrome 8, 616307 (3);
4.151;5;16;95;4p12;GABRA4;;Gamma-aminobutyric acid (GABA) A receptor, alpha-4;137141;Psh;cluster with GABRA2, B1, G1; ?involved in autism;;7(Gabra4)
4.152;10;23;87;4p14;PGM2;;Phosphoglucomutase-2;172000;S;;;5(Pgm1)
4.153;1;30;91;4q21.21;BMP3;;Bone morphogenetic protein-3;112263;H, REa;;;5(Bmp3)
4.154;8;21;92;4p12;GABRG1;;Gamma-aminobutyric acid (GABA) A receptor, gamma-1;137166;Psh, REl;;;
4.155;3;5;98;4p14;ARHH, TTF;;Ras homolog gene family, member H;602037;A;;;
4.156;2;19;10;4p12;GNPDA2, GNP2;;Glucosamine-6-phosphate deaminase 2;613222;REc;;;
4.157;2;25;10;4p13;GRXCR1;;Glutaredoxin, cysteine-rich, 1;613283;REc, H;;Deafness, autosomal recessive 25, 613285 (3);5(Grxcr1)
4.158;10;30;17;4p13;LIMCH1, LMO7B;;LIM and calponin homology domains-containing protein 1;617750;REc;;;
4.159;6;15;99;4p14;RPL9;;Ribosomal protein L9;603686;Psh, A;pseudogene on Xpter-p21;;
4.160;2;2;17;4p13;SHISA3;;Shisa family, member 3;617325;REc;;;
4.161;8;8;17;4p13;SLC30A9, C4orf1, HUEL, BILAPES;;Solute carrier family 30 (zinc transporter), member 9;604604;A;mutation identified in 1 BILAPES family;?Birk-Landau-Perez syndrome, 617595 (3);
4.162;1;25;12;4p12;GABRA2;;Gamma-aminobutyric acid (GABA) A receptor, alpha-2;137140;A;;{Alcohol dependence, susceptibility to}, 103780 (3);5(Gabra2)
4.163;10;12;16;4p12;GABRB1, EIEE45;;Gamma-aminobutyric acid (GABA) A receptor, beta-1;137190;A, Fd;;Epileptic encephalopathy, early infantile, 45, 617153 (3);5(Gabrb1)
4.164;1;6;09;4p13-q21;NRCLP2;;Narcolepsy 2;605841;Fd;max lod at D4S2987;Narcolepsy 2 (2);
4.165;11;20;15;4p12;COMMD8;;COMM domain-containing protein 8;616656;REc;;;
4.166;4;27;12;4p12;CORIN, CRN, TMPRSS10, ATC2, PEE5;;Corin, serine peptidase;605236;A, REc;;Preeclampsia/eclampsia 5, 614595 (3);
4.167;4;21;10;4p12;COX7B2;;Cytochrome C oxidase subunit VIIb2;609811;REc;;;
4.168;8;10;16;4p12;GUF1, EF4, EIEE40;;GTPase, S. cerevisiae, homolog of;617064;REc;mutation identified in 1 EIEE40 family;?Epileptic encephalopathy, early infantile, 40, 617065 (3);
4.169;1;31;18;4p13;PHOX2B, NBPHOX, PMX2B, NBLST2, CCHS;;Paired mesoderm homeo box 2B;603851;R;;Central hypoventilation syndrome, congenital, with or without Hirschsprung disease, 209880 (3); {Neuroblastoma, susceptibility to, 2}, 613013 (3); Neuroblastoma with Hirschsprung disease, 613013 (3);
4.170;10;22;99;4p14;PTTG2;;Pituitary tumor-transforming gene 2;604231;R;;;
4.171;12;13;95;4p12-p11;TEC;;tec protein tyrosine kinase;600583;A;;;
4.172;10;12;94;4p12;TXK, BTKL;;TXK tyrosine kinase;600058;A;;;5(Txk)
4.173;3;10;11;4p12;CNGA1, CNCG1, RP49;;Cyclic nucleotide gated channel, alpha 1;123825;REa, Psh;;Retinitis pigmentosa 49, 613756 (3);5(Cncg)
4.174;2;25;15;4p11;SLAIN2, KIAA1458;;SLAIN motif family, member 2;610492;REc, R, H;;;5(Slain2)
4.175;8;31;09;4p11;ZAR1;;Zygote arrest 1;607520;REc;;;5(Zar1)
4.176;10;23;87;4p15.32;PEPS;;Peptidase S;170250;S, EM;;;5(Pep7)
4.177;6;16;99;4p;MHW1;;Mental health wellness 1;603663;Fd;at D4S2949;{Mental health wellness-1} (2);
4.178;12;14;00;4p16.1;WDR1;;WD repeat-containing protein 1;604734;R;;;
4.179;6;16;99;4q;MHW2;;Mental health wellness 2;603664;Fd;at D4S397;{Mental health wellness-2} (2);
4.180;10;8;96;4q;PSORS3;;Psoriasis susceptibility 3;601454;Fd;;{Psoriasis susceptibility 3} (2);
4.181;9;20;00;4q25;RRH;;Rhodopsin homolog, retinal pigment epithelium-derived (peropsin);605224;H;;;3(Rrh)
4.182;2;28;07;4q;WM2;;Macroglobulinemia, Waldenstrom, susceptibility to, 2;610430;Fd;between D4S2910 and D4S1539;{Macroglobulinemia, Waldenstrom, susceptibility to, 2} (2);
4.183;12;17;07;4q12;PDCL2;;Phosducin-like 2;611676;REc;;;5(Pdcl2)
4.184;5;5;00;4q12;CHIC2, BTL;;Cysteine-rich hydrophobic domain 2 (Brx-like gene translocated in leukemia);604332;Ch;;{Leukemia, acute myeloid}, 601626 (3);
4.185;8;30;09;4q12;HOPX, HOP;;HOP homeobox;607275;R, REc;;;
4.186;7;15;09;4q12;SPATA18, SPETEX1;;Spermatogenesis-associated protein 18;612814;REc;;;
4.187;10;12;94;4q13.3;AFM, ALBA, ALB2;;Afamin;104145;REn, Psh;10kb 3' of AFP;;
4.188;9;20;14;4q13.3;AFP, HPAFP, AFPD;;Alpha-fetoprotein;104150;H, A, Fd, F;order: 5'-ALB-3'--5'-AFP-3';[Hereditary persistence of alpha-fetoprotein], 615970 (3); Alpha-fetoprotein deficiency, 615969 (3);5(Afp)
4.189;9;10;14;4q13.3;ALB, ANALBA, FDAH;;Albumin;103600;F, A, REa;linked to GC;Analbuminemia, 616000 (3); [Dysalbuminemic hyperthyroxinemia], 615999 (3);5(Alb1)
4.190;10;23;87;4q13.3;STATH;;Statherin;184470;REa;;;
4.191;12;5;11;4q12;AASDH, ACSF4;;Aminoadipate-semialdehyde dehydrogenase;614365;REc;;;
4.192;12;18;08;4q12;ARL9;;ADP-ribosylation factor-like 9;612405;REc;;;
4.193;5;3;17;4q12;CEP135, KIAA0635, MCPH8;;Centrosomal protein, 135kD;611423;REc;;Microcephaly 8, primary, autosomal recessive, 614673 (3);
4.194;8;27;01;4q12;CLOCK;;Circadian locomotor output cycles kaput;601851;R, H;;;5(Clock)
4.195;6;1;12;4q12;DANCR, ANCR, KIAA0114;;Differentiation-antagonizing noncoding RNA;614625;REc, R;;;
4.196;9;9;09;4q12;DCUN1D4, KIAA0276;;DCN1 domain-containing protein 4;612977;R, REc;;;
4.197;7;7;09;4q12;EXOC1, SEC3;;Exocyst complex component 1;607879;R, REc;;;
4.198;5;28;03;4q12;FIP1L1;;Fip1-like 1;607686;REn, REc;fused to PDGFRA in hypereosinophilic syndrome;;
4.199;9;4;14;4q13.3;GC, DBP;;Group-specific component (vitamin D-binding protein);139200;F, Fc, H, D, Ch, REa, A;4q13-q21.1 by in situ hybridization;;5(Gc)
4.200;12;4;03;4q13.2;GRINL1B;;Glutamate receptor, ionotropic, N-methyl D-aspartate-like 1B;608311;A;;;
4.201;3;23;15;4q12;GSX2, GSH2;;GS homeobox 2;616253;REc;;;
4.202;9;14;11;4q12;IGFBP7, MAC25, RAMSVPS;;Insulin-like growth factor-binding protein-7;602867;A, Psh;;Retinal arterial macroaneurysm with supravalvular pulmonic stenosis, 614224 (3);
4.203;12;28;08;4q12;LNX1, LNX, PDZRN2;;Ligand of numb protein X1;609732;R;;;
4.204;6;1;12;4q12;MIR4449;;Micro RNA 4449;614627;REc;;;
4.205;7;18;06;4q12;MYP9;;Myopia 9;609258;Fd;;Myopia 9 (2);
4.206;09;27;18;4q12;SGCB, LGMDR4;;Sarcoglycan, beta (43kD dystrophin-associated glycoprotein);600900;Psh, A, Fd, LD;;Muscular dystrophy, limb-girdle, autosomal recessive 4, 604286 (3);
4.207;12;24;08;4q12;KDR;;Kinase insert domain receptor;191306;REa, A, REn;?mutant in TAPVR1;Hemangioma, capillary infantile, somatic, 602089 (3); {Hemangioma, capillary infantile, susceptibility to}, 602089 (3);
4.208;6;25;18;4q12;KIT, PBT, MASTC;;Hardy-Zuckerman 4 feline sarcoma (v-kit) oncogene;164920;REa, A, H, Ch, H, REn;same 700bp segment as PDGFRA;Piebaldism, 172800 (3); Gastrointestinal stromal tumor, familial, 606764 (3); Leukemia, acute myeloid, 601626 (3); Germ cell tumors, somatic, 273300 (3); Mastocytosis, cutaneous, 154800 (3); Mastocytosis, systemic, somatic, 154800 (3);5(Kit; W)
4.209;12;12;12;4q12;NOA1, C4orf14;;Nitric oxide-associated protein 1;614919;REc;;;
4.210;6;16;94;4q12;PAICS, AIRC;;Phosphoribosylaminoimidazole carboxylase;172439;S, REn;bifunctional enzyme; ade-D; 625bp from PPAT;;
4.211;4;11;03;4q12;PDGFRA;;Platelet-derived growth factor receptor, alpha polypeptide;173490;A, REa, REn;same 700bp segment as KIT; fused to BCR or FIP1L1;Gastrointestinal stromal tumor, somatic, 606764 (3); Hypereosinophilic syndrome, idiopathic, resistant to imatinib, 607685 (3);5(Pdgfra)
4.212;5;2;94;4q12;POL2RB;;Polymerase (RNA) II (DNA directed) polypeptide B, 140kD;180661;A;;;
4.213;6;16;94;4q12;PPAT, GPAT;;Phosphoribosylpyrophosphate amidotransferase;172450;S, H, A;;;
4.214;12;18;08;4q12;RASL11B;;RAS-like, family 11, member B;612404;REc;;;
4.215;8;15;17;4q12;REST, NRSF, WT6, GINGF5, HGF5;;RE1-silencing transcription factor;600571;R, REc;;{Wilms tumor 6, susceptibility to}, 616806 (3); Fibromatosis, gingival, 5, 617626 (3);
4.216;6;1;12;4q12;SNORA26;;Small nucleolar RNA, H/ACA box, 26;614626;REc, R;;;
4.217;08;22;18;4q12;SPINK2, SPGF29;;Serine protease inhibitor, Kazal-type, 2;605753;Psh, REc;mutation identified in 1 SPGF29 family;?Spermatogenic failure 29, 618091 (3);
4.218;1;5;12;4q12;SRD5A3, SRD5A2L, CDG1Q, KRIZI;;Steroid 5-alpha-reductase 3;611715;REc, Fd;;Congenital disorder of glycosylation, type Iq, 612379 (3); Kahrizi syndrome, 612713 (3);
4.219;4;10;14;4q12;SRP72, BMFS1;;Signal recognition particle, 72kD;602122;R, REc;;Bone marrow failure syndrome 1, 614675 (3);
4.220;1;22;07;4q12;TAPVR1;;Total anomalous pulmonary venous return 1;106700;Fd;between D4S1630 and D4S3019; ?mutation in KDR;Total anomalous pulmonary venous return (2);
4.221;7;18;12;4q12;TMEM165, FT27, CDG2K;;Transmembrane protein 165;614726;REc;;Congenital disorder of glycosylation, type IIk, 614727 (3);
4.222;7;9;09;4q12;USP46;;Ubiquitin-specific peptidase 46;612849;REc;;;
4.223;8;28;02;4q13.3;CXCL1, GRO1, MGSA;;Chemokine, C-X-C, ligand 1 (GRO1 oncogene; melanoma growth stimulating activity, alpha);155730;REa, A;apparently cluster of 3 GRO genes;;5(Mgsa)
4.224;8;29;02;4q13.3;CXCL2, GRO2, MIP2A;;Chemokine, C-X-C motif, ligand 2 (GRO2 oncogene);139110;REa, A;;;5(Mip2a)
4.225;8;29;02;4q13.3;CXCL3, GRO3, MIP2B;;Chemokine, C-X-C motif, ligand 3 (GRO3 oncogene);139111;REa, A;;;5(Mip2b)
4.226;8;30;02;4q13.3;CXCL5, SCYB5, ENA78;;Chemokine, C-X-C motif, ligand 5 (epithelial-derived neutrophil-activating peptide 78);600324;Psh, REc;;;
4.227;8;30;02;4q13.3;CXCL6, SCYB6, GCP2;;Chemokine, C-X-C motif, ligand 6 (granulocyte chemotactic protein-2);138965;Psh, REc;;;
4.228;4;30;97;4q13.3;IL8;;Interleukin-8;146930;REa, A;;;
4.229;10;6;92;4q13.3;PF4;;Platelet factor 4;173460;REa, A, REn;6kb from PF4V1;;
4.230;10;6;92;4q13.3;PF4V1;;Platelet factor 4, variant 1 (PF4-like);173461;A, REa, REn;same region as PF4 and IP10;;
4.231;8;25;11;4q13.3;PPBP, CXCL7, SCYB7, CTAP3, TGB;;Pro-platelet basic protein;121010;Psh, A, REn;less than 7kb from PF4;;
4.232;6;18;04;4q13.3;PPBPL1, TGB2;;Pro-platelet basic protein-like 1 (thromboglobulin, beta-2);188035;REn;in cluster with PPBP, PF4, and PF4V1;;
4.233;11;19;11;4q12-q13.1;MRT31;;Mental retardation, autosomal recessive 31;614329;Fd;between rs11944876 and rs6551838;Mental retardation, autosomal recessive 31 (2);
4.234;12;4;08;4q12-q13.1;DFNA27;;Deafness, autosomal dominant 27;612431;Fd;max lod at D4S398;Deafness, autosomal dominant 27 (2);
4.235;3;13;06;4q12-q13.2;DFNB55;;Deafness, autosomal recessive 55;609952;Fd;max lod at D4S2638;Deafness, autosomal recessive 55 (2);
4.236;8;18;98;4q13.2;CENPC1, CENPC;;Centromere autoantigen C1;117141;A;?pseudogene on chr.12;;5(Cenpc)
4.237;3;30;12;4q21.21;RASGEF1B, GPIG4;;RASGEF domain family, member 1B;614532;REc;;;
4.238;3;13;06;4q13.1-q13.2;EPHA5, TYRO4, HEK7;;Ephrin receptor EphA5;600004;A;;;
4.239;7;9;06;4q13.3;GRSF1;;G-rich RNA sequence-binding factor 1;604851;A;;;
4.240;3;29;90;4q13.3;HTN1;;Histatin-1;142701;REa, A;3 genes in a 15kb segment;;
4.241;6;16;97;4q13.3;HTN3, HTN2, HIS2;;Histatin-3;142702;REa, A;;;
4.242;12;13;00;4q13.3;UGT2A1;;Uridine diphosphate glycosyltransferase 2 family, member A1;604716;A;;;
4.243;6;2;15;4q13.2;UGT2A3;;Uridine diphosphate glucuronosyltransferase 2 family, member A3;616382;REc;;;5(Ugt2a3)
4.244;6;23;98;4q13.3;UGT2B4, UGT2B11;;UDP-glucuronyltransferase, family 2, beta-4;600067;Psh, REn, A;cluster in order B7--B4--B15 in 195kb;;5(Ugt2b4)
4.245;6;23;98;4q13.2;UGT2B7, UGT2B9;;UDP-glucuronyltransferase, family 2, beta-7;600068;Psh, REn, A;;;
4.246;6;23;98;4q13.2;UGT2B15, UGT2B8;;UDP-glucuronyltransferase, family 2, beta-15;600069;Psh, REn, A;;;
4.247;5;25;13;4q13.2;UGT2B17, BMND12;;UDP-glucuronyltransferase, family 2, beta-17;601903;A;;{Bone mineral density QTL 12, osteoporosis}, 612560 (3);
4.248;11;19;11;4q13-q21;AIS4, VAMAS5;;Autoimmune disease, susceptibility to, 4;609400;Fd;between D4S392 and D4S3042;{Autoimmune disease, susceptibility to, 4} (2);
4.249;6;8;89;4q13.3;AREG;;Amphiregulin;104640;REa, A;;;5(Areg)
4.250;10;1;95;4q13.3;BTC;;Betacellulin;600345;H;tightly linked to Areg in mouse;;5(Btc)
4.251;6;2;15;4q13.3;CSN3, CNS10, CSNK;;Casein, kappa;601695;REc, A;;;
4.252;10;5;06;4q13.3;MUC7;;Mucin 7, salivary;158375;A, Psh;;{Asthma, protection against}, 600807 (3);
4.253;9;22;11;4q21.1;SCARB2, CD36L2, LIMPII, AMRF, EPM4;;Scavenger receptor class B, member 2;602257;Psh, Fd;;Epilepsy, progressive myoclonic 4, with or without renal failure, 254900 (3);
4.254;6;30;15;4q13.1;ADGRL3, LPHN3, CIRL3, CL3, LEC3, KIAA0768;;Adhesion G protein-coupled receptor L3;616417;REc;;;
4.255;6;13;18;4q31.21;GAB1, DFNB26;;Grb2-associated binding protein 1;604439;A;mutation identified in 1 family;?Deafness, autosomal recessive 26, 605428 (3);8(Gab1)
4.256;11;20;95;4q13.3;STE, EST;;Sulfotransferase, estrogen-preferring;600043;Psh, A;;;5(Ste)
4.257;12;15;16;4q13.1;TECRL, TERL, SRD5A2L2, GPSN2L, CPVT3;;Trans-2,3-enoyl-CoA reductase-like protein;617242;REc;;Ventricular tachycardia, catecholaminergic polymorphic, 3, 614021 (3);
4.258;5;5;98;4q21.21;PRKG2, PRKGR2;;Protein kinase, cGMP-dependent, type II;601591;Psh;;;
4.259;5;2;07;4q13.2;SYT14L, SYTDEP, CHR415SYT;;Synaptotagmin 14-like protein;610892;REc;;;
4.260;11;11;14;4q13.2;STAP1, BRDG1;;Signal transducing adaptor family member 1;604298;REc;;;
4.261;1;9;08;4q13.2;TMPRSS11A, ECRG1;;Transmembrane protease, serine 11A;611704;REc;;;
4.262;8;18;14;4q13.2;UGT2B10;;Uridine diphosphate glycosyltransferase 2 family, member B10;600070;REc;;;
4.263;4;4;05;4q13.2;UGT2B28;;Uridine diphosphate glycosyltransferase 2 family, member B28;606497;REc;;;
4.264;6;19;12;4q13.2;UGT2B11;;Uridine diphosphate glycosyltransferase 2 family, member B11;603064;REc;;;
4.265;1;3;17;4q13.2;YTHDC1, KIAA1966;;TYH domain-containing protein 1;617283;REc;;;
4.266;2;28;03;4q13.3;GPR74, NPFF2, NPGPR;;G protein-coupled receptor 74;607449;R;;;
4.267;11;6;14;4q13.2-q21.3;ETL3, FMTLE;;Epilepsy, familial temporal lobe, 3;611630;Fd;max lod at D4S1517;Epilepsy, familial temporal lobe, 3 (2);
4.268;8;4;17;4q13.3;AMTN, AI3B;;Amelotin;610912;REc, H;mutation identified in 1 AI3B family;?Amelogenesis imperfecta, type IIIB, 617607 (3);5(Amtn)
4.269;9;20;14;4q13.3;ANKRD17, GTAR;;Ankyrin repeat domain-containing protein 17;615929;REc;;;
4.270;9;27;17;4q13.3;EREG;;Epiregulin;602061;REc;;;
4.271;9;8;11;4q13.3;MTHFD2L;;Methylenetetrahydrofolate dehydrogenase 2-like, NADP(+)-dependent;614047;REc;;;
4.272;2;15;14;4q13.3;ODAM, APIN;;Odontogenic ameloblast-associated protein;614843;REc;;;
4.273;9;22;17;4q13.3;PARM1, CIPAR1;;Prostate androgen-regulated mucin-like protein 1;617688;REc;;;
4.274;11;15;17;4q13.3;PPBPP2, PPBPL2;;Pro-platelet basic protein pseudogene 2;611591;R, REc;;;
4.275;7;14;14;4q13.3;PROL1, PRL1, BPLP;;Proline-rich lacrimal protein 1;608936;REc;;;
4.276;2;18;09;4q13.3;RASSF6;;Ras association domain family, member 6;612620;REc;;;
4.277;8;19;13;4q13.3;RUFY3, SINGAR1, RIPX;;FUN and FYVE domains-containing protein 3;611194;REc;;;
4.278;2;23;08;4q13.3;SMR3B, SMR1B, PRL3, PBII;;Submaxillary gland androgen-regulated protein 3, mouse, homolog of, B;611593;REc;;;
4.279;8;8;13;4q13.3;SULT1B1, ST1B2;;Sulfotransferase family 1B, member 1;608436;REc;;;
4.280;8;19;13;4q13.2;TMPRSS11E, DESC1;;Transmembrane protease, serine 11E;610399;REc;;;5(Tmprss11e)
4.281;9;12;93;4q13.3;DCK;;Deoxycytidine kinase;125450;Psh, A;;;
4.282;10;24;18;4q13.3;ADAMTS3, HKLLS3;;A Disintegrin-like and metalloproteinase with thrombospondin type 1 motif, 3;605011;R, REa;mutation identified in 1 HKLLS3 family;?Hennekam lymphangiectasia-lymphedema syndrome 3, 618154 (3);
4.283;7;16;09;4q21.3-q22.1;AFF1, MLLT2, AF4;;AF4/FMR2 family, member 1;159557;Ch, H;fuses with ALL1;;5(Af4)
4.284;3;23;15;4q13.3;AMBN, AI1F;;Ameloblastin;601259;;mutation identified in 1 AI1F family;Amelogenesis imperfecta, type IF, 616270 (3);5(Ambn)
4.285;1;18;13;4q21.21;ANTXR2, CMG2, HFS;;Anthrax toxin receptor 2;608041;Fd, REc;;Hyaline fibromatosis syndrome, 228600 (3);
4.286;6;6;91;4q21.21;ANXA3, ANX3;;Annexin A3 (lipocortin III);106490;Psh, REa, A;;;
4.287;11;30;06;4q21.2-q21.3;ARHGAP24, RCGAP72, FILGAP;;RHO GTPase-activating protein 24;610586;REc;;;
4.288;12;15;10;4q21;DEL4q21, C4DELq21;;Chromosome 4q21 deletion syndrome;613509;Ch;contiguous gene deletion if at least 30 genes;Chromosome 4q21 deletion syndrome (4);
4.289;6;15;99;4q21.23;CDS1;;CDP-diacylglycerol synthase 1;603548;R, A;;;
4.290;8;29;02;4q21.1;CXCL9, MIG, SCYB9;;Chemokine, C-X-C motif, ligand 9;601704;A, REn;close to INP10;;
4.291;8;29;02;4q21.1;CXCL10, INP10;;Chemokine, C-X-C motif, ligand 10 (interferon-inducible cytokine IP-10);147310;A, REa, F;?involved in monocytic leukemia with t(4;11)(q21;q23);;
4.292;8;30;02;4q21.1;CXCL13, SCYB13, BCA1, BLC;;Chemokine, C-X-C motif, ligand 13;605149;REc;;;
4.293;1;23;09;4q22.1;DMP1, ARHR, ARHP;;Dentin matrix acidic phosphoprotein;600980;Fd, REn, Psh, A;;Hypophosphatemic rickets, AR, 241520 (3);
4.294;8;4;09;4q13.3;ENAM, AIH2, AI1C;;Enamelin;606585;REc;;Amelogenesis imperfecta, type IB, 104500 (3); Amelogenesis imperfecta, type IC, 204650 (3);
4.295;8;3;14;4q21.21;FGF5, TCMGLY;;Fibroblast growth factor-5;165190;REa, A;;Trichomegaly, 190330 (3);5(Fgf5)
4.296;9;13;17;4q21.21;FRAS1, FRASRS1;;FRAS1 gene;607830;Fd, REc;;Fraser syndrome 1, 219000 (3);5(bl, Fras1)
4.297;7;16;09;4q22.1;HSD17B11, RETSDR2, PAN1B;;17-beta-hydroxysteroid dehydrogenase XI;612831;R, REc;;;
4.298;3;30;00;4q13.3;IGJ;;Immunoglobulin J polypeptide, linker protein for;147790;REa, A;;;5(Igj)
4.299;11;11;14;4q21.22;PLAC8;;Placenta-specific gene 8;607515;H, REc;;;5(Plac8)
4.300;11;2;99;4q13.3;SLC4A4, NBC1, KNBC;;Solute carrier family 4, sodium bicarbonate cotransporter, member 4;603345;Psh;;Renal tubular acidosis, proximal, with ocular abnormalities, 604278 (3);
4.301;1;18;11;4q22.1;SNCA, NACP, PARK1, PARK4;;Synuclein, alpha (non A4 component of amyloid precursor);163890;Psh, A, Fd;;Parkinson disease 4, 605543 (3); Dementia, Lewy body, 127750 (3); Parkinson disease 1, 168601 (3);
4.302;2;18;08;4q13.3;UTP3, CRL1, CRLZ1;;UTP3, S. crevisiae, homolog of;611614;REc;;;5(Utp3)
4.303;6;12;17;4q21.23;WDFY3, ALFY, BCHS, MCPH18;;WD repeat- and FYVE domain-containing protein 3;617485;REc;mutation identified in 1 MCPH18 family;?Microcephaly 18, primary, autosomal dominant, 617520 (3);
4.304;8;7;13;4q21.22-q21.23;COQ2, COQ10D1, MSA1;;CoQ2, S. cerevisiae, homolog of (parahydroxybenzoate-polyprenyltransferase, mitochondrial);609825;REc;;Coenzyme Q10 deficiency, primary, 1, 607426 (3); {Multiple system atrophy, susceptibility to}, 146500 (3);
4.305;9;22;09;4q22.3;HPGDS, PGDS;;Prostaglandin D2 synthase, hematopoietic;602598;A;;;3(Pgds)
4.306;8;29;08;4q22.1;NAP1L5, DRLM;;Nucleosome assembly protein 1-like 5;612203;REc;;;
4.307;6;12;17;4q21-q23;PFM3;;Parietal foramina 3;609566;Fd;maximum lod between D4S2986 and D4S421;Parietal foramina 3 (2);
4.308;11;3;09;4q22.1;PKD2;;Polycystin-2;173910;Fd;;Polycystic kidney disease 2, 613095 (3);5(Pkd2)
4.309;8;9;99;4q22.3;UNC5C, UNC5H3;;UNC5, C. elegans, homolog of, C;603610;R;;;3(Unc5c)
4.310;9;9;90;4q23;ADH5, FDH;;Alcohol dehydrogenase (class III), chi polypeptide;103710;S, REa;;;
4.311;3;14;13;4q23;EIF4E, EIF4EL1, AUTS19;;Eukaryotic translation initiation factor 4E;133440;Psh;pseudogene on 20;{Autism, susceptibility to, 19}, 615091 (3);
4.312;9;12;93;4q21-q25;FECB;;Fecundity gene, Boorla, of sheep, homolog of;134720;H;sheep chr.6;;
4.313;2;18;96;4q22.1;IBSP;;Integrin-binding sialoprotein (bone sialoprotein II);147563;REa, A;;;5(Ibsp)
4.314;2;4;00;4q23;RAP1GDS1;;RAP1, GTP-GDP dissociation stimulator 1;179502;A, REa, Ch;fusion partner with NUP98 in ALL;Lymphocytic leukemia, acute T-cell (3);
4.315;1;27;97;4q22.1;SPP1, OPN;;Secreted phosphoprotein-1 (osteopontin, bone sialoprotein);166490;REa, REc;;;5(Spp1)
4.316;8;25;04;4q21-q31;OFC4;;Orofacial cleft 4;608371;Fd, Ch;;Orofacial cleft 4 (2);
4.317;7;27;12;4q21.1;ART3;;ADP-ribosyltransferase 3;603086;REa, A, REc;;;
4.318;10;5;17;4q21.1;ODAPH, C4orf26;;Odontogenesis-associated phosphoprotein;614829;REc;;Amelogenesis imperfecta, type IIA4, 614832 (3);
4.319;7;20;12;4q21.1;CCNG2;;Cyclin G2;603203;REc;;;
4.320;5;25;13;4q21.1;CDKL2, KKIAMRE, P56;;Cyclin-dependent kinase-like 2;603442;REc;;;
4.321;7;25;18;4q21.1;CNOT6L, CCR4B;;CCR4-NOT transcription complex, subunit 6-like;618069;REc;;;
4.322;5;24;13;4q13.3;COX18;;Cytochrome c oxidase assembly protein COX18;610428;REc;;;
4.323;8;3;97;4q13.3;CSN1;;Casein, alpha;115450;REa, A;;;
4.324;8;3;97;4q13.3;CSN2;;Casein, beta;115460;Psh, A;;;5(Csn2)
4.325;5;7;01;4q22.1;MEPE;;Matrix, extracellular, phosphoglycoprotein;605912;REa, R;;;
4.326;2;26;08;4q21.1;MRPL1;;Mitochondrial ribosomal protein L1;611821;REc;;;
4.327;12;26;13;4q21.1;NAAA, ASAHL;;N-acylethanolamine acid amidase;607469;A;;;
4.328;8;30;09;4q21.1;NUP54;;Nucleoporin, 54kD;607607;R, REc;;;
4.329;10;15;13;4q21.21;PCAT4, GDEP;;Prostate cancer-associated transcript 4;609717;R;;;
4.330;8;30;09;4q21.1;PPEF2;;Protein phosphatase, EF hand calcium-binding domain-2;602256;Psh, REc;;;
4.331;11;11;14;4q21.1;RCHY1, ZNF363, PIRH2, ARNIP;;Ring finger and CHY zinc finger domain containing 1, E3 ubiquitin protein ligase;607680;REc, A;;;
4.332;1;27;04;4q21.22;SCD4, ACOD4;;Stearoyl-CoA desaturase 4;608370;A, REc;;;
4.333;7;20;09;4q21.1;SEPT11;;Septin 11;612887;REc;;;
4.334;4;18;07;4q21.1;SHROOM3, SHRM, KIAA1481;;Shroom family member 3;604570;REa, REc;;;
4.335;1;20;09;4q21.1;THAP6;;THAP domain-containing protein 6;612535;REc;;;
4.336;7;20;12;4q21.1;USO1, TAP, p115;;USO1 vesicle docking protein, S. cerevisiae, homolog of;603344;REc;;;
4.337;12;1;98;4q21.22;HNRPD, AUF1, AUF1A;;Heterogeneous nuclear ribonucleoprotein D;601324;REa, A;;;3(Hnrpd)
4.338;8;30;02;4q21.1;CXCL11, SCYB11, IP9, SCYB9B;;Chemokine, C-X-C motif, ligand 11;604852;Psh, A, REc;;;5(Scyb11)
4.339;2;10;14;4q21.23;FAM175A, CCDC98, ABRAXAS, ABRA1;;Family with sequence similarity 175, member A;611143;REc;;;
4.340;9;28;12;4q13.2;GNRHR, LHRHR, HH7;;Gonadotropin-releasing hormone receptor;138850;REa, A, Psh;placed at 4q12 or 4q13 by some;Hypogonadotropic hypogonadism 7 without anosmia, 146110 (3);5(Gnrhr)
4.341;4;19;01;4q32.3;KLHL2, MAYVEN;;Kelch-like 2;605774;REa;;;8(Klhl2)
4.342;9;1;16;4q21.23;NKX6-1, NKX6A;;NK6, Drosophila, homolog of, 1;602563;A;;;
4.343;8;31;17;4q21.21;BMP2K, BIKE;;BMP2-inducible kinase;617648;REc;;;
4.344;4;19;12;4q21.21;PAQR3, RKTG;;Progestin and ADIPOQ receptor family, member 3;614577;REc;;;
4.345;11;17;15;4q21.21;PRDM8, EPM10;;PR domain-containing protein 8;616639;REc;mutation identified in 1 EPM10 family;?Epilepsy, progressive myoclonic, 10, 616640 (3);
4.346;09;27;18;4q21.22;HNRNPDL, HNRPDL, JKTBP, LGMDD3;;Heterogeneous nuclear ribonucleoprotein D-like protein;607137;A, REc, Fd;;Muscular dystrophy, limb-girdle, autosomal dominant 3, 609115 (3);
4.347;9;22;14;4q21.22;COPS4, CSN4;;COP9 signalosome, subunit 4;616008;REc;;;
4.348;4;20;10;4q21.22;LIN54;;Lin54, C. elegans, homolog of;613367;REc;;;
4.349;3;30;12;4q21.22;SEC31A, SEC31L1, KIAA0905;;Sec31, yeast, homolog of, A;610257;R, REc;;;
4.350;1;20;09;4q21.22;THAP9;;THAP domain-containing protein 9;612537;REc;;;
4.351;1;9;17;4q21.22;TMEM150C, TTN3;;Transmembrane protein 150C;617292;REc;;;
4.352;9;21;11;4q21.23;AGPAT9, GPAT3, MAG1;;1-acylglycerol-3-phosphate O-acyltransferase 9;610958;REc;;;
4.353;3;30;12;4q21.23;HELQ, HEL308;;Helicase, POLQ-like;606769;H, REc;;;5(Hel308)
4.354;4;24;08;4q21.23;MRPS18C, MRPS18-1;;Mitochondrial ribosomal protein S18C;611983;REc;6 pseudogenes;;
4.355;4;27;00;4q21.23;HPSE, HSE1, HPA;;Heparanase;604724;A, R;;;
4.356;1;22;97;4q21.3;PTPN13;;Protein tyrosine phosphatase, nonreceptor-type, 13 (APO-1/CD95 (Fas)-associated phosphatase);600267;A, Psh;633bp upstream of JNK3;;5(Ptpn13)
4.357;6;21;05;4q22.1;DSPP, DPP, DGI1, DFNA39, DTDP2;;Dentin sialophosphoprotein;125485;REa, A, F, Fd;;Dentinogenesis imperfecta, Shields type II, 125490 (3); Deafness, autosomal dominant 39, with dentinogenesis, 605594 (3); Dentinogenesis imperfecta, Shields type III, 125500 (3); Dentin dysplasia, type II, 125420 (3);
4.358;9;23;13;4q21.3;MAPK10, PRKM10, JNK3;;Mitogen-activated protein kinase 10;602897;REa, A, REn;;;
4.359;4;20;10;4q21.3;SLC10A6, SOAT;;Solute carrier family 10 (sodium/bile acid cotransporter family), member 6;613366;REc;;;
4.360;3;29;12;4q22.1;ABCG2, BCRP, ABCP, UAQTL1, GOUT1;;ATP-binding cassette, subfamily G, member 2;603756;R;;[Junior blood group system], 614490 (3); [Uric acid concentration, serum, QTL1], 138900 (3);6(Abcp)
4.361;8;26;02;4q23;ADH1A, ADH1;;Alcohol dehydrogenase IA (class I), alpha polypeptide;103700;REa;;;
4.362;6;5;18;4q23;ADH1B, ADH2;;Alcohol dehydrogenase IB (class I), beta polypeptide;103720;REa;;{Alcohol dependence, protection against}, 103780 (3); {Aerodigestive tract cancer, squamous cell, alcohol-related, protection against}, 103780 (3);
4.363;11;14;10;4q23;ADH1C, ADH3;;Alcohol dehydrogenase IC (class I), gamma polypeptide;103730;REa;;{Alcohol dependence, protection against}, 103780 (3); {Parkinson disease, susceptibility to}, 168600 (3);3(Adh3)
4.364;11;6;89;4q23;ADH4;;Alcohol dehydrogenase (class II), pi polypeptide;103740;REa, A;;;
4.365;8;28;97;4q22.2;ATOH1, ATH1;;Atonal, Drosophila, homolog of, 1;601461;REa, A;;;
4.366;8;9;01;4q22.3;ENH;;Enigma-like LIM domain protein;605904;Psh;;;
4.367;1;30;15;4q22.1-q22.2;GRID2, SCAR18;;Glutamate receptor, ionotropic, delta-2;602368;R, REc;;Spinocerebellar ataxia, autosomal recessive 18, 616204 (3);6(Grid2)
4.368;10;27;08;4q22;MUSQTL1;;Musical aptitude quantitative trait locus 1;612343;Fd;near D4S423 and D4S2460;[Musical aptitude QTL 1] (2);
4.369;1;2;91;4q22.3;PDHA2;;Pyruvate dehydrogenase, E1-alpha polypeptide, testis specific form;179061;REa;;;19(Pdhal)
4.370;12;29;15;4q24;SLC39A8, BIGM103, CDG2N;;Solute carrier family 39 (zinc transporter), member 8;608732;REc;;Congenital disorder of glycosylation, type IIn, 616721 (3);
4.371;3;9;17;4q22.3;SMARCAD1, KIAA1122, ETL1, HEL1, ADERM, BASNS;;SWI/SNF-related, matrix-associated actin-dependent regulator of chromatin, subfamily A, DEAD/H box-containing, 1;612761;A;;Adermatoglyphia, 136000 (3); Basan syndrome, 129200 (3);
4.372;7;26;15;4q24;BANK1, FLJ20706, BANK;;B-cell scaffold protein with ankyrin repeats 1;610292;REc;;;
4.373;12;18;07;4q24;CXXC4, IDAX;;CXXC finger protein 4;611645;R, REc;;;
4.374;12;29;06;4q23;MTP;;Microsomal triglyceride transfer protein, 88kD;157147;Psh, A;;Abetalipoproteinemia, 200100 (3); {Metabolic syndrome, protection against}, 605552 (3);3(Mtp)
4.375;10;8;07;4q24;CISD2, WFS2, ZCD2, ERIS;;CDGSH iron sulfur domain protein 2;611507;Fd, REc;;Wolfram syndrome 2, 604928 (3);
4.376;8;9;05;4q24;MANBA, MANB1;;Mannosidase, beta A, lysosomal;609489;H, REa;linked in mouse to Adl-3;Mannosidosis, beta, 248510 (3);3(Bmn)
4.377;3;17;06;4q25;HADHSC, SCHAD, HHF4;;L-3-hydroxyacyl-CoA dehydrogenase, short chain;601609;A;;3-hydroxyacyl-CoA dehydrogenase deficiency, 231530 (3); Hyperinsulinemic hypoglycemia, familial, 4, 609975 (3);
4.378;3;23;06;4q22-q27;MYP11;;Myopia 11;609994;Fd;max lod at D4S1564;Myopia 11 (2);
4.379;8;20;15;4q22.1;ATOD8;;Dermatitis, atopic, 8;613518;Fd;;{Dermatitis, atopic, susceptibility to, 8} (2);
4.380;3;16;10;4q22.1;FAM13A, FAM13A1, KIAA0914;;Family with sequence similarity 13, member A;613299;R, REc;overlaps with FAM13AOS;;
4.381;3;16;10;4q22.1;FAM13AOS, FAM13A1OS;;FAM13A opposite strand;613300;REc;overlaps with FAM13A;;
4.382;11;11;14;2q24.3;FIGN;;Fidgetin;605295;REc, H;;;2(Fign)
4.383;5;26;13;4q22.1;GPRIN3, GRIN3;;G protein-regulated inducer of neurite outgrowth 3;611241;REc;;;
4.384;11;11;14;4q22.1;HERC3;;HECT domain and RCC1-like domain 3;605200;A, REc;;;
4.385;8;18;08;4q22.1;HSD17B13, SCDR9;;17-beta-hydroxysteroid dehydrogenase XIII;612127;REc;;;
4.386;4;23;08;4q22.1;KLHL8, KIAA1378;;Kelch-like 8;611967;REc;;;
4.387;9;26;17;4q22.1;MMRN1, ECM;;Multimerin 1;601456;REc;;;
4.388;1;12;16;4q22.1;PIGY, HPMRS6;;Phosphatidylinositol glycan, class Y;610662;REc;;Hyperphosphatasia with mental retardation syndrome 6, 616809 (3);
4.389;7;20;15;4q22.1;PPM1K, PP2CM, PTMP, MSUDMV;;Protein phosphatase, PP2C domain-containing, 1K;611065;R, REc;mutation identified in 1 MSUDMV family;?Maple syrup urine disease, mild variant, 615135 (3);
4.390;9;10;09;4q22.1;TIGD2;;TIGGER transposable element-derived gene 2;612973;REc;;;
4.391;3;10;05;4q22.1;HERC5, CEB1;;HECT domain and RCC1-like domain 5;608242;A, REa;;;
4.392;5;25;17;4q23;DNAJB14;;DNAJ/HSP40 homolog, subfamily B, member 14;617487;REc;;;
4.393;7;18;12;4q23;LAMTOR3, MP1, MAPBP;;Late endosomal/lysosomal adaptor, mitogen-activated protein kinase and mammalian target of rapamycin activator 3;603296;REc;;;
4.394;2;21;18;4q23;C4orf54, LOC285556, FOPV;;Chromosome 4 open reading frame 54;617881;REc;;;
4.395;4;6;15;4q23;METAP1, KIAA0094;;Methionyl aminopeptidase 1;610151;R, REc;;;
4.396;9;30;14;4q23;TRMT10A, RG9MTD2, MSSGM1;;tRNA methyltransferase 10, S. cerevisiae, homolog of, A;616013;REc;;Microcephaly, short stature, and impaired glucose metabolism 1, 616033 (3);
4.397;12;21;09;4q23;TSPAN5, NET4;;Tetraspanin 5;613136;REn;;;
4.398;3;1;00;4q23;TYS, HRZ;;Sclerotylosis;181600;F, Fd;;Huriez syndrome (2);
4.399;8;26;02;4q23;ADH6;;Alcohol dehydrogenase 6 (aldehyde reductase);103735;REn;;;
4.400;12;19;96;4q23;ADH7;;Alcohol dehydrogenase-7;600086;A;;;
4.401;3;8;16;4q22.3;BMPR1B, ALK6, AMDD, BDA2, BDA1D;;Bone morphogenetic protein receptor, type IB;603248;A, R;;Brachydactyly, type A2, 112600 (3); Acromesomelic dysplasia, Demirhan type, 609441 (3); Brachydactyly, type A1, D, 616849 (3);
4.402;9;30;15;4q24;NFKB1, CVID12;;Nuclear factor of kappa light chain gene enhancer in B-cells 1 (p105);164011;REa, A;;Immunodeficiency, common variable, 12, 616576 (3);
4.403;7;9;06;4q25;LEF1;;Lymphoid enhancer-binding factor-1;153245;REa, A;;Sebaceous tumors, somatic (3);3(Lef1)
4.404;2;16;11;4q24;AIMP1, SCYE1, EMAP2, EMAPII, HLD3;;ARS-interacting multifunctional protein 1;603605;REc, R;;Leukodystrophy, hypomyelinating, 3, 260600 (3);
4.405;8;18;14;4q24;GSTCD;;Glutathione S-transferase C-terminal domain-containing protein;615912;REc;;;
4.406;4;7;94;4q23;H2AZ;;H2AZ histone;142763;REa, A;;;
4.407;3;24;14;4q24;INTS12, INT12;;Integrator complex subunit 12;611355;R, REc;;;
4.408;4;4;02;4q24;MGR1, MA;;Migraine with or without aura, susceptibility to, 1;157300;Fd;;{Migraine with or without aura, susceptibility to, 1} (2);
4.409;2;12;08;4q24;NHEDC2, NHA2;;NA+/H+ exchanger domain-containing protein 2;611789;REc, H;;;3(Nhedc1)
4.410;10;13;09;4q24;NHEDC1;;Na+/H+ exchanger domain-containing protein 1;611527;REc;;;
4.411;5;24;13;4q24;NPNT, POEM;;Nephronectin;610306;REc;;;
4.412;10;8;13;4q24;OCA5;;Albinism, oculocutaneous, type V;615312;Fd;max lod at D4S961;Albinism, oculocutaneous, type V (2);
4.413;6;11;02;4q25;PAPSS1, ATPSK1;;3'-phosphoadenosine 5'-phosphosulfate synthase 1 (ATP sulfurylase/APS kinase-1);603262;R, A;;;3(Atpsk1)
4.414;4;21;16;4q24;TBCK, IHPRF3;;TBC1 domain-containing kinase;616899;REc;;Hypotonia, infantile, with psychomotor retardation and characteristic facies 3, 616900 (3);
4.415;10;26;11;4q24;TET2, KIAA1546, MDS;;TET oncogene family, member 2;612839;REc;;Myelodysplastic syndrome, somatic, 614286 (3);
4.416;8;1;16;4q24;UBE2D3, UBCH5C;;Ubiquitin-conjugating enzyme E2D 3;602963;REc;;;
4.417;11;3;14;4q24;CENPE, MCPH13;;Centromere autoantigen E, 312kD;117143;A;mutation identified in 1 MCPH13 family;?Microcephaly 13, primary, autosomal recessive, 616051 (3);
4.418;8;30;09;4q24;DDIT4L, REDD2;;DNA damage-inducible transcript 4-like;607730;R, REc;;;
4.419;01;02;19;4q24;PPP3CA, PPP2B, CALNA, CNA1, IECEE1, ACCIID;;Protein phosphatase-3 (formerly 2B), catalytic subunit, alpha isoform (calcineurin A alpha);114105;REa, REc;;Epileptic encephalopathy, infantile or early childhood, 1, 617711 (3); Arthrogryposis, cleft palate, craniosynostosis, and impaired intellectual development, 618265 (3);
4.420;4;14;10;4q24-q28;HWE2;;Epilepsy, hot water, 2;613340;Fd;between D4S1572 and D4S2277;Epilepsy, hot water, 2 (2);
4.421;7;20;12;4q25;AGXT2L1;;Alanine-glyoxylate aminotransferase 2-like 1;614682;REc;;;
4.422;1;28;08;4q25;ALPK1, LAK, KIAA1527;;Alpha-kinase 1;607347;REc;;;
4.423;10;08;07;4q25;ATFB5;;Atrial fibrillation, familial, 5;611494;Fd;association with rs2200733 and rs10033464;{Atrial fibrillation, familial, 5} (2);
4.424;3;15;07;4q25;C4orf16, GBAR, 2C18;;Gamma-1 adaptin brefeldin-A resistance protein;610851;REc;;;
4.425;10;15;13;4q25;CFI, FI, AHUS3, ARMD13;;Complement factor I;217030;REa, Fd, A, RE;40kb distal to EGF;Complement factor I deficiency, 610984 (3); {Hemolytic uremic syndrome, atypical, susceptibility to, 3}, 612923 (3); {Macular degeneration, age-related, 13, susceptibility to}, 615439 (3);
4.426;2;12;15;4q25;COL25A1, CLAC, CFEOM5;;Collagen, type XXV, alpha-1 polypeptide;610004;REc;;Fibrosis of extraocular muscles, congenital, 5, 616219 (3);
4.427;1;28;13;4q25;CYP2U1, SPG56;;Cytochrome P450, family 2, subfamily U, polypeptide 1;610670;R, REc;;Spastic paraplegia 56, autosomal recessive, 615030 (3);
4.428;1;9;08;4q25;EGF, URG, HOMG4;;Epidermal growth factor (urogastrone);131530;REa, H, F, RE;linked to ADH3; cen-ADH3-EGF-IL2-qter;Hypomagnesemia 4, renal, 611718 (3);3(Egf)
4.429;11;5;97;4q25;ENPEP;;Glutamyl aminopeptidase (aminopeptidase A);138297;Psh, A, R, H;;;
4.430;8;20;08;4q25;ELOVL6, LCE, FACE;;Elongation of very long chain fatty acids-like 6;611546;REc;;;
4.431;4;27;09;4q25;NOLA1, GAR1;;Nucleolar protein family A, member 1;606468;R, REc;;;
4.432;2;12;13;4q25;LARP7, PIP7S, ALAZS;;La ribonucleoprotein domain family, member 7;612026;R, REc;;Alazami syndrome, 615071 (3);
4.433;7;23;09;4q25;LGV1;;Longevity 1, QTL;152430;Fd;maximum lod at D4S1564;[Longevity 1] (2);
4.434;1;31;13;4q25;LRIT3, FIGLER4, CSNB1F;;Leucine-rich repeat, immunoglobulin-like, and transmembrane domains-containing protein 3;615004;REc;;Night blindness, congenital stationary (complete), 1F, autosomal recessive, 615058 (3);
4.435;11;19;13;4q25;MIR297;;Micro RNA 297;615520;REc;;;
4.436;4;27;12;4q25;MIR302A;;Micro RNA 302A;614596;REc;;;
4.437;4;27;12;4q25;MIR302B;;Micro RNA 302B;614597;REc;;;
4.438;4;27;12;4q25;MIR302C;;Micro RNA 302C;614598;REc;;;
4.439;4;27;12;4q25;MIR302D;;Micro RNA 302D;614599;REc;;;
4.440;4;27;12;4q25;MIR367;;Micro RNA 367;614600;REc;;;
4.441;6;21;12;4q25;NEUROG2, NGN2, ATOH4;;Neurogenin 2;606624;REc;;;
4.442;1;3;17;4q25;PANCR;;PITX2 adjacent noncoding RNA;617286;REc;;;
4.443;11;23;16;4q24;PPA2, SCFI, SCFAI;;Pyrophosphatase, inorganic, 2;609988;REc;mutation identified in 1 SCFAI family;Sudden cardiac failure, infantile, 617222 (3); ?Sudden cardiac failure, alcohol-induced, 617223 (3);
4.444;3;20;16;4q25;RPL34;;Ribosomal protein L34;616862;REc;;;
4.445;3;13;15;4q25;SEC24B;;Sec24-related gene family, member B;607184;R, REc;;;
4.446;12;07;07;4q25;SGMS2, SMS2;;Sphingomyelin synthase 2;611574;R;;;
4.447;9;28;12;4q24;TACR3, NK3R, HH11;;Tachykinin receptor 3;162332;REc;;Hypogonadotropic hypogonadism 11 with or without anosmia, 614840 (3);
4.448;6;4;97;4q25;CASP6, MCH2;;Caspase 6, apoptosis-related cysteine protease;601532;A, R;;;
4.449;10;1;17;4q25;TIFA, T2BP;;TRAF-interacting protein with forkhead-associated domain;609028;REc;;;
4.450;12;18;07;4q25;PLA2G12A, GXII, ROSSY;;Phospholipase A2, Group XIIA;611652;REc;;;
4.451;1;29;13;4q26;NDST4;;N-deacetylase/N-sulfotransferase 4;615039;A, REn;;;
4.452;1;27;17;4q25;PITX2, IDG2, RIEG1, RGS, IGDS2, ASGD4;;Paired-like homeodomain transcription factor-2;601542;Ch, Fd, RE;;Axenfeld-Rieger syndrome, type 1, 180500 (3); Ring dermoid of cornea, 180550 (3); Anterior segment dysgenesis 4, 137600 (3);
4.453;2;21;06;4q26;PRSS12, BSSP3, MRT1;;Protease, serine, 12;606709;A;;Mental retardation, autosomal recessive 1, 249500 (3);
4.454;9;12;08;4q25-q26;ANK2, LQT4;;Ankyrin-2, nonerythrocytic;106410;REa, A, Fd;;Long QT syndrome 4, 600919 (3); Cardiac arrhythmia, ankyrin-B-related, 600919 (3);
4.455;8;27;01;4q23;DAPP1, BAM32;;Dual adaptor of phosphotyrosine and 3-phosphoinositides 1;605768;A;;;
4.456;7;5;92;4q28.1;FGF2, FGFB;;Fibroblast growth factor-2 (basic);134920;REa, A;many alternate names;;3(Fgf2)
4.457;4;2;16;4q13.2;UBA6, UBE1L2;;Ubiquitin activating enzyme 6;611361;R, REc;;;
4.458;2;28;03;4q21.1;GENEX3414;;Genethonin 1;607406;R;;;
4.459;5;19;06;4q26;ARSJ;;Arylsulfatase J;610010;REc;;;
4.460;8;30;09;4q26;CAMK2D;;Calcium/calmodulin-dependent protein kinase II-delta;607708;R, REc;;;
4.461;8;7;15;4q26;METTL14, KIAA1627;;Methyltransferase-like 14;616504;R, REc;;;
4.462;01;04;19;4q26;NDST3;;N-deacetylase/N-sulfotransferase 3;603950;REc;;;
4.463;11;24;98;4q26;PDE5A;;Phosphodiesterase 5A;603310;A, REc;;;
4.464;5;22;03;4q28.2;PGRMC2;;Progesterone receptor membrane component 2;607735;REc;;;
4.465;4;7;15;4q26;SEC24D, KIAA0755, CLCRP2;;Sec24-related gene family, member D;607186;R, REc;;Cole-Carpenter syndrome 2, 616294 (3);
4.466;6;12;17;4q26;TRAM1L1;;Translocation-associated membrane protein 1-like 1;617505;REc;;;
4.467;1;22;13;4q26;UGT8, CGT;;UDP glycosyltransferase 8 (cerebroside synthase);601291;Psh, A;;;
4.468;4;20;17;4q26;USP53, KIAA1350;;Ubiquitin-specific peptidase 53;617431;REc;;;
4.469;3;29;18;4q27;IL2;;Interleukin-2;147680;REa, A, F;;;3(Il2)
4.470;5;22;14;4q27;IL21, CVID11;;Interleukin 21;605384;R;mutation identified in 1 CVID11 patient;?Immunodeficiency, common variable, 11, 615767 (3);3(Il21)
4.471;3;28;11;4q26;MYOZ2, CMH16;;Myozenin 2;605602;REc;;Cardiomyopathy, hypertrophic, 16, 613838 (3);
4.472;5;4;12;4q27;ANXA5, ENX2, RPRGL3;;Annexin A5 (endonexin II);131230;REa, A, D;;{Pregnancy loss, recurrent, susceptibility to, 3}, 614391 (3);3(Anx5)
4.473;7;27;11;4q27;ADAD1, TENR;;Adenosine deaminase domain-containing protein 1, testis-specific;614130;REc;;;
4.474;10;16;14;4q27;BBS7;;BBS7 gene;607590;REc, REn;;Bardet-Biedl syndrome 7, 615984 (3);
4.475;1;7;06;4q27;BBS12, FLJ35630, C4orf24;;BBS12 gene;610683;Fd, REc;1Mb centromeric to BBS;Bardet-Biedl syndrome 12, 615989 (3);
4.476;8;24;92;4q27;CCNA, CCN1;;Cyclin A;123835;A;;;3(Cyca)
4.477;2;23;08;4q27;CELIAC6, AIS5;;Celiac disease, susceptibility to, 6;611598;Fd;;{Celiac disease, susceptibility to, 6} (2); {Autoimmune disease, susceptibility to, 5} (2);
4.478;7;25;18;4q27;EXOSC9, PMSCL1, PCH1D;;Exosome component 9;606180;R, REc;;Pontocerebellar hypoplasia, type 1D, 618065 (3);
4.479;2;18;09;4q27;IDDM23;;Diabetes mellitus, insulin-dependent, 23;612622;Fd;associated with rs6534347;{Diabetes mellitus, insulin-dependent, 23} (2);
4.480;1;11;18;4q27;KIAA1109, ALKKUCS;;KIAA1109 gene;611565;R, REc;;Alkuraya-Kucinskas syndrome, 617822 (3);
4.481;6;19;98;4q27;MAD2L1;;Mitotic arrest deficient, yeast, homolog-like 1;601467;REa, R, A;previously mapped to 5q23-q31;;
4.482;8;26;15;4q27;NDNF, C4orf31, NORD;;Neuron-derived neurotrophic factor;616506;REc;;;
4.483;8;25;11;4q27;PRDM5, BCS2;;PR domain-containing protein 5;614161;REc;;Brittle cornea syndrome 2, 614170 (3);
4.484;7;2;18;4q27;QRFPR, GPR103;;Pyroglutamylated RFamide peptide receptor;606925;REc;;;
4.485;6;17;15;4q27;TRPC3, TRP3, SCA41;;Transient receptor potential cation channel, subfamily C, member 3;602345;REc;mutation identified in one SCA41 patient;?Spinocerebellar ataxia 41, 616410 (3);
4.486;1;12;15;4q28.1;PLK4, STK18, SAK, MCCRP2;;Polo-like kinase 4 (serine/threonine protein kinase-18);605031;A;;Microcephaly and chorioretinopathy, autosomal recessive, 2, 616171 (3);13(Sak)
4.487;10;4;16;4q27-q28.2;MRT29;;Mental retardation, autosomal recessive 29;614333;Fd;between rs10518325 and rs10518608;Mental retardation, autosomal recessive 29 (2);
4.488;9;19;14;4q31.3;FGA;;Fibrinogen, alpha polypeptide;134820;RE, REa, H, D, LD, A;;Dysfibrinogenemia, congenital, 616004 (3); Hypodysfibrinogenemia, congenital, 616004 (3); Amyloidosis, familial visceral, 105200 (3); Afibrinogenemia, congenital, 202400 (3);
4.489;9;19;14;4q31.3;FGB;;Fibrinogen, beta polypeptide;134830;RE, REa, D, LD, A;4q31 by A; proximal to GYPB/GYPA;Dysfibrinogenemia, congenital, 616004 (3); Afibrinogenemia, congenital, 202400 (3); Hypofibrinogenemia, congenital, 202400 (3);
4.490;9;30;14;4q32.1;FGG;;Fibrinogen, gamma polypeptide;134850;F, REa, H, RE, D, LD, A;linked to MN;Dysfibrinogenemia, congenital, 616004 (3); Hypofibrinogenemia, congenital, 202400 (3); Afibrinogenemia, congenital, 202400 (3); Hypodysfibrinogenemia, 616004 (3);3(Fgg)
4.491;3;30;18;4q28.1;INTU, KIAA1284, PDZK6, SRTD20, OFD17;;Inturned, Drosophila, homolog of;610621;R, REc;mutation identified in 1 SRTD20 patient and 1 OFD17 patient;?Short-rib thoracic dysplasia 20 with polydactyly, 617925 (3); ?Orofaciodigital syndrome XVII, 617926 (3);
4.492;8;2;13;4q31.21;SMAD1, MADH1, MADR1, BSP1;;Mothers against decapentaplegic, Drosophila, homolog of, 1;601595;Psh;;;
4.493;12;21;87;4q26;FABP2;;Fatty acid-binding protein, intestinal;134640;REa, A;;;3(Fabpi)
4.494;3;30;18;4q31.21;GYPB, SS;;Glycophorin B;617923;F, Fc, AAS, EM;;[Blood group, Ss], 111740 (3); {Malaria, resistance to}, 611162 (3);
4.495;4;30;91;4q31.21;GYPE, GPE;;Glycophorin E;138590;REn, A;tandem: 5'-GYPA-GYPB-GYPE-3'; ?4q31.1;;
4.496;3;2;98;4q31.1;MGST2, GST2;;Microsomal glutathione S-transferase 2;601733;A;;;
4.497;10;23;87;4q28-q31;SF;;Stoltzfus blood group;111800;F;~25cM from MNSs;[Blood group, Stoltzfus system] (2);
4.498;2;17;09;4q31.21;HHIP, HIP;;Hedgehog-interacting protein;606178;R, H;;;8(Hip)
4.499;9;24;14;4q28.1;FAT4, VMLDS2, HKLLS2;;FAT tumor suppressor, Drosophila, homolog of, 4;612411;REc;;Van Maldergem syndrome 2, 615546 (3); Hennekam lymphangiectasia-lymphedema syndrome 2, 616006 (3);
4.500;7;2;18;4q28.1;NUDT6, ASFGF2;;Nudix hydrolase 6;606261;REc, Psh;;;
4.501;3;8;07;4q28.1;SLC25A31, ANT4, AAC4;;Solute carrier family 25 (mitochondrial carrier, adenine nucleotide translocator), member 31;610796;REc;;;
4.502;9;30;15;4q28.1;SPATA5, SPAF, EHLMRS;;Spermatogenesis-associated protein 5;613940;REc;;Epilepsy, hearing loss, and mental retardation syndrome, 616577 (3);
4.503;5;25;09;4q28.1;SPRY1;;Sprouty, Drosophila, homolog of;602465;R, REc;;;
4.504;1;8;15;4q28.2;MFSD8, MGC33302, CLN7, CCMD;;Major facilitator superfamily domain-containing protein 8;611124;REc, Fd;;Ceroid lipofuscinosis, neuronal, 7, 610951 (3); Macular dystrophy with central cone involvement, 616170 (3);
4.505;5;26;13;4q28.2;PHF17, JADE1;;PHD finger protein 17;610514;R, REc;;;
4.506;5;26;13;4q28.2;SCLT1, CAP1A;;Sodium channel and clathrin linker 1;611399;REc;;;
4.507;3;30;18;4q31.21;GYPA, MN, GPA;;Glycophorin A;617922;F, Fc, AAS, EM, A, D, Fc;;[Blood group, MNSs system], 111300 (3); {Malaria, resistance to}, 611162 (3);
4.508;6;4;99;4q31.1;NDUFC1;;NADH-ubiquinone oxidoreductase 1, subcomplex C1;603844;R;;;
4.509;11;2;04;4q31.1;MAML3, MAM2, KIAA1816;;Mastermind-like 3;608991;R, REc;;;
4.510;12;5;03;4q28.3;PCDH10, KIAA1400;;Protocadherin 10;608286;R, REc;;;
4.511;2;25;15;4q28.3;SLC7A11, XCT;;Solute carrier family 7 (cationic amino acid transporter, y+ system), member 11;607933;R, REc;;;
4.512;10;5;10;4q31;AAA2;;Aortic aneurysm, familial abdominal 2;609782;Fd;max lod at D4S1644;Aortic aneurysm, familial abdominal 2 (2);
4.513;11;1;99;4q31.21;ABCE1, RNASELI, RNS4I;;ATP-binding cassette, subfamily E, member 1 (ribonuclease L inhibitor);601213;A;;;
4.514;8;28;02;4q34.1;HMGB2, HMG2;;High-mobility group box 2 (high-mobility group (nonhistone chromosomal) protein 2);163906;A;;;
4.515;6;13;95;4q31.21;IL15;;Interleukin-15;600554;A;;;
4.516;4;8;10;4q32.1;LRAT, LCA14;;Lecithin retinol acyltransferase;604863;A;;Retinal dystrophy, early-onset severe, 613341 (3); Leber congenital amaurosis 14, 613341 (3); Retinitis pigmentosa, juvenile, 613341 (3);
4.517;2;20;97;4q32.1;NPY2R;;Neuropeptide Y receptor Y2;162642;REa, A;;;3(Npy2r)
4.518;12;5;03;4q28.3;PCDH18, KIAA1562;;Protocadherin 18;608287;R, REc;;;
4.519;5;5;09;4q31;STQTL12;;Stature quantitative trait locus 12;612224;Fd;associated with rs6854783;{Stature QTL 12} (2);
4.520;5;26;05;4q31.1;UCP1;;Uncoupling protein 1 (mitochondrial, proton carrier);113730;A;;{Obesity, susceptibility to}, 601665 (3);8(Ucp)
4.521;2;18;98;4q32.2;NPY5R;;Neuropeptide Y receptor Y5;602001;REa, REc, REn;;;8(Npy5r)
4.522;10;11;17;4q32.1;TDO2, TPH2, TRPO, HYPTRP;;Tryptophan oxygenase;191070;REa, A;mutation identified in 1 HYPTRP patient;[?Hypertryptophanemia], 600627 (3);
4.523;3;22;06;4q31-q34;PAND3;;Panic disorder 3;609985;Fd;max lod at D4S413;Panic disorder 3 (2);
4.524;7;21;03;4q31-q34;PSORS9;;Psoriasis susceptibility 9;607857;Fd;max lod at D4S1597;{Psoriasis susceptibility 9} (2);
4.525;9;9;08;4q31.1;CCRN4L, CCR4L, CCR4;;Carbon catabolite repression 4-like;608468;REc, H;;;3(Ccrn4l)
4.526;8;25;16;4q31.1;CLGN;;Calmegin;601858;REc;;;
4.527;3;11;09;4q31.1;ELMOD2;;ELMO domain-containing protein 2;610196;REc;;;
4.528;1;29;01;4q34.1;GALNT7;;UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 7;605005;REc;;;
4.529;3;10;09;4q31.1;LOC152586;;LOC152586 gene;610310;REc;;;
4.530;12;5;17;4q31.1;NAA15, NARG1, NATH, MRD50;;N-alpha-acetyltransferase 15, NatA auxiliary subunit;608000;REc;;Mental retardation, autosomal dominant 50, 617787 (3);
4.531;7;7;00;4q31.23;NR3C2, MLR, MCR;;Nuclear receptor subfamily 3, group C, member 2 (mineralocorticoid receptor; aldosterone receptor);600983;REa, M, A;;Pseudohypoaldosteronism type I, autosomal dominant, 177735 (3); Hypertension, early-onset, autosomal dominant, with exacerbation in pregnancy, 605115 (3);
4.532;5;3;13;4q31.1;RAB33B, SMC2;;Ras-associated protein RAB33B;605950;REc;;Smith-McCort dysplasia 2, 615222 (3);
4.533;6;30;15;4q31.1;SETD7, SET7, KIAA1717;;SET domain-containing protein 7;606594;R, REc;;;
4.534;3;11;03;4q31.21;MMAA;;MMAA gene;607481;REc;;Methylmalonic aciduria, vitamin B12-responsive, 251100 (3);
4.535;1;12;99;4q31.21;SMARCA5, SNF2H;;SWI/SNF-related, matrix-associated, actin-dependent regulator of chromatin, subfamily A, member 5;603375;A;;;
4.536;9;1;05;4q31.21;ZNF330, NOA36;;Zinc finger protein 330;609550;A, REc;;;
4.537;1;6;09;4q31.23;ARHGAP10, GRAF2, PSGAP;;RHO GTPase-activating protein 10;609746;R, REc;;;
4.538;2;28;94;4q31.22;BRN3B;;Brn3b POU domain transcription factor;113725;REa, A;;;
4.539;5;19;15;4q31.22-q31.23;EDNRA, MFDA;;Endothelin receptor type A;131243;REa;;{Migraine, resistance to}, 157300 (3); Mandibulofacial dysostosis with alopecia, 616367 (3);
4.540;10;1;09;4q31.21;FREM3;;FRAS1-related extracellular matrix protein 3;608946;REc;;;
4.541;8;30;09;4q31.22;LSM6;;LSM6 protein;607286;R, REc;;;
4.542;1;22;08;4q31.21;OTUD4, KIAA1046, HIN1;;OTD domain-containing protein 4;611744;REc;;;
4.543;6;15;99;4q31.3;RPS3A;;Ribosomal protein S3a;180478;REa, A, R;;;
4.544;8;24;09;4q31.3;PLRG1, PRL1;;Pleiotropic regulator 1;605961;R, REc;;;
4.545;2;17;11;4q31.21;ANAPC10, DOC1, APC10;;Anaphase-promoting complex, subunit 10;613745;REc;;;8(Anapc10)
4.546;6;28;18;4q31.21;TBC1D9, KIAA0882;;TBC1 domain family member 9;618035;REc, R;;;
4.547;4;26;11;4q31.23;TMEM184C, TMEM34;;Transmembrane protein 184C;613937;REc;;;
4.548;5;9;18;4q31.21-q31.22;ZNF827;;Zinc finger protein 827;617962;REc;;;
4.549;12;21;09;4q31.2-q31.3;DCLK2, DCK2, CLIK2, CL2;;Doublecortin-like kinase 2;613166;REc;;;3(Dclk2)
4.550;12;9;14;4q31.23;PRMT9, PRMT10;;Protein arginine methyltransferase 9;616125;REc;;;
4.551;10;13;09;4q31.3;DCHS2, CDHJ, PCDHJ;;Dachsous, Drosophila, homolog of, 2;612486;REc, H;;;3(Dchs2)
4.552;9;9;08;4q31.3;FBXW7, AGO, CDC4;;F-box and WD40 domain protein 7;606278;R;;;
4.553;11;23;16;4q31.3;GATB, PET112;;Glutamyl-tRNA amidotransferase, subunit B;603645;TM;;;
4.554;6;13;18;4q32.1;GLRB, HKPX2;;Glycine receptor, beta subunit;138492;A;;Hyperekplexia 2, 614619 (3);3(Glrb)
4.555;1;4;16;4q31.3;KIAA0922, TMEM131L;;KIAA0922 gene;616243;REc;;;
4.556;7;6;12;4q31.3;LRBA, LBA, CDC4L, CVID8;;Lipopolysaccharide-responsive, beige-like anchor protein;606453;REc, R;;Immunodeficiency, common variable, 8, with autoimmunity, 614700 (3);
4.557;6;12;17;4q31.3;MAB21L2, MCSKS14;;MAB21, C. elegans, homolog-like 2;604357;REc;;Microphthalmia/coloboma and skeletal dysplasia syndrome, 615877 (3);
4.558;8;27;15;4q31.3;MND1;;Meiotic nuclear division 1, S. cerevisiae, homolog of;611422;REc;;;
4.559;2;11;98;4q32.1;PPID;;Peptidylprolyl isomerase D (cyclophilin D);601753;REa, A;;;
4.560;10;19;99;4q31.3;SFRP2, SARP1;;Secreted frizzled-related protein 2;604157;REa, R, H;;;3(Sfrp2)
4.561;12;13;06;4q31.3;SH3D19, EBP;;SH3 domain protein 19;608674;REc, Ch;fused with AML1 in t(4;21);;
4.562;11;11;14;4q31.3;SNORD73A, RNU73;;Small nucleolar RNA, C/D box 73A;603568;A;;;
4.563;7;7;15;4q31.3;TRIM2, KIAA0517, CMT2R;;Tripartite motif-containing protein 2;614141;R, REc;;Charcot-Marie-Tooth disease, type 2R, 615490 (3);
4.564;12;17;15;4q32.1;ASIC5, HINAC;;Acid-sensing ion channel family member 5;616693;REc, H;;;3(Asic5)
4.565;6;10;94;4q32.2;NPY1R;;Neuropeptide Y receptor;162641;A;;;8(Npy1r)
4.566;12;18;07;4q31.3-q32.3;HSCR9;;Hirschsprung disease, susceptibility to, 9;611644;Fd;between D4S3049 and D4S1566;{Hirschsprung disease, susceptibility to, 9} (2);
4.567;4;22;09;4q32.1;ASAP;;Aster-associated protein;610070;REc;;;
4.568;4;29;14;4q32.1;GUCY1A3, GUC1A3, GUCSA3, MYMY6;;Guanylate cyclase 1, soluble, alpha 3;139396;A;;Moyamoya 6 with achalasia, 615750 (3);
4.569;8;18;98;4q32.1;GUCY1B3, GUC1B3, GUCSB3;;Guanylate cyclase 1, soluble, beta 3;139397;A;;;
4.570;2;16;04;4q32.1;PDGFC;;Platelet-derived growth factor C;608452;R, REc;;;
4.571;8;18;15;4q32.1;RXFP1, LGR7;;Relaxin/insulin-like family peptide receptor 1;606654;A;;;
4.572;4;5;13;4q31.3;TLR2, TIL4;;Toll-like receptor-2;603028;A;;{Leprosy, susceptibility to}, 246300 (3); {Colorectal cancer, susceptibility to}, 114500 (3); {Mycobacterium tuberculosis, susceptibility to}, 607948 (3);
4.573;2;21;10;4q34.3;AGA;;Aspartylglucosaminidase;613228;S, F, D, A;;Aspartylglucosaminuria, 208400 (3);8(Aga)
4.574;11;30;06;4p15.32;CPEB2;;Cytoplasmic polyadenylation element-binding protein 2;610605;REc;;;5(Cpeb2)
4.575;3;1;94;4q32.1;GRIA2, GLUR2;;Glutamate receptor, ionotropic, AMPA 2;138247;Psh, A;;;3(Glur2)
4.576;10;15;09;4q32.3;TLL1, TLL, ASD6;;Tolloid-like 1;606742;A;;Atrial septal defect 6, 613087 (3);8(Tll1)
4.577;7;31;08;4q32-q34;RP29;;Retinitis pigmentosa 29;612165;Fd;maximum lod at D4S415;Retinitis pigmentosa 29 (2);
4.578;2;25;16;4q32.3;MSMO1, SC4MOL, ERG25, MCCPD;;Methylsterol monooxygenase 1;607545;A;;Microcephaly, congenital cataract, and psoriasiform dermatitis, 616834 (3);
4.579;8;25;03;4q32.1;ETFDH, MADD;;Electron transfer flavoprotein:ubiquinone oxidoreductase;231675;REa, A;;Glutaric acidemia IIC, 231680 (3);3(Etfdh)
4.580;2;5;15;4q32.1;C4orf46, RCDG1;;Chromosome 4 open reading frame 46;616210;REc;;;
4.581;10;2;12;4q32.1;CTSO;;Cathepsin O;600550;REc;;;
4.582;5;19;09;4q32.1;FNIP2, FNIPL, KIAA1450;;Folliculin-interacting protein 2;612768;R, REc;;;
4.583;8;1;18;4q32.1;RAPGEF2, NRAPGEP, RAGEF, KIAA0313;;Rap guanine nucleotide exchange factor 2;609530;R, REc;mutation identified in 1 FAME7 patient;?Epilepsy, familial adult myoclonic, 7, 618075 (3);
4.584;1;27;11;4q32.1-q32.2;TRIP4q32.1q32.2, C4TRIPq32.1q32.2;;Chromosome 4q32.1-q32.2 triplication syndrome;613603;Ch;;Chromosome 4q32.1-q32.2 triplication syndrome (4);
4.585;1;28;08;4q33;AADAT, KAT2;;Alpha-aminoadipate aminotransferase;611754;A, REc, H;;;8(Aadat)
4.586;2;16;18;4q32.2;NAF1;;Nuclear assembly factor 1 ribonucleoprotein;617868;REc;;;8(Naf1)
4.587;6;7;10;4q32.2-q32.3;MARCH1;;Membrane-associated RING-CH finger protein 1;613331;REc;;;
4.588;8;30;09;4q32.3;ANP32C, PP32R1;;Acidic leucine-rich nuclear phosphoprotein 32 family, member C;606877;Psh, REc;;;
4.589;8;25;17;4q32.3;ELA, LOC100506013;;Elabela;615594;REc;;;
4.590;8;30;07;4q32.3;CINN;;Cinnamon odor, pleasantness of;611109;Fd;max lod at AFM295YES;[Cinnamon odor, pleasantness of] (2);
4.591;8;30;09;4q32.3;CPE;;Carboxypeptidase E;114855;REa, H, REc;;;8(Cpe)
4.592;6;11;11;4q32.3;DDX60;;DEAD box polypeptide 60;613974;REc;;;
4.593;1;4;16;4q32.3;DDX60L;;DEAD box polypeptide 60-like;616725;REc;;;
4.594;12;17;07;4q32.3;HDLCQ4;;High density lipoprotein cholesterol level QTL 4;610239;Fd;between D4S1597 and D4S1539;[High density lipoprotein cholesterol level QTL 4] (2);
4.595;8;26;15;4q33;MFAP3L, KIAA0626;;Microfibrillar-associated protein 3-like;616523;REc, Psh;;;
4.596;1;9;07;4q32.3;PALLD, KIAA0992, PNCA1;;Palladin, mouse, homolog of;608092;R, REc, Fd;;{Pancreatic cancer, susceptibility to, 1}, 606856 (3);
4.597;1;11;07;4q32.3;SPOCK3;;SPARC/osteonectin, CWCV, and KAZAL-like domains proteoglycan 3;607989;REc;;;
4.598;1;12;07;4q32.3;ANXA10;;Annexin A10;608008;A;;;8(Anxa10)
4.599;4;8;98;4q33;CLCN3;;Chloride channel-3;600580;REc, Fd, A;;;8(Clcn3)
4.600;11;10;05;4q34.1;HAND2, DHAND2, DHAND;;Heart- and neural crest derivative-expressed 2;602407;R;;;
4.601;5;19;16;4q33;HPF1, C4orf27;;Histone parylation factor 1;616614;REc;;;
4.602;3;5;18;4q33;NEK1, SRTD6, SRPS2A, ALS24;;Never in mitosis gene A-related kinase 1;604588;REc;1 patient showed heterozygous NEK2 and DYNC2H1 mutations;Short-rib thoracic dysplasia 6 with or without polydactyly, 263520 (3); {Amyotrophic lateral sclerosis, susceptibility to, 24}, 617892 (3);
4.603;10;20;98;4q34.1;GLRA3;;Glycine receptor, alpha-3 polypeptide;600421;A;;;8(Glra3)
4.604;4;3;03;4q34.1;MORF4, SEN1, CSRB;;Mortality factor 4 (senescence-related, cellular, 1);116960;M, A;;;
4.605;10;7;02;4q33-qter;HCA1;;Hypercalciuria, absorptive, 1;607258;Ch;;Hypercalciuria, absorptive (2);
4.606;1;29;01;4q34.1;ADAM29;;A disintegrin and metalloproteinase domain 29;604778;R;;;
4.607;9;28;96;4q34.2;GPM6A, M6A;;Glycoprotein M6A;601275;A;;;
4.608;11;2;04;4q34.2;WDR17;;WD repeat-containing protein 17;609005;A;;;
4.609;12;19;18;4q34.3;VEGFC, VRP, LMPHM4;;Vascular endothelial growth factor C;601528;REc;;Lymphatic malformation 4, 615907 (3);
4.610;4;20;10;4q34.3-q35.1;SCA30;;Spinocerebellar ataxia 30;613371;Fd;between rs1397413 and rs2175476; max lod 3.0;?Spinocerebellar ataxia 30 (2);
4.611;10;16;12;4q34.3-q35.2;HMSN5;;Hereditary motor and sensory neuropathy V;600361;Fd;D4S1552 and D4S2930;Hereditary motor and sensory neuropathy V (2);
4.612;9;18;08;4q35.1;ACSL1, FACL2, FACL1, LACS, ACS1;;Acyl-CoA synthetase long-chain family member 1;152425;REb, A;;;
4.613;2;18;96;4q35.2;FAT1, FAT;;FAT tumor suppressor, Drosophila, homolog of, 1;600976;A;;;
4.614;1;24;12;4q34.1;HPGD, PGDH1, PHOAR1;;Hydroxyprostaglandin dehydrogenase 15-(NAD);601688;REa, A;;Cranioosteoarthropathy, 259100 (3); Hypertrophic osteoarthropathy, primary, autosomal recessive 1, 259100 (3); Digital clubbing, isolated congenital, 119900 (3);
4.615;9;9;08;4q34.1;FBXO8, FBX8, FBS;;F-box only protein 8;605649;REc;;;8(Fbxo8)
4.616;4;6;13;4q34.1;GALNTL6, GALNACT20;;UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase-like 6;615138;REc;;;
4.617;12;6;16;4q34.1;HAND2AS1, UPH, DEIN;;HAND2 antisense RNA 1, noncoding (Upperhand);617240;REc;;;
4.618;3;23;15;4q34.1;MIR4276;;Micro RNA 4276;616274;REc;;;
4.619;7;20;12;4q34.1;SAP30;;SIN3-associated polypeptide, 30kD;603378;REc;;;
4.620;8;16;12;4q34.1;SCRG1;;Scraptie-responsive gene 1;603163;REc;;;
4.621;3;22;06;4q34.2;SPATA4, TSARG2;;Spermatogenesis-associated protein 4;609879;REc;;;
4.622;1;31;13;4q34.2;ASB5;;Ankyrin repeat- and SOCS box-containing protein 5;615050;REc;;;
4.623;5;7;01;4q35.1;ALP;;Actinin-associated LIM protein;605889;A;;;
4.624;5;8;97;4q35.1;CASP3, CPP32;;Caspase 3, apoptosis-related cysteine protease;600636;A, REc;;;
4.625;10;25;12;4q35.2;DBET;;D4A4 binding element transcript, noncoding;614865;REc;;;
4.626;3;19;03;4q35.1;DCTD;;Deoxycytidylate deaminase;607638;A;;;
4.627;3;22;01;4q35;DKBI;;Dyskeratosis, hereditary benign intraepithelial;127600;Fd;;Dyskeratosis, hereditary benign intraepithelial (2);
4.628;6;18;01;4q35.2;DUX4;;Double homeo box protein 4;606009;REc;;;
4.629;12;27;13;4q35.2;DUX4L9, DUX4C;;Double homeobox 4-like 9;615581;REc;;;
4.630;12;22;08;4q35.2;F11;;Coagulation factor XI (plasma thromboplastin antecedent);264900;A, H, Fd;not closely linked to MNS;Factor XI deficiency, autosomal recessive, 612416 (3); Factor XI deficiency, autosomal dominant, 612416 (3);8(cf11)
4.631;8;18;98;4q35.2;FRG1, FSG1;;Facioscapulohumeral muscular dystrophy region gene-1;601278;REn;;;
4.632;11;22;05;4q35.2;FRG2;;Facioscapulohumeral muscular dystrophy region gene 2;609032;REn;;;
4.633;7;19;04;4q35;FSHD1, FSHD1A;;Facioscapulohumeral muscular dystrophy 1;158900;Fd, REc;due to D4Z4 macrosatellite repeat on 4q35;Facioscapulohumeral muscular dystrophy 1 (4);?8(myd)
4.634;7;30;15;4q35.2;KLKB1, KLK3, PKKD;;Kallikrein B plasma 1 (Fletcher factor);229000;A;similar to F11;Fletcher factor (prekallikrein) deficiency, 612423 (3);8(Kal3)
4.635;11;22;16;4q35.1;SLC25A4, ANT1, T1, PEO3, PEO2, MTDPS12A, PEOA2;;Solute carrier family 25 (mitochondrial carrier) member 4 (adenine nucleotide translocator-1, skeletal muscle);103220;REa, REb, A, Fd;;Progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal dominant 2, 609283 (3); Mitochondrial DNA depletion syndrome 12A (cardiomyopathic type) AD, 617184 (3); Mitochondrial DNA depletion syndrome 12B (cardiomyopathic type) AR, 615418 (3);8(Ant1)
4.636;2;24;17;4q35.1;STOX2, KIAA1392;;Storkhead box 2;617359;Psh;;;
4.637;3;14;18;4q35.1;TLR3, IIAE2;;Toll-like receptor-3;603029;A;;{Encephalopathy, acute, infection-induced (herpes-specific), susceptibility to, 2}, 613002 (3); {HIV1 infection, resistance to}, 609423 (3);
4.638;9;27;01;4q35-qter;DFNA24;;Deafness, autosomal dominant 24;606282;Fd;;Deafness, autosomal dominant 24 (2);
4.639;9;23;13;4q35.1;CCDC111, MYP22;;Coiled-coil domain containing 111;615421;REc;;Myopia 22, autosomal dominant, 615420 (3);
4.640;8;18;14;4q35.1;CDKN2AIP, CARF;;Cyclin-dependent kinase inhibitor 2A-interacting protein;615914;REc;;;
4.641;10;12;14;4q35.1;CFAP97, HMW, KIAA1430;;Cilia- and flagella-associated protein 97;616047;R, REc;;;
4.642;5;31;05;4q35.1-q35.2;CYP4V2, BCD;;Cytochrome P450, family 4, subfamily V, polypeptide 2;608614;Fd, REc;;Bietti crystalline corneoretinal dystrophy, 210370 (3);
4.643;6;28;16;4q35.1;ENPP6;;Ectonucleotide pyrophosphatase/phosphodiesterase 6;616983;REc;;;
4.644;6;27;17;4q35.1;HELT, HESL, MGN;;HELT basic helix-loop-helix transcription factor;617546;REc;;;8(Helt)
4.645;3;2;06;4q35.1;ING2, ING1L;;Inhibitor of growth 2;604215;A, R;;;
4.646;11;4;93;4q35.1;IRF2;;Interferon regulatory factor-2;147576;A;;;
4.647;8;1;05;4q35.1;KMHN1;;Cancer/testis antigen KM-HN-1;609488;REc;;;
4.648;10;8;07;4q35.1;MLF1IP, CENPU, CENP50;;MLF1-interacting protein (centromere protein U);611511;REc, H;;;8(Mlf1ip)
4.649;10;22;95;4q35.2;MTNR1A;;Melatonin receptor 1A;600665;REa, Psh;;;8(Mtnr1a)
4.650;5;19;15;4q35.1;SORBS2, ARGBP2, KIAA0777;;Sorbin and SH3 domains-containing protein 2;616349;REc;;;
4.651;8;1;16;4q34.3-q35.1;TENM3, ODZ3, TNM3, KIAA1455, MCOPCB9;;Teneurin transmembrane protein 3;610083;REc, R;;Microphthalmia, isolated, with coloboma 9, 615145 (3);
4.652;09;27;18;4q35.1;TRAPPC11, C4orf41, LGMDR18;;Trafficking protein particle complex, subunit 11;614138;REc;;Muscular dystrophy, limb-girdle, autosomal recessive 18, 615356 (3);
4.653;5;11;18;4q35.1;UFSP2, C4orf20, BHD, SEMDDR;;UFM1-specific peptidase 2;611482;REc;mutation identified in 1 BHD family;?Hip dysplasia, Beukes type, 142669 (3); ?Spondyloepimetaphyseal dysplasia, Di Rocco type, 617974 (3);
4.654;10;2;12;4q35.2;DUX2;;Double homeobox protein 2;611442;REc;?10q26.3;;
4.655;4;19;12;4q35.2;ZFP42, REX1;;Zinc finger protein 42;614572;REc, H;;;8(Zfp42)
4.656;12;21;09;4p16.1;MIR95, MIRN95;;Micro RNA 95;613185;REc;;;
4.657;10;23;87;Chr.4;TS13;;Temperature sensitivity complementation, ts13;187320;S;;;
5.1;12;13;18;5p15.33;NDUFS6, MC1DN9;;NADH dehydrogenase (ubiquinone) Fe-S protein 6, 13kD;603848;R;;Mitochondrial complex I deficiency, nuclear type 9, 618232 (3);
5.2;5;9;18;5p15.32;ICE1, KIAA0947;;Interactor of little elongation complex ELL subunit 1;617958;REc;;;
5.3;1;11;93;5p15.31;ADCY2;;Adenylyl cyclase-2, brain;103071;A, REa;;;13(Adcy2)
5.4;12;27;01;5p15.33;AHRR, KIAA1234;;Arylhydrocarbon receptor repressor;606517;R, A;;;13(Ahrr)
5.5;8;17;01;5p15.33;IRX1;;Iroquois homeo box protein 1;606197;A;;;
5.6;8;17;01;5p15.33;IRX2;;Iroquois homeo box protein 2;606198;A;;;
5.7;7;3;06;5p15.33;IRX4;;Iroquois homeobox protein 4;606199;REa, R, H;;;13(Irx4)
5.8;3;5;08;5p15.33;MRPL36;;Mitochondrial ribosomal protein L36;611842;REc;;;
5.9;3;31;15;5p15.33;NKD2;;Naked cuticle, Drosophila, homolog of, 2;607852;REc, R;;;
5.10;5;12;00;5p15.33;SLC12A7, KCC4;;Solute carrier family 12 (potassium/chloride transporters), member 7;604879;R, REa;;;
5.11;7;5;18;5p15.33;SLC6A3, DAT1, PKDYS1;;Solute carrier family 6 (neurotransmitter transporter, dopamine), member 3;126455;Psh, A, Fd;;{Nicotine dependence, protection against}, 188890 (3); Parkinsonism-dystonia, infantile, 1, 613135 (3);13(Dat1)
5.12;3;20;16;5p15.33;SLC9A3, NHE3, DIAR8;;Solute carrier family 9 (sodium/hydrogen exchanger), member 3;182307;REa, Fd;pseudogene on chr.10;Diarrhea 8, secretory sodium, congenital, 616868 (3);13(Slc9a3)
5.13;7;22;09;5p15.33;TPPP, P25, P24;;Tubulin polymerization-promoting protein;608773;Psh, R;;;
5.14;2;25;15;5p15.33;AYTL2, LPCAT, LPCAT1;;Acyltransferase-like 2;610472;REc;;;
5.15;10;6;09;5p15.33;BCC3;;Basal cell carcinoma, susceptibility to, 3;613059;Fd;;{Basal cell carcinoma, susceptibility to, 3} (2);
5.16;5;26;13;5p15.33;CEI;;Coordinated expression to IRXA2;610522;REc;;;
5.17;7;23;15;5p15.33;CEP72, KIAA1519;;Centrosomal protein, 72kD;616475;REc;;;
5.18;2;17;09;5p15.33;CLPTM1L, CRR9;;CLPTM1-like protein;612585;REc;;;
5.19;9;8;11;5p15.33;EXOC3, SEC6;;Exocyst complex component 3;608186;REc;;;
5.20;11;26;09;5p15.33;GLM8;;Glioma susceptibility 8;613033;Fd;associated with rs2736100;{Glioma susceptibility 8} (2);
5.21;2;18;09;5p15.33;LNCR3;;Lung cancer susceptibility 3;612571;Fd;associated with rs402710 and rs2736100;{Lung cancer susceptibility 3} (2);
5.22;5;22;14;5p15.33;LSINCT5;;Long stress-induced noncoding transcript 5;615764;REc;;;
5.23;11;11;14;5p15.33;PDCD6, ALG2;;Programmed cell death 6;601057;REc;;;
5.24;9;9;09;5p15.33;SLC6A18, XTRP2;;Solute carrier family 6 (neurotransmitter transporter), member 18;610300;REc;;;
5.25;4;20;10;5p15.33;SLC6A19, HND;;Solute carrier family 6 (neurotransmitter transporter), member 19;608893;REc, Fd;;Hartnup disorder, 234500 (3); Iminoglycinuria, digenic, 242600 (3); Hyperglycinuria, 138500 (3);13(Slc6a19)
5.26;5;26;15;5p15.33;TERT, TCS1, EST2, DKCA2, DKCB4, PFBMFT1, CMM9;;Telomerase reverse transcriptase;187270;R, D;deleted in cri du chat;{Pulmonary fibrosis and/or bone marrow failure, telomere-related, 1}, 614742 (3); {Dyskeratosis congenita, autosomal recessive 4}, 613989 (3); {Dyskeratosis congenita, autosomal dominant 2}, 613989 (3); {Leukemia, acute myeloid}, 601626 (3); {Melanoma, cutaneous malignant, 9}, 615134 (3);
5.27;7;27;17;5p15.33;TRIP13, 16E1BP, MVA3;;Thyroid hormone receptor interactor 13;604507;REc;;Mosaic variegated aneuploidy syndrome 3, 617598 (3);
5.28;1;27;09;5p15.33-p15.2;MYP16;;Myopia 16;612554;Fd;max lod at D5S2505;Myopia 16 (2);
5.29;8;29;08;5p15.33-p13.1;MCDR3;;Macular dystrophy, retinal, 3;608850;Fd;maximum lod at D5S630;Macular dystrophy, retinal, 3 (2);
5.30;6;17;17;5p15.31;FASTKD3;;Fast kinase domains 3;617530;REc;;;
5.31;6;1;15;5p15.31;LINC01018, SRHC;;Long intergenic noncoding RNA 1018;616385;REc;;;
5.32;10;30;08;5p15.31;MED10, NUT2;;Mediator complex subunit 10;612382;REc;;;
5.33;5;30;17;5p15.31;NSUN2, TRM4, SAKI, MISU, MRT5;;NOP2/SUN RNA methyltransferase family, member 2;610916;REc;;Mental retardation, autosomal recessive 5, 611091 (3);13(Nsun2)
5.34;6;22;14;2q11.2;SEMA4C, SEMAF, KIAA1739;;Semaphorin 4C;604462;REc;;;
5.35;7;18;14;5p15.31;UBE2QL1;;Ubiquitin-conjugating enzyme E2Q family-like protein 1;615832;REc;;;
5.36;12;19;11;5p15.31-p15.1;FAME3, FCMTE3;;Epilepsy, myoclonic, familial adult, 3;613608;Fd;between D5S580 and D5S2096;Epilepsy, myoclonic, familial adult, 3 (2);
5.37;7;31;06;5p15.31;MTRR;;Methionine synthase reductase;602568;Psh, A;;Homocystinuria-megaloblastic anemia, cbl E type, 236270 (3); {Neural tube defects, folate-sensitive, susceptibility to}, 601634 (3);
5.38;5;30;06;5p15.2;CCT5, KIAA0098, CCTE;;chaperonin containing TCP1, subunit 5 (epsilon);610150;REc, Fd;;Neuropathy, hereditary sensory, with spastic paraplegia, 256840 (3);
5.39;4;26;10;5p15.2;CMBL;;Carboxymethylenebutenolidase-like protein;613379;REc;;;15(Cmbl)
5.40;1;29;14;5p15.2;CTNND2, NPRAP;;Catenin, delta-2;604275;Psh, A;;;
5.41;1;4;96;5p15.2;DAP;;Death-associated protein;600954;REa;;;
5.42;8;30;16;5p15.2;LINC01194, TAG;;Long intergenic noncoding RNA 1194;617097;REc;;;
5.43;3;16;10;5p15.2;MARCH6, TEB4, DOA10, KIAA0597;;Membrane-associated RING-CH finger protein 6;613297;REc;;;
5.44;9;1;16;5p15.2;OTULIN, FAM105B, GUM, AIPDS;;OTU deubiquitinase with linear linkage specificity;615712;REc;;Autoinflammation, panniculitis, and dermatosis syndrome, 617099 (3);15(Otulin)
5.45;1;28;08;5p15.2;ROPN1L, ASP;;ROPN1-like protein;611756;R, REc;;;
5.46;10;14;09;5p15.31;SEMA5A, SEMF;;Semaphorin 5a;609297;REc;;;15(Sema5a)
5.47;7;1;02;5p14.3;CDH18, CDH14;;Cadherin 18;603019;R, Fd;;;
5.48;2;17;09;5p15.2-p14;ADIPQTL2, CAQ5;;Adiponectin, serum level of, QTL 2;606770;Fd;near D5S817;{Adiponectin, serum level of, QTL2} (2);
5.49;11;2;02;5p15.2;ANKH, HANK, ANK, CMDJ, CCAL2, CPPDD;;Ank, mouse, homolog of;605145;R, Fd;;Craniometaphyseal dysplasia, 123000 (3); Chondrocalcinosis 2, 118600 (3);15(ank)
5.50;7;14;06;5p15.2-p14.3;ANIB4;;Aneurysm, intracranial berry, 4;610213;Fd;max lod at D5S1954;Aneurysm, intracranial berry, 4 (2);
5.51;10;8;07;5q12.3;CEMPK, SOLT;;Centromeric protein K;611502;REc;;;
5.52;11;13;09;5p15.1;FAM134B, HSAN2B;;Family with sequence similarity 134, member B;613114;REc;;Neuropathy, hereditary sensory and autonomic, type IIB, 613115 (3);
5.53;8;31;09;5p15.1;FBXL7, FBL7;;F-box and leucine-rich repeat protein 7;605656;R, REc;;;15(Fbxl7)
5.54;6;7;10;5p15.1;MARCH11;;Membrane-associated RING-CH finger protein 11;613338;REc;;;
5.55;10;31;13;5p15.1;PVNH3;;Periventricular nodular heterotopia 3;608098;A, Ch;;Periventricular nodular heterotopia 3 (2);
5.56;9;27;17;5p15.1;ZNF622, ZPR9;;Zinc finger protein 622;608694;REc, R;;;
5.57;5;7;01;5p15.1;BASP1, CAP23, NAP22;;Brain-abundant signal protein, membrane-attached, 1;605940;A;;;
5.58;7;1;02;5p13.3;CDH6;;Cadherin 6;603007;R, Fd;;;
5.59;5;30;17;5p13.2;RXFP3, RLN3R1, SALPR, GPCR135;;Relaxin/insulin-like family peptide receptor 3;609445;R;;;
5.60;9;6;16;5p15.2;TRIO, MRD44;;Triple functional domain;601893;A;;Mental retardation, autosomal dominant 44, 617061 (3);
5.61;11;12;96;5p15.1;MYO10;;Myosin X;601481;A;;;15(Myo10)
5.62;6;11;11;5p15.1-p13.3;MYP19;;Myopia 19, autosomal dominant;613969;Fd;highest lod at D5S419;Myopia 19 (2);
5.63;4;3;09;5p15.32;ADAMTS16;;A disintegrin-like and metalloproteinase with thrombospondin type 1 motif, 16;607510;REc;;;
5.64;8;25;11;5p15.33;SDHA, SDH1, SDHF, CMD1GG, PGL5;;Succinate dehydrogenase complex, subunit A, flavoprotein;600857;A;copy on 3q29;Leigh syndrome, 256000 (3); Mitochondrial respiratory chain complex II deficiency, 252011 (3); Cardiomyopathy, dilated, 1GG, 613642 (3); Paragangliomas 5, 614165 (3);
5.65;12;9;91;5p15.31;SRD5A1;;Steroid-5-alpha-reductase, alpha polypeptide 1 (3-oxo-5 alpha-steroid delta 4-dehydrogenase alpha 1);184753;REa, A;pseudogene on X;;13(Srd5a1)
5.66;5;9;18;5p15.31;TENT4A, POLS, TRF4, POLK;;Terminal nucleotidyltransferase 4A;605198;REc;;;
5.67;4;5;00;5p15.31;TRB7, T2R1;;Taste receptor, family B, member 7;604796;REc;;;15(T2R19)
5.68;11;22;10;5p15;TST2;;Tuberculin skin test reactivity quantitative trait locus;613637;Fd;max lod at 16:2.70Mb;[Tuberculin skin test reactivity QTL] (2);
5.69;12;4;08;5p15.2;DNAH5, HL1, PCD, CILD3;;Dynein, axonemal, heavy chain 5;603335;REn, Fd;;Ciliary dyskinesia, primary, 3, with or without situs inversus, 608644 (3);15(Dnahc5)
5.70;4;26;17;5q14.3;POLR3G, RPC32, RPC7;;Polymerase III, RNA, subunit G;617456;REc;;;
5.71;3;24;06;5p14.1;CDH9;;Cadherin 9;609974;REc;;;
5.72;8;15;90;5p14;MLVI2;;Moloney leukemia virus integration site-2;157960;REa, A;;;15(Mlvi2)
5.73;3;18;94;5p14.3;PMCHL1;;Pro-melanin-concentrating hormone-like 1;176793;REa, A;;;
5.74;2;18;10;5p14.2;PRDM9;;PR domain-containing protein 9;609760;REc;;;
5.75;3;8;00;5p14.2-p14.1;CDH10;;Cadherin 10;604555;A;;;
5.76;9;14;95;5p14.3;CDH12, CDHB;;Cadherin-12 (N-cadherin 2);600562;A;pseudogene on 5q13 in SMA region;;
5.77;10;23;87;5p12;HMGCS1;;3-hydroxy-3-methylglutaryl-Coenzyme A synthase 1;142940;S, REa, A;like HMGCR, regulated transcriptionally by steroid;;
5.78;11;9;05;5p13.3;RNASEN, DROSHA, RANSE3L, RN3;;Ribonuclease III, nuclear;608828;A;;;15(Rnasen)
5.79;1;1;96;5p13.3;NPR3, ANPRC;;Natriuretic peptide receptor C;108962;REa, A;;?Hypertension, salt-resistant (1);
5.80;9;2;08;5p13.3;GOLPH3, GPP34, MIDAS;;Golgi phosphoprotein 3;612207;R, REc;;;
5.81;8;31;09;5p13.3;MTMR12, 3PAP, KIAA1682;;Myotubularin-related protein 12;606501;R, REa, REc;;;
5.82;8;9;13;5p13.2;SLC45A2, MATP, AIM1, SHEP5, OCA4;;Solute carrier family 45, member 2;606202;REc;;Albinism, oculocutaneous, type IV, 606574 (3); [Skin/hair/eye pigmentation 5, black/nonblack hair], 227240 (3); [Skin/hair/eye pigmentation 5, dark/fair skin], 227240 (3); [Skin/hair/eye pigmentation 5, dark/light eyes], 227240 (3);
5.83;10;2;12;5p13.3;SUB1, PC4, p15;;Sub1, S. cerevisiae, homolog of;600503;REc;;;
5.84;2;13;14;5p13.3;ZFR;;Zinc finger RNA-binding protein;615635;REc;;;
5.85;12;17;14;5p13.3-p13.2;BDA1B;;Brachydactyly, type A1, locus B;607004;Fd;;Brachydactyly, type A1, B (2);
5.86;12;10;98;5p13.2;RAD1;;RAD1, S. pombe, homolog of;603153;A;;;
5.87;12;27;01;5p13.2;RAI14, KIAA1334;;Retinoic acid-induced 14;606586;REa, A;;;
5.88;4;24;18;5p13.2;CPLANE1, C5orf42, JBTS17, OFD6;;Ciliogenesis and planar polarity effector 1;614571;REc;;Joubert syndrome 17, 614615 (3); Orofaciodigital syndrome VI, 277170 (3);
5.89;8;1;16;5p13.2;DNAJC21, DNAJA5, BMFS3;;DNAJ/HSP40 homolog, subfamily C, member 21;617048;R, REc;;Bone marrow failure syndrome 3, 617052 (3);
5.90;9;21;17;5p13.2-p13.1;EGFLAM, PIKA, AGRINL;;EGF-like, fibronectin type III, and laminin G domains-containing protein;617683;REc;;;
5.91;2;23;09;5p13.2;MS3;;Multiple sclerosis, susceptibility to, 3;612595;Fd;associated with rs6897932;{Multiple sclerosis, susceptibility to, 3} (2);
5.92;10;12;14;5p13.2;NADK2, C5orf33, DECRD;;NAD kinase 2, mitochondrial;615787;REc;mutation identified in 1 DECRD family;?2,4-dienoyl-CoA reductase deficiency, 616034 (3);
5.93;1;17;07;5p13.3;PDZD2, PAPIN, PIN1, AIPC;;PDZ domain containing 2;610697;R, REc;;;
5.94;12;27;13;5p13.2;PRLR, MFAB, HPRL;;Prolactin receptor;176761;REa, A, REc;mutation identified in 1 family with HPRL;Multiple fibroadenomas of the breast, 615554 (3); ?Hyperprolactinemia, 615555 (3);
5.95;6;2;15;5p13.2;RANBP3L;;RAN-binding protein 3-like;616391;REc;;;
5.96;8;19;13;5p13.2;SPEF2, KPL2, KIAA1770;;Sperm flagellar 2;610172;Psh, REc;;;
5.97;6;2;15;5p13.2;TTC23L;;Tetratricopeptide repeat domain-containing protein 23-like;616344;REc;;;
5.98;6;2;15;5p13.2;UGT3A1;;Uridine diphosphate glucuronosyltransferase 3 family, member A1;616383;REc;;;15(Ugt3a1)
5.99;6;2;15;5p13.2;UGT3A2;;Uridine diphosphate glucuronosyltransferase 3 family, member A2;616384;REc;;;15(Ugt3a2)
5.100;12;6;16;5p13.2;WDR70;;WD repeat-containing protein 70;617233;REc;;;
5.101;10;26;11;5p13.2;AMACR, CBAS4, AMACRD;;Alpha-methylacyl-CoA racemase;604489;TM;;Alpha-methylacyl-CoA racemase deficiency, 614307 (3); Bile acid synthesis defect, congenital, 4, 214950 (3);
5.102;4;21;17;5p13.1;FYB, SLAP130, ADAP, THC3;;FYN-binding protein;602731;REc;;Thrombocytopenia 3, 273900 (3);
5.103;9;24;08;5p13.1;IBD18;;Inflammatory bowel disease 18;612262;Fd;associated with rs1373692;{Inflammatory bowel disease 18} (2);
5.104;2;10;04;5p13.1;LIFR, STWS, SWS, SJS2;;Leukemia inhibitory factor receptor;151443;REa, Fd;;Stuve-Wiedemann syndrome/Schwartz-Jampel type 2 syndrome, 601559 (3);15(Lifr)
5.105;2;26;08;5p13.1;OSMR, OSMRB, PLCA1;;Oncostatin M receptor;601743;REc, Fd;;Amyloidosis, primary localized cutaneous, 1, 105250 (3);
5.106;5;19;04;5p13.2;NIPBL, CDLS1;;Nipped-B-like (delangin);608667;Ch, REc;;Cornelia de Lange syndrome 1, 122470 (3);15(Nipbl)
5.107;7;1;16;5p13.1;PLCXD3;;Phospholipase C, phosphatidylinositol-specific, X domain-containing protein 3;617016;REc;;;
5.108;12;14;99;5p13.1;PTGER4;;Prostaglandin E receptor 4, EP4 subtype;601586;A;;;
5.109;09;06;18;5p13.1;RICTOR, AVO3, KIAA1999;;Rapamycin-insensitive campion of mTOR;609022;REc;;;
5.110;3;23;06;5p13.1;CARD6, CINCIN1;;Caspase recruitment domain-containing protein 6;609986;REc, H;;;15(Card6)
5.111;1;25;11;5p13.2;GDNF, HSCR3;;Glial cell line derived neurotrophic factor;600837;A, Psh;;Central hypoventilation syndrome, 209880 (3); {Pheochromocytoma, modifier of}, 171300 (3); {Hirschsprung disease, susceptibility to, 3}, 613711 (3);
5.112;9;22;04;5p13;ADHD4;;Attention deficit-hyperactivity disorder, susceptibility to, 4;608906;Fd;;{Attention deficit-hyperactivity disorder}, 143465 (2);
5.113;5;30;17;5p13.2;AGXT2, AGT2, BAIBA;;Alanine-glyoxylate aminotransferase 2;612471;REc;;[Beta-aminoisobutyric acid, urinary excretion of], 210100 (3);
5.114;6;9;08;5p13.2;C1ATNF3, CTRP3, CORS26;;C1q- and tumor necrosis factor-related protein 3;612045;A, H;;;15(C1qtnf3)
5.115;12;4;08;5p13.1;C6;;Complement component-6;217050;A, H, RE, Fd, LD;;C6 deficiency, 612446 (3); Combined C6/C7 deficiency (3);15(C6)
5.116;7;3;06;5p13.1;C7;;Complement component-7;217070;A, H, RE, Fd, LD;;C7 deficiency, 610102 (3);15(C7)
5.117;1;7;14;5p13.1;C9, C9D, ARMD15;;Complement component-9;120940;REa, A, Fd, LD;;C9 deficiency, 613825 (3); {Macular degeneration, age-related, 15, susceptibility to}, 615591 (3);
5.118;12;18;98;5p13.1;DAB2, DOC2;;Disabled, Drosophila, homolog of, 2 (differentially expressed in ovarian cancer-2);601236;A, REa;;;
5.119;2;16;10;5p13;DUP5p13, C5DUPp13;;Chromosome 5p13 duplication syndrome;613174;Ch;;Chromosome 5p13 duplication syndrome (4);
5.120;1;20;09;5p13.2;IL7R, IL7RA, CD127;;Interleukin-7 receptor;146661;REa, A;;Severe combined immunodeficiency, T-cell negative, B-cell/natural killer cell-positive type, 608971 (3);
5.121;7;3;06;5p13;KYPSC1;;Kyphoscoliosis 1;610170;Fd;;Kyphoscoliosis 1 (2);
5.122;5;22;14;5p13.2;NUP155, KIAA0791, ATFB15;;Nucleoporin, 155kD;606694;A, R;mutation identified in 1 ATFB15 family;?Atrial fibrillation 15, 615770 (3);
5.123;8;25;06;5p13.1;OXCT1, OXCT, SCOT;;3-oxoacid CoA transferase 1;601424;A;;Succinyl CoA:3-oxoacid CoA transferase deficiency, 245050 (3);
5.124;9;23;96;5p13.2;SKP2;;S-phase kinase-associated protein 2 (p45);601436;A;;;
5.125;3;31;09;5p13.2;SLC1A3, EAAT1, EA6;;Solute carrier family 1 (glial high affinity glutamate transporter), member 3;600111;A;;Episodic ataxia, type 6, 612656 (3);15(Eaat1)
5.126;5;2;06;5p12;FGF10;;Fibroblast growth factor-10;602115;A;;Aplasia of lacrimal and salivary glands, 180920 (3); LADD syndrome, 149730 (3);
5.127;5;17;18;5p13-p12;GHR, GHIP;;Growth hormone receptor;600946;REa, A;;Laron dwarfism, 262500 (3); {Hypercholesterolemia, familial, modifier of}, 143890 (3); Increased responsiveness to growth hormone, 604271 (3); Growth hormone insensitivity, partial, 604271 (3);15(Ghr)
5.128;10;23;87;5p13.3;TARS;;Threonyl-tRNA synthetase;187790;S;linked to LARS;;
5.129;7;18;06;5p13-q12;HYT6;;Hypertension, essential, susceptibility to, 6;610262;Fd;;{Hypertension, essential, susceptibility to, 6}, 145500 (2);
5.130;5;24;13;5p12;ANXA2R, C5orf39, AX2R, AXIIR;;Annexin A2 receptor;611296;Psh;;;
5.131;9;9;08;5p12;CCL28;;Chemokine, C-C motif, ligand 28;605240;REc;;;13(Ccl28)
5.132;9;9;08;5p13.1;FBXO4, FBX4;;F-box only protein 4;609090;A, REc;;;15(Fbxo4)
5.133;7;17;14;5p12;HCN1, BCNG1, EIEE24;;Hyperpolarization-activated cyclic nucleotide-gated potassium channel 1;602780;REc;;Epileptic encephalopathy, early infantile, 24, 615871 (3);
5.134;10;11;16;5p12;NNT, GCCD4;;Nicotinamide nucleotide transhydrogenase;607878;A;;Glucocorticoid deficiency 4, with or without mineralocorticoid deficiency, 614736 (3);13(Nnt)
5.135;8;20;07;5p12;PAIP1;;Polyadenylate-binding protein-interacting protein 1;605184;REc;;;
5.136;11;20;98;5p13.1;PRKAA1;;Protein kinase, AMP-activated, catalytic, alpha-1;602739;A;;;
5.137;5;4;00;5p12;ZNF131;;Zinc finger protein -31;604073;A;;;
5.138;4;24;08;5p12;MRPS30;;Mitochondrial ribosomal protein S30;611991;R, REc;;;
5.139;11;18;16;5p12;SELENOP, SEPP1;;Selenoprotein P;601484;REa, A, R;;;
5.140;9;12;08;5p;ASD1;;Atrial septal defect 1;108800;Fd;max lod at D5S406;Atrial septal defect 1 (2);
5.141;8;4;97;5p;MHS6;;Malignant hyperthermia susceptibility 6;601888;Fd;;{Malignant hyperthermia susceptibility 6} (2);
5.142;10;20;99;5p13.1;RPL37;;Ribosomal protein L37;604181;REa, R;;;
5.143;5;19;06;5q;BSZQTL2;;Bone size quantitative trait locus 2;609657;Fd;;{Bone size QTL} (2);
5.144;3;5;95;5q11.1;ISL1;;ISL1 transcription factor, LIM/homeodomain (islet-1);600366;Fd;between D5S395 and D5S407; proximal 5q;;
5.145;10;2;09;5q35.3;PROP1, CPHD2;;Prophet of Pit1, paired-like homeodomain transcription factor;601538;H, R;;Pituitary hormone deficiency, combined, 2, 262600 (3);11(df, Prop1)
5.146;5;6;13;5q11.2;ANKRD55;;Ankyrin repeat domain-containing protein 55;615189;REc;;;
5.147;10;1;95;5q11.2;IL6ST;;Interleukin-6 signal transducer (gp130, oncostatin M receptor);600694;A;;;
5.148;11;4;13;5q11.2;MOCS2, MPTS, MOCODB;;Molybdenum cofactor synthesis-2;603708;R;;Molybdenum cofactor deficiency B, 252160 (3);
5.149;8;13;98;5q11.2;GZMA, CTLA3, HFSP;;Granzyme A (Cytotoxic T-lymphocyte-associated serine esterase-3; Hanukah factor serine protease);140050;REa;;;13(Ctla3)
5.150;9;1;16;5q14.1;MSH3, FAP4;;mutS, E. coli, homolog of, 3;600887;REn;5' to DHFR;Endometrial carcinoma, somatic, 608089 (3); Familial adenomatous polyposis 4, 617100 (3);13(Msh3)
5.151;2;1;11;5q14.1;ARSB, MPS6;;Arylsulfatase B;611542;S;;Mucopolysaccharidosis type VI (Maroteaux-Lamy), 253200 (3);13(As1)
5.152;11;16;00;5q13.3;IQGAP2;;IQ motif-containing GTPase-activating protein-2;605401;Psh;;;
5.153;3;7;14;5q11.1;EMB, GP70;;Embigin;615669;REc;;;
5.154;12;13;18;5q11.2;NDUFS4, AQDQ, MC1DN1;;NADH dehydrogenase (ubiquinone) Fe-S protein 4, 18kD (NADH-coenzyme Q reductase);602694;REa, R;;Mitochondrial complex I deficiency, nuclear type 1, 252010 (3);
5.155;10;4;12;5q11.2;ACTBL2;;Actin, beta-like, 2;614835;REc;;;
5.156;7;17;14;5q11.2;CCNO, UNG2, CILD29;;Cyclin O;607752;Psh, REc;;Ciliary dyskinesia, primary, 29, 615872 (3);
5.157;4;30;09;5q11.2;DHX29;;DEAH (Asp-Glu-Ala-His) box polypeptide 29;612720;REc;;;
5.158;6;22;14;5q11.2;ESM1;;Endothelial cell-specific molecule 1;601521;REc;;;
5.159;2;20;01;5q11.2;FST, FS;;Follistatin;136470;A;;;
5.160;8;18;08;5q11.2;GPBP1, GPBP;;GC-rich promoter-binding protein 1;608412;REc;;;
5.161;11;23;16;5q11.2;GPX8;;Glutathione peroxidase 8;617172;REc;;;
5.162;9;26;17;5q11.2;GZMK, TRYP2;;Granzyme K;600784;REc, A;;;
5.163;9;11;14;5q11.2;HSPB3, HSPL27, HMN2C, DHMN2C;;Heat-shock 27kD protein 3;604624;A;mutation identified in 1 HMN2C family;?Neuronopathy, distal hereditary motor, type IIC, 613376 (3);
5.164;7;22;11;5q11.2;IDAS;;IDAS;614086;REc;;;
5.165;3;6;18;5q11.2;IL31RA, GLMR, GPL, PLCA2;;Interleukin 31 receptor A;609510;REc, H;mutation identified in 1 PLCA2 patient;?Amyloidosis, primary localized cutaneous, 2, 613955 (3);13(Il31ra)
5.166;8;31;09;5q11.2;ITGA1, VLA1;;Integrin, alpha-1;192968;H, REc;;;13(Vla1)
5.167;8;29;11;5q11.2;MAP3K1, MEKK1, MEKK, SRXY6;;Mitogen-activated protein kinase kinase kinase 1;600982;REa, REc;;46XY sex reversal 6, 613762 (3);13(Mekk)
5.168;12;2;09;5q11.2;MIR449A, MIRN449A;;Micro RNA 449A;613131;REc;;;
5.169;12;2;09;5q11.2;MIR449B, MIRN449B;;Micro RNA 449B;613132;REc;;;
5.170;10;10;18;5q11.2;MTREX, MTR4, SKIV2L2;;MTR4 exosome RNA helicase;618122;REc;;;
5.171;3;22;01;5q11.2;PELO;;Pelota, Drosophila, homolog of;605757;A;;;
5.172;10;26;17;5q11.2;PLPP1, PPAP2A;;Phopshplipid phosphatase 1;607124;REc;;;
5.173;12;28;08;5q13.1-q13.2;SLC30A5, ZNT5, ZTL1;;Solute carrier family 30 (zinc transporter), member 5;607819;REc;;;
5.174;3;31;15;5q11.2;SLC38A9, URLC11;;Solute carrier family 38, member 9;616203;REc;;;
5.175;7;16;02;5q11.2;DDX4, VASA;;DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 4 (vasa, Drosophila, homolog of);605281;R, A;;;13(Ddx4)
5.176;12;19;11;5q12.3;SREK1, SFRS12, SRRp508;;Splicing regulatory glutamine/lysine-rich protein 1;609268;REc;;;
5.177;6;7;12;5q12.3;HTR1A, ADRB2RL1, PFMCD;;5-hydroxytryptamine (serotonin) receptor-1A;109760;REa, A, Fd;;Periodic fever, menstrual cycle dependent, 614674 (3);13(Htr1a)
5.178;12;4;01;5q13.2;TAF9, TAF2G, TAFII32;;TAF9 RNA polymerase II, TATA box-binding protein-associated factor, 32kD;600822;REa, Psh, A;;;
5.179;3;31;11;5q14.1;DHFR;;Dihydrofolate reductase;126060;S, REa, H, D;;Megaloblastic anemia due to dihydrofolate reductase deficiency, 613839 (3);13(Dhfr)
5.180;3;5;95;5q13.3;CRHBP;;Corticotropin releasing hormone-binding protein;122559;Psh;;;13(Crhbp)
5.181;8;31;09;5q12.3;ADAMTS6;;A disintegrin-like and metalloproteinase with thrombospondin type 1 motif, 6;605008;REa, REc;;;
5.182;8;24;92;5q13.2;CCNB1;;Cyclin B1;123836;A, REa;;;13(Cycb4)
5.183;1;23;13;5q12.3;CD180, LY64, RP105;;CD180 antigen;602226;A;;;13(Ly64)
5.184;3;7;14;5q12;DEL5q12, C5DELq12;;Chromosome 5q12 deletion syndrome;615668;Ch;;Chromosome 5q12 deletion syndrome (4);
5.185;6;11;02;5q12.3;ERBB2IP, ERBIN;;ERBB2 interacting protein;606944;R, REc;;;
5.186;5;25;12;5q12.1;ERCC8, CKN1, CSA, UVSS2;;Excision repair cross-complementing rodent repair deficiency, complementation group 8;609412;Psh;;Cockayne syndrome, type A, 216400 (3); UV-sensitive syndrome 2, 614621 (3);
5.187;2;2;16;5q13.3;GCNT4;;Glucosaminyl (N-acetyl) transferase 4, core 2;616782;A;;;
5.188;6;1;00;5q12.1;PART1;;Prostate androgen-regulated transcript 1;604991;R, A;;;
5.189;5;4;12;5q11.2-q12.1;PDE4D, DPDE3, STRK1, ACRDYS2;;Phosphodiesterase-4D, cAMP-specific (dunce, Drosophila, homolog of, phosphodiesterase-E3);600129;REa, A, Fd;;{Stroke, susceptibility to, 1}, 606799 (3); Acrodysostosis 2, with or without hormone resistance, 614613 (3);13(Pde4D)
5.190;8;27;01;5q13.2;ANKRA2, ANKRA;;Ankyrin repeat-containing protein, family A, member 2;605787;R, Psh;;;
5.191;8;29;08;5q14.1;CMYA5, MYOSPRYN, TRIM76;;Cardiomyopathy-associated protein 5;612193;REc;;;13(Cmya5)
5.192;4;24;96;5q13.2;FOXD1, FKHL8;;Forkhead box D1;601091;A;;;
5.193;5;31;05;5q13.2;MCCC2, MCCB;;3-Methylcrotonyl-CoA carboxylase 2;609014;R;;3-Methylcrotonyl-CoA carboxylase 2 deficiency, 210210 (3);
5.194;8;9;05;5q11.2;PLK2, SNK;;Polo-like kinase 2;607023;R;;;
5.195;3;18;94;5q13.2;PMCHL2;;Pro-melanin-concentrating hormone-like 2;176794;REa, A;;;
5.196;10;11;07;5q12-q14;EJM4;;Myoclonic epilepsy, juvenile, 4;611364;Fd;max lod at D5S459;Myoclonic epilepsy, juvenile, 4 (2);
5.197;10;12;10;5q14.2-q14.3;VCAN, CSPG2, WGN, WGN1, ERVR;;Versican (chondroitin sulfate proteoglycan-2);118661;REa, A, H, Fd;;Wagner syndrome 1, 143200 (3);13(Cspg2)
5.198;11;3;14;5q12.1;DEPDC1B;;DEP domain-containing protein 1B;616073;REc;;;
5.199;2;1;11;5q12.1;DIMT1L, DIM1, HUSSY5;;Dimethyladenosine transferase 1-like;612499;REc;previously assigned to 8p12;;
5.200;1;30;12;5q12.1;ELOVL7;;Elongation of very long chain fatty acids-like 6;614451;REc;;;
5.201;3;29;07;5q12.1;IPO11, RANBP11, SLRN;;Importin 11;610889;REc;;;
5.202;9;23;13;5q12.1;KIF2A, CDCBM3;;Kinesin, heavy chain, 2;602591;R;;Cortical dysplasia, complex, with other brain malformations 3, 615411 (3);
5.203;4;24;08;5q13.2;MRPS36;;Mitochondrial ribosomal protein S36;611996;REc;6 pseudogenes;;
5.204;12;13;18;5q12.1;NDUFAF2, NDUFA12L, MMTN, B17.2L, MC1DN10;;NADH dehydrogenase 1 alpha subcomplex, assembly factor 2;609653;REc;pseudogene on chr.2;Mitochondrial complex I deficiency, nuclear type 10, 618233 (3);
5.205;2;16;18;5q12.1;ZSWIM6, KIAA1577, AFND, NEDMAGA;;Zinc finger SWIM domain-containing protein 6;615951;Psh, REc;;Acromelic frontonasal dysostosis, 603671 (3); Neurodevelopmental disorder with movement abnormalities, abnormal gait, and autistic features, 617865 (3);
5.206;2;28;03;5q13.2;BIRC1, NAIP;;Baculoviral IAP repeat-containing 1 (neuronal apoptosis inhibitory protein);600355;REn, H;?involved in SMA;;13(Naip)
5.207;4;19;01;5q14.1;DMGDH, DMGDHD;;Dimethylglycine dehydrogenase;605849;A;;Dimethylglycine dehydrogenase deficiency, 605850 (3);
5.208;4;21;97;5q13.2;GTF2H2;;General transcription factor IIH, polypeptide 2 (44kD subunit);601748;REc;2 copies;;
5.209;9;28;00;5q13.2;SERF1A, H4F5, SMAM1;;Small EDRK-rich factor 1A;603011;REc, D;;;13(M4f5)
5.210;9;30;03;5q13.2;SMN1, SMA1, SMA2, SMA3, SMA4;;Survival of motor neuron 1, telomeric;600354;REn;;Spinal muscular atrophy-1, 253300 (3); Spinal muscular atrophy-2, 253550 (3); Spinal muscular atrophy-3, 253400 (3); Spinal muscular atrophy-4, 271150 (3);13(Smn)
5.211;5;15;17;5q12.3;CWC27, SDCCAG10, RPSKA;;CWC27 spliceosome-associated protein, X. cerevisiae, homolog of;617170;REc;;Retinitis pigmentosa with or without skeletal anomalies, 250410 (3);
5.212;10;13;09;5q12.3;NLN, KIAA1226, AGTBP;;Neurolysin;611530;R, REc;;;
5.213;3;29;07;5q12.3;RGS7BP, R7BP;;Regulator of G protein signaling 7-binding protein;610890;REc;;;13(Rgs7bp)
5.214;6;26;18;5q12.3;SHLD3, RINN1;;Shield complex, subunit 3;618030;REc;;;
5.215;7;14;14;5q12.3;TRIM23, ARD1;;Tripartite motif-containing protein 23;601747;REc;;;
5.216;9;22;14;5q12.3;RNF180, RINES;;RING finger protein 180;616015;REc;;;
5.217;10;12;09;5q13.2;SMN2;;Survival of motor neuron 2, centromeric;601627;REn;;{Spinal muscular atrophy, type III, modifier of}, 253400 (3);
5.218;12;18;18;5q13.2;BDP1, TFNR, DFNB112;;B double prime 1, subunit of RNA polymerase III transcription initiation factor IIIB;607012;A;mutation identified in 1 DFNB112 family;?Deafness, autosomal recessive 112, 618257 (3);
5.219;12;11;01;5q13.3;EFG2;;Elongation factor G2;606544;REc;;;
5.220;9;20;00;5q13.3;ENC1, PIG10;;Ectodermal-neural cortex 1;605173;A;;;13(Enc1)
5.221;11;4;93;5q13.3;F2R, CF2R, PAR1;;Coagulation factor II (thrombin) receptor;187930;A, R, REc;within 900kb of GPR11;;13(Cf2r)
5.222;6;28;00;5q13.3;F2RL1, GPR11, PAR2;;Coagulation factor II, thrombin, receptor-like 1 (G protein-coupled receptor-11);600933;A, R, REc;within 900kb of F2R;;
5.223;8;24;98;5q13.3;F2RL2, PAR3;;Coagulation factor II receptor-like 2 (protease-activated receptor 3);601919;REn;order: PAR2-PAR1-PAR3;;
5.224;11;23;09;5q13.3;HEXB;;Hexosaminidase B, beta polypeptide;606873;S, Ch, D;;Sandhoff disease, infantile, juvenile, and adult forms, 268800 (3);13(Hex2)
5.225;3;22;93;5q13.2;MAP1B;;Microtubule-associated protein-1B;157129;A, Fd;;;
5.226;6;1;18;5q12.3;MAST4;;Microtubule-associated serine-threonine kinase 4;618002;REc;;;
5.227;8;25;11;5q13.3;PDE8B, PPNAD3, ADSD;;Phosphodiesterase 8B;603390;R, Fd;;Pigmented nodular adrenocortical disease, primary, 3, 614190 (3); Striatal degeneration, autosomal dominant, 609161 (3);
5.228;9;22;14;5q13.1;PIK3R1, GRB1, AGM7, SHORT, IMD36;;Phosphatidylinositol 3-kinase, regulatory, 1;171833;REa, A;mutation identified in 1 AGM7 family;?Agammaglobulinemia 7, autosomal recessive, 615214 (3); SHORT syndrome, 269880 (3); Immunodeficiency 36, 616005 (3);13(Pik3r1)
5.229;7;16;09;5q11.2;RAB3C;;Ras-associated protein RAB3C;612829;REc;;;
5.230;10;20;99;5q13.2;RAD17;;RAD17, S. pombe, homolog of;603139;A, H;;;13(Rad17)
5.231;12;11;02;5q14.1;RASGRF2;;Ras protein-specific guanine nucleotide-releasing factor 2;606614;A;;;13(Rasgrf2)
5.232;9;22;08;5q13;TSHQTL1;;Thyroid-stimulating hormone level QTL 1;612306;Fd;associated with rs4704397;[Thyroid-stimulating hormone level QTL 1] (2);
5.233;7;12;02;5q13-q14;AAT2, FAA2;;Aortic aneurysm, familial thoracic 2;607087;Fd;;Aortic aneurysm, familial thoracic 2 (2);
5.234;9;3;15;5q14.2;XRCC4, SSMED;;X-ray repair, complementing defective, repair in Chinese hamster cells-4;194363;S, REa, R;between D5S427 and D5S401;Short stature, microcephaly, and endocrine dysfunction, 616541 (3);
5.235;4;24;02;5q13-q22;GINGF2, GGF2, HGF2;;Fibromatosis, gingival, 2;605544;Fd;formerly GINGF2 used for a locus on 2p16-p13;Fibromatosis, gingival, 2 (2);
5.236;9;21;11;5q14.3;HAPLN1, CRTL1;;Hyaluronan and proteoglycan link protein 1;115435;A;;;
5.237;9;5;91;5q21.3;RPS20A;;Ribosomal protein S20A;180463;REa;?pseudogene;;
5.238;12;29;06;5q13.2;MARVELD2, MARVD2, TRIC, DFNB49;;Marvel domain-containing protein 2 (tricellulin);610572;REc, Fd, REc;;Deafness, autosomal recessive 49, 610153 (3);13(tric)
5.239;3;27;17;5q13.2;OCLN, BLCPMG, PTORCH1;;Occludin;602876;R, REc;;Pseudo-TORCH syndrome 1, 251290 (3);
5.240;2;20;01;5q13.3;POLK, POLQ, DINB1;;Polymerase, DNA, kappa;605650;REa, A;;;
5.241;4;30;09;5q14.1;BHMT;;Betaine-homocysteine methyltransferase;602888;REn;;;
5.242;5;7;01;5q14.1;BHMT2;;Betaine-homocysteine methyltransferase 2;605932;A, R;;;13(Bhmt2)
5.243;5;5;15;5q13.2;CARTPT, CART;;Cocaine- and amphetamine-regulated transcript prepropeptide;602606;REc;mutation identified in 1 family;{?Obesity, susceptibility to}, 601665 (3);
5.244;3;24;11;5q13.2;CCDC125, KENAE;;Coiled-coil domain-containing protein 125;613781;REc;;;
5.245;2;24;98;5q13.2;CDK7, STK1, CAK1;;Cyclin-dependent kinase 7 (homolog of Xenopus MO15 cdk-activating kinase);601955;REa, REc;previously mapped to 2p15-cen;;
5.246;4;10;14;5q13.2;CENPH;;Centromeric protein H;605607;REc;;;
5.247;9;7;10;5q13.2;FCHO2;;FCH domain-only protein 2;613438;REc;;;
5.248;11;5;99;5q14.1;JMY;;Junction-mediating and regulatory protein;604279;A;;;
5.249;4;24;08;5q13.2;MRPS27, KIAA0264;;Mitochondrial ribosomal protein S27;611989;R, REc;;;
5.250;11;10;13;5q13.2;PTCD2;;Pentatricopeptide repeat domain-containing protein 2;615484;REc;;;
5.251;5;26;09;5q13.2;RGNEF, p190RHOGEF;;Rgnef, mouse, homolog of;612790;REc;;;
5.252;12;10;12;5q13.2;TMEM174;;Transmembrane protein 174;614909;REc;;;
5.253;4;19;06;5q13.2;TNPO1, KPNB2, MIP1;;Transportin 1;602901;R;;;
5.254;2;4;15;5q13.2;UTP15;;UTP15, U3 small nucleolar ribonucleoprotein, S. cerevisiae, homolog of;616194;REc;;;
5.255;4;6;15;5q13.2;ZNF366, DCSCRIPT;;Zinc finger protein 366;610159;REc;;;
5.256;1;8;07;5q13.3;AGGF1, VG5Q, HUS84971, FLJ10283;;Angiogenic factor with G patch and FHA domains 1;608464;Ch;;;
5.257;1;2;95;5q14.1;CKMT2;;Creatine kinase, mitochondrial-2 (sarcomeric);123295;Psh, A;;;
5.258;5;11;15;5q13.3;COL4A3BP, GPBP, CERT, MRD34;;COL4A3-binding protein (ceramide transporter);604677;REc;;Mental retardation, autosomal dominant 34, 616351 (3);
5.259;5;22;14;5q13.3;FAM169A, SLAP75, KIAA0888;;Family with sequence similarity 169, member A;615769;REc;;;
5.260;12;11;18;5q13.3;LINC01157;;Long intergenic noncoding RNA 1157;618214;;;;13(Linc01157)
5.261;3;8;00;5q14.1;OTP;;Orthopedia, Drosophila, homolog of;604529;R, A;;;
5.262;11;26;18;5q14.3;RASA1, GAP, CMAVM1, PKWS;;RAS p21 protein activator 1 (GTPase activating protein);139150;REa, A;;Capillary malformation-arteriovenous malformation 1, 608354 (3); Basal cell carcinoma, somatic, 605462 (3);13(Gap)
5.263;7;3;06;5q13.3;S100Z;;S100 calcium-binding protein, zeta;610103;REc;;;
5.264;12;4;02;5q14.1;SSBP2;;Single-stranded DNA-binding protein 2;607389;REc;;;
5.265;8;3;12;5q13.3;SV2C;;Synaptic vesicle glycoprotein 2C;610291;REc;;;
5.266;12;22;08;5q13.3;TINP1, NSA2, HUSSY29;;Transforming growth factor-beta-inducible nuclear protein 1;612497;REc;;;
5.267;5;30;17;5q13.3-q14.1;WDR41;;WD repeat-containing protein 41;617502;REc;;;
5.268;5;31;13;5q13.3;ZBED3;;Zinc finger BED domain-containing protein 3;615250;REc;;;
5.269;6;19;98;5q14.3;CCNH, CAK;;Cyclin H;601953;REa, A, REc;;;
5.270;5;18;09;5q13.3;HMGCR, LDLCQ3;;3-hydroxy-3-methylglutaryl-Coenzyme A reductase; HMG CoA reductase;142910;REa, A;;[Statins, attenuated cholesterol lowering by] (3); [Low density lipoprotein cholesterol level QTL 3] (3);13(Hmgcr)
5.271;5;13;02;5q14.1;SCAMP1, SCAMP37;;Secretory carrier membrane protein 1;606911;R;;;
5.272;6;15;99;5q14.3;COX7C;;Cytochrome C oxidase, subunit VII C;603774;A, R;pseudogene on 13q14-q21;;
5.273;4;1;96;5q15;GLRX, GRX;;Glutaredoxin (thioltransferase);600443;REa, A;;;
5.274;6;5;13;5q14;HBT;;Telangiectasia, hereditary benign;187260;Fd;max lod at D5S641;Telangiectasia, hereditary benign (2);
5.275;7;8;10;5q14.3;MEF2C, C5DELq14.3, DEL5q14.3;;MADS box transcription enhancer factor 2, polypeptide C (myocyte enhancer factor 2C);600662;A, REa;;Mental retardation, stereotypic movements, epilepsy, and/or cerebral malformations, 613443 (3); Chromosome 5q14.3 deletion syndrome, 613443 (4);13(mef2c)
5.276;7;7;14;5q15;NR2F1, TFCOUP1, ERBAL3, EAR3, BBSOAS;;Nuclear receptor subfamily 2, group F, member 1 (transcription factor COUP 1);132890;A;;Bosch-Boonstra-Schaaf optic atrophy syndrome, 615722 (3);13(Tcfcoup1)
5.277;2;28;94;5q21.1;PAM;;Peptidylglycine alpha-amidating monooxygenase;170270;REa, A;;;1(Pam)
5.278;10;28;11;5q14.1;ACOT12, CACH;;Acyl-CoA thioesterase 12;614315;REc;;;13(Acot12)
5.279;5;31;05;5q14.1;AP3B1, ADTB3A, HPS2;;Adaptor-related protein complex 3, beta 1 subunit (adaptin, beta-3a);603401;REc;;Hermansky-Pudlak syndrome 2, 608233 (3);13(Ap3bi, pe)
5.280;12;28;08;5q14.1;LHFPL2, KIAA0206;;LHFP-like protein 2;609718;R, REc;;;
5.281;4;2;12;5q14.1;SERINC5, C5orf12, TPO1;;Serine incorporator 5;614551;REc;;;
5.282;09;05;18;5q14.1;SPZ1, PPP1R148;;Spermatogenic leucine zipper protein 1;618068;REc;;;
5.283;5;9;18;5q14.1;TENT2, APD4, GLD2;;Terminal nucleotidyltransferase 1;614121;REc;;;
5.284;9;26;17;5q14.1;THBS4;;Thrombospondin IV;600715;REc;;;
5.285;9;16;12;5q14.1;ZFYVE16, ENDOFIN, KIAA0305;;Zinc finger FYVE domain-containing protein 16;608880;REc;;;
5.286;5;9;12;5q14.1-q21.3;KTCN5;;Keratoconus 5;614622;Fd;between D5S2499 and D5S495;Keratoconus 5 (2);
5.287;3;8;07;5q14.1-q14.2;ATG10, APG10;;Autophagy 10, S. cerevisiae, homolog of;610800;R, REc;;;
5.288;7;9;06;5q14.1;HOMER1, HOMER1B, HOMER1C, HOMER1A;;Homer, homlog 1 (Drosophila);604798;R;;;
5.289;8;11;17;5q14.2;RPS23, BTDD, MCINS;;Ribosomal protein S23;603683;Psh, R, REc;;Brachycephaly, trichomegaly, and developmental delay, 617412 (3);
5.290;4;2;16;5q14.2;SCARNA18;;Small cajal body-specific RNA 18;611329;REc;in intron 1 of TMEM167;;
5.291;11;3;11;5q14.2;VUR4;;Vesicoureteral reflux 4;614317;Fd;closest marker rs1501656;Vesicoureteral reflux 4 (2);
5.292;5;13;02;5q15;LNPEP;;Leucyl-cystinyl aminopeptidase;151300;A;;;
5.293;12;24;08;5q14.3;ARRDC3, TLIMP, KIAA1376;;Arrestin domain-containing 3;612464;REc;;;
5.294;1;4;16;5q14.3;ADGRV1, GPR98, MASS1, VLGR1, KIAA0686, FEB4, USH2C;;Adhesion G protein-coupled receptor V1;602851;A, REc, R, Fd;mutation identified in 1 FEB4 family;?Febrile seizures, familial, 4, 604352 (3); Usher syndrome, type 2C, 605472 (3); Usher syndrome, type 2C, GPR98/PDZD7 digenic, 605472 (3);13(Frings, mass1)
5.295;5;25;13;5q14.3;CETN3, CDC31;;Centrin 3;602907;REc;;;
5.296;10;23;15;5q14.3;LINC00461, VISC;;Long intergenic noncoding RNA 461;616611;REc;;;
5.297;11;15;18;5q14.3;LUCAT1, SCAL1;;Lung cancer-associated transcript 1, noncoding;618190;REc;;;
5.298;3;23;09;5q14.3;MIR9-2, MIRN9-2;;Micro RNA 9-2;611187;REc;;;
5.299;5;6;03;5q15;RHOBTB3, KIAA0878;;Rho-related BTB domain-containing protein 3;607353;REc;;;
5.300;10;31;13;5q14.3-q15;PVNH5;;Periventricular nodular heterotopia 5;612881;Ch;deletion range 6.3-17Mb, common range 5.8Mb;Periventricular nodular heterotopia 5 (4);
5.301;5;19;06;5q15;ARSK;;Arylsulfatase K;610011;REc;;;
5.302;6;10;08;5q15;ELL2;;Elongation factor, RNA polymerase II, 2;601874;R, REc;;;
5.303;6;10;08;5q15;ERAP1, ALAP, ARTS1, PILSAP, KIAA0525;;Endoplasmic reticulum aminopeptidase 1;606832;REc;;;
5.304;12;30;09;5q15;ERAP2, LRAP;;Endoplasmic reticulum aminopeptidase 2;609497;REc;;;
5.305;12;22;16;5q15;KIAA0825;;KIAA0825 gene;617266;REc;;;
5.306;5;24;13;5q15;LIX1;;Limb expression 1, mouse, homolog of;610466;REc;;;
5.307;4;7;15;5q15;MCTP1;;Multiple C2 domains-containing transmembrane protein 1;616296;REc;;;
5.308;10;31;17;5q15;RIOK2, RIO2;;RIO kianse 2;617754;REc;;;
5.309;4;27;12;5q15;TTC37, KIAA0372;;Tetratricopeptide repeat domain 37;614589;REc;;Trichohepatoenteric syndrome 1, 222470 (3);
5.310;4;7;15;5q15;CAST, PLACK;;Calpastatin;114090;A, REb;;Peeling skin with leukonychia, acral punctate keratoses, cheilitis, and knuckle pads, 616295 (3);
5.311;9;21;17;5q15-q21;CHD1, PILBOS;;Chromodomain helicase DNA binding protein-1;602118;REc;;Pilarowski-Bjornsson syndrome, 617682 (3);
5.312;10;29;08;5q15;PCSK1, NEC1, PC1, PC3, BMIQ12;;Proprotein convertase subtilisin/kexin type 1;162150;A;;Obesity with impaired prohormone processing, 600955 (3); {Obesity, susceptibility to, BMIQ12}, 612362 (3);13(Nec1)
5.313;11;30;06;5q35.2;CPEB4, KIAA1673;;Cytoplasmic polyadenylation element-binding protein 4;610607;REa, REc;;;
5.314;12;5;13;5q22.2;MCC;;Mutated in colorectal cancers;159350;REn, D;;Colorectal cancer, somatic, 114500 (3);18(Mcc)
5.315;9;14;05;5q21;MGR8;;Migraine, susceptibility to, 8;609570;Fd;;{Migraine, susceptibility to, 8} (2);
5.316;7;14;98;5q21.1;PST, PST1;;Polysialyltransferase;602547;A;;;
5.317;1;24;06;5q22.2;DCP2;;Decapping enzyme 2, S. cerevisiae, homolog of;609844;REc;;;
5.318;2;27;01;5q23.1;DMXL1;;DMX-like 1;605671;A, R;;;
5.319;4;30;91;5q21.3;FER, TYK3;;fer (fps/fes related) tyrosine kinase;176942;REa, A;;;11(Fert)
5.320;10;26;97;5q21.3;MAN2A1, MANA2;;Mannosidase, alpha, class 2A, member 1;154582;REa, A;;;
5.321;5;27;93;5q22.2;SRP19;;Signal recognition particle 19kD;182175;REn;within 100kb of APC;;
5.322;12;4;90;5q22.1;CAMK4;;Ca(2+)-calmodulin-dependent protein kinase type IV of brain;114080;REa, A, H;;;18(Camk4)
5.323;10;23;15;5q21.1;C5orf30;;Chromosome 5 open reading frame 30;616608;REc;;;
5.324;12;18;07;5q21.1;HISPPD1, PPIP5K2, VIP2, KIAA0433;;Histidine acid phosphatase domain-containing protein 1;611648;R, REc;;;
5.325;3;31;09;5q15;RGMB, DRAGON;;RGM domain family, member B;612687;R, REc;;;
5.326;6;13;12;5q21.1;SLCO4C1, OATP4C1;;Solute carrier organic anion transporter family, member 4C1;609013;REc;;;
5.327;4;20;10;5q21.1;SLCO6A1, GST;;Solute carrier organic anion transporter family, member 6A1;613365;REc;;;
5.328;8;9;01;5q22.3;KCNN2, SK2;;Potassium channel, calcium-activated, intermediate/small conductance, subfamily N, member 2;605879;REc;;;
5.329;9;26;17;5q21.3;EFNA5, EPLG7, LERK7;;Ephrin A5;601535;REc;;;
5.330;9;9;08;5q21.3;FBXL17, FBL17, FBX13, FBXO13;;F-box and leucine-rich repeat protein 17;609083;REc;;;17(Fbxl17)
5.331;8;18;04;5q23.1;FTMT;;Ferritin, mitochondrial;608847;REc;;;
5.332;3;22;06;5q22.1;WDR36, TAWDRP, GLC1G;;WD repeat-containing protein 36;609669;REc;;Glaucoma 1, open angle, G, 609887 (3);
5.333;11;17;14;5q21.3-q33.2;MDBS2;;Macular dystrophy, butterfly-shaped pigmentary, 2;608970;Fd;between D5S433 and D5S410;Macular dystrophy, butterfly-shaped pigmentary, 2 (2);
5.334;7;8;10;5q22;EOE2;;Esophagitis, eosinophilic, 2;613412;Fd;association with rs3806932;{Esophagitis, eosinophilic, 2} (2);
5.335;6;28;02;5q22.1;STARD4;;Start domain-containing protein 4;607049;REc;;;
5.336;1;22;07;5q22.2;TSSK1, STK22D;;Testis-specific serine/threonine kinase 1;610709;REc;pseudogene on chr22;;16(Tssk1)
5.337;7;10;08;5q22.1-q22.2;EPB41L4A, EPB41L4, NBL4;;Erythrocyte membrane protein band 4.1-like 4A;612141;A;;;
5.338;9;28;96;5q22.2;ZRSR1, U2AF1RS1;;Zinc finger-, CCCH domain-, and RNA-binding motif-containing serine/arginine-rich protein 1;601079;A;;;11(U2af1rs1)
5.339;8;9;99;5q22.3;CDO1;;Cysteine dioxygenase, type 1;603943;Psh, A;;;18(Cdo1)
5.340;3;22;06;5q22.2;REEP5, D5S346, DP1, C5orf18;;Receptor expression-enhancing protein 5;125265;REn;;;
5.341;8;31;09;5q22.1;C5orf13, P311, PTZ17;;P311 protein;607332;R, REc;;;
5.342;9;9;08;5q22.1;TSLP;;Thymic stromal lymphopoietin;607003;R;;;18(Tslp)
5.343;10;30;06;5q22.1-q32;GLC1M;;Glaucoma 1, open angle, M;610535;Fd;between D5S2051 and D5S2090;Glaucoma 1, open angle, M (2);
5.344;8;7;15;5q22.1;SLC25A46, HMSN6B;;Solute carrier family 25, member 46;610826;REc;;Neuropathy, hereditary motor and sensory, type VIB, 616505 (3);8(Slc25a46)
5.345;11;21;14;5q22.2;APC, GS, FPC, BTPS2;;Adenomatous polyposis coli;611731;D, Fd, REn;150kb distal to MCC;Adenomatous polyposis coli, 175100 (3); Gastric cancer, somatic, 613659 (3); Adenoma, periampullary, somatic (3); Hepatoblastoma, somatic, 114550 (3); Desmoid disease, hereditary, 135290 (3); Colorectal cancer, somatic, 114500 (3); Brain tumor-polyposis syndrome 2, 175100 (3); Gardner syndrome, 175100 (3);18(Min, Apc)
5.346;11;13;13;5q22.3;PGGT1B;;Protein geranylgeranyltransferase type I, beta subunit;602031;REc;;;
5.347;8;17;17;5q22.3;TRIM36, RBCC728, ANPH;;Tripartite motif-containing protein 36;609317;R, REc;mutation identified in 1 ANPH patient;?Anencephaly, 206500 (3);
5.348;12;22;17;5q35.3;ADAMTS2, NPI, EDSDERMS;;A disintegrin-like and metalloproteinase with thrombospondin type 1 motif, 2 (procollagen I N-proteinase);604539;REa, H;;Ehlers-Danlos syndrome, dermatosparaxis type, 225410 (3);11(Adamts2)
5.349;3;16;99;5q31.1;CAMLG;;Calcium-modulating cyclophilin ligand;601118;A;;;13(Camlg)
5.350;10;28;99;5q23.2;CSNK1G3;;Casein kinase I, gamma-3;604253;R, A;;;
5.351;5;19;06;5q31.3;HBEGF, DTR, DTSF, HEGFL;;Heparin-binding EGF-like growth factor (diphtheria toxin receptor);126150;S, M;;{Diphtheria, susceptibility to} (1);18(Hegfl)
5.352;5;15;01;5q23.2;SNX2;;Sorting nexin 2;605929;R;;;
5.353;12;4;14;5q23.3;FBN2, CCA, EOMD;;Fibrillin-2;612570;Fd, A;;Contractural arachnodactyly, congenital, 121050 (3); Macular degeneration, early-onset, 616118 (3);18(Fbn2)
5.354;9;13;11;5q11.2;ITGA2, CD49B, BR, BDPLT9;;Integrin, alpha-2 (CD49B; alpha-2 subunit of VLA-2 receptor; platelet antigen Br);192974;S, Psh, A;;?Glycoprotein Ia deficiency, 614200 (1);
5.355;11;29;00;5q31.1;NEUROG1, NEUROD3;;Neurogenin 1;601726;A;;;13(Neurod3)
5.356;6;15;99;5q31.2;NME5, NM23H5;;Nonmetastatic cells 5, protein expressed in (nonmetastatic protein 23, homolog 5);603575;R;;;
5.357;7;11;93;5q31.1;PPP2CA;;Protein phosphatase-2 (formerly 2A), catalytic subunit, alpha isoform;176915;REa, A;;;
5.358;10;28;96;5q31.1;UBE2B, RAD6B;;Ubiquitin-conjugating enzyme E2B (RAD6 homolog);179095;A;;?Male infertility (1);
5.359;6;4;99;5q31.2;NRG2;;Neuregulin 2;603818;R, REc;;;
5.360;8;18;98;5q33.3;FABP6, ILLBP;;Fatty acid-binding protein 6, ileal (gastrotropin);600422;H, REa;;;11(Illbp)
5.361;5;5;09;5q23-q35;SCZD1;;Schizophrenia susceptibility locus, chromosome 5-related;181510;Fd;max lod at D5S820;{Schizophrenia}, 181500 (2);
5.362;2;1;11;5q22.3-q23.1;AP3S1, CLAPS3;;Adaptor-related protein complex 3, sigma 1 subunit;601507;REc;previously assigned to chr. 12 by FISH;;
5.363;12;22;15;5q23.1;COMMD10;;COMM domain-containing protein 10;616704;REc;;;
5.364;5;8;13;5q23.1;HSD17B4, PRLTS1;;Hydroxysteroid (17-beta) dehydrogenase 4;601860;A;;D-bifunctional protein deficiency, 261515 (3); Perrault syndrome 1, 233400 (3);
5.365;6;9;06;5q23.1;LVRN;;Laeverin;610046;R, REc;;;
5.366;8;18;14;5q23.1;PRR16, LARGEN;;Proline-rich protein 16;615931;REc;;;
5.367;4;21;15;5q23.1;SEMA6A;;Semaphorin 6A;605885;REc;;;
5.368;3;14;07;5q23.1;SRFBP1, P49;;Serum response factor binding protein 1;610479;R, REc;;;
5.369;12;8;03;5q22.3;TIRP, TRAM;;Toll/interleukin-1 receptor domain-containing protein;608321;REc;;;
5.370;6;30;08;5q23.1;TNFAIP8, SCCS2;;Tumor necrosis factor-alpha-induced protein 8;612111;R, REc;;;
5.371;3;15;10;5q23.2;SNCAIP;;Synuclein-alpha-interacting protein (synphilin 1);603779;R;;;
5.372;11;7;17;5q23.2;CEP120, CCDC100, SRTD13, JBTS31;;Centrosomal protein, 120kD;613446;REc;;Short-rib thoracic dysplasia 13 with or without polydactyly, 616300 (3); Joubert syndrome 31, 617761 (3);
5.373;11;11;13;5q23.2;LMNB1, ADLD;;Lamin B1;150340;H, A, Fd, REc;;Leukodystrophy, adult-onset, autosomal dominant, 169500 (3);18(Lmnb)
5.374;6;7;10;5q23.2;MARCH3;;Membrane-associated RING-CH finger protein 3;613333;REc;;;
5.375;5;4;12;5q23.2;MEGF10, KIAA1780, EMARDD;;Multiple epidermal growth factor-like domains 10;612453;REc;;Myopathy, areflexia, respiratory distress, and dysphagia, early-onset, 614399 (3); Myopathy, areflexia, respiratory distress, and dysphagia, early-onset, mild variant, 614399 (3);
5.376;8;31;09;5q23.2;PPIC;;Peptidyl-prolyl isomerase C;123842;R, REc;;;
5.377;7;22;16;5q23.2;PRDM6, PRISM, PDA3;;PR domain-containing protein 6;616982;REc;;Patent ductus arteriosus 3, 617039 (3);
5.378;3;31;15;5q23.2;RNUXA, PHAX;;RNA, U small nuclear, export adaptor;604924;REc;;;
5.379;11;30;06;5q31.1;FNIP1, KIAA1961;;Folliculin-interacting protein 1;610594;REc;;;
5.380;3;3;16;5q23.3-q31.1;LYRM7, MZM1L, MC3DN8;;LYR motif-containing protein 7;615831;REc;;Mitochondrial complex III deficiency, nuclear type 8, 615838 (3);
5.381;11;20;95;5q23.3;SLC12A2, NKCC1;;Solute carrier family 12 (sodium/potassium/chloride transporters), member 2;600840;A;;;
5.382;2;27;01;5q31.3;RNF14, ARA54;;RING finger protein-14;605675;REa, R;;;
5.383;10;25;16;5q23.1;LOX, AAT10;;Lysyl oxidase;153455;REa, A;;Aortic aneurysm, familial thoracic 10, 617168 (3);18(Lox)
5.384;9;18;08;5q31.1;ACSL6, FACL6, ACS2;;Acyl-CoA synthetase long-chain family member 6;604443;Ch;;Myelodysplastic syndrome (3); Myelogenous leukemia, acute (3);
5.385;8;31;12;5q23.3;ADAMTS19;;A disintegrin-like and metalloproteinase with thrombospondin type 1 motif, 19;607513;REc;;;
5.386;5;19;15;5q31.1;AFF4, AF5Q31, CHOPS;;AF4/FMR2 family, member 4;604417;Ch;;CHOPS syndrome, 616368 (3);
5.387;3;26;07;5q23.2;ALDH7A1, ATQ1, EPD, PDE;;Aldehyde dehydrogenase 7 family, member A1 (antiquitin 1);107323;A, Fd;;Epilepsy, pyridoxine-dependent, 266100 (3);18(Atq1)
5.388;8;31;09;5q31.3;APBB3, FE65L2;;Amyloid beta (A4) precursor protein-binding, family B, member 3;602711;R, REc;;;
5.389;8;27;15;5q31.3;ARHGAP26, GRAF;;RHO GTPase-activating protein 26;605370;Ch, A;;Leukemia, juvenile myelomonocytic, somatic, 607785 (3);
5.390;3;22;93;5q31.2;CDC25C;;Cell division cycle 25C;157680;A, REn;;;
5.391;2;16;04;5q31.1;CDKL3, NKIAMRE;;Cyclin-dependent kinase-like 3;608459;A;;;
5.392;4;13;10;5q23.3;CHSY3, CSS3;;Chondroitin sulfate synthase 3;609963;REc;;;
5.393;4;8;16;5q31.2;CTNNA1, MDPT2;;Catenin (cadherin-associated protein), alpha 1, 102kD;116805;A, REa;;Macular dystrophy, patterned, 2, 608970 (3);18(Catna1)
5.394;8;28;02;5q31.1;CXCL14, SCYB14, BRAK;;Chemokine, C-X-C motif, ligand 14;604186;REc;;;
5.395;11;13;15;5q31.3;DIAPH1, DFNA1, LFHL1, SCBMS;;Diaphanous, Drosophila, homolog of, 1;602121;Fd, REc;;Deafness, autosomal dominant 1, 124900 (3); Seizures, cortical blindness, microcephaly syndrome, 616632 (3);
5.396;2;20;14;5q31;DFNA54;;Deafness, autosomal dominant 54;615649;Fd;between D5S1972 and D5S410;Deafness, autosomal dominant 54 (2);
5.397;4;29;14;5q31.2;ECSCR, ECSM2, ARIA;;Endothelial cell surface-expressed chemotaxis and apoptosis regulator;615736;A, REc;;;
5.398;6;10;94;5q31.3;FGF1, FGFA;;Fibroblast growth factor-1 (acidic);131220;REa, A, D;;;
5.399;3;2;01;5q31.2;GFRA3;;GDNF family receptor alpha-3;605710;A;;;
5.400;2;19;10;5q31.3;GNPDA1, GNP1, GNPI, KIAA0060;;Glucosamine 6-phosphate deaminase 1;601798;A;;;
5.401;8;15;00;5q31.3;HDAC3;;Histone deacetylase 3;605166;A;;;
5.402;10;11;05;5q31.2;HNRPA0;;Heterogeneous nuclear ribonucleoprotein A0;609409;REc;;;
5.403;1;31;02;5q31;IBD5;;Inflammatory bowel disease 5;606348;Fd;;{Inflammatory bowel disease 5} (2);
5.404;10;30;03;5q31.1;IL13, ALRH, BHR1;;Interleukin-13;147683;REn, Fd;;{Asthma, susceptibility to}, 600807 (3); {Allergic rhinitis, susceptibility to}, 607154 (3);
5.405;10;24;11;5q31.2;KDM3B, C5orf7, KIAA1082, JMJD1B;;Lysine-specific demethylase 3B;609373;R, REc;;;
5.406;12;29;00;5q31.1;KIF3A;;Kinesin family member 3A;604683;R;;;
5.407;3;12;03;5q31.2;KIF20A, RAB6KIFL;;Kinesin family member 20A;605664;REc;;;
5.408;2;27;12;5q31.2;KLHL3, PHA2D;;Kelch-like 3;605775;REc;;Pseudohypoaldosteronism, type IID, 614495 (3);
5.409;10;14;98;5q31.1;MADH5, SMAD5;;Mothers against decapentaplegic, Drosophila, homolog of, 5;603110;REa, REc;;;
5.410;7;17;14;5q35.1;NEURL1B, NEUR2;;Neuralized E3 ubiquitin protein ligase 1B;615893;REc;;;17(Neurl1b)
5.411;1;31;07;5q33.1;MYOZ3, FRP3;;Myozenin 3;610735;REc;;;
5.412;2;18;98;5q31.2;NPY6R, PP2;;Neuropeptide Y receptor Y6;601770;A, H;?nonfunctional pseudogene;;18(Npy6r)
5.413;9;5;14;5q31.3;NR3C1, GCR, GRL, GCRST;;Nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor);138040;S, REa, Fd, H, A, D, REn;;Glucocorticoid resistance, 615962 (3);18(Grl1)
5.414;12;6;16;5q31.1;P4HA2, MYP25;;Procollagen-proline, 2-oxoglutarate-4-dioxygenase, alpha subunit, isoform 2;600608;REc;;Myopia 25, autosomal dominant, 617238 (3);
5.415;5;23;18;5q31.3;PCDH12, VECAD2, PCDH12;;Protocadherin 12 (cadherin, vascular endothelial, 2);605622;REc;;Microcephaly, seizures, spasticity, and brain calcification, 251280 (3);
5.416;5;24;00;5q31;PCDHA@;;Protocadherin-alpha gene cluster;604966;REc;;;
5.417;10;2;01;5q31.3;PCDHA1;;Protocadherin-alpha 1;606307;REc;;;
5.418;10;2;01;5q31.3;PCDHA2;;Protocadherin-alpha 2;606308;REc;;;
5.419;10;1;01;5q31.3;PCDHA3;;Protocadherin-alpha 3;606309;REc;;;
5.420;10;2;01;5q31.3;PCDHA4;;Protocadherin-alpha 4;606310;REc;;;
5.421;10;2;01;5q31.3;PCDHA5;;Protocadherin-alpha 5;606311;REc;;;
5.422;10;2;01;5q31.3;PCDHA6;;Protocadherin-alpha 6;606312;REc;;;
5.423;10;2;01;5q31.3;PCDHA7;;Protocadherin-alpha 7;606313;REc;;;
5.424;10;2;01;5q31.3;PCDHA8;;Protocadherin-alpha 8;606314;REc;;;
5.425;10;2;01;5q31.3;PCDHA9;;Protocadherin-alpha 9;606315;REc;;;
5.426;10;2;01;5q31.3;PCDHA10;;Protocadherin-alpha 10;606316;REc;;;
5.427;10;2;01;5q31.3;PCDHA11;;Protocadherin-alpha 11;606317;REc;;;
5.428;10;2;01;5q31.3;PCDHA12;;Protocadherin-alpha 12;606318;REc;;;
5.429;10;2;01;5q31.3;PCDHA13;;Protocadherin-alpha 13;606319;REc;;;
5.430;10;2;01;5q31.3;PCDHAC1;;Protocadherin-alpha, subfamily C, member 1;606320;REc;;;
5.431;10;2;01;5q31.3;PCDHAC2;;Protocadherin-alpha, subfamily C, member 2;606321;REc;;;
5.432;5;24;00;5q31;PCDHB@;;Protocadherin-beta gene cluster;604967;REc;;;
5.433;10;2;01;5q31.3;PCDHB1;;Protocadherin-beta 1;606327;REc;;;
5.434;10;2;01;5q31.3;PCDHB2;;Protocadherin-beta 2;606328;REc;;;
5.435;10;2;01;5q31.3;PCDHB3;;Protocadherin-beta 3;606329;REc;;;
5.436;10;2;01;5q31.3;PCDHB4;;Protocadherin-beta 4;606330;REc;;;
5.437;10;2;01;5q31.3;PCDHB5;;Protocadherin-beta 5;606331;REc;;;
5.438;10;2;01;5q31.3;PCDHB6;;Protocadherin-beta 6;606332;REc;;;
5.439;9;13;17;6p21.1;OARD1, C6orf130;;O-acyl-ADP-ribose deacylase 1;614393;REc;;;
5.440;10;2;01;5q31.3;PCDHB7;;Protocadherin-beta 7;606333;REc;;;
5.441;10;2;01;5q31.3;PCDHB8;;Protocadherin-beta 8;606334;REc;;;
5.442;10;2;01;5q31.3;PCDHB9;;Protocadherin-beta 9;606335;REc;;;
5.443;10;2;01;5q31.3;PCHB10;;Protocadherin-beta 10;606336;REc;;;
5.444;10;2;01;5q31.3;PCDHB11;;Protocadherin-beta 11;606337;REc;;;
5.445;10;2;01;5q31.3;PCDHB12;;Protocadherin-beta 12;606338;REc;;;
5.446;10;2;01;5q31.3;PCDHB13;;Protocadherin-beta 13;606339;REc;;;
5.447;10;2;01;5q31.3;PCDHB14;;Protocadherin-beta 14;606340;REc;;;
5.448;10;2;01;5q31.3;PCDHB15;;Protocadherin-beta 15;606341;REc;;;
5.449;10;2;01;5q31.3;PCDHB16;;Protocadherin-beta 16;606345;REc;;;
5.450;5;24;00;5q31;PCDHG;;Protocadherin-gamma gene cluster;604968;REc;;;
5.451;10;2;01;5q31.3;PCDHGA1;;Protocadherin-gamma, subfamily A, member 1;606288;REc;;;
5.452;10;2;01;5q31.3;PCDHGA2;;Protocadherin-gamma, subfamily A, member 2;606289;REc;;;
5.453;10;2;01;5q31.3;PCDHGA3;;Protocadherin-gamma, subfamily A, member 3;606290;REc;;;
5.454;10;2;01;5q31.3;PCDHGA4;;Protocadherin-gamma, subfamily A, member 4;606291;REc;;;
5.455;10;2;01;5q31.3;PCDHGA5;;Protocadherin-gamma, subfamily A, member 5;606292;REc;;;
5.456;10;2;01;5q31.3;PCDHGA6;;Protocadherin-gamma, subfamily A, member 6;606293;REc;;;
5.457;10;2;01;5q31.3;PCDHGA7;;Protocadherin-gamma, subfamily A, member 7;606294;REc;;;
5.458;10;2;01;5q31.3;PCDHGA8;;Protocadherin-gamma, subfamily A, member 8;606295;REc;;;
5.459;10;2;01;5q31.3;PCDHGA9;;Protocadherin-gamma, subfamily A, member 9;606296;REc;;;
5.460;10;2;01;5q31.3;PCDHGA10;;Protocadherin-gamma, subfamily A, member 10;606297;REc;;;
5.461;10;2;01;5q31.3;PCDHGA11;;Protocadherin-gamma, subfamily A, member 11;606298;REc;;;
5.462;10;2;01;5q31.3;PCDHGA12;;Protocadherin-gamma, subfamily A, member 12;603059;REc;;;
5.463;10;2;01;5q31.3;PCDHGB1;;Protocadherin-gamma, subfamily B, member 1;606299;REc;;;
5.464;10;2;01;5q31.3;PCDHGB2;;Protocadherin-gamma, subfamily B, member 2;606300;REc;;;
5.465;10;2;01;5q31.3;PCDHGB3;;Protocadherin-gamma, subfamily B, member 3;606301;REc;;;
5.466;10;2;01;5q31.3;PCDHGB4;;Protocadherin-gamma, subfamily B, member 4;603058;REc;;;
5.467;10;2;01;5q31.3;PCDHGB5;;Protocadherin-gamma, subfamily B, member 5;606302;REc;;;
5.468;10;2;01;5q31.3;PCDHGB6;;Protocadherin-gamma, subfamily B, member 6;606303;REc;;;
5.469;10;2;01;5q31.3;PCDHGB7;;Protocadherin-gamma, subfamily B, member 7;606304;REc;;;
5.470;10;2;01;5q31.3;PCDHGC3;;Protocadherin-gamma, subfamily C, member 3;603627;REc;;;
5.471;10;2;01;5q31.3;PCDHGC4;;Protocadherin-gamma, subfamily C, member 4;606305;REc;;;
5.472;10;2;01;5q31.3;PCDHGC5;;Protocadherin-gamma, subfamily C, member 5;606306;REc;;;
5.473;6;30;15;5q31;PDB4;;Paget disease of bone 4;606263;Fd;;Paget disease of bone 4 (2);
5.474;7;9;06;5q31.3;PFDN1;;Prefoldin 1;604897;R, REc;;;
5.475;11;1;12;5q31.1;PITX1, PTX1, BFT, POTX, CCF, LBNBG;;Paired-like homeodomain transcription factor-1;602149;A;;Clubfoot, congenital, with or without deficiency of long bones and/or mirror-image polydactyly, 119800 (3); Liebenberg syndrome, 186550 (4);13(Ptx1)
5.476;5;4;00;5q31.2;PKD2L2;;Polycystin 2-like 2;604669;R, Psh;;;
5.477;7;13;98;5q32;POU4F3, BRN3C;;POU domain, class 4, transcription factor-3;602460;REa, H;;Deafness, autosomal dominant 15, 602459 (3);18(pou4f3)
5.478;1;5;15;5q31.3;PURA, PUR1, MRD31;;Purine-rich element binding protein A;600473;REa, A;;Mental retardation, autosomal dominant 31, 616158 (3);
5.479;10;12;09;5q31.1;RAD50, NBSLD;;RAD50, S. cerevisiae, homolog of;604040;REc, REa;;Nijmegen breakage syndrome-like disorder, 613078 (3);
5.480;2;10;14;5q31.2;REEP2, C5orf19, SPG72;;Receptor expression-enhancing protein 2;609347;R, REc;mutation identified in 1 family each SPG72 AR and AD;?Spastic paraplegia 72, autosomal recessive, 615625 (3); ?Spastic paraplegia 72, autosomal dominant, 615625 (3);
5.481;5;6;13;5q31;RLS8;;Restless legs syndrome, susceptibility to, 8;615197;Fd;;{Restless legs syndrome 8} (2);
5.482;12;7;05;5q31.2;SIL1, BAP, MSS;;Sil1, S. cerevisiae, homolog of;608005;R, REc, Fd;;Marinesco-Sjogren syndrome, 248800 (3);
5.483;7;7;14;5q31.1;SKP1, SKP1A, TCEB1L, OCP2;;S-phase kinase-associated protein 1 (p19A);601434;A;pseudogene on chr.7;;
5.484;4;7;09;5q31.1;SLC22A4, OCTN1;;Solute carrier family 22 (organic cation transporter), member 4;604190;R;;{Rheumatoid arthritis, susceptibility to}, 180300 (3);
5.485;10;30;03;5q31.3;SLC25A2, ORNT2;;Solute carrier family 25 (mitochondrial carrier, ornithine transporter), member 2;608157;R;;;
5.486;8;9;99;5q31.2;SPOCK;;Testican;602264;A, REc;previously mapped to chr.21;;
5.487;12;4;01;5q31.3;TAF7, TAF2F, TAFII55;;TAF7 RNA polymerase II, TATA box-binding protein-associated factor, 55kD;600573;REc;;;18(Taf2f)
5.488;1;30;02;5q32;TCERG1, TAF2S, CA150;;Transcription elongation regulator 1 (transcription factor CA150);605409;R;;;18(Ca150)
5.489;1;19;07;5q31.1;TGFBI, CSD2, CDGG1, CSD, BIGH3, CDG2, EBMD;;Transforming growth factor, beta-induced, 68kD;601692;REc, Fd;;Corneal dystrophy, Groenouw type I, 121900 (3); Corneal dystrophy, lattice type I, 122200 (3); Corneal dystrophy, Reis-Bucklers type, 608470 (3); Corneal dystrophy, Avellino type, 607541 (3); Corneal dystrophy, lattice type IIIA, 608471 (3); Corneal dystrophy, Thiel-Behnke type, 602082 (3); Corneal dystrophy, epithelial basement membrane, 121820 (3);
5.490;09;25;18;5q31.2;MYOT, TTOD, MFM3;;Myotilin (titin immunoglobulin domain protein);604103;R;;Myopathy, myofibrillar, 3, 609200 (3); Myopathy, spheroid body, 182920 (3);
5.491;2;4;00;5q31.1;VDAC1;;Voltage-dependent anion channel 1;604492;A;;;11(Vdac1)
5.492;4;1;09;5q31.3;VTRNA1-1, HVG1, VAULTRC1;;Vault RNA 1-1;612695;REc;;;
5.493;3;31;09;5q31.3;VTRNA1-2, HVG2, VAULTRC2;;Vault RNA 1-2;612696;REc;;;
5.494;4;1;09;5q31.3;VTRNA1-3, HVG3, VAULTRC3;;Vault RNA 1-3;612697;REc;;;
5.495;12;17;12;5q31.1;VTRNA2-1, NC886, CBL3, VTRNA2;;Vault RNA 2-1;614938;REn;;;
5.496;8;28;01;5q32;SLC6A7, PROT;;Solute carrier family 6 (neurotransmitter transporter, L-proline), member 7;606205;REa, A;;;18(Slc6a7)
5.497;10;30;03;5q31-q33;AITD2;;Autoimmune thyroid disease, susceptibility to, 2;608174;Fd;;{Autoimmune thyroid disease, susceptibility to, 2} (2);
5.498;10;12;09;5q31-q33;ATOD6;;Dermatitis, atopic, 6;605845;Fd;between D5S436 and D5S643;{Dermatitis, atopic, susceptibility to, 6} (2);
5.499;9;14;95;5q32;CDX1;;Caudal type homeo box transcription factor 1;600746;REc, H, REn;100kb distal to CSF1R;;18(Cdx1)
5.500;3;17;06;5q31-q33;CELIAC2;;Celiac disease, susceptibility to, 2;609754;Fd;;{Celiac disease, susceptibility to, 2} (2);
5.501;9;9;08;5q33.2;CNOT8, CALIF, POP2;;CCR4-NOT transcription complex, subunit 8;603731;REc;;;
5.502;10;26;97;5q31-q33;EOS;;Eosinophilia, familial;131400;Fd;;Eosinophilia, familial (2);
5.503;6;9;98;5q32;HTR4;;5-hydroxytryptamine (serotonin) receptor-4;602164;A;;;
5.504;1;25;05;5q31-q33;PFBI;;Plasmodium falciparum blood infection levels;248310;Fd;;{Malaria, intensity of infection} (2);
5.505;12;29;99;5q32;PPP2R2B;;Protein phosphatase 2, regulatory subunit B, beta;604325;R, REc;;Spinocerebellar ataxia 12, 604326 (3);
5.506;7;22;09;5q31.1;SEPT8, KIAA0202;;Septin 8;608418;REc;;;11(Sept8)
5.507;10;11;02;5q33.1;SLC36A1, LYAAT1, PAT1;;Solute carrier family 36 (proton/amino acid symporter), member 1 (lysosomal amino acid transporter 1);606561;REc;;;
5.508;9;30;99;5q31-q33;SM1;;Schistosoma mansoni infection, susceptibility/resistance to;181460;Fd;;{Schistosoma mansoni infection, susceptibility/resistance to} (2);
5.509;4;4;02;5q32;SCGB3A2, UGRP1;;Secretoglobin, family 3A, member 2 (uteroglobin-related protein 1);606531;H, A;;{Asthma, susceptibility to}, 600807 (3);18(Ugrp1)
5.510;11;15;05;5q31.1;C5orf20, DCNP1;;Dendritic cell nuclear protein 1;609710;REc;;;
5.511;3;28;11;5q31.1;CATSPER3, CACRC;;Cation channel, sperm-associated, 3;609120;REc;;;13(Catsper3)
5.512;7;11;93;5q31.3;CD14;;CD14 antigen;158120;REa, A;;;18(Cd14)
5.513;6;15;99;5q31.2;CDC23, APC8;;Cell division cycle 23 (anaphase-promoting complex 8);603462;REc, A;;;
5.514;7;11;93;5q31.1;CSF2, GMCSF;;Colony-stimulating factor-2 (granulocyte-macrophage);138960;REa, A, RE, Fd;order: cen-CSF2-CSF1-FMS-qter;;11(Csfgm)
5.515;1;24;18;5q31.1;DDX46, PRP5, KIAA0801;;DEAD box helicase 46;617848;R, REc;;;
5.516;7;11;93;5q31.2;EGR1;;Early growth response-1;128990;REa, A;;;18(Egr1)
5.517;10;24;00;5q31.2;ETF1, RF1, ERF1;;Eukaryotic translation termination factor-1;600285;R;;;
5.518;6;13;12;5q31.1;FBXL21, FBL21, FBXL3B, FBL3B;;F-box and leucine-rich repeat protein 21;609087;REc;;;
5.519;6;13;18;5q31.1;GDF9, POF14;;Growth/differentiation factor 9;601918;REc;mutation identified in 1 patient;?Premature ovarian failure 14, 618014 (3);
5.520;7;26;95;5q31.1;IGES;;Immunoglobulin E concentration, serum;147061;Fd;;{?Allergy and asthma susceptibility} (2);
5.521;7;11;93;5q31.1;IL3;;Interleukin-3;147740;REa, A, H, RE, D, Fd;9kb from CSF2; order: cen-5'IL3-5'CF2-qter;;11(Il3)
5.522;7;11;93;5q31.1;IL4;;Interleukin-4;147780;REa, A, RE;;;11(Il4)
5.523;3;22;93;5q31.1;IL5;;Interleukin-5;147850;Ch, A, RE, REn;< 310kb from IL4;;11(Il5)
5.524;7;11;93;5q31.1;IL9;;Interleukin-9;146931;REa, A;;;13(Il9)
5.525;5;13;10;5q31.1;IRF1, MAR;;Interferon regulatory factor-1;147575;Fd, REa, A, REn, D, Ch;;Myelodysplastic syndrome, preleukemic (3); Myelogenous leukemia, acute (3); Gastric cancer, somatic, 613659 (3); Nonsmall cell lung cancer, somatic, 211980 (3);11(Irf1)
5.526;4;6;15;5q31.1;LEAP2;;Liver-expressed antimicrobial peptide 2;611373;REc, R, H;;;11(Leap2)
5.527;2;24;15;5q31.1;MEIKIN;;Meiotic kinetochore factor;616232;REc;;;
5.528;5;26;13;5q31.1;PHF15, JADE2, KIAA0239;;PHD finger protein 15;610515;R, Psh, REc;;;11(Phf15)
5.529;3;14;07;5q31.1;RAPGEF6, RAGEF2, PDZGEF2;;RAP guanine nucleotide exchange factor 6;610499;REc;;;
5.530;9;2;03;5q31.1;RIL;;LIM domain protein ril;603422;REc;;{Osteoporosis, susceptibility to}, 166710 (3);
5.531;4;2;09;5q31.1;SAR1B, CMRD, SARA2, ANDD;;Sar1a, S. cerevisiae, homolog 2;607690;REc;;Chylomicron retention disease, 246700 (3);
5.532;3;13;15;5q31.1;SEC24A;;Sec24-related gene family, member A;607183;R, REc;;;
5.533;5;23;13;5q31.1;SHROOM1, APXL2, KIAA1960;;SHROOM family member 1;611179;REc;;;
5.534;10;27;04;5q31.1;SLC22A5, OCTN2, CDSP, SCD;;Solute carrier, family 22 (organic cation transporter), member 5;603377;Fd, H;;Carnitine deficiency, systemic primary, 212140 (3);11(jvs)
5.535;12;30;14;5q31.1;SLC25A48;;Solute carrier family 25, member 48;616150;REc;;;
5.536;9;5;91;5q31.1;TCF7;;Transcription factor-7, T-cell specific;189908;REa, A;originally called TCF-1;;11(Tcf7)
5.537;11;16;17;5q31.1;TXNDC15, C5orf14, BUG;;Thioredoxin domain-containing protein 15;617778;REc;;;
5.538;4;8;13;5q31.1;UQCRQ, QPC, MC3DN4;;Ubiquinol-cytochrome c reductase, complex III subunit VII, 9.5kD;612080;R, REc;;Mitochondrial complex III deficiency, nuclear type 4, 615159 (3);
5.539;4;23;15;5q31.1;WSPAR, lncTCF7;;WNT signaling pathway activating noncoding RNA;616333;REc;;;
5.540;3;26;96;5q31.1;HSPA4;;Heat-shock 70kD protein-4;601113;A;;;
5.541;2;9;14;5q31.1-q32;DFNA52, DFNA42;;Deafness, autosomal dominant 52;607683;Fd;max lod at D5S2017;Deafness, autosomal dominant 52 (2);
5.542;10;14;98;5q31.1;LECT2;;Leukocyte cell-derived chemotaxin 2;602882;A, REa;;;13(Lect2)
5.543;1;31;01;5q31.1-q33.1;IDDM18;;Insulin-dependent diabetes mellitus-18;605598;Fd;close to IL12B;{Diabetes mellitus, insulin-dependent, 18} (2);
5.544;2;26;09;5q31.1-q33.1;PSORS11;;Psoriasis susceptibility 11;612599;Fd;associated with rs10045431;{Psoriasis susceptibility 11} (2);
5.545;4;7;94;5q34;GABRA6;;Gamma-aminobutyric acid (GABA) A receptor, alpha-6;137143;REa, Fd, REc;;;
5.546;9;27;17;5q31.2;BRD8, SMAP;;Bromodomain-containing protein 8;602848;REc;;;
5.547;12;6;16;5q31.2;FAM53C, C5orf6;;Family with sequence similarity 53, member C;609372;REc;;;
5.548;12;6;16;5q31.2;FAM13B, C5orf5;;Family with sequence similarity 13, member B;609371;REc;;;18(C5orf5)
5.549;3;17;16;5q31.2;HSPA9, HSPA9B, MOT2, GRP75, EVPLS, SIDBA4;;Heat-shock 70kD protein-9 (mortalin);600548;A, REc;;Anemia, sideroblastic, 4, 182170 (3); Even-plus syndrome, 616854 (3);18,X(mot2)
5.550;4;29;14;5q31.2;MATR3, MPD2, ALS21;;Matrin 3;164015;R, REc;;Amyotrophic lateral sclerosis 21, 606070 (3);
5.551;12;13;18;5q31.3;NDUFA2, MC1DN13;;NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 2 (8kD, B8);602137;A, R;;Mitochondrial complex I deficiency, nuclear type 13, 618235 (3);
5.552;10;17;12;5q23.3;HINT1, PRKCNH1, NMAN;;Histidine triad nucleotide-binding protein 1 (protein kinase C inhibitor 1);601314;A;;Neuromyotonia and axonal neuropathy, autosomal recessive, 137200 (3);
5.553;3;26;07;5q31.2;LRRTM2, KIAA0416;;Leucine-rich repeat transmembrane protein 2;610868;REc, H;;;18(Lrrtm2)
5.554;4;29;14;5q31.2;MZB1, PACAP, MGC29506;;Marginal zone B and B1 cell-specific protein;609447;REc;;;
5.555;8;20;07;5q31.2;PAIP2, PAIP2A;;Polyadenylate-binding protein-interacting protein 2;605604;R, REc;;;
5.556;1;20;06;5q31.1;PCBD2, DCOH2, DCOHM;;Pterin-4-alpha-carbinolamine dehydratase 2;609836;REc;;;
5.557;3;23;09;5q31.1;TIFAB;;TRAF-interacting protein with forkhead-associated domain, family member B;612663;REc;;;13(Tifab)
5.558;8;12;14;5q31.2;TMEM173, STING, MPYS, SAVI;;Transmembrane protein 173;612374;REc;;STING-associated vasculopathy, infantile-onset, 615934 (3);
5.559;6;13;12;5q31.2;UBE2D2, UBCH5B, UBC4;;Ubiquitin-conjugating enzyme E2D 2;602962;REc;;;
5.560;8;20;14;5q31.2;WNT8A;;Wingless-type MMTV integration site family, member 8A;606360;REc;;;
5.561;8;31;09;5q31.2;SLC23A1, SVCT1;;Solute carrier family 23 (nucleobase transporter), member 1 (sodium-dependent vitamin C transporter 1);603790;R, REn, H;opposite orientation to MATR3;;18(Slc23a1)
5.562;4;15;11;5q32;PDE6A, PDEA, RP43;;Phosphodiesterase-6A, cGMP-specific, rod, alpha;180071;REa, REn, A;;Retinitis pigmentosa 43, 613810 (3);18(Pde6a)
5.563;10;30;06;5q31.3;ANKHD1, MASK, KIAA1085, VBARP;;Ankyrin repeat and KH domain-containing protein 1;610500;REc;;;
5.564;2;24;17;5q31.3;ARAP3, CENTD3;;ArfGAP with RhoGAP domain, ankyrin repeat and PH domain 3;606647;R, REc;;;
5.565;5;12;09;5q31.2;CXXC5;;CXXC finger protein 5;612752;REc;;;
5.566;5;25;05;5q31.3;DND1;;Dead end, zebrafish, homolog of, 1;609385;REc;;;
5.567;11;27;18;5q31.3;EIF4EBP3;;Eukaryotic translation initiation factor 4E-binding protein 3;603483;REc;;;
5.568;7;6;17;5q31.3;FCHSD1, NWK2;;FCH and double SH3 domains protein 1;617555;REc, H;;;18(Fchsd1)
5.569;11;3;15;5q31.3;HARS, USH3B, CMT2W;;Histidyl-tRNA synthetase;142810;S, REc;;Usher syndrome type 3B, 614504 (3); Charcot-Marie-Tooth disease, axonal, type 2W, 616625 (3);
5.570;11;29;12;5q31.3;HARS2, HARSL, HARSR, HO3, PRLTS2;;Histidyl-tRNA synthetase 2;600783;REc;mutation identified in 1 PRLTS2 family;?Perrault syndrome 2, 614926 (3);
5.571;4;20;11;5q31.3;IK, RED;;IK cytokine, downregulator of HLA II;600549;R, REc;;;
5.572;7;26;10;5q31.3;KCTD16, KIAA1317;;Potassium channel tetramerization domain-containing 16;613423;R, REc;;;
5.573;4;29;14;5q31.3;KIAA0141, DELE;;KIAA0141 gene;615741;REc;;;
5.574;6;10;08;5q31.3;NDFIP1, N4WBP5;;NEDD4 family-interacting protein 1;612050;REc;;;
5.575;2;16;18;5q13.3;POC5, C5orf37;;POC5 centriolar protein;617880;REc;;;
5.576;5;26;13;5q31.3;RELL2;;Relt-like 2;611213;REc;;;
5.577;11;05;18;5q31.3;SLC4A9, AE4;;Solute carrier family 4 (anion exchanger), member 9;610207;REc;;;
5.578;6;11;13;5q31.3;SPRY4, HH17;;Sprouty, Drosophila, homolog of;607984;A;;Hypogonadotropic hypogonadism 17 with or without anosmia, 615266 (3);
5.579;8;11;17;5q31.3;SPRY4IT1;;SPRY4 intronic transcript 1, noncoding;617617;REc;in intron 2 of SPRY4;;
5.580;8;31;09;5q31.3;SRA1;;Steroid receptor RNA activator 1;603819;REc;;;
5.581;10;25;12;5q31.1;H2AFY, MH2A1;;H2A histone family, member Y;610054;R;;;
5.582;12;22;10;5q31.3-q32;HHT3, ORW3;;Hereditary hemorrhagic telangiectasia, type 3;601101;Fd;;Telangiectasia, hereditary hemorrhagic, type 3 (2);
5.583;8;6;15;5q33.1;SPARC, ON, OI17;;Osteonectin (secreted protein, acidic, cysteine-rich);182120;REa, A;;Osteogenesis imperfecta, type XVII, 616507 (3);11(Sparc)
5.584;11;23;09;5q33.1;GM2A;;GM2 ganglioside activator protein;613109;S, REa, Psh, A;pseudogene on chr.3;GM2-gangliosidosis, AB variant, 272750 (3);11(Gm2a)
5.585;4;2;16;5q32;ABLIM3, KIAA0843;;Actin-binding LIM protein family, member 3;611305;R, REc;;;
5.586;5;19;06;5q32;ARSI;;Arylsulfatase I;610009;REc;;;
5.587;3;1;00;5q33.1;ATOX1, HAH1;;Antioxidant protein 1 (ATX, yeast, homolog of);602270;A;;;
5.588;09;06;18;5q32;CAMK2A, KIAA0968, CAMKA, MRD53, MRT63;;Calcium/calmodulin-dependent protein kinase II-alpha;114078;H, R, REc;mutation identified in 1 MRT63 family;Mental retardation, autosomal dominant 53, 617798 (3); ?Mental retardation, autosomal recessive 63, 618095 (3);18(Camk2a)
5.589;6;10;94;5q33.1;CD74, DHLAG;;CD74 antigen (invariant polypeptide of major histocompatibility class II antigen-associated);142790;S, REb, REa, A;;;18(Ii)
5.590;1;9;13;5q32;CSF1R, FMS, HDLS;;Colony-stimulating factor-1 receptor; oncogene FMS (McDonough feline sarcoma);164770;REa, A;FMS2 is 5' end;Leukoencephalopathy, diffuse hereditary, with spheroids, 221820 (3);18(Fim2)
5.591;1;13;11;5q32;CSNK1A1;;Casein kinase-1, alpha-1 polypeptide;600505;REc;previously assigned to 13q13;;
5.592;1;30;01;5q32;DPYSL3, ULIP, DRP3;;Dihydropyrimidinase-like 3;601168;A;;;
5.593;6;13;18;5q33.1;GLRA1, STHE, HKPX1;;Glycine receptor, alpha-1 polypeptide;138491;Fd, R, A;;Hyperekplexia 1, 149400 (3);11(spd)
5.594;7;7;14;5q32;GRXCR2, DFNB101;;Glutaredoxin, cysteine-rich, 2;615762;REc;mutation identified in 1 DFNB101 family;?Deafness, autosomal recessive 101, 615837 (3);18(Grxcr2)
5.595;3;23;06;5q31.3;HLA-HB1;;Minor histocompatibility antigen HB-1;609961;REc;;;
5.596;3;27;13;5q33.3;ITK, EMT, LPFS1;;T-cell-specific tyrosine kinase; homolog of mouse T-cell itk/tsk tyrosine kinase;186973;A;;Lymphoproliferative syndrome 1, 613011 (3);11(Itk)
5.597;5;23;13;5q32;JAKMIP2, JAMIP2, NECC1, KIAA0555;;Janus kinase and microtubule-interacting protein 2;611197;REc, R;;;
5.598;9;23;14;5q32;LARS, LFIS, ILFS1;;Leucyl-tRNA synthetase;151350;S, H, REc;mutation identified in 1 family;?Infantile liver failure syndrome 1, 615438 (3);
5.599;10;13;15;5q32;PDGFRB, PDGFR, IBGC4, IMF1, PENTT, KOGS;;Platelet-derived growth factor receptor, beta polypeptide;173410;REa, A, REn;fusion gene with ETV6, HIP1, RABPT5, or H4 in chronic myeloproliferative disorders;Myeloproliferative disorder with eosinophilia, 131440 (4); Basal ganglia calcification, idiopathic, 4, 615007 (3); Myofibromatosis, infantile, 1, 228550 (3); Premature aging syndrome, Penttinen type, 601812 (3); Kosaki overgrowth syndrome, 616592 (3);18(Pdgfr)
5.600;5;13;10;5q33.1;RPS14, EMTB;;Ribosomal protein S14;130620;S, REc;;Macrocytic anemia, refractory, due to 5q deletion, somatic, 153550 (3);
5.601;6;7;10;5q32;SH3RF2, HEPP1;;SH3 domain-containing RING finger protein 2;613377;REc;;;
5.602;8;20;10;5q32;SH3TC2, KIAA1985, MNMN;;SH3 domain and tetratricopeptide repeat domain 2;608206;REc;;Charcot-Marie-Tooth disease, type 4C, 601596 (3); Mononeuropathy of the median nerve, mild, 613353 (3);
5.603;11;22;13;5q33.1;SMIM3, NID67;;Small integral membrane protein 3;608324;REc;;;
5.604;12;20;11;5q32;SPINK1, PSTI, PCTT, TATI, TCP;;Serine protease inhibitor, Kazal type I (pancreatic secretory trypsin inhibitor);167790;REb;;Pancreatitis, hereditary, 167800 (3); {Fibrocalculous pancreatic diabetes, susceptibility to}, 608189 (3); Tropical calcific pancreatitis, 608189 (3);
5.605;7;17;14;5q32;SPINK6;;Serine peptidase inhibitor, KAZAL-type, 6;615868;REn;;;
5.606;5;6;13;5q32;SPINK13;;Serine protease inhibitor, Kazal-type, 13;615205;REc;;;
5.607;7;31;17;5q32;SPINK5, LEKTI;;Serine protease inhibitor, Kazal type, 5;605010;A, Fd;;Netherton syndrome, 256500 (3);
5.608;1;9;17;5q32;SPINK7, ECRG2;;Serine peptidase inhibitor, Kazal-type, 7;617288;REc;;;
5.609;10;2;07;5q31.3;YIPF5, SMAP5, YIP1A;;Yip1 domain family, member 5;611483;REc;;;
5.610;5;20;99;5q33.3;ADAM19, MLTNB;;A disintegrin and metalloproteinase domain-19 (meltrin-beta, mouse, homolog of);603640;R;;;11(Adam19)
5.611;11;16;17;5q33.1;FAT2, MEGF1, SCA45;;Fat tumor suppressor, Drosophila, homolog of, 2;604269;R;;Spinocerebellar ataxia 45, 617769 (3);
5.612;8;28;01;5q35.1;GABRP;;Gamma-aminobutyric acid receptor, pi;602729;REc;;;
5.613;6;15;99;5q31.3;PCDH1, PC42;;Protocadherin 1 (cadherin-like 1);603626;Psh;;;18(Pcdh1)
5.614;1;30;96;5q33.1;GPX3;;Glutathione peroxidase-3, plasma;138321;REa, REn;;;
5.615;3;23;18;5q32;SLC26A2, DTD, DTDST, D5S1708, EDM4;;Solute carrier family 26 (sulfate transporter), member 2 (diastrophic dysplasia sulfate transporter);606718;Fd, REn;distal to APC;Diastrophic dysplasia, 222600 (3); Achondrogenesis Ib, 600972 (3); Epiphyseal dysplasia, multiple, 4, 226900 (3); Diastrophic dysplasia, broad bone-platyspondylic variant, 222600 (3); De la Chapelle dysplasia, 256050 (3); Atelosteogenesis, type II, 256050 (3);
5.616;1;31;11;5q32-q33;TCOF1, MFD1, TCS1;;Treacle;606847;Ch, Fd;prox. to SPARC;Treacher Collins syndrome 1, 154500 (3);18(Tcof1)
5.617;5;7;03;5q33.1;TNIP1, NAF1, KIAA0113;;TNFAIP3-interacting protein 1;607714;REc;;;
5.618;3;5;98;5q33.3;TTC1, TPR1;;Tetratricopeptide repeat domain-1;601963;REa;;;
5.619;6;13;95;5q33.2;MFAP3;;Microfibrillar-associated protein-3;600491;REa;;;
5.620;12;4;14;5q33.1;NDST1, HSST, MRT46;;N-deacetylase/N-sulfotransferase (heparan sulfate-N-deacetylase/N-sulfotransferase);600853;REn;;Mental retardation, autosomal recessive 46, 616116 (3);
5.621;12;16;05;5q32;ADRB2;;Adrenergic, beta-2-, receptor, surface;109690;S, REa, A, Fd, RE;;{Asthma, nocturnal, susceptibility to}, 600807 (3); {Obesity, susceptibility to}, 601665 (3); Beta-2-adrenoreceptor agonist, reduced response to (3);18(Adrb2)
5.622;2;1;90;5q33.1;ANXA6, CBP68;;Annexin A6 (calcium-binding protein p68);114070;REa, A, REn;;;
5.623;8;28;97;5q34;CCNG1;;Cyclin G1;601578;A;;;11(Ccng1)
5.624;4;5;00;5q32;IL17B;;Interleukin 17B;604627;R;;;
5.625;7;11;93;5q33.3;ADRA1B;;Adrenergic, alpha-1B-, receptor;104220;REa, A, RE;;;11(Adra1)
5.626;3;1;94;5q33.2;GRIA1, GLUR1;;Glutamate receptor, ionotropic, AMPA 1;138248;A, REa, R;;;11(Glur1)
5.627;2;28;08;5q33.2;MRPL22;;Mitochondrial ribosomal protein L22;611835;R;;;
5.628;1;18;13;5q33.3;NIPAL4, ICHYN, ARCI6;;NIPA-like domain-containing 4;609383;Fd, REc;;Ichthyosis, congenital, autosomal recessive 6, 612281 (3);
5.629;4;17;06;5q32;PPARGC1B, PGC1B, PERC;;Peroxisome proliferator-activated receptor-gamma, coactivator 1, beta;608886;REc;;{Obesity, variation in}, 601665 (3);
5.630;9;3;99;5q33.3;PTTG1, EAP1, TUTR1;;Pituitary tumor-transforming gene 1;604147;A, R;;;
5.631;09;27;18;5q33.2-q33.3;SGCD, SGD, LGMDR6, CMD1L;;Sarcoglycan, delta (35kD dystrophin-associated glycoprotein);601411;REa, A, Fd;mutant in Syrian hamster cardiomyopathy;Muscular dystrophy, limb-girdle, autosomal recessive 6, 601287 (3); Cardiomyopathy, dilated, 1L, 606685 (3);
5.632;12;29;06;5q35.3;F12, HAF, HAE3;;Coagulation factor XII (Hageman factor);610619;REa, A;;Factor XII deficiency, 234000 (3); Angioedema, hereditary, type III, 610618 (3);
5.633;9;5;91;5q32;RPS20B;;Ribosomal protein S20B;180464;REa;?pseudogene;;
5.634;1;5;12;5q32;AFAP1L1;;Actin filament-associated protein 1-like 1;614410;REc;;;
5.635;8;31;12;5q33.1;DCTN4, P62, DYN4;;Dynactin 4;614758;REc;;;
5.636;12;24;13;5q32;FBXO38, FBX38, MOKA, HMN2D;;F-box only protein 38;608533;REc;;Neuronopathy, distal hereditary motor, type IID, 615575 (3);18(Fbxo38)
5.637;9;2;11;5q33.1;G3BP1, G3BP;;GTPase-activating protein SH3 domain-binding protein 1;608431;REc, R;;;
5.638;8;2;16;5q33.1;IRGM, LRG47, IFI1, IBD19;;Immunity-related GTPase family, M;608212;REc;;{Mycobacterium tuberculosis, protection against}, 607948 (3); {Inflammatory bowel disease (Crohn disease) 19}, 612278 (3);
5.639;2;3;05;5q33.2;KIF4B;;Kinesin family member 4B;609184;A;;;
5.640;3;23;09;5q32;MIR143, MIRN143;;Micro RNA 143;612117;REc;;;
5.641;3;23;09;5q32;MIR145, MIRN145;;Micro RNA 145;611795;REc;;;
5.642;3;23;09;5q32;MIR378, MIRN378;;Micro RNA 378;611957;REc;;;
5.643;5;19;06;5q33.1;NMUR2, NMU2R, FM4;;Neuromedin U receptor 2;605108;REc;;;
5.644;12;4;08;5q33.1;RBM22;;RNA-binding motif protein 22;612430;REc;;;
5.645;4;20;10;5q33.1;SLC36A2, PAT2;;Solute carrier family 36 (proton/amino acid symporter), member 2;608331;REc, H;;Iminoglycinuria, digenic, 242600 (3); Hyperglycinuria, 138500 (3);11(Slc36a2)
5.646;12;15;10;5q32;SPINK9, LEKTI2;;Serine protease inhibitor, Kazal-type, 9;613511;REc;;;
5.647;3;22;07;5q33.1;SYNPO;;Synaptopodin;608155;R, REc;;;
5.648;12;18;08;5q33.1;ZNF300;;Zinc finger protein 300;612429;REc;;;
5.649;3;4;10;5q33.1-q35.2;FECD5, FCD3;;Corneal dystrophy, Fuchs endothelial, 5;613269;Fd;flanked by D5S470 and D5S2108;Corneal dystrophy, Fuchs endothelial, 5 (2);
5.650;1;26;97;5q35.1;LCP2, SLP76;;Lymphocyte cytosolic protein-2 (SH2 domain-containing leukocyte protein of 76kD);601603;Fd;;;
5.651;10;1;17;5q33.2;HAND1, EHAND;;Heart- and neural crest derivatives-expressed 1;602406;REc;;;
5.652;1;27;04;5q33.2;GALNT10, GalNAcT10;;UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 10;608043;R, REc;;;
5.653;8;31;09;5q33.2;GEMIN5;;GEM-associated protein 5;607005;R, REc;;;
5.654;7;31;17;5q33.3;HAVCR1, HAVCR;;Hepatitis A virus cellular receptor 1;606518;REc, H;;;
5.655;12;7;07;5q34;HMMR;;Hyaluronan-mediated motility receptor (RHAMM);600936;REa, H, REc;;{Breast cancer, susceptibility to}, 114480 (3);11(hmmr)
5.656;6;10;08;5q33.2;LARP1, LARP, KIAA0731;;La ribonucleoprotein domain family, member 1;612059;REc;incorrectly mapped to chromosome 10;;
5.657;8;19;13;5q33.2;SAP30L;;SAP30-like protein;610398;REc;;;
5.658;1;30;02;5q33.3;TIM3;;T-cell immunoglobulin- and mucin-domain-containing molecule;606652;REc;;;11(Tim3)
5.659;8;19;13;5q33.3;TIMED4, TIM4, SMUCKLER;;T-cell immunoglobulin and mucin domains-containing protein 4;610096;REc, H;;;11(Tim4)
5.660;5;31;13;5q33.3;C5orf54, ZBED8, BUSTER3;;Chromosome 5 open reading frame 54;615253;REc;;;
5.661;5;4;09;5q33.3;CLINT1, EPN4, EPNR, KIAA0171;;Clathrin interactor 1 (epsin 4);607265;R, Fd;;;
5.662;6;5;18;5q33.3;CYFIP2, EIEE65;;Cytoplasmic FMRP interacting protein 2;606323;R, REc;;Epileptic encephalopathy, early infantile, 65, 618008 (3);
5.663;5;19;15;5q33.3;IL12B, NKSF2, IMD29;;Interleukin-12B (natural killer cell stimulatory factor-2, cytotoxic lymphocyte maturation factor-2, p40);161561;R, REn, A, REc;between GLR1 and GABRA1;Immunodeficiency 29, mycobacteriosis, 614890 (3);11(Il12b)
5.664;4;6;18;5q33.3;LSM11;;Lsm11, U7 small nuclear RNA-associated protein;617910;REc;;;
5.665;8;31;09;5q33.3;MED7, CRSP9, CRSP33;;Mediator complex subunit 7;605045;R, REc;;;
5.666;2;23;09;5q33.3;MIR146A, MIRN146A;;Micro RNA 146A;610566;REc;;;
5.667;12;22;17;5q33.3;PWWP2A;;PWWP domain-containing protein 2A;617823;REc;;;
5.668;7;2;18;5q33.3;SOX30;;SRY-box 30;606698;REc;;;
5.669;2;7;06;5q33.3;UBLCP1;;Ubiquitin-like domain-containing CTD phosphatase 1;609867;REc;;;
5.670;12;14;95;5q35.1;DUSP1, CL100, PTPN10;;Dual specificity phosphatase-1;600714;A, REc;;;
5.671;8;10;98;5q33.3;EBF, OLF1;;Early B-cell factor (olfactory neuronal transcription factor 1);164343;REa, A;;;11(Ebf)
5.672;1;23;01;5q35.1;FGF18;;Fibroblast growth factor-18;603726;R;;;
5.673;12;7;07;5q35.1;FOXI1, FKHL10, FREAC6;;Forkhead box I1;601093;A;some patients have digenic mutations with SLC26A4;Enlarged vestibular aqueduct, 600791 (3);
5.674;8;8;17;5q34;GABRG2, GEFSP3, CAE2, ECA2;;Gamma-aminobutyric acid (GABA) A receptor, gamma-2;137164;REn, R, Psh;in alpha/beta/gamma cluster;Epilepsy, generalized, with febrile seizures plus, type 3, 611277 (3); {Epilepsy, childhood absence, susceptibility to, 2}, 607681 (3); Febrile seizures, familial, 8, 611277 (3);
5.675;5;6;04;5q35.1;KCNMB1;;Potassium large conductance calcium-activated channel, subfamily M, beta member 1;603951;Psh, A;;{Hypertension, diastolic, resistance to}, 608622 (3);
5.676;12;21;09;5q34;MIR103-1, MIRN103-1;;Micro RNA 103-1;613187;REc;;;
5.677;1;29;16;5q34;MIR218-2;;Micro RNA 218-2;616771;REn, REc;in intron of SLIT3;;11(Mir218-2)
5.678;9;23;13;5q35.1;NKX2-5, NKX2E, CSX, CHNG5, VSD3, HLHS2;;NK2 homeobox-5 gene;600584;A, Psh, REc;near border with 5q35;Atrial septal defect 7, with or without AV conduction defects, 108900 (3); Tetralogy of Fallot, 187500 (3); Hypothyroidism, congenital nongoitrous, 5, 225250 (3); Ventricular septal defect 3, 614432 (3); Hypoplastic left heart syndrome 2, 614435 (3); Conotruncal heart malformations, variable, 217095 (3);17(Csx)
5.679;1;3;02;5q35.1;RANBP17;;RAN-binding protein 17;606141;Ch;;;
5.680;12;26;14;5q34;RARS, HLD9;;Arginyl-tRNA synthetase;107820;S, REc;;Leukodystrophy, hypomyelinating, 9, 616140 (3);
5.681;2;5;15;5q34;TENM2, ODZ2, TNM2, KIAA1127;;Teneurin transmembrane protein 2;610119;REc;;;
5.682;1;22;18;5q34;GABRB2, ICEE2;;Gamma-aminobutyric acid (GABA) A receptor, beta-2;600232;Psh;;Epileptic encephalopathy, infantile or early childhood, 2, 617829 (3);
5.683;4;29;14;5q34;GABRA1, EJM5, ECA4, EIEE19;;Gamma-aminobutyric acid (GABA) A receptor, alpha-1;137160;A, R, Fd, REn;in same 200kb as GABRG2;{Epilepsy, juvenile myoclonic, susceptibility to, 5}, 611136 (3); {Epilepsy, childhood absence, susceptibility to, 4}, 611136 (3); Epileptic encephalopathy, early infantile, 19, 615744 (3);11(Gabra1)
5.684;6;15;99;5q35.3;GFPT2, GFAT2;;Glutamine: fructose-6-phosphate amidotransferase 2;603865;R, H;;;11(Gfat2)
5.685;11;4;16;5q35.2;MSX2, CRS2, HOX8;;msh, Drosophila, homeo box homolog of, 2;123101;Fd, REa, A;;Craniosynostosis 2, 604757 (3); Parietal foramina 1, 168500 (3); Parietal foramina with cleidocranial dysplasia, 168550 (3);
5.686;11;4;05;5q34-q35.2;NIDDM4;;Diabetes mellitus, noninsulin-dependent, 4;608036;Fd;;{Diabetes mellitus, noninsulin-dependent}, 125853 (2);
5.687;1;14;14;5q34;WWC1, KIBRA, KIAA0869, MEMRYQTL;;WW, C2, and coiled-coil domain-containing 1;610533;REc;;[Memory, enhanced, QTL], 615602 (3);
5.688;8;28;01;5p13.3-p13.2;ADAMTS12;;A disintegrin-like and metalloproteinase with thrombospondin type 1 motif, 12;606184;REa, R;;;
5.689;8;28;01;5q35.3;BTNL3;;Butyrophilin-like protein 3;606192;REa, R;;;
5.690;2;28;94;5q35.3;CANX;;Calnexin;114217;REa, A;;;
5.691;10;23;87;5q35;CHR;;Chromate resistance (sulfate transport);118840;S;;;
5.692;2;25;15;5q35.3;CLK4;;CDC-like kinase 4;607969;REc;;;
5.693;6;9;06;5q35.3;COL23A1;;Collagen, type XXIII, alpha-1;610043;REc;;;11(Col23a1)
5.694;5;29;12;5q35.3;GRK6, GPRK6;;G protein-coupled receptor kinase 6;600869;REa;;;
5.695;1;31;13;5q35.3;GRM6, MGLUR6, CSNB1B;;Glutamate receptor, metabotropic, 6;604096;REa, A;;Night blindness, congenital stationary (complete), 1B, autosomal recessive, 257270 (3);
5.696;7;1;11;5q35.3;LTC4S;;Leukotriene C4 synthase;246530;A;;Leukotriene C4 synthase deficiency, 614037 (1);
5.697;2;23;09;5q35.3;MAML1;;Mastermind, Drosophila, homolog of, 1;605424;R, REc;;;
5.698;11;20;98;5q35.3;MAPK9, PRKM9, JNK2;;Mitogen-activated protein kinase 9;602896;A;;;
5.699;11;4;98;5q35.3;MGAT1, GLYT1;;Mannosyl (alpha-1,3-)-glycoprotein beta-1,2, N-acetylglucosaminyltransferase;160995;REa, A;;;11(Glyt1)
5.700;3;8;00;5q35.3;MGAT4B;;Alpha-1,3-mannosyl-glycoprotein beta-1,4-N-acetylglucosaminyltransferase, isozyme B;604561;A;;;
5.701;9;18;17;5q35.3;NSD1, ARA267, STO, SOTOS1;;Nuclear receptor binding SET domain protein 1;606681;A;fusion gene with NUP98 in AML;Sotos syndrome 1, 117550 (3); Leukemia, acute myeloid, 601626 (1);
5.702;8;27;15;5q35.1;NPM1;;Nucleophosmin 1 (nucleolar phosphoprotein B23, numatrin);164040;Ch, A;fused with RARA in APL;Leukemia, acute myeloid, somatic, 601626 (3);
5.703;7;9;06;5q34;PANK3;;Pantothenate kinase 3;606161;REn;;;
5.704;3;25;02;5q35.3;SCGB3A1, HIN1;;Secretoglobin, family 3A, member 1;606500;A;;;
5.705;5;25;17;5q35.3;SLC34A1, SLC17A2, NPT2, NPHLOP1, FRTS2, HCINF2;;Solute carrier family 34 (sodium phosphate cotransporter), member 1;182309;Psh, A, R, REc;mutation identified in 1 FRTS2 family;Nephrolithiasis/osteoporosis, hypophosphatemic, 1, 612286 (3); ?Fanconi renotubular syndrome 2, 613388 (3); Hypercalcemia, infantile, 2, 616963 (3);13(Slc17a2)
5.706;6;15;99;5q34-q35;SLIT3, SLIL2, MEGF5;;Slit, Drosophila, homolog of, 3;603745;R;;;
5.707;6;21;05;5q35.2;SNCB;;Synuclein, beta;602569;A;;Dementia, Lewy body, 127750 (3);
5.708;11;23;16;5q35.3;SQSTM1, P62, PDB3, FTDALS3, NADGP, DMRV;;Sequestosome 1;601530;R, Fd;;Paget disease of bone 3, 167250 (3); Frontotemporal dementia and/or amyotrophic lateral sclerosis 3, 616437 (3); Neurodegeneration with ataxia, dystonia, and gaze palsy, childhood-onset, 617145 (3); Myopathy, distal, with rimmed vacuoles, 617158 (3);
5.709;6;5;08;5q35.1;UBTD2, DCUBP, MGC30022;;Ubiquitin domain-containing protein 2;610174;REc;;;
5.710;2;25;08;5q35.2;UIMC1, RAP80;;Ubiquitin interaction motif containing 1;609433;A;;;
5.711;8;20;07;5q35.1;ATP6V0E1, ATP6H;;ATPase, H+ transporting, V0 subunit e1;603931;R, REc;previously mapped to Chr.2;;
5.712;6;22;12;5q35.1;BNIP1, NIP1;;BCL2/adenovirus E1B 19kD protein-interacting protein 1;603291;REc;;;
5.713;9;2;16;5q35.1;CREBRF, LRF, C5orf41;;CREB3 recruitment factor;617109;REc;;;
5.714;6;23;15;5q35.1;DOCK2, IMD40;;Dedicator of cytokinesis 2;603122;R, Psh, REc;;Immunodeficiency 40, 616433 (3);
5.715;8;24;92;5q35.2;DRD1;;Dopamine receptor D1;126449;REa, A, Fd, REn, R;same 300kb fragment as GRL;;
5.716;5;13;09;5q35.1;FBXW11, FBXW1B, BTRC2, BTRCP2;;F-box and WD40 domain protein 11;605651;R, A;;;11(Fbxw11)
5.717;3;29;10;5q35.1;SH3PXD2B, TKS4, KIAA1295, FTHS;;SH3 and PX domains-containing protein 2B;613293;REc;;Frank-ter Haar syndrome, 249420 (3);11(Sh3pxd2b)
5.718;4;2;16;5q35.1;SNORA74B;;Small nucleolar RNA, H/ACA box, 74B;611331;REc;in intron 3 of ATP6V0E1;;
5.719;6;3;15;5q35.1;SPDL1, CCDC99, SPINDLY;;Spindly apparatus coiled-coil protein 1;616401;REc;;;
5.720;3;31;15;5q35.2;STC2, STCRP;;Stanniocalcin 2;603665;REc;;;
5.721;6;22;99;5q35.1;STK10, LOK;;Serine/threonine protein kinase-10;603919;A;;;11(Stk10)
5.722;7;15;02;5q35.1;TLX3, HOX11L2, RNX;;T-cell leukemia, homeobox 3;604640;R, A;activated in T-cell ALL;;11(Hox11l2)
5.723;2;20;03;5q35.2;FGFR4;;Fibroblast growth factor receptor-4;134935;REa, A, R;distal to DRD1;{Cancer progression/metastasis} (3);13(Fgfr4)
5.724;1;11;16;5q35.2;BOD1, FAM44B;;Biorientation of chromosomes in cell division 1;616745;REc;;;
5.725;9;29;10;5q35.2;CLTB;;Clathrin, light polypeptide (Lcb);118970;REa, A, REc;previously mapped to chr. 4;;
5.726;8;17;09;5q35.2;CPLX2, CPX2;;Complexin 2;605033;R, REc;;;
5.727;5;9;18;5q35.1;ERGIC1, ERGIC32, KIAA1181, AMCN;;Endoplasmic reticulum-golgi intermediate compartment protein 1;617946;REc;mutation identified in 1 AMCN family;?Arthrogryposis multiplex congenita, neurogenic type, 208100 (3);
5.728;5;2;16;5q35.2;FAF2, ETEA, UBXD8, KIAA0887;;Fas-associated factor family, member 2;616935;REc;;;
5.729;5;26;13;5q35.2;GPRIN1, GRIN1, KIAA1893;;G protein-regulated inducer of neurite outgrowth 1;611239;REc;;;
5.730;9;28;96;5q35.2;HK3;;Hexokinase-3, white cell;142570;A, Psh;;;
5.731;1;13;16;5q35.2;HMP19, NSG2;;Hypothalamus golgi apparatus-expressed protein, 19kD;616752;REc;;;
5.732;7;2;18;5q35.2;HRH2;;Histamine receptor H2;142703;REc;;;
5.733;7;7;09;5q35.2;MENOQ4;;Menopause, natural, age at, QTL4;612886;Fd;associated with rs365132, rs7718874, rs402511, rs691141, rs2278493;{Menopause, natural, age at, QTL4} (2);
5.734;7;13;09;5q35.2;NOP15, HSPC111;;Nop16, S. cerevisiae, homolog of;612861;REc;;;
5.735;7;15;09;5q35.3;PFN3;;Profilin 3;612812;REc;;;
5.736;12;29;13;5q35.2;SFXN1;;Sideroflexin 1;615569;REc;;;13(Sfxn1)
5.737;09;06;18;5q35.2;SIMC1, PLEIAD;;SUMO-interacting motifs-containing protein 1;618102;REc;;;
5.738;8;31;09;5q35.2;THOC3, TEX1;;THO complex 3 (Tex1, yeast, homolog of);606929;R, REc;;;
5.739;7;7;09;5q35.2;UNC5A, UNC5H1;;UNC5, C. elegans, homolog of, A;607869;REc;;;
5.740;9;27;17;5q35.2;ZNF346, JAZ;;Zinc finger protein 346;605308;REc;;;
5.741;12;22;17;5q35.3;B4GALT7, XGALT1, XGPT1, EDSSPD1;;Beta-1,4-galactosyltransferase 7;604327;REc, A;;Ehlers-Danlos syndrome, spondylodysplastic type, 1, 130070 (3);
5.742;2;2;14;5q35.3;BTNL8, BTN9.2;;Butyrophilin-like protein 8;615606;REc;;;
5.743;9;9;08;5q35.3;CNOT6, CCR4, KIAA1194;;CCR4-NOT transcription complex, subunit 6;608951;R, REc;;;
5.744;8;31;09;5q35.3;DBN1;;Drebrin-1;126660;REb, REc;;;13(Dbn1)
5.745;3;25;16;5q35.3;DDX41, ABS, MPLPF;;DEAD/H box 41;608170;R;;{Myeloproliferative/lymphoproliferative neoplasms, familial (multiple types), susceptibility to}, 616871 (3);
5.746;7;26;10;5q35.3;DOK3, DOKL;;Docking protein 3;611435;REc;;;
5.747;7;14;14;5q35.3;FAM193B, IRIZIO, KIAA1931;;Family with sequence similarity 193, member B;615813;REc;;;
5.748;12;19;18;5q35.3;FLT4, VEGFR3, PCL, LMPHM1;;fms-related tyrosine kinase-4 (vascular endothelial growth factor receptor 3);136352;A, R, Fd;;Lymphatic malformation 1, 153100 (3); Hemangioma, capillary infantile, somatic, 602089 (3);11(Flt4)
5.749;8;8;13;5q35.3;GNB2L1, RACK1;;Guanine nucleotide-binding protein, beta-2-like 1;176981;R, REc;;;
5.750;3;25;96;5q35.3;HNRPH1;;Heterogeneous nuclear ribonucleoprotein H;601035;A;;;
5.751;6;30;05;5q35.3;MXD3, MAD3;;MAX dimerization protein 3;609450;REc;;;
5.752;10;12;16;5q35.3;MRNIP, C5orf45;;MRN complex-interacting protein;617154;REc;;;
5.753;7;1;11;5q35.3;NOLA2, NHP2, DKCB2;;Nucleolar protein family A, member 2;606470;R, REc;;Dyskeratosis congenita, autosomal recessive 2, 613987 (3);
5.754;3;8;04;5q35.3;PDLIM7, ENIGMA;;PDZ and LIM domain 7 (enigma);605903;R;;;
5.755;5;19;15;5q35.3;PHYKPL, AGXT2L2, PHLU;;5-phosphohydroxy-L-lysine phospho-lyase;614683;REc;mutation identified in 1 PHLU patient;[?Phosphohydroxylysinuria], 615011 (3);
5.756;8;31;09;5q35.3;RGS14;;Regulator of G protein signaling 14;602513;REc;;;
5.757;7;22;09;5q35.3;PRELID1, PRELI, PX19;;PRELI domain-containing protein 1;605733;R, REc;;;
5.758;12;18;08;5q35.3;RAB24;;Ras-associated protein 24;612415;R, REc;;;
5.759;8;19;13;5q35.3;RUFY1;;RUN and FYVE domains-containing protein 1;610327;R, REc;;;
5.760;6;28;18;5q35.3;TBC1D9B, KIAA0676;;TBC domain family, member 9B;618039;R, REc;;;
5.761;3;18;98;5q35.3;TCF17, KID1;;Transcription factor-17;602444;A;;;11(Tcf17)
5.762;7;1;05;5q35.3;TRIM7, GNIP;;Tripartite motif-containing protein 7;609315;R, REc;;;
5.763;10;30;06;5q35.3;TRIM41;;Tripartite motif-containing 41;610530;REc;;;
5.764;7;17;14;5q35.3;TRK-CTT2-4, TRNAK2, TRK2;;Transfer RNA lysine (CTT) 2-4;612996;REc;;;
5.765;10;24;14;5q35.3;TRP-TGG3-5, TRNAP3, TRP3;;Transfer RNA-Pro (TGG) 3-5;189912;REa, A;;;
5.766;10;24;14;5q35.3;TRT-TGT6-1, TRNAT1, TRT1;;Transfer RNA-Thr (TGT) 6-1;189913;REa, A;;;
5.767;7;18;14;5q35.3;TRV-AAC1-4, TRNAV1, TRV1;;Transfer RNA valine (AAC) 1-4;189921;REc;;;
5.768;7;17;14;5q35.3;TRV-CAC1-2, TRNAV2, TRV2;;Transfer RNA valine (CAC) 1-2;612995;REc;;;
5.769;4;21;10;5q35.3;ZFP62;;Zinc finger protein 62;610281;R, REc;;;11(Zfp62)
5.770;7;10;15;6q22.31;GJA1, CX43, ODDD, SDTY3, ODOD, HSS, AVSD3, HLHS1, CMDR, EKVP3;;Gap junction protein, alpha-1, 43kD (connexin 43);121014;REa, REc;pseudogene on chr.5;Oculodentodigital dysplasia, 164200 (3); Syndactyly, type III, 186100 (3); Hypoplastic left heart syndrome 1, 241550 (3); Atrioventricular septal defect 3, 600309 (3); Oculodentodigital dysplasia, autosomal recessive, 257850 (3); Craniometaphyseal dysplasia, autosomal recessive, 218400 (3); Erythrokeratodermia variabilis et progressiva 3, 617525 (3); Palmoplantar keratoderma with congenital alopecia, 104100 (3);10(Gja1)
6.1;1;16;07;6p21.2;ZFAND3, TEX27;;Zinc finger AN1 domain-containing protein 3;607455;R, REc;;;
6.2;2;17;09;6pter-p24;DEL6pter, C6DELpter;;Chromosome 6pter-p24 deletion syndrome;612582;Ch;;Chromosome 6pter-p24 deletion syndrome (4);
6.3;2;28;03;6p21.33;MDC1, NFBD1, KIAA0170;;Mediator of DNA damage checkpoint protein 1;607593;Psh;;;
6.4;4;6;18;6p21.1;CNPY3, TNRC5, PRAT4A, ERDA5, EIEE60;;Canopy 3, zebrafish, homolog of;610774;R, REc;;Epileptic encephalopathy, early infantile, 60, 617929 (3);
6.5;10;1;95;6p25.2;ELANH2, EI;;Protease inhibitor 2 (anti-elastase), monocyte/neutrophil derived;130135;Psh, R;;;
6.6;3;8;91;6p21.31;CLPS;;Colipase, pancreatic;120105;REa;;;
6.7;5;9;07;6p21.31;ITPR3;;Inositol 1,4,5-triphosphate receptor, type 3;147267;REa, A;;{Diabetes, type 1, susceptibility to}, 222100 (2);
6.8;2;12;16;6p25.3;DUSP22, LMWDSP2, MKPX, VHX, JKAP, JSP1;;Dual-specificity phosphatase 22;616778;REc;;;
6.9;8;1;13;6p25.3;EXOC2, SEC5L1, SEC5;;Exocyst complex component 2;615329;REc;;;
6.10;12;4;98;6p25.3;FOXF2, FKHL6, FREAC2;;Forkhead box F2;603250;A, R;;;
6.11;11;15;05;6p25.3;HUS1B;;Hydroxyurea-sensitive 1, S. pombe, homolog of, B;609713;REc;;;
6.12;12;4;03;6p24.3;CTAG3, CAGE1;;Cancer/testis antigen 3;608304;REc;;;
6.13;4;22;10;6p25.3-p22.3;INTLQ3;;Intelligence quantitative trait locus 3;610294;Fd;;{Intelligence QTL3} (2);
6.14;11;11;14;6p25.2;ECI2, PECI, DRS1;;Enoyl-CoA delta isomerase 2;608024;R, REc;;;
6.15;7;20;12;6p25.2;FAM60B, X5L;;Family with sequence similarity 50, member B;614686;A, REc;;;
6.16;9;10;09;6p25.2;PRPF4B, PRP4;;Pre-mRNA processing factor 4, yeast, homolog of, B;602338;R, REc;;;
6.17;6;27;17;6p25.2;PSMG4, PAC4, C6orf86;;Proteasome assembly chaperone 4;617550;REc;;;
6.18;09;13;18;6p25.2;RIPK1, RIP1, RIP, IMD57;;Receptor-interacting serine/threonine kinase 1;603453;REc;;Immunodeficiency 57, 618108 (3);
6.19;1;2;08;6p25.2;SLC22A23, C6orf85;;Solute carrier family 22, member 23;611697;REc;;;19(Slc22a23)
6.20;4;29;14;6p25.2;TUBB2A, CDCBM5;;Tubulin, beta-2A;615101;REc;;Cortical dysplasia, complex, with other brain malformations 5, 615763 (3);
6.21;7;26;17;6p25.2;TUBB2B, CDCBM7;;Tubulin, beta-2B;612850;REc;TUBB2A is 70kb telomeric to TUBB2B;Cortical dysplasia, complex, with other brain malformations 7, 610031 (3);
6.22;6;8;15;6p24.3;TXNDC5, ERP46, ENDOPDI, HCC2;;Thioredoxin domain-containing protein 5;616412;REc;;;13(Txndc5)
6.23;10;29;03;6p25.2;WRNIP1, WHIP;;Werner helicase-interacting protein 1;608196;REc;;;
6.24;9;1;09;6p25.1;CDYL;;Chromodomain protein on Y chromosome-like;603778;R, REc;;;13(Cdyl)
6.25;2;19;18;6p25.1;FARS2, FARS1, COXPD14, SPG77;;Phenylalanyl-tRNA synthetase 2, mitochondrial;611592;R, REc;;Combined oxidative phosphorylation deficiency 14, 614946 (3); Spastic paraplegia 77, autosomal recessive, 617046 (3);
6.26;11;11;14;6p25.1;LY86, MD1;;Lymphocyte antigen 86;605241;REc;;;
6.27;1;9;14;6p25.1;LYRM4, ISD11, C6orf149, COXPD19;;LYR motif-containing protein 4;613311;REc;mutation identified in 1 family;?Combined oxidative phosphorylation deficiency 19, 615595 (3);
6.28;9;10;09;6p25.1;NRN1, NRN;;Neuritin 1;607409;R, REc;;;
6.29;9;10;09;6p25.1;RPP40;;Ribonuclease P, 40kD subunit;606117;R, REc;;;
6.30;9;18;08;6p24.3;EEF1E1;;Eukaryotic translation elongation factor 1, epsilon-1;609206;REc;;;
6.31;10;26;98;6p25.2;BPHL;;Biphenyl hydrolase-like;603156;A;;;
6.32;1;27;09;6p25;CLLS4;;Leukemia, chronic lymphocytic susceptibility to, 4;612558;Fd;associated with rs872071;{Leukemia, chronic lymphocytic susceptibility to, 4} (2);
6.33;1;26;17;6p25.3;FOXC1, FKHL7, FREAC3, IRID1, RIEG3, ASGD3;;Forkhead, Drosophila, homolog-like 7;601090;A;;Anterior segment dysgenesis 3, multiple subtypes, 601631 (3); Axenfeld-Rieger syndrome, type 3, 602482 (3);13(Fkhl7, ch, Mfl)
6.34;9;22;14;6p25.3;FOXCUT, LINC01379;;FOXC1 upstream transcript, noncoding;615976;REc;;;
6.35;5;19;09;6p25.3;FOXQ1, HFH1;;Forkhead box Q1;612788;A, REc, H;;;13(Foxq1)
6.36;11;20;98;6p25.3;GMDS;;GDP-mannose 4,6-dehydratase;602884;A;;;
6.37;4;15;04;6p25;LRSL;;Larsen-like syndrome;608545;Ch;;Larsen-like syndrome (2);
6.38;4;6;10;6p25.2;NQO2, NMOR2;;NAD(P)H dehydrogenase, quinone 2 (NAD(P)H menadione oxidoreductase-1, dioxin-inducible-2);160998;REa;;{?Breast cancer susceptibility}, 114480 (1);
6.39;11;5;97;6p25.2;PI9, CAP3, SERPINB9;;Protease inhibitor 9, ovalbumin type;601799;A;;;
6.40;5;28;98;6p24.3;RREB1;;RAS-responsive element binding protein-1;602209;Psh, R, A;;;
6.41;7;28;14;6p25.2;SERPINB6, PI6, PTI, SPI3, DFNB91;;Protease inhibitor 6 (placental thrombin inhibitor);173321;Psh, R, A;mutation identified in 1 DFNB91 family;?Deafness, autosomal recessive 91, 613453 (3);13(Spi3)
6.42;11;2;11;6p25.1;F13A1, F13A;;Coagulation factor XIII, A polypeptide;134570;F, Fd, A, D;;Factor XIIIA deficiency, 613225 (3); {Myocardial infarction, protection against}, 608446 (3); {Venous thrombosis, protection against}, 188050 (3);
6.43;11;24;14;6p25.3;IRF4, LSIRF, SHEP8;;Interferon regulatory factor-4;601900;A, Ch, Fd;dysregulated in t(6;14);[Skin/hair/eye pigmentation, variation in, 8], 611724 (3);
6.44;1;11;17;6p24.3;HIPSTR;;Long noncoding RNA HIPSTR;617136;REc;overlaps TFAP2A;;13(Hipstr)
6.45;9;2;08;6p24.3;HULC;;Highly upregulated in liver cancer;612210;REc;;;
6.46;9;1;95;6p24.3;OFC1, CL;;Orofacial cleft-1 (cleft lip with or without cleft palate; isolated cleft palate);119530;Fd, Ch;probable heterogeneity;Orofacial cleft-1 (2);
6.47;4;17;13;6p24.3;BLOC1S5, BLOS5, MUTED;;Biogenesis of lysosome-related organelles complex 1, subunit 5;607289;H, REc;;;13(mu)
6.48;10;31;17;6p24.3;RIOK1, RIO1;;RIO kinase 1;617753;REc;;;
6.49;3;15;07;6p24.3;SLC35B3, PAPST2;;Solute carrier family 25 (3'-phosphoadenosine 5'-phosphosulfate transporter), member B3;610845;REc;;;
6.50;6;13;12;6p24.3;SSR1;;Signal sequence receptor, alpha;600868;REc;;;
6.51;2;23;08;6p24.2;ELOVL2, SSC2;;Elongation of very long chain fatty acids-like 2;611814;REc;;;
6.52;2;13;17;6p24.2;GCM2, GCMB, HRPT4;;Glial cells missing, Drosophila, homolog of, 2;603716;REc;;Hypoparathyroidism, familial isolated, 146200 (3); Hyperparathyroidism 4, 617343 (3);
6.53;8;25;11;6p24.2;MAK, RP62;;Male germ cell-associated kinase;154235;H, REc;;Retinitis pigmentosa 62, 614181 (3);13(Mak)
6.54;9;10;12;6p24.2;NEDD9, HEF1, CASL;;Neural precursor cell expressed, developmentally downregulated 9;602265;R, REc;;;
6.55;12;28;08;6p24.2;PAK1IP1, PIP1;;PAK1-interacting protein;607811;R, REc;;;
6.56;2;9;16;6p24.2;SYCP2L, C6orf177;;Synaptonemal complex protein 2-like;616799;REc;;;
6.57;7;22;13;6p24.2;TMEM14C;;Transmembrane protein 14C;615318;REc;;;
6.58;11;19;11;6p24.1;C6orf105, ADTRP;;Chromosome 6 open reading frame 105 (androgen-dependent TFPI-regulating protein);614348;REc;;;
6.59;5;26;13;6p24.2;ERVFRD-1;;Endogenous retrovirus group FRD, member 1;610524;REc;;;
6.60;7;16;12;6p24.1;PHACTR1, KIAA1733;;Phosphatase and actin regulator 1;608723;REc;;;
6.61;8;22;14;6p24.1;TBC1D7, PIG51, TBC7, MGCPH;;TBC1 domain family, member 7;612655;REc;;Macrocephaly/megalencephaly syndrome, autosomal recessive, 248000 (3);
6.62;7;1;11;6p24.1-p22.3;DFNA21;;Deafness, autosomal dominant 21;607017;Fd;previously mapped to 6p21.3;Deafness, autosomal dominant 21 (2);
6.63;11;24;14;6p24.3;DSP, KPPS2, PPKS2, DCWHKTA;;Desmoplakin;125647;REa, REc, Fd;splice variants result in DP I and DP II;Keratosis palmoplantaris striata II, 612908 (3); Cardiomyopathy, dilated, with woolly hair and keratoderma, 605676 (3); Arrhythmogenic right ventricular dysplasia 8, 607450 (3); Skin fragility-woolly hair syndrome, 607655 (3); Epidermolysis bullosa, lethal acantholytic, 609638 (3); Dilated cardiomyopathy with woolly hair, keratoderma, and tooth agenesis, 615821 (3);
6.64;11;19;11;6p24.3;OFCC1, MRDS1;;OFC1 candidate gene 1;614287;REc;;;
6.65;6;27;08;6p24.3;TFAP2A, AP2TF, BOFS;;Transcription factor AP-2 alpha (activating enhancer-binding protein 2 alpha);107580;;;Branchiooculofacial syndrome, 113620 (3);13(Tcfap2)
6.66;2;18;98;6p24.3;BMP6;;Bone morphogenetic protein-6;112266;REa, REc;;;
6.67;3;24;14;6p24.1;EDN1, ARCND3, QME, HDLCQ7;;Endothelin-1;131240;REa, A, Fd;;Auriculocondylar syndrome 3, 615706 (3); Question mark ears, isolated, 612798 (3); {High density lipoprotein cholesterol level QTL 7} (3);13(Edn1)
6.68;5;6;15;6p24.3-p24.2;GCNT2, Ii, CTRCT13;;Glucosaminyl (N-acetyl) transferase 2, I-branching enzyme;600429;A;previously assigned to 9q21;[Blood group, Ii], 110800 (3); Cataract 13 with adult i phenotype, 116700 (3); Adult i phenotype without cataract, 110800 (3);
6.69;8;18;97;6p22.3;JMJ;;Jumonji;601594;A;;;13(jmj)
6.70;11;3;92;6p24.1;HIVEP1, ZNF40;;Human immunodeficiency virus type I enhancer-binding protein-1;194540;REa, A, REc;;;
6.71;5;4;00;6p23;CD83, HB15, BL11;;CD83 antigen;604534;REc;;;13(Cd83)
6.72;12;13;96;6p22.3;ATXN1, ATX1, SCA1;;Ataxin-1;601556;F, Fd, A;;Spinocerebellar ataxia 1, 164400 (3);13(Sca1, Atx1)
6.73;2;22;00;6p22.3;DEK, D6S231E;;DEK oncogene;125264;Ch;fused with CAN in t(6;9);Leukemia, acute nonlymphocytic (2);
6.74;11;22;17;6p23;ETM3;;Tremor, hereditary essential, 3;611456;Fd;max lod at D6S1630 and D6S1605;Essential tremor, hereditary, 3 (2);
6.75;3;18;94;6p22.3;GMPR, GMPR1;;Guanosine monophosphate reductase;139265;REb, A;;;
6.76;1;22;08;6p22.3;MBOAT1;;Membrane-bound O-acetyltransferase domain-containing 1;611732;REc;;;
6.77;5;23;16;6p23;MCUR1, CCDC90A, FMP32;;Mitochondrial calcium uniporter regulator 1;616952;REc;;;
6.78;1;5;09;6p23;NOL7;;Nucleolar protein 7;611533;A;;;
6.79;6;13;02;6p23;RANBP9, RANBPM;;RAN-binding protein 9;603854;R, REc;;;
6.80;12;14;98;6p23;SCZD3;;Schizophrenia susceptibility locus, chromosome 6-related;600511;Fd;?same as DTNBP1; cognitive deficit type;{Schizophrenia}, 181500 (2);
6.81;9;10;09;6p23;SIRT5;;Sirtuin, S. cerevisiae, homolog 5;604483;R, REc;;;
6.82;4;26;06;6p22.3;MYLIP, MIR;;Myosin regulatory light chain-interacting protein;610082;REc;;;
6.83;8;19;98;6p22.2;SLC17A1, NPT1;;Solute carrier family 17, sodium phosphate, member-1 (Sodium phosphate transport 1, kidney);182308;REa;;;13(Slc17a1)
6.84;1;19;07;6p23-p21;SCAR3, SCABD;;Spinocerebellar ataxia, autosomal recessive 3;271250;Fd;;Spinocerebellar ataxia, autosomal recessive 3 (2);
6.85;7;1;05;6p22.1;TRIM31, HCGI;;Tripartite motif-containing protein 31;609316;REc, R;;;
6.86;8;20;09;6p21.1;MEA1, MEA;;Male-enhanced antigen 1;143170;REb, REa;;;
6.87;9;2;09;6p22.1;TRNAM2, TRNAMI2, RNTMI2;;tRNA methionine-2;180620;REa;2 of 12+ RNTMI genes are on chr. 6;;
6.88;9;1;09;6p22.2;TRNAM1, TRMI2, TRM2, RNTMT1;;tRNA methionine-1;180621;REa;;;
6.89;3;7;14;6p22.3;ACOT13, THEM2;;Acyl-CoA thioesterase 13;615652;REc;;;
6.90;5;6;13;6p22.3;BWQTL4;;Birth weight quantitative trait locus 4;615192;Fd;associated with rs7756992;[Birth weight QTL4] (2);
6.91;10;23;15;6p22.3;CASC15, LINC00340;;Cancer susceptibility candidate 15, noncoding;616610;REc;;;
6.92;3;20;18;6p22.3;CDKAL1;;CDK5 regulatory subunit-associated protein 1-like 1;611259;REc;;;
6.93;3;15;10;6p22.3;CIHL;;Hearing loss, cisplatin-induced, susceptibility to;613290;Fd;associated with rs12201199;{?Hearing loss, cisplatin-induced, susceptibility to} (2);
6.94;6;21;16;6p22.3;DTNBP1, HPS7;;Dystrobrevin-binding protein 1 (dysbindin);607145;R, Fd;;Hermansky-Pudlak syndrome 7, 614076 (3);13(Dtnbp1)
6.95;2;26;16;6p22.3;GMNN, MGORS6;;Geminin;602842;R, REc;;Meier-Gorlin syndrome 6, 616835 (3);
6.96;10;13;09;6p22.3;KDM1B, LSD2, AOF1;;Lysine-specific demethylase 1B;613081;REc;;;
6.97;7;20;12;6p22.3;KIF13A;;Kinesin family member 13A;605433;REc;;;
6.98;9;12;03;6p22.3;NHLRC1, EPM2A, EPM2B;;NHL repeat-containing 1 gene (malin);608072;REc, Fd;;Epilepsy, progressive myoclonic 2B (Lafora), 254780 (3);
6.99;9;10;09;6p22.3;NUP153;;Nucleoporin, 153kD;603948;R, REc;;;
6.100;7;29;15;6p21.1;POLR1C, RPA39, RPA40, RPAC1, RPA5, TCS3, HLD11;;Polymerase I, RNA, subunit C;610060;REc;;Treacher Collins syndrome 3, 248390 (3); Leukodystrophy, hypomyelinating, 11, 616494 (3);
6.101;8;2;17;6p22.3;RBM24, RNPC6;;RNA-binding motif protein 24;617603;REc;;;
6.102;6;12;07;6p22.3-p21.3;OTSC3;;Otosclerosis 3;608244;Fd;;Otosclerosis 3 (2);
6.103;9;30;98;6p22.3;SOX4;;SRY (sex determining region Y)-box 4;184430;REa, A;;;13(Sox4)
6.104;4;19;16;6p22.3;TPMT, TPMTD;;Thiopurine S-methyltransferase;187680;Psh, A;;{Thiopurines, poor metabolism of, 1}, 610460 (3);
6.105;12;20;18;6p22.3;RIPOR2, FAM65B, C6orf32, KIAA0386, PL48, DFNB104;;RHO family interacting cell polarization regulator 2;611410;R, REc;mutation identified in 1 DFNB104 family;?Deafness, autosomal recessive 104, 616515 (3);
6.106;9;2;09;6p22.3-p21.1;TRNAA1;;tRNA alanine-1;601431;REa, A;;;
6.107;9;2;09;6p22.2;TRNAR3, TRR3;;tRNA arginine-3;601432;REa, A;;;
6.108;5;23;16;6p22.3;TDP2, TTRAP;;Tyrosyl-DNA phosphodiesterase 2;605764;REc;;Spinocerebellar ataxia, autosomal recessive 23, 616949 (3);
6.109;3;8;07;6p22.1;ZNF323;;Zinc finger protein 323;610794;REc;;;
6.110;12;5;13;6p22.3-p22.2;CMAHP, CMAH;;Cytidine monophospho-N-acetylneuraminic acid hydroxylase pseudogene;603209;A;mutation inactivates gene in humans;;13(Cmah)
6.111;09;04;18;6p22.2;CARMIL1, LRRC16A, LRRC16;;Capping protein regulator and myosin 1 linker 1;609593;R, REc;;;13(Lrrc16)
6.112;12;15;10;6p22.2;HISTH2AA, H2AFR, H2AA;;Histone gene cluster 1, H2A histone family, member A;613499;REc;;;
6.113;2;21;06;6p22.2;HIST1H2BA, TSH2B;;Histone 1, H2BA;609904;REc;;;
6.114;7;7;17;6p22.3;KIAA0319;;KIAA0319 gene;609269;REc;;;
6.115;7;22;13;6p22.2;TRNAR2;;Transfer RNA arginine 2;615305;REc;;;
6.116;7;22;13;6p22.2;TRNAV21;;Transfer RNA valine 21;615306;REc;;;
6.117;8;15;90;6p22.3;PRL;;Prolactin;176760;REa, D;?between 6cen and GLO1;;11(Prl)
6.118;8;24;09;6p22.1;ZSCAN12, ZNF96, KIAA0426;;Zinc finger- and SCAN domain-containing protein 12;603978;R, REc;;;
6.119;2;1;11;6p22.2;BTN1A1, BTN;;Butyrophilin;601610;REc;;;13(Btn)
6.120;2;1;11;6p22.2;BTN2A1, BTF1;;Butyrophilin, subfamily 2, member A1;613590;REc;;;
6.121;2;1;11;6p22.2;BTN2A2, BTF2;;Butyrophilin, subfamily 2, member A2;613591;REc;;;
6.122;2;1;11;6p22.2;BTN2A3;;Butyrophilin, subfamily 2, member A3;613592;REc;;;
6.123;2;1;11;6p22.2;BTN3A1, BTF5, CD277;;Butyrophilin, subfamily 3, member A1;613593;REc;;;
6.124;2;1;11;6p22.2;BTN3A2, BTF4;;Butyrophilin, subfamily 3, member A2;613594;REc;;;
6.125;2;1;11;6p22.2;BTN3A3, BTF3;;Butyrophilin, subfamily 3, member A3;613595;REc;;;
6.126;3;19;01;6p22.3;GPLD1, PIGPLD, GPIPLD;;Phospholipase D1, glycosylphosphatidylinositol-specific;602515;A;;;13(Gpld1)
6.127;11;19;11;6p22.1;GPX5;;Glutathione peroxidase 5 (epididymal);603435;REc;;;13(Gpx5)
6.128;9;9;13;6p22.1;GPX6;;Glutathione peroxidase 6;607913;REc;;;
6.129;3;6;08;6p22.3;KAAG1, RU2AS;;Kidney-associated antigen 1;608211;A;;;
6.130;2;21;13;6p22.1;OR2J3, C3HEXS;;Olfactory receptor, family 2, subfamily J, member 3;615016;REc;;[C3HEX, ability to smell], 615082 (3);
6.131;5;29;13;6p22.1;SCAND3, ZBED9, BUSTER4, KIAA1925;;SCAN domain-containing protein 3;615254;REc;;;
6.132;7;22;09;6p22.1;STQTL18;;Stature quantitative trait locus 18;612892;Fd;associated with rs10946808;{Stature QTL 18} (2);
6.133;6;17;16;6p22.1;TRIM40, RNF35;;Tripartite motif-containing protein 40;616976;REc;;;
6.134;7;17;14;6p22.1;TRS-TGA4-1, TRNAS3, TRS3;;Transfer RNA serine (TGA) 4-1;606172;REc;;;
6.135;7;22;13;6p22.1;TRNAT15;;Transfer RNA threonine 15;615309;REc;;;
6.136;7;22;13;6p22.1;TRNAV12;;Transfer RNA valine 12;615307;REc;;;
6.137;7;22;13;6p22.1;TRNAV17;;Transfer RNA valine 17;615308;REc;;;
6.138;7;18;14;6p22.1;TRS-AGA2-4, TRNAS2, TRS2, TRNS;;Transfer RNA serine (AGA) 2-4;189910;REc;;;
6.139;11;15;08;6p22.1;ZFP57, TNDM1;;Zinc finger protein 57, mouse, homolog of;612192;R, REc, Fd, Ch;;Diabetes mellitus, transient neonatal, 1, 601410 (3);
6.140;7;16;02;6p22.1;TRIM39, RNF23, TFP;;Tripartite motif-containing 39;605700;A;;;
6.141;3;28;17;6p22.3;DCDC2, RU2, KIAA1154, NPHP19, DFNB66, NSC;;Doublecortin domain-containing protein 2;605755;A;mutation identified in 1 DFNB66 family;Nephronophthisis 19, 616217 (3); ?Deafness, autosomal recessive 66, 610212 (3); Sclerosing cholangitis, neonatal, 617394 (3);
6.142;5;26;09;6p22.1;ZKSCAN3, ZNF306;;Zinc finger protein with KRAB and SCAN domains 3;612791;REc;;;
6.143;4;10;14;6p22.1;ZNRD1AS1, TCTEX4, HTEX4;;ZNRD1 antisense RNA 1;615714;REc, H;;;17(Znrd1as1)
6.144;3;15;07;6p22.2;ZNF322A, ZNF489, ZNF322;;Zinc finger protein 322A;610847;REc;;;
6.145;11;11;14;6p22.1;ZNRD1, TCTEX6, HTEX6;;Zinc ribbon domain-containing protein 1;607525;REc;;;
6.146;7;23;15;6p22.1;ZSCAN26, SREZBP;;Zinc finger- and SCAN domain-containing protein 26;616474;REc;;;
6.147;5;19;06;6p22.3;ALDH5A1, SSADH;;Succinic semialdehyde dehydrogenase;610045;REa, REc;;Succinic semialdehyde dehydrogenase deficiency, 271980 (3);
6.148;11;7;08;6p22;ALPQTL3;;Alkaline phosphatase, plasma level of, QTL 3;612368;Fd;linkage with rs9467160;{Alkaline phosphatase, plasma level of, QTL3} (2);
6.149;2;23;95;6p22.3;E2F3;;E2F transcription factor 3;600427;A;;;
6.150;2;5;15;6p22.3;NBAT1;;Neuroblastoma-associated transcript 1, noncoding;616206;REc;;;
6.151;9;22;09;6p22;NBLST4;;Neuroblastoma, susceptibility to, 4;613015;Fd;associated with rs6939340, rs4712653, rs9295536;{Neuroblastoma, susceptibility to, 4} (2);
6.152;11;17;15;6p22.3;NRSN1, VMP;;Neurensin 1;616630;REc;;;
6.153;9;10;09;6p22.1;TRIM27, RFP;;Tripartite motif-containing 27;602165;REc;;;
6.154;2;14;03;6p22.1;HIST1H1B, H1F5;;Histone 1, H1b;142711;REa;~2Mb centromeric of H1F1 cluster;;
6.155;1;14;13;6p22.1;HIST1H2AG, H2AG, H2AFP;;Histone gene cluster 1, H2A histone family, member 6;615012;REc;;;
6.156;1;14;13;6p22.1;HIST1H2AH, H2AH;;Histone gene cluster 1, H2A histone family, member H;615013;REc;;;
6.157;4;3;03;6p22.1;HIST1H2AI, H2AFC;;Histone 1, H2ai;602787;REc;;;
6.158;4;3;03;6p22.1;HIST1H2AK, HIST1H2AI, H2AFD;;Histone 1, H2ak;602788;REc;;;
6.159;4;3;03;6p22.1;HIST1H2AJ, HIST1H2AK, H2AFE;;Histone 1, H2aj;602791;REc;;;
6.160;2;14;03;6p22.1;HIST1H2AL, H2AFI;;Histone 1, H2al;602793;REc;;;
6.161;2;14;03;6p22.1;HIST1H2AM, H2AFN;;Histone 1, H2am;602796;REc;;;
6.162;1;31;13;6p22.1;HIST1H2BJ, H2BJ;;Histone gene cluster 1, H2B histone family, member J;615044;REc;;;
6.163;1;31;13;6p22.1;HIST1H2BK, H2BK;;Histone gene cluster 1, H2B histone family, member K;615045;REc;;;
6.164;3;11;03;6p22.1;HIST1H2BL, H2BFC;;Histone 1, H2bl;602800;REc;;;
6.165;3;11;03;6p22.1;HIST1H2BM, H2BFE;;Histone 1, H2bm;602802;REc;;;
6.166;3;11;03;6p22.1;HIST1H2BN, H2BFD;;Histone 1, H2bn;602801;REc;;;
6.167;4;3;03;6p22.1;HIST1H2BO, H2BFN;;Histone 1, H2bo;602808;REc;;;
6.168;3;11;03;6p22.1;HIST1H3I, H3FF;;Histone 1, H3i;602814;REc;in cluster of 16 histone genes centromeric of major cluster;;
6.169;3;11;03;6p22.1;HIST1H3J, H3FJ;;Histone 1, H3j;602817;REc;in 2nd cluster on 6p;;
6.170;3;11;03;6p22.1;HIST1H3H, H3FK;;Histone 1, H3h;602818;REc;in minor cluster on 6p;;
6.171;3;11;03;6p22.1;HIST1H4J, H4FE;;Histone 1, H4j;602826;REc;;;
6.172;3;11;03;6p22.1;HIST1H4K, H4FD;;Histone 1, H4k;602825;REc;;;
6.173;3;11;03;6p22.1;HIST1H4L, H4FK;;Histone 1, H4l;602831;REc;;;
6.174;6;13;95;6p22.3;ID4;;Inhibitor of DNA binding 4, dominant negative helix-loop-helix protein;600581;A;;;
6.175;8;27;02;6p22.1;PRSS16, TSSP;;Protease, serine, 16;607169;REc;;;13(Prss16)
6.176;10;19;99;6p22.2;SLC17A4;;Solute carrier family 17 (sodium phosphate), member 4;604216;REa, R;;;
6.177;6;11;11;6p21.31;FANCE, FACE;;Fanconi anemia, complementation group E gene;613976;Fd, LD;;Fanconi anemia, complementation group E, 600901 (3);
6.178;10;29;99;6p21.33;ABCF1, ABC50;;ATP-binding cassette 50, TNF-alpha stimulated;603429;A;;;
6.179;12;5;13;6p21.33;ATAT1, MEC17, C6orf134;;Alpha-tubulin acetyltransferase 1;615556;REc;;;
6.180;4;27;10;6p21.3;ATPLS;;Antiphospholipid syndrome, familial;107320;Fd;possible linkage with HLA-DRB1*14;?Antiphospholipid syndrome, familial (2);
6.181;4;28;10;6p21.33;AIF1, IRT1;;Allograft inflammatory factor 1;601833;R, REn;part of TNF block;;
6.182;9;22;09;6p21.33;FL1;;Follicular lymphoma, susceptibility to, 1;613024;Fd;associated with rs6457327;{Follicular lymphoma, susceptibility to, 1} (2);
6.183;4;21;17;6p21.33;G6B, C6orf25, THAMY;;G6B protein;606520;REc;mutation identified in 1 THAMY family;?Thrombocytopenia, anemia, and myelofibrosis, 617441 (3);
6.184;3;14;18;6p22.1;GABBR1, GABABR1;;Gamma-aminobutyric acid B receptor 1;603540;REc, H;;;17(Gabbr1)
6.185;2;18;09;6p21.33;LNCR4;;Lung cancer susceptibility 4;612593;Fd;associated with rs3117582 and rs3131379;{Lung cancer susceptibility 4} (2);
6.186;3;23;09;6p21.33;MIR877, MIRN877;;Micro RNA 877;611619;REc;;;
6.187;6;26;16;6p21.33;MUC21, C6orf205;;Mucin 21, cell surface-associated;616991;REc;;;17(Muc21)
6.188;4;20;17;6p21.33;MSH5, POF13;;MutS, E. coli, homolog of, 5;603382;REc;mutation identified in POF13 family;?Premature ovarian failure 13, 617442 (3);
6.189;7;20;12;6p21.33;VWA7, C6orf27, G7C;;von Willebrand factor A domain-containing protein 7;609693;REc;;;17(G7c)
6.190;12;18;07;6p22.1;ZKSCAN4, ZNF307;;Zinc finger with KRAB and SCAN domains 4;611643;REc;;;
6.191;2;21;06;6p21.32;EGFL8;;Epidermal growth factor-like 8;609897;R, REc;;;17(Eglf8)
6.192;12;15;10;6p21.32;HLA-DQA2, HLA-DXA;;Major histocompatibility complex, class II, DQ alpha-2;613503;REc;;;
6.193;8;17;13;6p21.32;HLA-DQB2, HLA-DXB;;Major histocompatibility complex, class II, DQ beta-2;615161;REc;;;
6.194;3;23;09;6p21.32;MRI219-1, MIRN219-1;;Micro RNA 219-1;611500;REc;;;
6.195;5;23;16;6p21.32;CUTA, ACHAP, C6orf82;;CutA, E. coli, homolog of;616953;REc;;;
6.196;10;26;18;6p21.32;TSBP1, TSBP, C6orf10;;Testis-expressed basic protein 1;618151;REc;;;
6.197;3;10;16;6p21.31;BRPF3, KIAA1286;;Bromodomain- and PHD finger-containing protein 3;616856;REc;;;
6.198;9;2;08;6p21.31;C6orf106;;Chromosome 6 open reading frame 106;612217;REc;;;
6.199;5;23;13;6p21.31;DEF6, IBP, SLAT;;Def6, mouse, homolog of;610094;REc, H;;;17(Def6)
6.200;8;12;14;6p21.31;KCTD20;;Potassium channel tetramerization domain-containing protein 20;615932;REc;;;
6.201;6;7;16;6p21.31;LEMD2, NET25, CTRCT42;;LEM domain-containing protein 2;616312;REc;;Cataract 46, juvenile-onset, 212500 (3);
6.202;1;18;13;6p21.31;PNPLA1, ARCI10;;Patatin-like phospholipase domain-containing protein 1;612121;REc;;Ichthyosis, congenital, autosomal recessive 10, 615024 (3);
6.203;11;1;13;6p21.1;PRICKLE4, C6orf49, OBTP;;Prickle, Drosophila, homolog of, 4;611389;REc;;;17(Prickle4)
6.204;3;7;14;6p21.31;RPL10A, CSA19;;Ribosomal protein L10A;615660;REc;;;
6.205;7;3;13;6p21.31;SLC26A8, TAT1, SPGF3;;Solute carrier family 26 (sulfate transporter), member 8;608480;REa, REc;;Spermatogenic failure 3, 606766 (3);
6.206;9;10;09;6p21.31;SNRPC;;Small nuclear ribonucleoprotein polypeptide C;603522;R, REc;;;
6.207;10;1;17;6p21.31;SRPK1;;Protein kinase, serine/arginine-specific, 1;601939;REc;;;
6.208;7;22;09;6p21.31;STQTL19;;Stature quantitative trait locus 19;612893;Fd;associated with rs1776897;{Stature QTL 19} (2);
6.209;9;10;09;6p21.31;TAF11, TAF2I, TAFII28;;TAF11 RNA polymerase II, TATA box-binding protein-associated factor, 28kD;600772;R, REc;;;
6.210;10;14;18;6p21.31;UQCC2, C6orf126, M19, MC3DN7;;Ubiquinol-cytochrome c reductase complex assembly factor 2;614461;REc;;Mitochondrial complex III deficiency, nuclear type 7, 615824 (3);
6.211;9;8;11;6p21.33;ABHD16A, BAT5, D6S82E;;Abhydrolase domain-containing 16A;142620;RE;;;
6.212;1;11;95;6p21.32;AGER, RAGE;;Advanced glycosylation end product-specific receptor;600214;RE, A;at junction of classes II, III MHC;;
6.213;10;15;98;6p21.32;AGPAT1, LPAATA;;1-acylglycerol-3-phosphate O-acyltransferase 1 (lysophosphatidic acid acyltransferase-alpha);603099;REn;;;
6.214;11;2;04;6p21.31;ANKS1, ODIN, KIAA0229;;Ankyrin repeat and sterile alpha motif domains-containing protein 1;608994;R, REc;;;
6.215;7;2;18;6p21.33;APOM, NG20;;Apolipoprotein M;606907;REc;;;
6.216;9;10;09;6p21.32;ATF6B, CREBL1;;Activating transcription factor 6 beta;600984;REc;;;
6.217;7;18;02;6p21.33;ATP6V1G2, ATP6G;;ATPase, H+ transporting, V1 subunit G2;606853;REc;;;
6.218;11;4;98;6p21.32;B3GALT4;;UDP-galactose:beta-N-acetylglucosamine beta-1,3-galactosyltransferase 4;603095;REc, REn;;;
6.219;9;8;11;6p21.33;BAG6, BAT3, D6S52E;;BCL2-associated athanogene 6;142590;RE;;;
6.220;12;10;08;6p21.32;BRD2, RING3, FSRG1;;Bromodomain-containing protein 2;601540;REn, Fd;between HLA-DNA and HLA-DMA;;
6.221;11;7;08;6p21.32;BTNL2, SS2;;Butyrophilin-like protein 2;606000;REc;;{Sarcoidosis, susceptibility to, 2}, 612387 (3);
6.222;12;27;13;6p21.33;C2, ARMD14;;Complement component-2;613927;F, LD, RE;no crossover with BF;C2 deficiency, 217000 (3); {Macular degeneration, age-related, 14, reduced risk of}, 615489 (3);17(C2)
6.223;12;19;11;6p21.33;C4A, C4S, C4AD;;Complement component-4A;120810;F, H, RE, Fd;order: HLA-B, C2, BF, C4A, C4B, CYP21, DR;C4a deficiency, 614380 (3); [Blood group, Rodgers], 614374 (3);17(C4)
6.224;12;19;11;6p21.33;C4B, C4F, C4BD;;Complement component-4B;120820;F, H, RE, Fd;10kb from C4S;C4B deficiency, 614379 (3);17(C4)
6.225;9;15;10;6p21.31;C6orf1, LBH;;Chromosome 6, open reading frame 1;611419;REc;opposite strand, tail-to-tail with HMGA1;;
6.226;10;28;09;6p21.33;CCHCR1, HCR, C6orf18;;Coiled-coil alpha-helical rod protein 1;605310;REn;?role in psoriasis;;
6.227;11;10;14;6p21.33;CDSN, HTSS1, HYPT2, PSS1;;Corneodesmosin;602593;REn, Fd;;Hypotrichosis 2, 146520 (3); Peeling skin syndrome 1, 270300 (3);
6.228;1;14;14;6p21.33;CFB, BF, GBG, AHUS4, ARMD14, CFBD;;Complement factor B;138470;F, RE;mutation identified in 1 CFBD family;{Macular degeneration, age-related, 14, reduced risk of}, 615489 (3); {Hemolytic uremic syndrome, atypical, susceptibility to, 4}, 612924 (3); ?Complement factor B deficiency, 615561 (3);17(Bf)
6.229;7;24;17;6p21.32;COL11A2, DFNA13, DFNB53, FBCG2, OSMEDA, OSMEDB;;Collagen XI, alpha-2 polypeptide;120290;REa, A, REn, Fd;45kb centromeric of HLA-DPB2; 3'--5'-cen;Otospondylomegaepiphyseal dysplasia, autosomal recessive, 215150 (3); Deafness, autosomal dominant 13, 601868 (3); Deafness, autosomal recessive 53, 609706 (3); Fibrochondrogenesis 2, 614524 (3); Otospondylomegaepiphyseal dysplasia, autosomal dominant, 184840 (3);17(Col11a2)
6.230;7;16;09;6p21.3;CTEPH1;;Pulmonary hypertension, chronic thromboembolic, without deep vein thrombosis, susceptibility to;612862;Fd;associated with DPB1*0202;{Pulmonary hypertension, chronic thromboembolic, without deep vein thrombosis, susceptibility to} (2);
6.231;10;11;96;6p21.33;CSNK2B;;Casein kinase-2, beta polypeptide;115441;REb, A;;;
6.232;3;24;11;6p21.33;CYP21A2, CYP21, CA21H;;Cytochrome P450, subfamily XXIA, polypeptide 2 (steroid 21-hydroxylase);613815;F, RE;linked to C2, C4, BF; 2 loci, A and B; only B active; pseudogene CYP21P contiguous on 6p;Adrenal hyperplasia, congenital, due to 21-hydroxylase deficiency, 201910 (3); Hyperandrogenism, nonclassic type, due to 21-hydroxylase deficiency, 201910 (3);17(Cyp21)
6.233;10;26;98;6p21.32;DAXX;;Death-associated protein 6;603186;A;;;
6.234;11;6;00;6p21.33;DDAH2;;Dimethylarginine dimethylaminohydrolase-2;604744;R, A;;;
6.235;9;8;11;6p21.33;DDX39B, BAT1, D6S81E;;DEAD box polypeptide 39Bipt-1;142560;RE;5 BATs in 160kb segment including also TNFA, TNFB;;
6.236;9;18;08;6p21.3;DFNA31;;Deafness, autosomal dominant 31;608645;Fd;between D6S276 and D6S273;Deafness, autosomal dominant 31 (2);
6.237;4;30;09;6p21.33;DHX16, DDX16, DBP2, PRP8;;DEAH (Asp-Glu-Ala-His) box polypeptide 16;603405;R, A;;;
6.238;7;17;01;6p21.33;DOM3Z;;DOM3, C. elegans, homolog of, Z;605996;REc;;;
6.239;4;26;11;6p21.33;DPCR1, C6orf37;;Diffuse panbronchiolitis critical region gene 1;613928;REc;;;
6.240;7;7;17;6p22-p21;DYX2;;Dyslexia, susceptibility to, 2;600202;Fd;?between D6S105 and TNFB;{Dyslexia, susceptibility to, 2} (2);
6.241;6;1;11;6p21.33;EHMT2, GAT8, G9A, NG36;;Euchromatic histone-lysine N-methyltransferase 2;604599;REc;;;
6.242;8;17;16;6p21.32;FKBPL, DIR1, WISP39;;FK506-binding protein-like;617076;REc;;;
6.243;9;10;09;6p21.33;FLOT1;;Flotillin 1;606998;R, REc;;;
6.244;1;29;01;6p21.33;G8;;G8 protein;605447;REc;;;
6.245;9;14;95;6p21.33;GNL1, HSR1;;Guanine nucleotide-binding protein-like 1;143024;REn;;;
6.246;9;8;11;6p21.33;GPANK1, BAT4, D6S54E;;G patch domain- and ankyrin repeats-containing protein 1;142610;RE;;;
6.247;3;7;01;6p21.31;GRM4, MGLUR4;;Glutamate receptor, metabotropic, 4;604100;R;;;
6.248;4;21;97;6p21.33;GTF2H4;;General transcription factor IIH, polypeptide 4;601760;A;;;
6.249;6;7;10;6p21.33;HCP5, 6S2650E;;Major histocompatibility complex, class I, gene P5-1;604676;REc;;;
6.250;6;22;14;6p21.3;HCG8, HCGVIII;;HLA complex group 8;615801;REc;;;
6.251;6;22;14;6p22.1;HCG9, HCGIX, HCGIX4;;HLA complex group 9, noncoding;615797;REc;;;
6.252;4;26;11;6p21.33;HCG22, PBMUCL2;;HLA complex group 22;613918;REc;;;
6.253;3;11;03;6p22.2;HIST1H1A, H1F1;;Histone 1, H1a;142709;Psh, A;;;
6.254;3;11;03;6p22.2;HIST1H1C, H1F2;;Histone 1, H1c;142710;REa, A;;;13(Hist1)
6.255;3;11;03;6p22.2;HIST1H1D, H1F3;;Histone 1, H1d;142210;A, Psh;;;
6.256;6;28;17;6p22.2;HIST1H1E, H1F4, RMNS;;Histone 1, H1e;142220;A;;Rahman syndrome, 617537 (3);
6.257;3;11;03;6p22.2;HIST1H1T, H1FT;;Histone 1, H1t;142712;REc;;;
6.258;2;14;03;6p22.2;HIST1H2AB, H2AFM;;Histone 1, H2ab;602795;REc;;;
6.259;3;11;03;6p22.2;HIST1H2AC, H2AFL;;Histone 1, H2ac;602794;REc;;;
6.260;3;11;03;6p22.2;HIST1H2AD, H2AFG;;Histone 1, H2ad;602792;REn;;;
6.261;3;11;03;6p22.2;HIST1H2AE, H2AFA;;Histone 1, H2ae;602786;REc;;;
6.262;2;14;03;6p22.2;HIST1H2BB, H2BFF;;Histone 1, H2bb;602803;REc;;;
6.263;3;11;03;6p22.2;HIST1H2BC, H2BFL;;Histone 1, H2bc;602847;REc;;;
6.264;3;11;03;6p22.2;HIST1H2BD, H2BFB;;Histone 1, H2bd;602799;REc;;;
6.265;2;14;03;6p22.2;HIST1H2BE, H2BFH;;Histone 1, H2be;602805;REc;;;
6.266;4;3;03;6p22.2;HIST1H2BF, H2BFG;;Histone 1, H2bf;602804;REc;;;
6.267;2;14;03;6p22.2;HIST1H2BG, H2BFA;;Histone 1, H2bg;602798;REc;;;
6.268;3;11;03;6p22.2;HIST1H2BH, H2BFJ;;Histone 1, H2bh;602806;REc;;;
6.269;3;11;03;6p22.2;HIST1H2BI, H2BFK;;Histone 1, H2bi;602807;REc;;;
6.270;3;11;03;6p22.2;HIST1H3A, H3FA;;Histone 1, H3a;602810;REc;;;
6.271;3;11;03;6p22.2;HIST1H3B, H3FL;;Histone 1, H3fl;602819;REc;in major cluster on 6p;;
6.272;3;11;03;6p22.2;HIST1H3C, H3FC;;Histone 1, H3c;602812;REc;;;
6.273;3;11;03;6p22.2;HIST1H3D, H3FB;;Histone 1, H3d;602811;REc;;;
6.274;12;14;01;6p22.2;HIST1H3E, H3FD, H3.1;;Histone 1, H3e;602813;REc;in cluster of 35 histone genes;;
6.275;3;11;03;6p22.2;HIST1H3F;;Histone 1, H3f;602816;REc;;;
6.276;3;11;03;6p22.2;HIST1H3G, H3FH;;Histone 1, H3g;602815;REc;;;
6.277;3;11;03;6p22.2;HIST1H4A, H4FA;;Histone 1, H4a;602822;REc;;;
6.278;3;11;03;6p22.2;HIST1H4B, H4FI;;Histone 1, H4b;602829;REc;;;
6.279;3;11;02;6p22.2;HIST1H4C, H4FG;;Histone 1, H4c;602827;REc;;;
6.280;3;11;03;6p22.2;HIST1H4D, H4FB;;Histone 1, H4d;602823;REc;;;
6.281;3;11;03;6p22.2;HIST1H4E, H4FJ;;Histone 1, H4e;602830;REc;;;
6.282;3;11;03;6p22.2;HIST1H4F, H4FC;;Histone 1, H4f;602824;REc;;;
6.283;3;11;03;6p22.2;HIST1H4G, H4FL;;Histone 1, H4g;602832;REc;;;
6.284;3;11;93;6p22.2;HIST1H4H, H4FH;;Histone 1, H4h;602828;REc;;;
6.285;2;14;03;6p22.1;HIST1H4I, H4FM, H4M;;Histone 1, H4i;602833;A;;;
6.286;9;1;11;6p22.2;HFE, HLA-H, HFE1, MVCD7, TFQTL2;;Hemochromatosis gene;613609;LD, F;;Hemochromatosis, 235200 (3); {Microvascular complications of diabetes 7}, 612635 (3); {Porphyria variegata, susceptibility to}, 176200 (3); {Porphyria cutanea tarda, susceptibility to}, 176100 (3); {Alzheimer disease, susceptibility to}, 104300 (3); [Transferrin serum level QTL2], 614193 (3);13(Mr2, Hfe)
6.287;6;13;11;6p22.1;HLA-A;;Major histocompatibility complex, class I, A;142800;F;;{Hypersensitivity syndrome, carbamazepine-induced, susceptibility to}, 608579 (3);17(H2)
6.288;6;13;11;6p21.33;HLA-B, SPDA1;;Major histocompatibility complex, class I, B;142830;F, REn, Fd;;{Spondyloarthropathy, susceptibility to, 1}, 106300 (3); {Abacavir hypersensitivity, susceptibility to} (3); {Synovitis, chronic, susceptibility to} (3); {Drug-induced liver injury due to flucloxacillin} (3); {Toxic epidermal necrolysis, susceptibility to}, 608579 (3); {Stevens-Johnson syndrome, susceptibility to}, 608579 (3);
6.289;3;16;10;6p21.33;HLA-C, PSORS1;;Major histocompatibility complex, class I, C;142840;F, REn;;{Psoriasis susceptibility 1}, 177900 (3); {HIV-1 viremia, susceptibility to}, 609423 (3);17(H2L)
6.290;5;24;90;6p22.1;HLA-F, HLA-CDA12, HLAF;;Major histocompatibility complex, class I, F;143110;REn, Fd;;;
6.291;1;8;95;6p21.32;HLA-DMA, RING6;;Major histocompatibility complex, class II, DM alpha;142855;D;;;
6.292;1;8;95;6p21.32;HLA-DMB, RING7;;Major histocompatibility complex, class II, DM beta;142856;D;;;
6.293;7;6;95;6p21.32;HLA-DOB;;Major histocompatibility complex, class II, DO beta;600629;RE;;;
6.294;10;23;87;6p21.32;HLA-DPA1, HLADP;;Major histocompatibility complex, class II, DP alpha-1;142880;F, RE;2 different alpha, 2 different beta chains;;
6.295;10;28;93;6p21.32;HLA-DPB1;;Major histocompatibility complex, class II, DP beta-1;142858;F, RE;;{Beryllium disease, chronic, susceptibility to} (3);
6.296;10;31;07;6p21.32;HLA-DQA1, CELIAC1;;Major histocompatibility complex, class II, DQ alpha-1;146880;F, RE;;{Celiac disease, susceptibility to}, 212750 (3);
6.297;10;31;07;6p21.32;HLA-DQB1, CELIAC1;;Major histocompatibility complex, class II, DQ beta-1;604305;REc;;{Creutzfeldt-Jakob disease, variant, resistance to}, 123400 (3); {Multiple sclerosis, susceptibility to, 1}, 126200 (3); {Celiac disease, susceptibility to}, 212750 (3);
6.298;8;28;17;6p21.32;HLA-DRB1, SS1;;Major histocompatibility complex, class II, DR beta-1;142857;F, RE;;{Sarcoidosis, susceptibility to, 1}, 181000 (3); {Multiple sclerosis, susceptibility to, 1}, 126200 (3);
6.299;5;15;89;6p21.32;HLA-DRA;;Major histocompatibility complex, class II, DR alpha;142860;F, RE;1 alpha, 3 different beta chains;;17(H2I)
6.300;10;23;87;6p21.32;HLA-DNA;;Major histocompatibility complex, class II, DN alpha;142930;F, RE;;;
6.301;5;5;09;6p21.3;HLA-DRB3, HLA-DR52;;Major histocompatibility complex, class II, DR beta-3;612735;REn;;;
6.302;4;6;00;6p21.32;HLA-DRB5;;Major histocompatibility complex, class II, DR beta-5;604776;REn;;;
6.303;6;8;89;6p22.1;HLA-E;;Major histocompatibility complex, class I, E;143010;REn;;;
6.304;1;25;05;6p22.1;HLA-G;;HLA-G histocompatibility antigen, class I;142871;REc, RE;;{Asthma, susceptibility to}, 600807 (2);17(Qa)
6.305;2;19;02;6p21.32;HSD17B8, FABGL, D6S2245E, HKE6;;Hydroxysteroid (17-beta) dehydrogenase 8 (Ke6 gene, mouse, homolog of);601417;REl;;;17(Ke6)
6.306;12;18;91;6p21.33;HSPA1A;;Heat-shock 70kD protein-1A;140550;S, REa, A;also 14q22-q24, chr.21, and at least 1 other chromosome;;17(Hsp70)
6.307;1;13;99;6p21.33;HSPA1B;;Heat-shock 70kD protein-1B;603012;REc;;;
6.308;12;18;91;6p21.33;HSPA1L;;Heat-shock 70kD protein-like-1;140559;REn;;;
6.309;10;22;08;6p21.3;IBD3;;Inflammatory bowel disease 3;604519;Fd;;{Inflammatory bowel disease 3} (2);
6.310;6;11;01;6p21.3;IDDM1;;Insulin-dependent diabetes mellitus-1;222100;F, LD;linkage or association, with HLA;{Diabetes mellitus, insulin-dependent-1} (2);
6.311;11;3;98;6p21.33;IER3, DIF2, IEX1, PRG1, GLY96;;Immediate early response-3;602996;A;;;
6.312;4;21;99;6p21.3;IGAD1;;Immunoglobulin A deficiency;137100;Fd;;Immunoglobulin A deficiency (2);
6.313;4;24;88;6p21.3;IGLP1;;Immune response to synthetic polypeptides-1;147080;F;;;
6.314;4;24;88;6p21.3;IGLP2;;Immune response to synthetic polypeptides-2;147090;F;;;
6.315;3;9;92;6p21.3;IGAT;;Immune response to synthetic polypeptide--IRGAT;146820;F;in B/D segment;;
6.316;10;23;87;6p21.3;ISCW;;Immune suppression to streptococcal antigen;146850;H, F;HLA-linked;;
6.317;3;23;09;6p21.32;KIFC1, KNSL2, HSET;;Kinesin family member C1;603763;REc;;;
6.318;1;31;08;6p21.31;LHFPL5, TMHS, DFNB67;;LHFP-like protein 5;609427;H, REc, Fd;;Deafness, autosomal recessive 67, 610265 (3);17(Lhfp15)
6.319;9;10;09;6p21.33;LSM2, C6orf28;;LSM2 protein;607282;R, REc;;;
6.320;1;6;09;6p21.33;LTA, TNFB;;Lymphotoxin alpha (formerly tumor necrosis factor beta);153440;REa, A, RE, Fd;cen-DR-21OH-C4-BF-C2-TNF-LTA-HLA-B;{Myocardial infarction, susceptibility to}, 608446 (3); {Psoriatic arthritis, susceptibility to}, 607507 (3); {Leprosy, susceptibility to, 4}, 610988 (3);17(Tnfb)
6.321;1;27;97;6p21.33;LTB, TNFC;;Lymphotoxin B;600978;REn;;;
6.322;5;24;13;6p21.33;LY6G5B, G5B;;Lymphocyte antigen 6 complex, locus G5B;610433;REc;;;
6.323;5;24;13;6p21.33;LY6G5C, G5C;;Lymphocyte antigen 6 complex, locus G5C;610434;REc;;;
6.324;5;24;13;6p21.33;LY6G6C, G6C;;Lymphocyte antigen 6 complex, locus G6C;610435;REc;;;
6.325;8;28;02;6p21.33;LY6G6D, MEGT1, G6D, C6orf23;;Lymphocyte antigen 6 complex, locus G6D;606038;REn;;;
6.326;5;24;13;6p21.33;LY6G6E, G6E;;Lymphocyte antigen 6 complex, locus G6E;610437;REc;;;
6.327;10;4;05;6p21.33;MCCD1;;Mitochondrial coiled-coil domain 1;609624;REc;;;
6.328;12;14;95;6p21.33;MICA;;MHC class I polypeptide-related sequence A;600169;REn;;;
6.329;3;18;98;6p21.33;MICB;;MHC class I polypeptide-related sequence B;602436;REn;;;
6.330;1;7;95;6p21.31;MLN;;Motilin;158270;REa, A, Fd;;;
6.331;11;4;13;6p21.2;MOCS1, MOCODA;;Molybdenum cofactor synthesis-1;603707;LD, A;;Molybdenum cofactor deficiency A, 252150 (3);
6.332;7;27;15;6p22.1;MOG, NRCLP7;;Myelin-oligodendrocyte glycoprotein;159465;A, REn;60kb telomeric to HLA-F; mutation identified in 1 NRCLP7 family;?Narcolepsy 7, 614250 (3);17(Mog)
6.333;2;26;08;6p21.1;MRPL2;;Mitochondrial ribosomal protein L2;611822;R;;;
6.334;2;26;08;6p21.1;MRPL14, MRPL32;;Mitochondrial ribosomal protein L14;611827;R;;;
6.335;4;24;08;6p21.1;MRPS18A, MRPS18-3;;Mitochondrial ribosomal protein S18A;611981;R, REc;;;
6.336;4;24;08;6p21.33;MRPS18B, MRPS18-2;;Mitochondrial ribosomal protein S18B;611982;REc;pseudogenes on chromosomes 1 and 2;;
6.337;10;18;11;6p21.33;MUC22, PBMUCL1;;Mucin 22;613917;REc;;;
6.338;7;2;02;6p21.3;MYAS1;;Myasthenia gravis with thymus hyperplasia;607085;Fd;;Myasthenia gravis with thymus hyperplasia (2);
6.339;3;20;08;6p21.33;NCR3, 1C7, NKP30, CD337, MALS;;Natural cytotoxicity triggering receptor 3;611550;REc;;{Malaria, mild, susceptibility to}, 609148 (3);
6.340;6;1;99;6p21.33;NEP, EDDR1, NTRK4, TRKE;;Neuroepithelial tyrosine kinase;600408;A;;;17(Nep)
6.341;12;3;03;6p21.33;NEU1, NEU, SIAL1;;Neuraminidase 1 (lysosomal sialidase; sialidase 1);608272;H, F, A;;Sialidosis, type I, 256550 (3); Sialidosis, type II, 256550 (3);17(Neu1)
6.342;3;3;03;6p21.33;NFKBIL1;;Nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor-like 1;601022;REn, Fd;;{Rheumatoid arthritis, susceptibility to}, 180300 (3);
6.343;12;9;91;6p21.1;NFYA;;Transcription factor NF-Y, A subunit;189903;REa, A;;;17(Nfya)
6.344;8;29;91;6p21.3;NKS1, EC1;;Susceptibility to lysis by alloreactive natural killer cells;272370;F;;;17(Hh1)
6.345;12;11;12;6p21.3;MBNP;;Membranous nephropathy, susceptibility to;614692;Fd;;{?Membranous nephropathy, susceptibility to} (2);
6.346;11;4;98;6p21.32;NOTCH4, INT3;;Notch, Drosophila, homolog of, 4;164951;A, REc;;;
6.347;11;3;09;6p21.3;NPCA2;;Nasopharyngeal carcinoma, susceptibility to, 2;161550;Fd;associated with rs2517713 and rs2975042;{Nasopharyngeal carcinoma, susceptibility to, 2} (2);
6.348;7;9;95;6p22.1;OR2H3, OLFR2;;Olfactory receptor, family 2, subfamily H, member 3 (olfactory receptor 2);600578;RE;in class I MHC region;;
6.349;9;10;09;6p21.3;PBC2;;Biliary cirrhosis, primary, 2;613007;Fd;associated with rs2856683;{Biliary cirrhosis, primary, 2} (2);
6.350;9;10;09;6p21.3;PBCA;;Pancreatic beta cell, agenesis of;600089;D;uniparental disomy;?Diabetes mellitus, insulin-dependent, neonatal (2);
6.351;4;10;00;6p21.3;PBLT;;Panbronchiolitis, diffuse;604809;Fd;;Panbronchiolitis, diffuse (2);
6.352;9;12;96;6p21.32;PBX2, HOX12, G17;;Pre-B-cell leukemia transcription factor-2;176311;A;;;
6.353;4;27;12;6p21.3;PDCOS;;Podoconiosis, susceptibility to;614590;Fd;;{Podoconiosis, susceptibility to} (2);
6.354;5;25;13;6p21.33;PPP1R10, PNUTS;;Protein phosphatase 1, regulatory subunit 10;603771;REc;;;
6.355;9;8;11;6p21.33;PRRC2A, BAT2, D6S51E;;Proline-rich coiled-coil protein 2A;142580;RE;;;
6.356;4;19;02;6p21.1;PTCRA;;Pre-T-cell receptor, alpha-chain precursor;606817;A, REc;;;17(Ptcra)
6.357;11;20;98;6p21.32;PHF1;;PHD finger protein-1;602881;A;;;
6.358;9;12;93;6p21.33;POU5F1, OTF3, OCT3;;Pou domain, class 5, transcription factor 1 (octamer-binding transcription factor 3);164177;REa, Fd, A, REn;OTF3L on 12; ?related pseudogene on chr.8;;17(Otf3)
6.359;2;4;02;6p22.1;PPP1R11, TCTEX5;;Protein phosphatase 1, regulatory subunit 11;606670;REc;;;17(Ppp1r11)
6.360;4;27;17;6p21.33;PPP1R18, KIAA1949;;Protein phosphatase 1 regulatory subunit 18;610990;REc;;;
6.361;11;19;98;6p21.32;PPT2;;Palmitoyl-protein thioesterase-2;603298;REc;;;
6.362;7;19;18;6p21.32;PSMB8, LMP7, RING10, JMP, NKJO, ALDD, PRAAS1;;Proteasome subunit, beta type, 8 (large multifunctional protease-7);177046;REn;between TAP1 and TAP2;Proteasome-associated autoinflammatory syndrome 1 and digenic forms, 256040 (3);
6.363;7;19;18;6p21.32;PSMB9, LMP2, RING12, PRAAS3;;Proteasome subunit, beta type, 9;177045;REn;mutation identified in 1 digenic family;?Proteasome-associated autoinflammatory syndrome 3, digenic, 617591 (3);17(Lmp2)
6.364;3;5;98;6p21.32;RAB2L;;RAB2, member RAS oncogene family-like;602306;A;;;
6.365;10;19;88;6p21.33;RDBP;;RD RNA-binding protein;154040;REn;between C4 and BF;;17(rd)
6.366;3;5;98;6p21.32;RING1, RNF1;;RING finger protein-1;602045;REc;;;
6.367;6;10;98;6p21.32;RNF5, RING5;;RING finger protein-5;602677;A, R;;;
6.368;1;2;08;6p21.2;RNF8, KIAA0646;;Ring finger protein 8;611685;R, Psh;;;
6.369;2;28;01;6p22.1;RNF9, RFB30, HERF1;;RING finger protein-9;605701;REc;;;
6.370;4;29;03;6p22.1;RNF39, HZFW, HZF, LIRF;;Ring finger protein 39;607524;REc;;;
6.371;12;14;95;6p21.32;RPS18;;Ribosomal protein S18;180473;REn;;;17(Ke3)
6.372;10;23;87;6p21.3;RWS;;Ragweed sensitivity;179450;F;?linkage or association, with HLA;?Ragweed sensitivity (2);
6.373;3;22;93;6p21.32;RXRB;;Retinoid X receptor, beta;180246;H, REa, Psh, A;;;17(Rxrb)
6.374;7;11;12;6p21.31;SCUBE3;;Signal peptide-, CUB domain-, and EGF-like domains-containing protein 3;614708;REc;;;17(Scube3)
6.375;8;27;15;6p21.33;SEEK1, C6orf16, PSORS1C1;;SEEK1 gene;613525;REc;;;
6.376;8;20;07;6p22.2;SLC17A2, NPT3;;Solute carrier family 17 (sodium phosphate cotransporter), member 2;611049;REc;;;
6.377;2;25;16;6p22.2;SLC17A3, NPT4, UAQTL4, GOUT4;;Solute carrier family 17 (sodium phosphate cotransporter), member 3;611034;REc, Fd;;[Uric acid concentration, serum, QTL4], 612671 (3); {Gout susceptibility 4}, 612671 (3);
6.378;6;1;04;6p21.32;SLC39A7, D6S2244E, HKE4;;Solute carrier family 39 (zinc transporter), member 7 (Ke4 gene, mouse, homolog of);601416;REl;;;17(Ke4)
6.379;8;7;17;6p21.33;SLC44A4, CTL4, C6orf29, DFNA72;;Solute carrier family 44, member 4;606107;REc;mutation identified in 1 DFNA72 family;?Deafness, autosomal dominant 72, 617606 (3);
6.380;8;25;04;6p21.31;SPDEF, PDEF;;SAM pointed domain-containing ETS transcription factor;608144;REc;;;
6.381;5;25;00;6p21.33;STK19;;Serine/threonine protein kinase 19;604977;REc;;;
6.382;3;7;13;6p21.32;SYNGAP1, MRD5;;Synaptic Ras GTPase activating protein 1;603384;REc;;Mental retardation, autosomal dominant 5, 612621 (3);
6.383;10;14;05;6p21.32;TAP1, ABCB2, RING4, PSF1;;Transporter 1, ATP-binding cassette, subfamily B;170260;REn;~7kb telomeric to TAP2;Bare lymphocyte syndrome, type I, 604571 (3);17(Ham1)
6.384;09;11;18;6p21.32;TAP2, ABCB3, PSF2, RING11;;Transporter 2, ATP-binding cassette, subfamily B;170261;REn;tel-TAP1-LMP2-LMP1-TAP2-cen;Bare lymphocyte syndrome, type I, due to TAP2 deficiency, 604571 (3);17(Ham2)
6.385;10;25;02;6p21.32;TAPBP, TPSN;;TAP-binding protein (tapasin);601962;A, REa;;Bare lymphocyte syndrome, type I, 604571 (3);17(Tapbp)
6.386;1;1;96;6p21.33;TCF19, SC1;;Transcription factor-19 (SC1);600912;REc;;;
6.387;8;9;99;6p21.31;TEAD3, TEF5, TEAD5;;TEA domain family member 3 (transcriptional enhancer factor 5);603170;A, R;;;17(Tead3)
6.388;6;23;06;6p21.33;TNF, TNFA;;Tumor necrosis factor (cachectin);191160;REa, A, RE;5'-LTA--TNF-3' in 7kb segment (pter-cen); 210kb from HLA-B;{Malaria, cerebral, susceptibility to}, 611162 (3); {Septic shock, susceptibility to} (3); {Asthma, susceptibility to}, 600807 (3); {Dementia, vascular, susceptibility to} (3); {Migraine without aura, susceptibility to}, 157300 (3);17(Tnfa)
6.389;5;31;18;6p21.33-p21.32;TNXB, TNX, TNXB1, TNXBS, TNXB2, EDSCLL1, VUR8;;Tenascin XB;600985;REn;;Ehlers-Danlos syndrome, classic-like, 1 606408 (3); Vesicoureteral reflux 8, 615963 (3);
6.390;1;7;16;6p21.33;TUBB, TUBB5, M40, CDCBM6, CSCSC1;;Tubulin, beta polypeptide;191130;REa, D;;Cortical dysplasia, complex, with other brain malformations 6, 615771 (3); Symmetric circumferential skin creases, congenital, 1, 156610 (3);
6.391;3;28;11;6p21.31;TULP1, RP14, LCA15;;Tubby-like protein-1;602280;Fd, A;;Retinitis pigmentosa 14, 600132 (3); Leber congenital amaurosis 15, 613843 (3);
6.392;8;20;08;6p22.1;UBD, FAT10;;Ubiquitin D;606050;REc;;;
6.393;12;8;17;6p21.33;VARS, VARS1, G7A, VARS2, NDMSCA;;Valyl-tRNA synthetase;192150;REc;;Neurodevelopmental disorder with microcephaly, seizures, and cortical atrophy, 617802 (3);17(Vars2)
6.394;8;5;14;6p21.33;VARS2, KIAA1885, COXPD20;;Valyl-tRNA synthetase 2;612802;REc;;Combined oxidative phosphorylation deficiency 20, 615917 (3);
6.395;11;19;11;6p21.3;VAMAS6;;Vitiligo-associated multiple autoimmune disease susceptibility 6;193200;Fd;possible second locus on 1p31.3-p32.2;{Vitiligo-associated multiple autoimmune disease susceptibility 6} (2);
6.396;7;18;14;6p21.32;VPS52, SACM2L;;Vacuolar protein sorting 52 homolog (S. cerevisiae);603443;REc;;;
6.397;8;27;15;6p21.32;WDR46, BING4;;WD repeat-containing protein 46;611440;REc;;;
6.398;09;11;18;6p21.3;GPA, WG;;Granulomatosis with polyangiitis;608710;Fd;;Granulomatosis with polyangiitis (2);
6.399;2;28;07;6p21.3;WM1;;Macroglobulinemia, Waldenstrom, susceptibility to, 1;153600;Fd;linked to HLA;{Macroglobulinemia, Waldenstrom, susceptibility to, 1} (2);
6.400;8;27;15;6p21.32;ZBTB22, BING1;;Zinc finger- and BTB domain-containing protein 22;611439;REc;;;
6.401;12;4;95;6p22.1;ZNF173;;Zinc finger protein-173;600830;REn;;;
6.402;10;20;99;6p22.1;ZNF184;;Zinc finger protein-184;602277;REf;;;
6.403;3;5;98;6p22.1;ZNF192;;Zinc finger protein-192;602240;REc;;;
6.404;3;5;98;6p22.1;ZNF193;;Zinc finger protein-193;602246;REc;;;
6.405;11;17;98;6p21.3;ZNF204;;Zinc finger protein-204;603282;A, Psh;?pseudogene;;
6.406;8;26;98;6p21.31;BAK1;;BCL2-antagonist/killer 1;600516;REa, H, REc;centromeric to MHC region;;17(bak)
6.407;9;16;88;6p21.3-p21.2;CP20;;Lymphocyte cytosolic protein, molecular weight 20kD;153380;LD;;;
6.408;5;31;05;6p21.31;FKBP5, FKBP51;;FK506-binding protein 5;602623;REc;;{Major depressive disorder and accelerated response to antidepressant drug treatment}, 608516 (3);
6.409;1;20;11;6p21.2;GLO1;;Glyoxalase I;138750;F, S, Fd;~3cM proximal to HLA;;17(Glo1)
6.410;10;23;87;6p21.3-p21.2;LAP;;Laryngeal adductor paralysis;150270;F;?linkage to HLA and GLO1;?Laryngeal adductor paralysis (2);
6.411;12;4;95;6p21.31;MAPK14, CSBP1;;Mitogen-activated protein kinase 14 (cytokine suppressive anti-inflammatory drug binding protein 1);600289;Psh, A;;;
6.412;5;29;12;6p21.3-p21.2;MPVQTL4;;Mean platelet volume quantitative trait locus 4;614644;Fd;associated with rs210134;Mean platelet volume QTL4 (2);
6.413;11;5;92;6p21.31;TCP11, D6S230E;;T-complex homolog tcp-11;186982;REa, R, A, REc;expressed only in testis at same time as ZNF76 (day 20 after birth);;17(tcp11)
6.414;11;5;92;6p21.31;ZNF76, D6S229E;;Zinc finger protein-76 (expressed in testis);194549;REa, R, A, REc;same 300kb fragment as TCP11;;17(Znf76)
6.415;10;11;99;6p21.33;LST1, D6S49E, B144;;Leukocyte-specific transcript 1 (B144 protein);109170;RE, REn;10kb 3' from TNFA;;
6.416;3;27;90;6p21.1;PGC;;Preprogastricsin;169740;REa, F, REb;cen-PGG-GLO1-HLA;;17(Upg1)
6.417;8;12;91;6p21.1;TCTE1;;T-complex-associated-testis-expressed-1;186975;A, Fd;;;
6.418;3;7;13;6p21.2;AD17;;Alzheimer disease 17;615080;Fd;associated with rs75932628T;Alzheimer disease 17 (2);
6.419;11;20;15;6p21.2;C6orf89, BRAP, AMFION;;Bombesin receptor-activated protein;616642;REc;;;
6.420;2;4;15;6p21.2;CMTR1, MTR1, ISG95, FTSJD2, KIAA0082;;CAP methyltransferase 1;616189;REc, R;;;
6.421;9;10;09;6p21.2;DAAM2, KIAA0381;;Dishevelled-associated activator of morphogenesis 2;606627;R, REc;;;
6.422;11;11;14;6p21.2;FGD2;;FYVE, RhoGEF, and PH domain-containing protein 2;605091;R, H;;;17(Fgd2)
6.423;7;15;09;6p21.2-p21.1;LRFN2, SALM1, KIAA1246;;Leucine-rich repeat and fibronectin type III domain-containing protein 2;612808;R, REc, H;;;17(Lrfn2)
6.424;11;23;16;6p21.2;PANDAR;;Promoter of CDKN1A antisense DNA damage-activated RNA;617179;REn, REc;;;
6.425;11;6;92;6p21.2;PIM1;;Oncogene PIM1;164960;REa, D, Fd;;;17(Pim1)
6.426;10;17;95;6p21.2;CDKN1A, WAF1, CIP1, CDKN1;;Cyclin-dependent kinase inhibitor 1A (p21, Cip1);116899;A;;;17(Waf1)
6.427;9;7;12;6p21.2;MTCH1, PSAP;;Mitochondrial carrier homolog 1;610449;REc, R;;;
6.428;3;29;16;6p21.2;TBC1D22B, C6orf197;;TBC1 domain family, member 22B;616880;REc;;;
6.429;6;2;15;6p21.2;TP53COR1;;Tumor protein p53 pathway corepressor 1, noncoding;616343;REc;;;17(Tp53cor1)
6.430;11;16;18;6p21.1;TREM2, PLOSL2;;Triggering receptor expressed on myeloid cells 2;605086;REa;;Polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy 2, 618193 (3);
6.431;4;30;09;6p12.3;CRISP1, AEGL1;;Cysteine-rich secretory protein 1;601193;A;;;17(Aeg1)
6.432;5;22;18;6p21.1;GTPBP2, JABELS;;GTP-binding protein 2;607434;A, R, REc;;Jaberi-Elahi syndrome, 617988 (3);17(Gtpbp2)
6.433;11;22;02;6p21.2;KCNK16, TALK1;;Potassium channel, subfamily K, member 16;607369;REc;;;
6.434;11;22;02;6p21.2;KCNK17, TASK4, TALK2;;Potassium channel, subfamily K, member 17;607370;REc;;;
6.435;1;16;96;6p12.3;MEP1A;;Meprin A, alpha;600388;REa, R, REc, Fd;;;17(Mep1a)
6.436;9;23;96;6p21.31;PPARD, NUC1;;Peroxisome proliferative activated receptor, delta;600409;Psh, A;;;
6.437;1;29;01;6p21.1;SLC22A7, OAT2;;Solute carrier family 22 (organic anion transporter), member 7;604995;R;;;
6.438;3;5;98;6p21.1;SLC29A1, ENT1;;Solute carrier family 29 (nucleoside transporters), member 1 (equilibrative nucleoside transporter-1);602193;A;;;
6.439;3;6;14;6p21.2;TDRG1, LINC00532;;Testis development-related gene 1, noncoding;615676;REc;;;
6.440;12;23;05;6p21.1;YIPF3, KLIP1;;YIP1 domain family, member 3;609775;R;;;
6.441;10;18;11;6p12.3;PLA2G7, PAFAH, PAFAD;;Phospholipase A2, group VII (platelet-activating factor acetylhydrolase);601690;A;;Platelet-activating factor acetylhydrolase deficiency, 614278 (3); {Asthma, susceptibility to}, 600807 (3); {Atopy, susceptibility to}, 147050 (3);
6.442;2;18;96;6p22.1;ZNF165, LD65;;Zinc finger protein-165;600834;REa, A, REc;;;
6.443;8;11;14;6p21.1;AARS2, KIAA1270, MTALARS, COXPD8, LKENP;;Alanyl-tRNA synthetase 2;612035;R, REc;;Combined oxidative phosphorylation deficiency 8, 614096 (3); Leukoencephalopathy, progressive, with ovarian failure, 615889 (3);
6.444;12;24;08;6p21.1;ABCC10, MRP7;;ATP-binding cassette, subfamily C, member 10;612509;Psh, R, REc, A;;;
6.445;6;18;99;6p21.1;BYSL;;By the ribosomal protein S6 gene, Drosophila, homolog-like (bystin);603871;A;;;
6.446;4;17;14;6p21.1;CUL7, 3M1;;Cullin 7;609577;REa, Fd;;3-M syndrome 1, 273750 (3);
6.447;6;13;12;6p21.1;CUL9, PARC, KIAA0708;;Cullin 9;607489;REc;;;
6.448;6;26;16;6p21.1;ENPP4, NPP4, KIAA0879;;Ectonucleotide pyrophosphatase/phosphodiesterase 4;617000;R, REc;;;
6.449;6;26;16;6p21.1;ENPP5, NPP5;;Ectonucleotide pyrophosphatase/phosphodiesterase 5;617001;REc;;;
6.450;9;15;10;6p21.1;FOXP4;;Forkhead box P4;608924;REc;;;
6.451;4;28;10;6p21.1;GUCA1A, GCAP, COD3, CORD14;;Guanylate cyclase activator 1A, retina;600364;Psh, A;;Cone dystrophy-3, 602093 (3); Cone-rod dystrophy 14, 602093 (3);
6.452;3;24;11;6p21.1;GUCA1B, GCAP2, GUCA2, RP48;;Guanylate cyclase activator 1B, retina;602275;REa, A;;Retinitis pigmentosa 48, 613827 (3);
6.453;9;8;08;6p21.1;HSP90AB1, HSPCB, HSPC2, HSP90B;;Heas-shock protein, 90kD, alpha, class B, member 1;140572;Psh, REn;;;
6.454;8;19;13;6p21.1;KLHDC3, PEAS;;KELCH domain-containing protein 3;611248;REc;;;17(Klhdc3)
6.455;10;09;18;6p21.1;MAD2L1BP;;MAD2L1-binding protein;618136;REc;;;
6.456;7;22;09;6p21.1;MED20, TRFP;;Mediator complex subunit 20;612915;REc;;;
6.457;12;28;08;6p21.1;NCR2, LY95, NKP44;;Natural cytotoxicity triggering receptor 2 (lymphocyte antigen 95, mouse, homolog of);604531;REa, REc;;;17(Ncr2)
6.458;10;18;15;6p21.1;NFKBIE, IKBE;;Nuclear factor of kappa light chain gene enhancer in B cells inhibitor, epsilon;604548;REc;;;
6.459;10;26;15;6p21.1;PEX6, PXAAA1, PAF2, PBD4A, PDB4B, HMLR2;;Peroxisomal biogenesis factor 6 (peroxisomal AAA-type ATPase 1);601498;REa, H, A;;Peroxisome biogenesis disorder 4A (Zellweger), 614862 (3); Peroxisome biogenesis disorder 4B, 614863 (3); Heimler syndrome 2, 616617 (3);17(Pxaaa1)
6.460;5;28;99;6p21.2;PPIL1, CYPL1;;Peptidylprolyl isomerase (cyclophilin)-like 1;601301;A, R;previously assigned to chr.2;;
6.461;5;12;15;6p21.1;PPP2R5D, MRD35;;Protein phosphatase-2, regulatory subunit B (B56), delta isoform;601646;A;;Mental retardation, autosomal dominant 35, 616355 (3);
6.462;11;30;10;6p21.1;PPR1;;Photoparoxysmal response 1;132100;Fd;max lod at D6S2427;Photoparoxysmal response 1 (2);
6.463;4;21;17;6p21.1;RPL7L1;;Ribosomal protein L7-like 1;617417;REc;;;
6.464;9;29;10;6p21.1;RRP36, C6orf153;;Ribosomal RNA-processing factor, 36;613475;REc;;;
6.465;3;19;09;6p21.1;RSPH9, CILD12;;Radial spoke head 9, Chlamydomonas, homolog of;612648;REc;;Ciliary dyskinesia, primary, 12, 612650 (3);
6.466;10;2;12;6p21.1;SRF;;Serum response factor;600589;REc;;;
6.467;11;22;13;6p21.1;SUPT3H, SPT3;;Suppressor of Ty 3, S. cerevisiae, homolog of;602947;REc;;;
6.468;8;18;14;6p21.1;TBCC, CFC;;Tubulin-specific chaperone C;602971;REc;;;
6.469;3;23;09;6p21.1;TJAP1, PILT, TJP4;;Tight junction-associated protein 1;612658;REc;;;
6.470;1;12;15;6p21.1;TOMM6, TOM6;;Translocase of outer mitochondrial membrane 6, yeast, homolog of;616168;REc;;;
6.471;8;19;13;6p21.1;TRERF1, TREP132;;Transcriptional regulating factor 1;610322;REc, R;;;
6.472;12;28;08;6p21.1;TREM1;;Triggering receptor expressed on myeloid cells 1;605085;REa;;;17(Trem1)
6.473;12;28;08;6p21.1;TREML1, TLT1;;Triggering receptor expressed on myeloid cells-like protein 1;609714;REc, H;;;17(Treml1)
6.474;12;28;08;6p21.1;TREML2, TLT2;;Triggering receptor expressed on myeloid cells-like protein 2;609715;REc, H;;;17(Treml2)
6.475;12;28;08;6p21.1;TREML3, TLT3;;Triggering receptor expressed on myeloid cells-like protein 3;609716;REc, H;;;17(Treml3)
6.476;4;1;08;6p21.1;UBR2, C6orf133, KIAA0349;;Ubiquitin-protein ligase E3 component N-recognin 2;609134;R, A, H;;;17(Ubr2)
6.477;4;26;17;6p21.1;UNC5CL, ZUD;;Unc5 family C-terminal-like protein;617464;REc;;;
6.478;12;23;05;6p21.1;XPO5, KIAA1291;;Exportin 5;607845;R, REc;;;
6.479;6;12;17;6p21.1;ZNF318, TZF, ZFP318;;Zinc finger protein 318;617512;REc;;;
6.480;11;24;14;6p21.1;CLIC5, DFNB103;;Chloride intracellular channel 5;607293;REc;mutation identified in 1 DFNB103 family;?Deafness, autosomal recessive 103, 616042 (3);
6.481;4;23;08;6p21.1;MRPS10;;Mitochondrial ribosomal protein S10;611976;REc;5 pseudogenes on chromosomes 1, 3, and 9;;
6.482;7;3;06;6p12.3;TFAP2D, TFAP2BL1;;Transcription factor AP2-delta;610161;REc;;;
6.483;2;21;03;6p21.1-p12.2;MGR3;;Migraine with or without aura, susceptibility to, 3;607498;Fd;lod 5.78 at D6S452;{Migraine with or without aura, susceptibility to, 3} (2);
6.484;6;25;97;6p21.1;PTK7;;PTK7 protein tyrosine kinase 7;601890;REa, A;;;
6.485;4;19;02;6p12.3;PGK2;;Phosphoglycerate kinase-2 (testicular PGK);172270;REa, A, REb;pseudogene on chr.12;;17(Pgk2)
6.486;1;23;01;6p21.1;POLH, XPV;;Polymerase, DNA, eta;603968;R, REa, A;;Xeroderma pigmentosum, variant type, 278750 (3);
6.487;5;7;01;6p12.3;CYP39A1;;Cytochrome P450, subfamily XXXIXA (oxysterol 7-alpha-hydroxylase), polypeptide 1;605994;R;;;17(Cyp39a1)
6.488;5;17;18;6p12.3;RHAG, RH50A, OHST, RHNR;;Rhesus blood group-associated glycoprotein;180297;REa, A;;Anemia, hemolytic, Rh-null, regulator type, 268150 (3); Overhydrated hereditary stomatocytosis, 185000 (3);
6.489;7;19;18;6p21.1;PRPH2, DS, RP7, PRPH, AVMD, AOFMD, CACD2, MDBS1;;Peripherin 2, mouse, homolog of;179605;REa, A;digenic RP with ROM1;Retinitis pigmentosa 7 and digenic form, 608133 (3); Leber congenital amaurosis 18, 608133 (3); Macular dystrophy, patterned, 1, 169150 (3); Retinitis punctata albescens, 136880 (3); Choroidal dystrophy, central areolar 2, 613105 (3); Macular dystrophy, vitelliform, 3, 608161 (3);17(rds)
6.490;1;29;01;6p21.1;APOBEC2;;Apolipoprotein B mRNA editing enzyme, catalytic polypeptide 2;604797;R, H;;;17(Apobec2)
6.491;7;16;09;6p21.2;BTBD9, KIAA1880;;BTB/POZ domain-containing protein 9;611237;REc;;;
6.492;7;12;92;6p21.1;CCND3;;Cyclin D3;123834;REa, A;pseudogene also on 6p21;;
6.493;8;11;98;6p21.1;CDC5L;;Cell division cycle 5, S. pombe, homolog-like;602868;REc, A;;;
6.494;10;20;99;6p21.2;CPNE5, CPN5;;Copine V;604209;REc;;;
6.495;9;5;07;6p21.2;DNAH8, HDHC9;;Dynein, axonemal, heavy chain 8;603337;REc;;;
6.496;8;25;04;6p21;EJM3;;Epilepsy, juvenile myoclonic 3;608816;Fd;;Epilepsy, juvenile myoclonic 3 (2);
6.497;7;22;09;6p21.31;ETV7, TEL2, TELB;;ETS variant gene 7;605255;A, REc;;;
6.498;5;9;95;6p21.2;GLP1R;;Glucagon-like peptide 1 receptor;138032;A;;;17(Glp1r)
6.499;5;23;11;6p21.31;HMGA1, HMGIY;;High-mobility group AT-hook 1;600701;Psh, R;;{Diabetes mellitus, noninsulin-dependent, susceptibility to}, 125853 (3);
6.500;9;30;02;6p21.31;IHPK3, INSP6K3, IP6K3;;Inositol hexaphosphate kinase 3;606993;REc;pseudogene on 6p24.1;;
6.501;6;18;99;6p21.2;KCNK5, TASK2;;Potassium channel, subfamily K, member 5;603493;R;;;
6.502;4;26;11;6p21.2;KIF6;;Kinesin family member 6;613919;REc;;;
6.503;4;29;02;6p21;LATD;;Laterality defects, autosomal dominant;601086;Fd;max lod 2.95 at theta = 0;;
6.504;3;31;09;6p22.1;MAS1L, MRG;;MAS1 oncogene-like;607235;REc;;;
6.505;10;4;05;6p21.2;MDGA1, GPIM;;MAM domain-containing glycosylphosphatidylinositol anchor 1;609626;REc;;;
6.506;7;6;00;6p21.1;MDFI;;MYOD family inhibitor;604971;R;;;17(Mdfi)
6.507;5;31;05;6p12.3;MUT, MCM;;Methylmalonyl Coenzyme A mutase;609058;REa, A, F, D;;Methylmalonic aciduria, mut(0) type, 251000 (3);17(Mut)
6.508;12;27;01;6p21.31;PACSIN1, KIAA1379;;Protein kinase C and casein kinase substrate in neurons 1;606512;R;;;
6.509;7;16;09;6p21;RLS6;;Restless legs syndrome, susceptibility to, 6;611185;Fd;associated with rs9296249 and rs9357271;{Restless legs syndrome 6} (2);
6.510;1;13;09;6p22.1;RPP21;;Ribonuclease P/MRP, 21kD subunit;612524;REc;;;
6.511;3;15;13;6p21.1;RUNX2, CBFA1, PEBP2A1, AML3, CCD, CLCD;;Runt-related transcription factor 2;600211;A, REc, Ch, Fd;;Cleidocranial dysplasia, 119600 (3); Cleidocranial dysplasia, forme fruste, with brachydactyly, 119600 (3); Cleidocranial dysplasia, forme fruste, dental anomalies only, 119600 (3); Metaphyseal dysplasia with maxillary hypoplasia with or without brachydactyly, 156510 (3);17(Cbfa1)
6.512;4;27;12;6p21.33;SKIV2L, SKI2, SKI2W, THES2;;Superkiller viralicidic activity 2, S. cerevisiae, homolog, like;600478;A;;Trichohepatoenteric syndrome 2, 614602 (3);
6.513;12;19;11;6p21.3-p21.2;SRSF3, SFRS3, SRP20;;Splicing factor, arginine/serine-rich, 3;603364;R, REc;;;17(Sfrs3)
6.514;9;10;09;6p21.31;STK38, NDR;;Serine/threonine protein kinase 38;606964;R, REc;;;
6.515;10;1;95;6p21.1;TFEB, TCFEB;;Transcription factor EB;600744;H;;;17(Tcfeb)
6.516;5;29;12;6p21.1;TREML4, TLT4;;Triggering receptor expressed on myeloid cells-like protein 4;614664;REc;;;17(Treml4)
6.517;4;20;17;6p12.3;ADGRF1, GPR110;;Adhesion G protein-coupled receptor F1;617430;REc;;;
6.518;9;1;16;6p12.3;ADGRF4, GPR115;;Adhesion G protein-coupled receptor F4;614268;REc;;;
6.519;10;8;07;6p12.3;CENPQ;;Centromeric protein Q;611506;REc;;;
6.520;7;25;18;6p12.3;CRISP3, SGP28;;Cysteine-rich secretory protein 3;618062;REc;;;
6.521;8;21;12;6p12.3;GLYATL3;;Glycine N-acyltransferase-like 3;614763;REc;;;
6.522;4;6;18;6p12.1;ICK, MRK, KIAA0936, ECO, EJM10;;Intestinal cell kinase;612325;R, REc;;Endocrine-cerebroosteodysplasia, 612651 (3); {Epilepsy, juvenile myoclonic, susceptibility to, 10}, 617924 (3);
6.523;3;7;14;6p12.3;OPN5, GRP136, PGR12;;Opsin 5;609042;REc;;;
6.524;4;21;16;6p12.3;PTCHD4, PTCH53, C6orf138;;Patched domain-containing protein 4;616908;REc;;;
6.525;9;24;08;6p12.3;RCAN2, ZAKI4, DSCR1L1, MCIP2, CSP2;;Regulator of calcineurin 2;604876;R, REc;;;
6.526;7;8;11;6p12.3;SLC25A27, UCP4;;Solute carrier family 25, member 17;613725;REc;;;
6.527;5;26;13;6p12.3;TDRD6;;TUDOR domain-containing protein 6;611200;REc;;;
6.528;10;29;03;6p12.1;LRRC1, LANO;;Leucine-rich repeat-containing protein 1;608195;REc;;;
6.529;8;7;17;6p12.3-p12.2;FCYT, PKHD1, ARPKD, PKD4;;Fibrocystin;606702;Fd, H, REc;;Polycystic kidney disease 4, with or without hepatic disease, 263200 (3);13(Pkhd1)
6.530;3;24;06;6p12.1;COL21A1;;Collagen, type XXI, alpha-1 polypeptide;610002;R, REc;;;
6.531;9;9;08;6p12.1;FBXO9, FBX9;;F-box only protein 9;609091;REc;;;9(Fbxo9)
6.532;3;6;94;6p12.2;GSTA1;;Glutathione S-transferase A1;138359;REn, REc;;;
6.533;12;6;91;6p12.2;GSTA2, GST2;;Glutathione S-transferase A2;138360;A, REa;;;9(Gsta)
6.534;3;11;03;6p12.2;GSTA3;;Glutathione S-transferase, alpha-3;605449;R, REc;;;
6.535;3;11;03;6p12.2;GSTA4;;Glutathione S-transferase, alpha-4;605450;A, REc;;;
6.536;3;10;03;6p12.2;GSTA5;;Glutathione S-transferase, alpha-5;607605;REc;;;
6.537;11;16;98;6p12.2;IL17A, IL17, CTLA8;;Interleukin-17a;603149;A, REc;previously mapped to 2q31;;1(Il17)
6.538;12;12;12;6p12.2;LINCMD1;;Long intergenic noncoding RNA, muscle differentiation 1;614933;REc;;;
6.539;3;20;16;6p12.2;TMEM14A;;Transmembrane protein 14A;616870;REc;;;
6.540;3;23;09;6p12.2;MIR133B, MIRN133B;;Micro RNA 133B;610946;REc;;;
6.541;3;23;09;6p12.2;MIR206, MIRN206;;Micro RNA 206;611599;REc;;;1(Mirn206)
6.542;8;8;13;6p12.2;TRAM2, KIAA0057;;Translocation-associated membrane protein 2;608485;REc, Psh;;;
6.543;11;19;11;6p12.2-q12;MRT24;;Mental retardation, autosomal recessive 24;614345;Fd;between rs651733 and rs1508668;Mental retardation, autosomal recessive 24 (2);
6.544;9;1;09;6p12.1;BMP5;;Bone morphogenetic protein-5;112265;REa, REc;;;
6.545;3;31;15;6p12.1;GCM1, GCMA;;Glial cells missing, Drosophila, homolog of, 1;603715;A, REc;;;
6.546;1;30;18;6p12.1;GFRAL, GRAL;;GDNF family receptor alpha-like protein;617837;REc;;;
6.547;9;27;17;6p12.1;HCRTR2, OX2R;;Hypocretin receptor 2;602393;REc, R;;;
6.548;9;8;11;6p12.1;MLIP, C6orf142;;Muscular LMNA-interating protein;614106;REc;;;
6.549;12;7;04;6p12.2;RN7SK, 7SK;;RNA, 7SK small nuclear;606515;REa;;;
6.550;3;25;14;6p12.1;ZNF451, COASTER;;Zinc finger protein 451;615708;REc;;;
6.551;3;8;07;6p21.1;SLC35B2, PAPST1, SLL;;Solute carrier family 35 (3'-phosphoadenosine 5')-phosphosulfate transporter), member B2;610788;REc;;;
6.552;4;19;12;6p12.2;PAQR8, C6orf33, LMPB1, MPRB;;Progestin and ADIPOQ receptor family, member 8;607780;REn;;;
6.553;1;29;01;6p21.1;CAPN11;;Calpain 11;604822;REa, R;;;
6.554;10;28;08;6p12.3;CD2AP, CMS;;CD2-associated protein;604241;R, REc;;Glomerulosclerosis, focal segmental, 3, 607832 (3);
6.555;4;30;09;6p12.3;CRISP2, TPX1, TSP1;;Cysteine-rich secretory protein 2;187430;REa;;;17(Tpx1)
6.556;5;23;13;6p12.3;DEFB114, DEFB14;;Defensin, beta, 114;615243;REc;;;
6.557;9;20;14;6p12.1;ELOVL5, HELO1, SCA38;;Elongation of very long chain fatty acids-like 5;611805;REc;;Spinocerebellar ataxia 38, 615957 (3);
6.558;1;6;09;6p12.1;GCLC, GLCLC;;Glutamate-cysteine ligase, catalytic subunit;606857;REa, Psh, A, Fd;;Hemolytic anemia due to gamma-glutamylcysteine synthetase deficiency, 230450 (3); {Myocardial infarction, susceptibility to}, 608446 (3);9(Glclc)
6.559;1;24;02;6p21.1;GNMT;;Glycine N-methyltransferase;606628;A;;Glycine N-methyltransferase deficiency, 606664 (3);
6.560;6;22;15;6p12.2;IL17F, ML1, CANDF6;;Interleukin 17F;606496;R;mutation identified in 1 CANDF6 family;?Candidiasis, familial, 6, autosomal dominant, 613956 (3);
6.561;2;7;07;6p12.1;KLHL31, KLHL;;Kelch-like 31;610749;REc, H;;;9(Klhl31)
6.562;11;4;98;6p12.2;MCM3;;Minichromosome maintenance, S. cerevisiae, homolog of, 3;602693;A;;;
6.563;4;16;14;6p12;NYS2, NYSA;;Nystagmus 2, congenital, autosomal dominant;164100;Fd;;Nystagmus 2, congenital, autosomal dominant (2);
6.564;7;14;16;6p12.3;TFAP2B, CHAR, PDA2;;Transcription factor AP-2 beta (activating enhancer-binding protein 2 beta);601601;A, Fd;;Char syndrome, 169100 (3); Patent ductus arteriosus 2, 617035 (3);1(Tfap2b)
6.565;2;18;09;6p21.1;VEGF, MVCD1;;Vascular endothelial growth factor;192240;A;;{Microvascular complications of diabetes 1}, 603933 (3);
6.566;3;3;03;6p12.1;TINAG, TIN1, TIN2;;Tubulointerstitial nephritis antigen;606749;A;;;
6.567;10;1;95;6p11.2;PRIM2A;;Primase polypeptide 2A, 58kD;176636;Psh, A;;;2(Prim2)
6.568;7;30;14;6p12.1;DST, BPAG1, DMH, D6S1101, HSAN6, EBSB2;;Dystonin (bullous pemphigoid antigen 1);113810;A, REa;?mutation identified in 1 HSAN6 family;?Neuropathy, hereditary sensory and autonomic, type VI, 614653 (3); Epidermolysis bullosa simplex, autosomal recessive 2, 615425 (3);1(Bpag1)
6.569;10;6;09;6p12.2;EFHC1, FLJ10466, EJM1, JAE, EJA1;;EF hand domain (C-terminal)-containing 1;608815;REc;;{Myoclonic epilepsy, juvenile, susceptibility to, 1}, 254770 (3); {Epilepsy, juvenile absence, susceptibility to, 1}, 607631 (3);
6.570;7;22;13;6p12-q12;CTRCT28, ARCC1;;Cataract 28;609026;Fd;;{Cataract 28, age-related cortical, susceptibility to} (2);
6.571;5;25;13;6p12.1;BAG2;;BCL2-associated athanogene 2;603882;REc;;;
6.572;10;30;03;6p11;AITD1;;Autoimmune thyroid disease, susceptibility to, 1;608173;Fd;;{Autoimmune thyroid disease, susceptibility to, 1} (2);
6.573;5;31;07;6p12.1-p11.2;RAB23;;Ras-associated protein RAB23;606144;REc, Fd;;Carpenter syndrome, 201000 (3);
6.574;10;23;87;6p;CSCI;;Corticosterone side-chain isomerase;122550;H;?linked to MHC;;
6.575;3;29;10;6p21.31;RPS10, DBA9;;Ribosomal protein S10;603632;R, RE;;Diamond-Blackfan anemia 9, 613308 (3);
6.576;4;14;05;6q;BPPV;;Vertigo, benign paroxysmal positional;193007;Fd;max lod at D6S1556;Vestibulopathy, familial (2);
6.577;8;9;99;6q23.2;RPS12;;Ribosomal protein S12;603660;Psh, R;;;
6.578;8;31;10;6q11-q14;DEL6q11q14, C6DELq11q14;;Chromosome 6q11-q14 deletion syndrome;613544;Ch;contiguous gene deletion syndrome;Chromosome 6q11-q14 deletion syndrome (4);
6.579;5;24;13;6q11.1;KHDRBS2, SLM1;;KH domain-containing, RNA-binding, signal transduction-associated protein 2;610487;REc;;;
6.580;9;30;04;6q12;ADHD3;;Attention deficit-hyperactivity disorder, susceptibility to, 2;608905;Fd;;{Attention deficit-hyperactivity disorder}, 143465 (2);
6.581;9;1;16;6q12-q13;ADGRB3, BAI3;;Adhesion G protein-coupled receptor B3;602684;A;;;
6.582;9;5;03;6q14.1;COX7A2;;Cytochrome c oxidase, subunit VIIa, polypeptide-2, liver;123996;R;previously thought to be on chr.4;;
6.583;11;20;08;6q12;EYS, RP25;;Eyes shut, Drosophila, homolog of;612424;Fd, REc;;Retinitis pigmentosa 25, 602772 (3);
6.584;10;22;18;6q12;GLULD1, LGS;;Glutamate-ammonia ligase (glutamine synthetase) domain-containing 1;611470;R, REc;;;
6.585;10;23;87;6q14.2;ME1;;Malic enzyme, cytoplasmic;154250;S;;;9(Mod1)
6.586;6;27;14;6q14.1;PGM3, AGM1, IMD23;;Phosphoglucomutase-3 (N-acetylglucosamine-phosphate mutase 1);172100;S, F, OT, REa;;Immunodeficiency 23, 615816 (3);9(Pgm3)
6.587;5;22;03;6q12;PHF3, KIAA0244;;PHD finger protein 3;607789;A, R;;;
6.588;3;1;01;6q12;PTP4A1, HH72, PRL1;;Protein tyrosine phosphatase, type 4A, 1;601585;A;;;
6.589;12;4;03;6q13;DDX43, HAGE;;DEAD/H box 43;606286;R;;;
6.590;10;11;07;6q13;RIMS1, RIM1, RIM, KIAA0340, CORD7;;Regulating synaptic membrane exocytosis 1;606629;R, REc, Fd;;Cone-rod dystrophy 7, 603649 (3);
6.591;3;2;01;6q13;COL19A1, D6S228E, COL9A1L;;Collagen XIX, alpha-1 polypeptide;120165;A, REa;;;1(Col19a1)
6.592;11;19;11;6q12-q15;MRT30;;Mental retardation, autosomal recessive 30;614342;Fd;between rs4612125 and rs285651;Mental retardation, autosomal recessive 30 (2);
6.593;1;30;01;6q12-q16;CMD1K;;Cardiomyopathy, dilated, 1K;605582;Fd;;Cardiomyopathy, dilated, 1K (2);
6.594;5;29;91;6q14.3;CGA;;Chorionic gonadotropin, alpha polypeptide;118850;REa, A;shared with LH, FSH, TSH;;4(Tsha)
6.595;1;11;07;6q13;CD109;;CD109 antigen;608859;REc;;;
6.596;12;8;14;6q13;COL9A1, EDM6, STL4;;Collagen IX, alpha-1 polypeptide;120210;A;mutation identified in 1 EDM6 family;?Epiphyseal dysplasia, multiple, 6, 614135 (3); Stickler syndrome, type IV, 614134 (3);1(Col9a1)
6.597;8;22;07;6q13;DPPA5, ESG1;;Developmental pluripotency-associated gene 5;611111;R, REc;;;
6.598;3;3;03;6q13;GLCATS, KIAA1963;;UDP-glucuronyltransferase S;607497;REc;;;1(Glcats)
6.599;8;20;92;6q14.1;HTR1B;;5-hydroxytryptamine (serotonin) receptor-1B;182131;REa, A;;;
6.600;1;2;08;6q13;KHDC1;;KH homology domain-containing protein 1;611688;REc;;;1(Khdc1)
6.601;3;7;13;6q13;KHDC3L, C6orf221, ECAT1, HYDM2;;KH domain containing 3-like, subcortical maternal complex member;611687;REc;;Hydatidiform mole, recurrent, 2, 614293 (3);
6.602;10;17;12;6q13;LMBRD1, LMBD1, NESI, MAHCF;;LMBR1 domain-containing protein 1;612625;REc;;Methylmalonic aciduria and homocystinuria, cblF type, 277380 (3);
6.603;4;6;18;6q13;CGAS, MB21D1, C6orf150;;Cyclic GMP-AMP synthase;613973;REc;;;
6.604;3;23;09;6q13;MIR30A, MIRN30A;;Micro RNA 30A;612329;REc;;;
6.605;7;18;12;6q13;MTO1, COXPD10;;Mitochondrial translation optimization 1, S. cerevisiae, homolog of;614667;REc;;Combined oxidative phosphorylation deficiency 10, 614702 (3);
6.606;1;7;11;6q14.1;MYO6, DFNA22, DFNB37;;Myosin VI;600970;A, H, Fd;;Deafness, autosomal dominant 22, 606346 (3); Deafness, autosomal recessive 37, 607821 (3); Deafness, autosomal dominant 22, with hypertrophic cardiomyopathy, 606346 (3);9(Sv, Myo6)
6.607;1;2;08;6q13;OOEP, KHDC2;;Oocyte-expressed protein, Dog, homolog of;611689;REc;;;9(Ooep)
6.608;12;28;08;6q14.1;SENP6, SSP1, SUSP1;;Sentrin-specific protease family, member 6;605003;REc, R;;;
6.609;4;21;16;6q13;SMAP1;;Small ADP-ribosylation factor GTPase-activating protein 1;611372;REc;;;
6.610;10;15;04;6q14.1;IBTK;;Inhibitor of Bruton agammaglobulinemia tyrosine kinase;606457;R;;;
6.611;4;5;18;6q13-q14;COL12A1, UCMD2, BTHLM2, EDSMYP;;Collagen, type XII, alpha-1;120320;REc;mutation identified in 1 UCMD2 family;?Ullrich congenital muscular dystrophy 2, 616470 (3); Bethlem myopathy 2, 616471 (3);
6.612;12;30;14;6q14.1;IMPG1, IPM150, VMD4;;Interphotoreceptor matrix proteoglycan-1;602870;Psh, A;;Macular dystrophy, vitelliform, 4, 616151 (3);
6.613;12;7;07;6q13-q16.1;OTSC7;;Otosclerosis 7;611572;Fd;between D6S1036 and D6S300;Otosclerosis 7 (2);
6.614;2;2;01;6q14.1;TTK, MPS1L1, PYT;;TTK protein kinase;604092;REa, R;;;
6.615;5;5;09;6q13-q26;SCZD5;;Schizophrenia susceptibility locus, chromosome 6q-related;603175;Fd;max lod at D6S1626 and D6S292;{Schizophrenia}, 181500 (2);
6.616;10;30;06;6q14.1;BCKDHB, E1B;;Branched chain keto acid dehydrogenase E1, beta polypeptide;248611;REa, A, REc;;Maple syrup urine disease, type Ib, 248600 (3);
6.617;8;20;98;6q13;EEF1A1, EF1A;;Eukaryotic translation elongation factor-1, alpha-1;130590;A, Psh;;;
6.618;7;31;17;6q14.1;ELOVL4, ADMD, STGD2, STGD3, ISQMR, SCA34;;Elongation of very long chain fatty acids 4;605512;Fd, REc;;Stargardt disease 3, 600110 (3); Ichthyosis, spastic quadriplegia, and mental retardation, 614457 (3); Spinocerebellar ataxia 34, 133190 (3);
6.619;8;4;17;6q13;KCNQ5, MRD46;;Potassium channel, voltage-gated, KQT-like subfamily, member 5;607357;A;;Mental retardation, autosomal dominant 46, 617601 (3);
6.620;6;1;18;6q14.1;PHIP, DIDOD;;Pleckstrin homology domain-interacting protein;612870;R, REc;;Developmental delay, intellectual disability, obesity, and dysmorphic features, 617991 (3);
6.621;5;3;18;6q14.1;TENT5A, FAM46A, C6orf37, OI18;;Terminal nucleotidyltransferase 5A;611357;REc;;Osteogenesis imperfecta, type XVIII, 617952 (3);9(Fam46a)
6.622;8;19;98;6q15;CNR1;;Cannabinoid receptor-1, brain;114610;Fd, A;;;4(Cnr1)
6.623;3;20;09;6q14.2;CYB5R4, NCB5OR;;Cytochrome b5 reductase 4;608343;REc;;;
6.624;10;13;94;6q14.3;HTR1E;;5-hydroxytryptamine (serotonin) receptor-1E;182132;Psh, A;;;
6.625;12;30;99;6q13;SLC17A5, SIASD, SLD;;Solute carrier family 17 (sodium phosphate), member 5;604322;Fd, LD, REc;;Salla disease, 604369 (3); Sialic acid storage disorder, infantile, 269920 (3);
6.626;8;13;91;6q14.1;TPBG;;Trophoblast glycoprotein;190920;REa;;;
6.627;12;29;06;6q15;ANKRD6, KIAA0957;;Ankyrin repeat domain-containing protein 6;610583;R, REc;;;
6.628;10;5;07;6q14-q16;ATFB2;;Atrial fibrillation, familial, 2;608988;Fd;max lod between D6S286 and D6S1021;Atrial fibrillation, familial, 2 (2);
6.629;6;16;99;6q14-q16.2;PBCRA, CRAPB;;Progressive bifocal chorioretinal atrophy;600790;Fd;;Chorioretinal atrophy, progressive bifocal (2);
6.630;5;22;92;6q15;GABRR1;;Gamma-aminobutyric acid (GABA) A receptor, rho-1;137161;Psh, H;;;4(Gabbr1)
6.631;5;22;92;6q15;GABRR2;;Gamma-aminobutyric acid (GABA) A receptor, rho-2;137162;Psh, H;;;4(Gabbr2)
6.632;7;8;11;6q14.3;NT5E, NT5;;5' nucleotidase, ecto (CD73);129190;S;;Calcification of joints and arteries, 211800 (3);
6.633;2;18;16;6q14.1;DOPEY1, DOP1, KIAA1117;;DOPEY family member 1;616823;R, REc;;;
6.634;10;4;16;6q15;MAP3K7, TAK1, CSCF, FMD2;;Mitogen-activated protein kinase kinase kinase 7;602614;Psh, REc;;Cardiospondylocarpofacial syndrome, 157800 (3); Frontometaphyseal dysplasia 2, 617137 (3);
6.635;9;2;09;6q14.1;FILIP, KIAA1275;;Filamin A-interacting protein;607307;R, REc;;;
6.636;9;10;09;6q14.1;HMGN3, TRIP7;;High-mobility group nucleosomal binding protein 3 (thyroid hormone receptor interactor 7);604502;R, REc;;;
6.637;9;9;13;6q14.1;IRAK1BP1, SIMPL;;Interleukin 1 receptor-associated kinase 1-binding protein 1;615375;REc;;;
6.638;9;10;07;6q14.1;LCA5, C6orf152;;Lebercilin;611408;Fd, REc;;Leber congenital amaurosis 5, 604537 (3);
6.639;9;24;15;6q14.2;RIPPLY2, C6orf59, SCDO6;;Ripply2, zebrafish, homolog of;609891;REc;mutation identified in 1 SCDO6 family;?Spondylocostal dysostosis 6, 616566 (3);
6.640;3;7;14;6q14.1;SH3BGRL2;;SH3 domain-binding glutamic acid-rich protein-like protein 2;615678;REc;;;
6.641;1;9;13;6q14.1;SHFLD2;;Split-hand/foot malformation with long bone deficiency 2;610685;Fd;between rs623155 and rs1547251;Split-hand/foot malformation with long bone deficiency 2 (2);
6.642;5;23;13;5q14.1;TBCA;;Tubulin-specific chaperone A;610058;REc;;;
6.643;8;20;07;6q14.1;TMEM30A, CDC50A;;Transmembrane protein 30A;611028;REc;;;
6.644;12;22;08;6q14.1;UBE2CBP, H10BH;;Ubiquitin-conjugating enzyme E2C-binding protein;612495;REc;;;
6.645;4;29;16;6q14.2;MRAP2, C6orf117, BMIQ18;;Melanocortin 2 receptor accessory protein 2;615410;REc;mutation identified in 1 BMIQ18 individual;{?Obesity, susceptibility to, BMIQ18}, 615457 (3);
6.646;2;25;15;6q14.2;SNAP91, AP180, KIAA0656;;Synaptosomal-associated protein, 91kD;607923;REc, R;;;
6.647;6;4;15;6q14.2-q14.3;CEP162, KIAA1009;;Centrosomal protein, 162kD;610201;R, REc;;;
6.648;5;13;15;6q14.3;SNX14, SCAR20;;Sorting nexin 14;616105;REc;;Spinocerebellar ataxia, autosomal recessive 20, 616354 (3);
6.649;12;9;15;6q14.3;SYNCRIP, NSAP1, GRYRBP, HNRNPQ;;Synaptotagmin-binding cytoplasmic RNA-interacting protein;616686;REc;;;
6.650;12;3;15;6q14.3;TBX18, CAKUT2;;T-box 18;604613;REc;;Congenital anomalies of kidney and urinary tract 2, 143400 (3);
6.651;2;5;15;6q14.3;ZNF292, ZFP292, KIAA0530;;Zinc finger protein 292;616213;REc, R, H;;;4(Znf292)
6.652;4;17;13;6q15;AKIRIN2;;Akirin 2;615165;REc;;;
6.653;11;28;01;6q15;BACH2;;BTB and CNC homology 2;605394;A;;;
6.654;9;1;09;6q15;CASP8AP2, FLASH;;Caspase 8-associated protein 2;606880;R, REc;;;
6.655;4;1;08;6q15;GJA10, CX62;;Gap junction protein, alpha-10;611924;REc;;;
6.656;4;1;08;6q14-q15;GJB7, CX25;;Gap junction protein, beta-7;611921;REc;;;
6.657;11;27;18;6q15;MDN1;;Midasin AAA Atpase 1;618200;REc;;;
6.658;9;10;09;6q15;ORC3, ORC3L, LAT;;Origin recognition complex, subunit 3, S. cerevisiae, homolog of;604972;H, REc;;;4(Orc3)
6.659;8;18;14;6q15;PM20D2, ACY1L2;;Peptidase M20 domain-containing 2;615913;REc;;;
6.660;3;11;08;6q15;PNRC1, PROL2;;Proline-rich nuclear receptor coactivator 1;606714;R, REc;;;
6.661;7;10;07;6q15;SLC35A1, CST, CDG2F;;Solute carrier family 35 (CMP-sialic acid transporter), member 1;605634;R, REc;;Congenital disorder of glycosylation, type IIf, 603585 (3);
6.662;3;4;10;6q14.3;SNHG5, U50HG;;Small nucleolar RNA host gene 5;613263;REc;;;
6.663;11;12;09;6q14.3;SNORD50A, RNU50;;Small nucleolar RNA, C/D box, 50A;613117;REc;;;
6.664;3;4;10;6q14.3;SNORD50B;;Small nucleolar RNA, C/D box;613264;REc;;;
6.665;2;4;15;6q15;UBE2J1, UBC6E;;Ubiquitin-conjugating enzyme E2J 1;616175;REc;;;
6.666;3;6;08;6q15;RRAGD, RAGD;;RAS-related GTP-binding protein D;608268;R, REc;;;
6.667;5;5;09;6q15;SPACA1, SAMP32;;Sperm acrosome-associated 1;612739;REc;;;
6.668;4;22;02;6q16.1;FUT9;;Fucosyltransferase 9;606865;A;;;
6.669;10;7;08;6q16.1;MANEA, ENDO;;Mannosidase, endo-alpha;612327;REc;;;
6.670;5;9;95;6q16.1;POU3F2, OCT7;;POU domain, class 3, transcription factor 2;600494;REa, A;;;4(Pou3f2)
6.671;6;18;99;6q15;RNGTT, HCE1, CAP1A;;RNA guanylyltransferase and 5'-phosphatase;603512;RE, R;;;
6.672;8;19;14;6q16.1;EPHA7, HEK11;;Ephrin receptor EphA7;602190;REc;;;
6.673;10;28;08;6q21;MICAL1, NICAL, MICAL;;Microtubule-associated monooxygenase, calponin and LIM domains-containing 1;607129;R, REc;;;
6.674;2;2;14;6q16.1;MMS22L, C6orf167;;MMS22-like protein;615614;REc;;;
6.675;12;13;18;6q16.1;NDUFAF4, HRPAP20, C6orf66, MC1DN15;;NADH dehydrogenase 1 alpha subcomplex, assembly factor 4;611776;REc, Fd;;Mitochondrial complex I deficiency, nuclear type 15, 618237 (3);
6.676;4;22;15;6q16.1;PNKY;;Long intergenic noncoding RNA Pinky;616328;REc;;;
6.677;10;15;07;6q15;RARS2, RARSL, PCH6;;Arginyl-tRNA synthetase 2;611524;REc, Fd;;Pontocerebellar hypoplasia, type 6, 611523 (3);
6.678;2;4;15;6q16.1;UFL1, KIAA0776, NLBP;;UFM1-specific ligase 1;613372;R, REc;;;
6.679;11;1;13;6q16.1-q16.2;FBXL4, FBL4, MTDPS13;;F-box and leucine-rich repeat protein 4;605654;REc;;Mitochondrial DNA depletion syndrome 13 (encephalomyopathic type), 615471 (3);4(Fbxl4)
6.680;2;2;10;6q16.1;FHL5, ACT;;Four-and-a-half LIM domains 5;605126;REc, A;;;
6.681;5;13;02;6q16.1;GPR63;;G protein-coupled receptor 63;606915;REc;;;
6.682;3;3;16;6q16.2;DHS6S1, MCDR1;;DNase1 hypersensitivity, chromosome 6, site 1;616842;REn, Fd;upstream of PRDM13 and CCNC;Macular dystrophy, North Carolina type, 136550 (3);
6.683;11;20;15;6q16.2;PNISR, SRRP130, SFRS18;;PNN-interacting serine/arginine-rich protein;616653;REc;;;
6.684;1;8;16;6q16.2;PRDM13;;PR domain-containing protein 13;616741;REc;;;
6.685;7;18;01;6q16.2;MCHR2, MCH2R, SLT, MCH2;;Melanin-concentrating hormone receptor 2;606111;REc, R, A;;;
6.686;12;19;18;6q16.2-q22.1;LMPHM2;;Lymphatic malformation 2;611944;Fd;max lod at D6S1671;Lymphatic malformation 2 (3);
6.687;9;8;11;6q16.3;ASCC3, p200;;Activating signal cointegrator 1 complex, subunit 3;614217;REc;;;
6.688;4;5;00;6q16.3;SIM1;;Single-minded, Drosophila, homolog of, 1;603128;A, R, Ch;;Obesity, severe, 601665 (3);10(Sim1)
6.689;9;11;12;6q16.3-q22.31;GEFSP8;;Generalized epilepsy with febrile seizures plus, type 8;613828;Fd;between D6S962 and D6S287;Epilepsy, generalized, with febrile seizures plus, type 8 (2);
6.690;4;26;17;6q21;AFG1L, AFG1, LACE1;;AFG1-like ATPase;617469;REc;;;
6.691;7;11;97;6q21;AIM1, ST4;;Absent in melanoma 1;601797;M, A;;;10(Aim1)
6.692;9;9;13;6q21;AK9;;Adenylate kinase 9;615358;REc;;;
6.693;7;24;17;6q21;ATG5, APG5, APG5L, ASP, SCAR25;;Autophagy 5, S. cerevisiae, homolog of;604261;A;mutation identified in one SCAR25 family;?Spinocerebellar ataxia, autosomal recessive 25, 617584 (3);
6.694;5;19;15;6q21;BEND3, KIAA1553;;BEN domain-containing protein 3;616374;Psh, REc;;;
6.695;4;10;90;6q21;BKMA1;;Banded krait minor satellite DNA-1;109780;A;related to heterogametic sex;;17(Bkma1)
6.696;09;27;18;6q21;BVES, HBVES, POPDC1, CARICK;;Blood vessel epicardial substance;604577;REc;mutation identified in 1 CARICK family;?Cardiac arrhythmia with increased serum creatine kinase, 616812 (3);
6.697;7;10;95;6q16.2;CCNC;;Cyclin C;123838;A;;;
6.698;9;7;12;6q21;CD24;;CD24 antigen;600074;A, Psh;pseudogenes at 15q21-q22; Yq11;;
6.699;6;2;16;6q21;CD164, DFNA66;;CD164 antigen;603356;REc;mutation identified in 1 DFNA66 family;?Deafness, autosomal dominant 66, 616969 (3);
6.700;7;18;12;6q21;CDK19, KIAA1028;;Cyclin-dependent kinase 19;614720;REc, R;;;
6.701;8;8;13;6q21;DDO, DASOX;;D-aspartate oxidase;124450;REc;;;
6.702;2;25;16;6q21;FIG4, KIAA0274, SAC3, ALS11, YVS, BTOP;;Fig4, S. cerevisiae, homolog of;609390;R, REc, Fd;mutation identified in 1 BTOP family;Charcot-Marie-Tooth disease, type 4J, 611228 (3); Amyotrophic lateral sclerosis 11, 612577 (3); Yunis-Varon syndrome, 216340 (3); ?Polymicrogyria, bilateral temporooccipital, 612691 (3);
6.703;9;9;08;6q21;FOXO3A, FOXO3, FKHRL1;;Forkhead box O3A;602681;A;;;
6.704;1;4;93;6q21;FYN;;FYN oncogene related to SRC, FGR, YES;137025;REa, A;proximal 6q21;;10(Fyn)
6.705;4;30;15;6q22.1;GOPC, PIST, FIG, CAL;;Golgi-associated PDZ and coiled-coil domains-containing protein;606845;REc;;;
6.706;10;15;07;6q16.3;GRIK2, GLUR6, MRT6;;Glutamate receptor, ionotropic, kainate 2;138244;REa, R, Fd;;Mental retardation, autosomal recessive, 6, 611092 (3);
6.707;2;11;08;6q21;GTF3C6, C6orf51;;General transcription factor 3C, polypeptide 6;611784;REc;;;
6.708;2;5;16;6q16.3;HACE1, KIAA1320, SPPRS;;HECT domain- and ankyrin repeat-containing E3 ubiquitin protein ligase 1;610876;REc;;Spastic paraplegia and psychomotor retardation with or without seizures, 616756 (3);
6.709;1;8;01;6q21;HDAC2;;Histone deacetylase 2;605164;Psh, A;;;10(Hdac2)
6.710;2;13;06;6q22.31;HEY2, HERP1, GRL;;Hairy/enhancer of split-related with YRPW motif 2;604674;A, R;;;
6.711;10;4;01;6q21;HTX3;;Heterotaxy, visceral, 3, autosomal;606325;Ch;;?Heterotaxy, visceral, 3, autosomal (2);
6.712;12;9;98;6q21;IDDM15;;Insulin-dependent diabetes mellitus-15;601666;Fd;;{Diabetes mellitus, insulin-dependent, 15} (2);
6.713;5;24;13;6q21;LAMA4, LAMA3, CMD1JJ;;Laminin, alpha-4;600133;A, REb;;Cardiomyopathy, dilated, 1JJ, 615235 (3);
6.714;7;23;09;6q21;LGV2;;Longevity 2;606460;Fd;associated with rs2802292;[Longevity 2] (2);
6.715;8;20;07;6q16-q21;LIN28B;;Lin28, C. elegans, homolog of, B;611044;REc, H;;;6(Lin28b)
6.716;1;31;11;6q21;MCOPS8, MMEP;;Microphthalmia, syndromic 8;601349;Ch;translocation with 13q12;Microphthalmia, syndromic 8 (2);
6.717;7;20;09;6q21;MENAQ2;;Menarche, age at, QTL2;612882;Fd;associated with rs7759938;{Menarche, age at, QTL2} (2);
6.718;2;2;17;6q21;MFSD4B, NAGLT1, Kiaa1919;;Major facilitator superfamily domain-containing protein 4B;617331;REc;;;
6.719;5;14;09;6q22.31;NKAIN2, TCBA;;Na+/K+ transporting ATPase interacting 2;609758;REc, Ch;fused with SUSP1 in T-cell lymphoma/leukemia;;
6.720;6;4;99;6q21;NR2E1, TLX;;Nuclear receptor subfamily 2, group E, member 1 (tailless, Drosophila, homolog of);603849;REc;;;
6.721;10;3;07;6q21;OSTM1, GL, OPTB5;;Osteopetrosis associated transmembrane protein 1 (grey-lethal, mouse, homolog of);607649;REc;;Osteopetrosis, autosomal recessive 5, 259720 (3);
6.722;5;24;12;6q21;PDSS2, DLP1, C6orf210, COQ10D3;;Prenyl diphosphate synthase, subunit 2;610564;REc;;Coenzyme Q10 deficiency, primary, 3, 614652 (3);
6.723;10;14;09;6q21;POPDC3, POP3;;Popeye domain-containing protein 3;605824;R, REc;;;
6.724;11;23;16;6q21;QRSL1, GATA;;Glutaminyl-tRNA synthase (glutamine-hydrolyzing)-like protein 1;617209;REc;;;
6.725;12;27;16;6q21;REV3L, POLZ, REV3;;Rev-3, yeast, homolog-like (polymerase, DNA, zeta);602776;REn;;;
6.726;1;6;16;6q21;RTN4IP1, NIMP, OPA10;;Reticulon 4-interacting protein 1;610502;REc;;Optic atrophy 10 with or without ataxia, mental retardation, and seizures, 616732 (3);
6.727;7;22;16;6q21;SEC63, PCLD2;;Sec63, S. cerevisiae, homolog of;608648;A;;Polycystic liver disease 2, 617004 (3);
6.728;1;11;07;6q21;SESN1, SEST1, PA26;;Sestrin 1;606103;REa, A, Ch;;;4(Pa26)
6.729;3;22;07;6q21;SLC22A16, FLIPT2, CT2;;Solute carrier family 22 (organic cation transporter), member 16;608276;REc, A;;;
6.730;11;27;18;6q21;SMPD2, NSMASE1;;Sphingomyelin phosphodiesterase 2;603498;REc;;;
6.731;7;25;06;6q21;SNX3;;Sorting nexin 3;605930;R, REc, Ch;t(6;13)(q21;q12);;
6.732;12;16;10;6q21;SOBP, JXC1, MRAMS;;Sine oculis-binding protein, Drosophila, homolog of;613667;REc;;Mental retardation, anterior maxillary protrusion, and strabismus, 613671 (3);
6.733;11;15;13;6q21;TRAF3IP2, C6orf5, ACT1, CIKS, C6orf4, C6orf6, PSORS13, CANDF8;;TRAF3-interacting protein 2;607043;REc;mutation identified in 1 family with CANDF8;{Psoriasis susceptibility 13}, 614070 (3); ?Candidiasis, familial, 8, 615527 (3);
6.734;7;22;09;6q21;TUBE1, TUBE;;Tubulin, epsilon-1;607345;REc;;;
6.735;3;24;06;6q22.1;VGLL2, VGL2, VITO1;;Vestigial-like 2;609979;REc;;;
6.736;7;1;11;6q21;ZBTB24, PATZ2, ZNF450, KIAA0441, ICF2;;Zinc finger- and BTB domain-containing protein 24;614064;R, REc;;Immunodeficiency-centromeric instability-facial anomalies syndrome 2, 614069 (3);
6.737;11;20;95;6q21;AMD1;;S-adenosylmethionine decarboxylase-1;180980;REa;pseudogene AMD2 on Xq28;;
6.738;8;18;04;6q21-q22;PLF;;Pulmonary function;608852;Fd;close to D6S281;{Pulmonary function} (2);
6.739;2;28;03;6q21;SLC16A10, TAT1;;Solute carrier family 16 (monocarboxylic acid transporter), member 10;607550;R, A;;;
6.740;11;13;17;6q21;WASF1, WAVE, WAVE1, SCAR1;;WAS protein family member 1;605035;R, A;;;
6.741;6;12;95;6q21;GPR6;;G protein-coupled receptor-6;600553;A;;;
6.742;6;18;99;6q21;PRDM1, BLIMP1;;PR domain-containing protein 1 (B-lymphocyte-induced maturation protein 1);603423;REc, Psh;;;10(Blimp1)
6.743;8;9;99;6q22.1;COL10A1;;Collagen X, alpha-1 polypeptide;120110;REa, A;;Metaphyseal chondrodysplasia, Schmid type, 156500 (3);10(Col10a1)
6.744;1;7;02;6q22.1;FRK, RAK, GTK;;FYN-related kinase;606573;REc;;;
6.745;8;11;91;6q24.1;NMBR;;Neuromedin B receptor;162341;Psh;;;
6.746;11;8;17;6q22.1;DSE, SART2, EDSMC2;;Dermatan sulfate epimerase;605942;REc;;Ehlers-Danlos syndrome, musculocontractural type 2, 615539 (3);
6.747;9;28;00;6q23.2;ENPP3, PDNP3;;Ectonucleotide pyrophosphatase/phosphodiesterase 3;602182;A;;;
6.748;9;10;09;6q22.31;MAN1A1;;Mannosidase, alpha, class 1A, member 1;604344;REc;;;
6.749;12;07;07;6q23.3;MYB;;Avian myeloblastosis viral (v-myb) oncogene homolog;189990;REa, A, Ch;;{T-cell acute lymphoblastic leukemia} (3);10(Myb)
6.750;2;10;97;6q21;PREP;;Prolyl endopeptidase;600400;A;;;
6.751;1;4;93;6q22.1;ROS1, MCF3;;Avian UR2 sarcoma virus oncogene (v-ros) homolog 1;165020;REa, A;;;10(Ros1)
6.752;2;17;09;6q23.3;BCLAF1, BTF, KIAA0164;;BCL2-associated transcription factor 1;612588;R, REc;;;
6.753;7;2;14;6q23.2;ENPP1, PDNP1, NPPS, M6S1, PCA1, ARHR2, COLED;;Ectonucleotide pyrophosphatase/phosphodiesterase 1 (Ly-41 antigen, mouse, homolog of);173335;A, H;;{Diabetes mellitus, non-insulin-dependent, susceptibility to}, 125853 (3); {Obesity, susceptibility to}, 601665 (3); Arterial calcification, generalized, of infancy, 1, 208000 (3); Hypophosphatemic rickets, autosomal recessive, 2, 613312 (3); Cole disease, 615522 (3);10(Ly41, Pca1)
6.754;11;3;98;6q23.1-q23.2;EPB41L2;;Erythrocyte membrane protein band 4.1-like 2;603237;A;;;
6.755;3;18;10;6q22.31;FABP7, FABPB, BLBP;;Fatty acid-binding protein 7;602965;REc;;;
6.756;1;7;14;6q22-q23;IGAN1;;IgA nephropathy, susceptibility to, 1;161950;Fd;;{IgA nephropathy, susceptibility to, 1} (2);
6.757;10;09;18;6q22.33;LAMA2, LAMM, MDC1A;;Laminin, alpha-2 (merosin);156225;REa, A, Fd;;Muscular dystrophy, limb-girdle, autosomal recessive 23, 618138 (3); Muscular dystrophy, congenital, merosin deficient or partially deficient, 607855 (3);10(dy, Lamm)
6.758;4;17;00;6q22-q23;SM2;;Hepatic fibrosis susceptibility due to Schistosoma mansoni infection;604201;Fd;?polymorphism of INFGR1;{Hepatic fibrosis susceptibility due to Schistosoma mansoni infection} (2);
6.759;10;15;13;6q22.31;TRDN, TDN, CPVT5;;Triadin;603283;A;;Ventricular tachycardia, catecholaminergic polymorphic, 5, with or without muscle weakness, 615441 (3);
6.760;7;19;04;6q22.1;TSPYL1, TSPYL, SIDDT;;Y-encoded testis-specific protein-like;604714;REa, A, H;;Sudden infant death with dysgenesis of the testes syndrome, 608800 (3);10(Tspyl)
6.761;8;19;04;6q21;WISP3, PPAC, PPD;;Wnt-1 inducible signaling pathway protein 3;603400;R, A, Fd;;Arthropathy, progressive pseudorheumatoid, of childhood, 208230 (3); Spondyloepiphyseal dysplasia tarda with progressive arthropathy, 208230 (3);
6.762;6;7;10;6q22.33;ARHGAP18;;RHO GTPase-activating protein 18;613351;REc;;;
6.763;8;9;05;6q22-q24;FEB5;;Febrile seizures, familial, 5;609255;Fd;between D6S1572 and D6S472;Febrile seizures, familial, 5 (2);
6.764;6;27;08;6q22-q24;FIQTL1;;Fasting insulin level quantitative trait locus 1;606035;Fd;max lod at D6S1569;[Fasting insulin level quantitative trait locus 1] (2);
6.765;10;18;00;6q23.3;MAP7, EMAP115;;Microtubule-associated protein-7;604108;H;;;10(Map7)
6.766;9;8;11;6q22.1;BET3L, TRAPPC3L;;Bet3, S. cerevisiae, homolog-like;614137;REc;;;
6.767;5;21;03;6q21;CDC40, PRP17;;Cell division cycle 40, S. cerevisiae, homolog of;605585;REn;;;
6.768;1;20;17;6q22.1;FAM26F, INAM;;Family with sequence similarity 26, member F;617305;REc;;;
6.769;4;25;14;6q22.1;KPNA5;;Karyopherin alpha-5;604545;REc;;;
6.770;4;11;11;6q22.31;PLN, PLB, CMD1P, CMH18;;Phospholamban;172405;REc, A;;Cardiomyopathy, dilated, 1P, 609909 (3); Cardiomyopathy, hypertrophic, 18, 613874 (3);
6.771;3;19;09;6q22.1;RSPH4A, CILD11;;Radial spoke head 4, Chlamydomonas, homolog of, A;612647;REc;;Ciliary dyskinesia, primary, 11, 612649 (3);
6.772;8;17;15;6q22.31;MCM9, MCMDC1, ODG4;;Minichromosome maintenance complex component 9;610098;REc;;Ovarian dysgenesis 4, 616185 (3);10(Mcm9)
6.773;8;18;08;6q22.33;RNF146;;Ring finger protein 146;612137;REc;;;
6.774;6;29;94;6q21;MRACKS, MACS, PKCSL;;Myristoylated alanine-rich protein kinase C substrate (MARCKS, 80K-L);177061;REb, REa;monomorphic;;10(Macs)
6.775;4;16;14;6q22.1;RFX6, RFXDC1, MTCHRS;;Regulatory factor X, 6;612659;REc;;Mitchell-Riley syndrome, 615710 (3);
6.776;5;26;13;6q22.33;RSPO3, PWTSR, CRISTIN1;;R-spondin family member 3;610574;REc;;;10(Rspo3)
6.777;5;20;99;6q22.33;PTPRK;;Protein-tyrosine phosphatase, receptor type, kappa;602545;REa, A, REc;;;10(Ptprk)
6.778;4;20;10;6q23.2;C6orf192;;Chromosome 6 open reading frame 192;613361;REc;;;
6.779;8;23;05;6q22.31;HSF2;;Heat-shock transcription factor 2;140581;R, REc;;;
6.780;2;3;05;6q22.31;ASF1A, CIA;;Anti-silencing function 1, S. cerevisiae, homolog of, A;609189;REc;;;
6.781;5;11;16;6q22.31;CLVS2;;Clavesin 2;616945;REc;;;
6.782;6;30;05;6q21-q22;HS3ST5, 3OST5;;Heparan sulfate 3-O-sulfotransferase 5;609407;REc;;;
6.783;1;22;18;6q22.1;NUS1, NGBR, C6orf68, CDG1AA, MRD55;;Nuclear undecaprenyl pyrophosphate synthase 1, S. cerevisiae, homolog of;610463;REc;mutation identified in 1 CDG1AA family;?Congenital disorder of glycosylation, type 1aa, 617082 (3); Mental retardation, autosomal dominant 55, with seizures, 617831 (3);
6.784;9;10;09;6q22.31;PKIB;;Protein kinase, cAMP-dependent catalytic, inhibitor beta;606914;R, REc;;;
6.785;4;2;12;6q22.31;SERINC1, TMS2, KIAA1253;;Serine incorporator 1;614548;REc;;;
6.786;1;29;07;6q22.31;SMPDL3A, ASML3A;;Sphingomyelin phosphodiesterase, acid-like, 3A;610728;REc, R;;;
6.787;7;3;14;6q22.31;TBC1D32, BROMI;;TBC1 domain family, member 32;615867;REc;;;10(Tbc1d32)
6.788;5;25;13;6q22.31;TPD52L1, D53;;Tumor protein D52-like 1;604069;REc, A;;;10(Tdp52l1)
6.789;4;6;13;6q22.32;CEMPW, C6orf173, CUG2;;Centromeric protein W;611264;REc;;;
6.790;8;18;08;6q22.33;ECHDC1;;Enoyl coenzyme A hydratase domain-containing protein 1;612136;REc;;;
6.791;3;24;06;6q22.32;HINT3;;Histidine triad nucleotide-binding protein 3;609998;REc;;;
6.792;6;23;99;6q23.3;MAP3K5, MEKK5, MAPKKK5, ASK1;;Mitogen-activated protein kinase kinase kinase 5;602448;R;;;
6.793;12;23;05;6q22.31-q22.32;NCOA7, ERAP140;;Nuclear receptor coactivator 7;609752;REc;;;
6.794;1;27;11;6q22.33;THEMIS, GASP, SPOT, C6orf190;;Thymocyte-expressed molecule involved in selection;613607;REc;;;10(Themis)
6.795;11;13;07;6q22.3-q23.1;HBFQTL2, FCP;;Fetal hemoglobin quantitative trait locus 2;142470;Fd;;Fetal hemoglobin quantitative trait locus 2 (2);
6.796;10;9;96;6q25.1;PCMT1;;Protein-L-isoaspartate (D-aspartate) O-methyltransferase;176851;REa, A;;;10(Pcmt1)
6.797;12;3;03;6q23.2;ARG1;;Arginase, liver;608313;REa;;Argininemia, 207800 (3);
6.798;4;4;11;6q23;CMD1F, CDCD3, LGMD1D;;Cardiomyopathy, dilated-1F, autosomal dominant;602067;Fd;;Cardiomyopathy, dilated, 1F and limb-girdle muscular dystrophy type 1D (2);
6.799;5;24;18;6q23.2;EYA4, DFNA10, CMD1J;;Eyes absent, Drosophila, homolog of, 4;603550;R, Fd, A;mutation identified in 1 CMD1J family;Deafness, autosomal dominant 10, 601316 (3); ?Cardiomyopathy, dilated, 1J, 605362 (3);
6.800;3;15;10;6q23;HCHGQ1;;Hematocrit/hemoglobin quantitative trait locus 1;609319;Fd;;[Hematocrit/hemoglobin quantitative trait locus 1] (2);
6.801;3;19;01;6q23.3;IL20RA;;Interleukin 20 receptor, alpha;605620;REc;;;
6.802;2;25;12;6q23;RP63;;Retinitis pigmentosa 63;614494;Fd;between D6S457 and D6S1656;Retinitis pigmentosa 63 (2);
6.803;1;31;08;6q23;RA;;Rheumatoid arthritis, susceptibility to;180300;REc;associated with SNP rs10499194 and rs6920220;{Rheumatoid arthritis, susceptibility to} (2);
6.804;1;13;99;6q23.2;SGK1;;Serum/glucocorticoid-regulated kinase 1;602958;A;;;
6.805;10;30;08;6q23;SLEB13;;Systemic lupus erythematosus, susceptibility to, 13;612378;Fd;associated with rs5029939;{Systemic lupus erythematosus, susceptibility to, 13} (2);
6.806;7;13;98;6q22.31;STL;;Six-twelve leukemia gene;602532;REc;;;
6.807;1;13;16;6q23.3;TNFAIP3, A20, OTUD7C, AISBL;;Tumor necrosis factor-alpha-induced protein 3;191163;REc;;Autoinflammatory syndrome, familial, Behcet-like, 616744 (3);
6.808;6;17;16;6q24.2;HIVEP2, MRD43;;Human immunodeficiency virus type I enhancer-binding protein-2;143054;REa, A;;Mental retardation, autosomal dominant 43, 616977 (3);
6.809;5;2;08;6q23-q24;MAFD6, BPAD;;Major affective disorder 6;611536;Fd;;{Major affective disorder 6} (2);
6.810;3;5;98;6q23-q24;NTT;;Noncoding transcript in T cells;602154;A;;;
6.811;12;21;09;6q23.3;PBOV1, UROC28, UC28;;Prostate and breast cancer overexpressed 1;605669;A;;;
6.812;11;23;98;6q23.2;TCF21, POD1;;Transcription factor-21 (epicardin; podocyte-expressed 1);603306;H;;;10(Tcf21)
6.813;12;17;07;6q23.2;VNN1, HDLCQ8;;Vanin 1;603570;A, H, Psh;;[High density lipoprotein cholesterol level QTL 8] (3);10(Vnn1)
6.814;6;18;99;6q23.2;VNN2;;Vanin 2;603571;A, Psh, REc;;;
6.815;2;20;02;6q23.2;VNN3;;Vanin 3;606592;REc;;;10(Vnn3)
6.816;4;27;12;6q23-q24.1;SPG25;;Spastic paraplegia 25, autosomal recessive, with disc herniation;608220;Fd;;Spastic paraplegia 25, autosomal recessive (2);
6.817;10;08;08;6q23-q25;BMIQ3;;Body mass index quantitative trait locus 3;607446;Fd;max lod at D6S305;[Body mass index QTL3] (2);
6.818;9;22;04;6q23-q25;LNCR1;;Lung cancer 1;608935;Fd;max hlod at D6S2436;{Lung cancer susceptibility} (2);
6.819;7;11;93;6q23.2;CTGF, NOV2;;Connective tissue growth factor;121009;REa, A;proximal to MYB;;
6.820;7;1;05;6q23.2;TAAR1, TA1;;Trace amine-associated receptor 1;609333;R, REc;;;10(Taar1)
6.821;11;2;04;6q23.2;MOXD1, MOX;;Monooxygenase, DBH-like, 1;609000;R, REc;;;
6.822;3;27;18;6q24.1;REPS1, NBIA7;;RALBP1-associated EPS domain-containing protein 1;614825;REc;mutation identified in 1 NBIA7 family;?Neurodegeneration with brain iron accumulation 7, 617916 (3);
6.823;9;1;09;6q23.3;ALDH8A1, ALDH12;;Aldehyde dehydrogenase 8 family, member A1;606467;R, REc;;;
6.824;5;28;02;6q23.2;GPR102, TA5;;G protein-coupled receptor 102;606927;REc, R;;;
6.825;9;26;11;6q23.2;MED23, MRT18;;Mediator complex subunit 23;605042;REc;;Mental retardation, autosomal recessive 18, 614249 (3);
6.826;2;28;03;6q23.2;PNR;;Putative neurotransmitter receptor;607405;A, REc;;;
6.827;8;19;13;6q23.2;SLC2A12, GLUT12;;Solute carrier family 2 (facilitated glucose transporter), member 12;610372;REc, R;;;10(Slc2a12)
6.828;9;22;04;6q23.2;STX7;;Syntaxin 7;603217;REa, REc;;;
6.829;12;5;03;6q23.2;TAR3, TA3;;Trace amine receptor 3;608282;R;;;
6.830;10;24;14;6q23.2;TARID;;TCF21 antisense RNA inducing promoter demethylation;616058;REc;;;
6.831;5;5;09;6q23.2;TAAR6, TRAR4;;Trace amine-associated receptor 6;608923;REc;;;
6.832;9;15;04;6q23.3;AHI1;;Abelson helper integration site 1;608894;Fd, REc, R;;Joubert syndrome 3, 608629 (3);
6.833;1;18;12;6q24.1;CITED2, MRG1, P35SRJ, VSD2, ASD8;;CBP/p300-interacting transactivator, with glu/asp-rich C-terminal domain, 2;602937;REc;?pseudogene on 1q22;Ventricular septal defect 2, 614431 (3); Atrial septal defect 8, 614433 (3);
6.834;9;22;14;6q23.3;IFNGR1, IMD27A, IMD27B;;Immune interferon, receptor for;107470;S, A, Fd, REc;;Immunodeficiency 27A, mycobacteriosis, AR, 209950 (3); {H. pylori infection, susceptibility to}, 600263 (3); {Tuberculosis, susceptibility to}, 607948 (3); Immunodeficiency 27B, mycobacteriosis, AD, 615978 (3); {Tuberculosis infection, protection against}, 607948 (3); {Hepatitis B virus infection, susceptibility to}, 610424 (3);10(Ifgr)
6.835;5;29;12;6q23.3;MPVQTL5;;Mean platelet volume quantitative trait locus 5;614645;Fd;associated with rs9399137;Mean platelet volume QTL5 (2);
6.836;7;1;05;6q23.3;OLIG3, BHLHB7;;Oligodendrocyte lineage transcription factor 3;609323;REc;;;
6.837;7;17;14;6q23.3;PDE7B;;Phosphodiesterase 7B, cAMP-specific, high-affinity;604645;REc;;;
6.838;12;6;16;6q23.3;PERP;;p53 effector related to PMP22;609301;REc;;;
6.839;1;11;16;6q23.3;PEX7, RCDP1, PBD9B;;Peroxisomal biogenesis factor-7;601757;REa, R, REc;;Rhizomelic chondrodysplasia punctata, type 1, 215100 (3); Peroxisome biogenesis disorder 9B, 614879 (3);
6.840;1;7;09;6q23.3;SLC35D3;;Solute carrier family 35, member D3;612519;REc, H;;;10(Slc35d3)
6.841;3;28;17;6q23.3-q24.1;ARFGEF3, BIG3, KIAA1244;;ADP-ribosylation factor guanine nucleotide exchange factor 3;617411;REc;;;
6.842;8;27;01;6q24.1;C6orf34, SOUL;;Soul, chicken, homolog of;605825;REc;;;
6.843;2;27;03;6q24.3;EPM2A, MELF, EPM2;;Laforin;607566;Fd;;Epilepsy, progressive myoclonic 2A (Lafora), 254780 (3);
6.844;9;9;08;6q24.3;FBXO30, FBX30;;F-box only protein 30;609101;REc;;;10(Fbxo30)
6.845;9;18;17;6q24.3;GRM1, MGLUR1, GRM1A, SCAR13, SCA44;;Glutamate receptor, metabotropic, 1;604473;REa, A;;Spinocerebellar ataxia, autosomal recessive 13, 614831 (3); Spinocerebellar ataxia 44, 617691 (3);
6.846;12;24;08;6q23.3;HBS1L, KIAA1038, ERFS;;HBS1-like protein;612450;REc;;;
6.847;11;15;08;6q24.2;HYMAI;;Hydatidiform mole-associated and imprinted transcript;606546;REc, Ch, Fd;;;
6.848;2;28;03;6q24.2;PLAGL1, ZAC, LOT1;;Pleomorphic adenoma gene-like 1 (ZAC tumor suppressor);603044;A, REc, Ch, Fd;relaxed imprinting in TNDM;{Diabetes mellitus, transient neonatal}, 601410 (1);10(Zac)
6.849;3;13;06;6q24.2;STX11, FHL4, HPLH4, HLH4;;Syntaxin-11;605014;Fd, REc;;Hemophagocytic lymphohistiocytosis, familial, 4, 603552 (3);
6.850;4;26;05;6q23.2;TAAR2, GPR58;;Trace amine-associated receptor 2;604849;A;;;
6.851;7;8;96;6q24.2;UTRN, DMDL, DRP1;;Utrophin (homologous to dystrophin);128240;REa, F, Fd, A;near dy in mouse;;10(Dmdl)
6.852;9;30;10;6q24-q25;DEL6q24q25, C6DELq25q25;;Chromosome 6q24-q25 deletion syndrome;612863;Ch;;Chromosome 6q25-q25 deletion syndrome (4);
6.853;9;29;09;6q25.1;IYD, DEHAL1, TDH4;;Iodotyrosine deiodinase;612025;REc;;Thyroid dyshormonogenesis 4, 274800 (3);
6.854;10;8;09;6q25.2;OPRM1;;Opioid receptor, mu-1;600018;A;;;10(Oprm)
6.855;3;10;03;6q25.1;PPIL4;;Peptidyl-prolyl isomerase-like 4;607609;REc, Psh;;;
6.856;2;17;09;6q24-q25;STQTL1;;Stature quantitative trait locus 1;606255;Fd;associated with rs4896582 and rs3748069;{Stature QTL 1} (2);
6.857;8;28;92;6q25.3;MAS1;;Oncogene MAS1;165180;A, REa;;;17(Mas1)
6.858;4;17;07;6q24.1-q24.2;C6orf55, SBP1, LIP5, VTA1, DRG1;;SKD1-binding protein 1;610902;R, REc;;;
6.859;8;2;13;6q24.1;CCDC28A, C6orf80;;Coiled-coil domain-containing 28A;615353;REc;;;
6.860;8;31;16;6q24.2;ADGRG6, PR126, VIGR, LCCS9;;Adhesion G protein-coupled receptor G6;612243;REc, H;;Lethal congenital contracture syndrome 9, 616503 (3);10(Gpr126)
6.861;2;25;15;6q24.1;HECA, HDC;;Headcase, Drosophila, homolog of;607977;REc;;;
6.862;1;30;02;6q23.3;IL22BP, IL22RA2;;Interleukin 22-binding protein;606648;REc, R;;;
6.863;9;9;13;6q24.2;ADAT2, TAD2;;Adenosine deaminase, tRNA-specific, 2;615388;REc;;;
6.864;2;24;12;6q24.2;FUCA2;;Fucosidase, alpha-L- 2, plasma;136820;F;linked to PLG;;
6.865;3;9;17;6q24.2;PEX3, PBD10A, PBD10B;;Peroxisomal biogenesis factor-3;603164;REc, A;mutation identified in 1 PBD10B patient;Peroxisome biogenesis disorder 10A (Zellweger), 614882 (3); ?Peroxisome biogenesis disorder 10B, 617370 (3);
6.866;7;16;12;6q24.2;PHACTR2, KIAA0680;;Phosphatase and actin regulator 2;608724;R, REc;;;
6.867;1;24;18;6q24.2;SF3B5, SF3B10;;Splicing factor 3B, subunit 5;617847;REc;;;
6.868;5;5;09;6q24.2-q25.2;DUH1, DUH;;Dyschromatosis universalis hereditaria 1;127500;Fd;max lod at D6S1553;Dyschromatosis universalis hereditaria 1 (2);
6.869;8;20;07;6q25.1;RAET1L;;Retinoic acid early transcript 1L;611047;REc;;;
6.870;6;1;12;6q24.3;ADGB;;Androglobin;614630;REc;;;
6.871;12;5;03;6q25.1;NUP43;;Nucleoporin, 43kD;608141;R, REc;;;
6.872;2;21;10;6q25.1;PPP1R14C, KEPI;;Protein phosphatase 1, regulatory subunit 14C;613242;REc;;;
6.873;7;22;09;6q24.3;RAB32;;Ras-associated protein RAB32;612906;REc;;;
6.874;2;26;09;6q24.3-q25.1;SASH1, KIAA0790;;Sterile alpha motifs- and SH3 domain-containing protein 1;607955;R, REc;;;
6.875;8;24;04;6q24.3;STXBP5;;Syntaxin-binding protein 5 (tomosyn);604586;R, REc;;;
6.876;6;30;08;6q25;BMND11;;Bone mineral density quantitative trait locus 11;612114;Fd;associated with rs4870044, rs1038304, and rs1999805;[Bone mineral density QTL 11] (2);
6.877;3;23;06;6q25.3;FNDC1, AGS8, KIAA1866;;Fibronectin type III domain-containing protein 1;609991;R, REc;;;
6.878;1;7;09;6q25;IDDM21;;Diabetes mellitus, insulin-dependent, 21;612521;Fd;associated with rs1738074;{Diabetes mellitus, insulin-dependent, 21} (2);
6.879;2;12;16;6q25.2;MYCT1, MTLC;;MYC target in myeloid cells 1;616805;REc;;;
6.880;11;12;12;6q25.1;RMND1, COXPD11;;Required for meiotic nuclear division 1, S. cerevisiae, homolog of;614917;REc;;Combined oxidative phosphorylation deficiency 11, 614922 (3);
6.881;11;20;13;6q25.2;SYNE1, KIAA0796, KIAA1756, KIAA1262, SCAR8, EDMD4;;Spectrin repeat-containing nuclear envelope protein 1 (nesprin 1);608441;A, Fd, REc;;Spinocerebellar ataxia, autosomal recessive 8, 610743 (3); Emery-Dreifuss muscular dystrophy 4, autosomal dominant, 612998 (3);
6.882;5;31;05;6q25.1;SUMO4, IDDM5;;Small ubiquitin-like modifier 4;608829;Fd, REc;;{Diabetes mellitus, insulin-dependent, 5}, 600320 (3);
6.883;1;11;16;6q25.1;TAB2, MAP3K7IP2, KIAA0733, CHTD2;;Tak1 (MAP3K7) binding protein 2;605101;R, REc;;Congenital heart defects, nonsyndromic, 2, 614980 (3);
6.884;9;10;09;6q25.3;TFB1M, CGI75;;Transcription factor B1, mitochondrial;607033;R, REc;;;
6.885;2;28;01;6q25.1;ULBP1;;UL16-binding protein 1;605697;REn;;;
6.886;2;28;01;6q25.1;ULBP2;;UL16-binding protein 2;605698;REn;;;
6.887;2;28;01;6q25.1;ULBP3;;UL16-binding protein 3;605699;REn;;;
6.888;9;9;08;6q25.2;FBXO5, FBX5, EMI1;;F-box only protein 5;606013;A, H;;;10(Fbxo5)
6.889;12;29;89;6q25-q26;RCD1;;Retinal cone dystrophy-1;180020;Ch;;?Retinal cone dystrophy-1 (2);
6.890;12;9;98;6q25-q27;IDDM8;;Insulin-dependent diabetes mellitus-8;600883;Fd;;{Diabetes mellitus, insulin-dependent, 8} (2);
6.891;1;29;04;6q26;PACRG;;Parkin coregulated gene;608427;REc;shares 5' regulatory region and both 3' UTRs with PARK2;;17(Pacrg)
6.892;4;28;16;6q25.3;ARID1B, BAF250B, KIAA1235, MRD12, CSS1;;AT-rich interaction domain-containing protein 1B;614556;R, REc;;Coffin-Siris syndrome 1, 135900 (3);
6.893;4;30;15;6q25.1;ARMT1, C6orf211;;Acidic residue methyltransferase 1;616332;REc;;;
6.894;8;19;13;6q25.1-q25.2;ESR1, ESR, ESTRR;;Estrogen receptor 1;133430;REa, A;;Estrogen resistance, 615363 (3); {HDL response to hormone replacement, augmented} (3); {Migraine, susceptibility to}, 157300 (3); {Atherosclerosis, susceptibility to} (3); {Myocardial infarction, susceptibility to}, 608446 (3); {Breast cancer}, 114480 (1);10(Esr)
6.895;9;10;09;6q25.1;KATNA1;;Katanin, p60 subunit, A1;606696;R, REc;;;
6.896;7;19;12;6q25.1;LATS1;;Large tumor suppressor, Drosophila, homolog of, 1;603473;REc;;;
6.897;9;10;09;6q25.3;NOX3;;NADPH oxidase 3;607105;REc;;;
6.898;2;12;07;6q25.1;UST;;Uronyl 2-sulfotransferase;610752;R, REc;;;
6.899;6;13;07;6q25.1;ZC3H12D, p34, C6orf95;;Zinc finger CCCH domain-containing protein 12D;611106;REc;;;
6.900;10;23;15;6q25.1;ZBTB2, ZNF437, KIAA1483;;Zinc finger- and BTB domain-containing protein 2;616595;REc;;;
6.901;5;10;17;6q25.2;CNKSR3, CNK3;;CNKSR family, member 3;617476;REc;;;
6.902;2;3;14;6q25.1;MTHFD1L, MTC1THFS;;Methylenetetrahydrofolate dehydrogenase 1-like, NADP(+)-dependent;611427;REc;;;
6.903;9;30;14;6q25.2;SCAF8, KIAA1116;;SR-related C-terminal domain-associated factor 8;616024;R, REc;;;
6.904;8;28;97;6q25.3;TCTEL1;;T-complex-associated-testis-expressed 1-like 1;601554;A;;;
6.905;10;2;12;6q25.2-q25.3;TIAM2;;T-cell lymphoma invasion and metastasis 2;604709;REc;;;
6.906;1;29;04;6q26;PRKN, PARK2, PDJ, LPRS2;;Parkin;602544;Fd, D;shares 5' regulatory region and both 3' UTRs with PACRG;Parkinson disease, juvenile, type 2, 600116 (3); Adenocarcinoma of lung, somatic, 211980 (3); Adenocarcinoma, ovarian, somatic, 167000 (3); {Leprosy, susceptibility to}, 607572 (3);17(Park2)
6.907;5;28;08;6q25.3;CELIAC12;;Celiac disease, susceptibility to, 12;612010;Fd;in LD block containing TAGAP;{Celiac disease, susceptibility to, 12} (2);
6.908;4;6;15;6q25.3;EZR, VIL2, CVL;;Ezrin;123900;REa, A;coamplified with MYB;;
6.909;6;2;15;6q25.3;GTF2H5, TTD3, TFB5, C6orf175, TTDA;;General transcription factor IIH, polypeptide 5;608780;REc, REn;;Trichothiodystrophy 3, photosensitive, 616395 (3);
6.910;2;28;08;6q25.3;MRPL18;;Mitochondrial ribosomal protein L18;611831;REc;;;
6.911;7;25;14;6q25.3;RSPH3, RSHL2, RSP3, CILD32;;Radial spoke head 3, Chlamydomonas, homolog of;615876;REc;;Ciliary dyskinesia, primary, 32, 616481 (3);
6.912;7;25;12;6q25.3;SERAC1, MEGDEL;;Serine active site-containing protein 1;614725;REc;;3-methylglutaconic aciduria with deafness, encephalopathy, and Leigh-like syndrome, 614739 (3);
6.913;7;9;09;6q25.3;SOD2, MNSOD, MVCD6;;Superoxide dismutase-2, mitochondrial;147460;S, D, REa, A;;{Microvascular complications of diabetes 6}, 612634 (3);17(Sod2)
6.914;6;30;05;6q25.3;SYNJ2, KIAA0348;;Synaptojanin 2;609410;R, H;;;17(Synj2)
6.915;12;28;08;6q25.3;TAGAP;;T-cell activation GTPase-activating protein;609667;R, REc;;;
6.916;2;18;10;6q25.3;TMEM181, GPR178, KIAA1423;;Transmembrane protein 181;613209;REc;;;
6.917;12;10;15;6q25.3;WTAP;;Wilms tumor 1-associating protein;605442;REa, A;;;17(Wtap)
6.918;9;28;96;6q25.3;ACAT2;;Acetyl-Coenzyme A acetyltransferase 2 (acetoacetyl Coenzyme A thiolase);100678;A;encoded on strand opposite TCP1;?ACAT2 deficiency, 614055 (1);
6.919;9;28;96;6q25.3;TCP1;;T-complex locus TCP-1;186980;REa, H, A, Fd, REn;tightly linked to PLG; ~15cM proximal to TCP10; overlap with ACAT2;;17(Tcp1)
6.920;9;2;12;6q26;AGPAT4;;1-acylglycerol-3-phosphate O-acyltransferase 4;614795;REc;;;
6.921;3;3;10;6q25.3;AIRN, AIR;;Antisense IGF2R RNA, noncoding;604893;REc;;;17(Airn)
6.922;9;20;14;6q26;CAHM, LINC00468;;Colorectal adenocarcinoma hypermethylated gene, noncoding;615930;REc;;;
6.923;12;5;13;6q25.3;IGF2R, MPRI;;Insulin-like growth factor-2 receptor (mannose-6-phosphate receptor, cation-independent);147280;REa, A;behaves as a tumor suppressor;Hepatocellular carcinoma, somatic, 114550 (3);17(Igf2r)
6.924;9;10;09;6q26;MAP3K4, MEKK4, MTK1, MAPKKK4;;Mitogen-activated protein kinase kinase kinase 4;602425;REa, REc;;;
6.925;9;4;14;6q26;PLG;;Plasminogen;173350;REa, A, LD, F;20cM from TCP10A;Dysplasminogenemia, 217090 (3); Plasminogen deficiency, type I, 217090 (3);17(Plg)
6.926;8;23;12;6q26;QKI, QK1;;Quaking, mouse, homolog of;609590;REc;;;
6.927;6;9;98;6q25.3;SLC22A1, OCT1;;Solute carrier family 22 (organic cation transporter), member 1;602607;Psh, A;;;
6.928;6;9;98;6q25.3;SLC22A2, OCT2;;Solute carrier family 22 (organic cation transporter), member 2;602608;Psh, A;;;17(Slc22a2)
6.929;1;27;04;6q26-q27;DFNB38;;Deafness, autosomal recessive 38;608219;Fd;;Deafness, autosomal recessive 38 (2);
6.930;9;24;08;6q27;FAM120B, PGCC1, CCPG, KIAA1838;;Family with sequence similarity 120, member B;612266;REc;;;17(Fam120b)
6.931;12;17;07;6q25.3;LPAL2, APOARGC;;Lipoprotein(a)-like 2;611682;REc;;;
6.932;11;19;11;6q26-q27;MRT28;;Mental retardation, autosomal recessive 28;614347;Fd;between rs6935718 and rs3886091;Mental retardation, autosomal recessive 28 (2);
6.933;11;22;88;6q25.2;VIP;;Vasoactive intestinal peptide;192320;REa, A, REb;;;
6.934;9;10;09;6q25.3;SNX9, SH3PX1;;Sorting nexin 9;605952;R, REc;;;
6.935;5;8;17;6q27;AFDN, MLLT4, AF6;;Afadin;159559;Ch, A;;;
6.936;7;26;12;6q27;BRP44L, MPC1, MPYCD;;Brain protein 44-like;614738;REc;;Mitochondrial pyruvate carrier deficiency, 614741 (3);
6.937;6;26;16;6q27;C6orf120;;Chromosome 6 open reading frame 120;616987;REc;;;
6.938;9;9;08;6q27;CCR6, CMKBR6, CKRL3, GPR29, GPRCY4;;Chemokine (C-C) receptor 6;601835;REa;;;
6.939;7;22;16;6q27;CHDM;;Chordoma;215400;Fd, Ch;associated with duplication of the T gene;{Chordoma, susceptibility to} (4);
6.940;9;10;09;6q27;DACT2, DPR2, DAPPER2;;Dapper, antagonist of beta-catenin, 2;608966;REc;;;
6.941;7;2;18;6q27;DLL1, DELTA1;;Delta-like 1;606582;A;;;
6.942;11;27;13;6q27;ERMARD, C6orf70, PVNH6;;Endoplasmic reticulum membrane-associated RNA degradation protein;615532;REc;;?Periventricular nodular heterotopia 6, 615544 (3);
6.943;5;21;03;6q27;FGFR1OP, FOP;;Fibroblast growth factor receptor-1 oncogene partner;605392;REc;fusion gene with ZNF198, CEP1, and FGFR1;Myeloproliferative disorder (2);
6.944;3;5;98;6q27;GPR31;;G protein-coupled receptor-31;602043;A;;;
6.945;3;8;16;6q27;HPAT5;;Human pluripotency-associated transcript 5, noncoding;616837;REc;;;
6.946;2;14;13;6q27;KAZA3;;Kala-azar, susceptibility to, 3;611382;Fd;;{Kala-azar, susceptibility to, 3} (2);
6.947;3;22;06;6q27;KIF25, KNSL3;;Kinesin family member 25;603815;A;;;
6.948;5;22;03;6q25-q26;LPA;;Apolipoprotein Lp(a);152200;REa, A, F, Fd;absent in mice;{Coronary artery disease, susceptibility to} (1); [LPA deficiency, congenital] (3);
6.949;12;14;95;6q27;PDCD2;;Programmed cell death 2;600866;A, H;;;17(Pdcd2)
6.950;5;2;16;6q27;PDE10A, IOLOD, ADSD2;;Phosphodiesterase 10A;610652;A, REc;;Dyskinesia, limb and orofacial, infantile-onset, 616921 (3); Striatal degeneration, autosomal dominant, 616922 (3);
6.951;10;13;09;6q27;PHF10, BAF45A;;PHD finger protein 10;613069;REc;;;
6.952;6;9;06;6q27;PSMB1;;Proteasome subunit, beta type, 1;602017;REc;incorrectly assigned to 7p;;
6.953;8;24;09;6q27;RNASET2, RNASE6PL;;Ribonuclease T2;612944;REc;;Leukoencephalopathy, cystic, without megalencephaly, 612951 (3);
6.954;12;9;98;6q27;RPS6KA2, RSK3;;Ribosomal protein S6 kinase, 90kD, 2;601685;REa, A;;;
6.955;10;17;00;6q25.3;SLC22A3, EMT;;Solute carrier family 22 (extraneuronal monoamine transporter), member 3;604842;A, REc;;;17(Slc22a3)
6.956;1;26;12;6q27;SMOC2, SMAP2, DTDP1;;Secreted modular calcium-binding protein 2;607223;R, REc;;Dentin dysplasia, type I, with microdontia and misshapen teeth, 125400 (3);
6.957;4;29;14;6q27;T, TFT, SAVA;;Brachyury, mouse, homolog of;601397;A, Fd;;{Neural tube defects, susceptibility to}, 182940 (3); Sacral agenesis with vertebral anomalies, 615709 (3);17(T)
6.958;11;15;10;6q27;TBP, SCA17, HDL4;;TATA box binding protein;600075;REa, A, Fd;;Spinocerebellar ataxia 17, 607136 (3); {Parkinson disease, susceptibility to}, 168600 (3);17(Tbp)
6.959;8;21;92;6q27;TCTE3;;T-complex-associated-testis-expressed-3;186977;REa, A;;;
6.960;6;26;08;6q27;THBS2;;Thrombospondin 2;188061;REa, A;;{Lumbar disc herniation, susceptibility to}, 603932 (3);17(Thbs2)
6.961;8;28;92;6q27;TCP10;;T-complex 10 (a murine tcp homolog);187020;Fd;;;17(Tcp10)
6.962;1;12;07;6q27;UNC93A;;UNC93, C. elegans, homolog of, A;607995;REc;;;
6.963;9;10;09;Chr.6;BEVI;;Baboon M7 virus replication;109180;S;;;
6.964;10;23;87;Chr.6;FEA;;F9 embryonic antigen;137010;H;;;
6.965;9;10;09;Chr.6;LAKLG, LAKL;;Lymphokine-activated killer cell ligand;153435;S;;;
6.966;10;23;87;Chr.6;MRBC;;Monkey RBC receptor;158050;S;;;
6.967;10;23;87;Chr.6;TS546;;Temperature sensitivity complementation, cell cycle specific, ts546 cells;187330;S;;;
7.1;9;12;93;7p22.3;PRKAR1B;;Protein kinase, cAMP-dependent, regulatory, type I, beta;176911;Fd;;;
7.2;4;17;13;7p22.3;AMZ1, KIAA1950;;Archaelysin family metallopeptidase 1;615168;REc;;;
7.3;08;10;18;7p22.3;BRAT1, BAAT1, C7orf27, RMFSL, NEDCAS;;BRCA1-associated ATM activator 1;614506;REc;;Rigidity and multifocal seizure syndrome, lethal neonatal, 614498 (3); Neurodevelopmental disorder with cerebellar atrophy and with or without seizures, 618056 (3);
7.4;5;10;04;7p22.3;CENTA1;;Centaurin, alpha-1;608114;REc;;;
7.5;3;19;13;7p22.3;COX19;;Cytochrome c oxidase assembly protein Cox19;610429;REc;;;
7.6;9;20;14;7p22.3;CYP2W1;;Cytochrome P450, family 2, subfamily W, polypeptide 1;615967;REc;;;
7.7;12;17;12;7p22.3;ELFN1, PPP1R28;;Extracellular leucine-rich repeat and fibronectin type III domain-containing protein 1;614964;REc;;;
7.8;9;8;10;7p22.3;GET4, C7orf20, CEE;;Golgi to ER traffic protein 4, S. cerevisiae, homolog of;612056;REc;;;
7.9;10;25;17;7p22.3;DNAAF5, HEATR2, CILD18;;Dynein axonemal assembly factor 5;614864;REc;;Ciliary dyskinesia, primary, 18, 614874 (3);
7.10;3;23;14;7p22.3;INTS1, INT1, KIAA1440;;Integrator complex subunit 1;611345;REc;;;
7.11;8;28;17;7p22.3;IQCE, KIAA1023, PAPA7;;IQ domain-containing protein E;617631;REc;mutation identified in 1 PAPA7 family;?Polydactyly, postaxial, type A7, 617642 (3);
7.12;9;22;14;7p22.3;MIR339;;Micro RNA 339;615977;REc;;;
7.13;6;17;17;7p22.3;PSMG3, PAC3;;Proteasome assembly chaperone 3;617528;REc;;;
7.14;12;10;12;7p22.3;SNX8;;Sorting nexin 8;614905;REc;;;
7.15;9;30;09;7p22.3;UNC84A, KIAA0810, SUN1;;UNC84, C. elegans, homolog of, A;607723;R, REc;;;
7.16;1;16;07;7p22.3;ZFAND2A, AIRAP;;Zinc finger AN1 domain-containing protein 2A;610699;REc;;;
7.17;9;28;11;7p22.3-p21.3;HYPT10;;Hypotrichosis 10;614238;Fd;between D7S1532 and D7S3047;Hypotrichosis 10 (2);
7.18;10;3;07;7p22.3;EIF3B, EIF3S9, PRT1;;Eukaryotic translation initiation factor 3, subunit B;603917;REc;;;
7.19;3;11;08;7p22.3-p22.2;GNA12;;Guanine nucleotide-binding protein, alpha-12;604394;R, REc;;;
7.20;10;18;15;7p22.2;SDK1;;Sidekick, Drosophila, homolog of, 1;607216;REc;;;5(Sdk1)
7.21;6;9;08;7p13;TMED4;;Transmembrane p24 trafficking protein 4;612038;REc;;;
7.22;3;9;17;7p22.1;WIPI2;;WD40 repeat protein interacting with phosphoinositides 2;609225;Psh;;;
7.23;9;18;12;7p22.1;AP5Z1, KIAA0415, SPG48;;Adaptor-related protein complex 5, zeta-1 subunit;613653;R, REc;;Spastic paraplegia 48, autosomal recessive, 613647 (3);
7.24;9;30;09;7p22.1;CYTH3, PSCD3, ARNO3, GRP1;;Cytohesin 3;605081;R, REc;;;
7.25;9;8;11;7p22.1;DAGLB;;Diacylglycerol lipase, beta;614016;REc;;;
7.26;11;22;10;7p22.1;EIF2AK1, HRI;;Eukaryotic translation initiation factor 2-alpha kinase 1;613635;REc;;;
7.27;10;28;15;7p22.1;FAM220A, SIPAR, ACPIN1, C7orf70;;Family with sequence similarity 220, member A;616628;REc;;;5(Fam220A)
7.28;6;13;12;7p22.1;FBXL18, FBL18;;F-box and leucine-rich repeat protein 18;609084;REc;;;
7.29;4;10;15;7p22.1;FOXK1, MNF;;Forkhead box K1;616302;REc, H;;;5(Foxk1)
7.30;4;19;12;7p22.1;MMD2, PAQR10;;Monocyte-to-macrophage differentiation-associated protein 2;614581;REc;;;
7.31;7;19;06;7p22.1;PAPOLB, TPAP;;Poly(A) polymerase, beta;607436;REc;;;
7.32;10;31;17;7p22.1;RAC1, MRD48;;Ras-related C3 botulinum toxin substrate 1;602048;REc;;Mental retardation, autosomal dominant 48, 617751 (3);
7.33;10;2;07;7p22.1;RADIL, KIAA1849;;RAP GTPase interactor;611491;REc;;;
7.34;11;11;14;7p22.1;RBAK;;RB-associated KRAB repressor;608191;R, REc;;;
7.35;2;4;13;7p22.1;SLC29A4, PMAT, ENT4;;Solute carrier family 29 (monoamine transporter), member 4;609149;REc;;;
7.36;10;4;05;7p22.1;STBMS1;;Strabismus, susceptibility to, 1;185100;Fd;max lod at marker 1911/1912;{Strabismus, susceptibility to, 1} (2);
7.37;6;13;95;7p21.2;MEOX2;;Mesenchyme homeo box 2;600535;A;;;
7.38;6;5;18;7p22.1;AIMP2, JTV1, HLD17;;Aminoacyl tRNA synthetase complex-interacting multifunctional protein 2;600859;A;;Leukodystrophy, hypomyelinating, 17, 618006 (3);
7.39;8;25;17;7p22.2;CARD11, CARMA1, BIMP3, PPBL, BENTA, IMD11A;;Caspase recruitment domain-containing protein 11;607210;R, REc;;B-cell expansion with NFKB and T-cell anergy, 616452 (3); Immunodeficiency 11A, 615206 (3); Immunodeficiency 11B with atopic dermatitis, 617638 (3);
7.40;8;19;13;7p22.3;CHST12, C4ST2;;Carbohydrate sulfotransferase 12;610129;R;;;
7.41;9;8;11;7p22;ERVK-6;;Endogenous retroviral group K, member 6;605626;A;;;
7.42;8;18;02;7p22.1;FSCN1, SNL;;Fascin homolog 1, actin-bundling protein (singed, Drosophila, homolog-like);602689;A;;;
7.43;6;11;02;7p22.3;FTSJ2, FJH1;;FTSJ, E. coli, homolog of, 2;606906;R;;;
7.44;1;1;12;7p21.3;GLCCI1, TSSN1, GCTR;;Glucocorticoid-induced transcript 1;614283;REc;;{Glucocorticoid therapy, response to}, 614400 (3);6(Glcci1)
7.45;6;21;10;7p22.3;GPER, CMKRL2, GPR30;;G protein-coupled estrogen receptor 1;601805;Psh;;;
7.46;2;20;97;7p21.3;ICA1;;Islet cell autoantigen 1, 69kD;147625;A;;;6(Ica1)
7.47;9;11;14;7p22.3;LFNG, SCDO3;;Lunatic fringe;602576;REa, R, A;mutation identified in 1 SDO3 family;?Spondylocostal dysostosis 3, autosomal recessive, 609813 (3);5(Lfng)
7.48;8;29;01;7p22.3;MAD1L1, TXBP181;;Mitotic arrest-deficient 1, yeast, homolog-like 1;602686;R;;Lymphoma, somatic (3); Prostate cancer, somatic, 176807 (3);5(Mad1l1)
7.49;7;10;95;7p21.2;ETV1;;ETS variant gene-1;600541;Ch, A;fused with EWS in some Ewing sarcoma;;
7.50;8;21;07;7p22.3;FAM20C, DMP4;;Family with sequence similarity 20, member C;611061;R, REc, Ch;;Raine syndrome, 259775 (3);
7.51;8;9;99;7p22.3;MAFK, NFE2U;;V-maf avian musculoaponeurotic fibrosarcoma oncogene family, protein K (nuclear factor erythroid 2, ubiquitous subunit);600197;A;;;5(Nfe2u)
7.52;6;8;95;7p22.3;NUDT1, MTH1;;Nudix-type motif 1;600312;A;;;
7.53;8;28;92;7p22.3;PDGFA;;Platelet-derived growth factor, alpha polypeptide;173430;REa, A;;;
7.54;11;19;11;7p22.1;PMS2, PMSL2, HNPCC4;;Postmeiotic segregation increased, S. cerevisiae, 2, homolog of;600259;REa, A;;Mismatch repair cancer syndrome, 276300 (3); Colorectal cancer, hereditary nonpolyposis, type 4, 614337 (3);
7.55;7;23;13;7p22.1;RNF216, TRIAD3, ZIN, CAHH;;RING finger protein 216;609948;REc;;Cerebellar ataxia and hypogonadotropic hypogonadism, 212840 (3);
7.56;4;7;94;7p21.3;RPA3;;Replication protein A3, 14kD;179837;REa, Psh, A;;;
7.57;6;7;91;7p22.1;ZNF12;;Zinc finger protein-12 (KOX3);194536;REa, A;;;
7.58;12;4;90;7p14.1;RALA;;RAS-like protein A (Simian leukemia viral (v-ral) oncogene homolog A, ras-related);179550;REb, A;;;13(Ral)
7.59;7;1;11;7p22-p14;CPVT3;;Ventricular tachycardia, catecholaminergic polymorphic, 3;614021;Fd;between D7S526 and D7S481;Ventricular tachycardia, catecholaminergic polymorphic, 3 (2);
7.60;5;24;12;7p22.1;ACTB, BRWS1;;Actin, beta;102630;REa, A;~20 pseudogenes also; mutation identified in twin DJO patients;?Dystonia, juvenile-onset, 607371 (3); Baraitser-Winter syndrome 1, 243310 (3);5(Actb)
7.61;11;28;01;7p21.1;AGR2, AG2;;Anterior gradient 2, Xenopus, homolog of;606358;R, A;;;
7.62;9;24;08;7p21.1;AGR3, BCMP11;;Anterior gradient 3, Xenopus, homolog of;609482;REc;;;
7.63;3;23;06;7p21.3;COL28A1;;Collagen, type XXVIII, alpha-1 polypeptide;609996;REc;;;6(Col28a1)
7.64;8;7;13;7p21.3;MIOS;;Missing oocyte/meiosis regulator, Drosophila, homolog of;615359;REc;;;
7.65;5;25;13;7p21.3;NDUFA4;;NADH-ubiquinone oxidoreductase 1 alpha subcomplex, 4;603833;REc;;;
7.66;7;18;14;7p21.3;NXPH1, NPH1;;Neurexophilin 1;604639;REc;;;
7.67;7;26;10;7p21.3;SCIN, KIAA1905;;Scinderin;613416;R, REc;;;
7.68;9;24;08;7p21.3;THSD7A, KIAA0960;;Thrombospondin type-1 domain-containing protein 7A;612249;R, REc;;;
7.69;5;9;18;7p21.3;TMEM106B, HLD16;;Transmembrane protein 106B;613413;REc;;Leukodystrophy, hypomyelinating, 16, 617964 (3);
7.70;6;26;16;7p21.3-p21.2;LOC105375159;;Long intergenic noncoding RNA AC011288.2;616986;REc;;;
7.71;4;26;11;7p21.2;AGMO, TMEM195;;Alkylglycerol monooxygenase;613738;REc;;;
7.72;9;29;09;7p21.2;DGKB, DGK, KIAA0718;;Diacylglycerol kinase, beta, 90kD;604070;R, REc;;;
7.73;09;27;18;7p21.2-p21.1;ISPD, MDDGA7, MDDGC7, LGMDR20;;Isoprenoid synthase domain-containing protein;614631;REc;;Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 7, 614643 (3); Muscular dystrophy-dystroglycanopathy (limb-girdle), type C, 7, 616052 (3);
7.74;10;30;07;7p21.1;PRPS1L1, PRPS3;;Phosphoribosylpyrophosphate synthetase 1-like 1;611566;REa, R;;;
7.75;12;28;08;7p21.2;SOSTDC1, ECTODIN, USAG1;;Sclerostin domain-containing protein 1;609675;REc;;;
7.76;7;8;10;7p21.2;FGQTL4;;Fasting plasma glucose level QTL 4;613462;Fd;associated with rs2191349;[Fasting plasma glucose level QTL 4] (2);
7.77;8;2;17;7p21.1;FERD3L, NTWIST, NATO3, PTFB;;Fer3, Drosophila, homolog of;617578;REc, H;;;12(Ferd3l)
7.78;01;04;19;7p21.1;ITGB8;;Integrin, beta-8;604160;REc;;;
7.79;3;11;09;7p21.1;MACC1;;Metastasis-associated gene in colon cancer 1;612646;REc;;;
7.80;4;18;05;7p21.1;SNX13, KIAA0713;;Sorting nexin 13;606589;R, REc;;;
7.81;12;21;09;7p21.1;TSPAN13, NET6;;Tetraspanin 13;613139;REn;;;
7.82;9;28;10;7p21.2-p14.3;EDSS2;;Ectodermal dysplasia-syndactyly syndrome 2;613576;Fd;between D7S488 and D7S817;Ectodermal dysplasia-syndactyly syndrome 2 (2);
7.83;12;3;08;7p15.3;DNAH11, DNAHC11, CILD7, DNAHBL;;Dynein, axonemal, heavy chain-11;603339;REa, REn;;Ciliary dyskinesia, primary, 7, with or without situs inversus, 611884 (3);
7.84;1;24;09;7p15.3;IL6, IFNB2, BSF2, HSF, HGF;;Interleukin-6 (interferon, beta-2);147620;REa, A, Fd;;{Rheumatoid arthritis, systemic juvenile}, 604302 (3); {Kaposi sarcoma, susceptibility to}, 148000 (3); {Diabetes, susceptibility to}, 222100, 125853 (3); {Intracranial hemorrhage in brain cerebrovascular malformations, susceptibility to}, 108010 (3); {Crohn disease-associated growth failure}, 266600 (3);5(Il6)
7.85;12;8;03;7p21.1;SP8, BTD;;Transcription factor Sp8;608306;REc;;;
7.86;10;26;17;7p21.1;TWIST1, ACS3, SCS, CRS1, SWCOS;;TWIST, Drosophila, homolog of, 1;601622;Fd, Ch, A, REa;;Saethre-Chotzen syndrome with or without eyelid anomalies, 101400 (3); Craniosynostosis 1, 123100 (3); Robinow-Sorauf syndrome, 180750 (3); Sweeney-Cox syndrome, 617746 (3);12(Twist)
7.87;12;4;03;7p21.1;TWISTNB;;TWIST neighbor;608312;REc;pseudogene on 6q14.3;;12(Twistnb)
7.88;3;5;98;7p14.3;CRHR2, CRFR2;;Corticotropin releasing hormone receptor-2;602034;R, A;;;6(Crhr2)
7.89;12;11;01;7p21.1;HDAC9, MITR, HDAC7B, KIAA0744;;Histone deacetylase 9;606543;R, REc;;;
7.90;4;7;94;7p21-p15;MDDC;;Macular dystrophy, dominant cystoid;153880;Fd;?allelic to RP9;Macular dystrophy, dominant cystoid (2);
7.91;9;30;02;7p15.3;MPP6, VAM1, PALS2;;Membrane protein, palmitoylated 6;606959;A;;;6(Pals2)
7.92;4;1;08;7q22.1;TSC22D4, THG1;;TSC22 domain family, member 4;611914;REc;;;
7.93;5;10;04;7p14.3;FAPP2;;Phosphatidylinositol 4-phosphate adaptor protein 2;608639;REc;;;
7.94;2;11;08;7p21.1;ABCB5;;ATP-binding cassette, subfamily B, member 5;611785;REc;;;
7.95;11;3;14;7p15.3;C7orf31;;Chromosome 7 open reading frame 31;616071;REc;;;
7.96;8;10;98;7p14.3;CHN2, ARHGAP3, RHOGAP3;;Chimerin 2 (GTPase-activating protein, rho, 3);602857;A;;;
7.97;12;5;08;7p15.3;FAM126A, DRCTNNB1A, HLD5;;Hyccin;610531;A;;Leukodystrophy, hypomyelinating, 5, 610532 (3);
7.98;3;27;18;7p15.3;GPNMB, PLCA3;;Glycoprotein NMB;604368;REc;;Amyloidosis, primary localized cutaneous, 3, 617920 (3);
7.99;9;28;05;7p15.2;HOXA1, HOX1F, BSAS;;Homeo box-A1;142955;RE, A, Fd;;Bosley-Salih-Alorainy syndrome, 601536 (3); Athabaskan brainstem dysgenesis syndrome, 601536 (3);6(Hox1.6)
7.100;9;1;16;7p15.3;KLHL7, RP42, CISS3;;Kelch-like 7;611119;REc;;Retinitis pigmentosa 42, 612943 (3); Cold-induced sweating syndrome 3, 617055 (3);
7.101;5;8;12;7p15.3;MALSU1, C7orf30;;Mitochondrial assembly of ribosomal large subunit 1;614624;REc;;;
7.102;6;26;16;7p15.3;NPVF, RFRP, C7orf9;;Neuropeptide VF precursor;616984;Psh, REc;;;
7.103;9;30;09;7p15.3;STK31;;Serine/threonine kinase 31;605790;R, REc;;;
7.104;12;18;13;7p15.3;TOMM7;;Translocase of outer mitochondrial membrane 7, yeast, homolog of;607980;REc;;;
7.105;5;25;13;7p15.3;TRA2A;;Transformer 2, Drosophila, homolog of;602718;REc;;;
7.106;5;11;00;7p14.3;INMT;;Indolethylamine N-methyltransferase;604854;REa, A;;;
7.107;11;11;14;7p15.2;CBX3;;Chromobox homolog 3;604477;R, REc;;;
7.108;1;14;09;7p15.3;CYCS, CYC, THC4;;Cytochrome C, somatic;123970;REc;;Thrombocytopenia 4, 612004 (3);
7.109;8;8;13;7p15.2;HIBADH;;3-hydroxyisobutyrate dehydrogenase;608475;REc, R;;;
7.110;7;1;11;7p15.2;HOTTIP, NCRNA00213;;HOXA distal transcript antisense RNA;614060;REc;;;
7.111;9;20;14;7p15.2;HOXA11AS;;Homeo box A11, antisense;607530;REc;;;6(Hoxa11s)
7.112;11;3;14;7p15.2;HOXAAS2;;HOXA cluster antisense RNA 2;616068;REc;;;
7.113;5;15;11;7p15.2;MIR148A, MIRN148A;;Micro RNA 148A;613786;REc;;;
7.114;6;22;14;7p15.2;SKAP2, SCAP2, SKAP55R;;src kinase associated phosphoprotein 2;605215;REc;;;
7.115;2;21;13;7p15.2;SNX10, OPTB8;;Sorting nexin 10;614780;REc;;Osteopetrosis, autosomal recessive 8, 615085 (3);
7.116;12;22;17;7p14.3;FKBP14, EDSKSCL2;;FK506-binding protein 14;614505;REc;;Ehlers-Danlos syndrome, kyphoscoliotic type, 2, 614557 (3);
7.117;5;9;95;7p15.3;NPY;;Neuropeptide Y;162640;REa, H, A;;;6(Npy)
7.118;12;4;08;7p14.3;WIPF3, CR16;;WAS/WASL-interacting protein family, member 3;612432;REc;;;
7.119;6;10;08;7p14.3;ZNRF2;;Zinc finger and ring finger protein 2;612061;REc;;;
7.120;12;28;18;7p15.1-p14.3;CREB5, CREBPA;;cAMP response element-binding protein 5;618262;REc;;;
7.121;10;19;97;7p21.1;AHR;;Aryl hydrocarbon receptor;600253;REa, A, Psh;;;
7.122;12;28;08;7p15.3;CDCA7L, R1, JPO2;;Cell division cycle-associated protein 7-like;609685;REc;;;
7.123;6;8;07;7p14.3;GARS, SMAD1, CMT2D, HMN5;;Glycyl-tRNA synthetase;600287;A, Fd;;Charcot-Marie-Tooth disease, type 2D, 601472 (3); Neuropathy, distal hereditary motor, type VA, 600794 (3);
7.124;8;28;17;7p15.3;GSDME, DFNA5;;Gasdermin E;608798;Fd, REc, H;;Deafness, autosomal dominant 5, 600994 (3);6(Dfna5)
7.125;12;30;03;7p14.3;GSBS;;G-substrate;604088;R;;{Hypercholesterolemia, susceptibility to}, 143890 (3);
7.126;10;7;13;7p15.2;HNRPA2B1, IBMPFD2;;Heterogeneous nuclear ribonucleoprotein A2/B1;600124;A;mutation identified in 1 family;?Inclusion body myopathy with early-onset Paget disease with or without frontotemporal dementia 2, 615422 (3);
7.127;3;22;06;7p15.3;IGF2BP3, IMP3, KOC1, VICKZ3;;Insulin-like growth factor 2 mRNA-binding protein 3;608259;A, H;;;6(Imp3)
7.128;6;22;14;7p15.2-p15.1;JAZF1, TIP27;;JAZF1 gene;606246;Ch;fused with JJAZ1;;
7.129;8;21;91;7p15;MYCLK1;;Avian myelocytomatosis viral (v-myc) oncogene homolog like 1;164865;A;;;
7.130;3;2;10;7p15;MYP17, MYP4;;Myopia 17;608367;Fd;previously assigned to 7q36 (MYP4);Myopia 17 (2);
7.131;5;7;03;7p15.3;OSBPL3, ORP3, KIAA0704;;Oxysterol-binding protein-like protein 3;606732;R, REc;;;
7.132;6;13;95;7p15.3;SP4;;Sp4 transcription factor;600540;Psh, A;;;
7.133;5;5;09;7p15;STQTL17;;Stature quantitative trait locus 17;612737;Fd;associated with rs1635852 and rs849140;{Stature QTL 17} (2);
7.134;9;30;09;7p15.2;TAX1BP1, TXBP151;;TAX1-binding protein 1;605326;R, REc;;;
7.135;12;20;05;7p14.3;CPVL, HVLP;;Carboxypeptidase, vitellogenic-like;609780;REc;;;
7.136;12;24;08;7p14.3;GGCT, GCTG, C7orf24;;Gamma-glutamylcyclotransferase;137170;S, REc;;;6(Ggc)
7.137;11;01;18;7p14.3;GHRHR, GHRFR, IGHD4;;Growth hormone releasing hormone receptor;139191;REa, A;;Growth hormone deficiency, isolated, type IV, 618157 (3);6(Lit, Ghrhr)
7.138;1;23;07;7p14.3;NOD1, CARD4;;Nucleotide-binding oligomerization domain protein 1;605980;REc;;;
7.139;7;11;11;7p14.1;TARP;;T-cell antigen receptor, gamma subunit, alternate reading frame protein;609642;REc;;;
7.140;2;26;93;7p15.2;HOXA3, HOX1E;;Homeo box-A3;142954;RE;homolog of Drosophila zen1, zen2;;6(Hox1.5)
7.141;2;26;93;7p15.2;HOXA4, HOX1D;;Homeo box-A4;142953;A, REa, H, RE;homolog of Drosophila Dfd;;6(Hox1.4)
7.142;2;26;93;7p15.2;HOXA5, HOX1C;;Homeo box-A5;142952;A, REa, H, RE;;;6(Hox1.3)
7.143;2;26;93;7p15.2;HOXA6, HOX1B;;Homeo box-A6;142951;A, REa, H, RE;;;6(Hox1.2)
7.144;2;26;93;7p15.2;HOXA7, HOX1A;;Homeo box-A7;142950;A, REa, H, RE;homolog of Drosophila Antp;;6(Hox1.1)
7.145;2;26;93;7p15.2;HOXA9, HOX1G;;Homeo box-A9;142956;RE, Ch;homolog of Drosophila Abd-B; fused to NUP98 in myeloid leukemia;;6(Hox1.7)
7.146;2;26;93;7p15.2;HOXA10, HOX1H;;Homeo box-A10;142957;A, REa, H, RE;;;
7.147;11;8;16;7p15.2;HOXA11, HOX1I, RUSAT1;;Homeo box-A11;142958;A, REa, H, RE;;Radioulnar synostosis with amegakaryocytic thrombocytopenia 1, 605432 (3);
7.148;5;17;02;7p15.2;HOXA13, HOX1J;;Homeo box-A13;142959;RE, Fd;;Hand-foot-uterus syndrome, 140000 (3); Guttmacher syndrome, 176305 (3);6(Hoxa13, Hd)
7.149;3;23;09;7p15.2;MIR196B, MIRN196B;;Micro RNA 196B;609688;REc;;;
7.150;4;21;04;7p14.3;AAA1;;Asthma-associated alternatively spliced gene 1;608596;REc;;;
7.151;3;23;95;7p15.2;EVX1;;Even-skipped homeo box-1 (homolog of Drosophila);142996;REn;at 5' end of HOX1 cluster;;
7.152;4;24;18;7p15.2;HOXA2, MCOHI;;Homeobox A2;604685;REc;mutation identified in 1 MCOHICP family;?Microtia, hearing impairment, and cleft palate (AR), 612290 (3); Microtia with or without hearing impairment (AD), 612290 (3);
7.153;10;08;07;7p14.3;NEUROD6, ATOH2, MATH2;;Neurogenic differentiation 6;611513;REc;;;
7.154;10;20;99;7p15.2;NFE2L3, NRF3;;Nuclear factor erythroid 2-like 3;604135;A;;;
7.155;5;21;09;7p14.3;NPSR1, GPR154, GPRA, VRR1, PGR14, ASRT2;;Neuropeptide S receptor 1;608595;REc;;{Asthma, susceptibility to, 2}, 608584 (3);
7.156;11;19;13;7p14.3;NT5C3A, NT5C3, UMPH1, PSN1;;5' nucleotidase, cytosolic IIIA (uridine 5' monophosphate hydrolase 1);606224;REc;pseudogenes on chr.4 and chr.7;Anemia, hemolytic, due to UMPH1 deficiency, 266120 (3);
7.157;8;29;07;7p14.2;TBX20, ASD4;;T-box 20;606061;REc;;Atrial septal defect 4, 611363 (3);
7.158;7;8;10;7p15-p13;FGQTL2, BWQTL1;;Fasting plasma glucose level QTL 2; Birth weight QTL 1;613219;Fd;associated with rs4607517;[Fasting plasma glucose level QTL 2] (2); [Birth weight QTL 1] (2);
7.159;8;12;15;7p13;GCK, HHF3;;Glucokinase (hexokinase-4);138079;Psh, Fd;proximal to TCRB;MODY, type II, 125851 (3); Diabetes mellitus, noninsulin-dependent, late onset, 125853 (3); Hyperinsulinemic hypoglycemia, familial, 3, 602485 (3); Diabetes mellitus, permanent neonatal, 606176 (3);
7.160;2;4;89;7p14.1;INHBA;;Inhibin, beta-1;147290;REa;;;13(Inhba)
7.161;8;17;09;7p14.3;AVL9, KIAA0241;;AVL9, S. cerevisiae, homolog of;612927;R, REc;;;
7.162;3;28;11;7p14.3;BMPER, CV2;;BMP binding endothelial regulator;608699;REc;;Diaphanospondylodysostosis, 608022 (3);9(Bmper)
7.163;7;15;11;7p14.2;DPY19L1, KIAA0877;;DPY19-like 1;613892;REc;;;7p14.3
7.164;9;30;09;7p14.3;LSM5;;LSM5 protein;607285;R, REc;;;
7.165;10;14;18;7p14.3;PDE1C, HCAM3, DFNA74;;Phosphodiesterase 1C;602987;REc;mutation identified in 1 DFNA74 family;?Deafness, autosomal dominant 74, 618140 (3);
7.166;4;26;10;7p14.3;TRIL, KIAA0644;;TLR4 interactor with leucine-rich repeats;613356;REc;;;
7.167;12;17;12;7p14.3;SCRN1, SES1, KIAA0193;;Secernin 1;614965;REc, R;;;
7.168;9;30;14;7p14.2;ANLN, FSFS8;;Actin-binding protein anillin;616027;REc;;Focal segmental glomerulosclerosis 8, 616032 (3);
7.169;11;23;16;7p14.2;EEPD1, KIAA1706;;Endonuclease/exonuclease/phosphatase family domain-containing protein 1;617192;REc;;;
7.170;3;21;14;7p14.3;RP9, PAP1;;RP9 gene (pim1-associated protein, mouse, homolog of);607331;Fd, REc;mutation identified in 1 patient;?Retinitis pigmentosa 9, 180104 (3);
7.171;2;24;17;7p14.1;CDK13, CDC2L5, CHED, CHDFIDD;;Cyclin-dependent kinase 13;603309;REc;;Congenital heart defects, dysmorphic facial features, and intellectual developmental disorder, 617360 (3);
7.172;6;13;12;7p14.1;GPR141, PGR13;;G protein -coupled receptor 141;609045;REc;;;13(Gpr141)
7.173;3;14;13;7p14.1;NME8, TXNDC3, SPTRX2, CILD6;;NME/NM23 family member 8;607421;R;;Ciliary dyskinesia, primary, 6, 610852 (3);
7.174;7;14;16;7p14.1;SFRP4, FRPHE, PYL;;Secreted frizzled-related protein 4;606570;H, REc;;Pyle disease, 265900 (3);13(Sfrp4)
7.175;10;15;13;7p14.1;TRGC1;;T-cell receptor gamma chain constant region 1;186970;REa, A, Ch;;;13(Tcrg)
7.176;10;15;13;7p14.1;TRGC2;;T-cell receptor gamma chain constant region 2;615450;REc;;;
7.177;10;15;13;7p14.1;TRGV@;;T-cell receptor gamma chain variable gene cluster;615454;REc;;;
7.178;10;15;13;7p14.1;TRGJ@;;T-cell receptor gamma chain joining gene cluster;615455;REc;;;
7.179;9;30;09;7p14.1;VPS41;;Vacuolar protein sorting 41, Yeast, homolog of;605485;R, REc;;;
7.180;1;7;95;7p14.3;ADCYAP1R1, PACAPR;;Adenylate cyclase activating polypeptide-1 (pituitary) receptor type 1;102981;Psh, A;;;
7.181;2;5;18;7p14.3;AQP1, CHIP28, CO;;Aquaporin-1 (channel-forming integral protein, 28kD);107776;REa, A, Fd;;[Blood group, Colton], 110450 (3); [Aquaporin-1 deficiency], 110450 (3);6(Aqp1)
7.182;7;24;15;7p14.1;C7orf10, GA3;;Chromosome 7 open reading frame 10;609187;A;;Glutaric aciduria III, 231690 (3);
7.183;12;7;17;7p13;CAMK2B, MRD54;;Calcium/calmodulin-dependent protein kinase II-beta;607707;REc;;Mental retardation, autosomal dominant 54, 617799 (3);
7.184;9;30;09;7p14.2-p14.1;ELMO1, CED12;;Engulfment and cell motility gene 1;606420;REc;;;
7.185;12;29;06;7p14;HHT4;;Telangiectasia, hereditary hemorrhagic, type 4;610655;Fd;between D7S2252 and D7S510;Telangiectasia, hereditary hemorrhagic, type 4 (2);
7.186;6;2;15;7p14.1;MPLKIP, C7orf11, ABHS, TTDN1, TTD4;;M-phase specific PLK1 interacting protein;609188;A;;Trichothiodystrophy 4, nonphotosensitive, 234050 (3);
7.187;2;28;08;7p14.1;MRPL32;;Mitochondrial ribosomal protein L32;611839;R;;;
7.188;4;24;08;7p13;MRPS24;;Mitochondrial ribosomal protein S24;611986;R, REc;;;
7.189;10;16;14;7p14.3;PTHB1, BBS9;;Parathyroid hormone-responsive B1 gene;607968;REc, Fd;;Bardet-Biedl syndrome 9, 615986 (3);
7.190;10;1;07;7p14.2;SEPT7, CDC10;;Septin 7;603151;REc;;;
7.191;3;26;95;7p14.1;AMPH;;Amphiphysin;600418;Psh, A;;;13(Amph)
7.192;11;8;06;7p22.1-p21.3;C1GALT1;;Core 1 synthase, glycoprotein-N-acetylgalactosamine 3-beta-galactosyltransferase, 1;610555;REc;;;
7.193;4;6;00;7p14-p13;HPVC1, PE5L;;Human papillomavirus E5 central sequence-like 1;600762;A;;;
7.194;9;21;09;7p13;OGDH;;Oxoglutarate dehydrogenase, lipoamide (alpha-ketoglutarate dehydrogenase);613022;REa, A;;Alpha-ketoglutarate dehydrogenase deficiency, 203740 (1);
7.195;12;7;04;7p14.1;POU6F2, WTSL, WT5;;POU domain, class 6, transcription factor 2;609062;Ch, D, REc;;{Wilms tumor susceptibility-5}, 601583 (3);
7.196;1;28;08;7p14.1;STARD3NL, MENTHO;;STARD3 N-terminal like;611759;REc;;;
7.197;10;13;94;7p14.2;AOAH;;Acyloxyacyl hydrolase (neutrophil);102593;A;;;
7.198;2;9;92;7p12.3;IGFBP1;;Insulin-like growth factor-binding protein-1;146730;REa, A, REn;;;
7.199;2;9;92;7p12.3;IGFBP3;;Insulin-like growth factor-binding protein-3;146732;REn;tail-to-tail 20kb from IGFBP1;;
7.200;5;31;18;7p13;AEBP1, ACLP;;AE-binding protein 1;602981;REc;;Ehlers-Danlos syndrome, classic-like, 2, 618000 (3);
7.201;8;16;11;7p13;BLVRA;;Biliverdin reductase A;109750;S, A;;Hyperbiliverdinemia, 614156 (3);2(Blvr)
7.202;2;10;04;7p13;C7orf22, CCM2, MGC4067;;Malcavernin;607929;Fd, REc;;Cerebral cavernous malformations-2, 603284 (3);
7.203;8;21;12;7p13;COA1, C7orf44;;Cytochrome c oxidase assembly factor 1, S. cerevisiae, homolog of;614769;REc;;;
7.204;8;29;13;7p13;DBNL, HIP55;;Drebrin-like;610106;REc, R;;;
7.205;11;11;14;7p13;DDX56, NOH61;;DEAD/H box 56;608023;R, REc;;;
7.206;8;5;11;7p14.1;GLI3, PAPA, PAPB;;GLI-Kruppel family member GLI3 (oncogene GLI3);165240;REa, A, Fd;amplified in glioblastoma;Greig cephalopolysyndactyly syndrome, 175700 (3); Pallister-Hall syndrome, 146510 (3); Polydactyly, preaxial, type IV, 174700 (3); Polydactyly, postaxial, types A1 and B, 174200 (3); {Hypothalamic hamartomas, somatic}, 241800 (3);13(Xt)
7.207;8;19;13;7p14-p13;HECW1, NEDL1, KIAA0322;;HECT, C2, and WW domains-containing E3 ubiquitin-protein ligase 1;610384;REc, R;;;
7.208;11;02;18;7p13;LUARIS, lncRNA32;;Long noncoding RNA upregulator of antiviral response interferon signaling;618172;REc;overlaps in antisense orientation with HECW1 gene;;
7.209;9;8;11;7p13;MYL7, MYL2A, MLC2A, MYLC2A;;Myosin, light chain 7, regulatory;613993;R, REc;;;11(Myl7)
7.210;7;2;14;7p13;MYO1G, HA2, HLA-HA2;;Myosin IG;600642;A;;;
7.211;5;24;13;7p13;NUDCD3, KIAA1068, NUDCL;;NUDC domain-containing protein 3;610296;REc, R;;;
7.212;5;9;18;7p13;NPC1L1, LDLCQ7;;NPC1-like 1;608010;REa, A;;[Ezetimibe, nonresponse to], 617966 (3); [Low density lipoprotein cholesterol level QTL 7], 617966 (3);
7.213;9;30;09;7p13;POLD2;;Polymerase (DNA directed), delta 2, regulatory subunit, 50kD;600815;Psh, REc;;;
7.214;9;20;14;7p13;POLM;;Polymerase, DNA, mu;606344;REc;;;
7.215;4;30;97;7p13;PPIA;;Peptidylprolyl isomerase A (cyclophilin A);123840;Psh, A;;;
7.216;6;9;06;7p14.1;PSMA2, PSC2, HC3;;Proteasome (prosome, macropain) subunit, alpha type, 2;176842;REc;incorrectly assigned to 6q;;
7.217;9;16;12;7p13;PURB;;Purine-rich element-binding protein B;608887;REc;;;
7.218;2;23;08;7p12.3;SEPT13;;Septin 13;611563;REc;;;
7.219;4;2;16;7p13;SNORA5C;;Small nucleolar RNA, H/ACA box, 5C;611335;REc;in intron 3 of TBRG4;;
7.220;8;28;17;7p13;SPDYE1, SPDYB2L2, RINGO1;;SPEEDY/RINGO cell cycle regulator family, member E1;617623;REc;;;
7.221;10;2;12;7p13;STK17A, DRAK1;;Serine/threonine protein kinase 17A;604726;REc;;;
7.222;4;6;15;7p13;TBRG4, KIAA0948, CPR2;;Transforming growth factor-beta regulator 4;611325;A, REc;;;
7.223;2;19;10;7p13;URGCP, URG4;;Upregulator of cell proliferation;610337;REc;;;
7.224;7;2;18;7p13;YKT6;;Ykt6, S. cerevisiae, homolog of;606209;REc;;;
7.225;5;23;13;7p13;ZMIZ2, KIAA1886, ZIMP7;;Zinc finger MIZ-domain containing 2;611196;REc;;;
7.226;8;17;09;7p13;PGAM2, PGAMM, GSD10;;Phosphoglycerate mutase, muscle form;612931;REa, A;;Glycogen storage disease X, 261670 (3);
7.227;7;17;14;7p12.3;ADCY1, DFNB44;;Adenylate cyclase-1, brain;103072;A, REa, Fd;mutation identified in 1 DFNB44 family;?Deafness, autosomal recessive 44, 610154 (3);11(Adcy1, brl)
7.228;6;16;99;7p12.3;HUS1;;Hydroxyurea-sensitive 1, S. pombe, homolog of;603760;A, R;;;
7.229;11;23;16;7p12.3;PKD1L1, HTX8;;Polycystin 1L1;609721;A;;Heterotaxy, visceral, 8, autosomal, 617205 (3);11(Pkd1l1)
7.230;2;15;01;7p13;RAMP3;;Receptor activity-modifying protein 3;605155;R;;;11(Ramp3)
7.231;2;23;92;7p22.1;OCM;;Oncomodulin;164795;REa;;;5(Ocm)
7.232;12;28;08;7p12.3;ABCA13;;ATP-binding cassette, subfamily A, member 13;607807;REc, H;;;11(Abca13)
7.233;1;2;08;7p12.3;TNS3, TEM6;;Tensin 3;606825;R, REc;;;
7.234;1;23;08;7p12.3;UPP1, UP;;Uridine phosphorylase 1;191730;S, REc;;;
7.235;11;3;14;7p11.2;EGFR, NISBD2;;Epidermal growth factor receptor;131550;S, Fd, D, REa;same as oncogene ERBB; mutation identified in 1 NISBD2 family;Nonsmall cell lung cancer, response to tyrosine kinase inhibitor in, 211980 (3); Adenocarcinoma of lung, response to tyrosine kinase inhibitor in, 211980 (3); {Nonsmall cell lung cancer, susceptibility to}, 211980 (3); ?Inflammatory skin and bowel disease, neonatal, 2, 616069 (3);11(Erbb)
7.236;10;13;09;7p12.2;ALL2;;Leukemia, acute lymphoblastic, susceptibility to, 2;613067;Fd;associated with rs11978267;{Leukemia, acute lymphoblastic, susceptibility to, 2} (2);
7.237;6;13;07;7p12.2;VWC2, BRORIN;;von Willebrand factor C domain-containing protein 2;611108;REc;;;
7.238;8;8;13;7p12.2;ZPBP, SP38;;Zona pellucida-binding protein;608498;REc;;;
7.239;9;9;13;7p12.2;FIGNL1;;Fidgetin-like protein 1;615383;REc;;;
7.240;6;7;12;7p12.1-q21;CMH21;;Cardiomyopathy, familial hypertrophic, 21;614676;Fd;max lod at D7S669;Cardiomyopathy, hypertrophic, 21 (2);
7.241;8;19;13;7p12.1;COBL, KIAA0633;;Cordon-bleu, mouse, homolog of;610317;REc;;;11(Cobl)
7.242;3;12;15;7p14.3;FKBP9, FKBP60, FKBP63;;FK506-binding protein 9;616257;A;;;
7.243;12;15;98;7p11.2;GBAS, NIPSNAP2;;Glioblastoma amplified sequence;603004;R;;;
7.244;3;25;16;7p12.2;IKZF1, ZNFN1A1, IK1, LYF1, CVID13;;Ikaros family zinc finger 1;603023;REa, Ch;fused with BCL6 in DLBL;Immunodeficiency, common variable, 13, 616873 (3);11(Ikaros)
7.245;1;7;02;7p12.1;GRB10, RSS;;Growth factor receptor-bound protein-10;601523;REa, R, A;;;11(Grb1)
7.246;7;11;93;7p12-cen;TTIM1;;T-cell tumor invasion and metastasis-1 (invasion-metastasis of neoplasms, chromosome 7 determined);147830;S;;;
7.247;10;12;90;7p11.2;PHKG1;;Phosphorylase kinase, gamma 1, muscle;172470;REa, A;presumed pseudogene on 11;;5(Phkg)
7.248;8;8;13;7p11.2;CCT6A, CCT6, HTR3, TCP20;;Chaperonin containing T-complex polypeptide 1, subunit 6A;104613;REc;;;
7.249;12;28;15;7p11.2;CHCHD2, PARK22;;Coiled-coil-helix-coiled-coil-helix domain-containing protein 2;616244;REc;;Parkinson disease 22, autosomal dominant, 616710 (3);
7.250;12;11;18;7p11.2;ELDR, LINC01156, FABL;;EGFR long noncoding downstream RNA;618217;REc;;;1(Eldr)
7.251;7;22;09;7p11.2;LANCL2, TASP;;LanC-like 2;612919;REc;;;
7.252;4;14;14;7p11.2;NYS3;;Nystagmus 3, congenital, autosomal dominant;608345;Ch;translocation t(7;15)(p11.2;q11.2);Nystagmus 3, congenital, autosomal dominant (2);
7.253;3;24;14;7p11.2;PSPH, PSP, PSPHD;;Phosphoserine phosphatase;172480;S, D;;Phosphoserine phosphatase deficiency, 614023 (3);5(Psph)
7.254;01;04;19;7p11.2;SEC61G;;Sec61 translocon, gamma subunit;609215;REc;;;
7.255;7;10;08;7p11.2;SEPT14;;Septin 14;612140;Psh, REc;;;
7.256;5;27;09;7p11.2;SRS, RSS;;Silver-Russell syndrome;180860;Ch;maternal uniparental disomy of chromosome 7;Silver-Russell syndrome (4);
7.257;2;25;15;7p11.2;SUMF2;;Sulfatase-modifying factor 2;607940;REc;;;
7.258;5;24;13;7p11.2;VOPP1, ECOP, GASP;;Vesicular, overexpressed in cancer, prosurvival protein 1;611915;REc;;;
7.259;4;20;17;7p11.2;ZNF479, KR19;;Zinc finger protein 479;617444;REc;;;
7.260;1;12;15;7p11.2;ZNF713;;Zinc finger protein 713;616181;REc;;;
7.261;8;25;04;7p12.2-p12.1;DDC;;DOPA decarboxylase (aromatic L-amino acid decarboxylase);107930;REa, A;;Aromatic L-amino acid decarboxylase deficiency, 608643 (3);
7.262;12;4;03;7q11.21;ASL;;Argininosuccinate lyase;608310;S, REa, A;;Argininosuccinic aciduria, 207900 (3);5(Asl)
7.263;2;1;01;7p21.3;ARL4;;ADP-ribosylation factor-like 4;604786;H;;;12(Arl4)
7.264;10;25;11;7q;MLSM7, DEL7q, C7DELq;;Monosomy 7 of bone marrow;252270;Ch;;Myelodysplasia and leukemia syndrome with monosomy 7 (4);
7.265;8;11;91;7q;HRX;;Hyperreflexia;145290;F;linked to KEL;;
7.266;12;1;98;7q11.23;CLDN3, CPETR2;;Claudin-3 (Clostridium perfringens enterotoxin receptor 2);602910;REa, R;;;
7.267;7;22;15;7q11.21;SBDS, SDS;;SBDS gene;607444;Fd, REc;;Shwachman-Diamond syndrome, 260400 (3); {Aplastic anemia, susceptibility to}, 609135 (3);
7.268;2;28;01;7q11.23;BAZ1B, WSTF, WBSCR9;;Bromodomain adjacent to zinc finger domain, 1B;605681;REa;;;
7.269;4;23;08;7p11.2;MRPS17;;Mitochondrial ribosomal protein S17;611980;R, REc;9 pseudogenes;;
7.270;8;16;06;7p11-q21;HPC4;;Prostate cancer, hereditary, 4;608658;Fd;;{Prostate cancer, susceptibility to, 4}, 176807 (2);
7.271;10;19;01;7q11.2;ANIB1;;Aneurysm, intracranial berry, 1;105800;Fd;in or near ELN;Aneurysm, intracranial berry, 1 (2);
7.272;2;28;08;7q22.1;ARMC10, SVH;;Armadillo repeat-containing 10;611864;REc;;;
7.273;7;18;14;7q11.22;KIAA0442, MRD26;;KIAA0442 gene;607270;A, Ch;translocation break at 7q11.2;Mental retardation, autosomal dominant 26, 615834 (3);
7.274;7;16;09;7q11.23;CCL26, SCYA26;;Chemokine, C-C motif, ligand 26;604697;A;;;
7.275;5;30;17;7q11.23;ELN, SVAS, ADCL1;;Elastin;130160;REa, A, F, Fd;;Supravalvar aortic stenosis, 185500 (3); Cutis laxa, autosomal dominant, 123700 (3);5(Eln)
7.276;7;8;10;7q11.2;EOE1, EE;;Esophagitis, eosinophilic, 1;610247;Fd;associated with rs2302009;{Esophagitis, eosinophilic, 1} (2);
7.277;2;1;01;7q11.21;ERV3;;Endogenous retroviral sequence-3 (includes zinc finger protein H-plk);131170;REa, R;;;
7.278;9;30;09;7q11.23;FGL2;;Fibrinogen-like 2;605351;R, REc;;;
7.279;3;22;06;7q22.1;POLR2J2, RPB11;;RNA polymerase II polypeptide J-related gene;609881;REc;;;
7.280;3;22;00;7q11.23;POMZP3;;POM121/ZP3 fusion protein;600587;A;;;
7.281;1;27;11;7q11.23;POR;;Cytochrome P450 oxidoreductase;124015;REa, A;;Antley-Bixler syndrome with genital anomalies and disordered steroidogenesis, 201750 (3); Disordered steroidogenesis due to cytochrome P450 oxidoreductase, 613571 (3);
7.282;3;23;14;7p11.2;PSPHP1, PSPHL, CO9;;Phosphoserine phosphatase-like (pseudogene);604239;TM;;;
7.283;6;16;99;7q11.23;STX1A, STX1;;Syntaxin 1A, brain;186590;A, Psh;;;
7.284;6;6;00;7q11.21;ZNF107;;Zinc finger protein-107;603989;A;;;
7.285;9;12;93;7q11.21;ZNF117;;Zinc finger protein-117;194624;A;;;
7.286;2;20;03;7q21.2;CCM1, CAM, KRIT1;;KREV interaction trapped 1;604214;Fd, A;;Cerebral cavernous malformations-1, 116860 (3); Hyperkeratotic cutaneous capillary-venous malformations associated with cerebral capillary malformations, 116860 (3); Cavernous malformations of CNS and retina, 116860 (3);
7.287;10;6;92;7q11.2-q21.3;EEC1;;Ectrodactyly, ectodermal dysplasia, cleft lip/palate, 1;129900;Ch;;?EEC syndrome-1 (2);
7.288;8;20;12;7q11.21;KCTD7, EPM3, CLN14;;Potassium channel tetramerization domain containing 7;611725;REc, Fd;;Epilepsy, progressive myoclonic 3, with or without intracellular inclusions, 611726 (3);
7.289;12;28;08;7q11.21;RABGEF1, RABEX5;;RAB guanine nucleotide exchange factor 1;609700;R, REc;;;
7.290;9;30;09;7q11.21;TPST1;;Tyrosylprotein sulfotransferase 1;603125;REc;;;
7.291;5;26;13;7q11.21;TYW1;;tRNA-wybutosine-synthesizing protein 1, S. cerevisiae, homolog of;611243;REc, R;;;
7.292;9;16;12;7q11.21;VKORC1L1;;Vitamin K epoxide reductase complex, subunit 1-like 1;608838;REc;;;
7.293;2;1;11;7q11.21;ZNF92;;Zinc finger protein-92;603974;REa, A, REc;sequence aligns with sequence on 19p13.1-p12;;
7.294;9;27;17;7q11.21;ZNF273, HZF9;;Zinc finger protein 273;604756;REc;;;
7.295;2;2;01;7q11.21;ZNF138;;Zinc finger protein-138;604080;A, REa;;;
7.296;4;6;13;7q11.22;WBSCR17, GALNTL3, GALNACT17;;Williams-Beuren syndrome chromosome region 17;615137;REc;;;
7.297;4;17;01;7q11.23;BCL7B;;B-cell CLL/lymphoma 7B;605846;REc;;;
7.298;11;10;17;7q11.23;BUD23, WBSCR22, MERM1;;rRNA methyltransferase and ribosome maturation factor Bud23;615733;REc, H;;;5(Wbscr22)
7.299;8;29;02;7q11.23;CCL24, SCYA24, MPIF2;;Chemokine, C-C motif, ligand 24;602495;Psh, REc, R;;;
7.300;10;4;05;7q11.23;CLDN4, CPETR1, CPER;;Claudin 4;602909;Psh, H;;;5(Cldn4)
7.301;2;11;09;7q11.23;CLIP2, CYLN2, WBSCR4, WSCR4;;CAP-GLY domain-containing linker protein 2;603432;A, H;?neurodevelopmental defect of Williams syndrome;;5(Cyln2)
7.302;2;22;11;7q11.23;DEL7q11.23, C7DELq11.23;;Chromosome 7q11.23 deletion syndrome, distal, 1.2Mb;613729;Ch;contiguous gene deletion syndrome;Chromosome 7q11.23 deletion syndrome, distal, 1.2Mb (4);
7.303;11;27;18;7q11.23;DNAJC30, WBSCR18;;DNAJ/HSP40 homolog, subfamily C, member 30;618202;REc;;;
7.304;12;21;09;7q11.23;DTX2, KIAA1528;;Deltex, Drosophila, homolog of, 2;613141;R, REc;;;
7.305;1;15;09;7q11.23;DUP7q11.23, C7DUPq11.23;;Chromosome 7q11.23 duplication syndrome;609757;Ch;;Chromosome 7q11.23 duplication syndrome (4);
7.306;2;12;09;7q11.23;EIF4H, WBSCR1, WSCR1;;Eukaryotic translation initiation factor 4H;603431;REc;;;
7.307;5;11;00;7q11.23;FKBP6;;FK506-binding protein 6;604839;REc;;;
7.308;8;28;97;7q11.23;FZD9, FZD3;;Frizzled, Drosophila, homolog of, 9;601766;REn;;;
7.309;7;14;16;7q11.23;GATSL2, CASTOR2;;GATS protein-like 2;617033;REc;;;
7.310;1;9;14;7q11.23;GSAP, PION;;Gamma-secretase-activating protein;613552;REc;;;
7.311;9;12;06;7q11.23;GTF2I, BAP135, WBS;;General transcription factor II-I (BTK-associated protein, 135kD);601679;D;;;
7.312;9;12;06;7q11.23;GTF2IRD1, GTF3, MUSTRD1, WBS;;GTF21 repeat domain-containing protein 1;604318;REc;;;
7.313;2;28;03;7q11.23;HIP1;;Huntingtin interacting protein-1;601767;A, R;;{Prostate cancer, progression of}, 176807 (1);5(Hip1)
7.314;6;8;07;7q11.23;HSPB1, HSP27, CMT2F, HMN2B;;Heat-shock 27kD protein-1;602195;REa, H, REc, Fd;;Neuropathy, distal hereditary motor, type IIB, 608634 (3); Charcot-Marie-Tooth disease, axonal, type 2F, 606595 (3);5(Hsp105)
7.315;2;12;09;7q11.23;LAT2, WBSCR5, LAB, NTAL;;Linker for activation of T cells family, member 2;605719;REc;;;5(Wbscr5)
7.316;9;3;96;7q11.23;LIMK1;;LIM domain kinase 1;601329;REn, Ch, A;;;5(Limk1)
7.317;2;10;17;7q11.23;MDH2, EIEE51;;Malate dehydrogenase, mitochondrial;154100;S, REc;;Epileptic encephalopathy, early infantile, 51, 617339 (3);5(Mor1)
7.318;3;17;08;7q11.23;MLXIPL, WBSCR14, MONDOB, CHREBP;;MLX interacting protein-like;605678;REn;;;
7.319;2;12;13;7q11.23;MIR590;;Micro RNA 590;615070;REc;;;
7.320;10;12;90;7q11.23;NCF1;;Neutrophil cytosolic factor-1, 47kD;608512;REa, A;;Chronic granulomatous disease due to deficiency of NCF-1, 233700 (3);
7.321;5;30;17;7q11.23;NSUN5, WBSCR20, WBSCR20A;;NOP2/SUN RNA methyltransferase family, member 5;615732;REc;;;
7.322;6;22;14;7q11.23;POM121, POM121A, KIAA0618;;POM121 transmembrane nucleoporin;615753;R, REc;;;
7.323;6;22;14;7q11.23;POM121C, POM121-2;;POM121 Transmembrane nucleoporin C;615754;REc;;;
7.324;12;5;13;7q11.23;PTPN12, PTPG1;;Protein tyrosine phosphatase, nonreceptor-type, 12;600079;A;;Colon cancer, somatic, 114500 (3);5(Ptpn12)
7.325;3;6;95;7q11.23;RFC2;;Replication factor C2, 40kD (activator 1, 40kD);600404;Psh, A;;;
7.326;5;6;13;7q11.23;RHBDD2;;Rhomboid domain-containing protein 2;615203;REc;;;
7.327;11;14;18;7q11.23;SSC4D, SRCRB4D;;Scavenger receptor cysteine-rich family member with 4 domains;607639;REc, R;;;
7.328;12;17;15;7q11.23;STYXL1, MKSTYX, DUSP24;;Serine/threonine/tyrosine-interacting protein-like 1;616695;REc;;;
7.329;4;17;01;7q11.23;TBL2;;Transducin-beta-like 2;605842;H, R;;;5(Tbl2)
7.330;9;24;15;7q11.23;TMEM120A, TMPIT, NET29;;Transmembrane protein 120A;616550;REc;;;
7.331;1;24;09;7q11.23;TRIM50, TRIM50A;;Tripartite motif-containing protein 50;612548;REc, H;;;5(Trim50)
7.332;1;24;09;7q11.23;TRIM73, TRIM50B;;Tripartite motif-containing protein 73;612549;REc;;;
7.333;1;24;09;7q11.23;TRIM74, TRIM50C;;Tripartite motif-containing protein 74;612550;REc;;;
7.334;3;11;08;7q11.23;UPK3B, UPIIIB, P35;;Uroplakin 3B;611887;REn;;;
7.335;6;9;06;7q11.23;VPS37D, WBSCR24;;Vacuolar protein sorting 37, yeast, homolog of, D;610039;REc;;;
7.336;1;13;09;7q11.23;WBS, WMS, WS, DEL7q11, C7DELq11;;Williams-Beuren syndrome (chromosome 7q11.23 deletion syndrome);194050;Ch;contiguous gene syndrome;Williams-Beuren syndrome (4);
7.337;1;24;09;7q11.23;WBSCR26;;Williams-Beuren syndrome chromosome region 26;612545;REc, H;;;5(Wbscr26)
7.338;1;24;09;7q11.23;WBSCR27;;Williams-Beuren syndrome chromosome region 27;612546;REc, H;;;5(Wbscr27)
7.339;1;24;09;7q11.23;WBSCR28;;Williams-Beuren syndrome chromosome region 28;612547;REc, H;;;5(Wbscr28)
7.340;9;21;17;7q11.23;YWHAG, EIEE56;;Tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, gamma isoform;605356;A, R;;Epileptic encephalopathy, early infantile, 56, 617665 (3);
7.341;10;10;17;7q11.23;ZP3, ZP3A, ZP3B, OOMD3;;Zona pellucida glycoprotein-3 (sperm receptor);182889;REa, A;;Oocyte maturation defect 3, 617712 (3);5(Zp3)
7.342;2;2;16;7q11.23-q21.11;PHTF2;;Putative homeodomain transcription factor 2;616785;REc;;;
7.343;6;23;15;7q21.11;PCLO, PCH3;;Piccolo, mouse, homolog of;604918;R, REc, Fd;mutation identified in 1 PCHD3 family;?Pontocerebellar hypoplasia, type 3, 608027 (3);
7.344;6;24;16;7q31.1;PPP1R3A, PPP1R3;;Protein phosphatase 1, regulatory subunit 3A;600917;R;;Insulin resistance, severe, digenic, 125853 (3);
7.345;4;12;18;7q21.12;ADAM22, EIEE61;;A disintegrin and metalloproteinase domain 22;603709;R;mutation identified in 1 EIEE61 patient;?Epileptic encephalopathy, early infantile, 61, 617933 (3);
7.346;10;12;14;7q11.23;APTR;;Alu-mediated CDKN1A/p21 transcriptional regulator, noncoding;616048;REc;;;
7.347;8;1;17;7q21.3;BHLHA15, MIST1;;Basic helix-loop-helix family, member A15;608606;REc;;;
7.348;1;2;08;7q21.3;CASD1, C7orf12;;CAS1 domain-containing protein 1;611686;REc;;;
7.349;8;19;13;7q21.13;CLKDN12;;Claudin 12;611232;REc;;;
7.350;4;6;18;7q22.1;EPO, MVCD2, ECYT5, DBAL;;Erythropoietin;133170;REa, A, REb, Fd;mutation identified in 1 DBAL family;{Microvascular complications of diabetes 2}, 612623 (3); Erythrocytosis, familial, 5, 617907 (3); ?Diamond-Blackfan anemia-like, 617911 (3);5(Epo)
7.351;1;12;99;7q21.13;FZD1;;Frizzled, Drosophila, homolog of, 1;603408;A;;;
7.352;6;1;88;7q21.11;GNAI1;;Guanine nucleotide-binding protein (G protein), alpha-inhibiting activity polypeptide-1;139310;REa, A;;;5(Gnai1)
7.353;2;10;00;7q22.1;GNB2;;Guanine nucleotide-binding protein, beta polypeptide-2;139390;REa, REn;30-70kb from EPO;;5(Gnb2)
7.354;07;27;18;7q21.11;MAGI2, AIP1, KIAA0705, NPHS15;;Membrane-associated guanylate kinase, WW and PDZ domains-containing, 2;606382;R;;Nephrotic syndrome, type 15, 617609 (3);
7.355;1;27;11;7q21;MAGI2IT, PR47;;MAGI2 intronic transcript;608950;REc;;;
7.356;12;22;05;7q21.3;PEG10, KIAA1051;;Paternally expressed gene 10;609810;R, REc;;;6(Peg10)
7.357;7;26;16;7q21.2;SAMD9, NFTC, MIRAGE;;Sterile alpha motif domain-containing protein 9;610456;REn;;Tumoral calcinosis, familial, normophosphatemic, 610455 (3); MIRAGE syndrome, 617053 (3);
7.358;9;9;03;7q21.3;SGCE, DYT11;;Sarcoglycan, epsilon;604149;R, H, Fd;pseudogene on 2q21; maternally imprinted;Dystonia-11, myoclonic, 159900 (3);6(Sgce)
7.359;1;31;00;7q21.13;STEAP;;Six-transmembrane epithelial antigen of the prostate;604415;R;;;
7.360;1;2;03;7q21.13;STEAP2, STAMP1, IPCA1, PCANAP1;;Six-transmembrane epithelial antigen of prostate 2;605094;REc;;;
7.361;8;22;07;7q21.12;STEAP4, STAMP2, TIARP;;Six-transmembrane epithelial antigen of prostate 4;611098;REc;;;
7.362;2;17;09;7q21;STQTL11;;Stature quantitative trait locus 11;612223;Fd;associated with rs2282978;{Stature QTL 11} (2);
7.363;2;26;08;7q21.2;AKAP9, YOTIAO, AKAP450;;A-kinase anchor protein 9;604001;REc;mutation identified in 1 LQT11 family;?Long QT syndrome-11, 611820 (3);
7.364;3;15;10;7q22.1;ARPC1A, SOP2L;;Actin-related protein 2/3 complex, subunit 1A;604220;REc;;;
7.365;10;25;17;7q22.1;ARPC1B, ARC41, PLTEID;;Actin-related protein 2/3 complex, subunit 1B;604223;REc;;Platelet abnormalities with eosinophilia and immune-mediated inflammatory disease, 617718 (3);
7.366;7;17;01;7q21.3;ASB4;;Ankyrin repeat-containing SOCS box protein 4;605761;REc;;;6(Asb4)
7.367;8;5;97;7q21.11;CACNA2, CACNL2A;;Calcium channel, voltage-dependent, L type, alpha 2/delta subunit;114204;Psh, Fd, A;;;
7.368;6;6;00;7q22.1;CPSF4, CPSF30, NEB1;;Cleavage-polyadenylation specificity factor 4, 30kD;603052;R;;;
7.369;11;5;14;7q21.2;CDK6, PLSTIRE, MCPH12;;Cyclin-dependent kinase 6;603368;R, REc, Psh;mutation identified in 1 MCPH12 family;?Microcephaly 12, primary, autosomal recessive, 616080 (3);
7.370;5;2;16;7q21.2;ERVW1, ERVWE1, HERVW;;Endogenous retroviral family W, member 1 (syncytin);604659;REc;;;
7.371;8;5;97;7q21-q22;MHS3;;Malignant hyperthermia susceptibility 3;154276;Fd;?mutation in CACNA2;{Malignant hyperthermia susceptibility 3} (2);
7.372;10;28;15;7q21.2;PEX1, ZWS1, PBD1A, PBD1B, HMLR1;;Peroxisome biogenesis factor-1;602136;Ch, REc;;Peroxisome biogenesis disorder 1A (Zellweger), 214100 (3); Peroxisome biogenesis disorder 1B (NALD/IRD), 601539 (3); Heimler syndrome 1, 234580 (3);
7.373;8;9;99;7q21.3;TAC1, TAC2, NKNA;;Tachykinin 1 (substance K; neurokinin A; neurokinin 2; neuromedin L; neuropeptide gamma; tachykinin 2);162320;REa, A, H;;;6(Nkna)
7.374;9;28;96;7q22.1;ZNF36, KOX18;;Zinc finger protein-36 (KOX 18);601260;A, REc;;;
7.375;9;28;96;7q22.1;ZNF38, KOX25;;Zinc finger protein-38 (KOX 25);601261;A, REc;;;
7.376;12;24;13;7q21.3;ASNS, ASNSD;;Asparagine synthetase;108370;S, REa, A;temperature sensitive G1 mutant;Asparagine synthetase deficiency, 615574 (3);
7.377;12;7;12;7q21.12;ABCB4, PGY3, MDR3, ICP3;;ATP-binding cassette, subfamily B, member 4 (P-glycoprotein-3/multiple drug resistance-3);171060;RE;within 500kb of MDR1;Cholestasis, progressive familial intrahepatic 3, 602347 (3); Cholestasis, intrahepatic, of pregnancy, 3, 614972 (3); Gallbladder disease 1, 600803 (3);
7.378;5;4;12;7q21.12;ABCB1, PGY1, MDR1, IBD13, CLCs;;ATP-binding cassette, subfamily B, member 1 (P-glycoprotein-1/multiple drug resistance-1);171050;REa, A, REb;;{Colchicine resistance}, 120080 (3); {Inflammatory bowel disease 13}, 612244 (3);5(Pgy1)
7.379;7;11;01;7q21.12;CROT, COT;;Carnitine octanoyltransferase;606090;REc;;;
7.380;8;24;09;7q21.11;HGF, DFNB39;;Hepatic growth factor;142409;REb, A, REa;;Deafness, autosomal recessive 39, 608265 (3);
7.381;6;4;89;7q21.12;SRI, SCN;;Sorcin (class 4 gene);182520;REa, H;;;
7.382;6;4;98;7q21.11-q21.12;GRM3;;Glutamate receptor, metabotropic-3;601115;A;;;
7.383;1;30;01;7q22.1;SMURF1;;SMAD ubiquitination regulatory factor 1;605568;REc;;;
7.384;9;1;16;7q21.11;CD36, CHDS7, BDPLT10;;CD36 antigen (collagen type I);173510;A, REc;;[Macrothrombocytopenia] (1); Platelet glycoprotein IV deficiency, 608404 (3); {Malaria, cerebral, susceptibility to}, 611162 (3); {Malaria, cerebral, reduced risk of}, 611162 (3); {Coronary heart disease, susceptibility to, 7}, 610938 (3);
7.385;7;17;14;7q21.11;GNAT3, GDCA;;Guanine nucleotide-binding protein, alpha-transducing activity polypeptide 3;139395;REc;;;
7.386;8;21;91;7q11.21;GUSB, MPS7;;Glucuronidase, beta-;611499;S, D, EM;;Mucopolysaccharidosis VII, 253220 (3);5(Gus)
7.387;6;11;13;7q21.11;SEMA3A, SEMAD, COLL1, HH16;;Semaphorin 3A;603961;REc, R;;{Hypogonadotropic hypogonadism 16 with or without anosmia}, 614897 (3);
7.388;4;21;15;7q21.11;SEMA3C;;Semaphorin 3C;602645;REc;;;
7.389;4;21;15;7q21.11;SEMA3D;;Semaphorin 3D;609907;R, REc;;;
7.390;8;8;13;7q21.12;DMTF1, DMP1;;Cyclin D-binding MYB-like transcription factor 1;608491;REc;;;
7.391;1;13;16;7q21.11;SEMA3E, SEMAH, KIAA0331;;Semaphorin 3E;608166;R, REc;mutation identified in 1 CHARGE patient;?CHARGE syndrome, 214800 (3);
7.392;9;8;11;7q21.12;KIAA1324L, EIG121L;;KIAA1324-like gene;614048;REc;;;
7.393;1;9;17;7q21.12;RUNDC3B, RPIP9;;RUN domain-containing protein 3B;617295;REc;;;
7.394;3;12;07;7q21.12;SLC25A40;;Solute carrier family 25, member 40;610821;REc;;;5(Slc25a40)
7.395;6;26;16;7q21.12;TMEM243, C7orf23, MMTRAG;;Transmembrane protein 243;616993;REc;;;
7.396;6;23;15;7q21.12;TP53TG1;;TP53 target gene 1;616403;REc;;;
7.397;4;17;13;7q21.13;CDK14, PFTK1, PFTAIRE1, KIAA0834;;Cyclin-dependent kinase 14;610679;R;;;
7.398;5;9;18;7q21.13;CFAP69, C7orf63, SPGF24;;Cilia- and flagella-associated protein 69;617949;REc;;Spermatogenic failure 24, 617959 (3);5(Cfap69)
7.399;4;18;07;7q21.13;GTPBP10, OBGH2;;GTP-binding protein 10;610920;R, REc;;;
7.400;4;22;15;7q21.2;GATAD1, ODAG, CMD2B;;GATA zinc finger domain-containing protein 1;614518;REc;mutation identified in 1 GATAD1 family;?Cardiomyopathy, dilated, 2B, 614672 (3);
7.401;10;7;13;7q21.2;MTERF;;Transcription termination factor, mitochondrial;602318;REc;;;
7.402;8;1;16;7q21.2;SAMD9L, ATXPC;;Sterile alpha motif domain-containing 9-like;611170;REc;;Ataxia-pancytopenia syndrome, 159550 (3);
7.403;3;5;03;7q21.2;CYP51A1, CYP51;;Cytochrome P450, family 51, subfamily A, polypeptide 1 (lanosterol 14-alpha-demethylase);601637;Psh, REc;;;
7.404;9;8;11;7q21.2;HEPACAM2, MIKI;;Hepacam family member 2;614133;REc;;;
7.405;4;21;11;7q21.2-q21.3;SHFM1, SHFD1, SHSF1;;Split hand/foot malformation (ectrodactyly) type 1;183600;Ch;contiguous gene deletion syndrome;Split hand/foot malformation 1 (4);
7.406;7;20;15;7q21.2-q21.3;VPS50, CCDC132, KIAA1861;;VPS50, EARP/GARPII complex subunit;616465;REc;;;
7.407;9;4;98;7q22.1;TRRAP;;Transformation/transcription domain-associated protein;603015;R;;;
7.408;5;22;14;7q21.3;ACN9;;Acn9, S. cerevisiae, homolog of;615773;REc;;;
7.409;11;22;99;7q21.12;ASK, DBF4;;Activator of S-phase kinase;604281;A;;;5(Dbf4)
7.410;7;14;14;7q21.3;BET1;;Bet1 golgi vesicular membrane-trafficking protein;605456;REc;;;
7.411;2;13;14;7q21.3;BRI3;;Brain protein I3;615628;REc;;;
7.412;3;16;99;7q21.3;CALCR, CRT;;Calcitonin receptor;114131;A, Psh;not deleted in Williams syndrome;{Osteoporosis, postmenopausal, susceptibility}, 166710 (3);6(Calcr)
7.413;5;25;13;7q21.3;GNG11;;Guanine nucleotide-binding protein, gamma 11;604390;REc;;;
7.414;6;16;99;7q21.3;GNGT1;;Guanine nucleotide-binding protein, gamma-transducing activity polypeptide 1;189970;Psh, REc;;;
7.415;3;30;12;7q21.3;MIR489;;Micro RNA 489;614523;REc;in intron 4 of CALCR;;
7.416;7;8;10;7q21.3;PON1, PON, ESA, MVCD5;;Paraoxonase-1;168820;F, Fd, REc;;{Coronary artery disease, susceptibility to} (3); {Coronary artery spasm 2, susceptibility to (3); {Organophosphate poisoning, sensitivity to} (3); {Microvascular complications of diabetes 5}, 612633 (3);6(Pon1)
7.417;9;9;98;7q21.3;PON2;;Paraoxonase-2;602447;REc;;{Coronary artery disease, susceptibility to} (3);
7.418;9;9;98;7q21.3;PON3;;Paraoxonase-3;602720;REc;;;
7.419;10;20;04;7q21.3;PPP1R9A, NRBI, NRB1, KIAA1222;;Protein phosphatase 1, regulatory subunit 9A (neurabin I);602468;R, REc;;;
7.420;8;20;02;7q21.3;SLC25A13, CTLN2;;Solute carrier family 25 (mitochondrial carrier, citrin), member 13;603859;Fd, LD;;Citrullinemia, adult-onset type II, 603471 (3); Citrullinemia, type II, neonatal-onset, 605814 (3);
7.421;8;31;12;7q21.3;TECPR1, KIAA1358;;Tectonin beta-propeller repeat-containing 1;614781;R, REc;;;
7.422;1;7;95;7q22.1;PCOLCE;;Procollagen C-endopeptidase enhancer;600270;REa, A;;;5(Pcolce)
7.423;4;13;10;7q22.1;PAI1, PLANH1, SERPINE1;;Plasminogen activator inhibitor, type I;173360;REa, REb, Fd, A, D;;Plasminogen activator inhibitor-1 deficiency, 613329 (3); {Transcription of plasminogen activator inhibitor, modulator of} (3);
7.424;8;28;01;7q11.21;RCP;;Calcitonin gene-related peptide receptor component protein;606121;REc;;;
7.425;3;5;08;7q21.3-q22.1;BAIAP2L1, IRTKS;;BAI1-associated protein 2-like 1;611877;REc;;;
7.426;6;16;99;7q21.3;DNCI1;;Dynein, cytoplasmic, intermediate chain 1;603772;REc;;;6(Dnci1)
7.427;5;22;07;7q21.3;LMTK2, KPI2, BREK, KIAA1079;;Lemur tyrosine kinase 2;610989;R, REc;;;
7.428;8;18;97;7q22.1;MCM7, MCM2;;Minichromosome maintenance deficient, S. cerevisiae, homolog of, 7;600592;A;;;
7.429;9;20;95;7q22.1;NPTX2;;Pentraxin II;600750;A;;;
7.430;11;4;98;7q21.3;PDK4;;Pyruvate dehydrogenase kinase, isoenzyme 4;602527;REc;;;
7.431;11;29;17;7q21.3;SEM!, DSS1;;Proteasome 26S subunit SEM1;601285;D;?gene mutant in SHFM1;;
7.432;8;28;92;7q22.1;ACHE, YT;;Acetylcholinesterase (YT blood group);100740;Psh, A, Fd, REb;blood group YT (112100) = epitope of ACHE;[Blood group, Yt system], 112100 (3);5(Ache)
7.433;12;24;08;7q22.1;ACTL6B, BAF53B;;Actin-like 6B;612458;REc;;;
7.434;1;31;01;7q22.1;APS;;Adaptor protein containing PH and SH2 domains;605300;REc;;;
7.435;5;16;07;7q22;AUTS1;;Autism, susceptibility to, 1;209850;Fd;;{Autism susceptibility 1} (2);
7.436;10;09;18;7q22.1;CUX1, CUTL1, CDP;;Cut-like homeobox 1;116896;REa;;;
7.437;2;16;12;7q21.3;DLX5, SHFM1D;;Distal-less homeo box-5;600028;REa, A, D;mutation identified in 1 family;?Split-hand/foot malformation 1 with sensorineural hearing loss, 220600 (3);6(Dlx5)
7.438;1;8;95;7q21.3;DLX6;;Distal-less homeo box-6;600030;REa, A;;;
7.439;12;20;18;7q22.1;EPHB4, HTK, MYK1, HFASD, CMAVM2, LMPHM7;;Ephrin receptor EphB4 (hepatoma transmembrane kinase);600011;REa, REc;;Lymphatic malformation 7, 617300 (3); Capillary malformation-arteriovenous malformation 2, 618196 (3);
7.440;9;30;09;7q22.1;DNAJC2, ZRF1, MPP11;;DnaJ (Hsp40) homolog, subfamily C, member 2;605502;R, REc;;;
7.441;9;9;08;7q22.1;FBXO24, FBX24;;F-box only protein 24;609097;REc;;;5(Fbxo24)
7.442;2;7;07;7q22.1;GAL3ST4;;Galactose-3-O-sulfotransferase 4;608235;REc;;;
7.443;1;18;11;7q22;IBD11;;Inflammatory bowel disease 11;191390;Fd;associated with MUC3A;{Inflammatory bowel disease 11} (2);
7.444;3;14;14;7q22.3;KMT2E, MLL5;;Lysine (K)-specific methyltransferase 2E;608444;REc;;;
7.445;10;13;09;7q22.1;MEPCE, BCDIN3;;Methylphosphate capping enzyme;611478;A;;;
7.446;9;2;09;7q22.1;MIR93, MIRN9;;Micro RNA 93;612984;REc;;;
7.447;9;3;09;7q22.1;MIR106B, MIRN106B;;Micro RNA 106B;612983;REc;;;
7.448;1;18;11;7q22.1;MUC3A;;Mucin 3A, intestinal;158371;REa, A;;;
7.449;2;12;01;7q22;MUC3B;;Mucin 3B, intestinal;605633;A;;;
7.450;1;4;08;7q22.1;MUC12, MUC11;;Mucin 12;604609;A;;;
7.451;11;5;08;7q22.1;MUC17;;Mucin 17;608424;R;;;
7.452;4;15;04;7q22;MYH16;;Myosin, heavy chain 16, skeletal muscle;608580;REc;inactivated in humans; expressed in masticatory muscles in nonhuman primates;;
7.453;8;24;04;7q22;PAPA4;;Polydactyly, postaxial, type A4;608562;Fd;highest lod with D7S1799;Polydactyly, postaxial, type A4 (2);
7.454;9;20;00;7q22.3;PIK3CG;;Phosphatidylinositol 3-kinase, catalytic, gamma;601232;A;;;
7.455;1;31;01;7q22.1;PILRA;;Paired immunoglobulin-like receptor, alpha;605341;REc, R;;;
7.456;1;31;01;7q22.1;PILRB;;Paired immunoglobulin-like receptor, beta;605342;REc, REn;;;
7.457;12;16;08;7q22.1;PLOD3, LH3;;Procollagen-lysine, 2-oxoglutarate 5-dioxygenase 3 (lysyl hydroxylase 3);603066;REa, A;previously assigned to 7q36;Lysyl hydroxylase 3 deficiency, 612394 (3);5(Plod3)
7.458;9;30;09;7q22.1;POP7, RPP20;;Processing of precursor 7, S. cerevisiae, homolog of;606113;R, REc;;;
7.459;5;23;95;7q22.3;PRKAR2B;;Protein kinase, cAMP-dependent, regulatory, type II, beta;176912;Fd, A, REc;;;
7.460;9;7;10;7q22.1;RASA4, CAPRI, GAPL, KIAA0538;;Ras p21 protein activator 4;607943;REc;;;
7.461;6;23;15;7q22.1;RELN, RL, LIS2, ETL7;;Reelin;600514;A, REc;;Lissencephaly 2 (Norman-Roberts type), 257320 (3); {Epilepsy, familial temporal lobe, 7}, 616436 (3);5(rl)
7.462;3;16;16;7q22.1;SLC12A9, CIP1, CCC6;;Solute carrier family 12 (potassium/chloride transporter), member 9;616861;Psh;;;
7.463;2;23;12;7q22.1;SRRT, ARS2;;Serrate RNA effector molecule, arabidopsis, homolog of;614469;REc;;;
7.464;4;8;16;7q22.1;STAG3, POF8;;Stromalin 3;608489;Psh, R, H, REc;;Premature ovarian failure 8, 615723 (3);5(Stag3)
7.465;9;15;96;7q21.3;TFPI2;;Tissue factor pathway inhibitor-2;600033;A;;;
7.466;5;3;00;7q22.1;TFR2, HFE3;;Transferrin receptor 2;604720;R;;Hemochromatosis, type 3, 604250 (3);
7.467;11;20;98;7q22.1;TRIP6, OIP1;;Thyroid hormone receptor interactor-6;602933;R;;;
7.468;3;5;98;7q22.1;VGF;;VGF nerve growth factor inducible;602186;A;;;
7.469;6;19;98;7q22.1;ZAN;;Zonadhesin;602372;A;;;5(Zan)
7.470;9;21;17;7q22.1;ZASP;;ZO2-associated speckle protein;617677;REc;;;5(Zasp)
7.471;6;16;99;7q31.1;IFRD1;;Interferon-related developmental regulator 1;603502;REc;;;
7.472;8;4;97;7q22.3;GPR22;;G protein-coupled receptor-22;601910;A;;;
7.473;10;19;99;7q22.1;POLR2J;;Polymerase II, RNA, subunit J;604150;REc;;;
7.474;6;22;14;7q22.3-q31.1;SLC26A3, DRA, CLD;;Solute carrier family 26 (sulfate transporter), member 3;126650;A, REc, Fd;5' and close to PDS;Diarrhea 1, secretory chloride, congenital, 214700 (3);
7.475;9;14;89;7q22-q32;G7P1;;Kinase-like protein;148750;REa, Fd;;;
7.476;11;4;04;7q22-q32;SCA18, SMNA;;Spinal cerebellar ataxia 18;607458;Fd;between D7S2418 and D7S1804;Spinocerebellar ataxia 18 (2);
7.477;9;9;08;7q33;CNOT4, NOT4;;CCR4-NOT transcription complex, subunit 4;604911;REc;;;
7.478;7;20;12;7q22-qter;NM, NCR;;Neutrophil migration, abnormal;162820;D;;?Neutrophil chemotactic response, abnormal (2);
7.479;7;18;14;7q22.1;AGFG2, HRBL, RABR;;ADP-ribosylation factor GTPase-activating protein with FG repeats 2;604019;REc;;;
7.480;3;16;10;7q22.1;ALKBH4, ABH4;;AlkB, E. coli, homolog of, 4;613302;REc;;;
7.481;1;14;13;7q22.1;AP1S1, CLAPS1, AP19, MEDNIK;;Adaptor-related protein complex 1, sigma 1 subunit;603531;REa, REc;;MEDNIK syndrome, 609313 (3);
7.482;4;27;12;7q22.1;AP4M1, SPG50, CPSQ3;;Adaptor-related protein complex 4, mu-1 subunit;602296;REc;;Spastic paraplegia 50, autosomal recessive, 612936 (3);
7.483;3;18;94;7q22.1;AZGP1, ZAG;;Alpha-2-glycoprotein, zinc;194460;REa, A;;;
7.484;5;25;13;7q22.1;BUD31, G10;;Bud31, S. cerevisiae, homolog of;603477;REc;;;
7.485;6;22;14;7q22.1;CLDN15;;Claudin 15;615778;REc;;;
7.486;4;23;09;7q22.1;CNPY4, PRAT4B, MGC40499;;Canopy 4, zebrafish, homolog of;610047;R, REc;;;
7.487;10;18;18;7q21.3;COL1A2, EDSCV, EDSARTH2;;Collagen I, alpha-2 polypeptide;120160;S, REa, D, A;~17cM from CF;Ehlers-Danlos syndrome, arthrochalasia type, 2, 617821 (3); Osteogenesis imperfecta, type IV, 166220 (3); Osteogenesis imperfecta, type III, 259420 (3); Osteogenesis imperfecta, type II, 166210 (3); {Osteoporosis, postmenopausal}, 166710 (3); Ehlers-Danlos syndrome, cardiac valvular type, 225320 (3);6(Cola2)
7.488;7;18;12;7q22.1;COPS6, CSN6;;COP9 signalosome, subunit 6;614729;REc;;;
7.489;12;14;95;7q22.1;CYP3A4;;Cytochrome P450, subfamily IIIA (nifedipine oxidase) polypeptide 4;124010;REa, D, Fd, A;;;6(Cyp3)
7.490;1;25;05;7q22.1;CYP3A5, P450PCN3;;Cytochrome P450, subfamily IIIA, polypeptide 5;605325;REc, REn;;{Hypertension, salt-sensitive essential, susceptibility to}, 145500 (3);
7.491;12;7;03;7q22.1;CYP3A7;;Cytochrome P450, subfamily IIIA, polypeptide 7;605340;REn;;;
7.492;12;11;01;7q22.1;CYP3A43;;Cytochrome P450, subfamily IIIa, polypeptide 43;606534;REc;;;
7.493;6;13;12;7q22.1;EBXL13, FBL13;;F-box and leucine-rich repeat protein 13;609080;REc;;;5(Fbxl13)
7.494;8;18;08;7q22.1;GAEC1;;Gene amplified in esophageal cancer 1;612130;REc;;;
7.495;6;10;08;7q22.1;GIGYF1;;GRB10-interacting GYF protein 1;612064;REc, H;;;5(Gigyf1)
7.496;4;1;08;7q22.1;GJC3, CX30.2, CX31.3;;Gap junction protein, gamma-3;611925;R, REc;;;
7.497;9;8;11;7q22.1;KPNA7;;Karyopherin alpha 7;614107;REc;;;
7.498;12;28;08;7q22.2-q22.3;LHFPL3;;LHFP-like protein 3;609719;R, REc;;;
7.499;4;17;13;7q22.1;LRWD1, ORCA;;Leucine-rich repeats- and WD repeat domain-containing protein 1;615167;REc;;;5(Lrwd1)
7.500;3;23;09;7q22.1;MIR25, MIRN25;;Micro RNA 25;612150;REc;;;
7.501;8;3;12;7q22.1;MOGAT3, MGAT3;;Monoacylglycerol O-acyltransferase 3;610184;REc;;;
7.502;11;23;16;7q22.1;MYL10, PLRLC;;Myosin light chain 10;617177;REc;;;
7.503;10;7;08;7q22.1;NAPEPLD;;N-acyl phosphatidylethanolamine-hydrolyzing phospholipase D;612334;REc;;;
7.504;6;22;14;7q22.1;NAT16;;N-acetyltransferase 16;615783;REc;;;
7.505;8;18;08;7q22.1;NFE4;;Transcription factor NFE4;612133;REc;;;
7.506;12;10;13;7q22.1;NYPA1;;Neuronal tyrosine-phosphorylated phosphoinositide 3-kinase adaptor 1;615477;REc;;;
7.507;7;22;09;7q22.1;ORAI2, MEM142B, C7orf19;;ORAI calcium release-activated calcium modulator 2;610929;REc;;;
7.508;2;18;98;7q22.1-q22.2;ORC5, ORC5L;;Origin recognition complex, subunit 5, S. cerevisiae, homolog of;602331;REa, Psh, A, REc;;;
7.509;9;30;09;7q22.1;PDAP1, PAP1, PAP;;PDGFA-associated protein 1;607075;R, REc;;;
7.510;5;3;18;7q22.1;PMPCB, MPPB;;Peptidase, mitochondrial processing, beta;603131;REc;;Multiple mitochondrial dysfunctions syndrome 6, 617954 (3);
7.511;11;11;14;7q22.1;PMS2P1, PMS2L1, PMS3;;Postmeiotic segregation increased 2 pseudogene 1;605038;Psh, A, REc;;;
7.512;4;26;17;7q22.1;PRKRIP1, C114;;PRKR-interacting protein 1, IL11-inducible;617458;REc;;;
7.513;8;21;12;7q22.1;PTCD1, KIAA0632;;Pentatricopeptide repeat domain 1;614774;R, REc;;;
7.514;7;27;16;7q22.1;PVRIG, CD112R, C7orf15;;Poliovirus receptor-related immunoglobulin domain-containing protein;617012;REc;;;
7.515;6;9;15;7q22.1;SLC26A5, PRES, DFNB61;;Solute carrier family 26, member 5;604943;REc;mutation identified in 1 DFNB61 family;?Deafness, autosomal recessive 61, 613865 (3);
7.516;11;05;18;7q22.1;SPDYE2, SPDYB2L1;;SPEEDY/RINGO cell cycle regulator family, member E2;617624;REc;;;
7.517;8;28;17;7q22.1;SPDYE3, SPDYB2;;SPEEDY/RINGO cell cycle regulator family, member E3;617625;REc;;;5(Spdye3)
7.518;9;22;16;7q22.1;TAF6, TAF2E, TAFII80, ALYUS;;TAF6 RNA polymerase II, TATA box-binding protein-associated factor, 80kD;602955;R, REc;;Alazami-Yuan syndrome, 617126 (3);
7.519;6;26;16;7q22.1;TRIM56;;Tripartite motif-containing protein 56;616996;REc;;;
7.520;5;24;13;7q22.1;ZKSCAN5, ZFP95, KIAA1015;;Zinc finger protein with KRAB and SCAN domains 5;611272;REc, R, A;;;5(Zkscan5)
7.521;11;2;04;7q22.1;TTC11, FIS1;;Tetratricopeptide repeat domain 11;609003;R, REc;;;
7.522;10;13;09;7q22.1;UFSP1;;UFM1-specific peptidase 1;611481;REc;;;
7.523;9;30;09;7q22.1;ZNF3;;Zinc finger protein-3;194510;R, REc;?relation to ZNF4, ZNF5; previous assignment to Chr.5;;
7.524;3;1;18;7q22.1;ZNF655, VIK;;Zinc finger protein 655;617891;REc;;;
7.525;11;4;98;7q22.1;PSMC2, MSS1, S7;;Proteasome 26S subunit, ATPase, 2;154365;A;;;
7.526;4;8;08;7q22.3;NAMPT, PBEF1, VF, PBEF;;Nicotinamide phosphoribosyltransferase;608764;R, REc;;;
7.527;10;9;08;7q22.3;CBLL1, HAKAI, RNF188;;Cas-Br-M murine ectopic retroviral transforming sequence like-1;606872;R, REc;;;
7.528;2;2;14;7q22.3;CDHR3;;Cadherin-related family, member 3;615610;REc;;;
7.529;12;22;15;7q22.3;HBP1;;HMG-box transcription factor 1;616714;REc;;;
7.530;5;29;12;7q22.3;MPVQTL6;;Mean platelet volume quantitative trait locus 6;614646;Fd;associated with rs342293;Mean platelet volume QTL6 (2);
7.531;3;12;15;7q22.3;PUS7, KIAA1897;;Pseudouridylate synthase 7, putative;616261;REc;;;
7.532;7;19;12;7q22.3;RINT1;;RAD50-interacting protein 1;610089;REc;;;
7.533;12;1;15;7q22.3;SYPL1, SYPL;;Synaptophysin-like 1;616665;REc;;;
7.534;3;1;06;7q22.3-q31.1;CMD1Q;;Cardiomyopathy, dilated, 1Q;609915;Fd;between D7S2545 and D7S2554;Cardiomyopathy, dilated, 1Q (2);
7.535;11;19;13;7q31;AUTS9;;Autism, susceptibility to, 9;611015;Fd;max lod near D7S530;{Autism, susceptibility to, 9} (2);
7.536;1;18;11;7q22.3;COG5, GOLTC1, GTC90, CDG2I;;Component of oligomeric golgi complex 5;606821;REc;;Congenital disorder of glycosylation, type IIi, 613612 (3);
7.537;12;20;05;7q31.31;CTTNBP2, CORTBP2, KIAA1758;;Cortactin-binding protein 2;609772;REn;;;
7.538;5;20;99;7q31;DFNB14;;Deafness, autosomal recessive 14;603678;Fd;?same as DFNB17;Deafness, autosomal recessive 14 (2);
7.539;9;9;98;7q31;DFNB17;;Deafness, autosomal recessive 17;603010;Fd;;Deafness, autosomal recessive 17 (2);
7.540;4;9;03;7q31.1;DOCK4, KIAA0716;;Dedicator of cytokinesis 4;607679;REc;;;12(Dock4)
7.541;11;4;98;7q31.33;GPR37;;G protein-coupled receptor-37;602583;REc;;;
7.542;9;15;00;7q31.1;GPR85, SREB2;;G protein-coupled receptor-85;605188;R;;;
7.543;5;4;00;7q31.32;HYAL4;;Hyaluronoglucosaminidase 4;604510;A, REc;;;
7.544;10;6;08;7q31.1;IMMP2L, IMP2;;Inner mitochondrial membrane peptidase, subunit 2, S. cerevisiae, homolog of;605977;Ch;;;
7.545;1;27;03;7q31.31;ING3, P47ING3;;Inhibitor of growth family, member 3;607493;REc;;;
7.546;11;27;00;7q31.31;KCND2, KIAA1044;;Potassium voltage-gated channel, Shal-related subfamily, member 2;605410;R;;;
7.547;4;21;16;7q31.2;MET, DFNB97, OSFD;;Oncogene MET;164860;REa, A, F;mutation identified in 1 DFNB97 family;Renal cell carcinoma, papillary, 1, familial and somatic, 605074 (3); Hepatocellular carcinoma, childhood type, somatic, 114550 (3); ?Deafness, autosomal recessive 97, 616705 (3); {Osteofibrous dysplasia, susceptibility to}, 607278 (3);6(Met)
7.548;5;4;15;7q31.1;PNPLA8, MMLA;;Patatin-like phospholipase domain-containing protein 8;612123;REc;mutation identified in 1 MMLA family;?Mitochondrial myopathy with lactic acidosis, 251950 (3);
7.549;7;6;12;7q22.3;SLC26A4, PDS, DFNB4, EVA, TDH2B;;Solute carrier family 26 (sulfate transporter), member 4;605646;Fd;some patients have digenic mutations with FOXI1;Pendred syndrome, 274600 (3); Deafness, autosomal recessive 4, with enlarged vestibular aqueduct, 600791 (3);
7.550;11;13;95;7q31.32;SPAM1;;Sperm adhesion molecule 1 (PH-20 hyaluronidase, zona pellucida binding);600930;A;;;
7.551;3;23;06;7q33;STRA8;;Stimulated by retinoic acid 8, mouse, homolog of;609987;REc;;;
7.552;11;26;01;7q31.1;FOXP2, SPCH1, TNRC10, CAGH44;;Forkhead box P2;605317;Fd, Ch, REc;;Speech-language disorder-1, 602081 (3);
7.553;9;8;11;7q33;EXOC4, SEC8, KIAA1699;;Exocyst complex component 4;608185;REc, R;;;
7.554;5;9;18;7q31.32;TAS2R16, T2R16, BGLPT;;Taste receptor type 2, member 16;604867;REc;;[Beta-glycopyranoside tasting], 617956 (3) {Alcohol dependence, susceptibility to}, 103780 (3);6(T2r18)
7.555;6;10;94;7q31.2;WNT2, INT1L1;;Wingless-type MMTV integration site family, member 2;147870;C;isolated by CMGT with MET;;6(Irp, Wnt2)
7.556;12;4;90;7q36.1;ABP1;;Amiloride-binding protein-1;104610;A;;;
7.557;3;20;08;7q32.1;CCDC136, NAG6, KIAA1793;;Coiled-coil domain-containing protein 136;611902;REn;;;
7.558;3;7;13;7q31.1;DLD, LAD, PHE3, DLDD;;Dihydrolipoamide dehydrogenase (E3 component of pyruvate dehydrogenase complex, 2-oxo-glutarate complex);238331;REa;;Dihydrolipoamide dehydrogenase deficiency, 246900 (3);12(Dld)
7.559;8;28;01;7q31.32;SLC13A1, NAS1;;Solute carrier family 13 (sodium/sulfate symporters), member 1;606193;R;;;
7.560;7;22;16;7q32.1;SMOH, SMO, CRJS;;Smoothened, Drosophila, homolog of;601500;A;;Basal cell carcinoma, somatic, 605462 (3); Curry-Jones syndrome, somatic mosaic, 601707 (3);
7.561;4;16;11;7q33;BPGM;;2,3-bisphosphoglycerate mutase;613896;A;;Erythrocytosis due to bisphosphoglycerate mutase deficiency, 222800 (3);
7.562;1;30;18;7q31.1;BMT2, SAMTOR, C7orf60;;Base methyltransferase of 25S rRNA 2, S. cerevisiae, homolog of;617855;REc;;;
7.563;4;10;14;7q31.2;CAV1, BSCL3, CGL3, PPH3, LCCNS;;Caveolin-1;601047;REc;mutation identified in 1 CGL3 family; mutation identified in 1 LCCNS family;?Lipodystrophy, congenital generalized, type 3, 612526 (3); Pulmonary hypertension, primary, 3, 615343 (3); ?Partial lipodystrophy, congenital cataracts, and neurodegeneration syndrome, 606721 (3);
7.564;3;29;99;7q31.2;CAV2;;Caveolin-2;601048;REc;;;6(Cav2)
7.565;2;1;11;7q31.1;DNAJB9, MDG1;;DnaJ, E. coli, homolog of, subfamily B, member 9 (microvascular endothelial differentiation gene-1);602634;REc;previously assigned to chr.14 by FISH;;
7.566;6;2;15;7q31.1;LAMB4;;Laminin, beta-4;616380;REc;;;
7.567;3;29;12;7q31.1-q31.2;MDFIC, HIC;;MYOD family inhibitor domain-containing protein;614511;REc;;;
7.568;11;7;01;7q31.2;ST7, TSG7, RAY1, FAM4A1;;Suppressor of tumorigenicity 7 (breast);600833;C, D;;;
7.569;3;29;10;7q31.31;TSPAN12, NET2, EVR5;;Tetraspanin 12;613138;REc;;Exudative vitreoretinopathy 5, 613310 (3);6(Tspan12)
7.570;1;20;09;7q31.1;THAP5;;THAP domain-containing protein 5;612534;REc;;;
7.571;1;29;01;7q31.1;ZNF277;;Zinc finger protein-277;605465;REn;;;
7.572;1;21;97;7q31.1;NRCAM;;Neuronal cell adhesion molecule;601581;A;;;
7.573;4;23;13;7q31.1;LAMB1, LIS5;;Laminin, beta-1;150240;REa, A, Ch;;Lissencephaly 5, 615191 (3);1(Lamb1)
7.574;4;9;18;7q31.2;CFTR, ABCC7, CF, MRP7;;Cystic fibrosis transmembrane conductance regulator (ATP-binding cassette, subfamily C, member 7);602421;F, Fd;distal and 5' to MET;Cystic fibrosis, 219700 (3); Congenital bilateral absence of vas deferens, 277180 (3); Sweat chloride elevation without CF (3); {Pancreatitis, hereditary}, 167800 (3); {Hypertrypsinemia, neonatal} (3); {Bronchiectasis with or without elevated sweat chloride 1, modifier of}, 211400 (3);6(Cftr)
7.575;7;11;01;7q31.2;TES;;Testin;606085;REc;;;6(Tes)
7.576;7;17;14;7q31.2;TFEC, TFECL;;Transcription factor EC;604732;REc;;;
7.577;2;19;97;7q31.2;CAPZA2, CAPPA2;;Capping protein (actin filament) muscle Z-line, alpha 2;601571;Psh, REn;;;6(Cappa2)
7.578;8;9;00;7q31.32;AASS;;Alpha-aminoadipic semialdehyde synthase;605113;R;;Hyperlysinemia, 238700 (3); Saccharopinuria, 268700 (1);
7.579;1;30;07;7q31.31;ANKRD7;;Ankyrin repeat domain-containing protein 7;610731;REc;;;
7.580;5;12;99;7q32.1;ARF5;;ADP-ribosylation factor 5;103188;REc;;;
7.581;4;30;09;7q31.2;ASZ1, ALP1, ANKL1, GASZ;;Ankyrin repeat, SAM, and basic leucine zipper domain-containing 1;605797;REc;;;
7.582;3;24;06;7q31.32;CADPS2, KIAA1591;;Calcium-dependent activator protein for secretion 2;609978;A;;;
7.583;5;28;13;7q31.31;FAM3C;;Family with sequence similarity 3, member C;608618;REc, R;;;
7.584;2;6;14;7q31.32;FEZF1, FEZ, ZNF312B, HH22;;FEZ family zinc finger protein 1;613301;REc;;Hypogonadotropic hypogonadism 22, with or without anosmia, 616030 (3);
7.585;11;25;14;7q31.32;LMOD2, CLMOD;;Leiomodin 2;608006;REc;;;
7.586;6;22;14;7q32.1;FSCN3;;Fascin actin-bundling protein 3, testicular;615800;A;;;
7.587;12;11;12;7q32.1;LEP, OB, LEPD;;Leptin (murine obesity homolog);164160;H, REa, REc, A;in mouse cen-Cola-2-Met-ob-Cpa-Tcrb-tel;Obesity, morbid, due to leptin deficiency, 614962 (3);6(ob)
7.588;1;23;01;7q32.1;P100, SND1;;EBNA-2 coactivator p100;602181;REc, REa, A;;;
7.589;7;13;18;7q31.32;PTPRZ1, PTP18;;Protein-tyrosine phosphatase, receptor-type, zeta-1, polypeptide;176891;REa, A;;;
7.590;2;17;09;7q31.3;STQTL2;;Stature quantitative trait locus 2;606256;Fd;max lod at D7S195;{Stature QTL 2} (2);
7.591;2;25;15;7q31.32;WASL, NWASP;;Wiskott-Aldrich syndrome gene-like;605056;REc;;;
7.592;7;19;12;7q31.31;WNT16;;Wingless-type MMTV integration site family, member 16;606267;REc;;;
7.593;3;19;14;7q31.31;LSM8;;LSM8, S. cerevisiae, homolog of, U6 small nuclear RNA associated;607288;REc;;;
7.594;3;31;11;7q32.1;IMPDH1, RP10, LCA11;;Inosine-5'-monophosphate dehydrogenase, type I;146690;Psh, A, Fd;pseudogene on 16p13.13;Retinitis pigmentosa 10, 180105 (3); Leber congenital amaurosis 11, 613837 (3);
7.595;8;30;10;7q32.1;OPN1SW, BCP, CBT;;Blue cone pigment (opsin 1, short-wave-sensitive);613522;REa, A;;Colorblindness, tritan, 190900 (3);6(Bcp)
7.596;4;28;00;7q34;TAS2R3, T2R3;;Taste receptor type 2, member 3;604868;REc;;;
7.597;4;28;00;7q34;TAS2R4, T2R4;;Taste receptor type 2, member 4;604869;REc;;;6(T2R8)
7.598;1;31;01;7q34;TAS2R5, T2R5;;Taste receptor type 2, member 5;605062;REc;;;
7.599;6;4;98;7q31.33;GRM8;;Glutamate receptor, metabotropic-8;601116;A;;;
7.600;9;24;15;7q31.33;POT1, CMM10, GLM9;;Protection of telomeres 1;606478;REc;;{Melanoma, cutaneous malignant, susceptibility to, 10}, 615848 (3); {Glioma susceptibility 9}, 616568 (3);
7.601;10;6;09;7q32;BCC6;;Basal cell carcinoma, susceptibility to, 6;613063;Fd;associated with rs157935;{Basal cell carcinoma, susceptibility to, 6} (2);
7.602;2;9;12;7q32.2;CEP41, TSGA14, JBTS15;;Centrosomal protein, 41kD;610523;REc;;Joubert syndrome 15, 614464 (3);
7.603;5;26;13;7q32.2;COPG2IT1, CIT1;;Coatomer protein complex, subunit gamma-2, intronic transcript 1;610581;REc;;;
7.604;3;20;03;7q32.2;CPA4, CPA3;;Carboxypeptidase A4;607635;RE;;;
7.605;11;12;96;7q32.2;MEST, PEG1;;Mesoderm specific transcript, mouse, homolog of;601029;A, H, REc;imprinted maternally;;6(Mest)
7.606;1;13;99;7q32.1;CALU;;Calumenin;603420;;;;7(Calu)
7.607;4;19;01;7q32;CATR1;;CATR tumorigenic conversion 1;600676;REc;;;
7.608;2;1;00;7q32.2;COPG2;;Coatomer protein complex, subunit gamma-2;604355;REc;;;
7.609;4;19;01;7q32.2;CPA2;;Carboxypeptidase A2, pancreatic;600688;REc;;;
7.610;7;22;16;7q32.1;FLNC, FLN2, ABPA, ABPL, MFM5, MPD4, CMH26, RCM5;;Filamin C (actin-binding protein-280);102565;REa, R, H;;Myopathy, myofibrillar, 5, 609524 (3); Myopathy, distal, 4, 614065 (3); Cardiomyopathy, familial hypertrophic, 26 (3); Cardiomyopathy, familial restrictive 5, 617047 (3);6(Fln2)
7.611;9;24;08;7q32.1;IRF5, IBD14, SLEB10;;Interferon regulatory factor 5;607218;REc;;{Inflammatory bowel disease 14}, 612245 (3); {Systemic lupus erythematosus, susceptibility to, 10}, 612251 (3);
7.612;2;9;01;7q32.3;MKLN1;;Muskelin 1;605623;REc, A;;;6(Mkln1)
7.613;5;8;97;7q31.32;NDUFA5, UQOR13;;NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 5 (13kD, B13);601677;REa, A;;;
7.614;4;1;96;7q32.2;NRF1;;Nuclear respiratory factor 1;600879;Psh, A;earlier location = 7q31;;
7.615;8;5;15;7q32.1;PAX4, MODY9, KPD;;Paired box homeotic gene-4;167413;REa, A;;Maturity-onset diabetes of the young, type IX, 612225 (3); Diabetes mellitus, type 2, 125853 (3); {Diabetes mellitus, ketosis-prone, susceptibility to}, 612227 (3);6(Pax4)
7.616;9;12;11;7q32;PBC4;;Biliary cirrhosis, primary, 4;614220;Fd;associated with rs10488631;Biliary cirrhosis, primary, 4 (2);
7.617;9;28;05;7q32;PPR3;;Photoparoxysmal response 3;609573;Fd;max lod at D7S1804;Photoparoxysmal response 3 (2);
7.618;4;19;01;7q32.2;UBE2H, UBCH2, UBC8;;Ubiquitin-conjugating enzyme E2H (homologous to yeast UBC8);601082;REa, REc;;;
7.619;1;23;09;7q33;AKR1D1, SRD5B1, CBAS2;;Bile acid synthesis defect, congenital, 2;604741;REc;;Bile acid synthesis defect, congenital, 2, 235555 (3);
7.620;11;4;98;7q32.3;PODXL, PCLP;;Podocalyxin-like;602632;A, Psh;;;
7.621;4;19;11;7q32-q33;SCA32;;Spinocerebellar ataxia 32;613909;Fd;between rs3847110 and rs2241728;Spinocerebellar ataxia 32 (2);
7.622;4;24;08;7q34;MRPS33;;Mitochondrial ribosomal protein S33;611993;REc;4 pseudogenes;;
7.623;8;14;15;7q33-q34;TRIM24, TIF1, TIF1A, PTC6;;Tripartite motif-containing protein 24 (Transcriptional intermediary factor 1);603406;A;fused with RET to form PTC6;;
7.624;11;5;97;7q34-q35;EPHA1, EPHT1;;eph tyrosine kinase 1 (erythropoietin-producing hepatoma amplified sequence; oncogene EPH; ephrin receptor EphA1);179610;REa, A;;;
7.625;7;13;89;7q34;PIP;;Prolactin-inducible protein;176720;REa, A;;;
7.626;6;11;91;7q32.2;CPA1;;Carboxypeptidase A;114850;REa, Fd;both CPA and TRY1 = serine proteases;;6(Cpa)
7.627;8;26;16;7q32.1;AHCYL2;;Adenosylhomocysteinase-like 2;616520;REc;;;
7.628;4;23;09;7q32.1;GCC1, GCC88;;GRIP and coiled-coil domains-containing protein 1;607418;R;;;
7.629;3;13;18;7q32.1;HILPDA, HIG2;;Hypoxia-inducible lipid droplet-associated protein;617905;REc;;;
7.630;2;25;15;7q32.1;LRRC4;;Leucine-rich repeat-containing protein 4;610486;REc;;;
7.631;2;9;15;7q32.1;RBM28, ANES;;RNA-binding motif protein 28;612074;R, REc, Fd;mutation identified in 1 ANES family;?Alopecia, neurologic defects, and endocrinopathy syndrome, 612079 (3);
7.632;3;23;18;7q32.1;STRIP2, FAR11B, FAM40B;;Striatin-interacting protein 2;617919;REc;;;
7.633;09;27;18;7q32.1;TNPO3, TRNSR, LGMDD2;;Transportin 3;610032;R, REc, Fd;;Muscular dystrophy, limb-girdle, autosomal dominant 2, 608423 (3);
7.634;3;20;14;7q32.1;TSPAN33, PEN;;Tetraspanin 33;610120;REc, A;;;
7.635;4;8;13;7q32.2;KLHDC10, SLIM;;KELCH domain-containing protein 10;615152;R, REc;;;
7.636;6;26;11;7q32.2;LKF14, BTEB5;;Kruppel-like factor 14;609393;REc;;;6(Klf14)
7.637;10;12;09;7q32.2;MIR96, MIRN96, DFNA50;;Micro RNA 96;611606;REc;;Deafness, autosomal dominant 50, 613074 (3);6(Mirn96)
7.638;3;23;09;7q32.2;MIR182, MIRN182;;Micro RNA 182;611607;REc, H;;;6(Mirn182)
7.639;3;23;09;7q32.2;MIR183, MIRN183;;Micro RNA 183;611608;R, REc;;;
7.640;9;12;11;7q32.2-q36.1;HYSP3;;Hypospadias 3, autosomal;146450;Fd;between D7S2519 and D7S2442.;Hypospadias 3, autosomal (2);
7.641;7;1;05;7q32.1;KCP;;Kielin/chordin-like protein;609344;REc;;;6(Kcp)
7.642;3;23;09;7q32.3;MIR29A, MIRN29A;;Micro RNA 29A;610782;REc;;;
7.643;10;08;08;7q32.3;BMIQ1;;Body mass index quantitative trait locus 1;606641;Fd;max lod at D7S1804;[Body mass index QTL1] (2);
7.644;12;11;18;7q32.3;LINC-PINT, PINT;;Long intergenic noncoding RNA, p53-induced transcript;618212;REc;;;6(Linc-Pint)
7.645;3;23;09;7q32.3;MIR29B1, MIRN29B1;;Micro RNA 29B1;610783;REc;;;
7.646;9;30;09;7q32.3;PLXNA4;;Plexin A4;604280;TM, REc;;;
7.647;2;2;01;7q33;DGKI;;Diacylglycerol kinase, iota, 130-kD;604072;A;;;
7.648;2;21;11;7q32-q33;CHCHD3;;Coiled-coil-helix-coiled-coil-helix domain-containing protein 3;613748;REc;;;
7.649;2;9;17;7q33;AGBL3, CCP3;;ATP/GTP-binding protein-like 3;617346;REc;;;
7.650;5;29;12;7q33;AKR1B10, ARL1;;Aldo-keto reductase family 1, member B10;604707;REc;;;
7.651;4;30;15;7q33;AKR1B15, AKR1B10L, AKR1R1B7;;Aldo-keto reductase family 1, member B15;616336;REc;;;
7.652;1;5;93;7q33;CALD1, CDM;;Caldesmon-1;114213;A;;;
7.653;3;24;06;7q34;CLEC5A, CLECSF5, MDL1;;C-type lectin domain family 5, member A;604987;A;;;
7.654;9;16;12;7q33;CREB3L2, BBF2H7;;cAMP response element-binding protein 3-like 2;608834;REc;;;
7.655;08;10;18;7q33;CYREN, C7orf49, MRI;;Cell cycle regulator of nonhomologous end joining;616980;REc;;;
7.656;9;11;12;7q34;KEL;;Kell blood group;613883;Fd, REa, A;;[Blood group, Kell], 110900 (3);
7.657;8;26;15;7q33;LRGUK;;Leucine-rich repeats- and guanylate kinase domain-containing protein;616478;REc;;;
7.658;4;23;09;7q33;LUZP6, MPD6;;Leucine zipper protein 6;611050;REc;;;
7.659;6;2;16;7q33;MIR490;;Micro RNA 490;616972;REc;;;
7.660;4;7;16;7q33;NUP205, C7orf14, KIAA0225, NPHS13;;Nucleoporin, 205kD;614352;R, REc;mutation identified in 1 NPHS13 family;?Nephrotic syndrome, type 13, 616893 (3);
7.661;9;27;94;7q33;PTN, NEGF1;;Pleiotrophin (heparin binding growth factor 8, neurite growth-promoting factor 1);162095;REa, A;;;6(Ptn)
7.662;12;14;99;7q33;SLC13A4, SUT1;;Solute carrier family 13 (sodium/sulfate symporters), member 4 (sulfate transporter 1);604309;REc;;;
7.663;4;18;07;7q33;SLC35B4;;Solute carrier family 35 (UDP-xylose/UDP-N-acetylglucosamine transporter), member B4;610923;REc;;;
7.664;5;23;16;7q33;WDR91, SORF1;;WD repeat-containing protein 91;616303;REc;;;
7.665;7;16;02;7q34;ATP6V0A4, ATP6N1B, VPP2, RTA1C, RTADR;;ATPase, H+ transporting, V0 subunit a4;605239;Fd;;Renal tubular acidosis, distal, autosomal recessive, 602722 (3);
7.666;4;23;02;7q34;HIPK2;;Homeodomain-interacting protein kinase 2;606868;A;;;
7.667;11;15;18;7q34;TRPV6, ECAC2, CAT1, CATL, HRPTTN;;Transient receptor potential cation channel, subfamily V, member 6;606680;A;;Hyperparathyroidism, transient neonatal, 618188 (3);
7.668;1;23;01;7q35;ARHGEF5, TIM;;Rho guanine nucleotide exchange factor-5 (oncogene TIM);600888;REa, A;;;
7.669;7;10;98;7q34;EPHB6, HEP;;Ephrin receptor EPHB6;602757;A;;;
7.670;1;10;02;7q33;MTPN;;Myotrophin;606484;A;;;
7.671;7;23;13;7q34;AGK, MULK, MTDPS10, CATC5, CTRCT38;;Acylglycerol kinase;610345;REc;;Sengers syndrome, 212350 (3); Cataract 38, autosomal recessive, 614691 (3);
7.672;2;8;11;7q34;BRAF, NS7;;Murine sarcoma viral (v-raf) oncogene homolog B1;164757;A, REa;pseudogene BRAF2 on Xq13 or 7q;Melanoma, malignant, somatic (3); Colorectal cancer, somatic (3); Adenocarcinoma of lung, somatic, 211980 (3); Nonsmall cell lung cancer, somatic (3); Cardiofaciocutaneous syndrome, 115150 (3); Noonan syndrome 7, 613706 (3); LEOPARD syndrome 3, 613707 (3);10(Braf)
7.673;10;2;12;7q34;GSTK1;;Glutathione S-transferase, kappa-1;602321;REc;;;
7.674;4;26;10;7q34;KIAA1549;;KIAA1549 gene;613344;Psh, REc;;;
7.675;9;30;09;7q34;LUC7L2;;Luc7, S. cerevisiae, homolog of, 2;613056;REc, H;;;6(Luc7l2)
7.676;4;1;03;7q34;MGAM, MGA;;Maltase-glucoamylase;154360;REc;similar to EST GS1365;;
7.677;11;27;18;7q34;NDUFB2;;NADH-ubiquinone oxidoreductase 1 beta subcomplex;603838;REc;;;
7.678;12;17;08;7q34;PARP12, ZC3HDC1, FLJ22693;;Poly(ADP-ribose) polymerase family, member 12;612481;REc;;;
7.679;1;18;96;7q34;SSBP1, SSBP;;Single-stranded DNA-binding protein 1;600439;Psh, A;;;
7.680;1;2;08;7q34;SVOPL;;SV2-related protein-like;611700;REc;;;6(Svopl)
7.681;9;21;11;7q34;TBXAS1, GHOSAL, CYP5, BDPLT14;;Thromboxane A synthase 1, platelet;274180;A, Fd;;Ghosal hematodiaphyseal syndrome, 231095 (3); ?Thromboxane synthase deficiency, 614158 (1);6(Tbxas1)
7.682;5;10;18;7q34;TAS2R38, T2R61, PTC, THIOT;;Taste receptor, type 2, member 38;607751;Fd, REc;;[Phenylthiocarbamide tasting], 171200 (3);
7.683;6;27;11;7q34;TAS2R40, T2R40;;Taste receptor, type 2, member 40;613964;REc;;;
7.684;8;26;15;7q34;TMEM139;;Transmembrane protein 139;616524;REc;;;
7.685;2;13;12;7q35;TPK1, THMD5;;Thiamine pyrophosphokinase;606370;A;;Thiamine metabolism dysfunction syndrome 5 (episodic encephalopathy type), 614458 (3);
7.686;10;15;13;7q34;TRBC1;;T-cell receptor beta chain constant region 1;186930;REa, A;;;6(Tcrb)
7.687;10;15;13;7q34;TRBC2;;T-cell receptor beta chain constant region 2;615445;REc;;;
7.688;10;15;13;7q34;TRBV@;;T-cell receptor beta chain variable gene cluster;615446;REc;;;
7.689;10;15;13;7q34;TRBJ@;;T-cell receptor beta chain joining gene cluster;615449;REc;;;
7.690;10;15;13;7q34;TRBD1;;T-cell receptor beta chain diversity gene 1;615447;REn;;;
7.691;10;15;13;7q34;TRBD2;;T-cell receptor beta chain diversity gene 2;615448;REc;;;
7.692;4;27;17;7q34;TTC26, IFT56;;Tetratricopeptide repeat domain-containing protein 26;617453;REc;;;
7.693;3;31;11;7q34;UBN2;;Ubinuclein 2;613841;REc;;;
7.694;6;10;18;7q34;WEE2, WEE1B, OOMD5;;Wee1, S. pombe, homolog of, 2;614084;REc;;Oocyte maturation defect 5, 617996 (3);
7.695;11;30;06;7q34;ZC3HAV1, ZAP, FLJ13288, FLB6421;;Zinc finger CCCH domain-containing antiviral protein 1;607312;REc;;;6(Zap)
7.696;9;30;98;7q34;ZYX;;Zyxin;602002;Psh, A;;;
7.697;10;16;12;7q34-q36;DHMN1;;Neuronopathy, distal hereditary motor, type I;182960;Fd;between D7S2513 and D7S637;Neuronopathy, distal hereditary motor, type I (2);
7.698;10;15;98;7q34-q36;DFNB13;;Deafness, autosomal recessive 13;603098;Fd;;Deafness, autosomal recessive 13 (2);
7.699;3;12;01;7q34-q36;OTSC2;;Otosclerosis 2;605727;Fd;;Otosclerosis 2 (2);
7.700;1;22;08;7q36.1;ACCN3, ASIC3, TNAC1, DRASIC;;Cation channel, amiloride-sensitive, neuronal 3;611741;R;;;
7.701;12;2;99;7q33;AKR1B1, ALDR1;;Aldo-keto reductase family 1, member B1;103880;REa, A;;;
7.702;8;30;95;7q34;CLCN1;;Chloride channel-1, skeletal muscle;118425;H, REa, Fd;;Myotonia congenita, recessive, 255700 (3); Myotonia congenita, dominant, 160800 (3); Myotonia levior, recessive (3);6(adr, Clc1)
7.703;8;19;98;7q34;CASP2, NEDD2, ICH1;;Caspase 2, apoptosis-related cysteine protease (neural precursor cell expressed, developmentally down-regulated 2);600639;R;;;
7.704;5;20;13;7q36.1;EZH2, EZH1, WVS;;Enhancer of zeste, Drosophila, homolog of, 2;601573;REc, Psh, A;pseudogene on 21q22;Weaver syndrome, 277590 (3);6(Ezh2)
7.705;10;6;08;7q36.1;FASTK, FAST;;Fas-activated serine/threonine kinase;606965;R, REc;;;
7.706;2;4;15;7q35;NOBOX, POF5;;Newborn ovary homeobox, mouse, homolog of;610934;REc;;Premature ovarian failure 5, 611548 (3);6(Nobox)
7.707;8;8;13;7q35;OR2F1, OLF3;;Olfactory receptor, family 2, subfamily F, member 1;608497;REa, Psh;;;
7.708;7;1;11;7q34;PRSS1, TRY1;;Protease, serine, 1 (trypsin 1);276000;REa, Fd, REn, R;8 trypsinogen genes embedded in TCRB locus;Pancreatitis, hereditary, 167800 (3); Trypsinogen deficiency, 614044 (1);6(Try1)
7.709;5;31;06;7q34;PRSS2, TRY2;;Protease, serine, 2 (trypsin 2);601564;REn, Fd;;{Pancreatitis, chronic, protection against}, 167800 (3);
7.710;6;26;11;7q35;TAS2R41, T2R59;;Taste receptor, type 2, member 41;613965;REa, REc;;;
7.711;6;26;11;7q35;TAS2R60, T2R60;;Taste receptor, type 2, member 60;613968;REa, REc;;;
7.712;1;4;16;7q35;TCAF1, FAM115A, KIAA0738;;TRPM8 channel-associated factor 1;616251;R, REc;;;
7.713;1;4;16;7q35;TCAF2, FAM115C, FAM139A;;TRPM8 channel-associated factor 2;616252;REc;;;
7.714;5;7;03;7q34;TRPV5, ECAC1, CAT2;;Transient receptor potential cation channel, subfamily V, member 5;606679;R, A;;;
7.715;1;29;01;7q36.1;ABCB8, MABC1;;ATP-binding cassette, subfamily B, member 8;605464;REc, REa;;;
7.716;2;19;10;7q35-q36;CNTNAP2, CASPR2, NRXN4, CDFE, AUTS15, PTHSL1;;Contactin-associated protein-like 2;604569;REc;;Cortical dysplasia-focal epilepsy syndrome, 610042 (3); {Autism susceptibility 15}, 612100 (3); Pitt-Hopkins like syndrome 1, 610042 (3);
7.717;8;11;91;7q33;CHRM2;;Cholinergic receptor, muscarinic, 2;118493;A, REa, Fd;;;
7.718;1;23;90;7q35-q36;D7S437, MS3315;;Minisatellite 33.15;157570;REa, A;;;
7.719;11;3;98;7q35-q36;GPDS1, PDS1;;Glaucoma-related pigment dispersion syndrome-1;600510;Fd;;Pigment dispersion syndrome (2);
7.720;1;13;11;7q36.1;KCNH2, LQT2, HERG, SQT1;;Potassium voltage-gated channel, subfamily H, member 2 (human ether-a-go-go-related gene);152427;Fd, REn, A;;Long QT syndrome 2, 613688 (3); {Long QT syndrome 2, acquired, susceptibility to}, 613688 (3); Short QT syndrome 1, 609620 (3);
7.721;11;28;94;7q36.1;SLC4A2, AE2, EPB3L1;;Solute carrier family 4, anion exchanger, member 2 (erythrocyte membrane protein band 3-like 1);109280;REa, A;;;5(Ae2)
7.722;1;5;09;7q35-q36;SLI4;;Specific language impairment 4;612514;Fd;associated with rs1723629;{Specific language impairment 4} (2);
7.723;6;16;99;7q36.1;SMARCD3, BAF60C;;SWI/SNF related, matrix-associated, actin-dependent regulator of chromatin, subfamily D, member 3;601737;Psh, R;;;
7.724;12;24;08;7q36.1;ABCF2, HUSSY18;;ATP-binding cassette, subfamily F, member 2;612510;Psh, R, REc;;;
7.725;6;14;01;7q36;ACRPS;;Acropectoral syndrome;605967;Fd;;Acropectoral syndrome (2);
7.726;10;7;05;7q36;AD10;;Alzheimer disease-10;609636;Fd;max lod with D7S798;Alzheimer disease-10 (2);
7.727;6;12;12;7q36.1;ATP6V0E2;;ATPase, H+ transporting, V0 subunit e2;611019;REc;;;
7.728;11;19;13;7q36;AUTS10;;Autism, susceptibility to, 10;611016;Fd;max lod at D7S483;{Autism, susceptibility to, 10} (2);
7.729;2;16;04;7q36.3;BLACE;;B-cell acute lymphoblastic leukemia-expressed gene;608450;R;;;
7.730;5;24;13;7q36.3;C7orf13;;Chromosome 7 open reading frame 13;610242;REc;overlaps RNF32 on the opposite strand;;
7.731;5;4;15;7q36.1;CDK5, LIS7;;Cyclin-dependent kinase 5;123831;A;mutation identified in 1 LIS7 family;?Lissencephaly 7 with cerebellar hypoplasia, 616342 (3);5(cdk5)
7.732;11;19;13;7q36.3;EN2;;Engrailed-2;131310;REa, A;;;5(En2)
7.733;6;16;99;7q36.1;GBX1;;Gastrulation brain homeobox 1;603354;A;;;5(Gbx1)
7.734;11;5;97;7q36.3;INSIG1;;Insulin-induced gene 1;602055;A;;;
7.735;11;14;17;7q36.1;KMT2C, MLL3, KIAA1506, KLEFS2;;Lysine (K)-specific methyltransferase 2C;606833;A;;Kleefstra syndrome 2, 617768 (3);
7.736;11;6;14;7q36.3;LMBR1, ACHP, C7orf2, PPD2, THYP, LSS;;Limb region 1, mouse, homolog of;605522;Fd, HZ, Fd;;Acheiropody, 200500 (3); Polydactyly, preaxial type II, 174500 (3); Triphalangeal thumb, type I, 174500 (3); Triphalangeal thumb-polysyndactyly syndrome, 174500 (3); Syndactyly, type IV, 186200 (3); Hypoplastic or aplastic tibia with polydactyly, 188740 (3); Laurin-Sandrow syndrome, 135750 (3);5(Lmbr1)
7.737;2;21;10;7q36.3;MNX1, HLXB9, HOXHB9, SCRA1;;Motor neuron and pancreas homeobox 1;142994;Fd, REc;;Currarino syndrome, 176450 (3);
7.738;5;26;13;7q36.3;NOM1, C7orf3;;Nucleolar protein with MIF4G domain 1;611269;REc;;;5(Nom1)
7.739;7;8;10;7q36.1;NOS3;;Nitric oxide synthase 3, endothelial cell;163729;REa, A, Psh;;{Coronary artery spasm 1, susceptibility to} (3); {Alzheimer disease, late-onset, susceptibility to}, 104300 (3); {Hypertension, susceptibility to}, 145500 (3); {Hypertension, pregnancy-induced}, 189800 (3); {Placental abruption} (3); {Ischemic stroke, susceptibility to}, 601367 (3);5(Nos3)
7.740;10;11;05;7q36.2;PAXIP1, PAXIP1L, PTIP;;PAX transcription activation domain-interacting protein 1;608254;R, A;;;
7.741;1;22;09;7q36.1;PRKAG2, WPWS, CMH6;;Protein kinase, AMP-activated, noncatalytic, gamma-2;602743;REc, R, Fd;;Wolff-Parkinson-White syndrome, 194200 (3); Cardiomyopathy, hypertrophic 6, 600858 (3); Glycogen storage disease of heart, lethal congenital, 261740 (3);
7.742;3;23;06;7q36.3;PTPRN2, IAR, ICAAR;;Protein-tyrosine phosphatase, receptor-type, N, polypeptide 2;601698;A, R;;;
7.743;9;10;09;7q36.1;RHEB, RHEB2;;Ras homolog enriched in brain;601293;A;;;
7.744;5;24;13;7q36.3;RNF32;;RING finger protein 32;610241;REc;;;
7.745;7;12;02;7q36.1;RNY1, Y1;;RNA, Y1 small cytoplasmic;601821;REa, REc;;;
7.746;7;12;02;7q36.1;RNY3, Y3;;RNA, Y3 small cytoplasmic;601822;REa, REc;;;
7.747;7;12;02;7q36.1;RNY4, Y4;;RNA, Y4 small cytoplasmic;601823;REa, REc;;;
7.748;7;12;02;7q36.1;RNY5, Y5;;RNA, Y5 small cytoplasmic;601824;REa, REc;;;
7.749;2;7;12;7q36.3;SHH, HPE3, HLP3, SMMCI, MCOPCB5;;Sonic hedgehog;600725;Fd, Psh, Ch;separate from TPT1;Holoprosencephaly 3, 142945 (3); Single median maxillary central incisor, 147250 (3); Microphthalmia with coloboma 5, 611638 (3); Schizencephaly, 269160 (3);
7.750;2;12;16;7q36.1;AGAP3, CENTG3, CRAG;;ARF GTPase-activating protein with GTPase domain, ankyrin repeat, and pleckstrin homology domain 3;616813;REc;;;
7.751;8;6;13;7q36.1;ASB10, GLC1F;;Ankyrin repeat- and SOCS box-containing protein 10;615054;REc, Fd;;Glaucoma 1, open angle, F, 603383 (3);
7.752;10;2;13;7q36.1;ATG9B, NOS3AS, APG9L2, SONE;;Autophagy 9, S. cerevisiae, homolog of, B;612205;REc;;;
7.753;2;1;11;7q36.1;CHPF2, KIAA1402, CSGlcAT;;Chondroitin polymerizing factor 2;608037;REc;;;
7.754;6;13;12;7q36.1;CUL1;;Cullin 1;603134;REc;;;
7.755;4;6;13;7q36.1;GALNT11, GALNACT11;;UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 11;615130;REc, H;;;5(Galnt11)
7.756;4;6;13;7q36.1;GALNTL5, GALNACT19;;UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase-like 5;615133;REc;;;
7.757;7;23;96;7q36.2;HTR5A;;5-hydroxytryptamine (serotonin) receptor-5A;601305;Psh, REc;;;5(Htr5a)
7.758;1;27;11;7q36.1;GIMAP1, IMAP1;;GTPase, IMAP family, member 1;608084;REc;;;
7.759;1;27;11;7q36.1;GIMAP2, IMAP2;;GTPase, IMAP family, member 2;608085;REc;;;
7.760;1;27;11;7q36.1;GIMAP4, IMAP4, IAN1;;GTPase, IMAP family, member 4;608087;REc;;;
7.761;1;27;11;7q36.1;GIMAP5, IAN4L1, IMAP3;;GTPase, IMAP family, member 5;608086;REc;;;6
7.762;6;2;16;7q36.1;GIMAP6;;GTPase, IMAP family, member 6;616960;REc;;;
7.763;6;2;16;7q36.1;GIMAP7;;GTPase IMAP family, member 7;616961;REc;;;
7.764;6;2;16;7q36.1;GIMAP8;;GTPase, IMAP family, member 8;616962;REc;;;
7.765;4;17;13;7q36.1;LOC100134040;;LOC100134040 gene;615171;REc;;;
7.766;8;19;13;7q36.1;LR8;;LR8 protein;610385;REc;;;
7.767;5;23;13;7q36.1;MIR671;;Micro RNA 671;615245;REc;;;
7.768;6;24;13;7q36.1;NUB1;;Negative regulator of ubiquitin-like proteins 1;607981;R, REc;;;
7.769;5;11;09;7q36.1;RARRES2, TIG2;;Retinoic acid receptor responder 2;601973;REc;;;
7.770;2;24;17;7q36.1;SSPO;;Subcommissural organ spondin;617356;REc, H;;;6(Sspo)
7.771;8;19;13;7q36.1;TEM176A, HCA112, GS188;;Transmembrane protein 176A;610334;R, REc;;;6(Gs188)
7.772;9;2;12;7q36.1;TMUB1, DULP, SB144, C7orf21;;Transmembrane and ubiquitin-like domain-containing protein 1;614792;REc;;;
7.773;12;15;16;7q36.1;XRCC2, FANCU;;X-ray repair, complementing defective, repair in Chinese hamster cells-2;600375;REa, R, C;mutation identified in 1 FANCU patient;?Fanconi anemia, complementation group U, 617247 (3);
7.774;5;31;13;7q36.1;ZBED6CL, C7orf29;;ZBED6 C terminus-like protein;615252;REc;;;
7.775;3;17;06;7q36.1;ZNF212, ZNFC150, ZNF182;;Zinc finger protein 212;602386;Psh;;;
7.776;7;20;12;7q36.1;ZNF282, HUB1;;Zinc finger protein 282;603397;REc;;;
7.777;9;8;11;7q36.1;ZNF467, EZI, ZFP467;;Zinc finger protein 467;614040;REc;;;
7.778;4;19;11;7q36.1;ZNF746, PARIS;;Zinc finger protein 746;613914;REc;;;
7.779;4;14;15;7q36.2;DPP6, VF2, MRD33;;Dipeptidylpeptidase VI;126141;Psh, REc;;{Ventricular fibrillation, paroxysmal familial, 2}, 612956 (3); Mental retardation, autosomal dominant 33, 616311 (3);5(Dppx, Dpp6)
7.780;5;24;13;7q36.3;NCAPG2, CAPG2, MTB;;Non-SMC condensin II complex subunit G2;608532;REc;;;
7.781;12;22;08;7q36.3;CNPY1;;Canopy 1, zebrafish, homolog of;612493;REc;;;
7.782;09;27;18;7q36.3;DNAJB6, MRJ, DJ4, LGMDD1;;DNAJ/HSP40 homolog, subfamily B, member 6;611332;REc, Fd;;Muscular dystrophy, limb-girdle, autosomal dominant 1, 603511 (3);
7.783;12;11;15;7q36.3;ESYT2, FAM62B;;Extended synaptotagmin-like protein 2;616691;REc;;;
7.784;11;22;11;7q36.3;SCZD16, C16DUPq36.3, DUP7q36.3;;Chromosome 7q36.3 duplication syndrome, 362kb;613959;Ch;362kb duplication that includes VIPR2;Schizophrenia 16 (4);
7.785;1;30;12;7q36.3;UBE3C, HECTH2, KIAA0010, KIAA10;;Ubiquitin protein ligase E3C;614454;Psh, REc;;;
7.786;11;22;11;7q36.3;VIPR2;;Vasoactive intestinal peptide receptor 2;601970;A;;;12(Vipr2)
7.787;2;11;14;7q36.3;WDR60, SRTD8, SRPS6;;WD repeat containing protein 60;615462;REc;;Short-rib thoracic dysplasia 8 with or without polydactyly, 615503 (3);
7.788;11;19;11;Chr.7;AIS2, VAMAS3;;Autoimmune disease, susceptibility to, 2;608391;Fd;;{Autoimmune disease, susceptibility to, 2} (2);
7.789;10;23;87;Chr.7;NHCP2;;Nonhistone chromosomal protein-2;118880;S;;;
8.1;9;9;08;8p23.3;FBXO25, FBX25;;F-box only protein 25;609098;REc;;;8(Fbxo25)
8.2;6;16;99;8p23.3;MYOM2;;Myomesin 2;603509;Psh, A;;;
8.3;7;20;01;8p23.3-p22;DBA2;;Diamond-Blackfan anemia 2;606129;Fd;;Diamond-Blackfan anemia 2 (2);
8.4;9;2;12;8p23.1;AGPAT5;;1-acylglycerol-3-phosphate O-acyltransferase 5;614796;REc;;;
8.5;5;26;13;8p23.1;CLDN23;;Claudin 23;609203;REc, REn;;;
8.6;9;9;08;8p23.1;DEFA1, DEF1, MRS;;Defensin, alpha-1, myeloid-related sequence;125220;REa, A;;;8(Defcr)
8.7;9;9;08;8p23.1;DEFA5, DEF5;;Defensin, alpha-5, Paneth cell-specific;600472;REa;;;
8.8;2;11;96;8p23.1;DEFA6, DEF6;;Defensin, alpha-6, Paneth cell-specific;600471;REa;;;
8.9;9;9;08;8p23.1;DEFB1;;Defensin, beta-1;602056;A;;;8(Defb1)
8.10;3;9;12;8p23.1;DEFB4A, DEFB4, DEFB2;;Defensin, beta-4a (formerly defensin, beta-2);602215;A, REc, Ch;;;
8.11;4;18;07;8p23.1;DEFB103A, DEFB3, HBD3, HBP3;;Defensin, beta 103A;606611;REc, Ch;;;
8.12;12;29;05;8p23.1;DIH2;;Hernia, congenital diaphragmatic 2;222400;Ch;;Hernia, congenital diaphragmatic 2 (2);
8.13;12;18;14;8p23.1;FAM86B1;;Family with sequence similarity 86, member B1;616122;REc;;;
8.14;12;18;14;8p23.1;FAM86B2;;Family with sequence similarity 86, member B2;616123;REc;;;
8.15;9;30;09;8p23.1;FAM90A3;;Family with sequence similarity 90, member A3;613042;REc;copy 2;;
8.16;9;30;09;8p23.1;FAM90A5;;Family with sequence similarity 90, member A5;613043;REc;copy 5;;
8.17;9;30;09;8p23.1;FAM90A7;;Family with sequence similarity 90, member A7;613044;REc;copy 8;;
8.18;9;30;09;8p23.1;FAM90A8;;Family with sequence similarity 90, member A8;613045;REc;copy 15;;
8.19;9;30;09;8p23.1;FAM90A9;;Family with sequence similarity 90, member A9;613046;REc;copy 18;;
8.20;9;30;09;8p23.1;FAM90A10;;Family with sequence similarity 90, member A10;613047;REc;copy 19;;
8.21;9;30;09;8p23.1;FAM90A12;;Family with sequence similarity 90, member A12;613048;REc;copy 22;;
8.22;9;30;09;8p23.1;FAM90A13;;Family with sequence similarity 90, member A13;613049;REc;copy 4;;
8.23;9;30;09;8p23.1;FAM90A14;;Family with sequence similarity 90, member A14;613050;REc;copy 12;;
8.24;9;30;09;8p23.1;FAM90A15;;Family with sequence similarity 90, member A15;613051;REc;copy 1;;
8.25;9;30;09;8p23.1;FAM90A18;;Family with sequence similarity 90, member A18;613052;REc;copy 13;;
8.26;9;30;09;8p23.1;FAM90A19;;Family with sequence similarity 90, member A19;613053;REc;copy 17;;
8.27;9;30;09;8p23.1;FAM90A20;;Family with sequence similarity 90, member A20;613054;REc;copy 6;;
8.28;11;26;01;8p23.1;MFHAS1, MASL1;;Malignant fibrous histiocytoma-amplified sequences with leucine-rich tandem repeats-1;605352;REc;;Malignant fibrous histiocytoma (2);
8.29;3;23;09;8p23.1;MIR124-1, MIR124A;;Micro RNA 124-1;609327;REc;;;
8.30;9;26;17;8p23.1;MSRA;;Peptide methionine sulfoxide reductase;601250;REc, H;;;14(Msra)
8.31;6;6;17;8p23.1;NEIL2, NEI2;;Endonuclease VIII-like 2;608933;REc;;;
8.32;2;9;17;8p23.1;PRAG1, PRAGMIN, NACK;;PEAK1-related kinase-activating pseudokinase 1;617344;REc;;;
8.33;4;8;13;8p23.1;PRSS55, TSP1;;Protease, serine, 55;615144;REc;;;
8.34;9;24;08;8p23.1;SLEB12;;Systemic lupus erythematosus, susceptibility to, 12;612254;Fd;associated with rs13277113;{Systemic lupus erythematosus, susceptibility to, 12} (2);
8.35;3;20;14;8p23.1;USP17L2, DUB3;;Ubiquitin specific peptidase 17-like family member 2;610186;REc;;;
8.36;11;20;95;8p22;NAT1, AAC1;;Arylamine N-acetyltransferase-1;108345;REa, A;;;8(Nat1)
8.37;8;29;08;8p22;NAT2, AAC2;;Arylamine N-acetyltransferase-2;612182;REa, A, H;acetylation polymorphism;[Acetylation, slow], 243400 (3);8(Nat2)
8.38;10;25;18;8p23.1;FDFT1, DGPT, SQSD;;Farnesyl-diphosphate farnesyltransferase 1 (squalene synthase);184420;Psh, A;;Squalene synthase deficiency, 618156 (3);
8.39;9;11;14;8p23.1;GATA4, ASD2, VSD1, TACHD, TOF;;GATA-binding protein-4;600576;REa, H, A;mutations identified in 1 TACHD family;Atrial septal defect 2, 607941 (3); Ventricular septal defect 1, 614429 (3); Atrioventricular septal defect 4, 614430 (3); ?Testicular anomalies with or without congenital heart disease, 615542 (3); Tetralogy of Fallot, 187500 (3);14(Gata4)
8.40;8;20;02;8p23.1;ANGPT2, ANG2;;Angiopoietin 2;601922;R, A;close to MCPH1;;8(Angpt2)
8.41;9;17;14;8p23.3;ARHGEF10, KIAA0294, SNCV;;Rho guanine nucleotide exchange factor 10;608136;REc;mutation identified in 1 SNCV family;?Slowed nerve conduction velocity, AD, 608236 (3);
8.42;9;9;08;8p23.3;CLN8, EPMR;;CLN8 gene;607837;Fd, H;;Ceroid lipofuscinosis, neuronal, 8, 600143 (3); Ceroid lipofuscinosis, neuronal, 8, Northern epilepsy variant, 610003 (3);8(mnd)
8.43;1;27;04;8p23.2;CSMD1, KIAA1890;;Cub and Sushi multiple domains 1;608397;REc;;;
8.44;10;6;09;8p23.1;DEFA4, DEF4, HP4;;Defensin, alpha-4, corticostatin;601157;REa, REc;;;
8.45;5;13;11;8p23.1;MCPH1;;Microcephalin;607117;Fd, REc;genetic heterogeneity;Microcephaly 1, primary, autosomal recessive, 251200 (3);8(Mcph1)
8.46;4;13;05;8p23;MYP10;;Myopia 10;609259;Fd;;Myopia 10 (2);
8.47;12;27;01;8p23.1;PINX1;;PIN2-interacting protein 1;606505;REc;;;
8.48;5;26;13;8p23.1;PPP1R3B, GL;;Protein phosphatase 1, regulatory subunit 3B;610541;A;;;
8.49;1;27;11;8p23.1;RP1L1;;RP1-like protein 1;608581;REc;;Occult macular dystrophy, 613587 (3);14(Rp1l1)
8.50;3;16;10;8p23;WS2C;;Waardenburg syndrome, type 2C;606662;Ch;;Waardenburg syndrome, type 2C (2);
8.51;4;22;10;8p23.1;BLK, MODY11;;BLK nonreceptor tyrosine kinase;191305;REa, A;;Maturity-onset diabetes of the young, type 11, 613375 (3);14(Blk)
8.52;8;29;08;8p23.1;FAM167A, C8orf13;;Family with sequence similarity 167, member A;610085;REc;;;
8.53;10;15;97;8p23-p22;KWE;;Keratolytic winter erythema;148370;Fd;;Keratolytic winter erythema (2);
8.54;9;5;02;8p23.1;MTMR9, MTMR8;;Myotubularin-related protein 9;606260;REc;;;
8.55;12;27;01;8p23.1;SPAG11, HE2, EP2;;Sperm-associated antigen 11;606560;REc;;;
8.56;4;17;13;8p23-p22;TDH;;L-threonine dehydrogenase, pseudogene;615174;REc;;;
8.57;1;13;99;8p21.3;EGR3;;Early growth response 3;602419;A;;;
8.58;9;11;12;8p23-p21;GEFSP6;;Generalized epilepsy with febrile seizures plus, type 6;612279;Fd;between D8S1706 and D8S549;Epilepsy, generalized, with febrile seizures plus, type 6 (2);
8.59;11;1;12;8p22;VPS37A, HCRP1, SPG53;;Vacuolar protein sorting 37A;609927;REc;;Spastic paraplegia 53, autosomal recessive, 614898 (3);
8.60;10;18;11;8p22;ANIB11;;Aneurysm, intracranial berry, 11;614252;Fd;max lod at D8S552;Aneurysm, intracranial berry, 11 (2);
8.61;6;9;08;8p22;CHDS9;;Coronary heart disease, susceptibility to, 9;612030;Fd;max lod at D8S1106;{Coronary heart disease, susceptibility to, 9} (2);
8.62;09;06;18;8p23.1;CTSB, CPSB, RECEUP;;Cathepsin B (regulatory element, cis-acting, enhancer upstream of CTSB, included);116810;REa, A, Psh, D;KWE due to duplication upstream of CTSB that disrupts a cis-acting regulatory element;Keratolytic winter erythema, 148370 (4);8(Ctsb)
8.63;10;7;09;8p22;FGL1, HFREP1;;Fibrinogen-like 1;605776;R, REc;;;
8.64;2;25;14;8p22;KIAA1456, TRM9L;;KIAA1456 gene;615666;REc;;;
8.65;12;17;07;8p21.3;LPL, LIPD, HDLCQ11;;Lipoprotein lipase;609708;REa, A, Fd;;Lipoprotein lipase deficiency, 238600 (3); Combined hyperlipidemia, familial, 144250 (3); [High density lipoprotein cholesterol level QTL 11] (3);8(Lpl)
8.66;12;11;01;8p21.3;LZTS1, F37, FEZ1;;Leucine zipper, putative tumor suppressor 1;606551;Ch, LOH;;Esophageal squamous cell carcinoma, 133239 (3);
8.67;1;14;14;8p22;MICU3, EFHA2;;Mitochondrial calcium uptake protein 3;610633;REc;;;
8.68;3;27;18;8p22;MSR1, SCARA1, SRA;;Macrophage scavenger receptor;153622;REa, Fd, A;~11cM distal to LPL;Barrett esophagus/esophageal adenocarcinoma, 614266 (3);
8.69;6;16;99;8p22;MTMR7;;Myotubularin-related protein 7;603562;R, Psh;;;
8.70;6;19;01;8q22.2;POLR2K, RPB12;;Polymerase II, RNA, subunit K;606033;R;;;
8.71;1;30;12;8p22;PSD3, HCA67, EFA6R;;Pleckstrin and Sec7 domains-containing protein 3;614440;REc;;;
8.72;11;11;14;8p22;SGCZ, ZSG1;;Sarcoglycan, zeta;608113;R, H;;;
8.73;12;17;12;8p21.3;SH2D4A, SH2A, PPP1R38;;SH2 domain-containing protein 4A;614968;REc;;;
8.74;3;2;98;8p22;SLC7A2, ATRC2, HCAT2;;Solute carrier family 7 (cationic amino acid transporter, y+ system), member 2;601872;A;;;
8.75;8;29;08;8p23.1;SOX7;;SRY-box 7;612202;A, H;;;14(Sox7)
8.76;11;18;11;8p22;TUSC3, M33, D8S1992, MRT7, MRT22;;Tumor suppressor candidate 3;601385;REn, Fd;;Mental retardation, autosomal recessive 7, 611093 (3);
8.77;7;20;12;8p22;ASAH1, AC, SMAPME;;N-acylsphingosine amidohydrolase (acid ceramidase) 1;613468;REc;;Farber lipogranulomatosis, 228000 (3); Spinal muscular atrophy with progressive myoclonic epilepsy, 159950 (3);
8.78;9;9;08;8p22;CNOT7, CAF1;;CCR4-NOT transcription complex, subunit 7;604913;REc;;;
8.79;6;11;09;8p22-p21.3;DFNB71;;Deafness, autosomal recessive 71;612789;Fd;max lod at D8S261;Deafness, autosomal recessive 71 (2);
8.80;8;6;15;8p22;DLC1;;Deleted in liver cancer 1;604258;A;;Colorectal cancer, somatic, 114500 (3);
8.81;4;10;14;8p22;FGF20, RHDA2;;Fibroblast growth factor-20;605558;REc;mutation identified in 1 RHDA2 family;?Renal hypodysplasia/aplasia 2, 615721 (3);
8.82;8;14;15;8p22;PCM1, PTC4;;Pericentriolar material 1;600299;A, REn, Ch;fused with RET to form PTC4;;
8.83;2;19;13;8p22;PDGFRL, PDGRL, PRLTS;;Platelet-derived growth factor receptor-like;604584;REc;;Hepatocellular cancer, somatic, 114550 (3); Colorectal cancer, somatic, 114500 (3);
8.84;11;16;05;8p21.3;TNFRSF10B, DR5, TRAILR2;;Tumor necrosis factor receptor superfamily, member 10B;603612;R, A;;Squamous cell carcinoma, head and neck, 275355 (3);
8.85;8;17;99;8p21.3;TNFRSF10C, DCR1, TRAILR3, TRID;;Tumor necrosis factor receptor superfamily, member 10C;603613;R;;;
8.86;1;12;99;8p21.2;PTK2B, FAK2, PYK2;;Protein tyrosine kinase-2, beta (focal adhesion kinase 2);601212;Psh, A;;;
8.87;5;23;13;3p25.1;TPRXL;;Tetrapeptide repeat homeobox-like;611167;REc;;;
8.88;11;4;93;8p11.21;FNTA;;Farnesyltransferase, CAAX box, alpha;134635;REa, Psh, A;related FNTAL1 on 11, FNTAL2 on 13;;8(Fnta)
8.89;7;3;06;8p22-q11;MPD3;;Myopathy, distal 3;610099;Fd;possible locus on 12q13-q22;Myopathy, distal 3 (2);
8.90;7;13;93;8p12;NRG1, HGL, HRGA, ARIA;;Neuregulin 1 (heregulin, alpha, 45kD; ERBB2 p185-activator);142445;Psh, A;;{?Schizophrenia, susceptibility to}, 603013 (1);7(Nrg1)
8.91;5;23;16;8p21.3;ATP6V1B2, ATP6B2, VPP3, DOOD, ZLS2;;ATPase, H+ transporting, V1 subunit B2;606939;R, REc;;Zimmermann-Laband syndrome 2, 616455 (3); Deafness, congenital, with onychodystrophy, autosomal dominant, 124480 (3);
8.92;10;6;09;8p21.3;BIN3;;Bridging integrator 3;606396;R, REc;;;
8.93;8;11;17;8p21.3;CCAR2, DBC1, KIAA1967;;Cell division cycle and apoptosis regulator 2;607359;REc;;;
8.94;9;10;07;8p21.3;CHMP7;;CHMP family, member 7;611130;REc;;;
8.95;10;28;15;8p21.3;CSGALNACT1;;Chondroitin sulfate N-acetylgalactosaminyltransferase 1;616615;REc;;;
8.96;7;26;10;8p21.3;DOK2, P56DOK;;Docking protein 2;604997;REc;;;
8.97;1;13;16;8p21.3;ENTPD4, LYSAL1, LAP70, KIAA0392;;Ectonucleoside triphosphate diphosphohydrolase 4;607577;R, REc;;;
8.98;6;11;13;8p21.3;FGF17, HH20;;Fibroblast growth factor 17;603725;REc;;Hypogonadotropic hypogonadism 20 with or without anosmia, 615270 (3);
8.99;3;24;14;8p21.3;INTS10, INT10;;Integrator complex subunit 10;611353;R, REc;;;
8.100;12;4;03;8p21.3;LGI3;;Leucine-rich gene, glioma-inactivated, 3;608302;R;;;14(Lgi3)
8.101;7;22;11;8p21.3;MIR320A, MIRN320A;;Micro RNA 320A;614112;REc;;;
8.102;9;16;03;8p21.3;NPM2;;Nucleophosmin/nucleoplasmin family, member 2;608073;REc;;;14(Npm2)
8.103;6;22;14;8p21.3;NUDT18, MTH3;;Nucleoside diphosphate-linked moiety X motif 18;615791;REc;;;
8.104;12;19;08;8p21.3;PIWIL2, MILI;;PIWI-like 2;610312;REc;;;14(Piwil2)
8.105;7;1;05;8p21.3;REEP4, C8orf20;;Receptor expression-enhancing protein 4;609349;R, REc;;;
8.106;9;29;96;8p21.3;SLC18A1, VMAT1, VAT1, CGAT;;Solute carrier family 18 (vesicular monoamine), member 1;193002;REa, A;;;19(Slc18a1)
8.107;5;6;13;8p23.1;SLC35G5, AMAC, AMAC1L2;;Solute carrier family 35, member G5;615199;REc;;;
8.108;5;9;18;8p21.3;SLC39A14, ZIP14, KIAA0062, HMNDYT2, HCIN;;Solute carrier family 39 (zinc transporter), member 14;608736;REc;mutation identified in 1 HCTN family;Hypermanganesemia with dystonia 2, 617013 (3); ?Hyperostosis cranalis interna, 144755 (3);
8.109;3;8;07;8p21.3;SORBS3, SCAM1, SH3D4;;Sorbin and SH3 domains-containing 3;610795;REc;;;
8.110;8;3;12;8p21.3;XPO7, RANBP16, KIAA0745;;Exportin 7;606140;R, REc;;;
8.111;2;4;02;8p21.3;LOXL2;;Lysyl oxidase-like 2;606663;R, A;;;
8.112;4;21;16;8p21.2;DOCK5;;Dedicator of cytokinesis 5;616904;REc;;;
8.113;3;22;06;8p21.2;EBF2;;Early B-cell factor 2;609934;R, REc;;;
8.114;7;16;14;8p21.3;HR, AU, MUHH1, HYPT4;;Hairless, mouse, homolog of;602302;H, R, Fd, LD;;Alopecia universalis, 203655 (3); Atrichia with papular lesions, 209500 (3); Hypotrichosis 4, 146550 (3);14(hr)
8.115;12;22;16;8p21.2;KCTD9, BTBD27;;Potassium channel tetramerization domain-containing protein 9;617265;REc;;;
8.116;12;28;08;8p21.3;PDLIM2, MYSTIQUE;;PDZ and LIM domain protein 2;609722;REc;;;
8.117;12;17;08;8p21.3;PEPB4, CORK1;;Phosphatidylethanolamine-binding protein 4;612473;REc;;;
8.118;3;4;17;8p21.2;PNMA2, MA2, MM2;;Paraneoplastic MA antigen 2;603970;REc;;;
8.119;6;4;18;8p21.3;RHOBTB2, DBC2, KIAA0717, EIEE64;;Rho-related BTB domain-containing protein 2;607352;R, REc;;Epileptic encephalopathy, early infantile, 64, 618004 (3);
8.120;11;21;02;8p12;LEPROTL1;;Leptin receptor overlapping transcript-like 1;607338;R;;;
8.121;5;7;09;8p21.1;ELP3, KAT9;;Elongation protein 3, S. cerevisiae, homolog of;612722;REc;;;
8.122;12;28;05;8p21.1;ESCO2;;Establishment of cohesion 1, S. cerevisiae, homolog of, 2;609353;REc, Fd;;Roberts syndrome, 268300 (3); SC phocomelia syndrome, 269000 (3);
8.123;11;20;95;8p21.3;EPB49, DMT;;Erythrocyte membrane protein band 49 (dematin);125305;REa, A;;;14(Epb4.9)
8.124;9;9;08;8p21.1;FBXO16, FBX16;;F-box only protein 16;608519;REc;?8p12;;14(Fbxo16)
8.125;10;23;87;8p12;GSR;;Glutathione reductase;138300;S, D;;Hemolytic anemia due to glutathione reductase deficiency (1);8(Gr1)
8.126;8;4;97;8p21.1;GULOP, GULO;;Gulonolactone (L-) oxidase pseudogene;240400;REb, A;;Scurvy (3);
8.127;3;23;14;8p21.1;INTS9, INT9, RC74;;Integrator complex subunit 9;611352;REc;;;
8.128;8;19;13;8p21.1;PBK, TOPK;;PDZ-binding kinase;611210;REc;;;
8.129;12;10;13;8p21.1;SCARA5;;Scavenger receptor class A, member 5;611306;REc;;;
8.130;6;27;16;8p21.2;TRIM35, MAIR, HLS5, KIAA1098;;Tripartite motif-containing protein 35;617007;REc;;;
8.131;9;27;17;8p21.1;ZNF395, PBF, HDBP2;;Zinc finger protein 395;609494;REc;;;
8.132;4;27;12;8p21.1-q13.3;SPG37;;Spastic paraplegia 37;611945;Fd;max lod at D8S601;Spastic paraplegia 37, autosomal dominant (2);
8.133;9;14;92;8p21.2;ADRA1C;;Adrenergic, alpha-1C-, receptor;104221;REc, Fd;.03cM from NEFL;;
8.134;10;11;12;8p21.3;BMP1, OI13;;Bone morphogenetic protein-1;112264;H, REa, A;1kb 3' to SFTP2;Osteogenesis imperfecta, type XIII, 614856 (3);14(Bmp1)
8.135;10;26;00;8p21.2;BNIP3L, NIX;;BCL2/adenovirus E1B 19-kD protein-interacting protein 3-like;605368;A;;;
8.136;8;28;06;8p21.2;CHRNA2;;Cholinergic receptor, nicotinic, alpha polypeptide-2;118502;REa;;Epilepsy, nocturnal frontal lobe, type 4, 610353 (3);14(Acra2)
8.137;5;1;98;8p21.2;DPYSL2, DRP2, CRMP2;;Dihydropyrimidinase-like 2;602463;TM;;;
8.138;4;17;17;8p21.1;EXTL3, EXTR1, ISDNA;;Exostosin-like 3;605744;R, Psh, A, REc;;Immunoskeletal dysplasia with neurodevelopmental abnormalities, 617425 (3);
8.139;8;28;01;8p21.1;FZD3;;Frizzled, Drosophila, homolog of, 3;606143;A;;;14(Fzd3)
8.140;7;15;99;8p21.3;GFRA2, GDNFRB;;GDNF family receptor alpha-2;601956;A;;;14(Gdnfrb)
8.141;5;19;06;3p24-p21.2;TRICY1;;Trichilemmal cyst 1;609649;Fd;max lod at D3S1277;Trichilemmal cyst 1 (2);
8.142;7;17;14;8p21.2;NEFM, NEF3, NFM;;Neurofilament protein, medium polypeptide;162250;REn;;;
8.143;3;6;18;8p21.2;NEFL, CMT2E, CMT1F, CMTDIG;;Neurofilament, light polypeptide;162280;REa, A, Fd;;Charcot-Marie-Tooth disease, type 2E, 607684 (3); Charcot-Marie-Tooth disease, type 1F, 607734 (3); Charcot-Marie-Tooth disease, dominant intermediate G, 617882 (3);14(Nfl)
8.144;7;18;14;8p21.2;NKX2-6, CSX2, CTHM;;NK2, Drosophila, homolog of, 6;611770;R;;Persistent truncus arteriosus, 217095 (3); Conotruncal heart malformations, 217095 (3);
8.145;4;14;10;8p21.2;NKX3-1, NKX3A, BAPX2;;NK3 homeo box 1;602041;A;;;
8.146;10;18;96;8p21.1;PNOC, PPNOC;;Prepronociceptin;601459;REc;;;
8.147;9;5;02;8p21.1;SCARA3, MSLR1, CSR;;Scavenger receptor class A, member 3;602728;REc;;;
8.148;12;15;98;8p21;SCZD6;;Schizophrenia susceptibility locus, chromosome 8p-related;603013;Fd;?neuregulin 1;{Schizophrenia}, 181500 (2);
8.149;5;21;07;8p21.3;SFTPC, SFTP2, SMDP2;;Surfactant, pulmonary-associated protein C (pulmonary surfactant apoprotein-2, SP-C);178620;REa, A, Fd;;Surfactant metabolism dysfunction, pulmonary, 2, 610913 (3);14(Sftp2)
8.150;8;19;13;8p21.2;SLC25A37, MFRN, MFRN1;;Solute carrier family 25 (mitochondrial iron carrier), member 37;610387;REc;;;14(Slc25a37)
8.151;8;17;99;8p21.3;TNFRSF10A, DR4, TRAILR1, APO2;;Tumor necrosis factor receptor superfamily, member 10A;603611;R;;;
8.152;8;17;99;8p21.3;TNFRSF10D, DCR2, TRAILR4;;Tumor necrosis factor receptor superfamily, member 10D;603614;R;;;
8.153;3;30;00;8p21.1;CLU, CLI, SGP2, TRPM2;;Clusterin (complement lysis inhibitor, SP-40,40; sulfated glycoprotein 2; testosterone-repressed prostate message-2; apolipoprotein J);185430;REa, REb, A, RE;;;14(Sgp2, Clu)
8.154;5;26;05;8p21.2-p21.1;EPHX2;;Epoxide hydrolase 2, cytoplasmic;132811;A;;{Hypercholesterolemia, familial, due to LDLR defect, modifier of}, 143890 (3);14(Ephx2)
8.155;5;11;16;8p12;GTF2E2, TTD6;;General transcription factor IIE, polypeptide 2, beta subunit, 34kD;189964;REc;;Trichothiodystrophy 6, nonphotosensitive, 616943 (3);
8.156;11;19;14;8p21.2;GNRH1, LNRH, HH12;;Gonadotropin-releasing hormone-1 (luteinizing-releasing hormone);152760;REa, A;mutation identified in 1 HH12 family;?Hypogonadotropic hypogonadism 12 with or without anosmia, 614841 (3);14(Gnrh)
8.157;1;7;99;8p21.2;STC1, STC;;Stanniocalcin 1;601185;A;;;
8.158;10;29;02;8p21.2;ADAM7;;A disintegrin and metalloproteinase domain 7;607310;REc;;;
8.159;10;29;02;8p21.2;ADAM28, MDCL;;A disintegrin and metalloproteinase domain 28;606188;REc;;;
8.160;2;28;03;8p21.2;ADAMDEC1, DECYSIN;;A disintegrin and metalloproteinase domain-like protein decysin 1;606393;REn;;;
8.161;9;1;16;8p11.23;ADGRA2, GPR124, TEM5, KIAA1531;;Adhesion G protein-coupled receptor A2;606823;R, REc;;;
8.162;6;19;98;8p11.23;EIF4EBP1, 4EBP1;;Eukaryotic translation initiation factor-4E binding protein-1;602223;A;;;8(Eif4ebp1)
8.163;5;2;16;8p12;FUT10, FUCTX;;Fucosyltransferase 10;616931;REc;;;
8.164;8;18;08;8p11.21;IDO2, INDOL1;;Indoleamine 2,3-dioxygenase 2;612129;REc;;;
8.165;7;20;12;8p12;KIF13B, GAKIN, KIAA0639;;Kinesin family member 13B;607350;R;;;
8.166;4;15;08;8p12;MBOAT4, GOAT;;Membrane-bound O-acetyltransferase domain-containing 4;611940;REc;;;
8.167;11;02;18;8p11.23;NSD3, WHSC1L1;;Nuclear receptor-binding SET domain protein 3;607083;A, Ch;pseudogene on 17q21; fusion partner with NUP98 in AML;;
8.168;10;28;08;8p11.21;PLAT, TPA;;Plasminogen activator, tissue type;173370;REa, A, REb;;Thrombophilia, familial, due to decreased release of PLAT, 612348 (1); Hyperfibrinolysis, familial, due to increased release of PLAT, 612348 (1);8(Plat)
8.169;6;28;18;8p12;PURG, PURGA, PURGB;;Purine-rich element-binding protein G;618041;REc;;;
8.170;12;1;15;8p12;SNORD13;;Small nucleolar RNA, C/D box, 13;616664;REc;;;
8.171;5;9;18;8p12;TEX15, SPGF25;;Testis-expressed gene 15;605795;R;;Spermatogenic failure 25, 617960 (3);
8.172;3;1;12;8p12;THPH9;;Thrombophilia due to decreased release of tissue plasminogen activator;612348;LD;;?Thrombophilia due to decreased release of tissue plasminogen (1);
8.173;8;21;12;8p12;TMEM66, SARAF;;Transmembrane protein 66;614768;REc;;;
8.174;11;22;13;8p12;TTI2, C8orf41, MRT39;;TELO2-interacting protein 2;614426;REc;;Mental retardation, autosomal recessive 39, 615541 (3);
8.175;7;29;15;8p12;UNC5D, UNC5H4;;Unc5. C. elegans, homolog of, D;616466;REc;;;
8.176;6;1;05;8p11.23;ADRB3;;Adrenergic, beta-3-, receptor;109691;A;;{Obesity, susceptibility to}, 601665 (3);8(Adrb3)
8.177;7;13;93;8p12;PPP2CB;;Protein phosphatase-2 (formerly 2A), catalytic subunit, beta isoform;176916;Psh, A, REc;pseudogene on 16;;
8.178;8;12;03;8p12;RECQL2, RECQ3, WRN;;DNA helicase, RecQ-like 2;604611;Fd, LD;;Werner syndrome, 277700 (3);8(wrn)
8.179;3;29;10;8p12;UBXN8, D8S2298E, REP8;;UBX domain protein 8;602155;A;;;
8.180;10;22;99;8p11.21;SFRP1, FRP, SARP2;;Secreted frizzled-related protein 1;604156;R, A;;;
8.181;9;10;09;8p12;DCTN6, WS3, P27;;Dynactin 6;612963;A, Psh;;;
8.182;11;20;98;8p12;DUSP4, MKP2, HVH2;;Dual-specificity phosphatase-4 (MAP kinase phosphatase-2);602747;A;;;
8.183;9;9;08;8p11.21;IDO1, INDO, IDO;;Indoleamine 2,3-dioxygenase;147435;Psh, REa, A;;;
8.184;1;20;09;8p12;RBPMS;;RNA-binding protein gene with multiple splicing;601558;REc;;;
8.185;6;4;07;8p12-q22;AD12;;Alzheimer disease 12;611073;Fd;max lod at D8S1119;{Alzheimer disease 12} (2);
8.186;12;29;06;8p11.23;RAB11FIP1, RCP;;RAB11 family-interacting protein 1;608737;REc;;;
8.187;8;19;13;8p11.22;TM2D2, BLP1;;TM2 domain-containing protein 2;610081;R, REc;;;
8.188;10;15;09;8p11.22;ADAM9, MDC9, MCMP, CORD9;;A disintegrin and metalloproteinase domain 9;602713;REc;;Cone-rod dystrophy 9, 612775 (3);
8.189;11;29;12;8p11.23;BAG4, SODD;;Bcl2-associated athanogene 4;603884;REc;;;
8.190;10;6;09;8p11.23;BRF2, BRFU, TFIIIB50;;BRF2 subunit of RNA polymerase III transcription initiation factor;607013;R, REc;;;
8.191;1;29;13;8p11.23;DDHD2, KIAA0725, SPG54;;DDHD domain-containing protein 2;615003;REc;;Spastic paraplegia 54, autosomal recessive, 615033 (3);
8.192;1;16;07;8p11.22;HTRA4;;HTRA serine peptidase 4;610700;REc;;;
8.193;5;6;13;8p11.23;KCNU1, SLO3;;Potassium channel, subfamily U, member 1;615215;REc;;;
8.194;10;26;17;8p11.23;PLPP5, PPAPDC1B, HTPAP;;Phospholipid phosphatase 5;610626;REc;;;
8.195;8;6;13;8p11.23;LSM1;;LSM1 protein;607281;R, REc;;;
8.196;7;22;16;8p11.23;ZNF703, ZEPPO1, NLZ1;;Zinc finger protein 703;617045;REc;;;
8.197;6;9;08;8p11.21;AGPAT6, LPAATZ;;1-acylglycerol-3-phosphate O-acyltransferase 6;608143;REc;;;
8.198;5;5;10;8p11.21;CHRNA6;;Cholinergic receptor, neuronal nicotinic, alpha polypeptide 6;606888;REc;;;
8.199;11;30;06;8p11.21;GINS4, SLD5;;GINS complex subunit 4;610611;R, REc;;;
8.200;7;7;09;8p11.21;HOOK3, HK3;;Hook, Drosophila, homolog of, 3;607825;REc;;;
8.201;12;27;13;8p11.21;SLC20A2, MLVAR, GLVR2, IBGC1;;Solute carrier family 20, phosphate transporter, member 2 (murine leukemia virus, amphotropic, receptor for);158378;S, REa;;Basal ganglia calcification, idiopathic, 1, 213600 (3);
8.202;5;14;09;8p11.21;THAP1, DYT6;;THAP domain-containing protein 1;609520;REc;;Dystonia 6, torsion, 602629 (3);
8.203;2;20;07;8p11.21;NKX6-3, NKX6.3;;NK6, Drosophila, homolog of;610772;REc;;;8(Nkx6-3)
8.204;11;16;05;8p11.22;ADAM2, FTNB, PH30, CRYN1, CRYN2;;A disintegrin and metalloproteinase domain 2 (fertilin, beta);601533;A, H;;;14(Ftnb)
8.205;11;17;15;8p11.21;ANK1, SPH1;;Ankyrin-1, erythrocytic;612641;F, Ch, D, REa, A, Fd, REb;;Spherocytosis, type 1, 182900 (3);8(nb)
8.206;5;24;13;8p11.21;AP3M2, CLA20;;Adaptor-related protein complex 3, mu-2 subunit;610469;A;;;
8.207;1;29;01;8p11.23;ASH2L, ASH2L2, ASH2L1;;ASH2, Drosophila, homolog of;604782;REc;;;
8.208;6;10;94;8p11.21;CHRNB3;;Cholinergic receptor, nicotinic, beta polypeptide-3;118508;REa, A;;;
8.209;4;27;12;8p11.23;ERLIN2, SPFH2, C8orf2, SPG18;;Endoplasmic reticulum lipid raft-associated protein 2;611605;REc;;Spastic paraplegia 18, autosomal recessive, 611225 (3);
8.210;11;28;18;8p11.21;IKBKB, NFKBIKB, IMD15B, IMD15A;;Inhibitor of kappa light polypeptide gene enhancer in B cells, kinase of, beta;603258;A, R;;Immunodeficiency 15B, 615592 (3); Immunodeficiency 15A, 618204 (3);
8.211;3;8;95;8p11.21;POLB;;Polymerase (DNA directed), beta;174760;REa, Fd, A;;;8(Polb)
8.212;1;9;17;8p11.23;PROSC, EPVB6D;;Proline synthetase cotranscribed, bacteria, homolog of;604436;REn;;Epilepsy, early-onset, vitamin B6-dependent, 617290 (3);
8.213;5;29;12;8p11.21;RNF170, SNAX1;;RING finger protein 170;614649;REc;;Ataxia, sensory, 1, autosomal dominant, 608984 (3);
8.214;9;27;17;8p11.21;TCIM, C8orf4;;Transcriptional and immune response regulator;607702;A;;;
8.215;2;12;96;8p11.23;STAR;;Steroidogenic acute regulatory protein;600617;REa, A;;Lipoid adrenal hyperplasia, 201710 (3);
8.216;4;19;06;8p11.21;VDAC3;;Voltage-dependent anion channel 3;610029;A, H;;;8(Vdac3)
8.217;11;20;95;8q11.21;CEBPD;;CCAAT/enhancer-binding protein (C/EBP), delta;116898;A, REa;earlier mapped to 8q11;;16(Cebpd)
8.218;3;3;03;8p11.21;DKK4;;Dickkopf, Xenopus, homolog of, 4;605417;A;;;
8.219;4;8;16;8p11.23;FGFR1, FLT2, OGD, KAL2, HH2, HRTFDS, ECCL;;Fibroblast growth factor receptor-1 (fms-related tyrosine kinase-2);136350;REa, A;fused with BCR, CEP1, FOP, FIM in hematologic malignancies;Pfeiffer syndrome, 101600 (3); Jackson-Weiss syndrome, 123150 (3); Hypogonadotropic hypogonadism 2 with or without anosmia, 147950 (3); Osteoglophonic dysplasia, 166250 (3); Trigonocephaly 1, 190440 (3); Hartsfield syndrome, 615465 (3); Encephalocraniocutaneous lipomatosis, 613001 (3);
8.220;9;10;15;8p11.2-p11.1;HGSNAT, TMEM76, MPS3C, RP73;;Heparan-alpha-glucosaminide N-acetyltransferase;610453;Fd, REc;;Mucopolysaccharidosis type IIIC (Sanfilippo C), 252930 (3); Retinitis pigmentosa 73, 616544 (3);
8.221;3;23;15;8p11.21;KAT6A, MYST3, MOZ, ZNF220, MRD32;;K(lysine) acetyltransferase 6A;601408;Ch;;Mental retardation, autosomal dominant 32, 616268 (3);
8.222;11;24;14;8p11.21;POMK, SGK196, MDDGA12, MDDGC12;;Protein-O-mannose kinase;615247;REc;mutation in 1 MDDGC12 family has been reported;Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 12, 615249 (3); ?Muscular dystrophy-dystroglycanopathy (limb-girdle), type C, 12, 616094 (3);
8.223;1;13;11;8p11;SCLL;;Chromosome 8p11 myeloproliferative syndrome (stem cell leukemia/lymphoma);613523;Ch;translocation of FGFR1 (8p11) and various partners;Chromosome 8p11 myeloproliferative syndrome (4);
8.224;1;31;01;8p11.22;TACC1;;Transforming, acidic, coiled-coil-containing protein-1;605301;REc;;;
8.225;11;30;00;8p23.3;DLGAP2, DAP2;;Discs large associated protein 2;605438;REc, R;;;
8.226;6;15;99;8q;CCAL1;;Chondrocalcinosis 1;600668;Fd;;Chondrocalcinosis with early-onset osteoarthritis (2);
8.227;11;13;07;8q;HBFQTL4;;Fetal hemoglobin quantitative trait locus 4;606789;Fd;;Fetal hemoglobin quantitative trait locus 4 (2);
8.228;10;23;87;8q;GPB;;Glycerol phosphatase, beta-;109640;S;;;
8.229;10;20;99;8q21.11;RPL7;;Ribosomal protein L7;604166;REa, R;pseudogene on chr.5;;
8.230;10;20;99;8q24.3;RPL8;;Ribosomal protein L8;604177;REa, R;;;
8.231;12;14;00;8q24.13;ZHX1;;Zinc finger and homeodomain protein 1;604764;REa, R;;;
8.232;7;13;93;8q12.1;MOS;;Oncogene MOS, Moloney murine sarcoma virus;190060;REa, A, REb;;;4(Mos)
8.233;8;31;15;8q11.21;PRKDC, HYRC1, DNPK1, IMD26;;Protein kinase, DNA-activated, catalytic polypeptide (hyperradiosensitivity of murine SCID mutation, complementing-1);600899;C, A;;Immunodeficiency 26, with or without neurologic abnormalities, 615966 (3);16(scid)
8.234;8;18;14;8q11.22-q11.23;PXDNL, PMR1, VPO2;;Peroxidasin, Drosophila, homolog-like;615904;REc;;;
8.235;2;20;03;8q11.23;RB1CC1, CC1, KIAA0203;;RB1-inducible coiled-coil 1;606837;R;;Breast cancer, somatic, 114480 (3);
8.236;1;21;11;8q11.21;SNAI2, SLUG, WS2D;;snail, Drosophila, homolog of, 2 (Neural crest transcription factor SLUG);602150;Psh, R;;Waardenburg syndrome, type 2D, 608890 (3); Piebaldism, 172800 (3);16(Slug)
8.237;11;30;06;8q11.21;SNTG1, SYN4;;Syntrophin, gamma-1;608714;REc, R;implicated in idiopathic scoliosis;;
8.238;2;21;06;8q12.1;TGS1, NCOA6IP, PIMT;;Trimethylguanosine synthase, S. cerevisiae, homolog of;606461;REc;;;
8.239;2;21;10;8q12.1;CA8, CALS, CARP, CAMRQ3;;Carbonic anhydrase VIII;114815;REa, A;;Cerebellar ataxia and mental retardation with or without quadrupedal locomotion 3, 613227 (3);4(Car)
8.240;10;7;02;8q24.3;CHARC1, CHARC15, YCL1;;Chromatin accessibility complex, subunit 1;607268;REc;;;
8.241;11;19;98;8q12.1;CYP7A1, CYP7;;Cytochrome P450, subfamily VII (cholesterol 7-alpha-monooxygenase), polypeptide 1;118455;REa, A;;;
8.242;1;21;04;8q11.2-q12.1;RP1, ORP1;;Oxygen-regulated photoreceptor protein-1 (retinitis pigmentosa-1);603937;Fd, R, A;;Retinitis pigmentosa 1, 180100 (3);
8.243;2;25;15;8q11.1;BEYLA;;BEYLA gene;609543;REc;;;
8.244;1;16;18;8q11.21;MCM4, NKGCD, NKCD, IMD54;;Minichromosome maintenance deficient, S. cerevisiae, homolog of, 4;602638;A, Fd;;Immunodeficiency 54, 609981 (3);
8.245;3;18;94;8q11.23;OPRK1;;Opiate receptor, kappa-1;165196;REa, A;;;
8.246;9;9;13;8q11.21;SPIDR, KIAA0146;;Scaffolding protein involved in DNA repair;615384;REc;;;
8.247;6;13;12;8q11.21;UBE2V2, UEV2, DDVIT1, EDPF1, MMS2;;Ubiquitin-conjugating enzyme E2 variant 2;603001;REc;;;
8.248;2;11;11;8q11.23;NPBWR1, GPR7;;Neuropeptides B and W receptor 1;600730;A, REc;previously assigned to 10q11.2-q21.1 by FISH;;
8.249;10;12;16;8q11.23;ST18, ZNF387, KIAA0535;;Suppression of tumorigenicity 18;617155;REc;;;
8.250;12;15;98;8q11.23;TCEA1, TF2S, GTF2S;;Transcription elongation factor A, SII, 1;601425;REa, A;previously mapped to 3p22-p21.3;;
8.251;2;26;08;8q11.23;MRPL15;;Mitochondrial ribosomal protein L15;611828;R;;;
8.252;4;28;10;8q11.2-q13.2;GCCD3, FGD3, GCCD2;;Glucocorticoid deficiency 3;609197;Fd;between D8S285 and D8S1718;Glucocorticoid deficiency 3 (2);
8.253;4;1;03;8q11.1-q13.3;PAFC;;Preauricular fistulae, congenital;128700;Fd;between D8S532 and D8S279;?Preauricular fistulae, congenital (2);
8.254;7;23;07;8q12.1;CHCHD7;;Coiled-coil-helix-coiled-coil-helix domain-containing protein 7;611238;REn;;;
8.255;3;12;15;8q12;IS3;;Scoliosis, isolated, susceptibility to, 3;608765;Fd;;{Scoliosis, isolated, susceptibility to, 3} (2);
8.256;12;11;15;8q12.1;PLAG1, SGPA, PSA;;Pleomorphic adenoma gene 1;603026;REc, A;fused with CTNNB1 in SGPA;Adenomas, salivary gland pleomorphic, somatic, 181030 (3);
8.257;4;10;90;8q21.13;IL7;;Interleukin-7;146660;REa, A;;;
8.258;8;20;07;8q12-q13;MTBS2;;Mycobacterium tuberculosis, susceptibility to, 2;611046;Fd;max lod at D8S1723;{Mycobacterium tuberculosis, susceptibility to, 2} (2);
8.259;10;24;00;8q12.1;NSMAF, FAN;;Neutral sphingomyelinase activation-associated factor;603043;A;;;
8.260;12;21;10;8q11.23;SOX17, VUR3;;SRY-box 17;610928;REc;;Vesicoureteral reflux 3, 613674 (3);
8.261;2;18;09;8q12.1;ANIB10;;Aneurysm, intracranial berry, 10;612587;Fd;associated with rs10958409;{Aneurysm, intracranial berry, 10} (2);
8.262;7;15;14;8q12.3;ASPH, HAAH, FDLAB;;Aspartate beta-hydroxylase (junctin; junctate);600582;REc, A;;Traboulsi syndrome, 601552 (3);
8.263;3;12;14;8q12.2;CHD7, HH5;;Chromodomain helicase DNA binding protein 7;608892;R, REc;;CHARGE syndrome, 214800 (3); Hypogonadotropic hypogonadism 5 with or without anosmia, 612370 (3);
8.264;4;2;16;8q12.1;FAM110B, C8orf72;;Family with sequence similarity 110, member B;611394;REc;;;
8.265;7;22;11;8q12.1;IMPAD1, GPAPP, IMPA3;;Inositol monophosphatase domain-containing protein 1;614010;REc;;Chondrodysplasia with joint dislocations, GPAPP type, 614078 (3);
8.266;2;28;03;8q12.1-q12.2;RAB2, RAB2A;;Ras-associated protein RAB2;179509;REc;;;
8.267;11;2;04;8q12.1;RDHE2;;Retinal dehydrogenase, epidermal, 2;608989;REc;;;
8.268;9;19;00;8q12.1;RPS20;;Ribosomal protein S20;603682;REa, R, REc;;;
8.269;9;20;14;8q12.1;SDCBP, TACIP18, MDA9;;Syndecan-binding protein;602217;REc;;;
8.270;3;22;13;8q12.1;TOX, KIAA0808;;Thymus high mobility group box protein, mouse, homolog of;606863;R, REc;;;
8.271;6;2;15;8q12.1;UBXN2B, LOC137886, p37;;UBX domain protein 2B;610686;REc;;;
8.272;5;11;16;8q12.2-q12.3;CLVS1, RLBP1L1, CRALBPL;;Clavesin 1;611292;REc;;;
8.273;5;4;12;8q12.2-q21.2;DEL8q12q21, C8DELq12q21;;Bor-Duane hydrocephalus contiguous gene syndrome (chromosome 8q12.1-q21.2 deletion syndrome);600257;Ch;;Bor-Duane hydrocephalus contiguous gene syndrome (4);
8.274;7;16;09;8q12.3;NKAIN3;;Na+/K+ transporting ATPase-interacting 3;612872;REc;;;4(Nkain3)
8.275;2;22;13;8q12.2-q21.2;HDCPH1;;Hydrocephalus, autosomal dominant;123155;Ch;;?Hydrocephalus, autosomal dominant (2);
8.276;7;18;06;8q12.3;GGH;;Gamma-glutamyl hydrolase;601509;REc;;;
8.277;5;24;13;8q13.1;SGK3, SGKL, CISK;;Serum/glucocorticoid-regulated kinase 3;607591;R;;;
8.278;8;31;99;8q13.2;ARFGEF1, ARFGEP1, BIG1, P200;;ADP-ribosylation factor guanine nucleotide exchange factor 1;604141;R;;;
8.279;9;30;10;8q12.3;BHLHE22, BHLHB5, BETA3;;Basic helix-loop-helix family, member E22;613483;A, H;;;3(Bhlhe22)
8.280;1;18;12;8q13.2;CPA6, CPAH, ETL5, FEB11;;Carboxypeptidase A6;609562;REc;;Epilepsy, familial temporal lobe, 5, 614417 (3); Febrile seizures, familial, 11, 614418 (3);
8.281;9;3;09;8q13.1;CRH;;Corticotropin releasing hormone;122560;REa, A;;;3(Crh)
8.282;10;29;10;8q13;DEL8q13, C8DELq13;;Mesomelia-synostoses syndrome (Chromosome 8q13 deletion syndrome);600383;REc;contiguous gene deletion of SULF1 and SLCO5A1;Mesomelia-synostoses syndrome (4);
8.283;8;9;99;8q13;DURS1, DUS;;Duane retraction syndrome 1;126800;Ch;;Duane retraction syndrome 1 (2);
8.284;9;2;08;8q13.1;SNHG6, U87HG;;Small nucleolar RNA host gene 6;612215;R, REc;;;
8.285;6;29;98;8q21.11;TERF1, TRF1;;Telomeric repeat binding factor 1;600951;A, Psh;;;17(Trf1)
8.286;9;2;08;8q13.1;SNORD87, U87;;Small nucleolar RNA, C/D box, 87;612216;REc;within intron 2 of SNHG6;;
8.287;7;28;17;8q21.11;TRPA1, ANKTM1, FEPS1;;Transient receptor potential cation channel, subfamily A, member 1 (ankyrin-like protein with transmembrane domains 1);604775;A;mutation identified in 1 FEPS1 family;?Episodic pain syndrome, familial, 1, 615040 (3);
8.288;1;22;08;8q13.1;VCPIP1 VCIP135, KIAA1850;;VCP/p47 complex-interacting protein 1;611745;R, REc;;;
8.289;8;9;05;8q13-q21;FEB1;;Febrile seizures, familial, 1;121210;Fd;;Febrile seizures, familial, 1 (2);
8.290;2;18;96;8q22.1;GEM;;GTP-binding protein overexpressed in skeletal muscle;600164;Fd;;;4(Gem)
8.291;5;14;01;8q21.11;STAU2;;Staufen, Drosophila, homolog of, 2;605920;REc;;;
8.292;11;3;11;8q21.11;UBE2W, UBC16;;Ubiquitin-conjugating enzyme 2W;614277;REc;;;
8.293;10;13;94;8q13.1;PDE7A, HCP1;;Phosphodiesterase-7A;171885;REa;;;
8.294;3;25;15;8q13-q23;CMT2H;;Charcot-Marie-Tooth disease, axonal, type 2H;607731;Fd;between D8S1807 and D8S548;Charcot-Marie-Tooth disease, axonal, type 2H (2);
8.295;8;22;90;8q12.1;LYN;;Yamaguchi sarcoma viral (v-yes-1) related oncogene homolog;165120;REa;;;4(Lyn)
8.296;8;21;07;8q13.1;ADHFE1, HOT, ADH8;;Alcohol dehydrogenase, iron-containing, 1;611083;REc;;;
8.297;5;23;11;8q13.1;DNAJC5B;;DNAJ/HSP40 homolog, subfamily C, member 5, beta;613945;REc;;;
8.298;6;27;17;8q13.1;MCMDC2, C8orf45;;Minichromosome maintenance domain-containing protein 2;617545;REc;;;
8.299;10;25;17;8q13.1;PPP1R42, TLRR, LRRC67;;Protein phosphatase 1, rebulatory subunit 42;617720;REc;;;
8.300;2;5;13;8q13.1;TRIM55, RNF29, MURF2;;Tripartite motif containing 55;606469;REc, R;;;
8.301;10;10;11;8q13.2;PREX2, DEPDC2;;Phosphatidylinositol 3,4,5-trisphosphate-dependent RAC exchanger 2;612139;REc;;;
8.302;12;11;95;8q12.3;TTPA, TTP1, AVED;;Tocopherol, alpha, transfer protein;600415;Fd, LD, REc, A, REa;;Ataxia with isolated vitamin E deficiency, 277460 (3);
8.303;6;13;12;8q13.1;COPS5, JAB1, SGN5;;COP9, subunit 5;604850;REc;;;
8.304;2;21;14;8q13.1-q13.2;CSPP1, CSPP, JBTS21;;Centrosome spindle pole-associated protein 1;611654;REc;;Joubert syndrome 21, 615636 (3);
8.305;9;7;10;8q13.3;NCOA2, GRIP1, TIF2, SRC2;;Nuclear receptor coactivator 2;601993;fused with MOZ in AML;;;
8.306;1;5;17;8q13.3;EYA1, BOR, BOS1, OFC1;;Eyes absent, Drosophila, homolog of, 1;601653;REc, Fd, Ch;mutation identified in 1 OFC1 family;Branchiootorenal syndrome 1, with or without cataracts, 113650 (3); Anterior segment anomalies with or without cataract, 602588 (3); Branchiootic syndrome 1, 602588 (3); ?Otofaciocervical syndrome, 166780 (3);
8.307;8;18;14;8q13.3;MSC, ABF1, MYOR;;Musculin;603628;REc;;;
8.308;12;13;18;8q24.13;NDUFB9, UQOR22, MC1DN24;;NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 9 (22kD, B22);601445;REc;mutation identified in 1 MC1DN24 family;?Mitochondrial complex I deficiency, nuclear type 24, 618245 (3);
8.309;2;11;08;8q13.3;PRDM14, PFM11;;PR domain-containing protein 14;611781;A;;;
8.310;8;27;15;8q13.3;SLCO5A1, OATPRP4, SLC21A15, OATPJ, OATP5A1;;Solute carrier organic anion transporter family, member 5A1;613543;REc;;;
8.311;5;19;06;8q13.2-q13.3;SULF1, KIAA1077;;Sulfatase 1;610012;REc;;;1(Sulf1)
8.312;11;27;13;8p21.3;POLR3D, BN51T, TSBN51;;Polymerase III, RNA, subunit D;187280;REa, A;;;
8.313;12;9;15;8q21.11;JPH1, JP1, CMT2K;;Junctophilin 1;605266;A;mutation identified in 1 CMT2K family;?Charcot-Marie-Tooth disease, axonal, autosomal dominant, type 2K, 607831 (3);
8.314;9;18;08;8q21.3;CNGB3, ACHM3, ACHM1;;Cyclic nucleotide-gated channel, beta-3;605080;REc, Fd;;Achromatopsia 3, 262300 (3); Macular degeneration, juvenile, 248200 (3);
8.315;11;10;06;8q21-q22;OPA6;;Optic atrophy 6;258500;Fd;between D8S1702 and D8S1794;Optic atrophy 6 (2);
8.316;12;14;06;8q24.3;CYP11B1, P450C11, FHI;;Cytochrome P450, subfamily XIB, polypeptide 1 (11-beta-hydroxylase; corticosteroid methyl-oxidase II (CMO II));610613;REa, A, Ch;chimeric CYP11B1/CYP11B2 gene = anti-Lepore-like;Adrenal hyperplasia, congenital, due to 11-beta-hydroxylase deficiency, 202010 (3); Aldosteronism, glucocorticoid-remediable, 103900 (3);
8.317;12;14;06;8q24.3;CYP11B2;;Cytochrome P450, subfamily XIB, polypeptide 2;124080;REa;;Hypoaldosteronism, congenital, due to CMO II deficiency, 610600 (3); Hypoaldosteronism, congenital, due to CMO I deficiency, 203400 (3); {Low renin hypertension, susceptibility to} (3); Aldosterone to renin ratio raised (3);
8.318;6;19;98;8q21.13;FABP4;;Fatty acid-binding protein-4, adipocyte;600434;A;;;
8.319;10;7;09;8q21.13;HNF4G;;Hepatocyte nuclear factor 4-gamma;605966;Psh, REc;;;3(Hnf4g)
8.320;3;2;98;8q21.3;MMP16;;Matrix metalloproteinase 16 (membrane-inserted);602262;A;;;
8.321;1;7;16;8q21.3;NBN, NBS1;;Nibrin;602667;Fd, M;;Nijmegen breakage syndrome, 251260 (3); Aplastic anemia, 609135 (3); Leukemia, acute lymphoblastic, 613065 (3);
8.322;5;25;13;8q21.13;TPD52, D52;;Tumor protein D52;604068;A;;;
8.323;8;24;09;8q21.3;WWP1, TIUL1;;WW domain-containing protein 1;602307;A;;;
8.324;10;25;12;8q21.13;PEX2, PAF1, PMP35, PBD5A, PBD5B, PXMP3;;Peroxisome biogenesis factor 2;170993;RE;;Peroxisome biogenesis disorder 5A (Zellweger), 614866 (3); Peroxisome biogenesis disorder 5B, 614867 (3);3(Pxmp3)
8.325;4;24;08;8q21.13;MRPS28, MRPS35;;Mitochondrial ribosomal protein S28;611990;R, REc;;;
8.326;10;23;87;8q21.1-qter;GLYB;;Glycine auxotroph B, complementation of hamster;138480;S;gly(-)B;;
8.327;9;21;11;8q21.11;DEL8q21.11, C8DELq21.11;;Chromosome 8q21.11 deletion syndrome;614230;Ch;contiguous gene deletion; minimal region (GRCh37, 8:77226464-77766239;Chromosome 8q21.11 deletion syndrome (4);
8.328;8;29;13;8q21.11;GDAP1, CMT4A, CMT2K, CMTRIA;;Ganglioside-induced differentiation-associated protein 1;606598;Fd, REc;;Charcot-Marie-Tooth disease, type 4A, 214400 (3); Charcot-Marie-Tooth disease, axonal, with vocal cord paresis, 607706 (3); Charcot-Marie-Tooth disease, axonal, type 2K, 607831 (3); Charcot-Marie-Tooth disease, recessive intermediate, A, 608340 (3);
8.329;5;30;13;8q21.11;LY96, MD2;;Lymphocyte antigen 96;605243;REc;;;
8.330;7;1;11;8q21.11;TMEM70, MC5DN2;;Transmembrane protein 70;612418;REc;;Mitochondrial complex V (ATP synthase) deficiency, nuclear type 2, 614052 (3);
8.331;4;23;12;8q21.13;CHMP4C, SNF7-3;;CHMP family, member 4C;610899;REc;;;
8.332;6;11;02;8q21.13;ZFHX4, ZFH4;;Zinc finger homeobox 4;606940;H, Ch;;?Ptosis, congenital, 178300 (2);
8.333;10;6;09;8q21.13;FABP5, PAFABP, EFABP;;Fatty acid-binding protein 5;605168;H, REc;;;3(Fabp5)
8.334;11;05;18;8q21.13;HEY1, NERP2, HESR1;;Hairy/enhancer of split-related with YRPW motif 1;602953;A, R, H;;;3(Hey1)
8.335;9;20;14;8q21.13;PI15, P25TI;;Protease inhibitor 15;607076;REc;;;
8.336;12;10;12;8q21.13;SNX16;;Sorting nexin 16;614903;REc;;;
8.337;5;4;12;8q21.13;STMN2, SCGN10, SCG10;;Stathmin-like 2;600621;R, REc;;;
8.338;2;17;09;8q21.13;STQTL15;;Stature quantitative trait locus 15;612578;Fd;associated with rs2220456;{Stature QTL 15} (2);
8.339;2;2;17;8q21.13;IMPA1, MRT59;;Inositol(myo)-1(or 4)-monophosphatase-1;602064;Psh, REc;;Mental retardation, autosomal recessive 59, 617323 (3);
8.340;12;11;18;8q22.1;TMEM67, MKS3, JBTS6, NPHP11;;Transmembrane protein 67 (meckelin);609884;Fd, REc;mutation identified in 1 RHYNS patient;Meckel syndrome 3, 607361 (3); Joubert syndrome 6, 610688 (3); {Bardet-Biedl syndrome 14, modifier of}, 615991 (3); COACH syndrome, 216360 (3); Nephronophthisis 11, 613550 (3); ?RHYNS syndrome, 602152 (3);
8.341;8;18;14;8q21.2;E2F5;;E2F transcription factor 5;600967;REc;;;
8.342;11;29;17;8q21.2;LRRCC1, CLERK, KIAA1764;;Leucine-rich repeat- and coiled-coil domain-containing centrosomal protein 1;617791;REc;;;
8.343;5;18;12;8q21.2;RALYL;;RALY-like protein;614648;REc;;;
8.344;3;1;16;8q22.3;SLC25A32, MFT, RREI;;Solute carrier family 25 (mitochondrial carrier, folate), member 32;610815;REc;mutation identified in 1 RREI patient;?Exercise intolerance, riboflavin-responsive, 616839 (3);15(Slc25a32)
8.345;3;22;06;8q21.3;TMEM55A;;Transmembrane protein 55A;609864;REc;;;
8.346;7;25;18;8q21.3;ATP6V0D2;;ATPase, H+ transporting, V0 subunit D2;618072;REc;;;
8.347;10;6;09;8q21.3;CPNE3, CPN3;;Copine III;604207;R, REc;;;
8.348;4;25;12;8q12.3;CYP7B1, CBAS3, SPG5A;;Cytochrome P450, subfamily VIIB (oxysterol 7-alpha-hydroxylase), polypeptide 1;603711;R, Fd;;Bile acid synthesis defect, congenital, 3, 613812 (3); Spastic paraplegia 5A, autosomal recessive, 270800 (3);
8.349;9;23;14;8q21.3;DECR1;;2,4-dienoyl CoA reductase;222745;A;;;
8.350;3;4;08;8q21.3;FAM82B, RMD1;;Family with sequence similarity 82, member B;611871;REc;;;
8.351;3;23;14;8q21.3;OSGIN2, C8orf1;;Oxidative stress-induced growth inhibitor family member 2;604598;REc;;;
8.352;5;3;17;8q21.3;OTUD6B, DUBA5, IDDFSDA;;OTU domain-containing protein 6B;612021;REc;;Intellectual developmental disorder with dysmorphic facies, seizures, and distal limb anomalies, 617452 (3);
8.353;5;21;14;8q21.3;RIPK2, CARDIAK, RIP2, RICK;;Receptor-interacting serine/threonine kinase 2;603455;REc;;;
8.354;12;15;16;8q21.3;SLC7A13, AGT1, XAT2;;Solute carrier family 7, member 13;617256;REc;;;
8.355;12;5;13;8q22.1;RAD54B;;RAD54, S. cerevisiae, homolog of, B;604289;A;;Lymphoma, non-Hodgkin, somatic, 605027 (3); Colon cancer, somatic, 114500 (3);
8.356;9;13;99;8q21.3;CALB1;;Calbindin 1, 28kD;114050;REa, A;;;4(Calb)
8.357;10;4;93;8q21.13;PMP2;;Peripheral myelin protein-2;170715;REb, A;not involved in CMT4A;;
8.358;6;28;99;8q23.1;ANGPT1, ANG1;;Angiopoietin-1;601667;A, R, H;;;15(Angpt1)
8.359;10;13;94;8q21.2;CA1;;Carbonic anhydrase I;114800;REa, H, A;;;3(Car1)
8.360;10;3;07;8q21.2;CA2;;Carbonic anhydrase II;611492;REa, H;CA1, CA2 linked in monkey and mouse;Osteopetrosis, autosomal recessive 3, with renal tubular acidosis, 259730 (3);3(Car2)
8.361;6;4;90;8q21.2;CA3;;Carbonic anhydrase III;114750;REa, A;;;3(Car3)
8.362;4;14;10;8q22.3;DPYS, DHP;;Dihydropyrimidinase;613326;A;;Dihydropyrimidinuria, 222748 (3);
8.363;6;28;18;8q22.3;GRHL2, TFCP2L3, DFNA28, ECTDS, PPCD4;;Grainyhead-like 2;608576;REc;;Deafness, autosomal dominant 28, 608641 (3); Ectodermal dysplasia/short stature syndrome, 616029 (3); Corneal dystrophy, posterior polymorphous, 4, 618031 (3);
8.364;6;30;05;8q22.2;HRSP12, PSP, UK114;;Heat-responsive protein 12;602487;REc;;;
8.365;1;25;05;8q22;HTC1;;Hypertrichosis universalis congenita, Ambras type;145701;Ch;;?Hypertrichosis universalis congenita, Ambras type (2);
8.366;11;20;98;8q22.2;KCNS2;;Potassium voltage-gated channel, delayed-rectifier, subfamily S, member-2;602906;REc;;;
8.367;1;23;01;8q22.1-q22.2;MATN2;;Matrilin 2;602108;A;;;
8.368;9;19;91;8q13.1;MYBL1;;Avian myeloblastosis viral (v-myb) oncogene homolog like-1;159405;REa, A;;;
8.369;11;27;94;8q22.3;ODF1;;Outer dense fiber of sperm tails 1;182878;REa, A;;;15(Odf1)
8.370;3;22;16;8q22.2;POP1, ANXD2;;Processing of precursor 1, S. cerevisiae, homolog of;602486;A;;Anauxetic dysplasia 2, 617396 (3);
8.371;2;10;14;8q22.1;PTDSS1, PSS1, KIAA0024, LMHD;;Phosphatidylserine synthase 1;612792;Psh, H, REc;;Lenz-Majewski hyperostotic dwarfism, 151050 (3);13(Pss1)
8.372;4;24;12;8q21.3;RUNX1T1, CBFA2T1, AML1T1, ETO;;unt-related transcription factor 1, translocated to, 1, cyclin D-related;133435;Ch;fused with AML1 in t(8;21);;4(Cbfa2t1h)
8.373;1;28;01;8q22.1;TP53DINP1, P53DINP1;;Tumor protein p53 inducible nuclear protein 1;606185;A;;;
8.374;5;4;00;8q22.3;PABPC1, PAB1, PABP1, PABP;;Polyadenylate-binding protein, cytoplasmic, 1;604679;Psh;;;
8.375;11;11;13;8q22.2;SPAG1, CILD28;;Sperm-associated antigen-1;603395;R;;Ciliary dyskinesia, primary, 28, 615505 (3);
8.376;5;19;06;8q22.3;TM7SF4, DCSTAMP, FIND;;Transmembrane 7 superfamily, member 4;605933;A;;;
8.377;7;18;12;8q22.1;TSPYL5, KIAA1750;;TSPY-like 5;614721;REc;;;
8.378;4;8;13;8q22.1;UQCRB, UQBP, QPC, MC3DN3;;Ubiquinol-cytochrome c reductase binding protein;191330;REa;;Mitochondrial complex III deficiency, nuclear type 3, 615158 (3);
8.379;6;16;99;8q22.2;COX6C;;Cytochrome c oxidase, subunit VIc;124090;A, R;pseudogene on 16p12;;
8.380;10;3;07;8q23.1;EIF3E, EIF3S6, INT6;;Eukaryotic translation initiation factor 3, subunit E (oncogene INT6);602210;Psh, H;;;15(Int6)
8.381;9;9;09;8q22.1;MTDH, AEG1, LYRIC;;Metadherin;610323;A, REc;;;15(Mtdh)
8.382;7;22;13;8q22.2;VPS13B, KIAA0532, COH1;;Vacuolar protein sorting 13, yeast, homolog of, B;607817;Fd, REc;;Cohen syndrome, 216550 (3);
8.383;8;19;98;8q22.1;SDC2, HSPG1;;Syndecan 2 (heparan sulfate proteoglycan 1, cell surface-associated; fibroglycan);142460;REa, A;;;
8.384;3;28;17;8q22.1;C8orf37, CORD16, RP64, BBS21;;Chromosome 8 open reading frame 37;614477;REc;;Retinitis pigmentosa 64, 614500 (3); Cone-rod dystrophy 16, 614500 (3); Bardet-Biedl syndrome 21, 617406 (3);
8.385;3;31;15;8q22.1;CCNE2;;Cyclin E2;603775;REc;;;
8.386;11;4;98;8q22.1;CDH17, CDH16, HPT1;;Cadherin-17, liver-intestine;603017;Psh, A;;;
8.387;4;28;14;8q22.1;DUP8q22.1, C8DUPq22.1;;Chromosome 8q22.1 duplication syndrome (Leri pleonosteosis);151200;Ch;duplication of 0.9-1.2 Mb on 8q22.1;Leri pleonosteosis chromosome duplication syndrome (4);
8.388;12;04;18;8q22.1;FAM92A, FAM92A1, PAPA9;;Family with sequence similarity 92, member A;617273;REc;mutation identified in 1 PAPA9 family;?Polydactyly, postaxial, type A9, 618219 (3);
8.389;4;10;15;8q22.1;FSBP;;Fibrinogen silencer-binding protein;616306;REc;;;
8.390;3;23;14;8q22.1;INTS8, INT8;;Integrator complex subunit 8;611351;R, REc;;;
8.391;7;9;15;8q22.1;KIAA1429;;KIAA1429 gene;616447;REc;;;
8.392;5;2;16;8q22.1;MTERF3, MTERFD1;;Transcription termination factor 3, mitochondrial;616930;REc;;;
8.393;12;13;18;8q22.1;NDUFAF6, C8orf38, MC1DN17;;NADH dehydrogenase (ubiquinone) complex I, assembly factor 6;612392;REc;;Mitochondrial complex I deficiency, nuclear type 17, 612392 (3);
8.394;5;4;12;8q22.1;NMLFS, DEL8q22.1, C8DELq22.1;;Nablus mask-like facial syndrome (chromosome 8q22.1 deletion syndrome);608156;Ch;;Nablus mask-like facial syndrome (4);
8.395;4;15;11;8q22.1;DPY19L4;;DPY19-like 4;613895;REc;;;
8.396;6;13;18;8q22.1;ESRP1, RMB35A, DFNB109;;Epithelial splicing regulatory protein 1;612959;REc;mutation identified in 1 DFNB109 family;?Deafness, autosomal recessive 109, 618013 (3);
8.397;3;5;18;8q22.1;GDF6, MCOP4, KFS1, MCOPCB6, LCA17, SYNS4;;Growth/differentiation factor 6;601147;REc, Ch;;Klippel-Feil syndrome 1, autosomal dominant, 118100 (3); Microphthalmia, isolated 4, 613094 (3); Microphthalmia with coloboma 6, digenic, 613703 (3); Leber congenital amaurosis 17, 615360 (3); Multiple synostoses syndrome 4, 617898 (3);
8.398;3;16;10;8q22.1;LAPTM4B;;Lysosome-associated protein, transmembrane 4, beta;613296;REc;pseudogenes on 1q, 3q,3p, 4q, and 7q33-q35;;
8.399;2;2;10;8q22.1;PDP1, PPM2C, PDPC;;Pyruvate dehydrogenase phosphatase catalytic subunit 1;605993;R, REc;;Pyruvate dehydrogenase phosphatase deficiency, 608782 (3);
8.400;5;6;13;8q22.1;PLEKHF2, EAPF, PHAFIN2;;Pleckstrin homology domain-containing protein, family F, member 2;615208;REc;;;
8.401;5;13;13;8q22.3;KLF10, TIEG;;Kruppel-like factor 10;601878;REc, H;;;1(Klf10)
8.402;6;17;02;8q22.3;NCALD;;Neurocalcin, delta;606722;R;;;
8.403;2;25;14;8q22.2;RGS22;;Regulator of G protein signaling 22;615650;REc;;;
8.404;11;11;14;8q22.2;STK3, MST2, KRS1;;Serine/threonine protein kinase 3;605030;REc;;;
8.405;10;6;09;8q22.3;ATP6V1C1, ATP6C, ATP6D;;ATPase, H+ transporting, V1 subunit C1;603097;R, REc;;;
8.406;8;18;08;8q22.3;AZIN1, OAZIN;;Antizyme inhibitor 1;607909;R, REc;;;
8.407;1;11;02;8q22.3;BAALC;;Brain and acute leukemia gene, cytoplasmic;606602;REc;;;
8.408;10;5;11;8q22.3;CTHRC1;;Collagen triple-helix repeat-containing protein 1;610635;R, REc;;Barrett esophagus/esophageal adenocarcinoma, 614266 (3);
8.409;2;4;15;8q22.3;DCAF13, WDSOF1;;DDB1- and CUL4-associated factor 13;616196;REc;;;
8.410;9;9;08;8q22.2;FBXO43, EMI2, ERP1, FBX43;;F-box only protein 43;609110;REc, H;;;15(Fbxo43)
8.411;1;8;06;8q22.3;KTWS, KTS;;Klippel-Trenaunay-Weber syndrome;149000;Ch;translocation with 14q13;Klippel-Trenaunay-Weber syndrome (2);
8.412;10;8;12;8q22.3;UBR5, EDD1, HYD, KIAA0896;;Ubiquitin protein ligase E3 component n-recognin 5;608413;A;;;
8.413;3;24;10;8q22.3;YWHAZ;;Tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, zeta polypeptide;601288;A;pseudogene on 2p25;;
8.414;3;29;10;8q22.3;MMD2;;Miyoshi muscular dystrophy 2;613318;Fd;max lod at D10S2325;Miyoshi muscular dystrophy 2 (2);
8.415;8;25;11;8q22.3;FZD6, NDNC10;;Frizzled, Drosophila, homolog of, 6;603409;A;;Nail disorder, nonsyndromic congenital, 10, (claw-shaped nails), 614157 (3);15(Mfz6)
8.416;3;22;07;8q23.2;KCNV1, KV8.1;;Potassium channel, voltage-gated, subfamily V, member 1;608164;A;;;
8.417;12;7;07;8q23.1;ABRA, STARS;;Actin-binding RHO-activating protein;609747;REc;;;
8.418;7;17;01;8q23.1;CML66;;Immunogenic tumor antigen CML66;606109;A;;;
8.419;6;16;99;8q24.12;COL14A1, UND;;Collagen, type XIV, alpha-1 (undulin);120324;A;;;
8.420;8;20;08;8q23;CRCS6;;Colorectal cancer, susceptibility to, 6;612231;Fd;associated with rs16892766;{Colorectal cancer, susceptibility to, 6} (2);
8.421;4;19;01;8q23.2;EBAG9, RCAS1, EB9;;Estrogen receptor-binding site-associated antigen 9;605772;A;;;
8.422;9;9;98;8q23;GLC1D;;Glaucoma 1, open angle, D;602429;Fd;;Glaucoma 1D, primary open angle (2);
8.423;12;7;07;8q23.2;GOLSYN, SYBU, KIAA1472;;Golgi-localized syntaphilin-related protein;611568;REc, H;;;15(Golsyn)
8.424;12;17;07;8q23;HDLCQ2;;High density lipoprotein cholesterol level QTL 2;607053;Fd;;[High density lipoprotein cholesterol level QTL 2] (2);
8.425;5;4;09;8q23;LBMQTL1;;Lean body mass quantitative trait locus 1;612729;Fd;associated with rs16892496 and rs7832552;[Lean body mass QTL 1] (2);
8.426;10;24;12;8q23;MYMY3;;Moyamoya disease 3;608796;Fd;max lod at D8S546;Moyamoya disease 3 (2);
8.427;7;30;09;8q22.2;OSR2;;Odd-skipped-related 2;611297;REc;;;
8.428;2;5;01;8q23.1;OXR1;;Oxidation resistance 1;605609;REc;?pseudogene on chr.15;;
8.429;9;2;09;8q23.1-q23.2;PKHD1L1;;PKHD1-like 1;607843;REc;;;
8.430;7;18;14;8q22.3;RIMS2, KIAA0751, RIM2, OBOE;;Regulating synaptic membrane exocytosis-2;606630;R, REc;;;
8.431;5;27;05;8q23.1;TRHR;;Thyrotropin-releasing hormone receptor;188545;A, H, REa;;Thyrotropin-releasing hormone resistance, generalized (3);15(Trhr)
8.432;11;3;14;8q23.1;ZFPM2, FOG2, DIH3, SRXY9;;Zinc finger protein, multitype 2 (friend of GATA2);603693;R, REc;;Tetralogy of Fallot, 187500 (3); Diaphragmatic hernia 3, 610187 (3); 46XY sex reversal 9, 616067 (3);
8.433;1;10;02;8q23-q24;HT;;Hashimoto thyroiditis;140300;Fd;?chr.12;Hashimoto thyroiditis (2);
8.434;10;11;07;8q23-q24;MGS;;Mungan syndrome;611376;Fd;between D8S1830 and D8S1799;Mungan syndrome (2);
8.435;10;23;87;8q12.1;PENK;;Proenkephalin;131330;REa, A;;;
8.436;1;8;95;8q24.12;SNT2B1, A1B, SNTB1;;Syntrophin, beta 1 (dystrophin-associated protein A1, 59kD, basic basic component 1);600026;REa, A;;;
8.437;4;18;07;8q24.22;ZFAT1, ZNF406, AITD3;;Zinc finger gene in autoimmune thyroid disease 1;610931;REn;;{Autoimmune thyroid disease, susceptibility to, 3}, 608175 (3);
8.438;4;17;17;8q24.12;COLEC10, CLL1, 3MC3;;Collectin 10;607620;A;;3MC syndrome 3, 248340 (3);
8.439;2;25;15;8q23.1;EMC2, KIAA0103;;ER membrane protein complex subunit 2;607722;REa;;;
8.440;12;27;10;8q22.3;RRM2B, P53R2, PEOA5, MTDPS8A, MTDPS8B;;Ribonucleotide reductase M2 B, TP53 inducible;604712;A;;Mitochondrial DNA depletion syndrome 8A (encephalomyopathic type with renal tubulopathy), 612075 (3); Progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal dominant 5, 613077 (3); Mitochondrial DNA depletion syndrome 8B (MNGIE type), 612075 (3);
8.441;6;22;18;8q23.1;RSPO2, CRISTIN2, TETAMS2, HHRRD;;R-spondin family, member 2;610575;REc;mutation identified in 1 HHRRD family;Tetraamelia syndrome 2, 618021 (3); ?Humerofemoral hypoplasia with radiotibial ray deficiency, 618022 (3);15(Rspo2)
8.442;4;26;11;8q23.1;TMEM74;;Transmembrane protein 74;613935;REc;;;
8.443;1;27;04;8q23.3;CSMD3, KIAA1894;;Cub and Sushi multiple domains 3;608399;REc;;;
8.444;12;24;08;8q24.3;ARC, KIAA0278;;Activity-regulated cytoskeleton-associated protein;612461;R, A;;;
8.445;9;1;16;8q24.3;ADGRB1, BAI1, GDAIF;;Adhesion G protein-coupled receptor B1;602682;A;;;
8.446;11;30;06;8q24.3;BOP1, KIAA0124;;Block of proliferation 1;610596;Psh, REc;;;
8.447;12;29;06;8q24;BSZQTL3;;Bone size quantitative trait locus 3;610649;Fd;;[Bone size quantitative trait locus 3] (2);
8.448;8;20;08;8q24;CRCS2;;Colorectal cancer, susceptibility to, 2;611469;Fd;associated with rs7014346;{Colorectal cancer, susceptibility to, 2} (2);
8.449;11;11;98;8q24;ECA1;;Epilepsy, childhood absence, 1;600131;Fd;;Epilepsy, childhood absence, 1 (2);
8.450;10;28;10;8q24;EIG1;;Epilepsy, idiopathic generalized, susceptibility to 1;600669;Fd;?same as EBN2;{Epilepsy, idiopathic generalized, susceptibility to, 1} (2);
8.451;5;11;16;8q24.3;AGO2, EIF2C2;;Argonaute 2, RISC catalytic component;606229;R, REc;;;
8.452;5;17;18;8q24.21;FAM149B;;Family with sequence similarity 49, member B;617978;REc;;;
8.453;12;15;17;8q24.3;GPAA1, GAA1, GPIBD15;;Glycophosphatidylinositol anchor attachment protein 1;603048;A, R;;Glycosylphosphatidylinositol biosynthesis defect 15, 617810 (3);
8.454;8;10;99;8q24.22;HHLA1;;Human endogenous retrovirus-H long terminal repeat-associating 1;604109;A, R;;;
8.455;8;9;07;8q24;HPC10;;Prostate cancer, hereditary, 10;611100;Fd;strongest assoc. with rs1447295;{Prostate cancer, hereditary, 10} (2);
8.456;2;22;92;8q24;HPV18I1;;Human papillomavirus type 18 integration site-1;167959;A;;;
8.457;10;7;09;8q24.3;JRK, JH8;;Jerky, mouse, homolog of;603210;R, A;;;15(Jrk)
8.458;2;2;18;8q24.22;KCNQ3, EBN2, BFNC2;;Potassium voltage-gated channel, KQT-like subfamily, member 3;602232;Psh, R, Fd;;Seizures, benign neonatal, 2, 121201 (3);
8.459;3;30;18;8q24.3;MAFA, RIPE3B1, INSDM;;v-MAF avian musculoaponeurotic fibrosarcoma oncogene homolog A;610303;REc;;Insulinomatosis and diabetes mellitus, 147630 (3);
8.460;8;10;99;8q24.22;OC90, PLA2L;;Otoconin 90 (phospholipase A2-like);601658;A, R;PLA2L = fusion between HHLA1 and OC90;;
8.461;10;12;14;8q24.21;PCAT1;;Prostate cancer-associated transcript 1, noncoding;616043;REc;;;
8.462;09;27;18;8q24.3;PLEC1, PLEC, PLTN, EBS1, LGMDR17, EBSOG, EBSPA, EBSMD, EBSND;;Plectin 1;601282;A, Psh, Fd;mutation identified in 1 EBSND family;Epidermolysis bullosa simplex with muscular dystrophy, 226670 (3); Epidermolysis bullosa simplex, Ogna type, 131950 (3); Epidermolysis bullosa simplex with pyloric atresia, 612138 (3); Muscular dystrophy, limb-girdle, autosomal recessive 17, 613723 (3); ?Epidermolysis bullosa simplex with nail dystrophy, 616487 (3);
8.463;10;15;13;8q24.21;PRNCR1, PCAT8;;Prostate cancer-associated noncoding RNA 1;615452;REc;;;
8.464;4;20;17;8q24.22;PTCSC1, NCRNA00197;;Papillary thyroid carcinoma susceptibility candidate 1 gene;617440;REc;;;
8.465;10;23;87;8q24.21;PVT1;;Oncogene PVT-1 (MYC activator);165140;RE, Ch;;;
8.466;09;07;18;8q24.11;RAD21, SCC1, NXP1, KIAA0078, CDLS4, MGS;;Rad21, S. pombe, homolog of;606462;REa, A;mutation identified in 1 MGS family;Cornelia de Lange syndrome 4, 614701 (3); ?Mungan syndrome, 611376 (3);
8.467;3;26;07;8q24.3;SPATC1;;Spermatogenesis- and centriole-associated 1 (speriolin);610874;REc, H;;;15(Spatc1)
8.468;6;30;15;8q24.12;TNFRSF11B, OPG, OCIF, PDB5;;Tumor necrosis factor receptor superfamily, member 11B (osteoprotegerin);602643;R;;Paget disease of bone 5, juvenile-onset, 239000 (3);
8.469;7;13;93;8q24.3;ZNF7, KOX4;;Zinc finger protein-7 (KOX4);194531;A, REa;;;
8.470;9;28;96;8q24.3;ZNF16, KOX9;;Zinc finger protein-16 (KOX 9);601262;A, REc;;;
8.471;8;28;01;8q24.3;LY6D, E48;;Lymphocyte antigen 6 complex, locus D;606204;REa, A;?pseudogene ono 15q22;;
8.472;7;6;99;8q24.3;PTK2, FADK;;PTK2 protein tyrosine kinase;600758;Psh, H;;;15(Fadk)
8.473;9;28;00;8q24.12;ENPP2, PDNP2;;Ectonucleotide pyrophosphatase/phosphodiesterase 2;601060;A;;;
8.474;2;26;04;8q24.13;MTSS1, MIM, KIAA0429;;Metastasis suppressor 1;608486;R, REc;;;
8.475;7;13;93;8q24.12;NOV;;Nephroblastoma overexpressed gene;164958;REa, A;proximal to MYC;;15(nov)
8.476;8;20;07;8q24.13;RNF139, TRC8, RCA1;;RING finger protein 139;603046;Ch;;Renal cell carcinoma, 144700 (3);
8.477;8;1;18;8q24.11-q24.12;SAMD12;;Sterile alpha motif domain containing 12;618073;REc;;Epilepsy, familial adult myoclonic, 1, 601068 (3);
8.478;8;16;99;8q24.13;SQLE;;Squalene epoxidase;602019;R, Psh, A;;;
8.479;10;1;99;8q24.1;THM;;Tibial hemimelia;275220;D;;?Tibial hemimelia (2);
8.480;10;16;98;8q24.13;ANX13, ISA;;Annexin XIII;602573;A;;;
8.481;7;20;15;8q24.21-q24.22;ASAP1, DDEF1;;Arf GTPase-activating protein with SH3 domain, ankyrin repeat, and PH domain 1;605953;R;;;
8.482;10;13;09;8q24.21;GSDMC, MLZE;;Gasdermin C;608384;A;;;
8.483;9;23;08;8q24.3;KCNK9, TASK3;;Potassium channel, subfamily K, member 9;605874;REc;;Birk-Barel mental retardation dysmorphism syndrome, 612292 (3);
8.484;5;16;01;8q24.12;MTBP;;Mouse double minute 2 homolog, binding protein of;605927;A;;;
8.485;3;29;99;8q24.22;WISP1;;Wnt-1 inducible signaling pathway protein 1;603398;R;;;
8.486;10;3;07;8q23.3-q24.1;EIF3H, EIF3S3;;Eukaryotic translation initiation factor 3, subunit H;603912;REc;;;
8.487;1;27;11;8q24.11;MED30, TRAP25, THRAP6;;Mediator complex subunit 30;610237;A;;;
8.488;2;25;08;8q24.11;SLC30A8, ZNT8;;Solute carrier family 30 (zinc transporter), member 8;611145;REc;;{Diabetes mellitus, noninsulin-dependent, susceptibility to}, 125853 (3);15(Slc30a8)
8.489;1;27;04;8q24.11;EXT1;;Exostosin 1;608177;Ch, Fd;distal to TRPS1;Exostoses, multiple, type 1, 133700 (3); Chondrosarcoma, 215300 (3);15(Ext1)
8.490;12;14;10;8q24.11-q24.13;TRPS2, LGCR, LGS;;Trichorhinophalangeal syndrome, type II (Langer-Giedion syndrome);150230;Ch;contiguous gene syndrome involving TRPS1 and EXT1;Trichorhinophalangeal syndrome, type II (4);
8.491;9;10;09;8q24.12;DEPDC6, DEPTOR;;DEP domain-containing protein 6;612974;REc;;;
8.492;2;2;10;8q24.12;DSCC1, DCC1;;Defective in sister chromatid cohesion 1, S. cerevisiae, homolog of;613203;REc;;;
8.493;6;19;98;8q24.13;HAS2;;Hyaluronan synthase-2;601636;Psh, REc;;;15(Has2)
8.494;4;6;15;8q24.12;MRPL13, RPML13, L13A;;Mitochondrial ribosomal protein L13;610200;R, REc;;;
8.495;1;14;14;8q24.12;TAF2, TAF2B, TAFII150, CIF150, MRT40;;TAF2 RAN polymerase II, TATA box-binding protein-associated factor, 150kD;604912;REc;;Mental retardation, autosomal recessive 40, 615599 (3);
8.496;7;20;06;8q23.3;TRPS1;;Zinc finger transcription factor TRPS1;604386;Ch, REc;;Trichorhinophalangeal syndrome, type I, 190350 (3); Trichorhinophalangeal syndrome, type III, 190351 (3);
8.497;12;9;91;8q24.21;MYC;;Avian myelocytomatosis viral (v-myc) oncogene homolog;190080;REa, A;cen-5'-3'-ter;Burkitt lymphoma, 113970 (3);15(Myc)
8.498;11;4;93;8q24.3;ZNF34, KOX32;;Zinc finger protein-34 (KOX32);194526;REa, A, D;;;
8.499;4;15;08;8q24.13;ATAD2, ANCCA;;ATPase family, AAA domain-containing, member 2;611941;R, REc;;;
8.500;5;24;13;8q24.13;DERL1, DER1;;DER1-like domain family, member 1;608813;REc;;;
8.501;9;9;08;8q24.13;FBXO32, MAFBX, FLJ32424, ATROGIN1;;F-box only protein 32;606604;REc;;;15(Fbxo32)
8.502;12;1;11;8q24.13;HAS2AS1, HASNT;;HAS2 antisense RNA 1;614353;REn;;;
8.503;12;15;16;8q24.13;NSMCE2, NSE2, MMS21;;Non-SMC element 2, S. cerevisiae, homolog of;617246;REc;;Seckel syndrome 10, 617253 (3);
8.504;10;28;15;8q24.13;TMEM65;;Transmembrane protein 65;616609;REc;;;2(Tmem65)
8.505;6;11;12;8q24.13;TRIB1, TRB1, SKIP1, C8FW;;Tribbles, Drosophila, homolog of, 1;609461;REc;;;
8.506;5;26;13;8q24.13;TRMT12, TRM12;;tRNA methyltransferase 12, S. cerevisiae, homolog of;611244;R, REc;;;
8.507;4;20;17;8q24.13;WSHC5, KIAA0196, SPG8, RTSC1;;WASH complex, subunit 5;610657;Fd, REc, R;;Spastic paraplegia 8, autosomal dominant, 603563 (3); Ritscher-Schinzel syndrome 1, 220210 (3);
8.508;12;17;12;8q24.13-q24.21;PPKP1B;;Keratoderma, palmoplantar, punctate type IB;614936;Fd;between D8S1804 and D8S1720;Keratoderma, palmoplantar, punctate type IB (2);
8.509;12;22;08;8q24.13-q24.22;ARHI1;;Age-related hearing impairment 1;612448;Fd;between rs3765212 and rs4601326;{Age-related hearing impairment 1} (2);
8.510;9;19;94;8q24.22;ADCY8, ADCY3;;Adenylyl cyclase-8, brain;103070;A;;;
8.511;4;19;06;8q24.2-q24.3;COL22A1;;Collagen, type XXII, alpha-1 polypeptide;610026;REc;;;15(Col22a1)
8.512;2;18;08;8q24.22;EFR3A, KIAA0143;;EFR3, S. cerevisiae, homolog of, A;611798;Psh, REc, H;;;15(Efr3a)
8.513;2;28;07;8q24.23;KHDRBS3, TSTAR, SALP, SLM2, ETOILE;;KH domain-containing, RNA-binding, signal transduction-associated protein 3;610421;REc;;;15(Khdrbs3)
8.514;4;8;98;8q24.3;PSCA;;Prostate stem cell antigen;602470;A;;;
8.515;8;4;97;8q24.3;GPR20;;G protein-coupled receptor-20;601908;A;;;
8.516;9;11;98;8q24.22;SLA;;Src-like-adaptor;601099;REa, REn;in intron of TG;;15(Slap)
8.517;10;11;17;8q24.21;CASC8, LINC00860, CARLO1;;Cancer susceptibility candidate 8, noncoding;617701;REc;;;
8.518;10;11;17;8q24.21;CASC11, LINC00990, CARLO7;;Cancer susceptibility candidate 11, noncoding;617704;REc;;;
8.519;10;11;17;8q24.21;CASC19, LINC01245, CARLO6;;Cancer susceptibility candidate 19, noncoding;617703;REc;;;
8.520;10;11;17;8q24.21;CASC21, LINC01244, CARLO2;;Cancer susceptibility candidate 21, noncoding;617702;REc;;;
8.521;10;1;17;8q24.21;CCAT1, CARLO5;;Colon cancer-associated transcript 1, noncoding;617705;REc;;;
8.522;9;29;09;8q24.22;TG, AITD3, TDH3;;Thyroglobulin;188450;A, REa, REb;distal to MYC;Thyroid dyshormonogenesis 3, 274700 (3); {Autoimmune thyroid disease, susceptibility to, 3}, 608175 (3);15(Tgn; cog)
8.523;9;30;09;8q24.21;CCD26, RAM;;Coiled-coil domain-containing protein 26;613040;REc;;;
8.524;9;24;08;8q24.21;FAM84B, BCMP101;;Family with sequence similarity 84, member B;609483;REc;;;
8.525;4;17;13;8q24.21;GLM7;;Glioma susceptibility 7;613032;Fd;associated with rs55705857;{Glioma susceptibility 7} (2);
8.526;9;21;17;8q24.21;PCAT2, PCA2, CARLO4;;Prostate cancer-associated transcript 2, noncoding;617678;REc;;;
8.527;4;29;14;8q24.21;POU5F1B, POU5F1P1, OCT4PG1;;POU domain, class 5, transcription factor 1B;615739;REc;;;
8.528;11;29;12;8q24.22;LRRC6, LRTP, CILD19;;Leucine-rich repeat-containing protein 6;614930;REc;;Ciliary dyskinesia, primary, 19, 614935 (3);
8.529;7;17;14;8q24.3;ARHGAP39, VILSE, KIAA1688;;RHO GTPase-activating protein 39;615880;REc, R;;;
8.530;6;26;16;8q24.3;C8orf17, MOST1;;Chromosome 8 open reading frame 17;616992;REc;;;
8.531;11;18;15;8q24.3;CYHR1, KIAA0496;;Cysteine- and histidine-rich protein 1;616635;REc;;;
8.532;6;9;08;8q24.3;COMMD5, HCARG;;COMM domain-containing protein 5;608216;REc;;;
8.533;10;15;13;8q24.3;CYC1, MC3DN6;;Cytochrome c1;123980;REa, A;;Mitochondrial complex III deficiency, nuclear type 6, 615453 (3);
8.534;5;30;17;8q24.3;DENND3, KIAA0870;;DENN domain-containing protein 3;617503;REc;;;
8.535;11;14;18;8q24.3;DGAT1, ARGP1, DIAR7;;Diacylglycerol O-acyltransferase 1;604900;A, H, REc;mutation identified in 1 DIAR7 family;?Diarrhea 7, protein-losing enteropathy type, 615863 (3);15(Dgat)
8.536;9;18;08;8q24.3;EEF1D, EF1D;;Eukaryotic translation elongation factor 1, delta;130592;REc;;;
8.537;8;18;14;8q24.3;EPPK1;;Epiplakin 1;607553;REc;;;
8.538;6;1;12;8q24.3;EXOSC4, RRP41;;Exosome component 4;606491;REc;;;
8.539;8;4;17;8q24.3;FAM83H, AI3A;;Family with sequence similarity 83, member H;611927;Fd, REc;;Amelogenesis imperfecta, type IIIA, 130900 (3);
8.540;3;30;99;8q24.3;FAST1;;Forkhead activin signal transducer 1, Xenopus, homolog of;603621;A;;;
8.541;6;13;12;8q24.3;FBXL6, FBL6, FBL6A;;F-box and leucine-rich repeat protein 6;609076;R, REc;;;15(FBXL6)
8.542;9;29;96;8q24.3;GLI4, HKR4;;GLI-Kruppel family member GLI4 (oncogene HKR4);165280;REa, A;;;
8.543;6;19;98;8q24.3;GML;;Glycosylphosphatidylinositol-anchored molecule-like protein;602370;A;;;
8.544;8;22;14;8q24.3;GPIHBP1, HYPL1D;;Glycosylphosphatidylinositol-anchored high density lipoprotein-binding protein 1;612757;REc;;Hyperlipoproteinemia, type 1D, 615947 (3);
8.545;7;22;16;8q24.3;GSDMD, GSDMDC1, DFNA5L;;Gasdermin D;617042;REc;;;
8.546;5;19;16;8q24.3;KIFC2;;Kinesin family member C2;615216;REc;;;
8.547;7;11;12;8q24.3;SLC52A2, GPR172A, GPCR41, PAR1, FLJ11856, BVVLS2;;Solute carrier family 52, riboflavin transporter, member 2;607882;REc;;Brown-Vialetto-Van Laere syndrome 2, 614707 (3);
8.548;6;17;99;8q24.3;GPT, GPT1, AAT1;;Glutamic-pyruvate transaminase (alanine aminotransferase);138200;S, EM, H, Fd, D, A;;;15(Gpt1)
8.549;3;14;96;8q24.3;GRINA, NMDARA1;;Glutamate receptor, ionotropic, N-methyl;138251;REa, A, R;;;
8.550;9;9;08;8q24.3;HSF1;;Heat-shock transcription factor 1;140580;R, REc;;;
8.551;1;7;99;8q24.3;LY6E, RIGE, SCA2;;Lymphocyte antigen 6 complex, locus E (retinoic acid induced gene E);601384;A;;;15(Ly6e)
8.552;8;17;99;8q24.3;LY6H;;Lymphocyte antigen 6 complex, locus H;603625;A;;;
8.553;3;14;13;8q24.3;LY6K;;Lymphocyte antigen 6 complex, locus K;615093;REc;;;
8.554;1;28;11;8q24.3;MAF1;;Maf1, S. cerevisiae, homolog of;610210;R, REc;;;
8.555;1;31;11;8q24.3;MIR661, MIRN661;;Micro RNA 661;613716;REc;;;
8.556;3;17;08;8q24.3;NAPRT1;;Nicotinate phosphoribosyltransferase domain-containing 1;611552;REc;;;
8.557;10;2;03;8q24.22;NDRG1, HMSNL, CMT4D;;N-myc downstream-regulated gene 1;605262;REc, Fd, LD;;Charcot-Marie-Tooth disease, type 4D, 601455 (3);
8.558;9;7;00;8q24.3;NFKBIL2, IKBR;;Nuclear factor of kappa light chain gene enhancer in B cells inhibitor-like 2;604546;Psh, A;;;
8.559;12;27;13;8q24.3;NRBP2;;Nuclear receptor-binding protein 2;615563;REc;;;
8.560;7;13;09;8q24.3;OFC12;;Orofacial cleft 12;612858;Fd;associated with rs987525;Orofacial cleft 12 (2);
8.561;3;30;12;8q24.3;OPLAH, OPLAHD;;5-oxoprolinase (ATP-hydrolyzing);614243;REc;;5-oxoprolinase deficiency, 260005 (3);
8.562;12;6;01;8q24.3;PTP4A3, PRL3;;Protein-tyrosine phosphatase, type 4A, 3;606449;R;;;
8.563;1;7;14;8q24.3;PUF60, FIR, SIAHBP1, VRJS;;Poly-U-binding splicing factor, 60kD;604819;REc;;Verheij syndrome, 615583 (3);
8.564;6;3;15;8q24.3;PYCRL, PYCR3;;Pyrroline-5-carboxylate reductase-like;616408;REc;;;
8.565;5;22;14;8q24.3;RECQL4, RTS, RECQ4;;DNA helicase, RecQ-like 4;603780;Ch, A;;Rothmund-Thomson syndrome, 268400 (3); RAPADILINO syndrome, 266280 (3); Baller-Gerold syndrome, 218600 (3);
8.566;8;18;14;8q24.3;RHPN1, ODF5;;Rhophilin 1;601031;REc;;;
8.567;10;16;13;8q24.3;SCRIB, SCRB1, KIAA0147;;Scribble, Drosophila, homolog of;607733;R, REc;;;
8.568;4;25;08;8q24.3;SCXA, SCX;;Scleraxis, mouse, homolog of, A;609067;REc;;;
8.569;3;11;08;8q24.3;SHARPIN, SIPL1;;SHANK-associated RH domain interactor;611885;REc;;;
8.570;6;24;02;8q24.3;SLC39A4, ZIP4;;Solute carrier family 36 (zinc transporter), member 4;607059;REc, Fd;;Acrodermatitis enteropathica, 201100 (3);
8.571;10;15;01;8q24.3;TOP1MT;;Topoisomerase I, mitochondrial;606387;A;;;
8.572;12;30;09;8q24.3;TRAPPC9, NIBP, KIAA1882, MRT13;;Trafficking protein particle complex 9;611966;REc;;Mental retardation, autosomal recessive 13, 613192 (3);
8.573;11;20;98;8q24.3;TSTA3;;Tissue-specific transplantation antigen-3;137020;A;;;
8.574;4;23;08;8q24.3;VPS28;;Vacuolar protein sorting 28, yeast, homolog of;611952;R, REc;;;
8.575;8;23;01;8q24.3;SLURP1, MDM;;Secreted LY6/uPAR-related protein 1;606119;Fd, R;;Meleda disease, 248300 (3);
8.576;11;19;11;Chr.8;AIS3, VAMAS4;;Autoimmune disease, susceptibility to, 3;608392;Fd;;{Autoimmune disease, susceptibility to, 3} (2);
8.577;5;28;99;Chr.8;IFNB3;;Interferon, beta-3, fibroblast;147860;S, REa;previously assigned to 2p23-qter;;
8.578;5;22;03;8q21.11;KCNB2, KV2.2;;Potassium channel, voltage-gated, shab-related subfamily, member 2;607738;R;;;
8.579;3;17;03;8q24.3;LYNX1;;Lynx1, mouse, homolog of;606110;R;;;
8.580;1;30;01;8q11.23;LYPLA1;;Lysophospholipase I;605599;R;;;
8.581;8;27;01;8q21.13;PAG;;Phosphoprotein associated with glycosphingolipid-enriched microdomains;605767;R;;;
8.582;6;26;01;8q21.13;PKIA;;Protein kinase, cAMP-dependent catalytic, inhibitor alpha;606059;R;;;
8.583;5;22;03;8p11.22;PLEKHA2, TAPP2;;Pleckstrin homology domain-containing protein, family A, member 2;607773;R;;;
8.584;1;22;93;8p21.3;PPP3CC, CALNA3;;Protein phosphatase-3 (formerly 2B), catalytic subunit, gamma isoform (calcineurin A gamma);114107;REa;;;
8.585;3;10;03;8q21.11;RDH10;;Retinol dehydrogenase 10;607599;R;;;
8.586;7;13;92;8q22.2;RPL30;;Ribosomal protein L30;180467;Psh;;;
8.587;6;21;01;8q24.3;SCRT1;;Scratch, mouse, homolog of;605858;REc;;;
8.588;2;21;03;8q21.11;TCEB1;;Transcription elongation factor B, polypeptide 1, 15kD (elongin C);600788;R;;;
8.589;8;27;02;8p23.1;TNKS;;TRF1-interacting, ankyrin-related ADP-ribose polymerase (tankyrase);603303;R;;;8(Tnks)
8.590;9;20;00;8q13.3;TRAM;;Translocating chain-associating membrane protein;605190;R;;;
8.591;9;14;89;Chr.8;ZNF1;;Zinc finger protein-1;194490;REa;;;8(Zfp2)
9.1;10;23;87;9p24.1;RLN1;;Relaxin, H1;179730;REa;;;19(Rln1)
9.2;10;23;87;9p24.1;RLN2;;Relaxin, H2;179740;REa;;;
9.3;8;21;07;9p24.3;CBWD1;;Cobalamin synthetase W domain-containing protein 1;611078;REc;;;19(Cbwd)
9.4;8;29;11;9p24.3;DEL9p24.3, C9DELp24.3, SRXY4;;Chromosome 9p24.3 deletion syndrome;154230;A, Ch;;46XY sex reversal 4 (4);
9.5;6;23;99;9p24.3;DMRT1, DMT1;;Double sex and mab-3-related transcription factor-1;602424;A, Ch;;;
9.6;5;12;00;9p24.3;DMRT2;;Double sex and mab-3-related transcription factor-2;604935;A;;;
9.7;8;3;12;9p24.3;DMRT3, DMRTA3;;Doublesex-and mab3-related transcription factor 3;614754;REc;;;
9.8;5;4;12;9p24.3;KANK1, KANK, ANKRD15, KIAA0172, CPSQ2;;KN motif- and ankyrin repeat domain-containing protein 1;607704;REc;;Cerebral palsy, spastic quadriplegic, 2, 612900 (3);
9.9;4;20;17;9p24.3;WASHC1, WASH1;;WASH complex, subunit 1;613632;REc;pseudogenes on 1p, 15q, 16p, Xq/Yq;;
9.10;5;19;16;9p24.2;GLIS3, ZNF515, NDH;;GLIS family zinc finger protein 3;610192;REc;;Diabetes mellitus, neonatal, with congenital hypothyroidism, 610199 (3);19(Glis3)
9.11;8;8;08;9p24-p23;PTPRD, PTPD, HPTP;;Protein tyrosine phosphatase, receptor type, delta polypeptide;601598;H, REc;;;4(Ptprd)
9.12;3;31;10;9p24.2;KCNV2, KV11.1, RCD3B;;Potassium channel, voltage-gated, subfamily V, member 2;607604;REc;;Retinal cone dystrophy 3B, 610356 (3);
9.13;3;23;06;9p24.2;KIAA0020, HLA-HA8;;Minor histocompatibility antigen HA-8;609960;R, REc;;;
9.14;3;19;01;9p24.1;PDCD1L2, PDL2;;Programmed cell death 1 ligand 2;605723;REc;;;19(Pdcd1l2)
9.15;5;25;13;9p24.2;RFX3;;Regulatory factor X, 3;601337;REc;;;
9.16;7;1;13;9p24.1;AK3, AK3L1;;Adenylate kinase 3;609290;REc, Psh;;;4(Ak3)
9.17;8;19;13;9p24.1;CDC37L1, HARC, FLJ20639;;CDC37-like 1;610346;REc;;;
9.18;8;19;13;9p24.1;CIP150, KIAA1432;;Connexin 43-interacting protein, 150kD;610354;R, REc;;;
9.19;4;1;08;9p24.1;IL33, C9orf26, NFEHEV;;Interleukin 33;608678;REc, H;;;19(Il33)
9.20;7;20;12;9p24.1;KDM4C, JMJD2C, GASC1, KIAA0780;;Lysine-specific demethylase 4C;605469;R, REc;;;
9.21;1;30;01;9p24.1;MLANA, MART1;;Melan A;605513;R;;;
9.22;3;23;09;9p24.1;MIR101-2, MIRN101-2;;Micro RNA 101-2;612512;REc;another locus, MIRN101-1, on 1p31;;
9.23;10;1;95;9p23-p22;NFIB;;Nuclear factor I/B;600728;A, Ch;;;4(Nfib)
9.24;10;25;17;9p24.1;PLPP6, PPAPDC2;;PPAP2 domain-containing protein 2;611666;R, REc;;Phospholipid phosphatase 6, 611666 (3);
9.25;5;26;13;9p24.1;RCL1, RPCL1, RNAC;;RNA terminal phosphate cyclase-like 1;611405;R, REc;;;
9.26;7;11;17;9p24.1;TPD52L3;;Tumor protein D52-like 3;617567;REc;;;
9.27;12;22;16;9p24.1;TMEM261, DMAC1, C9orf123;;Transmembrane protein 261;617261;REc;;;
9.28;5;6;13;9p24.1;UHRF2, NIRF;;Ubiquitin-like protein containing PDH and RING finger domains 2, E3 ubiquitin protein ligase;615211;REc;;;
9.29;3;4;10;9p24.1-p22.1;FECD7, FCD4;;Corneal dystrophy, Fuchs endothelial, 7;613271;Fd;max lod at D9S256;Corneal dystrophy, Fuchs endothelial, 7 (2);
9.30;11;13;17;9p24.1;CD274, PDCD1LG1, B7H1;;CD274 molecule;605402;REc;;;
9.31;8;4;15;9p24.3;DOCK8;;Dedicator of cytokinesis 8;611432;REc;;Hyper-IgE recurrent infection syndrome, autosomal recessive, 243700 (3);
9.32;4;23;09;9p24.1;ERMP1, KIAA1815, FXNA;;Endoplasmic reticulum metallopeptidase 1;611156;R, REc;;;
9.33;5;24;13;9p24.2;SLC1A1, EAAC1, SCZD18, DCBXA;;Solute carrier family 1, member 1 (high-affinity glutamate transporter; excitatory amino acid carrier 1);133550;REa, A;mutation identified in 1 SCZD18 family;{?Schizophrenia susceptibility 18}, 615232 (3); Dicarboxylic aminoaciduria, 222730 (3);
9.34;11;6;95;9p24.1;INSL4;;Insulin-like 4, placenta;600910;A;;;
9.35;11;1;01;9p24.1;INSL6;;Insulin-like 6;606414;R;;;19(Insl6)
9.36;8;23;17;9p24.1;JAK2, THCYT3;;Janus kinase 2 (a protein-tyrosine kinase);147796;A;;Polycythemia vera, somatic, 263300 (3); Thrombocythemia 3, 614521 (3); Myelofibrosis, somatic, 254450 (3); Erythrocytosis, somatic, 133100 (3); Leukemia, acute myeloid, somatic, 601626 (3); {Budd-Chiari syndrome, somatic}, 600880 (3);19(Jak2)
9.37;11;30;15;9p24;MRD2;;Mental retardation, autosomal dominant 2;614113;Ch;2 patients reported with genomic deletion or rearrangement including disruption of DOCK8;Mental retardation, autosomal dominant 2 (4);
9.38;2;21;10;9p24.2;VLDLR, CAMRQ1;;Very low density lipoprotein receptor;192977;A, Psh;;Cerebellar hypoplasia and mental retardation with or without quadrupedal locomotion 1, 224050 (3);19(Vldlr)
9.39;10;30;08;9p24-p22;RLS3;;Restless legs syndrome, susceptibility to, 3;610438;Fd;associated with rs4626664 and rs1975197;{Restless legs syndrome 3} (2);
9.40;5;4;12;9p24.3;SMARCA2, SNF2L2, NCBRS;;SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 2;600014;A;;Nicolaides-Baraitser syndrome, 601358 (3);19(Snf2l2)
9.41;12;30;14;9p23;LURAP1L, LRAP35B;;Leucine-rich adaptor protein 1-like;616130;REc;;;
9.42;09;06;18;9p23;MPDZ, MUPP1, HYC2;;Multiple PDZ domain protein;603785;R, Psh;;Hydrocephalus, congenital, 2, with or without brain or eye anomalies, 615219 (3);
9.43;2;25;16;9p23;TYRP1, CAS2, GP75, SHEP11;;Tyrosinase-related protein 1;115501;Psh, REa, A, Fd;;Albinism, oculocutaneous, type III, 203290 (3); [Skin/hair/eye pigmentation, variation in, 11 (Melanesian blond hair)], 612271 (3);4(b;trp1)
9.44;9;6;11;9p23-p13.3;MRT16;;Mental retardation, autosomal recessive 16;614208;Fd;between rs10738277 and rs12376565;Mental retardation, autosomal recessive 16 (2);
9.45;9;5;01;9p23-p11;FRDA2;;Friedreich ataxia 2;601992;Fd;;Friedreich ataxia 2 (2);
9.46;1;7;11;9p23-p21.2;DFNB83;;Deafness, autosomal recessive 83;613685;Fd;between rs4742645 and rs1471364;Deafness, autosomal recessive 83 (2);
9.47;2;20;12;9p22.3;FREM1, C9orf154, BNAR, MOTA, TRIGNO2;;FRAS1-related extracellular matrix protein 1;608944;REc, R;;Bifid nose with or without anorectal and renal anomalies, 608980 (3); Manitoba oculotrichoanal syndrome, 248450 (3); Trigonocephaly 2, 614485 (3);
9.48;10;2;12;9p22.3;SNAPC3, SNAP50;;Small nuclear RNA-activating protein complex, polypeptide 3;602348;REc;;;
9.49;10;5;10;9p22.3;TTC39B;;Tetratricopeptide repeat domain 39B;613574;REc;;;
9.50;4;27;12;9p22.3;ZDHHC21, DHHC21;;Zinc finger DHHC domain-containing protein 21;614605;REc;;;
9.51;3;4;08;9p22.2;CNTLN, C9orf101, C9orf39;;Centlein;611870;REc;;;
9.52;8;3;06;9p22.3;PSIP1, LEDGF;;PC4- and SFRS1-interacting protein 1;603620;A;;;
9.53;12;15;10;9p22.1;ACER2;;Alkaline ceramidase 2;613492;REc;;;
9.54;7;12;06;9p22.1;AD11;;Alzheimer disease 11;609790;Fd;between D9S157 and D9S259;Alzheimer disease-11 (2);
9.55;6;7;04;9p22.3-p22.2;BNC2;;Basonuclin 2;608669;REc;;;4(Bnc2)
9.56;9;7;10;9p22.1;HAUS6, DGT6, FAM29A;;HAUS, augmin-like complex, subunit 6;613433;REc;;;
9.57;1;21;01;9p22.1;PLIN2;;Perilipin 2;103195;REc;;;4(Plin2)
9.58;8;29;08;9p22.1;RRAGA, RAGA, FIP1;;Ras-related GTP-binding protein A;612194;R, REc;;;
9.59;4;10;15;9p22.1;SAXO1, FAM154A;;Stabilizer of axonemal microtubules 1;616292;REc;;;
9.60;2;25;14;9p22.1;SCARNA8;;Small Cajal body-specific RNA 8;615646;REc;;;
9.61;12;24;08;9p13.3;UBE2R2, UBC3B;;Ubiquitin-conjugating enzyme E2R 2;612506;REc;;;
9.62;5;27;09;9p22.2-p22.1;ADAMTSL1;;ADAMTS-like protein 1;609198;REc, H;;;4(Adamtsl1)
9.63;6;14;99;9p22.3;CER1;;Cerebrus 1, Xenopus, homolog of;603777;R, H;;;4(Cer1)
9.64;5;4;01;9p24.1;GLDC, HYGN1, GCSP, GCE, NKH;;Glycine dehydrogenase (decarboxylating; glycine decarboxylase, glycine cleavage system protein P);238300;Ch, A;;Glycine encephalopathy, 605899 (3);19(Gldc)
9.65;12;14;95;9p21.3;IFNA1, IFNA@;;Interferon, alpha-1;147660;REa, A, RE;very close to IFF by Fd, LD; 15-30 genes;Interferon, alpha, deficiency (1);4(Ifa)
9.66;12;14;95;9p21.3;IFNA2;;Interferon, alpha-2;147562;D;;;
9.67;12;14;95;9p21.3;IFNA4;;Interferon, alpha-4;147564;D;;;
9.68;12;14;95;9p21.3;IFNA5;;Interferon, alpha-5;147565;D;;;
9.69;12;14;95;9p21.3;IFNA6;;Interferon, alpha-6;147566;D;;;
9.70;12;14;95;9p21.3;IFNA7;;Interferon, alpha-7;147567;D;;;
9.71;12;15;95;9p21.3;IFNA8;;Interferon, alpha-8;147568;D;;;
9.72;12;15;95;9p21.3;IFNA10;;Interferon, alpha-10;147577;D;;;
9.73;12;15;95;9p21.3;IFNA13;;Interferon, alpha-13;147578;D;;;4(Ifna13)
9.74;12;15;95;9p21.3;IFNA14;;Interferon, alpha-14;147579;D;;;
9.75;12;15;95;9p21.3;IFNA16;;Interferon, alpha-16;147580;D;;;
9.76;12;15;95;9p21.3;IFNA17;;Interferon, alpha-17;147583;D;;;
9.77;12;15;95;9p21.3;IFNA21;;Interferon, alpha-21;147584;D;;;
9.78;7;13;93;9p21.3;MLLT3, AF9;;Myeloid/lymphoid or mixed-lineage leukemia, translocated to, 3;159558;Ch;fuses with ALL1;;
9.79;5;4;00;9p22.2;SH3GL2, SH3P4;;SH3 domain, GRB2-like, 2;604465;REa, A;;;
9.80;1;20;06;9p22.1-p21.3;SLC24A2, NCKX2;;Solute carrier family 24 (sodium/potassium/calcium exchanger), member 2;609838;REc;;;
9.81;1;6;11;9p22-p21;DFNA47, DFNB83;;Deafness, autosomal dominant 47;608652;Fd;between D9S268 and D9S942; possibly allelic to DFNB83;Deafness, autosomal dominant 47 (2);
9.82;11;7;89;9p22-p21;LALL;;Lymphomatous acute lymphoblastic leukemia;247640;Ch;;Leukemia, acute lymphoblastic (2);
9.83;12;20;05;9p13.3;UBAP1, UBAP;;Ubiquitin-associated protein 1;609787;REc;;;
9.84;12;23;05;9p21.2-p21.1;LRRN6C, LINGO2, LERN3;;Leucine-rich repeat protein, neuronal, 6C;609793;REc;;;
9.85;2;20;11;9p21.1;ACO1, IREB1;;Aconitase, soluble (iron-responsive element-binding protein-1);100880;S, REc;;;4(Aco1)
9.86;8;31;17;9p21.2;EMICER1;;EQTN, MOB3B, IFNK, and C9orf72 enhancer RNA I, noncoding;617651;REc;;;
9.87;8;31;17;9p21.2;EQTN, AFAF, SPACA8, C9orf11;;Equatorin;617653;REc;;;
9.88;7;23;13;9p21.2;IFNK;;Interferon, kappa;615326;R;;;
9.89;9;22;16;9p21.2;IFT74, CCDC2, CMG1, BBS20;;Intraflagellar transport 74, Chlamydomonas, homolog of;608040;REc;mutation identified in 1 BBS20 patient;?Bardet-Biedl syndrome 20, 617119 (3);
9.90;8;30;17;9p21.2;MOB3B, MOB1D, MOBKL2B, C9orf35;;MOB kinase activator 3B;617652;REn;;;
9.91;6;27;17;9p21.2;PLAA, PLAP, NDMSBA;;Phospholipase A2-activating protein;603873;REc;;Neurodevelopmental disorder with progressive microcephaly, spasticity, and brain anomalies, 617527 (3);
9.92;4;10;15;9p21.1;DDX58, RIGI, SGMRT2;;DEAD box polypeptide 58;609631;REc;;Singleton-Merten syndrome 2, 616298 (3);
9.93;12;30;14;9p21.1;MIR873;;Micro RNA 873;616137;REc;;;
9.94;11;27;18;9p21.1;NDUFB6;;NADH-ubiquinone oxidoreductase 1 beta subcomplex 6;603322;REc;;;
9.95;12;15;17;9p21.1;SMU1;;DNA replication regulator and spliceosomal factor SMU1;617811;REc;;;
9.96;3;13;08;9p21;AAA3;;Aneurysm, familial abdominal 3;611891;Fd;associated with rs10757278;{Aneurysm, familial abdominal 3} (2);
9.97;3;13;08;9p21;ANIB6;;Aneurysm, intracranial berry, 6;611892;Fd;associated with rs10757278;{Aneurysm, intracranial berry, 6} (2);
9.98;10;6;09;9p21;BCC5;;Basal cell carcinoma, susceptibility to, 5;613062;Fd;associated with rs2151280;{Basal cell carcinoma, susceptibility to, 5} (2);
9.99;7;7;15;9p21.2;C9orf72, FTDALS1, FTDALS, ALSFTD;;Chromosome 9 open reading frame 72;614260;REc;;Frontotemporal dementia and/or amyotrophic lateral sclerosis 1, 105550 (3);
9.100;3;3;03;9p21.3;CDKN2A, MTS1, P16, MLM, CMM2;;Cyclin-dependent kinase inhibitor 2A (p16, inhibits CDK4);600160;RE, D, Fd;;{Melanoma, cutaneous malignant, 2}, 155601 (3); Melanoma and neural system tumor syndrome, 155755 (3); Pancreatic cancer/melanoma syndrome, 606719 (3); Orolaryngeal cancer, multiple, (3);4(Cdkn2a)
9.101;7;10;95;9p21.3;CDKN2B, MTS2, P15, INK4B;;Cyclin-dependent kinase inhibitor 2B (p15, inhibits CDK4);600431;A;tandem with MTS1;;
9.102;12;21;09;9p21.3;CDKN2BAS, ANRIL;;CDKN2B antisense RNA;613149;REc;;;
9.103;2;23;08;9p21;CHDS8;;Coronary heart disease, susceptibility to, 8;611139;Fd;strongest linkage with dbSNP rs1333049;{Coronary heart disease, susceptibility to, 8} (2);
9.104;2;24;97;9p21.3;ELAVL2, HELN1, HUB;;Embryonic lethal, abnormal vision, Drosophila, homolog of, like-2 (Hu antigen B);601673;Psh, A, H;;;4(Hub)
9.105;4;10;90;9p21.3;IFNB1;;Interferon, beta-1, fibroblast;147640;REa, A, Fd, LD, RE;distal to IFL; ?9p23-p22; IFF duplicate in some;;4(Ifb)
9.106;5;6;13;9p21.3;IFNE, INFE1, IFNT1;;Interferon, epsilon;615223;REc;;;
9.107;5;6;97;9p21.3;IFNW1;;Interferon, omega-1;147553;D;pseudogene IFNWP2; interspersed with IFNA;;
9.108;6;16;08;9p21;MFT2, TEM;;Trichoepithelioma, multiple familial, 2;612099;Fd;max lod at D9S171;Trichoepithelioma, multiple familial, 2 (2);
9.109;9;10;12;9p21.3;DMRTA1, DMRT4;;Doublesex- and MAB3-related transcription factor A1;614803;REc;;;4(Dmrta1))
9.110;5;4;12;9p21.3;FOCAD, KIAA1797;;Focadhesin;614606;REc;;;
9.111;4;13;10;9p21.3;GLM5;;Glioma susceptibility 5;613030;Fd;associated with rs4977756;{Glioma susceptibility 5} (2);
9.112;5;6;13;9p21.3;KLHL9, KIAA1354;;Kelch-like 9;611201;REc;;;4(Klhl9)
9.113;3;23;09;9p21.3;MIR31, MIRN31;;Micro RNA 31;612155;REc;;;
9.114;6;2;15;9p21.3;MIR31HG, LOC554202;;Micro RNA 31 host gene, noncoding;616356;REc;;;
9.115;8;18;14;9p21.3;PTPLAD2, HACD4;;Protein tyrosine phosphatase-like A domain-containing protein 2;615941;REc;;;
9.116;5;4;12;9p21.3;MTAP, DMSMFH;;Methylthioadenosine phosphorylase;156540;S, D, Fd;;Diaphyseal medullary stenosis with malignant fibrous histiocytoma, 112250 (3);
9.117;1;6;93;9p22.1;RPS6;;Ribosomal protein S6;180460;Psh, A;;;
9.118;12;23;16;9p21.2;TEK, TIE2, VMCM, GLC3E;;TEK tyrosine kinase, endothelial;600221;A, D, REc;;Venous malformations, multiple cutaneous and mucosal, 600195 (3); Glaucoma 3, primary congenital, E, 617272 (3);4(tek)
9.119;11;13;07;9p21.1;TOPORS, P53BP3, LUN, RP31;;Topoisomerase I-binding arginine/serine-rich protein;609507;Fd, A, REc;;Retinitis pigmentosa 31, 609923 (3);
9.120;10;30;06;9p21.2;TUSC1, TSG9;;Tumor suppressor candidate 1;610529;REc;;;4(Tusc1)
9.121;8;26;15;9p13.3;NPR2, ANPRB, AMDM, ECDM, SNSK;;Natiuretic peptide receptor 2;108961;REa, A, Fd;;Acromesomelic dysplasia, Maroteaux type, 602875 (3); Epiphyseal chondrodysplasia, Miura type, 615923 (3); Short stature with nonspecific skeletal abnormalities, 616255 (3);
9.122;10;17;05;9p13.3;RMRP, RMRPR, CHH;;Mitochondrial RNA-processing endoribonuclease;157660;REa, A, Fd, LD, REc;;Cartilage-hair hypoplasia, 250250 (3); Metaphyseal dysplasia without hypotrichosis, 250460 (3); Anauxetic dysplasia 1, 607095 (3);4(Rmrpn)
9.123;5;24;13;9p12;CNTNAP3, KIAA1714;;Contactin-associated protein-like 3;610517;REc;;;
9.124;9;9;08;9p13.2;FBXO10, FBX10;;F-box only protein 10;609092;REc;;;4(Fbxo10)
9.125;9;7;12;9p13.1;IGFBPL1, IGFBPRP4;;Insulin-like growth factor binding protein-like 1;610413;REc, R;;;
9.126;11;27;17;9p13.3;RUSC2, KIAA0375, IPORIN, MRT61;;RUN and SH3 domain-containing 2;611053;REc;;Mental retardation, autosomal recessive 61, 617773 (3);
9.127;12;4;03;9p13.3;STOML2;;Stomatin-like protein 2;608292;REc, R;;;
9.128;6;27;08;9p13.1-q21.11;OTSC8;;Otosclerosis 8;612096;Fd;between D9S970 and D9S1799;Otosclerosis 8 (2);
9.129;6;1;12;9p21.1;APTX, AOA, AOA1;;Aprataxin;606350;REc, Fd;;Ataxia, early-onset, with oculomotor apraxia and hypoalbuminemia, 208920 (3);
9.130;2;1;11;9p13.3;CA9, MN;;Carbonic anhydrase IX;603179;REc;previously assigned to 17q21.2;;
9.131;4;10;14;9p13.3;CCIN;;Calicin;603960;REc;;;
9.132;4;17;07;9p13.3;CHMP5;;CHMP family, member 5;610900;REc;;;
9.133;1;13;11;9p13.3;CLTA;;Clathrin, light polypeptide (Lca);118960;REc;previously mapped to 12q23-q24;;
9.134;9;16;16;9p13.3;CREB3, LZIP;;cAMP response element-binding protein 3;606443;R, REc;;;
9.135;2;6;13;9p13.3;DNAI1, CILD1, ICS, PCD;;Dynein, axonemal, intermediate chain 1;604366;Psh, A, REc;;Ciliary dyskinesia, primary, 1, with or without situs inversus, 244400 (3);
9.136;3;23;14;9p13.3;DNAJB5, KIAA1045, HSC40;;DNAJ/HSP40 homolog, subfamily B, member 5;611328;REc;;;
9.137;4;17;13;9p13.3;GBA2, KIAA1605, SPG46;;Glucosidase, beta, acid 2;609471;REc;;Spastic paraplegia 46, autosomal recessive, 614409 (3);
9.138;2;21;13;9p13.3;GLIPR2, GAPR1, C9orf19;;GLI pathogenesis-related 2;607141;REc;;;
9.139;12;10;15;9p13.3;GNE, GLCNE, IBM2, DMRV, NM;;UDP-N-acetylglucosamine 2-epimerase/N-acetylmannosamine kinase;603824;TM, R, Fd;;Sialuria, 269921 (3); Nonaka myopathy, 605820 (3);
9.140;2;21;11;9p13.3;KIF24;;Kinesin family member 24;613747;REc;;;
9.141;12;12;18;9p13.3;MYORG, NET37, KIAA1161;;Myogenesis-regulating glycosidase;618255;REc;;;
9.142;10;15;13;9p13.3;MSMP, PSMP;;Microseminoprotein, prostate-associated;612191;REc;;;4(Psmp)
9.143;11;11;14;9p13.3;NFX1;;Nuclear transcription factor, X box-binding, protein 1;603255;REc, H;;;4(Nfx1)
9.144;8;27;15;9p13.3;PTENP1;;Phosphatase and tensin homolog pseudogene 1 (functional);613531;Psh, REc;;;
9.145;4;29;14;9p13.3;RGP1, KIAA0258;;RGP1 retrograde golgi transport, S. cerevisiae, homolog of;615742;REc, R;;;
9.146;8;28;17;9p13.3;SPAAR, LINC00961;;Small regulatory polypeptide of amino acid response;617627;REc;;;
9.147;4;25;11;9p13.3;SPINK4, PEC60;;Serine protease inhibitor, Kazal-type, 4;613929;REc;;;
9.148;4;8;16;9p13.3;TMEM8B, NGX6, NAG5;;Transmembrane protein 8B;616888;REc;;;
9.149;6;13;12;9p13.2;EXOSC3, RRP40, PCH1B;;Exosome component 3;606489;REc;;Pontocerebellar hypoplasia, type 1B, 614678 (3);
9.150;4;27;16;9p13.2;FRMPD1, FRMD2, KIAA0967;;FERM and PDZ domains-containing protein 1;616919;REc;;;
9.151;1;12;15;9p13.2;TOMM5, TOM5;;Translocase of outer mitochondrial membrane 5, yeast, homolog of;616169;REc;;;
9.152;10;13;15;9p13.2;ZBTB5, KIAA0354;;Zinc finger- and BTB domain-containing protein 5;616590;REc, R;;;
9.153;8;2;13;9p13.3;TPM2, TMSB, AMCD1, DA1, DA2B, NEM4;;Tropomyosin-2, beta;190990;REa, A, R, Fd;;Arthrogryposis multiplex congenita, distal, type 1, 108120 (3); Arthrogryposis, distal, type 2B, 601680 (3); Nemaline myopathy 4, autosomal dominant, 609285 (3); CAP myopathy 2, 609285 (3);
9.154;4;2;01;9p13.1;ALDH1B1, ALDH5;;Aldehyde dehydrogenase 1 family, member B1;100670;REa, A;;;
9.155;2;28;03;9p13.3;AQP3;;Aquaporin-3;600170;A;incorrectly mapped to chr.7;[Blood group GIL], 607457 (3);
9.156;1;5;12;9p13.3;AQP7, GLYCQTL;;Aquaporin-7;602974;A;;[Glycerol quantitative trait locus], 614411 (3);
9.157;7;11;02;9p21.1;B4GALT1, GGTB2, GT1, GTB, CDG2D;;Glycoprotein-4-beta-galactosyltransferase-2 (EC 2.4.1.22);137060;REa, A;;Congenital disorder of glycosylation, type IId, 607091 (3);4(Ggtb)
9.158;8;29;02;9p13.3;CCL19, SCYA19, ELC, MIP3B;;Chemokine, C-C motif, ligand 19;602227;Psh, REa, R;;;
9.159;8;29;02;9p13.3;CCL21, SCYA21, SLC;;Chemokine, C-C motif, ligand 21;602737;REa, R, REc;;;
9.160;8;29;02;9p13.3;CCL27, SCYA27, ILC, CTACK;;Chemokine, C-C motif, ligand 27;604833;REc;;;4(Scya27)
9.161;1;2;96;9p13.3;CNTFR;;Ciliary neurotrophic factor receptor;118946;Psh, R, A;;;4(Cntfr)
9.162;12;4;02;9p13.3;DCTN3, DCTN22;;Dynactin 3;607387;R;;;
9.163;6;10;02;9p13.3;GALT;;Galactose-1-phosphate uridyltransferase;606999;S, D, F;;Galactosemia, 230400 (3);4(Galt)
9.164;8;25;11;9p13.3;IL11RA, CRSDA;;Interleukin-11 receptor, alpha;600939;A;;Craniosynostosis and dental anomalies, 614188 (3);4(Il11ra, Etl2)
9.165;1;5;09;9p13.3;NOL6, NRAP;;Nucleolar protein 6;611532;REc;;;
9.166;9;3;99;9p13.3;NUDT2, APAH1;;Nudix-type motif 1 (AP4A hydrolase-1);602852;A;;;
9.167;2;21;14;9p13.2;PAX5, BSAP, ALL3;;Paired box homeotic gene-5 (B-cell lineage specific activator protein);167414;REa, A, Fd, Ch;;{Leukemia, acute lymphoblastic, susceptibility to, 3}, 615545 (3);4(Pax5)
9.168;10;11;05;9p13;PEE3;;Preeclampsia/eclampsia 3;609403;Fd;;Preeclampsia/eclampsia 3 (2);
9.169;8;20;12;9p13.3;PIGO, HPMRS2;;Phosphatidylinositol glycan, class O;614730;REc;;Hyperphosphatasia with mental retardation syndrome 2, 614749 (3);
9.170;10;5;10;9p13.3;PRSS3, TRY3, T9;;Protease, serine, 3;613578;REc;;;
9.171;12;14;10;9q21.2;PRUNE2, BMCC1, KIAA0367;;PRUNE, Drosophila, homolog of, 2;610691;R, REc;;;
9.172;12;24;08;9p13.2;RNF38;;Ring finger protein 38;612488;REc;;;
9.173;10;23;15;9p13.3;SIGMAR1, SRBP, ALS16, DSMA2;;Sigma nonopioid intracellular receptor 1;601978;Psh, A;mutation identified in 1 ALS16 family and 1 DSMA2 family;?Amyotrophic lateral sclerosis 16, juvenile, 614373 (3); ?Spinal muscular atrophy, distal, autosomal recessive, 2, 605726 (3);
9.174;5;15;97;9p13.3;TESK1;;Testis-specific protein kinase-1;601782;A;;;
9.175;7;13;11;9p13.3;XRCC9, FANCG;;X-ray repair, complementing defective, in Chinese hamster, 9;602956;A, Fd, LD;;Fanconi anemia, complementation group G, 614082 (3);
9.176;9;20;00;9p13.3;RECK, ST15;;Reversion-inducing cysteine-rich protein with kazal motifs (suppressor of tumorigenicity 15);605227;REc;;;
9.177;2;20;02;9p13.3;SIT;;SHP2-interacting transmembrane adaptor protein;604964;A;;;
9.178;3;19;01;9p13.3;SPAG8, SMP1;;Sperm-associated antigen 8;605731;R, A;;;
9.179;12;17;15;9p13.3;VCP, IBMPFD1, ALS14, CMT2Y;;Valosin-containing protein;601023;REa, A;;Inclusion body myopathy with early-onset Paget disease and frontotemporal dementia 1, 167320 (3); Amyotrophic lateral sclerosis 14, with or without frontotemporal dementia, 613954 (3); Charcot-Marie-Tooth disease, type 2Y, 616687 (3);4(Vcp)
9.180;11;13;96;9p13.3;BAG1;;BCL2-associated athanogene;601497;REa, A;;;
9.181;6;8;95;9p13.1;SHB;;SHB adaptor protein (a Src homology 2 protein);600314;Psh, A;;;
9.182;11;6;00;9p12-q12;ACP;;Cerebral palsy, ataxic, autosomal recessive;605388;Fd, HZ;;Cerebral palsy, ataxic, autosomal recessive (2);
9.183;2;18;96;9q21.11;PGM5;;Phosphoglucomutase-5;600981;A;;;19(Pgm5)
9.184;8;26;15;9q21.11;FOXD4L4, FOXD4L2;;Forkhead box D4-like 4;611085;REc;;;
9.185;3;24;06;9p13.3;HINT2;;Histidine triad nucleotide-binding protein 2;609997;REc;;;
9.186;3;8;95;9p11;MROS;;Melkersson-Rosenthal syndrome;155900;Ch;;?Melkersson-Rosenthal syndrome (2);
9.187;11;4;91;9p13.3;CD72, LYB2;;CD72 antigen;107272;REa;;;4(Lyb2)
9.188;1;24;09;9p;DEL9p, C9DELp;;Chromosome 9p deletion syndrome;158170;Ch;;Chromosome 9p deletion syndrome (4);
9.189;12;17;07;9p;HDLCQ1;;High density lipoprotein cholesterol level QTL 1;606613;Fd;;[High density lipoprotein cholesterol level QTL 1] (2);
9.190;10;1;95;9p13.3;TLN1;;Talin 1;186745;Psh;;;
9.191;11;22;99;9p13.2;GRHPR, GLXR;;Glyoxylate reductase/hydroxypyruvate reductase;604296;R, Fd;;Hyperoxaluria, primary, type II, 260000 (3);
9.192;6;11;94;9q34.11;FPGS;;Folylpolyglutamate synthetase;136510;S, H;;;2(Fpgs)
9.193;3;15;10;9q;HCHGQ2;;Hematocrit/hemoglobin quantitative trait locus 2;609320;Fd;;[Hematocrit/hemoglobin quantitative trait locus 2] (2);
9.194;4;27;12;9q;SPG19;;Spastic paraplegia-19;607152;Fd;;Spastic paraplegia 19, autosomal dominant (2);
9.195;1;25;91;9q21.13;ANXA1, LPC1;;Annexin A1 (lipocortin I);151690;REa, A;;;19(Lpc1)
9.196;1;29;01;9q22.32;BARX1;;BarH-like homeo box gene 1;603260;R;;;
9.197;10;23;87;9q12;DNCM;;Cytoplasmic membrane DNA;126330;A;in 9qh;;
9.198;10;13;15;9q12;SPATA31A7, AEP1, FAM75A7, C9orf36;;Spermatogenesis-associated protein 31, subfamily A, member 7;616584;REc;;;
9.199;7;17;14;9q21.11;TJP2, ZO2, PFIC4;;Tight junction protein 2;607709;REc, Fd;;Hypercholanemia, familial, 607748 (3); Cholestasis, progressive familial intrahepatic 4, 615878 (3);
9.200;1;13;99;9q21.12;BTEB1, BTEB;;Basic transcription element-binding protein 1;602902;Psh, A;;;
9.201;8;21;07;9q21.11;CBWD3;;Cobalamin synthetase W domain-containing protein 3;611080;REc;;;
9.202;11;12;96;9q13;CMD1B, CMPD1, FDC;;Cardiomyopathy, dilated-1B, autosomal dominant;600884;Fd;;Cardiomyopathy, dilated 1B (2);
9.203;8;21;07;9q21.11;FOXD4L3;;Forkhead box D4-like 3;611086;REc;;;
9.204;11;30;06;9q21.11;FXN, FRDA, FARR, X25;;Frataxin;606829;Fd;;Friedreich ataxia, 229300 (3); Friedreich ataxia with retained reflexes, 229300 (3);
9.205;4;10;02;9q21.13;GCNT1;;Glucosaminyl (N-acetyl) transferase 1, core 2 (beta-1,6-N-acetylglucosaminyltransferase);600391;A, Psh, R;;;13(Gcnt1)
9.206;9;18;98;9q21.11;PIP5K1B, STM7, MSS4;;Phosphatidylinositol-4-phosphate 5-kinase, type I, beta;602745;REn, REc;;;
9.207;2;13;98;9q13-q21;GSM1, GSP;;Geniospasm 1;190100;Fd;;Geniospasm (2);
9.208;2;26;02;9q21.13;TMC1, DFNB7, DFNB11, DFNA36;;Transmembrane channel-like protein 1;606706;Fd, REc;;Deafness, autosomal recessive 7, 600974 (3); Deafness, autosomal dominant 36, 606705 (3);19(Tmc1, dn, Bth)
9.209;4;26;01;9q21.13;TMEM2;;Transmembrane protein 2;605835;REc;;;19(Tmem2)
9.210;5;7;03;9q21.12;X123;;X123 gene;607710;REc;;;
9.211;1;16;07;9q21.13;ZFAND5, ZNF216;;Zinc finger AN1 domain-containing protein 5;604761;REc;;;19(Znf216)
9.212;7;22;13;9q13-q22;CTRCT26, CAAR;;Cataract 26, multiple types;605749;Fd;;Cataract 26, multiple types (2);
9.213;1;28;88;9q21.13;ALDH1A1;;Aldehyde dehydrogenase-1 family, member A1, soluble;100640;REa, A;;;19(Ahd2)
9.214;1;3;00;9q21.2;GNA14;;Guanine nucleotide-binding protein, alpha-14;604397;A, REc;;;
9.215;6;11;13;9q21.2;GNAQ, SWS, CMC1;;Guanine nucleotide-binding protein (G protein), q;600998;REa, A;pseudogene on 2q;Sturge-Weber syndrome, somatic, mosaic, 185300 (3); Capillary malformations, congenital, 1, somatic, mosaic, 163000 (3);
9.216;8;31;16;9q22.31;IARS, GRIDHH;;Isoleucine-tRNA synthetase;600709;Psh, A;;Growth retardation, intellectual developmental disorder, hypotonia, and hepatopathy, 617093 (3);
9.217;10;15;09;9q21;PVOP2;;Pelvic organ prolapse, susceptibility to, 2;613088;Fd;between rs4077632 and rs10868525;{Pelvic organ prolapse, susceptibility to, 2} (2);
9.218;2;29;04;9q21.2;VPS13A, CHAC;;Vacuolar protein sorting 13A (chorein);605978;Fd, LD;;Choreoacanthocytosis, 200150 (3);
9.219;10;20;92;9q22.33;COL15A1;;Collagen XV, alpha-1 polypeptide;120325;REa, A;;;4(Col15a1)
9.220;3;22;93;9q21.33;CTSL;;Cathepsin L;116880;REa, A, Psh;\'like\' sequence on 10q23-q24;;13(Ctsl)
9.221;1;10;12;9q21-q22;ETL4, ETOLM;;Epilepsy, familial temporal lobe, 4;611631;Fd;between GATA152H04 and D9S253;Epilepsy, familial temporal lobe, 4 (2);
9.222;1;12;08;9q21.32;FRMD3, EPB41LO;;FERM domain-containing 3;607619;REc;;;
9.223;1;29;01;9q21.2;PCA3, DD3;;Prostate cancer antigen 3;604845;REa;;;
9.224;12;27;16;9q21.11;FAM122A, C9orf42;;Family with sequence similarity 122, member A;617249;REc;;;
9.225;9;16;09;9q21.13;RFK;;Riboflavin kinase;613010;REc;;;
9.226;11;1;10;9q21.11;DFNA51, C9DUPq21.11, DUP9q21.11;;Deafness, autosomal dominant 51 (chromosome 9q21.11 duplication syndrome);613558;Ch;259kb duplication involving TJP2 and FAM189A2;Deafness, autosomal dominant 51 (4);
9.227;10;2;13;9p24.3;FOXD4, FKHL9;;Forkhead box D4;601092;A, REc;;;19(Foxd4)
9.228;7;20;09;9q21.12;MAMDC2;;MAM domain-containing 2;612879;REc;;;
9.229;12;28;15;9q21.12;MIR204, MIRN204, RDICC;;Micro RNA 204;610942;REc;mutation identified in 1 RDICC family;?Retinal dystrophy and iris coloboma with or without cataract, 616722 (3);
9.230;9;1;16;9q21.11;PRKACG, BDPLT19;;Protein kinase, cAMP-dependent, catalytic, gamma;176893;REa, A, REc;mutation identified in 1 BDPLT19 family;?Bleeding disorder, platelet-type, 19, 616176 (3);
9.231;10;4;05;9q21.12;SMC5L1, SMC5, KIAA0594;;Structural maintenance of chromosomes 5-like 1;609386;R, REc;;;
9.232;1;4;16;9q21.11;ZNF658;;Zinc finger protein 658;616290;REc;;;
9.233;8;20;98;9q21.12;APBA1, X11, D9S411E, MINT1, LIN10;;Amyloid beta A4 precursor protein-binding, family A, member 1;602414;RE, REc;;;
9.234;10;31;08;9q21.12-q21.13;TRPM3, MLSN2, LTRPC3, KIAA1616;;Transient receptor potential cation channel, subfamily M, member 3;608961;REc;;;
9.235;4;24;18;9q21.13;ABHD17B, FAM108B1;;Abhydrolase domain-containing protein 17B;617943;REc;;;
9.236;9;24;15;9q21.13;CARNMT1, C9orf41, UPF0586;;Carnosine N-methyltransferase 1;616552;REc;;;
9.237;9;9;13;9q21.13;GDA, CYPIN;;Guanine deaminase;139260;REc;;;
9.238;8;3;18;9q21.13;NMRK1, C9orf95;;Nicotinamide riboside kinase 1;608704;REc;;;
9.239;12;27;16;9q21.13;OSTF1, OSF, SH3P2;;Osteoclast-stimulating factor 1;610180;REc;;;
9.240;12;6;16;9q21.2;CEP78, CRDHL;;Centrosomal protein, 78kD;617110;REc;;Cone-rod dystrophy and hearing loss, 617236 (3);
9.241;6;26;00;9q21.32;UBQLN1, DA41;;Ubiquilin 1 (Da41, rat, homolog of);605046;A;;;
9.242;8;11;17;9q21.33;ISCA1, HBLD2, HISCA, MMDS5;;Iron-sulfur cluster assembly 1, S. cerevisiae, homolog of;611006;REc;;Multiple mitochondrial dysfunctions syndrome 5, 617613 (3);
9.243;5;1;97;9q21.13;PCSK5;;Proprotein convertase subtilisin/kexin type 5;600488;REa, A, REc;?close to LPC1 on 9q;;19(Pcsk5)
9.244;2;3;06;9q21.32;TLE1, ESG1;;Transducin-like enhancer of split 1 (homolog of Drosophila E(spl));600189;REa, A, REn, R;conflicting assignment to chr.19;;
9.245;4;15;09;9q22.31;ASPN, PLAP1, OS3;;Asporin;608135;REc;;{Osteoarthritis susceptibility 3}, 607850 (3); {Lumbar disc degeneration}, 603932 (3);
9.246;3;13;06;9q21.3-q22;FHL1, HPLH1, HLH1;;Hemophagocytic lymphohistiocytosis, familial, 1;267700;Fd;;Hemophagocytic lymphohistiocytosis, familial, 1 (2);
9.247;3;18;94;9q21.33;GAS1;;Growth arrest-specific gene-1;139185;Psh, A;;;13(Gas1)
9.248;10;2;14;9q21.2;PSAT1, PSAT, EPIP, PSATD, NLS2;;Phosphoserine aminotransferase 1;610936;REc;mutation identified in 1 PSATD family;?Phosphoserine aminotransferase deficiency, 610992 (3); Neu-Laxova syndrome 2, 616038 (3);
9.249;3;23;14;9q21.32;C9orf64;;Chromosome 9 open reading frame 64;611342;REc;;;
9.250;3;23;14;9q21.32;C9orf103;;Chromosome 9 open reading frame 103;611343;REc;;;
9.251;4;2;16;9q21.32;GKAP1, GKAP42;;G kinase-anchoring protein 1;611356;REc;;;
9.252;5;26;13;9q21.32;KIF27;;Kinesin family member 27;611253;REc;;;
9.253;5;24;13;9q21.32;MIR7-1;;Micro RNA 7-1;615239;REc;;;
9.254;2;23;14;9q21.32;RASEF;;RAS and EF-hand domains-containing protein;611344;REc;;;
9.255;08;21;18;9q21.32;RMI1, BLAP75, C9orf76;;RecQ-mediated genome instability 1, S. cerevisiae, homolog of;610404;REc;;;
9.256;10;13;15;9q21.32;HNRNPK, HNRPK, AUKS;;Heterogeneous nuclear ribonucleoprotein K;600712;REa, A;;Au-Kline syndrome, 616580 (3);
9.257;4;6;11;9q21.33;AGTPBP1, NNA1, KIAA1035, CCP1;;ATP/GTP-binding protein 1;606830;REc;;;
9.258;8;14;14;9q21.33;GOLM1, GOLPH2, GP73, C9orf155;;Golgi membrane protein 1;606804;REc;;;
9.259;1;22;18;9q21.33;NTRK2, TRKB, OBHD, EIEE58;;Neurotrophic tyrosine kinase, receptor, type 2;600456;REa, A;;Obesity, hyperphagia, and developmental delay, 613886 (3); Epileptic encephalopathy, early infantile, 58, 617830 (3);
9.260;3;23;15;9q21.33;ZCCHC6, TUT7, KIAA1711;;Zinc finger CCHC domain-containing protein 6;613467;REc;;;
9.261;4;30;15;9q22.33;ALG2, CDGII, CMSTA3, CMS14;;Alg2, S. cerevisiae, homolog of;607905;REc;mutation identified in 1 CDGII patient;?Congenital disorder of glycosylation, type Ii, 607906 (3); Myasthenic syndrome, congenital, 14, with tubular aggregates, 616228 (3);
9.262;9;2;08;9q31.1;CSMF;;Chondrosarcoma, extraskeletal myxoid, fused to EWS in;600542;Ch, A;t(9;17)(q22;q11); t(9;22)(q22;q11-q12);Chondrosarcoma, extraskeletal myxoid, 612237 (3);
9.263;9;2;15;9q22.33;FOXE1, FKHL15, TITF2, TTF2, NMTC4;;Forkhead box E1 (thyroid transcription factor-2);602617;Psh, REc;;Bamforth-Lazarus syndrome, 241850 (3); {Thyroid cancer, nonmedullary, 4}, 616534 (3);4(Titf2)
9.264;10;5;10;9q22.33;GALNT12, CRCS1;;UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 12;610290;REc;;{Colorectal cancer, susceptibility to, 1}, 608812 (3);
9.265;1;23;07;9q22.33;HEMGN, EDAG;;Hemogen;610715;A;;;4(Hemgn)
9.266;11;17;94;9q22.32;HSD17B3, EDH17B3;;Hydroxysteroid (17-beta) dehydrogenase 3;605573;A;;Pseudohermaphroditism, male, with gynecomastia, 264300 (3);
9.267;8;25;04;9q22;JOAG2;;Glaucoma, primary open angle, juvenile-onset, 2;608695;Fd;between D9S1803 and D9S196;Glaucoma, primary open angle, juvenile-onset, 2 (2);
9.268;6;9;98;9q22.31;NINJ1;;Ninjurin;602062;A;;;13(Ninj1)
9.269;2;2;01;9q22.31;PHF2;;PHD finger protein-2;604351;REn, REc, R;;;
9.270;8;14;00;9q22.31;ROR2, BDB1, BDB, NTRKR2;;Receptor tyrosine kinase-like orphan receptor 2;602337;Fd, R, REc, Ch;;Brachydactyly, type B1, 113000 (3); Robinow syndrome, autosomal recessive, 268310 (3);13(Ror2)
9.271;12;3;98;9q21.13;RORB, RZRB;;RAR-related orphan receptor B;601972;A;;;4(Rorb)
9.272;7;3;06;9q22;STQTL8;;Stature quantitative trait locus 8;610114;Fd;between GATA81C04M and ATA18A07M;{Stature QTL 8} (2);
9.273;1;7;95;9q22.2;SYK;;Spleen tyrosine kinase;600085;A;;;13(Syk)
9.274;4;7;14;9q22.33;TGFBR1, ALK5, AAT5, LDS1, MSSE;;Transforming growth factor, beta receptor I (activin A receptor type II-like kinase, 53kD);190181;Psh, A;;Loeys-Dietz syndrome 1, 609192 (3); {Multiple self-healing squamous epithelioma, susceptibility to}, 132800 (3);4(Tgfbr1)
9.275;9;30;02;9q21.13;TRPM6, CHAK2, HOMG1;;Transient receptor potential cation channel, subfamily M, member 6;607009;REc;;Hypomagnesemia 1, intestinal, 602014 (3);
9.276;4;8;08;9q31.1;ABCA1, ABC1, HDLDT1, TGD;;ATP-binding cassette 1;600046;A, REc;;Tangier disease, 205400 (3); HDL deficiency, type 2, 604091 (3); {Coronary artery disease in familial hypercholesterolemia, protection against}, 143890 (3);
9.277;12;27;01;9q22.33;TRIM14, KIAA0129;;Tripartite motif-containing protein 14;606556;REa, R;;;
9.278;10;15;98;9q31.1;ZNF189;;Zinc finger protein-189;603132;A;;;
9.279;4;17;13;9q22.1;CDK20, CCRK, CDCH, P42;;Cyclin-dependent kinase 20;610076;R, REc;;;
9.280;4;6;18;9q22.33;GABBR2, GPR51, EIEE59, NDPLHS;;Gamma-aminobutyric acid B receptor 2;607340;R, A;;{Nicotine dependence, susceptibility to}, 188890 (3); {Nicotine dependence, protection against}, 188890 (3); Epileptic encephalopathy, early infantile, 59, 617904 (3); Neurodevelopmental disorder with poor language and loss of hand skills, 617903 (3);
9.281;7;12;13;9q22.1;NXNL2, RDCVF2;;Nucleoredoxin-like protein 2;615299;REc, H;;;13(Nxnl2)
9.282;11;11;14;9q22.1;SHC3, NSHC, RAI, SHCC;;SHC transforming protein 3;605263;R, REc;;;
9.283;9;18;08;9q22.1;S1PR3, EDG3;;Sphingosine-1-phosphate receptor 3;601965;A;;;
9.284;5;25;00;9q22.2;GADD45G, GRP17;;Growth arrest- and DNA damage-inducible gene 45, gamma;604949;A, R;;;
9.285;10;11;00;9q22.31;NFIL3, NFIL3A, E4BP4;;Nuclear factor, interleukin 3-regulated;605327;REc;;;
9.286;3;2;06;9q22.1;SPIN, SPIN1;;Spindlin;609936;REc;;;
9.287;3;5;01;9q22.31;SPTLC1, LBC1, SPT1, HSN1, HSAN;;Serine palmitoyltransferase, long-chain base subunit 1;605712;Fd;;Neuropathy, hereditary sensory and autonomic, type IA, 162400 (3);
9.288;3;31;15;9q22.2;CKS2;;CDC2-associated protein CKS2;116901;A, REc;;;
9.289;7;12;01;9q22.33;CTSL2, CTSV;;Cathepsin L2;603308;A;;;
9.290;3;31;15;9q22.2;DIRAS2;;DIRAS family, GTP-binding Ras-like protein 2;607863;R, REc;;;
9.291;11;9;05;9q22.2;SECISBP2, SBP2;;Selenocysteine insertion sequence-binding protein 2;607693;REc;;Thyroid hormone metabolism, abnormal, 609698 (3);
9.292;9;27;17;9q22.2;SEMA4D, SEMAJ, CD100, COLL4;;Semaphorin 4D;601866;REc;;;
9.293;3;22;07;9q21.32-q21.33;SLC28A3, CNT3;;Solute carrier family (sodium-coupled nucleoside transporter), member 3;608269;A, REc;;;
9.294;11;13;07;9q22.32;FBP1;;Fructose-bisphosphatase 1;611570;A, Fd, REc;;Fructose-1,6-bisphosphatase deficiency, 229700 (3);
9.295;4;30;09;9q31.1;ALDOB;;Aldolase B, fructose-bisphosphatase;612724;REb, REa, A, D, REc;;Fructose intolerance, hereditary, 229600 (3);4(Aldo2)
9.296;5;2;03;9q31.1;BAAT;;Bile acid coenzyme A:amino acid N-acyltransferase (glycine N-choloyltransferase);602938;REc, H;;Hypercholanemia, familial, 607748 (3);4(Baat)
9.297;7;12;13;9q22.31;BICD2, KIAA0699, SMALED2;;Bicaudal D, Drosophila, homolog of, 2;609797;R, REc;;Spinal muscular atrophy, lower extremity-predominant, 2, AD, 615290 (3);
9.298;10;20;99;9q22.33;CORO2A, WDR2, IR10;;Coronin 2A;602159;REc;;;
9.299;6;14;99;9q22.31;ECM2;;Extracellular matrix protein-2;603479;A;;;
9.300;4;19;11;9q22.32;FANCC, FACC;;Fanconi anemia, complementation group C;613899;Fd, REc;;Fanconi anemia, complementation group C, 227645 (3);13(Facc)
9.301;5;4;00;9q22.31;OGN, OIF;;Osteoglycin;602383;R, A;;;
9.302;3;1;07;9q22.32;PTCH1, NBCCS, BCNS, HPE7;;Patched, Drosophila, homolog of;601309;R, Fd, D;;Basal cell nevus syndrome, 109400 (3); Basal cell carcinoma, somatic, 605462 (3); Holoprosencephaly 7, 610828 (3);13(Ptc)
9.303;2;3;05;9q22.32;SLC35D2, HFRC1, SQV7L;;Solute carrier family 35, member D2;609182;REc;;;
9.304;3;22;06;9q22.33;TBC1D2, PARIS1;;TBC1 domain family, member 2;609871;REc;;;
9.305;5;20;99;9q22.33;TMOD;;Tropomodulin;190930;A, REc;;;4(Tmod)
9.306;5;26;05;9q22.31;WNK2, PRKWNK2;;WNK lysine deficient protein kinase 2;606249;R, REc;;;
9.307;8;30;07;9q22.33;XPA, XPAC;;XPA complementing gene;611153;S, A, M, REc;;Xeroderma pigmentosum, group A, 278700 (3);4(Xpa)
9.308;1;12;99;9q22.32;ZNF169;;Zinc finger protein-169;603404;A, REn;;;
9.309;5;9;97;9q22.33;NCBP1;;Nuclear cap binding protein 1, 80kD;600469;REa, REc;in 500kb of XPA;;4(Ncbp)
9.310;8;9;12;9q22.31;AUH;;AU-specific RNA-binding protein (3-methylglutaconyl-CoA hydratase);600529;R, REc;;3-methylglutaconic aciduria, type I, 250950 (3);
9.311;10;08;07;9q22.31;CENPP;;Centromeric protein P;611505;R, REc;;;
9.312;9;24;08;9q22.31;FAM120A, C9orf10, KIAA0183;;Family with sequence similarity 120, member A;612265;REc;;;
9.313;6;30;17;9q22.31;FGD3, ZFYVE5;;FYVE, RhoGEF, and Ph domain-containing protein 3;617554;REc;;;
9.314;6;23;15;9q22.31;SUSD3;;SUSHI domain-containing protein 3;616429;REc;;;
9.315;10;25;17;9q22.31;CARD19, BINCARD, C9orf89;;Caspase recruitment domain-containing protein 19;617726;REc;;;
9.316;4;10;14;9q22.32;ERCC6L2, RAD26L, BMFS2;;ERCC6-like 2;615667;REc;;Bone marrow failure syndrome 2, 615715 (3);
9.317;11;21;18;9q22.32;HABP4, IHABP4;;Hyaluronan-binding protein 4;617369;A, REc;;;
9.318;3;23;09;9q22.32;MIR189, MIRN24-1;;Micro RNA 24-1;609705;REc;;;
9.319;3;23;09;9q22.32;MIR23B, MIRN23B;;Micro RNA 23B;610723;REc;;;
9.320;3;23;09;9q22.32;MIR27B, MIRN27B;;Micro RNA 27B;610636;REc;;;
9.321;3;23;09;9q22.32;MIRLET7A1, LET7A1, MIRNLET7A1;;Micro RNA Let7a1;605386;REc;;;
9.322;3;23;09;9q22.32;MIRLET7D, LET7D, MIRNLET7D;;Micro RNA Let7d;612145;REc;;;
9.323;3;23;09;9q22.32;MIRLET7F1, LET7F1, MIRNLET7F1;;Micro RNA Let7f1;612146;REc;;;
9.324;8;20;08;9q22.31;NOL8, NOP132;;Nucleolar protein 8;611534;REc;;;
9.325;8;19;13;9q22.32;ZNF367, AFF29;;Zinc finger protein 367;610160;REc;;;
9.326;3;13;12;9q22.32-q22.33;CDC14B;;Cell division cycle 14, S. cerevisiae, homolog B;603505;R, REc;;;
9.327;9;9;13;9q22.33;ANKS6, PKDR1, NPHP16;;Ankyrin repeat and sterile alpha motif domains-containing protein 6;615370;REc;;Nephronophthisis 16, 615382 (3);
9.328;8;29;16;9q22.33;NANS, SAS, SEMDCG;;N-acetylneuraminic acid synthase (sialic acid synthase);605202;R, REc;;Spondyloepimetaphyseal dysplasia, Camera-Genevieve type, 610442 (3);
9.329;01;04;19;9q22.33;SEC61B;;Sec61 translocon, beta subunit;609214;REc;;;
9.330;7;23;13;9q22.33;TDRD7, KIAA1529, TRAP, CATC4, CTRCT36;;Tudor domain-containing protein 7;611258;REc, R, Ch;;Cataract 36, 613887 (3);
9.331;1;12;07;9q31.3;ACTL7A;;Actin-like 7A;604303;REa, REn, H;;;4(Actl7a)
9.332;1;12;07;9q31.3;ACTL7B;;Actin-like 7B;604304;REc, REn, H;;;4(Actl7b)
9.333;10;11;17;9q31.1;CAVIN4, MURC;;Caveolae-associated protein 4;617714;REc;;;
9.334;09;27;18;9q31.2;FKTN, FCMD, CMD1X, LGMDR13, MDDGA4, MDDGB4, MDDGC4;;Fukutin;607440;Fd, LD;;Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 4, 253800 (3); Muscular dystrophy-dystroglycanopathy (congenital without mental retardation), type B, 4, 613152 (3); Cardiomyopathy, dilated, 1X, 611615 (3); Muscular dystrophy-dystroglycanopathy (limb-girdle), type C, 4, 611588 (3);
9.335;3;20;06;9q31.2;FSD1NL, FSD1L, MIR1, CCDC10;;FSD1 N-terminus-like protein;609829;REc;;;
9.336;2;2;11;9q31;HSCR5;;Hirschsprung disease, susceptibility to, 5;600156;LD;;{Hirschsprung disease, susceptibility to, 5} (2);
9.337;4;5;01;9q31.3;IKBKAP, IKAP;;Inhibitor of kappa light polypeptide gene enhancer in B cells, kinase complex-associated protein;603722;REc, Fd;;Dysautonomia, familial, 223900 (3);
9.338;8;12;03;9q31.1;INVS, INV, NPHP2, NPH2;;Inversin;243305;REc, A, Fd;;Nephronophthisis 2, infantile, 602088 (3);
9.339;1;29;01;9q31.2;KLF4, EZF, GKLF;;Kruppel-like factor 4;602253;R;;;4(Ezf)
9.340;12;20;05;9q31;PAND2;;Panic disorder 2;607853;Fd;max lod at D9S271;Panic disorder 2 (2);
9.341;12;19;01;9q34.11;SIAT7D, SIAT3C;;Sialyltransferase 7D;606378;A, R, REc;;;
9.342;12;8;04;9q31.1;STX17;;Syntaxin 17;604204;REc;;;
9.343;8;28;15;9q31.2;TAL2;;T-cell acute lymphocytic leukemia-2;186855;REa, A, RE, Ch;33kb from breakpoint in t(7;9);Leukemia, T-cell acute lymphocytic, somatic, 613065 (3);4(Tal2)
9.344;6;14;99;9q31.1;TMEFF1, C9orf2;;Transmembrane protein with EGF-like and 2 follistatin-like domains 1;603421;A, REa;;;
9.345;5;9;95;9q31.3;TXN;;Thioredoxin;187700;A, Psh;incorrectly assigned to 3;;4(Txn)
9.346;8;10;98;9q31.3;UGCG, GCS;;UDP-glucose ceramide glucosyltransferase;602874;A;;;4(Ugcg)
9.347;4;21;10;9q31.3;EPB41L4B, EHM2;;Erythrocyte membrane protein band 4.1-like 4B;610340;REc;;;
9.348;6;29;05;9q31-q32;HNP1;;Hypertensive nephropathy;608026;Fd;;Hypertensive nephropathy (2);
9.349;11;4;98;9q32;SLC31A1, COPT1, CTR1;;Solute carrier family 31 (copper transporter), member 1;603085;REn;;;
9.350;12;13;00;9q32;SLC13A2, COPT2, CTR2;;Solute carrier family 31 (copper transporter), member 2;603088;REn;;;
9.351;11;22;04;9q31.3;AKAP2, AKAPKL, KIAA0920, PALM2;;A-kinase anchor protein 2;604582;R;multiple splice variants;;
9.352;8;8;14;9q32;PRPF4, PRP4, HPRP4, RP70;;Precursor mRNA-processing factor 4, S. cerevisiae, homolog of;607795;A;;Retinitis pigmentosa 70, 615922 (3);
9.353;3;5;98;9q32;RGS3;;Regulator of G-protein signaling-3;602189;R;;;
9.354;12;17;07;9q32;SLC46A2, TSCOT;;Solute carrier family 46, member 2;608956;H, REc;;;4(Slc46a2)
9.355;1;19;07;9q31-q34;SPDA2;;Spondyloarthropathy, susceptibility to, 2;183840;Fd;max lod at D9S1776;{Spondyloarthropathy, susceptibility to, 2} (2);
9.356;09;27;18;9q33.1;TRIM32, HT2A, LGMDR8, BBS11;;Tripartite-motif-containing protein 32;602290;Fd, REc;mutation identified in 1 BBS11 family;Muscular dystrophy, limb-girdle, autosomal recessive 8, 254110 (3); ?Bardet-Biedl syndrome 11, 615988 (3);
9.357;11;30;12;9q31.1;CHDT3;;Congenital heart defects, multiple types, 3;614954;Fd;max lod at D9S1690;Congenital heart defects, multiple types, 3 (2);
9.358;3;24;09;9q31.1;CYLC2;;Cylicin 2;604035;REc;;;
9.359;3;24;09;9q31.1;GRIN3A, NR3A;;Glutamate receptor, ionotropic, N-methyl-D-aspartate 3A;606650;REc;;;
9.360;3;5;08;9q31.1;MRPL50;;Mitochondrial ribosomal protein L50;611854;REc;pseudogenes on 2, 5, and 10;;
9.361;9;16;12;9q31.1;NIPSNAP3A, TASSC;;NIPSNAP, C. elegans, homolog of, 3A;608871;REc;;;
9.362;4;15;11;9q31.1;PPP3R2, PPP3RL, CBLP;;Protein phosphatase 3, regulatory subunit B, beta;613821;R, REc;;;
9.363;4;21;14;9q31.1;RNF20, BRE1A;;Ring finger protein 20;607699;REc;;;
9.364;12;23;15;9q31.1;TEX10;;Testis-expressed gene 10;616717;REc;;;
9.365;10;7;13;9q31.1;TXNDC4, KIAA0573;;Thioredoxin domain-containing protein 4;609170;R, REc;;;
9.366;1;12;07;9q31.3;CTNNAL1;;Catenin, alpha-like, 1;604785;R, A, REn;;;
9.367;7;20;09;9q31.2;MENAQ3;;Menarche, age at, QTL3;612883;Fd;associated with rs2090409;{Menarche, age at, QTL3} (2);
9.368;7;18;14;9q31.2;RAD23B;;RAD23 (Saccharomyces cerevisiae) homolog of, B;600062;A, RE, REc;previously 3p25.1;;4(Rad23b)
9.369;4;24;09;9q31.1-q31.2;SLC44A1, CTL1, CDW92;;Solute carrier family 44, member 1;606105;REc;;;
9.370;2;8;13;9q31.2;TMEM38B, TRICB, OI14;;Transmembrane protein 38B;611236;REc;;Osteogenesis imperfecta, type XIV, 615066 (3);
9.371;3;18;17;9q31.2;ZNF462, KIAA1803;;Zinc finger protein 462;617371;REc;;;
9.372;9;22;08;9q31.2-q34.2;IS4;;Scoliosis, idiopathic, susceptibility to, 4;612238;Fd;max lod at D9S2157;{Scoliosis, idiopathic, susceptibility to, 4} (2);
9.373;6;28;18;9q31.3;C9orf84, SHOC1, ZIP2;;Chromosome 9 open reading frame 84;618038;REc;;;
9.374;6;26;16;9q31.3;FRRS1L, C9orf4, CG6, EIEE37;;Ferric-chelate reductase 1-like;604574;REc, REa;;Epileptic encephalopathy, early infantile, 37, 616981 (3);
9.375;5;25;13;9q31.3;GNG10;;Guanine nucleotide-binding protein, gamma 10;604389;REc;;;
9.376;12;17;15;9q31.3;KIAA0368, ECM29;;KIAA0368 gene;616694;R, REc;;;
9.377;9;18;08;9q31.3;LPAR1, EDG2, LPA1, VZG1;;Lysophosphatidic acid receptor 1;602282;R, REc;;;4(vzg1)
9.378;3;23;09;9q31.3;MIR32, MIRN32;;Micro RNA 32;609355;REc;;;
9.379;4;10;14;9q31.3;PTGR1, LTB4DH;;Prostaglandin reductase 1;601274;REc;;;
9.380;8;8;13;9q31.3;PTPN3, PTPH1;;Protein-tyrosine phosphatase, nonreceptor-type, 3;176877;A, REc;;;
9.381;8;4;15;9q31.3;MUSK, CMS9, FADS;;Receptor tyrosine kinase MuSK;601296;A;;Myasthenic syndrome, congenital, 9, associated with acetylcholine receptor deficiency, 616325 (3); Fetal akinesia deformation sequence, 208150 (3);4(Musk)
9.382;08;08;18;9q32;ATP6V1G1, ATP6G1;;ATPase, H+ transporting, V1 subunit G1;607296;R, REc;;;
9.383;3;30;12;9q32;CDC26, APC12;;Cell division cycle 26, S. cerevisiae, homolog of;614533;REc;pseudogene on 7q32.1;;
9.384;08;01;18;9q32;COL27A1, KIAA1870, STLS;;Collagen, type XXVII, alpha-1;608461;REc;;Steel syndrome, 615155 (3);4(Col27a1)
9.385;4;17;00;9q33.1;DEC1;;Deleted in esophageal cancer 1;604767;D;;Esophageal squamous cell carcinoma, 133239 (1);
9.386;3;27;17;9q32;FKBP15, FKBP133, KIAA0674, WAFL;;FK506-binding protein 15;617398;REc;;;
9.387;4;30;09;9q32;IBD16;;Inflammatory bowel disease 16, susceptibility to;612259;Fd;;{Inflammatory bowel disease 16} (2);
9.388;8;2;17;9q32;INIP, C9orf80, SOSSC;;INST3- and NABP-interacting protein;613273;REc;;;
9.389;3;9;17;9q32;KIAA1958;;KIAA1958 gene;617390;REc;;;
9.390;8;19;13;9q32;KIF12;;Kinesin family member 12;611278;REc;;;
9.391;1;2;08;9q31.3;SVEP1, POLYDOM, SELOB;;Sushi, von willebrand factor type A, EGF, and pentraxin domain-containing 1;611691;A, H, REc;;;4(Svep1)
9.392;9;26;08;9q32;TNFSF15, TL1, VEGI;;Tumor necrosis factor ligand superfamily, member 15 (vascular endothelial growth inhibitor);604052;R, A;;;
9.393;11;29;17;9q31.3;TXNDC8, SPTRX3;;Thioredoxin domain-containing protein 8;617789;REc;;;
9.394;8;10;98;9q32;ZFP37;;Zinc finger protein-37, mouse, homolog of;602951;REa, A;?candidate for Nager syndrome;;4(Zfp37)
9.395;8;17;16;9q32;ZNF618, NEDD10, KIAA1952;;Zinc finger protein 618;617077;REc;;;
9.396;1;6;93;9q32;AMBP, ITIL, ITI, HCP;;Alpha-1-microglobulin/bikunin precursor (inter-alpha-trypsin inhibitor, light chain; protein HC);176870;REa, A, H;;;4(Intin4)
9.397;5;5;16;9q32-q33;ARMD10;;Macular degeneration, age-related, 10;611488;Fd;;Macular degeneration, age-related, 10 (2);
9.398;10;6;09;9q32-q33;EIG3;;Epilepsy, idiopathic generalized, susceptibility to 3;608762;Fd;;{Epilepsy, idiopathic generalized, susceptibility to, 3} (2);
9.399;5;5;16;9q33.1;TLR4;;Toll-like receptor-4;603030;A;;;
9.400;12;24;08;9q33.2;MEGF9, EGFL5;;Multiple epidermal growth factor-like domains 9;604268;R;;;
9.401;1;7;95;9q33.2;PTGS1, COX1, PGHS1, COX3, PCOX1;;Prostaglandin-endoperoxide synthase 1 (prostaglandin G/H synthase and cyclooxygenase);176805;REa, A;;;
9.402;10;11;07;9q32;WHRN, CIP98, KIAA1526, DFNB31, USH2D;;Whirlin;607928;Fd, REc;;Deafness, autosomal recessive 31, 607084 (3); Usher syndrome, type 2D, 611383 (3);4(Whrn)
9.403;1;8;01;9q33.2;MRFF, RRF;;Ribosome-recycling factor, mitochondrial;604602;R;;;
9.404;3;29;10;9q33;ASRT8;;Asthma-related traits, susceptibility to, 8;613207;Fd;associated with rs3789873;{Asthma-related traits, susceptibility to, 8} (2);
9.405;1;30;01;9q33.2;CEP1, CEP110, FAN;;Centrosomal protein 1;605496;R;;;2(Cep1)
9.406;5;5;10;9q33.2;DAB2IP, AIP1, KIAA1743;;DAB2-interacting protein;609205;REc;;;
9.407;8;4;97;9q33.2;GPR21;;G protein-coupled receptor-21;601909;A;;;
9.408;5;30;17;9q33.3;NR5A1, FTZF1, FTZ1, SF1, AD4BP, POF7, SRXY3, SPGF8, SRXX4;;Nuclear receptor subfamily 5, group A, member 1;184757;A;;46XY sex reversal 3, 612965 (3); Premature ovarian failure 7, 612964 (3); Adrenocortical insufficiency, 612964 (3); 46, XX sex reversal 4, 617480 (3); Spermatogenic failure 8, 613957 (3);2(Ftzf1)
9.409;10;7;02;9q32;POLE3, CHARAC17, YBL1;;Polymerase, DNA, epsilon-3;607267;REc;;;
9.410;2;10;14;9q33.1;TNC, HXB, DFNA56;;Tenascin C (hexabrachion);187380;REa, A;proximal to ABL;Deafness, autosomal dominant 56, 615629 (3);4(Hxb)
9.411;6;14;99;9q32-q33;TNFSF8, CD30L, CD30LG;;Tumor necrosis factor ligand superfamily, member 8 (CD30 ligand);603875;A;;;4(Cd30l)
9.412;8;20;98;9q33.3;GCNF;;Germ cell nuclear factor;602778;A;;;
9.413;12;22;17;9q33.2;GGTA1P, GGTA1;;Glycoprotein, alpha-galactosyltransferase-1 pseudogene;104175;REa, A;processed pseudogene GGTA1P on 12q14-q15;;
9.414;7;27;11;9q34.12;LAMC3, OCCM;;Laminin, gamma-3;604349;REc, A;;Cortical malformations, occipital, 614115 (3);
9.415;6;11;94;9q33.3;PBX3;;Pre-B-cell leukemia transcription factor-3;176312;A, H;;;2(Pbx3)
9.416;9;29;10;9q34.11;SPTAN1, NEAS, EIEE5;;Spectrin, alpha, nonerythrocytic-1 (alpha-fodrin);182810;REa, A;;Epileptic encephalopathy, early infantile, 5, 613477 (3);2(Spna2)
9.417;3;2;98;9q33.2;TRAF1;;TNF receptor-associated factor 2;601711;A;;;
9.418;6;30;08;8q24;BMND10;;Bone mineral density quantitative trait locus 10;612113;Fd;associated with rs6469804 and rs6993813;[Bone mineral density QTL 10] (2);
9.419;7;12;99;9q33.3;LHX2, LH2;;LIM/homeodomain protein LHX2;603759;REa, A;;;
9.420;7;13;09;9q33.1;ASTN2, KIAA0634;;Astrotactin 2;612856;R, REc;;;
9.421;4;29;14;9q33.1;BRINP1, DBC1, DBCCR1;;Bone morphogenetic protein/retinoic acid-inducible neural-specific protein 1;602865;REc;;;
9.422;1;8;07;9q33.1;DIPAS;;DIPLA1, antisense;610689;REc;;;
9.423;7;13;93;9q33.1;PAPPA;;Pregnancy-associated plasma protein A;176385;A;;;4(Pappa)
9.424;11;22;10;9q33.3;DENND1A, KIAA1608;;DENN/MADD domain-containing protein 1A;613633;R, REc;;;
9.425;12;10;13;9q33.2;LHX6;;LIM homeobox gene 6;608215;REc;;;
9.426;9;8;17;9q33.2;PSMD5, S5B;;Proteasome 26S subunit, non-ATPase, 5;604452;REa;;;
9.427;3;31;09;9q33.2;RAB14;;Ras-associated protein;612673;REc;;;
9.428;7;17;14;9q33.2-q33.3;RABGAP1, GAPCENA, TBC1D11;;RAB GTPase-activating protein 1;615882;REc;;;
9.429;6;15;99;9q33.2;NDUFA8;;NADH-ubiquinone oxidoreductase 1 beta subcomplex, 8;603359;R, Psh;;;
9.430;2;25;15;9q33.3;ANGPTL2, ARP2;;Angiopoietin-like 2;605001;REc;;;
9.431;4;25;05;9q33.2;CDK5RAP2, KIAA1633, MCPH3;;CDK5 regulatory subunit-associated protein 2;608201;REc, Fd;;Microcephaly 3, primary, autosomal recessive, 604804 (3);
9.432;2;17;15;9q33.3;CRB2, FSGS9, VMCKD;;Crumbs, Drosophila, homolog of;609720;REc;;Focal segmental glomerulosclerosis 9, 616220 (3); Ventriculomegaly with cystic kidney disease, 219730 (3);2(Crb2)
9.433;1;4;08;9q33.3;GAPVD1, RAP6, GAPEX5, KIAA1521;;GTPase-activating protein and VPS9 domains 1;611714;REc;;;
9.434;5;25;13;9q33.3;GOLGA1;;Golgi autoantigen, golgin subfamily A, 1;602502;REc;;;
9.435;5;26;13;9q33.3;MAPKAP1, SIN1, MIP1, JC310;;Mitogen-activated protein kinase-associated protein 1;610558;REc, R;;;
9.436;5;11;09;9q33.3;MIR181A2, MIRN181A2;;Micro RNA 181A2;612743;REc;;;
9.437;5;11;09;9q33.3;MIR181B2, MIRN181B2;;Micro RNA 181B2;612745;REc;;;
9.438;8;1;14;9q33.3;OLFML2A;;Olfactomedin-like 2A;615899;REc;;;
9.439;12;23;05;9q33.2;PHF19;;PHD finger protein 19;609740;REc;;;
9.440;4;15;09;9q33.3;PPP6C;;Protein phosphatase 6, catalytic subunit;612725;A, REc;highly related sequence on Xq22.3;;
9.441;1;30;12;9q33.3;RALGPS1, RALGEF2, KIAA0351;;Ral guanine nucleotide exchange factor with PH domain and SH3 domain-binding motif 1;614444;R, REc;;;
9.442;8;21;07;9q33.3;RPL12;;Ribosomal protein L12;180475;REc;;;
9.443;1;2;08;9q33.3;ZBTB34, KIAA1993;;Zinc finger- and BTB domain-containing protein 34;611692;REc;;;
9.444;1;19;12;9q33.3-q34.1;LRSAM1, TAL, RIFLE, CMT2P;;Leucine-rich repeat- and sterile alpha motif-containing 1;610933;REc;;Charcot-Marie-Tooth disease, axonal, type 2P, 614436 (3);
9.445;5;11;00;9q33.3;NEK6;;Never-in-mitosis gene A-related kinase 6;604884;R;;;
9.446;10;29;99;9q34.3;ABCA2, ABC2;;ATP-binding cassette 2;600047;A;;;
9.447;11;18;14;9q34.2;ABO;;ABO glycosyltransferase;110300;F, Fc;linked to AK1;[Blood group, ABO system], 616093 (3);
9.448;3;5;04;9q34.2;ADAMTS13, VWFCP, TTP;;A disintegrin-like and metalloprotease with thrombospondin type 1 motif, 13;604134;Fd, REc;;Thrombotic thrombocytopenic purpura, familial, 274150 (3);
9.449;5;19;09;9q32;ALAD, ALADH, PBGS;;Aminolevulinate, delta-, dehydratase;125270;F, S, A, REa;linked to ABO; ORM-ALAD-AK-ABO;Porphyria, acute hepatic, 612740 (3); {Lead poisoning, susceptibility to}, 612740 (3);4(Lv)
9.450;4;8;02;9q34.13;BARHL1;;BARH-like 1;605211;R;;;2(Barh1)
9.451;3;28;15;9q34.3;CACNA1B, CACNL1A5, DYT23;;Calcium channel, voltage-dependent, L type, alpha 1B subunit;601012;A;mutation identified in 1 DYT23 family;?Dystonia 23, 614860 (3);
9.452;10;9;12;9q34.11;CIZ1, ZNF356, LSFR1, NP94;;CDKN1A-interacting zinc finger protein 1;611420;R, A;;;
9.453;9;24;08;9q34.3;COBRA1, NELFB, KIAA1182;;Cofactor of BRCA1;611180;R, REc;;;
9.454;6;13;12;9q33.2;FBXW2, FBW2, FWD2;;F-box and WD40 domain protein 2;609071;A;;;2(Fbxw2)
9.455;11;7;08;9q34.13;MED27, CRSP8, CRAP34;;Mediator complex subunit 27;605044;R;;;
9.456;11;14;18;9q34.2;DBH, ORTHYP1;;Dopamine-beta-hydroxylase;609312;F, A;tightly linked to ABO;Orthostatic hypotension 1, due to DBH deficiency, 223360 (3);2(Dbh)
9.457;5;8;15;9q34.11;DNM1, EIEE31;;Dynamin-1;602377;A, REa;;Epileptic encephalopathy, early infantile, 31, 616346 (3);2(Dnm1)
9.458;10;21;15;9q34.11;DYT1, TOR1A;;Torsin A;605204;Fd;;Dystonia-1, torsion, 128100 (3); {Dystonia-1, modifier of} (3);
9.459;9;28;00;9q34.3;ENTPD2, CD39L1;;Ectonucleoside triphosphate diphosphohydrolase 2;602012;Psh, REc;same cosmid as ABC2;;
9.460;1;13;16;9q34.3;ENTPD8;;Ectonucleoside triphosphate diphosphohydrolase 8;616748;REc;;;
9.461;2;26;04;9q34.11;FNBP1, FBP17;;Formin-binding protein 17;606191;Ch, REc;fused with MLL in chronic myeloid leukemia;;
9.462;6;5;97;9q34.3;FCN1;;Ficolin (collagen/fibrinogen domain-containing) 1;601252;A, Psh;;;
9.463;6;5;97;9q34.3;FCN2;;Ficolin (collagen/fibrinogen domain-containing lectin) 2;601624;A;;;
9.464;3;3;03;9q34.11;FREQ, NCS1;;Frequenin, Drosophila, homolog of;603315;REc;;;
9.465;7;17;01;9q34.2;GBGT1, FS;;Globoside alpha-1,3-N-acetylgalactosaminyltransferase 1 (Forssman synthetase);606074;REc;;;
9.466;2;9;92;9q33.2;GSN;;Gelsolin;137350;A, REa, RE;40kb proximal to ABL;Amyloidosis, Finnish type, 105120 (3);2(Gsn)
9.467;8;5;97;9q33.3;HSPA5, GRP78;;Heat-shock 70kD protein-5 (glucose-regulated protein, 78kD);138120;REa, H, Psh, A;;;2(Grp78)
9.468;3;13;08;9q34.11;GLE1, GLE1L, LCCS, LCCS1;;Gle1, RNA export mediator, S. cerevisiae, homolog of;603371;Fd, REc;;Lethal congenital contracture syndrome 1, 253310 (3); Arthrogryposis, lethal, with anterior horn cell disease, 611890 (3);
9.469;5;9;12;9q34;KTCN6;;Keratoconus 6;614623;Fd;max lod at 159cM;Keratoconus 6 (2);
9.470;10;13;94;9q34.3;LCN1;;Lipocalin 1 (protein migrating faster than albumin, tear prealbumin);151675;A, Psh, Fd;;;2(Lcn1)
9.471;11;22;94;9q34.11;LCN2, NGAL;;Lipocalin 2 (oncogene 24p3);600181;REa;;;2(Lcn2)
9.472;5;23;05;9q34.3;LCN6;;Lipocalin 6;609379;REc;;;
9.473;7;22;09;9q34.3;LCN8;;Lipocalin 8;612902;REc, H;;;2(Lcn8)
9.474;7;22;09;9q34.3;LCN9;;Lipocalin 9;612903;REc, H;;;2(Lcn9)
9.475;7;22;09;9q34.3;LCN10;;Lipocalin 10;612904;REc, H;;;2(Lcn10)
9.476;7;22;09;9q34.3;LCN12;;Lipocalin 12;612905;REc, H;;;2(Lcn12)
9.477;5;9;18;9q34.3;MRPS2, COXPD36;;Mitochondrial ribosomal protein S2;611971;R, REc;;Combined oxidative phosphorylation deficiency 36, 617950 (3);
9.478;6;15;99;9q34.11;ODF2, ODF84;;Outer dense fiber of sperm tails 2;602015;A;;;
9.479;2;28;00;9q34.3;OBP2A;;Odorant-binding protein 2A;164320;REc;;;
9.480;2;28;00;9q34.2;OBP2B;;Odorant-binding protein 2B;604606;REc;;;
9.481;9;4;91;9q34.3;PAEP, PP14;;Progestagen-associated endometrial protein (placental protein 14);173310;REa, A, H;;;2(Paep)
9.482;10;1;95;9q34.11;PPP2R4, PTPA;;Protein phosphatase-2A, regulatory subunit B' (PR 53);600756;A;proximal to ABL;;
9.483;8;18;97;9q34.1-q34.2;RALGDS;;ral guanine nucleotide dissociation stimulator;601619;R, REc;;;
9.484;5;24;13;9q33.2;RC3H2, MNAB;;RING finger and CCCH-type zinc finger domains-containing protein 2;615231;REc;;;
9.485;9;28;05;9q34.2;REXO4, XPMC2H;;RNA exonuclease 4, S. cerevisiae, homolog of;602930;REc;;;
9.486;12;3;96;9q34.2;RING3L, ORFX;;RING3-like gene (open reading frame X);601541;REn;;;
9.487;5;27;93;9q34.2;RPL7A, SURF3;;Ribosomal protein L7a (surfeit-3);185640;REa, A;in cluster with SURF1;;2(Surf3)
9.488;3;23;15;9q34.13;SETX, SCAR1, AOA2, ALS4;;Senataxin;608465;Fd, REc;;Amyotrophic lateral sclerosis 4, juvenile, 602433 (3); Spinocerebellar ataxia, autosomal recessive 1, 606002 (3);
9.489;09;06;18;9q34.11;SET, MRD58;;SET gene;600960;A;fused with CAIN in acute undifferentiated leukemia;Mental retardation, autosomal dominant 58, 618106 (3);
9.490;4;4;02;9q34.2;SLC2A6;;Solute carrier family 2, member 6;606813;REc;;;
9.491;10;12;09;9q34.11;SLC27A4, FATP4, IPS;;Solute carrier family 27 (fatty acid transporter), member 4;604194;R, REc;;Ichthyosis prematurity syndrome, 608649 (3);
9.492;2;14;06;9q34.3;SLC34A3, NPTIIC, HHRH;;Solute carrier family 34 (sodium/phosphate cotransporter), member 3;609826;REc, Fd;;Hypophosphatemic rickets with hypercalciuria, 241530 (3);
9.493;9;10;07;9q33.3;STRBP, SPNR, p74;;Spermatid perinuclear RNA-binding protein;611138;A, H;;;2(Spnr)
9.494;12;17;15;9q34.2;SURF1, CMT4K;;Surfeit-1;185620;REa, A;distal to ABL, CAN;Leigh syndrome, due to COX IV deficiency, 256000 (3); Charcot-Marie-Tooth disease, type 4K, 616684 (3);2(Surf)
9.495;5;27;93;9q34.2;SURF2;;Surfeit-2;185630;REa, A;;;2(Surf2)
9.496;5;27;93;9q34.2;SURF4;;Surfeit-4;185660;REa, A;;;2(Surf4)
9.497;5;27;93;9q34.2;SURF5;;Surfeit-5;185641;H, A;;;2(Surf5)
9.498;8;25;03;9q34.11;TOR1B, DQ1;;Torsin 1B;608050;REc;centromeric to TOR1A; pseudogene on chr.2;;
9.499;4;20;17;9q34.13;TSC1, LAM;;Hamartin (tuberous sclerosis 1 gene);605284;F, Fd;linked to ABO, ABL;Tuberous sclerosis-1, 191100 (3); Lymphangioleiomyomatosis, 606690 (3); Focal cortical dysplasia, type II, somatic, 607341 (3);
9.500;5;27;93;9q34.2;SURF6;;Surfeit-6;185642;H, A;;;2(Surf6)
9.501;8;2;17;19p13.2;TSPAN16, TM4SF16;;Tetraspanin 16;617580;REc;;;
9.502;5;14;95;9q34.2;VAV2;;Oncogene VAV2;600428;RE;;;
9.503;7;13;93;9q33.3;ZNF79;;Zinc finger protein-79 (pT7);194552;REa;;;
9.504;8;1;17;9q34.12;ABL1, CHDSKM;;Abelson murine leukemia viral (v-abl) oncogene homolog 1;189980;REa, Ch, A;fusion hybrid gene with BCR1 in CML;Leukemia, Philadelphia chromosome-positive, resistant to imatinib (3); Congenital heart defects and skeletal malformations syndrome, 617602 (3);2(Abl)
9.505;2;23;09;9q34.11;AK1;;Adenylate kinase-1;103000;F, S, D, Fc;proximal to Ph1 break, 9q34.1; AK1 to ORM = 17cM;Hemolytic anemia due to adenylate kinase deficiency, 612631 (3);2(Ak1)
9.506;9;28;09;9q34.11;ASS1, ASS;;Argininosuccinate synthetase 1;603470;S, D, REa, Fd;14 pseudogenes on 11 chromosomes, including X and Y and ASSP2 on 6p23-q12;Citrullinemia, 215700 (3);2(Ass1)
9.507;9;30;14;9q33.2;C5, C5D, ECLZB;;Complement component-5;120900;REa, A;;C5 deficiency, 609536 (3); [Eculizumab, poor response to], 615749 (3);2(Hc)
9.508;11;5;98;9q34.11;CDK9, CDC2L4;;Cyclin-dependent kinase-9;603251;Psh;;;
9.509;1;27;09;9q34.1;CLLS3;;Leukemia, chronic lymphocytic, susceptibility to, 3;612557;Fd;associated with SNP -6531 upstream of DAPK1 promoter;{Leukemia, chronic lymphocytic, susceptibility to, 3} (2);
9.510;3;27;18;9q34.11;CRAT, CAT1, NBIA8;;Carnitine acetyltransferase;600184;REa;mutation identified in 1 NBIA8 patient;?Neurodegeneration with brain iron accumulation 8, 617917 (3);
9.511;10;14;95;9q21.33;DAPK1;;Death-associated protein kinase-1;600831;REa, A;;;
9.512;3;29;12;9q34.11;DOLPP1, LSFR2;;Dolichyl pyrophosphate phosphatase 1;614516;R, A;;;
9.513;3;9;95;9q34.11;ENDOG;;Endonuclease G;600440;Psh, A;;;
9.514;10;13;97;9q34.11;ENG, END, HHT1, ORW;;Endoglin;131195;A, H, Fd;;Telangiectasia, hereditary hemorrhagic, type 1, 187300 (3);2(Eng)
9.515;6;7;10;9q34.12;FIBCD1;;Fibrinogene C domain-containing protein 1;613357;REc;;;
9.516;6;1;09;9q33.3;LMX1B, NPS1;;LIM homeo box transcription factor 1, beta;602575;F, Fd, Ch;;Nail-patella syndrome, 161200 (3);2(Lmx1b)
9.517;8;27;15;9q34.13;NUP214, D9S46E, CAN, CAIN;;Nucleoporin, 214kD;114350;Ch;fused with DEK in AML; fused with ABL1 in T-ALL;Leukemia, acute myeloid, somatic, 601626 (3); Leukemia, T-cell acute lymphoblastic, somatic, 613065 (3);2(D2H9S46E)
9.518;09;27;18;9q34.13;POMT1, MDDGA1, MDDGB1, MDDGC1, LGMDR11;;Protein O-mannosyltransferase 1;607423;R, REa, Fd;;Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 1, 236670 (3); Muscular dystrophy-dystroglycanopathy (congenital with mental retardation), type B, 1, 613155 (3); Muscular dystrophy-dystroglycanopathy (limb-girdle), type C, 1, 609308 (3);
9.519;7;29;15;9q34.12;PRDM12, HSAN8;;PR domain-containing protein 12;616458;REc;;Neuropathy, hereditary sensory and autonomic, type VIII, 616488 (3);
9.520;2;6;01;9q34.11;PRRX2, PRX2;;Paired-related homeo box gene 2;604675;A;;;
9.521;12;10;15;9q33.2;STOM, EPB72, BND7;;Stomatin (erythrocyte membrane protein band 7.2);133090;REa, Ch, A;proximal to ABL;;2(Epb7.2)
9.522;8;29;08;9q34.11;STXBP1, UNC18, EIEE4;;Syntaxin-binding protein 1;602926;A;;Epileptic encephalopathy, early infantile, 4, 612164 (3);
9.523;8;20;88;9q32;ORM1, AGP1;;Orosomucoid-1 (alpha-1-acid glycoprotein-1);138600;F, S, REa, Fc, A;linked to ABO, AK1, ALAD;;4(Orm1)
9.524;8;20;88;9q32;ORM2;;Orosomucoid-2;138610;RE, LD;;;4(Orm2)
9.525;1;31;13;9q34.11;ASB6;;Ankyrin repeat- and SOCS box-containing protein 6;615051;REc;;;
9.526;12;29;06;9q34.11;C9orf90, NAIF1;;Nuclear apoptosis-inducing factor 1;610673;REc;;;
9.527;12;29;06;9q34.11;CCBL1;;Cysteine conjugate beta-lyase 1;600547;Psh, REc;;;
9.528;10;28;15;9q34.11;CERCAM;;Cerebral endothelial cell adhesion molecule;616626;REc;;;
9.529;3;27;17;9q34.11;DOLK, TMEM15, DK1, SEC59, KIAA1094, CDG1M;;Dolichol kinase;610746;R, REc;;Congenital disorder of glycosylation, type Im, 610768 (3);
9.530;1;31;13;9q34.11;DPM2, CDG1U;;Dolichyl-phosphate mannosyltransferase 2, regulatory subunit;603564;REc;;Congenital disorder of glycosylation, type Iu, 615042 (3);
9.531;8;26;15;9q34.11;GOLGA2, GM130;;Golgi autoantigen, golgin subfamily A, 2;602580;REc;;;
9.532;9;2;12;9q34.11;MIR199B;;Micro RNA 199B;614791;REc;;;
9.533;7;8;10;9q34.11;MIR2861, MIRN2861, BMND15;;Micro RNA 2861;613405;REc;;[Bone mineral density QTL 15], 613418 (3);
9.534;7;17;14;9q34.11;NTMT1, METTL11A, NRMT, C9orf32;;N-terminal X-Pro-Lys N-methyltransferase 1;613560;REc;;;
9.535;1;6;14;9q34.11;NUP188, KIAA1069;;Nucleoporin, 188kD;615587;R, REc;;;
9.536;7;13;09;9q34.11;PIP5KL1, PIPKH;;Phosphatidylinositol-4-phosphate-5-kinase-like 1;612865;REc;;;
9.537;2;7;07;9q34.11;PKN3;;Protein kinase N3;610714;REc;;;
9.538;8;23;12;9q34.11;SH2D3C, NSP3;;SH2 domain-containing protein 3C;604722;REc;;;
9.539;8;9;17;9q34.11;SPOUT1, CENP32, C9orf114;;SPOUT domain-containing methyltransferase 1;617614;REc;;;
9.540;3;20;14;9q34.11;ST6GALNAC6, SIAT7F;;ST6 alpha-N-acetyl-neuraminyl-2,3-beta-galactosyl-1, 3-N-acetylgalactosaminide alpha-2,6-sialyltransferase 6;610135;REc, R;;;
9.541;8;26;15;9q34.11;SWI5, SAE3, C9orf119;;SWi5 homologous recombination repair protein;616528;REc;;;
9.542;2;17;15;9q34.11;TBC1D13;;TBC1 domain family, member 13;616218;REc;;;
9.543;7;17;14;9q34.11;TOR2A, TORP1;;Torsin 2A;608052;REc;;;
9.544;1;29;07;9q34.11;TRUB2;;TRUB pseudouridine synthase, E. coli, homolog of, 2;610727;REc;;;
9.545;3;31;09;9q34.11;URM1;;Ubiquitin-related modifier 1, S. cerevisiae, homolog of;612693;REc;;;
9.546;4;8;13;9q34.11;USP20, VDU2;;Ubiquitin-specific protease 20;615143;REc;;;
9.547;2;9;14;9q34.11;WDR34, SRTD11;;WD repeat-containing protein 34;613363;REc;;Short-rib thoracic dysplasia 11 with or without polydactyly, 615633 (3);
9.548;11;10;17;9q34.11;ZER1, ZYG11BL, C9orf60;;Zyg11-related cell cycle regulator;617764;REc;;;
9.549;5;25;13;9q34.11-q34.12;FUBP3, FBP3;;FAR upstream element-binding protein 3;603536;REc;;;
9.550;8;17;99;9q33.3;PSMB7;;Proteasome subunit, beta-type, 7;604030;A;;;
9.551;11;10;17;9q34.12;EXOSC2, RRP4, SHRF;;Exosome component 2;602238;REc;;Short stature, hearing loss, retinitis pigmentosa, and distinctive facies, 617763 (3);
9.552;9;16;12;9q34.12;QRFP, P518, 26RFA;;Pyroglutamylated FR-amide peptide precursor protein;609795;REc;;;
9.553;8;11;13;9q34.13;AK8;;Adenylate kinase 8;615365;REc;;;
9.554;11;7;08;9q34.13;ALPQTL1;;Alkaline phosphatase, plasma level of, QTL 1;171720;Fd;linkage with rs657152;{Alkaline phosphatase, plasma level of, QTL1} (2);
9.555;3;28;15;9q34.11;COQ4, COQ10D7;;Coenzyme Q4, S. cerevisiae, homolog of;612898;REc;;Coenzyme Q10 deficiency, primary, 7, 616276 (3);
9.556;8;27;15;9q34.13;DDX31, PPP1R25;;DEAD box polypeptide 31;616533;REc;;;
9.557;3;29;07;9q34.11;FAM102A, EEIG1;;Family with sequence similarity 102, member A;610891;REc;;;
9.558;9;8;11;9q34.11;FAM129B, MINERVA;;Family with sequence similarity 129, member B;614045;REc;;;
9.559;2;2;14;9q34.13;GFI1B, BDPLT17;;Growth factor-independent 1B;604383;REc;;Bleeding disorder, platelet-type, 17, 187900 (3);
9.560;3;28;16;9q34.11;LRRC8A, KIAA1437, AGM5;;Leucine-rich repeat-containing 8A;608360;REc, R, Ch;mutation identified in 1 AGM5 patient;?Agammaglobulinemia 5, 613506 (3);2(Lrrc8)
9.561;3;22;07;9q34.11;PTGES2, PGES2, GBF1;;Prostaglandin E synthase 2;608152;REc, REn;;;
9.562;9;26;17;9q34.13;TTF1;;Transcription termination factor, RNA polymerase I;600777;REc;;;
9.563;8;31;11;9q34.2;ADAMTSL2, KIAA0605, GPHYSD1;;ADAMTS-like protein 2;612277;R, REc;;Geleophysic dysplasia 1, 231050 (3);
9.564;08;10;18;9q34.2;CACFD1, FLOWER, C9orf7;;Calcium channel FLOWER-domain containing protein 1;613104;REc;;;
9.565;7;18;14;9q34.13;GTF3C5, TFIIIC63;;General transcription factor 3C, polypeptide 5;604890;REc;;;
9.566;7;25;17;9q34.2;MYMK, TMEM8C;;Myomaker;615345;REc;;Carey-Fineman-Ziter syndrome, 254940 (3);
9.567;9;26;17;9q34.2;RNU6ATAC, U6ATAC;;RNA, U6ATAC small nuclear;601429;REc;;;
9.568;7;1;05;9q34.13;UCK1;;Uridine/cytidine kinase 1;609328;REc;;;
9.569;1;31;13;9q34.2;SARDH, SARD, SAR;;Sarcosine dehydrogenase;604455;H, REc;;[Sarcosinemia], 268900 (3);2(sar)
9.570;12;22;17;9q34.3;COL5A1, EDSCL1;;Collagen V, alpha-1 polypeptide;120215;REa, A, Fd;;Ehlers-Danlos syndrome, classic type, 1, 130000 (3);2(Col5a1)
9.571;6;11;94;9q34.3;PTGDS;;Prostaglandin D2 synthase (21kD, brain);176803;A, H;distal to ABL;;2(Ptgds)
9.572;5;5;04;9q34.3;AGPAT2, LPAAB, BSCL, BSCL1;;1-acylglycerol-3-phosphate O-acyltransferase 2 (lysophosphatidic acid acyltransferase-beta);603100;A, Fd;;Lipodystrophy, congenital generalized, type 1, 608594 (3);
9.573;11;26;97;9q34.3;C8G;;Complement component-8, gamma polypeptide;120930;REa, H, Fd;;;2(C8g)
9.574;3;29;12;9q34.3;C9orf116, PIERCE1;;p53-induced expression in RB-null cells 1;614502;REc, H;;;2(Pierce1)
9.575;3;24;11;9q34.3;CAMSAP1;;Calmodulin-regulated spectrin-associated protein 1;613774;REc;;;
9.576;4;26;10;9q34.3;CARD9, CANDF2;;Caspase recruitment domain-containing protein 9;607212;REc;;Candidiasis, familial, 2, autosomal recessive, 212050 (3);
9.577;8;17;14;9q34.3;CCDC183, KIAA1984;;Coiled-coil domain-containing protein 183;615955;REc;;;
9.578;11;30;06;9q34.13;CEL, BSSL, CELL, MODY8;;Carboxyl-ester lipase (bile-salt stimulated lipase);114840;REa, A;;Maturity-onset diabetes of the young, type VIII, 609812 (3);
9.579;5;26;13;9q34.3;DPP7, QPP;;Dipeptidyl peptidase VII;610537;R, REc;;;
9.580;11;12;09;9q34.3;EGFL7;;Epidermal growth factor-like 7;608582;A, R;;;2(Egfl7)
9.581;11;15;17;9q34.3;EHMT1, EUHMTASE1, KMT1D, DEL9q34, KLEFS1;;Euchromatic histone methyltransferase 1;607001;REc, Ch;;Kleefstra syndrome 1, 610253 (3);
9.582;4;2;12;9q34.3;FAM69B;;Family with sequence similarity 69, member B;614543;REc;;;
9.583;6;13;12;9q34.3;FBXW5, FBW5;;F-box and WD40 domain protein 5;609072;REc;;;2(Fbxw5)
9.584;1;16;18;9q34.3;GRIN1, NMDAR1, NDHMSR, NDHMSD;;Glutamate receptor, ionotropic, N-methyl D-aspartate 1;138249;REb, A, Fd;;Neurodevelopmental disorder with or without hyperkinetic movements and seizures, autosomal recessive, 617820 (3); Neurodevelopmental disorder with or without hyperkinetic movements and seizures, autosomal dominant, 614254 (3);
9.585;1;20;11;9q34.3;GLT6D1, GT6M7, GLTDC1;;Glycosyltransferase 6 domain-containing 1;613699;REc;;;
9.586;8;15;14;9q34.3;INPP5E, MORMS, JBTS1, CORS1;;Inositol polyphosphate-5-phosphatase, 72kD;613037;REc;;Mental retardation, truncal obesity, retinal dystrophy, and micropenis, 610156 (3); Joubert syndrome 1, 213300 (3);
9.587;1;9;13;9q34.3;KCNT1, KIAA1422, EIEE14, ENFL5;;Potassium channel, subfamily T, member 1;608167;R, REc;;Epileptic encephalopathy, early infantile, 14, 614959 (3); Epilepsy, nocturnal frontal lobe, 5, 615005 (3);
9.588;10;2;09;9q34.3;LHX3, CPHD3;;LIM/homeodomain protein LHX3;600577;H, A, REa;in mouse, close to Notch1; centromeric to ABL;Pituitary hormone deficiency, combined, 3, 221750 (3);2(Lhx3)
9.589;12;15;10;9q34.3;LRRC26, CAPC;;Leucine-rich repeat-containing protein 26;613505;REc;;;
9.590;9;1;11;9q34.3;MAN1B1, MRT15;;Mannosidase, alpha, class 1B member 1;604346;REc;;Mental retardation, autosomal recessive 15, 614202 (3);
9.591;3;23;09;9q34.3;MIR126, MIRN126;;Micro RNA 126;611767;REc;;;
9.592;3;5;08;9q34.3;MRPL41, MRPL27;;Mitochondrial ribosomal protein L41;611846;R, REc;;;
9.593;11;23;16;9q34.3;MAMDC4;;MAM domain-containing protein 4;617208;REc;;;
9.594;6;22;14;9q34.3;NACC2, RBB;;NACC family, member 2, BEN and BTB/POZ domains-containing;615786;REc;;;
9.595;3;14;13;9q34.3;NSMF, NELF, HH9;;NMDA receptor synaptonuclear signaling and neuronal migration factor;608137;R, REc;;Hypogonadotropic hypogonadism 9 with or without anosmia, 614838 (3);
9.596;9;30;14;9q34.3;NOTCH1, TAN1, AOS5, AOVD1;;Notch, Drosophila, homolog of, 1, translocation-associated;190198;Ch, H, A;;Aortic valve disease 1, 109730 (3); Adams-Oliver syndrome 5, 616028 (3);2(Notch1)
9.597;5;26;13;9q34.3;NOXA1;;NADPH oxidase activator 1;611255;REc;;;2(Noxa1)
9.598;7;17;01;9q34.3;NR1;;NADPH-dependent FMN- and FAD-containing oxidoreductase;606073;A;;;
9.599;4;14;15;9q34.3;PAXX, C9orf142;;Paralog of XRCC4 and XLF;616315;REc;;;
9.600;7;3;06;9q34.3;PHPT1;;Phosphohistidine phosphatase 1;610167;REc;;;
9.601;2;5;16;9q34.3;PMPCA, KIAA0123, SCAR2;;Peptidase, mitochondrial processing, alpha;613036;REc;;Spinocerebellar ataxia, autosomal recessive 2, 213200 (3);
9.602;8;27;08;9q34.3;PNPLA7;;Patatin-like phospholipase domain containing 7;612122;REc;;;
9.603;6;1;12;9q34.3;PPP1R26, KIAA0649;;Protein phosphatase 1, regulatory subunit 26;614056;REc, R;;;
9.604;8;23;00;9q34.11;PTGES, PGES, PIG12, MGST1L1;;Prostaglandin E synthase;605172;A;;;
9.605;7;13;09;9q34.3;QSOX2, SOXN;;Quiescin Q6 sulfhydryl oxidase 2;612860;A;;;
9.606;8;3;17;9q34.3;RABL6, PARF, C9orf86;;RAB-like protein 6;610615;R, REc;;;
9.607;3;14;07;9q34.13;RAPGEF1, GRF2, C3G;;RAP guanine nucleotide exchange factor 1;600303;A;;;
9.608;5;19;94;9q34.2;RXRA;;Retinoid X receptor, alpha;180245;Psh, A;distal to DBH;;2(Rxra)
9.609;08;10;18;9q34.3;SAPCD2, C9orf140, P42.3;;Suppressor APC domain-containing protein 2;612057;REc, H;;;2(P42.3)
9.610;7;13;09;9q34.3;SEC16A, SEC16L, KIAA0310, p250;;Sec16, S. Cerevisiae, homolog of, A;612854;R, REc;;;
9.611;10;2;12;9q34.3;SNAPC4, SNAP190;;Small nuclear RNA-activating protein complex, polypeptide 4;602777;REc;;;
9.612;09;12;18;9q34.3;SOHLH1, NOHLH, TEB2, ODG5, SPGF32;;Spermatogenesis- and oogenesis-specific basic helix-loop-helix protein 1;610224;REc;;Ovarian dysgenesis 5, 617690 (3); Spermatogenic failure 32, 618115 (3);
9.613;4;17;07;9q34.3;SSNA1, NA14;;Sjogren syndrome nuclear autoantigen 1;610882;REc;;;
9.614;9;12;15;9q34.3;TMEM203;;Transmembrane protein 203;616499;REc;;;
9.615;4;20;10;9q34.3;TPRN, C9orf75, DFNB79;;Taperin;613354;REc, H, Fd;;Deafness, autosomal recessive 79, 613307 (3);2(Tprn)
9.616;8;19;14;9q34.3;TRAF2, TRAP;;TNF receptor-associated factor 2;601895;REc;;;
9.617;2;16;18;9q34.3;TUBB4B, TUBB2C, LCAEOD;;Tubulin, beta-4B;602660;REc;;Leber congenital amaurosis with early-onset deafness, 617879 (3);
9.618;4;1;09;9q34.3;UBAC1, GBDR1;;Ubiquitin-associated domain-containing protein 1;608129;Psh, REc;;;
9.619;2;18;10;9q34.3;WDR85;;WD repeat-containing protein 85;613210;REc;;;
9.620;9;18;08;9q34.3;ZMYND19, MIZIP;;Zinc finger MYND domain-containing protein 19;611424;REc, H;;;2(Zmynd19)
9.621;5;16;02;9q34.3;ANAPC2, APC2, KIAA1406;;Anaphase-promoting complex, subunit 2;606946;R;;;
9.622;1;24;01;9q31.1;CAPE;;Chromosome-associated protein E;605576;R;;;
9.623;12;27;01;9q34.3;CLIC3;;Chloride intracellular channel 3;606533;R;;;
9.624;7;15;02;9q22.32;FBP2;;Fructose-1,6-bisphosphatase 2;603027;R;;;
9.625;3;5;98;9q34.3;FUT7;;Fucosyltransferase 7 (alpha (1,3) fucosyltransferase);602030;REa;;;
9.626;10;23;87;Chr.9;H142T;;Temperature sensitivity complementation, H142;187290;S;;;
9.627;6;13;02;9p13.2;MELK, KIAA0175;;Maternal embryonic leucine zipper kinase;607025;REa;;;4(Melk)
9.628;8;27;01;9q34.3;NPDC1, CAB1;;Neural proliferation, differentiation, and control protein 1;605798;R;;;
9.629;12;14;01;9q34.3;OLFM1, AMY;;Olfactomedin 1;605366;R;;;
9.630;5;4;00;9q33.2;PDCL;;Phosducin-like;604421;REa, R;;;
9.631;2;21;03;9q32;ROD1;;Regulator of differentiation 1;607527;R;;;
9.632;11;15;00;9q33.3;SLC2A8, GLUT8;;Solute carrier family 2, (facilitated glucose transporter) member 8;605245;R;;;
9.633;4;26;01;9p13.3;UNC13, MUNC13;;UNC13, C. elegans, homolog of;605836;R;;;
10.1;3;6;94;10p15.1;CALML3;;Calmodulin-like 3;114184;REa, Psh, A;;;
10.2;10;15;97;10p13;PHYH, PAHX;;Phytanoyl-CoA hydroxylase;602026;LD, R;;Refsum disease, 266500 (3);
10.3;3;6;00;10pter-q11;ST12, PAC1;;Suppression of tumorigenicity 12, prostate;601188;M;;Prostate adenocarcinoma (2);
10.4;8;29;07;10p15.3;DIP2C, KIAA0934;;Disco-interacting protein 2, Drosophila, homolog of, C;611380;R, REc;;;
10.5;8;26;15;10p15.3;LARP4B, LARP5, KIAA0217;;La ribonucleoprotein domain family, member 4B;616513;R, REc;;;
10.6;2;2;16;10p15.3;TUBB8, OOMD2;;Tubulin, beta 8;616768;REc;;Oocyte maturation defect 2, 616780 (3);
10.7;2;9;92;10p15.2;PFKP;;Phosphofructokinase, platelet type;171840;S, A, D;;;
10.8;12;11;18;10p15.2;PITRM1, MP1, PREP;;Pitrilysin metallopeptidase 1;618211;REc;;;
10.9;6;20;18;10p15.1;ANKRD16;;Ankyrin repeat domain-containing protein 16;618017;REc;;;
10.10;1;31;13;10p15.1;ASB13;;Ankyrin repeat- and SOCS box-containing protein 13;615055;REc;;;
10.11;4;25;17;10p15.1;AKR1E2, HTSP, TAKR;;Aldo-keto reductase family 1, member E2;617451;REc;;;
10.12;8;26;09;10p14;ATP5C1, ATP5CL1, ATP5C;;ATP synthase, H+ transporting, mitochondrial F1 complex, gamma polypeptide-1;108729;REa, REc;;;
10.13;9;9;08;10p15.1;FBXO18, FBH1, FBX18;;F-box only protein 18;607222;REc;;;2(Fbxo18)
10.14;7;20;15;10p15.1;IL2RA, CD25, IL2R, IDDM10, IMD41;;Interleukin-2 receptor, alpha;147730;REa, A, Fd, LD;;Immunodeficiency 41 with lymphoproliferation and autoimmunity, 606367 (3); {Diabetes, mellitus, insulin-dependent, susceptibility to, 10}, 601942 (3);2(Il2ra)
10.15;2;23;09;10p15.1;MS2;;Multiple sclerosis, susceptibility to, 2;612594;Fd;associated with rs12722489 and rs2104286;{Multiple sclerosis, susceptibility to, 2} (2);
10.16;7;2;18;10p15.1;NET1;;Neuroepithelial cell transforming gene 1;606450;REc;;;
10.17;9;17;07;10p15.1;RBM17, SPF45;;RNA binding motif protein 17;606935;REc;;;
10.18;7;9;09;10p13;TRDMT1, DMNT2;;tRNA aspartic acid methyltransferase 1 (DNA methyltransferase 2);602478;R, A;;;
10.19;3;6;98;10p15.3;ADARB2, RED2;;Adenosine deaminase, RNA-specific, B2 (homolog of rat BLUE);602065;REa;;;
10.20;8;3;11;10p14;GATA3, HDR, HDRS;;GATA-binding protein-3;131320;A, Ch;;Hypoparathyroidism, sensorineural deafness, and renal dysplasia, 146255 (3);2(Gata3)
10.21;1;13;99;10p15.1;GDI2, RABGDIB;;GDP dissociation inhibitor 2;600767;A;pseudogene on chr.7;;
10.22;9;9;13;10p15.3;IDI1;;Isopentenyl-diphosphate delta isomerase 1;604055;REc;;;13(Idi1)
10.23;9;9;13;10p15.3;IDI2, IPPI2;;Isopentenyl-diphosphate delta isomerase 2;615389;REc;;;13(Idi2)
10.24;9;9;13;10p15.3;IDI2AS1;;IDI2 antisense RNA 1, noncoding;615391;REc;;;
10.25;10;6;92;10p14;ITIH2;;Inter-alpha (globulin) inhibitor, H2 polypeptide;146640;A, H;;;2(Intin2)
10.26;12;20;05;10p14;ITIH5;;Inter-alpha-trypsin inhibitor, heavy chain 5;609783;REc;;;
10.27;10;7;05;10p15.2;KLF6, COPEB, BCD1, ZF9;;Kruppel-like factor-6;602053;REa, A;;Prostate cancer, somatic, 176807 (3); Gastric cancer, somatic, 613659 (3);
10.28;8;2;13;10p15;PFFE1;;Plasmodium falciparum fever episodes QTL1;611384;Fd;;{Plasmodium falciparum fever episodes QTL1} (2);
10.29;9;27;95;10p15.1;PRKCQ;;Protein kinase C, theta;600448;A;;;2(Pkcq)
10.30;8;18;99;10p15.1;AKR1C1, DDH1, DD1, HAKRC;;Aldo-keto reductase family 1, member 1 (dihydrodiol dehydrogenase, type 1);600449;Psh, A;;;
10.31;4;24;18;10p15.1;AKR1C2, DDH2, DD2, HAKRD, SRXY8;;Aldo-keto reductase family 1, member C2 (dihydrodiol dehydrogenase, type II);600450;Psh, A;;46XY sex reversal 8, 614279 (3);
10.32;8;18;99;10p15.1;AKR1C3, HAKRB, DD3;;Aldo-keto reductase family 1, member C3;603966;REa, A;;;
10.33;10;10;11;10p15.1;AKR1C4, CHDR, CDR, HAKRA, DD4;;Aldo-keto reductase family 1, member C4 (chlordecone reductase);600451;REa, A;;{46XY sex reversal 8, modifier of}, 614279 (3);
10.34;2;15;96;10p15.1;IL15RA;;Interleukin-15 receptor, alpha;601070;A;;;2(Il15ra)
10.35;2;26;01;10p14;KIN, KIN17, BTCD;;Antigenic determinant of recombination protein A, mouse, homolog of;601720;A;;;2(kin17)
10.36;7;26;10;10p13;OPTN, GLC1E, FIP2, HYPL, NRP, ALS12;;Optineurin;602432;Fd;;Glaucoma 1, open angle, E, 137760 (3); {Glaucoma, normal tension, susceptibility to}, 606657 (3); Amyotrophic lateral sclerosis 12, 613435 (3);
10.37;1;31;01;10p15.1;PFKFB3, IPFK2;;6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3;605319;A;;;
10.38;3;11;03;10p14;UPF2, RENT2;;UPF2 regulator of nonsense transcripts, yeast, homolog of;605529;R;;;
10.39;8;20;08;10p14;CRCS5;;Colorectal cancer, susceptibility to, 5;612230;Fd;associated with rs10795668;{Colorectal cancer, susceptibility to, 5} (2);
10.40;11;21;14;10p14;DHTKD1, KIAA1630, AMOXAD, CMT2Q;;Dehydrogenase E1 and transketolase domains-containing protein 1;614984;Psh, REc;mutation identified in 1 CMT2Q family;2-aminoadipic 2-oxoadipic aciduria, 204750 (3); ?Charcot-Marie-Tooth disease, axonal, type 2Q, 615025 (3);
10.41;01;03;19;10p14;SEC61A2;;Sec61 translocon, alpha-2 subunit;618271;REc;;;
10.42;10;11;12;10p14;TAF3, TAFII140;;TAF3 RNA polymerase II, TATA box-binding protein-associated factor, 140kD;606576;REc;;;
10.43;1;20;17;10p12.1;YME1L1, YME1L, PAMP, OPA11;;Mitochondrial escape 1-like 1;607472;REc;mutation identified in1 OPA11 family;?Optic atrophy 11, 617302 (3);
10.44;9;9;13;10p14;SFMBT2, KIAA1617;;SCM-like protein with 4 MBT domains 2;615392;REc;;;2(Sfmbt2)
10.45;11;6;14;10p15.3;ZMYND11, BS69, BRAM1, MRD30;;Zinc finger MYND domain-containing protein 11;608668;A;;Mental retardation, autosomal dominant 30, 616083 (3);
10.46;10;1;17;10p14-p13;CDC123;;Cell division cycle 123;617708;REc;;;
10.47;9;2;96;10p14-p13;DGCR2, DGS2;;DiGeorge syndrome chromosome region-2;601362;Ch;;DiGeorge syndrome/velocardiofacial syndrome complex-2 (2);
10.48;3;2;98;10p12.33;STAM;;Signal transducing adaptor molecule;601899;A;;;2(Stam)
10.49;1;6;00;10p14-p12;ARVD6;;Arrhythmogenic right ventricular dysplasia 6;604401;Fd;;Arrhythmogenic right ventricular dysplasia 6 (2);
10.50;12;15;05;10p13;AD7;;Alzheimer disease 7;606187;Fd;max LOD at D10S1423;Alzheimer disease-7 (2);
10.51;5;26;13;10p13;ARMETL1, CDNF;;Arginine-rich protein mutated in early stage tumors-like 1;611233;REc;;;
10.52;11;4;93;10p12.2;BMI1;;Oncogene BMI-1;164831;A;;;
10.53;5;13;13;10p13;C1QL3, CTRP13, K100;;Complement component 1, q subcomponent-like 3;615227;REc, H;;;1(C1ql3)
10.54;2;25;15;10p13;CAMK1D, CKLIK;;Calcium/calmodulin-dependent protein kinase I-delta;607957;REc;;;
10.55;8;2;13;10p14;CELF2, CUGBP2, ETR3, BRUNOL3;;CUGbp- and ELAV-like family, member 2;602538;REc;;;
10.56;2;17;16;10p13;FRMD4A, KIAA1294, CCAFCA;;FERM domain-containing protein 4A;616305;R, REc;mutation identified in 1 CCAFCA family;?Corpus callosum, agenesis of, with facial anomalies and cerebellar ataxia, 616819 (3);
10.57;4;10;14;10p13;ITGA8, RHDA1;;Integrin, alpha-8;604063;REc;;Renal hypodysplasia/aplasia 1, 191830 (3);
10.58;2;16;06;10p13;LPRS;;Leprosy, paucibacillary type, susceptibility to;609888;Fd;;{Leprosy, paucibacillary type, susceptibility to} (2);
10.59;5;16;05;10p13;MCM10, CNA43;;Minichromosome maintenance 10, S. cerevisiae, homolog of;609357;R, REc;;;
10.60;9;6;11;10p13;MEIG1;;Meiosis-expressed gene 1, mouse, homolog of;614174;REc;;;
10.61;8;3;17;10p13;MINDY3, C10orf97, CARP;;MINDY lysine-48 deubiquitinase 3;611649;REc;;;
10.62;10;14;94;10p12.33;MRC1, MMR;;Mannose receptor, C type 1;153618;Psh, A;;;2(Mrc1)
10.63;9;17;08;10p13;NMT2;;N-myristoyltransferase 2;603801;REc;;;
10.64;8;26;09;10p13;PRPF18, PRP18;;Prp18, S. cerevisiae, homolog of;604993;R, REc;;;
10.65;8;26;09;10p13;RPP38;;Ribonuclease P, 38-kD subunit;606116;R, REc;;;
10.66;8;26;09;10p13;RSU1;;Ras suppressor protein 1;179555;REa, REc;;;
10.67;3;24;11;10p13;SEPHS1, SPS1;;Selenophosphate synthetase 1;600902;REc;;;
10.68;8;26;09;10p13;SUV39H2, FLJ23414;;Suppressor of variegation 3-9, Drosophila, homolog of, 2;606503;R, REc;;;2(Suv39h2)
10.69;8;25;04;10p14;USP6NL, RNTRE;;USP6 N-terminal-like;605405;Ch;;;
10.70;5;10;17;10p13;VIM, CTRCT30;;Vimentin;193060;REa;;Cataract 30, pulverulent, 116300 (3);2(Vim)
10.71;1;12;09;10p12.31;NEBL;;Nebulette;605491;R, A;;;
10.72;6;4;10;10p11.22;ARHGAP12;;Rho GTPase-activating protein 12;610577;REc;;;
10.73;1;8;16;10p12.33;HACD1, PTPLA;;3-hydroxyacyl-CoA dehydratase 1;610467;REc;;;
10.74;1;23;13;10p12.31;ARL5B, ARL8;;ADP-ribosylation factor-like 5B;608909;REc;;;
10.75;10;11;17;10p12.31;MALRD1, C10orf112, DIET1;;MAM and LDL receptor class A domain-containing protein 1;617715;REc, H;;;2(Malrd1)
10.76;8;19;13;10p12.31;DNAJC1, HTJ1;;DNAJ/HSP40 homolog, subfamily C, member 1;611207;REc, R;;;
10.77;5;6;13;10p12.31;MIR1915;;Micro RNA 1915;615202;REc;;;
10.78;11;23;16;10p12.31;NSUN6;;NOP2/SUN RNA methyltransferase family, member 6;617199;REc;;;
10.79;4;6;15;10p12.33;ST8SIA6, SIAT8F;;ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 6;610139;REc;;;
10.80;3;22;06;10p12.1;ARHGAP21, KIAA1424;;GTPase-activating protein, Rho, 21;609870;REc;pseudogene on chr.6;;
10.81;3;3;10;10p12.31;EBLN1;;Endogenous Borna-like N element-containing protein 1;613249;REc;;;
10.82;9;9;08;10p13;HSPA14, HSP70L1;;Heat-shock 70kD protein 14;610369;REc;;;
10.83;11;30;06;10p12.31;PLXDC2, TEM7R;;Plexin domain containing 2;606827;R;;;
10.84;7;19;06;10p12.1;BAMBI, NMA;;BMP and activin membrane-bound inhibitor, xenopus, homolog of;604444;Psh, A;;;
10.85;8;18;14;10p12.2;PTF1A, PACA, PAGEN2;;Pancreas transcription factor 1, alpha subunit;607194;REc, Fd;;Pancreatic and cerebellar agenesis, 609069 (3); Pancreatic agenesis 2, 615935 (3);
10.86;5;26;13;10p12.2;ARMC3;;Armadillo repeat-containing protein 3;611226;REc;;;
10.87;12;22;15;10p12.2;COMMD3;;COMM domain-containing protein 3;616700;REc;;;
10.88;2;24;17;10p12.2-p12.1;KIAA1217, SKT;;KIAA1217 gene;617367;REc;;;
10.89;6;5;08;10p12.2;OTUD1, DUBA7;;OTU domain-containing protein 1;612022;REc;;;
10.90;7;22;16;10p12.2;PIP4K2A, PI5P4KA, PIP5K2A;;Phosphatidylinositol 5-phosphate 4-kinase, type II, alpha;603140;R, REc;;;
10.91;10;28;15;10p12.1;ACBD5, KIAA1996;;Acyl-CoA-binding domain-containing protein 5;616618;REc;;;
10.92;2;24;11;10p12.1;ANKRD26, KIAA1074, THC2;;Ankyrin repeat domain-containing protein 26;610855;REc;;Thrombocytopenia 2, 188000 (3);6(Ankrd26)
10.93;10;15;13;10p12.1;ARMC4, CILD23;;Armadillo repeat-containing protein 4;615408;REc;;Ciliary dyskinesia, primary, 23, 615451 (3);
10.94;2;21;03;10p13;CUBN, IFCR, MGA1;;Cubilin (intrinsic factor-cobalamin receptor);602997;A, R, REc;;Megaloblastic anemia-1, Finnish type, 261100 (3);
10.95;7;14;14;10p12.1;ENKUR, C10orf63;;Enkurin, TRPC channel-interacting protein;611025;REc;;;2(4933434I06Rik)
10.96;4;19;12;10p12.1;GPR158, KIAA1136;;G protein-coupled receptor 158;614573;REc;;;2(Gpr158)
10.97;11;1;16;10p12.1;MASTL, FLJ14813, GWL;;Microtubule-associated serine/threonine kinase-like;608221;Fd, REc;;;
10.98;4;1;09;10p12.1;MKX, IFRX, IRXL1;;Mohawk homeobox;601332;Psh, Fd;;;18(Mkx)
10.99;5;21;07;10p12.1;MPP7;;Membrane protein, palmitoylated 7;610973;REc;;;
10.100;5;24;12;10p12.1;PDSS1, TPT, COQ1, COQ10D2;;Prenyl diphosphate synthase, subunit 1;607429;R, REc;;Coenzyme Q10 deficiency, primary, 2, 614651 (3);
10.101;2;12;07;10p12.1;PRTFDC1;;Phosphoribosyl transferase domain-containing protein 1;610751;R, REc;;;
10.102;2;14;08;10p12.1;PTCHD3;;Patched domain-containing protein 3;611791;REc;;;
10.103;9;17;11;10p12.1;RAB18, WARBM3;;Ras-associated protein RAB18;602207;H, REc;;Warburg micro syndrome 3, 614222 (3);18(Rab18)
10.104;5;26;13;10p12.1;THNSL1, TSH1;;Threonine synthase-like 1;611260;REc;;;
10.105;3;6;94;10p11.21;CREM;;cAMP-responsive element modulator;123812;A;;;18(Crem)
10.106;1;13;16;10p12.1;WAC, KIAA1844, DESSH;;WW domain-containing adaptor with coiled-coil region;615049;REc;;Desanto-Shinawi syndrome, 616708 (3);
10.107;8;28;15;10p12.31;AF10;;ALL1 fused gene from chromosome 10;602409;A, Ch;fuses with MLL and HEAB;Leukemia, acute myeloid, 601626 (3);
10.108;3;5;08;10p12.33-p12.31;CACNB2;;Calcium channel, voltage-dependent, beta 2 subunit;600003;A, REc;;Brugada syndrome 4, 611876 (3);
10.109;3;24;11;10p12.2;MSRB2, CBS1;;Methionine sulfoxide reductase B2;613782;R;;;
10.110;5;25;00;10p11.22;NRP1, NRP, VEGF165R;;Neuropilin 1;602069;REa, R;;;
10.111;5;4;00;10p13;PTER;;Phosphotriesterase-related protein;604446;A;;;
10.112;3;19;01;10p12.2;SPAG6;;Sperm-associated antigen 6;605730;A;;;
10.113;3;9;95;10p12.1;GAD2;;Glutamate decarboxylase-2, pancreas;138275;A;;;2(Gad2)
10.114;5;12;09;10p11.23;LYZL2;;Lysozyme-like 2;612748;REc;;;
10.115;10;27;16;10p11.23;MTPAP, PAPD1, SPAX4;;Mitochondrial poly(A) polymerase;613669;REc;mutation identified in 1 SPAX4 family;?Spastic ataxia 4, autosomal recessive, 613672 (3);
10.116;5;5;09;10p11.23-q21.1;DFNB33;;Deafness, autosomal recessive 33;607239;Fd;prev. assignment to chr. 9 an error;Deafness, autosomal recessive 33 (2);
10.117;4;15;08;10p11.22;EIG5;;Epilepsy, idiopathic generalized, susceptibility to, 5;611934;Fd;max lod at D10S1426;{Epilepsy, idiopathic generalized, susceptibility to, 5} (2);
10.118;9;23;13;10p11.22;KIF5B, KNS1, UKHC;;Kinesin 1;602809;REc;;;18(Ukhc)
10.119;4;21;16;10p11.22;ZEB1AS1;;ZEB1 antisense RNA 1, noncoding;616915;REc;;;
10.120;3;20;07;10p11.21;ANKRD30A;;Ankyrin repeat domain-containing protein 30A;610856;REc;;;
10.121;4;1;08;10p11.21;GJD4, CX40.1;;Gap junction protein, delta-4;611922;REc;;;
10.122;8;26;09;10p11.22-p11.21;PARD3, PAR3;;Partitioning-defective protein 3, C. elegans, homolog of;606745;R, REc;;;
10.123;1;9;13;10p11.21-q21.1;USH1K;;Usher syndrome, type IK;614990;Fd;max lod at D10S539;Usher syndrome, type IK (2);
10.124;10;7;98;10p12.1;ABI1;;ABL-interactor 1;603050;Ch;;;
10.125;5;19;09;10p11.21;CCNY, CFP1, CCNX, C10orf9;;Cyclin Y;612786;REc;;;
10.126;8;28;01;10p11.21;FZD8;;Frizzled, Drosophila, homolog of, 8;606146;A;;;18(Fzd8)
10.127;3;13;92;10p11.22;ITGB1, FNRB;;Integrin, beta-1 (fibronectin receptor, beta polypeptide; antigen CD29 includes MDF2, MSK12);135630;REb, REa, F, A, S;pseudogene FNRBL on 19p;;
10.128;10;4;05;10p11.23;MAP3K8, COT, EST, TPL2;;Mitogen-activated protein kinase kinase kinase 8 (cancer Osaka thyroid oncogene);191195;Psh, A, H;;Lung cancer, somatic, 211980 (3);18(Tpl2)
10.129;8;17;99;10p11.23;SVIL;;Supervillin;604126;A;;;
10.130;2;25;10;10p11.22;ZEB1, TCF8, NIL2A, PPCD3, FECD6;;Zinc finger E box-binding homeobox 1;189909;REa, A, Fd;;Corneal dystrophy, posterior polymorphous, 3, 609141 (3); Corneal dystrophy, Fuchs endothelial, 6, 613270 (3);
10.131;5;12;09;10p11.21;CUL2;;Cullin 2;603135;A;;;
10.132;8;20;92;10p11.21;ZNF25, KOX19;;Zinc finger protein-25 (KOX 19);194528;REa, A;;;
10.133;8;27;15;10p12.1;MYO3A, DFNB30;;Myosin IIIA;606808;REa, R, Fd;;Deafness, autosomal recessive 30, 607101 (3);
10.134;11;11;14;10p11.1;ZNF37A, KOX21, ZNF37;;Zinc finger protein 37A;616085;REc;;;
10.135;8;20;07;10p11.22;EPC1;;Enhancer of polycomb, Drosophila, homolog of, 1;610999;R;;;
10.136;12;19;11;10p11.23;KIAA1462, JCAD;;KIAA1462 gene;614398;REc;;;
10.137;2;21;03;10p;BULN;;Bulimia nervosa, susceptibility to;607499;Fd;between D10S1430 and D10S1423;{Bulimia nervosa, susceptibility to} (2);
10.138;9;14;05;10p13;DCLRE1C, ARTEMIS, SCIDA;;DNA cross-link repair protein 1C;605988;Fd, REc;;Severe combined immunodeficiency, Athabascan type, 602450 (3); Omenn syndrome, 603554 (3);
10.139;10;8;08;10p;BMIQ8;;Body mass index quantitative trait locus 8;603188;Fd;;{Obesity, susceptibility to, BMIQ8} (2);
10.140;10;30;03;10q;AITD4;;Autoimmune thyroid disease, susceptibility to, 4;608176;Fd;;{Autoimmune thyroid disease, susceptibility to, 4} (2);
10.141;1;12;99;10q26.11;TIAL1, TIAR, TCBP;;Tia1 cytotoxic granule-associated RNA-binding protein-like 1;603413;REc, R;;;
10.142;5;26;13;10q11.22-q11.23;ARHGAP22;;Rho GTPase-activating protein 22;610585;REc;;;
10.143;5;19;16;10q11.23;ERCC6, CKN2, COFS1, CSB, ARMD5, UVSS1, POF11;;Excision repair cross complementing rodent repair deficiency, complementation group 6;609413;A, M;;Cockayne syndrome, type B, 133540 (3); Cerebrooculofacioskeletal syndrome 1, 214150 (3); De Sanctis-Cacchione syndrome, 278800 (3); {Macular degeneration, age-related, susceptibility to, 5}, 613761 (3); UV-sensitive syndrome 1, 600630 (3); {Lung cancer, susceptibility to}, 211980 (3); Premature ovarian failure 11, 616946 (3);
10.144;8;18;98;10q22.1;TACR2, TAC2R, NKNAR;;Tachykinin receptor 2 (substance K receptor; neurokinin 2 receptor);162321;REa, A;;;
10.145;10;24;11;10q22.2;ADK;;Adenosine kinase;102750;S, D, EM;;Hypermethioninemia due to adenosine kinase deficiency, 614300 (3);14(Adk)
10.146;8;30;02;10q11.21;CXCL12, SDF1;;Chemokine, C-X-C motif, ligand 12 (stromal cell-derived factor 1);600835;A;;{AIDS, resistance to}, 609423 (3);
10.147;9;16;03;10q11.22;SYT15;;Synaptotagmin 15;608081;REc;;;14(Syt15)
10.148;5;27;05;10q11.21;ALOX5;;Arachidonate 5-lipoxygenase;152390;Psh;;{Atherosclerosis, susceptibility to} (3); {Asthma, diminished response to antileukotriene treatment in}, 600807 (3);
10.149;3;6;98;10q11.22;ANXA8;;Annexin A8;602396;A;;;14(Anx8)
10.150;4;30;15;10q11.23;CHAT, CMS6;;Choline acetyltransferase;118490;REa, A;;Myasthenic syndrome, congenital, 6, presynaptic, 254210 (3);
10.151;1;29;01;10q21.1;DKK1;;Dickkopf, Xenopus, homolog of, 1;605189;A;;;
10.152;3;23;06;10q11.22;MAPK8, PRKM8, JNK1, SAPK1;;Mitogen-activated protein kinase 8;601158;R, REc;;;
10.153;4;23;08;10q11.22;MSMB, HPC13;;Microseminoprotein, beta;157145;REa, A;;{Prostate cancer, hereditary, 13}, 611928 (3);
10.154;8;14;15;10q11.22;NCOA4, ELE1, PTC3;;Nuclear receptor coactivator 4;601984;REn;fused with RET to form PTC3;;
10.155;8;10;13;10q11.22;PTPN20A;;Protein tyrosine phosphatase, nonreceptor-type, 20A;610630;Psh, A;;;
10.156;8;19;13;10q11.22;PTPN20B;;Protein tyrosine phosphatase, nonreceptor-type, 20B;610631;Psh, A;;;
10.157;9;29;13;10q11.2-q21.1;PRKG1, PRKG1B, PRKGR1B, AAT8;;Protein kinase, cGMP-dependent, regulatory, type I;176894;REa, A;;Aortic aneurysm, familial thoracic 8, 615436 (3);
10.158;6;4;13;10q11.22;RBP3, RP66;;Retinol-binding protein-3, interstitial;180290;REa, A, Fd;1 family identified with mutation;?Retinitis pigmentosa 66, 615233 (3);14(Rbp3)
10.159;4;24;17;10q11.21;RET, MEN2A, HSCR1;;RET transforming sequence; oncogene RET;164761;A, REn, Fd, Ch, D;;Multiple endocrine neoplasia IIA, 171400 (3); Medullary thyroid carcinoma, 155240 (3); Multiple endocrine neoplasia IIB, 162300 (3); Central hypoventilation syndrome, congenital, 209880 (3); Pheochromocytoma, 171300 (3); {Hirschsprung disease, susceptibility to, 1}, 142623 (3); {Hirschsprung disease, protection against}, 142623 (3);
10.160;12;7;07;10q11.23;SGMS1, SMS1, TMEM23, MOB;;Sphingomyelin synthase 1;611573;REc;;;
10.161;12;6;16;10q11.23;SLC18A3, VACHT, CMS21;;Solute carrier family 18 (vesicular acetylcholine), member 3;600336;REn;;Myasthenic syndrome, congenital, 21, presynaptic, 617239 (3);
10.162;8;28;92;10q11.21;ZNF22, KOX15;;Zinc finger protein-22 (KOX15);194529;A, REa;;;
10.163;3;12;07;10p11.1;ZNF33A, NF11A, KOX2;;Zinc finger protein-33a;194521;REa, A;;;
10.164;3;12;07;10q11.21;ZNF33B, ZNF11B, KOX2;;Zinc finger protein-33b;194522;REa, A;;;
10.165;8;26;09;10q11.21;ZNF239, MOK2;;Zinc finger protein-239;601069;R, REc;previously 19q13.2-q13.3;;6(Mok2)
10.166;12;21;12;10q21.1;MBL2, MBL, MBP1, MBL2D, MBPD;;Mannose-binding lectin 2, soluble (opsonic defect);154545;REa, A, Fd;near MEN2A;{Chronic infections, due to MBL deficiency}, 614372 (3);14(Mbl1)
10.167;1;30;09;10q11.2-q21;STHAG5;;Tooth agenesis, selective, 5;610926;Fd;D10S604 and D10S568;Tooth agenesis, selective, 5 (2);
10.168;12;5;07;10q21.1;UBE2D1, UBCH5A, UBCH5;;Ubiquitin-conjugating enzyme E2D 1;602961;Psh, R;;;
10.169;2;18;98;10q11.22;PPYR1, NPY4R, PP1;;Pancreatic polypeptide receptor-1;601790;REa, REc;;;14(Ppyr1)
10.170;11;21;18;10q11.23;A1CF, ASP;;APOBEC1 complementation factor;618199;REc;;;
10.171;8;5;14;10q11.21;BMS1, BMS1L, KIAA0187, ACC;;Bms1, ribosome assembly protein, S. cerevisiae, homolog of;611448;REc;mutation identified in one ACC family;?Aplasia cutis congenita, nonsyndromic, 107600 (3);
10.172;4;6;15;10q11.21;C10orf10, DEPP, FIG;;Chromosome 10 open reading frame 10;611309;REc;;;
10.173;4;27;16;10q11.21;FXYD4, CHIF;;FXYD domain-containing ion transport regulator 4;616926;REc;;;
10.174;6;7;10;10q11.21-q11.22;MARCH8;;Membrane-associated RING-CH finger protein 8;613335;REc;;;
10.175;3;30;12;10q11.21;RASFEF1A;;RASGEF domain family, member 1A;614531;REc;;;
10.176;5;26;13;10q11.21;RASSF4, AD037;;Ras association domain family, member 4;610559;REc;;;
10.177;3;25;96;10q11.21;HNRPF;;Heterogeneous nuclear ribonucleoprotein F;601037;A;;;
10.178;1;29;01;10q11.22;TIMM23;;Translocase of inner mitochondrial membrane 23, Yeast, homolog of;605034;A;;;
10.179;10;28;15;10q11.21;CSGALNACT2;;Chondroitin sulfate N-acetylgalactosaminyltransferase 2;616616;REc;;;
10.180;3;29;10;10q11.22;FRMPD2;;FERM and PDZ domains-containing protein 2;613323;REc;;;
10.181;11;11;13;10q11.22;GDF2, BMP9, HHT5;;Growth differentiation factor 2 (bone morphogenetic protein 9);605120;REc;;Telangiectasia, hereditary hemorrhagic, type 5, 615506 (3);
10.182;9;26;17;10q11.22;GDF10, BMP3B;;Growth/differentiation factor 10;601361;REc, Psh;;;
10.183;5;26;13;10q11.22;GPRIN2, GRIN2;;G protein-regulated inducer of neurite outgrowth 2;611240;REc;;;
10.184;4;20;17;10q11.22;WASHC2C, FAM21C, VPEF, KIAA0592;;WASH complex, subunit 2C;613631;R, REc;;;
10.185;3;29;10;10q11.23;WDFY4, KIAA1607;;WD repeat- and FYVE domain-containing protein 4;613316;Psh, REc;;;
10.186;5;26;13;10q11.23;ASAH2;;N-acylsphingosine amidohydrolase 2;611202;REc;;;
10.187;5;22;07;10q11.23;ASAH2C, ASAH2L;;N-acylsphingosine amidohydrolase 2C;610987;REc;;;
10.188;8;26;09;10q11.23;DRGX, DRG11;;Dorsal root ganglia homeobox;606701;REc;;;
10.189;6;12;17;10q11.23;OGDHL, KIAA1290;;Oxoglutarate dehydrogenase-like protein;617513;R, REc;;;
10.190;2;20;01;10q11.23;PARG;;Poly(ADP-ribose) glycohydrolase;603501;A;;;14(Parg)
10.191;9;28;11;10q11.23-q22.3;HYPT9;;Hypotrichosis 9;614237;Fd;between D10S538 and D10S2327;Hypotrichosis 9 (2);
10.192;10;13;09;10q21;ALL1;;Leukemia, acute lymphocytic, susceptibility to, 1;613065;Fd;associated with rs10821936;{Leukemia, acute lymphocytic, susceptibility to, 1} (2);
10.193;11;7;08;10q21;ALPQTL4;;Alkaline phosphatase, plasma level of, QTL 4;612369;Fd;linkage with rs12355784;{Alkaline phosphatase, plasma level of, QTL4} (2);
10.194;11;11;13;10q21.2;ANK3, MRT37;;Ankyrin-3, node of Ranvier;600465;A;mutation identified in 1 family;?Mental retardation, autosomal recessive, 37, 615493 (3);10(Ank3)
10.195;8;14;15;10q21.2;CCDC6, D10S170, H4, TST1;;Coiled-coil domain-containing 6;601985;REn;fused with RET to form PTC1;;
10.196;2;2;14;10q21.3;CTNNA3, ARVD13;;Catenin, alpha-3;607667;A, Psh;;Arrhythmogenic right ventricular dysplasia, familial, 13, 615616 (3);
10.197;7;9;06;10q22.1;DDX21;;DEAD/H box 21;606357;R, REc;;;10(Ddx21)
10.198;9;24;08;10q21;IBD15;;Inflammatory bowel disease 15;612255;Fd;association with rs10761659;{Inflammatory bowel disease 15} (2);
10.199;3;20;06;10q21.1;IPMK;;Inositol polyphosphate multikinase;609851;REc;;;
10.200;10;30;08;10q21;MAFD8;;Major affective disorder 8;612357;Fd;associated with rs20994336;{Major affective disorder-8, susceptibility to} (2);
10.201;2;28;03;10q22.1;NPFF1;;Neuropeptide FF1;607448;R;;;
10.202;10;17;16;10q21.1;TFAM, TCF6L2, TCF6L1, TCF6L3, MTTF1, TCF6, MTDPS15;;Transcription factor A, mitochondrial;600438;Psh, A;mutation identified in 1 MTDPS15 family;?Mitochondrial DNA depletion syndrome 15 (hepatocerebral type), 617156 (3);10(Tfam)
10.203;8;26;17;10q22.1;CDH23, USH1D, DFNB12, PITA5;;Cadherin-23 (otocadherin);605516;Fd, REc;between D10S529 and D10S573;Usher syndrome, type 1D, 601067 (3); Deafness, autosomal recessive 12, 601386 (3); Usher syndrome, type 1D/F digenic, 601067 (3); {Pituitary adenoma 5, multiple types}, 617540 (3);10(Cdh23, v)
10.204;6;19;98;10q22.1;EIF4EBP2, 4EBP2;;Eukaryotic translation initiation factor-4E binding protein-1;602224;A;;;10(Eif4ebp2)
10.205;3;18;08;10q21.1;PCDH15, DFNB23, USH1F;;Protocadherin 15;605514;REc;;Usher syndrome, type 1F, 602083 (3); Deafness, autosomal recessive 23, 609533 (3); Usher syndrome, type 1D/F digenic, 601067 (3);10(av)
10.206;9;29;96;10q22.2;PPP3CB, CALNB;;Protein phosphatase-3 (formerly 2B), catalytic subunit, beta isoform (calcineurin A beta);114106;REa;;;
10.207;7;7;09;10q22.1;UNC5B, UNC5H2;;Unc5, C. elegans, homolog of, B;607870;R, REc;;;
10.208;2;2;16;10q21.1;ZWINT, SIP30;;ZW10 interacting kinetochore protein;609177;REc;;;
10.209;1;11;07;10q22.1;SPOCK2, KIAA0275;;SPARC/osteonectin, CWCV, and KAZAL-like domains proteoglycan 2;607988;R, REc;;;
10.210;5;14;95;10q23.31;HTR7;;5-hydroxytryptamine (serotonin) receptor-7, adenylate cyclase-coupled;182137;REa, Fd;;;
10.211;6;14;10;10q21.2;CDK1, CDC2;;Cyclin-dependent kinase 1;116940;REa, A;;;10(Cdc2a)
10.212;4;8;08;10q21.1;CISD1, MITONEET;;CDGSH iron sulfur domain protein 1;611932;REc;;;
10.213;3;9;17;10q21.3;DNAJC12, JDP1, HPANBH4;;DNAJ/HSP40 homolog, subfamily C, member 12;606060;REc;;Hyperphenylalaninemia, mild, non-BH4-deficient, 617384 (3);
10.214;5;4;09;10q21.1;MYP15;;Myopia 15;612717;Fd;max lod at D10S1643;Myopia 15 (2);
10.215;2;7;13;10q21.3;MYPN, CMD1DD, CMH22, RCM4, NEM11;;Myopalladin;608517;REc;;Cardiomyopathy, dilated, 1KK, 615248 (3); Cardiomyopathy, hypertrophic, 22, 615248 (3); Cardiomyopathy, familial restrictive, 4, 615248 (3); Nemaline myopathy 11, autosomal recessive, 617336 (3);
10.216;8;29;08;10q21.3;PBLD, MAWBP, MAWDBP;;Phenazine biosynthesis-like protein domain-containing protein;612189;Psh, R;;;
10.217;5;6;03;10q21.2;RHOBTB1, KIAA0740;;Rho-related BTB domain-containing protein 1;607351;REc;;;
10.218;8;19;13;10q21.3;RUFY2, KIAA1537;;RUN and FYVE domains-containing protein 2;610328;REc, R;;;
10.219;12;29;00;10q22.1;VPS26A, VPS26, HB58;;Vacuolar protein sorting 26, yeast, homolog of, A;605506;R;;;
10.220;10;13;94;10q22.2;ANXA7, SNX;;Annexin A7 (synexin);186360;REa, A;;;14(Anx7)
10.221;11;28;18;10q21.3;EGR2, KROX20, CHN1;;KROX-20, Drosophila, homolog of (early growth response-2);129010;D, REa, A, F;;Hypomyelinating neuropathy, congenital, 1, 605253 (3); Charcot-Marie-Tooth disease, type 1D, 607678 (3); Dejerine-Sottas disease, 145900 (3);10(Krox20; Egr2)
10.222;9;10;09;10q21.2;ARID5B, MRF2, DESRT;;AT-rich interaction domain-containing protein 5B;608538;R, REc;;;
10.223;2;22;18;10q21.1;BICC1, BICC, CYSRD;;Bicaudal C, Drosophila, homolog of, 1;614295;REc;;{Renal dysplasia, cystic, susceptibility to}, 601331 (3);10(Bicc1)
10.224;2;27;15;10q21.2;MRLN, LINC00948;;Myoregulin;616246;REc, H;;;10(Mrln)
10.225;9;28;11;10q21.2;SLC16A9, MCT9;;Solute carrier family 16 (monocarboxylic acid transporter), member 9;614242;REc;;;
10.226;12;8;17;10q21.2;TMEM26;;Transmembrane protein 26;617803;REc;;;
10.227;5;31;05;10q21.2;ZNF365, UAN;;Zinc finger protein 365;607818;Fd, REc;;{Nephrolithiasis, uric acid, susceptibility to}, 605990 (3);
10.228;12;20;12;10q21.3;ADO, C10orf22;;2-aminoethanethiol dioxygenase;611392;REc;;;
10.229;2;12;09;10q21.3;CCAR1, CARP1;;Cell division cycle and apoptosis regulator 1;612569;REc;;;
10.230;4;6;16;10q21.3;JMJD1C, TRIP8, KIAA1380;;Jumonji domain-containing protein 1C;604503;REc;;;
10.231;3;26;07;10q21.3;LRRTM3;;Leucine-rich repeat transmembrane protein 3;610869;REc, H;;;10(Lrrtm3)
10.232;1;9;13;10q21.3;MSE;;Myelinating Schwann cell element;614996;REc, REn;;;
10.233;11;05;18;10q22.2;FUT11, FUCTXI;;Fucosyltransferase 11;616932;REc;;;
10.234;1;6;09;10q22.1;NEUROG3, NGN3, ATOH5;;Neurogenin 3;604882;REc;;Diarrhea 4, malabsorptive, congenital, 610370 (3);
10.235;7;23;15;10q21.3;NRBF2, COPR;;Nuclear receptor-binding factor 2;616477;REc;;;
10.236;7;1;05;10q22.1;OIT3, LZP;;Oncoprotein-induced transcript 3, mouse, homolog of;609330;REc;;;10(Lzp)
10.237;3;24;06;10q22.1;PP;;Inorganic pyrophosphatase;179030;S, D, R;;;10(Pyp)
10.238;7;1;05;10q21.3;REEP3, C10orf74;;Receptor expression-enhancing protein 3;609348;R, REc;;;
10.239;9;9;08;10q21.3;SIRT1, SIR2L1;;Sirtuin, S. cerevisiae, homolog 1;604479;REc;;;
10.240;8;25;14;10q21.3;ATOH7, PHPVAR, NCRNA;;Atonal, Drosophila, homolog of, 7;609875;A, H, Fd;;Persistent hyperplastic primary vitreous, autosomal recessive, 221900 (3);10(Atoh7)
10.241;6;3;14;10q21.3;DNA2, DNA2L, KIAA0083, PEOA6, SCKL8;;DNA replication helicase 2, yeast, homolog of;601810;A;mutation identified in 1 SCKL8 family;Progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal dominant 6, 615156 (3); ?Seckel syndrome 8, 615807 (3);
10.242;4;16;14;10q21.3-q22.1;HCFP2;;Facial paresis, hereditary congenital, 2;604185;Fd;;Facial paresis, hereditary congenital, 2 (2);
10.243;8;2;99;10q21.3;SLC25A16, D10S105E, GDA;;Solute carrier family 25 (mitochondrial carrier), member 16 (Graves disease autoantigen);139080;A;;;
10.244;4;10;90;10q22.1;P4HA1, P4HA;;Procollagen-proline, 2-oxoglutarate 4-dioxygenase (proline 4-hydroxylase), alpha polypeptide 1;176710;REa, A, REn;;;
10.245;4;14;10;10q21.3-q22.3;HWE1;;Epilepsy, hot water, 1;613339;Fd;max lod at D10S412;Epilepsy, hot water, 1 (2);
10.246;3;6;98;10q22.2;CAMK2G, CAMKG;;Calcium/calmodulin-dependent protein kinase (CaM kinase) II gamma;602123;REa, A;in intron of PCDH15;;14(Camkg)
10.247;12;30;15;10q22.1;COL13A1, CMS19;;Collagen XIII, alpha-1 polypeptide;120350;REa, A;~550kb proximal to P4HA;Myasthenic syndrome, congenital, 19, 616720 (3);
10.248;8;25;11;10q24.2;GOLGA7B, C10orf132;;Golgin A7 family, member B;614189;REc;;;
10.249;1;5;07;10q23.1-q23.2;GRID1, KIAA1220;;Glutamate receptor, inotropic, delta 1;610659;R, H, REc;;;14(Grid1)
10.250;4;27;17;10q22.1;HK1, HKD, HMSNR, RP79;;Hexokinase-1;142600;S, D, A, REa;10p11.2 conflicting assignment; ?2 loci on chr.10;Hemolytic anemia due to hexokinase deficiency, 235700 (3); Neuropathy, hereditary motor and sensory, Russe type, 605285 (3); Retinitis pigmentosa 79, 617460 (3);10(Hk1)
10.251;6;19;98;10q21.3;HNRPH3, 2H9;;Heterogeneous nuclear ribonucleoprotein H3;602324;A;;;
10.252;4;19;12;10q22.2;KAT6B, MYST4, MORF, GTPTS;;Lysine acetyltransferase 6B;605880;A;;SBBYSS syndrome, 603736 (3); Genitopatellar syndrome, 606170 (3);
10.253;9;18;08;10q22.3;MAT1A, MATA1, SAMS1;;Methionine adenosyltransferase I, alpha;610550;A;;Hypermethioninemia, persistent, autosomal dominant, due to methionine adenosyltransferase I/III deficiency, 250850 (3); Methionine adenosyltransferase deficiency, autosomal recessive, 250850 (3);
10.254;11;16;98;10q22.2;NDST2;;N-deacetylase/N-sulfotransferase 2;603268;A;in intron of PCDH15;;
10.255;1;8;01;10q23.1;NRG3;;Neuregulin 3;605533;REa;;;
10.256;1;30;15;10q22.1;PCBD1, DCOH;;Pterin-4a-carbinolamine dehydratase 1;126090;REa, H, A;;Hyperphenylalaninemia, BH4-deficient, D, 264070 (3);10(Dcoh)
10.257;7;22;15;10q22.1;PRF1, HPLH2, FLH2;;Perforin;170280;A;mistakenly assigned to chr.17;Hemophagocytic lymphohistiocytosis, familial, 2, 603553 (3); Lymphoma, non-Hodgkin, 605027 (3); Aplastic anemia, 609135 (3);10(Prf1)
10.258;5;9;07;10q22;SQTL1;;Smoking as a quantitative trait locus 1;611003;Fd;near D10S1432;{Smoking as a quantitative trait locus 1} (2);
10.259;5;28;09;10q21.3;TET1, CXXC6, LCX, KIAA1676;;tet oncogene 1;607790;REc, A;;;
10.260;2;4;00;10q22.2;VDAC2;;Voltage-dependent anion channel 2;193245;A;;;14(Vdac2)
10.261;12;5;01;10q23.32;BTAF1, TAFII170, TAF172, MOT1;;BTAF1 RNA polymerase II, B-TFIID transcription factor-associated, 170kD (Mot1, S. cerevisiae, homolog of);605191;A, R;;;
10.262;4;23;08;10q21.1;CSTF2T, KIAA0689;;Cleavage stimulation factor, 3-prime pre-RNA, subunit 2, 64kD, tau variant;611968;Psh, R;;;19(Cstf2t)
10.263;6;27;08;10q22-q23;MGR12;;Migraine, with or without aura, susceptibility to, 12;611706;Fd;max lod at 100cM;{Migraine, with or without aura, susceptibility to, 12} (2);
10.264;3;1;00;10q22.3;PPIF, CYP3;;Peptidylprolyl-cis-trans-isomerase, mitochondrial;604486;Fd;;;
10.265;3;11;09;10q22.3;SFTPA2, SPA2, COLEC5;;Surfactant, pulmonary-associated protein A2;178642;Psh;contiguous with SFTPA1;Pulmonary fibrosis, idiopathic, 178500 (3);
10.266;12;29;06;10q22.3;RPS24, DBA3;;Ribosomal protein S24;602412;R, Psh;;Diamond-blackfan anemia 3, 610629 (3);
10.267;7;1;11;10q23.31;ACTA2, ACTSA, AAT6, MYMY5;;Actin, alpha-2, smooth muscle, aorta;102620;REa, A;;Aortic aneurysm, familial thoracic 6, 611788 (3); Multisystemic smooth muscle dysfunction syndrome, 613834 (3); Moyamoya disease 5, 614042 (3);
10.268;8;29;07;10q23.31;MPHOSPH1, MPP1;;M-phase phosphoprotein 1;605498;R, REc;;;
10.269;1;14;13;10q23.2-q23.3;PAPSS2, ATPSK2, BCYM4;;3'-phosphoadenosine 5'-phosphosulfate synthase 2;603005;REc, A;;Brachyolmia 4 with mild epiphyseal and metaphyseal changes, 612847 (3);19(Atpsk2, bm)
10.270;10;5;07;10q22-q24;ATFB1;;Atrial fibrillation, familial, 1;608583;Fd;;Atrial fibrillation, familial, 1 (2);
10.271;11;11;14;10q22.1;ADAMTS14;;A disintegrin-like and metalloproteinase with thrombospondin type 1 motif, 14;607506;REc;;;
10.272;7;26;10;10q22.1;ANAPC16, MSAG, C10orf104;;Anaphase-promoting complex, subunit 16;613427;REc;;;
10.273;3;25;16;10q22.1;ASCC1, p50, SMABF2;;Activating signal cointegrator 1 complex, subunit 1;614215;REc;mutation identified in 1 SMABF2 family;Barrett esophagus/esophageal adenocarcinoma, 614266 (3); ?Spinal muscular atrophy with congenital bone fractures 2, 616867 (3);
10.274;3;3;09;10q22.1;C10orf27;;chromosome 10 open reading frame 27;612640;REc;;;
10.275;11;18;10;10q22.1;CHST3, C6ST, C6ST1, HSD;;Carbohydrate sulfotransferase 3;603799;REc;;Spondyloepiphyseal dysplasia with congenital joint dislocations, 143095 (3);
10.276;8;19;13;10q22.1;DDX50, GUB;;DEAD/H box 50;610373;REc;;;10(Ddx50)
10.277;11;23;16;10q22.1;HKDC1;;Hexokinase domain-containing protein 1;617221;REc;;;
10.278;5;29;12;10q22.1;KIAA1274, PALD;;Paladin, mouse, homolog of;614656;REc, R;;;
10.279;7;1;05;10q22.1;KIAA1279;;KIAA1279 gene;609367;R, REc;;Goldberg-Shprintzen megacolon syndrome, 609460 (3);
10.280;9;2;11;10q22.1;MCU, CCDC109A;;Mitochondrial calcium uniporter;614197;REc;;;
10.281;3;5;14;10q22.1;MICU1, CBARA1, MPXPS;;Mitochondrial calcium uptake protein 1;605084;REc;;Myopathy with extrapyramidal signs, 615673 (3);
10.282;1;5;07;10q22.2;MRPS16, COXPD2;;Mitochondrial ribosomal protein S16;609204;R, REc;;Combined oxidative phosphorylation deficiency 2, 610498 (3);
10.283;1;30;01;10q22.2;MYOZ1;;Myozenin 1 (calsarcin 2);605603;R;;;
10.284;8;26;09;10q22.1;NODAL, HTX5;;Nodal, mouse, homolog of;601265;R, REc;;Heterotaxy, visceral, 5, 270100 (3);10(nodal)
10.285;12;18;07;10q22.1;PLA2G12B, GXIIB;;Phospholipase A2, group XIIB;611653;REc;;;
10.286;1;22;08;10q22.1;PSAP, SAP1;;Prosaposin (sphingolipid activator protein-1);176801;S, REa, A, D, Fd;;Metachromatic leukodystrophy due to SAP-b deficiency, 249900 (3); Gaucher disease, atypical, 610539 (3); Combined SAP deficiency, 611721 (3); Krabbe disease, atypical, 611722 (3);10(Psap)
10.287;5;22;03;10q22.1;SARA1, SAR1A;;Sar1a, S. cerevisiae, homolog 1;607691;REc, R;;;
10.288;4;18;12;10q22.1;SLC29A3, ENT3, PHID, HCLAP;;Solute carrier family 29 (nucleoside transporter), member 3;612373;R, REc;;Histiocytosis-lymphadenopathy plus syndrome, 602782 (3);
10.289;07;27;18;10q22.1;SGPL1, SPL, NPHS14;;Sphingosine-1-phosphate lyase 1;603729;H, REc;;Nephrotic syndrome, type 14, 617575 (3);10(Spl)
10.290;12;21;09;10q22.1;SRGN, PRG1, PRG;;Serglycin;177040;REa, A;;;
10.291;10;11;05;10q22.1;STOX1, PEE4;;Storkhead box 1;609397;REc, Fd;;Preeclampsia/eclampsia 4, 609404 (3);
10.292;1;31;01;10q22.1;SUPV3L1;;Suv3-like 1;605122;A;;;
10.293;12;21;09;10q22.1;TSPAN15, NET7;;Tetraspanin 15;613140;REn;;;
10.294;8;20;07;10q22.1;TYSND1;;Trypsin domain-containing protein 1;611017;R, REc;;;
10.295;08;10;18;10q22.1;VSIR, C10orf54, B7H5;;V-set immunoregulatory receptor;615608;REc;;;
10.296;2;2;04;10q22.3;RAI17, KIAA1224, ZIMP10;;Retinoic acid-induced gene 17;607159;REc;;;
10.297;3;3;10;10q22.2;VCL, CMD1W, CMH15;;Vinculin;193065;REa, Fd, REb;;Cardiomyopathy, dilated, 1W, 611407 (3); Cardiomyopathy, hypertrophic, 15, 613255 (3);
10.298;4;27;12;10q22.1-q24.1;SPG27;;Spastic paraplegia-27, autosomal recessive;609041;Fd;between D10S606 and D10S1758;Spastic paraplegia 27, autosomal recessive (2);
10.299;5;24;13;10q22.2;AP3M1;;Adaptor-related protein complex 3, mu-1 subunit;610366;R, REc;;;
10.300;1;27;04;10q22.1;DNAJB12, DJ10, FLJ0027;;DNAJ, E. coli, homolog of, subfamily B, member 12;608376;R;;;
10.301;9;24;08;10q22.2;DNAJC9, JDD1, KIAA0974;;DNAJ/HSP40 homolog, subfamily C, member 9;611206;R, REc;;;
10.302;12;21;09;10q22.2;DUSP13, TMDP, MDSP;;Dual-specificity phosphatase 13;613191;REc;;;
10.303;7;13;15;10q22.2;ECD, SGT1;;Ecdysoneless, Drosophila, homolog of;616464;REc;;;
10.304;8;21;12;10q22.2;MSS51, ZMYND17;;MSS51 mitochondrial translational activator, S. cerevisiae, homolog of;614773;REc;;;
10.305;12;7;07;10q22.2;SAMD8, SMSR;;Sterile alpha motif domain-containing 8;611575;REc;;;
10.306;3;13;15;10q22.2;SEC24C, KIAA0079;;Sec24-related gene family, member C;607185;R, REc;;;
10.307;4;26;11;10q22.2;ZNF503, NOLZ1;;Zinc finger protein 503;613902;REc;;;
10.308;3;20;18;10q22.3;SFTPA1, SFTP1;;Surfactant, pulmonary-associated protein A1;178630;REa, A;contiguous with SFTPA2;;14(Sftp1)
10.309;4;21;15;10q23.2;LDB3, ZASP, CYPHER, KIAA01613, MFM4, CMD1C, CMH24, LVNC3;;LIM domain binding 3;605906;R, Psh, Fd;;Myopathy, myofibrillar, 4, 609452 (3); Cardiomyopathy, dilated, 1C, with or without LVNC, 601493 (3); Cardiomyopathy, hypertrophic, 24, 601493 (3); Left ventricular noncompaction 3, 601493 (3);
10.310;1;2;08;10q23.2;BMPR1A, ACVRLK3, ALK3;;Bone morphogenetic protein receptor, type IA;601299;R, A;;Polyposis, juvenile intestinal, 174900 (3); Polyposis syndrome, hereditary mixed, 2, 610069 (3); Juvenile polyposis syndrome, infantile form, 174900 (3);
10.311;2;4;15;10q22.1;H2AFY2;;H2A histone family, member Y2;616141;REc;;;
10.312;8;31;17;10q22.3;KCNMA1, SLO, PNKD3, CADEDS;;Potassium large conductance calcium-activated channel, subfamily M, alpha member 1 (slowpoke, Drosophila, homolog of);600150;Psh, REc, Fd;mutation identified in 1 CADEDS family;Paroxysmal nonkinesigenic dyskinesia, 3, with or without generalized epilepsy, 609446 (3); ?Cerebellar atrophy, developmental delay, and seizures, 617643 (3);
10.313;07;19;18;10q22.2-q22.3;LRMDA, C10orf11, OCA7;;Leucine-rich melanocyte differentiation-associated protein;614537;REc;;Albinism, oculocutaneous, type VII, 615179 (3);
10.314;7;13;09;10q22.3;PLAC9;;Placenta-specific gene 9;612857;REc, H;;;15(Plac9)
10.315;10;3;11;10q22.3;POLR3A, RPC1, RPC155, ADDH, HLD7;;Polymerase III, RNA, subunit A;614258;REc;;Leukodystrophy, hypomyelinating, 7, with or without oligodontia and/or hypogonadotropic hypogonadism, 607694 (3);
10.316;9;22;03;10q22.3;SCZD11;;Schizophrenia susceptibility locus, chromosome 10q-related;608078;Fd;between D10S1677 and D10S1753;{Schizophrenia}, 181500 (2);
10.317;12;11;03;10q22.3;SLEN1;;Systemic lupus erythematosus with nephritis, susceptibility to, 1;607965;Fd;;{Systemic lupus erythematosus with nephritis, susceptibility to, 1} (2);
10.318;11;07;08;10q22.3;SS3;;Sarcoidosis, susceptibility to, 3;612388;Fd;associated with rs2789679 and rs1049550;{Sarcoidosis, susceptibility to, 3} (2);
10.319;1;29;18;10q22.3;ANXA11, ANX11, ALS23;;Annexin A11 (annexin XI);602572;A;;Amytrophic lateral sclerosis 23, 617839 (3);
10.320;3;28;15;10q23;DEL10q23, C10DELq23;;Chromosome 10q22.3-q23.2 deletion syndrome;612242;DS;;Chromosome 10q22.3-q23.2 deletion syndrome (4);
10.321;3;9;00;10q23.31;CH25H;;Cholesterol 25-hydroxylase;604551;A, R;;;
10.322;5;31;05;10q22.3;DLG5, PDLG, KIAA0583;;Discs large, Drosophila, homolog of, 5;604090;R;;;
10.323;3;15;13;10q23.31;KLLN, CWS4;;Killin;612105;REc;;Cowden syndrome 4, 615107 (3);
10.324;5;31;05;10q23.2;MINPP1, HIPER1;;Multiple inositol polyphosphate phosphatase 1;605391;A, R, REc;;Thyroid carcinoma, follicular, 188470 (3);19(Minpp1)
10.325;7;9;06;10q23.31;PANK1;;Pantothenate kinase 1;606160;REn;;;
10.326;1;26;07;10q23.33;PLCE1, KIAA1516, NPHS3;;Phospholipase C, epsilon-1;608414;R, REc;;Nephrotic syndrome, type 3, 610725 (3);
10.327;8;26;09;10q24.32;POLL;;Polymerase, DNA, lambda;606343;R, REc;;;
10.328;2;25;11;10q23.1;RGR, RP44;;Retinal G protein coupled receptor;600342;A;;Retinitis pigmentosa 44, 613769 (3);
10.329;3;16;99;10q25.2;SMNR, SPF30;;Survival motor neuron-related protein;603519;Psh, R;;;
10.330;10;28;08;10q23.31;STAMBPL1, KIAA1373;;STAM-binding protein-like 1;612352;R, REc;;;19(Stambpl1)
10.331;5;22;03;10q24.2;CNNM1, ACDP1;;Cyclin M1 (ancient conserved domain protein 1);607802;R;;;
10.332;3;31;08;10q23-q24;CPROTQ;;C-reactive protein QTL;611920;Fd;max lod at D10S1239;[C-reactive protein QTL] (2);
10.333;6;15;99;10q23.33;CYP26A1;;Cytochrome p450, subfamily XXVIA, polypeptide 1;602239;A;;;19(Cyp26a1)
10.334;10;23;87;10q24.1;DNTT, TDT;;Terminal deoxynucleotidyltransferase;187410;REa, A, Ch;;;19(Tdt)
10.335;1;14;16;10q24.2;ENTPD7, LALP1;;Ectonucleoside triphosphate diphosphohydrolase 7;616753;REc;;;
10.336;3;15;13;10q24.2;HPSE2, HPA2, UFS1;;Heparanase 2;613469;R;;Urofacial syndrome 1, 236730 (3);
10.337;10;21;08;10q23-q24;IBD20;;Inflammatory bowel disease 20;612288;Fd;associated with rs11190140;{Inflammatory bowel disease 20} (2);
10.338;8;20;01;10q23.32;PPP1R3C, PPP1R5;;Phosphatase 1, regulatory subunit 3C;602999;R;;;
10.339;3;6;02;10q24.1;TLL2, KIAA0932;;Tolloid-like 2;606743;A;;;19(Tll2)
10.340;11;4;93;10q11.21;ZNF32, KOX30;;Zinc finger protein-32 (KOX30);194539;A;;;8(Zfp4)
10.341;2;9;92;10q23.33;IDE;;Insulin-degrading enzyme;146680;REa, A;;;19(Ide)
10.342;11;14;17;10q23.1;C10orf99, CSBF, AP57;;Chromosome 10 open reading frame 99;617775;REc;;;
10.343;10;8;12;10q23.1;CDHR1, PCDH21, PRCAD, CORD15, RP65;;Cadherin-related family, member 1;609502;REc;;Cone-rod dystrophy 15, 613660 (3); Retinitis pigmentosa 65, 613660 (3);
10.344;4;8;13;10q23.1;DYDC1;;DPY30 domain-containing protein 1;615154;REc;;;
10.345;10;25;16;10q23.1;FAM213A, PAMM;;Family with sequence similarity 213, member A;617165;REc;;;
10.346;4;20;17;10q23.1;HOST2;;Long noncoding RNA HOST2;617434;REc;;;
10.347;6;11;02;10q24.2;HPS1;;HPS gene 1;604982;LD, Fd;;Hermansky-Pudlak syndrome 1, 203300 (3);19(ep, ru)
10.348;11;24;14;10q23.1;LRIT1, PAL;;Leucine-rich repeat, immunoglobulin-like, and transmembrane domains-containing protein 1;616103;;REc, A;;
10.349;1;11;18;10q24.1;BLNK, SLP65, AGM4;;B-cell linker protein (SH2 domain-containing leukocyte protein, 65kD);604515;A;mutation identified in 1 AGM4 family;?Agammaglobulinemia 4, 613502 (3);
10.350;8;19;13;10q23.2;MIR346;;Micro RNA 346;611190;REc;;;
10.351;4;10;15;10q23.2;OPN4;;Opsin 4;606665;R, REc;;;
10.352;6;26;18;10q23.2;SHLD2, RINN2, FAM35A;;Shield complex, subunit 2;618029;REc;;;
10.353;2;12;07;10q23.2;WAPAL, KIAA0261, FOE, WAPL;;Wings apart-like protein, Drosophila, homolog of;610754;R, REc;;;
10.354;10;15;98;10q23.2;SNCG, BCSG1;;Synuclein, gamma (breast cancer-specific gene 1);602998;R, A;;;
10.355;12;13;18;10q24.31;NDUFB8, MC1DN32;;NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 2 (8kD, AGGG);602140;R;previously assigned to 12q21;Mitochondrial complex I deficiency, nuclear type 32, 618252 (3);
10.356;11;09;18;10q24.32;ARL3, ARFL3, JBTS35, RP83;;ADP-ribosylation factor-like 3;604695;REa, R;mutation identified in 1 RP83 family;Joubert syndrome 35, 618161 (3); ?Retinitis pigmentosa 83, 618173 (3);
10.357;11;30;06;10q23.32;CPEB3, KIAA0940;;Cytoplasmic polyadenylation element-binding protein 3;610606;R, REc;;;
10.358;6;22;18;10q23.33;CYP2C8, CYP2C8DM;;Cytochrome P450, subfamily IIc, polypeptide 8;601129;REc;;{Drug metabolism, altered, CYP2C8-related}, 618018 (3);
10.359;1;15;13;10q23.33;CYP26C1, FFDD4;;Cytochrome P450, subfamily XXVIC, polypeptide 1;608428;REc;;Focal facial dermal dysplasia 4, 614974 (3);
10.360;2;21;02;10q23.2;GLUD1;;Glutamate dehydrogenase-1;138130;REa, A;pseudogene on Xq26-q28;Hyperinsulinism-hyperammonemia syndrome, 606762 (3);14(Glud)
10.361;5;4;00;10q23.31;IFIT1, IFI56, G10P1, IFNAI1;;Interferon-induced protein with tetratricopeptide repeats 1;147690;REa, A;10q25-q26 = conflicting site;;
10.362;5;4;00;10q23.31;IFIT4;;Interferon-induced protein with tetratricopeptide repeats 4;604650;A;;;
10.363;5;4;00;10q23.31;IFIT2, IFI54, G10P2;;Interferon-induced protein with tetratricopeptide repeats 2;147040;A, REa;;;
10.364;6;7;10;10q23.32-q23.33;MARCH5;;Membrane-associated RING-CH finger protein 5;610637;R, REc;;;
10.365;11;18;08;10q23.3;RCM2;;Cardiomyopathy, familial restrictive, 2;609578;Fd;max lod at D10S1242;Cardiomyopathy, familial restrictive, 2 (2);
10.366;8;19;98;10q22.3;SFTPD, SFTP4;;Surfactant, pulmonary-associated protein D;178635;Psh;;;
10.367;8;2;16;10q23.31;SLC16A12, MCT12, CTRCT47;;Solute carrier family 16 (monocarboxylic acid transporter), member 12;611910;REc, Fd;mutation identified in 1 CTRCT47 family;Cataract 47, juvenile, with microcornea, 612018 (3);
10.368;10;10;01;10q25.1;SORCS1;;SORCS receptor 1;606283;REc;;;
10.369;10;10;01;10q25.1;SORCS3, KIAA1059;;SORCS receptor 3;606285;R, REc;;;
10.370;2;8;08;10q23.33;C10orf4, FRA10AC1, FRA10A;;Chromosome 10 open reading frame 4;608866;REc;;;
10.371;9;27;17;10q23.33;CEP55, MARCH;;Centrosomal protein, 55kD;610000;REc;;Multinucleated neurons, anhydramnios, renal dysplasia, cerebellar hypoplasia, and hydranencephaly, 236500 (3);
10.372;9;26;17;10q23.33;CYP2C18;;Cytochrome P450, subfamily IIC, polypeptide 18;601131;REc, REn;;;
10.373;12;28;08;10q23.33;EXOC6, SEC15L1, SEC15L, SEC15;;Exocyst complex component 6;609672;R, REc;;;
10.374;3;14;13;10q23.33;FFAR4, O3FAR1, GPR120, PGR4, BMIQ10;;Free fatty acid receptor 4;609044;REc;;{Obesity, susceptibility to}, 607514 (3);
10.375;5;29;12;10q23.33;KIF11, KNSL1, MCLMR;;Kinesin family member 11;148760;A, REc;;Microcephaly with or without chorioretinopathy, lymphedema, or mental retardation, 152950 (3);18(Kns)
10.376;9;9;09;10q23.31;RNLS, C10orf59;;Renalase;609360;REc;;;
10.377;10;25;16;10q23.33;SLC35G1, POST, TMEM20, C10orf60;;Solute carrier family 35, member G1;617167;REc;;;
10.378;7;18;06;10q24.1;SORBS1, SH3D5, SH3P12, KIAA1296;;Sorbin and SH3 domain containing 1;605264;R, REc, REn;;;
10.379;4;21;16;10q23.33;HELLS, LSH, ICF4;;Helicase, lymphoid-specific;603946;A, H;;Immunodeficiency-centromeric instability-facial anomalies syndrome 4, 616911 (3);19(Hells)
10.380;10;28;14;10q23.31;ANKRD1, CARP;;Ankyrin repeat domain-containing protein 1;609599;REc;;;
10.381;6;10;18;10q23.31;ATAD1, THORASE, HKPX4;;ATPase family, AAA domain-containing, member 1;614452;REc;;Hyperekplexia 4, 618011 (3);
10.382;9;9;09;10q23.31;IDDM24;;Diabetes mellitus, insulin-dependent, 24;613006;Fd;associated with rs10509540;{Diabetes mellitus, insulin-dependent, 24} (2);
10.383;12;30;14;10q23.31;IFIT5, RI58, ISG58;;Interferon-induced protein with tetratricopeptide repeats 5;616135;REc;;;
10.384;12;15;10;10q23.31;LIPA, CESD;;Lipase A, lysosomal acid, cholesterol esterase;613497;S, H;?close to GOT;Wolman disease, 278000 (3); Cholesteryl ester storage disease, 278000 (3);19(Lip1)
10.385;9;27;17;10q23.31;LIPF;;Lipase F, gastric type;601980;REc, R;;;
10.386;4;26;11;10q23.31;LIPM, LIPL3;;Lipase family, member M;613923;REc, H;;;19(Lipm)
10.387;1;18;13;10q23.31;LIPN, LIPL4, ARCI8, LI4;;Lipase family, member N;613924;REc, H;;Ichthyosis, congenital, autosomal recessive 8, 613943 (3);19(Lipn)
10.388;4;26;11;10q23.31;LIPK, LIPL2;;Lipase family, member K;613922;REc, H;;;19(Lipk)
10.389;4;26;11;10q23.31;LIPJ, LIPL1;;Lipase J;613921;REc, H;;;19(Lipj)
10.390;12;21;09;10q23.31;MIR107, MIRN107;;Micro RNA 107;613189;REc;;;
10.391;11;27;18;10q23.31;PTEN, MMAC1, GLM2, CWS1;;Phosphatase and tensin homolog (mutated in multiple advanced cancers 1);601728;REc, REa, A, Ch;;Cowden syndrome 1, 158350 (3); Lhermitte-Duclos syndrome, 158350 (3); {Meningioma}, 607174 (3); {Glioma susceptibility 2}, 613028 (3); Macrocephaly/autism syndrome, 605309 (3); VATER association with macrocephaly and ventriculomegaly, 276950 (3); {Prostate cancer, somatic}, 176807 (3);19(Pten)
10.392;8;26;09;10q23.31;RPP30;;Ribonuclease P, 30kD subunit;606115;R, REc;;;
10.393;1;30;07;10q24.2;ANKRD2, ARPP;;Ankyrin repeat domain-containing protein 2;610734;R;;;
10.394;3;28;17;10q23.32;PCGF5;;Polycomb group ring finger protein 5;617407;REc, H;;;19(Pcgf5)
10.395;11;1;99;10q24.2;ABCC2, CMOAT;;ATP-binding cassette, subfamily C, member 2 (canalicular multispecific organic anion transporter);601107;A;;Dubin-Johnson syndrome, 237500 (3);19(Cmoat)
10.396;7;26;16;10q24;AD6;;Alzheimer disease 6;605526;Fd;;Alzheimer disease 6 (2);
10.397;2;23;08;10q24.32;AS3MT, CYT19;;Arsenic (+3 oxidation state) methyltransferase;611806;REc;;;
10.398;12;17;02;10q24.31;CHUK, IKBKA, NFKBIKA, IKKA, IKK1;;Conserved helix-loop-helix ubiquitous kinase;600664;A, Psh;;Cocoon syndrome, 613630 (3);
10.399;4;25;13;10q24.2;COX15, CEMCOX2;;Cytochrome c oxidase, subunit 15;603646;REc, Fd;;Leigh syndrome due to cytochrome c oxidase deficiency, 256000 (3); Cardioencephalomyopathy, fatal infantile, due to cytochrome c oxidase deficiency 2, 615119 (3);
10.400;7;3;06;10q24.2;CUTC;;CutC copper transporter, E. coli, homolog of;610101;REc;;;
10.401;8;3;99;10q23.33;CYP2C9;;Cytochrome P450, subfamily IIC (mephenytoin 4-hydroxylase), polypeptide 9;601130;REn, H;;Tolbutamide poor metabolizer (3); Warfarin sensitivity, 122700 (3);7(War)
10.402;10;14;15;10q24.1;ENTPD1, CD39, SPG64;;Ectonucleoside triphosphate diphosphohydrolase 1 (CD39 antigen);601752;REc;;Spastic paraplegia 64, autosomal recessive, 615683 (3);
10.403;9;22;08;10q24.31;FAM178A, C10orf6;;Family with sequence similarity 178, member A;610348;REc;;;
10.404;5;2;07;10q24.32;FBXW4, DAC, FBW4, FBWD4;;F-box and WD repeat domain containing 4;608071;H, REc;;;19(Dac)
10.405;9;28;12;10q24.32;FGF8, HH6;;Fibroblast growth factor-8;600483;H, REa, A, Fd;;Hypogonadotropic hypogonadism 6 with or without anosmia, 612702 (3);19(Fgf8)
10.406;6;15;99;10q24.32;GBF1;;Golgi-specific brefeldin-A resistance factor 1;603698;REa, A;;;
10.407;3;3;03;10q23.33;HHEX, PRHX, PRH;;Hematopoietically expressed homeo box;604420;REc, A;;;
10.408;12;11;02;10q24.31;HIF1AN, FIH1;;Hypoxia-inducible factor 1-alpha inhibitor;606615;REc;;;
10.409;1;10;12;10q23.33;LGI1, EPT, ETL1, ADLTE, ADPEAF;;Leucine-rich gene, glioma-inactivated, 1;604619;Ch, Fd;;Epilepsy, familial temporal lobe, 1, 600512 (3);
10.410;10;26;99;10q24.32;LBX1, LBX1H;;Lady bird late, Drosophila, homolog of, 1;604255;A;;;19(Lbx1)
10.411;2;28;03;10q24.2;LOXL4;;Lysyl oxidate-like 4;607318;REc;;;
10.412;3;5;08;10q24.31;MRPL43;;Mitochondrial ribosomal protein L43;611848;R, REc;;;
10.413;5;31;12;10q23.33;MYOF, FER1L3;;Myoferlin;604603;REc, REn;;;
10.414;12;27;13;10q24.32;NFKB2, LYT10, CVID10;;Nuclear factor of kappa light chain gene enhancer in B-cells 2 (p49/p100); oncogene Lyt-10;164012;REa, A, Ch;;Immunodeficiency, common variable, 10, 615577 (3);
10.415;2;16;07;10q23.33;NOC3L, FAD24;;Nucleolar complex-associated 3, S. cerevisiae, homolog of;610769;REc;;;
10.416;11;21;16;10q24.1;OPALIN, TMEM10, TMP10;;Oligodendrocytic myelin paranodal and inner loop protein;617200;REc;;;
10.417;3;20;08;10q25.2;PDCD4;;Programmed cell death 4;608610;A;;;
10.418;11;3;09;10q23.33;PDE6C, PDEA2, COD4;;Phosphodiesterase-6C, cGMP-specific, cone, alpha prime;600827;A;;Cone dystrophy 4, 613093 (3);
10.419;3;18;08;10q24.2;PI4K2A;;Phosphatidylinositol 4-kinase type 2 alpha;609763;R, REc;;;
10.420;9;12;11;10q22.2;PLAU, URK, QPD, BDPLT5;;Plasminogen activator, urokinase;191840;REa, A, Psh;proximal to HOX11;{Alzheimer disease, late-onset, susceptibility to}, 104300 (3); Quebec platelet disorder, 601709 (3);14(Plau)
10.421;2;18;98;10q24.32;PSD;;Pleckstrin and Sec7 domain protein;602327;REn;;;
10.422;6;19;15;10q23.33;RBP4, RDCCAS, MCOPCB10;;Retinol-binding protein-4, interstitial;180250;REa, A;just centromeric of CYP2C cluster;Retinal dystrophy, iris coloboma, and comedogenic acne syndrome, 615147 (3); Microphthalmia, isolated, with coloboma 10, 616428 (3);19(Rbp4)
10.423;8;10;10;10q24;SHFM3, SHSF3, DUP10q24, C10DUPq24;;Split-hand/foot malformation 3 (Chromosome 10q24 duplication syndrome);246560;Fd;contiguous gene duplication syndrome;Split-hand/foot malformation 3, gene duplication syndrome (4);
10.424;1;12;06;10q24.2;SLC25A28, MRS4L, NPD016;;Solute carrier family 25 (mitochondrial carrier), member 28;609767;Psh, REn;;;
10.425;5;4;09;10q24.31;TD1;;TLX1 divergent gene;612734;REc;;;
10.426;7;17;02;10q24.31;TLX1, HOX11, TCL3;;T-cell leukemia, homeobox 1;186770;Ch, RE, H;t(7;10) or t(10;4) in T-ALL;;
10.427;3;28;17;10q24.31;TWNK, C10orf2, TWINKLE, PEOA3, IOSCA, MTDPS7, PRLTS5;;Twinkle mtDNA helicase;606075;Fd, REc;PEO digenic with POLG;Progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal dominant 3, 609286 (3); Mitochondrial DNA depletion syndrome 7 (hepatocerebral type), 271245 (3); Perrault syndrome 5, 616138 (3);
10.428;12;10;13;10q24.33;USMG5, DAPIT;;Upregulated during skeletal muscle growth 5, mouse, homolog of;615204;REc;;;19(Usmg5)
10.429;8;29;96;10q24.31;WNT8B;;Wingless-type MMTV integration site family, member 8B;601396;Psh, A;;;
10.430;1;13;16;10q24.1;ZDHHC16, APH2;;Zinc finger DHHC domain-containing protein 16;616750;REc;;;
10.431;8;18;99;10q24.32;BTRC, BTRCP;;Beta-transducin repeat-containing protein;603482;R, A;;;
10.432;8;26;09;10q25.1;GSTO1;;Glutathione S-transferase, omega-1;605482;REc, REn;;;
10.433;10;6;08;10q25.1;GSTO2;;Glutathione S-transferase, omega-2;612314;REc;;;
10.434;2;4;99;10q24.32;LDB1, CLIM2, NLI;;LIM domain-binding factor-1;603451;R, H;;;19(Ldb1)
10.435;3;9;00;10q24.31;PKD2L1, PKDL, PKD2L;;Polycystin L;604532;A, R, REa;;;19(Pkdl)
10.436;11;7;17;10q24.32;SUFU, SUFUXL, SUFUH, JBTS32;;Suppressor of fused;607035;A, R;;Medulloblastoma, desmoplastic, 155255 (3); {Meningioma, familial, susceptibility to}, 607174 (3); Basal cell nevus syndrome, 109400 (3); Joubert syndrome 32, 617757 (3);
10.437;12;4;01;10q24.33;TAF5, TAF2D, TAFII100;;TAF5 RNA polymerase II, TATA box binding protein-associated factor, 100kD;601787;REa, A;;;
10.438;3;7;92;10q25.2;ADRA2A, ADRA2R;;Adrenergic, alpha-2A-, receptor;104210;REa, A, Fd, RE;;;19(Adra2)
10.439;2;23;09;10q25.3;ADRB1, ADRB1R, RHR;;Adrenergic, beta-1-, receptor;109630;REa, Fd, A;close linkage to ADRA2R;[Resting heart rate], 607276 (3); {Congestive heart failure and beta-blocker response, modifier of} (3);19(Adrb1)
10.440;6;6;00;10q26.13;BUB3;;Budding uninhibited by benzimidazoles 3, S. cerevisiae, homolog of;603719;R;;;
10.441;1;13;99;10q25.2;GPAM;;Glycerol-3-phosphate acyltransferase;602395;H;;;19(Gpam)
10.442;1;10;02;10q24.32;NPM3;;Nucleophosmin/nucleoplasmin family, member 3;606456;REc;;;19(Npm3)
10.443;11;20;98;10q25.3;NRAP;;Nebulin-related anchoring protein;602873;R, H;;;19(Nrap)
10.444;5;29;12;10q26.11;GRK5, GPRK5;;G protein-coupled receptor kinase 5;600870;REa;;;
10.445;12;7;07;10q24.1;ARHGAP19;;RHO GTPase-activating protein 19;611587;REc;;;
10.446;6;1;12;10q24.1;EXOSC1, CSL4;;Exosome component 1;606493;REc;;;
10.447;12;30;14;10q23.31;FAS, TNFRSF6, APT1, CD95, ALPS1A;;Fas cell surface death receptor;134637;A;;{Autoimmune lymphoproliferative syndrome}, 601859 (3); Squamous cell carcinoma, burn scar-related, somatic (3); Autoimmune lymphoproliferative syndrome, type IA, 601859 (3);19(Fas1)
10.448;11;27;18;10q24.1;FRAT1;;Frequently rearranged in advanced T-cell lymphomas 1;602503;H, REc;;;19(Frat1)
10.449;8;27;01;10q24.1;FRAT2;;Frequently rearranged in advanced T-cell lymphomas 2;605006;REc;;;
10.450;2;18;08;10q24.1;LCOR, MLR2, KIAA1795;;Ligand-dependent nuclear receptor corepressor;607698;R, REc;;;
10.451;8;31;12;10q24.1;MMS19, MMS19L;;MMS19 nucleotide excision repair, S. Cerevisiae, homolog of;614777;A, REc, R;;;
10.452;9;20;14;10q24.1;PIK3AP1, BCAP, FLJ35564;;Phosphoinositide 3-kinase adaptor protein 1;607942;R, REc;;;
10.453;10;25;17;10q24.1;RRP12, KIAA0690;;Ribosomal RNA-processing protein 12, S. cerevisiae, homolog of;617723;REc, R;;;
10.454;10;22;99;10q24.2;SFRP5, SARP3;;Secreted frizzled-related protein 5;604158;A, R, Psh;;;
10.455;12;10;13;10q24.1;SLIT1, SLIL1, MEGF4;;Slit, Drosophila, homolog of, 1;603742;Psh, REc;;;
10.456;9;10;12;10q24.1;TCTN3, TECT3, C10orf61, OFD4, JBTS18;;Tectonic family, member 3;613847;REc;;Orofaciodigital syndrome IV, 258860 (3); Joubert syndrome 18, 614815 (3);
10.457;3;24;16;10q24.1;TM9SF3, SMBP;;Transmembrane 9 superfamily, member 3;616872;REc;;;
10.458;10;25;17;10q24.1;ZNF518A, KIAA0335;;Zinc finger protein 518A;617733;R, REc;;;
10.459;6;1;15;10q24.1-q24.2;UBTD1;;Ubiquitin domain-containing protein 1;616388;REc;;;
10.460;11;24;15;10q23.33;CYP2C, CYP2C19;;Cytochrome P450, subfamily IIC (mephenytoin 4'-hydroxylase);124020;REa, A;4 genes in order: cen-C18-C19-C9-C8-tel;Mephenytoin poor metabolizer, 609535 (3); Omeprazole poor metabolizer, 609535 (3); Proguanil poor metabolizer, 609535 (3); Clopidogrel, impaired responsiveness to, 609535 (3);19(P4502c)
10.461;8;31;99;10q24.32;MGEA5;;Meningioma-expressed antigen 5;604039;Psh, A;;;
10.462;7;25;12;10q24.1-q25.1;CMTDIA;;Charcot-Marie-Tooth disease, dominant intermediate A;606483;Fd;;Charcot-Marie-Tooth disease, dominant intermediate A (2);
10.463;1;18;12;10q24.2;GOT1, ASTQTL1;;Glutamic-oxaloacetic transaminase-1, soluble (EC 2.6.1.1);138180;S, D, H, A;10q26.1 = conflicting localization;Aspartate aminotransferase, serum level of, QTL1, 614419 (3);19(Got1)
10.464;3;10;03;10q24.2;CPN1, SCPN, CPN;;Carboxypeptidase N, polypeptide 1, 50-kD;603103;Psh, R;;Carboxypeptidase N deficiency, 212070 (3);
10.465;7;2;18;10q24.2;CRTAC1, CEP68, LOTUS;;Cartilage acidic protein 1;606276;REc;;;
10.466;5;26;13;10q24.2;DNMBP, TUBA, KIAA1010;;Dynamin-binding protein;611282;R, REc;;;19(Dnmbp)
10.467;12;17;12;10q24.2;HOGA1, DHDPSL, HP3;;4-hydroxy-2-oxoglutarate aldolase 1;613597;REc;;Hyperoxaluria, primary, type III, 613616 (3);
10.468;6;26;16;10q24.2;MARVELD1, MARVD1;;Marvel domain-containing protein 1;616970;REc;;;
10.469;10;25;17;10q24.2;MORN4, RTP, UTA;;MORN repeat-containing protein 4;617736;REc;;;
10.470;6;16;08;10q24.2;NKX2C, NK2.3, CSX3;;NK2, Drosophila, homolog of, C;606727;REc;;;
10.471;3;1;18;10q24.2;PYROXD2, C10orf33, YUEF;;Pyridine nucleotide-disulphide oxidoreductase domain-containing protein 2;617889;REc;;;
10.472;4;27;12;10q24.2;ZFYVE27, SPG33;;Zinc finger FYVE domain-containing protein 27;610243;REc;;Spastic paraplegia 33, autosomal dominant, 610244 (3);
10.473;6;30;16;10q25.1-q25.2;ADD3, ADDL, CPSQ3;;Adducin-3, gamma;601568;A, Ch;fusion with NUP98 in T-ALL;Cerebral palsy, spastic quadriplegic, 3, 617008 (3);
10.474;4;26;17;10q24.32;PPRC1, PRC, KIAA0595;;Peroxisome proliferator-activated receptor-gamma, coactivator-related protein 1;617462;REc;;;
10.475;10;7;08;10q24.33;PDCD11, ALG4, NFBP, KIAA0185;;Programmed cell death 11;612333;A;;;
10.476;10;23;15;10q24.1;ALDH18A1, PYCS, GSAS, ARCL3A, SPG9A, SPG9B, ADCL3;;Aldehyde dehydrogenase 18 family, member A1 (1-pyrroline-5-carboxylate synthetase);138250;S, A;GOT1 and GSAS in same pathway;Cutis laxa, autosomal recessive, type IIIA, 219150 (3); Spastic paraplegia 9A, autosomal dominant, 601162 (3); Spastic paraplegia 9B, autosomal recessive, 616586 (3); Cutis laxa, autosomal dominant 3, 616603 (3);
10.477;9;24;15;10q25.1;COL17A1, BPAG2, ERED;;Collagen XVII, alpha-1 polypeptide;113811;A, H;;Epidermolysis bullosa, junctional, non-Herlitz type, 226650 (3); Epidermolysis bullosa, junctional, localisata variant, 226650 (3); Epithelial recurrent erosion dystrophy, 122400 (3);19(Bpag2)
10.478;8;9;05;10q24.32;CYP17A1, CYP17, P450C17;;Cytochrome P450, family 17, subfamily A, polypeptide 1 (steroid 17-alpha-hydroxylase);609300;REa, H, A;at least 2 genes; distal to GOT1;17-alpha-hydroxylase/17,20-lyase deficiency, 202110 (3); 17,20-lyase deficiency, isolated, 202110 (3);19(Cyp17)
10.479;5;24;13;10q24.31;LZTS2, KIAA1813, LAPSER1;;Leucine zipper, putative tumor suppressor 2;610454;REc;;;
10.480;10;14;15;10q24.32-q24.33;NT5C2, NT5B, PNT5, SPG45;;5' nucleotidase, cytosolic II;600417;R, REc;;Spastic paraplegia 45, autosomal recessive, 613162 (3);
10.481;6;1;18;10q24.31;PDZD7, DFNB57;;PDZ domain-containing 7;612971;REc;;{Retinal disease in Usher syndrome type IIA, modifier of}, 276901 (3); Usher syndrome, type IIC, GPR98/PDZD7 digenic, 605472 (3); Deafness, autosomal recessive 57, 618003 (3);
10.482;3;30;12;10q24.31;SEC31B, SEC31L2;;Sec31, yeast, homolog of, B;610258;REc;;;
10.483;7;10;02;10q24.32;TRIM8, RNF27, GERP;;Tripartite motif-containing 8;606125;REc;;;
10.484;10;23;15;10q24.31;PAX2, PAPRS, FSGS7;;Paired box homeotic gene-2;167409;REa, A;;Papillorenal syndrome, 120330 (3); Glomerulosclerosis, focal segmental, 7, 616002 (3);19(Pax2)
10.485;8;28;97;10q26.3;CYP2E, CYP2E1, P450C2E;;Cytochrome P450, subfamily IIE, ethanol-inducible;124040;REa;;;7(Cyp2e)
10.486;12;28;08;10q24.31;BLOC1S2, BLOS2;;Biogenesis of lysosome-related organelles complex 1, subunit 2;609768;R;;;
10.487;8;23;16;10q24.31;CWF19L1, C19L1, SCAR17;;CWF19-like protein 1;616120;REc;;Spinocerebellar ataxia, autosomal recessive 17, 616127 (3);
10.488;5;23;16;10q24.31;ERLIN1, SPG62;;Endoplasmic reticulum lipid raft-associated protein 1;611604;R, REc;;Spastic paraplegia 62, 615681 (3);
10.489;2;25;15;10q24.31;OLMALINC, LINC00263, OLMALINCAS;;Oligodendrocyte maturation-associated long intergenic noncoding RNA;616240;REc;OLMALINCAS is on opposite strand overlapping exon 1 of OLMALINC;;
10.490;8;26;09;10q24.31;SCD;;Stearoyl-CoA desaturase;604031;REa, REc;pseudogene on chr.17;;19(ab)
10.491;12;27;13;10q24.31;SFXN3;;Sideroflexin 3;615571;REc;;;
10.492;4;2;16;10q24.31;SNORA12;;Small nucleolar RNA, H/ACA box, 12;611330;REc;in intron 11 of CWF19L1;;
10.493;8;31;12;10q24.32;ACTR1A, ARP1;;Actin-related protein 1A;605143;REc;;;
10.494;10;23;15;10q24.32;BORCS7, C10orf32;;BLOC1-related complex, subunit 7;616600;REc;;;
10.495;9;10;07;10q24.32;C10orf26, OPAL1;;Chromosome 10 open reading frame 26;611129;R, REc;;;
10.496;8;6;11;10q24.32;CUEDC2;;Cue domain-containing protein 2;614142;REc;;;
10.497;7;28;15;10q24.32;DPCD;;Deleted in primary ciliary dyskinesia, mouse, homolog of;616467;REc, H;;;19(Dpcd)
10.498;2;23;08;10q24.32;ELOVL3, CIG30;;Elongation of very long chain fatty acids-like 3;611815;REc;;;
10.499;5;24;13;10q24.32;FBXL15, JET;;F-box and leucine-rich repeat protein 15;610287;REc;;;
10.500;1;29;03;10q24.32;HPS6, RU;;HPS gene 6;607522;REc;;Hermansky-Pudlak syndrome 6, 614075 (3);19(ru)
10.501;5;26;13;10q24.32;MIR146B;;Micro RNA 146B;610567;REc;;;
10.502;10;2;12;10q24.32;NOLC1, p130, NOPP140;;Nucleolar and coiled-body phosphoprotein 1;602394;REc;;;
10.503;12;27;13;10q24.32;SFXN2;;Sideroflexin 2;615570;REc;;;
10.504;11;14;12;10q24.32-q25.1;ECTD5;;Ectodermal dysplasia 5, hair/nail type;614927;Fd;between D10S1239 and D10S1264;Ectodermal dysplasia 5, hair/nail type (2);
10.505;9;8;08;10q24.33;CALHM1, FAM26C;;Calcium homeostasis modulator 1;612234;REc;?Alzheimer disease, 605526;;
10.506;9;8;08;10q24.33;CALHM2, FAM26B;;Calcium homeostasis modulator 2;612235;REc;;;
10.507;12;28;18;10q24.33;CALHM3;;Calcium homeostasis modulator 3;618263;REc;;;
10.508;6;17;15;10q24.32;CNNM2, ACDP2, HOMG6, HOMGSMR;;Cyclin M2;607803;R, REc;;Hypomagnesemia 6, renal, 613882 (3); Hypomagnesemia, seizures, and mental retardation, 616418 (3);19(Cnnm2)
10.509;1;27;11;10q22.1;DDIT4, REDD1, RTP801;;DNA damage-inducible transcript 4;607729;REc;;;
10.510;2;10;17;10q24.33;STN1, OBFC1, AAF44;;STN1, CST complex subunit;613128;REc;;Cerebroretinal microangiopathy with calcifications and cysts 2, 617341 (3);19(Obfc1)
10.511;12;28;08;10q24.33;PCGF6, RNF134, MBLR;;Polycomb group ring finger 6;607816;R, REc;;;
10.512;9;24;15;10q24.3-q25.1;SLK, LOSK, KIAA0204;;STE20-like protein kinase;616563;R, REc;;;
10.513;11;13;15;10q25.2;SMC3, CSPG6, HCAP, BAM, CDLS3;;Structural maintenance of chromosomes 3;606062;R, H;;Cornelia de Lange syndrome 3, 610759 (3);19(Bam)
10.514;11;4;98;10q25.2;DUSP5, HVH3;;Dual-specificity phosphatase-5;603069;A;;;
10.515;12;9;98;10q25;IDDM17;;Insulin-dependent diabetes mellitus-17;603266;Fd;;{Diabetes mellitus, insulin-dependent, 17} (2);
10.516;2;18;98;10q25.3;LIMAB1;;LIM actin-binding protein-1;602330;A, R;;;19(Limab1)
10.517;10;26;18;10q25.2;MXI1;;MAX-interacting protein 1;600020;A, D;;Neurofibrosarcoma, somatic (3); {Prostate cancer, susceptibility to, somatic}, 176807 (3);19(Mxi1)
10.518;1;26;17;10q24.32;PITX3, CTPP4, CTRCT11, ASGD1;;Paired-like homeodomain transcription factor-3;602669;R;;Anterior segment dysgenesis 1, multiple subtypes, 107250 (3); Cataract 11, multiple types, 610623 (3); Cataract 11, syndromic, autosomal recessive, 610623 (3);19(Pitx3)
10.519;10;12;09;10q25.2;SHOC2, SIAA0862, SOC2, SUR8;;Suppressor of clear, C. elegans, homolog of;602775;A;;Noonan-like syndrome with loose anagen hair, 607721 (3);
10.520;7;5;18;10q25.3;SLC18A2, VAT2, SVMT, PKDYS2;;Solute carrier family 18 (vesicular monoamine), member 2;193001;REa, A;mutation identified in 1 PKDYS2 family;?Parkinsonism-dystonia, infantile, 2, 618049 (3);19(Slc18a2)
10.521;5;19;06;10q26.13;ACADSB, SBCAD;;Acyl-Coenzyme A dehydrogenase, short/branched chain;600301;REa, A;;2-methylbutyrylglycinuria, 610006 (3);
10.522;12;2;05;10q25-q26;EIG4;;Epilepsy, idiopathic generalized, susceptibility to 4;609750;Fd;between D16S397 and D16S3095;{Epilepsy, idiopathic generalized, susceptibility to 4} (2);
10.523;9;1;15;10q25.3;HABP2, PHBP, HGFAL, FSAP, NMTC5;;Hyaluronan-binding protein 2;603924;A;mutation identified in 1 NMTC5 family;{?Thyroid cancer, nonmedullary, 5}, 616535 (3); {Venous thromboembolism, susceptibility to}, 188050 (3);
10.524;12;14;00;10q26.11;PRDX3, AOP1;;Peroxiredoxin 3 (antioxidant protein 1);604769;A;;;19(Aop1)
10.525;10;15;91;10q26.2;MKI67;;Proliferation-related Ki-67 antigen;176741;S, REa, A;;;7(Mki67)
10.526;7;24;17;10q25.1;CFAP43, WDR96, C10orf79, SPGF19;;Cilia- and flagella-associated protein 43;617558;REc;;Spermatogenic failure 19, 617592 (3);
10.527;12;28;08;10q25.3;DCLRE1A, SNM1, SNM1A, KIAA0086;;DNA cross-link repair protein 1A;609682;Psh, REc;;;
10.528;7;17;14;10q24.33;NEURL1, NEURL, NEUR1;;Neuralized E3 ubiquitin protein ligase 1;603804;R, A;;;
10.529;8;26;15;10q25.1;SFR1, MEI5, C10orf78;;SWI5-dependent homologous recombination repair protein 1;616527;REc;;;
10.530;9;18;08;10q25.2;ACSL5, FACL5, ACS5;;Acyl-CoA synthetase long-chain family member 5;605677;REc;;;
10.531;7;1;97;10q25.3;CASP7, MCH3;;Caspase 7, apoptosis-related cysteine protease;601761;R;;;
10.532;10;24;14;10q25.2;BBIP1, NCRNA00081, BBIP10, BBS18;;BBSome interacting protein 1;613605;REc;mutation identified in 1 BBS18 family;?Bardet-Biedl syndrome 18, 615995 (3);
10.533;12;21;09;10q25.2;RBM20;;RNA-binding motif protein 20;613171;REc;;Cardiomyopathy, dilated, 1DD, 613172 (3);
10.534;11;10;14;10q25.2;VTI1A, VTI1RP2, MMDS3;;VTI1, S. cerevisiae, homolog of, A;614316;REc;;;
10.535;1;27;04;10q26.3;DPYSL4, CRMP3, ULIP4;;Dihydropyrimidinase-like 4;608407;A, H;;;7(Ulip4)
10.536;8;6;13;10q26.11;BAG3, MFM6;;BCL2-associated athanogene 3;603883;REc;;Myopathy, myofibrillar, 6, 612954 (3); Cardiomyopathy, dilated, 1HH, 613881 (3);
10.537;9;27;17;10q25.2;TECTB;;Tectorin, beta;602653;REc;;;
10.538;3;20;97;10q26.13;HMX2;;Homeo box (H6 family) 2;600647;REa;;;
10.539;5;14;02;10q26.2;UROS;;Uroporphyrinogen III synthase;606938;REa, Psh;;Porphyria, congenital erythropoietic, 263700 (3);7(Uros)
10.540;12;18;08;10q25.3;AFAP1L2, XB130, KIAA1914;;Actin filament-associated protein 1-like protein 2;612420;A, REc;;;
10.541;1;26;17;10q25.3;FAM160B1, KIAA1600;;Family with sequence similarity 160, member B1;617312;REc;;;
10.542;4;24;18;10q25.3;SHTN1, KIAA1598, SHOOTIN1;;Shootin1;611171;REc, R;;;
10.543;11;22;10;10q25.3;KCNK18, TRESK, TRIK, MGR13;;Potassium channel, subfamily K, member 18;613655;REc, H;;{Migraine, with or without aura, susceptibility to, 13}, 613656 (3);19(Kcnk18)
10.544;6;5;89;10q24.1;PGAM1;;Phosphoglycerate mutase A, nonmuscle form;172250;D, H;;;19(Pgam1)
10.545;3;18;12;10q25.3;PNLIPRP1, PLRP1;;Pancreatic lipase-related protein 1;604422;REc;;;
10.546;8;23;10;10q25.3;PNLIPRP2, PLRP2;;Pancreatic lipase-related protein 2;604423;REc;;;
10.547;7;3;06;10q25.2-q25.3;TCF7L2, TCF4;;Transcription factor 7-like 2;602228;A, Fd;;{Diabetes mellitus, type 2, susceptibility to}, 125853 (3);
10.548;8;26;09;10q25.3;TDRD1;;Tudor domain protein 1;605796;R, REc;;;
10.549;1;29;07;10q25.3;TRUB1, PUS4;;TRUB pseudouridine synthase, E. coli, homolog of, 1;610726;REc;;;
10.550;10;11;05;10q25.1;XPNPEP1, SAMP, XPNPEPL;;X-prolyl aminopeptidase P1;602443;A, REa;;;
10.551;11;5;95;10q26.11;GPR10;;G protein-coupled receptor-10;600895;A;;;
10.552;10;29;09;10q26.13;DMBT1;;Deleted in malignant brain tumors 1;601969;D;;;
10.553;9;21;11;10q25.3-q26.1;PDZD8;;PDZ domain-containing protein 8;614235;REc;;;
10.554;3;11;08;10q26.2;BCCIP, TOK1;;BRCA2- and CDKN1A-interacting protein;611883;A, REc;;;
10.555;2;3;16;10q26.13;HTRA1, PRSS11, ARMD7, CARASIL, CADASIL2;;HTRA serine peptidase 1;602194;A;;{Macular degeneration, age-related, 7}, 610149 (3); {Macular degeneration, age-related, neovascular type}, 610149 (3); CARASIL syndrome, 600142 (3); Cerebral arteriopathy, autosomal dominant, with subcortical infarcts and leukoencephalopathy, type 2, 616779 (3);
10.556;2;25;16;10q26.13;PLEKHA1, TAPP1;;Pleckstrin homology domain-containing protein, family A, member 1;607772;REc;;;
10.557;8;20;98;10q25.3-q26.3;ADORA2L1, ADORA2L;;Adenosine A2 receptor-like 1;102777;A;;;
10.558;7;20;09;10q25.3;ATRNL1, KIAA0534, ALP;;Attractin-like 1;612869;R, REc;;;
10.559;7;1;09;10q26.11;CASC2;;Cancer susceptibility candidate 2;608598;REc;head-to-head orientation with RAB11FIP2;;
10.560;9;7;10;10q26.13;CHST15, BRAG, KIAA0598;;Carbohydrate sulfotransferase 15;608277;R, REa;;;
10.561;4;7;13;10q26;CORD17;;Cone-rod dystrophy 17;615163;Fd;between D10S1757 and D10S1782;Cone-rod dystrophy 17 (2);
10.562;11;16;08;10q26;DEL10q26, C10q26DEL;;Chromosome 10q26 deletion syndrome;609625;Ch;;Chromosome 10q26 deletion syndrome (4);
10.563;4;30;09;10q26.2;DHX32, DDX32;;DEAH (Asp-Glu-Ala-His) box polypeptide 32;607960;REc;;;
10.564;10;3;07;10q26.11;EIF3A, EIF3S10, P167;;Eukaryotic translation initiation factor 3, subunit A;602039;REc, A;;;
10.565;9;1;05;10q26;ENDO1;;Endometriosis, susceptibility to, 1;131200;Fd;max lod at D10S587;{Endometriosis, susceptibility to, 1} (2);
10.566;2;19;04;10q26.13;FGFR2, BEK, CFD1, JWS, TK14, BBDS;;Fibroblast growth factor receptor-2 (bacteria-expressed kinase);176943;A, Psh, Fd;;Crouzon syndrome, 123500 (3); Jackson-Weiss syndrome, 123150 (3); Beare-Stevenson cutis gyrata syndrome, 123790 (3); Pfeiffer syndrome, 101600 (3); Apert syndrome, 101200 (3); Saethre-Chotzen syndrome, 101400 (3); Craniosynostosis, nonspecific (3); Gastric cancer, somatic, 613659 (3); Craniofacial-skeletal-dermatologic dysplasia, 101600 (3); Antley-Bixler syndrome without genital anomalies or disordered steroidogenesis, 207410 (3); Scaphocephaly and Axenfeld-Rieger anomaly (3); LADD syndrome, 149730 (3); Scaphocephaly, maxillary retrusion, and mental retardation, 609579 (3); Bent bone dysplasia syndrome, 614592 (3);7(Fgfr2)
10.567;6;29;98;10q25.3;GFRA1, GDNFRA, GDNFR;;GDNF family receptor, alpha-1;601496;A, R;;;19(Gfra1)
10.568;9;12;93;10q26.3;MGMT;;Methylguanine-DNA methyltransferase;156569;REa, A;;;
10.569;7;28;17;10q26.3;NKX6-2, NKX6B, NKX6.2, SPAX8;;NK6 transcription factor related, locus 2 (Drosophila);605955;REc, R;;Spastic ataxia 8, autosomal recessive, with hypomyelinating leukodystrophy, 617560 (3);7(Nkx6b)
10.570;4;20;10;10q26.13;OAT, GACR;;Ornithine aminotransferase;613349;S, REa, A, Fd;pseudogene at Xp11.2;Gyrate atrophy of choroid and retina with or without ornithinemia, 258870 (3);7(Oat)
10.571;5;7;01;10q23.33;PDLIM1, CLP36, CLIM1;;PDZ and LIM domain protein 1;605900;A, R, REa;;;
10.572;1;1;96;10q26.2;PTPRE;;Protein tyrosine phosphatase, receptor type, epsilon;600926;A;;;7(Ptpre)
10.573;12;29;06;10q26.11;RAB11FIP2, KIAA0941;;RAB11 family-interacting protein 2;608599;REc;;;
10.574;1;25;05;10q26;RRIS;;Respiratory rhythmicity in sleep;609116;Fd;;[Respiratory rhythmicity in sleep] (2);
10.575;1;31;01;10q26.13;TACC2;;Transforming, acidic, coiled-coil-containing protein 2;605302;REc;;;
10.576;8;17;99;10q26.3;UTF1;;Undifferentiated embryonic cell transcription factor 1;604130;A;;;7(Utf1)
10.577;10;11;12;10q26.12;WDR11, DR11, KIAA1351, BRWD2, HH14;;WD repeat-containing protein 11;606417;REc, Ch;;Hypogonadotropic hypogonadism 14 with or without anosmia, 614858 (3);
10.578;4;15;02;10q26.11;EMX2;;Empty spiracles, Drosophila, homolog of, 2;600035;REa, A;close to VAX1;Schizencephaly, 269160 (3);19(Emx2)
10.579;5;23;14;10q26.3;JAKMIP3, C10orf39, NECC2, JAMIP3;;Janus kinase and microtubule interacting protein 3;611198;REc;;;
10.580;3;20;03;10q26.11;EMX2OS;;EMX2 opposite strand;607637;REc;non-coding RNA;;19(Emx2os)
10.581;5;30;17;10q25.3;PNLIP, PNLIPD;;Pancreatic lipase;246600;REa, A;mutation identified in 1 family;?Pancreatic lipase deficiency, 614338 (3);
10.582;2;2;15;10q25.3;VAX1, MCOPS11;;Ventral anterior homeo box 1;604294;H, REc;mutation identified in one MCOPS11 family;?Microphthalmia, syndromic 11, 614402 (3);19(Vax1)
10.583;12;6;16;10q26.11;INPP5F, SAC2, KIAA0966;;Inositol polyphosphate 5-phosphatase F;609389;REc;;;
10.584;4;17;07;10q26.11;MCMBP, C10orf119;;Minichromosome maintenance complex-binding protein;610909;R, REc;;;
10.585;9;23;13;10q26.11;NANOS1, NOS1, SPGF12;;NANOS, Drosophila, homolog of, 1;608226;R, REc;;Spermatogenic failure 12, 615413 (3);
10.586;1;2;14;10q26.11;SFXN4, COXPD18;;Sideroflexin 4;615564;REc;;Combined oxidative phosphorylation deficiency 18, 615578 (3);
10.587;1;25;18;10q26.11-q26.12;SEC23IP;;Sec23-interacting protein;617852;REc;;;
10.588;1;16;07;10q25.3;HSPA12A, KIAA0417;;Heat-shock 70kD protein 12A;610701;R, REc;;;19(Hspa12a)
10.589;2;10;17;10q26.13;CPXM2, CPX2;;Carboxypeptidase X, M14 family, member 2;617348;REc;;;
10.590;4;23;08;10q26.13;CTBP2;;C-terminal-binding protein 2;602619;REc;;;
10.591;11;20;15;10q26.13;CUZD1, ERG1, ITMAP1;;Cub and zona pellucida-like domains 1;616644;REc;;;
10.592;12;6;17;10q26.13;EEF1AKMT2, METTL10;;EEF1A lysine methyltransferase 2;617794;REc;;;
10.593;1;9;17;10q26.13;FAM53B, KIAA0140;;Family with sequence similarity 53, member B;617289;Psh, REc;;;
10.594;4;23;09;10q26.13;FAM175B, ABRO1, KIAA0157;;Family with sequence similarity 175, member B;611144;Psh, REc;;;
10.595;4;26;10;10q26.13;HMX3, NKX5.1;;H6 family homeobox 3;613380;REc;;;7(Hmx3)
10.596;9;27;17;10q26.13;IFZF5, ZNFN1A5, PEGASUS;;Ikaros family zinc finger 5;606238;REc;;;
10.597;12;5;16;10q26.13;LHPP;;Phospholysine phosphohistidine inorganic pyrophosphate phosphatase;617231;REc;;;
10.598;3;10;11;10q26.13;LOC387715, ARMD8;;LOC387715 gene;611313;REc, Fd;;{Macular degeneration, age-related, 8}, 613778 (3);
10.599;1;20;16;10q26.2;MMP21, HTX7;;Matrix metalloproteinase 21;608416;REc;;Heterotaxy, visceral, 7, autosomal, 616749 (3);
10.600;9;9;09;10q26.13;NSMCE4A, NSE4A;;Non-SMC element 4, S. cerevisiae, homolog of, A;612987;REc;;;
10.601;4;6;15;10q26.13;PSTK, C10orf89;;Phosphoseryl-tRNA kinase;611310;R, REc;;;
10.602;1;23;08;10q26.13;ZRANB1, TRABID;;Zinc finger- and RAN-binding domain-containing protein 1;611749;R, REc;;;
10.603;6;3;98;10q26.2;DOCK1, DOCK180;;Dedicator of cytokinesis-1;601403;A;;;
10.604;10;25;17;10q26.2;C10orf90, FATS;;Chromosome 10 open reading frame 90;617735;REc;;;
10.605;9;26;16;10q26.2;FAM196A, C10orf141, INSYN2;;Family with sequence similarity 196, member A;617129;REc;;;
10.606;12;18;07;10q26.2;FANK1;;Fibronectin type III and ankyrin repeat domains 1;611640;R, REc;;;
10.607;11;23;16;10q26.2;FOXI2;;Forkhead box I2;617202;REc;;;
10.608;8;17;09;10q26.2;NPS;;Neuropeptide S;609513;REc;;;
10.609;3;27;15;10q26.3;ECHS1, SCEH, ECHS1D;;Enoyl-CoA hydratase, short-chain, 1, mitochondrial;602292;A;;Mitochondrial short-chain enoyl-CoA hydratase 1 deficiency, 616277 (3);
10.610;5;11;00;10q26.13;GPR26;;G protein-coupled receptor 26;604847;A;;;
10.611;7;13;98;10q26.3;ADAM8, CD156;;A disintegrin and metalloprotease domain 8;602267;A;;;7(Adam8)
10.612;12;11;98;10q26.2;ADAM12, MLTN;;A disintegrin and metalloproteinase domain 12 (Meltrin-alpha, mouse, homolog of);602714;A, R;;;
10.613;9;1;16;10q26.3;ADGRA1, GPR123, KIAA1828;;Adhesion G protein-coupled receptor A1;612302;REc;;;
10.614;6;10;11;10q26.3;BNIP3, NIP3;;BCL2/adenovirus E1B 19-kD protein-interacting protein 3;603293;REc;;;
10.615;6;27;14;10q26.3;CALY, DRD1IP;;Calcyon neuron-specific vesicular protein;604647;REc;;;
10.616;2;9;17;10q26.3;EBF3, COE3, HADDS;;Early B-cell factor 3;607407;REc;;Hypotonia, ataxia, and delayed development syndrome, 617330 (3);
10.617;10;25;17;10q26.3;FUOM, FUCU;;Fucose mutarotase;617725;REc;;;
10.618;5;12;09;10q26.3;GLRX3, PICOT;;Glutaredoxin 3;612754;REc;;;
10.619;1;20;98;10q26.3;INPP5A;;Inositol polyphosphate-5-phosphatase, 40kD;600106;A;;;
10.620;2;25;15;10q26.3;KNDC1, RASGEF2, KIAA1768;;Kinase noncatalytic C-lobe domain-containing protein 1;616237;R, REc;;;
10.621;7;18;14;10q26.3;PAOX, PAO;;Polyamine oxidase;615853;REc;;;7(Paox)
10.622;9;8;11;10q26.3;PPP2R2D;;Protein phosphatase 2, regulatory subunit B, delta;613992;REc;;;
10.623;12;20;05;10q26.3;PRAP1;;Proline-rich acidic protein 1;609776;R, REc;;;
10.624;12;1;06;10q26.3;SPRN, SHADOO, SHO;;Shadow of prion protein;610447;REc;;;7(Sprn)
10.625;5;23;16;10q26.3;SYCE1, POF12, SPGF15;;Synaptonemal complex central element protein 1;611486;REc;mutation identified in 1 POF12 and 1 SPGF15 family;?Premature ovarian failure 12, 616947 (3); ?Spermatogenic failure 15, 616950 (3);
10.626;12;22;17;10q26.3;TUBGCP2, GCP2, GRIP103, SPC97, ALP4;;Tubulin-gamma complex-associated protein 2;617817;REc;;;
10.627;6;12;12;10q26.3;VENTX, VENTX2, HPX42B;;VENT homeobox;607158;A;;;
11.1;2;22;18;11q14.1;ALG8, CDG1H, PCLD3;;Alg8, S. cerevisiae, homolog of;608103;REc;;Congenital disorder of glycosylation, type Ih, 608104 (3); Polycystic liver disease 3 with or without kidney cysts, 617874 (3);
11.2;12;11;01;11p15.2;RRAS2, TC21;;Related Ras viral oncogene homolog 2;600098;R;;Ovarian carcinoma (3);
11.3;7;20;09;11p15.4;AMPD3;;Adenosine monophosphate deaminase-3, isoform E;102772;REa;;[AMP deaminase deficiency, erythrocytic], 612874 (3);7(Ampd3)
11.4;5;4;12;11p13;CD44, MDU2, MDU3, MIC4, IN;;CD44 antigen (homing function);107269;S;;[Blood group, Indian system], 609027 (3);2(Ly24)
11.5;3;6;94;11pter-p11.2;TP250;;T-cell activation antigen p250;186710;S;;;
11.6;5;12;08;11p15.5;AP2A2, KIAA0899;;Adaptor-related protein complex 2, alpha-2 subunit;607242;R, REc;;;
11.7;8;4;97;11p15.5;ASCL2;;Achaete-scute complex, Drosophila, homolog-like 2;601886;A;;;
11.8;9;23;13;11p15.5;BET1L, GS15;;BET1-like protein;615417;REc;;;
11.9;5;23;13;11p15.5;BRSK2, SAD1, PEN11B;;BR serine/threonine kinase 2;609236;A;;;
11.10;8;20;07;11p15.5;C11orf21;;Chromosome 11 open reading frame 21;611033;REc;;;
11.11;11;4;93;11p15.4;CARS;;Cysteinyl-tRNA synthetase;123859;REa, A;;;
11.12;7;20;06;11p15.5;CD151, PETA3, SFA1, MER2;;CD151 antigen;602243;A, S, REa;;Nephropathy with pretibial epidermolysis bullosa and deafness, 609057 (3); [Blood group, Raph], 179620 (3);
11.13;12;10;10;11p15.5;CDHR5, MUCDHL;;Cadherin-related family, member 5;606839;REc;;;
11.14;7;20;12;11p15.4;CDKN1C, KIP2, BWS, IMAGE;;Cyclin-dependent kinase inhibitor 1C (p57, Kip2);600856;A, Ch, Fd;rare cause of BWS;Beckwith-Wiedemann syndrome, 130650 (3); IMAGE syndrome, 614732 (3);7(Kip2)
11.15;12;19;11;11p15.5;CEND1, BM88;;Cell cycle exit and neuronal differentiation 1;608213;REc, A;;;
11.16;3;14;14;11p15.5;CHID1, SICLP;;Chitinase domain-containing protein 1;615692;REc;;;
11.17;11;28;01;11p15.4;CHRNA10;;Cholinergic receptor, neuronal nicotinic, alpha polypeptide 10;606372;A, R;;;
11.18;5;31;06;11p15.5;CTSD, CPSD, CLN10;;Cathepsin D (lysosomal aspartyl protease);116840;REa, A;;Ceroid lipofuscinosis, neuronal, 10, 610127 (3);
11.19;11;15;16;11p15.5;DEAF1, SPN, ZMYND5, MRD24;;Deaf1, Drosophila, homolog of;602635;REc;mutation identified in 1 DYSEIDD family;Mental retardation, autosomal dominant 24, 615828 (3); ?Dyskinesia, seizures, and intellectual developmental disorder, 617171 (3);
11.20;11;16;10;11p15.5;DRD4;;Dopamine receptor D4;126452;Fd;proximal to HRAS;Autonomic nervous system dysfunction (3); [Novelty seeking personality], 601696 (1); {Attention deficit-hyperactivity disorder}, 143465 (3);
11.21;3;9;98;11p15.5;DUSP8, HVH8;;Dual specificity phosphatase-8;602038;A;pseudogene on 10q11.2;;7(Dusp8)
11.22;9;6;11;11p15.5;EFCAB4A, CRACR2B;;EF-hand calcium-binding domain-containing protein 4A;614177;REc;;;
11.23;7;23;09;11p15.5;H19, D11S813E, ASM1, BWS, WT2;;H19 gene;103280;REa, A, RE;same 200kb fragment as IGF2;Beckwith-Wiedemann syndrome, 130650 (3); Silver-Russell syndrome, 180860 (3); Wilms tumor 2, 194071 (3);7(H19)
11.24;4;23;08;11p15.5;HCCA2;;HCCA2 gene;611969;REc;;;
11.25;2;3;15;11p15.5;ICR1;;H19-IGF2-imprinting control region;616186;REn;;Beckwith-Wiedemann syndrome, 130650 (3);
11.26;8;9;12;11p15.5;IFITM1, IFI17, LEU13;;Interferon-induced transmembrane protein 1;604456;R, REc;;;
11.27;8;9;12;11p15.5;IFITM2;;Interferon-induced transmembrane protein 1;605578;R, REc;;;
11.28;7;20;12;11p15.5;IFITM3;;Interferon-induced transmembrane protein 3;605579;R, REc;;{Influenza, severe, susceptibility to}, 614680 (3);
11.29;9;21;12;11p15.5;IFITM5, OI5;;Interferon-induced transmembrane protein 5;614757;REc;;Osteogenesis imperfecta, type V, 610967 (3);
11.30;5;13;15;11p15.5;IRF7, IRF7A, IRF7B, IRF7C, IRF7H, IMD39;;Interferon regulatory factor 7;605047;REc;mutation identified in 1 family;?Immunodeficiency 39, 616345 (3);
11.31;10;28;10;11p15.5-p15.4;KCNQ1, KCNA9, LQT1, KVLQT1, ATFB3, SQT2;;Potassium voltage-gated channel, KQT-like subfamily, member 1;607542;Fd;;Long QT syndrome 1, 192500 (3); Jervell and Lange-Nielsen syndrome, 220400 (3); Atrial fibrillation, familial, 3, 607554 (3); Short QT syndrome 2, 609621 (3); {Long QT syndrome 1, acquired, susceptibility to}, 192500 (3);7(Kcnq1)
11.32;8;25;03;11p15.4;LCRB;;Locus control region beta;152424;REc;;Thalassemia, Hispanic gamma-delta-beta, 613985 (3);
11.33;12;28;18;11p15.5;LRRC56, CILD39;;Leucine-rich repeat-containing protein 56;618227;REc;;Ciliary dyskinesia, primary, 39, 618254 (3);
11.34;9;9;09;11p15.5;MIR210, MIRN210;;Micro RNA 210;612982;REc;;;
11.35;3;31;09;11p15.4;MRGPRG, MRGG;;MAS-related G protein-coupled receptor family, member G;607234;REc;;;
11.36;8;28;92;11p15.5;MUC2;;Mucin 2, intestinal/tracheal;158370;REa;;;
11.37;6;13;95;11p15.5;MUC5AC, MUC5;;Mucin 5, subtypes A and C, tracheobronchial/gastric;158373;REa, A;;;
11.38;6;14;18;11p15.4;HBB, ECYT6;;Hemoglobin beta;141900;LD, AAS, F, Fd;pseudogene HBBP1 between HBG and HBD loci;Sickle cell anemia, 603903 (3); Thalassemia, beta, 613985 (3); Methmoglobinemia, beta type, 617971 (3); Heinz body anemia, 140700 (3); Thalassemia-beta, dominant inclusion-body, 603902 (3); Delta-beta thalassemia, 141749 (3); Hereditary persistence of fetal hemoglobin, 141749 (3); {Malaria, resistance to}, 611162 (3); Erythrocytosis 6, 617980 (3);7(Hbb)
11.39;6;16;97;11p15.4;HBD;;Hemoglobin delta;142000;AAS;;Thalassemia, delta- (3); Thalassemia due to Hb Lepore (3);
11.40;11;13;07;11p15.4;HBG1;;Hemoglobin, gamma A;142200;RE;;Fetal hemoglobin quantitative trait locus 1, 141749 (3);
11.41;6;15;11;11p15.4;HBG2, TNCY;;Hemoglobin, gamma G;142250;RE;;Fetal hemoglobin quantitative trait locus 1, 141749 (3); Cyanosis, transient neonatal, 613977 (3);
11.42;3;1;89;11p15.4;HBE1;;Hemoglobin epsilon;142100;RE;;;
11.43;6;18;15;11p15.5;HRAS;;Harvey rat sarcoma viral (v-Ha-ras) oncogene homolog;190020;S;pseudogene HRASP on X;{Bladder cancer, somatic}, 109800 (3); Costello syndrome, 218040 (3); {Thyroid carcinoma, follicular, somatic}, 188470 (3); Congenital myopathy with excess of muscle spindles, 218040 (3); {Nevus sebaceous or woolly hair nevus, somatic}, 162900 (3); Schimmelpenning-Feuerstein-Mims syndrome, somatic mosaic, 163200 (3); {Spitz nevus or nevus spilus, somatic}, 137550 (3);7(Hras1)
11.44;7;28;15;11p15.5;IGF2, GRDF;;Insulin-like growth factor-2, or somatomedin A;147470;REa, A, RE;mutation identified in 1 GRDF family;?Growth restriction, severe, with distinctive facies, 616489 (3);7(Igf2)
11.45;7;8;13;11p15.5;IGF2AS, PEG8;;Insulin-like growth factor II, antisense;610146;REc;;;
11.46;2;5;15;11p15.5;INS, MODY10, IDDM2;;Insulin;176730;HS, A, REb, Fd, D;5'--INS-12.6kb-IGF2--3'; cen-HBBC-10cM-INS-2cM-HRAS1-3cM-TH;Hyperproinsulinemia, 616214 (3); Maturity-onset diabetes of the young, type 10, 613370 (3); Diabetes mellitus, permanent neonatal, 606176 (3); Diabetes mellitus, insulin-dependent, 2, 125852 (3);6(Ins1); 7(Ins2)
11.47;2;28;03;11p15.5;IRDN, ILPR;;Insulin-related DNA polymorphism (insulin-related VNTR);147510;Fd;;;
11.48;5;22;07;11p15.4;KCNQ1DN;;KCNQ1 downstream neighbor;610980;REc;;;
11.49;4;29;17;11p15.5;PHRF1, KIAA1542;;PHD and RING finger domain-containing protein 1;611780;R, REc;;;
11.50;8;16;99;11p15.5;KCNQ1OT1, LIT1;;KCNQ1-overlapping transcript 1;604115;REc;;Beckwith-Wiedemann syndrome, 130650 (3);7(Kcnq10t1)
11.51;12;19;90;11p15.5;KRTAP5-1, KRN1L;;Keratin associated protein 5-1;148022;A;;;
11.52;3;23;93;11p15.5;LSP1;;Lymphocyte-specific protein pp52;153432;A;;;
11.53;11;22;13;11p15.5;MIR675;;Micro RNA 675;615509;REc;;;
11.54;3;7;06;11p15.5;NALP6, PYPAF5;;NACHT domain-, leucine-rich repeat-, and PYD-containing protein 6;609650;REc;;;
11.55;6;9;98;11p15.4;NAP1L4, NAP2L, NAP2;;Nucleosome assembly protein 1-like 4;601651;REc;;;
11.56;1;27;04;11p15.5;ODF3, SHIPPO1;;Outer dense fiber of sperm tails 3;608356;REc;;;7(Odf3)
11.57;5;23;13;11p15.4;PGAP2, FRAG1, HPMRS3, MRT17, MRT21;;Post-GPI attachment to proteins 2;615187;A, R;;Hyperphosphatasia with mental retardation syndrome 3, 614207 (3);
11.58;7;14;16;11p15.5;PGGHG, ATHL1;;Protein-glucosylgalactosylhydroxylysine glucosidase;617032;REc;;;
11.59;10;28;04;11p15.4;PHLDA2, TSSC3, IPL, BRW1C;;Pleckstrin homology-like domain, family A, member 2;602131;REn;;;7(Ipl)
11.60;11;11;14;11p15.5;PIDD1, LRDD;;p53-induced death domain protein 1;605247;REc, H;;;
11.61;1;24;07;11p15.5;PNPLA2, TTS2, ATGL;;Patatin-like phospholipase domain-containing protein 2;609059;R;;Neutral lipid storage disease with myopathy, 610717 (3);7(Pnpla2)
11.62;9;24;12;11p15.5;PSMD13, S11;;Proteasome 26S subunit, non-ATPase, 13;603481;REc, R;;;
11.63;5;26;09;11p15.5;PTDSS2, PSS2;;Phosphatidylserine synthase 2;612793;REc;;;
11.64;9;7;12;11p15.5;RASSF7, C11orf13, HRC1;;RAS association domain family, member 7;143023;REn;29kb 5' to HRAS1; divergently transcribed;;
11.65;12;10;12;11p15.5;RIC8A;;Ric8, C. elegans, homolog of, A;609146;REc, R;;;
11.66;1;22;15;11p15.5;RNH1, RNH;;Ribonuclease/angiogenin inhibitor 1;173320;REa, A;;;
11.67;12;22;98;11p15.5;RPL23L, L23MRP, MRPL23;;Ribosomal protein L23-like (L23 mitochondrial-related protein);600789;REn;;;
11.68;6;22;12;11p15.5;RPLP2;;Ribosomal phosphoprotein, large, P2;180530;REc;;;
11.69;7;13;93;11p15.4;RRM1;;Ribonucleotide reductase, M1 polypeptide;180410;S, REa, A;;;7(Rrm1)
11.70;2;25;15;11p15.5;SCGB1C1, RYD5;;Secretoglobin, family 1C, member 1;610176;REc;;;
11.71;2;14;01;11p15.5;SCT;;Secretin;182099;R;;;
11.72;1;30;01;11p15.5;SIGIRR;;Single immunoglobulin domain-containing IL1R-related protein;605478;R;;;
11.73;5;4;00;11p15.5;SIRT3, SIR2L3;;Sirtuin, S. cerevisiae, homolog 3;604481;REc;;;
11.74;2;3;00;11p15.4;SLC22A1LS, ORCTL2S, BWSCR1B;;Solute carrier family 22, member 1-like-antisense;603240;REc;;;
11.75;6;23;11;11p15.4;SLC22A1L, BWSCR1A, IMPT1;;Solute carrier family 22, member 1-like (Beckwith-Wiedemann region 1A; organic-cation transporter-like 2);602631;REn;;Breast cancer, somatic, 114480 (3); Rhabdomyosarcoma, somatic, 268210 (3); Lung cancer, somatic, 211980 (3);
11.76;4;7;05;11p15.5;SLC25A22, GC1, EIEE3;;Solute carrier family 25 (mitochondrial carrier, glutamate), member 22;609302;REc, Fd;;Epileptic encephalopathy, early infantile, 3, 609304 (3);
11.77;12;11;03;11p15.5;SLEN3;;Systemic lupus erythematosus with nephritis, susceptibility to, 3;607967;Fd;;{Systemic lupus erythematosus with nephritis, susceptibility to, 3} (2);
11.78;7;17;14;11p15.4;STIM1, TAM1, IMD10, STRMK;;Stromal interaction molecule 1;605921;REn;;Immunodeficiency 10, 612783 (3); Myopathy, tubular aggregate, 1 160565 (3); Stormorken syndrome, 185070 (3);
11.79;5;22;13;11p15.5;SYT8;;Synaptotagmin 8;607719;REc;;;
11.80;1;20;09;11p15.5;TH, TYH;;Tyrosine hydroxylase;191290;REa, A, Fd, RE;distal to HRAS1;Segawa syndrome, recessive, 605407 (3);7(Th)
11.81;3;3;03;11p15.5;TNNI2, AMCD2B, DA2B, FSSV;;Troponin I, fast-twitch skeletal muscle isoform;191043;R, Fd;;Arthrogryposis multiplex congenita, distal, type 2B, 601680 (3);
11.82;8;11;03;11p15.5;TNNT3, AMCD2B, DA2B, FSSV;;Troponin-T3, skeletal, fast;600692;REa, A, Fd;;Arthrogryposis, distal, type 2B, 601680 (3);7(Tnnt3)
11.83;3;8;07;11p15.4;TRIM21, SSA1, RO52;;Tripartite motif-containing protein 21;109092;A;;;
11.84;7;9;06;11p15.5;TOLLIP;;Toll-interacting protein;606277;R, REc;;;
11.85;1;14;14;11p15.4;TPP1, CLN2, SCAR7;;Tripeptidyl peptidase 1;607998;Fd, LD;;Ceroid lipofuscinosis, neuronal, 2, 204500 (3); Spinocerebellar ataxia, autosomal recessive 7, 609270 (3);
11.86;1;14;02;11p15.5;TRPM5, MTR1;;Transient receptor potential cation channel, subfamily M, member 5 (MLSN1- and TRP-related gene 1);604600;REc;maternal allele imprinted;;7(Mtr1)
11.87;1;20;06;11p15.5;TSPAN4, TM4SF7, NAG2;;Tetraspanin 4;602644;REc;;;
11.88;1;20;06;11p15.5;TSPAN32, PHEMX, TSSC6;;Tetraspanin 32;603853;RE;not imprinted;;
11.89;11;2;04;11p15.4;TSSC2;;Tumor-suppressing subtransferable fragment candidate gene 2;608999;REc;;;
11.90;8;31;99;11p15.5;TSSC4;;Tumor-suppressing subchromosomal transferable fragment cDNA 4;603852;RE;not imprinted;;
11.91;3;9;98;11p15.4;ZNF195;;Zinc finger protein-195;602187;REc;;;
11.92;12;4;02;11p15.4;FXC1, TIMM10B;;Fracture callus 1, rat, homolog of;607388;A, R;;;
11.93;7;13;93;11p15.4;ARHG;;ras homolog gene family, member G (rho G);179505;A;;;
11.94;3;6;94;11p15.4;CCKBR, GASR;;Cholecystokinin B receptor;118445;REa, A;;;7(Cckbr)
11.95;12;17;87;11p15.4;HPX;;Hemopexin;142290;REa, A;;;
11.96;6;25;99;11p15.4;ILK, P59;;Integrin-linked kinase;602366;A;;;
11.97;2;26;08;11p15.4;MRPL17;;Mitochondrial ribosomal protein L17;611830;R;;;
11.98;2;20;97;11p15.5;MUC6;;Mucin 6, gastric;158374;A;order: tel-HRAS-MUC6-MUC2-MUC5AC-MUC5B-IGF2-cen;;
11.99;8;9;01;11p15.5;TALDO1;;Transaldolase-1;602063;REa, A, R;pseudogene on chr.1;Transaldolase deficiency, 606003 (3);
11.100;10;16;89;11p15.1;LDHC, LDH3;;Lactate dehydrogenase C;150150;REa, A, REb;closely linked to LDHB in other species; in man syntenic with LDHA; ?close to LDHA;;7(Ldh3)
11.101;7;15;99;11p15.4;ADM;;Adrenomedullin;103275;REa;;;7(Adm)
11.102;10;2;12;11p15.4;ARFIP2, POR1;;ADP-ribosylation factor-interacting protein 2;601638;REc;;;
11.103;4;13;15;11p15.4;BGLT3, LINC01083;;Beta-globin locus transcript 3, noncoding;616308;REc;;;
11.104;3;20;09;11p15.4;CYB5R2;;Cytochrome b5 reductase 2;608342;REc;;;
11.105;11;17;15;11p15.4;DCHS1, PCDH16, FIB1, CDH19, VMLDS1, MVP2;;Dachsous, Drosophila, homolog of, 1;603057;REc;;Van Maldergem syndrome 1, 601390 (3); Mitral valve prolapse 2, 607829 (3);
11.106;1;11;17;11p15.4;DENND5A, RAB6IP1, KIAA1091, EIEE49;;DENN domain-containing protein 5A;617278;REc;;Epileptic encephalopathy, early infantile, 49, 617281 (3);
11.107;12;27;16;11p15.4;DHND1, FLJ00251;;Dynein heavy chain domain 1;617277;REc;;;
11.108;10;3;07;11p15.4;EIF3F, EIF3S5;;Eukaryotic translation initiation factor 3, subunit F;603914;REc;;;
11.109;12;8;14;11p15.4;GVINP1, VLIG1;;GTPase, very large interferon-inducible, pseudogene 1;616121;REc;;;7(Gvin1)
11.110;8;17;09;11p15.1;LDHA, LDH1, GSD11;;Lactate dehydrogenase A;150000;S, D, REb, C, A;;Glycogen storage disease XI, 612933 (3);7(Ldh1)
11.111;3;31;09;11p15.4;MRGPRE, MRGE;;Mas-related G protein-coupled receptor family, member E;607232;REc;;;
11.112;4;30;91;11p15.1;MYOD1, MYF3;;Myogenic factor-3;159970;REa, A;proximal to CALCA, HBB, BWS, PTH; ?11p14.3;;7(Myod1)
11.113;4;17;13;11p15.4;NLRP1, NALP14, NOD5;;NLR family, pyrin domain containing 1;609665;REc;;;
11.114;8;8;13;11p15.4;OR10A1;;Olfactory receptor, family 10, subfamily A, member 1;608493;REc, A;;;
11.115;8;8;13;11p15.4;OR2D2;;Olfactory receptor, family 2, subfamily D, member 2;608494;REc, A;;;
11.116;8;19;13;11p15.4;OR51E1, DGPCR, PSGR2;;Olfactory receptor, family 51, subfamily E, member 1;611267;REn;;;
11.117;8;19;13;11p15.4;OR51E2, PSGR;;Olfactory receptor, family 51, subfamily E, member 2;611268;REn;;;
11.118;5;7;03;11p15.4;OSBPL5, ORP5, KIAA1534;;Oxysterol-binding protein-like protein 5;606733;R, REc;;;
11.119;11;27;18;11p15.4;PPFIB2;;Protein-tyrosine phosphatase, receptor-type, F polypeptide-interacting protein-binding protein 2;603142;REc;;;
11.120;12;10;12;11p15.4;RIC3;;Resistance to inhibitors of cholinesterase 3, C. elegans, homolog of;610509;REc;;;
11.121;7;18;14;11p15.4;RRP8, NML, KIAA0409;;Ribosomal RNA processing protein 8, homolog of;615818;R, REc;;;
11.122;4;19;12;11p15.4;SCUBE2;;Signal peptide-, CUB domain-, and EGF-like domains-containing protein 2;611747;REc;;;
11.123;4;2;16;11p15.4;SNORA3B, SNORA45;;Small nucleolar RNA, H/ACA box 3B;611333;REc;;;
11.124;8;17;10;11p15.4;SYT9;;Synaptotagmin 9;613528;REc;;;
11.125;4;17;12;11p15.4;TRIM3, RNF22, BERP;;Tripartite motif-containing 3;605493;R, REc;;;
11.126;4;23;08;11p15.4;TRIM66, TIF1D, KIAA0298;;Tripartite motif-containing protein 66;612000;R, REc;;;
11.127;12;21;09;11p15.4;TRIM68, SS56, GC109;;Tripartite motif-containing protein 68;613184;REc;incorrectly assigned to 2p24 by FISH;;
11.128;2;3;15;11p15.4;TUB, RDOB;;Tubby, mouse, homolog of;601197;REc, H;mutation identified in 1 RDOB family;?Retinal dystrophy and obesity, 616188 (3);
11.129;6;26;00;11p15.4;ZNF214;;Zinc finger protein-214;605015;REc;;;
11.130;6;26;00;11p15.4;ZNF215;;Zinc finger protein-215;605016;REc;;;
11.131;2;25;15;11p15.4;MRVI1, IRAG;;Murine retrovirus integration site 1, homolog of;604673;REc;;;
11.132;2;28;01;11p15.4;TRIM34, RNF21, IFP1;;Tripartite motif-containing 34 (RING finger protein-21);605684;A;;;
11.133;6;6;00;11p15.4;ZNF143, SBF;;Zinc finger protein-143;603433;A;;;
11.134;3;31;03;11p15.4;SMPD1, NPD;;Sphingomyelin phosphodiesterase-1, acid lysosomal;607608;REa, A;;Niemann-Pick disease, type A, 257200 (3); Niemann-Pick disease, type B, 607616 (3);7(Smpd1)
11.135;9;11;08;11p15.4;AKIP1, BCA3, C11orf17;;Protein kinase A-interacting protein 1;609191;R, REc;;;7(Akip1)
11.136;4;6;13;11p15.4;GALNT18, GALNACT18, GALNTL4;;UPD-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 18;615136;REc;;;
11.137;10;28;08;11p15.3;MICAL2, KIAA0750;;Microtubule-associated monooxygenase, calponin and LIM domains-containing 2;608881;R, REc;;;
11.138;10;28;08;11p15.3;MICALCL, EBITEIN1;;MICAL C terminus-like protein;612355;REc;;;
11.139;12;2;09;11p15.4;NRIP3;;Nuclear receptor-interacting protein 3;613125;REc;;;
11.140;5;16;05;11p15.4;SH2BP1, KIAA0155, p150;;SH2 domain-binding protein 1;609366;Psh, REc;;;7(Sh2bl1)
11.141;4;3;03;11p15.4;STK33;;Serine/threonine protein kinase 33;607670;REc, H;;;7(Stk33)
11.142;12;4;01;11p15.4;TAF10, TAF2H, TAF2A;;TAF10 RNA polymerase II, TATA box-binding protein-associated factor, 30kD;600475;A;;;
11.143;2;23;12;11p15.3;USP47;;Ubiquitin-specific protease 47;614460;REc;;;
11.144;5;29;13;11p15.4;ZBED5, BUSTER1;;Zinc finger BED domain-containing protein 5;615251;REc;;;
11.145;10;7;02;11p15.2;SOX6;;SRY-box 6;607257;A;;;7(Sox6)
11.146;7;20;06;11p15.3;PTH;;Parathyroid hormone;168450;REa, REb, A, Fd;~9cM distal to CALC1; distal to MYOD;Hypoparathyroidism, autosomal dominant, 146200 (3); Hypoparathyroidism, autosomal recessive, 146200 (3);7(Pth)
11.147;3;23;93;11p15.4;WEE1;;wee1+, S. pombe, homolog of;193525;A;;;
11.148;8;21;91;11p15.1;TPH1, TPH;;Tryptophan hydroxylase 1 (tryptophan-5-monooxygenase);191060;REa, A;;;7(Tph)
11.149;8;12;14;11p15.3;BTBD10;;BTB/POZ domain-containing protein 10;615933;REc;;;
11.150;10;15;10;11p15.2;COPB1, COPB;;Coatomer protein complex, subunit beta 1;600959;REc;;;
11.151;7;20;04;11p15.2;CYP2R1;;Cytochrome P450, subfamily IIR, polypeptide 1 (vitamin D 25-hydroxylase);608713;REc;;Rickets due to defect in vitamin D 25-hydroxylation, 600081 (3);
11.152;1;5;15;11p15.3;FAR1, MLSTD2, PFCRD;;Fatty acyl CoA reductase 1;616107;REc;;Peroxisomal fatty acyl-CoA reductase 1 disorder, 616154 (3);7(Far1)
11.153;12;29;06;11p15.2;INSC;;Inscuteable, Drosophila, homolog of;610668;REc;;;
11.154;7;18;12;11p15.3;RASSF10;;Ras association domain family, member 10;614713;REc;;;
11.155;9;18;06;11p15.3;TEAD1, TCF13, REF1;;TEA domain family member 1;189967;Psh, R;;Sveinsson chorioretinal atrophy, 108985 (3);
11.156;5;8;97;11p15.2;CALCA, CALC1;;Calcitonin/calcitonin-related polypeptide, alpha;114130;REa, A, REb, D, Fd, REn;same 220kb fragment as CALCB;;7(Calc)
11.157;3;23;93;11p15.2;CALCB, CALC2;;Calcitonin-related polypeptide, beta;114160;A, REa, REb, D;;;
11.158;6;19;98;11p15.1;NELL1;;Nel-like 1;602319;A;;;
11.159;2;18;96;11p15.1;PTPN5, STEP;;Protein tyrosine phosphatase, nonreceptor-type, 5 (striatum-enriched);176879;Psh, A;;;7(Ptpn5)
11.160;5;10;12;11p15.1;SLC6A5, GLYT2, HKPX3;;Solute carrier family 6 (neurotransmitter transporter, glycine), member 5;604159;R;;Hyperekplexia 3, 614618 (3);
11.161;08;16;18;11p15.1;TSG101;;Tumor susceptibility gene 101;601387;R, A;;;
11.162;4;27;07;11p15.1;UEVLD, UEV3, ATTP;;Ubiquitin E2 variant and lactate/malate dehydrogenase domains-containing protein;610985;REc;;;
11.163;7;14;98;11p14.3;GAS2;;Growth arrest-specific 2;602835;R, A, H;;;7(Gas2)
11.164;8;31;06;11p15.1;ABCC8, SUR, PHHI, SUR1, HHF1, TNDM2;;ATP-binding cassette, subfamily C, member 8 (sulfonylurea receptor);600509;A, REn, Fd, LD;;Hyperinsulinemic hypoglycemia, familial, 1, 256450 (3); Hypoglycemia of infancy, leucine-sensitive, 240800 (3); Diabetes mellitus, transient neonatal 2, 610374 (3); Diabetes mellitus, noninsulin-dependent, 125853 (3); Diabetes mellitus, permanent neonatal, 606176 (3);
11.165;1;31;11;11p15.1;B7H6;;B7 homolog 6;613714;REc;;;
11.166;6;24;08;11p15.1;CSRP3, CRP3, CLP, CMD1M, CMH12;;Cysteine- and glycine-rich protein 3;600824;A;mutation identified in 1 CMD1M family;?Cardiomyopathy, dilated, 1M, 607482 (3); Cardiomyopathy, hypertrophic, 12, 612124 (3);
11.167;8;11;15;11p15.3;DKK3, RIG;;Dickkopf, Xenopus, homolog of, 3;605416;A;;;
11.168;6;9;08;11p15.1;E2F8;;E2F transcription factor 8;612047;REc;;;7(E2f8)
11.169;6;1;04;11p15.1;HTATIP2, TIP30, CC3;;HIV-1 TAT-interacting protein 2, 30kD;605628;R, REc;;;
11.170;1;31;17;11p15.1;KCNJ11, BIR, PHHI, HHF2, TNDM3, MODY13;;Potassium inwardly-rectifying channel, subfamily J, member 11;600937;A, REn, Fd, LD;4.5kb 3' of SUR;Hyperinsulinemic hypoglycemia, familial, 2, 601820 (3); Diabetes, permanent neonatal, with or without neurologic features, 606176 (3); {Diabetes mellitus, type 2, susceptibility to}, 125853 (3); Diabetes mellitus, transient neonatal, 3, 610582 (3); Maturity-onset diabetes of the young, type 13, 616329 (3);
11.171;3;31;09;11p15.1;MRGPRX1, MRGX1;;Mas-related G protein-coupled receptor family, member X1;607227;REc;;;
11.172;3;31;09;11p15.1;MRGPRX2, MRGX2;;Mas-related G protein-coupled receptor family, member X2;607228;REc;;;
11.173;3;31;09;11p15.1;MRGPRX3, MRGX3;;Mas-related G protein-coupled receptor family, member X3;607229;REc;;;
11.174;3;31;09;11p15.1;MRGPRX4, MRGX4;;Mas-related G protein-coupled receptor family, member X4;607230;REc;;;
11.175;1;2;08;11p15.1;NAV2, RAINB1, KIAA1419;;Neuron navigator 2;607026;R, REc;;;
11.176;3;31;15;11p15.1;PIK3C2A, CPK;;Phosphatidylinositol 3-kinase, class 2, alpha;603601;REc;;;
11.177;3;31;09;11p15.2-p15.1;PLEKHA7;;Pleckstrin homology domain-containing protein, family A, member 7;612686;REc;;;
11.178;1;13;99;11p15.2;PSMA1, PROS30;;Proteasome subunit, alpha-type, 1;602854;A;;;
11.179;3;18;94;11p15.1;SAA1;;Serum amyloid A1;104750;REa, H, A, Psh;;;7(Saa1)
11.180;3;18;94;11p15.1;SAA2;;Serum amyloid A2;104751;REn, A, Fd, Psh;pseudogene = SAA3;;
11.181;3;18;94;11p15.1;SAA4;;Serum amyloid A4, constitutive;104752;REn, A, Psh;;;7(Saa4)
11.182;11;29;12;11p15.1;USH1C, DFNB18A;;Harmonin (Usher syndrome 1C gene);605242;Fd;Acadian and Samaritan variety;Usher syndrome, type 1C, 276904 (3); Deafness, autosomal recessive 18A, 602092 (3);
11.183;7;15;09;11p15.1;ZDHHC13, HIP14L;;Zinc finger DHHC domain-containing protein 13;612815;REc;;;
11.184;3;18;95;11p15.1;GTF2H1;;General transcription factor IIH, polypeptide 1 (62kD subunit);189972;A, REn;within 50kb of LDHA;;
11.185;6;19;98;11p15.4;APBB1, FE65;;Amyloid beta A4 precursor protein-binding, family B, member-1;602709;A;;;7(Apbb1)
11.186;8;20;98;11p15.3;ARNTL, BMAL1, TIC;;Aryl hydrocarbon receptor nuclear translocator-like;602550;A;;;7(Arntl)
11.187;2;24;97;11p15.4;ART1;;ADP-ribosyltransferase 1;601625;REa;;;7(Art1)
11.188;11;30;06;11p15.4;ART5;;ADP-ribosyltransferase 5;610625;REc;;;7(Art5)
11.189;6;19;98;11p15.4;EIF4G2, DAP5;;Eukaryotic translation initiation factor 4G-like 1;602325;A, H;;;7(Eif4G2)
11.190;8;23;17;11p15.5;EPS8L2, EPS8R2, DFNB106;;EPS8-like protein 2;614988;REc;;Deafness autosomal recessive 106, 617637 (3);7(Eps8l2)
11.191;12;29;99;11p14.3;FANCF;;Fanconi anemia, complementation group F;613897;REc;;Fanconi anemia, complementation group F, 603467 (3);
11.192;8;20;07;11p15;GINGF4, HGF4, GGF4;;Fibromatosis, gingival, 4;611010;Fd;between D11S1984 and D11S1338;Fibromatosis, gingival, 4 (2);
11.193;2;12;07;11p15;IH, HHP;;Hemihyperplasia, isolated;235000;Fd;epigenetic or uniparental disomy;Hemihypertrophy (2);
11.194;2;4;15;11p15.1;KCNC1, EPM7;;Potassium voltage-gated channel, Shaw-related subfamily, member 1;176258;A, REn;;Epilepsy, progressive myoclonic 7, 616187 (3);7(Kcnc1)
11.195;4;17;97;11p15.4;LMO1, RBTN1, RHOM1;;LIM domain only 1 (rhombotin 1);186921;Ch, D;;Leukemia, T-cell acute lymphoblastic (2);7(Ttg1)
11.196;7;26;10;11p15;LVNC2;;Left ventricular noncompaction 2;609470;Fd;max lod at D11S902;Left ventricular noncompaction 2 (2);
11.197;1;8;01;11p15.4;MMP26;;Matrix metalloproteinase 26 (matrilysin 2);605470;REa, R;;;
11.198;7;22;11;11p15.5;MUC5B;;Mucin 5, subtype B, tracheobronchial;600770;REa, A;;{Pulmonary fibrosis, idiopathic, susceptibility to}, 178500 (3);
11.199;2;5;16;11p15;NBLST7;;Neuroblastoma, susceptibility to, 7;616792;Fd;associated with rs2168101;{Neuroblastoma, susceptibility to, 7} (2);
11.200;4;17;13;11p15.4;NLRP10, NALP10, PYNOD, NOD8;;NLR family, pyrin domain containing 10;609662;REc;;;
11.201;2;4;00;11p15.4;NUP98;;Nucleoporin, 98kD;601021;Ch, REc, Psh;fused with HOXA9, NSD1, NSD3, PMX1, HOXC13, DDX10, TOP1, HOXD11 in myeloid leukemia;;
11.202;7;9;14;11p15.4;OR6A2, OR6A1;;Olfactory receptor, family 6, subfamily A, member 2;608495;REc, A;;;
11.203;10;29;09;11p15.3;PARVA;;Parvin, alpha;608120;REc;;;
11.204;3;9;98;11p15.2;PDE3B;;Phosphodiesterase-3B, cGMP-inhibited;602047;A, Psh;;;
11.205;3;6;01;11p15.5;PKP3;;Plakophilin-3;605561;A;;;
11.206;2;16;01;11p15.5;POLR2L, RPB10;;Polymerase II, RNA, subunit L;601189;A;;;
11.207;9;24;08;11p15.4;RBMXL2, HNRNPGT, HNRPGT;;RNA-binding motif protein, X chromosome, like 2;605444;A, R;;;
11.208;11;20;15;11p15.4;RNF141, ZNF230;;RING finger protein 141;616641;REc;;;7(Rnf141)
11.209;2;20;01;11p15.4;RPL27A;;Ribosomal protein L27a;603637;RE, R;;;7(Rpl27a)
11.210;11;16;05;11p15.4;SBF2, MTMR13, CMT4B2;;SET binding factor 2 (myotubularin-related 13);607697;Fd, REc;;Charcot-Marie-Tooth disease, type 4B2, 604563 (3);
11.211;10;23;92;11p15.4;ST5, HTS1;;Suppression of tumorigenicity-5;140750;S, REa, A;;;
11.212;5;23;00;11p15.4;SWAP70;;Switch-associated protein 70;604762;A, H;;;7(Swap70)
11.213;2;26;04;11p15.4;TRIM5, RNF88;;Tripartite motif-containing protein 5;608487;R;;;
11.214;2;19;03;11p15.4;TRIM6;;Tripartite motif-containing protein 6;607564;R;;;
11.215;2;19;03;11p15.4;TRIM22, STAF50;;Tripartite motif-containing protein 22;606559;A, R;;;
11.216;1;30;01;11p15.4;UBQLN3;;Ubiquilin 3;605473;R;;;
11.217;1;20;09;11p15-p14;DEL11p15p14, C11DELp15p14;;Chromosome 11p15-p14 deletion syndrome (homozygous);606528;Ch;contiguous gene deletion syndrome;Chromosome 11p15-p14 deletion syndrome (4);
11.218;1;12;07;11p15.1;NUCB2, NEFA;;Nucleobindin 2;608020;REc;;;
11.219;1;9;01;11p13;ELF5, ESE2;;E74-like factor 5 (epithelium-specific ETS factor 2);605169;Psh, R;;;
11.220;1;29;03;11p15.1;HPS5, RU2, KIAA1017;;HPS gene 5 (ruby-eye 2, mouse, homolog of);607521;REc, H;;Hermansky-Pudlak syndrome 5, 614074 (3);7(ru2)
11.221;09;27;18;11p14.3;ANO5, TMEM16E, GDD1, LGMDR12;;Anoctamin 5;608662;REn, H, Fd;;Gnathodiaphyseal dysplasia, 166260 (3); Muscular dystrophy, limb-girdle, autosomal recessive 12, 611307 (3); Miyoshi muscular dystrophy 3, 613319 (3);7(Tmem16e)
11.222;11;29;12;11p15.1;OTOG, OTGN, DFNB18B;;Otogelin;604487;A;;Deafness, autosomal recessive 18B, 614945 (3);7(Otog)
11.223;2;19;03;11p14.3;SLC17A6, VGLUT2, DNPI;;Solute carrier family 17 (sodium-dependent inorganic phosphate cotransporter), member 6;607563;A;;;
11.224;4;10;90;11p14.3-p12;ST2;;Suppression of tumorigenicity-2;185440;Ch;;;
11.225;9;28;11;11p14.2;BBOX1, BBOX;;Butyrobetaine-gamma, 2-oxoglutarate dioxygenase 1;603312;R, REc;;;
11.226;8;22;16;11p14.2;FIBIN;;Fin bud initiation factor, zebrafish, homolog of;617085;REc, H;;;2(Fibin)
11.227;12;24;08;11p14.2;SLC5A12, SMCT2;;Solute carrier family 5 (sodium/glucose cotransporter), member 12;612455;REc;;;
11.228;3;19;09;11p14.2-q12.3;DFNA59;;Deafness, autosomal dominant 59;612642;Fd;between D22S929 and D11S480;Deafness, autosomal dominant 59 (2);
11.229;10;6;08;11p14.1;CCDC34;;Coiled-coil domain-containing protein 34;612324;REc;;;
11.230;10;6;08;11p14.1;DCDC5, KIAA1493;;Doublecortin domain-containing protein 5;612321;REc, H;;;2(Dcdc5)
11.231;9;8;08;11p14.1;HSP90AA2, HSPCAL3;;Heat-shock protein, 90kD, alpha, class A, member 2;140575;REa, A;;;
11.232;7;22;13;11p14.1;LGR4, GPR48, BNMD17;;Leucine-rich repeat-containing G protein-coupled receptor 4;606666;REc, Psh, R;previously mapped to 5q34-q35.1;{Bone mineral density, low, susceptibility to}, 615311 (3);
11.233;10;7;08;11p14.1;LIN7C, VELI3, MALS3;;Lin7, C. elegans, homolog of, C;612332;REc;;;
11.234;3;23;09;11p14.1;MIR610, MIRN610;;Micro RNA 610;612330;REc;;;
11.235;9;23;08;11p14.1;C11orf46;;Chromosome 11 open reading frame 46;612295;REc;;;
11.236;9;23;08;11p13;LOC283267;;LOC283267 gene;612296;REc;;;
11.237;4;20;10;11p14.1-p11.2;SPG41;;Spastic paraplegia 41;613364;Fd;max lod 2.36; between D11S1324 and D11S1993;?Spastic paraplegia 41, autosomal dominant (2);
11.238;1;28;13;11p14.3-p14.2;ANO3, TMEM16C, C11orf25, DYT24;;Anoctamin 3;610110;REc;;Dystonia 24, 615034 (3);
11.239;8;27;15;11p14.1;BDNFAS, BDNFOS;;BDNF antisense RNA;611468;REc;;;
11.240;8;19;13;11p14.1;KIF18A;;Kinesin family member 18A;611271;REc;;;
11.241;8;1;13;11p15.1;SERGEF, DELGEF;;Secretion-regulating guanine nucleotide exchange factor;606051;REc, Psh;;;
11.242;11;10;10;11p14;TST1;;Tuberculin skin test reactivity, absence of;613636;Fd;at chr11:26.37M;[Tuberculin skin test reactivity, absence of] (2);
11.243;1;27;04;11p14.3;LUZP2;;Leucine zipper protein 2;608178;R;;;
11.244;3;16;10;11p14.1;MPPED2, C11orf8, D11S302E, 239FB;;Metallophosphoesterase domain-containing protein 2;600911;REn;;;
11.245;12;22;08;11p13;APIP, CGI29, MMRP19;;APAF1-interacting protein;612491;REc;;;
11.246;4;25;18;11p14.1;BDNF;;Brain-derived neurotrophic factor;113505;A, REa, D;homeology with NRF3 on 12p; at p14 boundary;;1(Bdnf)
11.247;4;21;16;11p13;DEL11p13, C11DELp13;;Chromosome 11p13 deletion syndrome, distal;616902;Ch;;Chromosome 11p13 deletion syndrome, distal, 616902 (4);
11.248;12;14;10;11p13;DEL11p13, C11DELp13, WAGR;;Wilms tumor, aniridia, genitourinary anomalies and mental retardation syndrome (chromosome 11p13 deletion syndrome);194072;Ch;deletion of WT1 and PAX6 genes;Wilms tumor, aniridia, genitourinary anomalies and mental retardation syndrome (4);
11.249;9;23;08;11p13;C11orf41, G2;;Chromosome 11 open reading frame 41;612297;REc, REn;;;
11.250;11;19;13;11p13;CAPRIN1, M11S1, GPIAP1, GRIP137;;Cell cycle associated protein 1;601178;REc;;;
11.251;9;21;11;11p13;CAT;;Catalase;115500;S, D, Fd;cen-CAT-WT1-AN2-pter;Acatalasemia, 614097 (3);2(Cas1)
11.252;10;7;08;11p13;CCDC73;;Coiled-coil domain-containing protein 73;612328;REc;;;
11.253;9;23;08;11p13;CD59, MIC11;;CD59 antigen (p18-20);107271;REa, A, D;in mouse Ly-6 = multigene complex;Hemolytic anemia, CD59-mediated, with or without immune-mediated polyneuropathy, 612300 (3);15(Ly6)
11.254;9;23;08;11p13;COMM9;;COMM domain-containing protein 9;612299;REc, REn;;;
11.255;5;25;13;11p13;CSTF3;;Cleavage stimulation factor, 3' pre-RNA, subunit 3, 77kD;600367;REc;;;
11.256;8;29;03;11p14-p13;DCDC1;;Doublecortin domain-containing protein 1;608062;REc;;;
11.257;9;23;08;11p13;DEPDC7, TR2;;DEP domain-containing protein 7;612294;REc, REn;;;
11.258;8;21;07;11p13;DPH4;;DPH4, S. cerevisiae, homolog of;611072;R, REc;;;
11.259;3;9;10;11p13;ECT, BECTS;;Centrotemporal epilepsy;117100;Fd;previously assigned to 15q14;Centrotemporal epilepsy (2);
11.260;10;3;07;11p13;EIF3M, PCID1, B5, GA17;;Eukaryotic translation initiation factor 3, subunit M;609641;REc;;;
11.261;10;3;16;11p13;ELP4, PAX6NEB, AN2;;Elongation protein 4, S. cerevisiae, homolog of;606985;REc;mutation identified in 1 AN2 patient;?Aniridia 2, 617141 (3);
11.262;9;9;08;11p13;FBXO3, FBX3, FBA;;F-box only protein 3;609089;REc;;;2(Fbxo3)
11.263;8;29;08;11p13;FJX1;;Four-jointed box, Drosophila, homolog of, 1;612206;REc;;;
11.264;4;6;15;11p14.1;FSHB, HH24;;Follicle-stimulating hormone, beta polypeptide;136530;D, REa;distal to AN2;Hypogonadotropic hypogonadism 24 without anosmia, 229070 (3);2(Fshb)
11.265;10;24;00;11p13;HIPK3, PKY, DYRK6;;Homeodomain-interacting protein kinase-3;604424;A;;;
11.266;10;6;08;11p13;IMMP1L, IMP1;;Inner mitochondrial membrane peptidase, subunit 1, S. cerevisiae, homolog of;612323;REc;;;
11.267;5;17;18;11p13;LDLRAD3, LRAD3;;Low density lipoprotein receptor class A domain-containing protein 3;617986;REc;;;
11.268;12;11;95;11p13;LMO2, RBTNL1, RHOM2, TTG2;;LIM domain only 2 (rhombotin-like 1);180385;REa, REc;3rd rhombotin gene not on 11;Leukemia, acute T-cell (2);
11.269;4;13;05;11p13;MYP7;;Myopia 7;609256;Fd;;Myopia 7 (2);
11.270;5;9;14;11p13;NAT10, ALP, KIAA1709;;N-acetyltransferase 10;609221;REc, REn;;;
11.271;1;27;17;11p13;PAX6, AN2, MGDA, FVH1, ASGD5;;Paired box homeotic gene-6;607108;Ch, Fd;mutation identified in 1 patient each with MDGA, COLBN, or COLB;Aniridia, 106210 (3); Cataract with late-onset corneal dystrophy, 106210 (3); Anterior segment dysgenesis 5, multiple subtypes, 604229 (3); Foveal hypoplasia 1, 136520 (3); Keratitis, 148190 (3); Optic nerve hypoplasia, 165550 (3); ?Morning glory disc anomaly, 120430 (3); ?Coloboma of optic nerve, 120430 (3); ?Coloboma, ocular, 120200 (3);2(Sey)
11.272;12;15;17;11p13;PDHX, PDX1, E3BP, PDHXD;;Pyruvate dehydrogenase complex, lipoyl-containing component X;608769;A, R, Psh, REc;;Lacticacidemia due to PDX1 deficiency, 245349 (3);
11.273;1;2;08;11p13;PRRG4, PRGP4, TMG4;;Proline-rich gamma-carboxyglutamic acid protein 4;611690;REc;;;
11.274;6;9;08;11p12;RAG1;;Recombination activating gene-1;179615;REa, D;assignment to 14 in error;Severe combined immunodeficiency, B cell-negative, 601457 (3); Omenn syndrome, 603554 (3); Alpha/beta T-cell lymphopenia with gamma/delta T-cell expansion, severe cytomegalovirus infection, and autoimmunity, 609889 (3); Combined cellular and humoral immune defects with granulomas, 233650 (3);2(Rag1)
11.275;6;9;08;11p12;RAG2;;Recombination activating gene-2;179616;REa, D;assignment to 14 in error;Severe combined immunodeficiency, B cell-negative, 601457 (3); Omenn syndrome, 603554 (3); Combined cellular and humoral immune defects with granulomas, 233650 (3);2(Rag2)
11.276;7;13;98;11p13;RCN1;;Reticulocalbin 1;602735;REc;;;2(Rcn1)
11.277;10;3;16;11p13;TRIM44, AN3;;Tripartite motif-containing protein 44;612298;REc, REn;mutation identified in 1 AN3 family;?Aniridia 3, 617142 (3);
11.278;8;16;11;11p13;WT1, NPHS4;;Wilms tumor-1;607102;Ch;clumped: pter-FSHB-AN2-WT1-CAT;Wilms tumor, type 1, 194070 (3); Denys-Drash syndrome, 194080 (3); Nephrotic syndrome, type 4, 256370 (3); Frasier syndrome, 136680 (3); Meacham syndrome, 608978 (3); Mesothelioma, somatic, 156240 (3);2(Wt1)
11.279;2;12;16;11p13;WT1AS, WIT1;;WT1 antisense RNA;607899;REc;;;
11.280;3;13;06;11p13-p12;DFNB51;;Deafness, autosomal recessive 51;609941;Fd;max lod at D11S4102;Deafness, autosomal recessive 51 (2);
11.281;4;6;01;11p13-p12;EVR3;;Exudative vitreoretinopathy 3;605750;Fd;;Exudative vitreoretinopathy 3 (2);
11.282;11;24;15;11p13-p12;PRR5L, PROTOR2, FLJ14213;;Proline-rich protein 5-like;611728;R, REc;;;
11.283;2;24;97;11p11.2;PSMC3, TBP1;;Proteasome (prosome, macropain) 26S subunit, ATPase, 3;186852;Psh, A;;;
11.284;9;22;16;11p13;SLC1A2, EAAT2, EIEE41;;Solute carrier family 1 (glial high affinity glutamate transporter), member 2;600300;A, REa;;Epileptic encephalopathy, early infantile, 41, 617105 (3);2(Eaat2)
11.285;12;24;08;11p13-p12;WAGRO, DEL11p14p12;;Wilms tumor, aniridia, genitourinary anomalies, mental retardation, and obesity syndrome;612469;Ch;contiguous gene deletion syndrome;WAGRO syndrome (4);
11.286;7;20;09;11q14.3;FOLH1B, PSMAL, GCP3;;Folate hydrolase 1B;609020;A, REc;;;
11.287;4;26;10;11p13-q12;CANDF3, CANDN1, FCNC;;Candidiasis, familial, 3;607644;Fd;between D11S1312 and D11S4191;Candidiasis, familial, 3 (2);
11.288;11;18;11;11p13-q14.1;MRT23;;Mental retardation, autosomal recessive 23;614344;Fd;between rs604518 and rs10899421;Mental retardation, autosomal recessive 23 (2);
11.289;12;23;05;11p12;API5, AAC11;;Apoptosis inhibitor 5;609774;REc;;;
11.290;1;22;08;11p12;BMND8;;Bone mineral density QTL 8;611739;Fd;between D11S1392 and D11S4102;{Osteoporosis}, 166710 (2);
11.291;1;29;01;11p13;EHF, ESE3;;ETS homologous factor;605439;REa, A;;;
11.292;9;12;08;11p12;LRRC4C, NGL1, KIAA1580;;Leucine rich repeat containing 4C (netrin-G1 ligand);608817;R, REc;;;
11.293;3;13;06;11p12;TRAF6;;TNF receptor-associated factor 6;602355;REc, R;;;
11.294;3;15;92;11p11.2;CHRM4;;Cholinergic receptor, muscarinic, 4;118495;A, REa, Fd;;;
11.295;4;30;15;11p11.2;LRP4, MEGF7, CLSS, SOST2, CMS17;;Low density lipoprotein receptor-related protein 4;604270;R;mutation identified in 1 CMS17 family;Cenani-Lenz syndactyly syndrome, 212780 (3); Sclerosteosis 2, 614305 (3); ?Myasthenic syndrome, congenital, 17, 616304 (3);
11.296;3;1;00;11p11.2;MAPK8IP1, IB1;;Mitogen-activated protein kinase 8-interacting protein 1;604641;R, A;;{Diabetes mellitus, noninsulin-dependent}, 125853 (3);
11.297;12;28;16;11p11.2;PEX16, PBD8A, PBD8B;;Peroxisome biogenesis factor 16;603360;R, H;;Peroxisome biogenesis disorder 8A (Zellweger), 614876 (3); Peroxisome biogenesis disorder 8B, 614877 (3);2(Pex16)
11.298;12;13;96;11p11.2;DDB2;;Damage-specific DNA binding protein 2, 48kD;600811;A;;Xeroderma pigmentosum, group E, DDB-negative subtype, 278740 (3);
11.299;12;29;15;11p11.2;EXT2, SSMS;;Exostosin 2;608210;Fd, D;mutation identified in 1 SSMS family;Exostoses, multiple, type 2, 133701 (3); ?Seizures, scoliosis, and macrocephaly syndrome, 616682 (3);2(Ext2)
11.300;4;17;07;11p12-p11;PSNP3;;Supranuclear palsy, progressive, 3;610898;Fd;;Supranuclear palsy, progressive, 3 (2);
11.301;3;14;07;11p11.2;ARHGAP1, RHOGAP1, CDC42GAP;;RHO GTPase-activating protein 1;602732;R, REc;;;
11.302;10;2;91;11q24.2;ACRV1;;Acrosomal vesicle protein-1;102525;REa;;;
11.303;4;20;11;11p11.2;ACP2;;Acid phosphatase 2, lysosomal;171650;S, REa;;?Lysosomal acid phosphatase deficiency, 200950 (1);2(Acp2)
11.304;2;9;17;11p11.2;AGBL2, CCP2;;ATP/GTP-binding protein-like 2;617345;REc;;;
11.305;11;19;13;11p11.2;ALX4, PFM2, FPP, FND2, CRS5;;Aristaless-like 4, mouse, homolog of;605420;REc, Fd;;Parietal foramina 2, 609597 (3); Frontonasal dysplasia 2, 613451 (3); {Craniosynostosis 5, susceptibility to}, 615529 (3);
11.306;9;9;10;11p11.2;AMBRA1, KIAA1736;;Activating molecule in beclin 1-regulated autophagy;611359;R, REc;;;
11.307;3;14;13;11p11.2;ATG13, KIAA0652, PARATARG8;;Autophagy 13, S. cerevisiae, homolog of;615088;REc, R;;;
11.308;12;10;12;11p11.2;C1QTNF4, CTRP4;;C1q- and tumor necrosis factor-related protein 4;614911;REc, R;;;
11.309;1;20;06;11p11.2;CD82, SAR2, KAI1, ST6;;CD82 antigen;600623;M;;{Prostate cancer, susceptibility to}, 176807 (2);
11.310;2;23;08;11p11.2;CKAP5, CHTOG, MSPS, KIAA0097;;Cytoskeleton-associated protein 5;611142;REa, REc;;;
11.311;08;07;18;11p11.2;CREB3L1, OASIS, OI16;;cAMP response element-binding protein 3-like 1;616215;REc;;Osteogenesis imperfecta, type XVI, 616229 (3);
11.312;2;11;15;11p11.2;DGKZ;;Diacylglycerol kinase, zeta, 104kD;601441;REc;;;
11.313;6;4;13;11p11.2;FNBP4, FBP30, KIAA1014;;Formin-binding protein 4;615265;REc;;;
11.314;10;11;00;11p11.12;FOLH1, FOLH, PSM, PSMA;;Folate hydrolase 1 (prostate-specific membrane antigen);600934;A, REc;?pseudogene on 11q14;;
11.315;11;15;05;11p11.2;GYLTL1B, LARGE2;;Glycosyltransferase-like 1B;609709;REc;;;
11.316;3;7;13;11p11.2;HARBI1;;Harbinger transposase-derived gene 1;615086;REc, Ch;;;
11.317;8;31;17;11p11.2;KBTBD4, HSPC252, BKLHD4;;KELCH repeat- and BTB/POZ domain-containing protein 4;617645;REc;;;
11.318;5;12;99;11p11.2;MADD, DENN;;MAP kinase-activating death domain (differentially expressed in normal and neoplastic cells);603584;A;;;
11.319;6;13;12;17p12-p11;NCOR1;;Nuclear receptor corepressor 1;600849;REc;;;
11.320;9;14;94;11p11.2;MDK, NEGF2;;Midkine (neurite growth-promoting factor 2);162096;REa, A;;;2(Mdk)
11.321;11;12;18;11p11.2;NUP160, KIAA0197, NPHS19;;Nucleoporin, 160kD;607614;Psh, REc;mutation identified in 1 NPHS19 family;?Nephrotic syndrome, type 19, 618178 (3);
11.322;9;9;13;11p11.2;MYBPC3, CMH4, CMD1MM, LVNC10;;Myosin-binding protein C, cardiac;600958;A, Fd;;Cardiomyopathy, hypertrophic, 4, 115197 (3); Cardiomyopathy, dilated, 1MM, 615396 (3); Left ventricular noncompaction 10, 615396 (3);
11.323;10;1;17;11p11.2;NR1H3, LXRA;;Nuclear receptor subfamily 1, group H, member 3;602423;REc;;;
11.324;9;28;10;11p11.2;PHF21A, BHC80, KIAA1696;;PHD finger protein 21A;608325;R, REc;;;
11.325;5;19;15;11p11.2;PRDM11, PFM8;;PR domain-containing protein 11;616347;REc;;;
11.326;5;13;10;11p11.2;PSS;;Potocki-Shaffer syndrome;601224;Ch;contiguous gene syndrome caused by deletion of 11p11.2;Potocki-Shaffer syndrome (4);
11.327;6;27;02;11p11.2;PTPRJ, DEP1;;Protein tyrosine phosphatase, receptor type, J polypeptide;600925;H, A;;Colon cancer, somatic, 114500 (3);2(Ptprj)
11.328;2;10;05;11p11.2;SLC35C1, FUCT1, CDG2C;;Solute carrier family 35, member C1 (GDP-Fucose transporter 1);605881;REc;;Congenital disorder of glycosylation, type IIc, 266265 (3);
11.329;4;5;18;11p11.2;SLC39A13, ZIP13, EDSSPD3;;Solute carrier family 39 (zinc transporter), member 13;608735;REc;;Ehlers-Danlos syndrome, spondylodysplastic type, 3, 612350 (3);
11.330;2;10;00;11p11.2;SPI1, SFPI1;;Oncogene SPI1;165170;REa, A;;;
11.331;2;16;18;11p11.2;TP53I11, PIG11;;Tumor protein p53-inducible protein 11;617867;REc;;;
11.332;9;19;88;11p11.2;TYRL;;Tyrosinase-like;191270;REa, A;;;
11.333;7;21;15;11p11.2;ZNF408, EVR6, RP72;;Zinc finger protein 408;616454;REc;mutation identified in 1 EVR6 family;?Exudative vitreoretinopathy 6, 616468 (3); Retinitis pigmentosa 72, 616469 (3);
11.334;12;4;08;11p11.2;ARFGAP2, ZNF289;;ADP-ribosylation factor GTPase-activating protein 2;606908;R, REc;;;
11.335;9;3;04;11p11.2;CHST1, KSGAL6ST;;Carbohydrate sulfotransferase-1;603797;A, R;;;
11.336;4;30;15;11p11.2;RAPSN, CMS1D, CMS11, FADS;;Receptor-associated protein of the synapse, 43kD;601592;REa;;Myasthenic syndrome, congenital, 11, associated with acetylcholine receptor deficiency, 616326 (3); Fetal akinesia deformation sequence, 208150 (3);
11.337;3;8;07;11q12.1;SLC43A1, LAT3, POV1;;Solute carrier family 43 (L-type amino acid transporter), member 1;603733;A;;;
11.338;11;30;06;11p11.2;ALKBH3, PCA1, DEPC1, ABH3;;AlkB, E. coli, homolog of, 3;610603;REc;;;
11.339;10;5;11;11q11;OR4C46;;Olfactory receptor, family 4, subfamily C, member 46;614273;REc;;;
11.340;7;20;01;11q14.3;RNF18;;RING finger protein-18;606124;R;;;
11.341;12;13;18;11p11.2;NDUFS3, MC1DN8;;NADH dehydrogenase (ubiquinone) Fe-S protein 3, 30kD;603846;REa, R;;Mitochondrial complex I deficiency, nuclear type 8, 618230 (3);
11.342;1;31;12;11p11.2;ACCS, ACS, PHACS;;1-aminocyclopropane-1-carboxylate synthase;608405;REc;;;
11.343;8;2;13;11p11.2;CELF1, CUGBP1, NAB50, BRUNOL2, CUGBP;;CUGbp and ELAV-like family, member 1;601074;REc;;;
11.344;5;22;14;11p11;CLLS1;;Leukemia, chronic lymphocytic, susceptibility to, 1;609630;Fd;;{Leukemia, chronic lymphocytic, susceptibility to, 1} (2);
11.345;12;27;01;11p11.2;PACSIN3;;Protein kinase C and casein kinase substrate in neurons 3;606513;R;;;
11.346;5;4;12;11p11.2;F2, THPH1, RPRGL2;;Coagulation factor II (thrombin);176930;REa, A;;Hypoprothrombinemia, 613679 (3); Dysprothrombinemia, 613679 (3); Thrombophilia due to thrombin defect, 188050 (3); {Stroke, ischemic, susceptibility to}, 601367 (3); {Pregnancy loss, recurrent, susceptibility to, 2}, 614390 (3);2(Cf2)
11.347;12;15;10;11p15.5;CD81, TAPA1, CVID6;;CD81 antigen (target of antiproliferative antibody-1);186845;REa;;Immunodeficiency, common variable, 6, 613496 (3);7(Tapa1)
11.348;3;10;00;11p;HYPLIP2;;Hyperlipidemia, combined, 2;604499;Fd;;Hyperlipidemia, combined, 2 (2);
11.349;12;15;98;11p;NNO1;;Nanophthalmos 1;600165;Fd;;Nanophthalmos-1 (2);
11.350;8;9;99;11p15.1;RPS13;;Ribosomal protein S13;180476;Psh, R;;;
11.351;4;4;02;11q12.1;PRG2, MBP;;Proteoglycan 2;605601;R, A;;;
11.352;4;4;02;11q12.1;PRG3, MBPH;;Proteoglycan 3;606814;A;;;
11.353;9;16;03;11q14.2;ME3;;Malic enzyme 3;604626;R;;;
11.354;12;23;15;11q12.1;TMX2;;Thioredoxin-related transmembrane protein 2;616715;REc;;;
11.355;9;21;17;11q12.1;CTNND1, CTNND, BCDS2;;Catenin (cadherin-associated protein), delta 1;601045;A;;Blepharocheilodontic syndrome 2, 617681 (3);2(Catns)
11.356;8;30;07;11q12.2;VWC1, URG11;;von Willebrand factor C and EGF domain-containing protein;611115;R, REn;;;
11.357;9;12;91;11q12.1;TCN1, TC1;;Transcobalamin I;189905;A;;;
11.358;1;24;09;11q12.1;C1NH, HAE1, HAE2, SERPING1;;Complement component-1 inhibitor;606860;REa, A;;Angioedema, hereditary, types I and II, 106100 (3); Complement component 4, partial deficiency of, 120790 (3);2(C1nh)
11.359;5;24;13;11q12.2;CCDC86, CYCLON;;Coiled-coil domain-containing protein 86;611293;REc;;;19(Ccdc86)
11.360;1;9;14;11q12.1;APLNR, AGTRL1, APJ;;Apelin receptor;600052;Psh, A;;;
11.361;11;5;97;11q13.1;ESRRA, ESRL1;;Estrogen-related receptor, alpha;601998;A;;;19(Estrra)
11.362;3;18;95;11q12.2;FEN1;;Flap structure-specific endonuclease 1;600393;A, R;;;19(Fen1)
11.363;10;24;18;11q13.1;FERMT3, KIND3, URP2, MIG2B;;Fermitin family, member 3;607901;REc;;Leukocyte adhesion deficiency, type III, 612840 (3);
11.364;12;15;17;11q13.1;LTBP3, LTBP2, DASS, GPHYSD3;;Latent transforming growth factor beta binding protein-3;602090;Psh, A, REc;;Dental anomalies and short stature, 601216 (3); Geleophysic dysplasia 3, 617809 (3);19(Ltbp2)
11.365;4;30;09;11q12.1;MIR130A, MIRN130A;;Micro RNA 130A;610175;REc;;;
11.366;1;2;08;11q13.1;NAALADL1, I100;;N-acetylated alpha-linked acidic dipeptidase-like 1;602640;A;;;
11.367;7;14;98;11q12.1;P2RX3, P2X3;;Purinergic receptor P2X, ligand-gated ion channel, 3;600843;A;;;2(P2rx3)
11.368;11;2;04;11q13.4;P4HA3;;Procollagen-proline, 2-oxoglutarate-4-dioxygenase, alpha subunit, isoform 3;608987;REc;;;
11.369;5;24;13;11q21;PIWIL4, HIWI2, MIWI2;;PIWI-like 4;610315;REc;;;
11.370;4;11;11;11q12;SCA20, DUP11q12, C11DUPq12;;Spinocerebellar ataxia 20 (chromosome 11q12 duplication syndrome, 260kb);608687;Fd;contiguous gene duplication syndrome;Spinocerebellar ataxia 20 (4);
11.371;5;15;14;11q12.2;SLC15A3, PHT2;;Solute carrier family 15 (oligopeptide transporter), member 3;610408;REc;;;
11.372;2;2;01;11q12.1;SSRP1, FACT;;Structure-specific recognition protein 1;604328;REa;;;
11.373;8;11;17;11q12.2;TMEM258, C11orf10;;Transmembrane protein 258;617615;REc;;;
11.374;7;12;02;11q12.1;TNKS1BP1, TAB182, KIAA1741;;Tankyrase 1-binding protein 1, 182kD;607104;REc;;;
11.375;2;1;01;11q12.1;UBE2L6, UBCH8;;Ubiquitin-conjugating enzyme E2L 6;603890;A;;;
11.376;8;6;97;11q12.3;AHNAK;;AHNAK nucleoprotein (desmoyokin);103390;REa, A, REc;;;
11.377;5;5;16;11q12.3;B3GAT3, GLCATI, JDSCD;;Beta-1,3-glucuronyltransferase 3;606374;A;pseudogene on chr.3;Multiple joint dislocations, short stature, craniofacial dysmorphism, with or without congenital heart defects, 245600 (3);
11.378;8;29;02;11q13.1;CDC42EP2, CEP2, BORG1;;CDC42 effector protein 2;606132;REc;;;
11.379;12;15;13;11q12.2;DDB1;;Damage-specific DNA binding protein 1, 127kD;600045;A, H;;;19(Ddb1)
11.380;2;3;05;11q13.4;DHCR7, SLOS;;Delta-7-dehydrocholesterol reductase;602858;R;;Smith-Lemli-Opitz syndrome, 270400 (3);
11.381;1;29;01;11q13.1;FLRT1;;Fibronectin-like domain-containing leucine-rich transmembrane protein-1;604806;A;;;
11.382;11;19;13;11q12.3;FTH1, FTHL6, HFE5;;Ferritin, heavy polypeptide 1;134770;REa, H, REn, R;mutation identified in 1 family;?Hemochromatosis, type 5, 615517 (3);19(Fth)
11.383;2;16;16;11q13.2;KLC2, SPOAN;;Kinesin, light chain 2;611729;REc, H, Fd;;Spastic paraplegia, optic atrophy, and neuropathy, 609541 (3);19(Klc2)
11.384;5;21;07;11q13.1;MARK2, EMK1;;MAP/microtubule affinity-regulating kinase 2;600526;A, REa, REn;;;19(Emk1)
11.385;11;29;01;11q12.1;MS4A3, HTM4, CD20L;;Membrane-spanning 4-domains, subfamily A, member 3;606498;A;;;
11.386;12;27;01;11q12.2;MS4A4A, MS4A4;;Membrane-spanning 4-domains, subfamily A, member 4A;606547;REc;;;
11.387;11;29;01;11q12.2;MS4A5, TETM4, CD20L2;;Membrane-spanning 4-domains, subfamily A, member 5;606499;A, R;;;
11.388;12;27;01;11q12.2;MS4A6A, MS4A6;;Membrane-spanning 4-domains, subfamily A, member 6A;606548;REc;;;
11.389;11;27;01;11q12.2;MS4A7, CFFM4;;Membrane-spanning 4-domains, subfamily A, member 7;606502;REc;;;
11.390;12;27;01;11q12.2;MS4A8B;;Membrane-spanning 4-domains, subfamily A, member 8B;606549;REc;;;
11.391;12;27;01;11q12.2;MS4A12;;Membrane-spanning 4-domains, subfamily A, member 12;606550;REc;;;
11.392;12;21;03;11q12.3;NXF1, TAP, MEX67;;Nuclear RNA export factor 1;602647;REc;;;
11.393;11;15;95;11q13.1;RELA, NFKB3;;v-rel avian reticuloendotheliosis viral oncogene homolog A (nuclear factor of kappa light polypeptide gene enhancer in B-cells 3 (p65));164014;A, REa;;;
11.394;12;11;02;11q13.2;DPP3;;Dipeptidyl peptidase III;606818;A;;;
11.395;5;27;09;11q12.2;FADS1;;Fatty acid desaturase 1;606148;REc;;;
11.396;5;27;09;11q12.2;FADS2;;Fatty acid desaturase 2;606149;REc;;;
11.397;5;27;09;11q12.2;FADS3;;Fatty acid desaturase 3;606150;REc;;;
11.398;2;26;08;11q12.1;MRPL16;;Mitochondrial ribosomal protein L16;611829;R;;;
11.399;1;27;04;11q12.2;MS4A4E;;Membrane-spanning 4-domains, subfamily A, member 4E;608401;REc;;;
11.400;1;27;04;11q12.2;MS4A6E;;Membrane-spanning 4-domains, subfamily A, member 6E;608402;REc;;;
11.401;1;27;04;11q12.2;MS4A10;;Membrane-spanning 4-domains, subfamily A, member 10;608403;REc;;;
11.402;6;22;14;11q12.3;MTA2, MTA1L1;;Metastasis-associated protein 2;603947;A;;;
11.403;7;20;09;11q12-q13.1;PURAQTL1;;Polyunsaturated fatty acids plasma level QTL1;612795;Fd;associated with rs174537;[Polyunsaturated fatty acids plasma level QTL1] (2);
11.404;3;6;01;11q14.1;RAB30;;Ras-associated protein RAB30;605693;REa, REc;;;
11.405;5;22;14;11q12.1;CLP1, HEAB, PCH10;;Cleavage and polyadenylation factor I subunit 1, yeast, homolog of;608757;REc, Psh, A, Ch;;Pontocerebellar hypoplasia, type 10, 615803 (3);
11.406;12;2;14;11q12.1;DTX4, RNF155, KIAA0937;;Deltex, Drosoophila, homolog of, 4;616110;REc;;;
11.407;7;23;13;11q12.1;FAM111A, KIAA1895, KCS2, GCLEB;;Family with sequence similarity 111, member A;615292;REc;;Kenny-Caffey syndrome, type 2, 127000 (3); Gracile bone dysplasia, 602361 (3);
11.408;3;26;14;11q12.1;FAM111B, POIKTMP;;Family with sequence similarity 111, member B;615584;REc;;Poikiloderma, hereditary fibrosing, with tendon contractures, myopathy, and pulmonary fibrosis, 615704 (3);
11.409;8;21;12;11q12.1;GLYAT, ACGNAT, CAT;;Glycine-N-acyltransferase;607424;R, REc;;;
11.410;8;21;12;11q12.1;GLYATL1;;Glycine-N-acyltransferase-like 1;614761;REc;;;
11.411;8;21;12;11q12.1;GLYATL2;;Glycine N-acyltransferase-like 2;614762;REc;;;
11.412;9;8;17;11q12.1;LPXN;;Leupaxin;605390;R;;;
11.413;5;6;13;11q12.1;LRRC55;;Leucine-rich repeat-containing protein 55;615213;REc;;;
11.414;11;7;08;11q12.1;MED19;;Mediator complex subunit 19;612385;REc;;;
11.415;8;19;13;11q12.1;MPEG1, MPG1;;Macrophage expressed gene 1;610390;R, REc;;;
11.416;2;19;10;11p11.2;MTCH2;;Mitochondrial carrier homolog 2;613221;REc;;;
11.417;3;25;14;11q12.1;OR5AN1;;Olfactory receptor, family 5, subfamily AN, member 1;615702;REc;;;
11.418;8;8;13;11q12.1;OR5F1;;Olfactory receptor, family 5, subfamily F, member 1;608492;REc, A;;;
11.419;8;8;13;11q12.1;OR5I1, OLF1;;Olfactory receptor, family 5, subfamily I, member 1;608496;REc, Psh;;;
11.420;5;7;03;11q12.1;OSBP;;Oxysterol-binding protein;167040;REa, R;;;19(Osbp)
11.421;5;29;12;11q12.1;PATL1, PAT1B;;Protein associated with topoisomerase II, S. cerevisiae, homolog of, 1;614660;REc;;;
11.422;5;24;13;11q12.1;RTN4RL2, NGRH1, NGR2;;Reticulon 4 receptor-like 2;610462;REc;;;
11.423;11;18;16;11q12.1;SELENOH, SELH;;Selenoprotein H;607914;REc;;;
11.424;6;28;18;11q12.1;SLC43A3, EEG1, ENBT1;;Solute carrier family 43, member 3;618034;REc;;;
11.425;12;14;10;11q12.1;SMTNL1, CHASM;;Smoothelin-like 1;613664;REc;;;
11.426;1;21;11;11q12.1;STX3, STX3A;;Syntaxin 3;600876;REc;;;
11.427;12;28;08;11q12.1;YPEL4;;Yippee-like 4;609725;REc;;;2(Ypel4)
11.428;4;27;12;11q12.1;ZDHHC5, DHHC5, ZNF375, KIAA1748;;Zinc finger DHHC domain-containing protein 5;614586;REc;;;
11.429;12;4;02;11q12.1;TIMM10, TIM10A, TIM10;;Translocase of inner mitochondrial membrane 10, yeast, homolog of;602251;A, R;;;
11.430;10;23;87;11q12.1-q13.5;FNL2;;Fibronectin-like-2;135610;S, A;;;
11.431;7;13;93;11q12.1;CNTF;;Ciliary neurotrophic factor;118945;REa, A;;;19(Cntf)
11.432;9;8;11;11q12.2;DAGLA, KIAA0659;;Diacylglycerol lipase, alpha;614015;REc, R;;;
11.433;7;18;14;11q12.2;DAK;;Dihydroxyacetone kinase 2, S. cerevisiae, homolog of;615844;REc;;;
11.434;10;10;18;11q12.2;MYRF, 11orf9, KIAA0954, MMERV;;Myelin regulatory factor;608329;REc;;Encephalitis/encephalopathy, mild, with reversible myelin vacuolization, 618113 (3);
11.435;2;23;09;11q12.2;PRPF19, PRP19, PSO4, NMP200;;Precursor mRNA-processing factor 19, S. cerevisiae, homolog of;608330;R, REc;;;
11.436;7;23;15;11q12.2;PTGDR2, GPR44;;Prostaglandin D2 receptor 2;604837;A;;;
11.437;2;24;17;11q12.2;TMEM132A, KIAA1583;;Transmembrane protein 132A;617363;REc;;;
11.438;2;9;12;11q12.2;TMEM138, JBTS16;;Transmembrane protein 138;614459;REc;;Joubert syndrome 16, 614465 (3);
11.439;2;24;12;11q12.2;TMEM216, JBTS2, CORS2, MKS2;;Transmembrane protein 216;613277;REc, Fd;;Joubert syndrome 2, 608091 (3); Meckel syndrome 2, 603194 (3);
11.440;6;9;06;11q12.2;VPS37C;;Vacuolar protein sorting 37, yeast, homolog of, C;610038;R, REc;;;
11.441;2;11;16;11q12.2;ZP1, OOMD1;;Zona pellucida glycoprotein 1;195000;REc;;Oocyte maturation defect 1, 615774 (3);
11.442;3;5;18;11q12.3;CSKMT, METTL12;;Citrate synthase lysine methyltransferase;617897;REc;;;
11.443;9;18;08;11q12.3;EEF1G, EF1G;;Eukaryotic translation elongation factor 1, gamma;130593;REc;;;
11.444;10;10;18;11q12.3;EML3, EMAP3, EMAP95;;Echinoderm microtubule-associated protein-like 3;618118;REc;;;
11.445;4;7;11;11q12.3;HRASLS2;;HRAS-like suppressor 2;613866;REc;;;
11.446;11;11;14;11q12.3;INCENP;;Inner centromere protein;604411;R, REc;;;
11.447;3;23;14;11q12.3;INTS5, INT5, KIAA1698;;Integrator complex subunit 5;611349;REc;;;
11.448;2;22;13;11q12.3;SCGB2A1, MGB2, LPNC;;Secretoglobin, family 2A, member 1 (mammaglobin 2);604398;A, REc;;;
11.449;2;22;13;11q12.3;SCGB1D1, LPNA;;Secretoglobin, family 1D, member 1;615060;REc;previously mapped to 15q12-q13;;
11.450;2;22;13;11q12.3;SCGB1D2, LPNB;;Secretoglobin, family 1D, member 2;615061;REc;previously mapped to 10q23;;
11.451;2;22;13;11q12.3;SCGB1D4, IIS;;Secretoglobin, family 1D, member 4;615062;REc;;;
11.452;8;18;14;11q12.3;SLC22A9, OAT4, UST3;;Solute carrier family 22 (organic anion/cation transporter), member 9;607579;REc;;;
11.453;8;18;14;11q12.3;SLC22A10, OAT5;;Solute carrier family 22 (organic anion/cation transporter), member 10;607580;REc;;;
11.454;1;2;08;11q12.3;SLC22A24;;Solute carrier family 22, member 24;611698;REc;;;19(Slc22a24)
11.455;1;21;11;11q12.3;STX5, STX5A;;Syntaxin 5;603189;REc;;;
11.456;5;29;15;11q12.3;UBXN1, SAKS1;;UBX domain protein 1;616378;REc;;;
11.457;12;1;14;11q12.3;UQCC3, C11orf83, MC3DN9;;Ubiquinol-cytochrome C reductase complex assembly factor 3;616097;REc;mutation identified in 1 MC3DN9 patient;?Mitochondrial complex III deficiency, nuclear type 9, 616111 (3);
11.458;3;8;07;11q12.3;UST6;;Organic anion transporter UST6;610792;REc;;;
11.459;4;24;18;11q12.3;WDR74;;WD repeat-containing protein 74;617947;REc;;;
11.460;3;23;02;11q12.3;MGB1, SCGB2A2;;Mammaglobin 1 (secretoglobin, family 2A, member 2);605562;A, R;;;
11.461;4;6;11;11q12.3-q13.1;PLA2G16, HRASLS3, HRSL3, HREV107;;Phospholipase A2, group XVI;613867;REc;;;
11.462;10;16;14;11q12.3;SCGB1A1, UGB, CC10, CCSP;;Secretoglobin, family 1A, member 1 (uteroglobin);192020;REa, Fd, REc, A;;;
11.463;11;24;08;11q13.3;ANO1, TMEM16A, FLJ10261;;Anoctamin 1, calcium activated chloride channel;610108;REc;;;7(Tmem16a)
11.464;8;26;98;11q13.1;ARL2;;ADP=ribosylation factor-like 2;601175;REc;;;
11.465;12;11;95;11q13.4;ARRB1;;Arrestin, beta 1;107940;A;;;
11.466;3;5;03;11q13.2;BBS1;;BBS1 gene;209901;Fd;;Bardet-Biedl syndrome 1, 209900 (3);
11.467;8;18;14;11q12.3;BSCL2, SPG17, HMN5, PELD;;Seipin;606158;Fd;;Lipodystrophy, congenital generalized, type 2, 269700 (3); Silver spastic paraplegia syndrome, 270685 (3); Neuropathy, distal hereditary motor, type VA, 600794 (3); Encephalopathy, progressive, with or without lipodystrophy, 615924 (3);
11.468;3;29;07;11q13.2;C11orf24;;Chromosome 11 open reading frame 24;610880;REc;;;
11.469;3;23;14;11q13.1;C11orf95;;Chromosome 11 open reading frame 95;615699;REc;;;
11.470;5;6;16;11q13.1;CAPN1, SPG76;;Calpain, large polypeptide L1;114220;REb;;Spastic paraplegia 76, autosomal recessive, 616907 (3);
11.471;4;20;10;11q13.2;CARNS1, ATPGD1, KIAA1394;;Carnosine synthase 1;613368;REc;;;19(Carns1)
11.472;2;13;14;11q13.3;CCND1, PRAD1, BCL1;;Cyclin D1;168461;REn, R, REa, A;pseudogene on 11q13;{Colorectal cancer, susceptibility to}, 114500 (3); {von Hippel-Lindau syndrome, modifier of}, 193300 (3); {Multiple myeloma, susceptibility to}, 254500 (3);
11.473;5;25;00;11q13.2;CCS;;Copper chaperone for superoxide dismutase;603864;A;;;9(Ccs)
11.474;6;8;89;11q12.2;CD5, LEU1;;CD5 antigen (p56-62);153340;REa, A;;;19(Ly1)
11.475;12;7;07;11q13.2;CD248, TEM1;;CD248 antigen;606064;REa, REc;;;
11.476;9;8;11;11q13.1;CDC42BPG, MRCKG;;CDC42-binding protein kinase, gamma;613991;REc;;;
11.477;1;8;97;11q13.1;CFL1;;Cofilin 1 (non-muscle);601442;REn, A, Psh, R;;;19(Cfl1)
11.478;8;6;97;11q12.3;CHRM1;;Cholinergic receptor, muscarinic, 1;118510;REa, A, REn;;;
11.479;2;25;16;11q13.1;COX8A;;Cytochrome c oxidase, subunit VIIIA;123870;A, R, REn;mutation identified in 1 COX4D patient;?Mitochondrial complex IV deficiency, 220110 (3);
11.480;10;8;98;11q13.3;CPT1A;;Carnitine palmitoyltransferase I, liver;600528;Psh, A;;CPT deficiency, hepatic, type IA, 255120 (3);
11.481;8;5;97;11q13.1;CST6;;Cystatin-M;601891;A;;;
11.482;9;24;08;11q13.3;CTTN, EMS1;;Cortactin;164765;RE;amplified in breast cancer and squamous cell cancer;;
11.483;3;12;01;11q13.1;DANJC4, HSPF2;;DnaJ, E. coli, homolog of, subfamily C, member 4 (heat-shock 40kD protein 2);604189;REc;;;
11.484;6;28;18;11q13.1;DPF2, REQ, UBID4, CSS7;;D4, zinc, and double PHD fingers family, member 2;601671;A;;Coffin-Siris syndrome 7, 618027 (3);6(Req)
11.485;1;30;12;11q13.1;EFEMP2, FBLN4, UPH1, ARCL1B;;EGF-containing fibulin-like extracellular matrix protein 2 (fibulin 4);604633;REc;;Cutis laxa, autosomal recessive, type IB, 614437 (3);
11.486;5;2;01;11q13.1;EHD1;;EH domain-containing 1 protein;605888;REc, R;;;19(Ehd1)
11.487;9;12;93;11q13.1;FAU;;Finkel-Biskis-Reilly murine sarcoma virus (FBR-MuSV) ubiquitously expressed (fox derived);134690;A, REa, REc, R;;;19(Fau)
11.488;3;8;92;11q13.3;FGF4, HSTF1;;Fibroblast growth factor-4 (heparin secretory transforming protein-1; Kaposi sarcoma oncogene);164980;A, REa, RE;coamplified with FGF3 in melanoma;;7(Hstf1)
11.489;1;22;07;11q13.3;FGF3, INT2;;Fibroblast growth factor-3 (oncogene INT2);164950;REa, A, RE;35kb 5' to HST1;Deafness, congenital with inner ear agenesis, microtia, and microdontia, 610706 (3);7(Int2)
11.490;12;28;93;11q13.1;FOSL1;;FOS-like antigen-1;136515;REl;;;
11.491;2;7;07;11q13.1;GAL3ST3, GAL3ST2;;Galactose-3-O-sulfotransferase 3;608234;REc;;;
11.492;5;31;05;11q12.1;GIF, IF;;Gastric intrinsic factor;609342;REa, H;;Intrinsic factor deficiency, 261000 (3);19(Gif)
11.493;7;6;99;11q13.2;GSTP1, GST3;;Glutathione S-transferase pi;134660;S, A, REa, R, Fd;formerly called GST1;;19(Gst3)
11.494;3;15;04;11q14.1;HBXAP, RSF1;;Hepatitis B virus X-associated protein;608522;A, REc;;;
11.495;4;23;08;11q13;HPC14;;Prostate cancer, hereditary, 14;611958;Fd;associated with rs7931342;{Prostate cancer, hereditary, 14} (2);
11.496;12;9;98;11q13;IDDM4;;Insulin-dependent diabetes mellitus-4;600319;Fd;;{Diabetes mellitus, insulin-dependent, 4} (2);
11.497;12;8;09;11q13.1;KAT5, HTATIP, TIP60, ESA1, PLIP;;K(lysine) acetyltransferase 5;601409;R, REc;;;
11.498;3;7;01;11q13.1;KCNK4, TRAAK;;Potassium channel, subfamily K, member 4;605720;R;;;
11.499;6;6;00;11q13.1;KCNK7;;Potassium channel, subfamily K, member 7;603940;R;;;
11.500;4;18;05;11q12.3;LGALS12;;Lectin, galactoside-binding, soluble, 12;606096;REc;;;
11.501;9;20;99;11q13.1;MAP4K2, RAB8IP, GCK;;Mitogen-activating protein kinase kinase kinase kinase 2 (RAB8-interacting protein; germinal center kinase);603166;REc;;;
11.502;2;9;11;11q13.1;MEN1;;Menin;613733;Fd, D;linked distal to PYGM;Multiple endocrine neoplasia 1, 131100 (3); Carcinoid tumor of lung (3); Parathyroid adenoma, somatic (3); Lipoma, somatic (3); Angiofibroma, somatic (3); Adrenal adenoma, somatic (3);19(Men1)
11.503;9;26;17;11q13.3;CUPID1, LINC01488, BRCAT8;;CCND1 upstream intergenic DNA repair 1, noncoding;617696;REc;;;
11.504;9;28;17;11q13;CUPID2;;CCND1 upstream intergenic DNA repair 2, noncoding;617697;REc;;;
11.505;2;22;11;11q13.4;MIR326, MIRN326;;Micro RNA 326;613755;REc;;;
11.506;4;29;02;11q13.1;MRPL49, NOF1;;Mitochondrial ribosomal protein L49;606866;REc;;;19(Mrpl49)
11.507;9;27;01;11q12.1;MS4A2, FCER1B;;Membrane-spanning 4-domains, subfamily A, member 2 (Fc fragment of IgE, high affinity I, receptor for, beta polypeptide);147138;Fd, REn;;{Atopy, susceptibility to}, 147050 (3);
11.508;12;15;10;11q12.2;MS4A1, CD20, CVID5;;Membrane-spanning 4-domains, subfamily A, member 1;112210;REa, A, R;;Immunodeficiency, common variable, 5, 613495 (3);19(Ly44)
11.509;1;7;02;11q13.1;MUS81;;Mus81, S. cerevisiae, homolog of;606591;A, REc;;;
11.510;12;13;18;11q13.2;NDUFS8, MC1DN2;;NADH dehydrogenase (ubiquinone) Fe-S protein 8, 23kD (NADH-coenzyme Q reductase);602141;A, REc, R;previously assigned to 3q28;Mitochondrial complex I deficiency, nuclear type 2, 618222 (3);
11.511;12;13;18;11q13.2;NDUFV1, UQOR1, MC1DN4;;NADH dehydrogenase (ubiquinone) flavoprotein 1, 51kD;161015;REa, A;;Mitochondrial complex I deficiency, nuclear type 4, 618225 (3);
11.512;8;29;08;11q13.2;NPAS4, NXF;;Neuronal PAS domain protein 4;608554;REc;;;
11.513;6;6;00;11q13.1;NRXN2;;Neurexin 2;600566;REc;;;
11.514;8;28;15;11q13.4;NUMA1;;Nuclear mitotic apparatus protein-1;164009;A, Ch;fused with RARA in APL;Leukemia, acute promyelocytic, somatic, 612376 (3);
11.515;12;7;07;11q13.3;ORAOV1, TAOS1;;Oral cancer overexpressed gene 1;607224;REc, H;;;7(Oraov1)
11.516;5;4;12;11q13;OTDD, DEL11q13, C11DELq13;;Otodental dysplasia (chromosome 11q13 deletion syndrome);166750;Ch;between rs9666584 and rs41408348;Otodental dysplasia chromosome deletion syndrome (4);
11.517;7;15;99;11q13.1;OVOL1;;Ovo, Drosophila, homolog-like, 1;602313;H, Psh, A;;;19(Ovol1)
11.518;10;23;87;11q13;PGA3;;Pepsinogen A3;169710;REa, RE, A;;;
11.519;10;23;87;11q12.2;PGA4;;Pepsinogen A4;169720;REa, RE, A;;;
11.520;10;23;87;11q12.2;PGA5;;Pepsinogen A5;169730;REa, A;pter-5'HRAS--5'INS--cen;;
11.521;1;7;95;11q13.1;PLCB3;;Phospholipase C, beta 3 (phosphatidylinositol-specific);600230;REn, Ch;within 900kb of MEN1;;19(Plcb3)
11.522;10;13;09;11q13.2;POLD4, POLDS, P12;;Polymerase, DNA-directed, delta 4;611525;R, REc;;;
11.523;12;18;08;11q13.2;RBM14, PSP2, COAA, SIP;;RNA-binding motif protein 14;612409;REc;;;
11.524;12;29;15;11q13.1;SCYL1, NTKL, SCAR21;;SCY1-like 1;607982;REc;;Spinocerebellar ataxia, autosomal recessive 21, 616719 (3);
11.525;3;14;18;11q13.2;UNC93B1, IIAE1;;UNC93, C. elegans, homolog of, B1;608204;A;;{Encephalopathy, acute, infection-induced (herpes-specific), susceptibility to, 1}, 610551 (3);
11.526;7;17;01;11q13.1;PPP1R14B, PLCB3N, PNG;;Protein phosphatase 1, regulatory subunit 14B;601140;REc;;;
11.527;8;20;98;11q13.2;PPP1CA, PPP1A;;Protein phosphatase-1, catalytic subunit, alpha isoform;176875;REa, A, R;;;7(Ppp1a)
11.528;10;19;97;11q13.1;PPP2R5B;;Protein phosphatase-2, regulatory subunit B (B56), beta isoform;601644;A, REc;;;
11.529;1;7;02;11q13.1;PRDX5, AOEB166;;Peroxiredoxin 5;606583;R;;;
11.530;3;9;04;11q13.1;PYGM;;Phosphorylase, glycogen, muscle;608455;REb, Fd, REn;;McArdle disease, 232600 (3);19(Pygm)
11.531;7;17;14;11q13.1;RASGRP2, CDC25L;;Ras guanyl nucleotide-releasing protein 2;605577;REc;mutation identified in 1 BDPLT18 family;?Bleeding disorder, platelet-type, 18, 615888 (3);
11.532;6;25;99;11q13.2;RBM4. LARK;;RNA-binding motif protein-4 (lark, Drosophila, homolog of);602571;A, R;;;
11.533;12;18;13;11q13.2;RCE1;;Ras converting CAAX endopeptidase 1;605385;R, REc;;;
11.534;2;25;15;11q12.3;RNU22;;RNA, U22 small nucleolar;603223;A, R;;;
11.535;2;25;15;11q12.3;RNU25;;RNA, U25 small nucleolar;603224;A, R;;;
11.536;11;11;14;11q12.3;RNU26;;RNA, U26 small nucleolar;603225;A, R;;;
11.537;11;11;14;11q12.3;RNU27;;RNA, U27 small nucleolar;603226;A, R;;;
11.538;11;11;14;11q12.3;RNU28;;RNA, U28 small nucleolar;603227;A, R;;;
11.539;11;11;14;11q12.3;RNU29;;RNA, U29 small nucleolar;603228;A, R;;;
11.540;11;1;14;11q12.3;RNU30;;RNA, U30 small nucleolar;603229;A, R;;;
11.541;11;11;14;11q12.3;RNU31;;RNA, U31 small nucleolar;603230;A, R;;;
11.542;7;19;18;11q12.3;ROM1, ROSP1, RP7;;Rod outer segment membrane protein-1;180721;REa, A;digenic RP with RDS;Retinitis pigmentosa 7, digenic form, 608133 (3);19(Rosp1)
11.543;10;22;99;11q13.1;RTN3, NSPL2;;Reticulon 3;604249;REa, R, REc;pseudogene on chr.4;;
11.544;3;29;07;11q13.2;SAPS3, PP6R3, C11orf23, KIAA1558;;SAPS domain family, member 3;610879;Psh, REc;;;
11.545;9;17;92;11q13;SEA;;Oncogene SEA (S13 avian erythroblastosis);165110;REa, A, R;;;19(Sea)
11.546;1;28;01;11q13.1;SF1, ZNF162, D11S636, ZFM1;;Splicing factor 1 (zinc finger protein-162);601516;REf, REa, A;;;
11.547;5;30;00;11q12.3;SLC3A2, MDU1, NACAE;;Solute carrier family 3 (activators of dibasic and neutral amino acid transport), member 2;158070;S, H;prob. 11q13;;19(Mdu1)
11.548;7;12;02;11q13.1;SLC22A11, OAT4;;Solute carrier family 22 (organic anion/cation transporter), member 11;607097;REc;;;
11.549;7;12;02;11q13.1;SLC22A12, OAT4L, URAT1;;Solute carrier family 22 (urate transporter), member 12;607096;REc;;Hypouricemia, renal, 220150 (3);
11.550;3;9;98;11q13.2;SLC29A2, HNP36, DER12;;Solute carrier family 29 (nucleoside transporters), member 2 (hydrophobic nucleolar protein, 36kD);602110;A;;;19(Hnp36)
11.551;7;2;02;11q13;SMAR;;Spinal muscular atrophy, chronic distal, autosomal recessive;607088;Fd;no mutations found in IGHMBP2;Spinal muscular atrophy, chronic distal, autosomal recessive (2);
11.552;5;25;01;11q13.1;SNX15;;Sorting nexin 15;605964;REc;;;
11.553;9;9;13;11q13.2;SPTBN2, SCA5, SCAR14;;Spectrin, beta, nonerythrocytic, 2;604985;R, H, Fd;;Spinocerebellar ataxia 5, 600224 (3); Spinocerebellar ataxia, autosomal recessive 14, 615386 (3);19(Spnb3)
11.554;12;9;91;11q13;ST3;;Suppression of tumorigenicity-3 (tumor-suppressor gene, HELA cell type);191181;S, D;;Cervical carcinoma (2);
11.555;3;18;17;11q13.4;STARD10;;START domain-containing protein 10;617382;REc;;;
11.556;1;31;01;11q13.1;STIP1, HOP;;Stress-induced phosphoprotein 1;605063;R;;;
11.557;6;6;00;11q12.2;SYT7;;Synaptotagmin 7;604146;REc;;;
11.558;12;7;05;11q13.1;SYVN1, HRD1, KIAA1810;;Synovial apoptosis inhibitor 1;608046;R, REc;;;
11.559;1;13;99;11q13.1;TM7SF2, ANG1;;Transmembrane 7 superfamily, member 2;603414;REc;;;
11.560;3;14;07;11q13.1;TRPT1;;Transfer RNA phosphotransferase 1;610470;REc;;;
11.561;10;08;08;11q13.4;UCP2, BMIQ4;;Uncoupling protein-2;601693;REc, Fd, REn;;{Obesity, susceptibility to, BMIQ4}, 607447 (3);7(Ucp2)
11.562;5;31;05;11q13.4;UCP3;;Uncoupling protein-3;602044;REn, R, Psh;;{Obesity, severe, and type II diabetes}, 601665 (3);
11.563;11;5;98;11q12.3;UHG, U22HG;;U22 host gene;603222;A, R;;;
11.564;6;25;99;11q13.5;UVRAG;;UV radiation resistance-associated gene;602493;A, Psh;;;
11.565;10;5;15;11q12.3;BEST1, VMD2, ARB, RP50;;Bestrophin 1;607854;Fd, Psh;;Macular dystrophy, vitelliform, 2, 153700 (3); Bestrophinopathy, autosomal recessive, 611809 (3); Vitreoretinochoroidopathy, 193220 (3); Microcornea, rod-cone dystrophy, cataract, and posterior staphyloma, 193220 (3); Retinitis pigmentosa-50, 613194 (3); Retinitis pigmentosa, concentric, 613194 (3);
11.566;1;27;97;11q13.1;VEGFB, VRF;;Vascular endothelial growth factor B;601398;REc, Psh;;;
11.567;2;16;18;11q22.1;YAP1, COB1;;Yes-associated protein 1, 65kD;606608;A, REa;;Coloboma, ocular, with or without hearing impairment, cleft lip/palate, and/or mental retardation, 120433 (3);
11.568;10;2;07;11q13.2;YIF1A, YIF1;;Yip1-interacting factor, S. cerevisiae, homolog of, A;611484;R, REc;;;
11.569;2;22;11;11q13.1;ZNHIT2, C11orf5, FON;;Zinc finger HIT domain containing protein 2;604575;REc;;;
11.570;10;30;17;11q13.2;ACTN3, ACTN3D;;Actinin, alpha-3;102574;REa, A;;[Alpha-actinin-3 deficiency], 617749 (3); [Sprinting performance], 617749 (3);19(Actn3)
11.571;11;23;09;11q13.4;KCNE3, HOKPP, HYPP;;Potassium voltage-gated channel, ISK-related subfamily, member 3;604433;R;mutation identified in 1 BRGDA6 family;?Brugada syndrome 6, 613119 (3);
11.572;11;02;18;11q13.5-q14.1;PAK1, IDDMSSD;;p21/CDC42/RAC1-activated kinase 1;602590;REc;;Intellectual developmental disorder with macrocephaly, seizures, and speech delay, 618158 (3);
11.573;3;25;03;11q13.4;PLEKHB1, PHR1, KPL1;;Pleckstrin homology domain-containing protein, family B, member 1;607651;A, R, H;;;7(Tyr)
11.574;10;23;87;11q13-q22;ESA4;;Esterase-A4;133220;S;;;9(Es17)
11.575;7;15;16;11q12.3;GANAB, PKD3;;Neutral alpha-glucosidase AB;104160;S;;Polycystic kidney disease 3, 600666 (3);
11.576;9;18;12;11q13.1;AP5B1, DKFZp761E198;;Adaptor-related protein complex 5, beta-1 subunit;614367;REc;;;
11.577;2;17;15;11q13.1;ATG2A, KIAA0404;;Autophagy 2, S. cerevisiae, homolog of, A;616225;R, REc;;;
11.578;2;13;14;11q13.1;ATL3, HSN1F;;Atlastin 3;609369;REc;;Neuropathy, hereditary sensory, type IF, 615632 (3);
11.579;11;16;09;11q13.1;BAD, BCL2L8;;BCL1 antagonist of cell death;603167;REc;;;
11.580;7;1;11;11q13.1;BANF1, BAF, NGPS;;Barrier to autointegration factor 1;603811;R;;Nestor-Guillermo progeria syndrome, 614008 (3);
11.581;1;15;13;11q13.1;BATF2, SARI;;Basic leucine zipper transcription factor, ATF-like 2;614983;REc;;;
11.582;10;26;12;11q13.2;CABP2, DFNB93;;Calcium-binding protein 2;607314;A, REn;;Deafness, autosomal recessive 93, 614899 (3);
11.583;6;21;15;11q13.2;CABP4, CRSD, CSNB2B;;Calcium-binding protein 4;608965;REc;;Cone-rod synaptic disorder, congenital nonprogressive, 610427 (3);
11.584;11;3;11;11q13.1;CATSPER1, CATSPER, SPGF7;;Cation channel, sperm-associated, 1;606389;REc;;Spermatogenic failure 7, 612997 (3);
11.585;6;12;17;11q13.1;CATSPERZ, TEX40;;Cation channel, sperm-associated, auxiliary subunit zeta;617511;REc, H;;;11(Catsperz)
11.586;6;22;14;11q13.1;DIPA;;Delta antigen-interacting protein A;605360;R, REc;;;
11.587;8;30;11;11q13.1;CCDC88B, GIPIE;;Coiled-coil domain-containing protein 88B;611205;REc;;;
11.588;4;5;11;11q13.1;CDCA5, SORORIN;;Cell division cycle-associated protein 5 (sororin);609374;R, REc;;;
11.589;8;19;13;11q13.2;CTSF, CLN13;;Cathepsin F;603539;A, REa;;Ceroid lipofuscinosis, neuronal, 13, Kufs type, 615362 (3);
11.590;2;12;99;11q13.1;CTSW;;Cathepsin W;602364;A;;;
11.591;9;20;14;11q13.1;DRAP1;;DR1-associated protein 1;602289;REc;;;
11.592;12;18;14;11q13.1;FAM89B, MTVR, LRAP25;;Family with sequence similarity 89, member B;616128;REc;;;19(Fam89b)
11.593;11;16;06;11q13.3;FGF19;;Fibroblast growth factor 19;603891;REc;;;7(Fgf15)
11.594;9;16;16;11q13.1;FIBP, TROFAS;;Fibroblast growth factor, acidic, intracellular binding protein;608296;A;;Thauvin-Robinet-Faivre syndrome, 617107 (3);
11.595;9;27;17;11q13.1;GPHA2, GPA2;;Glycoprotein hormone, alpha-2;609651;REc;;;
11.596;7;15;09;11q13.2;LRFN4, SALM3;;Leucine-rich repeat and fibronectin type III domain-containing protein 4;612810;REc, H;;;19(Lrfn4)
11.597;2;25;15;11q13.1;MACROD1, LRP16;;Macro domain-containing 1;610400;R, REc;;;
11.598;9;26;16;11q13.1;MAJIN, C11orf85;;Membrane-anchored junction protein;617130;REc;;;
11.599;5;19;09;11q13.1;MALAT1, PRO1073;;Metastasis-associated lung adenocarcinoma transcript 1;607924;Ch, REc;fused with TFEB in renal tumors;;
11.600;3;23;09;11q13.1;MIR192, MIRN192;;Micro RNA 192;610939;REc;;;
11.601;3;23;09;11q13.1;MIR194-2, MIRN194-2;;Micro RNA 194-2;610941;REc;;;
11.602;3;1;01;11q13.3;MYEOV;;Myeloma overexpressed gene;605625;A;;;
11.603;7;11;16;11q13.1;NEAT1, TNCRNA;;Noncoding nuclear-enriched abundant transcript 1;612769;REc, H;;;19(Ncrna00084)
11.604;6;5;08;11q13.1;OTUB1, OTU1, OTB1;;OTU domain-containing ubiquitin aldehyde-binding protein 1;608337;REc;;;
11.605;7;29;16;11q13.1-q13.2;PACS1, SHMS, MRD17;;Phosphofurin acidic cluster sorting protein 1;607492;REc;;Schuurs-Hoeijmakers syndrome, 615009 (3);
11.606;8;31;17;11q13.1;PCNX3;;Pecanex, Drosophila, homolog of, 3;617657;REc;;;19(Pcnx3)
11.607;10;15;97;11q12.3;POLR2G;;Polymerase (RNA) II (DNA directed) polypeptide G;602013;R, REc;;;
11.608;2;4;09;11q13.2;RAB1B;;Ras-associated protein RAB1B;612565;REc;;;
11.609;10;12;14;11q13.1;RCOR2;;Rest corepressor 2;616019;REc;;;
11.610;5;25;13;11q13.1;RPS6KA4, RSKB, MSK2;;Ribosomal protein S6 kinase, 90kD, 4;603606;REc;;;
11.611;9;17;09;11q12.2;SDHAF2, SDH5, PGL2;;Succinate dehydrogenase complex assembly factor 2;613019;REc, Fd;;Paragangliomas 2, 601650 (3);
11.612;1;2;08;11q13.1;SLC22A20, OAT6;;Solute carrier family 22, member 20;611696;REc;;;19(Slc22a20)
11.613;3;12;07;11q13.1;SLC25A45;;Solute carrier family 25, member 45;610825;REc;;;19(Slc25a45)
11.614;9;8;11;11q13.1;SPDYC, RINGOC;;Speedy, xenopus, homolog of, C;614030;REc;;;
11.615;3;8;07;11q13.2;TBC1D10C, CARABIN;;TBC1 domain family, member 10C;610831;REc;;;
11.616;4;29;14;11q13.1;VPS51, ANG2;;Vacuolar protein sorting 51, S. cerevisiae, homolog of;615738;REc;;;
11.617;9;13;01;11q13.2;BRMS1;;Breast cancer metastasis suppressor 1;606259;A;;;
11.618;6;25;99;11q13.2;RAD9A, RAD9;;RAD9, S. pombe, homolog of;603761;A, RE;;;
11.619;2;27;03;11q12.3;SLC22A6, OAT1, PAHT;;Solute carrier family 22 (organic anion transporter), member 6;607582;REa, R, A;;;
11.620;12;13;00;11q13.2;TBX10;;T-box 10;604648;A, REc;;;19(Tbx10)
11.621;3;23;93;11q13.1;FKBP2;;FK506-binding protein-2, 13kD;186946;A;;;
11.622;1;8;95;11q13.1;MAP3K11, MLK3, PTK1, SPRK;;Mitogen-activated protein kinase kinase kinase 11;600050;A;;;
11.623;1;5;12;11q13.2;ACY3, HCBP1;;Aminoacylase 3;614413;REc;;;19(Acy3)
11.624;4;6;13;11q13.2;ANKRD13D;;Ankyrin repeat domain-containing protein 13D;615126;REc;;;
11.625;1;11;18;11q13.2;B4GAT1, B3GNT1, IGNT, IGAT, MDDGA13;;Beta-1,4glucuronyltransferase 1;605517;R, REc;;Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 13, 615287 (3);
11.626;12;1;14;11q13.2;C11orf80;;Chromosome 11 open reading frame 80;616109;A, REc;;;
11.627;5;24;13;11q13.2;CNIH2, CNIL;;Cornichon, Drosophila, homolog of, 2;611288;REc;;;
11.628;7;22;11;11q13.2;CHKA, CHK;;Choline kinase, alpha;118491;REc;;;
11.629;1;24;06;11q13.2;CORO1B;;Coronin 1B;609849;REc;;;19(Coro1b)
11.630;10;24;18;11q13.2;GRK2, ADRBK1;;G protein-coupled receptor kinase 2;109635;REa;;;19(Adrbk1)
11.631;12;5;17;11q13.2;KMT5B, SUV420H1, CGI85, MRD51;;Lysine methyltransferase 5B;610881;REc;;Mental retardation, autosomal dominant 51, 617788 (3);
11.632;3;31;09;11q13.3;MRGPRD, MRGD;;Mas-related G protein-coupled receptor family, member D;607231;REc;;;
11.633;3;31;09;11q13.3;MRGPRF, MRGF, RTA;;Mas-related G protein-coupled receptor family, member F;607233;REc;;;
11.634;2;28;08;11q13.3;MRPL21;;Mitochondrial ribosomal protein L21;611834;REc;;;
11.635;3;5;08;11q13.4;MRPL48;;Mitochondrial ribosomal protein L48;611853;REc;pseudogene on 6;;
11.636;12;5;03;11q13.4;NADSYN1;;NAD synthetase 1;608285;R, REc;;;
11.637;9;2;12;11q13.2;PELI3;;Pellino, Drosophila, homolog of, 3;609827;REc;;;
11.638;10;15;07;11q13.1;RNASEH2C, AYP1, FLJ20974, AGS3;;Ribonuclease H2, subunit C;610330;REc, Fd;;Aicardi-Goutieres syndrome 3, 610329 (3);
11.639;4;3;12;11q13.2;SSH3;;Slingshot, Drosophila, homolog of, 3;606780;R;;;
11.640;6;7;10;11q13.2;SYT12, SRG1;;Synaptotagmin 12;606436;REc;;;
11.641;9;24;08;11q13.3;TPCN2, TPC2, SHEP10;;Two-pore segment channel 2;612163;REc;;[Skin/hair/eye pigmentation 10, blond/brown hair], 612267 (3);
11.642;2;2;01;11q13.3;MTL5, TESMIN;;Metallothionein-like 5, testis-specific;604374;A;;;19(Mtl5)
11.643;1;5;15;11q13.3;IGHMBP2, SMUBP2, CATF1, SMARD1, HMN6, CMT2S;;Immunoglobulin mu binding protein 2;600502;A;;Neuronopathy, distal hereditary motor, type VI, 604320 (3); Charcot-Marie-Tooth disease, axonal, type 2S, 616155 (3);19(Ighmbp2)
11.644;9;27;17;11q13.2;AIP, XAP2, ARA9, PITA1;;Aryl hydrocarbon receptor-interacting protein;605555;REa, A;;Pituitary adenoma 1, multiple types, 102200 (3); Pituitary adenoma predisposition, 102000 (3);
11.645;11;10;14;11q13.2;CLCF1, BSF3, CLC, CISS2;;Cardiotrophin-like cytokine;607672;A, R;;Cold-induced sweating syndrome 2, 610313 (3);
11.646;9;1;16;11q13.4;DNAJB13, TSARG6, CILD34;;DNAJ/HSP40 homolog, subfamily B, member 13;610263;REc;;Ciliary dyskinesia, primary, 34, 617091 (3);
11.647;3;10;11;11q13.3;FADD;;FAS-associating protein with death domain;602457;REa, A;;Infections, recurrent, with encephalopathy, hepatic dysfunction, and cardiovascular malformations, 613759 (3);
11.648;2;26;08;11q13.2;MRPL11;;Mitochondrial ribosomal protein L11;611826;R;;;
11.649;8;21;07;11q13.3;PPFIA1, LIP1;;Protein-tyrosine phosphatase, receptor-type, F polypeptide-interacting protein alpha-1;611054;R, REc;;;
11.650;8;28;97;11q13.2;PTPRCAP, LPAP;;Protein tyrosine phosphatase, receptor type, c polypeptide-associated protein;601577;A;;;
11.651;10;17;05;11q13.1;SIPA1, SPA1;;Signal-induced proliferation-associated gene-1;602180;A, REc, H;;;19(Spa1)
11.652;12;23;05;11q13.4;XRRA1;;X-ray radiation resistance-associated 1;609788;REc;;;
11.653;11;24;08;11q13.4;LRTOMT, LRTOMT1, LRTOMT2, DFNB63;;Leucine-rich transmembrane O-methyltransferase;612414;REc, REn;;Deafness, autosomal recessive 63, 611451 (3);7(Lrrc51, Tomt)
11.654;3;20;03;11q13.4;PHOX2A, ARIX, CFEOM2;;Paired-like (astraless) homeobox 2a;602753;REa, A, Fd;;Fibrosis of extraocular muscles, congenital, 2, 602078 (3);7(Arix)
11.655;9;7;10;11q13.3-q13.4;SHANK2, CORTBP1, AUTS17;;SH3 and multiple ankyrin repeat domains 2;603290;R, REc;;{Autism susceptibility 17}, 613436 (3);
11.656;3;23;93;11q13.3-q13.4;ZNF126;;Zinc finger protein-126 (HZF-2);194633;A;;;
11.657;10;12;09;11q13.4;FOLR1;;Folate receptor-1, adult;136430;REa, A, Fd, REn;telomeric of FGF3;Neurodegeneration due to cerebral folate transport deficiency, 613068 (3);
11.658;10;20;92;11q13.4;FOLR2;;Folate receptor-2 (fetal);136425;A, REn;23kb from FOLR1;;
11.659;7;13;15;11q13.2;GAL, GALN, GLNN, ETL8;;Galanin;137035;Psh, A;mutation identified in 1 ETL8 family;?Epilepsy, familial temporal lobe, 8, 616461 (3);19(Glnn)
11.660;3;18;95;11q13.4;RNU15A;;RNA, U15a small nucleolar;600455;Psh, A, REn;processed from intron of RPS3;;
11.661;3;18;95;11q13.4;RPS3;;Ribosomal protein S3;600454;Psh, A, REn;;;
11.662;7;13;12;11q13.4;ANAPC15, APC15;;Anaphase-promoting complex, subunit 15;614717;REc;;;
11.663;2;23;17;11q13.4;ARAP1, CENTD2, KIAA0782;;ArfGAP with RhoGAP domain, ankyrin repeat and PH domain 1;606646;R, REc;;;
11.664;7;22;16;11q13.4;ARHGEF17, RHOGEF17, TEM4, KIAA0337;;Rho guanine nucleotide exchange factor 17;617043;R, REc;;;
11.665;8;22;14;11q13.4;C2CD3, OFD14;;C2 calcium-dependent domain-containing protein 3;615944;REc;mutation identified in 1 OFD14 patient and 1 OFD14 fetus;?Orofaciodigital syndrome XIV, 615948 (3);
11.666;1;12;07;11q13.4;CHCHD8, E2IG2;;Coiled-coil-helix-coiled-coil-helix domain containing 8;608016;REc, R;;;
11.667;12;2;09;11q13.4;CHRDL2, CHL2, BNF1;;Chordin-like 2;613127;REc, H;;;7(Chrdl2)
11.668;3;23;15;11q13.4;CLPB, SKD3, MEGCANN, MGCA7;;Caseinolytic peptidase B;616254;REc;;3-methylglutaconic aciduria, type VII, with cataracts, neurologic involvement and neutropenia, 616271 (3);
11.669;12;18;14;11q13.4;FAM86C1;;Family with sequence similarity 86, member C1;616124;REc;;;
11.670;7;6;17;11q13.4;FCHSD2, KIAA0769, NWK;;FCH and double SH3 domains protein 2;617556;REc, H;;;7(Fchsd2)
11.671;9;27;17;11q13.4;FOLR3;;Folate receptor 3;602469;REc;;;
11.672;4;22;15;11q13.4;RAM168A, TCRP1, KIAA0280;;Family with sequence similarity 168, member A;616316;Psh, REc;;;
11.673;8;22;13;11q13.4;IL18BP;;Interleukin 18-binding protein;604113;REc;;;
11.674;2;5;15;11q13.4;LAMTOR1, C11orf59, PDRO;;Late endosomal/lysosomal adaptor, mitogen-activated protein kinase and mammalian target of rapamycin activator 1;613510;REc;;;
11.675;9;15;17;11q13.4;LIPT2;;Lipoyl(octanoyl) transferase 2;617659;REc;;Encephalopathy, neonatal severe, with lactic acidosis and brain abnormalities, 617668 (3);
11.676;2;22;18;11q13.2;LRP5, BMND1, LRP7, LR3, OPPG, VBCH2, OPTA1, EVR4, PCLD4;;Low density lipoprotein receptor-related protein-5;603506;H, A, R;;Osteoporosis-pseudoglioma syndrome, 259770 (3); [Bone mineral density variability 1], 601884 (3); Hyperostosis, endosteal, 144750 (3); van Buchem disease, type 2, 607636 (3); Osteosclerosis, 144750 (3); {Osteoporosis}, 166710 (3); Exudative vitreoretinopathy 4, 601813 (3); Osteopetrosis, autosomal dominant 1, 607634 (3); Polycystic liver disease 4 with or without kidney cysts, 617875 (3);19(Lrp5)
11.677;3;7;13;11q13.4;MIR139, MIR139-3p;;Micro RNA 139;615017;REc;;;
11.678;5;25;13;11q13.4;PDE2A;;Phosphodiesterase 2A;602658;REc;;;
11.679;2;18;08;11q13.4;PGM2L1;;Phosphoglucomutase 2-like 1;611610;R, REc;;;
11.680;9;10;07;11q13.4;PPME1;;Protein phosphatase methylesterase 1;611117;R, REc;;;
11.681;10;12;90;11q13.4;RAB6A, RAB6;;Oncogene RAB6;179513;A, REc;previously assigned to 2q14-q21;;
11.682;9;18;08;11q13.4;RELT, TNFRSF19L;;Receptor expressed in lymphoid tissues;611211;R, REc;;;
11.683;4;20;04;11q13.5;EMSY, C11orf30;;EMSY gene;608574;A, R, REn;100kb from GARP;;
11.684;3;3;03;11q14.1;GAB2;;GRB2-associated binding protein 2;606203;R, A;;;7(Gab2)
11.685;2;19;10;11q13.4-q13.5;GDPD5, GDE2, PP1665;;Glycerophosphodiester phosphodiesterase domain-containing protein 3;609632;REc;;;
11.686;8;25;04;11q13.2;PC;;Pyruvate carboxylase;608786;REa, H, A;;Pyruvate carboxylase deficiency, 266150 (3);19(Pc)
11.687;6;26;00;11q13.2;TCIRG1, TIRC7, OC116, OPTB1;;T-cell immune regulator 1;604592;A, Fd, H;;Osteopetrosis, autosomal recessive 1, 259700 (3);19(oc)
11.688;1;9;94;11p14.1;KCNA4, KCNA8;;Potassium voltage-gated channel, shaker-related subfamily, member 4;176266;REa, A, H;other map to 11p;;2(Kcna4)
11.689;3;23;93;11q13.5;OMP;;Olfactory marker protein;164340;REa, A;;;7(Omp)
11.690;11;10;17;11q13.5;ACER3, APHC, PHCA, PLDECO;;Alkaline ceramidase 3;617036;REc;mutation identified in 1 PLDECO family;?Leukodystrophy, progressive, early childhood-onset, 617762 (3);
11.691;10;12;09;11q13.5;ATOD7;;Dermatitis, atopic, 7;613064;Fd;associated with rs7927894;{Dermatitis, atopic, susceptibility to, 7} (2);
11.692;2;18;16;11q13.5;DGAT2;;Diacylglycerol O-acyltransferase 2;606983;R, REc;;;
11.693;10;4;91;11q13.4;KRTAP5-9, KRN1;;Keratin associated protein 5-9;148021;A, R;;;
11.694;6;21;12;11q13.5;LRRC32, GARP, D11S833E;;Leucine rich repeat containing 32;137207;A, REn;;;7(Garp)
11.695;9;27;17;11q13.5;MAP6, MTAP6, STOP, KIAA1878;;Microtubule-associated protein 6;601783;R, REc, A;;;
11.696;8;3;12;11q13.5;MOGAT2, MGAT2;;Monoacylglycerol O-acyltransferase 2;610270;REc;;;
11.697;11;26;97;11q13.5;MYO7A, USH1B, DFNB2, DFNA11;;Myosin VIIA;276903;Fd;;Usher syndrome, type 1B, 276900 (3); Deafness, autosomal recessive 2, 600060 (3); Deafness, autosomal dominant 11, 601317 (3);7(sh1, Myo7a)
11.698;3;9;00;11q13.4;NEU3, SIAL3;;Neuraminidase 3 (membrane sialidase; sialidase 3);604617;A;;;
11.699;7;15;99;11q13.4;P2RY2, P2Y2, P2U;;Purinergic receptor P2Y, G-protein coupled, 2;600041;Psh, A;;;
11.700;7;15;99;11q13.4;P2RY6, P2Y6;;Pyrimidinergic receptor P2Y, G protein-coupled, 6;602451;Psh, A;;;
11.701;7;14;14;11q13.5;PRKRIR;;PRKR inhibitor, repressor of;607374;REc;;;
11.702;10;12;16;11q13.5;SERPINH1, SERPINH2, PPROM, CBP2, CBP1, OI10;;Serpin peptidase inhibitor, clade H, member 1;600943;A;;{Preterm premature rupture of the membranes, susceptibility to}, 610504 (3); Osteogenesis imperfecta, type X, 613848 (3);
11.703;6;9;98;11q14.1;THRSP;;Thyroid hormone responsive SPOT14, rat, homolog of;601926;A;;;
11.704;1;12;07;11q13.5;TSKU, E2IG4, TSK;;Tsukushin;608015;REc;;;
11.705;6;25;99;11q13.5;WNT11;;Wingless-type MMTV integration site family, member 11;603699;A, Psh;;;
11.706;3;9;98;11q14.1;CLNS1A, CLNS1B;;Chloride channel, nucleotide-sensitive, 1A;602158;A;CLNS1B on 6p12.1-q13 = pseudogene?;;
11.707;11;21;02;11q14.2;RAB38;;Ras-family, member RAB38;606281;R, H, REc;;;7(Rab38, cht)
11.708;3;1;06;11q14.1;AQP11, AQPX1;;Aquaporin 11;609914;REc;;;
11.709;7;22;13;11q13.5;B3GNT6;;Beta-1,3-N-acetylglucosaminyltransferase 6;615315;REc;;;
11.710;2;21;14;11q13.5;CAPN5, HTRA3, VRNI;;Calpain 5;602537;R, Fd;;Vitreoretinopathy, neovascular inflammatory, 193235 (3);
11.711;4;17;07;11q14;GCRG224;;Gastric cancer-related gene 224;610888;REc;;;
11.712;8;27;15;11q14.2;PICALM, CALM, CLTH, LAP;;Phosphatidylinositol-binding clathrin assembly protein;603025;Ch;fuses with AF10 in t(10;11);Leukemia, acute myeloid, somatic, 601626 (3);
11.713;6;9;98;11q14.1;PRCP, PCP;;Prolylcarboxypeptidase (angiotensinase C);176785;Psh, REc, R;;;
11.714;10;28;02;11q14;SLEH1;;Systemic lupus erythematosus with hemolytic anemia, susceptibility to, 1;607279;Fd;;{Systemic lupus erythematosus with hemolytic anemia} (2);
11.715;7;20;09;11q14.1;SYTL2, SLP2, SLP2A, EXO4, KIAA1597;;Synaptotagmin-like 2;612880;R, REc;;;
11.716;12;14;98;11q14-q21;SCZD2;;Schizophrenia susceptibility locus, chromosome 11-related;603342;Ch;;{?Schizophrenia}, 181500 (2);
11.717;8;25;14;11q14.2;FZD4, EVR1;;Frizzled, Drosophila, homolog of, 4;604579;A, Fd;;Exudative vitreoretinopathy 1, 133780 (3); Retinopathy of prematurity, 133780 (3);
11.718;10;8;13;11q14.3;TYR, SHEP3, CMM8, OCA1A, ATN;;Tyrosinase;606933;REa, A, H, F;;Albinism, oculocutaneous, type IA, 203100 (3); Waardenburg syndrome/albinism, digenic, 103470 (3); Albinism, oculocutaneous, type IB, 606952 (3); [Skin/hair/eye pigmentation 3, light/dark/freckling skin], 601800 (3); {Melanoma, cutaneous malignant, susceptibility to, 8}, 601800 (3); [Skin/hair/eye pigmentation 3, blue/green eyes], 601800 (3);7(Tyr)
11.719;5;15;08;11q14-q22;IHPS3;;Pyloric stenosis, infantile hypertrophic, 3;612017;Fd;max lod at rs541821;Pyloric stenosis, infantile hypertrophic, 3 (2);
11.720;7;2;18;11q14.1;CREBZF, ZF;;CREB/ATF bZIP transcription factor;606444;REc;;;
11.721;7;2;18;11q14.1;DDIAS, NOXIN, C11orf82;;DNA damage-induced apoptosis suppressor;618045;REc;;;7(Ddias)
11.722;3;23;14;11q14.1;INTS4, INT4;;Integrator complex subunit 4;611348;REc;;;
11.723;2;25;15;11q14.1;NARS2, COXPD24;;Asparaginyl-tRNA synthetase 2;612803;REc;;Combined oxidative phosphorylation deficiency 24, 616239 (3);
11.724;5;25;13;11q14.1;NDUFC2;;NADH-ubiquinone oxidoreductase 1, subunit C2;603845;REc;;;
11.725;9;16;12;11q14.1;PCF11, KIAA0824;;PCF11, yeast, homolog of;608876;REc;;;
11.726;11;22;17;11q14.1;TENM4, ODZ4, TNM4, DOC4, KIAA1302, ETM5;;Teneurin transmembrane protein 4;610084;REc, R, H;;Essential tremor, hereditary, 5, 616736 (3);7(Odz4)
11.727;12;13;18;11q14.1;TMEM126B, MC1DN29;;Transmembrane protein 126B;615533;REc;;Mitochondrial complex I deficiency, nuclear type 29, 618250 (3);
11.728;12;21;12;11q14.2;CTSC, CPPI, PALS, PLS, HMS, PDON1, JPD;;Cathepsin C;602365;A, REc, Fd;;Papillon-Lefevre syndrome, 245000 (3); Haim-Munk syndrome, 245010 (3); Periodontitis 1, juvenile, 170650 (3);7(Ctsc)
11.729;9;2;09;11q14.1;TMEM126A, OPA7;;Transmembrane protein 126A;612988;REc;;Optic atrophy 7, 612989 (3);
11.730;8;9;17;11q14.2;HIKESHI, C11orf73, HLD13;;Hikeshi;614908;REc;;Leukodystrophy, hypomyelinating, 13, 616881 (3);
11.731;5;19;15;11q14.2;TMEM135, PMP52;;Transmembrane protein 135;616360;REc;;;
11.732;4;19;12;11q14.2-q14.3;GRM5, MGLUR5;;Glutamate receptor, metabotropic, 5;604102;REc;;;7(Grm5)
11.733;7;12;02;11q14.3;NOX4, RENOX;;NADPH oxidase 4;605261;REc, A;;;
11.734;7;11;17;11q14.2;EED, WAIT1, COGIS;;Embryonic ectoderm development protein, mouse, homolog of;605984;A;;Cohen-Gibson syndrome, 617561 (3);
11.735;01;04;19;11q14.3;CHRODC1, CHP1;;Cysteine- and histidine-rich domain-containing protein 1;604353;REc;;;
11.736;8;3;12;11q13.2;RHOD, ARHD, RHOHP1;;Ras homolog gene family, member D;605781;R;;;
11.737;3;24;11;11q21;SLC36A4, PAT4;;Solute carrier family 36, member 4;613760;REc;;;
11.738;1;18;11;11q14.3;UBTFL1, HMGPI;;Upstream binding transcription factor (RNA polymerase I)-like 1;613696;REc;;;
11.739;12;17;08;11q14.3;FAT3;;FAT tumor suppressor, Drosophila, homolog of, 3;612483;R, REc;;;
11.740;1;2;08;11q14.3;NAALAD2;;N-acetylated alpha-linked acidic dipeptidase 2;611636;A;;;
11.741;5;29;12;11q21;AMOTL1, JEAP;;Angiomotin-like 1;614657;REc;;;
11.742;7;14;14;11q21;C11orf54, PTOD012;;Chromosome 11 open reading frame 54;615810;REc;;;
11.743;9;21;11;11q21;C11orf75, FN5;;FN5, pufferfish, homolog of;609477;R, Psh;;;
11.744;7;28;11;11q21;CEP57, PIG8, TSP57, KIAA0092, MVA2;;Centrosomal protein 57kD;607951;REc;;Mosaic variegated aneuploidy syndrome 2, 614114 (3);
11.745;10;25;17;11q21;CEP295, KIAA1731;;Centrosomal protein, 295kD;617728;REc;;;
11.746;10;11;16;11q21;DEUP1, CCDC67;;Deuterosome assembly protein 1;617148;REc;;;
11.747;6;25;99;11q14.1;DLG2;;Discs large, Drosophila, homolog of, 2 (channel-associated protein of synapses, 110kD);603583;R, REc;;;
11.748;4;22;05;11q21;GPR83, GIR, GPR72;;G protein-coupled receptor 83;605569;R;;;9(Gpr83)
11.749;4;29;14;11q21;FOLR4;;Folate receptor 4;615737;REc;;;9(Folr4)
11.750;5;19;94;11q21;FUT4, FCT3A, CD15;;Fucosyltransferase 4 (alpha (1,3) fucosyltransferase, myeloid-specific);104230;S, REa, R;;;9(Fut4)
11.751;11;3;98;11q21;JRKL, HHMJG;;Jerky, mouse, homolog-like;603211;A;;;
11.752;5;16;18;11q21;KDM4D, JMJD2D;;Lysine demethylase 4D;609766;REc, REn;;;
11.753;9;29;15;11q21;KDM4E, JMJD2E;;Lysine-specific demethylase 4E;616581;REc;;;
11.754;3;3;03;11q21;MAML2, MAM3;;Mastermind-like 2;607537;Ch;t(11;19);Mucoepidermoid salivary gland carcinoma (3);
11.755;12;21;10;11q21;MED17, CRSP6, CRSP77, TRAP80, DRIP80;;Mediator complex subunit 17;603810;R, REc;;Microcephaly, postnatal progressive, with seizures and brain atrophy, 613668 (3);
11.756;12;29;99;11q21;MRE11A, MRE11, ATLD;;Meiotic recombination 11, S. cerevisiae, homolog A of;600814;REa, A;;Ataxia-telangiectasia-like disorder 1, 604391 (3);
11.757;8;8;13;11q21;PANX1, PX1;;Pannexin 1;608420;REc, R;;;
11.758;5;13;03;11q21;SEST3;;Sestrin 3;607768;A;;;10(Sest3)
11.759;7;16;09;11q21;TAF1D, RAFI41, JOSD3;;TATA box-binding protein-associated factor 1D;612823;REc;;;
11.760;2;21;10;11q21-q22;FGQTL3;;Fasting plasma glucose level QTL 3;613233;Fd;associated with rs10830963;[Fasting plasma glucose level QTL 3] (2);
11.761;8;18;98;11q22.3;GUCY1A2, GUC1A2;;Guanylate cyclase 1, soluble, alpha 2;601244;A;;;
11.762;9;29;96;11q22.2;MMP7;;Matrix metalloproteinase 7 (matrilysin, uterine);178990;H, REa, Psh, A;;;
11.763;11;15;94;11q22.2;MMP8, CLG1;;Matrix metalloproteinase 8 (neutrophil collagenase);120355;A;;;
11.764;3;30;12;11q14.3;MTNR1B;;Melatonin receptor 1B;600804;REa;;{Diabetes mellitus, type 2, susceptibility to}, 125853 (3);
11.765;9;9;13;11q21;MIR1260B;;Micro RNA 1260B;615372;REc;;;
11.766;7;6;05;11q22.1;TRPC6, TRP6, FSGS2;;Transient receptor potential channel-6;603652;A, Fd;;Glomerulosclerosis, focal segmental, 2, 603965 (3);
11.767;10;17;02;11q22.1;CNTN5, NB2;;Contactin 5;607219;A;;;
11.768;4;1;03;11q22.1;ANGPTL5;;Angiopoietin-like 5;607666;REc;;;
11.769;3;21;14;11q22.3;CARD16, COP1;;Caspase recruitment domain-containing protein 16;615680;REn;;;
11.770;10;27;92;11q22.3;FDX1, ADX;;Ferredoxin-1 (adrenodoxin);103260;REa, A;pseudogene on 20q11-q12;;
11.771;8;1;05;11q22.3;INCA;;Inhibitory caspase recruitment domain protein;609490;REc;;;
11.772;5;28;03;11q21;MTMR2, CMT4B1;;Myotubularin-related protein 2;603557;A, R, Psh;;Charcot-Marie-Tooth disease, type 4B1, 601382 (3);
11.773;10;21;02;11q22.1;PGR;;Progesterone receptor;607311;REa, A, REb;11q13 = earlier regionalization;?Progesterone resistance, 264080 (2);9(Pgr)
11.774;12;19;11;11q21;SRSF8, SFRS2B, SRp46;;Splicing factor, arginine/serine-rich, 8;603269;A;;;
11.775;9;22;98;11q22.2;API2, HAIP1;;Apoptosis inhibitor-2;601721;A;fused with MALT1 in MALT lymphoma;;
11.776;7;6;99;11q22.2;API1, HIAP2;;Apoptosis inhibitor-1;601712;A;;;
11.777;11;4;98;11q24.2;CHEK1, CHK1;;Checkpoint kinase 1, S. pombe, homolog of;603078;R;;;
11.778;2;17;09;11q24.1;CRTAM;;Cytotoxic and regulatory T-cell molecule;612597;REc, H;;;9(Crtam)
11.779;1;7;99;11q22.3;CUL5, VACM1;;Cullin-5 (vasopressin-activated calcium-mobilizing receptor-1);601741;REc;;;
11.780;4;30;96;11q22.3;DDX10;;DEAD/H box-10 (RNA helicase);601235;REa, Ch;400kb telomeric to ATM; pseudogene on 9q21-q22; fused with NUP98 in AML;;
11.781;2;16;17;11q22.3;GRIA4, GLUR4, NEDSGA;;Glutamate receptor, ionotropic, AMPA 4;138246;Psh, A;;Neurodevelopmental disorder with or without seizures and gait abnormalities, 617864 (3);9(Glur4)
11.782;3;9;98;11q23.1;HSPB2;;Heat-shock 27kD protein-2;602179;REc;;;
11.783;6;24;08;11q22.2;MMP1, CLG;;Matrix metalloproteinase 1 (interstitial collagenase);120353;REn;;COPD, rate of decline of lung function in, 606963 (3); {Epidermolysis bullosa dystrophica, autosomal recessive, modifier of}, 226600 (3);
11.784;5;28;98;11q22.3;SLN;;Sarcolipin;602203;Psh, R;;;
11.785;10;15;98;11q23.1;PPP2R1B;;Protein phosphatase 2, structural/regulatory subunit A, beta;603113;REc, R;;Lung cancer, 211980 (3);
11.786;6;27;08;11q23.3;TECTA, DFNA8, DFNA12, DFNB21;;Tectorin, alpha;602574;Psh, REc;;Deafness, autosomal dominant 8/12, 601543 (3); Deafness, autosomal recessive 21, 603629 (3);
11.787;4;24;90;11q22-qter;ANC;;Anal canal carcinoma;105580;Ch;3p22 also deleted;?Anal canal carcinoma (2);
11.788;8;12;14;11q22.1;ARHGAP42, GRAF3;;Rho GTPase-activating protein 42;615936;REc;;;
11.789;8;3;18;11q22.1;CFAP300, C11orf70, CILD38;;Cilia- and flagella-associated protein 300;618058;REc;;Ciliary dyskinesia, primary, 38, 618063 (3);
11.790;6;1;12;11q22.1;KIAA1377;;KIAA1377 gene;614634;R, REc;;;
11.791;7;9;06;11q22.2;TMEM123, PORIMIN;;Transmembrane protein 123;606356;REc;;;
11.792;09;06;18;11q22.2;MMP27;;Matrix metalloproteinase 27;618101;REc;;;
11.793;8;20;98;11q22.3;CASP1, IL1BC;;Caspase 1, apoptosis-related cysteine protease (interleukin-1, beta convertase);147678;REa, A;;;9(Ilb1bc)
11.794;3;16;99;11q22.3;CASP4;;Caspase 4, apoptosis-related cysteine protease;602664;REc;;;
11.795;3;16;99;11q22.3;CASP5;;Caspase 5, apoptosis-related cysteine protease;602665;REc;;;
11.796;6;25;99;11q23.1;IL18, IGIF;;Interleukin-18;600953;R, Psh;;;
11.797;5;19;97;11q22.2;MMP12;;Matrix metalloproteinase 12 (macrophage elastase);601046;A;;;
11.798;12;6;16;11q22.3;AASDHPPT;;Alpha-aminoadipate semialdehyde dehydrogenase-phosphopantetheinyl transferase;607756;REc;;;
11.799;3;16;10;11q22.3;ALKBH8, ABH8;;AlkB, E. coli, homolog of, 8;613306;REc;;;
11.800;1;27;16;11q22.3;ATM, ATA, AT1;;Ataxia-telangiectasia mutated (includes complementation groups A, C, D, and E);607585;Fd, C, M;;Ataxia-telangiectasia, 208900 (3); Lymphoma, B-cell non-Hodgkin, somatic (3); {Breast cancer, susceptibility to}, 114480 (3); Lymphoma, mantle cell, somatic (3); T-cell prolymphocytic leukemia, somatic (3);9(Atm)
11.801;5;5;17;11q23.3;ATP5JG;;ATP synthase, H+ transporting, mitochondrial F0 complex, subunit G;617473;REc;;;
11.802;3;21;14;11q22.3;CARD18, ICEBERG;;Caspase recruitment domain-containing protein 18;605354;REc;;;
11.803;5;31;05;11q22.3;CASP12, CASP12P1;;Caspase 12, apoptosis-related cysteine protease;608633;REc;;{Sepsis, susceptibility to} (3);
11.804;8;26;15;11q22.3;DCUN1D5, SCCRO5;;DCN1 domain-containing protein 5;616522;REc, Ch;;;
11.805;2;11;14;11q22.3;DYNC2H1, DNCH2, DHC2, ATD3, SRPS2B, SRTD3;;Dynein, cytoplasmic-2, heavy chain-1;603297;Psh, R, REc;1 patient showed heterozygous NEK2 and DYNC2H1 mutations;Short-rib thoracic dysplasia 3 with or without polydactyly, 613091 (3);
11.806;12;10;13;11q22.3;ELMOD1;;ELMO/CED12 domain-containing protein 1;615456;REc;;;
11.807;1;24;13;11q22.3;EXPH5, SLAC2B, KIAA0624;;Exophilin 5;612878;R, REc;;Epidermolysis bullosa, nonspecific, autosomal recessive, 615028 (3);
11.808;1;7;95;11q23.3;GRIK4;;Glutamate receptor, ionotropic, kainate 4;600282;REa, A;;;9(Grik4)
11.809;8;1;16;11q22.2;MMP13, CLG3, MANDP1, MDST;;Matrix metalloproteinase 13 (collagenase 3);600108;A, REn, Fd;;Spondyloepimetaphyseal dysplasia, Missouri type, 602111 (3); Metaphyseal anadysplasia 1, 602111 (3); Metaphyseal dysplasia, Spahr type, 250400 (3);
11.810;1;12;99;11q22.3;NPAT, E14;;Nuclear protein, ataxia-telangiectasia locus;601448;REn, REc;;;
11.811;12;28;08;11q22.3;PDGFD, SCDGFB, IEGF;;Platelet-derived growth factor D;609673;REc, R;;;
11.812;1;9;13;11q22.3;ZC3H12C, MCPIP3;;Zinc finger CCCH domain-containing protein 12C;615001;REc;;;
11.813;7;13;94;11q22.2;MMP10, STMY2;;Matrix metalloproteinase 10 (stromelysin 2);185260;A;;;
11.814;8;4;09;11q22.2;MMP20, AI2A2;;Matrix metalloproteinase-20 (enamelysin);604629;A;;Amelogenesis imperfecta, type IIA2, 612529 (3);
11.815;10;29;03;11q22.3;ACAT1;;Acetyl-Coenzyme A acetyltransferase-1 (acetoacetyl Coenzyme A thiolase);607809;A;cluster: cen-STMY2-CLG-STMY1-ter;Alpha-methylacetoacetic aciduria, 203750 (3);
11.816;1;4;18;11q23.1;BCO2, BCDO2;;Beta-carotene oxygenase 2;611740;R, REc;;;
11.817;8;6;13;11q23.1;CRYAB, CRYA2, CTPP2, CMD1II, CTRCT16, MFM2;;Crystallin, alpha B;123590;REa, A, Ch;;Myopathy, myofibrillar, 2, 608810 (3); Cataract 16, multiple types, 613763 (3); Myopathy, myofibrillar, fatal infantile hypertonic, alpha-B crystallin-related, 613869 (3); Cardiomyopathy, dilated, 1II, 615184 (3);
11.818;4;15;09;11q23.1;PTS;;6-pyruvoyltetrahydropterin synthase;612719;A;;Hyperphenylalaninemia, BH4-deficient, A, 261640 (3);
11.819;5;19;16;11q23.1;ALG9, DIBD1, CDG1L, GIKANIS;;Alg9, yeast, homolog of;606941;REc, Ch;;Congenital disorder of glycosylation, type Il, 608776 (3); Gillessen-Kaesbach-Nishimura syndrome, 263210 (3);
11.820;12;20;05;11q23.3;AMICA1, JAML;;Adhesion molecule, interacts with CXADR antigen 1;609770;REc;;;
11.821;7;21;06;11q23.3;APOA1;;Apolipoprotein A-I;107680;REa, RE, Fd, F, D;;ApoA-I and apoC-III deficiency, combined (3); Hypoalphalipoproteinemia, 604091 (3); Corneal clouding, autosomal recessive (3); Amyloidosis, 3 or more types, 105200 (3);9(Apoa1)
11.822;11;24;14;11q23.3;APOC3, HALP2;;Apolipoprotein C-III;107720;REa, RE, F;2.6kb 3' to APOA1;Apolipoprotein C-III deficiency, 614028 (3);
11.823;3;15;91;11q23.3;APOA4;;Apolipoprotein A-IV;107690;F, RE;12 kb 3' to APOA1;;9(Apoa4)
11.824;11;14;05;11q23.3;APOA5;;Apolipoprotein A-V;606368;REc;proximal to APOA1, APOC3, APOA4;{Hypertriglyceridemia, susceptibility to}, 145750 (3); Hyperchylomicronemia, late-onset, 144650 (3);
11.825;5;18;05;11q23;BMND5;;Bone mineral density QTL 5;609354;Fd;between D11S901 and D11S925;[Bone mineral density QTL 5] (2);
11.826;2;27;01;11q23.1;BTG4, PC3B;;B-cell translocation gene 4;605673;R;;;
11.827;2;5;14;11q23.3;CD3D, T3D, IMD19;;CD3D antigen, delta polypeptide (TiT3 complex);186790;REa, A, RE;3 CD3 genes in 50kb;Immunodeficiency 19, 615617 (3);9(T3d)
11.828;2;10;14;11q23.3;CD3E, IMD18;;CD3E antigen, epsilon polypeptide (TiT3 complex);186830;REa, A, RE;;Immunodeficiency 18, 615615 (3); Immunodeficiency 18, SCID variant, 615615 (3);9(T3e)
11.829;2;2;14;11q23.3;CD3G, IMD17;;CD3G antigen, gamma polypeptide (TiT3 complex);186740;RE, REa, A;;Immunodeficiency 17, CD3 gamma deficient, 615607 (3);9(T3g)
11.830;3;23;14;11q23.1;COLCA1;;Colorectal cancer-associated gene 1;615693;REc;;;
11.831;3;23;14;11q23.1;COLCA2;;Colorectal cancer-associated gene 2;615694;REc;opposite strand from COLCA1;;
11.832;8;20;08;11q23;CRCS7;;Colorectal cancer, susceptibility to, 7;612232;Fd;associated with rs3802842;{Colorectal cancer, susceptibility to, 7} (2);
11.833;2;11;08;11q23.3;DSCAML1, KIAA1132;;Down syndrome cell adhesion molecule-like 1;611782;R, A, H;;;9(Dscaml1)
11.834;8;3;12;11q24.2;EI24, PIG8, EPG4;;Etoposide-induced 1.4 mRNA;605170;A;;;9(Ei24)
11.835;11;1;00;11q23.3;FXYD2, ATP1G1, HOMG2;;FXYD domain-containing ion transport regulator 2 (sodium-potassium-ATPase, gamma polypeptide);601814;REc, Fd;;Hypomagnesemia 2, renal, 154020 (3);
11.836;11;21;00;11q23;GTS;;Gilles de la Tourette syndrome;137580;Fd;several loci suspected (e.g., 17q25);Tourette syndrome (2);
11.837;3;7;13;11q13.4;INPPL1, OPSMD;;Inositol polyphosphate phosphatase-like 1;600829;Psh;;Opsismodysplasia, 258480 (3);
11.838;7;20;06;11q23;JBS;;Jacobsen syndrome;147791;Ch;contiguous gene deletion syndrome;Jacobsen syndrome (4);
11.839;3;14;14;11q23.3;KMT2A, MLL, HRX, HTRX1, WDSTS;;Lysine (K)-specific methyltransferase 2E;159555;Ch, RE;fuses with ENL, AF4, AF9, GMPS;Wiedemann-Steiner syndrome, 605130 (3); Leukemia, myeloid/lymphoid or mixed-lineage (2);9(All1)
11.840;5;4;12;11q23.3;MFRP, MCOP5, NNO2;;Membrane-type frizzled-related protein;606227;REc;;Microphthalmia, isolated 5, 611040 (3); Nanophthalmos 2, 609549 (3);
11.841;3;31;03;11q22.2;MMP3, STMY1, CHDS6;;Matrix metalloproteinase 3 (stromelysin 1, progelatinase);185250;REa, A;;{Coronary heart disease, susceptibility to, 6}, 614466 (3);
11.842;6;7;10;11q23;NAFLD2;;Fatty liver disease, nonalcoholic, susceptibility to, 2;613387;Fd;associated with rs2854116, rs2854117;{Fatty liver disease, nonalcoholic, susceptibility to, 2} (2);
11.843;10;2;98;11q23.3;PAFAH1B2;;Platelet-activating factor acetylhydrolase, isoform Ib, beta subunit;602508;R, REc, A;;;
11.844;1;5;07;11q23.3;PDZD3, IKEPP;;PDZ domain-containing 3;607146;REc;;;
11.845;1;31;01;11q12.3;RARRES3, TIG3;;Retinoic acid receptor responder 3;605092;REc;;;
11.846;8;22;07;11q22.3;RDX, DFNB24;;Radixin;179410;REa, Psh, A;;Deafness, autosomal recessive 24, 611022 (3);
11.847;7;20;01;11q23.3;RNF26;;RING finger protein-26;606130;REc;;;
11.848;9;9;13;11q23.3;SCN2B, ATFB14;;Sodium channel, voltage-gated, type II, beta polypeptide;601327;H, A, REc, R;;Atrial fibrillation, familial, 14, 615378 (3);9(Scn2b)
11.849;7;30;14;11q23.3;SCN4B, LQT10, ATFB17;;Sodium channel, voltage-gated, type IV, beta subunit;608256;REc;;Long QT syndrome-10, 611819 (3); Atrial fibrillation, familial, 17, 611819 (3);
11.850;07;28;18;11q23.1;SDHD, PGL1;;Succinate dehydrogenase complex, subunit D, integral membrane protein;602690;A;;Paragangliomas 1, with or without deafness, 168000 (3); Pheochromocytoma, 171300 (3); Paraganglioma and gastric stromal sarcoma, 606864 (3); Mitochondrial complex II deficiency, 252011 (3);
11.851;5;19;09;11q23.3;SLC37A4, G6PT1;;Solute carrier family 37 (glucose-6-phosphate transporter), member 4;602671;Fd, Psh, R;;Glycogen storage disease Ib, 232220 (3); Glycogen storage disease Ic, 232240 (3);
11.852;6;20;94;11q23;TCPT;;Thrombocytopenia, Paris-Trousseau type (deletion 11q23 syndrome);188025;Ch;contiguous gene deletion of 11q23;?Thrombocytopenia, Paris-Trousseau type (4);
11.853;6;9;06;11q23.3;TMPRSS13, MSPL, MSPS;;Transmembrane protease, serine 13;610050;R, REc;;;
11.854;1;24;18;11q23.3;TREH, TREHD;;Trehalase;275360;H, REc;;Trehalase deficiency, 612119 (3);9(Treh)
11.855;12;31;99;11q23;TSG11;;Tumor suppressor gene on chromosome 11;603040;D;;{Nonsmall cell lung cancer} (2);
11.856;2;7;07;11q23.2;USP28, KIAA1515;;Ubiquitin-specific protease 28;610748;R, REc;;;
11.857;7;20;12;11q24.2;VWA5A, LOH11CR2A, BCSC1;;von Willebrand factor A domain-containing protein 5A;602929;REc;;;
11.858;2;23;09;11q23-q24;ADIPQTL4;;Adiponectin, serum level of, quantitative trait locus locus 4;612629;Fd;between D11S925 and D11S968;{Adiponectin, serum level of, QTL4} (2);
11.859;3;29;16;11q24.2;SRPRA, SRPR, DP;;Signal recognition particle receptor, alpha subunit;182180;REa, A, Psh;;;
11.860;12;19;11;11q24.2;TIRAP, BACTS1;;TIR domain-containing adaptor protein;606252;R;;{Pneumococcal disease, invasive, protection against}, 610799 (3); {Bacteremia, protection against}, 614382 (3); {Malaria, protection against}, 611162 (3); {Tuberculosis, protection against}, 607948 (3);
11.861;7;8;17;11q24.2;ROBO3, RBIG1, RIG1, HGPPS1;;Roundabout, Drosophila, homolog of, 3;608630;Fd, R, REc;;Gaze palsy, familial horizontal, with progressive scoliosis, 1, 607313 (3);
11.862;2;25;15;11q23.1;DIXDC1, CCD1, KIAA1735;;DIX domain-containing protein 1;610493;REc;;;
11.863;1;23;09;11q23.1;DLAT, PDCE2;;Dihydrolipoamide S-acetyltransferase;608770;A;;Pyruvate dehydrogenase E2 deficiency, 245348 (3);
11.864;10;20;15;11q23.2;DRD2;;Dopamine receptor D2;126450;Fd, REa, Ch;11q22-q23 junction; 150kb 5' to NCAM; centromeric to APOA1; telomeric to STMY1;;
11.865;10;23;87;11q23.1;EBVM1;;Epstein-Barr virus modification site-1;132860;V;;;
11.866;3;9;00;11q23.2;HTR3B;;5-hydroxytryptamine receptor 3B;604654;REc;;;
11.867;3;23;14;11q23.1;MIR34B;;Micro RNA 34B;611374;REc;;;
11.868;4;2;16;11q23.1;MIR34C;;Micro RNA 34C;611375;REc;;;
11.869;8;20;98;11q23.2;NCAM1, MSK39;;Neural cell adhesion molecule 1;116930;A, Fd;defective in "staggerer" in mice;;9(Ncam)
11.870;10;4;05;11q23.2;NNMT;;Nicotinamide N-methyltransferase;600008;A;;Homocysteine plasma level (2);
11.871;4;23;96;11q23.1;POU2AF1, OBF1;;POU domain, class 2, associating factor 1;601206;REa, A;;;
11.872;8;21;12;11q23.1;SIK2, KIAA0781;;Salt-inducible kinase 2;608973;R, REc;;;
11.873;7;2;18;11q23.1;TIMM8B, DDP2;;Translocase of inner mitochondrial membrane 8, yeast, homolog of, B;606659;REc;;;
11.874;12;4;08;11q23.2;ZBTB16, ZNF145, PLZF;;Zinc finger- and BTB domain-containing protein 16 (promyelocytic leukemia zinc finger);176797;Ch, A;fused with RARA in APL of t(11;17) type;Leukemia, acute promyelocytic, PL2F/RARA type (3); Skeletal defects, genital hypoplasia, and mental retardation, 612447 (3);9(lu)
11.875;12;9;95;11q23.2;HTR3;;5-hydroxytryptamine (serotonin) receptor-3;182139;REa, A;;;
11.876;12;18;08;11q23.2;RBM7;;RNA-binding motif protein 7;612413;REc;;;
11.877;9;28;05;11q23.2;REXO2, RFN;;RNA exonuclease 2, S. cerevisiae, homolog of;607149;REc;;;
11.878;3;23;93;11q24.3;ZNF123;;Zinc finger protein-123 (HZF-1);194630;A;;;
11.879;3;23;93;11q23.1-q23.2;ZNF125;;Zinc finger protein-125 (HZF-3);194632;A;;;
11.880;5;23;18;11q23.2;ANKK1;;Ankyrin repeat and kinase domain containing 1;608774;REc, REn;;;
11.881;5;14;09;11q23.1;C11orf34, PLET1;;Chromosome 11 open reading frame 34;611904;REc, H;;;9(Plet1)
11.882;6;28;17;11q23.3;CADM1, IGSF4, TSLC1;;Cell adhesion molecule 1;605686;REc;;;
11.883;10;10;18;11q23.2;NXPE4, C11orf33;;Neurexophilin and PC-esterase domain family, member 4;618133;REc;;;
11.884;5;28;99;11q23.3;TAGLN, SMCC, SM22;;Transgelin;600818;Psh, R;;;9(Tagln)
11.885;1;30;07;11q23.2;TTC12, TPARM;;Tetratricopeptide repeat domain 12;610732;REc;;;
11.886;2;2;16;11q23.2;ZW10;;Zeste-white 10, Drosophila, homolog of;603954;R;;;
11.887;3;2;98;11q23.3;H2AX;;H2AX histone;601772;A;;;
11.888;7;26;16;11q24.1;SORL1, LR11, SORLA;;Sortilin-related receptor, L(DLR class) A repeats-containing;602005;A;;;
11.889;5;22;03;11q23.3;ABCG4, WHITE2;;ATP-binding cassette, subfamily G, member 4;607784;REc, H;;;9(Abcg4)
11.890;10;25;16;11q23.3;ARCN1, SRMMD;;Archain 1;600820;Ch;60kb telomeric to MLL;Short stature, rhizomelic, with microcephaly, micrognathia, and developmental delay, 617164 (3);
11.891;6;25;15;11q23.3;ARHGEF12, LARG, KIAA0382;;Rho guanine nucleotide exchange factor 12, leukemia-associated;604763;A, R;fused with MLL in AML;;
11.892;2;20;01;11q23.3;BACE1, BACE;;Beta-site amyloid beta A4 precursor protein-cleaving enzyme (secretase, beta; memapsin 2);604252;REc, R;;;
11.893;10;3;11;11q23.3;BACE1AS;;BACE1 antisense RNA;614263;REc;;;
11.894;11;2;04;11q23.3;BCL9L;;B-cell CLL/lymphoma 9-like;609004;REc;;;
11.895;5;31;05;11q23.3;C1QTNF5, CTRP5, LORD;;C1q- and tumor necrosis factor-related protein 5;608752;REn, REc;;Retinal degeneration, late-onset, autosomal dominant, 605670 (3);
11.896;5;19;16;11q23.3;CBL, CBL2, NSLL;;Cas-Br-M ecotropic retroviral transforming sequence (Oncogene CBL2);165360;REa, Ch;mutation identified in 1 JMML family;Noonan syndrome-like disorder with or without juvenile myelomonocytic leukemia, 613563 (3); ?Juvenile myelomonocytic leukemia, 607785 (3);9(Cbl2)
11.897;8;2;17;11q23.3;C2CD2L, TMEM24;;C2 calcium-dependent domain-containing protein 2-like;617582;REc;;;
11.898;10;4;12;11q23.3;CEP164, KIAA1052;;Centrosomal protein, 164kD;614848;R, REc;;Nephronophthisis 15, 614845 (3);
11.899;9;9;08;11q23.3;CXCR5, BLR1;;Chemokine, CXC motif, receptor 5;601613;REc;;;
11.900;3;4;96;11q23.3;DDX6, HLR2;;DEAD/H box-6 (RNA helicase, 54kD);600326;Ch, REn;;;9(Ddx6)
11.901;4;30;15;11q23.3;DPAGT1, DPAGT2, DGPT, CDG1J, CMSTA2, CMS13;;Dolichyl-phosphate N-acetylglucosamine phosphotransferase;191350;R, REa, A;;Congenital disorder of glycosylation, type Ij, 608093 (3); Myasthenic syndrome, congenital, 13, with tubular aggregates, 614750 (3);17(Dpagt2)
11.902;1;13;93;11q24.3;ETS1;;Avian erythroblastosis virus E26 (v-ets) oncogene homolog-1;164720;REa, A, Ch;shown by HSR; 19cM distal to THY1; Ewing sarcoma breakpoint region-2 splices to EWSR1;;9(Ets1, Fli1)
11.903;4;29;14;11q23.3;FOXR1, FOXN5;;Forkhead box R1;615755;REc;;;
11.904;7;18;12;11q23.3;HDLCQ14, HYLAP;;High density lipoprotein cholesterol level quantitative trait locus 14;605201;Fd;;High density lipoprotein cholesterol level QTL14 (2);
11.905;1;13;06;11q23.3;HMBS, PBGD, UPS;;Hydroxymethylbilane synthase;609806;S, D, Fd, REn;;Porphyria, acute intermittent, 176000 (3); Porphyria, acute intermittent, nonerythroid variant, 176000 (3);9(Ups)
11.906;12;27;18;11q23.3;HYOU1, IMD59;;Hypoxia-upregulated 1;601746;R;mutation identified in 1 IMD59 patient;?Immunodeficiency 59 and hypoglycemia, 233600 (3);
11.907;1;12;11;11q23.3;IL10RA, IL10R, IBD28;;Interleukin-10 receptor, alpha;146933;REa, A;;Inflammatory bowel disease 28, early onset, autosomal recessive, 613148 (3);
11.908;5;24;13;11q23.3;LRRC35, EL;;Leucine-rich repeat-containing protein 35;610451;REc, R;;;
11.909;6;18;12;11q23.3;MCAM, MUC18, CD146;;Melanoma adhesion molecule;155735;R, REc;;;
11.910;1;2;08;11q23.3;MPZL3;;Myelin protein zero-like 3;611707;REc;;;9(Mpzl3)
11.911;5;23;16;11q23.3;NECTIN1, PVRL1, HVEC, PVRR1, PRR1, ED4, OFC7, CLPED1;;Nectin 1;600644;A;;Cleft lip/palate-ectodermal dysplasia syndrome, 225060 (3); Orofacial cleft 7, 225060 (3);
11.912;4;23;08;11q23.3;NLRX1, NOD9, CLR11.3;;NLR family member X1;611947;REc;;;
11.913;8;3;12;11q23.3;PCSK7, PC8, PC7, LPC;;Proprotein convertase, subtilisin/kexin-type, 7;604872;REc;;;
11.914;7;16;09;11q23.3;PHLDB1, LL5A, KIAA0638;;Pleckstrin homology-like domain, family B, member 1;612834;R, REc;;;
11.915;12;4;02;11q23.3;POU2F3, OCT11;;POU domain, class 2, transcription factor 3;607394;A;;;9(Oct11)
11.916;3;18;94;11q23.3;RPS25;;Ribosomal protein S25;180465;A;;;
11.917;11;1;02;11q23.3-q24.1;SC5DL, ERG3;;Sterol C5-desaturase-like;602286;A;;Lathosterolosis, 607330 (3);
11.918;8;1;14;11q24.1;SCN3B, SCNB3, BRGDA7, ATFB16;;Sodium channel, voltage-gated, type III, beta subunit;608214;R;;Brugada syndrome 7, 613120 (3); Atrial fibrillation, familial, 16, 613120 (3);
11.919;8;29;17;11q23.3;SIDT2;;SID1 transmembrane family, member 2;617551;REc;;;9(Sidt2)
11.920;11;05;18;11q23.3;SIK3, KIAA0999, SEMDK;;Salt-inducible kinase 3;614776;REc, R;mutation identified in 1 SEMDK family;?Spondyloepimetaphyseal dysplasia, Krakow type, 618162 (3);
11.921;1;7;14;11q24.2;STT3A, ITM1, TMC;;STT3A, subunit of the oligosaccharyltransferase complex (catalytic);601134;REa, H, A, REc;mutation identified in 1 family;?Congenital disorder of glycosylation, type Iw, 615596 (3);9(Itm1)
11.922;7;4;95;11q23.3;THY1;;Thy-1 T-cell antigen;188230;REa, H, A, Fd, REn;;;9(Thy1)
11.923;4;26;11;11q23.3;TMEM25;;Transmembrane protein 25;613934;REc;;;9(Tmem25)
11.924;12;17;01;11q23.3;TMPRSS4;;Transmembrane protease, serine 4;606565;R;;;
11.925;3;3;03;11q23.2;TMPRSS5;;Transmembrane protease, serine 5;606751;REc;;;
11.926;5;21;07;11q23.3;TRAPPC4;;Trafficking protein particle complex, subunit 4 (synbindin);610971;R, REc;;;
11.927;9;27;17;11q23.3;TRIM29, ATDC;;Tripartite motif-containing protein 29;610658;REc, R;;;
11.928;3;17;08;11q23.3;UPK2, UP2, UPII;;Uroplakin 2;611558;REc;;;
11.929;1;12;16;11q23.3;VPS11, HLD12;;Vacuolar protein sorting 11, yeast, homolog of;608549;REc;;Leukodystrophy, hypomyelinating, 12, 616683 (3);
11.930;6;25;99;11q24.1;ZNF202;;Zinc finger protein-202;603430;D;;;
11.931;12;21;15;11q23.3;ZPR1, ZNF259;;ZPR1 zinc finger protein;603901;REc;;;
11.932;7;12;02;11q23.3-q24;AAT1, FAA1;;Aortic aneurysm, familial thoracic 1;607086;Fd;;Aortic aneurysm, familial thoracic 1 (2);
11.933;10;4;95;11q24.1;HSPA8, HSP73;;Heat-shock 70kD protein-8 (HSP73);600816;REa, A;;;
11.934;10;24;00;11q24.3;APLP2;;Amyloid beta (A4) precursor-like protein-2;104776;REa, A;;;9(Aplp2)
11.935;5;5;17;11q24.3;FLI1, BDPLT21;;Friend leukemia virus integration 1;193067;REa, Ch, A;fused with EWS in Ewing sarcoma;Bleeding disorder, platelet-type, 21, 617443 (3);
11.936;4;3;03;11q24.2;GRTH;;Gonadotropin-regulated testicular RNA helicase;607663;A, H;;;9(Grth)
11.937;5;23;11;11q24.2;HEPACAM, MLC2A, MLC2B;;Hepatocyte cell adhesion molecule;611642;REc;;Megalencephalic leukoencephalopathy with subcortical cysts 2A, 613925 (3); Megalencephalic leukoencephalopathy with subcortical cysts 2B, remitting, with or without mental retardation, 613926 (3);
11.938;8;23;04;11q24.3;KCNJ1, ROMK1;;Potassium inwardly-rectifying channel, subfamily J, member 1;600359;A;;Bartter syndrome, type 2, 241200 (3);
11.939;6;11;11;11q24.3;KCNJ5, GIRK4, KATP1, LQT13;;Potassium inwardly-rectifying channel, subfamily J, member 5;600734;Psh, R, REc;;Long QT syndrome 13, 613485 (3); Hyperaldosteronism, familial, type III, 613677 (3);9(Girk4)
11.940;4;21;01;11q24;MGR9;;Migraine with aura, susceptibility to, 9;609670;Fd;max lod at GATA64D03;{Migraine with aura, susceptibility to, 9} (2);
11.941;10;14;18;11q23.3;MPZL2, EVA1, EVA, DFNB111;;Myelin protein zero-like 2;604873;REc;;Deafness, autosomal recessive 111, 618145 (3);9(Eva)
11.942;10;7;05;11q24;NEDE;;Nephropathy, progressive, with deafness;609469;Fd;max lod at D11S4464;Nephropathy, progressive, with deafness (2);
11.943;6;19;98;11q24.2;NRGN;;Neurogranin;602350;REc;;;9(Nrgn)
11.944;4;18;02;11q24.2;PATE;;Prostate- and testis-expressed gene;606861;REc;;;
11.945;1;26;12;11q24.2;SIAE, AIS6;;Sialic acid acetylesterase;610079;R;;{Autoimmune disease, susceptibility to, 6}, 613551 (3);
11.946;6;22;14;11q24.3;TP53AIP1, P53AIP1;;Tumor protein p53-regulated apoptosis-inducing protein 1;605426;A;;;
11.947;7;10;08;11q24-q25;ANIB7;;Aneurysm, intracranial berry, 7;612161;Fd;between rs618176 and rs1940033;Aneurysm, intracranial berry, 7 (2);
11.948;10;21;92;11q24.3;NFRKB;;Nuclear factor related to kappa B-binding protein;164013;REa, A;most telomeric 11q marker;;
11.949;10;2;09;11q24.2;PKNOX2, PREP2;;PBX/Knotted 1 homeobox 2;613066;A;;;
11.950;4;10;14;11q24.3;ST14, MTSP1, ARCI11;;Suppression of tumorigenicity 14;606797;A;;Ichthyosis, congenital, autosomal recessive 11, 602400 (3);
11.951;9;24;08;11q24.1;BLID, BRCC@;;BH3-like motif-containing cell death inducer;608853;REc, REn;distal to SORL1;;
11.952;8;21;07;11q24.1;BSX1;;Brain-specific homeobox, mouse, homolog of;611074;REc, H;;;9(Bsx)
11.953;1;27;09;11q24.1;CLLS5;;Leukemia, chronic lymphocytic susceptibility to, 5;612559;Fd;associated with rs735665;{Leukemia, chronic lymphocytic susceptibility to, 5} (2);
11.954;5;24;13;11q24.1;CLMP, ASAM, ACAM, CSBS;;Coxsackievirus- and adenovirus receptor-like membrane protein;611693;REc;;Congenital short bowel syndrome, 615237 (3);9(Clmp)
11.955;7;30;18;11q24.1;JHY, C11orf63;;Jhy, mouse, homology of;617594;REc;;;9(Jhy)
11.956;12;21;09;11q24.1;MIR100, MIRN100;;Micro RNA 100;613186;REc, REn;;;
11.957;9;20;14;11q24.1;MIR100HG, AGD1;;MIR100-LET7A2 cluster host gene, noncoding;615965;REc;;;
11.958;3;23;09;11q24.1;MIR125B1, MIRN125B1;;Micro RNA 125B-1;610104;REc;;;
11.959;3;23;09;11q24.1;MIRLET7A2, LET7A2, MIRNLET7A2;;Micro RNA let7a2;612142;REc;;;
11.960;7;14;14;11q24.3;SENCR, lncRNA9;;Smooth muscle- and endothelial cell-enriched migration/differentiation-associated long noncoding RNA;615815;REc;;;
11.961;7;10;08;11q24.1;UBASH3B, STS1, KIAA1959, P70;;Ubiquitin-associated and SH3 domain-containing protein B;609201;R, REc;;;
11.962;9;21;11;11q24.2;CDON, CDO, HPE11;;Cell adhesion molecule-related/downregulated by oncogenes;608707;R, REc;;Holoprosencephaly 11, 614226 (3);
11.963;7;13;15;11q24.2;DCPS, HINT5, DCS1, ARS;;Decapping enzyme, scavenger;610534;REc;;Al-Raqad syndrome, 616459 (3);
11.964;10;10;11;11q24.2;ESAM;;Endothelial cell adhesion molecule;614281;REc;;;
11.965;10;13;15;11q24.2;FAM118B;;Family with sequence similarity 118, member B;616587;REc;;;
11.966;11;16;11;11q24.2;FEZ1;;Fasciculation and elongation protein zeta 1;604825;R, REc;;;
11.967;12;13;18;11q24.2;FOXRED1, MC1DN19;;FAD-dependent oxidoreductase domain-containing protein 1;613622;REc;;Mitochondrial complex I deficiency, nuclear type 19, 618241 (3);
11.968;12;18;07;11q24.2;HEPN1;;Cancer susceptibility gene HEPN1;611641;REc;;;
11.969;1;10;07;11q24.2;HYLS1, FLJ32915;;HYLS1 gene;610693;Fd, REc;;Hydrolethalus syndrome, 236680 (3);
11.970;4;25;18;11q24.2;KIRREL3, NEPH2, KIAA1867, KIRRE;;Kin of IRRE-like 3;607761;R;;;
11.971;4;25;18;11q24.2;MRD4;;Mental retardation, autosomal dominant 4;612581;Ch;translocation t(11;16)(q24.2;q24);Mental retardation, autosomal dominant 4 (2);
11.972;11;2;14;11q24.2;PANX3, PX3;;Pannexin 3;608422;R, REc;;;
11.973;7;25;16;11q24.2;PUS3, MRT55;;Pseudouridylate synthase 3;616283;REc;mutation identified in 1 MRT55 family;?Mental retardation, autosomal recessive 55, 617051 (3);
11.974;2;21;03;11q24.2;ROBO4;;Roundabout, Drosophila, homolog of, 4;607528;REc;;;
11.975;11;12;17;11q24.2;RPUSD4;;RNA pseudouridylate synthase domain-containing protein 4;617488;REc;;;
11.976;7;14;14;11q24.2;ST3GAL4, SIAT4C, SIAT4, CGS23, NANTA3;;ST3 beta-galactoside alpha-2,3-sialyltransferase 4;104240;S, Psh, REc;;;
11.977;11;30;06;11q24.2;TBRG1, NIAM;;Transforming growth factor-beta regulator 1;610614;R, REc;;;
11.978;9;27;17;11q24.2;VSIG2, CTXL;;V-set and immunoglobulin domains-containing protein 2;606011;R, REc;;;
11.979;11;11;14;11q24.3;ADAMTS15;;A disintegrin-like and metalloproteinase with thrombospondin type 1 motif, 15;607509;REc;;;
11.980;12;10;12;11q24.3;ARHGAP32, RICS, GRIT, p200RHOGAP, p250GAP;;Rho GTPase activating protein 32;608541;REc, R;;;
11.981;8;30;07;11q25;ACAD8;;Acyl-CoA dehydrogenase family, member 8;604773;REc;;Isobutyryl-CoA dehydrogenase deficiency, 611283 (3);
11.982;1;31;01;11q24.3;ADAMTS8, METH2;;A disintegrin-like and metalloproteinase with thrombospondin type-1 motif, 8;605175;R, H;;;9(Adamts8)
11.983;4;17;07;11q25;B3GAT1, GLCATP, CD57, HNK1;;Beta-1,3-glucuronyltransferase 1;151290;A, S;;;
11.984;1;29;01;11q24.3;BARX2;;BarH-like homeo box gene 2;604823;A;;;
11.985;2;24;11;11q25;IGSF9B, KIAA1030;;Immunoglobulin superfamily, member 9B;613773;R, REc;;;
11.986;2;11;11;11q25;JAM3;;Junctional adhesion molecule 3;606871;REc;;Hemorrhagic destruction of the brain, subependymal calcification, and cataracts, 613730 (3);
11.987;5;17;18;11q25;NCAPD3, CAPD3, KIAA0056, MCPH22;;Non-SMC condensin II complex subunit D3;609276;REc, R;;Microcephaly 22, primary, autosomal recessive, 617984 (3);
11.988;1;11;07;11q25;NTM, HNT;;Neurotrimin;607938;REc;;;9(Ntm)
11.989;2;11;09;11q25;OPCML;;Opioid-binding protein/cell adhesion molecule-like;600632;REa, H, REc;;{Ovarian cancer, somatic}, 167000 (3);9(Obcam)
11.990;12;23;05;11q25;SPATA19;;Spermatogenesis-associated protein 19;609805;REc;;;
11.991;2;8;11;11q25;THYN1, HSPC144, THY28;;Thymocyte nuclear protein 1;613739;R, REc;;;
11.992;4;19;06;11q25;VPS26B;;Vacuolar protein sorting 26, yeast, homolog of, B;610027;REc;;;9(Vps26b)
11.993;10;20;99;11q25-qter;DFNB20;;Deafness, autosomal recessive 20;604060;Fd;;Deafness, autosomal recessive 20 (2);
11.994;4;2;01;11q13.2;ALDH3B1, ALDH7;;Aldehyde dehydrogenase 3 family, member B1;600466;R;;;
11.995;7;9;01;Chr.11;AOCH;;Acromegaloid features, overgrowth, cleft palate, and hernia;606049;Ch;pericentric inversion (46,XY,inv(11)(p15.3;q23.3));Acromegaloid features, overgrowth, cleft palate, and hernia (2);
11.996;4;2;01;11q13.2;ALDH3B2, ALDH8;;Aldehyde dehydrogenase 3 family, member B2;601917;R;;;
11.997;7;3;88;11q12.2;CD6, TP120;;CD6 antigen;186720;S;;;
11.998;4;28;99;11p11.2;CRY2;;Cryptochrome 2;603732;R;;;2(Cry2)
11.999;2;20;01;11q13.2;FBXL11, FBL11;;F-box and leucine-rich repeat protein-11;605657;R;;;
11.1000;2;21;02;11q23.3;FXYD6;;FXYD domain-containing ion transport regulator 6;606683;R;;;
11.1001;3;11;03;11p15.4;IPO7, RANBP7;;Importin 7;605586;R;;;
11.1002;2;28;01;11p15.4;LYVE1;;Lymphatic vessel endothelial hyaluronan receptor 1;605702;R;;;
11.1003;7;12;02;11q23.3;MIZF;;MBD2-interaction zinc finger protein;607099;R;;;
11.1004;5;7;01;11q13.1;SART1, HOMS1;;Squamous cell carcinoma antigen recognized by T cells 1;605941;R;;;
11.1005;2;5;01;11q13.1;SF3B2, SF3B145, SAP145;;Splicing factor 3B, subunit 2;605591;R;;;
11.1006;1;29;01;11q13.4;SLC21A9, OATPB;;Solute carrier family 21 (organic anion transporter), member 9;604988;R;;;
11.1007;2;27;03;11q12.3;SLC22A8, OAT3;;Solute carrier family 22 (organic anion transporter), member 8;607581;R;;;
11.1008;1;29;01;11p15.2;SPON1;;F-spondin, Rat, homolog of;604989;R;;;
11.1009;5;7;03;11p11.2;SYT13, KIAA1427;;Synaptotagmin 13;607716;R;;;
11.1010;3;29;01;11q23.1;TEX12;;Testis-expressed gene 12;605791;R;;;
11.1011;6;6;00;11q23.3;UBE4A, UFD2, E4;;Ubiquitination factor E4A;603753;REa;;;
12.1;1;24;06;12p13.33;DCP1B, DCP1;;Decapping enzyme 1, S. cerevisiae, homolog of;609843;REc, R;;;
12.2;6;13;12;12p13.33;FBXL14, FBL14;;F-box and leucine-rich repeat protein 14;609081;REc;;;6(Fbxl14)
12.3;4;20;17;12p13.33;ITFG2, FGGAP1;;Integrin-alpha FG-GAP repeat-containing protein 2;617421;REc;;;
12.4;12;11;18;12p13.32;C12orf4;;Chromosome 12 open reading frame 4;616082;REc;;Mental retardation, autosomal recessive 66, 618221 (3);
12.5;12;18;14;12p13.33;RHNO1, RHINO, C12orf32;;Rad9-, Rad1-, and Hus1-interacting nuclear orphan 1;614085;REc;;;
12.6;4;10;12;12p13.33;FKBP4, FKBP52;;FK506-binding protein 4;600611;REc;;;
12.7;6;30;08;12p13.33;IQSEC3, KIAA1110;;IQ motif- and SEC7 domain-containing protein 3;612118;R, REc;;;
12.8;4;8;13;12p13.32;DYRK4;;Dual-specificity tyrosine phosphorylation-regulated kinase 4;609181;REc;;;
12.9;9;6;11;12p13.32;EFCAB4B, CRACR2A;;EF-hand calcium-binding domain-containing protein 4B;614178;REc;;;
12.10;2;22;92;12p13.31;LAG3;;Lymphocyte activation gene-3;153337;A;;;
12.11;12;21;09;12p13.33-p13.32;TSPAN9, NET5;;Tetraspanin 9;613137;REc;;;
12.12;12;1;11;12p13.31;ACSM4;;Acyl-CoA synthetase medium-chain family, member 4;614360;REc;;;
12.13;1;4;12;12p13.33;ADIPOR2, FLJ21432;;Adiponectin receptor 2;607946;REc;;;6(Adipor2)
12.14;2;17;09;12p13.31;ATN1, DRPLA, HRS, NOD;;Atrophin 1;607462;Fd, D, A;;Dentatorubro-pallidoluysian atrophy, 125370 (3);6(Drpla)
12.15;7;6;18;12p13.31;A2ML1, OMS;;Alpha-2-macroglobulin-like 1;610627;REc;;{Otitis media, susceptibility to}, 166760 (3);
12.16;11;2;04;12p13.31;C1RL, CLSPA, C1RLP;;Complement component C1r-like protein;608974;REc;;;
12.17;11;11;14;12p13.31;C3AR1, C3AR;;Complement component 3a receptor 1;605246;REc;;;
12.18;5;23;11;12p13.31;CD4;;CD4 antigen (p55);186940;REa, A;CD = \'cluster of differentiation\' = nomenclature of leukocyte differentiation antigens;OKT4 epitope deficiency, 613949 (3);6(Ly4)
12.19;1;13;09;12p13.31;CLEC2A;;C-type lectin domain family 2, member A;612087;REc;;;
12.20;9;24;08;12p13.2;CLEC9A, DNGR1;;C-type lectin domain family 9, member A;612252;REc;;;
12.21;2;12;14;12p13.31;CLECL1, DCAL1;;C-type lectin-like 1;607467;REc;;;
12.22;9;22;14;12p13.31;COPS7A, CSN7;;COP9 signalosome, subunit 7A;616009;REc;;;
12.23;1;27;04;12p13.31;DPPA3;;Developmental pluripotency-associated gene 3;608408;REc, H;;;6(Dppa3)
12.24;9;30;09;12p13.31;FAM90A1;;Family with sequence similarity 90, member A1;613041;REc;other family members on chr. 8;;
12.25;2;25;15;12p13.31;IFFO1;;Intermediate filament family orphan 1;610495;REc;;;
12.26;3;15;04;12p13.31;ING4;;Inhibitor of growth-4;608524;R, REc, D;;;
12.27;3;23;14;12p13.31;KLRG1, MAFA, MAFAL;;Killer cell lectin-like receptor, subfamily G, member 1;604874;Psh, REc;;;6(Klrg1)
12.28;10;25;16;12p13.31;LPCAT3, MBOAT5, NESSY;;Lysophosphatidylcholine acyltransferase 3;611950;REc;;;
12.29;3;23;09;12p13.31;MIR141, MIRN141;;Micro RNA 141;612093;REc;;;
12.30;3;23;09;12p13.31;MIR200C, MIRN200C;;Micro RNA 200C;612092;REc;;;
12.31;6;13;12;12p13.31;NANOG;;Homeobox transcription factor NANOG;607937;REc, H;;;6(Nanog)
12.32;5;27;18;12p13.31;NCAPD2, CNAP1, KIAA0159, MCPH21;;Non-SMC condensin I complex subunit D2;615638;Psh, REc;mutation identified in 1 MCPH21 patient;?Microcephaly 21, primary, autosomal recessive, 617983 (3);
12.33;7;7;14;12p13.31;NECAP1, EIEE21;;NECAP endocytosis-associated protein 1;611623;REc;mutation identified in 1 EIEE21 family;?Epileptic encephalopathy, early infantile, 21, 615833 (3);
12.34;9;23;13;12p13.31;PHC1, EDR1, HPH1, RAE28, MCPH11;;Polyhomeotic-like 1;602978;REc;mutations identified in 1 family;?Microcephaly 11, primary, autosomal recessive, 615414 (3);
12.35;11;3;14;12p13.31;PIANP, PANP, LEDA1;;PILR-alpha-associated neural protein;616065;REc;;;
12.36;4;24;18;12p13.31;PLEKHG6, MYOGEF;;Pleckstrin homology domain- and RhoGEF domain-containing protein G6;611743;REc;;;
12.37;7;8;11;12p13.31;PTMS;;Parathymosin;168440;REc;previously assigned to 17q12-q22;;
12.38;2;28;08;12p13.31;RBP5, CRBP3;;Retinol-binding protein 5;611866;REc;;;
12.39;7;1;11;12p13.31;RIMKLB, NAAGS;;Ribosomal modification protein RimK-like family, member B;614054;R, REc;;;
12.40;2;16;18;12p13.31;RNU7-1, RNU7;;RNA, U7 small nuclear, 1;617876;REc;;;6(Rnu7-1)
12.41;3;7;13;12p13.31;SCARNA10;;Small cajal body-specific RNA 10;615639;REc, REn;in intron 4 of NCAPD2;;
12.42;2;25;14;12p13.31;SCARNA12;;Small Cajal body-specific RNA 12;615642;REc;;;
12.43;12;18;07;12p13.31;SPSB2, SSB2;;SPRY domain- and SOCS box-containing 2;611658;REc;;;
12.44;6;27;14;12p13.31;VAMP1, SYB1, SPAX1;;Vesicle-associated membrane protein-1 (synaptobrevin-1);185880;REa, Fd;;Spastic ataxia 1, autosomal dominant, 108600 (3);6(Syb1)
12.45;10;5;10;12p13.31;CLEC6A, CLEC4N;;C-type lectin domain family 6, member A;613579;REc;;;
12.46;10;23;87;12p13.31;GAPDH, GAPD;;Glyceraldehyde-3-phosphate dehydrogenase;138400;S, D, R;pseudogene on Xp21-q11;;6(Gapd)
12.47;9;2;08;12p13.33;B4GALNT3;;Beta-1,4-N-acetylgalactosaminyltransferase 3;612220;REc;;;
12.48;3;5;08;12p13.33;CACNA1C, CACNL1A1, CCHL1A1, TS;;Calcium channel, voltage-dependent, L type, alpha 1C subunit;114205;Psh, Fd, REa, A;;Timothy syndrome, 601005 (3); Brugada syndrome 3, 611875 (3);
12.49;10;11;06;12p13.33;CACNA2D4, RCD4;;Calcium channel, voltage-dependent, alpha-2/delta subunit 4;608171;REc;;Retinal cone dystrophy 4, 610478 (3);
12.50;1;23;01;12p13.31;CD163;;CD163 antigen (hemoglobin scavenger receptor);605545;A, REa, R;;;
12.51;9;30;09;12p13.31;CD164L1, CD163B, M160;;CD164 antigen-like 1;606079;A, R;;;
12.52;6;1;18;12p13.32;FGF23, ADHR, HPDR2, PHPTC, HFTC2;;Fibroblast growth factor 23;605380;Fd, REc;;Hypophosphatemic rickets, autosomal dominant, 193100 (3); Osteomalacia, tumor-induced (1); Tumoral calcinosis, hyperphosphatemic, familial, 2, 617993 (3);6(Fgf23)
12.53;1;27;04;12p13.32;GALNT8;;UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 8;606250;REc;;;
12.54;1;2;03;12p13.1;GPRC5D;;G protein-coupled receptor, family C, group 5, member D;607437;REc;;;
12.55;10;30;08;12p13.3;MAFD9;;Major affective disorder 9;612372;Fd;associated with rs1006737;{Major affective disorder-9, susceptibility to} (2);
12.56;12;23;15;12p13.32;PARP11, ARTD11;;Poly(ADP-ribose) polymerase family, member 11;616706;REc;;;
12.57;12;23;15;12p13.31;PEX5, PXR1, PTS1R, PBD2A, PBD2B, RCDP5;;Peroxisome biogenesis factor 5;600414;REa, A, R;;Peroxisome biogenesis disorder 2A (Zellweger), 214110 (3); Peroxisome biogenesis disorder 2B, 202370 (3); Rhizomelic chondrodysplasia punctata, type 5, 616716 (3);
12.58;4;6;15;12p13.32;PRMT8, HRMT1L3, HRMT1L4;;Protein arginine methyltransferase 8;610086;REc, H;;;6(Prmt8)
12.59;11;28;94;12p13.31;SLC2A3, GLUT3;;Solute carrier family 2 (facilitated glucose transporter), member 3;138170;A;pseudogene SLC2A3P on 5q34;;
12.60;8;20;07;12p13.31;SLC2A14, GLUT14;;Solute carrier family 2 (facilitated glucose transporter), member 14;611039;REc;;;
12.61;3;14;13;12p13.33;SLC6A13, GAT2, GAT3;;Solute carrier family 6 (neurotransmitter transporter, GABA), member 13;615097;REc;;;
12.62;7;2;02;12p13.31;TAPBPR;;TAP-binding protein-related protein;607081;REc;;;
12.63;2;20;07;12p13.32;TIGAR, C12orf5;;TP53-induced glycolysis and apoptosis regulator;610775;REc;;;
12.64;10;4;10;12p13.31;VWF, F8VWF;;Coagulation factor VIII VWF (von Willebrand factor);613160;A, REa, REb, Fd;pseudogene on chr. 22;von Willebrand disease, types 2A, 2B, 2M, and 2N, 613554 (3); von Willebrand disease, type 1, 193400 (3); von Willibrand disease, type 3, 277480 (3);6(Vwf)
12.65;11;4;04;12p13.33;WNT5B;;Wingless-type MMTV integration site family, member 5B;606361;REc;;;
12.66;10;15;98;12p13.33;TEAD4, TCF13L1, RTEF1;;TEA domain family, member 4;601714;A;;;6(Tcf13l1)
12.67;7;1;11;12p13.31;A2M , A2MD;;Alpha-2-macroglobulin;103950;REa, A;cluster of genes;Alpha-2-macroglobulin deficiency, 614036 (1); {Alzheimer disease, susceptibility to}, 104300 (3);6(A2m)
12.68;3;5;08;12p13.31;MRPL51, MRP64;;Mitochondrial ribosomal protein L51;611855;R, REc;;;
12.69;12;28;15;12p13.2;LRP6, ADCAD2, STHAG7;;Low density lipoprotein receptor-related protein 6;603507;A, R;;{Coronary artery disease, autosomal dominant, 2}, 610947 (3); Tooth agenesis, selective, 7, 616724 (3);6(Lrp6)
12.70;12;24;08;12p13.1;APOLD1, VERGE;;Apolipoprotein L domain-containing 1;612456;REc;;;
12.71;10;23;15;12p13.2;BORCS5, LOH12CR1, MYRLYSIN;;BLOC1-related complex, subunit 5;616598;REc;;;
12.72;7;13;17;12p13.2;CLEC12B;;C-type lectin domain family 12, member B;617573;REc;;;6(Clec12b)
12.73;3;27;90;12p13.2;PRB1;;Proline-rich protein BstNI, subfamily-1;180989;F, RE;;;
12.74;3;27;90;12p13.2;PRB2;;Proline-rich protein BstNI, subfamily-2 (parotid size variant);168810;F, RE;Ps allele;;
12.75;3;27;90;12p13.2;PRB3;;Proline-rich protein BstNI, subfamily-3 (parotid salivary glycoprotein);168840;LD, F, RE;G1 allele;;
12.76;3;27;90;12p13.2;PRB4;;Proline-rich protein BstNI, subfamily-4;180990;F, RE;Po, CON1, CON2 alleles;;
12.77;4;10;90;12p13.2;PRH1;;Proline-rich protein HaeIII, subfamily-1;168730;F, LD, RE;Pa, Db, PIF alleles;;
12.78;3;27;90;12p13.2;PRH2;;Proline-rich protein HaeIII, subfamily-2;168790;F, LD, RE;Pr allele;;
12.79;1;28;88;12p13.2;PCS;;Parotid proline-rich salivary protein Pc;168710;F;linked to PRB2;;
12.80;8;27;15;12p13.2;STYK1, NOK;;Serine/threonine/tyrosine kinase 1;611433;REc;;;
12.81;6;11;11;12p13.2;TAS2R20, T2R56;;Taste receptor, type 2, member 20;613962;Psh, REc;;;
12.82;6;27;11;12p13.2;TAS2R30, T2R30, T2R47;;Taste receptor, type 2, member 30;613963;REc;previously assigned to chr.1;;
12.83;6;26;11;12p13.2;TAS2R45, T2R45;;Taste receptor, type 2, member 45;613967;REc;;;
12.84;3;23;09;12p13.2;TAS2R43, T2R52;;Taste receptor, type 2, member 43;612668;REc;;;
12.85;1;24;12;12p13.2;TAS2R31, TAS2R44, T2R53;;Taste receptor, type 2, member 31;612669;REc;;;
12.86;9;15;09;12p13.2;TAS2R46, T2R46, T2R54;;Taste receptor, type 2, member 46;612774;REc;;;
12.87;11;4;08;12p13.2;TAS2R50, T2R50, TAS2R51, T2R51;;Taste receptor, type 2, member 50;609627;Psh, REc;;;
12.88;9;7;12;12p13.31;TNFRSF1A, TNFR1, TNFAR, FPF, MS5;;Tumor necrosis factor receptor superfamily, member 1A;191190;REa, A, Psh;;Periodic fever, familial, 142680 (3); {Multiple sclerosis, susceptibility to, 5}, 614810 (3);6(Tnfr2)
12.89;11;12;07;12p13.32;RAD51AP1, PIR51;;Rad51-associated protein 1;603070;A;;;6(Pir51)
12.90;2;15;02;12p13.31;CLEC4C, CLECSF11, DLEC, BDCA2;;C-type lectin domain family 4, member C;606677;REc;;;
12.91;9;8;11;12p13.2;CLEC7A, CLECSF12, DECTIN1, CANDF4;;C-type lectin domain family 7, member A;606264;A, REc;in natural killer gene complex;Candidiasis, familial, 4, autosomal recessive, 613108 (3); {Aspergillosis, susceptibility to}, 614079 (3);
12.92;1;13;99;12p13.1;GPR19;;G protein-coupled receptor-19;602927;A, REn;;;
12.93;1;13;99;12p13.2;KLRC1, NKG2, NKG2A;;Killer cell lectin-like receptor, subfamily C, member 1;161555;REa, A;family of at least 3 genes on 12;;6(Klrc1)
12.94;1;13;99;12p13.2;KLRC2, NKG2C;;Killer cell lectin-like receptor, subfamily C, member 2;602891;REc;;;
12.95;1;13;99;12p13.2;KLRC3, NKG2E;;Killer cell lectin-like receptor, subfamily C, member 3;602892;REc;;;
12.96;9;3;98;12p13.2;KLRC4, NKG2F, D12S2489E;;Killer cell lectin-like receptor, subfamily C, member 4;602893;REc;;;
12.97;1;13;99;12p13.2;KLRD1, CD94;;Killer cell lectin-like receptor, subfamily D, member 1;602894;REc;;;
12.98;1;29;01;12p13.31;KLRF1;;Killer cell lectin-like receptor, subfamily F, member 1;605029;REc;;;
12.99;2;26;08;12p13.2;KLRK1, NKG2D;;Kill cell lectin-like receptor, subfamily K, member 1;611817;REc;;;
12.100;7;18;06;12p13.2-p11.23;DFNB62;;Deafness, autosomal recessive 62;610143;Fd;between D12S358 and D12S1042;Deafness, autosomal recessive 62 (2);
12.101;1;6;97;12p13.2-q24.1;IBD2;;Inflammatory bowel disease 2;601458;Fd, LD;mainly ulcerative colitis;{Inflammatory bowel disease 2} (2);
12.102;1;7;95;12p13.31;APOBEC1, BEDP;;Apolipoprotein B mRNA editing enzyme, catalytic polypeptide 1;600130;A;;;
12.103;11;22;10;12p13.1;ATF7IP, AM, MCAF, MCAF1;;Activating transcription factor 7-interacting protein;613644;REc;;;
12.104;1;22;99;12p13.2;CSDA, DBPA;;Cold-shock domain protein A;603437;A;;;
12.105;10;7;13;12p13.1;DDX47;;DEAD box polypeptide 47;615428;REc;;;
12.106;1;30;18;12p13.1;FAM234B, KIAA1467;;Family with sequence similarity 234, member B;617838;REc;;;
12.107;1;20;11;12p13.31;GDF3, KFS3, MCOPCB6, MCOP7;;Growth differentiation factor 3;606522;R;;Klippel-Feil syndrome 3, autosomal dominant, 613702 (3); Microphthalmia with coloboma 6, 613703 (3); Microphthalmia, isolated 7, 613704 (3);
12.108;10;12;14;12p13.1;GNAI2P1, GNAI2L, GNAI2A;;Guanine nucleotide-binding protein (G protein), alpha-inhibiting, polypeptide 2 pseudogene 1;139180;REa, A;;;
12.109;2;8;13;12p12.3;HIST4H4;;Histone gene cluster 4, H4 histone;615069;REc;;;
12.110;1;8;15;12p13.31;MFAP5, MAGP2, AAT9;;Microfibril-associated protein 5;601103;A;;Aortic aneurysm, familial thoracic 9, 616166 (3);
12.111;11;25;14;12p12.3;MGP;;Matrix Gla protein;154870;REa, R, Fd, LD;;Keutel syndrome, 245150 (3);6(Mglap)
12.112;4;17;12;12p13.1;GPRC5A, RAI3, RAIG1;;G protein-coupled receptor, family C, group 5, member A;604138;R, REc;;;
12.113;9;19;00;12p13.31;AICDA, AID, HIGM2;;Activation-induced cytidine deaminase;605257;A, Fd;;Immunodeficiency with hyper-IgM, type 2, 605258 (3);
12.114;11;24;08;12p13.31;ANO2, TMEM16B, C12orf3;;Anoctamin 2;610109;REc;;;
12.115;10;29;16;12p13.31;C1R, EDSPD1;;Complement component-1, r subcomponent;613785;REa, Fd, RE, A;;Ehlers-Danlos syndrome, periodontal type, 1, 130080 (3);
12.116;10;29;16;12p13.31;C1S, EDSPD2;;Complement component-1, s subcomponent;120580;REa, Fd, RE, A;;C1s deficiency, 613783 (3); Ehlers-Danlos syndrome, periodontal type, 2, 617174 (3);
12.117;4;23;13;12p13.31;C12orf57, C10, TEMTYS;;Chromosome 12 open reading frame 57;615140;REc, H;;Temtamy syndrome, 218340 (3);6(C12orf57)
12.118;8;22;14;12p13.32;CCND2, MPPH3;;Cyclin D2;123833;REa, A;;Megalencephaly-polymicrogyria-polydactyly-hydrocephalus syndrome 3, 615938 (3);
12.119;6;5;89;12p13.31;CD9, MIC3;;CD9 antigen (p24);143030;S, REa, A;;;
12.120;5;22;07;12p13.1;CDKN1B, KIP1, CDKN4, MEN4;;Cyclin-dependent kinase inhibitor 1B (p27, Kip1);600778;Psh, A, REc, REn;;Multiple endocrine neoplasia, type IV, 610755 (3);7(Cdkn1b)
12.121;10;18;16;12p13.31;CHD4, SIHIWES;;Chromodomain helicase DNA-binding protein-4;603277;A;;Sifrim-Hitz-Weiss syndrome, 617159 (3);
12.122;11;09;18;12p13.2;CLEC1A, CLEC1;;C-type lectin domain family 1, member A;606782;REa;;{Aspergillosis, susceptibility to}, 614079 (3);
12.123;3;26;02;12p13.3-p13.2;CLEC2B, CLEC2;;C-type lectin domain family 1, member B;606783;REa;;;
12.124;3;23;06;12p13.31;CLEC4D, CLECSF8, CLEC6;;C-type lectin domain family 4, member D;609964;REc;;;
12.125;3;24;06;12p13.31;CLEC2D, LLT1;;C-type lectin domain family 2, member D;605659;REc;;;
12.126;3;23;06;12p13.31;CLEC4E, MINCLE;;C-type lectin domain family 4, member E;609962;REc;;;6(Clec4e)
12.127;1;31;01;12p13.31;CLEC4A, CLECSF6, DCIR, DDB27;;C-type lectin domain family 4, member A;605306;REa, R;;;
12.128;6;27;08;12p13.31;CLEC12A, MICL;;C-type lectin domain family 12, member A;612088;REc, H;;;6(Clec12a)
12.129;3;23;13;12p13.31;CLSTN3, KIAA0726;;Calsyntenin 3;611324;R, REc;;;
12.130;6;25;99;12p13.1;CREBL2;;Cyclic AMP response element-binding protein-like 2;603476;D, A;;;
12.131;5;13;98;12p13.31;DDX12, CHLR2;;DEAD/H box-12;601151;Psh, A;;;
12.132;8;24;09;12p13.31;EMG1, NEP1, C2F, BWCNS;;Essential for mitotic growth 1, S. cerevisiae, homolog of;611531;REc, Fd;;Bowen-Conradi syndrome, 211180 (3);
12.133;8;11;91;12p13.31;ENO2;;Enolase-2, gamma, neuronal;131360;S, D, A, REa;;;
12.134;2;13;15;12p13.2;ETV6, TEL, THC5;;ETS variant gene-6 (TEL oncogene);600618;RE, Fd, D;fused to PDGFRB or AML1 in leukemia;Leukemia, acute myeloid, somatic, 601626 (3); Thrombocytopenia 5, 616216 (3);
12.135;3;18;94;12p13.32;FGF6;;Fibroblast growth factor-6;134921;A, Ch, Psh;;;
12.136;11;9;98;12p13.33;FOXM1, FKHL16, HFH11;;Forkhead box M1;602341;Psh, R, A;;;
12.137;7;11;16;12p13.31;GNB3, CSNB1H;;Guanine nucleotide-binding protein, beta polypeptide-3;139130;REa, A;;{Hypertension, essential, susceptibility to}, 145500 (3); Night blindness, congenital stationary, type 1H, 617024 (3);6(Gnb3)
12.138;2;11;96;12p13.32;KCNA1, AEMK, EA1;;Potassium voltage-gated channel, shaker-related subfamily, member 1;176260;REa, Fd, A, H;close to VWF;Episodic ataxia/myokymia syndrome, 160120 (3);6(Kcna1)
12.139;9;8;08;12p13.32;KCNA5, ATFB7;;Potassium voltage-gated channel, shaker-related subfamily, member 5;176267;REa, Fd, H;;Atrial fibrillation, familial, 7, 612240 (3);6(Kcna5)
12.140;3;17;94;12p13.32;KCNA6;;Potassium voltage-gated channel, shaker-related subfamily, member 6;176257;REa;;;6(Kcna6)
12.141;4;19;16;12p13.31;P3H3, LEPREL2;;Prolyl 3-hydroxylase 3;610342;REc;;;
12.142;8;21;98;12p12.3;LMO3, RBTNL2, RHOM3;;LIM domain only 3 (rhombotin-like 2);180386;A, Ch;expressed mainly in brain;;
12.143;4;24;08;12p13.31;LPAR5, GPR92, GPR93, LPA5;;Lysophosphatidic acid receptor 5;606926;REc;;;
12.144;8;21;98;12p13.31;LTBR, TNFCR;;Lymphotoxin-beta receptor (tumor necrosis factor C receptor);600979;H;tightly linked to TNFR1 in mouse;;6(Tnfcr)
12.145;12;4;95;12p13.31;M6PR;;Mannose-6-phosphate receptor, cation-dependent;154540;REa, Psh, A;;;6(Mprd)
12.146;8;29;96;12p13.31;MLF2;;Myeloid leukemia factor-2;601401;A, REc;;;
12.147;4;29;03;12p13.33;NINJ2;;Nerve injury-induced protein 2;607297;REc;;;
12.148;10;15;94;12p13.31;NOL1;;Nucleolar protein 1, 120kD;164031;Psh, A;;;
12.149;6;21;91;12p13.31;NTF3;;Neurotrophin-3;162660;A, REa;;;6(Ntf3)
12.150;10;25;12;12p12.3;PDE6H, RCD3, ACHM6;;Phosphodiesterase 6H, cGMP-specific, cone, gamma;601190;A;;Retinal cone dystrophy 3, 610024 (3); Achromatopsia 6, 610024 (3);
12.151;1;17;07;12p13.31;PHB2, REA;;Prohibitin 2;610704;R, REc;;;
12.152;12;30;14;Xp21.1;PRRG1, PRGP1;;Proline-rich gamma-carboxyglutamic acid protein 1;300935;REc;;;
12.153;1;6;93;12p13.31;PTPN6;;Protein tyrosine phosphatase, nonreceptor-type, 6;176883;A;;;6(Hcph)
12.154;09;19;18;12p13.31;SCNN1A, BESC2, LIDLS3;;Sodium channel, nonvoltage-gated 1, alpha;600228;REa, Psh, A, Fd;mutation identified in 1 LIDLS3 patient;Pseudohypoaldosteronism, type I, 264350 (3); Bronchiectasis with or without elevated sweat chloride 2, 613021 (3); ?Liddle syndrome 3, 618126 (3);6(Scnn1)
12.155;10;2;98;12p13.33;SLC6A12;;Solute carrier family 6 (neurotransmitter transporter, betaine/GABA), member 12;603080;A;;;
12.156;6;11;11;12p13.2;TAS2R19, T2R19, T2R48;;Taste receptor, type 2, member 19;613961;REc;;;
12.157;6;26;11;12p13.2;TAS2R42, T2R42, T2R55;;Taste receptor, type 2, member 42;613966;REc;;;
12.158;6;27;17;12p13.31;CD27, TNFRSF7, S152. LPFS2;;CD27 antigen;186711;Psh, A;;Lymphoproliferative syndrome 2, 615122 (3);
12.159;11;13;13;12p13.31;TPI1, TPID;;Triosephosphate isomerase-1;190450;S, D, R, REa;;Hemolytic anemia due to triosephosphate isomerase deficiency, 615512 (3);6(Tpi1)
12.160;4;5;00;12p13.2;TRB1, T2R14;;Taste receptor, family B, member 1;604790;REc;;;
12.161;4;5;00;12p13.2;TRB2, T2R10;;Taste receptor, family B, member 2;604791;REc;;;
12.162;4;5;00;12p13.2;TRB3, T2R13;;Taste receptor, family B, member 3;604792;REc;;;
12.163;4;5;00;12p13.2;TRB4, T2R7;;Taste receptor, family B, member 4;604793;REc;;;
12.164;4;5;00;12p13.2;TRB5, T2R8;;Taste receptor, family B, member 5;604794;REc;;;
12.165;4;5;00;12p13.2;TRB6, T2R9;;Taste receptor, family B, member 6;604795;REc;;;
12.166;12;14;00;12p13.33;TULP3;;Tubby-like protein 3;604730;R;;;6(Tulp3)
12.167;2;5;99;12p13.31;USP5, ISOT;;Ubiquitin-specific protease-5 (ubiquitin isopeptidase T);601447;REn;;;
12.168;2;27;12;12p13.33;WNK1, PRKWNK1, KDP, PHA2C, HSAN2, HSN2;;WNK lysine deficient protein kinase 1;605232;Fd, REc;;Pseudohypoaldosteronism, type IIC, 614492 (3); Neuropathy, hereditary sensory and autonomic, type II, 201300 (3);
12.169;6;8;89;12p13.31;PZP;;Pregnancy zone protein;176420;REa, A;;;
12.170;3;18;95;12p13.33;RAD52;;RAD52, yeast, homolog of;600392;Psh, A;;;
12.171;10;24;14;12p12.3;ART4, DO, DOK1;;ADP-ribosyltransferase-4 (Dombrock blood group);110600;A, Psh;;[Blood group, Dombrock], 616060 (3);
12.172;3;1;94;12p13.31;CD69;;CD69 antigen (p60, early T-cell activation antigen);107273;REa, A;;;
12.173;3;24;06;12p13.31;CLEC2B, CLECSF2, AICL;;C-type lectin domain family 2, member B;603242;REc;;;
12.174;11;3;99;12p13.2;KLRA1, LY49L;;Killer cell lectin-like receptor, subfamily A, member 1;604274;H, REc;?functional;;6(Ly49)
12.175;1;13;99;12p13.31;KLRB1, NKRP1A;;Killer cell lectin-like receptor, subfamily B, member 1;602890;Psh, A, REc;;;
12.176;11;29;11;12p13.2;OLR1, LOX1;;Low density lipoprotein, oxidized, receptor 1;602601;A, REn;;{Myocardial infarction, susceptibility to}, 608446 (3);
12.177;9;6;11;12p12.3;PTPRO, GLEPP1, NPHS6;;Protein tyrosine phosphatase, receptor type, O;600579;A;;Nephrotic syndrome, type 6, 614196 (3);
12.178;6;21;94;12q13.3;ATP5B, ATPSB;;ATP synthase, H+ transporting, mitochondrial F1 complex, beta polypeptide;102910;REa, REb;;;
12.179;4;24;18;12p12.3;AEBP2;;AE-binding protein 2;617934;REc;;;
12.180;7;14;98;12p12.3;ARHGDIB, GDID4, D4;;Rho GDP dissociation inhibitor (GDI) beta;602843;A;;;
12.181;10;10;18;Xp11.3;PPP1R2C;;Protein phosphatase 1, regulatory subunit 2C;301017;REc;;;
12.182;10;20;99;12p13.1;EMP1, TMP;;Epithelial membrane protein-1;602333;REa, A, R;;;6(Emp1)
12.183;9;2;14;12p12.3;EPS8, DFNB102;;Epidermal growth factor receptor pathway substrate-8;600206;REa, A;mutation identified in 1 DFNB102 family;?Deafness, autosomal recessive 102, 615974 (3);
12.184;2;28;03;12p13.2;GABARAPL1, GEC1;;GABA-A receptor-associated protein-like protein 1;607420;R, REc;;;
12.185;11;22;16;12p12.3;PLCZ1, SPGF17;;Phospholipase C, zeta-1;608075;REc;mutation identified in 1 SPGF17 family;?Spermatogenic failure 17, 617214 (3);
12.186;7;18;14;12p11.23;STK38L, NDR2, KIAA0965;;Serine/threonine protein kinase 38-like protein;615836;R, REc;;;6(Stk38l)
12.187;5;18;10;12p12.3;STRAP, UNRIP, MAWD;;Serine/threonine kinase receptor-associated protein;605986;R, REc;previously assigned to 12q;;
12.188;8;10;18;12p12.3;WBP11, NPWBP, SIPP1;;WW-binding protein 11;618083;REc;;;
12.189;4;25;93;12p12.1;IAPP;;Islet amyloid polypeptide (diabetes-associated peptide; amylin);147940;REa, A;;;
12.190;4;23;13;12p12.1;GYS2;;Glycogen synthase-2, liver;138571;A, Fd;;Glycogen storage disease 0, liver, 240600 (3);
12.191;6;23;15;12p12.2;PDE3A, HTNB;;Phosphodiesterase 3A, cGMP-inhibited;123805;REc, Fd;;Hypertension and brachydactyly syndrome, 112410 (3);
12.192;1;18;12;12p12.2;SLCO1B3, OATP8, OATP1B3, SLC21A8, HBLRR;;Solute carrier organic anion transporter family, member 1B3;605495;REc;HBLRR digenic with SLCO1B1;Hyperbilirubinemia, Rotor type, digenic, 237450 (3);
12.193;6;21;04;12p12.2-p12.1;HYT4;;Hypertension, essential, susceptibility to, 4;608742;Fd;;{Hypertension, essential, susceptibility to, 4}, 145500 (2);
12.194;9;4;15;12p12.1;LDHB, LDHBD;;Lactate dehydrogenase B;150100;S, D, Fd;;[Lactate dehydrogenase-B deficiency], 614128 (3);6(Ldh2)
12.195;7;6;12;12p12.1;ABCC9, SUR2, CMD1O, ATFB12, CANTU;;ATP-binding cassette, subfamily C, member 9 (sulfonylurea receptor 2);601439;A;;Cardiomyopathy, dilated, 1O, 608569 (3); Atrial fibrillation, familial, 12, 614050 (3); Hypertrichotic osteochondrodysplasia, 239850 (3);
12.196;6;28;18;12p12.1;C2CD5, CDP138, KIAA0528;;C2 calcium-dependent domain-containing protein 5;618044;REc, R;;;
12.197;4;19;16;12p12.1;CASC1, LAS1, PPP1R54;;Cancer susceptibility candidate 1;616906;REc, H;;;6(Casc1)
12.198;4;19;06;12p12.1;CMAS;;Cytidine monophosphate N-acetylneuraminic acid synthetase;603316;REn;;;
12.199;3;7;13;12p12.1;GOLT1B, GOT1B, GCT2;;Golgi transport 1B;615078;REc;;;
12.200;6;20;13;12p12.1;KRAS, KRAS2, RASK2, NS, CFC2, RALD;;Kirsten rat sarcoma-2 viral (v-Ki-ras2) oncogene homolog;190070;REa, A, Fd;pseudogene KRAS1P on 6p12-p11;Lung cancer, somatic, 211980 (3); Bladder cancer, somatic, 109800 (3); Pancreatic carcinoma, somatic, 260350 (3); Gastric cancer, somatic, 137215 (3); Leukemia, acute myeloid, 601626 (3); Noonan syndrome 3, 609942 (3); Cardiofaciocutaneous syndrome 2, 615278 (3); Breast cancer, somatic, 114480 (3); Schimmelpenning-Feuerstein-Mims syndrome, somatic mosaic, 163200 (3); RAS-associated autoimmune leukoproliferative disorder, 614470 (3); Arteriovenous malformation of the brain, somatic, 108010 (3);6(Kras2)
12.201;12;15;16;12p12.1;LMNTD1, IFLTD1, LMNARS1, PAS1C1;;Lamin tail domain-containing protein 1;617254;REc;;;
12.202;4;29;14;12p12.1;LRMP, JAW1;;Lymphoid-restricted membrane protein;602003;REc;;;
12.203;12;19;16;12p12.1;PYROXD1, MFM8;;Pyridine nucleotide-disulfide oxidoreductase domain-containing protein 1;617220;REc;;Myopathy, myofibrillar, 8, 617258 (3);
12.204;9;7;12;12p12.1;RASSF8, C12orf2;;RAS association domain family, member 8;608231;REc;;;
12.205;2;12;16;12p12.1;SOX5, LAMSHF;;SRY-box 5;604975;A, H;some LAMSHF patients have 12p12 deletions;Lamb-Shaffer syndrome, 616803 (3);6(Sox5)
12.206;8;24;09;12p12.1;BHLHE41, BHLHB3, DEC2, SHARP1;;Basic helix-loop-helix domain-containing protein, member E41;606200;A;;[Short sleeper], 612975 (3);6(Dec2)
12.207;3;20;06;12p12.1;ETNK1, EKI1;;Ethanolamine kinase 1;609858;REc;;;12(Etnk1)
12.208;3;22;06;12p12.1;DADR;;DAD1-related gene;609860;A;;;
12.209;4;24;18;12p11.22;PTHLH, BDE2;;Parathyroid hormone-like hormone;168470;REa, A;;Brachydactyly, type E2, 613382 (3);6(Pthlh)
12.210;3;14;96;12p12.1;SIAT8;;Sialyltransferase-8 (alpha-N-acetylneuraminate: alpha-2,8-sialyltransferase, GD3 synthase);601123;Psh, A;;;6(Siat8)
12.211;7;6;00;12q13.13;TARBP2;;TAR RNA-binding protein 2;605053;Psh;pseudogene on 8q22-qter;;15(Tarbp2)
12.212;9;15;98;12p12.1;BCAT1, BCT1;;Branched chain aminotransferase-1, cytosolic;113520;S, H;;?Hyperleucinemia-isoleucinemia or hypervalinemia (1);6(Bcat1)
12.213;8;30;01;12p13.2;BCLG;;Apoptosis regulator BCLG;606126;REc;;;
12.214;6;10;04;12p12.3;CAPZA3, CAPPA3;;Capping protein, actin, alpha-3;608722;REc;;;6(Capza3)
12.215;6;27;12;12p13.2;DUSP16, MKP7, KIAA1700;;Dual-specificity phosphatase 16;607175;REc;;;
12.216;12;26;14;12p13.1;GRIN2B, NMDAR2B, MRD6, EIEE27;;Glutamate receptor, ionotropic, N-methyl D-aspartate 2B;138252;A, REa;;Mental retardation, autosomal dominant 6, 613970 (3); Epileptic encephalopathy, early infantile, 27, 616139 (3);6(Nmdar2b)
12.217;5;29;12;12p12.3;GUCY2C, GUC2C, DIAR6, MECIL;;Guanylate cyclase 2C (heat stable enterotoxin receptor);601330;A;;Diarrhea 6, 614616 (3); Meconium ileus, 614665 (3);6(Gucy2c)
12.218;8;25;09;12p12.3;PEPP2, KIAA1686;;Phosphatidylinositol 3-phosphate-binding PH domain protein 2;607770;R, REc;;;
12.219;11;2;04;12p12.3;PIK3C2G;;Phosphatidylinositol 3-kinase, class 2, gamma;609001;A, H;;;6(Pik3c2g)
12.220;3;23;09;12p12.3;RERG;;Ras-like and estrogen-regulated growth inhibitor;612664;REc;;;
12.221;7;7;14;12p12.3;SKP1P2, SKP1B;;S-phase kinase-associated protein 1 pseudogene 2 (p19B);601435;A;;;
12.222;1;13;99;12p12.1;SLC21A3, OATP;;Solute carrier family 21 (organic anion transporter), member 3;602883;Psh, A;;;
12.223;1;18;12;12p12.1;SLCO1B1, LST1, OATP2, OATPC, OATP1B1, HBLRR;;Solute carrier organic anion transporter family, member 1B1;604843;R, REn;HBLRR digenic with SLCO1B3;Hyperbilirubinemia, Rotor type, digenic, 237450 (3);
12.224;6;7;10;12p12.2;SLCO1C1, OATPF, OATP14, SLC21A14;;Solute carrier organic anion transporter family, member 1C1;613389;REc;;;
12.225;3;14;06;12p13.31;ZNF384, CIZ, CAGH1, NMP4;;Zinc finger protein 384;609951;REc, H;;;6(Znf384)
12.226;5;22;14;12p12.1;RECQL, RECQL1;;RecQ helicase-like (DNA helicase, RecQ-like 1);600537;Psh, A;;;
12.227;11;19;13;12p11.21;CAPRIN2, C1QDC1, EEG1, KIAA1873;;Caprin family, member 2;610375;REc;;;
12.228;12;27;16;12p11.21;DENND5B;;DENN domain-containing protein 5B;617279;REc;;;
12.229;11;8;17;12p11.21;DNM1L, DRP1, DVLP, DYMPLE, EMPF1, OPA5;;Dynamin 1-like;603850;R, REc;;Encephalopathy, lethal, due to defective mitochondrial peroxisomal fission 1, 614388 (3); Optic atrophy 5, 610708 (3);
12.230;4;6;18;12p11.21;ETFBKMT, METTL20, C12orf72;;Electron transfer flavoprotein beta-subunit lysine methyltransferase;615256;REc;;;
12.231;12;30;14;12p11.21;H3F3C;;H3 histone, family 3C;616134;REc, A;;;
12.232;9;17;10;12p11.21;YARS2, TYRRS, MLASA2;;Tyrosyl-tRNA synthetase 2;610957;R, REc;;Myopathy, lactic acidosis, and sideroblastic anemia 2, 613561 (3);
12.233;3;29;12;12p11.23;ARNTL2, BMAL2, CLIF;;Aryl hydrocarbon receptor nuclear translocator-like protein 2;614517;A, REc;;;
12.234;3;7;13;12p11.23;ASUN, MAT89BB, GCT1;;Asunder, spermatogenesis regulator;615079;REc;;;
12.235;1;8;15;12p11.22;FAR2, MLSTD1;;Fatty acyl CoA reductase 2;616156;REc;;;12(Far2)
12.236;2;5;15;12p12.1;KCNJ8;;Potassium inwardly-rectifying channel, subfamily J, member 8;600935;A;;;
12.237;7;22;09;12p11.23;MED21, SURB7, SRB7;;Mediator complex subunit 21;603800;REc;;;
12.238;7;25;16;12p11.23-q13.12;AD5;;Alzheimer disease, familial, type 5;602096;Fd;;Alzheimer disease-5 (2);
12.239;2;24;17;12p11.22;CCDC91;;Coiled-coil domain-containing protein 91;617366;REc;;;
12.240;9;22;08;12p11.22;ERGIC2, CDA14, PTX1;;Endoplasmic reticulum-golgi intermediate compartment protein 2;612236;Psh, REc;;;
12.241;3;15;07;12p11.22;REP15;;Rab15 effector protein;610848;R, REc;;;
12.242;7;18;14;12p11.22;TMTC1;;Transmembrane and tetratricopeptide repeat domains-containing protein 1;615855;REc;;;
12.243;7;2;07;12p11.21;FGD4, FRABIN, CMT4H;;FYVE, RhoGEF, and PH domain-containing protein 4;611104;R, Fd;;Charcot-Marie-Tooth disease, type 4H, 609311 (3);
12.244;11;27;18;12p11.23-p11.22;PPFIBP1;;Protein-tyrosine phosphatase, receptor-type, F polypeptide-interacting protein-binding protein 1;603141;REc;;;
12.245;1;26;97;12p12.1;SSPN, KRAG;;Sarcospan (Kirsten-ras associated gene);601599;A;;;
12.246;5;28;98;12p11.21;BICD1;;Bicaudal-D, Drosophila, homolog of, 1;602204;REc;second homolog on 9q;;
12.247;1;18;13;12p11.2-q13.1;ARCI7;;Ichthyosis, congenital, autosomal recessive 7;615022;Fd;between D12S345 and D12S390;Ichthyosis, congenital, autosomal recessive 7 (2);
12.248;2;17;09;12p11.2-q14;STQTL3;;Stature quantitative trait locus 3;606257;Fd;max lod at D12S398 and D12S10990;{Stature QTL 3} (2);
12.249;2;5;14;12p11.1;ALG10, KCR1;;Alg10, S. cerevisiae, homolog of;603313;REc;;{Long QT syndrome, acquired, reduced susceptibility to}, 613688 (3);
12.250;6;14;10;12p11.21;DDX11, CHLR1, KRG2;;DEAD/H box-11 (CHL1-related helicase gene-1);601150;Psh, A;;Warsaw breakage syndrome, 613398 (3);
12.251;4;3;15;12p11.23;ITPR2, ANHD;;Inositol 1,4,5-triphosphate receptor, type 2;600144;A;mutation has been identified in 1 ANHD family;?Anhidrosis, isolated, with normal sweat glands, 106190 (3);
12.252;7;9;09;12p13.33;KDM5A, JARID1A, RBP2, RBBP2;;Lysine(K)-specific demethylase 5A;180202;Psh, A;;;
12.253;12;30;04;12p11.21;PKP2, ARVD9;;Plakophilin-2;602861;A, Psh;pseudogene on 12p13;Arrhythmogenic right ventricular dysplasia 9, 609040 (3);
12.254;11;10;17;12p11.21;SINHCAF, FAM60A;;SIN3-HDAC complex associated factor;615027;REc;;;
12.255;9;9;13;12p11-q13;VUR7;;Vesicoureteral reflux 7;615390;Fd;max lod at D12S1048;Vesicoureteral reflux 7 (2);
12.256;1;28;88;12p;KAR;;Aromatic alpha-keto acid reductase;107920;S;?same as MDH1;;
12.257;12;13;18;12p13.32;NDUFA9, MC1DN26;;NADH-ubiquinone oxidoreductase 1 alpha subcomplex, 9;603834;REc;;Mitochondrial complex I deficiency, nuclear type 26, 618247 (3);
12.258;5;7;03;12q21.2;OSBPL8, ORP8, KIAA1451;;Oxysterol-binding protein-like protein 8;606736;R, REc;;;
12.259;5;4;12;12p;PKS;;Pallister-Killian syndrome;601803;Ch;;Pallister-Killian syndrome (4);
12.260;12;12;18;12q21.2;SYT1, BAGOS;;Synaptotagmin-1;185605;REa, H;;Baker-Gordon syndrome, 618218 (3);10(Syt1)
12.261;7;8;10;12q;IHPS1, IHPS;;Pyloric stenosis, infantile hypertrophic 1;179010;Fd;;Pyloric stenosis, infantile hypertrophic 1 (2);
12.262;6;25;99;12q24.13;RPL6;;Ribosomal protein L6;603703;Psh, R;;;
12.263;3;29;10;12q13.2;RPS26, DBA10;;Ribosomal protein S26;603701;Psh, R;;Diamond-Blackfan anemia 10, 613309 (3);
12.264;5;22;03;12q13.13;SMUG1;;Single-strand-selective monofunctional uracil-DNA glycosylase 1;607753;REc;;;
12.265;1;2;08;12q12;ADAMTS20;;A disintegrin-like and metalloproteinase with thrombospondin type 1 motif, 20;611681;REc;;;
12.266;10;29;99;12q12;ABCD2, ALDR, ALDL1;;ATP-binding cassette, subfamily D, member 2;601081;A, Psh;;;15(Aldl1)
12.267;7;7;14;12q12;CNTN1, MYPCN;;Contactin 1;600016;A;mutation identified in 1 MYPCN family;?Myopathy, congenital, Compton-North, 612540 (3);
12.268;1;31;01;12p11.23;TM7SF3;;Transmembrane 7 superfamily, member 3;605181;A, R;;;
12.269;1;25;93;12q13.13;ITGA5, FNRA, VLA5A;;Integrin, alpha-5 (fibronectin receptor, alpha subunit; very late activation protein-5, alpha subunit);135620;REa, A;;;15(Itga5)
12.270;6;7;95;12q13.13;KRT2, KRT2A, KRT2E;;Keratin 2;600194;Fd;;Ichthyosis bullosa of Siemens, 146800 (3);
12.271;3;3;09;12q13.11-q13.12;CCNT1, CCNT;;Cyclin T1;143055;R, REc;;;
12.272;12;11;97;12q13.13;ACVRL1, ACVRLK1, ALK1, HHT2;;Activin A receptor, type II-like kinase 1;601284;REc;;Telangiectasia, hereditary hemorrhagic, type 2, 600376 (3);
12.273;1;13;99;12q13.12;ACCN2;;Cation channel, amiloride-sensitive, neuronal, 2;602866;A;;;
12.274;9;15;11;12q12;ANO6, TMEM16F, SCTS, BDPLT7;;Anoctamin 6;608663;REc;;Scott syndrome, 262890 (3);15(Tmem16f)
12.275;12;15;17;12q12;ARID2, BAF200, KIAA1557, CSS6;;AT-rich interaction domain-containing protein 2;609539;REc;;Coffin-Siris syndrome 6, 617808 (3);
12.276;3;29;10;12q12;GXYLT1, GLT8D3;;Glucoside xylosyltransferase 1;613321;REc;;;
12.277;3;8;07;12q12;IRAK4, REN64, IPD1;;Interleukin 1 receptor-associated kinase 4;606883;REc;;IRAK4 deficiency, 607676 (3); Invasive pneumococcal disease, recurrent isolated, 1, 610799 (3);
12.278;2;17;10;12q12;KIF21A, KIAA1708, FEOM1, CFEOM1, CFEOM3B;;Kinesin family member 21A;608283;Fd, REc;;Fibrosis of extraocular muscles, congenital, 1, 135700 (3); Fibrosis of extraocular muscles, congenital, 3B, 135700 (3);15(Kif21a)
12.279;4;10;15;12q12;LRRK2, PARK8;;Leucine-rich repeat kinase 2 (dardarin);609007;Fd, REc;;{Parkinson disease 8}, 607060 (3);
12.280;7;31;08;12q12;MUC19;;Mucin 19, oligomeric;612170;REc;;;15(Muc19)
12.281;12;28;08;12q12;PDZRN4;;PDZ domain-containing ring finger protein 4;609730;REc;;;
12.282;7;9;06;12q13.13;PFDN5, MM1;;Prefoldin 5;604899;R;;;
12.283;3;22;07;12q12;PPHLN1;;Periphilin 1;608150;REc;;;
12.284;12;24;08;12q12;PRICKLE1, RILP, EPM1B;;Prickle-like 1;608500;REc;;Epilepsy, progressive myoclonic 1B, 612437 (3);15(Prickle1)
12.285;8;20;07;12q12;SLC2A13, HMIT;;Solute carrier family 2 (facilitated glucose transporter), member 13;611036;R, REc;;;
12.286;4;19;07;12q12;TWF1, PTK9;;Twinfilin, Drosophila, homolog of, 1;610932;R, REc;;;
12.287;8;18;14;12q12;YAF2;;YY1-associated factor 2;607534;REc;;;
12.288;2;12;07;12q12;ZCRB1, MADP1;;Zinc finger CCHC domain- and RNA-binding motif-containing protein 1;610750;REc;possible pseudogenes on chr16, X, and 6;;
12.289;3;31;15;12q13.12;ADCY6, LCCS8;;Adenylate cyclase-6;600294;A, REa;mutation identified in 1 LCCS8 family;?Lethal congenital contracture syndrome 8, 616287 (3);15(Adcy6)
12.290;10;1;95;12q13.2;CD63, MLA1;;CD63 antigen (melanoma 1 antigen);155740;REa, A;;;10(Cd63)
12.291;2;21;12;12q13.12;GPD1, HTGTI;;Glycerol-3-phosphate dehydrogenase, soluble;138420;S, R;;Hypertriglyceridemia, transient infantile, 614480 (3);15(Gdc1)
12.292;5;27;05;12q13.12;PRPH;;Peripherin;170710;A;;{Amyotrophic lateral sclerosis, susceptibility to}, 105400 (3);15(Prph)
12.293;6;25;99;12q13.3;TIMELESS, TIM, TIM1;;Timeless, Drosophila, homolog of;603887;A, R, H;;;10(Tim)
12.294;5;6;13;12q13.12;WNT1, INT1, OI15, BMND16;;Wingless-type MMTV integration site family, member 1 (oncogene INT1);164820;REa, A;;Osteogenesis imperfecta, type XV, 615220 (3); {Osteoporosis, early-onset, susceptibility to, autosomal dominant}, 615221 (3);15(Int1, Wnt1)
12.295;2;1;11;12q12;SCAF11, SFRS2IP, SIP1, CASP11, SRRP129;;SR-related C-terminal domain-associated factor 11;603668;REc;previously assigned to 21q22.3;;
12.296;12;13;95;12q13.13;KRT7;;Keratin 7;148059;REa, A;;;
12.297;12;17;07;12q13.12;TUBA1A, TUBA3, LIS3;;Tubulin, alpha-1A;602529;REc;;Lissencephaly 3, 611603 (3);
12.298;11;16;05;12q13.11;VDR;;Vitamin D (1,25-dihydroxyvitamin D3) receptor;601769;REa, A;;Rickets, vitamin D-resistant, type IIA, 277440 (3); ?Osteoporosis, involutional, 166710 (1);
12.299;2;28;07;12q12-q21;RLS1;;Restless legs syndrome, susceptibility to, 1;102300;Fd;between D12S1044 and D12S78;{Restless legs syndrome 1} (2);
12.300;11;1;00;12q13.13;AAAS, AAA;;Aladin;605378;Fd, REc;;Achalasia-addisonianism-alacrimia syndrome, 231550 (3);
12.301;4;26;01;12q13.13;ACVR1B, ACVRLK4, ALK4;;Activin A receptor, type IB;601300;REa, A;;Pancreatic cancer, somatic (3);
12.302;8;21;98;12q13.13;AMHR2, AMHR;;Anti-Mullerian hormone receptor, type II;600956;A;;Persistent Mullerian duct syndrome, type II, 261550 (3);15(Amhr)
12.303;11;16;05;12q13.12;AQP2;;Aquaporin-2 (collecting duct);107777;A;;Diabetes insipidus, nephrogenic, 125800 (3);
12.304;11;5;97;12q13.12;AQP6, AQP2L;;Aquaporin-6, kidney specific;601383;Psh, A;;;
12.305;10;7;13;12q13.12;AQP5, PPKB;;Aquaporin-5;600442;A, Fd;;Palmoplantar keratoderma, Bothnian type, 600231 (3);15(Aqp2)
12.306;5;6;98;12q13.12;ARF3;;ADP-ribosylation factor-3;103190;REc, A;;;
12.307;1;31;13;12q13.11;ASB8;;Ankyrin repeat- and SOCS box-containing protein 8;615053;R, REc;;;
12.308;2;1;01;12q13.12;ATF1, TREB36;;Activating transcription factor 1;123803;A, Ch;fused with EWS in soft tissue clear cell sarcoma, with FUS in angiomatoid fibrous histiocytoma;;
12.309;10;6;09;12q13;BCC4;;Basal cell carcinoma, susceptibility to, 4;613061;Fd;associated with rs11170164;{Basal cell carcinoma, susceptibility to, 4} (2);
12.310;5;13;13;12q13.12;C1QL4, CTRP11;;Complement component 1, q subcomponent-like 4;615229;REc;;;5(C1ql4)
12.311;7;17;13;12q13.13;C12orf10, MYG1;;Chromosome 12 open reading frame 10;611366;REc;;;
12.312;10;19;97;12q13.12;CACNB3;;Calcium channel, voltage-dependent, beta 3 subunit;601958;A;;;
12.313;5;19;94;12q13.2;CDK2;;Cyclin-dependent kinase 2;116953;A;;;
12.314;9;2;12;12q13.13;CELA1, ELA1;;Chymotrypsin-like elastase family, member 1;130120;REa, A, REc;on proximal 12p;;15(Ela1)
12.315;1;12;15;12q13;CMTS;;Chronic mountain sickness, susceptibility to;616182;Fd;;{Chronic mountain sickness, susceptibility to} (2);
12.316;11;09;18;12q13.2;ERBB3, LCCS2, FERLK;;Transformation gene ERBB-3;190151;A;mutations identified in 1 LCCS2 family and 1 FERLK family;?Lethal congenital contractural syndrome 2, 607598 (3); {?Erythroleukemia, familial, susceptibility to}, 133180 (3);
12.317;3;10;09;12q13.13;ESPL1, ESP1;;Extra spindle poles-like 1;604143;REc;prev. mapping to chr.8;;
12.318;7;20;04;12q13.12;FAIM2, LFG, NMP35;;FAS apoptotic inhibitory molecule 2;604306;Psh, A, REc;;;
12.319;5;26;13;12q13.12;FKBP11, FKBP19;;FK506-binding protein 11;610571;REc;;;
12.320;3;31;15;12q13.12;FMNL3, FRL2;;Formin-like 3;616288;REc;;;
12.321;1;27;04;12q13.13;GALNT6, GalNAcT6;;UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 6;605148;A;;;
12.322;5;19;09;12q13.3;GLS2, GA;;Glutaminase, liver;606365;R, REc;;;
12.323;3;30;12;12q14.3;HELB, HDHB;;Helicase, DNA, B;614539;REc;;;
12.324;2;4;02;12q13.3;HSE;;3-alpha-hydroxysteroid epimerase;606623;A;;;
12.325;2;26;93;12q13.13;HOXC4, HOX3E;;Homeo box-C4;142974;RE;;;
12.326;2;26;93;12q13.13;HOXC5, HOX3D;;Homeo box-C5;142973;RE;;;15(Hox6.2)
12.327;2;26;93;12q13.13;HOXC6, HOX3C;;Homeo box-C6;142972;RE;;;15(Hox6.1)
12.328;2;26;93;12q13.13;HOXC8, HOX3A;;Homeo box-C8;142970;RE;;;15(Hox3.1)
12.329;2;26;93;12q13.13;HOXC9, HOX3B;;Homeo box-C9;142971;RE;;;15(Hox3.2)
12.330;2;26;93;12q13.13;HOXC12, HOX3F;;Homeo box-C12;142975;RE;;;
12.331;11;19;12;12q13.13;HOXC13, HOX3G, ECTD9;;Homeo box-C13;142976;RE;fused with NUP98 in AML;Ectodermal dysplasia 9, hair/nail type, 614931 (3);
12.332;12;9;91;12q13;HPV18I2;;Human papillomavirus type 18 integration site-2;167960;REa, A;on 8 near MYC in HeLa;;
12.333;8;29;08;12q13.11;HRG1;;Heme-responsive gene 1;612187;REc;;;
12.334;9;10;07;12q13.2;IKZF4, ZNFN1A4, EOS, KIAA1782;;Ikaros family zinc finger 4;606239;R, REc;;;
12.335;2;2;10;12q13.2;ITGA7;;Integrin, alpha-7;600536;A;;Muscular dystrophy, congenital, due to ITGA7 deficiency, 613204 (3);
12.336;8;27;01;12q13.12;KCNH3, BEC1;;Potassium voltage-gated channel, subfamily H (eag-related), member 3;604527;REc;;;
12.337;3;30;18;12q13.3;KIF5A, NKHC, SPG10, NEIMY, ALS25;;Kinesin family member 5A;602821;A, REc, Fd;;Spastic paraplegia 10, autosomal dominant, 604187 (3); Myoclonus, intractable, neonatal, 617235 (3); {Amyotrophic lateral sclerosis, susceptibility to, 25}, 617921 (3);2(Nkhc)
12.338;2;3;12;12q13.13;KRT1, EPPK, NEPPK, EHK;;Keratin 1;139350;H, REa, A;close to Hox-3 in mouse; class II keratin;Epidermolytic hyperkeratosis, 113800 (3); Ichthyosis, cyclic, with epidermolytic hyperkeratosis, 607602 (3); Ichthyosis histrix, Curth-Macklin type, 146590 (3); Palmoplantar keratoderma, nonepidermolytic, 600962 (3); Palmoplantar keratoderma, epidermolytic, 144200 (3); Keratosis palmoplantaris striata III, 607654 (3);15(Krt2)
12.339;10;27;97;12q13.13;KRT3;;Keratin 3;148043;A, Fd, R;;Meesmann corneal dystrophy, 122100 (3);
12.340;5;22;14;12q13.13;KRT4, CYK4, WSN1;;Keratin 4;123940;REa, A;class II keratin;White sponge nevus 1, 193900 (3);
12.341;11;1;13;12q13.13;KRT5, DDD1;;Keratin 5;148040;A, Fd;;Epidermolysis bullosa simplex, Dowling-Meara type, 131760 (3); Epidermolysis bullosa simplex, Koebner type, 131900 (3); Epidermolysis bullosa simplex, Weber-Cockayne type, 131800 (3); Epidermolysis bullosa simplex-MP, 131960 (3); Dowling-Degos disease 1, 179850 (3); Epidermolysis bullosa simplex-MCR, 609352 (3); Epidermolysis bullosa simplex, recessive 1, 601001 (3);
12.342;4;10;14;12q13.13;KRT6A, PC3;;Keratin 6A;148041;REa, A;;Pachyonychia congenita 3, 615726 (3);
12.343;4;10;14;12q13.13;KRT6B, PC4;;Keratin 6B;148042;REa;;Pachyonychia congenita 4, 615728 (3);
12.344;11;5;13;12q13.13;KRT8;;Keratin 8;148060;Psh;;Cirrhosis, cryptogenic, 215600 (3); {Cirrhosis, noncryptogenic, susceptibility to}, 215600 (3);
12.345;12;5;13;12q13.13;KRT18;;Keratin 18;148070;REn, A;contiguous to KRT8, type II heteromer partner;Cirrhosis, cryptogenic, 215600 (3); {Cirrhosis, noncryptogenic, susceptibility to}, 215600 (3);
12.346;7;17;14;12q13.13;KRT71, K6IRS1, KRT6IRS1, HYPT13;;Keratin 71;608245;REc;mutation identified in 1 HYPT13 family;?Hypotrichosis 13, 615896 (3);
12.347;3;22;07;12q13.13;KRT72, K6IRS2, KRT6IRS2;;Keratin 72;608246;REc, REn;;;
12.348;3;22;07;12q13.13;KRT73, K6IRS3, KRT6IRS3;;Keratin 73;608247;REc, REn;;;
12.349;2;17;15;12q13.13;KRT74, K6IRS4, KRT6IRS4, HTSS2, HYPT3, ADWH;;Keratin 74;608248;REc, Fd;mutation identified in 1 HYPT3 family and ECTD7 family;Woolly hair, autosomal dominant, 194300 (3); ?Hypotrichosis 3, 613981 (3); ?Ectodermal dysplasia 7, hair/nail type, 614929 (3);
12.350;10;9;08;12q13.13;KRT75, K6HF, PFB;;Keratin 75;609025;REc;;{Pseudofolliculitis barbae, susceptibility to}, 612318 (3);
12.351;3;7;08;12q13.13;KRT81, KRTHB1, HB1;;Keratin 81;602153;A, Fd;;Monilethrix, 158000 (3);
12.352;11;1;17;12q13.13;KRT83, KRTHB3, HB3, MNLIX, EKVP5;;Keratin 83;602765;REc;;Monilethrix, 158000 (3); Erythrokeratodermia variabilis et progressiva 5, 617756 (3);
12.353;12;17;12;12q13.13;KRT85, KRTHB5, HB5, ECTD4;;Keratin 85;602767;REc;;Ectodermal dysplasia 4, hair/nail type, 602032 (3);
12.354;3;7;08;12q13.13;KRT86, KRTHB6, HB6;;Keratin 86;601928;A, Fd;;Monilethrix, 158000 (3);
12.355;12;18;02;12q13.2;LACRT;;Lacritin;607360;A;;;
12.356;10;23;87;12q13.11;LALBA;;Lactalbumin, alpha;149750;REa, A;;;
12.357;08;10;18;12q13.12;LIMA1, EPLIN, SREBP3, LDLCQ8;;LIM domain and actin-binding protein 1;608364;REc;;[Low density lipoprotein cholesterol level QTL 8], 618079 (3);
12.358;2;2;01;12q14.1;METTL1;;Methyltransferase-like 1;604466;R;;;
12.359;8;6;13;12q13.3;MIP, AQP0, CTRCT15;;Major intrinsic protein of lens fiber;154050;REa, A;slightly distal to AQP2;Cataract 15, multiple types, 615274 (3);10(Mip)
12.360;3;23;09;12q13.13;MIR196A2, MIRN196A2;;Micro RNA 196A2;609687;REc;;;
12.361;1;2;08;12q13.2;NEUROD4, MATH3;;Neurogenic differentiation 4;611635;R, REc;;;10(Neurod4)
12.362;10;15;94;12q13.13;NFE2;;Nuclear factor, erythroid-derived 2, 45kD;601490;A, H;;;15(Nfe2)
12.363;9;15;99;12q13.13;MAP3K12, ZPK;;Mitogen-activated protein kinase kinase kinase 12;600447;REa, A;;;
12.364;9;7;90;12q13.13;NR4A1, HMR, NP10, GFRP1;;Nuclear receptor subfamily 4, group A, member 1;139139;A;;;15(np10)
12.365;3;17;16;12q13.12;SLC11A2, NRAMP2, DCT1, DMT1, AHMIO1;;Solute carrier family 11 (proton-coupled divalent metal ion transporter) member 2;600523;A;;Anemia, hypochromic microcytic, with iron overload 1, 206100 (3);15(Nramp2, mk)
12.366;12;28;08;12q13.3-q14.1;OS9;;Amplified in osteosarcoma 9;609677;REc, Psh, A;;;
12.367;6;4;98;12q13.2;PA2G4;;Proliferation-associated 2G4, 38kD;602145;A;family of genes on 7 chromosomes;;
12.368;9;28;98;12q13.2;PDE1B1, PDES1B, PDE1B;;Phosphodiesterase-1B;171891;Psh, REc;;;15(Pde1b)
12.369;11;5;97;12q13.3;PRIM1;;Primase, polypeptide-1, 49kD;176635;Psh, A, REc, H;;;10(Prim1)
12.370;8;18;99;12q13.2;RAB5B;;Ras-associated protein RAB5B;179514;A;;;
12.371;8;11;91;12q13.13;RARG;;Retinoic acid receptor, gamma polypeptide;180190;A, REa;;;15(Rarg)
12.372;9;8;11;12q13.2;SARNP, CIP29, HCC1, HSPC316;;SAP domain-containing ribonucleoprotein;610049;REc;fused with MLL in AML;;
12.373;8;22;16;12q13.13;SCN8A, CIAT, EIEE13, BFIS5;;Sodium channel, voltage gated, type VIII, alpha polypeptide;600702;REa, A;mutation identified in 1 CIAT family;?Cognitive impairment with or without cerebellar ataxia, 614306 (3); Epileptic encephalopathy, early infantile, 13, 614558 (3); Seizures, benign familial infantile, 5, 617080 (3);2(med, Scn8a)
12.374;7;13;93;12q13.3;SHMT2, GLYA;;Serine hydroxymethyltransferase;138450;S, R, A;glycine A auxotroph;;
12.375;8;18;99;12q14.1;SLC16A7, MCT2;;Solute carrier family 16 (monocarboxylic acid transporters), member 7;603654;REa, A;;;
12.376;8;29;03;12q13.11;SLC38A4, NAT3, ATA3;;Solute carrier family 38 (amino acid transporter), member 4;608065;REc, Psh, A;;;
12.377;9;9;03;12q13.13;SOAT2, ACACT2;;Sterol O-acyltransferase 2;601311;REc;;;
12.378;9;10;14;12q13;SPDT;;Spondyloepiphyseal dysplasia tarda, autosomal dominant;184100;Fd;;Spondyloepiphyseal dysplasia tarda, autosomal dominant (2);
12.379;6;10;98;12q13.3;STAT6;;Signal transducer and activator of transcription-6, interleukin-4 induced;601512;A, H, REc;;;10(Stat6)
12.380;4;24;96;12q13.12-q13.13;TFCP2;;Transcription factor CP2, alpha globin;189889;REa, H, A;;;
12.381;8;17;16;12q13.12;WNT10B, SHFM6, STHAG8;;Wingless-type MMTV integration site family, member 10B;601906;A;;Split-hand/foot malformation 6, 225300 (3); Tooth agenesis, selective, 8, 617073 (3);
12.382;12;17;15;12q13-q14;DFNA48;;Deafness, autosomal dominant 48;607841;Fd;;Deafness, autosomal dominant 48 (2);
12.383;10;18;96;12q13.2;GCN5L1;;GCN5 (general control of amino-acid synthesis, yeast, homolog)-like 1;601444;A;;;
12.384;3;11;03;12p11.21;IPO8, RANBP8;;Importin 8;605600;R;;;
12.385;5;28;99;12q13-q14;PABPL2;;Poly(A)-binding protein-like 2;604681;A;?pseudogenes on 3q and 13q;;
12.386;6;2;99;12q13.2;RDH5;;Retinol dehydrogenase-5;601617;REa, A;;Fundus albipunctatus, 136880 (3);
12.387;8;31;98;12q13.2;SILV, D12S53E, PMEL17;;Silver, mouse, homolog of;155550;REa;;;10(si)
12.388;6;25;99;12q13.2;SMARCC2, BAF170;;SW1/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily c, member 2;601734;Psh, R;;;
12.389;6;25;99;12q13.12;SMARCD1, BAF60A;;SW1/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily d, member 1;601735;Psh, R;;;
12.390;1;5;07;12q14.1;TSFM, COXPD3;;Ts translation elongation factor, mitochondrial;604723;REa, A;;Combined oxidative phosphorylation deficiency 3, 610505 (3);
12.391;1;20;06;12q14.1;TSPAN31, SAS;;Tetraspanin 31;181035;REa, A;;;
12.392;12;17;15;12q13.3;MYO1A;;Myosin IA;601478;A;;;10(Myo1a)
12.393;6;2;98;12q15;YEATS4, GAS41;;YEATS domain-containing protein 4;602116;REc;;;
12.394;9;30;95;12q13-q21;ENUR2;;Enuresis, nocturnal, 2;600808;Fd;;Enuresis, nocturnal, 2 (2);
12.395;9;28;12;12q13.3;TAC3, NKNB, HH10;;Tachykinin 3 (neuromedin K, neurokinin B);162330;REa, A;;Hypogonadotropic hypogonadism 10 with or without anosmia, 614839 (3);
12.396;3;18;94;12q24.33;ZNF10, KOX1;;Zinc finger protein-10 (KOX 1);194538;REa;same 300kb fragment as ZNF26;;
12.397;12;21;03;12q13.2;DCD;;Dermcidin;606634;R;;;
12.398;11;30;06;12q13.12;DDN, KIAA0749;;Dendrin;610588;R, REc;;;
12.399;8;14;09;12q13.12;DHH, SRXY7, GDXYM;;Desert hedgehog;605423;A;;46XY partial gonadal dysgenesis, with minifascicular neuropathy, 607080 (3); 46XY sex reversal 7, 233420 (3);
12.400;2;21;14;12q13.11;ENDOU, PP11;;Endonuclease polyU-specific;606720;REc;;;
12.401;4;25;93;12q13.1-q13.2;HEM1;;Hematopoietic protein-1;141180;REb, A;;;
12.402;11;5;13;12q13.13;HNRNPA1, IBMPFD3, ALS20;;Heterogeneous nuclear ribonucleoprotein A1;164017;A;mutation identified in 1 family with IBMPFD3;?Inclusion body myopathy with early-onset Paget disease without frontotemporal dementia 3, 615424 (3); Amyotrophic lateral sclerosis 20, 615426 (3);
12.403;1;27;97;12q13.3;INHBC;;Inhibin, beta C;601233;A;;;10(Inhbc)
12.404;1;13;99;12q13.12;PRKAG1;;Protein kinase, AMP-activated, noncatalytic, gamma-1;602742;A;;;
12.405;7;10;08;12q13.11;SENP1;;Sentrin-specific protease family, member 1;612157;REc;;;
12.406;11;4;93;12q13.13;SP1;;Sp1 transcription factor;189906;REa, A;;;15(Sp1)
12.407;10;12;10;12q13.3;DDIT3, GADD153, CHOP10;;DNA-damage-inducible transcript-3;126337;REa, A, Ch;fused with FUS in myxoid liposarcoma;Myxoid liposarcoma, 613488 (1);
12.408;8;26;03;12q13.2;DRIP78, HDJ3;;Dopamine receptor-interacting protein, 78kD;606092;REc;;;
12.409;4;17;06;12q14.1;CYP27B1, VDD1, PDDR;;Cytochrome P450, subfamily XXVIIB, polypeptide 1;609506;A, Fd;;Vitamin D-dependent rickets, type I, 264700 (3);
12.410;11;23;16;12q13.3;LRP1, A2MR, KPA;;Low density lipoprotein-related protein-1 (alpha-2-macroglobulin receptor);107770;A;mutation identified in 1 KPA family;?Keratosis pilaris atrophicans, 604093 (3);15(A2mr)
12.411;3;12;14;12q13.11;AMIGO2, ALI1;;Adhesion molecule with Ig-like domain 2;615690;REc, H;;;15(Amigo2)
12.412;9;30;13;12q13.11;ANP32D, PP32R2;;Acidic leucine-rich nuclear phosphoprotein 32 family, member D;606878;REc;;;
12.413;9;30;14;12q13.3;ARHGEF25, GEFT;;Rho guanine nucleotide exchange factor 25;610215;REc;;;
12.414;12;10;13;12q13.11;KANSL2, NSL2, C12orf41;;KAT8 regulatory NSL complex, subunit 2;615488;REc;;;15(Kansl2)
12.415;10;13;09;12q13.11;RPAP3;;RNA polymerase II-associated protein 3;611477;REc;;;
12.416;3;12;04;12q13.11;SLC38A1;;Solute carrier family 38 (amino acid transporter), member 1;608490;REc, R;;;
12.417;3;15;14;12q13.11;SLC38A2, ATA2, KIAA1382;;Solute carrier family 38, member 2;605180;REc;;;
12.418;4;8;16;12q13.11;SNORA2C, SNORA34, ACA34, MIR1291;;Small nucleolar RNA, H/ACA box, 34;615487;REc, REn;MIR1291 in intron of SNORA34;;
12.419;5;16;11;12q13.11;ZNF641;;Zinc finger protein 641;613906;REc;;;
12.420;6;19;98;12q12;NELL2;;Nel-like 2;602320;A;;;
12.421;10;13;15;12q13.11;COL2A1;;Collagen II, alpha-1 polypeptide;120140;REa, A;;Stickler syndrome, type I, 108300 (3); Kniest dysplasia, 156550 (3); Achondrogenesis, type II or hypochondrogenesis, 200610 (3); SED congenita, 183900 (3); SMED Strudwick type, 184250 (3); Epiphyseal dysplasia, multiple, with myopia and deafness, 132450 (3); Spondyloperipheral dysplasia, 271700 (3); Osteoarthritis with mild chondrodysplasia, 604864 (3); Vitreoretinopathy with phalangeal epiphyseal dysplasia (3); Platyspondylic skeletal dysplasia, Torrance type, 151210 (3); Avascular necrosis of the femoral head, 608805 (3); Legg-Calve-Perthes disease, 150600 (3); Stickler sydrome, type I, nonsyndromic ocular, 609508 (3); Czech dysplasia, 609162 (3); Spondyloepiphyseal dysplasia, Stanescu type, 616583 (3);15(Col2a1, seds)
12.422;11;19;11;12q13.11-q15;MRT25;;Mental retardation, autosomal recessive 25;614346;Fd;between rs4760658 and rs1882033;Mental retardation, autosomal recessive 25 (2);
12.423;11;11;13;12q13.12;CCDC65, CILD27;;Coiled-coil domain-containing protein 65;611088;REc;;Ciliary dyskinesia, primary, 27, 615504 (3);
12.424;8;2;13;12q13.12;CERS5, LASS5, TRH4;;Ceramide synthase 5;615335;REc;;;
12.425;9;8;14;12q13.12;COX14, C12orf62;;Cytochrome c oxidase assembly protein COX14;614478;REc, H;mutation identified in 1 Cox4 deficient family;?Mitochondrial complex IV deficiency, 220110 (3);15(C12orf62)
12.426;8;27;08;12q13.12;DDX23, PRP28;;Dead box polypeptide 23;612172;REc;;;
12.427;8;29;07;12q13.12;DIP2B, KIAA1463;;Disco-interacting protein 2, Drosophila, homolog of, B;611379;A, REc;;Mental retardation, FRA12A type, 136630 (3);
12.428;3;14;14;12q13.12;KMT2D, MLL2, ALR, KABUK1;;Lysine (K)-specific methyltransferase 2D;602113;Psh, R;;Kabuki syndrome 1, 147920 (3);
12.429;3;28;06;12q13.12;LMBR1L, LIMR, KIAA1174;;Limb region 1 homolog-like;610007;R, REc;;;
12.430;2;25;15;12q13.12;MCRS1, MSP58, MCRS2;;Microspherule protein 1 (microspherule protein 2, included);609504;R, REc;;;
12.431;3;14;13;12q13.12;NCKAP5L, KIAA1602;;NCK-associated protein 5-like;615104;REc;;;
12.432;5;13;13;12q13.12;RCGAP1, MGCRACGAP, CYK4;;GTPase-activating protein, Rac, 1;604980;R, REc;;;
12.433;6;13;12;12q13.12;RND1, RHO6;;Rho family GTPase 1;609038;REc, A;;;
12.434;6;22;14;12q13.12;TMBIM6, TEGT;;Transmembrane BAX inhibitor motif-containing protein 6;600748;REa, A;;;15(Tegt)
12.435;9;27;17;12q13.12;TUBA1B;;Tubulin, alpha-1B;602530;REc;;;15(Tuba1b)
12.436;3;9;98;12q13.13;PCBP2;;Poly(rC)-binding protein-2;601210;A;;;
12.437;3;14;13;12q13.13;ATG101, C12orf44;;Autophagy-related protein 101;615089;REc;;;
12.438;5;7;01;12q13.13;BIN2;;Bridging integrator 2;605936;A, REc;previously mapped to 4q22.1;;
12.439;11;11;14;12q13.13;CBX5, HP1;;Chromobox homolog 5;604478;R, REc;;;
12.440;12;10;13;12q13.13;COPZ1, COPZ;;Coatomer protein complex, subunit zeta-1;615472;REc;;;
12.441;9;28;15;12q13.13;CSAD, CSD, PCAP;;Cysteine sulfinic acid decarboxylase;616569;REc;;;
12.442;5;25;13;12q13.13;EIF4B;;Eukaryotic translation initiation factor 4B;603928;REc;;;
12.443;3;8;04;12q13.2;GDF11, BMP11;;Growth/differentiation factor 11;603936;R, REc;;;
12.444;11;28;01;12q13.13;GPR84;;G protein-coupled receptor 84;606383;REc;;;15(Gpr84)
12.445;6;5;08;12q13.13;GRASP, TAMALIN;;GRP1-associated scaffold protein;612027;R, REc;;;
12.446;12;4;08;12q13.13;HOTAIR;;Hox transcript antisense RNA;611400;R, REc;;;
12.447;7;12;92;12q13.13;ITGB7;;Integrin, beta-7;147559;REa, A;;;15(Itgb7)
12.448;4;11;14;12q13.13;KRT6C, PPKNEFD;;Keratin 6C;612315;REc;;Palmoplantar keratoderma, nonepidermolytic, focal or diffuse, 615735 (3);
12.449;12;2;15;12q13.13;KRT76, K76, KRT2P;;Keratin 76, type II;616671;REc;;;
12.450;2;25;08;12q13.13;KRT77, K1B;;Keratin 77;611158;REc;;;
12.451;2;25;08;12q13.13;KRT78, K5B;;Keratin 78;611159;REc;;;
12.452;3;7;08;12q13.13;KRT79,  KRT6L, K6L;;Keratin 79;611160;REc;;;
12.453;2;28;08;12q13.13;KRT80, KB20;;Keratin 80;611161;REc;;;
12.454;11;13;13;12q13.13;KRT82, KRTHB2, HB2;;Keratin 82;601078;REc;;;
12.455;11;13;13;12q13.13;KRT84, KRTHB4, HB4;;Keratin 84;602766;REc;;;
12.456;5;13;11;12q13.13;MIR148B, MIRN148B;;Micro RNA 148B;613787;REc;;;
12.457;7;20;09;12q13.2;MYL6B, MLC1SA;;Myosin, light chain 6B, alkali, smooth muscle and nonmuscle, slow;609930;R, REc;;;
12.458;6;28;18;12q13.13;POU6F1, BRN5, MPOU;;POU domain, class 6, transcription factor 1;618043;REc;;;
12.459;5;24;13;12q13.13;PRR13, TXR1;;Proline-rich protein 13;610459;REc;;;
12.460;08;31;18;12q13.13;SP7, OSX, OI12;;Transcription factor Sp7;606633;A, H;;Osteogenesis imperfecta, type XII, 613849 (3);15(Sp7)
12.461;3;3;16;12q13.13;TNS2, TENC1, C1TEN, KIAA1075;;Tensin 2;607717;R, REc;;;
12.462;10;27;08;12q13.13;ZNF385A, ZNF385, RZF, HZF;;Zinc finger protein 385A;609124;REc;;;
12.463;12;1;15;12q13.2;ESYT1, MBC2, FAM62A;;Extended synaptotagmin-like protein 1;616670;REc;;;
12.464;5;17;17;12q13.13;GTSF1, FAM112B;;Gametocyte-specific factor 1;617484;REc;;;
12.465;2;6;09;12q13.3;IL23A, SGRF, P19, IL23P19;;Interleukin 23, p19 subunit;605580;R, REc;;;
12.466;2;25;09;12q14.1;LIRG3, LIG3;;Leucine-rich repeats- and immunoglobulin-like domains-containing protein 3;608870;A, H;;;10(Lrig3)
12.467;3;1;06;12q13.2;MYL6;;Myosin light chain 6, alkali, smooth muscle and nonmuscle;609931;R, REc;;;
12.468;4;7;10;12q13.2;ORMDL2;;ORM1-like protein 2;610074;REc;pseudogene on 8q22.1;;
12.469;3;3;10;12q13.2;PPP1R1A, IPP1, I1;;Protein phosphatase 1, regulatory subunit 1A;613246;REc;;;
12.470;3;29;10;12q13.2;RPL41, HG12;;Ribosomal protein L41;613315;REc;;;
12.471;3;20;07;12q13.2;SBEM;;Small breast epithelial mucin;610857;REc;;;
12.472;12;17;07;12q13.12;SPATS2, SPATA10, P59SCR, SCR59;;Spermatogenesis-associated serine-rich protein 2;611667;REc;;;
12.473;12;1;15;12q13.3;STAT2, IMD44;;Signal transducer and activator of transcription 2;600556;R, REc;;Immunodeficiency 44, 616636 (3);
12.474;3;7;14;12q13.2;TESPA1, KIAA0748;;Thymocyte-expressed positive selection-associated protein 1;615664;REc;;;
12.475;11;27;18;12q13.12;TROAP, TASTIN;;Trophinin-associated protein;603872;REc;;;
12.476;11;23;09;12q13.3;CS;;Citrate synthase, mitochondrial;118950;S, D, REc;;;10(Cs)
12.477;09;19;18;12q13.3;GLI1, PAPA8;;GLI family zinc finger 1;165220;REa, A;;Polydactyly, postaxial, type A8, 618123 (3);10(Gli)
12.478;12;19;11;12q13.3;AAA4;;Aortic aneurysm, familial abdominal, 4;614375;Fd;associated with rs1466535;Aortic aneurysm, familial abdominal, 4 (2);
12.479;12;3;13;12q13.3;APOF, LTIP;;Apolipoprotein F;107760;REc, Psh;;;
12.480;2;25;16;12q13.3;B4GALNT1, GALGT, GALNACT, SPG26;;Beta-1,4-N-acetylgalactosaminyltransferase 1;601873;A, Fd;;Spastic paraplegia 26, autosomal recessive, 609195 (3);
12.481;12;17;15;12q13.3;DCTN2, DCTN50;;Dynactin 2;607376;R, REc;;;
12.482;10;15;98;12q13.2;DGKA, DAGK1;;Diacylglycerol kinase, alpha, 80kD;125855;REa, A, H;;;10(Dagk1)
12.483;12;21;09;12q13.3;DTX3;;Deltex, Drosophila, homolog of, 3;613142;REc;;;
12.484;6;9;08;12q13.3;INHBE;;Inhibin, beta E;612031;REc;;;
12.485;6;19;15;12q13.3;MARS, MTRNS, METRS, ILLD, CMT2U;;Methioninyl-tRNA synthetase;156560;S, REc;;Interstitial lung and liver disease, 615486 (3); Charcot-Marie-Tooth disease, axonal, type 2U, 616280 (3);
12.486;2;20;12;12q13.3;MIR616;;Micro RNA 616;614489;REc;;;
12.487;1;13;16;12q13.3;NEMP1, TMEM194A;;Nuclear envelope integral membrane protein 1;616496;REc;;;
12.488;11;3;14;12q13.3;NXPH4, NPH4;;Neuroexophilin 4;604637;REc;;;
12.489;6;26;08;12q13.3;OBFC2B, SSB1;;Oligonucleotide/oligosaccharide-binding fold-containing protein 2B;612104;REc;;;
12.490;5;19;17;12q13.3;PAN2, USP52, KIAA0710;;PABP-dependent poly(A) nuclease 2;617447;R, REc;;;
12.491;3;12;07;12q13.11;PFKM, GSD7;;Phosphofructokinase, muscle type;610681;Psh, A, Fd;incorrectly assigned to chr.1;Glycogen storage disease VII, 232800 (3);15(Pfk4)
12.492;9;1;16;12q13.3;PIP4K2C, PIP5K2C;;Phosphatidylinositol 5-phosphate 4-kinase, type II, gamma;617104;REc;;;
12.493;3;1;11;12q13.3;PTGES3, P23, CPGES;;Prostaglandin E synthase 3;607061;R, REc;;;
12.494;9;20;14;12q13.3;RBMS2, SCR3;;RNA-binding motif protein, single strand interacting, 2;602387;REc;;;
12.495;7;14;17;12q13.3;SDR9C7, SDRO, ARCI13;;Short chain dehydrogenase/reductase family 9C member 7;609769;REc;;Ichthyosis, congenital, autosomal recessive 13, 617574 (3);10(Sdro)
12.496;8;22;14;12q13.3;SLC39A5, MYP24;;Solute carrier family 39 (zinc transporter), member 5;608730;REc;;Myopia 24, autosomal dominant, 615946 (3);
12.497;08;22;18;12q13.3;STAC3, NAM, MYPBB;;SH3 and cystein-rich domains 3;615521;REc;;Myopathy, congenital, Baily-Bloch, 255995 (3);
12.498;6;19;98;12q13.3;NAB2;;NGFIA-binding protein-2;602381;A;;;10(Nab2)
12.499;6;7;10;12q14.1;AVIL;;Advillin;613397;A, H;;;10(Avil)
12.500;5;12;11;12q14.1;CDK4, CMM3;;Cyclin-dependent kinase 4;123829;A;;{Melanoma, cutaneous malignant, 3}, 609048 (3);
12.501;11;5;13;12q13.3;ARHGAP9;;Rho GTPase-activating protein 9;610576;REc;;;
12.502;2;3;05;12q15;DYRK2;;Dual-specificity tyrosine phosphorylation-regulated kinase 2;603496;REc;;;
12.503;5;6;13;12q14;GLC1P;;Glaucoma 1, open angle, P;177700;Ch;caused by 300kb duplication;Glaucoma 1, open angle, P (4);
12.504;3;27;03;12q14.3;GNS, G6S;;N-acetylglucosamine-6-sulfatase;607664;A, REa;;Mucopolysaccharidosis type IIID, 252940 (3);
12.505;2;22;10;12q15;IFNG, IFG, IFI;;Interferon, gamma;147570;REa, A;3 introns; none in IFF, IFL;{TSC2 angiomyolipomas, renal, modifier of}, 613254 (3); {Aplastic anemia}, 609135 (3); {Tuberculosis, protection against}, 607948 (3); {AIDS, rapid progression to}, 609423 (3);{Hepatitis C virus, response to therapy of}, 609532 (3);10(Ifg)
12.506;6;26;17;12q14.3;LEMD3, MAN1;;LEM domain-containing 3;607844;R, Fd;;Osteopoikilosis with or without melorheostosis, 166700 (3); Buschke-Ollendorff syndrome, 166700 (3);
12.507;9;24;15;12q13.2;MMP19, MMP18, CODA;;Matrix metalloproteinase-19;601807;A, Fd;triplication in upstream regulatory region;Cavitary optic disc anomalies, 611543 (3);
12.508;12;1;11;12q14;PRO2268;;PRO2268 gene;614354;REc;;;
12.509;9;15;89;12q15;RAP1B;;RAS-related protein RAP1B;179530;A;;;
12.510;8;5;97;12q14.2;AVPR1A;;Arginine vasopressin receptor-1A;600821;Psh, A;;;
12.511;3;22;06;12q21.2;ZDHHC17, HIP14;;Zinc finger DHHC domain-containing protein 17;607799;A;;;
12.512;2;11;16;12q14.1;AGAP2, CENTG1, PIKE;;ARF-GAP with GTP-binding protein-like, ankyrin repeat, and pleckstrin homology domains 2;605476;REc;;;
12.513;11;05;18;12q14.1;CTDSP2, SCP2, OS4;;CTD small phosphatase 2;608711;REc;;;
12.514;12;5;17;12q14.1;EEF1AKMT3, METTL21B, FAM119B;;EEF1A lysine methyltransferase 3;615258;REc;;;
12.515;5;30;17;12q14.1;FAM19A2, TAFA2;;Family with sequence similarity 19, member A2, CC motif chemokine-like;617496;REc;;;
12.516;6;7;10;12q14.1;MARCH9;;Membrane-associated RING-CH finger protein 9;613336;REc;;;
12.517;10;6;09;12q14.1;MIR26A2, MIRN26A2;;Micro RNA 26A2;613057;REc;;;
12.518;3;23;09;12q14.1;MIRLET7I, LET7I, MIRNLET7I;;Micro RNA Let7i;612148;REc;;;
12.519;2;17;16;12q14.1;MON2, KIAA1040;;Mon2, S. cerevisiae, homolog of;616822;REc;;;
12.520;9;30;02;12q14.2;RASSF3;;Ras association domain family protein 3;607019;REc;;;
12.521;10;2;12;12q14.1;USP15;;Ubiquitin-specific protease 15;604731;REc;;;
12.522;9;30;14;12q14.1-q14.2;PPM1H, KIAA1157;;Protein phosphatase, magnesium/manganese-dependent, 1H;616016;REc;;;
12.523;9;20;00;12q15;KCNMB4;;Potassium large conductance calcium-activated channel, subfamily M, beta member 4;605223;REc;;;
12.524;1;20;06;12q21.1;TSPAN8, TM4SF3;;Tetraspanin 8;600769;REc;;;
12.525;8;23;09;12q14.2;AUTS13;;Autism, susceptibility to, 13;610908;Fd;linkage with rs1445442;{Autism susceptibility 13} (2);
12.526;4;20;17;12q14.2;C12orf66;;Chromosome 12 open reading frame 66;617420;REc;;;
12.527;6;11;11;12q14.2;DPY19L2, SPGF9;;DPY19-like 2;613893;REc;pseudogene on 7p14.3;Spermatogenic failure 9, 613958 (3);9(Dpy19l2)
12.528;9;1;15;12q14.2;SRGAP1, KIAA1304, NMTC2;;Slit-robo GTPase-activating protein, rho, 1;606523;R, REc;;{Thyroid cancer, nonmedullary, 2}, 188470 (3);
12.529;3;14;18;12q14.2;TBK1, NAK, FTDALS4, IIAE8;;TANK-binding kinase 1;604834;REc;;Frontotemporal dementia and/or amyotrophic lateral sclerosis 4, 616439 (3); {Encephalopathy, acute, infection-induced (herpes-specific), susceptibility to, 8}, 617900 (3);
12.530;1;16;18;12q14.2;RXYLT1, TMEM5, MDDGA10;;Ribitol xylosyltransferase 1;605862;REc;;Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 10, 615041 (3);
12.531;9;8;06;12q15;BEST3, VMD2L3;;Bestrophin 3;607337;A;;;
12.532;9;13;17;12q14.3;GRIP1, FRASRS3;;Glutamate receptor-interacting protein 1;604597;REc;;Fraser syndrome 3, 617667 (3);
12.533;2;25;16;12q14.3;HMGA2, HMGIC, BABL;;High-mobility group AT-hook 2;600698;A, Psh, Ch, RE, Fd;fusion partners with RAD51B, ALDH2, COX6C, HEI10 in uterine leiomyomas;Leiomyoma, uterine, somatic, 150699 (1);10(pg, Hmgic)
12.534;5;31;07;12q14.3;IRAK3, IRAKM, ASRT5;;Interleukin 1 receptor-associated kinase 3;604459;REc;;{Asthma susceptibility 5}, 611064 (3);
12.535;6;26;16;12q14.3;LLPH;;LLP, Aplysia, homolog of;616998;REc;;;
12.536;2;1;11;12q14.3;MSRB3, DFNB74;;Methionine sulfoxide reductase B3;613719;REc;;Deafness, autosomal recessive 74, 613718 (3);
12.537;2;17;09;12q14.3;STQTL9;;Stature quantitative trait locus 9;611547;Fd;associated with rs1042725;{Stature QTL 9} (2);
12.538;3;7;13;12q14.3;TBC1D30, KIAA0984;;TBC1 domain family, member 30;615077;REc;;;
12.539;3;25;16;12q14.3;TMBIM4, GAAP;;Transmembrane BAX inhibitor motif-containing protein 4;616874;REc;;;
12.540;6;13;12;12q14-q15;CAND1, TIP120A, TIP120, KIAA0829;;Cullin-associated neddylation-dissociated protein 1;607727;A, REc;;;
12.541;12;19;11;12q15;MDM2, ACTFS;;Mouse double minute 2, homolog of (p53-binding protein);164785;REa, A;;{Accelerated tumor formation, susceptibility to}, 614401 (3);10(Mdm2)
12.542;4;30;03;12q21.1-q21.2;CAPS2;;Calcyphosine 2;607724;REc;;;
12.543;9;9;08;12q15;CNOT2, NOT2;;CCR4-NOT transcription complex, subunit 2;604909;REc;;;
12.544;4;23;09;12q13.3;CNPY4, TMEM4, MSAP;;Canopy 2, zebrafish, homolog of;605861;R, REc;;;
12.545;2;18;96;12q15;CPM;;Carboxypeptidase M;114860;Psh, REc, A;;;
12.546;4;8;16;12q15;FRS2, FRS1A, SNT1;;Fibroblast growth factor receptor substrate 2;607743;REc;;;
12.547;3;3;09;12q15;IBD26;;Inflammatory bowel disease 26;612639;Fd;associated with rs1558744;{Inflammatory bowel disease 26} (2);
12.548;10;17;00;12q15;IL22, IL21, ILTIF;;Interleukin 22;605330;R;;;
12.549;11;26;01;12q15;IL26, AK155;;Interleukin 26;605679;REc;;;
12.550;3;15;07;12q15;LRRC10, HRLRRP;;Leucine-rich repeat-containing protein 10;610846;R, REc;;;
12.551;1;9;09;12q15;LYZ;;Lysozyme;153450;REa, REc;;Amyloidosis, renal, 105200 (3);
12.552;3;15;11;12q15;MDM1;;Mouse double minute 1 homolog;613813;REc;;;10(Mdm1)
12.553;08;07;18;12q15;NUP107, NUP84, NPHS11, ODG6;;Nucleoporin, 107kD;607617;R;mutation identified in 1 ODG6 family;Nephrotic syndrome, type 11, 616730 (3); ?Ovarian dysgenesis 6, 618078 (3);
12.554;7;17;14;12q15;PTPRR, PCPTP1;;Protein-tyrosine phosphatase, receptor type, R;602853;REc;;;
12.555;4;25;93;12q15;PTPRB;;Protein tyrosine phosphatase, receptor type, beta polypeptide;176882;A;;;
12.556;2;16;02;12q21.1;TRHDE;;Thyrotropin-releasing hormone-degrading ectoenzyme;606950;A;;;
12.557;1;31;01;12q21.2;PHLDA1, TDAG51;;Pleckstrin homology-like domain, family A, member 1;605335;R;;;
12.558;8;30;01;12q21.2-q21.3;PPP1R12A, MYPT1;;Protein phosphatase 1, regulatory subunit 12A (myosin phosphatase target subunit 1);602021;A, R;;;
12.559;12;24;13;12q21.1;ATXN7L3B;;Ataxin 7-like 3B;615579;REc;;;
12.560;4;10;14;12q21.33;EPYC, DSPG3;;Epiphycan;601657;A, REc;;;
12.561;2;23;09;12q21.2;GLIPR1, GLIPR, RTVP1;;Glioma pathogenesis-related protein 1;602692;REc;;;10(Glipr1)
12.562;8;19;13;12q21.2;GLIPR1L1;;GLIPR1-like protein 1;610395;REc;;;10(Glipr1l1)
12.563;8;19;13;12q21.2;GLIPR1L2;;GLIPR1-like protein 2;610394;REc;;;10(Glipr1l2)
12.564;12;4;02;12q21.31-q21.32;GNTIVH;;UDP-N-acetylglucosamine:alpha-1,3-D-mannoside beta-1,4-N-acetylglucosaminyltransferase IV;607385;A;;;
12.565;10;25;18;12q21.31;MYF5, EORVA;;Myogenic factor-5;159990;REa, A, RE;;Ophthalmoplegia, external, with rib and vertebral anomalies, 618155 (3);
12.566;11;7;17;12q21.31;MYF6, CNM3;;Myogenic factor-6;159991;REa, A, RE, REc;6.5kb upstream from MYF5; both prob. 12q15, by H;Centronuclear myopathy 3, 614408 (3);10(Myf6)
12.567;8;28;97;12q21.31;NTS;;Neurotensin;162650;REa, A;;;
12.568;12;15;98;12q21.2;PAWR, PAR4;;PRKC, apoptosis, WT1, regulator;601936;A, Psh, R;;;
12.569;10;23;87;12q21;PEPB;;Peptidase B;169900;S;;;10(Pep2)
12.570;1;27;11;12q23.1;RMST, NCRMS, NCRNA00054;;Rhabdomyosarcoma 2-associated transcript;607045;REc;;;
12.571;4;12;92;12q21.33;ATP2B1, PMCA1;;ATPase, Ca++ transporting, plasma membrane, 1;108731;REa, A;;;
12.572;5;5;09;12q21-q23;DUH2;;Dyschromatosis universalis hereditaria 2;612715;Fd;between rs1921045 and rs2373584;Dyschromatosis universalis hereditaria 2 (2);
12.573;11;12;98;12q21-q23;MYP3;;Myopia, high grade, 3, autosomal dominant;603221;Fd;;Myopia-3 (2);
12.574;11;24;98;12q21.2;CSRP2, LMO5;;Cysteine and glycine-rich protein-2 (LIM domain only 5, smooth muscle);601871;A, R;pseudogene on 3q21.1;;
12.575;2;2;17;12q21.1;KCNC2;;Potassium voltage-gated channel, Shaw-related subfamily, member 2;176256;R, REc;previously on 19q13.3-q13.4;;10(Kcnc2)
12.576;10;29;18;12q21.1;LGR5, GPR49;;Leucine-rich repeat-containing G protein-coupled receptor 5;606667;R, A;;;
12.577;2;6;08;12q21.2;NAV3, POMFIl1, KIAA0938;;Neuron navigator 3;611629;R, REc;;;
12.578;12;18;08;12q21.1;RAB21, KIAA0118;;RAB-associated protein RAB21;612398;R, REc;;;
12.579;3;23;09;12q21.1;TBC1D15;;TBC1 domain family, member 15;612662;REc;;;
12.580;1;20;09;12q21.1;THAP2;;THAP domain-containing protein 2;612531;REc;;;
12.581;9;8;09;12q21.1;TPH2, NTPH, ADHD7;;Tryptophan hydroxylase 2;607478;REc;;{Unipolar depression, susceptibility to}, 608516 (3); {Attention deficit-hyperactivity disorder, susceptibility to, 7}, 613003 (3);
12.582;4;24;08;12p11.22;MRPS35, MRPS28;;Mitochondrial ribosomal protein S35;611995;REc;3 pseudogenes;;
12.583;10;16;14;12q21.2;BBS10, C12orf58, FLJ23560;;BBS10 gene;610148;REc, Fd;;Bardet-Biedl syndrome 10, 615987 (3);
12.584;6;11;09;12q21.2;KRR1;;KRR1, yeast, homolog of;612817;REc;;;
12.585;5;19;06;12q21.2;NAP1L1, NAP1L;;Nucleosome assembly protein 1-like 1;164060;R, REc;;;
12.586;9;12;17;12q21.31;PTPRQ, PTPGMC1, DFNB84A, DFNA73;;Protein-tyrosine phosphatase, receptor-type, Q;603317;A, REc;mutation identified in 1 DFNA73 family;Deafness, autosomal recessive 84A, 613391 (3); Deafness, autosomal dominant 73, 617663 (3);10(Ptpgmc1)
12.587;10;11;14;12q21.32;CEP290, KIAA0373, 3H11AG, JBTS5, SLSN6, LCA10, BBS14;;Centrosomal protein, 290kD;610142;R, REc, Fd;mutation identified in 1 BBS14 family;Joubert syndrome 5, 610188 (3); Senior-Loken syndrome 6, 610189 (3); Leber congenital amaurosis 10, 611755 (3); Meckel syndrome 4, 611134 (3); ?Bardet-Biedl syndrome 14, 615991 (3);
12.588;3;11;09;12q21.33;DCN, CSCD;;Decorin;125255;REa, A;conflicting assignments to 12q23 and 12q13.2;Corneal dystrophy, congenital stromal, 610048 (3);10(Dcn)
12.589;6;9;08;12q21.2;E2F7;;E2F transcription factor 7;612046;REc;;;10(E2f7)
12.590;5;19;14;12q21.31;ALX1, CART1, FND3;;Aristaless-like homeobox 1 (cartilage homeoprotein 1);601527;REa, REc;mutation identified in 1 FND3 patient;?Frontonasal dysplasia 3, 613456 (3);
12.591;6;25;99;12q21.33;GALNT4, GalNAcT4;;UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 4;603565;A, Fd;;;
12.592;5;27;97;12q21.33;LUM, LDC;;Lumican;600616;A, Psh;;;10(Ldc)
12.593;4;26;12;12q21.31;SLC6A15, SBAT1;;Solute carrier family 6 (neurotransmitter transporter), member 15;607971;R, REc;;;
12.594;12;1;11;12q21.31;ACSS3;;Acyl-CoA synthetase short-chain family, member 3;614356;REc;;;
12.595;10;1;17;12q21.31;LIN7A, VELI1, MALS1;;Lin7, C. elegans, homolog of, A;603380;REc;;;
12.596;12;29;06;12q24.31;MLXIP, MONDOA, KIAA0867;;MLX-interacting protein;608090;R, A;;;
12.597;11;20;12;12q21.31;OTOGL, C12orf64, DFNB84B;;Otogelin-like protein;614925;REc;;Deafness, autosomal recessive 84B, 614944 (3);
12.598;11;27;18;12q21.31;PPFIA2;;Protein-tyrosine phosphatase, receptor-type, F polypeptide-interacting protein alpha 2;603143;REc;;;
12.599;7;18;12;12q21.31;RASSF9, PAMCI, PCIP1;;Ras association domain family, member 9;610383;REc;;;
12.600;7;18;14;12q21.31;TMTC2;;Transmembrane and tetratricopeptide repeat domains-containing protein 2;615856;REc;;;
12.601;12;19;16;12q21.32;TMTC3, SMILE, LIS8;;Transmembrane and tetratricopeptide repeat domains-containing protein 3;617218;REc;;Lissencephaly 8, 617255 (3);
12.602;7;22;16;12q21.33;CNA1;;Cornea plana 1, autosomal dominant;121400;Fd;between D12S82 and D12S351;Cornea plana 1, autosomal dominant (2);
12.603;6;11;13;12q21.33;DUSP6, MKP3, PYST1, HH19;;Dual-specificity phosphatase-6;602748;Psh, A, REc;;Hypogonadotropic hypogonadism 19 with or without anosmia, 615269 (3);
12.604;5;24;16;12q21.33;PACD;;Corneal dystrophy, posterior amorphous;612868;REc;contiguous gene deletion syndrome;Corneal dystrophy, posterior amorphous (4);
12.605;9;24;14;12q21.33;POC1B, PIX1, CORD20;;POC1 centriolar protein, Chlamydomonas, homolog of, B;614784;REc;;Cone-rod dystrophy 20, 615973 (3);
12.606;12;19;16;12q22;CRADD, RAIDD, MRT34;;Caspase and RIP adaptor with death domain;603454;R;;Mental retardation, autosomal recessive 34, with variant lissencephaly, 614499 (3);10(Raidd)
12.607;3;17;94;12q21.33;BTG1;;B-cell translocation gene 1, anti-proliferative;109580;Ch;;;
12.608;6;27;14;12q22;CEP83, CCDC41, NPHP18;;Centrosomal protein, 83kD;615847;REc;;Nephronophthisis 18, 615862 (3);
12.609;6;26;16;12q22;CLLU1;;Chronic lymphocytic leukemia upregulated gene 1;616988;REc;;;
12.610;6;26;16;12q22;CLLU1OS;;Chronic lymphocytic leukemia upregulated 1, opposite strand;616989;REc;;;
12.611;7;10;13;12q22;EEA1;;Early endosome antigen 1;605070;REc, R;;;
12.612;8;27;15;12q22;FGD6, ZFYVE24;;FYVE, RhoGEF, and ph domain-containing protein 6;613520;REc;;;
12.613;3;6;01;12q21.33;KERA, CNA2;;Keratocan;603288;H, Fd, LD, A;;Cornea plana 2, autosomal recessive, 217300 (3);10(Kera)
12.614;5;27;16;12q21.32;KITLG, MGF, SF, SCF, SHEP7, FPHH, DCUA, DFNA69;;KIT ligand (mast cell growth factor; steel, mouse, homolog of);184745;REa, A;associated with dbSNP rs12821256;[Skin/hair/eye pigmentation 7, blond/brown hair], 611664 (3); Hyperpigmentation with or without hypopigmentation, 145250 (3); Deafness, autosomal dominant 69, unilateral or asymmetric, 616697 (3);10(Sl; Scf)
12.615;10;1;95;12q23.1;LTA4H;;Leukotriene A4 hydrolase;151570;A;;;
12.616;8;3;12;12q22;METAP2, p67;;Methionine aminopeptidase 2;601870;REc;;;
12.617;12;19;11;12q22;MIR492;;Micro RNA 492;614384;REc;within KRT19;;
12.618;3;5;08;12q22;MRPL42, MRPL31, MRPS32;;Mitochondrial ribosomal protein L42;611847;R, REc;;;
12.619;12;13;18;12q22;NDUFA12, MC1DN23;;NADH-ubiquinone oxidoreductase 1 alpha subcomplex, 12;614530;REc;;Mitochondrial complex I deficiency, nuclear type 23, 618244 (3);
12.620;3;18;95;12q23.1;NEDD1;;Neural precursor cell expressed, developmentally down-regulated 1;600372;A;;;
12.621;9;27;17;12q22;NR2C1, TR2;;Nuclear receptor subfamily 2, group C, member 1;601529;R, REc;;;
12.622;12;22;16;12q22;SOCS2AS1;;SOCS2 antisense RNA 1;617269;REc;;;
12.623;2;12;09;12q23.2;SPIC;;SPIC transcription factor;612568;REc;;;
12.624;4;26;17;12q22;TMCC3;;Transmembrane and coiled-coil domain family, member 3;617459;REc;;;
12.625;2;3;17;12q23.1;TMPO, LAP2;;Thymopoietin;188380;A;;;10(Tmpo)
12.626;8;18;14;12q22;UBE2N, UBCHBEN; UBC13;;Ubiquitin-conjugating enzyme E2N;603679;REc;;;
12.627;1;13;06;12q23.2;ASCL1, ASH1;;Achaete-scute complex, Drosophila, homolog-like 1;100790;REa, A;distal to PAH and proximal to TRA1;Central hypoventilation syndrome, congenital, 209880 (3); Haddad syndrome, 209880 (3);
12.628;12;17;07;12q24.13;DDX54, DP97;;Dead/H Box 54;611665;REc;;;
12.629;8;9;05;12q23.1;HAL, HSTD;;Histidine ammonia-lyase (histidase);609457;REa, A;;[Histidinemia], 235800 (3);10(Hstd)
12.630;9;18;06;12q22;NTN4;;Netrin 4;610401;A;;;
12.631;1;11;07;12q23.1-q23.2;SLC5A8, AIT, SMCT;;Solute carrier family (iodide transporter), member 8;608044;REc;;;
12.632;8;21;07;12q23.3;NT5DC3, TU12B1TY, GNN;;5' nucleotidase domain-containing protein 3;611076;A, REc;;;10(Nt5dc3)
12.633;6;7;04;12q22-q23.2;MDD1;;Major depressive disorder;608520;Fd;max lod with D12S1706;Major depressive disorder 1, 608516 (2);
12.634;1;10;12;12q22-q23.3;ETL2, FTLE;;Epilepsy, familial temporal lobe;608096;Fd;max lod at D12S1706;Epilepsy, familial temporal lobe, 2 (2);
12.635;8;25;04;12q23.2;IGF1;;Insulin-like growth factor-1, or somatomedin C;147440;REa, A, Fd;;Growth retardation with deafness and mental retardation due to IGF1 deficiency, 608747 (3);10(Igf1)
12.636;4;30;02;12q24.31;ACADS, SCAD;;Acyl-Coenzyme A dehydrogenase, C-2 to C-3 short chain;606885;REa, A;;Acyl-CoA dehydrogenase, short-chain, deficiency of, 201470 (3);5(Bcd1)
12.637;10;24;00;12q23.1;APAF1;;Apoptotic protease activating factor 1;602233;A;;;
12.638;1;12;11;12q23.2;C12orf48, AROM, PARPBP;;Chromosome 12 open reading frame 48;613687;REc;;;
12.639;11;02;18;12q23.3;CHST11, C4ST1, OCBMD;;Carbohydrate sulfotransferase 11;610128;R;mutation identified in 1 OCBMD family;?Osteochondrodysplasia, brachydactyly, and overlapping malformed digits, 618167 (3);
12.640;1;7;95;12q23.1;ELK3, SAP2, ERP;;ELK3, ETS-domain protein (SRF accessory protein 2);600247;REa;;;6(Scnn1)
12.641;2;7;06;12q23.1;IKIP;;I-kappa-B kinase-interacting protein;609861;REc;;;
12.642;9;24;08;12q23.1;SLC17A8, VGLUT3, DFNA25;;Solute carrier family 17 (sodium-dependent inorganic phosphate cotransporter), member 8 (vesicular glutamate transporter 3);607557;REc, Fd;;Deafness, autosomal dominant 25, 605583 (3);
12.643;2;19;07;12q23.1;SLC25A3, PHC;;Solute carrier family 25 (mitochondrial carrier), member 3;600370;REa, A;;Mitochondrial phosphate carrier deficiency, 610773 (3);
12.644;2;12;16;12q23.2;SYCP3, SCP3, COR1, SPGF4, RPRGL4;;Synaptonemal complex protein 3;604759;REc;;Spermatogenic failure 4, 270960 (3); Pregnancy loss, recurrent, 4, 270960 (3);
12.645;11;24;08;12q23.1;TMEM16D, FLJ34272;;Transmembrane protein 16D;610111;REc;;;
12.646;5;22;07;12q22;USP44;;Ubiquitin-specific protease 44;610993;R, REc;;;
12.647;3;18;94;12q23.2;PMCH;;Pro-melanin-concentrating hormone;176795;REa, A;;;
12.648;8;16;99;12q24.13;RASAL1, RASAL;;Ras protein activator-like 1;604118;R;;;
12.649;4;27;12;12q23-q24;SPG36;;Spastic paraplegia-36;613096;Fd;between D12S360 and D12S354;Spastic paraplegia 36, autosomal dominant (2);
12.650;12;22;08;12q24.11;USP30;;Ubiquitin-specific protease 30;612492;REc;;;
12.651;2;25;03;12q24.11;ATP2A2, ATP2B, DAR;;ATPase, Ca++ transporting, slow-twitch, cardiac muscle-2;108740;REa, A, Fd;;Darier disease, 124200 (3); Acrokeratosis verruciformis, 101900 (3);11(Atpb2)
12.652;5;30;17;12q23.3;CRY1, PHLL1, DSPD;;Cryptochrome 1 (photolyase-like);601933;A;;{Delayed sleep phase disorder, susceptibility to}, 614163 (3);10(Cry1)
12.653;9;2;09;12q23.3;EID3, NSMCE4B, NSE4B;;E1A-like inhibitor of differentiation 3;612986;REc;;;10(Eid3)
12.654;1;27;97;12q13.3;NACA;;Nascent-polypeptide-associated complex alpha polypeptide;601234;A, REa;;;
12.655;4;10;96;12q24.31;PLA2G1B, PLA2A, PLA2, PPLA2;;Phospholipase A2, group IB, pancreas;172410;REa, Fd;;;
12.656;4;19;01;12q23.3;PRDM4, PFM1;;PR domain-containing protein 4;605780;REc, Psh;;;
12.657;12;4;03;12q24.31;RNF34, RFI;;Ring finger protein 34;608299;A;;;
12.658;2;20;98;12q23.3;TXNRD1, TXNR;;Thioredoxin reductase-1;601112;A;;;
12.659;6;15;12;12q24.11;UNG, DGU, HIGM5;;Uracil-DNA glycosylase;191525;REa, R;;Immunodeficiency with hyper IgM, type 5, 608106 (3);
12.660;6;16;10;12q24.11;MYL2, CMH10;;Myosin, light polypeptide-2, regulatory, cardiac, slow;160781;A, REa;;Cardiomyopathy, hypertrophic, 10, 608758 (3);
12.661;12;28;08;12q23.1;ANKS1B, EB1;;Ankyrin repeat and sterile alpha motif domain-containing protein 1B;607815;R, REc;;;
12.662;7;18;14;12q23.1;CDK17, PCTK2, PCTAIRE2;;Cyclin-dependent kinase 17;603440;REc;;;
12.663;11;23;16;12q23.1;GAS2L3, G2L3;;Growth arrest-specific 2-like 3;617224;REc;;;
12.664;8;1;16;12q23.1;NR1H4, FXR, RIP14, PFIC5;;Nuclear receptor subfamily 1 group H member 4;603826;REc;;Cholestasis, progressive familial intrahepatic, 5, 617049 (3);10(Fxr)
12.665;5;25;13;12q23.1;SNRPF;;Small nuclear ribonucleoprotein polypeptide F;603541;REc;;;
12.666;5;19;15;12q23.1;SCYL2, CVAK104, KIAA1360;;SCY1-like protein 2;616365;REc;;;
12.667;7;20;12;12q23.2;ARL1;;ADP-ribosylation factor-like 1;603425;REc;;;
12.668;1;11;16;12q23.2;CHPT1, CPT, CPT1;;Choline phosphotransferase 1;616747;REc;;;
12.669;4;20;10;12q23.2;DRAM1;;Damage-regulated autophagy modulator 1;610776;R, REc;;;
12.670;1;9;13;12q23.2;HELLPAR, lncHELLP;;HELLP syndrome-associated long noncoding RNA;614985;REc;;;
12.671;12;12;12;12q23.2;MYBPC1, LCCS4;;Myosin-binding protein C, slow type;160794;REa, REc;;Arthrogryposis, distal, type 1B, 614335 (3); Lethal congenital contracture syndrome 4, 614915 (3);
12.672;11;12;18;12q23.2;NUP37, p37, MCPH24;;Nucleoporin, 37kD;609264;REc;mutation identified in 1 MCPH24 family;?Microcephaly 24, primary, autosomal recessive, 618179 (3);
12.673;7;16;09;12q23.2;UTP20, DRIM;;UTP20, S. cerevisiae, homolog of;612822;A;;;
12.674;4;6;15;12q23.3;ALDH1L2;;Aldehyde dehydrogenase 1 family, member L2;613584;REc;;;
12.675;11;30;06;12q24.11;ALKBH2, ABH2;;AlkB, E. coli, homolog of, 2;610602;REc;;;
12.676;3;13;08;12q23.2;GNPTAB, GNPTA;;N-acetylglucosamine-1-phosphate transferase, alpha/beta subunits;607840;F, S, D, REc;conflicting assignment to 4q;Mucolipidosis III alpha/beta, 252600 (3); Mucolipidosis II alpha/beta, 252500 (3);
12.677;9;7;04;12q23.3;HCFC2, HCF2;;Host cell factor C2;607926;R, REc;;;
12.678;9;8;08;12q23.3;HSP90B1, TRA1, GRP94, GP96;;Heat-shock protein, 90kD, beta, 1;191175;REa, A, REc;;;10(Tra1)
12.679;5;2;16;12q23.3;MTERF2, MTERFD3;;Transcription termination factor 2, mitochondrial;616929;REc;;;
12.680;8;29;13;12q23.3;NFYB;;Transcription factor NF-Y, B subunit;189904;REa, A, REc;;;10(Nfyb)
12.681;5;29;12;12q23.3;NUAK1, ARK5,  KIAA0537;;NUAK family, SNF1-like kinase, 1;608130;REc, R;;;
12.682;12;19;11;12q23.3;POLR3B, RPC2, C128, HLD8;;Polymerase III, RNA, subunit B;614366;REc;;Leukodystrophy, hypomyelinating, 8, with or without oligodontia and/or hypogonadotropic hypogonadism, 614381 (3);
12.683;12;10;12;12q23.3;RIC8B;;Ric8, C. elegans, homolog of, B;609147;REc;;;
12.684;01;04;19;12q23.3;RFX4;;Regulatory factor X, 4;603958;REc;;;
12.685;2;27;07;12q23.3;SLC41A2;;Solute carrier family 41, member 2;610802;REc;;;10(Slc41a2)
12.686;4;20;17;12q23.3;WASHC4, KIAA1033, SWIP, MRT43;;WASH complex, subunit 4;615748;REc, Psh;mutation identified in 1 MRT43 family;?Mental retardation, autosomal recessive 43, 615817 (3);
12.687;1;29;01;12q24.31;ABCB9;;ATP-binding cassette, subfamily B, member 9;605453;REc;;;
12.688;4;14;15;12q24.12;ATXN2, ATX2, SCA2, ASL13;;Ataxin-2;601517;Fd;;Spinocerebellar ataxia 2, 183090 (3); {Amyotrophic lateral sclerosis, susceptibility to, 13}, 183090 (3); {Parkinson disease, late-onset, susceptibility to}, 168600 (3);
12.689;3;9;09;12q24.12;BRAP, BRAP2, IMP;;BRCA1-associated protein;604986;REc;;;
12.690;5;28;08;12q24;CELIAC13;;Celiac disease, susceptibility to, 13;612011;Fd;associated with rs3184504;{Celiac disease, susceptibility to, 13} (2);
12.691;2;10;04;12q24;CIMT;;Carotid intimal medial thickness;608447;Fd;161cM from pter; near SCARB1;Carotid intimal medial thickness (2);
12.692;5;16;18;12q24.11;DAO, DAMOX;;D-amino-acid oxidase;124050;REa, Fd, LD;;;
12.693;1;19;01;12q24.13;DTX1;;Deltex, Drosophila, homolog of, 1;602582;R, A;;;
12.694;6;8;07;12q24.23;HSPB8, H11, E2IG1, DHMN2, CMT2L, HMN2A;;Heat-shock 22-kD protein 8;608014;REc, Fd;;Neuropathy, distal hereditary motor, type IIA, 158590 (3); Charcot-Marie-Tooth disease, axonal, type 2L, 608673 (3);
12.695;2;5;16;12q24.21;MED13L, THRAP2, PROSIT240, TRAP240L, KIAA1025, MRFACD;;Mediator complex subunit 13-like;608771;A, REc;;Transposition of the great arteries, dextro-looped 1, 608808 (3); Mental retardation and distinctive facial features with or without cardiac defects, 616789 (3);5(Med13l)
12.696;2;20;03;12q24.11;MMAB;;MMAB gene;607568;Fd;;Methylmalonic aciduria, vitamin B12-responsive, due to defect in synthesis of adenosylcobalamin, cblB complementation type, 251110 (3);
12.697;11;7;15;12q24.11;MVK, MVLK, POROK3;;Mevalonate kinase;251170;REa, A;;Mevalonic aciduria, 610377 (3); Hyper-IgD syndrome, 260920 (3); Porokeratosis 3, multiple types, 175900 (3);
12.698;2;1;00;12q24.31;NCOR2, SMRT;;Nuclear receptor corepressor 2;600848;A;;;
12.699;6;8;15;12q24.31;ORAI1, TMEM142A, CRACM1, IMD9, TAM2;;ORAI calcium release-activated calcium modulator 1;610277;Fd, REc;;Immunodeficiency 9, 612782 (3); Myopathy, tubular aggregate, 2, 615883 (3);
12.700;1;27;09;12q24.31;P2RX7, P2X7;;Purinergic receptor P2X, ligand-gated ion channel, 7;602566;A, R;;;
12.701;8;17;12;12q24;PDA1;;Patent ductus arteriosus;607411;Fd;;{Patent ductus arteriosus, susceptibility to} (2);
12.702;6;25;99;12q24.23;PXN;;Paxillin;602505;A;;;
12.703;12;30;03;12q24.11;RAD9B;;RAD9, S. pombe, homolog of, A;608368;REc;;;5(Rad9b)
12.704;10;1;95;12q24.11;SELPLG, PSGL1;;Selectin P ligand;600738;REa, A;;;5(Selpl)
12.705;7;12;11;12q24.12;SH2B3, LNK;;SH2B adaptor protein 3;605093;R, Fd;;Myelofibrosis, somatic, 254450 (3); Thrombocythemia, somatic, 187950 (3); Erythrocytosis, somatic, 133100 (3);
12.706;3;30;18;12q24.13;SLC8B1, SLC24A6, NCKX6;;Solute carrier family 8 member B1;609841;REc;;;5(Slc24a6)
12.707;2;16;04;12q24;SLEB4;;Systemic lupus erythematosus, susceptibility to, 4;608437;Fd;;{Systemic lupus erythematosus, susceptibility to, 4} (2);
12.708;11;2;05;12q24.31;HPD;;4-hydroxyphenylpyruvate dioxygenase;609695;REa, A;;Tyrosinemia, type III, 276710 (3); Hawkinsinuria, 140350 (3);
12.709;6;9;98;12q24.11;ACACB, ACCB, ACC2;;Acetyl-Coenzyme A carboxylase, beta;601557;A;;;
12.710;2;25;14;12q24.12;ACAD10;;Acyl-CoA dehydrogenase family, member 10;611181;REc;;;
12.711;2;20;07;12q23.3;APPL2, FLJ10659;;Adaptor protein, phosphotyrosine interaction, PH domain, and leucine zipper-containing protein 2;606231;Ch, REc;;;
12.712;8;21;98;12q24.31;BCL7A, BCL7;;B-cell CLL/lymphoma-7A;601406;Ch;;B-cell non-Hodgkin lymphoma, high-grade (3);
12.713;3;16;99;12q23.3;CMKLR1;;Chemokine-like receptor 1;602351;A;;;
12.714;1;31;01;12q24.11;CORO1C;;Coronin 1C;605269;A;;;
12.715;10;09;18;12q24.11-q24.12;CUX2, CDP2, CUTL2, EIEE67;;Cut-like homeobox 2;610648;REc;;Epileptic encephalopathy, early infantile, 67, 618141 (3);
12.716;6;30;05;12q24.11;FOXN4;;Forkhead box N4;609429;R, REc;;;
12.717;4;13;10;12q23.3;ISCU, HML;;Iron-sulfur cluster scaffold, E. coli, homolog of;611911;R, REc, Fd;;Myopathy with lactic acidosis, hereditary, 255125 (3);
12.718;3;24;09;12q23.2;PAH, PKU1;;Phenylalanine hydroxylase;612349;REa, A, Fd;close to IGF1;Phenylketonuria, 261600 (3); [Hyperphenylalaninemia, non-PKU mild], 261600 (3);10(Pah)
12.719;12;28;08;12q24.11;PPTC7, TAPP2C;;PTC7 protein phosphatase, S. cerevisiae, homolog of;609668;R, REc;;;
12.720;1;13;99;12q24.23;PRKAB1;;Protein kinase, AMP-activated, noncatalytic, beta-1;602740;A;;;
12.721;8;27;15;12q24.13;PTPN11, PTP2C, SHP2, NS1, JMML, METCDS;;Protein tyrosine phosphatase, nonreceptor-type, 11;176876;A, Fd;;Noonan syndrome 1, 163950 (3); LEOPARD syndrome 1, 151100 (3); Leukemia, juvenile myelomonocytic, somatic, 607785 (3); Metachondromatosis, 156250 (3);
12.722;7;10;08;12q24.13;RPH3A, KIAA0985;;Rabphilin 3A;612159;R, REc;;;
12.723;10;16;14;12q23.3;SART3, P100, KIAA0156, TIP110;;Squamous cell carcinoma antigen recognized by T cells 3;611684;Fd, Psh, REc, H;;;5(Sart3)
12.724;5;2;07;12q24.1;STUT2;;Stuttering, familial persistent, 2;609261;Fd;max lod with PAH;Stuttering, familial persistent, 2 (2);
12.725;1;2;08;12q24.11;SVOP;;SV2-related protein;611699;REc;;;5(Svop)
12.726;8;4;97;12q24.21;TBX3;;T-box 3;601621;REc, A;;Ulnar-mammary syndrome, 181450 (3);5(Tbx3)
12.727;2;19;97;12q24.21;TBX5;;T-box 5;601620;Fd, REc, Ch;;Holt-Oram syndrome, 142900 (3);5(Tbx5)
12.728;3;23;09;12q24.11;TCHP;;Trichoplein;612654;R, REc;;;
12.729;6;2;98;12q23.3;TDG;;Thymine-DNA glycosylase;601423;A;;;10(Tdg)
12.730;8;25;11;12q24.11;TECT1, JBTS13;;Tectonic family, member 1;609863;REc, R;;Joubert syndrome 13, 614173 (3);5(Tect1)
12.731;5;19;06;12q24.13;TPCN1, TPC1, KIAA1169;;Two-pore segment channel 1;609666;R, REc;;;
12.732;7;18;12;12q24.11;TRPV4, VROAC, HMSN2C, CMT2C, SPSMA, SSQTL1, SMAL, BCYM3;;Transient receptor potential cation channel, subfamily V, member 4 (vanilloid receptor-related osmotically activated channel);605427;REc, Fd;mutation identified in 1 ANFH2 family;Brachyolmia type 3, 113500 (3); Spondylometaphyseal dysplasia, Kozlowski type, 184252 (3); Metatropic dysplasia, 156530 (3); Hereditary motor and sensory neuropathy, type IIc, 606071 (3); Scapuloperoneal spinal muscular atrophy, 181405 (3); [Sodium serum level QTL 1], 613508 (3); Parastremmatic dwarfism, 168400 (3); SED, Maroteaux type, 184095 (3); Spinal muscular atrophy, distal, congenital nonprogressive, 600175 (3); Digital arthropathy-brachydactyly, familial, 606835 (3); ?Avascular necrosis of femoral head, primary, 2, 617383 (3);5(Vroac)
12.733;8;16;94;12q24.11;PPP1CC;;Protein phosphatase-1, catalytic subunit, gamma isoform;176914;REa, A;;;10(Ppp1cc)
12.734;11;13;12;12q24.1-q24.2;POROK2, PPPD1;;Porokeratosis 2, palmar, plantar, and disseminated;175850;Fd;between D12S1613 and D12S1341;Porokeratosis 2, palmar, plantar, and disseminated (2);
12.735;9;2;16;12q24.23;CIT, STK21, CRIK, MCPH17;;Citron rho-interacting serine/threonine kinase;605629;REc;;Microcephaly 17, primary, autosomal recessive, 617090 (3);
12.736;12;10;98;12q24.31;MSI1;;Musashi, Drosophila, homolog of, 1;603328;A, Psh, REc;;;
12.737;8;18;14;12q24.11;ANAPC7, APC7;;Anaphase-promoting complex, subunit 7;606949;REc;;;
12.738;4;5;13;12q24.11;ANKRD13A;;Ankyrin repeat domain-containing protein 13A;615123;REc;;;
12.739;11;11;14;12q24.11;ARPC3, ARC21;;Actin-related protein 2/3 complex, subunit 3;604225;REc;;;
12.740;5;9;18;12q24.11;CCDC63, ODA5;;Coiled-coil domain-containing protein 63;617969;REc;;;
12.741;11;1;13;12q24.11;GLTP;;Glycolipid transfer protein;608949;REc;;;
12.742;1;3;12;12q24.11;HVCN1, HV1, VSOP;;Hydrogen voltage-gated channel 1;611227;REc;;;
12.743;7;26;10;12q24.11;KCTD10;;Potassium channel tetramerization domain-containing 10;613421;REc;;;
12.744;6;1;12;12q24.11;MYO1H;;Myosin IH;614636;REc;;;
12.745;4;3;12;12q24.11;SSH1, KIAA1298;;Slingshot, Drosophila, homolog of, 1;606778;R;;;
12.746;4;10;15;12q24.11;UBE3B, BPIDS, KOS;;Ubiquitin-protein ligase E3B;608047;REc;;Kaufman oculocerebrofacial syndrome, 244450 (3);5(Ube3b)
12.747;9;30;11;12q24.12;FAM109A, SES1, IPIP27A;;Family with sequence similarity 109, member A;614239;REc;;;
12.748;7;8;10;12q24.12-q24.13;MAPKAPK5, PRAK;;Mitogen-activated protein kinase-activated protein kinase 5;606723;R, REc;;;
12.749;3;5;18;12q24.11;IFT81, DV1, CDV1R, SRTD19;;Intraflagellar transport 81, Chlamydomonas, homolog of;605489;H, REc;;Short-rib thoracic dysplasia 19 with or without polydactyly, 617895 (3);5(Cdv1, Cdv1r)
12.750;5;12;09;12q24.13;MDM20, C12orf30;;Mitochondrial distribution and morphology 20, yeast, homolog of;612755;REc;;;
12.751;5;25;13;12q24.13;SDS, SDH;;Serine dehydratase;182128;REc;;;
12.752;12;29;09;12q24.13;TRAFD1, FLN29;;TRAF-type zinc finger domain-containing 1;613197;REc;;;
12.753;6;30;15;12q24.13-q24.21;RBM19, KIAA0682;;RNA-binding motif protein 19;616444;R, REc;;;
12.754;7;8;10;12q24.12;ALDH2;;Aldehyde dehydrogenase 2 family, mitochondrial;100650;REa, A, H;;Alcohol sensitivity, acute, 610251 (3); {Hangover, susceptibility to}, 610251 (3); {Sublingual nitroglycerin, susceptibility to poor response to} (3); {Esophageal cancer, alcohol-related, susceptibility to} (3);4(Aldh2)
12.755;1;9;13;12q24.31;CAMKK2, KIAA0787, CAMKKB;;Calcium/calmodulin-dependent protein kinase kinase 2, beta;615002;REc;;;
12.756;10;9;14;12q24.31;COX6A1, CMTRID;;Cytochrome c oxidase, subunit VIa, polypeptide-1;602072;REc;pseudogenes on chr.7 and chr.6;Charcot-Marie-Tooth disease, recessive intermediate D, 616039 (3);
12.757;2;21;06;12q24.31;DYNLL1, DNCL1, DLC1, PIN;;Dynein, light chain, LC8-type 1;601562;A, REc, REn;possible pseudogene on 14q24;;
12.758;2;9;01;12q24.23;GCN1L1;;General control of amino acid synthesis 1, yeast, homolog-like 1;605614;R, REa;;;
12.759;3;29;12;12q24.31;HNF1A, TCF1, MODY3, IDDM20;;HNF1 homeobox B;142410;A, Fd;;MODY, type III, 600496 (3); {Diabetes mellitus, noninsulin-dependent, 2}, 125853 (3); {Diabetes mellitus, insulin-dependent}, 222100 (3); Hepatic adenoma, somatic, 142330 (3); Renal cell carcinoma, 144700 (3); Diabetes mellitus, insulin-dependent, 20, 612520 (3);5(Tcf1)
12.760;8;8;13;12q24.22;HRK, DP5;;Harakiri;603447;REc;;;
12.761;1;31;07;12q24.22-q24.23;KSR2;;Kinase suppressor of RAS 2;610737;REc;;;
12.762;12;11;02;12q24.2;NIDDM2;;Diabetes mellitus, noninsulin-dependent, 2;601407;Fd;no mutations found in HNF1A;Diabetes mellitus, noninsulin-dependent, 2 (2);
12.763;7;3;18;12q24.13;OAS1, OIAS;;2',5'-oligoadenylate synthetase-1;164350;REa, A, REc;;;
12.764;6;24;99;12q24.13;OAS2;;2',5'-oligoadenylate synthetase-2;603350;A, REc;;;
12.765;6;24;99;12q24.13;OAS3;;2',5'-oligoadenylate synthetase-3;603351;A, REc;;;
12.766;11;16;98;12q24.31;OASL, TRIP14;;2',5'-oligoadenylate synthetase-like;603281;REc;;;
12.767;12;7;07;12q24.22;TESC, TSC;;Tescalcin, mouse, homolog of;611585;R, REc, H;;;5(Tesc)
12.768;6;26;16;12q24.23;BICDL1, BICDR1, CCDC64;;BICD family-like cargo adaptor 1;617002;REc;;;
12.769;9;9;08;12q24.22;FBXO21, FBX21, KIAA0875;;F-box only protein 21;609095;REc;;;5(Fbxo21)
12.770;9;9;08;12q24.22;FBXW8, FBW8, FBXW6, FBW6, FBXO29, FBX29;;F-box and WD40 domain protein 8;609073;REc;;;5(Fbxw8)
12.771;9;8;08;12q24.23;PEBP1, PBP, RKIP;;Phosphatidylethanolamine-binding protein 1;604591;R, REc;;;
12.772;10;26;15;12q24.23;RAB35;;Ras-associated protein Rab35;604199;REc;;;
12.773;11;11;09;12q24.23;SRRM4, KIAA1853, NSR100;;Serine/arginine repetitive matrix protein 4;613103;R, REc;;;
12.774;12;22;15;12q24.23;TAOK3, JIK, DPK;;TAO kinase 3;616711;REc;;;
12.775;8;18;16;12q24.2-q24.3;RPL21P1, ALFN1, HALF1;;Ribosomal protein L21 pseudogene 1;603416;A;;;
12.776;7;23;13;12q24.2-q24.3;CTRCT37, CCA5;;Cataract 37;614422;Fd;between D12S1718 and D12S1723;Cataract 37, autosomal dominant (2);
12.777;5;19;09;12q24.31;HIP1R, HIP12;;Huntingtin-interacting protein 1-related protein;605613;A;;;
12.778;11;16;98;12q24.31;PSMD9;;Proteasome 26S subunit, non-ATPase, 9;603146;A;;;
12.779;7;8;10;12q24.22;NOS1;;Nitric oxide synthase 1, neuronal;163731;REa, A;;;5(Nos1)
12.780;3;18;95;12q24.23;RFC5;;Replication factor C5, 36.5kD (activator 1, 36.5kD);600407;Psh, A;;;
12.781;1;30;12;12q24.31;ATP6V0A2, WSS, ARCL2A;;ATPase, H+ transporting, V0 subunit A2;611716;R, REc, Fd;;Cutis laxa, autosomal recessive, type IIA, 219200 (3); Wrinkly skin syndrome, 278250 (3);
12.782;6;15;15;12q24.31;CLIP1, RSN, CYLN1, CLIP170;;CAP-GLY domain containing linker protein 1;179838;A;;;
12.783;10;19;97;12q24.33;MUC8;;Mucin 8, tracheobronchial;601932;REa, A;;;
12.784;4;27;13;12q24.33;POLE1, CRCS12, FILS;;Polymerase (DNA directed), epsilon-1;174762;REa, A;;{Colorectal cancer, susceptibility to, 12}, 615083 (3); FILS syndrome, 615139 (3);5(Pole)
12.785;6;1;09;12q24.33;RAN, ARA24;;Ras-related nuclear protein;601179;REc;;;
12.786;5;26;13;12q24.33;TMEM132D, KIAA1944, MOLT;;Transmembrane protein 132D;611257;REc;;;
12.787;2;9;92;12q24.31;UBC;;Ubiquitin C;191340;REa, A;;;
12.788;6;25;99;12q24.33;ULK1, UNC51;;UNC51-like kinase 1;603168;Psh, R, A;;;
12.789;3;24;04;12q24.33;ZNF268;;Zinc finger protein 268;604753;REc;;;
12.790;3;1;18;12q24.31;ZNF664, ZFOC1;;Zinc finger protein 664;617890;REc, A;;;
12.791;2;28;01;12q13.3;BAZ2A;;Bromodomain adjacent to zinc finger domain, 2A;605682;REa, R;;;
12.792;12;6;11;12q24.31;AACS, ACSF1;;Acetoacetyl-CoA synthetase;614364;REc;;;
12.793;10;23;14;12q24.31;ARL6IP4;;ADP-ribosylation-like factor 6 interacting protein 4;607668;R, REc;;;
12.794;4;26;10;12q24.31;B3GNT4;;Beta-1,3-N-acetylglucosaminyltransferase 4;605864;REc;;;
12.795;2;13;14;12q24.31;BRI3BP;;BRI3-binding protein;615627;REc;;;
12.796;12;5;13;12q24.31;C12orf65, COXPD7, SPG55;;Chromosome 12 open reading frame 65;613541;REc;;Combined oxidative phosphorylation deficiency 7, 613559 (3); Spastic paraplegia 55, autosomal recessive, 615035 (3);
12.797;9;29;10;12q24.31;CCDC62, ERAP75;;Coiled-coil domain-containing protein 62;613481;REc;;;
12.798;5;19;15;12q24.31;COQ5;;Coq5, S. cerevisiae, homolog of;616359;REc;;;
12.799;2;24;17;12q24.31;DHX37, KIAA1517;;DEAH box polypeptide 37;617362;R, REc;;;
12.800;12;10;15;12q24.31;EIF2B1, EIF2BA;;Eukaryotic translation initiation factor 2B, subunit 1;606686;R, REc;;Leukoencephalopathy with vanishing white matter, 603896 (3);
12.801;10;1;17;12q24.31;GTF2H3, TFB4;;General transcription factor IIH, polypeptide 3;601750;REc;;;
12.802;3;25;14;12q24.31;DENR, DRP;;Density-regulated protein;604550;REc;;;
12.803;11;23;16;12q24.31;GATC;;Glutamyl-tRNA amidotransferase, subunit C;617210;REc;;;
12.804;2;5;15;12q24.31;NRAV, DYNLL1AS1;;Negative regulator of antiviral response, noncoding;616207;REc;overlaps intron 1 of DYNLL1 in antisense orientation;;
12.805;8;18;14;12q24.31;FAM101A, CFM2;;Family with sequence similarity 101, member A;615927;REc;;;
12.806;8;25;11;12q24.31;SMAC, DIABLO, DFNA64;;Second mitochondria-derived activator of caspase;605219;REc;;Deafness, autosomal dominant 64, 614152 (3);
12.807;2;21;06;12q24.31;DNAH10;;Dynein, axonemal, heavy chain 10;605884;A, R, REc;previously assigned to 13q14;;
12.808;6;26;01;12q24.31;CDK2AP1, DOC1;;CDK-associated protein 1 (deleted in oral cancer-1);602198;A;;;
12.809;7;14;14;12q24.31;HCAR1, GPR81, TAGPCR;;Hydroxycarboxylic acid receptor 1;606923;REc;;;
12.810;7;14;14;12q24.31;HCAR2, GPR109A, HM74A;;Hydroxycarboxylic acid receptor 2;609163;REc;;;
12.811;7;14;14;12q24.31;HCAR3, GPR109B, HM74, PUMAG;;Hydroxycarboxylic acid receptor 3;606039;REn;;;
12.812;2;25;15;12q24.31;IL31;;Interleukin 31;609509;REc;;;
12.813;5;6;15;12q24.31;KDM2B, FBXL10, FBL10, CXXC2, JHDM1B;;Lysine-specific demethylase 2B;609078;REc;;;
12.814;2;1;11;12q24.31;KNTC1, ROD, KIAA0166;;Kinetochore-associated protein 1;607363;REc;previously assigned to chr.17;;
12.815;3;15;11;12q24.31;MLEC, KIAA0152;;Malectin;613802;REc;;;
12.816;3;11;09;12q24.31;MPVQTL1;;Mean platelet volume quantitative trait locus 1;612573;Fd;associated with rs7961894;[Mean platelet volume QTL1] (2);
12.817;3;23;06;12q24.31;POP5, HSPC004;;Processing of precursor 5, S. cerevisiae, homolog of;609992;R;;;
12.818;7;22;11;12q24.31;RILPL1, RLP1, GOSPEL;;RAB-interacting lysosomal protein-like 1;614092;REc, H;;;5(Rilpl1)
12.819;7;22;11;12q24.31;RILPL2, RLP2;;RAB-interacting lysosomal protein-like 2;614093;REc;;;
12.820;9;22;14;12q24.31;RNF10, KIAA0262;;RING finger protein 10;615998;R, REc, H;;;5(Rnf10)
12.821;10;5;11;12q24.31;SBNO1;;Strawberry notch, Drosophila, homolog of, 1;614274;REc;;;
12.822;1;31;11;12q24.31;SCARB1, CD36L1, CLA1, HDLQTL6;;Scavenger receptor class B, member 1 (CD36 antigen-like 1);601040;Psh, REc;;[High density lipoprotein cholesterol level QTL6], 610762 (3);
12.823;8;21;07;12q24.31;SETD1B, SET1B, KIAA1076;;SET domain-containing protein 1B;611055;R, REc;;;
12.824;3;31;15;12q24.23-q24.31;SIRT4, SIR2L4;;Sirtuin, S. cerevisiae, homolog 4;604482;REc;;;
12.825;3;22;07;12q24.31;SPPL3, IMP2;;Signal peptide peptidase-like 3;608240;R, REc;;;
12.826;12;19;11;12q24.31;SRSF9, SFRS9, SRp30c;;Splicing factor, serine/arginine-rich, 9;601943;REc;;;
12.827;11;23;15;12q24.31;TCTN2, TECT2, MKS8, JBTS24;;Tectonic family, member 2;613846;REc;mutation identified in 1 MKS8 family;?Meckel syndrome 8, 613885 (3); Joubert syndrome 24, 616654 (3);
12.828;2;2;14;12q24.31;THRIL, LINC1992, BRI3BPAS1;;TNF- and HNRNPL-related immunoregulatory long noncoding RNA;615622;REc;;;
12.829;9;24;15;12q24.31;TMEM120B;;Transmembrane protein 120B;616551;REc;;;
12.830;12;17;12;12q24.31;TRIAP1, HSPC132;;TP53-regulated inhibitor of apoptosis 1;614943;REc;;;
12.831;1;26;17;12q24.31;VPS33A, MPSPS;;Vacuolar protein sorting 33, yeast, homolog of, A;610034;R, REc;;Mucopolysaccharidosis-plus syndrome, 617303 (3);
12.832;6;1;15;12q24.31;ZCCHC8;;Zinc finger CCHC domain-containing protein 8;616381;REc;;;
12.833;6;9;06;12q24.31;VPS37B;;Vacuolar protein sorting 37, yeast, homolog of, B;610037;R, REc;;;
12.834;10;22;18;12q24.31;WDR66, CFAP251, SPGF33;;WD repeat-containing protein 66;618146;REc;;Spermatogenic failure 33, 618152 (3);
12.835;6;8;01;12q24.13;LHX5;;LIM homeo box protein 5;605992;A;;;
12.836;7;14;98;12q24.31;P2RX4, P2X4;;Purinergic receptor P2X, ligand-gated ion channel, 4;600846;A;;;
12.837;6;22;14;12q24.33;SLC15A4, PHT1, PTR4;;Solute carrier family 15 (oligopeptide transporter), member 4;615806;REc;;;
12.838;6;19;00;12q24.33;ZNF140;;Zinc finger protein-140;604082;A;;;
12.839;9;1;16;12q24.33;ADGRD1, GPR133, PGR25;;Adhesion G protein-coupled receptor D1;613639;REc;;;
12.840;12;9;15;12q24.33;ANKLE2, LEM4, KIAA0692, MCPH16;;Ankyrin repeat- and LEM domain-containing protein 2;616062;R, REc;mutation identified in 1 MCPH16 family;?Microcephaly 16, primary, autosomal recessive, 616681 (3);
12.841;5;25;09;12q24.33;CHFR;;Checkpoint protein with FHA and ring-finger domains;605209;REc;;;
12.842;2;21;02;12q24.33;EP400, TNRC12, KIAA1498;;p400 SWI2/SNF2-related protein;606265;R;;;
12.843;4;6;13;12q24.33;GALNT9, GALNACT9;;UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 9;606251;;REc;;
12.844;9;30;09;12q24.33;STX2, EPIM, STX2C, STX2B, STX2A;;Epimorphin (syntaxin 2);132350;A, REc;;;5(Epim)
12.845;8;30;01;12q24.33;FZD10;;Frizzled, Drosophila, homolog of, 10;606147;A;;;
12.846;5;12;99;12q24.33;MMP17;;Matrix metalloproteinase 17;602285;A, Psh, R;;;5(Mmp17)
12.847;7;15;09;12q24.33;NOC4L, NOC4;;Nucleolar complex-associated protein 4, S. cerevisiae, homolog of;612819;REc;;;
12.848;11;25;13;12q24.33;P2RX2, P2X2, DFNA41;;Purinergic receptor P2X, ligand-gated ion channel, 2;600844;REc, Fd;;Deafness, autosomal dominant 41, 608224 (3);
12.849;11;29;12;12q24.33;PGAM5;;Phosphogycerate mutase family, member 5;614939;REc;;;
12.850;3;17;16;12q24.33;PUS1, MLASA1;;Pseudourine synthase 1;608109;R, REc;;Myopathy, lactic acidosis, and sideroblastic anemia 1, 600462 (3);
12.851;3;27;17;12q24.33;PXMP2;;Peroxisomal membrane protein 2;617399;REc;;;
12.852;2;19;08;12q24.33;RIMBP2, KIAA0318;;RIMS-binding protein 2;611602;R, REc;;;
12.853;4;29;14;12q24.33;SFSWAP, SFRS8, SWAP;;Splicing factor, suppressor-of-white-apricot family;601945;REc;;;
12.854;6;7;91;12q24.33;ZNF26;;Zinc finger protein-26 (KOX20);194537;REa, A;;;
12.855;5;16;02;12q24.31;ANAPC5, APC5;;Anaphase-promoting complex, subunit 5;606948;R;;;
12.856;11;28;01;12q13.13;ATF7;;Activating transcription factor 7;606371;R;;;
12.857;11;5;98;12q13.13;ATP5G2;;ATP synthase, H+ transporting, mitochondrial F0 complex, subunit C, isoform 2;603193;REn;;;
12.858;12;11;02;12q24.13;C12orf8, ERP28, ERP29;;Endoplasmic reticulum lumenal protein 28;602287;R;;;
12.859;1;31;01;12q15;CCT2, CCTB;;Chaperonin containing T-complex polypeptide 1, subunit 2;605139;R;;;
12.860;2;6;01;12q15;CPSF6, CFIM;;Cleavage and polyadenylation specific factor 6, 68kD subunit;604979;R;;;
12.861;8;21;98;12p12.3;MGST1, GST12;;Microsomal glutathione S-transferase 1;138330;RE, REa;pseudogene at 12q13-q14;;
12.862;7;17;01;12q13.11;EPAC;;cAMP-regulated guanine nucleotide exchange factor I;606057;R;;;
12.863;5;12;03;12q24.33;GOLGA3;;Golgi autoantigen, golgin subfamily A, 3;602581;R;;;
12.864;12;11;01;12q13.11;HDAC7A, HDAC7;;Histone deacetylase 7A;606542;R;;;
12.865;8;27;01;12p13.1;HEBP1, HBP;;Heme-binding protein 1;605826;R;;;
12.866;1;19;01;12q13.13;HOXC10;;Homeo box-C10;605560;REc;;;15(Hoxc10)
12.867;1;19;01;12q13.13;HOXC11;;Homeo box-C11;605559;REc;;;15(Hoxc11)
12.868;1;25;93;12q13.13;IGFBP6;;Insulin-like growth factor-binding protein-6;146735;Psh;;;
12.869;1;30;01;12q24.31;MPHOSPH9, MPP9;;M-phase phosphoprotein 9;605501;R;;;
12.870;1;23;01;12q24.33;PIWIL1;;Piwi, Drosophila, homolog of;605571;R;;;
12.871;1;28;02;12p13.2;PROL4, LPRP;;Proline rich 4, lacrimal;605359;R;;;
12.872;4;15;02;12q24.23;RPLP0;;Ribosomal phosphoprotein, large, P0;180510;R;;;
12.873;1;29;01;12q13.13;SLC4A8, NBC3;;Solute carrier family 4 (sodium bicarbonate cotransporter), member 8;605024;R;;;
12.874;5;9;02;12q13.2;SUOX;;Sulfite oxidase;606887;R;;Sulfite oxidase deficiency, 272300 (3);
12.875;4;16;93;Chr.12;TUBAL1;;Tubulin, alpha-like-1;191120;REa;;;
12.876;10;28;99;12q22;VESPR;;Virus-encoded semaphorin protein receptor;604259;R;;;
12.877;4;3;02;12q14.3;WIF1;;WNT inhibitory factor 1;605186;R;;;
13.1;9;2;11;13pter-q12.13;FECD2, FCD1;;Corneal dystrophy, Fuchs endothelial, 2;610158;Fd;max lod at D13S1304;Corneal dystrophy, Fuchs endothelial, 2 (2);
13.2;4;26;90;13p12;RNR1;;Ribosomal RNA-1;180450;A;;;
13.3;2;28;03;13q12.11;IL17D;;Interleukin 17D;607587;REc;?associated with Hodgkin lymphoma;;
13.4;2;20;07;13q;CLQTL1, CLF;;Cholesterol level quantitative trait locus 1;604595;Fd;;[Cholesterol level QTL 1] (2);
13.5;7;25;13;13q12.11;GJA3, CX46, CZP3, CAE3, CTRCT14;;Gap junction protein, alpha-3, 46kD (connexin 46);121015;REa, A, Fd;;Cataract 14, multiple types, 601885 (3);14(Gja3)
13.6;4;19;06;13q12.12;PARP4, ADPRTL1, VPARP, KIAA0177;;Poly(ADP-ribose) polymerase 4;607519;REc;;;
13.7;6;15;99;13q12.11;TUBA2;;Tubulin, alpha 2;602528;REc;;;
13.8;10;25;17;13q12.11;FGF9, SYNS3;;Fibroblast growth factor-9 (glia-activating factor);600921;A;;Multiple synostoses syndrome 3, 612961 (3);
13.9;3;6;09;13q12.11;GJB2, CX26, DFNB1A, PPK, DFNA3A, KID, HID;;Gap junction protein, beta-2, 26kD (connexin 26);121011;REa, A, Fd;;Deafness, autosomal recessive 1A, 220290 (3); Deafness, autosomal dominant 3A, 601544 (3); Vohwinkel syndrome, 124500 (3); Keratoderma, palmoplantar, with deafness, 148350 (3); Keratitis-ichthyosis-deafness syndrome, 148210 (3); Hystrix-like ichthyosis with deafness, 602540 (3); Bart-Pumphrey syndrome, 149200 (3);14(Gjb2)
13.10;5;11;00;13q12.11;LATS2;;Large tumor suppressor, Drosophila, homolog of, 2;604861;A;;;14(Lats2)
13.11;1;6;09;13q12.3;ALOX5AP, FLAP;;Arachidonate 5-lipoxygenase-activating protein;603700;R, A, REc;;{Stroke, susceptibility to}, 601367 (3);
13.12;7;2;13;13q12.13;ATP8A2, ATPIB, CAMRQ4;;ATPase, class I, type 8A, member 2;605870;A;;?Cerebellar ataxia, mental retardation, and dysequilibrium syndrome 4, 615268 (3);
13.13;10;26;98;13q12.13;CDK8;;Cyclin-dependent kinase 8;603184;REc;;;
13.14;1;2;91;13q12.3;FLT1;;fms-related tyrosine kinase-1 (vascular endothelial growth factor/vascular permeability factor receptor);165070;REa, A;150kb from FLT3;;
13.15;8;27;15;13q12.2;FLT3;;fms-related tyrosine kinase-3;136351;A, Psh, REn;;Leukemia, acute myeloid, reduced survival in, somatic, 601626 (3); Leukemia, acute myeloid, somatic, 601626 (3); Leukemia, acute lymphoblastic, somatic, 613065 (3);5(Flt3)
13.16;12;17;12;13q12.11;GJB6, CX30, DFNA3B, DFNB1B, ECTD2, HED2;;Gap junction protein, beta-6 (connexin-30);604418;Fd, H;;Deafness, autosomal dominant 3B, 612643 (3); Deafness, autosomal recessive 1B, 612645 (3); Deafness, digenic GJB2/GJB6, 220290 (3); Ectodermal dysplasia 2, Clouston type, 129500 (3);
13.17;10;1;95;13q12.13;GPR12;;G protein-coupled receptor-12;600752;A;;;
13.18;8;28;02;13q12.3;HMGB1, HMG1;;High-mobility group box 1 (high-mobility group (nonhistone chromosomal) protein 1);163905;A;;;5(Hmg1)
13.19;6;1;18;13q13.1;KL, KLOTHO, HFTC3;;Klotho;604824;A, REc;mutation identified in 1 HFTC3 patient;?Tumoral calcinosis, hyperphosphatemic, familial, 3, 617994 (3);
13.20;5;7;03;13q13.3-q14.1;LHFP;;Lipoma HMGIC fusion partner;606710;REc;;;
13.21;1;6;09;13q12;MCI2;;Myocardial infarction, susceptibility to, 2;608557;Fd;defined by 4-SNP haplotype HapA;{Myocardial infarction, susceptibility to, 2} (2);
13.22;12;6;98;13q12.12;MIPEP, COXPD31;;Mitochondrial intermediate peptidase;602241;A;;Combined oxidative phosphorylation deficiency 31, 617228 (3);
13.23;6;15;99;13q12.13;MTMR6;;Myotubularin-related protein 6;603561;R, REc, Psh;;;
13.24;2;1;00;13q12.12;SACS, ARSACS;;Sacsin;604490;LD, Fd;;Spastic ataxia, Charlevoix-Saguenay type, 270550 (3);1(Sacs)
13.25;09;27;18;13q12.12;SGCG, LGMDR5, DMDA1, SCG3;;Sarcoglycan, gamma (35kD dystrophin-associated glycoprotein);608896;Fd, LD, A;;Muscular dystrophy, limb-girdle, autosomal recessive 5, 253700 (3);
13.26;11;13;17;13q12.13;WASF3, WAVE3, SCAR3;;WAS protein family member 3;605068;A;;;
13.27;12;14;00;13q12.3;UBL3;;Ubiquitin-like 3;604711;REa, R;;;5(Ubl3)
13.28;10;12;09;13q12-q14;ATOD5;;Dermatitis, atopic, 5;605844;Fd;max lod at D13S218;{Dermatitis, atopic, susceptibility to, 5} (2);
13.29;8;2;13;13q13.3;MADH9, SMAD9, MADH6, PPH2;;Mothers against decapentaplegic, Drosophila, homolog of, 9;603295;R, A;;Pulmonary hypertension, primary, 2, 615342 (3);
13.30;5;1;08;13q14.11;RGC32;;Response gene to complement 32;610077;Psh, R;;;
13.31;3;29;99;13q14.13;TPT1, HRF;;Tumor protein, translationally-controlled 1;600763;Psh, R;;;
13.32;8;3;14;13q12.11;IFT88, D13S1056E, TG737;;Intraflagellar transport 88, Chlamydomonas, homolog of;600595;A;;;14(TgN737Rpw)
13.33;10;26;15;13q12.13;NUP58, NUPL1, KIAA0410;;Nucleoporin 58kDa;607615;R, REc;;;
13.34;8;22;16;13q12.2;PDX1, IPF1, MODY4, PAGEN1;;Pancreas/duodenum homeobox protein 1;600733;Psh, A;;Pancreatic agenesis 1, 260370 (3); MODY, type IV, 606392 (3); {Diabetes mellitus, type II, susceptibility to}, 125853 (3);5(Ipf1)
13.35;7;27;09;13q12.12;RNF17;;RING finger protein-17;605793;R, REc;;;
13.36;11;8;00;13q12.12;ATP12A, ATP1AL1;;ATPase, H+/K+ transporting, nongastric, alpha polypeptide;182360;REa, Fd;;;
13.37;9;23;08;13q12.11;ADHD6;;Attention deficit-hyperactivity disorder, susceptibility to, 6;612312;Fd;max lod at rs1974047;{Attention deficit-hyperactivity disorder, susceptibility to, 6} (2);
13.38;2;22;10;13q12.11;CFEOM3C, FEOM4;;Fibrosis of extraocular muscles, congenital, 3C;609384;Ch;;Fibrosis of extraocular muscles, congenital, 3C (2);
13.39;2;7;06;13q12.11;CRYL1;;Crystallin, lambda-1;609877;R, REc, H;;;14(Cryl1)
13.40;11;29;17;13q12.11;EEF1AKMT1, N6AMT2;;EEF1A lysine methyltransferase 1;617793;REc;;;
13.41;1;14;14;13q12.11;MICU2, EFHA1;;Mitochondrial calcium uptake protein 2;610632;REc;;;
13.42;2;6;08;13q12.11;MPHOSPH8, TWA3;;M-phase phosphoprotein 8;611626;REc;;;
13.43;4;24;08;13q12.11;MRP63;;Mitochondrial ribosomal protein 63;611997;R, REc;10 pseudogenes;;
13.44;12;18;08;13q12.11;PSPC1, PSP1;;Paraspeckle component 1;612408;REc;;;
13.45;10;17;02;13q12.13;RNF6;;RING finger protein-6;604242;A, REn;;Esophageal carcinoma, somatic, 133239 (3);
13.46;8;3;12;13q12.11;SAP18;;Sin3-associated polypeptide, 18kD;602949;REc;;;
13.47;7;14;14;13q12.11;TPTE2, TPIP;;Transmembrane phosphoinositide 3-phosphatase and tensin homolog 2;606791;REc;;;
13.48;5;11;18;13q12.11;ZDHHC20, DHHC20;;Zinc finger DHHC domain-containing protein 20;617972;REc;;;
13.49;6;30;15;13q12.11;ZMYM2, ZNF198, RAMP, FIM;;Zinc finger, MYM-type 2;602221;REc, R, Ch;;;
13.50;6;30;15;13q12.11;ZMYM5, ZNF237, ZNF198L1;;Zinc finger, MYM-type 5;616443;A, R, REc;;;
13.51;8;30;01;13q12.12;TAJ, TROY;;Toxicity and JNK inducer;606122;REc;;;14(Troy)
13.52;11;19;11;13q12.12;C1QTNF9A, CTRP9, C1QTNF9;;C1q- and tumor necrosis factor-related protein 9A;614285;REc;;;14(C1qtnf9a)
13.53;8;5;11;13q12.12;C1QTNF9B, CTRP9B;;C1q- and tumor necrosis factor-related protein 9B;614148;REc;;;
13.54;9;22;16;13q12.12;C1QTNF9BAS1, PCOTH;;C1QTNF9B antisense RNA 1;617122;REc;;;
13.55;8;25;11;13q12.12;MYP20;;Myopia 20, autosomal dominant;614166;Fd;associated with rs9318086;Myopia 20, autosomal dominant (2);
13.56;3;29;10;13q12.12;SPATA13, ASEF2;;Spermatogenesis-associated protein 13;613324;REc;;;
13.57;5;29;12;13q12.13;FAM123A, AMER2;;Family with sequence similarity 123, member A (APC membrane recruitment protein 2);614659;REc;;;
13.58;2;2;17;13q12.13;SHISA2, C13orf13, TMEM46;;Shisa family, member 2;617324;REc;;;
13.59;12;5;17;13q12.13;USP12, UBH1;;Ubiquitin-specific protease 12;603091;REc;;;
13.60;4;25;05;13q12.12-q12.13;CENPJ, CPAP, MCPH6, SCKL4;;Centromeric protein J;609279;Fd, REc;mutation identified in 1 SCKL4 family;Microcephaly 6, primary, autosomal recessive, 608393 (3); ?Seckel syndrome 4, 613676 (3);
13.61;9;3;15;13q12.2;GSX1, GSH1;;GS homeobox 1;616542;REc;;;5(Gsx1)
13.62;12;28;08;13q12.2;LNX2, PDZRN1;;Ligand of numb protein X2;609733;REc;;;
13.63;5;19;17;13q12.2;PAN3;;PABP-dependent poly(A) nuclease 3;617448;REc;;;
13.64;1;31;11;13q12.2;POLR1D, RPA16, RPAC2, TCS2;;Polymerase I, RNA, subunit D;613715;REc;;Treacher Collins syndrome 2, 613717 (3);
13.65;12;18;08;13q12.2;RASL11A;;RAS-like, family 11, member A;612403;REc;;;
13.66;7;17;14;13q12.2;RPL21, HYPT12;;Ribosomal protein L21;603636;REa, R, REc;;Hypotrichosis 12, 615885 (3);
13.67;6;22;14;13q12.2;URAD;;Ureidoimidazoline (2-oxo-4-hydroxy-4-carboxy-5-) decarboxylase;615804;REc;;;
13.68;4;17;00;13q12.2-q13;MBS, MBS1;;Moebius syndrome;157900;Ch;;?Moebius syndrome (2);
13.69;10;16;00;13q13.1;AS3;;Androgen-induced prostate proliferative shutoff-associated protein;605333;REc;;;
13.70;2;19;16;13q12.3;B3GLCT, B3GALTL, B3GTL;;Beta 3-glucosyltransferase;610308;REc;;Peters-plus syndrome, 261540 (3);
13.71;11;16;15;13q13.1;BRCA2, FANCD1, BROVCA2, GLM3, PNCA2;;BRCA2 gene;600185;Fd;;{Breast-ovarian cancer, familial, 2}, 612555 (3); Fanconi anemia, complementation group D1, 605724 (3); {Prostate cancer}, 176807 (3); {Breast cancer, male, susceptibility to}, 114480 (3); Wilms tumor, 194070 (3); {Medulloblastoma}, 155255 (3); {Glioblastoma 3}, 613029 (3); {Pancreatic cancer 2}, 613347 (3);5(Brca2)
13.72;8;21;98;13q12.2;CDX2, CDX3;;Caudal type homeo box transcription factor 2;600297;A, Psh;;;5(Cdx2)
13.73;1;16;07;13q12.3;HSPH1, HSP105, KIAA0201;;Heat-shock 105/110kD protein 1;610703;R, REc;;;
13.74;8;21;12;13q12.3;KATNAL1;;Katanin p60 subunit A-like 1;614764;REc;;;
13.75;7;19;18;13q12.3;POMP, UMP1, PRAAS2;;Proteasome maturation protein;613386;REc;;Keratosis linearis with ichthyosis congenita and sclerosing keratoderma, 601952 (3); Proteasome-associated autoinflammatory syndrome 2, 618048 (3);
13.76;8;21;98;13q12.3;SLC7A1, ATRC1;;Solute carrier family 7 (cationic amino acid transporter, y+ system), member 1;104615;Fd, A, REa;distal to ATP1AL1;;5(Rec1)
13.77;1;20;16;13q12.3;SLC46A3;;Solute carrier family 46, member 3;616764;REc;;;
13.78;7;26;02;13q13.3;SPG20;;Spartin;607111;REc;;Troyer syndrome, 275900 (3);
13.79;3;22;06;13q13.1-q13.2;STARD13, DLC2;;Start domain-containing protein 13;609866;REc;;;
13.80;4;28;17;13q12.3;USPL1;;Ubiquitin-specific peptidase-like 1;617470;REc;;;
13.81;6;6;00;13q13.3;CCNA1;;Cyclin A1;604036;R;;;
13.82;3;20;95;13q13.2;RFC3;;Replication factor C3, 38kD (activator 1, 38kD);600405;Psh, A;;;
13.83;12;17;95;13q12.2;GTF3A, TFIIIA;;General transcription factor IIIA;600860;A;;;
13.84;12;21;09;13q13.3;DCLK1, DCAMKL1, CLICK1, CL1, KIAA0369;;Doublecortin-like kinase 1;604742;R, A;;;3(Dclk1)
13.85;10;18;96;13q13.3;MAB21L1;;mab-21 (C. elegans)-like 1;601280;REa, Fd, R;;;
13.86;12;7;03;13q13.3;STOML3, SRO;;Stomatin-like protein 3;608327;REc;;;
13.87;7;4;95;13q13-q14.3;ENUR1;;Enuresis, nocturnal, 1;600631;Fd;;Enuresis, nocturnal, 1 (2);
13.88;11;11;14;13q13.3;EXOSC8, OIP2, RRP43, PCH1C;;Exosome component 8;606019;R, REc;;Pontocerebellar hypoplasia, type 1C, 616081 (3);
13.89;9;14;12;13q13.1;FRY, C13orf14;;Furry, Drosophila, homolog of;614818;REc;;;
13.90;6;27;08;13q13.1;HPRHP;;Hypophosphatemic rickets and hyperparathyroidism;612089;Ch;?due to altered KLOTHO expression;Hypophosphatemic rickets and hyperparathyroidism (2);
13.91;8;5;15;13q13.1;LGR8, GREAT;;Leucine-rich repeat-containing G protein-coupled receptor 8;606655;REc;;;
13.92;6;22;14;13q13.1;N4BP2L2, PFAAP5;;NEDD4-binding protein 2-like 2;615788;REc;;;
13.93;3;3;03;13q13.3;TRPC4, TRP4;;Transient receptor potential cation channel, subfamily C, member 4;603651;A;;;
13.94;3;14;06;13q13.3;NBEA;;Neurobeachin;604889;REc, R, REa, Ch;site of FRA13A;;3(Nbea)
13.95;3;25;14;13q13.3;ALG5;;Alg5, S. cerevisiae, homolog of;604565;REc;;;
13.96;8;14;13;13q14.11;COG6, COD2, KIAA1134, CDG2L, SHNS;;Component of oligomeric golgi complex 6;606977;R, REc;;Congenital disorder of glycosylation, type IIl, 614576 (3); Shaheen syndrome, 615328 (3);
13.97;2;28;03;13q14.11;EPSTI1;;Epithelial stromal interaction 1;607441;REc, REa;;;
13.98;7;26;10;13q13.3;FAM48A, P38IP, C13orf19;;Family with sequence similarity 48, member A;613417;A, R;;;
13.99;9;13;17;13q13.3;FREM2, FRASRS2;;FRAS1-related extracellular matrix protein 2;608945;REc;;Fraser syndrome 2, 617666 (3);3(my)
13.100;6;9;09;13q13.3;IBD27;;Inflammatory bowel disease 27;612796;Fd;;{Inflammatory bowel disease 27} (2);
13.101;4;24;08;13q14.11;MRPS31;;Mitochondrial ribosomal protein S31;611992;REc;4 pseudogenes;;
13.102;11;3;14;13q13.3;SOHLH2;;Spermatogenesis- and oogenesis-specific basic helix-loop-helix protein 2;616066;REc;;;3(Sohlh2)
13.103;2;11;13;13q13.3-q21;PAPA5;;Polydactyly, postaxial, type A5;263450;Fd;between D13S1288 and D13S632;Polydactyly, postaxial, type A5 (2);
13.104;3;23;09;13q13.3;POSTN, OSF2, PN;;Periostin;608777;R, REc;;;
13.105;3;5;18;13q13.3;UFM1, HLD14;;Ubiquitin-fold modifier 1;610553;REc;;Leukodystrophy, hypomyelinating, 14, 617899 (3);
13.106;10;8;08;13q14;BMIQ2;;Body mass index quantitative trait locus 2;606643;Fd;max lod at D13S257;[Body mass index QTL2] (2);
13.107;6;30;08;13q14;BMND9;;Bone mineral density quantitative trait locus 9;612110;Fd;associated with rs9594759;[Bone mineral density QTL 9] (2);
13.108;12;7;07;13q14.3;CKAP2, TMAP, LB1;;Cytoskeleton-associated protein 2;611569;A;;;
13.109;10;28;08;13q14.2;CLLD6, C13orf1;;Chronic lymphocytic leukemia deletion region gene 6;607866;REc;;;
13.110;8;29;02;13q14.2;CYSLTR2, CYSLT2;;Cysteinyl leukotriene receptor 2;605666;R;;;
13.111;10;28;08;13q14;CLLS2, D13S25, DBM;;Leukemia, chronic lymphocytic, susceptibility to, 2;109543;D;>530kb telomeric to RB1;{Leukemia, chronic lymphocytic, susceptibility to, 2} (2);
13.112;5;6;11;13q14;DEL13q14, C13DELq14;;Chromosome 13q14 deletion syndrome;613884;Ch;;Chromosome 13q14 deletion syndrome (4);
13.113;4;19;01;13q14.2-q14.3;DLEU1, LEU1;;Deleted in lymphocytic leukemia 1;605765;REc;;;
13.114;4;19;01;13q14.2;DLEU2, LEU2, BCMSUN;;Deleted in lymphocytic leukemia 2;605766;REc;;;
13.115;10;24;00;13q14;GER;;Gastroesophageal reflux;109350;Fd;;Gastroesophageal reflux (2);
13.116;11;11;14;13q14.2;ITM2B, BRI, ABRI, FBD, RDGCA;;Integral membrane protein 2B (BRI gene);603904;A;mutation identified in 1 RDGCA family;Dementia, familial British, 176500 (3); Dementia, familial Danish, 117300 (3); ?Retinal dystrophy with inner retinal dysfunction and ganglion cell abnormalities, 616079 (3);
13.117;12;18;08;13q14.1-q14.2;LRCH1, KIAA1016;;Leucine-rich repeats and calponin homology domain-containing 1;610368;R, REc;;;
13.118;2;1;01;13q14.12;NUFIP1, NUFIP;;Nuclear fragile X mental retardation protein-interacting protein 1;604354;REa, A;pseudogene on 6q12;;
13.119;11;15;16;13q14.2;RCBTB1, CLLD7, GLP, RDEOA;;RCC1 domain- and BTB domain-containing protein 1;607867;REc;;Retinal dystrophy with or without extraocular anomalies, 617175 (3);
13.120;11;2;98;13q13.3;RFXAP;;Regulatory factor X-associated protein;601861;R;;Bare lymphocyte syndrome, type II, complementation group D, 209920 (3);
13.121;12;4;96;13q14;RIEG2, RGS2;;Rieger syndrome, type 2;601499;Fd, Ch;;Rieger syndrome, type 2 (2);
13.122;10;28;08;13q14.2;SETDB2, CLLD8;;SET domain protein, bifurcated, 2;607865;REc;;;
13.123;6;4;99;13q14.11;SLC25A15, ORNT1, HHH;;Solute carrier family 25 (mitochondrial carrier), member 15 (ornithine transporter 1);603861;D, Ch, REc;with deficiency of factors VII and X in 3 unrelated cases;Hyperornithinemia-hyperammonemia-homocitrullinemia syndrome, 238970 (3);
13.124;4;27;12;13q14;SPG24;;Spastic paraplegia 24, autosomal recessive;607584;Fd;;Spastic paraplegia 24, autosomal recessive (2);
13.125;2;19;07;13q14.11;TSC22D1, TSC22;;TSC22 domain family, member 1;607715;A;;;
13.126;12;7;07;13q14.11;TNFSF11, OPGL, TRANCE, OPTB2;;Tumor necrosis factor ligand superfamily, member 11 (osteoprotegerin ligand);602642;R, H;;Osteopetrosis, autosomal recessive 2, 259710 (3);14(Trance)
13.127;10;23;87;13q14;XRS;;X-ray sensitivity;194370;Ch;;;
13.128;7;19;12;13q14.3;CTAGE3;;Cutaneous T-cell lymphoma-associated antigen 3;608857;REc;;;
13.129;5;31;06;13q14.2;HTR2A;;5-hydroxytryptamine (serotonin) receptor-2A;182135;REa, A, Fd;;{Schizophrenia, susceptibility to}, 181500 (3); {Obsessive-compulsive disorder, susceptibility to}, 164230 (3); {Seasonal affective disorder, susceptibility to}, 608516 (3); {Alcohol dependence, susceptibility to}, 103780 (3); {Anorexia nervosa, susceptibility to}, 606788 (3); {Major depressive disorder, response to citalopram therapy in}, 608516 (3);14(Htr2)
13.130;3;11;03;13q14.3;LECT1, CHM1;;Leukocyte cell derived chemotaxin 1 (chondromodulin);605147;A;;;
13.131;3;23;09;13q14.2;MLNR, GPR38;;Motilin receptor;602885;A;;;
13.132;8;2;13;13q14.11;DNAJC15, MCJ;;DNAJ/HSP40 homolog, subfamily C, member 15;615339;A, REc;;;
13.133;8;28;02;13q14.11;FOXO1A, FKHR;;Forkhead box O1A (forkhead in rhabdomyosarcoma);136533;Ch;chimeric with PAX3 in t(2;13); fuses with PAX3;Rhabdomyosarcoma, alveolar, 268220 (3);
13.134;8;1;17;13q14.2;PHF11, NYREN34;;PHD finger protein 11;607796;REc;;;
13.135;1;6;09;13q14.3;RNASEH2B, DLEU8, FLJ11712, AGS2;;Ribonuclease H2, subunit B;610326;REc, Fd;;Aicardi-Goutieres syndrome 2, 610181 (3);
13.136;6;16;97;13q14.2;RB1;;Retinoblastoma-1;614041;Ch, F, Fd;;Retinoblastoma, 180200 (3); Osteosarcoma, somatic, 259500 (3); Bladder cancer, somatic, 109800 (3); Small cell cancer of the lung, somatic, 182280 (3); Retinoblastoma, trilateral, 180200 (3);14(Rb1)
13.137;10;23;87;13q14.13;LCP1;;Lymphocyte cytosolic protein-1 (plasmin);153430;F, D;;;
13.138;1;8;01;13q14.11;MTRF1;;Translational release factor, mitochondrial, 1;604601;R;;;
13.139;12;10;13;13q14.11;AKAP11, AKAP220;;A-kinase anchor protein 11;604696;REc, R;;;
13.140;2;11;15;13q14.11;DGKH;;Diacylglycerol kinase, eta, 130kD;604071;REc;;;
13.141;9;23;13;13q14.11;LACC1, C13orf31;;Laccase (multicopper reductase) domain-containing protein 1;613409;REc;;;
13.142;7;6;10;13q14.11;CCDC122;;Coiled-coil domain-containing protein 122;613408;REc;;;
13.143;8;5;99;13q14.13;CPB2, CPU, TAFI;;Carboxypeptidase B2, plasma (carboxypeptidase U);603101;Psh;;;
13.144;8;8;13;13q14.11;ELF1, RIA1, EFTUD1;;E74-like factor 1;189973;A, REc;;;
13.145;4;4;07;13q14.11;ENOX1, CNOX;;ECTO-NOX disulfide-thiol exchanger 1;610914;REc;;;
13.146;10;23;87;13q14.2;ESD;;Esterase D; S-formylglutathione hydrolase;133280;S, F, D;proximal to RB1, WND;;14(Es10)
13.147;10;25;17;13q14.11;KBTBD6;;Kelch repeat- and BTB domain-containing protein 6;617738;REc;;;
13.148;10;25;17;13q14.11;KBTBD7;;Kelch repeat- and BTB domain-containing protein 7;617739;REc;;;
13.149;7;8;10;13q14.11;LPRS6;;Leprosy, susceptibility to, 6;613407;Fd;associated with rs9533634 and rs3764147;{Leprosy, susceptibility to, 6} (2);
13.150;3;8;07;13q14.13;SLC25A30, KMCP1;;Solute carrier family 25 (mitochondrial carrier, kidney), member 30;610793;REc;;;
13.151;6;12;17;13q14.11;VWA8, KIAA0564;;von Willebrand factor A domain-containing protein 8;617509;REc, H;;;14(Vwa8)
13.152;3;31;15;13q14.11;WBP4, FBP21;;WW domain-containing binding protein 4;604981;REc;;;
13.153;7;27;09;13q14.13;COG3, SEC34;;Component of oligomeric golgi complex 3;606975;REc;;;
13.154;2;2;14;13q14.13;SIAH3;;SIAH E3 ubiquitin protein ligase family, member 3;615609;REc;;;
13.155;5;25;13;13q14.12-q14.13;GTF2F2, TF2F2, RAP30;;General transcription factor IIF, polypeptide 2, 30kD;189969;REc;;;
13.156;11;3;11;13q14.2;LPAR6, P2RY5, P2Y5, LAH3, ARWH1, HYPT8;;Lysophosphatidic acid receptor 6;609239;REc, Fd;in intron 17 of RB gene;Hypotrichosis 8, 278150 (3); Woolly hair, autosomal recessive 1, with or without hypotrichosis, 278150 (3);
13.157;7;13;15;13q14.13;ZC3H13, KIAA0853;;Zinc finger CCCH domain-containing protein 13;616453;R, REc;;;
13.158;8;1;08;13q14.2;CAB39L;;Calcium-binding protein 39-like protein;612175;REc;;;
13.159;2;7;17;13q14.2;EBPL;;Emopamil-binding protein-like;617335;REc;;;
13.160;6;22;14;13q14.2;FNDC3A, KIAA0970, HUGO;;Fibronectin type III domain-containing protein 3A;615794;REc;;;
13.161;3;23;06;13q14.2;MED4, DRIP36, HSPC126;;Mediator of RNA polymerase II transcription, subunit 4, S. cerevisiae, homolog of;605718;REc;;;
13.162;7;17;02;13q14.3;NEK3;;Never in mitosis gene A-related kinase 3;604044;REa, R;;;
13.163;4;19;16;13q14.2;NUDT15, MTH2, NUDT15D;;Nucleoside diphosphate-linked moiety X motif 15;615792;REc;;{Thiopurines, poor metabolism of, 2}, 616903 (3);
13.164;6;2;15;13q14.2;SUCLA2, MTDPS5;;Succinate-CoA ligase, ADP-forming, beta subunit;603921;REc;;Mitochondrial DNA depletion syndrome 5 (encephalomyopathic with or without methylmalonic aciduria), 612073 (3);
13.165;8;15;03;13q14.2-q14.1;AUTS3;;Autism, susceptibility to, 3;608049;Ch;;{Autism susceptibility 3} (2);
13.166;12;14;10;13q14.3;ALG11, KIAA1266, CDG1P;;Alg11, S. cerevisiae, homolog of;613666;R, REc;;Congenital disorder of glycosylation, type Ip, 613661 (3);
13.167;1;29;09;13q14.2;ARL11, ARLTS1;;ADP-ribosylation factor-like 11;609351;REc;;;
13.168;12;30;14;13q14.3;DHRS12, SDR40C1;;Short-chain dehydrogenase reductase family, member 12;616163;REc;;;
13.169;6;15;99;13q14.3;GUCY1B2;;Guanylate cyclase 1, soluble, beta-2;603695;A, Fd;;;
13.170;3;23;14;13q14.3;INTS6, DDX26, DICE1;;Integrator complex subunit 6;604331;Ch, REc;;;
13.171;2;25;15;13q14.2;KCNRG, DLTET;;Potassium channel regulator;607947;REc, H;;;14(Kcnrg)
13.172;8;5;97;13q14.2;KPNA3;;Karyopherin (importin) alpha-3;601892;A;;;
13.173;3;23;09;13q14.2;MIR15A, MIRN15A;;Micro RNA 15A;609703;REc;;;
13.174;3;23;09;13q14.2;MIR16-1, MIRN16-1;;Micro RNA 16-1;609704;REc;;;
13.175;1;13;16;13q14.3;NEK5;;Never in mitosis gene A-related kinase 5;616731;REc;;;
13.176;7;1;11;13q14.3;OLFM4, GC1, GW112;;Olfactomedin 4;614061;A, R;;;
13.177;6;15;99;13q14.3;PCDH8;;Protocadherin 8;603580;REc, H;;;14(Pcdh8)
13.178;1;27;11;13q14.2;RCBTB2, CHC1L;;RCC1 domain- and BTB domain-containing protein 2;603524;REc;;;
13.179;7;22;09;13q14.3;STQTL20;;Stature quantitative trait locus 20;612894;Fd;associated with rs3118914;{Stature QTL 20} (2);
13.180;7;20;12;13q14.3;SUGT1, SGT1;;Suppressor of G2 allele of Skp1, S. Cerevisiae, homolog of;604098;REc;;;
13.181;2;16;16;13q14.3;THSD1, TMTSP;;Thrombospondin type 1 domain-containing protein 1;616821;REc;;;
13.182;8;20;07;13q14.2;TRIM13, RFP2, LEU5;;Tripartite motif-containing protein 13;605661;REc, H;;;14(Trim13)
13.183;4;17;07;13q14.3;VPS36, EAP45;;Vacuolar protein sorting 36, S. cerevisiae, homolog of;610903;R, REc;;;
13.184;5;24;13;13q14.3;WDFY2;;WD repeat- and FYVE domain-containing protein 2;610418;REc, R;;;
13.185;4;30;02;13q14.3;ATP7B, WND;;ATPase, Cu++ transporting, beta polypeptide;606882;F, Fd;;Wilson disease, 277900 (3);8(Atp7b)
13.186;3;15;10;13q21;ATXN8;;Ataxin 8;613289;REc;CAG repeat results in polyglutamine expansion protein;Spinocerebellar ataxia 8, 608768 (3);
13.187;3;9;10;13q21.33;ATXN8OS, SCA8, KLHL1AS;;Ataxin 8 opposite strand;603680;REc;due to CTG repeat in untranslated DNA;Spinocerebellar ataxia 8, 608768 (3);
13.188;10;13;00;13q21.33;KLHL1;;Kelch-like 1;605332;REc;;;
13.189;5;26;13;13q22.3;KCTD12, PFET1, KIAA1778, C13orf2;;Potassium channel tetramerization domain-containing protein 12;610521;REc, A;;;14(Kctd12)
13.190;11;7;05;13q21;SLI3;;Specific language impairment QTL, 3;607134;Fd;max with D13S1317;Specific language impairment QTL, 3 (2);
13.191;2;3;03;13q21.33;DIS3, KIAA1008;;Dis3, S. pombe, homolog of;607533;REc;;;
13.192;11;10;17;13q21.3-q22.1;PIBF1, JBTS33;;Progesterone-induced blocking factor 1;607532;REc;;Joubert syndrome 33, 617767 (3);
13.193;9;9;08;13q22.2;LMO7, FBXO20, FBX20, KIAA0858;;LIM domain only 7;604362;REa, REc;;;14(Lmo7)
13.194;10;27;97;13q21-q32;PAPA2;;Postaxial polydactyly, type A2;602085;Fd;;Postaxial polydactyly, type A2 (2);
13.195;6;15;99;13q21.32;PCDH9;;Protocadherin 9;603581;A, D, H;;;14(Pcdh9)
13.196;1;29;08;13q21.1;PCDH17, PCDH68;;Protocadherin 17;611760;R, REc;;;
13.197;2;28;97;13q31.1;POU4F1, BRN3A;;POU domain, class 4, transcription factor 1;601632;Psh, REc;;;
13.198;4;19;12;13q21.2;DIAPH3, DIA2, DRF3, AUNA1, NSDAN;;Diaphanous, Drosophila, homolog of, 3;614567;Fd, REc;;Auditory neuropathy, autosomal dominant, 1, 609129 (3);
13.199;1;30;12;13q21.2;PCDH20, PCDH13;;Protocadherin 20;614449;REc;;;
13.200;1;1;12;13q21.2;TDRD3;;Tudor domain-containing protein 3;614392;REc;;;
13.201;9;9;10;13q21.33;C13orf37, MOZART1;;Mitotic spindle-organizing protein associated with a ring of gamma-tubulin;613448;REc;;;
13.202;3;11;09;13q22.2;COMMD6;;COMM domain-containing protein 6;612377;REc, H;;;14(Commd6)
13.203;5;21;99;13q21.33;DACH;;Dachshund, Drosophila, homolog of;603803;R, A;;;13(Dach)
13.204;2;2;14;13q22;DDH1;;Developmental dysplasia of the hip 1;142700;Fd;;Developmental dysplasia of the hip 1 (2);
13.205;3;16;10;13q22.3;EDNRB, HSCR2, ABCDS, WS4A;;Endothelin receptor type B;131244;REa, Ch, LD;?piebald lethal in mouse;{Hirschsprung disease, susceptibility to, 2}, 600155 (3); ABCD syndrome, 600501 (3); Waardenburg syndrome, type 4A, 277580 (3);
13.206;2;15;01;13q22.3;FBXL3A, FBL3A, FBL3;;F-box and leucine-rich repeat protein 3A;605653;A;;;14(Fbxl3)
13.207;2;3;03;13q22.1;KLF12, AP2REP;;Kruppel-like factor 12;607531;A;;;
13.208;8;19;13;13q22.3;MYCBP2, PAM, KIAA0916;;Myc-binding protein 2;610392;REc;;;
13.209;8;10;99;13q22.3;SCEL;;Sciellin;604112;A;;;
13.210;10;15;01;13q22.3;TNFRSF11B, OPG, OCIF;;Tumor necrosis factor receptor superfamily, member 11B;602543;A;;;
13.211;3;11;09;13q22.2;UCHL3;;Ubiquitin carboxyl-terminal esterase L3;603090;REc, H;;;14(Uchl3)
13.212;12;20;04;13q22-q32;PAND1;;Panic disorder syndrome 1;167870;?locus on 22;;Panic disorder syndrome 1 (2);
13.213;5;26;13;13q21.33;BORA, C13orf34;;Aurora borealis;610510;REc;;;
13.214;6;9;06;13q31.1;NDFIP2, N4WBP5A, KIAA1165;;NEDD4 family-interacting protein 2;610041;R, REc;;;
13.215;12;30;14;13q22.2;TBC1D4, AS160, KIAA0603, NIDDM5;;TPC1 domain family, member 4;612465;REc, R;;{Diabetes mellitus, noninsulin-dependent, 5}, 616087 (3);
13.216;3;2;18;13q22.3;ACOD1, IRG1;;Aconitate decarboxylase 1;615275;REc;;;
13.217;5;17;18;13q22.3;lncRNA-ACOD1, LOC105370268;;Long noncoding RNA near ACOD1;617979;REc;;;
13.218;7;18;14;13q22.3;CLN5;;CLN5 gene;608102;Fd, REc;;Ceroid lipofuscinosis, neuronal, 5, 256731 (3);
13.219;4;6;15;13q22.3;SLAIN1;;SLAIN motif family, member 1;610491;REc;;;14(Slain1)
13.220;11;30;06;13q34;ADPRHL1, ARH2;;ADP-ribosylhydrolase-like 1;610620;REc;;;
13.221;7;13;17;13q32.1;DZIP1, KIAA0996;;DAZ-interacting zinc finger protein 1;608671;REc;;;
13.222;5;19;15;13q32.1;GPR180, ITR;;G protein-coupled receptor 180;607787;A;;;
13.223;8;5;15;13q31.1;SLITRK1, KIAA1910, TTM;;SLIT- and NTRK-like family, member 1;609678;REc, H;mutation identified in 1 TTM patient;Tourette syndrome, 137580 (3); ?Trichotillomania, 613229 (3);17(Slitrk1)
13.224;12;28;08;13q31.2;SLITRK5, KIAA0918;;SLIT- and NTRK-like family, member 5;609680;R, REc, H;;;14(Slitrk5)
13.225;11;22;13;13q31.1;SLITRK6, DFNMYP;;SLIT- and NTRK-like family, member 6;609681;REc, H;;Deafness and myopia, 221200 (3);14(Slitrk6)
13.226;8;21;98;13q32.1;DCT, TYRP2;;Dopachrome tautomerase (dopachrome delta-isomerase; tyrosinase-related protein 2);191275;A;;;14(Tyrp2)
13.227;1;29;01;13q32.1;SOX21;;SRY-box 21;604974;Psh, A;;;
13.228;7;27;09;13q32.2;STK24, MST3, MST3B;;Serine/threonine protein kinase 24;604984;REc;;;
13.229;4;16;14;13q31-q33;NYS4;;Nystagmus 4, congenital, autosomal dominant;193003;Fd;;Nystagmus 4, congenital, autosomal dominant (2);
13.230;8;18;14;13q31.1;RNF219, C13orf7;;Ring finger protein 219;615906;REc;;;
13.231;2;17;16;13q31.1;SPRY2, IGAN3;;Sprouty, Drosophila, homolog of, 2;602466;R, REc;mutation identified in 1 IGAN3 family;{?IgA nephropathy, susceptibility to, 3}, 616818 (3);
13.232;5;13;13;13q31.1;LNCR13Q1;;Long noncoding RNA on 13q (TCONS_00021856);615230;REc;;;
13.233;3;23;09;13q31.3;MIR17, MIR91, MIRN17;;Micro RNA 17;609416;A, REc;within C13orf25; sequence encodes 2 micro RNAs;;
13.234;11;3;11;13q31.3;MIR17HG, MIRH1, MIHG1, MIRHG1, C13orf25, FGLDS2;;Micro RNA 17 host gene;609415;A, REc;;Feingold syndrome 2, 614326 (3);
13.235;3;23;09;13q31.3;MIR18A, MIRN18A;;Micro RNA 18A;609417;A, REc;within C13orf25;;
13.236;3;23;09;13q31.3;MIR19A, MIRN19A;;Micro RNA 19A;609418;A, REc;within C13orf25;;
13.237;3;23;09;13q31.3;MIR19B1, MIRN19B1;;Micro RNA 19B1;609419;A, REc;within C13orf25;;
13.238;3;23;09;13q31.3;MIR20A, MIRN20A;;Micro RNA 20A;609420;A, REc;within C13orf25;;
13.239;9;7;10;13q31.3;MIR92A1, MIR92-1, MIRN92-1;;Micro RNA 92A1;609422;A, REc;within C13orf25;;
13.240;9;28;05;13q31.3;PPR2;;Photoparoxysmal response 2;609572;Fd;max lod at D13S1230;Photoparoxysmal response 2 (2);
13.241;3;8;07;13q31.3-q32.1;MMVP3;;Mitral valve prolapse, myxomatous 3;610840;Fd;max lod at D13S132;Mitral valve prolapse, myxomatous 3 (2);
13.242;9;1;00;13q32.1;ABCC4, MRP4, MOATB;;ATP-binding cassette, subfamily C, member 4;605250;R, A;;;
13.243;12;23;05;13q32.3;CLYBL, CLB;;Citrate lyase beta-like;609686;R, REc;;;
13.244;2;4;15;13q32.1;DNAJC3, PRKRI, P58, ACPHD;;DnaJ, E. coli, homolog of, subfamily C, member 3 (protein kinase inhibitor p58);601184;A;mutation identified in 1 ACPHD family;?Ataxia, combined cerebellar and peripheral, with hearing loss and diabetes mellitus, 616192 (3);
13.245;6;15;99;13q31.3;GPC5;;Glypican 5;602446;A;;;
13.246;10;15;09;13q31.3-q32.1;GPC6, OMIMD1;;Glypican 6;604404;R, A;;Omodysplasia 1, 258315 (3);
13.247;6;18;98;13q32.3;GPR18;;G protein-coupled receptor-18;602042;A;;;14(Gpr18)
13.248;6;1;12;13q32;KTCN7;;Keratoconus 7;614629;Fd;max lod at D13S159;Keratoconus 7 (2);
13.249;5;19;15;13q32;MCOR, C13DELq32, DEL13q32;;Microcoria, congenital (chromosome 13q32 deletion syndrome);156600;Fd, Ch;35-80kb deletion encompassing TGDS and GPR180;Microcoria, congenital (4);
13.250;6;21;01;13q32.3;PCCA;;Propionyl Coenzyme A carboxylase, alpha polypeptide;232000;REa, D, A, Fd;;Propionicacidemia, 606054 (3);14(Pcca)
13.251;12;15;98;13q32;SCZD7;;Schizophrenia susceptibility locus, chromosome 13q-related;603176;Fd;;{Schizophrenia}, 181500 (2);
13.252;2;21;06;13q32;SLEB5;;Systemic lupus erythematosus, susceptibility to, 5;609903;Fd;max lod at D13S892;{Systemic lupus erythematosus, susceptibility to, 5} (2);
13.253;10;7;05;13q32.3;ZIC2, HPE5;;ZIC family, member 2;603073;Ch;;Holoprosencephaly 5, 609637 (3);
13.254;6;30;05;13q32.1;HS6ST3;;Heparan sulfate 6-O-sulfotransferase 3;609401;REc;;;
13.255;2;17;09;13q32-q33;STQTL4;;Stature quantitative trait locus 4;606258;Fd;max lod at D13S779 and D13S797;{Stature QTL 4} (2);
13.256;9;15;93;13q33.1;TPP2;;Tripeptidyl peptidase II;190470;REa, A;;;1(Tpp2)
13.257;8;4;99;13q33.3;TNFSF13B, BLYS, BAFF;;Tumor necrosis factor ligand superfamily, member 13B;603969;TM;;;
13.258;9;15;17;13q32.1;CLDN10, OSPL, CPETRL3, HELIX;;Claudin 10;617579;REc;;HELIX syndrome, 617671 (3);
13.259;10;27;08;13q32.1;GPR80;;G protein-coupled receptor 80;606922;REc;;;
13.260;2;13;15;13q32.1;TGDS, SDR2E1, CATMANS;;TDP-glucose 4,6-dehydratase;616146;REc;;Catel-Manzke syndrome, 616145 (3);
13.261;8;27;09;13q32.1;UGGT2, HUGT2;;UDP-glucose glycoprotein glucosyltransferase 2;605898;REc;;;
13.262;12;10;13;13q32.2;FARP1, CDEP;;FERM, ARHGEF, and pleckstrin domain-containing protein 1;602654;REc;;;
13.263;9;27;17;13q32.2;IPO5, RANBP5, KPNB3;;Importin 5;602008;REc;;;
13.264;4;26;10;13q32.3;A2LD1, GGACT;;AIG1-like domain-containing protein 1;613378;REc;;;
13.265;9;29;10;13q32.3;GPR183, EBI2;;G protein-coupled receptor 183;605741;R;;;
13.266;7;18;14;13q32.3;TM9SF2;;Transmembrane 9 superfamily, member 2;604678;REc;;;
13.267;11;27;18;13q32.3;TMTC4;;Transmembrane and tetratricopeptide repeat domains-containing protein 4;618203;REc;;;
13.268;3;5;18;13q32.3;ZIC5, OPR;;Zic family, member 5;617896;REc;;;
13.269;7;27;09;13q32.3;ZIZ1, KIAA1058;;Zizimin 1;607325;R, REc;;;
13.270;9;28;15;13q33.1;ERCC5, XPG, COFS3;;Excision-repair, complementing defective, in Chinese hamster, number 5;133530;S, A;;Xeroderma pigmentosum, group G, 278780 (3); Xeroderma pigmentosum, group G/Cockayne syndrome, 278780 (3); Cerebrooculofacioskeletal syndrome 3, 616570 (3);1(Ercc5)
13.271;11;5;97;13q33.3;EFNB2, EPLG5, LERK5, HTKL;;eph-related receptor tyrosine kinase ligand 5 (ephrin-B2);600527;A;;;8(Lerk5)
13.272;10;21;99;13q33.1;ITGBL1, TIED;;Integrin, beta-like 1;604234;A;;;
13.273;2;18;08;13q33.1;KDELC1, EP58;;KDEL motif-containing 1;611613;REc;;;
13.274;3;16;10;13q33.1;SLC10A2, NTCP2, PBAM;;Solute carrier family 10 (sodium/bile acid cotransporter family), member 2;601295;REa, A;;Bile acid malabsorption, primary, 613291 (3);8(Slc10a2)
13.275;8;21;98;13q32.2-q32.3;SLC15A1, HPECT1;;Solute carrier family 15 (oligopeptide transporter), member 1;600544;REa, A;;;
13.276;6;4;13;13q33.1;METTL21C, C13orf39;;Methyltransferase-like 21C;615259;REc;;;
13.277;2;11;16;13q32.3-q33.1;NALCN, IHPRF1, CLIFAHDD;;Sodium leak channel, nonselective;611549;R, REc;;Hypotonia, infantile, with psychomotor retardation and characteristic facies 1, 615419 (3); Congenital contractures of the limbs and face, hypotonia, and developmental delay, 616266 (3);
13.278;4;22;10;13q33.1-q34;OFC9;;Orofacial cleft 9;610361;Fd;associated with rs1830756;Orofacial cleft 9 (2);
13.279;11;3;11;13q33.2;VUR5;;Vesicoureteral reflux 5;614318;Fd;nearest marker rs4476030;Vesicoureteral reflux 5 (2);
13.280;9;8;11;13q33.3;ARGLU1;;Arginine- and glutamate-rich protein 1;614046;REc;;;
13.281;11;13;13;13q33.3;MYO16, MYAP3, KIAA0865;;Myosin XVI;615479;REc, R;;;
13.282;7;17;14;13q33.3;LIG4, LIG4S;;Ligase IV, DNA, ATP-dependent;601837;A;;LIG4 syndrome, 606593 (3); {Multiple myeloma, resistance to}, 254500 (3);
13.283;7;27;09;13q34;ARHGEF7, PIXB, COOL1;;Rho guanine nucleotide exchange factor 7 (PAK-interacting exchange factor, beta);605477;R, REc;;;
13.284;1;23;93;13q34;ATP4B;;ATPase, H+, K+ transporting, beta;137217;A;;;
13.285;7;27;09;13q34;ATP11A, ATPIS, ATPIH;;ATPase, class VI, type 11A;605868;REc;;;
13.286;8;18;14;13q34;CARKD;;Carbohydrate kinase domain-containing protein;615910;REc;;;
13.287;12;3;15;13q34;CARS2, COXPD27;;Cysteinyl-tRNA synthetase 2;612800;R, REc;;Combined oxidative phosphorylation deficiency 27, 616672 (3);
13.288;8;8;13;13q34;CDC16, APC6;;Cell division cycle 16, S. cerevisiae, homolog of;603461;REc;;;
13.289;9;29;15;13q34;CHAMP1, ZNF828, C13orf8, KIAA1802, MRD40;;Chromosome alignment-maintaining phosphoprotein 1;616327;REc;;Mental retardation, autosomal dominant 40, 616579 (3);
13.290;9;28;17;13q34;COL4A1, POREN1, HANAC, ICH, BSVD, RATOR;;Collagen IV, alpha-1 polypeptide;120130;REa, A, REb, RE, Fd;mutation identified in 1 RATOR family;Porencephaly 1, 175780 (3); Brain small vessel disease with or without ocular anomalies, 607595 (3); Angiopathy, hereditary, with nephropathy, aneurysms, and muscle cramps, 611773 (3); {Hemorrhage, intracerebral, susceptibility to}, 614519 (3); ?Retinal arteries, tortuosity of, 180000 (3); Schizencephaly, 269160 (3);8(Col4a1)
13.291;3;18;13;13q34;COL4A2, POREN2, ICH;;Collagen IV, alpha-2 polypeptide;120090;REa, A, RE, Fd;;Porencephaly 2, 614483 (3); {Hemorrhage, intracerebral, susceptibility to}, 614519 (3);8(Col4a2)
13.292;10;29;09;13q34;CUL4A;;Cullin 4A;603137;Psh, A;;;
13.293;5;19;09;13q33.2;DAOA, G72;;D-amino acid oxidase activator;607408;Fd;;{Schizophrenia}, 181500 (2);
13.294;1;27;11;13q33.2;DAOAAS, G30;;DAOA antisense RAN;607415;REn;;;
13.295;9;15;11;13q34;DFNA33;;Deafness, autosomal dominant 33;614211;Fd;maximum lod at D13S285;Deafness, autosomal dominant 33 (2);
13.296;4;15;11;13q34;F7;;Coagulation factor VII;613878;D;;Factor VII deficiency, 227500 (3); {Myocardial infarction, decreased susceptibility to}, 608446 (3);
13.297;10;23;87;13q34;F10;;Coagulation factor X;613872;D, A, REa;;Factor X deficiency, 227600 (3);8(Cf10)
13.298;8;9;05;13q33.1;FGF14, FHF4, SCA27;;Fibroblast growth factor-14;601515;REa, H, Fd;;Spinocerebellar ataxia 27, 609307 (3);14(Fhf4)
13.299;2;15;96;13q34;GAS6, AXLLG, AXSF;;Growth arrest-specific 6;600441;A;;;8(Gas6)
13.300;4;2;07;13q34;GRK1, RHOK, RK;;G protein-dependent receptor kinase 1 (rhodopsin kinase);180381;REa, A;;Oguchi disease-2, 613411 (3);
13.301;11;16;05;13q34;ING1;;Inhibitor of growth 1;601566;A, R;;Squamous cell carcinoma, head and neck, somatic, 275355 (3);
13.302;2;5;01;13q34;IRS2;;Insulin receptor substrate 2;600797;R, REc;;{Diabetes mellitus, noninsulin-dependent}, 125853 (3);
13.303;2;9;92;13q34;LAMP1;;Lysosome-associated membrane protein-1;153330;A, REa;;;8(Lamp1)
13.304;9;26;11;13q34;MCF2L, OST, KIAA0362;;MCF2-like protein;609499;R, REc;;;
13.305;1;31;11;13q34;PCID2;;PCI domain-containing protein 2;613713;REc;;;
13.306;4;10;15;13q34;PROZ, PZ;;Protein Z;176895;REc;;[Protein Z deficiency], 614024 (3);
13.307;7;17;91;13q32.1;RAP2A;;RAP2, member of RAS oncogene family (K-rev);179540;A;;;
13.308;7;27;09;13q34;RASA3;;Ras p21 protein activator 3;605182;R, REc;;;
13.309;6;9;98;13q34;SOX1;;SRY (sex determining region Y)-box 1;602148;A;;;
13.310;11;1;99;13q34;TFDP1, DP1, DRTF1;;Transcription factor Dp-1;189902;A;pseudogene on 1q32.3;;
13.311;9;29;16;13q34;TMCO3, C13orf11;;Transmembrane and coiled-coil domains protein 3;617134;REc;;;
13.312;12;22;17;13q34;TUBGCP3, GCP3, GRIP104, SPC98, ALP6;;Tubulin-gamma complex-associated protein 3;617818;REc;;;
13.313;2;1;11;13q34;UPF3A, RENT3A;;UPF3 regulator of nonsense transcripts, yeast, homolog of, A;605530;REc;;;
14.1;4;26;90;14p12;RNR2;;Ribosomal RNA-2;180451;A;;;
14.2;2;17;09;14p11.2-q13;ADIPQTL3, CAQ14;;Adiponectin, serum level of, quantitative trait locus 3;606771;Fd;between D14S608 and D14S599;{Adiponectin, serum level of, QTL3} (2);
14.3;1;31;01;14q12;ADAP6, ADAP100;;A-kinase anchor protein 6;604691;R, REc;;;
14.4;8;14;15;14q32.12;GOLGA5, RFG5;;Golgi autoantigen, golgin subfamily A, 5;606918;REc;fused with RET to form PTC5;;
14.5;11;16;18;14q23.2-q23.3;ESR2, ODG8;;Estrogen receptor-2 (ER beta);601663;REa, R;mutation identified in 1 ODG8 patient;?Ovarian dysgenesis 8, 618187 (3);
14.6;6;2;98;14q21.1;MGEA, MEA6;;Meningioma-expressed antigen 6;602132;A;?pseudogenes on other chromosomes;;
14.7;8;18;14;14q21.3;RPS29, DBA13;;Ribosomal protein S29;603633;R,;;Diamond-Blackfan anemia 13, 615909 (3);
14.8;7;7;17;14q32.2;YY1, GADEVS;;YY1 transcription factor;600013;REa, H;;Gabriele-de Vries syndrome, 617557 (3);12(Yy1)
14.9;3;30;11;14q11.2;RPGRIP1, LCA6, CORD13;;Retinitis pigmentosa GTPase regulator-interacting protein;605446;R, REa;;Leber congenital amaurosis 6, 613826 (3); Cone-rod dystrophy 13, 608194 (3);
14.10;9;2;09;14q11.2;TRNAP1, TRP1;;tRNA proline-1;189930;REa, A, Fd;;;
14.11;1;16;18;14q11;ZFHX2AS1;;ZFHX2 antisense RNA 1;617833;REc, H;;;14(Zfhx2as1)
14.12;6;26;00;14q11.2;ZNF219;;Zinc finger protein-219;605036;REc;;;
14.13;01;04;19;14q11.2;PRMT5, SKB1, IBP72, JBP1, HSL7;;Protein arginine methyltransferase 5;604045;REc, A;;;
14.14;5;6;09;14q11.2;DAD1;;Defender against cell death 1;600243;A;;;14(Dad1)
14.15;2;21;02;14q11-q12;IBD4;;Inflammatory bowel disease 4;606675;Fd;;{Inflammatory bowel disease 4} (2);
14.16;10;7;13;14q11.2;MMP14, WNCHRS;;Matrix metalloproteinase 14 (membrane-inserted);600754;A;mutation identified in 1 family;?Winchester syndrome, 277950 (3);
14.17;3;28;15;14q11.2;TRL-AAG2-1, TRNAL1, TRL1;;tRNA leucine (AAG) 2-1;189932;REa, A, Fd;;;
14.18;9;2;09;14q11.2;TRNAP2, TRP2;;tRNA proline-2;189931;REa, A, Fd;;;
14.19;9;2;09;14q11.2;TRNAT2, TRT2;;tRNA threonine-2;189933;REa, A, Fd;;;
14.20;4;27;12;14q22.1;ATL1, SPG3A, HSN1D;;Atlastin GTPase 1;606439;REc, Fd;;Spastic paraplegia 3A, autosomal dominant, 182600 (3); Neuropathy, hereditary sensory, type ID, 613708 (3);
14.21;1;21;07;14q12;GMPR2;;Guanosine monophosphate reductase 2;610781;REc;;;
14.22;9;29;10;14q11-q22;DEL14q11q22, C14DELq11q22;;Chromosome 14q11-q22 deletion syndrome;613457;Ch;contiguous gene syndrome;Chromosome 14q11-q22 deletion syndrome (4);
14.23;1;27;04;14q11.2;C14orf18, HEI10;;Human enhancer of invasion 10;608249;REc;;;
14.24;12;17;08;14q11.2;METTL3, IME4;;Methyltransferase-like 3;612472;R, REc;;;
14.25;3;7;05;14q11-q12;NRL, D14S46E, RP27;;Neural retina leucine zipper;162080;REa, A, Fd;;Retinitis pigmentosa 27, 613750 (3); Retinal degeneration, autosomal recessive, clumped pigment type (3);14(Nrl)
14.26;1;14;03;14q11.2;RAB2B;;Ras-associated protein RAB2B;607466;REc;;;
14.27;9;8;14;14q11.2;SALL2, HSAL2, COLB;;Sal-like 2;602219;A;mutation identified in 1 COLB family;?Coloboma, ocular, autosomal recessive, 216820 (3);
14.28;4;30;12;14q11.2;ACIN1, KIAA0670;;Acinus;604562;R, REc;;;
14.29;5;16;95;14q12;ADCY4;;Adenylate cyclase-4;600292;REa;;;14(Adcy4)
14.30;11;27;18;14q11.2;AP1G2;;Adaptor-related protein complex 1, gamma-2 subunit;603534;REc;;;
14.31;12;18;08;14q11.2;ANG, RNASE5, ALS9;;Angiogenin;105850;A, REa, Fd, REn;proximal to TCRA/TCRD;Amyotrophic lateral sclerosis 9, 611895 (3);14(Ang)
14.32;5;27;05;14q11.2;CEBPE, CRP1;;CCAAT/enhancer-binding protein (C/EBP), epsilon;600749;H, A;;Specific granule deficiency, 245480 (3);14(Cebpe)
14.33;1;24;13;14q11.2;CHD8, DUPLIN, KIAA1564, AUTS18;;Chromodomain helicase DNA-binding protein 8;610528;R, REc;;{Autism, susceptibility to, 18}, 615032 (3);
14.34;1;21;00;14q12;CMA1;;Chymase-1, mast cell;118938;REa, REn;;;
14.35;12;5;11;14q11.2;CMTM5, CKLFSF5;;CKLF-like marvel transmembrane domain-containing 5;607888;REc;;;14(Cklfsf5)
14.36;2;28;01;14q11.2;CPNE6;;Copine VI;605688;R, REc;;;
14.37;4;25;93;14q12;CTSG;;Cathepsin G;116830;A, REn;;;
14.38;3;29;10;14q12;DCAF11, WDR23;;DDB1- and CUL4-associated factor 11;613317;REc;;;
14.39;5;6;13;14q11.2;DHRS2, HEP27;;Short-chain dehydrogenase/reductase family, member 2;615194;A, REc;;;
14.40;2;23;08;14q11.2;DHRS4, NRDR;;Short-chain dehydrogenase/reductase family, member 4;611596;REc;;;
14.41;4;27;16;14q11.2;DHRS4AS1, AS1DHRS4, C14orf67;;DDHRS4 antisense RNA 1, noncoding;616925;REc;;;
14.42;5;6;13;14q11.2;DHRS4L1;;Short-chain dehydrogenase/reductase family, member 4-like 1;615195;REc;;;
14.43;5;6;13;14q11.2;DHRS4L2;;Short-chain dehydrogenase/reductase family, member 4-like 2;615196;REc;;;
14.44;4;12;18;14q11.2;EDDM3A, FAM12A, HE3A;;Epididymal protein 3A;611580;R, REc;;;
14.45;12;7;07;14q11.2;FAM12B, HE3B;;Family with sequence similarity 12, member B;611582;REc;;;
14.46;8;21;98;14q12;GZMB, CTLA1, CSPB;;Granzyme B (cytotoxic T-lymphocyte-associated serine esterase-1; cathepsin G-like 1);123910;A, REa, RE;;;14(Ctla1)
14.47;8;20;98;14q12;GZMH, CTSGL2;;Granzyme H (cathepsin G-like 2);116831;A, REn;;;
14.48;9;7;10;14q11.2;HAUS4, C14orf94;;HAUS augmin-like complex, subunit 4;613431;REc;;;
14.49;6;1;12;14q11.2;HNRNPC, HNRPC;;Heterogeneous nuclear ribonucleoprotein C;164020;R, REc;;;
14.50;11;11;14;14q11.2;HOMEZ, KIAA1443;;Homeodomain leucine zipper-containing factor;608119;REc, H;;;14(Homez)
14.51;2;2;07;14q11.2;IL25, IL17E;;Interleukin 25;605658;REc;;;
14.52;6;22;99;14q12;ISGF3, ISGF3G;;Interferon-stimulated gene transcription factor 3, gamma, 48kD;147574;RE;;;
14.53;3;1;06;14q11.2;LRP10, LRP9;;Low density lipoprotein receptor-related protein 10;609921;R, H;;;14(Lrp10)
14.54;7;18;12;14q11.2;LRRC16B;;Leucine-rich repeat-containing protein 16B;614716;REc;;;
14.55;11;24;14;14q11.2;METTL17, METT11D1;;Methyltransferase-like 17;616091;REc;;;
14.56;11;24;14;14q11.2;MHRT;;Myosin heavy chain-associated RNA transcript, noncoding;616096;REc, H;;;14(Mhrt)
14.57;1;27;11;14q11.2;MIR208B, MIRN208B;;Micro RNA 208B;613613;REc;;;14(Mir208b)
14.58;3;5;08;14q11.2;MRPL52;;Mitochondrial ribosomal protein L52;611856;R, REc;;;
14.59;9;19;00;14q11.2;NDRG2;;N-myc downstream-regulated gene 2;605272;R;;;
14.60;2;20;07;14q11.2;NGDN, NGD;;Neuroguidin;610777;R, REc;;;
14.61;7;13;09;14q11.2;NRCLP5;;Narcolepsy 5;612851;Fd;associated with rs1154155, rs12587781, rs1263646;{Narcolepsy 5} (2);
14.62;2;15;96;14q11.2;OXA1L;;Oxidase (cytochrome c) assembly 1-like;601066;A;;;
14.63;4;19;06;14q11.2;PARP2, ADPRTL2, ADPRT2;;Poly(ADP-ribose) polymerase 2;607725;R, A;;;14(Adprtl2)
14.64;6;19;98;14q11.2;PSMB5, LMPX;;Proteasome subunit, beta type, 5;600306;REn;;;
14.65;9;10;07;14q11.2;PSMB11;;Proteasome subunit, beta-type, 11;611137;REc;;;
14.66;6;19;98;14q12;PSME1, IFI5111;;Proteasome activator subunit-1;600654;A;;;
14.67;6;19;98;14q12;PSME2;;Proteasome activator subunit-2;602161;A;;;
14.68;3;2;98;14q12;RABGGTA;;Rab geranylgeranyltransferase, alpha subunit;601905;REa, A;;;
14.69;6;2;16;14q11.2;REM2;;RRAD- and GEM-like GTPase 2;616955;REc;;;
14.70;8;27;01;14q12;RIPK3, RIP3;;Receptor-interacting serine/threonine kinase 3;605817;A;;;
14.71;12;18;08;14q11.2;RNASE1, RNS1;;Ribonuclease, RNase A family, 1 (pancreatic);180440;H, REn;;;14(Rib1)
14.72;12;18;08;14q11.2;RNASE2, RNS2, EDN;;Ribonuclease, RNase A family, 2, liver (eosinophil-derived neurotoxin);131410;REa, A, REn;;;
14.73;12;18;08;14q11.2;RNASE3, RNS3, ECP;;Ribonuclease, RNase A family, 3 (eosinophil cationic protein);131398;REa, A, REn;;;
14.74;12;18;08;14q11.2;RNASE4, RNS4;;Ribonuclease, RNase A family, 4;601030;Psh, REn;;;
14.75;12;18;08;14q11.2;RNASE6;;Ribonuclease, RNase A family, k6;601981;Psh, REn;;;
14.76;12;24;08;14q11.2;RNASE7;;Ribonuclease A family 7;612484;REc;;;
14.77;12;18;08;14q11.2;RNASE8;;Ribonuclease A family, 8;612485;REn;;;
14.78;9;8;11;14q11.2;RNAE9;;Ribonuclease A family, 9;614014;REc;;;
14.79;12;24;08;14q12;RNF31, ZIBRA;;Ring finger protein 31;612487;REc;;;
14.80;9;23;13;14q11.2;RPPH1, H1RNA;;Ribonuclease P, RNA component H1;608513;REc;;;
14.81;12;8;00;14q11.2;RSCIS;;Radiation sensitivity/chromosome instability syndrome, autosomal dominant;605463;Ch;;Radiation sensitivity/chromosome instability syndrome, autosomal dominant (1);
14.82;3;10;99;14q11.2;SLC7A7, LPI;;Solute carrier family 7 (cationic amino acid transporter, y+ system), member 7;603593;A, Fd, LD;;Lysinuric protein intolerance, 222700 (3);
14.83;10;22;99;14q11.2;SLC7A8, LAT2;;Solute carrier family 7 (cationic amino acid transporter, y+ system), member 8;604235;R;;;
14.84;10;13;09;14q11.2;SLC22A17, NGALR, BOIT, BOCT, NGALR2, NGALR3;;Solute carrier family 22, organic cation transporter, member 17;611461;R, REc;;;
14.85;2;26;03;14q13.3;SLC25A21, ODC;;Solute carrier family 25 (mitochondrial oxodicarboxylate carrier), member 21;607571;A;;;
14.86;7;31;08;14q11.2;SLC39A2, ZIP2;;Solute carrier family 39 (zinc transporter), member 2;612166;R, REc;;;
14.87;4;25;06;14q11.2;SOLO, FLJ10357;;SOLO gene;610018;REc;;;
14.88;2;25;15;14q11.2;SUPT16H, SPT16;;Suppressor of ty 16, S. cerevisiae, homolog of;605012;REc;;;
14.89;10;15;13;14q11.2;TRAC, TRCA, TRA, IMD7;;T-cell receptor alpha;186880;H, REa, A, REn;cen--V-C--ter;Immunodeficiency 7, TCR-alpha/beta deficient, 615387 (3);14(Tcra)
14.90;10;15;13;14q11.2;TRDC;;T-cell receptor delta chain constant region;186810;RE, Ch, REc;in midst of TCRA;;14(Tcrd)
14.91;10;15;13;14q11.2;TRDD@;;T-cell receptor delta chain diversity gene cluster;615460;REc;;;
14.92;10;15;13;14q11.2;TRDV@;;T-cell receptor delta chain variable gene cluster;615459;REc;;;
14.93;10;15;13;14q11.2;TRDJ@;;T-cell receptor delta chain joining gene cluster;615461;REc;;;
14.94;5;28;98;14q11.2;TEP1, TP1;;Telomerase-associated protein-1;601686;A, H;;;14(Tep1)
14.95;1;18;13;14q12;TGM1, ICR2, ARCI1;;Transglutaminase-1 (K polypeptide epidermal type I, protein-glutamine gamma-glutamyltransferase);190195;REa, A, Fd;;Ichthyosis, congenital, autosomal recessive 1, 242300 (3);
14.96;2;18;08;14q11.2;THTPA;;Thiamine triphosphatase;611612;REc;;;
14.97;6;8;11;14q11.2;TOX4, LCP1, KIAA0737;;TOX high mobility group box family member 4;614032;R, REc;;;
14.98;6;2;16;14q11.2;TPPP2, p18;;Tubulin polymerization-promoting protein family, member 2;616956;REc;;;
14.99;10;15;13;14q11.2;TRAJ@;;T-cell receptor alpha chain joining gene cluster;615443;REc, Ch;;;
14.100;10;15;13;14q11.2;TRAV@;;T-cell receptor alpha chain variable gene cluster;615442;REn, Ch;;;
14.101;1;22;07;14q12;TSSK4, TSSK5;;Testis-specific serine/threonine kinase 4;610711;REc;;;
14.102;1;16;18;14q11.2;ZFHX2, ZFH5, ZNF409, KIAA1056, KIAA1762, MARSIS;;Zinc finger homeobox 2;617828;REc;mutation identified in 1 MARSIS family;?Marsili syndrome, 147430 (3);
14.103;3;3;98;14q11.2;BCL2L2, BCLW;;BCL2-like 2;601931;A;;;
14.104;3;16;06;14q11.2-q12;DFNA53;;Deafness, autosomal dominant 53;609965;Fd;max lod at D14S1280;Deafness, autosomal dominant 53 (2);
14.105;3;16;06;14q11.2;EFS;;Embryonal FYN-associated substrate;609906;A;;;
14.106;10;15;98;14q12;LTB4R, CMKRL1, P2RY7, BLTR;;Leukotriene b4 receptor (purinergic receptor P2Y, G protein-coupled, 7; chemokine receptor-like 1);601531;A;;;
14.107;8;27;01;14q12;LTB4R2, BLTR2, BLT2;;Leukotriene B4 receptor 2;605773;REc;;;
14.108;12;20;11;14q11.2-q12;MRT9, MRT26;;Mental retardation, autosomal recessive, 9/26;611095;Fd;between rs1998463 and rs243286;Mental retardation, autosomal recessive, 9/26 (2);
14.109;5;24;13;14q11.2-q12;PAURT1;;Preauricular tag, isolated, autosomal dominant, 1;610420;Fd;between D14S990 and D14S264;Preauricular tag, isolated, autosomal dominant, 1 (2);
14.110;7;11;11;14q11-q12;PCK2, PEPCK2;;Phosphoenolpyruvate carboxykinase 2, mitochondrial;614095;A;;PEPCK deficiency, mitochondrial, 261650 (1);
14.111;10;31;17;14q11.2;OSGEP, FLJ20411, GAMOS3;;O-sialoglycoprotein endopeptidase;610107;REc;;Galloway-Mowat syndrome 3, 617729 (3);
14.112;10;29;03;14q12;REC8L1, REC8;;Rec8, S. pombe, homolog of;608193;A;;;
14.113;1;30;12;14q11.2-q13;HHPP;;Hyperhidrosis palmaris et plantaris;144110;Fd;between D14S283 and D14S264;Hyperhidrosis palmaris et plantaris (2);
14.114;11;16;05;14q11.2;PABPN1, PABP2, PAB2;;Poly(A)-binding protein, nuclear 1;602279;REc, Fd;;Oculopharyngeal muscular dystrophy, 164300 (3);
14.115;7;19;06;14q11.2-q12;SPD3;;Synpolydactyly 3;610234;Fd;max lod at D14S264;Synpolydactyly 3 (2);
14.116;4;27;12;14q12;AP4S1, CPSQ6, SPG52;;Adaptor-related protein complex 4, sigma-1 subunit;607243;R, REc;;Spastic paraplegia 52, autosomal recessive, 614067 (3);
14.117;6;24;94;14q11.2;APEX, APE;;APEX nuclease (multifunctional DNA repair enzyme);107748;Psh, A;;;14(Apex)
14.118;3;14;07;14q12;ARHGAP5, RHOGAP5;;RHO GTPase-activating protein 5;602680;R, REc;;;
14.119;9;9;09;14q12;CBLN3;;Precerebellin 3;612978;REc;;;14(Cbln3)
14.120;8;2;13;14q13.1;CFL2, NEM7;;Cofilin 2, muscle;601443;Psh, REc;;Nemaline myopathy 7, autosomal recessive, 610687 (3);
14.121;3;29;07;14q12;CHMP4A, SNF7;;CHMP family, member 4A;610051;R, REc;;;
14.122;01;04;19;14q12;CIDEB;;Cell death-inducing DFFA-like effector B;604441;REc;;;
14.123;12;3;96;14q12;DFNB5;;Deafness, autosomal recessive 5;600792;Fd;;Deafness, autosomal recessive 5 (2);
14.124;2;16;18;14q12;FITM1, FIT1;;Fat storage-inducing transmembrane protein 1;612028;R, REc;;;
14.125;5;24;13;14q12;G2E3, KIAA1333;;G2/M phase-specific E3 ubiquitin ligase;611299;REc;;;
14.126;2;25;14;14q12;GPR33;;G protein-coupled receptor 33;610118;REc, A;;;
14.127;1;27;11;14q11.2;MIR208A, MIRN208A, MIR208, MIRN208;;Micro RNA 208A;611116;REc;;;
14.128;7;22;11;14q11.2;MYH6, ASD3, MYHCA, CMD1EE, CMH14, SSS3;;Myosin, heavy polypeptide-6, cardiac muscle, alpha;160710;REa, RE, D, A, Fd;;Cardiomyopathy, hypertrophic, 14, 613251 (3); Atrial septal defect 3, 614089 (3); Cardiomyopathy, dilated, 1EE, 613252 (3); {Sick sinus syndrome 3}, 614090 (3);14(Myhca)
14.129;6;9;15;14q11.2;MYH7, CMH1, MPD1, CMD1S, SPMM, SPMD;;Myosin, heavy polypeptide-7, cardiac muscle, beta;160760;REa, RE, D, A;5'-B-4.5kb-A-3';Cardiomyopathy, hypertrophic, 1, 192600 (3); Cardiomyopathy, dilated, 1S, 613426 (3); Myopathy, myosin storage, autosomal dominant, 608358 (3); Laing distal myopathy, 160500 (3); Scapuloperoneal syndrome, myopathic type, 181430 (3); Left ventricular noncompaction 5, 613426 (3); Myopathy, myosin storage, autosomal recessive, 255160 (3);
14.130;6;13;12;14q12;NEDD8;;Neural precursor cel expressed, developmentally downregulated 8;603171;REc;;;
14.131;12;13;18;14q12;NUBPL, IND1, MC1DN21;;Nucleotide-binding protein-like protein;613621;REc;;Mitochondrial complex I deficiency, nuclear type 21, 618242 (3);
14.132;2;24;17;14q12;PRKD1, PRKCM, PKD, CHDED;;Protein kinase D1;605435;REa, R, REc;;Congenital heart defects and ectodermal dysplasia, 617364 (3);
14.133;12;11;18;14q12;SCFD1, SLY1, RA410;;Sec1 family domain-containing protein 1;618207;REc;;;
14.134;12;30;14;14q12;SDR39U1;;Short-chain dehydrogenase/reductase family 39U, member 1;616162;REc;;;
14.135;8;21;12;14q12;STRN3, SG2NA;;Striatin, calmodulin-binding protein 3;614766;REc, A;;;
14.136;11;18;11;14q12;STXBP6, AMISYN, HSPC156;;Syntaxin-binding protein 6;607958;R, REc;;;
14.137;12;24;11;14q12;TINF2, TIN2, DKCA3;;TRF1-interacting nuclear factor 2;604319;REc;;Dyskeratosis congenita, autosomal dominant 3, 613990 (3); Revesz syndrome, 268130 (3);
14.138;5;29;13;1p34.3;ZMYM6, ZNF258;;Zinc finger, MYM-type 6;613567;A;;;
14.139;2;28;01;14q13.1-q13.2;BAZ1A;;Bromodomain adjacent to zinc finger domain, 1A;605680;REa, R;;;
14.140;08;27;18;14q12;COCH, DFNA9, DFNB110;;Cochlin;603196;Fd, A;mutation identified in 1 DFNB110 family;Deafness, autosomal dominant 9, 601369 (3); ?Deafness, autosomal recessive 110, 618094 (3);12(Coch5B2)
14.141;2;11;08;14q13.3;NKX2-8, NKX2H, NKX2.8;;NK2 homeobox 8;603245;REn, H;;;12(Nkx2-9)
14.142;4;24;09;14q13.3;PAX9, STHAG3;;Paired box gene 9;167416;REa, A;;Tooth agenesis, selective, 3, 604625 (3);
14.143;4;27;12;14q12-q21;SPG32;;Spastic paraplegia-32;611252;Fd;between D14S264 and D14S978;Spastic paraplegia 32, autosomal recessive (2);
14.144;10;27;97;14q12-q22;ARVD3;;Arrhythmogenic right ventricular dysplasia 3;602086;Fd;?distinct from ARVD1;Arrhythmogenic right ventricular dysplasia 3 (2);
14.145;1;2;03;14q21.1;FOXA1, HNF3A;;Forkhead box A1 (hepatocyte nuclear factor-3, alpha);602294;A, D;;;12(Hnf3a)
14.146;7;22;11;14q12;FOXG1, FOXG1B, FKHL1, FKH2, QIN, BF1;;Forkhead box G1B;164874;REa, A;;Rett syndrome, congenital variant, 613454 (3);
14.147;3;1;07;14q13;HPE8;;Holoprosencephaly 8;609408;Fd;between D14S49 and D14S1014;Holoprosencephaly 8 (2);
14.148;3;14;06;14q13.2;KIAA0391;;KIAA0391 gene;609947;R, REc;;;
14.149;11;6;14;14q13.3-q21.1;MIPOL1;;MIPOL1 gene;606850;Ch;;;
14.150;11;14;18;14q13.2;NFKBIA, IKBA, EDAID2;;Nuclear factor of kappa light chain gene enhancer in B-cells inhibitor, alpha;164008;A;;Ectodermal dysplasia and immunodeficiency, 612132 (3);12(ikba)
14.151;9;1;15;14q13.3;NKX2-1, TITF1, NKX2A, TTF1, NMTC1;;NK2 homeobox 1;600635;A;;{Thyroid cancer, nonmedullary, 1}, 188550 (3); Chorea, hereditary benign, 118700 (3); Choreoathetosis, hypothyroidism, and neonatal respiratory distress, 610978 (3);
14.152;9;8;17;14q12;NOVA1;;NOVA alternative splicing regulator 1;602157;H, REc;;;12(Nova1)
14.153;3;24;06;14q13.1;NPAS3, MOP6;;Neuronal PAS domain protein 3;609430;REc, H;;;12(Npas3)
14.154;11;2;11;14q13.2;PSMA6, PROS27, P27K;;Proteasome subunit, alpha-type, 6;602855;A;;{Myocardial infarction, susceptibility to}, 608446 (3);
14.155;4;25;93;14q21.1;SSTR1;;Somatostatin receptor-1;182451;REa;;;12(Sstr1)
14.156;5;23;00;14q21.3;POLE2, DPE2;;Polymerase, DNA, epsilon-2;602670;REa, A;;;
14.157;8;25;04;14q13-q21;RLS2;;Restless legs syndrome, susceptibility to, 2;608831;Fd;max lod at D14S288;{Restless legs syndrome 2} (2);
14.158;9;11;02;14q22.1;WW45, SAV;;WW domain-containing protein, 45kD;607203;R;;;
14.159;4;27;12;14q13.1;EGLN3, PHD3, HIFP4H3;;Egl9, C. elegans, homolog of, 3;606426;REc;;;
14.160;12;17;09;14q11.2;PNP, NP;;Purine nucleoside phosphorylase;164050;S, D;centromeric to TCRA;Immunodeficiency due to purine nucleoside phosphorylase deficiency, 613179 (3);14(Np1,2)
14.161;12;10;12;14q13.1;SNX6;;Sorting nexin 6;606098;R, REc;;;
14.162;9;8;11;14q13.2;INSM2, IA6;;Insulinoma-associated 2;614027;REc;;;
14.163;9;10;12;14q13.1;SPTSSA, C14orf147, SSSPTA;;Serine palmitoyltransferase, small subunit, A;613540;REc;;;
14.164;8;19;14;14q13.2;PPP2RC2, G5PR;;Protein phosphatase 2, regulatory subunit B-double prime, gamma;615902;REc;;;
14.165;7;9;06;14q13.2;SRP54;;Signal recognition particle, 54kD;604857;R;;;
14.166;6;22;10;14q13.2;RALGAPA1, GARNL1, TULIP1, GRIPE, KIAA0884;;Ral GTPase activating protein, alpha subunit 1 (catalytic);608884;Psh, A;pseudogene on 9q31.1;;12(Garnl1)
14.167;2;4;09;14q21.1;FBXO33, FBX33, BMND12;;F-box only protein 33;609103;REc;;;12(Fbxo33)
14.168;6;30;05;14q13.3;MBIP;;MAP3K12-binding inhibitory protein;609431;R, REc;;;
14.169;9;14;12;14q13.3;PTCSC3;;PTCSC3 gene;614821;REc;;;
14.170;1;3;18;14q13.3;SFTA3, SPH;;Surfactant-associated protein 3;617860;REc;;;
14.171;2;1;11;14q13.3-q21.1;HPV6AI1;;Human papillomavirus type 6A integration site 1;604461;REc;previously assigned to 10q24;;
14.172;5;28;02;14q22.1;GNG2;;Guanine nucleotide-binding protein, gamma-2;606981;Psh, A;;;14(Gng2)
14.173;9;10;07;14q21.3;MDGA2;;MAM domain-containing glycosylphosphatidylinositol anchor 2;611128;REc, H;;;12(Mdga2)
14.174;4;16;10;14q21.3;MGAT2, CDGS2, CDG2A;;Mannosyl (alpha-1,6-)-glycoprotein beta-1,2-N-acetylglucosaminyl- transferase;602616;A;;Congenital disorder of glycosylation, type IIa, 212066 (3);
14.175;9;2;12;14q22.3;PELI2;;Pellino, Drosophila, homolog of, 2;614798;REc;;;
14.176;9;24;15;14q21.3;SOS2, NS9;;Son of sevenless, Drosophila, homolog of, 2;601247;A;;Noonan syndrome 9, 616559 (3);12(Sos2)
14.177;12;4;02;14q23.1;TIMM9, TIM9;;Translocase of inner mitochondrial membrane 9, yeast, homolog of;607384;REc, A, R;;;
14.178;10;15;97;14q22.3;LGALS3, MAC2, GALBP;;Lectin, galactose-binding, soluble, 3;153619;A;assigned earlier to 1p13;;
14.179;9;4;98;14q23.1;RTN1, NSP;;Reticulon 1 (neuroendocrine-specific protein);600865;A;;;
14.180;6;15;99;14q23.2;HIF1A, MOP1;;Hypoxia-inducible factor 1, alpha subunit;603348;A,;;;12(Hif1a)
14.181;12;27;01;14q22.1;TRIM9, SPRING, KIAA0282;;Tripartite motif-containing protein 9;606555;R;;;
14.182;3;3;16;14q21.1;CLEC14A;;C-type lectin domain family 14, member A;616845;REc;;;
14.183;9;30;15;14q21.1;GEMIN2, SIP1;;GEM-associated protein 2;602595;A;;;
14.184;11;1;06;14q21.1;SEC23A, CLSD;;Sec23, S. cerevisiae, homolog of, A;610511;R, Fd;;Craniolenticulosutural dysplasia, 607812 (3);
14.185;2;16;18;14q21.1;TRAPPC6B, TPC6, NEDMEBA;;Trafficking protein particle complex, subunit 6B;610397;REc, R;;Neurodevelopmental disorder with microcephaly, epilepsy, and brain atrophy, 617862 (3);12(Trappc6b)
14.186;3;10;11;14q21.2;FKBP3, FKBP25;;FK506-binding protein 3;186947;REc;;;
14.187;7;15;09;14q21.1;LRFN5, SALM5;;Leucine-rich repeat and fibronectin type III domain-containing protein 5;612811;REc, H;;;12(Lrfn5)
14.188;10;09;18;14q21.2;MIS18BP, C14orf106;;Mis18-binding protein 1;618139;REc;;;
14.189;12;10;12;14q21.2;PRPF39;;Precursor mRNA-processing factor 39, S. cerevisiae, homolog of;614907;REc;;;
14.190;8;11;17;14q21.2;TOGARAM1, FAM179B, KIAA0423;;TOG array regulator of axonemal microtubules 1;617618;REc;;;
14.191;3;3;03;14q21.2-q22.3;MGR4, MGOA;;Migraine without aura, susceptibility to, 4;607501;Fd;between D14S976 and D14S978;{Migraine without aura, susceptibility to, 4} (2);
14.192;9;16;12;14q21.3;ARF6;;ADP-ribosylation factor 6;600464;REc;;;
14.193;5;25;13;14q21.3;CDKL1, KKIALRE, p42;;Cyclin-dependent kinase-like 1;603441;REc;;;
14.194;9;7;12;14q12;DHRS1;;Short-chain dehydrogenase/reductase family, member 1;610410;REc;;;
14.195;08;27;18;14q21.2;FANCM, KIAA1596, SPGF28, POF15;;FANCM gene;609644;REc;mutation identified in 1 POF15 family;Spermatogenic failure 28, 618086 (3); ?Premature ovarian failure 15, 618096 (3);
14.196;2;11;08;14q21.2;FSCB, C14orf155;;Fibrous sheath cabyr-binding protein;611779;REc;;;12(Fscb)
14.197;5;26;13;14q21.3;KLHDC1;;KELCH domain-containing protein 1;611281;REc;;;
14.198;5;26;13;14q21.3;KLHDC2, HCLP1;;KELCH domain-containing protein 2;611280;REc;;;
14.199;1;7;09;14q21.3;KTU, C14orf104, CILD10;;Kintoun, Medaka, homolog of;612517;REc;;Ciliary dyskinesia, primary, 10, 612518 (3);
14.200;1;10;18;14q21.3;VCPKMT, METTL21D, C14orf138;;Valosin-containing protein lysine methyltransferase;615260;REc;;;
14.201;12;22;16;14q21.3;NEMF, SDCCAG1;;Nuclear export mediator factor;608378;A;;;
14.202;9;14;95;14q22.2;CDKN3;;Cyclin-dependent kinase inhibitor 3 (CDK2-associated dual specificity phosphatase);123832;A;;;
14.203;4;1;96;14q22.3;KTN1, CG1;;Kinectin;600381;REa, A;;;
14.204;8;21;07;14q22.1;PTGER2;;Prostaglandin E receptor 2, EP2 subtype, 53kD;176804;A;;{Asthma, aspirin-induced, susceptibility to}, 208550 (3);15(Ptgerep2)
14.205;7;22;13;14q22-q23;CTRCT32, CTAA1, CAP, CTPP5;;Cataract 32, multiple types;115650;Ch, Fd;between D14S980 and D14S1069;Cataract 32, multiple types (2);
14.206;3;8;07;14q23.1;PRKCH, PKCL, PRKCL;;Protein kinase C, eta;605437;A, REc;;{Cerebral infarction, susceptibility to}, 601367 (3);
14.207;4;29;17;14q24.2;ZFYVE1, ZNFN2A1, DFCP1, TAFF1;;Zinc finger FYVE type-containing protein 1;605471;REc;;;
14.208;12;19;01;14q24.1;ZFP36L1, BRF1, ERF1;;Zinc finger protein 36, C3H type-like 1 (butyrate response factor 1; EGF-response factor 1);601064;A;;;
14.209;3;20;07;14q22.1;C14orf166, CGI99;;Chromosome 14 open reading frame 166;610858;R, REc;;;
14.210;1;29;13;14q22.1;DDHD1, PAPLA1, KIAA1705, SPG28;;DDHD domain-containing protein 1;614603;REc, Fd;;Spastic paraplegia 28, autosomal recessive, 609340 (3);
14.211;10;7;13;14q22.1;ERO1L, ERO1LA;;Endoplasmic reticulum oxidoreduction 1-like;615435;A, H, REc;;;14(Ero1l)
14.212;4;30;09;14q22.2;GCRRF1, CGR19;;Cell growth regulator with ring finger domain 1;606138;R, REc;;;
14.213;8;26;15;14q22.1;GNPNAT1, GNA1;;Glucosamine-phosphate N-acetyltransferase 1;616510;REc;;;
14.214;10;24;18;14q22.1;FERMT2, PLEKHC1, MIG2, UNC112, KIND2;;Fermitin family, member 2;607746;R, REc;;;
14.215;4;2;12;14q22.1;FRMD6, WILLIN, C14orf31;;FERM domain-containing protein 6;614555;REc;;;
14.216;10;7;05;14q21.3;L2HGDH, C14orf160, L2HGA;;L-2-hydroxyglutarate dehydrogenase;609584;REc;;L-2-hydroxyglutaric aciduria, 236792 (3);
14.217;5;1;16;14q22.1;NIN, KIAA1565, SCKL7;;Ninein;608684;REc;mutation identified in 1 SCKL7 family;?Seckel syndrome 7, 614851 (3);
14.218;8;27;08;14q21.3;RN7SL1, 7SL, 7L1A;;RNA, 7SL, cytoplasmic 1;612177;REc;;;
14.219;8;27;08;14q21.3;RN7SL2, 7L1C;;RNA, 7SL, cytoplasmic 2;612179;REc;;;
14.220;8;27;08;14q21.3;RN7SL3;;RNA, 7SL, cytoplasmic 3;612180;REc;;;
14.221;2;1;11;14q22.1;PSMC6;;Proteasome 26S subunit, ATPase, 6;602708;REc;previously assigned to 12q15 by FISH;;
14.222;12;9;04;14q22.1;PTGDR, AS1, ASRT1;;Prostaglandin D2 receptor;604687;Fd, REc;;{Asthma, susceptibility to, 1}, 607277 (3);
14.223;6;23;98;14q22.1;PYGL;;Phosphorylase, glycogen, liver;613741;REb, Fd, REc;;Glycogen storage disease VI, 232700 (3);12(Pygl)
14.224;7;16;09;14q23.2;SGPP1, SPPASE1;;Sphingosine-1-phosphate phosphatase 1;612826;REc;;;
14.225;7;14;14;14q22.1;STYX;;Serine/threonine/tyrosine-interacting protein;615814;REc;;;
14.226;10;27;06;14q22.1;TXNDC1, TMX;;Thioredoxin domain-containing 1;610527;REc;;;
14.227;2;4;15;14q22.1;TXNDC16, KIAA1344;;Thioredoxin domain-containing protein 16;616179;REc;;;
14.228;5;4;09;14q22.2;GCH1, DYT5, HPABH4B;;GTP cyclohydrolase 1;600225;Psh, A;;Dystonia, DOPA-responsive, with or without hyperphenylalaninemia, 128230 (3); Hyperphenylalaninemia, BH4-deficient, B, 233910 (3);
14.229;6;3;14;14q22.1-q22.3;FRIASS, DEL14q22, C14DELq22;;Frias syndrome;609640;Ch;deletion spans 4.1 Mb on 14q22.1-q22.3;Frias syndrome (4);
14.230;3;7;11;14q22.1-q24.2;MYP18;;Myopia 18;255500;Fd;between D14S984 and D14S999;Myopia 18 (2);
14.231;3;7;14;14q22.2;BMP4, BMP2B1, BMP2B, MCOPS6, OFC11;;Bone morphogenetic protein-4;112262;H, REa, A, Ch, REc;;Microphthalmia, syndromic 6, 607932 (3); Orofacial cleft 11, 600625 (3);14(Bmp2b1)
14.232;5;25;13;14q22.2;CNIH, TGAM77;;Cornichon, Drosophila, homolog of;611287;REc;;;
14.233;2;23;09;14q22.2;CRCS8;;Colorectal cancer, susceptibility to, 8;612589;Fd;associated with rs4444235;{Colorectal cancer, susceptibility to, 8} (2);
14.234;9;9;08;14q22.3;FBXO34, FBX34;;F-box only protein 34;609104;REc;;;14(Fbxo34)
14.235;9;27;17;14q22.2;GMFB, GMF;;Glia maturation factor, beta;601713;REc;;;
14.236;2;7;07;14q22.2;SAMD4A, SMAUG1, KIAA1053;;Sterile alpha motif domain-containing 4A;610747;REc;;;14(Samd4a)
14.237;11;11;14;14q22.2-q22.3;WDHD1, AND1;;WD repeat and HMG-box DNA binding protein 1;608126;R, REc;;;
14.238;9;18;12;14q22.3;AP5M1, MUDENG, MUD, C14orf108;;Adaptor-related protein complex 5, mu-1 subunit;614368;REc;;;
14.239;8;27;15;14q22.3;ATG14, ATG14L, KIAA0831, BARKOR;;Autophagy 14, S. cerevisiae, homolog of;613515;R, REc;;;
14.240;5;1;17;14q23.1;DACT1, DPR1, DAPPER1, FRODO, TBS2;;Dapper, antagonist of beta-catenin, 1;607861;REc;mutation identified in 1 TBS2 family;?Townes-Brocks syndrome 2, 617466 (3);
14.241;1;31;18;14q22.3;DLGAP5, DLG7, HURP, KIAA0008;;Discs large-associated protein 5;617859;Psh, REc;;;
14.242;9;8;11;14q22.3;EXOC5, SEC10L1;;Exocyst complex component 5;604469;REc;;;
14.243;11;23;16;14q22.3;MAP1IP1L, MISS;;Mitogen-activated protein kinase 1-interacting protein 1-like protein;617226;REc;;;
14.244;6;1;18;14q22.3;NAA30, NAT12, MAK3, C14orf35;;N-alpha-acetyltransferase 30, NatC catalytic subunit;617989;REc;;;
14.245;5;8;15;14q22.3;OTX2, MCOPS5, CPHD6;;Orthodenticle, Drosophila, homolog of, 2;600037;A, REa;;Microphthalmia, syndromic 5, 610125 (3); Pituitary hormone deficiency, combined, 6, 613986 (3); Retinal dystrophy, early-onset, with or without pituitary dysfunction, 610125 (3);
14.246;4;30;15;14q22.3;SOCS4, SOCS7;;Suppressor of cytokine signaling 4;616337;REc;;;
14.247;4;24;17;14q22.3;TMEM260, C14orf101, SHDRA;;Transmembrane protein 260;617449;REc;;Structural heart defects and renal anomalies syndrome, 617478 (3);
14.248;7;10;08;14q23;ANIB8;;Aneurysm, intracranial berry, 8;612162;Fd;associated with rs767603;Aneurysm, intracranial berry, 8 (2);
14.249;10;6;09;14q23;EIG2;;Epilepsy, idiopathic generalized, susceptibility to, 2;606972;Fd;;{Epilepsy, idiopathic generalized, susceptibility to, 2} (2);
14.250;6;6;18;14q23.3;FUT8, CDGF;;Fucosyltransferase 8;602589;REc, A;;Congenital disorder of glycosylation with defective fucosylation, 618005 (3);
14.251;8;14;11;14q23.3;MAX;;MAX protein;154950;A;interacts with MYC;{Pheochromocytoma, susceptibility to}, 171300 (3);12 (Myn)
14.252;6;15;99;14q23.1;MNAT1, MAT1;;Menage a trois 1;602659;A,;;;
14.253;12;9;97;14q23.1;PSMA3;;Proteasome (prosome, macropain) subunit, alpha type, 3;176843;Fd;;;
14.254;8;1;06;14q23.1;SIX1, BOS3, DFNA23;;Sine oculis homeo box, Drosophila, homolog of, 1;601205;REa, A;;Branchiootic syndrome 3, 608389 (3); Deafness, autosomal dominant 23, 605192 (3);
14.255;10;4;01;14q23.1;SIX4;;Sine oculis homeo box, Drosophila, homolog of, 4;606342;A;;;
14.256;4;10;15;14q23.1;SIX6, ODRMD;;Sine oculis homeo box, Drosophila, homolog of, 6;606326;A, R, D;;Optic disc anomalies with retinal and/or macular dystrophy, 212550 (3);
14.257;11;20;13;14q23.2;SYNE2, NUANCE, KIAA1011, EDMD5;;Spectrin repeat-containing nuclear envelope protein 2 (nesprin 2);608442;A;;Emery-Dreifuss muscular dystrophy 5, autosomal dominant, 612999 (3);
14.258;11;4;93;14q23.3;FNTB;;Farnesyltransferase, CAAX box, beta;134636;REa, Psh, A;related FNTBL1 on 9;;
14.259;1;4;12;14q23.3;ZBTB25, ZNF46, KUP;;Zinc finger and BTB domain containing 25;194541;A;;;
14.260;12;28;08;14q23.1;ARID4A, RBP1, RBBP1;;AT-rich interactive domain-containing protein 4A;180201;R, REc;;;
14.261;1;26;17;14q23.1;C14orf39, SIX6OS1;;Chromosome 14 open reading frame 39;617307;REc;;;
14.262;4;30;12;14q23.1;DAAM1, KIAA0666;;Dishevelled-associated activator of morphogenesis 1;606626;R, REc;;;
14.263;7;16;09;14q23.1;DHRS7, RETSDR4;;Short-chain dehydrogenase/reductase family, member 7;612833;REc;;;
14.264;2;25;15;14q23.1;GPR135;;G protein-coupled receptor 135;607970;R, REc;;;12(Gpr135)
14.265;5;23;13;14q23.1;JKAMP, C24orf100, JAMP;;JNK1/MAPK8-associated membrane protein;611176;REc;;;
14.266;9;21;15;14q23.1;KIAA0586, TALPID3, JBTS23, SRTD14;;KIAA0586 gene;610178;REc, R;;Joubert syndrome 23, 616490 (3); Short-rib thoracic dysplasia 14 with polydactyly, 616546 (3);
14.267;9;10;12;14q23.1;L3HYPDH, C14orf149;;L-3-hydroxyproline dehydratase, trans;614811;REc;;;
14.268;10;12;14;14q23.1;PPM1A, PP2CA;;Protein phosphatase, magnesium/manganese-dependent, 1A;606108;REc;;;
14.269;10;7;05;14q23.2;PPP2R5E;;Protein phosphatase-2, regulatory subunit B (B56), epsilon isoform;601647;REc;incorrectly assigned to 7p12-p11.2 by FISH;;
14.270;8;26;15;14q23.1;SLC38A6, SNAT6;;Solute carrier family 38 (amino acid transporter), member 6;616518;REc;;;
14.271;5;2;07;14q23.2;SYT16, STREP14;;Synaptotagmin 16;610950;REc;;;
14.272;8;20;07;14q23.1;TMEM30B, CDC50B;;Transmembrane protein 30B;611029;REc;;;
14.273;9;4;15;14q23.1;TRMT5, TRM5, KIAA1393, COXPD26;;tRNA methyltransferase 5, S. cerevisiae, homolog of;611023;R, REc;;Combined oxidative phosphorylation deficiency 26, 616539 (3);
14.274;9;27;17;14q23.2;GPHB5, GPB5;;Glycoprotein hormone, beta-5;609652;REc;;;
14.275;3;30;12;14q23.2;HIF1AAS1;;HIF1A antisense RNA 1;614528;REc;;;
14.276;3;30;12;14q23.2;HIF1AAS2;;HIF1A antisense RNA 2;614529;REc;;;
14.277;4;30;12;14q23.2;KCNH5;;Potassium voltage-gated channel, subfamily H, member 5;605716;REc;;;
14.278;4;30;12;14q23.2;RHOJ, ARHJ, TCL;;Ras homolog gene family, member J;607653;REc;;;
14.279;10;2;12;14q23.2;SNAPC1, SNAP43;;Small nuclear RNA-activating protein complex, polypeptide 1;600591;REc;;;
14.280;2;28;06;14q23.2;TELM;;Telomere length, mean leukocyte;609113;Fd;suggestive QTL on 12, 10q, 3p;[Telomere length, mean leukocyte] (2);
14.281;2;25;15;14q23.3;AKAP5, AKAP79;;A-kinase anchor protein 5;604688;REc;;;
14.282;9;26;16;14q23.3;CHURC1, CHCH, C14orf52;;Churchill domain-containing 1;608577;REc;;;
14.283;01;04;19;14q23.3;EIF2S1;;Eukaryotic translation initiation factor 2, subunit 1;603907;REc;;;
14.284;7;22;13;14q23.3;MPP5, PALS1;;Membrane protein, palmitoylated 5;606958;R, REc;;;12(Pals1)
14.285;7;17;14;14q23.3-q24.1;PLEK2;;Pleckstrin 2;608007;REc;;;
14.286;4;24;18;14q23.3;PLEKHG2, ARHGEF43, KIAA0599;;Pleckstrin homology domain- and RhoGEF domain-containing protein G3;617940;R, REc;;;
14.287;12;1;14;14q24.1;RDH11, PSDR1, RALR1, RDJCSS;;Retinol dehydrogenase 11;607849;R, REn;mutation identified in 1 RDJCSS family;?Retinal dystrophy, juvenile cataracts, and short stature syndrome, 616108 (3);12(Rdh11)
14.288;9;23;04;14q24.1;RDH12, LCA13;;Retinol dehydrogenase 12;608830;Fd, REn;near RDH11;Leber congenital amaurosis 13, 612712 (3);
14.289;4;25;18;14q23.3;SPTB, SPH2, EL3, HS2;;Spectrin, beta, erythrocytic;182870;REb, F, H, REa, A, RE;;Elliptocytosis-3, 617948 (3); Spherocytosis, type 2, 616649 (3); Anemia, neonatal hemolytic, fatal or near-fatal, 617948 (3);12(Sptb1)
14.290;9;28;15;14q23.3;ZBTB1;;Zinc finger- and BTB domain-containing protein 1;616578;REc;;;12(Zbtb1)
14.291;8;25;11;14q24.1;RAD51L1;;RAD51. S. cerevisiae, homolog of, like 1;602948;REc, A, R;fused with HMGA2 in uterine leiomyoma;;
14.292;11;30;06;14q24.3;ALKBH1, ALKB;;AlkB, E. coli, homolog of, 1;605345;A;;;
14.293;12;6;16;14q23.3;ATP6V1D, ATP6M;;ATPase, H+ transporting, V1 subunit D;609398;REc;;;
14.294;12;17;08;14q24.3;BATF, BATF1, SFA2;;Basic leucine zipper transcription factor, ATF-like;612476;A;;;
14.295;10;29;03;14q24.3;EIF2B2;;Eukaryotic translation initiation factor 2B, subunit 2;606454;R, Fd;;Leukoencephalopathy with vanishing white matter, 603896 (3); Ovarioleukodystrophy, 603896 (3);
14.296;9;28;00;14q24.3;ENTPD5, CD39L4;;Ectonucleoside triphosphate diphosphohydrolase 5;603162;R,;;;12(Cd39l4)
14.297;11;8;17;14q24.3;ERG28, C14orf1;;Ergosterol biosynthesis 28 homolog;604576;R;;;
14.298;11;4;13;14q23.3-q24.1;GPHN, GPH, KIAA1385, GEPH, MOCODC;;Gephyrin;603930;REc, Ch;;Molybdenum cofactor deficiency C, 615501 (3);
14.299;11;20;17;14q24.3;LTBP2, LTBP3, GLC3D, MSPKA, WMS3;;Latent transforming growth factor beta binding protein-2;602091;RE, A;mutation identified in 1 WMS3 family;Glaucoma 3, primary congenital, D, 613086 (3); Microspherophakia and/or megalocornea, with ectopia lentis and with or without secondary glaucoma, 251750 (3); ?Weill-Marchesani syndrome 3, recessive, 614819 (3);
14.300;11;21;17;14q23.3;MTHFD1, MTHFC, CIMAH;;Methylenetetrahydrofolate dehydrogenase 1;172460;S, REa, A;trifunctional protein;{Neural tube defects, folate-sensitive, susceptibility to}, 601634 (3); Combined immunodeficiency and megaloblastic anemia with or without hyperhomocysteinemia, 617780 (3);
14.301;9;28;00;14q24.3;NGB;;Neuroglobin;605304;R;;;
14.302;7;14;15;14q24.3;TGFB3, ARVD1, RNHF, LDS5;;Transforming growth factor, beta-3;190230;REa, A;;Arrhythmogenic right ventricular dysplasia 1, 107970 (3); Loeys-Dietz syndrome 5, 615582 (3);12(Tgfb3)
14.303;5;10;04;14q24.3;ZADH1;;Zinc-binding alcohol dehydrogenase domain-containing protein 1;608642;REc;;;
14.304;3;12;15;14q32.11;CALM1, PHKD, CPVT4, LQT14;;Calmodulin-1 (phosphorylase kinase, delta);114180;REa, Psh, A;;Ventricular tachycardia, catecholaminergic polymorphic, 4, 614916 (3); Long QT syndrome 14, 616247 (3);
14.305;3;14;96;14q24.3;PGF, PLGF;;Placental growth factor, vascular endothelial growth factor-related protein;601121;A;;;12(Plgf)
14.306;1;29;01;14q31.3;FLRT2;;Fibronectin-like domain-containing leucine-rich transmembrane protein-2;604807;R, REc;;;
14.307;5;3;13;14q24.1;ACTN1, BDPLT15;;Actinin, alpha-1;102575;REa, A, REc;;Bleeding disorder, platelet-type, 15, 615193 (3);12(Actn1)
14.308;6;6;00;14q24.2;ADAM20;;A disintegrin and metalloproteinase domain 20;603712;R;;;
14.309;6;6;00;14q24.2;ADAM21;;A disintegrin and metalloproteinase domain 21;603713;R;;;
14.310;7;25;18;14q24.2;COX16;;Cytochrome c oxidase assembly factor 16;618064;REc;;;
14.311;6;29;07;14q24.1;ERH;;Enhancer of rudimentary, Drosophila, homolog of;601191;REc;possible pseudogene on 7q34;;
14.312;5;9;16;14q24.1;EXD2, EXDL2;;Exonuclease 3'-to-5' domain-containing protein 2;616940;REc;;;
14.313;4;6;13;14q24.1;GALNT16, GALNACT16, GALNTL1, KIAA1130;;UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 16;615132;R, REc;;;
14.314;4;9;96;14q23.3;GPX2;;Glutathione peroxidase-2, gastrointestinal;138319;REa, A;;;
14.315;10;15;94;14q23.3;HSPA2;;Heat-shock 70kD protein-2;140560;REa, A;;;12(Hspa2)
14.316;6;22;18;14q24.1;PIGH;;Phosphatidylinositol glycan, class H;600154;H, REc;;Glycosylphosphatidylinositol biosynthesis defect 17, 618010 (3);12(Pigh)
14.317;10;4;02;14q24.1;SLC10A1, NTCP1;;Solute carrier family 10 (sodium/bile acid cotransporter family), member 1;182396;REa, REc;;;12(Slc10a1)
14.318;2;21;11;14q24.2;SMOC1, OAS;;SPARC-related modular calcium-binding 1;608488;REc;;Microphthalmia with limb anomalies, 206920 (3);
14.319;1;15;16;14q24.1;SUSD6, DRAGO, KIAA0247;;SUSHI domain-containing protein 6;616761;R, REc;;;
14.320;9;23;13;14q24.1;VTI1B, VTI1, VTI1L;;Vti1, S. cerevisiae, homolog of, B;603207;REc;;;
14.321;4;27;12;14q24.1;ZFYVE26, KIAA0321, SPG15;;Zinc finger FYVE domain-containing protein 26;612012;R, REc, Fd;;Spastic paraplegia 15, autosomal recessive, 270700 (3);
14.322;9;9;10;14q24.1;DCAF5, WDR22, BCRP2, D14S1461E;;DDB1- and CUL4-associated factor 5;603812;REc;;;
14.323;6;15;99;14q24.1;ARG2;;Arginase II;107830;A, R, Psh;;;
14.324;11;21;02;14q32.11;KCNK13, THIK1;;Potassium channel, subfamily K, member 13;607367;REc;;;
14.325;5;19;15;14q24.2;DCAF4, WDR21, WDR21A;;DDB1- and CUL4-associated factor 4;616372;REc;;;
14.326;11;27;17;14q24.2;PAPLN, PPN;;Papilin, proteoglycan-like sulfated glycoprotein;617785;REc;;;
14.327;8;31;17;14q24.2;PCNX1, KIAA0995;;Pecanex, Drosophila, homolog of, 1;617655;R, REc;;;12(Pcnx1)
14.328;12;22;08;14q24.2;RBM25, RED120;;RNA-binding motif protein 25;612427;REc;;;
14.329;6;13;17;14q24.2;SIPA1L1, E6TP1, KIAA0440;;SIPA1-like protein 1;617504;REc;;;
14.330;12;19;11;14q24.1;SRSF5, SFRS5, SRp40;;Splicing factor, serine/arginine-rich, 5;600914;R, REc;;;
14.331;6;30;05;14q24.2;SYNJ2BP, OMP25, ARIP2;;Synaptojanin 2-binding protein;609411;R, REc;;;
14.332;2;25;15;14q24.2;TTC9, KIAA0227;;Tetratricopeptide repeat domain-containing protein 9;610488;Psh, REc;;;
14.333;10;17;12;14q24.3;ABCD4, PXMP1L, P79R, PMP69, MAHCJ;;ATP-binding cassette, subfamily D, member 4 (peroxisomal membrane protein 1-like);603214;Psh, A;;Methylmalonic aciduria and homocystinuria, cblJ type, 614857 (3);
14.334;10;25;11;14q24.3;ACOT1;;Acyl-CoA thioesterase 1;614313;REc;;;12(Acot1)
14.335;3;17;06;14q24.3;ACOT2, PTE2, MTE1;;Acyl-CoA thioesterase 2;609972;REc, R;;;12(Acot2)
14.336;10;28;11;14q24.3;ACOT4;;Acyl-CoA thioesterase 4;614314;REc;?pseudogene on 19q13.12;;12(Acot4)
14.337;10;5;11;14q24.3;ACOT6;;Acyl-CoA thioesterase 6;614267;REc, H;;;12(Acot6)
14.338;5;25;00;14q24.3;ACYP1, ACYPE;;Acylphosphatase, erythrocyte;600875;A, REa;;;
14.339;8;8;13;14q24.3;AHSA1, AHA1;;Activator of heat-shock 90kD protein ATPase 1;608466;REc, R;;;
14.340;8;3;11;14q24.3;ALDH6A1, MMSDH;;Aldehyde dehydrogenase 6 family, member A1 (methylmalonate semialdehyde dehydrogenase);603178;REc;;Methylmalonate semialdehyde dehydrogenase deficiency, 614105 (3);
14.341;9;9;13;14q24.3;AREL1, KIAA0317;;Apoptosis-resistant E3 ubiquitin protein ligase 1;615380;REc;;;
14.342;2;16;18;14q24.3;RIOX1, C14orf169, NO66, MAPJD;;Ribosomal oxygenase 1;611919;R, REc;;;
14.343;7;17;06;14q24.3;CHX10, HOX10, MCOP2, MCOPCB3;;C. elegans ceh-10 homeo domain-containing homolog;142993;REa, A;;Microphthalmia with coloboma 3, 610092 (3); Microphthalmia, isolated 2, 610093 (3);12(Hox10)
14.344;6;26;16;14q24.3;CIPC, KIAA1737;;Clock-interacting pacemaker;616995;REc;;;
14.345;5;24;12;14q24.3;COQ6, CGI10, COQ10D6;;Coq6, S. cerevisiae, homolog of;614647;REc;;Coenzyme Q10 deficiency, primary, 6, 614650 (3);
14.346;11;9;05;14q31.1;DIO2, TXDI2, D2;;Deiodinase, iodothyronine, type II;601413;R, A;;;
14.347;10;15;94;14q24.3;DLST;;Dihydrolipoamide S-succinyltransferase (E2 component of 2-oxo-glutarate complex);126063;A;;;
14.348;6;8;11;14q24.3;DNAL1, C14orf168, CILD16;;Dynein, axonemal, light chain 1;610062;REc;;Ciliary dyskinesia, primary, 16, 614017 (3);12(Dnal1)
14.349;2;7;08;14q24.3;ESRRB, ESRL2, DFNB35;;Estrogen-related receptor beta;602167;A, Fd;;Deafness, autosomal recessive 35, 608565 (3);12(Estrrb)
14.350;4;20;10;14q24.3;FLVCR2, C14orf58, CCT, PVHH, EPV;;Feline leukemia virus subgroup C receptor 2;610865;REc;;Proliferative vasculopathy and hydranencephaly-hydrocephaly syndrome, 225790 (3);12(Flvcr2)
14.351;6;5;92;14q24.3;FOS;;FBJ murine osteosarcoma viral (v-fos) oncogene homolog (oncogene FOS);164810;REa, A;;;12(Fos)
14.352;10;14;09;14q24.3;GLC3C;;Glaucoma 3, primary congenital, C;613085;Fd;between D14S61 and D14S1000;Glaucoma 3, primary congenital, C (2);
14.353;7;26;17;14q24.3;GSTZ1, MAAI, MAAID;;Glutathione S-transferase, zeta-1 (maleylacetoacetate isomerase);603758;A, R;;[Maleylacetoacetate isomerase deficiency], 617596 (3);
14.354;2;9;18;14q24.3;IFT43, C14orf179, CED3, SRTD18, RP81;;Intraflagellar transport 43, Chlamydomonas, homolog of;614068;REc;mutation identified in 1 CED3 family and 1 RP81 family;?Cranioectodermal dysplasia 3, 614099 (3); Short-rib thoracic dysplasia 18 with polydactyly, 617866 (3); ?Retinitis pigmentosa 81, 617871 (3);
14.355;08;20;18;14q24.3;IRF2BPL, C14orf4, EAP1, NEDAMSS;;Interferon regulatory factor 2-binding protein like;611720;R, REc;;Neurodevelopmental disorder with regression, abnormal movements, loss of speech, and seizures, 618088 (3);
14.356;5;19;15;14q24.3;ISCA2, MMDS4;;Iron-sulfur cluster assembly 2, S. cerevisiae, homolog of;615317;REc;;Multiple mitochondrial dysfunctions syndrome 4, 616370 (3);
14.357;3;31;09;14q24.3;ISM2, THSD3, TAIL1;;Isthmin 2, zebrafish, homolog of;612684;REc;;;
14.358;7;24;13;14q24.3;JDP2;;JUN dimerization protein 2;608657;REc;;;
14.359;5;9;12;14q24.3;KTCN8;;Keratoconus 8;614628;Fd;between rs1074501 and rs755212;Keratoconus 8 (2);
14.360;10;28;08;14q24.3;MUSTQTL1;;Muscle strength quantitative trait locus 1;612083;Fd;;Muscle strength quantitative trait locus 1 (2);
14.361;3;31;03;14q24.3;NPC2, HE1;;Epididymal secretory protein HE1;601015;REc, R;;Niemann-pick disease, type C2, 607625 (3);
14.362;6;22;14;14q24.3;MLH3, HNPCC7;;Mismatch repair gene MLH3;604395;A;;Colorectal cancer, somatic, 114500 (3); Colorectal cancer, hereditary nonpolyposis, type 7, 614385 (3); {Endometrial cancer, susceptibility to}, 608089 (3);12(Mlh3)
14.363;7;11;16;14q24.3;NEK9, NERCC1, LCCS10, APUG, NC;;Never in mitosis gene A-related kinase 9;609798;REc;mutation identified in 1 APUG family;Lethal congenital contracture syndrome 10, 617022 (3); ?Arthrogryposis, Perthes disease, and upward gaze palsy, 614262 (3); Nevus comedonicus, somatic, 617025 (3);
14.364;6;15;99;14q24.2-q24.3;NUMB, S171;;Numb, Drosophila, homolog of;603728;REn;;;
14.365;3;7;14;14q24.3;PNMA1, MA1;;Paraneoplastic MA antigen 1;604010;REc;;;
14.366;09;27;18;14q24.3;POMT2, MDDGA2, MDDGB2, MDDGC2, LGMDR14;;Putative protein O-mannosyltransferase 2;607439;REc;;Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 2, 613150 (3); Muscular dystrophy-dystroglycanopathy (congenital with mental retardation), type B, 2, 613156 (3); Muscular dystrophy-dystroglycanopathy (limb-girdle), type C, 2, 613158 (3);
14.367;3;14;13;14q24.3;PROX2;;Prospero-related homeobox 2;615094;REc, H;;;12(Prox2)
14.368;1;11;18;14q24.2;PSEN1, AD3, ACNINV3;;Presenilin 1;104311;Fd;mutation identified in 1 ACNINV3 family;Alzheimer disease, type 3, 607822 (3); Alzheimer disease, type 3, with spastic paraparesis and unusual plaques, 607822 (3); Alzheimer disease, type 3, with spastic paraparesis and apraxia, 607822 (3); Dementia, frontotemporal, 600274 (3); Pick disease, 172700 (3); Cardiomyopathy, dilated, 1U, 613694 (3); ?Acne inversa, familial, 3, 613737 (3);
14.369;8;18;99;14q24.2;RGS6;;Regulator of G protein signaling 6;603894;REa, R;;;
14.370;6;13;12;14q24.3;SKIIP, SKIP, SNW1, BX42;;SKI-interacting protein;603055;REc;;;
14.371;12;21;09;14q24.3;SLIRP, C14orf156;;SRA stem loop-interacting RNA-binding protein;610211;REc;;;
14.372;11;19;11;14q24.3;SYNDIG1L, TMEM90A, CAPUCIN;;Synapse differentiation-induced gene 1-like;609999;REc;;;12(Capucin)
14.373;7;15;14;14q24.3;TTLL5, STAMP, KIAA0998, CORD19;;Tubulin tyrosine ligase-like family, member 5;612268;REc;;Cone-rod dystrophy 19, 615860 (3);
14.374;5;23;06;14q24.3;TMED10, TMP21;;Transmembrane p24 trafficking protein 10;605406;Fd;;;
14.375;3;14;13;14q24.3;VIPAS39, VIPAR, SPE39, C14orf133;;VPS33B-interacting protein, apical-basolateral polarity regulator, spe-39 homolog;613401;REc;;Arthrogryposis, renal dysfunction, and cholestasis 2, 613404 (3);
14.376;5;6;98;14q22.3;UBE2L1, UBCL, UBC4;;Ubiquitin-conjugating enzyme E2L 1;600012;Psh, A;;;
14.377;5;19;09;14q31.3-q32.1;FOXN3, CHES1;;Forkhead box N3;602628;Fd;;;
14.378;12;9;98;14q24.3-q31;IDDM11;;Insulin-dependent diabetes mellitus-11;601208;Fd;;{Diabetes mellitus, insulin-dependent, 11} (2);
14.379;12;17;95;14q24.2;MAP3K9, MLK1;;Mitogen-activated protein kinase kinase kinase 9;600136;REa, A;;;
14.380;11;17;10;14q24.3;SPTLC2, KIAA0526, SPT2, LCB2, HSN1C, NSAN1C;;Serine palmitoyltransferase, long-chain base subunit 2;605713;REc, R;;Neuropathy, hereditary sensory and autonomic, type IC, 613640 (3);12(Sptlc2)
14.381;11;5;08;14q24.2;DPF3, CERD4;;D4, zinc and double PHD fingers, family 3;601672;A;;;
14.382;10;4;02;14q24.3-q31.1;NRXN3;;Neurexin 3;600567;REc;;;
14.383;01;04;19;14q32.13;DICER1, HERNA, KIAA0928, MNG1, RMSE2, GLOW;;Dicer, Drosophila, homolog of, 1;606241;REa, R;;Pleuropulmonary blastoma, 601200 (3); Goiter, multinodular 1, with or without Sertoli-Leydig cell tumors, 138800 (3); Rhabdomyosarcoma, embryonal, 2, 180295 (3); GLOW syndrome, somatic mosaic, 618272 (3);
14.384;5;1;02;14q31.3;GALC;;Galactosylceramidase;606890;REa, A, H, Fd;;Krabbe disease, 245200 (3);12(tw)
14.385;10;14;09;14q31;GRD1;;Graves disease, susceptibility to, 1;275000;Fd;associated with rs2268458;{Graves disease, susceptibility to, 1} (2);
14.386;11;22;16;14q32.11;GPR68, OGR1, AI2A6;;G protein-coupled receptor 68;601404;Psh, A;;Amelogenesis imperfecta, hypomaturation type, IIA6, 617217 (3);
14.387;8;25;11;14q31;HPPD;;Hypertelorism, preauricular sinus, punctal pits, and deafness;614187;Fd;;Hypertelorism, preauricular sinus, punctal pits, and deafness (2);
14.388;4;24;01;14q31.3;KCNK10, TREK2;;Potassium channel, subfamily K, member 10;605873;REc;;;
14.389;2;18;98;14q31.1;SEL1L;;Suppressor of lin 12 (sel-1), C. elegans, homolog of;602329;Psh, A, R;;;
14.390;2;21;06;14q31.1;TSHR, CHNG1;;Thyroid-stimulating hormone receptor;603372;REa, Fd, A, R;;Hypothyroidism, congenital, nongoitrous, 1 275200 (3); Thyroid adenoma, hyperfunctioning, somatic (3); Hyperthyroidism, nonautoimmune, 609152 (3); Thyroid carcinoma with thyrotoxicosis (3); Hyperthyroidism, familial gestational, 603373 (3);12(Tshr)
14.391;10;24;00;14q32.11;RPS6KA5, MSK1;;Ribosomal protein S6 kinase, 90kD, 5;603607;R;;;
14.392;12;11;02;14q32.11;TDP1;;Tyrosyl-DNA phosphodiesterase 1;607198;REc, Fd;;Spinocerebellar ataxia, autosomal recessive with axonal neuropathy, 6072